broad_name	name	synonyms	smiles	status	statusSource	target	targetSource	moa	diseaseArea	indication	indicationSource
capobenic-acid	capobenic acid	capobenic acid	COc1cc(cc(OC)c1OC)C(=O)NCCCCCC(O)=O	Preclinical							
bicuculline-methochloride-(-)	(-)-bicuculline-methochloride		C[N+]1(C)CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21	Preclinical				GABA receptor antagonist			
telmisartan	telmisartan	BIBR 277 SE|BIBR-277-SE|BIBR-277SE|micardis	CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C	Launched	FDA Orange Book: telmisartan	PPARA|PPARG|AGTR1|CYP2C19|CYP2J2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=195173|https://www.drugbank.ca/drugs/DB00966|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=195173|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=195173	angiotensin receptor antagonist	cardiology	hypertension	https://en.wikipedia.org/wiki/Telmisartan
acetophenazine	acetophenazine	tindal	CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1	Launched	FDA Orange Book: acetophenazine maleate	DRD2|DRD1	https://www.drugbank.ca/drugs/DB01063|https://www.drugbank.ca/drugs/DB01063	dopamine receptor antagonist	neurology/psychiatry	psychosis	https://en.wikipedia.org/wiki/Acetophenazine
fesoterodine	fesoterodine	toviaz	CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C	Launched	FDA Orange Book: fesoterodine fumarate	CHRM1|CHRM3|CHRM2|CHRM5|CHRM4	https://www.drugbank.ca/drugs/DB06702|https://www.drugbank.ca/drugs/DB06702|https://www.drugbank.ca/drugs/DB06702|https://www.drugbank.ca/drugs/DB06702|https://www.drugbank.ca/drugs/DB06702	acetylcholine receptor antagonist	urology	urinary incontinence	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5be745f0-8ae7-4c3c-9962-37d6263326f1
meptazinol	meptazinol		CCC1(CCCCN(C)C1)c1cccc(O)c1	Launched	http://www.drugs.com/international/Meptazinol.html	BCHE	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013581	opioid receptor agonist	neurology/psychiatry	pain relief	http://patient.info/medicine/meptazinol-for-pain-relief-meptid
procainamide	procainamide	Procan|Procapan|Pronestyl-SR|procainamide hydrochloride|procanbid|pronestyl	CCN(CC)CCNC(=O)c1ccc(N)cc1	Launched	FDA Orange Book: procainamide hydrochloride	SCN5A|DNMT1	https://www.drugbank.ca/drugs/DB01035|https://www.drugbank.ca/drugs/DB01035	sodium channel blocker	cardiology|cardiology	ventricular arrhythmias|ventricular tachycardia (VT)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17e47845-daad-434c-a784-6d3875b0d704|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17e47845-daad-434c-a784-6d3875b0d704
alectinib	alectinib	AF802|AF802; CH5424802|CH5424802|alecensa	CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1	Launched	FDA Orange Book: alectinib hydrochloride	MET|ALK	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7739|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7739	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb
melphalan-n-oxide	melphalan-n-oxide		N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00522652	HIF1A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000206	hypoxia inducible factor inhibitor			
A-839977	A-839977		Clc1cccc(c1Cl)-n1nnnc1NCc1ccccc1Oc1ccccn1	Preclinical		P2RX7|IL1B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4122|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=735021	purinergic receptor antagonist			
ivabradine	ivabradine	corlanor	COc1cc2C[C@@H](CN(C)CCCN3CCc4cc(OC)c(OC)cc4CC3=O)c2cc1OC	Launched	http://www.drugs.com/international/Ivabradine.html	HCN4|HCN3|HCN2|HCN1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2357|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2357|https://citeline.informa.com/?query=#/drugs/details/9761|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2357	HCN channel antagonist|potassium channel blocker|sodium channel blocker	cardiology	angina pectoris	https://en.wikipedia.org/wiki/Ivabradine
idelalisib	idelalisib	CAL-101|GS-1101|GS-11CAL-101|zydelig	CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1	Launched	FDA Orange Book: idelalisib	CCL4|CCL3|PIK3CG|PIK3CA|PIK3CB|PIK3CD	https://citeline.informa.com/?query=#/drugs/details/30949|https://citeline.informa.com/?query=#/drugs/details/30949|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6741|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6741|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6741|ChEMBL	PI3K inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)	https://en.wikipedia.org/wiki/Idelalisib
MNITMT	MNITMT		Cn1cnnc1Sc1c(ncn1C)[N+]([O-])=O	Preclinical				lymphocyte inhibitor			
BMS-191095	BMS-191095		CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N(Cc1ncc[nH]1)c1ccc(Cl)cc1)C#N	Phase 1	https://books.google.com/books?id=6jEUCTTcE3MC&pg=PA338&lpg=PA338&dq=BMS-191095+clinical+trials&source=bl&ots=KcAu9gQGgC&sig=BuEAQEJyP3IQ5oNOqjASh9ZzviA&hl=en&sa=X&ved=0ahUKEwj6_p666enPAhUBWz4KHdIoBjYQ6AEILzAD#v=onepage&q=BMS-191095%20clinical%20trials&f=false			KATP activator|potassium channel agonist			
vincamine	vincamine		CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@@](O)(C2)C(=O)OC	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	CHRM4|CHRM3|CHRM2|CHRM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=349|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=349|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=349|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=349	adrenergic receptor antagonist			
mericitabine	mericitabine		CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01482390			HCV inhibitor			
10-DEBC	10-DEBC		CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12	Preclinical		PIM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5922	AKT inhibitor			
apremilast	apremilast	CC-10004|otezla	CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O	Launched	FDA Orange Book: apremilast	TNFRSF1A|PDE4B|PDE4C|PDE4D|PDE4A|TNF	https://citeline.informa.com/?query=#/drugs/details/31098|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=392619	phosphodiesterase inhibitor	dermatology|rheumatology	psoriasis|psoriatic arthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3acf6751-827d-11e2-9e96-0800200c9a66|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3acf6751-827d-11e2-9e96-0800200c9a66
atiprimod	atiprimod		CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00388063	CASP9|CASP3|JAK2|IL6|STAT3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=203907|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=203907|https://www.tocris.com/dispprod.php?ItemId=350977#.V-FlwJMrKYU|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=203907|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000707	JAK inhibitor|STAT inhibitor			
xaliproden	xaliproden	SR 57746	FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00103649	HTR1A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000663	serotonin receptor agonist			
citiolone	citiolone		CC(=O)NC1CCSC1=O	Preclinical				lipotropic|mucolytic agent			
TUG-891	TUG-891		Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1	Preclinical		FFAR4	https://www.tocris.com/products/tug-891_4601	free fatty acid receptor agonist			
cloperastine	cloperastine	HT-11|cloperastine fendizoate|cloperastine hydrochloride	Clc1ccc(cc1)C(OCCN1CCCCC1)c1ccccc1	Launched	http://www.drugs.com/international/cloperastine.html			antitussive	pulmonary	cough suppressant	https://en.wikipedia.org/wiki/Cloperastine
Y16	Y16		Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1	Preclinical		RHOA|ARHGEF12|NR1H4	https://www.medchemexpress.com/Y16.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=652475|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=652475	rho associated kinase inhibitor			
GP1a	GP1a		Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1	Preclinical		CNR2	https://www.tocris.com/dispprod.php?ItemId=5469#.Vyj9M2QrImI	cannabinoid receptor agonist			
PF-8380	PF-8380		Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1	Preclinical		ENPP2	https://www.tocris.com/dispprod.php?ItemId=278934#.V-1-o5MrLy8	autotaxin inhibitor			
diperodon	diperodon		O=C(Nc1ccccc1)OCC(CN1CCCCC1)OC(=O)Nc1ccccc1	Preclinical				local anesthetic			
DQP-1105	DQP-1105		Cc1ccc2[nH]c(=O)c(C3=NN(C(C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1	Preclinical		GRIN2C|GRIN2D	https://www.tocris.com/products/dqp-1105_4491|https://www.tocris.com/products/dqp-1105_4491	glutamate receptor antagonist			
lumacaftor	lumacaftor	VRT-826809|VX-809	Cc1ccc(NC(=O)C2(CC2)c2ccc3OC(F)(F)Oc3c2)nc1-c1cccc(c1)C(O)=O	Launched	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206038Orig1s000lbl.pdf	CFTR	https://en.wikipedia.org/wiki/Lumacaftor	CFTR channel agonist	pulmonary	cystic fibrosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fc1c40e-cfac-47a1-9e1a-61ead3570600
quiflapon	quiflapon	L-686708|MK-591	CC(C)(C)Sc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12	Phase 2	Pharmaprojects	ALOX5AP|ALOX5	http://www.medchemexpress.com/product/MK-0591.html|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000307	leukotriene synthesis inhibitor			
carnosine	carnosine		NCCC(=O)NC(Cc1cnc[nH]1)C(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00810368			antiglycating agent			
AC-186	AC-186		Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F	Preclinical		ESR2	https://www.tocris.com/products/ac-186_5053	estrogen receptor agonist			
flindokalner	flindokalner	BMS-204352|maxipost	COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F	Phase 3	https://www.acsmedchem.org/?nd=Meanwell	KCNMA1|KCNMB1|KCNN4|KCNQ4|KCNQ2|KCNQ5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2307|https://citeline.informa.com/?query=#/drugs/details/2479|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000330|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2307|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2307|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2307	potassium channel agonist			
Ro-19-4605	Ro-19-4605	RO-194603|Ro-19-4603	CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C	Preclinical		GABRA1|GABRA3|GABRA2|GABRA5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4297|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4297|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4297|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4297				
fenclonine-(+/-)	(+/-)-fenclonine		NC(Cc1ccc(Cl)cc1)C(O)=O	Preclinical				tryptophan hydroxylase inhibitor			
ABT-491	ABT-491		CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C	Phase 1	Pharmaprojects	PTAFR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1850	platelet activating factor receptor antagonist			
alacepril	alacepril		C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O	Launched	https://www.drugs.com/international/alacepril.html	ACE	https://www.drugs.com/international/alacepril.html	angiotensin converting enzyme inhibitor	cardiology	hypertension	https://www.drugs.com/international/alacepril.html
rucinol	rucinol	N-Butylresorcinol	CCCCc1ccc(O)cc1O	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/17388924	TYR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013716	tyrosinase inhibitor			
CYM-5520	CYM-5520		Cc1cc(C(=O)Cn2cc(ccc2=O)C#N)c(C)n1Cc1ccccc1	Preclinical		S1PR2	https://www.tocris.com/products/cym-5520_5418	sphingosine 1 phosphate receptor agonist			
cinacalcet	cinacalcet	AMG073|sensipar	C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12	Launched	FDA Orange Book: cinacalcet hydrochloride	CASR	https://www.drugbank.ca/drugs/DB01012	calcium channel activator	endocrinology|nephrology|oncology|endocrinology	hyperparathyroidism|chronic kidney disease (CKD)|parathyroid carcinoma|hypercalcemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45028573-13c4-4c8b-ae62-6c75bba97c81|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45028573-13c4-4c8b-ae62-6c75bba97c81|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45028573-13c4-4c8b-ae62-6c75bba97c81|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45028573-13c4-4c8b-ae62-6c75bba97c81
CEP-37440	CEP-37440		CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01922752	ALK	http://www.apexbt.com/cep-37440.html	ALK tyrosine kinase receptor inhibitor			
moguisteine	moguisteine		CCOC(=O)CC(=O)N1CCSC1COc1ccccc1OC	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/7613554			ATP-sensitive potassium channel inhibitor			
efatutazone	efatutazone		Cc1cc(Oc2ccc3nc(COc4ccc(CC5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02249949	PPARG	http://www.ncbi.nlm.nih.gov/pubmed/23589525	PPAR receptor agonist			
naltrindole	naltrindole		Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O	Preclinical		OPRM1|OPRK1|OPRD1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1641|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1641|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1641	opioid receptor antagonist			
dideoxyadenosine	dideoxyadenosine	2',3'-Dideoxyadenosine	Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/2111751			nucleoside reverse transcriptase inhibitor			
9-aminocamptothecin	9-aminocamptothecin		CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00001427	TOP1	http://clincancerres.aacrjournals.org/content/3/2/287	topoisomerase inhibitor			
amiloride	amiloride	Hydro-Ride|amiloride hydrochloride|midamor	NC(=N)NC(=O)c1nc(Cl)c(N)nc1N	Launched	FDA Orange Book: amiloride hydrochloride	TRPV2|AOC1|PKD2L1|ASIC2|ASIC1|ASIC3|TRPC7|SCNN1D|SCNN1G|SCNN1A|SCNN1B|SLC9A1|PKD2|PLAU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2421|https://www.drugbank.ca/drugs/DB00594|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2421|https://www.drugbank.ca/drugs/DB00594|https://www.drugbank.ca/drugs/DB00594|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2421|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2421|https://www.drugbank.ca/drugs/DB00594|https://www.drugbank.ca/drugs/DB00594|https://www.drugbank.ca/drugs/DB00594|https://www.drugbank.ca/drugs/DB00594|https://www.drugbank.ca/drugs/DB00594|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2421|https://www.drugbank.ca/drugs/DB00594	sodium channel blocker	cardiology|cardiology	hypertension|congestive heart failure	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b2c581a-f955-4a8e-bf85-e768e903fd10|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b2c581a-f955-4a8e-bf85-e768e903fd10
phenelzine	phenelzine	nardil	NNCCc1ccccc1	Launched	FDA Orange Book: phenelzine sulfate	ABAT|GPT|SLC6A4|SLC6A3|SLC6A2|MAOB|MAOA|GPT2|AOC3|GAD2	https://www.drugbank.ca/drugs/DB00780|https://www.drugbank.ca/drugs/DB00780|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7266|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7266|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7266|https://www.drugbank.ca/drugs/DB00780|https://www.drugbank.ca/drugs/DB00780|https://www.drugbank.ca/drugs/DB00780|https://www.drugbank.ca/drugs/DB00780|https://www.drugbank.ca/drugs/DB00780	monoamine oxidase inhibitor	neurology/psychiatry	depression	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40483372-448f-4284-976c-8462ef256661
bay-w-9798	bay-w-9798		COC(=O)C1=C(C)N(C)C(C)=C(C1c1ccc(cc1)C(F)(F)F)C(=O)OC	Phase 2	http://adisinsight.springer.com/drugs/800005142			antioxidant			
ethyl-vanillin	ethyl vanillin	ethyl vanillin	CCOc1cc(C=O)ccc1O	Preclinical							
tetrahydrofolic-acid	tetrahydrofolic acid		Nc1nc(O)c2NC(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2n1	Launched	https://www.drugbank.ca/drugs/DB00116	ATIC|MTHFR|MTFMT|MTR|MTHFD2|MTHFD1|FTCD|AMT|SHMT1|SHMT2|ALDH1L1|FOLR2	https://www.drugbank.ca/drugs/DB00116|https://www.drugbank.ca/drugs/DB00116|https://www.drugbank.ca/drugs/DB00116|https://www.drugbank.ca/drugs/DB00116|https://www.drugbank.ca/drugs/DB00116|https://www.drugbank.ca/drugs/DB00116|https://www.drugbank.ca/drugs/DB00116|https://www.drugbank.ca/drugs/DB00116|https://www.drugbank.ca/drugs/DB00116|https://www.drugbank.ca/drugs/DB00116|https://www.drugbank.ca/drugs/DB00116|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001308				
bunazosin	bunazosin	bunazosin hydrochloride	CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1	Launched	http://www.drugs.com/international/Bunazosin.html	ADRA1A	http://www.ncbi.nlm.nih.gov/pubmed/15867947	adrenergic receptor antagonist	ophthalmology|ophthalmology	glaucoma|intraocular pressure	https://en.wikipedia.org/wiki/Bunazosin|https://en.wikipedia.org/wiki/Bunazosin
RITA	RITA		OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1	Preclinical		MDM2|TXNRD2|TXNRD1	https://www.caymanchem.com/app/template/Product.vm/catalog/10006426|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=236869|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=236869	MDM inhibitor			
M-14157	M-14157		CCCCCC(O)CCCC(O)=O	Phase 2	Pharmaprojects	KCNQ1	http://www.enzolifesciences.com/BML-KC141/5-hydroxydecanoate-.-sodium-salt/	ATP-sensitive potassium channel antagonist			
AG-14361	AG-14361	AG-014361	CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23	Preclinical		PARP1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8094	PARP inhibitor			
SGC-0946	SGC-0946		CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12	Preclinical				histone lysine methyltransferase inhibitor			
BAY-K-8644-(+/-)	(+/-)-BAY-K-8644		COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1C(F)(F)F)[N+]([O-])=O	Preclinical				L-type calcium channel activator			
afimoxifene	afimoxifene	4-Hydroxytamoxifen	CC\C(c1ccccc1)=C(/c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00952731	CYP3A5|ESR2|ESR1|PLD1|ESRRG|PRKCE|PRKCD|PRKCQ|PRKCZ	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=286016|https://www.drugbank.ca/drugs/DB04468|https://www.drugbank.ca/drugs/DB04468|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004000|https://www.drugbank.ca/drugs/DB04468|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004000|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004000|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004000|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004000	estrogen receptor antagonist			
sulfinpyrazone	sulfinpyrazone	anturane|sulphinpyrazone	O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c1ccccc1)c1ccccc1	Launched	FDA Orange Book: sulfinpyrazone	FPR1|SLC22A12|ABCC2|ABCC1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5826|ChEMBL|https://www.drugbank.ca/drugs/DB01138|https://www.drugbank.ca/drugs/DB01138	uricosuric blocker	rheumatology	gout	https://en.wikipedia.org/wiki/Sulfinpyrazone
trazodone	trazodone	Trialodine|desyrel|oleptro|trazodone hydrochloride	Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1	Launched	FDA Orange Book: trazodone hydrochloride	HTR1A|HTR2A|HTR2B|HTR2C|HRH1|SLC6A4|ADRA1A|ADRA2A	https://www.drugbank.ca/drugs/DB00656|https://www.drugbank.ca/drugs/DB00656|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=213|https://www.drugbank.ca/drugs/DB00656|https://www.drugbank.ca/drugs/DB00656|https://www.drugbank.ca/drugs/DB00656|https://www.drugbank.ca/drugs/DB00656|https://www.drugbank.ca/drugs/DB00656	adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor	neurology/psychiatry	depression	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5f0457f-b722-48b7-8901-61da7fbb4090&audience=consumer
doxofylline	doxofylline	ABC 12/3|maxivent	Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O	Launched	http://www.drugs.com/international/Doxofylline.html	PDE4D|PDE4C|PDE4B|PDE4A|ADORA1	http://www.genome.jp/dbget-bin/www_bget?dr:D03898|http://www.genome.jp/dbget-bin/www_bget?dr:D03898|http://www.genome.jp/dbget-bin/www_bget?dr:D03898|http://www.genome.jp/dbget-bin/www_bget?dr:D03898|http://www.genome.jp/dbget-bin/www_bget?dr:D03898	adenosine receptor antagonist	pulmonary	asthma	https://en.wikipedia.org/wiki/Doxofylline
AH6809	AH6809		CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O	Preclinical		PTGER2|PTGER1|PTGER3|PTGDR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1896|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1896|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1896|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1896	prostanoid receptor antagonist			
chlorophyllide-cu-complex-na-salt	chlorophyllide-cu-complex-na-salt		CCc1c(C)c2=Cc3c(C=C)c(C)c4C=c5c(C)c(CCC(O)=O)c6=C7C(C(O)=O)C(=O)c8c(C)c9C=c1n2[Cu](n34)(n9c78)n56	Preclinical							
methyl-nicotinate	methyl nicotinate	methyl nicotinate	COC(=O)c1cccnc1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/22887778						
verbascoside	verbascoside	Acetoside|Acteoside|Verbacoside	C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)\C=C\c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT02662283			PKC inhibitor|NFkB pathway inhibitor			
delta-Tocotrienol	delta-Tocotrienol		CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@]1(C)CCc2cc(O)cc(C)c2O1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00985777	HMGCR	https://en.wikipedia.org/wiki/Tocotrienol	HMGCR inhibitor			
broxaterol	broxaterol		CC(C)(C)NCC(O)c1cc(Br)no1	Phase 3	https://www.ncbi.nlm.nih.gov/pubmed/2572038	ADRB2	https://en.wikipedia.org/wiki/Broxaterol	adrenergic receptor agonist			
9-anthracenecarboxylic-acid	9-anthracenecarboxylic acid	ANTHRACENE-9-CARBOXYLIC ACID	OC(=O)c1c2ccccc2cc2ccccc12	Preclinical		ANO1|CLCN1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4113|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4113				
arecoline	arecoline		COC(=O)C1=CCCN(C)C1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/3048224	CHRM1|CHRM2|CHRM3|CHRM4	https://www.drugbank.ca/drugs/DB04365|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=296|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=296|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=296	acetylcholine receptor agonist			
RWJ-21757	RWJ 21757	RWJ 21757|loxoribine	Nc1nc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(=O)n(CC=C)c2c(=O)[nH]1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/11565955	TLR7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5018	toll-like receptor agonist			
RLX	RLX		O=c1n2CCCCCc2nc2ccccc12	Preclinical							
ravoxertinib	ravoxertinib	GDC-0994	Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1	Phase 1	http://www.chemietek.com/gdc-0994--ravoxertinib--rg7842-details.aspx	MAPK1|MAPK3	http://www.medkoo.com/products/5487|http://www.medkoo.com/products/5487	ERK1 and ERK2 phosphorylation inhibitor			
hexylresorcinol	hexylresorcinol		CCCCCCc1ccc(O)cc1O	Launched	http://www.drugs.com/international/hexylresorcinol.html	TYR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013696	local anesthetic	infectious disease|infectious disease	skin infections|first-aid antiseptic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94be7c2a-b372-4f43-8cf1-f382ab629ebe|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94be7c2a-b372-4f43-8cf1-f382ab629ebe
capsaicin	capsaicin	qutenza	COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O	Launched	FDA Orange Book: capsaicin	TRPV1|ENOX2|CFTR	ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=285220|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2486	TRPV agonist	neurology/psychiatry|rheumatology	muscle pain|rheumatoid arthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0548b21-bac7-43f1-a9ff-c4aa7b4e52b4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0548b21-bac7-43f1-a9ff-c4aa7b4e52b4
vinflunine	vinflunine		CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC	Launched	https://www.drugs.com/international/vinflunine.html			microtubule inhibitor	oncology	bladder cancer	https://en.wikipedia.org/wiki/Vinflunine
RS-102895	RS-102895		FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1	Preclinical		CCR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=779	CCR antagonist			
Rec-15/2615	Rec-15/2615		COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)COc1c(OC)cccc1C(C)C	Phase 2	https://www.pharmacodia.com/web/drug/1_5550.html	ADRA1A|ADRA1B	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001201|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=287385	adrenergic receptor antagonist			
indoramin	indoramin	Baratol|WY 21901	O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1	Launched	http://www.drugs.com/uk/baratol-tablets-25mg-leaflet.html	ADRA2B|ADRA2C|ADRA1D|ADRA1A|ADRA1B	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003773|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003773|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=501|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=501|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=501	adrenergic receptor antagonist	urology|cardiology	benign prostatic hyperplasia (BPH)|hypertension	http://www.netdoctor.co.uk/medicines/heart-and-blood/a6609/doralese-indoramin/|http://www.netdoctor.co.uk/medicines/heart-and-blood/a6609/doralese-indoramin/
protionamide	protionamide	RP 9778|TH-1321|prothionamide	CCCc1cc(ccn1)C(S)=N	Launched	http://www.drugs.com/international/Protionamide.html				infectious disease	tuberculosis	https://en.wikipedia.org/wiki/Prothionamide
midafotel	midafotel		OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1	Phase 3	http://www.medscape.com/viewarticle/439169_2	GRIN2A|GRIN2D|GRIN2C|GRIN2B|GRIN1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4170|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4170|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4170|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4170|https://citeline.informa.com/?query=#/drugs/details/12067	glutamate receptor antagonist			
mifobate	mifobate	SR-202|clenicor	COP(=O)(OC)OC(c1ccc(Cl)cc1)P(=O)(OC)OC	Phase 2	Pharmaprojects	PPARG|REN	https://www.tocris.com/dispprod.php?ItemId=99402#.Vytv42QrJZI|https://citeline.informa.com/?query=#/drugs/details/12084	PPAR receptor antagonist			
AF38469	AF38469		Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1	Preclinical		SORT1	http://www.sciencedirect.com/science/article/pii/S0960894X13013371	sortilin inhibitor			
cetrorelix	cetrorelix	cetrotide	CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	Launched	FDA Orange Book: cetrorelix	GNRHR|GNRH1|LHCGR	https://www.drugbank.ca/drugs/DB00050|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=148387|https://www.drugbank.ca/drugs/DB00050	gonadotropin releasing factor hormone receptor antagonist	endocrinology	premature luteinizing hormone surges	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79
seocalcitol	seocalcitol	CB-1089|EB-1089	CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00051545	VDR	https://www.drugbank.ca/drugs/DB04258	vitamin D receptor agonist			
lycopene	lycopene	E160d	CC(C)=CCC\C(C)=C\C=C\C(C)=C\C=C\C(C)=C\C=C\C=C(C)\C=C\C=C(C)\C=C\C=C(/C)CCC=C(C)C	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01221558			free radical scavenger			
CGS-15943	CGS-15943		Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1	Preclinical		ADORA3|ADORA1|ADORA2B|ADORA2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=384|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=384|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=384|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=384	adenosine receptor antagonist			
apricitabine	apricitabine		Nc1ccn([C@H]2CO[C@@H](CO)S2)c(=O)n1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00686270			nucleoside reverse transcriptase inhibitor			
sulmetozine	sulmetozine	tritiozine	COc1cc(cc(OC)c1OC)C(=S)N1CCOCC1	Launched	http://nomenclator.org/medicamento/tolentil-200mg-30-capsulas.html	GAST	https://books.google.com/books?id=4OjtCAAAQBAJ&pg=PA264&lpg=PA264&dq=tritiozine+gastrin&source=bl&ots=OdSqvFTCaV&sig=71VBJz-1zpTpOgfxIA88vIHnxv4&hl=en&sa=X&ved=0ahUKEwim2JSyzOfPAhVMWx4KHXmHDNoQ6AEIHjAA#v=onepage&q=tritiozine%20gastrin&f=false	gastrin inhibitor	gastroenterology	peptic ulcer disease (PUD)	http://www.medicatione.com/?c=drug&s=clositol&ingredient=tritiozine
MR-16728	MR-16728		O=C(NCCCN1CCCCCC1)C(C1CCCCC1)c1ccccc1	Preclinical				acetylcholine release enhancer			
CITCO	CITCO		Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1	Preclinical		NR1I3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2758	constitutive androstane receptor (CAR) agonist			
impentamine	impentamine		NCCCCCc1cnc[nH]1	Preclinical		HRH3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1252	histamine receptor antagonist			
WIKI4	WIKI4		COc1ccc(cc1)-n1c(SCCCN2C(=O)c3cccc4cccc(C2=O)c34)nnc1-c1ccncc1	Preclinical		TNKS2	https://www.tocris.com/dispprod.php?ItemId=374316#.V_P0K5MrLy8	Wnt pathway inhibitor|tankyrase inhibitor			
taprenepag	taprenepag		OC(=O)COc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)c1	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/21851167	PTGER2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5816	prostaglandin receptor agonist			
omeprazole-sulfide	Omeprazole sulfide	Omeprazole sulfide|ufiprazole	COc1ccc2nc(SCc3ncc(C)c(OC)c3C)[nH]c2c1	Phase 1	Pharmaprojects			ATPase inhibitor			
bromantan	bromantan		Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1	Launched	http://en.wikipedia.org/wiki/Bromantane			dopamine reuptake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry	neurasthenia	https://en.wikipedia.org/wiki/Bromantane
cyclosporin-a	cyclosporin a	neoral|restasis|sandimmune	CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	Launched	FDA Orange Book: cyclosporine	PPP3CA	http://en.wikipedia.org/wiki/Ciclosporin	calcineurin inhibitor	rheumatology|dermatology	rheumatoid arthritis|psoriasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8893395a-6bfa-4b3c-84c2-d1d0c923304f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8893395a-6bfa-4b3c-84c2-d1d0c923304f
ergocalciferol	ergocalciferol	Oleovitamin D|VITAMIN D2|Vitamin D 2|Vitamin d|calciferol|deltalin|drisdol|oleovitamin d, synthetic	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C	Launched	FDA Orange Book: ergocalciferol	VDR	ChEMBL	vitamin analog	endocrinology|orthopedics|endocrinology	hypoparathyroidism|rickets|hypophosphatemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1b24841-75a3-4eb8-8854-17ce832ff09d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1b24841-75a3-4eb8-8854-17ce832ff09d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1b24841-75a3-4eb8-8854-17ce832ff09d
1-octanol	1-octanol	Octan-1-ol|octanol	CCCCCCCCO	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00080366	GJA9|GJA8|GJA5|GJA4|GJA3|GJA1|GJD4|GJD3|GJD2|GJE1|GJB7|GJB6|GJB5|GJB4|GJB3|GJB2|GJB1|GJC3|GJC2|GJC1|GJA10	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278				
pidotimod	pidotimod		OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1	Launched	http://www.drugs.com/international/Pidotimod.html			interferon receptor agonist|interleukin receptor agonist	infectious disease	immune adjuvant	http://www.drugs.com/international/pidotimod.html
salirasib	salirasib		CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00531401	MTOR|TRPA1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=262216|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6281	mTOR inhibitor			
tremorine	tremorine		C(C#CCN1CCCC1)N1CCCC1	Preclinical				acetylcholine receptor agonist			
L-Cysteinesulfinic-acid	L-Cysteinesulfinic acid	L-Cysteinesulfinic Acid|L-Cysteinesulphinic Acid	N[C@@H](CS(O)=O)C(O)=O	Preclinical		PRDX2|HMGCS2|PAPOLA|GSR|GRM5|GRM1	https://www.drugbank.ca/drugs/DB02153|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002689|https://www.drugbank.ca/drugs/DB02153|https://www.drugbank.ca/drugs/DB02153|http://www.tocris.com/dispprod.php?ItemId=1259#.VgLhttNViko|http://www.tocris.com/dispprod.php?ItemId=1259#.VgLhttNViko	glutamate receptor agonist			
TC-ASK-10	TC-ASK-10		CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1	Preclinical		MAP3K6|MAP3K5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8133|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8133	MAP kinase inhibitor			
tenoxicam	tenoxicam		CN1C(C(=O)Nc2ccccn2)C(=O)c2sccc2S1(=O)=O	Launched	http://www.drugs.com/international/Tenoxicam.html	PTGS1|PTGS2	https://www.drugbank.ca/drugs/DB00469|https://www.drugbank.ca/drugs/DB00469	cyclooxygenase inhibitor	rheumatology|rheumatology|rheumatology|orthopedics|rheumatology|rheumatology	rheumatoid arthritis|osteoarthritis|ankylosing spondylitis|tendinitis|bursitis|periarthritis	https://en.wikipedia.org/wiki/Tenoxicam|https://en.wikipedia.org/wiki/Tenoxicam|https://en.wikipedia.org/wiki/Tenoxicam|https://en.wikipedia.org/wiki/Tenoxicam|https://en.wikipedia.org/wiki/Tenoxicam|https://en.wikipedia.org/wiki/Tenoxicam
PD-173074	PD-173074		CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1	Preclinical		FLT4|FLT1|PDGFRA|PDGFRB|FGFR3|FGFR4|FGFR1|FGFR2|KDR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005395|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005395|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005395|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005395|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005395|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005395|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005395|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005395|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005395	FGFR inhibitor|VEGFR inhibitor			
AP1903	AP1903		CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT00868595						
IBMX	IBMX		CC(C)Cn1c2[nH]cnc2c(=O)n(C)c1=O	Preclinical		PDE3B|PDE2A|PDE5A|PDE4D|PDE7A|PDE6G|PDE9A|PDE8A|ADORA1	https://www.drugbank.ca/drugs/DB07954|https://www.drugbank.ca/drugs/DB07954|https://www.drugbank.ca/drugs/DB07954|https://www.drugbank.ca/drugs/DB07954|https://www.drugbank.ca/drugs/DB07954|https://www.drugbank.ca/drugs/DB07954|https://www.drugbank.ca/drugs/DB07954|https://www.drugbank.ca/drugs/DB07954|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=388	phosphodiesterase inhibitor			
scopolamine-n-oxide	scopolamine-n-oxide		C[N+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	Preclinical		CHRM1|CHRM3|CHRM2|CHRM5|CHRM4|SI	https://www.drugbank.ca/drugs/DB00747|https://www.drugbank.ca/drugs/DB00747|https://www.drugbank.ca/drugs/DB00747|https://www.drugbank.ca/drugs/DB00747|https://www.drugbank.ca/drugs/DB00747|https://www.drugbank.ca/drugs/DB00747	acetylcholine receptor antagonist			
E-4031	E-4031		Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/9127398	KCNH2|KCNH1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2605|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2605	potassium channel blocker			
navitoclax	navitoclax	ABT-263	CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01423539	BCL2|BCL2L2|BCL2L1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000415|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000415|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000415	BCL inhibitor			
2'-MeCCPA	2'-MeCCPA		C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12	Preclinical		ADORA1	https://en.wikipedia.org/wiki/Adenosine_receptor	adenosine receptor agonist			
N-(2-chlorophenyl)-2-({(2E)-2-[1-(2-pyridinyl)ethylidene]hydrazino}carbothioyl)hydrazinecarbothioamide	N-(2-chlorophenyl)-2-({(2E)-2-[1-(2-pyridinyl)ethylidene]hydrazino}carbothioyl)hydrazinecarbothioamide		Clc1ccccc1NC(=S)NNC(=S)NNC(=C)c1ccccn1	Preclinical							
trebenzomine	trebenzomine		CC1Oc2ccccc2CC1N(C)C	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/6113618						
losartan	losartan	cozaar	CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1	Launched	FDA Orange Book: losartan potassium	AGTR1	https://www.drugbank.ca/drugs/DB00678	angiotensin receptor antagonist	cardiology|nephrology	hypertension|diabetic nephropathy	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a98a821c-7b81-4f9b-9801-1a16d71871ce|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a98a821c-7b81-4f9b-9801-1a16d71871ce
pipamperone	pipamperone	R 3345|floropipamide|pipamperone hydrochloride|pipaneperone	NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1	Launched	http://www.drugs.com/international/pipamperone.html	HTR2A|HTR1A|HTR1B|HTR1D|HRH1|DRD2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=92|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=92|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=92|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=92|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=92|http://www.scbt.com/datasheet-253278-pipamperone-dihydrochloride.html	dopamine receptor antagonist	neurology/psychiatry	schizophrenia	https://en.wikipedia.org/wiki/Pipamperone
adrenalone	adrenalone	adrenone	CNCC(=O)c1ccc(O)c(O)c1	Launched	http://en.wikipedia.org/wiki/Adrenalone	ADRA1A	https://en.wikipedia.org/wiki/Adrenalone#Pharmacology	adrenergic receptor agonist	hematology	hemorrhage	https://en.wikipedia.org/wiki/Adrenalone
HER2-Inhibitor-1	HER2-Inhibitor-1		Cc1cc(Nc2ncnc3ccc(cc23)-c2ccc(CNCCS(C)(=O)=O)o2)ccc1Oc1ccn2ncnc2c1	Preclinical		ERBB2		EGFR inhibitor			
MK-2894	MK-2894		Cc1sc(C)c(C(=O)NC2(CC2)c2ccc(cc2)C(O)=O)c1Cc1ccc(cc1)C(F)(F)F	Preclinical		PTGER4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4041	prostaglandin inhibitor			
gemcitabine-elaidate	gemcitabine elaidate	CP-4126|gemcitabine elaidate	CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01641575	CMPK1|RRM1|TYMS	https://www.drugbank.ca/drugs/DB00441|https://www.drugbank.ca/drugs/DB00441|https://www.drugbank.ca/drugs/DB00441	DNA synthesis inhibitor|apoptosis inhibitor			
folic-acid	folic acid	Vitamin Bc|Vitamin M|folacin|folic acid|folicet|folvite|pteroylglutamic acid	Nc1nc(=O)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2[nH]1	Launched	FDA Orange Book: folic acid	SLC19A1|FOLR3|FOLR2|SLC46A1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4562|https://www.drugbank.ca/drugs/DB00158|https://www.drugbank.ca/drugs/DB00158|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4562	folate receptor ligand	hematology	megaloblastic anemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2caab63-1e0d-44e8-b9a8-bdfb59ce1288
strychnine	strychnine		O=C1CC2OCC=C3CN4CC[C@@]56C4C[C@@H]3[C@@H]2C5N1c1ccccc61	Preclinical		CHRNA9|GLRA3|GLRA2|GLRA1|CHRNA10|CHRM3|CHRM2|CHRM5|CHRM4|CHRM1|GLRB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013108	acetylcholine receptor antagonist			
cyclocytidine	cyclocytidine		OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O	Preclinical				DNA synthesis inhibitor|RNA synthesis inhibitor			
arachidonic-acid	Arachidonic Acid	Arachidonic Acid|Cis-5,8,11,14-Eicosatetraenoic Acid	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02092857	CYP2J2|PTGS1|CYP4F2|KCNK2|KCNJ4|TRPM2|TRPC6|KCNK18|KCNK10|CLCN2|PRKCZ	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=314647|https://www.drugbank.ca/drugs/DB04557|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=314647|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391	cytochrome P450 inhibitor			
trifluoperazine	trifluoperazine	stelazine|trifluoperazine hydrochloride	CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	Launched	FDA Orange Book: trifluoperazine hydrochloride	S100A4|SCN9A|SCN4A|DRD4|DRD2|HTR2A|HTR2C|HRH1|ABCG2|ADRA1A|CALY|CALM1|TNNC1|CAMK2A	https://www.drugbank.ca/drugs/DB00831|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091383|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091383|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=214|https://www.drugbank.ca/drugs/DB00831|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=214|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=214|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=214|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091383|https://www.drugbank.ca/drugs/DB00831|https://www.drugbank.ca/drugs/DB00831|https://www.drugbank.ca/drugs/DB00831|https://www.drugbank.ca/drugs/DB00831|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091383	dopamine receptor antagonist	neurology/psychiatry	schizophrenia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2575a86-19e5-44df-8603-ff066bb9c9c5&audience=consumer
oxybuprocaine	oxybuprocaine	benoxinate	CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC	Launched	http://www.drugs.com/international/Oxybuprocaine.html	SCN10A	https://www.drugbank.ca/drugs/DB00892	local anesthetic	neurology/psychiatry	local anesthetic	http://www.drugs.com/international/oxybuprocaine.html
erythromycin-estolate	erythromycin estolate	erythromycin estolate|erythromycin propionate|ilosone	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	Launched	FDA Orange Book: erythromycin estolate	CYP51A1|MLNR|ABCB1|ALB|CYP3A4|KCNH2|SLC47A1	http://www.drugbank.ca/drugs/DB00199|http://www.drugbank.ca/drugs/DB00199|http://www.drugbank.ca/drugs/DB00199|http://www.drugbank.ca/drugs/DB00199|http://www.drugbank.ca/drugs/DB00199|http://www.drugbank.ca/drugs/DB00199|http://www.drugbank.ca/drugs/DB00199	bacterial 50S ribosomal subunit inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a
cleviprex	cleviprex	clevidipine|clevidipine butyrate	CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(Cl)c1Cl)C(=O)OC	Launched	http://www.drugs.com/Cleviprex.html	CACNA1D|CACNA1F|CACNA1C|CACNA1S	ChEMBL|ChEMBL|ChEMBL|ChEMBL	calcium channel blocker	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=095081a0-1398-11dc-82e1-0002a5d5c51b
RWJ-50271	RWJ-50271		Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO	Preclinical		ICAM1	https://www.tocris.com/products/rwj-50271_4227	integrin inhibitor			
pasiniazid	pasiniazid		NNC(=O)c1ccncc1	Launched	http://www.drugs.com/international/pasiniazid.html			cyclooxygenase inhibitor	infectious disease	tuberculosis	http://www.drugs.com/international/pasiniazid.html
paroxypropione	paroxypropione	B-360|H 365	CCC(=O)c1ccc(O)cc1	Launched	http://en.wikipedia.org/wiki/Paroxypropione			gonadotropin inhibitor			
edoxudine	edoxudine	EUDR|ORF 15817|RWJ 15817	CCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O	Launched	Pharmaprojects			DNA directed DNA polymerase inhibitor	infectious disease	virus herpes simplex (HSV)	https://en.wikipedia.org/wiki/Edoxudine
RN-1747	RN-1747		[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1	Preclinical		TRPV4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4295	TRPV agonist			
mecysteine	mecysteine	methyl cysteine	COC(=O)C(N)CS	Launched	http://www.drugs.com/international/mecysteine.html			analgesic agent	pulmonary	chest congestion	http://www.drugs.com/international/mecysteine.html
N-methyllidocaine-iodide	N-methyllidocaine iodide		CC[N+](C)(CC)CC(=O)Nc1c(C)cccc1C	Preclinical				antiarrhythmic medication			
ganciclovir	ganciclovir	BW 759U|Cymevene|RS-21592|cytovene|vitrasert|zirgan	Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1	Launched	FDA Orange Book: ganciclovir, ganciclovir sodium, valganciclovir hydrochloride			DNA polymerase inhibitor	infectious disease	cytomegalovirus (CMV)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38e8f819-985c-4d20-aafd-3ba953af26ca
BMS-806	BMS-806	BMS-377806|BMS-378806	COc1cc[nH]c2ncc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12	Phase 1	http://www.thebody.com/content/art16848.html			HIV attachment inhibitor			
bismuth-subsalicylate	bismuth subsalicylate			Launched	FDA Orange Book: bismuth subsalicylate			antacid	gastroenterology	diarrhea	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38053579-3a2f-407b-b660-a5df5b420fcb
carbimazole	carbimazole	athyromazole	CCOC(=O)n1ccn(C)c1=S	Launched	http://en.wikipedia.org/wiki/Carbimazole	TPO	https://www.drugbank.ca/drugs/DB00389	antithyroid agent	endocrinology	hyperthyroidism	https://en.wikipedia.org/wiki/Carbimazole#Clinical_use
pivanex	pivanex	Butyric Acid 2,2-Dimethyl-Propionyloxymethyl Ester|Butyric Acid 2,2-Dimethyl-Propionyloxymethyl Ester(An9)	CCCC(=O)OCOC(=O)C(C)(C)C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00073385	HDAC8|HDAC2|HDAC3|HDAC1	https://books.google.com/books?id=HpbBCQAAQBAJ&pg=PA607&lpg=PA607&dq=pivanex+HDAC1&source=bl&ots=WozDQp1aSn&sig=wbK92tW3Spf7e3vhAmsXOD7uex4&hl=en&sa=X&ved=0ahUKEwiT-tTGs7fPAhVCkh4KHa1LCF8Q6AEILTAD#v=onepage&q=pivanex%20HDAC1&f=false|https://books.google.com/books?id=HpbBCQAAQBAJ&pg=PA607&lpg=PA607&dq=pivanex+HDAC1&source=bl&ots=WozDQp1aSn&sig=wbK92tW3Spf7e3vhAmsXOD7uex4&hl=en&sa=X&ved=0ahUKEwiT-tTGs7fPAhVCkh4KHa1LCF8Q6AEILTAD#v=onepage&q=pivanex%20HDAC1&f=false|https://books.google.com/books?id=HpbBCQAAQBAJ&pg=PA607&lpg=PA607&dq=pivanex+HDAC1&source=bl&ots=WozDQp1aSn&sig=wbK92tW3Spf7e3vhAmsXOD7uex4&hl=en&sa=X&ved=0ahUKEwiT-tTGs7fPAhVCkh4KHa1LCF8Q6AEILTAD#v=onepage&q=pivanex%20HDAC1&f=false|https://books.google.com/books?id=HpbBCQAAQBAJ&pg=PA607&lpg=PA607&dq=pivanex+HDAC1&source=bl&ots=WozDQp1aSn&sig=wbK92tW3Spf7e3vhAmsXOD7uex4&hl=en&sa=X&ved=0ahUKEwiT-tTGs7fPAhVCkh4KHa1LCF8Q6AEILTAD#v=onepage&q=pivanex%20HDAC1&f=false	HDAC inhibitor			
zebularine	zebularine		OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O	Preclinical		DNMT1|CDA	http://www.scbt.com/datasheet-203315-zebularine.html|https://en.wikipedia.org/wiki/Zebularine	DNA methyltransferase inhibitor			
4-carboxy-3-hydroxyphenylglycine-(RS)	4-carboxy-3-hydroxyphenylglycine-(RS)		NC(C(O)=O)c1ccc(C(O)=O)c(O)c1	Preclinical		GRM1	http://www.linscottsdirectory.com/products/r-d-systems-inc/-RS-4-Carboxy-3-hydroxyphenylglycine-6062620	glutamate receptor agonist|glutamate receptor antagonist			
allylisothiocyanate	allylisothiocyanate	allyl isothiocyanate|mustard oil	C=CCN=C=S	Preclinical		TRPA1	https://en.wikipedia.org/wiki/Allyl_isothiocyanate	TRPV agonist			
CPI-203	CPI-203		Cc1sc-2c(c1C)C(=N[C@@H](CC(N)=O)c1nnc(C)n-21)c1ccc(Cl)cc1	Preclinical		IL6|BRD4	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=753524|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7513	bromodomain inhibitor			
eluxadoline	eluxadoline	JNJ-27018966|viberzi	COc1ccc(CN([C@@H](C)c2ncc([nH]2)-c2ccccc2)C(=O)[C@@H](N)Cc2c(C)cc(cc2C)C(N)=O)cc1C(O)=O	Launched	FDA Orange Book: eluxadoline	OPRM1|OPRK1|OPRD1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7691|https://en.wikipedia.org/wiki/Eluxadoline#Mechanism_of_action|https://en.wikipedia.org/wiki/Eluxadoline#Mechanism_of_action	opioid receptor modulator	gastroenterology	irritable bowel syndrome	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7821bd40-4c84-4984-951b-6436ae20421a
ICI-89406	ICI-89406		OC(CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/6156341	ADRB2|ADRB1	http://www.tocris.com/dispprod.php?ItemId=1499|http://www.tocris.com/dispprod.php?ItemId=1499	adrenergic receptor antagonist			
Ko143	Ko143		COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O	Preclinical		ABCG2|ABCC1|ABCB1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=745798|https://www.tocris.com/dispprod.php?ItemId=213642#.V-qwa5MrLy8|https://www.tocris.com/dispprod.php?ItemId=213642#.V-qwa5MrLy8	BCRP inhibitor			
LUF-5834	LUF-5834		Nc1nc(SCc2ncc[nH]2)c(C#N)c(-c2ccc(O)cc2)c1C#N	Preclinical		ADORA2A|ADORA2B	https://www.tocris.com/products/luf-5834_4603|https://www.tocris.com/products/luf-5834_4603	adenosine receptor agonist			
bilobalide	bilobalide		CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]22C(=O)O[C@@H]3OC(=O)[C@H](O)C123	Preclinical		HTR3B|HTR3A|GLRB|GLRA1|GLRA2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2366|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2366|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2366|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2366|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2366	GABA receptor modulator			
SB-939	SB-939		CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01075308	HDAC10|HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC9	http://www.apexbt.com/pracinostat-sb939.html?gclid=CNb_mqrhw8wCFcskhgoduWAHtw|http://www.apexbt.com/pracinostat-sb939.html?gclid=CNb_mqrhw8wCFcskhgoduWAHtw|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=448241|http://www.apexbt.com/pracinostat-sb939.html?gclid=CNb_mqrhw8wCFcskhgoduWAHtw|http://www.apexbt.com/pracinostat-sb939.html?gclid=CNb_mqrhw8wCFcskhgoduWAHtw|http://www.apexbt.com/pracinostat-sb939.html?gclid=CNb_mqrhw8wCFcskhgoduWAHtw|http://www.apexbt.com/pracinostat-sb939.html?gclid=CNb_mqrhw8wCFcskhgoduWAHtw	HDAC inhibitor			
fluvoxamine	fluvoxamine	fluvoxamine maleate|luvox|luvox cr	COCCCC\C(c1ccc(cc1)C(F)(F)F)=N/OCCN	Launched	FDA Orange Book: fluvoxamine maleate	SLC6A4|CYP2C19	https://www.drugbank.ca/drugs/DB00176|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091104	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	obsessive compulsive disorder (OCD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=85b61f83-ab47-470d-8673-02fea29247be
baicalein	baicalein	5,6,7-TRIHYDROXYFLAVONE	Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1	Preclinical		ALOX12|SELP|SELL|ALOX5|TNF|PREP|XDH|GLO1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=203056|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007144|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007144|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007144|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007144|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007144|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007144|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007144	lipoxygenase inhibitor			
YM-750	YM-750		Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/7887979	SOAT1	https://www.tocris.com/dispprod.php?ItemId=190686#.V_P6JJMrLy8	ACAT inhibitor			
acetohydroxamic-acid	acetohydroxamic acid	acetohydroxamic acid|lithostat	CC(=O)NO	Launched	FDA Orange Book: acetohydroxamic acid	MMP12	https://www.drugbank.ca/drugs/DB00551	urease inhibitor	infectious disease	urinary tract infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6660b616-a82d-9109-19ce-2bdf9747acea
gemfibrozil	gemfibrozil	CI-719|lopid	Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1	Launched	FDA Orange Book: gemfibrozil	SLCO2B1|SLCO1B3|SLCO1B1|CYP2C8|PPARA|LPL	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3439|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3439|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3439|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091114|ChEMBL|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000210	lipoprotein lipase activator	endocrinology|cardiology	hyperlipidemia|coronary heart disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1da5a84-7529-4f62-867f-808a6cab40b8|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1da5a84-7529-4f62-867f-808a6cab40b8
IOX1	IOX1		OC(=O)c1ccc(O)c2ncccc12	Preclinical		EGLN1|KDM4A|KDM4C|KDM3A|KDM6B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8230|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=844336|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8230|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8230|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8230	histone demethylase inhibitor			
IOX2	IOX2		OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O	Preclinical		EGLN1|KDM2A|KDM5C	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8229|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8229|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8229	hypoxia inducible factor inhibitor			
guanaben-acetate	guanaben acetate	WY-8678|guanabenz|guanabenz acetate|wytensin	NC(=N)N\N=C\c1c(Cl)cccc1Cl	Launched	FDA Orange Book: guanabenz acetate	ADRA2B|ADRA2C|ADRA2A	https://www.drugbank.ca/drugs/DB00629|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5443|https://www.drugbank.ca/drugs/DB00629	adrenergic receptor agonist	cardiology	hypertension	http://www.drugs.com/pro/guanabenz.html
EO-1428	EO-1428		Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl	Preclinical		MAPK11|MAPK14	http://www.tocris.com/dispprod.php?ItemId=5402|http://www.tocris.com/dispprod.php?ItemId=5402	p38 MAPK inhibitor			
UH-232-(+)	(+)-UH-232		CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C	Preclinical				dopamine receptor antagonist			
CIM-0216	CIM-0216		Cc1cc(NC(=O)C(N2CCCc3ccccc23)c2ccccc2)no1	Preclinical		TRPM3	https://www.tocris.com/products/cim-0216_5521	transient receptor potential channel agonist			
atrasentan	atrasentan	A-127722|Xinlay	CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00036543	EDNRA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3487	endothelin receptor antagonist			
alpha-methylhistamine-dihydrobromide-(S)-(+)	(S)-(+)-alpha-methylhistamine-dihydrobromide		C[C@H](N)Cc1c[nH]cn1	Preclinical				histamine receptor agonist			
A-803467	A-803467		COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1	Preclinical		SCN10A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001572	sodium channel blocker			
AZ3146	AZ3146		COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1	Preclinical				monopolar spindle 1 kinase inhibitor			
ALS-8176	ALS-8176		Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02202356			RNA polymerase inhibitor			
symclosene	symclosene		Cln1c(=O)n(Cl)c(=O)n(Cl)c1=O	Preclinical							
polythiazide	polythiazide	P-2525|renese	CN1C(CSCC(F)(F)F)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O	Launched	FDA Orange Book: polythiazide	SLC12A3	ChEMBL	sodium/chloride cotransporter inhibitor	cardiology|cardiology|gastroenterology|rheumatology|nephrology|nephrology|cardiology	edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure|hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abd6ecf0-dc8e-41de-89f2-1e36ed9d6535|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abd6ecf0-dc8e-41de-89f2-1e36ed9d6535|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abd6ecf0-dc8e-41de-89f2-1e36ed9d6535|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abd6ecf0-dc8e-41de-89f2-1e36ed9d6535|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abd6ecf0-dc8e-41de-89f2-1e36ed9d6535|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abd6ecf0-dc8e-41de-89f2-1e36ed9d6535|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abd6ecf0-dc8e-41de-89f2-1e36ed9d6535
CP-724714	CP-724714		COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00102895	ERBB2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7883	EGFR inhibitor|protein tyrosine kinase inhibitor			
LX1031	LX1031		COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00813098	TPH1	http://www.ncbi.nlm.nih.gov/pubmed/21154152	tryptophan hydroxylase inhibitor			
pergolide	pergolide	permax	CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	KCNA5|HTR2B|HTR2C|HTR2A|HTR1A|HTR1B|HTR1D|ADRA1B|ADRA1A|ADRA1D|ADRA2A|ADRA2C|ADRA2B|DRD4|DRD5|DRD2|DRD3|DRD1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090111|https://www.drugbank.ca/drugs/DB01186|https://www.drugbank.ca/drugs/DB01186|https://www.drugbank.ca/drugs/DB01186|https://www.drugbank.ca/drugs/DB01186|https://www.drugbank.ca/drugs/DB01186|https://www.drugbank.ca/drugs/DB01186|https://www.drugbank.ca/drugs/DB01186|https://www.drugbank.ca/drugs/DB01186|https://www.drugbank.ca/drugs/DB01186|https://www.drugbank.ca/drugs/DB01186|https://www.drugbank.ca/drugs/DB01186|https://www.drugbank.ca/drugs/DB01186|https://www.drugbank.ca/drugs/DB01186|https://www.drugbank.ca/drugs/DB01186|https://www.drugbank.ca/drugs/DB01186|https://www.drugbank.ca/drugs/DB01186|https://www.drugbank.ca/drugs/DB01186	dopamine receptor agonist			
captan	captan	Merpan|Orthocide|Vancide	ClC(Cl)(Cl)SN1C(=O)C2CC=CCC2C1=O	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/21381057						
AK-7	AK-7		Brc1cccc(NC(=O)c2cccc(c2)S(=O)(=O)N2CCCCCC2)c1	Preclinical		SIRT2	https://www.tocris.com/products/ak-7_4754	SIRT inhibitor			
ryuvidine	ryuvidine		Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O	Preclinical		CDK2|CDK4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5952|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5952	histone lysine methyltransferase inhibitor			
acriflavinium	acriflavinium	acriflavine	C[n+]1c2cc(N)ccc2cc2ccc(N)cc12	Launched	http://en.wikipedia.org/wiki/Acriflavinium_chloride	HIF1A	https://en.wikipedia.org/wiki/Acriflavinium_chloride	hypoxia inducible factor inhibitor	infectious disease	fungal infection	https://en.wikipedia.org/wiki/Acriflavinium_chloride
L-asparagine	L-asparagine	asparagine	N[C@@H](CC(N)=O)C(O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00408005	SLC1A5|NARS|NARS2|ASRGL1|SLC38A3|ASNS	https://www.drugbank.ca/drugs/DB00174|https://www.drugbank.ca/drugs/DB00174|https://www.drugbank.ca/drugs/DB00174|https://www.drugbank.ca/drugs/DB00174|https://www.drugbank.ca/drugs/DB00174|https://www.drugbank.ca/drugs/DB00174				
4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine		Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1	Preclinical		HTR2A	http://www.tocris.com/dispprod.php?ItemId=1393#.VeXu0SxVhHw	serotonin receptor antagonist			
sulbactam	sulbactam	CP-45899		Launched	FDA Orange Book: sulbactam sodium			beta lactamase inhibitor	infectious disease|infectious disease|infectious disease	skin infections|intra-abdominal infections|gynecologic infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1edd149e-02ff-4500-ae1d-f3334af39dd6|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1edd149e-02ff-4500-ae1d-f3334af39dd6|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1edd149e-02ff-4500-ae1d-f3334af39dd6
ASP3026	ASP3026	ASP-3026	COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01284192	ALK	https://www.tocris.com/dispprod.php?ItemId=429779#.VyeKKGQrImI	ALK tyrosine kinase receptor inhibitor			
sotalol	sotalol	MJ-1999|Sorine|betapace|betapace af|sotalol hydrochloride|sotylize	CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1	Launched	FDA Orange Book: sotalol hydrochloride	ADRB2|ADRB1|KCNH2	https://www.drugbank.ca/drugs/DB00489|https://www.drugbank.ca/drugs/DB00489|https://www.drugbank.ca/drugs/DB00489	adrenergic receptor antagonist	cardiology|cardiology	atrial fibrillation (AF)|ventricular arrhythmias	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6616d1a2-09a6-429c-8d19-0ac6354980bb&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6616d1a2-09a6-429c-8d19-0ac6354980bb&audience=consumer
hematoporphyrin	hematoporphyrin		CC(O)c1c(C)c2cc3[nH]c(cc4nc(cc5[nH]c(cc1n2)c(C)c5CCC(O)=O)c(CCC(O)=O)c4C)c(C)c3C(C)O	Launched	https://www.drugs.com/international/hematoporphyrin.html				neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	depression|psychosis|psychosis|depression	https://en.wikipedia.org/wiki/Hematoporphyrin|https://en.wikipedia.org/wiki/Hematoporphyrin|https://en.wikipedia.org/wiki/Hematoporphyrin|https://en.wikipedia.org/wiki/Hematoporphyrin
R406	R406		COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC	Phase 1	https://www.fdanews.com/articles/70568-rigel-completes-phase-i-clinical-trial-of-r406-in-rheumatoid-arthritis	IL6|IL2|RET|TNF|SYK|FLT3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=396529|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=396529|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5706|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=396529|https://www.drugbank.ca/drugs/DB07159|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=396529	SYK inhibitor			
chloramphenicol-palmitate	chloramphenicol palmitate	chloromycetin palmitate	CCCCCCCCCCCCCCCC(=O)OC[C@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O	Launched	FDA Orange Book: chloramphenicol palmitate			protein synthesis inhibitor	infectious disease|endocrinology|infectious disease	meningitis|fever|cholera	https://en.wikipedia.org/wiki/Chloramphenicol|https://en.wikipedia.org/wiki/Chloramphenicol|https://en.wikipedia.org/wiki/Chloramphenicol
cycloheximide	cycloheximide	GNF-Pf-5118|NSC-171|TCMDC-125838|cicloheximide	C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1	Preclinical		GSK3B|RPL3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=281473|http://en.wikipedia.org/wiki/Cycloheximide	protein synthesis inhibitor			
PJ-34	PJ-34	PJ34	CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1	Preclinical		EEF2|PARP15|PARP3|PARP1	https://www.drugbank.ca/drugs/DB08348|https://www.drugbank.ca/drugs/DB08348|https://www.drugbank.ca/drugs/DB08348|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001128	PARP inhibitor			
etidronic-acid	etidronic acid	Etidronate|cintichem technetium 99m hedspa|didronel|etidronic acid|mpi stannous diphosphonate|osteoscan|technetium tc 99m diphosphonate-tin kit	CC(O)(P(O)(O)=O)P(O)(O)=O	Launched	FDA Orange Book: etidronate disodium, technetium tc-99m etidronate kit	FDPS|ATP6V1A|PTPRS	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=102157|https://www.drugbank.ca/drugs/DB01077|https://www.drugbank.ca/drugs/DB01077	bone resorption inhibitor	endocrinology|orthopedics	Paget's disease|heterotopic ossification	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dcbd076e-3989-4cae-9466-54a0e9118128|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dcbd076e-3989-4cae-9466-54a0e9118128
amrubicin	amrubicin		CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1	Launched	https://www.drugs.com/international/amrubicin.html	TOP2B|TOP2A	http://www.genome.jp/kegg-bin/ddi_list?drug=D08854|http://www.genome.jp/kegg-bin/ddi_list?drug=D08854	topoisomerase inhibitor	oncology|oncology	small cell lung cancer|small cell lung cancer	http://www.nature.com/articles/srep18999|http://www.nature.com/articles/srep18999
PACOCF3	PACOCF3		CCCCCCCCCCCCCCCC(=O)C(F)(F)F	Preclinical		PLA2G4A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009575	phospholipase inhibitor			
AZ-628	AZ-628		Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1	Preclinical		RAF1|BRAF	http://www.selleckchem.com/products/az628.html|http://www.selleckchem.com/products/az628.html	RAF inhibitor			
acecainide	acecainide	N-Acetyl Procainamide(<30%)	CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/1693889	SCN5A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000146	polarization inhibitor			
stigmasterol	stigmasterol		CC[C@H](\C=C\[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C	Preclinical							
adiphenine	adiphenine		CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1	Launched	http://www.drugs.com/international/adiphenine.html	CHRNA1	https://en.wikipedia.org/wiki/Adiphenine	acetylcholine receptor antagonist	neurology/psychiatry	spasms	http://www.merriam-webster.com/medical/adiphenine
MM-102	MM-102		CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(c1ccc(F)cc1)c1ccc(F)cc1	Preclinical				WDR5/MLL interaction inhibitor			
piclamilast	piclamilast	RP 73401|RP-73041|RP-73401	COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl	Phase 2	http://newdrugapprovals.org/2014/03/19/piclamilast/	PDE4C|PDE4D|PDE4A|PDE4B	https://www.drugbank.ca/drugs/DB01791|https://www.drugbank.ca/drugs/DB01791|https://www.drugbank.ca/drugs/DB01791|https://www.drugbank.ca/drugs/DB01791	phosphodiesterase inhibitor			
mefexamide	mefexamide		CCN(CC)CCNC(=O)COc1ccc(OC)cc1	Preclinical				psychoactive drug			
SKF-86002	SKF-86002	SK&F-86002|SK-86002	Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1	Preclinical		MAPK14|ALOX5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6040|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001335	p38 MAPK inhibitor			
deserpidine	deserpidine	harmonyl|recanescin	CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1	Launched	FDA Orange Book: deserpidine	ACE|SLC18A2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000909|ChEMBL	angiotensin converting enzyme inhibitor	cardiology	hypertension	https://en.wikipedia.org/wiki/Deserpidine
mesulergine	mesulergine		CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/3517235	HTR3B|HTR3A|HTR2C|HTR2A|HTR2B|HTR7|HTR6	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005817|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005817|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=206|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=206|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=206|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=206|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=206	dopamine receptor agonist			
T-0901317	T-0901317	T0901317|T091317	OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F	Preclinical		RORA|RORC|ABCA1|RXRB|NR1H2|NR1H3|NR1I2|NCOA2|NCOA1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=301638|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=301638|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=301638|https://www.drugbank.ca/drugs/DB07080|https://www.drugbank.ca/drugs/DB07080|https://www.drugbank.ca/drugs/DB07080|https://www.drugbank.ca/drugs/DB07080|https://www.drugbank.ca/drugs/DB07080|https://www.drugbank.ca/drugs/DB07080	LXR agonist			
monostearin	monostearin	EASTMAN 600|glyceryl monostearate	CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO	Preclinical							
PF-04447943	PF-04447943		C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc2n(ncc2c(=O)[nH]1)C1CCOCC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00930059	PDE9A	http://www.axonmedchem.com/product/2148	phosphodiesterase inhibitor			
rosuvastatin	rosuvastatin	crestor	CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O	Launched	FDA Orange Book: rosuvastatin calcium	HMGCR	https://www.drugbank.ca/drugs/DB01098	HMGCR inhibitor	endocrinology|cardiology|endocrinology|endocrinology|cardiology	hyperlipidemia|dyslipidemia|hypertriglyceridemia|hypercholesterolemia|atherosclerosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ff30eb1-95a6-437e-a618-297891c0c03d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ff30eb1-95a6-437e-a618-297891c0c03d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ff30eb1-95a6-437e-a618-297891c0c03d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ff30eb1-95a6-437e-a618-297891c0c03d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ff30eb1-95a6-437e-a618-297891c0c03d
cinnamaldehyde	cinnamaldehyde		O=CC=Cc1ccccc1	Preclinical		TRPA1|AKR1B1	http://www.cell.com/biophysj/abstract/S0006-3495(13)03137-8|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=322387	aldose reductase inhibitor|TRPV agonist			
altiratinib	altiratinib	DCC-2701|DP-5164	Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1	Phase 1	http://www.paradigmdx.com/paradigm-announces-molecular-profiling-collaboration-for-study-of-altiratinib-in-genomically-defined-cancer-patients/	KDR|MET|TEK	http://www.ncbi.nlm.nih.gov/pubmed/26285778|http://www.ncbi.nlm.nih.gov/pubmed/26285778|http://www.ncbi.nlm.nih.gov/pubmed/26285778	VEGFR inhibitor|MET inhibitor			
telotristat-ethyl	telotristat-ethyl		CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1	Launched	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f11c21f8-f725-445e-b38e-1e4c5b05bcc6	TPH1	http://www.lexpharma.com/pipeline/telotristat-etiprate.html	tryptophan hydroxylase inhibitor	gastroenterology	diarrhea	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f11c21f8-f725-445e-b38e-1e4c5b05bcc6
benazepril	benazepril	Lotrel|lotensin	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O	Launched	FDA Orange Book: benazepril hydrochloride	ACE	https://www.drugbank.ca/drugs/DB00542	angiotensin converting enzyme inhibitor	cardiology	hypertension	http://www.drugs.com/cdi/benazepril.html
gamma-linolenic-acid	gamma-linolenic acid	gamolenic acid	CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/12121728	PTGS1|PTGS2|TBXAS1	http://www.drugbank.ca/drugs/DB00154|http://www.drugbank.ca/drugs/DB00154|https://citeline.informa.com/?query=#/drugs/details/7856	cyclooxygenase inhibitor|prostanoid receptor agonist			
eucalyptol	eucalyptol		CC12CCC(CC1)C(C)(C)O2	Launched	http://www.drugs.com/international/eucalyptol.html	ACHE	http://www.ncbi.nlm.nih.gov/pubmed/15025863	acetylcholinesterase inhibitor	dental	gingivitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db61a617-849e-45e8-940b-3b39ddf78209
reversan	reversan		O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1	Preclinical		ABCC1	https://www.tocris.com/products/reversan_3722	MRP inhibitor			
BRL-50481	BRL-50481		CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O	Preclinical		PDE7A|PDE7B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5154|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5154	phosphodiesterase inhibitor			
famotidine	famotidine	MK-208|Pepcid ac (geltab)|famotidine preservative free|fluxid|pepcid|pepcid ac|pepcid ac |pepcid preservative free|pepcid rpd	NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1	Launched	FDA Orange Book: famotidine	HRH2	ChEMBL	histamine receptor antagonist	gastroenterology	heartburn	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7935672-75f3-4378-99c1-63097ffd329e
STF-31	STF-31		CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1	Preclinical		SLC2A1|NAMPT	https://www.tocris.com/products/stf-31_4484|https://www.tocris.com/products/stf-31_4484	NAMPT inhibitor			
hematoxylin	hematoxylin		Oc1cc2C[C@@]3(O)COc4c(ccc(O)c4O)[C@H]3c2cc1O	Preclinical							
mebrofenin	mebrofenin	SQ 26962	Cc1cc(C)c(NC(=O)CN(CC(O)=O)CC(O)=O)c(C)c1Br	Launched	FDA Orange Book: technetium tc-99m mebrofenin kit				radiology	diagnostic agent	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aeefa6ee-f45c-49fe-b38e-6cfd99a33030
FPS-ZM1	FPS-ZM1		Clc1ccc(cc1)C(=O)N(Cc1ccccc1)C1CCCCC1	Preclinical		AGER	https://www.emdmillipore.com/US/en/product/RAGE-Antagonist,-FPS-ZM1---Calbiochem,EMD_BIO-553030	RAGE receptor antagonist			
decamethonium	decamethonium	syncurine	C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C	Launched	FDA Orange Book: decamethonium bromide	CHRNA2|ACHE	https://www.drugbank.ca/drugs/DB01245|https://www.drugbank.ca/drugs/DB01245	acetylcholine receptor agonist	neurology/psychiatry	muscle relaxant	https://en.wikipedia.org/wiki/Decamethonium
ZD-7114	ZD-7114		COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/11126205	ADRB3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001536	adrenergic receptor agonist			
TCS-2210	TCS-2210		ONC(=O)c1ccc2[nH]c(=O)c(CCCc3ccccc3)nc2c1	Preclinical				neural stem cell inducer			
GPi-688	GPi-688		OC[C@H](O)CN1C(=O)C(Cc2ccccc12)NC(=O)c1cc2cc(Cl)sc2[nH]1	Preclinical				glycogen phosphorylase inhibitor			
actarit	actarit		CC(=O)Nc1ccc(CC(O)=O)cc1	Launched	http://en.wikipedia.org/wiki/Actarit			interleukin receptor agonist	rheumatology	rheumatoid arthritis	https://en.wikipedia.org/wiki/Actarit
TCS-3035	TCS-3035		OC(=O)COc1ccc(cc1)\C=C1/SC(=O)NC1=O	Preclinical		GPR35	https://www.tocris.com/products/tcs-3035_4244	G protein-coupled receptor agonist			
nitrosodimethylurea	nitrosodimethylurea		CNC(=O)N(C)[N+][O-]	Preclinical				DNA synthesis inhibitor			
dihydrexidine	dihydrexidine	Rel-Dihydrexidine	Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01466205	DRD2|DRD1|DRD5|DRD4|DRD3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010201|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010201|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010201|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010201|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010201	dopamine receptor agonist			
siramesine	siramesine		Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/11816842	SIGMAR1|PGRMC1|ADRA1D|ADRA1A|ADRA1B	https://citeline.informa.com/?query=#/drugs/details/10588|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=188408|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012651|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012651|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012651	sigma receptor antagonist			
PTC-209	PTC-209		COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1	Preclinical				BMI-1 inhibitor			
cloranolol	cloranolol		CC(C)(C)NCC(O)COc1cc(Cl)ccc1Cl	Launched	https://www.whocc.no/atc_ddd_index/?code=C07AA27&showdescription=yes	ADRB3|ADRB2|ADRB1	http://www.genome.jp/dbget-bin/www_bget?dr:D07183|http://www.genome.jp/dbget-bin/www_bget?dr:D07183|http://www.genome.jp/dbget-bin/www_bget?dr:D07183	adrenergic receptor antagonist			
CK-636	CK-636		Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1	Preclinical		ARPC1B|ARPC2|ARPC5|ARPC3|ARPC4|ACTR2|ACTR3	https://www.drugbank.ca/drugs/DB08235|https://www.drugbank.ca/drugs/DB08235|https://www.drugbank.ca/drugs/DB08235|https://www.drugbank.ca/drugs/DB08235|https://www.drugbank.ca/drugs/DB08235|https://www.drugbank.ca/drugs/DB08235|https://www.drugbank.ca/drugs/DB08235	actin related protein inhibitor			
abafungin	abafungin		Cc1ccc(Oc2ccccc2-c2csc(N=C3NCCCN3)n2)c(C)c1	Phase 3	https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-002112-26/HU			sterol methyltransferase inhibitor			
argatroban	argatroban		C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)c1cccc2CC(C)CNc12	Launched	FDA Orange Book: argatroban	F2|CYP3A5	https://www.drugbank.ca/drugs/DB00278|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090744	thrombin inhibitor	hematology	heparin-induced thrombocytopenia (HIT)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35db0a86-76af-4f5e-a5c6-0a664f53f6da
mibampator	mibampator	LY451395	CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00843518	GRIA1	http://www.medchemexpress.com/ly451395.html	glutamate receptor modulator			
flumequine	flumequine	Apurone	CC1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O	Launched	http://www.drugs.com/international/Flumequine.html			topoisomerase inhibitor	infectious disease	urinary tract infections	https://en.wikipedia.org/wiki/Flumequine
amidopyrine	amidopyrine	aminophenazone|aminopyrine	CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O	Launched	http://archinte.jamanetwork.com/article.aspx?articleid=537928			analgesic agent	dermatology	dermatitis herpetiformis (DH)	http://www.abcam.com/amidopyrine-aminophenazone-ab143347.html
ABT-702	ABT-702		Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1	Preclinical		ADK	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5131	adenosine kinase inhibitor			
metitepine	metitepine	methiothepin	CSc1ccc2Sc3ccccc3CC(N3CCN(C)CC3)c2c1	Preclinical		HTR5A|HTR1E|HTR1D|HTR1F|HTR1A|HTR1B|HTR2B|HTR2A|HTR2C|HTR6|HTR7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=89|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=89|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=89|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=89|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=89|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=89|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=89|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=89|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=89|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=89|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=89	anti-HCVE2			
savolitinib	savolitinib		C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1	Phase 2	http://www.chi-med.com/savolitinib-global-phase-ii-trial-initiated-in-egfr-mutant-non-small-cell-lung-cancer/	MET	http://www.pharmaceutical-technology.com/news/newsastrazeneca-chi-med-amend-agreement-savolitinib-treat-several-cancers-4966666	c-Met inhibitor			
AZD8835	AZD8835	AZD-8835	CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02260661	PIK3CA|PIK3CD	http://openinnovation.astrazeneca.com/what-we-offer/compound/azd8835/|http://openinnovation.astrazeneca.com/what-we-offer/compound/azd8835/	PI3K inhibitor			
CRT0044876	CRT0044876		OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1	Preclinical							
chlorpropamide	chlorpropamide	diabinese|glucamide	CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1	Launched	FDA Orange Book: chlorpropamide	ABCC8|KCNJ11|KCNJ10	ChEMBL|ChEMBL|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000923	ATP channel blocker	endocrinology	diabetes mellitus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=baa54287-8065-da1a-f19e-ce8daf61bd01
pitavastatin	pitavastatin	itavastatin|livalo	O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O	Launched	FDA Orange Book: pitavastatin calcium	HMGCR|APOA1|CYP2C8	https://www.drugbank.ca/drugs/DB08860|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=192009|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=192009	HMGCR inhibitor	endocrinology	hyperlipidemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3c41a2f-da77-4465-8af6-038006a7ea58
iohexol	iohexol	Exypaque|WIN 39424|WIN-39424|omnipaque|omnipaque 140|omnipaque 180|omnipaque 210|omnipaque 240|omnipaque 300|omnipaque 350|omnipaque 70|oraltag	CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I	Launched	FDA Orange Book: iohexol			radiopaque medium	radiology	contrast agent	https://en.wikipedia.org/wiki/Iohexol
RGFP966	RGFP966		Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1	Preclinical		HDAC3|HDAC1|HDAC2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7500|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=787460|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=787460	HDAC inhibitor			
guanethidine	guanethidine	Esimil|ismelin	NC(=N)NCCN1CCCCCCC1	Launched	FDA Orange Book: guanethidine monosulfate	SLC6A2	https://www.drugbank.ca/drugs/DB01170	adrenergic inhibitor	cardiology	hypertension	https://en.wikipedia.org/wiki/Guanethidine
SD-2590	SD-2590		COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1	Preclinical		MMP8|MMP9|MMP2|MMP1|MMP3|MMP14|MMP13	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=711143|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=711143|https://www.tocris.com/products/sd-2590-hydrochloride_4775|https://www.tocris.com/products/sd-2590-hydrochloride_4775|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=711143|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=711143|https://www.tocris.com/products/sd-2590-hydrochloride_4775	matrix metalloprotease inhibitor			
fenofibric-acid	fenofibric acid	Fenocor-67|Fenogal|Lipanthyl|Lipofen|Lofibra|Supralip|Trilipix|fenofibric acid|fibricor	CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O	Launched	FDA Orange Book: fenofibric acid	CLCN1|PPARA|CYP2C8|CYP2C19	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2662|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=330232|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=330232	cytochrome P450 inhibitor	cardiology	dyslipidemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3152797a-4bfd-4a5d-9ed2-037e79416842
dexrazoxane	dexrazoxane	ADR-529|ICRF-187|totect|zinecard	C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1	Launched	FDA Orange Book: dexrazoxane hydrochloride	TOP2B|TOP2A	https://www.drugbank.ca/drugs/DB00380|https://www.drugbank.ca/drugs/DB00380	chelating agent|topoisomerase inhibitor	cardiology	cardiomyopathy	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77702d60-d1ea-4e4c-a837-aaa813b66064
centpropazine	centpropazine		CCC(=O)c1ccc(OCC(O)CN2CCN(CC2)c2ccccc2)cc1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/21455398			inositol monophosphatase inhibitor			
lorcaserin	lorcaserin	belviq	C[C@H]1CNCCc2ccc(Cl)cc12	Launched	FDA Orange Book: lorcaserin hydrochloride	HTR2C|HTR2B|HTR2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2941|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2941|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2941	serotonin receptor agonist	endocrinology	obesity	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7cbbb12f-760d-487d-b789-ae2d52a3e01f
medroxyprogesterone	medroxyprogesterone		C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12	Launched	FDA Orange Book: medroxyprogesterone acetate	ESR1|PGR	https://www.drugbank.ca/drugs/DB00603|https://www.drugbank.ca/drugs/DB00603	progesterone receptor agonist	endocrinology	contraceptive	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=428481bb-b7cf-4d76-b57d-0d6bfa2b6ac3
ethenzamide	ethenzamide	etenzamide	CCOc1ccccc1C(N)=O	Launched	http://www.drugs.com/international/ethenzamide.html			analgesic agent	neurology/psychiatry|endocrinology|otolaryngology	headache|fever|common cold	https://en.wikipedia.org/wiki/Ethenzamide|https://en.wikipedia.org/wiki/Ethenzamide|https://en.wikipedia.org/wiki/Ethenzamide
7-keto-DHEA	7-keto-DHEA		CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3C(=O)C=C2C1	Launched	http://www.webmd.com/vitamins-supplements/ingredientmono-835-7-KETO-DHEA.aspx?activeIngredientId=835&activeIngredientName=7-KETO-DHEA&source=2			steroid			
acriflavine	acriflavine		Nc1ccc2cc3ccc(N)cc3nc2c1.C[n+]1c2cc(N)ccc2cc2ccc(N)cc12	Launched	http://www.druginfosys.com/drug.aspx?drugcode=782&type=1	HIF1A	http://www.pnas.org/content/106/42/17910.full	hypoxia inducible factor inhibitor	infectious disease	fungal infection	https://en.wikipedia.org/wiki/Acriflavine
erythrosine	erythrosine	erythrosin b|tetraidofluorescein	OC(=O)c1ccccc1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12	Preclinical				coloring agent			
naloxegol	naloxegol	NKTR-118|movantik	COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC=C)c45	Launched	FDA Orange Book: naloxegol oxalate	OPRM1	https://www.movantikhcp.com/	opioid receptor antagonist	gastroenterology	constipation	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f49c6978-ca7b-4a66-919b-757f8f92ef64
phenytoin	phenytoin	Dilabid|Hydantol|Phentytoin|Phenytex|dilantin|dilantin-125|dilantin-30|diphenylhydantoin|phenytek|phenytoin sodium	O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1	Launched	FDA Orange Book: fosphenytoin sodium, mephenytoin, phenytoin, phenytoin sodium	CYP2C19|SCN4A|SCN3A|SCN2A|SCN1A|SCN8A|SCN7A|SCN5A|SCN9A|CYP3A4|CYP2B6|SCN10A|SCN11A|ABCB1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091452|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091452|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091452|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091452	hydantoin antiepileptic	neurology/psychiatry	seizures	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e467c02-49a0-4b62-b537-430fdfa4f10e
EIPA	EIPA		CCN(C(C)C)c1nc(N)c(nc1Cl)C(=O)N=C(N)N	Preclinical		ASIC1|ADRA2A|PKD2L1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4186|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4186|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4186	transient receptor potential polycystic inhibitor|sodium/hydrogen exchanger inhibitor			
neohesperidin-dihydrochalcone	neohesperidin-dihydrochalcone		COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O	Preclinical							
tipiracil	tipiracil	MA-1|tpi (freebase)	Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O	Launched	http://en.wikipedia.org/wiki/Tipiracil	TYMP	https://www.drugbank.ca/drugs/DB02631	thymidine phosphorylase inhibitor	oncology	colorectal cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5beed22-d71d-4c0d-8dca-2c7317d65d85&audience=consumer
bromosporine	bromosporine		CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1	Preclinical				bromodomain inhibitor			
trioxsalen	trioxsalen	trioxysalen|trisoralen	Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1	Launched	FDA Orange Book: trioxsalen			DNA synthesis inhibitor	dermatology|dermatology	vitiligo|eczema	https://en.wikipedia.org/wiki/Trioxsalen|https://en.wikipedia.org/wiki/Trioxsalen
pinitol	pinitol		COC1C(O)[C@@H](O)C(O)C(O)[C@H]1O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01928420			gamma secretase inhibitor			
colistimethate	colistimethate	coly-mycin m		Launched	FDA Orange Book: colistimethate sodium			bacterial permeability inducer	infectious disease	gram-negative bacterial infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dddcd6e6-09dd-4523-802e-21765e7abb5d
piretanide	piretanide	HOE 118|S 73 4118|arlix	NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O	Launched	http://www.drugs.com/international/Piretanide.html	SLC12A1|SLC12A2	https://www.drugbank.ca/drugs/DB02925|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4742	glucocorticoid receptor agonist	cardiology|cardiology	hypertension|edema	http://www.drugs.com/international/piretanide.html|http://www.drugs.com/international/piretanide.html
caroxazone	caroxazone		NC(=O)CN1Cc2ccccc2OC1=O	Withdrawn	https://en.wikipedia.org/wiki/Caroxazone	MAOA|MAOB	https://en.wikipedia.org/wiki/Caroxazone|https://en.wikipedia.org/wiki/Caroxazone	monoamine oxidase inhibitor			
sulfafurazole	sulfafurazole	Entusil|Eryzole|Neazolin|Pediazole|Sosol|Soxazole|Sulfalar|Sulsoxin|gantrisin|sulfisoxazole|sulphafurazole	Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C	Launched	FDA Orange Book: sulfisoxazole, sulfisoxazole acetyl, sulfisoxazole diolamine			bacterial antifolate	infectious disease	urinary tract infections	http://www.drugs.com/international/sulfafurazole.html
enzastaurin	enzastaurin	LY-317615	Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00332202	AKT1|GSK3B|PRKCG|PRKCD|PRKCB|PRKCA	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000109|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000109|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5693|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5693|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5693|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5693	PKC inhibitor			
amisulpride	amisulpride		CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC	Launched	http://www.drugs.com/international/Amisulpride.html	DRD2|DRD3|HTR7|HTR2A	https://www.drugbank.ca/drugs/DB06288|https://www.drugbank.ca/drugs/DB06288|https://www.drugbank.ca/drugs/DB06288|https://www.drugbank.ca/drugs/DB06288	dopamine receptor antagonist	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	psychosis|bipolar disorder|schizophrenia	https://en.wikipedia.org/wiki/Amisulpride|https://en.wikipedia.org/wiki/Amisulpride|https://en.wikipedia.org/wiki/Amisulpride
azaserine	azaserine		NC(COC(=O)C=[N+]=[N-])C(O)=O	Preclinical				purine antagonist			
pinaverium	pinaverium		COc1cc(Br)c(C[N+]2(CCOCCC3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)cc1OC	Launched	https://clinicaltrials.gov/ct2/show/NCT02173964	CACNA1C	http://www.ncbi.nlm.nih.gov/pubmed/9360010	T-type calcium channel blocker	gastroenterology	irritable bowel syndrome	http://www.medicinenet.com/pinaverium-oral/article.htm
UK-356618	UK-356618		C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1	Preclinical		MMP14|MMP13|MMP9|MMP2|MMP3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003632|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003632|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003632|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003632|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6528	metalloproteinase inhibitor			
lufenuron	lufenuron		FC(C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl	Veterinary Launched	http://www.drugs.com/international/lufenuron.html			chitin inhibitor	infectious disease	flea control	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7388680b-5c63-4e55-9627-23da2f73e536
daclatasvir	daclatasvir	BMS-790052|daklinza	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C	Launched	http://en.wikipedia.org/wiki/Daclatasvir			HCV inhibitor	infectious disease	hepatitis C	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9803a6ff-8a3e-4c64-b3d0-7825c7123bf2
CHIR-99021	CHIR-99021		Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl	Preclinical		MAPK1|GSK3A|GSK3B|CDK1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8014|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8014|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8014|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8014	glycogen synthase kinase inhibitor			
WAY-100635	WAY-100635	WAY-100,635	COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/18362913	HTR1A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=80	serotonin receptor antagonist			
RG4733	RG4733		CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O	Phase 2	https://www.clinicaltrials.gov/show/NCT01070927	PSEN1|NOTCH1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7338|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=400333	gamma secretase inhibitor			
SB-203580	SB-203580		CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1	Preclinical		MAPK1|MAPK8|MAPK9|SGK1|SRC|RAF1|PRKCA|TNF|RPS6KB1|ROCK1|CHEK1|RIPK2|GSK3B|GAK|CYP2D6|CYP3A4|ALOX5|AKT1|MAPK14|MAPK12|MAPK11|MAPK10|LCK	https://www.drugbank.ca/drugs/DB08521|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003726|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003726|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003726|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003726|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003726|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003726|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003726|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003726|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003726|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003726|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003726|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003726|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5269|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003726|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003726|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003726|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003726|https://www.drugbank.ca/drugs/DB08521|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003726|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5269|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003726|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003726	p38 MAPK inhibitor			
cibenzoline	cibenzoline		C1C(=C2NCCN2)C1(c1ccccc1)c1ccccc1	Launched	https://www.drugs.com/international/cibenzoline.html			sodium channel blocker			
gallium-triquinolin-8-olate	gallium-triquinolin-8-olate		O([Ga](Oc1cccc2cccnc12)Oc1cccc2cccnc12)c1cccc2cccnc12	Phase 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371751						
gadobutrol	gadobutrol	gadavist	OCC(O)[C@@H](CO)N1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C3)OC(=O)C2	Launched	FDA Orange Book: gadobutrol			radiopaque medium	radiology	MRI contrast agent	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c5101a0-0c7e-4078-8dc3-a57beb9a0e92
mezlocillin	mezlocillin	mezlin	CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O	Launched	FDA Orange Book: mezlocillin sodium monohydrate			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	http://www.drugbank.ca/drugs/DB00948|http://www.drugbank.ca/drugs/DB00948
AZ5104	AZ5104		COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1c[nH]c2ccccc12	Preclinical		EGFR	https://www.caymanchem.com/product/17994	EGFR inhibitor			
melevodopa	melevodopa			Launched	http://adisinsight.springer.com/drugs/800002239	DDC	http://www.medicatione.com/?c=drug&s=levomet&ingredient=carbidopa/levodopa	dopamine precursor|dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease	http://www.drugs.com/international/melevodopa.html
SHA-68	SHA-68		Fc1ccc(CNC(=O)N2CCN3C(C2)C(OC3=O)(c2ccccc2)c2ccccc2)cc1	Preclinical		NPSR1	https://www.tocris.com/products/sha-68_4510	neuropeptide receptor antagonist			
cabagin	cabagin		C[S+](C)CC[C@H](N)C(O)=O	Launched	http://www.drugs.com/international/cabagin-u.html				gastroenterology	dyspepsia	http://hc.kowa.co.jp/en/otc/66
PRX-08066	PRX-08066		Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00345774	HTR2B	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000938	serotonin receptor antagonist			
sulfaphenazole	sulfaphenazole	Sulfafenazol|sulfabid|sulphaphenazole	Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1	Launched	FDA Orange Book: sulfaphenazole	DHPS	http://www.drugbank.ca/drugs/DB06729	dihydropteroate synthetase inhibitor	infectious disease	urinary tract infections	http://www.drugs.com/international/sulfaphenazole.html
BLU9931	BLU9931		COc1cc(OC)c(Cl)c(-c2ccc3nc(Nc4c(C)cccc4NC(=O)C=C)ncc3c2)c1Cl	Preclinical		FGFR4	http://www.ncbi.nlm.nih.gov/pubmed/25776529	FGFR inhibitor			
oxymetholone	oxymetholone	anadrol-50		Launched	FDA Orange Book: oxymetholone	AR	https://en.wikipedia.org/wiki/Oxymetholone	androgen receptor agonist	hematology	anemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b9c6c34-9cb2-4d70-b70e-c7ce2fda4212
bedaquiline	bedaquiline	R-207910|TMC207|sirturo	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12	Launched	FDA Orange Book: bedaquiline fumarate			ATPase inhibitor	infectious disease	tuberculosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1534c9ae-4948-4cf4-9f66-222a99db6d0e
VU0238429	VU0238429		COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1	Preclinical		CHRM5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3257	acetylcholine receptor allosteric modulator			
INCA-6	INCA-6		O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12	Preclinical		NFATC1	http://www.tocris.com/dispprod.php?ItemId=113687#.UtgQ2f15mf0	calcineurin inhibitor			
PI3K-IN-2	PI3K-IN-2		Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02669511	MTOR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=695920	PI3K inhibitor			
carbadox	carbadox	GS-6244|mecadox	COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-]	Veterinary Launched	http://en.wikipedia.org/wiki/Carbadox			other antibiotic	infectious disease|gastroenterology	dysentry|enteritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df49e55f-c531-4ac8-8dc2-58dbb3291cdf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df49e55f-c531-4ac8-8dc2-58dbb3291cdf
LOXO-101	LOXO-101		O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02576431	NTRK1|NTRK2|NTRK3	https://www.medchemexpress.com/loxo-101.html?gclid=CLSm_frLpNICFQgJaQodV50HwQ|https://www.medchemexpress.com/loxo-101.html?gclid=CLSm_frLpNICFQgJaQodV50HwQ|https://www.medchemexpress.com/loxo-101.html?gclid=CLSm_frLpNICFQgJaQodV50HwQ	tropomyosin receptor kinase inhibitor			
pregnenolone-succinate	pregnenolone-succinate		CC(=O)[C@H]1CCC2C3CC=C4C[C@H](CC[C@]4(C)C3CC[C@]12C)OC(=O)CCC(O)=O	Preclinical				GABA receptor negative allosteric modulator			
SGC-707	SGC-707		O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1	Preclinical		PRMT3	https://www.tocris.com/products/sgc-707_5367	protein arginine N-methyltransferase inhibitor			
FH1	FH1	FH1(BRD-K4477)	CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1	Preclinical				hepatocyte function enhancer			
ixazomib-citrate	ixazomib-citrate	MLN-9708	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)CC(CC(O)=O)(O1)C(O)=O	Launched	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf			proteasome inhibitor	hematologic malignancy	multiple myeloma	https://en.wikipedia.org/wiki/Ixazomib
swainsonine	swainsonine	tridolgosir	O[C@@H]1CN2CCC[C@@H](O)[C@@H]2[C@@H]1O	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/16034517	MAN2A1	https://www.drugbank.ca/drugs/DB02034	alpha mannosidase inhibitor			
SNX-2112	SNX-2112		CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1	Phase 1	Pharmaprojects			HSP inhibitor			
aloperine	aloperine		C1CCN2C[C@H]3C[C@H](C=C4CCCN[C@@H]34)[C@H]2C1	Preclinical							
U-75799E	U-75799E		C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/2026752	GH1|GHSR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=143690|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1093	growth hormone releasing factor agonist			
uric-acid	Uric Acid	Uric Acid	O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/24703208	PYGL	https://www.drugbank.ca/drugs/DB08844				
rheochrysidin	rheochrysidin	Physcion	COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1	Preclinical		PTPN1|IL6	http://www.ncbi.nlm.nih.gov/pubmed/22449699|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=439598	protein tyrosine kinase inhibitor			
retinyl-acetate	Retinyl Acetate	Retinyl Acetate	CC(=O)OC\C=C(C)\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C	Launched	http://en.wikipedia.org/wiki/Retinyl_acetate						
guaifenesin	guaifenesin	Amonidron|Gecolate|Glycerol Guaiacolate|Humabid|Robitussin|glyceryl guaiacolate|guaiacol glyceryl ether|guaiphenesin|methphenoxydiol|mucinex	COc1ccccc1OCC(O)CO	Launched	FDA Orange Book: guaifenesin			expectorant	pulmonary	cough suppressant	https://en.wikipedia.org/wiki/Guaifenesin#Medical_uses
floxuridine	floxuridine	fudr		Launched	FDA Orange Book: floxuridine	TYMS	https://www.drugbank.ca/drugs/DB00322	DNA synthesis inhibitor	oncology	colorectal cancer	https://en.wikipedia.org/wiki/Floxuridine
ML-9	ML-9		Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1	Preclinical		TRPC6	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4256	myosin light chain kinase inhibitor			
apixaban	apixaban	BMS-562247|BMS-562247-01|eliquis	COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O	Launched	FDA Orange Book: apixaban	F10|CYP2C8|CYP2J2|CYP2C19	ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=404724|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=404724|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=404724	coagulation factor inhibitor	neurology/psychiatry|hematology|hematology|cardiology|hematology	stroke|systemic embolism|pulmonary embolism (PE)|atrial fibrillation (AF)|deep vein thrombosis (DVT)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0
JNJ-42041935	JNJ-42041935		OC(=O)c1cnn(c1)-c1nc2cc(Cl)c(OC(F)(F)F)cc2[nH]1	Preclinical		PDK2	https://www.caymanchem.com/product/14316	hypoxia inducible factor prolyl hydroxylase inhibitor			
DMH4	DMH4		C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1	Preclinical		KDR	https://www.tocris.com/products/dmh4_4471	VEGFR inhibitor			
DMH1	DMH1		CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12	Preclinical		ACVR1	http://www.tocris.com/dispprod.php?ItemId=282756#.VfmyINNViko	ALK tyrosine kinase receptor inhibitor			
altrenogest	altrenogest		C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(O)CC=C	Veterinary Launched	http://www.drugs.com/international/Altrenogest.html	PGR	http://en.wikipedia.org/wiki/Altrenogest	progestogen hormone	endocrinology	estrus	https://en.wikipedia.org/wiki/Altrenogest
letosteine	letosteine		CCOC(=O)CSCCC1NC(CS1)C(O)=O	Launched	http://www.ndrugs.com/?s=viscotiol			mucolytic agent	pulmonary|infectious disease	bronchitis|pneumonia	http://www.drugbank.ca/drugs/DB08939|http://www.drugbank.ca/drugs/DB08939
carmoterol	carmoterol	CHF 4226|TA-2005	COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c3nc(O)ccc23)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00640484	ADRB2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000740	adrenergic receptor agonist			
N-methylpyrrolidone	N-methylpyrrolidone	N-Methyl Pyrrolidinone	CN1CCCC1=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02468687						
lumefantrine	lumefantrine	GNF-Pf-1971	CCCCN(CCCC)CC(O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12	Launched	FDA Orange Book: lumefantrine	ATP1A1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001491	antimalarial agent	infectious disease	malaria	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7866ec19-dfac-47d4-a53f-511a12643cbf
caffeic-acid	Caffeic acid	Caffeic acid|trans-Caffeate	OC(=O)\C=C\c1ccc(O)c(O)c1	Preclinical		TNF|ALOX5|MIF	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=340863|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000378|https://www.drugbank.ca/drugs/DB01880	HIV integrase inhibitor|lipoxygenase inhibitor|nitric oxide production inhibitor|tumor necrosis factor production inhibitor			
metamizole	metamizole	dipyrone	CN(CS(O)(=O)=O)c1c(C)n(C)n(-c2ccccc2)c1=O	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	PTGS1	https://www.drugbank.ca/drugs/DB04817	cyclooxygenase inhibitor|opioid receptor agonist			
mafenide	mafenide	4-HOMOSULFANILAMIDE|sulfamylon	NCc1ccc(cc1)S(N)(=O)=O	Launched	FDA Orange Book: mafenide acetate	CA12|CA14|CA6|CA4|CA9|CA2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004886|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004886|https://www.drugbank.ca/drugs/DB06795|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004886|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004886|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004886	carbonic anhydrase inhibitor	infectious disease|infectious disease	first-aid antibiotic|skin infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e48cc935-2058-48c0-9281-b8b919629493|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e48cc935-2058-48c0-9281-b8b919629493
deoxyarbutin	deoxyarbutin		Oc1ccc(OC2CCCCO2)cc1	Preclinical				tyrosinase inhibitor			
PP-2	PP-2	AG-1879	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12	Preclinical		LCK|LYN|SRC|RIPK2|ABL1	https://www.drugbank.ca/drugs/DB03023|https://www.drugbank.ca/drugs/DB03023|https://www.drugbank.ca/drugs/DB03023|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006280|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006280	src inhibitor			
PP-1	PP-1		Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C	Preclinical		RET|SRC|HCK	https://www.drugbank.ca/drugs/DB01809|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=334420|https://www.drugbank.ca/drugs/DB01809	src inhibitor			
homatropine	homatropine		CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)c1ccccc1	Launched	http://www.drugs.com/mtm/homatropine-ophthalmic.html	CES1|CHRM1	https://www.drugbank.ca/drugs/DB02161|http://en.wikipedia.org/wiki/Homatropine	acetylcholine receptor antagonist	ophthalmology	pupil dilation	http://www.drugs.com/mtm/homatropine-ophthalmic.html
viloxazine	viloxazine		CCOc1ccccc1OCC1CNCCO1	Launched	http://en.wikipedia.org/wiki/Viloxazine	SLC6A4|SLC6A2	https://citeline.informa.com/?query=#/drugs/details/19052|https://en.wikipedia.org/wiki/Viloxazine	norepinephrine reuptake inhibitor	neurology/psychiatry	depression	https://en.wikipedia.org/wiki/Viloxazine
atenolol-(-)	(-)-atenolol	S-Atenolol|esatenolol	CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/21189915			adrenergic receptor antagonist			
pimethixene	pimethixene	BP 400|pimetixene	CN1CCC(CC1)=C1c2ccccc2Sc2ccccc12	Launched	http://www.drugs.com/international/pimethixene.html			antihistamine	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|allergy	attention-deficit/hyperactivity disorder (ADHD)|anxiety|sleep cycle support|allergic rhinitis	https://en.wikipedia.org/wiki/Pimethixene|https://en.wikipedia.org/wiki/Pimethixene|https://en.wikipedia.org/wiki/Pimethixene|https://en.wikipedia.org/wiki/Pimethixene
yoda-1	yoda-1		Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1	Preclinical		SLC6A5|PIEZO1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=325865|https://www.tocris.com/products/yoda-1_5586	piezo channel activator			
filanesib	filanesib	ARRY-520	CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F	Phase 3	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001052-39	KIF11	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000053	kinesin inhibitor|kinesin-like spindle protein inhibitor			
IPI-145	IPI-145	INK-1147|INK-1197|IPI-145; INK-1197|duvelisib	C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02049515	PIK3CG|PIK3CD|PIK3CB|PIK3CA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7795|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7795|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7795|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7795	PI3K inhibitor			
amcinonide	amcinonide	cyclocort	CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1CC1C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C	Launched	FDA Orange Book: amcinonide	NR3C1|ANXA1	https://www.drugbank.ca/drugs/DB00288|https://www.drugbank.ca/drugs/DB00288	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac5c3e79-52f7-434e-92ae-24bd32b45edc
FR-122047	FR-122047		COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1	Preclinical				cyclooxygenase inhibitor			
diltiazem	diltiazem	Dilt-CD|Diltzac|cardizem|cardizem cd|cardizem la|cardizem sr|dilacor xr|diltiazem hydrochloride|tiamate|tiazac		Launched	FDA Orange Book: diltiazem hydrochloride, diltiazem malate	KCNA5|HTR3A|CACNG1|CACNA1S|CACNA1C|CACNA2D1|CYP3A5|CYP3A7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2298|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2298|https://www.drugbank.ca/drugs/DB00343|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2298|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2298|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001262|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=134801|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=134801	calcium channel blocker	cardiology|cardiology	hypertension|angina pectoris	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6a81f9f-3a51-4e86-aeb3-8352186b3528|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6a81f9f-3a51-4e86-aeb3-8352186b3528
PK-44	PK-44		N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1n[nH]c2c(F)c(F)ccc12	Preclinical		DPP4	https://www.tocris.com/products/pk-44-phosphate_4145	dipeptidyl peptidase inhibitor			
entecavir	entecavir	BMS-200475-01|SQ34676|baraclude	Nc1nc(=O)c2ncn([C@H]3C[C@H](O)[C@@H](CO)C3=C)c2[nH]1	Launched	FDA Orange Book: entecavir			DNA replication inhibitor|nucleoside reverse transcriptase inhibitor	infectious disease	hepatitis B	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=def332bf-2906-4a6c-b85d-dfb56bb94312
modaline	modaline		Cc1nccnc1N1CCCCC1	Preclinical							
mefloquine	mefloquine	GNF-Pf-5544|Mefaquin|RO 21-5998|WR 142,490|lariam|mefloquine hydrochloride	OC(C1CCCCN1)c1cc(nc2c(cccc12)C(F)(F)F)C(F)(F)F	Launched	FDA Orange Book: mefloquine hydrochloride	PANX1|ADORA2A|HBA1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=115072|https://www.drugbank.ca/drugs/DB00358|https://www.drugbank.ca/drugs/DB00358	adenosine receptor antagonist|hemoglobin antagonist	infectious disease	malaria	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09716a24-d7da-42b2-af29-c03a1b6670bd
tenidap	tenidap		NC(=O)N1C(=O)C(C(=O)c2cccs2)c2cc(Cl)ccc12	Phase 3	https://www.pharmamedtechbi.com/publications/the-pink-sheet/52/050/pfizer-nda-for-nsaid-tenidap-set-for-end-1992	ALOX5|PTGS1|KCNJ4	https://citeline.informa.com/?query=#/drugs/details/17975|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014533|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2395	cyclooxygenase inhibitor			
otamixaban	otamixaban		COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01076764	F10	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000586	coagulation factor inhibitor			
NS-8	NS-8		Cc1c([nH]c(N)c1C#N)-c1ccccc1F	Phase 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191079/	KCNMA1|KCNMB1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191079/|https://citeline.informa.com/?query=#/drugs/details/22888	potassium channel agonist			
CL-218872	CL-218872	CI-218872	Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F	Phase 1	Pharmaprojects	GABRG2|GABRA2|GABRA3|GABRA1|GABRB2|GABRA5	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004062|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004062|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004062|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004062|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004062|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004062	benzodiazepine receptor agonist			
XL-147	XL-147	SAR-245408|pilaralisib	Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01013324	PIK3CA|PIK3CD|PIK3CG	http://www.selleckchem.com/products/XL147.html|http://www.selleckchem.com/products/XL147.html|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000262	PI3K inhibitor			
astragaloside-a	astragaloside a		CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C	Preclinical				antiinflammatory agent			
metacetamol	metacetamol	BS 749	CC(=O)Nc1cccc(O)c1	Preclinical				analgesic agent			
dronedarone	dronedarone	multaq	CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12	Launched	FDA Orange Book: dronedarone hydrochloride	CACNA1D|CACNA1C|CACNA1F|CACNA1S|SLCO1B3|KCNK2|KCNH2|KCNA5|SLC22A8|SLC22A2|ADRA1B|ADRA1A|ADRA1D|ADRA2A|ADRA2C|ADRA2B|ADRB1|SCN1A|CACNB3|CACNB4|CACNB1|CACNB2	https://www.drugbank.ca/drugs/DB04855|https://www.drugbank.ca/drugs/DB04855|https://www.drugbank.ca/drugs/DB04855|https://www.drugbank.ca/drugs/DB04855|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=191769|https://www.drugbank.ca/drugs/DB04855|https://www.drugbank.ca/drugs/DB04855|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000783|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=191769|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=191769|https://www.drugbank.ca/drugs/DB04855|https://www.drugbank.ca/drugs/DB04855|https://www.drugbank.ca/drugs/DB04855|https://www.drugbank.ca/drugs/DB04855|https://www.drugbank.ca/drugs/DB04855|https://www.drugbank.ca/drugs/DB04855|https://www.drugbank.ca/drugs/DB04855|https://www.drugbank.ca/drugs/DB04855|https://www.drugbank.ca/drugs/DB04855|https://www.drugbank.ca/drugs/DB04855|https://www.drugbank.ca/drugs/DB04855|https://www.drugbank.ca/drugs/DB04855	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fa41601-7fb5-4155-8e50-2ae903f0d2d6
NS-309	NS-309		ON=C1C(=O)Nc2c1ccc(Cl)c2Cl	Preclinical		KCNN3|KCNN4|KCNN1|KCNN2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2317|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2317|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2317|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2317	calcium-activated potassium channel activator			
PF-04937319	PF-04937319		CN(C)C(=O)c1ncc(Oc2cc(cc3oc(C)cc23)C(=O)Nc2cnc(C)cn2)cn1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01475461	GCK	http://www.sigmaaldrich.com/catalog/product/sigma/pz0320?lang=en&region=US	glucokinase activator			
isosorbide-dinitrate	isosorbide dinitrate	dilatrate|dilatrate-sr|isordil|isosorbide dinitrate|sorbide nitrate|sorbitrate	[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O	Launched	FDA Orange Book: isosorbide dinitrate	GUCY1B3|GUCY1B2|GUCY1A3|GUCY1A2|NPR1	ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00883	nitric oxide stimulant	cardiology|cardiology	angina pectoris|coronary artery disease (CAD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a4cd065-a1dd-4b88-9f7a-7ba93502f972|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a4cd065-a1dd-4b88-9f7a-7ba93502f972
chidamide	chidamide		Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1	Launched	https://en.wikipedia.org/wiki/Chidamide	HDAC3|HDAC10	https://en.wikipedia.org/wiki/Chidamide|https://en.wikipedia.org/wiki/Chidamide	HDAC inhibitor			
adapalene	adapalene	CD 271|CD-271|differin	COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O	Launched	FDA Orange Book: adapalene	RARA|RARB|RARG|RXRB|RXRG|RXRA	https://www.drugbank.ca/drugs/DB00210|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00210|https://www.drugbank.ca/drugs/DB00210|https://www.drugbank.ca/drugs/DB00210	retinoid receptor agonist	dermatology	acne vulgaris (AV)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94cf9af1-afab-4064-a2ca-619b54218262
nalidixic-acid	nalidixic acid	Neg Gram|Uroneg|WIN 18,320|WIN-18320|Wintomylon|nalidixane|nalidixic acid|neggram	CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12	Launched	FDA Orange Book: nalidixic acid			bacterial DNA gyrase inhibitor	infectious disease	urinary tract infections	http://www.drugs.com/cdi/nalidixic-acid.html
A-867744	A-867744		CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O	Preclinical		CHRNA3|CHRNA4|CHRNA7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3986|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3986|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3986	acetylcholine receptor allosteric modulator			
buparvaquone	buparvaquone		CC(C)(C)C1CCC(CC2C(=O)C(=O)c3ccccc3C2=O)CC1	Launched	http://en.wikipedia.org/wiki/Buparvaquone			antiprotozoal agent			
meloxicam	meloxicam	mobic|vivlodex	CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O	Launched	FDA Orange Book: meloxicam	PTGS2|PTGS1	https://www.drugbank.ca/drugs/DB00814|https://www.drugbank.ca/drugs/DB00814	cyclooxygenase inhibitor	rheumatology|rheumatology	osteoarthritis|rheumatoid arthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fefb555f-ef66-4020-826d-002c76df0225|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fefb555f-ef66-4020-826d-002c76df0225
D-64131	D-64131		COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1	Preclinical		TUBB	http://www.tocris.com/dispprod.php?ItemId=59009	microtubule inhibitor			
SB-706375	SB-706375		COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(c(O[C@@H]2CCN(C)C2)c1)C(F)(F)F	Preclinical		UTS2R	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2165	urotensin receptor antagonist			
anethole	anethole		COc1ccc(cc1)\C=C\C	Launched	http://www.drugs.com/international/anethole.html			glutathione transferase stimulant			
AT-7519	AT-7519		Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01627054	CDK2|CDK1|CDK4|CDK6|CDK5|CDK9	https://www.drugbank.ca/drugs/DB08142|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5662|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5662|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5662|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5662|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5662	CDK inhibitor			
cimetropium	cimetropium		C[N+]1(CC2CC2)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	Launched	https://clinicaltrials.gov/ct2/show/NCT01842932	CHRM1	http://www.genome.jp/kegg-bin/ddi_list?drug=D08838	acetylcholine receptor antagonist	gastroenterology	irritable bowel syndrome	https://drug.mynahcare.com/drugs/genericdetail/cimetropium-bromide-NTAy
BW-373U86	BW-373U86	SNC-86	CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1	Preclinical		OPRD1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000362	opioid receptor agonist			
oxolinic-acid	oxolinic acid	Aqualinic|Aquinox|Microlinic|Nidantin|W 4565|oxolinic acid|utibid	CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12	Preclinical				bacterial DNA gyrase inhibitor			
Ro-106-9920	Ro-106-9920		O=S(c1ccccc1)c1ccc2nnnn2n1	Preclinical				NFkB pathway inhibitor			
AVL-292	AVL-292	CC-292|spebrutinib	COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT01975610	JAK3|ITK|EGFR|YES1|BTK	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=685115|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=685115|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=685115|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7837|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7837	Bruton's tyrosine kinase (BTK) inhibitor			
molidustat	molidustat		O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02064426	EGLN2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4497972/	hypoxia inducible factor inhibitor			
CID-2011756	CID-2011756		Clc1cccc(c1)-c1ccc(o1)C(=O)Nc1ccc(CN2CCOCC2)cc1	Preclinical		PKD1	https://www.tocris.com/products/cid-2011756_4644	protein kinase inhibitor			
tenatoprazole	tenatoprazole		COc1ccc2[nH]c(nc2n1)S(=O)Cc1ncc(C)c(OC)c1C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00282555	ATP4A|IDO1	https://citeline.informa.com/?query=#/drugs/details/17825|https://www.researchgate.net/publication/232811484_Identification_of_selective_inhibitors_of_indoleamine_23-dioxygenase_2	ATPase inhibitor			
JNJ-16259685	JNJ-16259685		CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1	Preclinical		GRM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1385	glutamate receptor antagonist			
metafolin	metafolin	LMSR|levomefolic acid	CN1[C@@H](CNc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2nc(N)[nH]c(=O)c12	Launched	http://www.metafolin.com/about-metafolin/regulatory-status/	AMT	https://www.drugbank.ca/drugs/DB04789				
edaglitazone	edaglitazone		Cc1oc(nc1CCOc1ccc(CC2SC(=O)NC2=O)c2sccc12)-c1ccccc1	Phase 2	http://adisinsight.springer.com/drugs/800016463	INS|PPARG	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=283575|https://www.tocris.com/products/edaglitazone_4784	PPAR receptor agonist			
carisoprodol	carisoprodol	rela|soma	CCCC(C)(COC(N)=O)COC(=O)NC(C)C	Launched	FDA Orange Book: carisoprodol	CYP2C19	https://en.wikipedia.org/wiki/Carisoprodol	acetylcholine receptor antagonist	neurology/psychiatry	muscle relaxant	https://en.wikipedia.org/wiki/Carisoprodol
tecalcet	tecalcet		COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl	Phase 2	http://en.pharmacodia.com/web/drug/1_9012.html	CASR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=718	calcium-sensing receptor agonist			
A205804	A205804		Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1	Preclinical		ICAM1|SELE	https://www.tocris.com/dispprod.php?ItemId=160288#.VydxmWQrImI|https://www.tocris.com/dispprod.php?ItemId=160288#.VydxmWQrImI	ICAM1 expression inhibitor			
compound-58112	compound-58112		COc1cccc(CN2C[Si](C)(C)O[Si](C)(C)C2)c1	Preclinical							
mechlorethamine	mechlorethamine	chlormethine|mustargen|valchlor		Launched	FDA Orange Book: mechlorethamine hydrochloride			DNA inhibitor	hematologic malignancy|hematologic malignancy|hematologic malignancy|hematology|infectious disease|oncology	Hodgkin's lymphoma|chronic myeloid leukemia (CML)|chronic lymphocytic leukemia (CLL)|polycythemia vera|mycosis|bronchogenic carcinoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=920e22b5-823b-0961-c776-9280ce6c62a1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=920e22b5-823b-0961-c776-9280ce6c62a1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=920e22b5-823b-0961-c776-9280ce6c62a1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=920e22b5-823b-0961-c776-9280ce6c62a1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=920e22b5-823b-0961-c776-9280ce6c62a1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=920e22b5-823b-0961-c776-9280ce6c62a1
clofoctol	clofoctol		CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1	Launched	http://en.wikipedia.org/wiki/Clofoctol			protein synthesis inhibitor	infectious disease	gram-positive bacterial infections	https://en.wikipedia.org/wiki/Clofoctol
disulfiram	disulfiram	NSC-25953|antabuse	CCN(CC)C(=S)SSC(=S)N(CC)CC	Launched	FDA Orange Book: disulfiram	ALDH1A2|ALDH5A1|DBH|ALDH2|CYP2E1|DNMT1|ALDH7A1|TRPA1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091421|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091421|https://www.drugbank.ca/drugs/DB00822|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091421|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091421|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091421|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091421	aldehyde dehydrogenase inhibitor|DNA methyltransferase inhibitor|TRPV agonist	neurology/psychiatry	abstinence from alcohol	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2361d16-94fc-43a9-8009-ed03dce0544f
echinomycin	echinomycin		CSC1SCC2N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C(=O)C1N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/9445185			DNA intercalating agent			
bacampicillin	bacampicillin	spectrobid	CCOC(=O)OC(C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O	Launched	FDA Orange Book: bacampicillin hydrochloride			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease	gram-positive bacterial infections|gram-negative bacterial infections	https://en.wikipedia.org/wiki/Bacampicillin|https://en.wikipedia.org/wiki/Bacampicillin
MUT056399	MUT056399		CCc1cc(O)c(Oc2ccc(cc2F)C(N)=O)cc1F	Phase 1	http://www.businesswire.com/news/home/20090912005007/en/FAB-Pharma-Biopharma-Company-Developing-Drugs-Treat			FABI inhibitor			
CB-03-01	CB-03-01		CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02608476	AR	http://www.ru58841.info/ru58841-vs-cb-03-01/	androgen receptor antagonist			
VX-11e	VX-11e		Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1	Preclinical		MAPK1	http://www.selleckchem.com/products/vx-11e.html	MAP kinase inhibitor			
ribitol	ribitol		OC[C@H](O)[C@H](O)[C@H](O)CO	Preclinical							
rofecoxib	rofecoxib	MK-0966|MK-966|vioxx	CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	CYP3A4|ELN|PTGS2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=221147|https://www.drugbank.ca/drugs/DB00533|ChEMBL	cyclooxygenase inhibitor			
clofibrate	clofibrate	AY-61123|ICI 28257|ICI-28257|atromid|atromid-s|chlorfenisate	CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1	Launched	FDA Orange Book: clofibrate	LPL|PPARA	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000262|ChEMBL	PPAR receptor agonist	endocrinology|cardiology	hyperlipidemia|cholesterol	http://druginfosys.com/Drug.aspx?drugCode=185&DrugName=clofibate&type=1|http://druginfosys.com/Drug.aspx?drugCode=185&DrugName=clofibate&type=1
nithiamide	nithiamide	CL 5,279|acinitrazole|aminitrozole	CC(=O)Nc1ncc(s1)[N+]([O-])=O	Preclinical				bacterial DNA inhibitor			
ASC-J9	ASC-J9	Di-O-Methylcurcumin|Tetramethoxycurcumin	COc1ccc(cc1OC)\C=C\C(=O)CC(=O)\C=C\c1ccc(OC)c(OC)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01289574	AR	http://www.apexbt.com/asc-j9.html?gclid=CKjb6fD9xcwCFQ9Zhgodh2cOgA	androgen receptor enhancer			
PI-103	PI-103		Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1	Preclinical		PIK3CA|PIK3CB|PIK3CD|PIK3CG|MTOR|PRKDC	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701	mTOR inhibitor|PI3K inhibitor			
cis-urocanic-acid	cis-urocanic acid	4-Imidazoleacrylic Acid	OC(=O)\C=C\c1c[nH]cn1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01320579	HTR2A	http://www.sigmaaldrich.com/catalog/product/sigma/u6883?lang=en&region=US	serotonin receptor agonist			
didanosine	didanosine	BMY-40900|dideoxyinosine (ddi)|videx|videx ec	OC[C@@H]1CC[C@@H](O1)n1cnc2c(O)ncnc12	Launched	FDA Orange Book: didanosine	PNP	https://www.drugbank.ca/drugs/DB00900	nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22e2ca82-c7b5-4f03-9a81-81e130237565
PFK-015	PFK-015		O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1	Phase 1	Pharmaprojects	PFKFB3	https://www.sbir.gov/sbirsearch/detail/399952	phosphofructokinase inhibitor			
BAG-956	BAG-956		Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1	Preclinical		PDPK1|PIK3CG	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=629364|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002336	phosphoinositide dependent kinase inhibitor			
edrophonium	edrophonium	Reversol|enlon|enlon-plus|tensilon|tensilon preservative free	CC[N+](C)(C)c1cccc(O)c1	Launched	FDA Orange Book: edrophonium chloride	ACHE|BCHE	https://www.drugbank.ca/drugs/DB01010|https://www.drugbank.ca/drugs/DB01010	acetylcholinesterase inhibitor	neurology/psychiatry	myasthenia gravis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98a5a2f6-3194-4202-963f-0fcd28ecadbc
SCH-23390	SCH-23390		CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1	Preclinical		DRD5|DRD1|HTR2C|KCNJ6|KCNJ4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=943|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=943|http://www.tocris.com/dispprod.php?ItemId=2267#.UugHa_30BaE|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=943|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=943	dopamine receptor antagonist			
BMS-690514	BMS-690514		COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00743938	KDR|FLT1|FLT3|FLT4|EGFR|ERBB2|ERBB4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7879|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=427936|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7879|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=427936|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7879|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7879|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=427936	EGFR inhibitor|VEGFR inhibitor			
7-hydroxystaurosporine	7-hydroxystaurosporine	(7S)-HYDROXYL-STAUROSPORINE|KRX-0601|KW-2401|UCN-01|UCN-02	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00030888	CDK1|CDK2|CDK4|CDK6|PDPK1|MARK3|CHEK1|CHEK2|PRKCA|AKT1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=133940|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=133940|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=133940|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=133940|https://www.drugbank.ca/drugs/DB01933|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001064|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001064|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=133940|https://citeline.informa.com/?query=#/drugs/details/18707|https://citeline.informa.com/?query=#/drugs/details/18707	CDK inhibitor|CHK inhibitor|PKC inhibitor			
AS-252424	AS-252424		Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1	Preclinical		PIK3CG	http://www.tocris.com/dispprod.php?ItemId=222714#.Ve8YUixVhHw	PI3K inhibitor			
indiplon	indiplon	CL-285489|NBI-34060	CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00232167	GABRA2|GABRA1|GABRA5|GABRA3	https://citeline.informa.com/?query=#/drugs/details/12431|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4221|https://citeline.informa.com/?query=#/drugs/details/12431|https://citeline.informa.com/?query=#/drugs/details/12431	benzodiazepine receptor agonist			
acetylsalicylsalicylic-acid	acetylsalicylsalicylic acid	2-(2-Methylcarbonyloxyphenylcarbonyloxy)Benzoic Acid|diplosalsalate	CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O	Preclinical				cyclooxygenase inhibitor			
GSK-1562590	GSK-1562590		CN([C@@H](CN1CCCC1)c1ccc(cc1)-c1cccc(c1)C(N)=O)C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc12	Preclinical		UTS2R	https://www.tocris.com/products/gsk-1562590-hydrochloride_5110	urotensin receptor antagonist			
thonzonium	thonzonium		CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1	Launched	FDA Orange Book: thonzonium bromide			ATPase inhibitor			
pyrantel-tartrate	pyrantel-tartrate		CN1CCCN=C1\C=C\c1cccs1	Preclinical		CHRNA1	http://www.sigmaaldrich.com/catalog/product/sigma/p7674?lang=en&region=US	acetylcholine receptor agonist			
CFM-1571	CFM-1571		COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1	Preclinical				guanylate cyclase activator			
tromaril	tromaril	enfenamic acid	OC(=O)c1ccccc1NCCc1ccccc1	Launched	http://indiatoday.intoday.in/story/indian-scientists-achieve-major-breakthrough-with-anti-inflammatory-drug-tromaril/1/401542.html			prostanoid receptor antagonist			
butacaine	butacaine		CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1	Launched	http://www.drugs.com/international/butacaine.html			local anesthetic	neurology/psychiatry	local anesthetic	http://www.drugs.com/international/butacaine.html
anandamide	anandamide		CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO	Phase 2	http://adisinsight.springer.com/drugs/800020326	CACNA1I|CACNA1H|CACNA1G|KCND3|KCNA2|KCNK3|KCNK9|GPR55|CNR2|CNR1|GPR18|TRPV1|TRPM8|GLRA1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=216334|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364	cannabinoid receptor agonist			
nalmefene	nalmefene	revex		Launched	FDA Orange Book: nalmefene hydrochloride	OPRK1|OPRM1|OPRD1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1628|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1628|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1628	opioid receptor antagonist	pulmonary	respiratory depression	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49fd02f8-12b8-460c-ae1f-f26738d86998
laurocapram	laurocapram	N-0252	CCCCCCCCCCCCN1CCCCCC1=O	Phase 3	Pharmaprojects						
SNAP-94847	SNAP-94847		CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1	Preclinical		ADRA1A|MCHR1|DRD2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007567|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=376384|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007567				
VP-20629	VP-20629	3-Indolepropionicacid|Indole-3-Propionic Acid|indolylpropionic acid	OC(=O)CCc1c[nH]c2ccccc12	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01898884	APP|PLA2G2E|SLC36A1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=280233|https://www.drugbank.ca/drugs/DB02758|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4709	beta amyloid antagonist			
ercalcitriol	ercalcitriol		C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	Phase 1	http://www.bloomberg.com/apps/news?pid=conewsstory&tkr=TAY:GR&sid=aIP3w9LV7EIo	VDR	https://www.tocris.com/dispprod.php?ItemId=267866#.VyjpfmQrImI	vitamin D receptor agonist			
menatetrenone	menatetrenone		CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O	Launched	https://www.drugs.com/international/menatetrenone.html			bone resorption inhibitor	orthopedics	osteoporosis	https://en.wikipedia.org/wiki/Menatetrenone
brigatinib	brigatinib	AP-26113|AP26113	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1	Launched	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07b71b73-1ca3-4e78-a787-e458917f1f23	ALK|ROS1|EGFR|IGF1R	https://en.wikipedia.org/wiki/Brigatinib|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=657871|https://en.wikipedia.org/wiki/Brigatinib|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=657871	ALK tyrosine kinase receptor inhibitor|EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07b71b73-1ca3-4e78-a787-e458917f1f23
NPC-15199	NPC-15199	N- (9-FLUORENYLMETHOXYCARBONYL)-L-LEUCINE	CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O	Phase 2	Pharmaprojects	PPARG|ICAM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2705|https://citeline.informa.com/?query=#/drugs/details/12608	ICAM1 antagonist			
ceramide	ceramide	N-Acetylspingosine	CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(C)=O	Launched	http://www.epiceram-us.com/prescribing_information.html			phosphoenolpyruvate carboxylase activator|serine/threonine protein phosphatase activator	dermatology	cosmetic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6ae9905-f6fa-46bb-ac44-0b40ce516ac4
hetacillin	hetacillin	versapen	CC1(C)S[C@@H]2C(N3C(=O)[C@H](NC3(C)C)c3ccccc3)C(=O)N2[C@H]1C(O)=O	Launched	FDA Orange Book: hetacillin, hetacillin potassium			bacterial cell wall synthesis inhibitor	obstetrics/gynecology	mastitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ed719f4-1a8f-4230-92fd-0efc0829ff14
JNJ-7777120	JNJ-7777120		CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1	Preclinical		HRH4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1278	histamine receptor antagonist			
Ro-20-1724	Ro-20-1724	RO-201724	CCCCOc1cc(CC2CNC(=O)N2)ccc1OC	Preclinical		PDE4A|PDE4B|PDE4C|PDE4D|PDE3A	https://www.drugbank.ca/drugs/DB06842|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5258|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5258|https://www.drugbank.ca/drugs/DB06842|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004221	phosphodiesterase inhibitor			
K-Ras(G12C)-inhibitor-6	K-Ras(G12C)-inhibitor-6		SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl	Preclinical				K-ras inhibitor			
AP26113	AP26113		COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02094573	EGFR|ALK	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7741|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7741	ALK tyrosine kinase receptor inhibitor			
MCOPPB	MCOPPB		CC1(CCCCCCC1)N1CCC(CC1)n1c(nc2ccccc12)[C@@H]1CCCNC1	Preclinical		OPRL1	https://www.tocris.com/products/mcoppb-trihydrochloride_3763	nociceptin/orphanin FQ (NOP) receptor agonist			
PSI-7976	PSI-7976		CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1	Preclinical				HCV inhibitor			
1-(1,2-Diphenylethyl)piperidine-(+/-)	(+/-)-1-(1,2-Diphenylethyl)piperidine		C(C(N1CCCCC1)c1ccccc1)c1ccccc1	Preclinical				glutamate receptor antagonist			
PF-04457845	PF-04457845		FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00981357	FAAH	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6694	FAAH inhibitor			
ipidacrine	ipidacrine		Nc1c2CCCc2nc2CCCCc12	Phase 3	http://adisinsight.springer.com/drugs/800000668	ACHE	https://en.wikipedia.org/wiki/Ipidacrine	acetylcholinesterase inhibitor			
methoxyflurane	methoxyflurane	Metofane|Pentrane|methoxiflurane|penthrane	COC(F)(F)C(Cl)Cl	Launched	http://www.drugs.com/international/Methoxyflurane.html	GABRE|GABRD|GABRQ|GABRP|KCNA1|MT-ND1|GLRB|GRIA1|ATP5D|GABRG2|GABRG1|GABRG3|GLRA1|ATP2C1|GABRA4|GABRA3|GABRA6|GABRA5|GABRA2|GABRA1|GABRB1|GABRB3|GABRB2	ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB01028|https://www.drugbank.ca/drugs/DB01028|ChEMBL|https://www.drugbank.ca/drugs/DB01028|https://www.drugbank.ca/drugs/DB01028|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB01028|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic	http://www.drugbank.ca/drugs/DB01028
butorphanol-(+)-tartrate	butorphanol-(+)-tartrate		Oc1ccc2C[C@H]3N(CC4CCC4)CC[C@@]4(CCCC[C@@]34O)c2c1	Launched				opioid receptor agonist|opioid receptor antagonist			
fudosteine	fudosteine		N[C@@H](CSCCCO)C(O)=O	Launched	http://www.drugs.com/international/Fudosteine.html			mucolytic agent	pulmonary	chest congestion	http://www.drugs.com/international/fudosteine.html
loxistatin-acid	loxistatin acid	E-64c	CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O	Preclinical		CTSB	http://www.selleckchem.com/products/loxistatin-acid-e-64c.html	cysteine peptidase inhibitor			
salmeterol	salmeterol	GR 33343 X|GR-33343X|salmaterol|serevent	OCc1cc(ccc1O)C(O)CNCCCCCCOCCCCc1ccccc1	Launched	FDA Orange Book: salmeterol xinafoate	ADRB2	https://www.drugbank.ca/drugs/DB00938	adrenergic receptor agonist	pulmonary|pulmonary|pulmonary	asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm	https://en.wikipedia.org/wiki/Salmeterol|https://en.wikipedia.org/wiki/Salmeterol|https://en.wikipedia.org/wiki/Salmeterol
loteprednol	loteprednol	CDDD 5604|CDDD-5604|HGP-1|P-5604|airex|alrex|lotemax|loteprednol etabonate	CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl	Launched	FDA Orange Book: loteprednol etabonate	NR3C1	ChEMBL	glucocorticoid receptor agonist|phospholipase inhibitor	ophthalmology	conjunctivitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=21c76da0-50a1-41c0-91b8-8cc4dcc27f60
ivermectin	ivermectin	sklice|soolantra|stromectol	CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2	Launched	FDA Orange Book: ivermectin	CHRNA7|GABRB3|P2RX7|GLRA3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2373|https://www.drugbank.ca/drugs/DB00602|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2373|https://www.drugbank.ca/drugs/DB00602	benzodiazepine receptor agonist	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	gastrointestinal roundworms|lungworms|cattle grubs|mites|lice|horn flies	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e31349c-f6b3-4770-921b-f8b120cd2325|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e31349c-f6b3-4770-921b-f8b120cd2325|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e31349c-f6b3-4770-921b-f8b120cd2325|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e31349c-f6b3-4770-921b-f8b120cd2325|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e31349c-f6b3-4770-921b-f8b120cd2325|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e31349c-f6b3-4770-921b-f8b120cd2325
2-APB	2-APB	2-(Diphenylboryloxy)Ethanamine|2-Aminoethoxydiphenyl Borate	NCCOB(c1ccccc1)c1ccccc1	Preclinical		ITPR1|TRPV1|TRPV6|TRPC1|TRPC3|TRPC5|TRPC4|TRPC7|TRPC6|TRPM3|TRPM2|TRPM6	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=358965|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433	1,4,5-trisphosphate inhibitor			
CDK9-IN-6	CDK9-IN-6		COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1	Preclinical		CDK9|CCNT1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8053|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=722088	CDK inhibitor			
NVP-TNKS656	NVP-TNKS656		COc1ccc(cc1)C(=O)C1CCN(CC(=O)N(CC2CC2)Cc2nc3CCOCc3c(=O)[nH]2)CC1	Preclinical		TNKS|TNKS2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=825055|https://www.medchemexpress.com/NVP-TNKS656.html?gclid=CJG15YGStc8CFQ1ahgodGX0Jrg	tankyrase inhibitor			
crystal-violet	crystal violet	crystal violet|hexamethyl pararosaniline	CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C	Launched	http://en.wikipedia.org/wiki/Crystal_violet			other antibiotic			
nicorandil	nicorandil	Aprior|Dancor|Ikorel|Nikoran|Nitorubin|SG-75|Sigmart	[O-][N+](=O)OCCNC(=O)c1cccnc1	Launched	http://www.drugs.com/international/Nicorandil.html	KCNJ11|KCNJ8|ABCC9	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2411|https://citeline.informa.com/?query=#/drugs/details/12953|https://citeline.informa.com/?query=#/drugs/details/12953	nitric oxide donor|potassium channel activator	cardiology	angina pectoris	https://en.wikipedia.org/wiki/Nicorandil
ARQ-621	ARQ-621		NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F	Phase 1	https://www.clinicaltrials.gov/ct2/show/NCT00825487	KIF11	http://www.selleckchem.com/products/arq-621.html	kinesin-like spindle protein inhibitor			
AZ960	AZ960		C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1	Preclinical		JAK2|JAK3	http://www.scbt.com/datasheet-364732-az-960.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=658103	JAK inhibitor			
nilvadipine	nilvadipine	CL 287,389|FK 235|SK&F 102,362|nivadipine	COC(=O)C1=C(NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N	Launched	http://www.drugs.com/international/Nilvadipine.html	CACNB2|CACNA1S|CACNA1G|CACNA1C|CACNA1D|CACNA2D1|CACNA2D3	https://www.drugbank.ca/drugs/DB06712|https://www.drugbank.ca/drugs/DB06712|https://citeline.informa.com/?query=#/drugs/details/13025|https://www.drugbank.ca/drugs/DB06712|https://www.drugbank.ca/drugs/DB06712|https://www.drugbank.ca/drugs/DB06712|https://www.drugbank.ca/drugs/DB06712	calcium channel blocker	cardiology|cardiology	hypertension|cerebral artery occlusion	https://en.wikipedia.org/wiki/Nilvadipine|https://en.wikipedia.org/wiki/Nilvadipine
vigabatrin	vigabatrin	MDL 71,754|gamma-vinyl gaba|sabril|vinyl gamma-aminobutyric acid	NC(CCC(O)=O)C=C	Launched	FDA Orange Book: vigabatrin	SLC32A1|ABAT|GABBR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4821|ChEMBL|https://www.drugbank.ca/drugs/DB01080	GABA aminotransferase inhibitor	neurology/psychiatry|neurology/psychiatry	seizures|spasms	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5d389d2-d0e1-4395-a2a2-b552808e7f98|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5d389d2-d0e1-4395-a2a2-b552808e7f98
sumanirole	sumanirole	PNU-95666E	CN[C@@H]1Cc2cccc3nc(O)n(C1)c23	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00036205	DRD2|HTR1A|HTR1D	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3949|https://citeline.informa.com/?query=#/drugs/details/13964|https://citeline.informa.com/?query=#/drugs/details/13964	dopamine receptor agonist			
GANT-58	GANT-58		c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1	Preclinical		GLI1|DHH|IHH	http://www.tocris.com/dispprod.php?ItemId=250605|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=452350|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=452350	GLI antagonist			
CC-115	CC-115		CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01353625	MTOR	https://www.medchemexpress.com/CC-115.html	mTOR inhibitor|DNA protein kinase inhibitor			
SDZ-205-557	SDZ-205-557	SDZ-205557	CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC	Preclinical		HTR4|HTR3B|HTR3A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=176833|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012698|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012698	serotonin receptor antagonist			
pranoprofen	pranoprofen		CC(C(O)=O)c1ccc2Oc3ncccc3Cc2c1	Launched	http://www.drugs.com/international/Pranoprofen.html			cyclooxygenase inhibitor	neurology/psychiatry	pain relief	http://www.drugs.com/international/pranoprofen.html
fiacitabine	fiacitabine	FIAC	Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00000981			DNA synthesis inhibitor			
carbenicillin	carbenicillin	geocillin|geopen|pyopen	CC1(C)S[C@@H]2[C@H](NC(=O)C(C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O	Launched	FDA Orange Book: carbenicillin disodium, carbenicillin indanyl sodium			bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections	https://en.wikipedia.org/wiki/Carbenicillin
indoximod	indoximod	D-1-Methyltryptophan|D-1MT	Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01792050	IDO1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8225	indoleamine 2,3-dioxygenase inhibitor			
VCH-916	VCH-916		CO[C@H]1CC[C@@H](CC1)N(C(=O)[C@H]1CC[C@H](C)CC1)c1cc(sc1C(O)=O)C1=CCCCC1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00623649			HCV inhibitor			
phortress	phortress		Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1	Phase 1	http://www.pharmaceutical-journal.com/opinion/comment/phortress-the-smart-antitumour-agent-which-induces-its-own-metabolism/10991856.article	AHR	https://www.tocris.com/dispprod.php?ItemId=387303#.V-1_m5MrLy8	aryl hydrocarbon receptor ligand			
donitriptan	donitriptan	F-11356	NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12	Phase 2	http://en.wikipedia.org/wiki/Donitriptan	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR5A|HTR2A|HTR6	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=39|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=39|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=39|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=39|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=39|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=39|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=39|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=39	serotonin receptor agonist			
H2L-5765834	H2L-5765834		OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1	Preclinical		LPAR3|LPAR1	https://www.tocris.com/products/h2l-5765834_4870|https://www.tocris.com/products/h2l-5765834_4870	lysophosphatidic acid receptor antagonist			
MEK1-2-inhibitor	MEK1-2-inhibitor	SL-327	N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F	Preclinical		MAP2K1|MAP2K2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=314820|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6008	MEK inhibitor			
cefazolin	cefazolin	SK&F-41558|ancef|cefazolin and dextrose|cefazolin sodium|cephazolin	Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1	Launched	FDA Orange Book: cefazolin sodium	PON1|SLC22A8	https://www.drugbank.ca/drugs/DB01327|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070093	bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	urinary tract infections|skin infections|bacterial septicemia|endocarditis|surgical prophylaxis|bone and joint infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1ca2a2e-c860-4031-8276-be86be6a72ea|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1ca2a2e-c860-4031-8276-be86be6a72ea|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1ca2a2e-c860-4031-8276-be86be6a72ea|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1ca2a2e-c860-4031-8276-be86be6a72ea|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1ca2a2e-c860-4031-8276-be86be6a72ea|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1ca2a2e-c860-4031-8276-be86be6a72ea
ABT-724	ABT-724		C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1	Phase 2	http://media.corporate-ir.net/media_files/nys/abt/rdday/PharmDev.pdf	DRD4	https://www.tocris.com/dispprod.php?ItemId=124748	dopamine receptor agonist			
BIMU-8	BIMU-8		CC(C)n1c2ccccc2n(C(=O)NC2C[C@@H]3CC[C@H](C2)N3C)c1=O	Preclinical		HTR4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=234	serotonin receptor agonist			
aripiprazole	aripiprazole	OPC-14597|OPC-31|abilify|abilify maintena kit|aristada	Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl	Launched	FDA Orange Book: aripiprazole	HTR3A|HTR1A|HTR1D|HTR1E|HTR1B|HTR2A|HTR2C|CHRM5|CHRM3|CHRM4|CHRM1|CHRM2|DRD5|DRD1|DRD2|DRD3|DRD4|HTR7|HTR6|HRH1|ADRA1B|ADRA1A|ADRA2C|ADRA2A|ADRA2B	https://www.drugbank.ca/drugs/DB01238|ChEMBL|https://www.drugbank.ca/drugs/DB01238|https://www.drugbank.ca/drugs/DB01238|https://www.drugbank.ca/drugs/DB01238|ChEMBL|https://www.drugbank.ca/drugs/DB01238|https://www.drugbank.ca/drugs/DB01238|https://www.drugbank.ca/drugs/DB01238|https://www.drugbank.ca/drugs/DB01238|https://www.drugbank.ca/drugs/DB01238|https://www.drugbank.ca/drugs/DB01238|https://www.drugbank.ca/drugs/DB01238|https://www.drugbank.ca/drugs/DB01238|ChEMBL|https://www.drugbank.ca/drugs/DB01238|https://www.drugbank.ca/drugs/DB01238|https://www.drugbank.ca/drugs/DB01238|https://www.drugbank.ca/drugs/DB01238|https://www.drugbank.ca/drugs/DB01238|https://www.drugbank.ca/drugs/DB01238|https://www.drugbank.ca/drugs/DB01238|https://www.drugbank.ca/drugs/DB01238|https://www.drugbank.ca/drugs/DB01238|https://www.drugbank.ca/drugs/DB01238	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	depression|schizophrenia|bipolar disorder	https://en.wikipedia.org/wiki/Aripiprazole|https://en.wikipedia.org/wiki/Aripiprazole|https://en.wikipedia.org/wiki/Aripiprazole
metoprolol	metoprolol	Lopressidone|lopressor|metoprolol tartrate|toprol-xl	COCCc1ccc(OCC(O)CNC(C)C)cc1	Launched	FDA Orange Book: metoprolol tartrate	ADRB2|ADRB1	https://www.drugbank.ca/drugs/DB00264|https://www.drugbank.ca/drugs/DB00264	adrenergic receptor antagonist	cardiology|cardiology|cardiology	hypertension|angina pectoris|myocardial infarction	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09566368-f91d-43a3-b683-30c844fb125a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09566368-f91d-43a3-b683-30c844fb125a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09566368-f91d-43a3-b683-30c844fb125a
caricotamide	caricotamide		NC(=O)CN1C=CCC(=C1)C(N)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00746590	NQO2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001125	NADPH quinone oxidoreductase inhibitor			
4-DAMP	4-DAMP		C[N+]1(C)CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1	Preclinical		CHRM5|CHRM4|CHRM1|CHRM3|CHRM2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=307|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=307|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=307|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=307|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=307	cholinergic receptor antagonist			
AC-7954-(+/-)	(+/-)-AC-7954		CN(C)CCC1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1	Preclinical				urotensin receptor agonist			
dianhydrogalactitol	dianhydrogalactitol	NSC-1323313|VAL-083	O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1	Phase 1	http://adisinsight.springer.com/drugs/800034748			DNA alkylating agent			
UAMC-00039	UAMC-00039		N[C@@H](CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1	Preclinical		DPP4|DPP7	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006854|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6538	dipeptidyl peptidase inhibitor			
atorvastatin	atorvastatin	lipitor	CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1	Launched	FDA Orange Book: atorvastatin calcium	AHR|CYP3A5|FASLG|HMGCR|DPP4	https://www.drugbank.ca/drugs/DB01076|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=180072|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=180072|https://www.drugbank.ca/drugs/DB01076|https://www.drugbank.ca/drugs/DB01076	HMGCR inhibitor	neurology/psychiatry|cardiology	stroke|heart attack	http://www.drugs.com/atorvastatin.html|http://www.drugs.com/atorvastatin.html
PI-828	PI-828		Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1	Preclinical				PI3K inhibitor			
fulvestrant	fulvestrant	faslodex	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31	Launched	FDA Orange Book: fulvestrant	GPER1|ESR1|ESR2|EPHX2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1015|https://www.drugbank.ca/drugs/DB00947|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1015|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=177872	estrogen receptor antagonist	oncology	breast cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83d7a440-e904-4e36-afb5-cb02b1c919f7
ethimizol	ethimizol		CCn1cnc(C(=O)NC)c1C(=O)NC	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/4034651						
walrycin-b	walrycin b		Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F	Preclinical				transcriptional regulatory protein WalR			
sirtinol	sirtinol		CC(NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1	Preclinical		SIRT2|SIRT1	https://www.tocris.com/dispprod.php?ItemId=224760#.VyuwGGQrJZI|https://www.tocris.com/dispprod.php?ItemId=224760#.VyuwGGQrJZI	SIRT inhibitor			
cytisine	cytisine	(-)-cytisine|4, (-)-CYTISINE	O=c1cccc2[C@H]3CNC[C@H](C3)Cn12	Launched	http://www.drugs.com/international/Cytisine.html	CHRNA3|CHRNA4|CHRNA6|CHRNA2|CHRNB4|CHRNB2|CHRNA7	https://www.drugbank.ca/drugs/DB09028|https://www.drugbank.ca/drugs/DB09028|https://www.drugbank.ca/drugs/DB09028|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3979|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005608|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005608|https://www.drugbank.ca/drugs/DB09028	acetylcholine receptor agonist	neurology/psychiatry	nicotinism	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=253592cd-0735-2bd7-e054-00144ff88e88
warfarin	warfarin	athrombin|athrombin-k|coumadin|panwarfin	CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O	Launched	FDA Orange Book: warfarin potassium, warfarin sodium	CYP2C8|CYP4F2|VKORC1|CYP2C19	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091527|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091527|https://www.drugbank.ca/drugs/DB00682|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091527	vitamin K antagonist	hematology|hematology|cardiology|cardiology	deep vein thrombosis (DVT)|pulmonary embolism (PE)|atrial fibrillation (AF)|myocardial infarction	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=558b7a0d-5490-4c1b-802e-3ab3f1efe760|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=558b7a0d-5490-4c1b-802e-3ab3f1efe760|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=558b7a0d-5490-4c1b-802e-3ab3f1efe760|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=558b7a0d-5490-4c1b-802e-3ab3f1efe760
labetalol	labetalol	Normozide|labetalol hydrochloride|normodyne|trandate	CC(CCc1ccccc1)NCC(O)c1ccc(O)c(c1)C(N)=O	Launched	FDA Orange Book: labetalol hydrochloride	ADRA1A|ADRA1B|ADRA1D|ADRB1|ADRB2	https://www.drugbank.ca/drugs/DB00598|https://www.drugbank.ca/drugs/DB00598|https://www.drugbank.ca/drugs/DB00598|https://www.drugbank.ca/drugs/DB00598|https://www.drugbank.ca/drugs/DB00598	adrenergic receptor antagonist	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8e0af49-8c2a-4ada-804f-17ce2abad15b
rotigotine	rotigotine	SPM 962|neupro	CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1	Launched	FDA Orange Book: rotigotine	HTR1A|ADRA2B|DRD4|DRD3|DRD5|DRD2|DRD1	https://www.drugbank.ca/drugs/DB05271|https://www.drugbank.ca/drugs/DB05271|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB05271|ChEMBL|https://www.drugbank.ca/drugs/DB05271	dopamine receptor agonist	neurology/psychiatry|neurology/psychiatry	Parkinson's Disease|restless leg syndrome	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=939e28c5-f3a9-42c0-9a2d-8d471d82a6e0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=939e28c5-f3a9-42c0-9a2d-8d471d82a6e0
cyanopindolol	cyanopindolol		CC(C)(C)NCC(O)COc1cccc2[nH]c(cc12)C#N	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/11081321	HTR1A|HTR1D|ADRB1	https://en.wikipedia.org/wiki/Cyanopindolol|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=132|https://en.wikipedia.org/wiki/Cyanopindolol	adrenergic receptor antagonist			
1E-1-(2-hydroxy-5-methylphenyl)-1-dodecanone oxime	1E-1-(2-hydroxy-5-methylphenyl)-1-dodecanone oxime		CCCCCCCCCCCC([N+][O-])c1cc(C)ccc1O	Preclinical							
roxatidine-acetate	roxatidine acetate	roxatidine|roxatidine acetate	CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1	Launched	http://www.drugs.com/international/roxatidine-acetate-hydrochloride.html	HRH2	https://www.drugbank.ca/drugs/DB08806	histamine receptor antagonist	gastroenterology|gastroenterology|gastroenterology|gastroenterology	Zollinger-Ellison syndrome|erosive esophagitis (EE)|gastroesophageal reflux disease (GERD)|gastritis	https://en.wikipedia.org/wiki/Roxatidine_acetate|https://en.wikipedia.org/wiki/Roxatidine_acetate|https://en.wikipedia.org/wiki/Roxatidine_acetate|https://en.wikipedia.org/wiki/Roxatidine_acetate
IKK-2-inhibitor	IKK-2-inhibitor	SC-514	NC(=O)c1sc(cc1N)-c1ccsc1	Preclinical		IKBKB	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005318	IKK inhibitor|SYK inhibitor			
caramiphen	caramiphen		CCN(CC)CCOC(=O)C1(CCCC1)c1ccccc1	Launched	http://www.drugs.com/international/caramiphen.html	CHRM2|CHRM1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011755|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011755	cholinergic receptor antagonist	neurology/psychiatry	Parkinson's Disease	https://en.wikipedia.org/wiki/Caramiphen
cis-aconitic-acid	cis-aconitic acid	Cis-Aconitate	OC(=O)C\C(=C\C(O)=O)C(O)=O	Preclinical		ACO2	https://www.drugbank.ca/drugs/DB04351				
brolitene	brolitene	idrocilamide	OCCNC(=O)\C=C\c1ccccc1	Launched	http://en.wikipedia.org/wiki/Idrocilamide	RYR1|PTAFR	http://www.minapharm.com/public/ProductDetails.aspx?langParam=en&ProductCode=SRILANE|https://citeline.informa.com/?query=#/drugs/details/9081	muscle relaxant			
albendazole-oxide	albendazole oxide	albendazole oxide	CCCS(=O)c1ccc2nc(NC(=O)OC)[nH]c2c1	Launched	http://www.drugs.com/mtm/albendazole.html			anthelmintic agent	infectious disease|infectious disease	cystic hydatid disease|parenchymal neurocysticercosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845
perphenazine	perphenazine	Chlorpiprazine|Decentan|Fentazin|Trilafon-LA|etaperazine|perphenazine fendizoate|perphenazine maleate|trilafon	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1	Launched	FDA Orange Book: perphenazine	HTR6|HTR7|HTR2A|HTR2C|HRH1|CALM1|DRD1|DRD2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=209|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=209|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=209|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=209|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=209|https://www.drugbank.ca/drugs/DB00850|https://www.drugbank.ca/drugs/DB00850|ChEMBL	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|gastroenterology	schizophrenia|nausea|vomiting	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fbfe9da-26e8-4705-98f3-42acd3d7b439|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fbfe9da-26e8-4705-98f3-42acd3d7b439|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fbfe9da-26e8-4705-98f3-42acd3d7b439
allopurinol-riboside	allopurinol-riboside		OC[C@H]1O[C@H](C(O)[C@H]1O)n1[nH]cc2c1ncnc2=O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/1651060			anti-leishmanial agent			
capadenoson	capadenoson	BAY 68-4986|BAY-684986	Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00568945	ADORA1	http://www.ncbi.nlm.nih.gov/pubmed/22370739	adenosine receptor agonist			
diaveridine	diaveridine	BW 49-210	COc1ccc(Cc2cnc(N)nc2N)cc1OC	Veterinary Launched	http://www.drugs.com/international/diaveridine.html			dihydrofolate reductase inhibitor			
camylofine-chlorhydrate	camylofine-chlorhydrate	acamylophenine|acamylophenine hydrochloride|camylofin	CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1	Launched	http://www.drugs.com/international/camylofin.html				gastroenterology	abdominal pain	https://en.wikipedia.org/wiki/Camylofin
cridanimod	cridanimod		OC(=O)Cn1c2ccccc2c(=O)c2ccccc12	Launched	http://www.drugs.com/international/cridanimod.html	PGR	https://clinicaltrials.gov/ct2/show/NCT02064725	progesterone receptor agonist			
diosmin	diosmin		COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1	Launched	http://www.drugs.com/international/Diosmin.html	AHR	http://www.ncbi.nlm.nih.gov/pubmed/9661887	aryl hydrocarbon receptor agonist|capillary stabilizing agent	cardiology|cardiology|hematology|dermatology|cardiology	chronic venous insufficiency (CVI)|edema|deep vein thrombosis (DVT)|statis dermatitis|heavy leg syndrome	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=563d3d34-a547-471e-aecd-f4a4a57cbf1d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=563d3d34-a547-471e-aecd-f4a4a57cbf1d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=563d3d34-a547-471e-aecd-f4a4a57cbf1d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=563d3d34-a547-471e-aecd-f4a4a57cbf1d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=563d3d34-a547-471e-aecd-f4a4a57cbf1d
dipyridamole	dipyridamole	RA-8|iv persantine|persantine	OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO	Launched	FDA Orange Book: dipyridamole	PDE10A|ADA|PDE5A|PDE7A|PDE6H|PDE6G|PDE6B|PDE6A|PDE6D|PDE6C|PDE3B|PDE3A|PDE4D|PDE4C|PDE4B|PDE4A|PDE1A|PDE1C|PDE1B|PDE2A|SLC29A1|PDE8B|PDE8A|PDE7B|PDE9A	ChEMBL|https://www.drugbank.ca/drugs/DB00975|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	phosphodiesterase inhibitor	cardiology|cardiology|cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension	https://en.wikipedia.org/wiki/Dipyridamole|https://en.wikipedia.org/wiki/Dipyridamole|https://en.wikipedia.org/wiki/Dipyridamole
diosmetin	diosmetin	Diosmetine	COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1	Launched	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d58e2d8f-ff4a-4299-a1aa-fa91965072c1	CYP1B1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011122	aryl hydrocarbon receptor agonist	dermatology	cosmetic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d58e2d8f-ff4a-4299-a1aa-fa91965072c1
dantron	dantron	chrysazin|danthron|dorbane|istizin	Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs			laxative			
SMI-4a	SMI-4a		FC(F)(F)c1cccc(c1)\C=C1\SC(=O)NC1=O	Preclinical		AKR1B1|PIM1|PIM2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=407488|http://www.sigmaaldrich.com/catalog/product/sigma/sml0323?lang=en&region=US|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=407488	Pim kinase inhibitor			
PD-168568	PD-168568		Cc1ccc(cc1C)N1CCN(CCC2NC(=O)c3ccccc23)CC1	Preclinical		DRD4|DRD2	https://www.tocris.com/products/pd-168568-dihydrochloride_3529|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003779	dopamine receptor antagonist			
avobenzone	avobenzone	PARSOL 1789|butyl methoxydibenzoylmethane	COc1ccc(cc1)C(=O)CC(=O)c1ccc(cc1)C(C)(C)C	Launched	FDA Orange Book: avobenzone	TYR	ChEMBL	UV blocker	dermatology|dermatology	cosmetic|sunscreen lotion	https://en.wikipedia.org/wiki/Avobenzone|https://en.wikipedia.org/wiki/Avobenzone
zoledronic-acid	zoledronic acid	CGP 42446|CGP-42446|reclast|zoledronic acid|zometa	OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O	Launched	FDA Orange Book: zoledronic acid	FDPS|GGPS1	ChEMBL|https://www.drugbank.ca/drugs/DB00399	bone resorption inhibitor	endocrinology	Paget's disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c8e02635-4473-8ba2-248f-ced58dbeabce
sonidegib	sonidegib	LDE225|erismodegib|odomzo	C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1	Launched	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77bd079b-7168-454a-ac38-963f8ba34324	SMO	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8199	smoothened receptor antagonist	oncology	basal cell carcinoma (BCC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77bd079b-7168-454a-ac38-963f8ba34324
oxaprozin	oxaprozin	WY-21,743|WY-21743|daypro|daypro alta	OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1	Launched	FDA Orange Book: oxaprozin, oxaprozin potassium	PTGS1|PTGS2	ChEMBL|ChEMBL	cyclooxygenase inhibitor	rheumatology|rheumatology	osteoarthritis|rheumatoid arthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a6586f8-6572-4eed-ba24-ecce792d6eb2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a6586f8-6572-4eed-ba24-ecce792d6eb2
remacemide	remacemide		CC(Cc1ccccc1)(NC(=O)CN)c1ccccc1	Phase 3	http://en.wikipedia.org/wiki/Remacemide	GRIN1	http://en.wikipedia.org/wiki/Remacemide	glutamate receptor antagonist			
tangeritin	tangeritin	NSC-53909|tangeretin	COc1ccc(cc1)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1	Preclinical				cell cycle inhibitor			
pindolol	pindolol	LB-46|prinodolol|visken	CC(C)NCC(O)COc1cccc2[nH]ccc12	Launched	FDA Orange Book: pindolol	ADRB2|ADRB1|HTR1B|HTR1A|HTR2B|HTR2A	ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00960|https://www.drugbank.ca/drugs/DB00960|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=91|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=91	adrenergic receptor antagonist	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05dfb38c-b832-4ae0-b28b-d271008e670b
bezafibrate	bezafibrate	BM 15.075	CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O	Launched	http://en.wikipedia.org/wiki/Bezafibrate	HSD11B1|LPL|PPARD|PPARA|PPARG	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=282546|https://citeline.informa.com/?query=#/drugs/details/2914|https://www.drugbank.ca/drugs/DB01393|https://www.drugbank.ca/drugs/DB01393|https://www.drugbank.ca/drugs/DB01393	PPAR receptor agonist	cardiology	cholesterol	http://www.medicinenet.com/bezafibrate-oral/article.htm
YK-4-279	YK-4-279		COc1ccc(cc1)C(=O)CC1(O)C(=O)Nc2c1c(Cl)ccc2Cl	Preclinical		EWSR1|FLI1	https://www.caymanchem.com/product/13661|https://www.caymanchem.com/product/13661	apoptosis inhibitor			
teniposide	teniposide	VM-26|vumon		Launched	FDA Orange Book: teniposide	TOP2B|TOP2A|CYP3A5	ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=282568	topoisomerase inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f19cf6d7-a1c8-42ec-844c-c798512139d9&audience=consumer
monensin	monensin		CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C	Veterinary Launched	http://www.drugs.com/international/Monensin.html			bacterial permeability inducer			
ezetimibe	ezetimibe	SCH-58235|SCH58235|zetia		Launched	FDA Orange Book: ezetimibe	SOAT1|ANPEP|NPC1L1	https://www.drugbank.ca/drugs/DB00973|https://www.drugbank.ca/drugs/DB00973|ChEMBL	cholesterol inhibitor|Niemann-Pick C1-like 1 protein antagonist	endocrinology|endocrinology|metabolism	hyperlipidemia|hypercholesterolemia|sitosterolemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb18564f-663f-4da2-9dd9-700ea9bdd398|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb18564f-663f-4da2-9dd9-700ea9bdd398|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb18564f-663f-4da2-9dd9-700ea9bdd398
nandrolone	nandrolone	Anabolin Forte|Nandrolin|Nortestosterone|deca-durabolin|durabolin|nandrolone decanoate	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2O	Launched	FDA Orange Book: nandrolone decanoate, nandrolone phenpropionate	CYP19A1|MAOA|MAOB|AR|NISCH	http://www.drugbank.ca/drugs/DB08804|http://www.drugbank.ca/drugs/DB08804|http://www.drugbank.ca/drugs/DB08804|http://www.drugbank.ca/drugs/DB08804|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090333	imidazoline receptor agonist	hematology	anemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a586b484-1b46-40b9-9508-fd28002ad383
ranitidine	ranitidine	ranitidine hydrochloride|tritec|zantac|zantac 150|zantac 25|zantac 300|zantac 75	CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O	Launched	FDA Orange Book: ranitidine bismuth citrate, ranitidine hydrochloride	SLC22A2|HRH2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091558|https://www.drugbank.ca/drugs/DB00863	histamine receptor antagonist	gastroenterology	heartburn	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0b66aaf-b40d-4827-ae13-549d1ddef96c
bisphenol-a	bisphenol a	bisphenol a	CC(C)(c1ccc(O)cc1)c1ccc(O)cc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01573429	PPARG|ESR1|ESR2|AR|ESRRG	http://www.ncbi.nlm.nih.gov/pubmed/11030710|https://en.wikipedia.org/wiki/Bisphenol_A|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7865|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7865|https://www.drugbank.ca/drugs/DB06973	synthetic estrogen			
norfloxacin	norfloxacin	Baccidal|MK-366|Quinabic|chibroxin|noroxin	CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1	Launched	FDA Orange Book: norfloxacin	TOP2A	https://www.drugbank.ca/drugs/DB01059	bacterial DNA gyrase inhibitor	infectious disease|infectious disease|urology	urinary tract infections|gonorrhea|prostatitis	http://www.rxlist.com/noroxin-drug/indications-dosage.htm|http://www.rxlist.com/noroxin-drug/indications-dosage.htm|http://www.rxlist.com/noroxin-drug/indications-dosage.htm
quercetin	quercetin	C.I. Natural Red 1|Meletin|NSC-9219|Sophoretin|Xanthaurine	Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O	Launched	https://clinicaltrials.gov/ct2/show/NCT00913081	STK17B|XDH|ATP5B|SCN5A|PTPN1|PIK3CG|HIBCH|ATP5C1|ATP5A1|EGFR|PIM1|AKR1B1|GAA|HCK|CYP2C8|UGT3A1|MAOA|SIRT1	https://www.drugbank.ca/drugs/DB04216|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=131055|https://www.drugbank.ca/drugs/DB04216|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=131055|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=131055|https://www.drugbank.ca/drugs/DB04216|https://www.drugbank.ca/drugs/DB04216|https://www.drugbank.ca/drugs/DB04216|https://www.drugbank.ca/drugs/DB04216|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=131055|https://www.drugbank.ca/drugs/DB04216|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=131055|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=131055|https://www.drugbank.ca/drugs/DB04216|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=131055|https://www.drugbank.ca/drugs/DB04216|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=131055|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=131055	polar auxin transport inhibitor	neurology/psychiatry|allergy|neurology/psychiatry	fatigue|allergic rhinitis|drowsiness	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74d757cd-6eb0-4a14-8b32-4ddd3619d0ca|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74d757cd-6eb0-4a14-8b32-4ddd3619d0ca|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74d757cd-6eb0-4a14-8b32-4ddd3619d0ca
hordenine	hordenine		CN(C)CCc1ccc(O)cc1	Preclinical							
tetrazol-5-yl-glycine-(RS)	tetrazol-5-yl-glycine-(RS)	(Tetrazol-5-yl)glycine-(RS)	NC(C(O)=O)c1nnn[nH]1	Preclinical		GRIN1|GRIN2B|GRIN2A|GRIN2D|GRIN2C	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4068|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4068|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4068|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4068|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4068	glutamate receptor agonist			
furosemide	furosemide	Aquamed|Disal|LB-502|frusemide|lasix	NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl	Launched	FDA Orange Book: furosemide	GPR35|CA2|SLC12A2|SLC12A1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4839|https://www.drugbank.ca/drugs/DB00695|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4839|ChEMBL	diuretic	cardiology|cardiology|cardiology|rheumatology	edema|hypertension|congestive heart failure|nephrotic syndrome	http://www.drugs.com/furosemide.html|http://www.drugs.com/furosemide.html|http://www.drugs.com/furosemide.html|http://www.drugs.com/furosemide.html
ruxolitinib	ruxolitinib	jakafi	N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12	Launched	FDA Orange Book: ruxolitinib phosphate	TYK2|JAK3|JAK2|JAK1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5688|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5688|https://www.drugbank.ca/drugs/DB08877|https://www.drugbank.ca/drugs/DB08877	JAK inhibitor	hematologic malignancy|hematology	myelofibrosis|polycythemia vera	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1c82580-87ae-11e0-bc84-0002a5d5c51b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1c82580-87ae-11e0-bc84-0002a5d5c51b
methotrexate	methotrexate	Abitrexate|CL 14377|Folex|Mexate-AQ|TCMDC-123832|TCMDC-125488|TCMDC-125858|amethopterin|methotrexate lpf|methotrexate preservative free|methotrexate sodium|methotrexate sodium preservative free|methylaminopterin|mexate|otrexup|rasuvo|rheumatrex|trexall		Launched	FDA Orange Book: methotrexate, methotrexate sodium	AOX1|TYMS|FOLR1|DHFR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091367|https://citeline.informa.com/?query=#/drugs/details/11947|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091367|ChEMBL	dihydrofolate reductase inhibitor	oncology|oncology|hematologic malignancy|dermatology|rheumatology	gestational choriocarcinoma|hydatidiform mole|acute lymphoblastic leukemia (ALL)|psoriasis|rheumatoid arthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cf2e15a-6286-41f7-aa7d-3968d735c864|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cf2e15a-6286-41f7-aa7d-3968d735c864|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cf2e15a-6286-41f7-aa7d-3968d735c864|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cf2e15a-6286-41f7-aa7d-3968d735c864|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cf2e15a-6286-41f7-aa7d-3968d735c864
bromopride	bromopride		CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC	Launched	http://en.wikipedia.org/wiki/Bromopride	DRD2	https://www.drugbank.ca/drugs/DB09018	dopamine receptor antagonist	gastroenterology|gastroenterology|gastroenterology	nausea|vomiting|gastroesophageal reflux disease (GERD)	https://en.wikipedia.org/wiki/Bromopride|https://en.wikipedia.org/wiki/Bromopride|https://en.wikipedia.org/wiki/Bromopride
phenprocoumon	phenprocoumon	liquamar	CCC(c1ccccc1)c1c(O)c2ccccc2oc1=O	Launched	FDA Orange Book: phenprocoumon	VKORC1	https://www.drugbank.ca/drugs/DB00946	vitamin K antagonist	hematology|hematology	thrombosis|pulmonary embolism (PE)	https://en.wikipedia.org/wiki/Phenprocoumon|https://en.wikipedia.org/wiki/Phenprocoumon
DMNB	DMNB		COc1cc(C=O)c(cc1OC)[N+]([O-])=O	Preclinical				DNA dependent protein kinase inhibitor			
melperone	melperone	FG 5111|flubuperone	CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1	Launched	http://www.drugs.com/international/Melperone.html	DRD2|HTR2A|HTR1A	http://www.tocris.com/dispprod.php?ItemId=158202#.UuKAhf30BaE|http://www.tocris.com/dispprod.php?ItemId=158202#.UuKAhf30BaE|https://citeline.informa.com/?query=#/drugs/details/11838	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	psychosis	https://en.wikipedia.org/wiki/Melperone
NU-1025	NU-1025		Cc1nc2c(O)cccc2c(=O)[nH]1	Preclinical		PARP1	https://www.drugbank.ca/drugs/DB02690	PARP inhibitor			
solifenacin-succinate	solifenacin-succinate	solifenacin|vesicare	O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1	Launched	FDA Orange Book: solifenacin succinate	CHRM4|CHRM5|CHRM2|CHRM3|CHRM1	https://www.drugbank.ca/drugs/DB01591|https://www.drugbank.ca/drugs/DB01591|https://www.drugbank.ca/drugs/DB01591|https://www.drugbank.ca/drugs/DB01591|https://www.drugbank.ca/drugs/DB01591	acetylcholine receptor antagonist	urology|urology	urinary incontinence|urinary frequency	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9acee910-cdb2-4052-b8b3-c26aff1c8716&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9acee910-cdb2-4052-b8b3-c26aff1c8716&audience=consumer
erythromycin	erythromycin	A/T/S|Benzamycin|Bristamycin|C-SOLVE-2|E-Base|E-Glades|E-Mycin|E-solve 2|Eryc 125|Erypar|Erythra-Derm|Erythro 200|Gallimycin|Pfizer-E|R-p mycin|Robimycin|Sansac|Wyamycin|akne-mycin|emgel|ery-tab|eryc|eryc sprinkles|erycette|eryderm|erygel|erymax|erythro-statin|erythrocin|erythrocin stearate|ilotycin|ilotycin gluceptate|pce|staticin|t-stat	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	Launched	FDA Orange Book: erythromycin, erythromycin estolate, erythromycin ethylsuccinate, erythromycin gluceptate, erythromycin lactobionate, erythromycin stearate	MLNR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1456	NFkB pathway inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a
senicapoc	senicapoc	ICA-17043|PF-05416266	NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/21323872	KCNN4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2331	intermediate conductance potassium channel blocker			
AZM-475271	AZM-475271		COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1	Preclinical		SRC	https://www.tocris.com/products/azm-475271_3963	src inhibitor			
LDN193189	LDN193189		C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12	Preclinical		BMPR1A|ACVR1	http://www.selleckchem.com/products/ldn193189.html?gclid=CL7eqbrKpNICFQK4wAodk4QLHA|http://www.selleckchem.com/products/ldn193189.html?gclid=CL7eqbrKpNICFQK4wAodk4QLHA	bone morphogenic protein inhibitor			
r(-)-apomorphine	apomorphine	r(-)-apomorphine		Launched	http://en.wikipedia.org/wiki/Apomorphine	DRD2|TRPA1|HTR5A	https://en.wikipedia.org/wiki/Apomorphine|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=231571|https://en.wikipedia.org/wiki/Apomorphine	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab5d4084-3121-4043-bc88-a77c5277bc35
tetramethylthiuram-monosulfide	tetramethylthiuram-monosulfide	bis(dimethylaminethiocarbonyl)monosulfide	CN(C)C(=S)SC(=S)N(C)C	Preclinical							
5-aminolevulinic-acid	5-aminolevulinic acid	ameluz|aminolevulinic acid|levulan	NCC(=O)CCC(O)=O	Launched	https://clinicaltrials.gov/ct2/show/NCT01491711	ALAD	https://www.drugbank.ca/drugs/DB00855	oxidizing agent			
traxoprodil	traxoprodil	CP-101,606|CP-101606	C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00163059	GRIN2B	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001022	glutamate receptor antagonist			
loratadine	loratadine	Claritin-D|Loratadine redidose|SCH 29851|SCH-29851|alavert|children's claritin|claritin|claritin hives relief|claritin hives relief reditab|claritin reditabs	CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12	Launched	FDA Orange Book: desloratadine, loratadine	HRH1|CYP3A5|CYP2C19	ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090791|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090791	histamine receptor antagonist	allergy|neurology/psychiatry	allergic rhinitis|itching	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a2f0eef-7803-497d-926c-a6163a89eb56|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a2f0eef-7803-497d-926c-a6163a89eb56
bismuth-oxalate	bismuth-oxalate		[Bi].[Bi].OC(=O)C(O)=O.OC(=O)C(O)=O.OC(=O)C(O)=O	Preclinical							
sodium-gualenate	sodium gualenate	guaiazulene sulfonic acid	CC(C)c1ccc(C)c2c(cc(C)c2c1)S(O)(=O)=O	Launched	http://www.drugs.com/international/sodium gualenate.html			antacid			
sofosbuvir	sofosbuvir	sovaldi	CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1	Launched	FDA Orange Book: sofosbuvir			RNA polymerase inhibitor	infectious disease	hepatitis C	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80beab2c-396e-4a37-a4dc-40fdb62859cf&audience=consumer
triclocarban	triclocarban	tcc soap	Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1	Launched	https://en.wikipedia.org/wiki/Triclocarban			other antibiotic			
Ro-48-8071	Ro-48-8071		CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C	Preclinical		LSS	https://www.drugbank.ca/drugs/DB02016	oxidosqualene cyclase inhibitor			
taurolidine	taurolidine		O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1	Launched	https://www.drugs.com/international/taurolidine.html			apoptosis stimulant	infectious disease	catheter-related bloodstream infection	https://en.wikipedia.org/wiki/Taurolidine#Medical_uses
oxandrolone	oxandrolone	SC 11585|SC-11585|oxandrin	C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)OC[C@]4(C)[C@H]3CC[C@]12C	Launched	FDA Orange Book: oxandrolone	AR	ChEMBL	androgen receptor agonist	endocrinology	weight-gain aid	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f622616e-4c11-4149-bf00-5ea5ce97800b
monastrol	monastrol		CCOC(=O)C1=C(C)NC(=S)NC1c1cccc(O)c1	Preclinical		KIF11	https://www.drugbank.ca/drugs/DB04331	kinesin inhibitor			
ISRIB	ISRIB		Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1	Preclinical		EIF2A|EIF2AK3	http://www.sigmaaldrich.com/catalog/product/sigma/sml0843?lang=en&region=US|http://www.sigmaaldrich.com/catalog/product/sigma/sml0843?lang=en&region=US	eukaryotic translation initiation factor inhibitor|PERK inhibitor			
MK-0773	MK-0773		CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6cccnc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00529659	AR	http://www.merck.com/licensing/news-and-events/gtx-press-release.html	androgen receptor modulator			
GR-135531	GR-135531		COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1	Preclinical				melatonin receptor agonist			
purmorphamine	purmorphamine		C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12	Preclinical		IHH|DHH|PTCH1|SMO	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=832315|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=832315|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=832315|https://www.caymanchem.com/app/template/Product.vm/catalog/10009634	smoothened receptor agonist			
besifloxacin	besifloxacin	besivance	N[C@@H]1CCCCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1	Launched	FDA Orange Book: besifloxacin hydrochloride			bacterial DNA gyrase inhibitor	ophthalmology	conjunctivitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3e6d688-7e5e-4ca3-b27e-79756c322a32
PNU-142633	PNU-142633		CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/12485205	HTR1D	https://www.tocris.com/dispprod.php?ItemId=90707#.V-6EwJMrLy8	serotonin receptor agonist			
Ro-67-7476	Ro-67-7476		Cc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1c1ccc(F)cc1	Preclinical		GRM1	https://www.tocris.com/products/ro-67-7476_4346	glutamate receptor positive allosteric modulator			
clevudine	clevudine		Cc1cn([C@H]2O[C@@H](CO)[C@H](O)[C@@H]2F)c(=O)[nH]c1=O	Launched	http://www.drugs.com/international/Clevudine.html			DNA polymerase inhibitor	infectious disease	hepatitis B	https://en.wikipedia.org/wiki/Clevudine
norvancomycin	norvancomycin		CC(C)CC(N)C(=O)NC1C(O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)C(O)C5NC(=O)C(NC(=O)C4NC(=O)C(CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1C(NC5=O)C(O)=O)c3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1)c(Cl)c2	Preclinical							
PETCM	PETCM		OC(Cc1ccncc1)C(Cl)(Cl)Cl	Preclinical		CASP3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5242	caspase activator			
sorbinil	sorbinil		Fc1ccc2OCCC3(NC(=O)NC3=O)c2c1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00000159	AKR1B1	https://www.drugbank.ca/drugs/DB02712	aldose reductase inhibitor			
tesaglitazar	tesaglitazar	AR-H039242XX|AZ-242|BR-44608|galida	CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00261352	INS|PPARA|PPARG	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=259635|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005195|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005195	insulin sensitizer|PPAR receptor agonist			
terciprazine	terciprazine		OC(COC1(CCCCC1)C#C)CN1CCN(CC1)c1cccc(c1)C(F)(F)F	Phase 1	Pharmaprojects						
xylose	xylose	xylo-pfan	OC[C@@H](O)[C@H](O)[C@@H](O)C=O	Launched	FDA Orange Book: xylose						
oritavancin	oritavancin	LY-333328|orbactiv	CNC(CC(C)C)C(=O)NC1C(O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)C(OC5CC(C)(N)C(O)C(C)O5)C5NC(=O)C(NC(=O)C4NC(=O)C(CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1C(NC5=O)C(O)=O)c3OC1OC(CO)C(O)C(O)C1OC1CC(C)(NCc3ccc(cc3)-c3ccc(Cl)cc3)C(O)C(C)O1)c(Cl)c2	Launched	FDA Orange Book: oritavancin diphosphate			bacterial cell wall synthesis inhibitor	infectious disease	skin infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=085d6d1a-21c2-11e4-8c21-0800200c9a66
M8-B	M8-B		COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1	Preclinical		TRPM8	https://www.tocris.com/products/m8-b-hydrochloride_5324	transient receptor potential channel antagonist			
thiram	thiram	Fernasan|NSC-1771|Puralin|SQ 1489|Thiurad|rezifilm	CN(C)C(=S)SSC(=S)N(C)C	Launched	http://www.drugs.com/international/thiram.html	JAK2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011376		ophthalmology	contact dermatitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f082b68-dc74-418a-9e6f-b3c285b41d44&audience=consumer
atenolol-(+)	(+)-atenolol		CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1	Preclinical				adrenergic receptor antagonist			
SEW-2871	SEW-2871		FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F	Preclinical		S1PR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2926	lysophospholipid receptor agonist			
TC-Mps1-12	TC-Mps1-12		CC(C)(C)Nc1nc(Nc2ccc(cc2)C(N)=O)cc(N)c1C#N	Preclinical		TTK	https://www.tocris.com/products/tc-mps1-12_4750	monopolar spindle 1 kinase inhibitor			
mecamylamine	mecamylamine	inversine	CNC1(C)C2CCC(C2)C1(C)C	Launched	FDA Orange Book: mecamylamine hydrochloride	CHRNA1|CHRNA2|CHRNA3|CHRNA4|CHRNA6|CHRNA7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3990|https://www.drugbank.ca/drugs/DB00657|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3990|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3990|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3990|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3990	acetylcholine receptor antagonist	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b87994ee-26a5-4d00-99e7-796bc17961f1
icaritin	icaritin		COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01972672	PDE5A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008647	PPAR receptor antagonist			
GSK1059615	GSK1059615	GSK-1059615|GSK-615	O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00695448	PIK3CG|PIK3CA	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001089|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=466724	PI3K inhibitor			
VU0357121	VU0357121		CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F	Preclinical		GRM5	http://www.tocris.com/dispprod.php?ItemId=330281#.VhQKIRNViko	glutamate receptor positive allosteric modulator			
tacalcitol	tacalcitol		CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	Launched	http://en.wikipedia.org/wiki/Tacalcitol	VDR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2780	vitamin D receptor agonist	dermatology|dermatology	psoriasis|chapped lips	https://en.wikipedia.org/wiki/Tacalcitol|https://en.wikipedia.org/wiki/Tacalcitol
GSK3787	GSK3787	GSK-3787	FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1	Preclinical		PPARD	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010551	PPAR receptor antagonist			
oxibendazole	oxibendazole	SK&F 30310|anthelcide eq|filaribits plus	CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1	Veterinary Launched	http://www.drugs.com/international/Oxibendazole.html	TUBB|TUBB4B	http://www.merckmanuals.com/vet/pharmacology/anthelmintics/mechanisms_of_action_of_anthelmintics.html|https://www.drugbank.ca/drugs/DB04910	tubulin polymerization inhibitor	infectious disease	strongyles	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35090c5f-09d1-4102-8c5a-fb18e43f10dc
MSX-122	MSX-122		C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00591682	CXCR4	https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=586491	CC chemokine receptor antagonist			
CT-7758	CT-7758		OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00484536	ITGA4	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000743	integrin antagonist			
benzoquinonium-dibromide	benzoquinonium-dibromide	benzoquinonium	CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1	Preclinical		CHRNA1	http://www.tocris.com/dispprod.php?ItemId=2000#.Ve8KLixVhHw	cholinergic receptor antagonist			
TUG-770	TUG-770		OC(=O)CCc1ccc(cc1F)C#Cc1ccccc1CC#N	Preclinical		FFAR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6483	free fatty acid receptor agonist			
carumonam	carumonam		NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O	Launched	http://www.drugs.com/international/carumonam.html			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease	urinary tract infections|gram-negative bacterial infections	https://pubchem.ncbi.nlm.nih.gov/compound/Carumonam#section=Top|https://pubchem.ncbi.nlm.nih.gov/compound/Carumonam#section=Top
fusidic-acid	fusidic acid		C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)C2[C@H](O)C[C@@H]2[C@]1(C)C[C@H](OC(C)=O)\C2=C(/CCC=C(C)C)C(O)=O	Launched	https://clinicaltrials.gov/ct2/show/NCT00986856			bacterial 30S ribosomal subunit inhibitor	dermatology	acne vulgaris (AV)	https://en.wikipedia.org/wiki/Fusidic_acid#Uses
oleoylethanolamide	oleoylethanolamide	N-(2-Hydroxyethyl)Oleamide|N-Oleoylethanolamine|N-Oleylethanolamine|Oleoyl Ethanolamide|Oleoylethanolamine	CCCCCCCC\C=C/CCCCCCCC(=O)NCCO	Preclinical		GPR55|GPR119|CNR1|KCND3|PPARA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006339|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=312610|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661	cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist			
antagonist-g	antagonist-g		CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/11595697	MAPK8	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374683/pdf/83-6691362a.pdf	neuropeptide receptor antagonist			
benaxibine	benaxibine		OC1COC(Nc2ccc(cc2)C(O)=O)C(O)C1O	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/6985199						
thalidomide	thalidomide	K-17|thalomid	O=C1N(C2CCC(=O)NC2=O)C(=O)c2ccccc12	Launched	FDA Orange Book: thalidomide	CRBN|NFKB1|PTGS2|ORM2|ORM1|TNF|CYP1A2|FGFR2|CYP3A5|CYP2B6|CYP2C19	https://www.drugbank.ca/drugs/DB01041|https://www.drugbank.ca/drugs/DB01041|https://www.drugbank.ca/drugs/DB01041|https://www.drugbank.ca/drugs/DB01041|https://www.drugbank.ca/drugs/DB01041|https://www.drugbank.ca/drugs/DB01041|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091361|https://www.drugbank.ca/drugs/DB01041|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091361|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091361|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091361	tumor necrosis factor production inhibitor			
lacosamide	lacosamide	ADD 243037|SPM 927|erlosamide|vimpat	COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1	Launched	FDA Orange Book: lacosamide	DPYSL2|CYP2C19|SCN1A|SCN3A|SCN2A|SCN5A|SCN4A|SCN8A|SCN7A|SCN9A|SCN10A|SCN11A	https://citeline.informa.com/?query=#/drugs/details/24189|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=278582|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	collapsin response mediator protein inhibitor|collapsin response mediator protein stimulant|sodium channel blocker	neurology/psychiatry	seizures	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e79b42c-38a3-4b2c-a196-a5a1948250e2
L-689560	L-689560		OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1	Preclinical		GRIN2D|GRIN2C|GRIN2B|GRIN2A|GRIN1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4239|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4239|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4239|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4239|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4239	glutamate receptor antagonist			
tribomsalan	tribomsalan	ET-394|TUASOL 100|tribromsalan	Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1	Preclinical							
ferulic-acid	Ferulic acid	Ferulic acid	COc1cc(\C=C\C(O)=O)ccc1O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/21272180	CA1|CA2|CA9|CA6|CA4|CA14|CA12	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010453|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010453|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010453|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010453|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010453|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010453|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010453	antioxidant			
DPO-1	DPO-1		CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1	Preclinical		KCNA5	https://www.tocris.com/dispprod.php?ItemId=160533#.VyjUz2QrImI	potassium channel blocker			
sodium-glucoheptonate	sodium glucoheptonate		OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O	Launched	http://www.drugs.com/pro/glucoheptonate-injection.html						
diethyltoluamide	diethyltoluamide	DEET	CCN(CC)C(=O)c1cccc(C)c1	Launched	http://www.drugs.com/international/diethyltoluamide.html			ionotropic receptor IR40a activator	dermatology	sunscreen lotion	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ccdc093-8af9-4bd8-84b0-f229fccd2f1c
phenformin	phenformin		NC(=N)NC(=N)NCCc1ccccc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	KCNJ8|PRKAA1	https://www.drugbank.ca/drugs/DB00914|https://www.drugbank.ca/drugs/DB00914	AMPK activator			
felbamate	felbamate	W-554|felbatol	NC(=O)OCC(COC(N)=O)c1ccccc1	Launched	FDA Orange Book: felbamate	GRIN1|GRIN2A|GRIN2D|GRIN2B|GRIN2C|GRIN3A|GRIN3B	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	glutamate receptor antagonist	neurology/psychiatry	epilepsy	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0c15d60-1171-11e1-9be0-0002a5d5c51b
chloramphenicol-sodium-succinate	chloramphenicol sodium succinate	Chloramphenicol succinate|chloramphenicol sodium succinate|chloramphenicol succinic acid|chloromycetin	O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)c1ccc(cc1)[N+]([O-])=O	Launched	FDA Orange Book: chloramphenicol sodium succinate			protein synthesis inhibitor	infectious disease	gram-negative bacterial infections	http://www.rxlist.com/chloramphenicol-sodium-succinate-drug/indications-dosage.htm#I
S-07662	S-07662		Cc1oc2ccccc2c1CNC(=O)NCc1cccs1	Preclinical		NR1I3	https://www.tocris.com/products/s-07662_5188	CAR antagonist			
trimethoprim	trimethoprim	BW 56-72|BW-56-72|Monotrim|Polytrim|Proloprin|TCMDC-125538|primsol|proloprim|trimpex|trimpex 200	COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC	Launched	FDA Orange Book: trimethoprim, trimethoprim hydrochloride, trimethoprim sulfate	DHFR|SLC22A2|TYMS|CYP2C8	https://www.drugbank.ca/drugs/DB00440|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070196|https://www.drugbank.ca/drugs/DB00440|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070196	dihydrofolate reductase inhibitor	infectious disease|infectious disease|gastroenterology	urinary tract infections|ear infections|diarrhea	https://en.wikipedia.org/wiki/Trimethoprim|https://en.wikipedia.org/wiki/Trimethoprim|https://en.wikipedia.org/wiki/Trimethoprim
riociguat	riociguat	adempas	COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12	Launched	FDA Orange Book: riociguat	GUCY1B2|GUCY1A3|GUCY1A2|GUCY1B3	ChEMBL|ChEMBL|ChEMBL|ChEMBL	guanylate cyclase stimulant	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b57509a-3d5d-41d4-8fed-1471e26372a3
clindamycin-palmitate	clindamycin palmitate	cleocin	CCCCCCCCCCCCCCCC(=O)OC1C(O)C(O)C(OC1SC)C(NC(=O)C1CC(CCC)CN1C)C(C)Cl	Launched	FDA Orange Book: clindamycin palmitate hydrochloride			bacterial 50S ribosomal subunit inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	intra-abdominal infections|skin infections|pneumonia|peritonitis|gynecologic infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bfe1e25-f0a1-4e11-9827-82912557c46b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bfe1e25-f0a1-4e11-9827-82912557c46b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bfe1e25-f0a1-4e11-9827-82912557c46b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bfe1e25-f0a1-4e11-9827-82912557c46b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bfe1e25-f0a1-4e11-9827-82912557c46b
AM-251	AM-251		Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	Preclinical		GPR18|GPR55|CNR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3317|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3317|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000189	cannabinoid receptor antagonist			
HA-14-1	HA-14-1		CCOC(=O)C(C#N)C1c2cc(Br)ccc2OC(N)=C1C(=O)OCC	Preclinical		BCL2	http://www.tocris.com/dispprod.php?ItemId=40985#.Utleaf30DmE	BCL inhibitor			
methapyrilene	methapyrilene		CN(C)CCN(Cc1cccs1)c1ccccn1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	HRH1	http://www.sigmaaldrich.com/catalog/product/sigma/m9125?lang=en&region=US	histamine receptor antagonist			
iopanic-acid	iopanic acid	iodopanoic acid|iopanoic acid|jopanoic acid|telepaque	CCC(Cc1c(I)cc(I)c(N)c1I)C(O)=O	Preclinical				thyroid hormone inhibitor			
GW-583340	GW-583340		CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1	Preclinical		EGFR|ERBB2	http://www.tocris.com/dispprod.php?ItemId=129574#.Ut_kKv30BaE|http://www.tocris.com/dispprod.php?ItemId=129574#.Ut_kKv30BaE	EGFR inhibitor			
sevelamer	sevelamer	renagel|renvela	NCC=C.ClCC1CO1	Launched	FDA Orange Book: sevelamer carbonate, sevelamer hydrochloride			phosphate antagonist	nephrology	chronic kidney disease (CKD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fda5030-f763-46af-93be-72edd2c7df14&audience=consumer
PF-915275	PF-915275		Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1	Phase 1	https://books.google.com/books?id=-Z_Sz4tljHEC&pg=PA139&lpg=PA139&dq=PF-915275+clinical+trials&source=bl&ots=shbkAyLrzZ&sig=xaZXn3Oz1_tBU3WpQ0MBN6eyPmU&hl=en&sa=X&ved=0ahUKEwjTpPeOtOfPAhXB0h4KHYvZBnIQ6AEIKDAC#v=onepage&q=PF-915275%20clinical%20trials&f=false	HSD11B1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014069	11-beta hydroxysteroid dehydrogenase inhibitor			
9-aminoacridine	9-aminoacridine	aminacrine|aminoacridine	Nc1c2ccccc2nc2ccccc12	Preclinical							
nepafenac	nepafenac	AHR-9434|AL-6515|ilevro|nevanac	NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N	Launched	FDA Orange Book: nepafenac	PTGS2|PTGS1	ChEMBL|ChEMBL	cyclooxygenase inhibitor	ophthalmology	eye inflammation	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c212466-ff8d-ecfc-ede2-ef8bdcaaf114
cetilistat	cetilistat	ATL-962	CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1	Phase 3	http://en.wikipedia.org/wiki/Cetilistat	PNLIP|LIPG|LIPC|LIPE	http://www.ncbi.nlm.nih.gov/pubmed/18500680|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=292439|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=292439|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=292439	triacylglycerol lipase inhibitor			
sitaxentan	sitaxentan	Thelin	Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	EDNRA	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000593	endothelin receptor antagonist			
SRPIN340	SRPIN340		FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1	Preclinical		SRPK2|SRPK1	https://www.tocris.com/dispprod.php?ItemId=394480#.VyuzgGQrJZI|https://www.tocris.com/dispprod.php?ItemId=394480#.VyuzgGQrJZI	serine arginine protein kinase inhibitor			
clotrimazole	clotrimazole	BAY 5097|BAY-5097|Canesten|GNF-Pf-3499|Gynix|gyne-lotrimin|gyne-lotrimin 3|gyne-lotrimin 3 combination pack|gyne-lotrimin combination pack|lotrimin|mycelex|mycelex-7|mycelex-7 combination pack|mycelex-g|trivagizole 3	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	Launched	FDA Orange Book: clotrimazole	CYP3A4|KCNN4|TRPM2|TRPM4|TRPM8|NR1I2|NR1I3|CYP51A1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000138|https://www.drugbank.ca/drugs/DB00257|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2330|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2330|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2330|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2330|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2330|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070353	cytochrome P450 inhibitor|imidazoline receptor ligand	infectious disease|infectious disease	vulvovaginal candidiasis|oropharyngeal candidiasis	https://en.wikipedia.org/wiki/Clotrimazole|https://en.wikipedia.org/wiki/Clotrimazole
atomoxetine	atomoxetine	strattera	CNCC[C@@H](Oc1ccccc1C)c1ccccc1	Launched	FDA Orange Book: atomoxetine hydrochloride	SLC6A3|SLC6A4|SLC6A2|GRIN2D|GRIN2A|GRIN2C|GRIN2B|GRIN3B|GRIN3A|GRIN1	https://www.drugbank.ca/drugs/DB00289|https://www.drugbank.ca/drugs/DB00289|https://www.drugbank.ca/drugs/DB00289|https://www.drugbank.ca/drugs/DB00289|https://www.drugbank.ca/drugs/DB00289|https://www.drugbank.ca/drugs/DB00289|https://www.drugbank.ca/drugs/DB00289|https://www.drugbank.ca/drugs/DB00289|https://www.drugbank.ca/drugs/DB00289|https://www.drugbank.ca/drugs/DB00289	norepinephrine transporter inhibitor	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47137273-b9c1-4cb4-99ca-2dab9690b560
dihomo-gamma-linolenic-acid	dihomo-gamma-linolenic acid	Cis-8,11,14-Eicosatrienoicacid|dihomo-gamma-linolenic acid	CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/2870533	PTGS2|PTGS1	https://www.drugbank.ca/drugs/DB00154|https://www.drugbank.ca/drugs/DB00154	prostanoid receptor agonist			
dehydrocholate-acid	dehydrocholate acid		CC(CCC(O)=O)[C@H]1CCC2C3C(CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O	Preclinical							
lopinavir	lopinavir	A-157378-0|A-157378.0|ABT-378|Kaletra	CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1	Launched	FDA Orange Book: lopinavir			HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7fc2d1e-802e-4da1-9763-3355f8aafe3a
pasireotide	pasireotide	signifor|signifor lar	NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1	Launched	FDA Orange Book: pasireotide diaspartate	SSTR1|SSTR3|SSTR2|SSTR5|GH1	https://www.drugbank.ca/drugs/DB06663|https://www.drugbank.ca/drugs/DB06663|https://www.drugbank.ca/drugs/DB06663|https://www.drugbank.ca/drugs/DB06663|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=305198	somatostatin receptor agonist	endocrinology|endocrinology	Cushing's syndrome|acromegaly	https://en.wikipedia.org/wiki/Pasireotide|https://en.wikipedia.org/wiki/Pasireotide
dabigatran	dabigatran	BIBR 953 ZW|BIBR-953|pradaxa	Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1	Launched	FDA Orange Book: dabigatran etexilate mesylate	F2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6380	thrombin inhibitor	neurology/psychiatry|hematology|hematology|hematology	stroke|systemic embolism|pulmonary embolism (PE)|deep vein thrombosis (DVT)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9
SB-216641	SB-216641		COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C	Preclinical		HTR1D|HTR2C|HTR2A|HTR2B|HTR1B|HTR1A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=28|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=28|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=28|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=28|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=28|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=28	serotonin receptor antagonist			
TC2559	TC2559		CCOc1cncc(\C=C\CCNC)c1	Preclinical		CHRNA4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3987	acetylcholine receptor agonist			
calcium-levofolinate	calcium-levofolinate	levoleucovorin	Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1	Launched	http://en.wikipedia.org/wiki/Folinic_acid						
dextran	dextran	Gentran|Hemodex|Hyskon|Onkotin|Rheomacrodex|dexferrum|infed|iron dextran|proferdex	OC[C@H]1O[C@H](OC[C@H]2O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	Launched	FDA Orange Book: iron dextran				hematology|critical care	thrombosis|hypovolemia	https://en.wikipedia.org/wiki/Dextran|https://en.wikipedia.org/wiki/Dextran
6-aminochrysene	6-aminochrysene	Chrysen-6-ylamine	Nc1cc2c3ccccc3ccc2c2ccccc12	Phase 2	https://eurekamag.com/research/029/743/029743970.php			transferase inhibitor			
naphazoline	naphazoline	Nafazair|naphazoline hydrochloride	C(C1=NCCN1)c1cccc2ccccc12	Launched	FDA Orange Book: naphazoline hydrochloride	ADRA2A|ADRA1A	https://www.drugbank.ca/drugs/DB06711|https://www.drugbank.ca/drugs/DB06711	adrenergic receptor agonist	ophthalmology	eye irritation	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6665d0e3-e35b-45e4-b0fe-24c25e26f5ad
GSK923295	GSK923295		CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00504790	CENPE	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000395	centromere associated protein inhibitor			
CCMQ	CCMQ		OC(=O)Cc1cc2ccccc2nc1C(O)=O	Preclinical				homoquinolinic acid binding inhibitor			
CCMI	CCMI		Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1	Preclinical		CHRNA7	http://www.tocris.com/dispprod.php?ItemId=247969#.VfHIRmTBwXA	acetylcholine receptor allosteric modulator			
trapidil	trapidil	AR 12008|trapymin	CCN(CC)c1cc(C)nc2ncnn12	Launched	http://www.drugs.com/international/Trapidil.html	PDGFRA	http://www.sigmaaldrich.com/catalog/product/sigma/sml0071?lang=en&region=US	PDGFR tyrosine kinase receptor inhibitor	cardiology	coronary artery disease (CAD)	http://www.drugbank.ca/drugs/DB09283
cephalexin	cephalexin	cefalexin|keflet|keflex|keftab	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O	Launched	FDA Orange Book: cephalexin, cephalexin hydrochloride			bacterial cell wall synthesis inhibitor	infectious disease|otolaryngology|infectious disease|infectious disease|infectious disease	respiratory tract infections|otitis|skin infections|bone and joint infections|genitourinary tract infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19307ff0-71de-477b-965d-ea243e5ede3a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19307ff0-71de-477b-965d-ea243e5ede3a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19307ff0-71de-477b-965d-ea243e5ede3a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19307ff0-71de-477b-965d-ea243e5ede3a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19307ff0-71de-477b-965d-ea243e5ede3a
desoxypeganine	desoxypeganine		C1CN2Cc3ccccc3N=C2C1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/18560630	MAOA|ACHE	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=410376|http://www.scbt.com/datasheet-204712-desoxypeganine-hydrochloride.html	acetylcholinesterase inhibitor|monoamine oxidase inhibitor			
R112	R112	R-112	Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1	Preclinical		SYK	https://www.ncbi.nlm.nih.gov/pubmed/15806000	syk inhibitor			
paritaprevir	paritaprevir	ABT-450	Cc1cnc(cn1)C(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)Oc1nc2ccccc2c2ccccc12)C(=O)NS(=O)(=O)C1CC1	Launched	FDA Orange Book: paritaprevir			HCV inhibitor	infectious disease	hepatitis C	https://en.wikipedia.org/wiki/Paritaprevir
BX-795	BX-795		Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1	Preclinical		CDK2|CHEK1|PDK1|IKBKE|TBK1|KDR|GSK3B|PDPK1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8006|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8006|http://www.selleckchem.com/products/bx-795.html?gclid=CLj64ay5zLoCFYqi4AodWFIAOQ|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=380880|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=380880|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8006|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8006|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8006	IKK inhibitor			
kynurenic-acid	Kynurenic Acid	Kynurenic Acid|transtorine	OC(=O)c1cc(O)c2ccccc2n1	Preclinical		GPR35|GRIN1|GRIN2B|GRIN2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2918|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012515|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012515|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012515	glutamate receptor antagonist			
LY-404187	LY-404187		CC(CNS(=O)(=O)C(C)C)c1ccc(cc1)-c1ccc(cc1)C#N	Preclinical		GRIA2|GRIA3|GRIA4|GRIA1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4249|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4249|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4249|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4249	glutamate receptor positive allosteric modulator			
oxyclozanide	oxyclozanide	ICI 46683	Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl	Veterinary Launched	http://www.drugs.com/international/oxyclozanide.html				infectious disease	fascioliasis	https://en.wikipedia.org/wiki/Oxyclozanide
SBHA	SBHA		ONC(=O)CCCCCCC(=O)NO	Preclinical		HDAC3|HDAC1	https://www.tocris.com/products/sbha_3810|https://www.tocris.com/products/sbha_3810	HDAC inhibitor			
chlorpropham	chlorpropham	Chloropropham	CC(C)OC(=O)Nc1cccc(Cl)c1	Phase 1	http://www.ipha.ie/GetAttachment.aspx?id=cc791f7e-cfa5-4432-911d-32ce28daad42			antiviral			
MPEP	MPEP		Cc1cccc(n1)C#Cc1ccccc1	Preclinical		GRM4|GRM5|GRM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1426|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1426|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006125	glutamate receptor antagonist			
DCPIB	DCPIB		CCCCC1(Cc2cc(OCCCC(O)=O)c(Cl)c(Cl)c2C1=O)C1CCCC1	Preclinical		SLC1A2	http://www.ncbi.nlm.nih.gov/pubmed/23012257	chloride channel blocker|gap junction modulator|glutamate inhibitor			
2-hydroxysaclofen	2-hydroxysaclofen		NCC(O)(CS(O)(=O)=O)c1ccc(Cl)cc1	Preclinical		GABBR1|GABBR2	http://www.tocris.com/dispprod.php?ItemId=1497#.VeSkLCxVhHw|http://www.tocris.com/dispprod.php?ItemId=1497#.VeSkLCxVhHw	GABA receptor antagonist			
ETC-159	ETC-159		Cn1c2ncn(CC(=O)Nc3ccc(nn3)-c3ccccc3)c2c(=O)n(C)c1=O	Phase 1	https://www.duke-nus.edu.sg/news/first-made-singapore-cancer-drug-enters-clinical-testing	PORCN	https://www.ncbi.nlm.nih.gov/pubmed/26257057	porcupine inhibitor|beta catenin inhibitor			
levomepromazine	levomepromazine	CL 36467|CL 39743|CL-36467|CL-39743|Nirvan|RP 7044|RP-7044|SK&F 5116|SK&F-5116|Tisercin|XP03|levoprome|methotrimeprazine	COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1	Launched	http://en.wikipedia.org/wiki/Levomepromazine	HRH1|ADRA1A|ADRA1B|ADRA1D|ADRA2B|ADRA2C|ADRA2A|HTR2A|HTR2C|DRD1|DRD4|DRD5|DRD2|DRD3|CHRM4|CHRM5|CHRM1|CHRM2|CHRM3	https://www.drugbank.ca/drugs/DB01403|https://www.drugbank.ca/drugs/DB01403|https://www.drugbank.ca/drugs/DB01403|https://www.drugbank.ca/drugs/DB01403|https://www.drugbank.ca/drugs/DB01403|https://www.drugbank.ca/drugs/DB01403|https://www.drugbank.ca/drugs/DB01403|https://www.drugbank.ca/drugs/DB01403|https://www.drugbank.ca/drugs/DB01403|https://www.drugbank.ca/drugs/DB01403|ChEMBL|https://www.drugbank.ca/drugs/DB01403|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB01403|https://www.drugbank.ca/drugs/DB01403|https://www.drugbank.ca/drugs/DB01403|https://www.drugbank.ca/drugs/DB01403|https://www.drugbank.ca/drugs/DB01403	dopamine receptor antagonist	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|gastroenterology|neurology/psychiatry	psychosis|schizophrenia|bipolar disorder|nausea|insomnia	https://en.wikipedia.org/wiki/Levomepromazine#Medical_uses|https://en.wikipedia.org/wiki/Levomepromazine#Medical_uses|https://en.wikipedia.org/wiki/Levomepromazine#Medical_uses|https://en.wikipedia.org/wiki/Levomepromazine#Medical_uses|https://en.wikipedia.org/wiki/Levomepromazine#Medical_uses
desogestrel	desogestrel	ORG 2969|ORG-2969	CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	Launched	FDA Orange Book: desogestrel	PGR|ESR1	ChEMBL|https://www.drugbank.ca/drugs/DB00304	progesterone receptor agonist	endocrinology	contraceptive	https://en.wikipedia.org/wiki/Desogestrel
pirenoxine	pirenoxine		OC(=O)c1cc(O)c2c3nc4ccccc4oc3cc(=O)c2n1	Launched	http://www.drugs.com/international/Pirenoxine.html			AGE inhibitor	ophthalmology	cataracts	https://en.wikipedia.org/wiki/Pirenoxine
elafibranor	elafibranor		CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02704403	PPARD|PPARA	https://en.wikipedia.org/wiki/Elafibranor|https://en.wikipedia.org/wiki/Elafibranor	PPAR receptor agonist			
YM022	YM022		Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1	Phase 2	http://adisinsight.springer.com/drugs/800004033	CCKBR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=888	CCK receptor antagonist			
GDC-0980	GDC-0980	G-038390|G-038390.1|GDC-0980.1|RG-7422|RG7422|apitolisib	C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01442090	PIK3CA|PIK3CB|PIK3CD|PIK3CG|MAP3K9|FGR|MTOR|SYK	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888	mTOR inhibitor|PI3K inhibitor			
stanozolol	stanozolol	Stromba|Tevabolin|WIN 14833|WIN-14833|Winstrol Depot|winstrol	C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4Cc5[nH]ncc5C[C@]4(C)[C@H]3CC[C@]12C	Launched	FDA Orange Book: stanozolol	AR	ChEMBL	androgen receptor agonist	hematology	anemia	https://en.wikipedia.org/wiki/Stanozolol
carvedilol	carvedilol	BM 14.190|BM-14-190|BM-14.190|coreg|coreg cr	COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12	Launched	FDA Orange Book: carvedilol, carvedilol phosphate	ADRA2A|ADRA2C|ADRA2B|ADRA1D|ADRA1B|ADRA1A|CYP2E1|KCNH2|NPPB|RYR2|ADRB3|ADRB2|ADRB1|SELE|NDUFC2|GJA1|CYP2C19|VEGFA|VCAM1|HIF1A	https://www.drugbank.ca/drugs/DB01136|https://www.drugbank.ca/drugs/DB01136|https://www.drugbank.ca/drugs/DB01136|ChEMBL|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090701|https://www.drugbank.ca/drugs/DB01136|https://www.drugbank.ca/drugs/DB01136|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090701|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB01136|https://www.drugbank.ca/drugs/DB01136|https://www.drugbank.ca/drugs/DB01136|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090701|https://www.drugbank.ca/drugs/DB01136|https://www.drugbank.ca/drugs/DB01136|https://www.drugbank.ca/drugs/DB01136	adrenergic receptor antagonist	cardiology|cardiology	myocardial infarction|hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6eb861c-085e-442a-8e71-722587493d5d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6eb861c-085e-442a-8e71-722587493d5d
GF109203X	GF109203X	BIM-1|BISINDOLYLMALEIMIDE 1|GF-109203|GF-109203X	CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12	Preclinical		PRKCI|PRKCZ|CDK4|PIM1|CCND1|PDPK1|LRRK2	https://www.drugbank.ca/drugs/DB03777|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000324|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=191295|https://www.drugbank.ca/drugs/DB03777|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=191295|https://www.drugbank.ca/drugs/DB03777|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=191295	PKC inhibitor			
micafungin	micafungin	mycamine		Launched	FDA Orange Book: micafungin sodium			fungal 1,3-beta-D-glucan synthase inhibitor	infectious disease|infectious disease|infectious disease	candidemia|peritonitis|esophageal candidiasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc234dd7-5221-4a68-b153-aa0393c75bbf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc234dd7-5221-4a68-b153-aa0393c75bbf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc234dd7-5221-4a68-b153-aa0393c75bbf
TAK-632	TAK-632		Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F	Preclinical		BRAF|RAF1	http://www.biovision.com/tak-632-7906.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=698424	RAF inhibitor			
tecovirimat	tecovirimat		FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02474589			orthopoxvirus egress inhibitor			
ZD-7155	ZD-7155		CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nnn[nH]3)C(=O)CCc2c(CC)n1	Preclinical		AGTR1	http://www.tocris.com/dispprod.php?ItemId=1327#.Ut7Aff30DmE	angiotensin receptor antagonist			
tetrandrine	tetrandrine	(+)-Isotetrandrine|D-Tetrandrine	COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34	Preclinical		SLC6A3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013982	calcium channel blocker			
JNJ-7706621	JNJ-7706621		Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F	Preclinical		AURKA|AURKB|CDK1|CDK2	http://www.selleckchem.com/products/JNJ-7706621.html|http://www.selleckchem.com/products/JNJ-7706621.html|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5932|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5932	CDK inhibitor			
INS316	INS316		OC1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H](C1O)n1ccc(=O)[nH]c1=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00008255			purinergic receptor antagonist			
BRD4770	BRD4770		COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1	Preclinical		EHMT2	https://www.caymanchem.com/product/11787	histone lysine methyltransferase inhibitor			
paraxanthine	paraxanthine		Cn1cnc2[nH]c(=O)n(C)c(=O)c12	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/8529334			adenosine receptor antagonist			
midecamycin	midecamycin		CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C	Launched	http://www.drugs.com/international/midecamycin.html			protein synthesis inhibitor	infectious disease|infectious disease|infectious disease	respiratory tract infections|ear infections|skin infections	http://www.druginfosys.com/drug.aspx?drugcode=932&type=1|http://www.druginfosys.com/drug.aspx?drugcode=932&type=1|http://www.druginfosys.com/drug.aspx?drugcode=932&type=1
KW-2478	KW-2478		CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT01063907			HSP inhibitor			
fumagillin	fumagillin		CO[C@@H]1[C@@H](CC[C@]2(CO2)C1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O	Launched	http://www.drugs.com/international/fumagillin.html	METAP2	https://www.drugbank.ca/drugs/DB02640	methionine aminopeptidase inhibitor	infectious disease	microsporidiosis	https://en.wikipedia.org/wiki/Fumagillin
quinethazone	quinethazone	chinethazone|hydromox	CCC1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O	Launched	FDA Orange Book: quinethazone	SLC12A2|SLC12A3|SLC12A1|CA1|CA2	https://www.drugbank.ca/drugs/DB01325|ChEMBL|https://www.drugbank.ca/drugs/DB01325|https://www.drugbank.ca/drugs/DB01325|https://www.drugbank.ca/drugs/DB01325	thiazide diuretic	cardiology	hypertension	https://en.wikipedia.org/wiki/Quinethazone
pyrrolidine-dithiocarbamate	Pyrrolidine Dithiocarbamate	Pyrrolidine Dithiocarbamate|Pyrrolidine-1-Carbodithioic Acid|Pyrrolidinedithiocarbamate	SC(=S)N1CCCC1	Preclinical		HSD11B1|RELA	http://en.wikipedia.org/wiki/Pyrrolidine_dithiocarbamate|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001177	NFkB pathway inhibitor			
oxonic-acid	oxonic acid	oteracil	OC(=O)c1nc(=O)[nH]c(=O)[nH]1	Preclinical				uricase inhibitor			
vatalanib	vatalanib	BAY-86-5127|CGP-79787|K-222584|NVP-PTK787|PTK-787|PTK787|ZK-222584	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00056446	PDGFRB|PDGFRA|KIT|KDR|CYP19A1|EGFR|FLT1|FLT4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5705|https://citeline.informa.com/?query=#/drugs/details/24885|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=271217|https://www.drugbank.ca/drugs/DB04879|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=271217|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005636|https://www.drugbank.ca/drugs/DB04879|https://www.drugbank.ca/drugs/DB04879	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor			
metrizoic-acid	metrizoic acid	Metrizoate|metrizoic acid	CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	Launched	FDA Orange Book: metrizoic acid			radiopaque medium	radiology	contrast agent	https://en.wikipedia.org/wiki/Metrizoic_acid
prucalopride	prucalopride	R-093877	COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12	Launched	http://www.drugs.com/international/Prucalopride.html	HTR4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=243	serotonin receptor agonist	gastroenterology	constipation	https://en.wikipedia.org/wiki/Prucalopride
cinnarazine	cinnarazine	516 MD|R 1575|R 516|Stugeron|Stunarone|cinnarizine|stutgin	C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1	Launched	http://www.drugs.com/international/cinnarizine.html			calcium channel blocker	neurology/psychiatry|gastroenterology|gastroenterology|ophthalmology	Meniere's disease|nausea|vomiting|Cogan's syndrome	https://en.wikipedia.org/wiki/Cinnarizine|https://en.wikipedia.org/wiki/Cinnarizine|https://en.wikipedia.org/wiki/Cinnarizine|https://en.wikipedia.org/wiki/Cinnarizine
KY02111	KY02111		COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC	Preclinical		DKK1	http://www.selleckchem.com/products/ky02111.html	Wnt pathway inhibitor			
propagermanium	propagermanium		OC(=O)CC[Ge](=O)O[Ge](=O)CCC(O)=O	Launched	https://www.drugs.com/international/propagermanium.html	CCR2	http://www.jvascsurg.org/article/S0741-5214(14)00561-8/abstract	interferon receptor agonist|CCR agonist	infectious disease	hepatitis B	https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=propagermanium
2-fluoro-2-deoxy-D-galactose	D-galactose, 2-deoxy-2-fluoro-		OCC1OC(O)C(F)C(O)C1O	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/24591487	LCT	https://www.drugbank.ca/drugs/DB04282				
ML204	ML204		Cc1cc(nc2ccccc12)N1CCCCC1	Preclinical		TRPC4|TRPC5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4255|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4255	transient receptor potential channel antagonist			
bucillamine	bucillamine		CC(C)(S)C(=O)N[C@@H](CS)C(O)=O	Launched	http://www.drugs.com/international/Bucillamine.html			immunosuppressant	rheumatology	rheumatoid arthritis	http://www.marketwired.com/press-release/revive-therapeutics-ltd-announces-us-fda-acceptance-ind-commence-clinical-trial-bucillamine-tsx-venture-rvv-1971861.htm
AGM-1470	AGM-1470		CO[C@@H]1[C@@H](CC[C@]2(CO2)C1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl	Phase 2	http://adisinsight.springer.com/drugs/800001587	METAP2	https://www.drugbank.ca/drugs/DB08633	cell cycle inhibitor			
dicyclohexylamine	dicyclohexylamine		C1CCC(CC1)NC1CCCCC1	Preclinical							
dimethindene-(S)-(+)	(S)-(+)-dimethindene		C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1	Preclinical				acetylcholine receptor antagonist			
dipeptamin	dipeptamin		C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O	Launched	https://clinicaltrials.gov/ct2/show/NCT02130674						
hydroxychloroquine	hydroxychloroquine	plaquenil	CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12	Launched	FDA Orange Book: hydroxychloroquine sulfate	TLR7|TLR9	https://www.drugbank.ca/drugs/DB01611|https://www.drugbank.ca/drugs/DB01611	antimalarial agent	infectious disease	malaria	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6016af90-6311-4f35-bfc3-ce49c105ba4f
JNJ-38877605	JNJ-38877605		Cn1cc(cn1)-c1ccc2nnc(n2n1)C(F)(F)c1ccc2ncccc2c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00651365	MET	http://www.selleckchem.com/products/JNJ-38877605.html	tyrosine kinase inhibitor			
tricaprylin	tricaprylin	tricaprilin	CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC	Launched	https://en.wikipedia.org/wiki/Axona				dermatology	cosmetic	https://www.ewg.org/skindeep/ingredient/706616/TRICAPRYLIN/
iloperidone	iloperidone	HP 873|fanapt	COc1cc(ccc1OCCCN1CCC(CC1)c1noc2cc(F)ccc12)C(C)=O	Launched	FDA Orange Book: iloperidone	HRH1|HTR6|HTR7|HTR2A|HTR1A|DRD1|DRD2|DRD3|DRD4|ADRA1A|ADRA2C	https://www.drugbank.ca/drugs/DB04946|https://www.drugbank.ca/drugs/DB04946|https://www.drugbank.ca/drugs/DB04946|ChEMBL|https://www.drugbank.ca/drugs/DB04946|https://www.drugbank.ca/drugs/DB04946|ChEMBL|https://www.drugbank.ca/drugs/DB04946|https://www.drugbank.ca/drugs/DB04946|https://www.drugbank.ca/drugs/DB04946|https://www.drugbank.ca/drugs/DB04946	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43452bf8-76e7-47a9-a5d8-41fe84d061f0
benfluorex	benfluorex		CC(Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1	Withdrawn	http://en.wikipedia.org/wiki/Benfluorex	HMGCR	http://www.ncbi.nlm.nih.gov/pubmed/3816510	gluconeogenesis inhibitor			
2-(chloromethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one	2-(chloromethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one		ClC=C1Nc2sc3CCCCc3c2C(=O)N1	Preclinical							
beta-Hydroxybutyrate	beta-Hydroxybutyrate	3-Hydroxybutanoate	CC(O)CC(O)=O	Phase 1	http://www.businesswire.com/news/home/20041213005559/en/KetoCytonyx-Reports-Positive-Phase-Study-Neuroprotectant-KTX	HCAR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1593				
sulfanilamide	sulfanilamide	avc	Nc1ccc(cc1)S(N)(=O)=O	Launched	FDA Orange Book: sulfanilamide	CYP3A4|CYP2E1|CYP2D6|CYP2C9|CA1|CA2|CA9|CYP2C19	http://www.drugbank.ca/drugs/DB00259|http://www.drugbank.ca/drugs/DB00259|http://www.drugbank.ca/drugs/DB00259|http://www.drugbank.ca/drugs/DB00259|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=343194|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=343194|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=343194|http://www.drugbank.ca/drugs/DB00259	carbonic anhydrase inhibitor	infectious disease	vulvovaginal candidiasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d344f475-1bf2-4aaf-aae3-0cd0be4995d1&audience=consumer
AZD3839	AZD3839		NC1N[C@](c2cccc(F)c12)(c1ccnc(c1)C(F)F)c1cccc(c1)-c1cncnc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01348737	BACE1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6931	beta-secretase inhibitor			
NBI-74330-(+/-)	(+/-)-NBI-74330		CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)C(C)N(Cc1cccnc1)C(=O)Cc1ccc(F)c(c1)C(F)(F)F	Preclinical				CC chemokine receptor antagonist			
rubitecan	rubitecan	9-NC|RFS 2000	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00005871	TOP1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000115	topoisomerase inhibitor			
RS-16566	RS-16566		CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1CN2CCC1CC2	Preclinical				serotonin receptor antagonist			
rivanicline	rivanicline	TC-2403	CNCC\C=C\c1cccnc1	Phase 2	http://adisinsight.springer.com/drugs/800015463	CXCL8|CHRNB2|CHRNA4	https://www.drugbank.ca/drugs/DB05855|https://www.drugbank.ca/drugs/DB05855|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3994	acetylcholine receptor agonist			
EX-527	EX-527		NC(=O)C1CCCc2c1[nH]c1ccc(Cl)cc21	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01521585	SIRT1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8100	SIRT inhibitor			
deracoxib	deracoxib	Deramaxx|SC-59046	COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F	Veterinary Launched	http://www.drugs.com/international/deracoxib.html	PTGS2	http://en.wikipedia.org/wiki/Deracoxib	cyclooxygenase inhibitor	rheumatology	osteoarthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eced868b-c101-425a-8c5c-1a23ea43152f
AA-29504	AA-29504		CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N	Preclinical		GABRB3|GABRA4|GABRA1	https://www.tocris.com/products/aa-29504_3972|https://www.tocris.com/products/aa-29504_3972|https://www.tocris.com/products/aa-29504_3972	GABA receptor positive allosteric modulator			
BMS-863233	BMS-863233		Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT00838890	CDC7|PIM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8113|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8113	CDC inhibitor			
org-9768	org-9768		CC1(CN)Cc2ccccc2C1	Phase 1	Pharmaprojects	ADRA2A|SLC6A2	http://www.nswo.nl/userfiles/files/publications/jaarboek-1990/Ruigt%20G_c.pdf|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=161109	adrenergic receptor antagonist			
cis-9,trans-11-Conjugated-linoleic-acid	cis-9,trans-11-Conjugated-linoleic acid		CCCCCC\C=C\C=C/CCCCCCCC(O)=O	Launched							
S18986	S18986		O=S1(=O)N[C@H]2CCCN2c2ccccc12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00202540	GRIA2|GRIA1|GRIA4|GRIA3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4304|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4304|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4304|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4304	glutamate receptor modulator			
asunaprevir	asunaprevir	BMS-650032	COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01497834			HCV inhibitor			
3-carboxy-4-hydroxyphenylglycine-(R)	(R)-3-carboxy-4-hydroxyphenylglycine		N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O	Preclinical		GRIN2B|GRIN2A|GRIN2C|GRIN1	http://www.tocris.com/dispprod.php?ItemId=2114#.VeXSoSxVhHw|http://www.tocris.com/dispprod.php?ItemId=2114#.VeXSoSxVhHw|http://www.tocris.com/dispprod.php?ItemId=2114#.VeXSoSxVhHw|http://www.tocris.com/dispprod.php?ItemId=2114#.VeXSoSxVhHw	glutamate receptor antagonist			
diatrizoic-acid	diatrizoic acid	amidotrizoic acid|diatrizoic acid	CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	Launched	http://en.wikipedia.org/wiki/Diatrizoic_acid				radiology	contrast agent	https://en.wikipedia.org/wiki/Diatrizoic_acid
nor-Binaltorphimine-dihydrochloride	nor-Binaltorphimine-dihydrochloride	(-)-Norbinaltorphimine|Nor-Binaltorphamine|Nor-Binaltorphimine|Norbinaltorphimine|nor-BNI|norBNI	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O	Preclinical		OPRD1|OPRK1|OPRM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1642|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1642|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1642	opioid receptor antagonist			
aclidinium	aclidinium	tudorza pressair	OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1cccs1)c1cccs1	Launched	FDA Orange Book: aclidinium bromide	CHRM4|CHRM5|CHRM2|CHRM3|CHRM1	https://www.drugbank.ca/drugs/DB08897|https://www.drugbank.ca/drugs/DB08897|https://www.drugbank.ca/drugs/DB08897|https://www.drugbank.ca/drugs/DB08897|https://www.drugbank.ca/drugs/DB08897	acetylcholine receptor antagonist	pulmonary|pulmonary|pulmonary	bronchitis|emphysema|chronic obstructive pulmonary disease (COPD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acdd5932-375b-4966-8a06-3806ab74c36d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acdd5932-375b-4966-8a06-3806ab74c36d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acdd5932-375b-4966-8a06-3806ab74c36d
antalarmin	antalarmin		CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C	Preclinical		CRHR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3489	corticosteroid releasing factor receptor antagonist			
xenalipin	xenalipin	BW 207U	OC(=O)c1ccccc1-c1ccc(cc1)C(F)(F)F	Phase 2	Pharmaprojects						
ginsenoside-rg3	ginsenoside rg3	20(S)-Ginsenoside Rg3	CC(C)=CCCC(C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C	Launched	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811485/#R23	KCNH2|SCN2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7658|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=314607	angiogenesis inhibitor|apoptosis stimulant			
L-701252	L-701252		Oc1c(C(=O)C2CC2)c(=O)[nH]c2cc(Cl)ccc12	Preclinical		GRIN1	http://www.scbt.com/datasheet-205726-l-701-252.html	glutamate receptor antagonist			
diphenhydramine	diphenhydramine	Antitussive|Beldin|Belix|Dibenil|Diphen|Hydramine|Silphen|benadryl|benadryl preservative free|benylin|diphenhydramine hydrochloride	CN(C)CCOC(c1ccccc1)c1ccccc1	Launched	FDA Orange Book: bromodiphenhydramine hydrochloride, diphenhydramine citrate, diphenhydramine hydrochloride	HRH1	https://www.drugbank.ca/drugs/DB01075	histamine receptor antagonist	neurology/psychiatry	headache	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26f5fdd4-d841-2e12-e054-00144ff88e88
trospium	trospium	sanctura|sanctura xr	OC(C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]21CCCC1)(c1ccccc1)c1ccccc1	Launched	FDA Orange Book: trospium chloride	CHRM1	https://www.drugbank.ca/drugs/DB00209	acetylcholine receptor antagonist	urology|urology	urinary incontinence|urinary frequency	https://en.wikipedia.org/wiki/Trospium_chloride#Medical_uses|https://en.wikipedia.org/wiki/Trospium_chloride#Medical_uses
TC-LPA5-4	TC-LPA5-4		COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O	Preclinical		LPAR5	https://www.tocris.com/products/tc-lpa5-4_4708	lysophosphatidic acid receptor antagonist			
MC1568	MC1568		Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1	Preclinical		HDAC2	http://www.tocris.com/dispprod.php?ItemId=278832#.VgQqHdNViko	HDAC inhibitor			
phthalylsulfacetamide	phthalylsulfacetamide	phthalylsulphacetamide|talsigel|thalamyd	CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1	Preclinical							
SAR405838	SAR405838			Phase 1	https://clinicaltrials.gov/ct2/show/NCT01636479	MDM2	http://www.ncbi.nlm.nih.gov/pubmed/25145672	MDM inhibitor			
TG-100572	TG-100572		Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl	Preclinical		SRC|KDR|EPHB4	http://www.adooq.com/tg-100572.html|http://www.adooq.com/tg-100572.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=411136	src inhibitor|VEGFR inhibitor			
HA14-1	HA14-1		CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC	Preclinical		BCL2	https://www.tocris.com/dispprod.php?ItemId=40985#.Vyj_p2QrImI	BCL inhibitor			
rivastigmine	rivastigmine	ENA-713|SDZ-212-713|SDZ-ENA-713|exelon	CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C	Launched	FDA Orange Book: rivastigmine, rivastigmine tartrate	BCHE|ACHE	ChEMBL|ChEMBL	acetylcholinesterase inhibitor	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	Alzheimer's disease|Parkinson's Disease|senile dementia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92a58ebb-748d-49f4-bf11-ecbcf5424152|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92a58ebb-748d-49f4-bf11-ecbcf5424152|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92a58ebb-748d-49f4-bf11-ecbcf5424152
baclofen	baclofen	BA-34,647|BA-34647|gablofen|kemstro|lioresal	NCC(CC(O)=O)c1ccc(Cl)cc1	Launched	FDA Orange Book: baclofen	GABBR2|GABBR1|KCTD8|KCTD16|KCTD12	ChEMBL|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1084|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1084|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1084	benzodiazepine receptor agonist	neurology/psychiatry|neurology/psychiatry	multiple sclerosis|spasms	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=346af8fe-3816-49de-bfd3-5a7425e728f9|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=346af8fe-3816-49de-bfd3-5a7425e728f9
thiamphenicol	thiamphenicol	Dextrosulphenidol|Thiophenicol|WIN 5063-2|thiamphenicol aminoacetate hydrochloride|thiocymetin	CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	Launched	http://www.drugs.com/international/Thiamphenicol.html			bacterial 50S ribosomal subunit inhibitor	infectious disease	pelvic inflammatory disease	https://en.wikipedia.org/wiki/Thiamphenicol
tilorone	tilorone	Amixin IC	CCN(CC)CCOc1ccc2-c3ccc(OCCN(CC)CC)cc3C(=O)c2c1	Launched	http://www.drugs.com/international/tilorone.html			interferon inducer	infectious disease|gastroenterology|infectious disease|neurology/psychiatry|infectious disease|infectious disease|infectious disease	influenza A virus infection|diarrhea|hepatitis B|multiple sclerosis|urinary tract infections|virus herpes simplex (HSV)|hepatitis C	https://en.wikipedia.org/wiki/Tilorone|https://en.wikipedia.org/wiki/Tilorone|https://en.wikipedia.org/wiki/Tilorone|https://en.wikipedia.org/wiki/Tilorone|https://en.wikipedia.org/wiki/Tilorone|https://en.wikipedia.org/wiki/Tilorone|https://en.wikipedia.org/wiki/Tilorone
ZK811752	ZK811752	BX-471|BX-741	C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00185341	CCR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=767	CC chemokine receptor antagonist			
GDC-0068	GDC-0068		CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01485861	CYP3A5|AKT1|AKT2|AKT3|PRKG1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=691990|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7887|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7887|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7887|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7887	AKT inhibitor			
BAZ2-ICR	BAZ2-ICR		Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1	Preclinical		ZNF215	https://www.tocris.com/products/baz2-icr_5266	bromodomain inhibitor			
tyrphostin-AG-99	tyrphostin-AG-99	AG-99	NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N	Preclinical		EGFR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004534	tyrosine kinase inhibitor			
eglumetad	eglumetad	LY-354740	N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/16192835	GRM2|GRM3|GRM6|GRM8	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1393|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1393|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1393|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1393	glutamate receptor agonist			
nevirapine	nevirapine	BIRG 0587|BIRG-0587|viramune|viramune xr	Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1	Launched	FDA Orange Book: nevirapine	CYP3A5|CYP3A4|CYP2D6|CYP2C9|CYP2B6|CYP2A6|CYP1A2|CYP2C19	http://www.drugbank.ca/drugs/DB00238|http://www.drugbank.ca/drugs/DB00238|http://www.drugbank.ca/drugs/DB00238|http://www.drugbank.ca/drugs/DB00238|http://www.drugbank.ca/drugs/DB00238|http://www.drugbank.ca/drugs/DB00238|http://www.drugbank.ca/drugs/DB00238|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=170581	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=645607af-3ef3-4765-bbff-ba9c483be141
sasapyrine	sasapyrine	disalcid|salicylsalicylic acid|salsalate	OC(=O)c1ccccc1OC(=O)c1ccccc1O	Launched	http://www.drugs.com/international/Sasapyrine.html	PTGS2|PTGS1	https://www.drugbank.ca/drugs/DB01399|https://www.drugbank.ca/drugs/DB01399	NFkB pathway inhibitor	rheumatology|rheumatology	osteoarthritis|rheumatoid arthritis	http://www.genome.jp/dbget-bin/www_bget?dr:D00428|http://www.genome.jp/dbget-bin/www_bget?dr:D00428
arbidol	arbidol	umifenovir	CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12	Launched	http://www.drugs.com/international/Arbidol.html	CYP2C19|CYP3A4|CYP3A5|CYP2E1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=187868|http://aac.asm.org/content/early/2013/01/22/AAC.02282-12.full.pdf|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=187868|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=187868	cytochrome P450 inhibitor	infectious disease	influenza A virus infection	https://en.wikipedia.org/wiki/Umifenovir
CP-339818	CP-339818		CCCCCN=c1ccn(Cc2ccccc2)c2ccccc12	Preclinical		KCNAB2|KCNQ3|KCNQ2|KCNQ1|KCNQ5|KCNS3|KCNH2|KCNH1|KCNC3|KCNC2|KCNE3|KCNE2|KCNE1|KCNE4|KCNA3|KCNA2|KCNA5|KCNC1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=302930|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=302930|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=302930|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=302930|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=302930|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=302930|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=302930|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=302930|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=302930|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=302930|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=302930|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=302930|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=302930|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=302930|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003721|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=302930|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=302930|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=302930	potassium channel blocker			
zardaverine	zardaverine		COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/7644776	PDE3A|PDE4A|PDE4B|PDE4C|PDE4D	https://citeline.informa.com/?query=#/drugs/details/19676|https://citeline.informa.com/?query=#/drugs/details/19676|https://citeline.informa.com/?query=#/drugs/details/19676|https://citeline.informa.com/?query=#/drugs/details/19676|https://www.drugbank.ca/drugs/DB02918	phosphodiesterase inhibitor			
prulifloxacin	prulifloxacin		CC1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCN(Cc2oc(=O)oc2C)CC1	Launched	http://www.drugs.com/international/prulifloxacin.html			bacterial DNA gyrase inhibitor	infectious disease|pulmonary|gastroenterology	urinary tract infections|bronchitis|diarrhea	https://en.wikipedia.org/wiki/Prulifloxacin#Licensed_uses|https://en.wikipedia.org/wiki/Prulifloxacin#Licensed_uses|https://en.wikipedia.org/wiki/Prulifloxacin#Licensed_uses
antimonyl	antimonyl		O=C1O[SbH]23OC1C1O[SbH]4(OC(C(O2)C(=O)O3)C(=O)O4)OC1=O	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/8768589						
norethindrone-acetate	norethindrone acetate	aygestin|norlutate	CC(=O)O[C@]1(CCC2C3CCC4=CC(=O)CC[C@@H]4C3CC[C@]12C)C#C	Launched	FDA Orange Book: norethindrone acetate	PGR	https://citeline.informa.com/?query=#/drugs/details/65009	progesterone receptor agonist	endocrinology|orthopedics|obstetrics/gynecology	menopause|osteoporosis|vaginal atrophy	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44125b2f-10ac-435c-bdb4-a29bf8450dbf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44125b2f-10ac-435c-bdb4-a29bf8450dbf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44125b2f-10ac-435c-bdb4-a29bf8450dbf
alizapride	alizapride	Litican|Plitican|Superan|Vergentan	COc1cc2[nH]nnc2cc1C(=O)NCC1CCCN1CC=C	Launched	http://www.drugs.com/international/Alizapride.html	DRD2	https://www.drugbank.ca/drugs/DB01425	dopamine receptor antagonist	gastroenterology	nausea	https://en.wikipedia.org/wiki/Alizapride
propylthiouracil	propylthiouracil	Propacil|Prothyran|Thyreostat	CCCc1cc(=O)[nH]c(=S)[nH]1	Launched	FDA Orange Book: propylthiouracil	DIO1|TPO	ChEMBL|ChEMBL	thyroid peroxidase inhibitor	endocrinology|endocrinology|endocrinology	hyperthyroidism|Grave's disease|goiter	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a57c49ae-d659-49fa-84e3-cf6d1f9e6f97|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a57c49ae-d659-49fa-84e3-cf6d1f9e6f97|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a57c49ae-d659-49fa-84e3-cf6d1f9e6f97
torcetrapib	torcetrapib		CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00145431	CETP	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000252	cholesteryl ester transfer protein inhibitor			
ASA-404	ASA-404	vadimezan	Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00738387			angiogenesis inhibitor			
foropafant	foropafant	SR-27417	CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C	Phase 3	http://en.pharmacodia.com/web/drug/1_6838.html	PTAFR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1856	platelet activating factor receptor antagonist			
rauwolscine	rauwolscine		COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12	Preclinical		HTR2B|HTR1B|HTR1D|HTR1E|ADRA2A|ADRA2B|ADRA2C	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=136|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=136|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=136|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=136|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=136|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=136|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=136	adrenergic receptor antagonist			
ML-218	ML-218		CC(C)(C)CCN1C[C@H]2[C@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1	Preclinical		CACNA1I|CACNA1G|CACNA1H	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7720|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7720|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7720	T-type calcium channel binder			
tropicamide	tropicamide	mydriacyl|mydriafair|tropicacyl	CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1	Launched	FDA Orange Book: tropicamide	CHRM1|CHRM2|CHRM3|CHRM4	https://www.drugbank.ca/drugs/DB00809|https://www.drugbank.ca/drugs/DB00809|ChEMBL|https://www.drugbank.ca/drugs/DB00809	acetylcholine receptor antagonist	ophthalmology|ophthalmology	mydriasis diagnostic|cycloplegia diagnostic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=521592d1-53a1-4314-8b3f-d808f3bccfcd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=521592d1-53a1-4314-8b3f-d808f3bccfcd
ML-213	ML-213		Cc1cc(C)c(NC(=O)C2CC3CCC2C3)c(C)c1	Preclinical		KCNQ2|KCNQ4	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=764816|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7665	potassium channel activator			
DIPT	DIPT		CC(C)N(CCc1c[nH]c2ccccc12)C(C)C	Launched	https://www.drugs.com/international/DIPT.html	HTR2C|HTR2A|HTR1A	http://www.ncbi.nlm.nih.gov/pubmed/27461536|http://www.ncbi.nlm.nih.gov/pubmed/27461536|http://www.ncbi.nlm.nih.gov/pubmed/27461536	dopamine reuptake inhibitor|serotonin reuptake inhibitor			
AGP-103	AGP-103	Behenic Acid|Docosanoic Acid	CCCCCCCCCCCCCCCCCCCCCC(O)=O	Launched	http://www.catalog.md/drugs/esapent.html			membrane permeability inhibitor			
polidocanol	polidocanol	asclera|varithena	CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO	Launched	FDA Orange Book: polidocanol			local anesthetic	dermatology	varicose veins	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfd6b4a0-b0dc-11e2-9e96-0800200c9a66
NVP-ADW742	NVP-ADW742		Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1	Preclinical		IGF1R	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001052	insulin growth factor receptor inhibitor			
NMDA	NMDA	(R)-2-(Methylamino)Succinic Acid|2-Methylamino-Succinic Acid|N-Methyl-Daspartate|n-methyl-d-aspartic acid (nmda)	CN[C@H](CC(O)=O)C(O)=O	Preclinical		GRIN1|GRIN2B|GRIN2A|GRIN2D|GRIN2C	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4268|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4268|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4268|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4268|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4268	glutamate receptor agonist			
temoporfin	temoporfin		Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2	Launched	http://www.drugs.com/international/Temoporfin.html			radical formation stimulant	oncology	head and neck squamous cell carcinoma (HNSCC)	https://en.wikipedia.org/wiki/Temoporfin
LY411575	LY411575	LY-411575	C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O	Preclinical				gamma secretase inhibitor			
ginsenoside-rd	Ginsenoside Rd	Ginsenoside Rd	CC(C)=CCCC(C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00815763			calcium channel blocker			
parachlorophenol	parachlorophenol		Oc1ccc(Cl)cc1	Launched	http://www.drugs.com/international/parachlorophenol.html			antiinfective drug			
SANT-2	SANT-2		CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1	Preclinical		SHH|SMO|IHH|PTCH1|DHH	http://www.tocris.com/dispprod.php?ItemId=232162#.Vg2LTWRVhHw|http://www.tocris.com/dispprod.php?ItemId=232162#.Vg2LTWRVhHw|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=668808|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=668808|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=668808	smoothened receptor antagonist			
SANT-1	SANT-1		Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1	Preclinical		SHH|SMO|IHH|DHH|PTCH1	https://www.tocris.com/dispprod.php?ItemId=89793#.Vyuk02QrJZI|https://www.tocris.com/dispprod.php?ItemId=89793#.Vyuk02QrJZI|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=417924|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=417924|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=417924	smoothened receptor antagonist			
JX-401	JX-401		COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1	Preclinical		MAPK14	http://www.tocris.com/dispprod.php?ItemId=5188	p38 MAPK inhibitor			
TP-003	TP-003		CC(C)(O)c1ccn2c(cnc2c1F)-c1ccc(F)c(c1)-c1ccc(F)cc1C#N	Preclinical		GABRG2|GABRB3|GABRA3|GABRA2|GABRA1|GABRA5	https://citeline.informa.com/?query=#/drugs/details/32654|https://citeline.informa.com/?query=#/drugs/details/32654|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4326|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4326|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4326|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4326	GABA receptor inverse agonist			
dihydroxyacetone	dihydroxyacetone		OCC(=O)CO	Launched	https://www.drugs.com/international/dihydroxyacetone.html				dermatology	skin protectant	https://en.wikipedia.org/wiki/Dihydroxyacetone
varespladib	varespladib	LY-315920|varepladib|varespladib sodium	CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01130246	PLA2G2A|PLA2G2D	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000258|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=232171	secretory phospholipase inhibitor			
betulinic-acid	betulinic acid	betulinic acid	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT00346502	CASP3|CASP8|GPBAR1|TOP1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=277467|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=277467|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3945|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=277467	apoptosis stimulant|NFkB pathway inhibitor			
cevipabulin	cevipabulin		CNCCCOc1cc(F)c(c(F)c1)-c1c(Cl)nc2ncnn2c1NC(C)C(F)(F)F	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00195325	TUBB	http://www.medkoo.com/products/4618	microtubule stimulant|tubulin polymerization inhibitor			
dichlorophen	dichlorophen	Anaplex|Dichlorophene|Hyosan|Vermiplex|Worm-Kaps	Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O	Launched	http://www.drugs.com/international/dichlorophen.html			anticestodal agent			
AD-5467	AD-5467		CC(C)C1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C	Phase 2	http://adisinsight.springer.com/drugs/800001300	AKR1B1	http://cancerres.aacrjournals.org/content/71/12/4161.full	aldose reductase inhibitor			
TFC-007	TFC-007		O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1	Preclinical		HPGDS	https://www.tocris.com/products/tfc-007_5108	prostaglandin inhibitor			
bentazepam	bentazepam	CI-718	O=C1CN=C(c2c3CCCCc3sc2N1)c1ccccc1	Launched	https://www.drugs.com/international/bentazepam.html	GABRA1|GABRA2|GABRA3|GABRA5	https://citeline.informa.com/?query=#/drugs/details/23378|https://citeline.informa.com/?query=#/drugs/details/23378|https://citeline.informa.com/?query=#/drugs/details/23378|https://citeline.informa.com/?query=#/drugs/details/23378	benzodiazepine receptor agonist	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	anxiety|sedative|muscle relaxant	https://en.wikipedia.org/wiki/Bentazepam|https://en.wikipedia.org/wiki/Bentazepam|https://en.wikipedia.org/wiki/Bentazepam
KRCA-0008	KRCA-0008		COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccc(cc2OC)N2CCN(CC2)C(C)=O)n1)N1CCN(CC1)C(C)=O	Preclinical		ALK	https://www.tocris.com/products/krca-0008_5098	ALK inihibitor			
dasatinib	dasatinib	BMS-354825|BMS-354825-03|sprycel	Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1	Launched	FDA Orange Book: dasatinib	EPHA2|SRC|PDGFRA|PDGFRB|SRMS|DDR2|DDR1|STAT5B|HCK|FYN|FRK|FGR|ABL2|ABL1|YES1|BLK|BCR|BTK|LYN|LCK|KIT	ChEMBL|ChEMBL|https://citeline.informa.com/?query=#/drugs/details/32014|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=365055|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=365055|https://www.drugbank.ca/drugs/DB01254|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB01254|ChEMBL|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=365055|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=365055|ChEMBL|ChEMBL|ChEMBL	Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|src inhibitor|tyrosine kinase inhibitor	hematologic malignancy|hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4764f37b-c9e6-4ede-bcc2-8a03b7c521df|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4764f37b-c9e6-4ede-bcc2-8a03b7c521df
rac-BHFF	rac-BHFF		CC(C)(C)c1cc2c(OC(=O)C2(O)C(F)(F)F)c(c1)C(C)(C)C	Preclinical		GABBR1	https://www.tocris.com/products/rac-bhff_3313	GABA receptor positive allosteric modulator			
LY255283	LY255283	LY-255283	CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nnn[nH]1	Preclinical		LTB4R2|LTB4R	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004038|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004038	leukotriene receptor antagonist			
DCC-2618	DCC-2618		Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02571036	PDGFRA|KIT	https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=776638|https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=776638	PDGFR tyrosine kinase receptor inhibitor|KIT inhibitor			
bromebric-acid	bromebric acid		COc1ccc(cc1)C(=O)C(\Br)=C\C(O)=O	Preclinical				purine antagonist|DNA synthesis inhibitor			
Nampt-IN-1	Nampt-IN-1		CC(C)(O)CS(=O)(=O)Nc1ccc2CN(CCc2c1)C(=O)COc1cccnc1	Preclinical							
IPAG	IPAG		Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1	Preclinical							
glafenine	glafenine	R 1707|glaphenine|glycerylaminophenaquine	OCC(O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	CFTR	http://www.ncbi.nlm.nih.gov/pubmed/20200141?dopt=Abstract	DeltaF508-CFTR Correctors			
climbazole	climbazole		CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1	Launched	http://en.wikipedia.org/wiki/Climbazole			enzyme inducer	dermatology|dermatology	dandruff|eczema	https://en.wikipedia.org/wiki/Climbazole|https://en.wikipedia.org/wiki/Climbazole
MM77	MM77		COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1	Preclinical		ADRA1A|HTR1A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=286720|http://www.tocris.com/dispprod.php?ItemId=1662#.VglWpGRVhHw	serotonin receptor antagonist			
alpha-methylhistamine-dihydrobromide-(R)-(-)	(R)-(-)-alpha-methylhistamine-dihydrobromide	(R)-Alpha-Methylhistamine	C[C@@H](N)Cc1c[nH]cn1	Preclinical		HRH3	http://www.sigmaaldrich.com/catalog/product/sigma/h128?lang=en&region=US	histamine receptor agonist			
hydroxyamphetamine	hydroxyamphetamine	hydroxyamfetamine|paredrine	CC(N)Cc1ccc(O)cc1	Launched	FDA Orange Book: hydroxyamphetamine hydrobromide	TAAR1	https://en.wikipedia.org/wiki/4-Hydroxyamphetamine#Pharmacology	trace amine associated receptor agonist	ophthalmology	mydriasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da8a8a19-ac1b-4160-aac4-c4c57598eb5d
beta-funaltrexamine	beta-funaltrexamine		COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45	Preclinical		OPRM1|OPRK1|OPRD1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1631|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1631|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1631	opioid receptor antagonist			
hydrochlorothiazide	hydrochlorothiazide	HCTZ|Hydro-D|Hydrochlorothiazide intensol|ZIDE|esidrix|hydrodiuril|microzide|oretic	NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl	Launched	FDA Orange Book: hydrochlorothiazide	KCNMA1|SLC12A3|CA12|CA1|CA4|CA2|CA9	https://www.drugbank.ca/drugs/DB00999|ChEMBL|https://www.drugbank.ca/drugs/DB00999|https://www.drugbank.ca/drugs/DB00999|https://www.drugbank.ca/drugs/DB00999|https://www.drugbank.ca/drugs/DB00999|https://www.drugbank.ca/drugs/DB00999	thiazide diuretic	cardiology|cardiology	hypertension|congestive heart failure	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b2c581a-f955-4a8e-bf85-e768e903fd10|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b2c581a-f955-4a8e-bf85-e768e903fd10
alfadolone-acetate	alfadolone acetate		CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/6846760			benzodiazepine receptor agonist			
3-bromocamphor	3-bromocamphor		CC1(C)C2CCC1(C)C(=O)C2Br	Launched	http://www.drugs.com/international/bromocamphor.html						
NM107	NM107		CC1(O)C(O)C(CO)OC1n1ccc(N)nc1=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00395421			RNA polymerase inhibitor			
nitrocaramiphen	nitrocaramiphen		CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O	Preclinical		CHRM1	http://www.tocris.com/dispprod.php?ItemId=1702#.Vgmem2RVhHw	cholinergic receptor antagonist			
SNX-5422	SNX-5422		CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT01848756	HSP90AA1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000231	HSP inhibitor			
BQ-123	BQ-123		CC(C)CC1NC(=O)C(NC(=O)C2CCCN2C(=O)C(CC(O)=O)NC(=O)C(Cc2c[nH]c3ccccc23)NC1=O)C(C)C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00759408	EDNRA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=997	endothelin receptor antagonist			
SIB-1553A	SIB-1553A		CN1CCCC1CCSc1ccc(O)cc1	Phase 2	http://www.pharmacodia.com/yaodu/html/v1/chemicals/ae6a4a6014477b7bd45df64152491e23.html	CHRNB4	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001327	acetylcholine receptor agonist			
AZD2461	AZD2461		COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01247168			PARP inhibitor			
icariin	icariin		COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01979133	SORD|PDE5A|NMUR2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=260563|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008644|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=260563	phosphodiesterase inhibitor			
cloxacillin	cloxacillin	Cloxapen|tegopen	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl	Launched	FDA Orange Book: cloxacillin sodium, dicloxacillin sodium			bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections	http://www.drugs.com/mtm/cloxacillin.html
fomocaine	fomocaine		C(CN1CCOCC1)Cc1ccc(COc2ccccc2)cc1	Launched	http://www.drugs.com/international/fomocaine.html			voltage-gated sodium channel modulator	neurology/psychiatry	local anesthetic	http://www.ncbi.nlm.nih.gov/pubmed/15212188
UNC0224	UNC0224		COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1	Preclinical		EHMT1|EHMT2	https://www.caymanchem.com/product/13631|https://www.caymanchem.com/product/13631	histone lysine methyltransferase inhibitor			
U-0126	U-0126			Preclinical		AKT1|LCK|MAP2K7|MAP2K2|MAP2K1|PRKCA|RAF1|JAK2|MAPK12|MAPK14|MAPK11|CHEK1|ROCK1|SGK1|MAPK1|MAPK8|GSK3B|RPS6KB1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005005|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=270001|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005005	MEK inhibitor			
A-887826	A-887826		CCCCOc1ccc(cc1Cl)-c1cncc(c1)C(=O)NCc1cccnc1N1CCOCC1	Preclinical		SCN10A	https://www.tocris.com/products/a-887826_4249	sodium channel blocker			
phenol	phenol	carbolic acid|phenol, liquefied	Oc1ccccc1	Preclinical		CA14|CA12|CA2|CA1|CA9|CA4	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010455|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010455|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010455|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010455|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010455|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010455		otolaryngology	pharyngitis	https://pubchem.ncbi.nlm.nih.gov/compound/phenol#section=Depositor-Supplied-Synonyms
valspodar	valspodar	amdray	C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00005823	ABCB1	http://www.sigmaaldrich.com/catalog/product/sigma/sml0572?lang=en&region=US	P glycoprotein inhibitor			
BNTX	BNTX		Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1	Preclinical		OPRD1|OPRM1|OPRK1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1634|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1634|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1634	opioid receptor antagonist			
isoetharine	isoetharine	WIN 3406|WIN-3406|bronkometer|bronkosol|etyprenaline|isoetarine	CCC(NC(C)C)C(O)c1ccc(O)c(O)c1	Launched	FDA Orange Book: isoetharine mesylate	ADRB2|ADRB1	https://www.drugbank.ca/drugs/DB00221|https://www.drugbank.ca/drugs/DB00221	adrenergic receptor agonist	pulmonary|pulmonary	bronchospasm|asthma	https://en.wikipedia.org/wiki/Isoetarine|https://en.wikipedia.org/wiki/Isoetarine
metergoline	metergoline	FI 6337		Launched	http://www.drugs.com/international/Metergoline.html	HTR6|HTR7|HTR5A|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|DRD2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=133|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=133|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=133|http://www.tocris.com/dispprod.php?ItemId=1578#.Uuc5JqX0CMI|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=133|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=133|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=133|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=133|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=133|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=133|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=133|https://citeline.informa.com/?query=#/drugs/details/11931	dopamine receptor agonist|serotonin receptor antagonist			
GNF-5	GNF-5		OCCNC(=O)c1cccc(c1)-c1ncnc(Nc2ccc(cc2)OC(F)(F)F)c1	Preclinical		ABL1|BCR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8065|https://www.tocris.com/products/gnf-5_4908	Bcr-Abl kinase inhibitor			
BU226	BU226		C1CN=C(N1)c1cc2ccccc2cn1	Preclinical				imidazoline receptor ligand			
GNF-2	GNF-2		NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1	Preclinical		ABL1|BCR	http://www.sigmaaldrich.com/catalog/product/sigma/g9420?lang=en&region=US|http://www.sigmaaldrich.com/catalog/product/sigma/g9420?lang=en&region=US	Bcr-Abl kinase inhibitor			
nafcillin	nafcillin	Nallpen|nafcillin sodium|unipen	CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	Launched	FDA Orange Book: nafcillin sodium	CYP3A4|CYP1A2|SLC22A6	http://www.drugbank.ca/drugs/DB00607|http://www.drugbank.ca/drugs/DB00607|http://www.drugbank.ca/drugs/DB00607	bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections	https://en.wikipedia.org/wiki/Nafcillin
FCE-22250	FCE-22250		COC1\C=C\OC2(C)Oc3c(C2=O)c2c(O)c(\C=N\N=C\N4CCCCC4)c(NC(=O)\C(C)=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C)c(O)c2c(O)c3C	Phase 1	Pharmaprojects			DNA directed DNA polymerase inhibitor			
immepip	immepip		C(C1CCNCC1)c1c[nH]cn1	Preclinical		HRH3|HRH4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1251|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1251	histamine receptor agonist			
levosimendan	levosimendan	(-)-OR-1259|simdax	C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1	Launched	http://www.drugs.com/international/Levosimendan.html	PDE3A|KCNJ11|KCNJ8|TNNC1	https://www.drugbank.ca/drugs/DB00922|https://www.drugbank.ca/drugs/DB00922|https://www.drugbank.ca/drugs/DB00922|https://www.drugbank.ca/drugs/DB00922	calcium sensitizer	cardiology	congestive heart failure	https://en.wikipedia.org/wiki/Levosimendan
lonidamine	lonidamine	Doridamina	OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12	Launched	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1477627/	GCK	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000153	glucokinase inhibitor			
zosuquidar	zosuquidar		O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00046930	ABCB4|ABCB1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000157|http://en.wikipedia.org/wiki/Zosuquidar	P glycoprotein inhibitor			
omeprazole-magnesium	omeprazole magnesium	H 168/68 MAGNESIUM|omeprazole magnesium|prilosec|prilosec otc	COc1ccc2n([Mg]n3c(nc4cc(OC)ccc34)S(=O)Cc3ncc(C)c(OC)c3C)c(nc2c1)S(=O)Cc1ncc(C)c(OC)c1C	Launched	https://clinicaltrials.gov/ct2/show/NCT00903448	ATP4A|ATP4B	ChEMBL|ChEMBL	proton pump inhibitor	gastroenterology|gastroenterology	gastroesophageal reflux disease (GERD)|heartburn	https://www.drugs.com/omeprazole.html|https://www.drugs.com/omeprazole.html
etomidate	etomidate	amidate	CCOC(=O)c1cncn1[C@H](C)c1ccccc1	Launched	FDA Orange Book: etomidate	GABRA4|GABRA5|GABRA6|GABRA1|GABRA2|GABRA3|GABRB1|GABRB2|GABRB3|GABRG2|GABRG3|GABRG1|ADRA2B|GABRP|GABRQ|GABRD|GABRE	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00292|ChEMBL|ChEMBL|ChEMBL|ChEMBL	GABA receptor modulator	neurology/psychiatry	general anaesthetic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a11458d3-12ad-438e-ac48-ef66196b8fe2
apratastat	apratastat	TMI-005|TMI-05	CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/17117591	ADAM17|MMP9|MMP1|MMP13	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6482|http://www.nature.com/nrd/journal/v6/n6/fig_tab/nrd2308_T6.html|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006333|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006333	matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor			
febuxostat	febuxostat	TMX-67|uloric	CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O	Launched	FDA Orange Book: febuxostat	XDH	ChEMBL	xanthine oxidase inhibitor	nephrology	hyperuricemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54de10ef-fe5f-4930-b91d-6bbb04c664bd
piperacetazine	piperacetazine	PC-1421|quide	CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1	Launched	FDA Orange Book: piperacetazine			dopamine receptor antagonist	neurology/psychiatry	schizophrenia	https://en.wikipedia.org/wiki/Piperacetazine
idasanutlin	idasanutlin	RG-7388	COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02545283	MDM2|TP53	http://pubs.acs.org/doi/abs/10.1021/jm400487c|http://pubs.acs.org/doi/abs/10.1021/jm400487c	MDM inhibitor			
dalargin	dalargin		CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)C(N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/2232471	OPRM1	http://www.ncbi.nlm.nih.gov/pubmed/7635255	opioid receptor agonist			
BYK-204165	BYK-204165		Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12	Preclinical		PARP1	http://www.tocris.com/dispprod.php?ItemId=241267#.VfGX_yxVhHw	PARP inhibitor			
linaclotide	linaclotide	linzess	C[C@@H](O)C1NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CSSC[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N2	Launched	FDA Orange Book: linaclotide	GUCY2C	https://www.drugbank.ca/drugs/DB08890	guanylate cyclase activator	gastroenterology|gastroenterology	irritable bowel syndrome|constipation	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09beda19-56d6-4a56-afdc-9a77b70b2ef3|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09beda19-56d6-4a56-afdc-9a77b70b2ef3
lacidipine	lacidipine	GR 43659X	CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC	Launched	http://www.drugs.com/international/Lacidipine.html	CACNA1C	http://www.genome.jp/dbget-bin/www_bget?dr:D04657	calcium channel blocker	cardiology	hypertension	https://www.medicines.org.uk/emc/medicine/29968
trequinsin	trequinsin		COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC	Phase 1	http://adisinsight.springer.com/drugs/800000447	PDE5A|PDE4D|PDE4C|PDE4B|PDE4A|PTGIR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012103|https://citeline.informa.com/?query=#/drugs/details/18431|https://citeline.informa.com/?query=#/drugs/details/18431|https://citeline.informa.com/?query=#/drugs/details/18431|https://citeline.informa.com/?query=#/drugs/details/18431|https://citeline.informa.com/?query=#/drugs/details/18431	phosphodiesterase inhibitor			
rifampin	rifampin	rifadin|rimactane		Launched	FDA Orange Book: rifampin	CYP2C19|CYP2C8|CYP2B6|CYP3A4|CYP3A5|NR1I2|ABCB1|SLCO1B3|SLCO1B1|SLCO1A2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=125551|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=125551|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=125551|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=125551|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=125551|https://www.drugbank.ca/drugs/DB01045|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=125551|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2765|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2765|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2765	RNA polymerase inhibitor	infectious disease|infectious disease	tuberculosis|meningitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55816042-946d-4bec-9461-bd998628ff45|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55816042-946d-4bec-9461-bd998628ff45
pentolinium	pentolinium	ansolysen	C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1	Launched	FDA Orange Book: pentolinium tartrate	CHRNA10|CHRNB4|CHRNA4|CHRNA3	https://www.drugbank.ca/drugs/DB01090|https://www.drugbank.ca/drugs/DB01090|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001144|https://www.drugbank.ca/drugs/DB01090	cholinergic receptor antagonist	cardiology	hypertension	https://en.wikipedia.org/wiki/Pentolinium
cedrol-(+)	(+)-cedrol		C[C@@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O	Phase 2				sedative			
taltobulin	taltobulin	HTI-286	CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@@H](C(C)C)\C=C(/C)C(O)=O)C(C)(C)C)C(C)(C)c1ccccc1	Phase 1	http://adisinsight.springer.com/drugs/800019128			tubulin polymerization inhibitor			
amikacin	amikacin	amikacin sulfate|amikin		Launched	FDA Orange Book: amikacin sulfate			bacterial 30S ribosomal subunit inhibitor	infectious disease	gram-negative bacterial infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ec3129b-c53b-4bdb-913d-a2d0060fa140
CPI-360	CPI-360		COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCOCC2)c2ccccc12	Preclinical		EZH2	http://www.selleckchem.com/products/cpi-360.html	histone lysine methyltransferase inhibitor			
SB-268262	SB-268262		CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)S(=O)c1nccs1)c1ccccc1C	Preclinical		CALCA|CALCRL	https://www.tocris.com/products/sb-268262_4314|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=301259	calcitonin antagonist			
metrifonate	metrifonate	BAYER L 1359|DETF|Dipterex 80|Dylox|Metriniphate|Neguvon|metriphonate|trichlorfon	COP(=O)(OC)C(O)C(Cl)(Cl)Cl	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/10718203	BCHE|ACHE	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=163528|https://en.wikipedia.org/wiki/Metrifonate	acetylcholinesterase inhibitor			
mycophenolic-acid	mycophenolic acid	RS-61443 [AS MOFETIL]|mycophenolic acid|myfortic	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O	Launched	FDA Orange Book: mycophenolic acid	IMPDH1|IMPDH2	ChEMBL|ChEMBL	dehydrogenase inhibitor|inositol monophosphatase inhibitor	transplant	organ rejection	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7fbf301-0b08-4b19-bfa0-e0c0067cb5ab
zomepirac	zomepirac	Zomax	Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	PTGDR2	https://www.drugbank.ca/drugs/DB04828	prostaglandin synthesis inhibitor			
ku-0063794	ku-0063794	AZD-2014	COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1	Preclinical		MTOR	https://www.tocris.com/dispprod.php?ItemId=241120#.VykOSGQrImI	mTOR inhibitor			
tinidazole	tinidazole	CP-12,574|Fasigyn|Symplotan|Trimonase|tindamax	CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O	Launched	FDA Orange Book: tinidazole			antiprotozoal agent	infectious disease|infectious disease|obstetrics/gynecology|infectious disease	giardiasis|amebiasis|bacterial vaginosis|trichomoniasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f55bcc41-2e8d-4ee5-9993-05c7d86f2d2c&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f55bcc41-2e8d-4ee5-9993-05c7d86f2d2c&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f55bcc41-2e8d-4ee5-9993-05c7d86f2d2c&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f55bcc41-2e8d-4ee5-9993-05c7d86f2d2c&audience=consumer
N-benzylnaltrindole	N-benzylnaltrindole		Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1c(C[C@@]35O)c2ccccc2n1Cc1ccccc1	Preclinical				opioid receptor antagonist			
FK-962	FK-962		CC(=O)N1CCC(CC1)NC(=O)c1ccc(F)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00087724			somatostatin receptor agonist			
EMD-53998	EMD-53998	EMD-57033|EMD-57439	COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)SC1C	Phase 1	Pharmaprojects	PDE3A|TNNC1	https://citeline.informa.com/?query=#/drugs/details/6090|https://www.drugbank.ca/drugs/DB03944	phosphodiesterase inhibitor			
isotiquimide	isotiquimide	WY-24,377	Cc1ccnc2C(CCCc12)C(N)=S	Phase 1	Pharmaprojects						
tirasemtiv	tirasemtiv	CK2017357	CCC(CC)n1c2nc(cnc2[nH]c1=O)C#C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01131013			troponin activator			
CYM-5442	CYM-5442		CCOc1ccc(cc1OCC)-c1nc(no1)-c1cccc2C(CCc12)NCCO	Preclinical		S1PR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2928	sphingosine 1 phosphate receptor agonist			
CYM-50769	CYM-50769		COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc34)c2=O)cc1	Preclinical		NPBWR1	https://www.tocris.com/products/cym-50769_4948	neuropeptide receptor antagonist			
FR-139317	FR-139317		CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O	Phase 1	Cortellis	EDNRA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=998	endothelin receptor antagonist			
EIT-hydrobromide	EIT-hydrobromide	2-Ethyl-Isothiourea|ethylisothiourea	CCSC(N)=N	Preclinical		NOS3|NOS2	https://www.drugbank.ca/drugs/DB02234|https://www.drugbank.ca/drugs/DB02234	nitric oxide synthase inhibitor			
WAY-213613	WAY-213613		N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O	Preclinical		SLC1A2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4531	glutamate inhibitor			
ethylenediaminetetraacetic-acid	ethylenediaminetetraacetic acid	EDTA|Edetate|edetic acid|versene acid	OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O	Launched	http://en.wikipedia.org/wiki/Ethylenediaminetetraacetic_acid			PKC inhibitor	neurology/psychiatry	metal toxicity	https://en.wikipedia.org/wiki/Ethylenediaminetetraacetic_acid#Medicine
cyproheptadine	cyproheptadine	cyproheptadine hydrochloride|periactin	CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12	Launched	FDA Orange Book: cyproheptadine hydrochloride	HRH1|CHRM1|CHRM3|CHRM2|ADRA1D|ADRA1A|ADRA1B|HTR2A|HTR2C|HTR2B|HTR7|HTR6	https://www.drugbank.ca/drugs/DB00434|https://www.drugbank.ca/drugs/DB00434|https://www.drugbank.ca/drugs/DB00434|https://www.drugbank.ca/drugs/DB00434|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=277|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=277|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=277|https://www.drugbank.ca/drugs/DB00434|https://www.drugbank.ca/drugs/DB00434|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091326|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=277|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=277	histamine receptor antagonist	allergy|otolaryngology|ophthalmology|allergy|dermatology	allergic rhinitis|vasomotor rhinitis|conjunctivitis|urticaria|dermatographism	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f90faaa3-f40f-4653-8fb8-144d61c6b1d4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f90faaa3-f40f-4653-8fb8-144d61c6b1d4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f90faaa3-f40f-4653-8fb8-144d61c6b1d4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f90faaa3-f40f-4653-8fb8-144d61c6b1d4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f90faaa3-f40f-4653-8fb8-144d61c6b1d4
methantheline	methantheline	banthine	CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc12	Launched	FDA Orange Book: methantheline bromide	CHRM1|HRH2	https://www.drugbank.ca/drugs/DB00940|https://www.drugbank.ca/drugs/DB00940	acetylcholine receptor antagonist	gastroenterology|gastroenterology|gastroenterology|neurology/psychiatry|urology	peptic ulcer disease (PUD)|irritable bowel syndrome|pancreatitis|dyskinesia|neurogenic bladder	http://www.drugbank.ca/drugs/DB00940|http://www.drugbank.ca/drugs/DB00940|http://www.drugbank.ca/drugs/DB00940|http://www.drugbank.ca/drugs/DB00940|http://www.drugbank.ca/drugs/DB00940
ZM-323881	ZM-323881		Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O	Preclinical		KDR	http://www.selleckchem.com/products/zm-323881-hcl.html?gclid=COv7zPrflLwCFcI-MgodXGYAKA	VEGFR inhibitor			
W-54011	W-54011		COc1ccc2CCCC(C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1	Preclinical		C5AR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=581	anaphylatoxin chemotactic receptor antagonist			
agomelatine	agomelatine	Melitor|Thymanax|Valdoxan	COc1ccc2cccc(CCNC(C)=O)c2c1	Launched	http://www.drugs.com/international/Agomelatine.html	HTR2C|HTR2A|HTR2B|MTNR1A|MTNR1B|CYP2C19|CYP1A2	https://www.drugbank.ca/drugs/DB06594|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=198|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=198|https://www.drugbank.ca/drugs/DB06594|https://www.drugbank.ca/drugs/DB06594|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=193166|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=193166	melatonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression	https://en.wikipedia.org/wiki/Agomelatine
dapiprazole	dapiprazole	dapiprazole hydrochloride	Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1	Launched	FDA Orange Book: dapiprazole hydrochloride	ADRA1D|ADRA1A|ADRA1B	https://www.drugbank.ca/drugs/DB00298|https://www.drugbank.ca/drugs/DB00298|https://www.drugbank.ca/drugs/DB00298	adrenergic receptor antagonist	ophthalmology	mydriasis	https://en.wikipedia.org/wiki/Dapiprazole
WB-4101	WB-4101		COc1cccc(OC)c1OCCNCC1COc2ccccc2O1	Preclinical		HTR1A|ADRA2C|ADRA2A|ADRA2B|ADRA1D|ADRA1B|ADRA1A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003793|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=499|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=499|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=499|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=499|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=499|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=499	adrenergic receptor antagonist			
Q-203	Q-203		CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(cc1)N1CCC(CC1)c1ccc(OC(F)(F)F)cc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02530710			ATP synthase inhibitor			
metformin	metformin	fortamet|glucophage|glucophage xr|glumetza|riomet	CN(C)C(=N)NC(N)=N	Launched	FDA Orange Book: metformin hydrochloride	ACACB|PRKAB1|INS	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000205|https://www.drugbank.ca/drugs/DB00331|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=220882	insulin sensitizer	endocrinology	diabetes mellitus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0569d5d5-70df-46d7-954a-fe00542a7191
clomethiazole	clomethiazole	sctz [as edisylate]	Cc1ncsc1CCCl	Launched	http://en.wikipedia.org/wiki/Clomethiazole	GABRA1	http://en.wikipedia.org/wiki/Clomethiazole	GABA receptor antagonist|GABA receptor modulator	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	Parkinson's Disease|sedative|muscle relaxant	https://en.wikipedia.org/wiki/Clomethiazole|https://en.wikipedia.org/wiki/Clomethiazole|https://en.wikipedia.org/wiki/Clomethiazole
GW-441756	GW-441756	GW441756|GW441756X	Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12	Preclinical		LRRK2|NTRK1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=338145|http://www.selleckchem.com/products/gw-441756.html?gclid=CPXZkNKlobwCFa9aMgodYQMAeA	growth factor receptor inhibitor			
ZM-241385	ZM-241385		Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1	Preclinical		ADORA2A|ADORA2B|ADORA1|ADORA3	https://www.drugbank.ca/drugs/DB08770|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=405|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=405|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=405	adenosine receptor antagonist			
1-((Z)-3-Chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium	1-((Z)-3-Chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium		Cl\C=C/C[N+]12CN3CN(CN(C3)C1)C2	Preclinical							
tyrphostin-AG-879	Tyrphostin Ag 879	Tyrphostin Ag 879|Tyrphostin Ag-879	CC(C)(C)c1cc(cc(c1O)C(C)(C)C)\C=C(/C#N)C(N)=S	Preclinical		NTRK1|KDR|ERBB2	http://www.scbt.com/datasheet-3557-tyrphostin-ag-879.html|http://www.scbt.com/datasheet-3557-tyrphostin-ag-879.html|http://www.selleckchem.com/products/tyrphostin-ag-879-ag-879.html?gclid=CLzNz8-XzLoCFQif4AodFzoAgw	tyrosine kinase inhibitor			
oxytocin	oxytocin	pitocin|syntocinon	CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O	Launched	FDA Orange Book: oxytocin	OXTR|AVPR1B|AVPR1A|AVPR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2174|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2174|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2174|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2174	oxytocin receptor agonist	obstetrics/gynecology	labor induction	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d707ecc1-198d-40cd-98c1-e43ff6f071e6
ceftazidime	ceftazidime	ceptaz|fortaz		Launched	FDA Orange Book: ceftazidime, ceftazidime sodium			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	respiratory tract infections|skin infections|bacterial septicemia|bone and joint infections|gynecologic infections|intra-abdominal infections|meningitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b41f272-0727-4ce5-a4af-6255061a08b0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b41f272-0727-4ce5-a4af-6255061a08b0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b41f272-0727-4ce5-a4af-6255061a08b0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b41f272-0727-4ce5-a4af-6255061a08b0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b41f272-0727-4ce5-a4af-6255061a08b0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b41f272-0727-4ce5-a4af-6255061a08b0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b41f272-0727-4ce5-a4af-6255061a08b0
ranolazine	ranolazine	CVT-303|RS-43285-003|ranexa	COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1	Launched	FDA Orange Book: ranolazine	SCN9A|SCN5A|SCN4A|SLC22A2|SCN10A	https://www.drugbank.ca/drugs/DB00243|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=101796|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000875	sodium channel blocker	cardiology	chronic stable angina	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d442b8c-97a8-40a9-8603-f9cd0542cedc
adaptavir	adaptavir		C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00951743	CCR5	http://www.pharmacodia.com/web/drug/1_6400.html	CC chemokine receptor antagonist			
terameprocol	terameprocol	EM-1421	COc1ccc(C[C@H](C)[C@H](C)Cc2ccc(OC)c(OC)c2)cc1OC	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT00404248	BIRC5|CDK1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001082|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001082	lipoxygenase inhibitor			
ceforanide	ceforanide	precef	NCc1ccccc1CC(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CC(O)=O)=C(N2C1=O)C(O)=O	Launched	FDA Orange Book: ceforanide			penicillin binding protein inhibitor	infectious disease	gram-negative bacterial infections	http://www.drugbank.ca/drugs/DB00923
JK-184	JK-184		CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1	Preclinical				hedgehog pathway inhibitor			
resorcinol	resorcinol	resorcin	Oc1cccc(O)c1	Launched	http://www.drugs.com/international/resorcinol.html	CA2|PTGS1|CA14|CA12	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008512|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008512|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008512|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008512	phosphodiesterase inhibitor	dermatology|dermatology|dermatology|dermatology	acne vulgaris (AV)|eczema|psoriasis|seborrheic dermatitis	http://www.drugs.com/mtm/resorcinol-topical.html|http://www.drugs.com/mtm/resorcinol-topical.html|http://www.drugs.com/mtm/resorcinol-topical.html|http://www.drugs.com/mtm/resorcinol-topical.html
decitabine	decitabine	dacogen	Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1	Launched	FDA Orange Book: decitabine	DNMT3A|DNMT1	ChEMBL|ChEMBL	DNA methyltransferase inhibitor	hematologic malignancy|hematology|hematologic malignancy	myelodysplastic diseases (MDS)|anemia|chronic myeloid leukemia (CML)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99cea19b-cabf-8a6d-b2ef-f04920952b93|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99cea19b-cabf-8a6d-b2ef-f04920952b93|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99cea19b-cabf-8a6d-b2ef-f04920952b93
rose-bengal-lactone	rose-bengal-lactone	Rose Bengal Sodium|Rose bengal	Oc1c(I)cc2c(Oc3c(I)c(O)c(I)cc3C22OC(=O)c3c2c(Cl)c(Cl)c(Cl)c3Cl)c1I	Launched	http://www.amconlabs.com/product/1257/101/Rose-Bengal-Glostrips%C3%82%E2%84%A2-by-Amcon/			coloring agent	ophthalmology	staining agent	https://en.wikipedia.org/wiki/Rose_bengal
L-leucine	L-leucine	E641|l-leucine|leucine	CC(C)C[C@H](N)C(O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00026312	LCMT2|LCMT1|LARS2|LARS|BCAT1|BCAT2	https://www.drugbank.ca/drugs/DB00149|https://www.drugbank.ca/drugs/DB00149|https://www.drugbank.ca/drugs/DB00149|https://www.drugbank.ca/drugs/DB00149|https://www.drugbank.ca/drugs/DB00149|https://www.drugbank.ca/drugs/DB00149				
carbarsone	carbarsone		NC(=O)Nc1ccc(cc1)[As](O)(O)=O	Veterinary Launched	http://en.wikipedia.org/wiki/Carbarsone			antiprotozoal agent	infectious disease	amebiasis	https://en.wikipedia.org/wiki/Carbarsone
parecoxib	parecoxib	SC-69124	CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1	Launched	http://www.drugs.com/international/Parecoxib.html	PTGS2|LTF	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=258759|https://www.drugbank.ca/drugs/DB08439	cyclooxygenase inhibitor	neurology/psychiatry	pain relief	http://www.drugs.com/international/parecoxib.html
AMG-837	AMG-837		CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1	Phase 1	http://library.corporate-ir.net/library/61/616/61656/items/328994/F06AE826-EE65-4465-B4FB-B536B0F2BE15_AMGENINC10K2006.pdf	FFAR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6485	free fatty acid receptor agonist			
AT7867	AT7867		Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1	Preclinical		AKT2|PRKACA|GSK3B|ROCK2|PKIA	https://www.drugbank.ca/drugs/DB07859|https://www.drugbank.ca/drugs/DB07859|https://www.drugbank.ca/drugs/DB07859|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=441878|https://www.drugbank.ca/drugs/DB07859	AKT inhibitor			
5-hydroxytryptophan	5-hydroxytryptophan		NC(Cc1c[nH]c2ccc(O)cc12)C(O)=O	Launched	http://en.wikipedia.org/wiki/5-Hydroxytryptophan	SLC36A2|SLC36A1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671	neurotransmitter	neurology/psychiatry	insomnia	https://en.wikipedia.org/wiki/5-Hydroxytryptophan
entrectinib	entrectinib	NMS-E628|RXDX-101	CN1CCN(CC1)c1ccc(C(=O)Nc2n[nH]c3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02568267	NTRK3|NTRK2|NTRK1|IGF1R|ALK|ROS1|AURKB	https://en.wikipedia.org/wiki/Entrectinib|https://en.wikipedia.org/wiki/Entrectinib|https://en.wikipedia.org/wiki/Entrectinib|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=653437|https://en.wikipedia.org/wiki/Entrectinib|https://en.wikipedia.org/wiki/Entrectinib|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=653437	ALK tyrosine kinase receptor inhibitor|proto-oncogene tyrosine protein kinase inhibitor			
sodium-tanshinone-ii-a-sulfonate	sodium-tanshinone-ii-a-sulfonate		Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/6381893			potassium channel activator			
fluvastatin	fluvastatin	lescol|lescol xl	CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12	Launched	FDA Orange Book: fluvastatin sodium	HMGCR|CYP2C8	https://www.drugbank.ca/drugs/DB01095|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=129568	HMGCR inhibitor	endocrinology|cardiology	hypercholesterolemia|congenital heart defects	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aad8b373-0aec-4efb-8e61-3d8114b31127|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aad8b373-0aec-4efb-8e61-3d8114b31127
BMS-833923	BMS-833923	XL139	CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01357655	IHH|DHH|SMO	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=467492|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=467492|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001165	smoothened receptor antagonist			
semapimod	semapimod		NC(=N)NNC(=C)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(=C)NNC(N)=N)C(=C)NNC(N)=N)cc(c1)C(=C)NNC(N)=N	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00741910	DHPS|MAPK14|RAF1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=226520|https://en.wikipedia.org/wiki/Semapimod|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=226520	cytokine production inhibitor|p38 MAPK inhibitor			
dynasore	dynasore		Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O	Preclinical		DNM2|DNM1|DNM1L	https://www.tocris.com/dispprod.php?ItemId=122658#.VyjWgmQrImI|https://www.tocris.com/dispprod.php?ItemId=122658#.VyjWgmQrImI|https://www.tocris.com/dispprod.php?ItemId=122658#.VyjWgmQrImI	dynamin inhibitor			
PA-824	PA-824	pretomanid	[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02333799	FASN	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001088	nitric oxide donor			
saccharin	saccharin	E954|benzosulfinide|gluside|sweeta	O=C1NS(=O)(=O)c2ccccc12	Launched	http://en.wikipedia.org/wiki/Saccharin	CA12|CA9|CA1|CA2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008189|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008189|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008189|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008189	DNA polymerase inhibitor			
inosine	inosine	INO-1001	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12	Launched	http://www.drugs.com/international/Inosine.html	PNP|PARP1	https://www.drugbank.ca/drugs/DB04335|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000136	neurotrophic agent			
sertraline	sertraline	zoloft	CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12	Launched	FDA Orange Book: sertraline hydrochloride	SLC6A4|SLC6A3|CYP2C19	https://www.drugbank.ca/drugs/DB01104|https://www.drugbank.ca/drugs/DB01104|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=167978	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|obstetrics/gynecology|neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|panic disorders|posttraumatic stress disorder|premenstrual syndrome|social anxiety disorder	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9641190-9151-4f7e-89ff-1e7a818c30ee&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9641190-9151-4f7e-89ff-1e7a818c30ee&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9641190-9151-4f7e-89ff-1e7a818c30ee&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9641190-9151-4f7e-89ff-1e7a818c30ee&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9641190-9151-4f7e-89ff-1e7a818c30ee&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9641190-9151-4f7e-89ff-1e7a818c30ee&audience=consumer
tramadol	tramadol	conzip|rybix odt|ryzolt|tramadol hydrochloride|ultram|ultram er	COc1cccc(c1)[C@]1(O)CCCC[C@H]1CN(C)C	Launched	FDA Orange Book: tramadol hydrochloride	CHRM3|OPRD1|OPRK1|OPRM1|CHRFAM7A|CYP2B6|GRIN3A|HTR2C|SLC6A4|SLC6A2	https://www.drugbank.ca/drugs/DB00193|https://www.drugbank.ca/drugs/DB00193|https://www.drugbank.ca/drugs/DB00193|https://www.drugbank.ca/drugs/DB00193|https://www.drugbank.ca/drugs/DB00193|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091079|https://www.drugbank.ca/drugs/DB00193|https://www.drugbank.ca/drugs/DB00193|https://www.drugbank.ca/drugs/DB00193|https://www.drugbank.ca/drugs/DB00193	norepinephrine reputake inhibitor|opioid receptor agonist|serotonin reuptake inhibitor	neurology/psychiatry|neurology/psychiatry	acute pain|chronic pain	https://en.wikipedia.org/wiki/Tramadol|https://en.wikipedia.org/wiki/Tramadol
tolperisone	tolperisone	N-553 [AS HYDROCHLORIDE]|mydeton|tolperisone hydrochloride	CC(CN1CCCCC1)C(=O)c1ccc(C)cc1	Launched	http://www.drugs.com/international/Tolperisone.html	CYP2B6|CYP2D6|CYP2C19	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=272907|http://www.ncbi.nlm.nih.gov/pubmed/25953735|http://www.ncbi.nlm.nih.gov/pubmed/25953735	voltage-gated sodium channel blocker	neurology/psychiatry|neurology/psychiatry|infectious disease|rheumatology|cardiology|rheumatology	muscle relaxant|multiple sclerosis|encephalomyelitis|ankylosing spondylitis|atherosclerosis|Raynaud's disease	https://en.wikipedia.org/wiki/Encephalomyelitis|https://en.wikipedia.org/wiki/Encephalomyelitis|https://en.wikipedia.org/wiki/Encephalomyelitis|https://en.wikipedia.org/wiki/Encephalomyelitis|https://en.wikipedia.org/wiki/Encephalomyelitis|https://en.wikipedia.org/wiki/Encephalomyelitis
levamisole	levamisole	TCMDC-125847|ergamisol	C1CN2C[C@@H](N=C2S1)c1ccccc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	ALPL|ALPPL2|CHRNA3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000570|https://www.drugbank.ca/drugs/DB00848|https://www.drugbank.ca/drugs/DB00848	acetylcholine receptor agonist			
erythromycin-ethylsuccinate	erythromycin ethylsuccinate	E.E.S. 200|PEDIAMYCIN 400|e-mycin|e-mycin e|e.e.s.|e.e.s. 400|eryped|erythromycin ethyl succinate|erythromycin ethylsuccinate|pediamycin|wyamycin|wyamycin e	CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C	Launched	FDA Orange Book: erythromycin ethylsuccinate	MLNR|ABCB1|KCNH2|SLC47A1|ALB|CYP3A4|CYP51A1	http://www.drugbank.ca/drugs/DB00199|http://www.drugbank.ca/drugs/DB00199|http://www.drugbank.ca/drugs/DB00199|http://www.drugbank.ca/drugs/DB00199|http://www.drugbank.ca/drugs/DB00199|http://www.drugbank.ca/drugs/DB00199|http://www.drugbank.ca/drugs/DB00199	cytochrome P450 inhibitor|protein synthesis inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f7cd94-d842-4f6b-a582-a38c751a790a
GSK2838232	GSK2838232		CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02289495			HIV gag inhibitor			
L-NAME	L-NAME		COC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT00753948	NOS3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000150	nitric oxide synthase inhibitor			
4-CMTB	4-CMTB		CC(C)C(C(=O)Nc1nccs1)c1ccc(Cl)cc1	Preclinical		FFAR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5803	free fatty acid receptor agonist			
nystatin	nystatin	BARSTATIN 100|Myco 20|Nystex|candex|korostatin|mycostatin|mykinac|nilstat|nysert|nystop		Launched	FDA Orange Book: nystatin			fungal ergosterol inhibitor	infectious disease|infectious disease|infectious disease	esophageal candidiasis|skin infections|yeast infection	https://en.wikipedia.org/wiki/Nystatin#Medical_uses|https://en.wikipedia.org/wiki/Nystatin#Medical_uses|https://en.wikipedia.org/wiki/Nystatin#Medical_uses
AZD2858	AZD2858		CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1	Preclinical		GSK3B|GSK3A	https://www.caymanchem.com/product/16728|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=460997	glycogen synthase kinase inhibitor			
amitriptyline	amitriptyline	Amitid|Amitril|Endep|Etrafon-A|Etrafon-Forte|Limbitrol|amitriptyline hydrochloride|elavil	CN(C)CCC=C1c2ccccc2CCc2ccccc12	Launched	FDA Orange Book: amitriptyline hydrochloride	HTR1B|HTR1A|HTR1D|HTR2A|HTR2C|KCND3|KCND2|KCNQ3|KCNQ2|CYP3A5|KCNA1|HTR7|HTR6|HRH4|HRH1|HRH2|ADRA1D|ADRA1A|ADRA1B|ADRA2A|CHRM3|CHRM2|CHRM5|CHRM4|CHRM1|ADRB3|ADRB2|ADRB1|NTRK2|NTRK1|SLC6A2|SLC6A4|SCN4A|SIGMAR1|OPRM1|OPRD1|OPRK1|CYP2C19	https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091325|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091325|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://www.drugbank.ca/drugs/DB00321|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091325	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61d2da8d-b435-4ada-a013-401786f7cace
8-hydroxy-PIPAT	8-hydroxy-PIPAT		CCCN(C\C=C\I)C1CCc2cccc(O)c2C1	Preclinical		DRD3|DRD2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=951|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=951	dopamine receptor ligand			
desmopressin-acetate	desmopressin acetate	concentraid|ddavp|ddavp (needs no refrigeration)|desmopressin acetate|minirin|stimate|stimate (needs no refrigeration)	NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CCSSCC(NC(=O)C(CC(N)=O)NC1=O)C(=O)N1CCCC1C(=O)NC(CCCNC(N)=N)C(=O)NCC(N)=O	Launched	FDA Orange Book: desmopressin acetate	AVPR1A|AVPR1B|AVPR2|OXTR	https://www.drugbank.ca/drugs/DB00035|https://www.drugbank.ca/drugs/DB00035|https://www.drugbank.ca/drugs/DB00035|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2182	vasopressin receptor agonist	endocrinology|urology	central diabetes insipidus|nocturnal enuresis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bb9b8d5-eed6-45cb-b1b9-e43d3ee6fecd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bb9b8d5-eed6-45cb-b1b9-e43d3ee6fecd
etofylline-clofibrate	etofylline clofibrate	ML-1024|duolip|etofylline clofibrate|theofibrate	Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O	Launched	http://www.drugs.com/international/etofylline-clofibrate.html	LPL|PPARA	https://citeline.informa.com/?query=#/drugs/details/6700|http://www.genome.jp/dbget-bin/www_bget?dr:D06102	platelet aggregation inhibitor			
ethacridine-lactate-monohydrate	ethacridine-lactate-monohydrate	ethacridine	CCOc1ccc2nc3cc(N)ccc3c(N)c2c1	Preclinical				DNA intercalating agent			
misonidazole	misonidazole	RO 7-0582	COCC(O)Cn1ccnc1[N+]([O-])=O	Phase 3	http://europepmc.org/abstract/med/15064016						
TAK-960	TAK-960		COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01179399	PLK1	https://www.caymanchem.com/product/17701	PLK inhibitor			
ARRY-334543	ARRY-334543	ARRY-543|ASLAN-001|varlitinib	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01614522	EGFR|ERBB4|ERBB2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=398005|https://citeline.informa.com/?query=#/drugs/details/30661|http://www.arraybiopharma.com/product-pipeline/other-compounds/aslan001-arry-543/	EGFR inhibitor			
sclareol	sclareol		CC(O)(CC[C@H]1[C@](C)(O)CCC2C(C)(C)CCC[C@]12C)C=C	Preclinical							
4-phenyl-1,2,3,4-tetrahydroisoquinoline	4-phenyl-1,2,3,4-tetrahydroisoquinoline		Cl.C1NCc2ccccc2C1c1ccccc1	Preclinical				dopamine release inhibitor			
THZ2	THZ2		CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1	Preclinical		CDK7	https://www.medchemexpress.com/thz2.html?gclid=COXdo_Kwv88CFQYKaQodH-QECQ	CDK inhibitor			
THZ1	THZ1		CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1	Preclinical		CDK7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8052	CDK inhibitor			
3-CPMT	3-CPMT		CN1C2CCC1CC(C2)OC(c1ccccc1)c1ccc(Cl)cc1	Preclinical				dopamine reuptake inhibitor			
CID-2745687	CID-2745687		COC(=O)c1cnn(c1\C=N\N=C(/S)NC(C)(C)C)-c1ccc(F)cc1F	Preclinical		GPR35	https://www.tocris.com/products/cid-2745687_4293	G protein-coupled receptor antagonist			
EVP-6124	EVP-6124	MT-4666|encenicline	Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01714661	CHRNA7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6926	acetylcholine receptor agonist			
LY393558	LY393558		CC(C)N1Cc2cc(ccc2N(CCN2CCC(=CC2)c2c[nH]c3cc(F)ccc23)S1(=O)=O)S(C)(=O)=O	Preclinical		SLC6A4|HTR1B|HTR1D|HTR2B|HTR2A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=290684|http://www.tocris.com/dispprod.php?ItemId=219986#.VgQZNtNViko|http://www.tocris.com/dispprod.php?ItemId=219986#.VgQZNtNViko|http://www.tocris.com/dispprod.php?ItemId=219986#.VgQZNtNViko|http://www.tocris.com/dispprod.php?ItemId=219986#.VgQZNtNViko	serotonin receptor antagonist			
NK-252	NK-252		O=C(NCc1ccccn1)Nc1nnc(o1)-c1ccco1	Preclinical		NFE2L2	https://www.tocris.com/products/nk-252_5293	NRF2 activator			
sesamin	sesamin	(-)-sesamin	C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1	Preclinical				NFkB pathway inhibitor			
IBC-293	IBC-293		CC(C)n1nnc2cc(ccc12)C(O)=O	Preclinical		HCAR3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1597	hydroxycarboxylic acid receptor agonist			
PF-5274857	PF-5274857		Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O	Preclinical		SMO|PTCH1	http://www.tocris.com/dispprod.php?ItemId=423198#.VgwGk9NViko|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=765437	smoothened receptor antagonist			
BRL-26314	BRL-26314		OC(=O)C(Cc1ccccc1)NCc1ccc(Cl)cc1	Phase 1	Pharmaprojects	LPL	http://www.ncbi.nlm.nih.gov/pubmed/6546691	cholesterol inhibitor			
digitoxin	digitoxin		C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C	Launched	FDA Orange Book: acetyldigitoxin, digitoxin	ATP1A1	https://www.drugbank.ca/drugs/DB01396	ATPase inhibitor			
ospemifene	ospemifene	FC-1271|FC-1271A|osphena	OCCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1	Launched	FDA Orange Book: ospemifene	CYP2B6|ESR1|ESR2|CYP2C19	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=289319|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=289319	selective estrogen receptor modulator (SERM)	obstetrics/gynecology|obstetrics/gynecology|endocrinology	vaginal atrophy|dyspareunia|menopause	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8462d6ab-e3cd-4efa-a360-75bf8f917287|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8462d6ab-e3cd-4efa-a360-75bf8f917287|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8462d6ab-e3cd-4efa-a360-75bf8f917287
miocamycin	miocamycin	Miokamycin	CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)OC(C)=O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](OC(C)=O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C	Launched	https://www.drugs.com/international/miocamycin.html			other antibiotic	infectious disease|infectious disease	urinary tract infections|chlamydia	https://www.ncbi.nlm.nih.gov/pubmed/7506653|https://www.ncbi.nlm.nih.gov/pubmed/7506653
DMeOB	DMeOB		COc1cccc(c1)\C=N\N=C\c1cccc(OC)c1	Preclinical		GRM5	http://www.tocris.com/dispprod.php?ItemId=85560#.Vfmx5NNViko				
PF-03814735	PF-03814735		CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00424632	AURKB|AURKA	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001076|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001076	Aurora kinase inhibitor			
bithionol	bithionol	Actamer|lorothidol	Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	ESR1|ESR2|MCL1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011355|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011355|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011355	autotaxin inhibitor			
vercirnon	vercirnon	CCX282|GSK1605786|Verecimon	CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1	Phase 3	https://us.gsk.com/en-us/media/press-releases/2013/gsk-announces-phase-iii-study-of-vercirnon-in-patients-with-moderate-to-severe-crohns-disease-did-not-meet-its-primary-endpoint/	CCR9	https://www.medchemexpress.com/vercirnon.html?gclid=CPPKsOi7wc8CFQEQaQodCSEEzA	CC chemokine receptor antagonist			
delphinidin	delphinidin		Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1	Phase 2	Integrity	KDR|GLO1|EGFR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=164095|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011198|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=164095	membrane permeability inhibitor			
SCH-221510	SCH-221510		Cc1ccccc1C(N1C2CCC1CC(O)(C2)c1ccccc1)c1ccccc1C	Preclinical		OPRL1	https://www.tocris.com/products/sch-221510_3240	nociceptin/orphanin FQ (NOP) receptor agonist			
spizofurone	spizofurone	AG-629	CC(=O)c1ccc2OC3(CC3)C(=O)c2c1	Withdrawn	https://books.google.com/books?id=Plq6RpLymIcC&pg=PA343&lpg=PA343&dq=Maon+spizofurone&source=bl&ots=-w2B-AwPYh&sig=wrouMHAcQ74ZTWFVGL_4XdWxlrg&hl=en&sa=X&ved=0ahUKEwjI6t_SkejRAhVX4GMKHfiEAEYQ6AEINzAH#v=onepage&q=Maon%20spizofurone&f=false	GAST	https://citeline.informa.com/?query=#/drugs/details/17213				
tifenazoxide	tifenazoxide		CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00400283	KCNJ11|ABCC8	http://www.sciencedirect.com/science/article/pii/S0028390816303823|http://www.sciencedirect.com/science/article/pii/S0028390816303823	ATP-sensitive potassium channel agonist			
PLX-647	PLX-647		FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1	Preclinical		CSF1R|KIT	https://www.tocris.com/products/plx-647-dihydrochloride_5102|https://www.tocris.com/products/plx-647-dihydrochloride_5102	receptor tyrosine protein kinase inhibitor			
merbromin	merbromin		O[Hg]c1c(O)c(Br)cc2c(-c3ccccc3C(O)=O)c3cc(Br)c(=O)cc3oc12	Launched	http://www.drugs.com/international/merbromin.html			antiseptic	infectious disease	first-aid antiseptic	https://en.wikipedia.org/wiki/Merbromin
Ro-60-0175	Ro-60-0175	Ro-600175	C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12	Preclinical		HTR2C|HTR2B|HTR2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=166|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=166|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=166				
4-hydroxy-phenazone	4-hydroxy-phenazone		Cc1c(O)c(=O)n(-c2ccccc2)n1C	Preclinical							
octinoxate	octinoxate		CCCC[C@@H](CC)COC(=O)\C=C\c1ccc(OC)cc1	Launched	FDA Orange Book: octinoxate				dermatology	sunscreen lotion	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4e17fb-22c8-4c79-a140-17000ff13802
EXO-1	EXO-1	Methyl 2-(4-Fluorobenzamido)Benzoate	COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1	Preclinical				ARF inhibitor			
masitinib	masitinib	AB-1010	CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1	Veterinary Launched	http://www.drugs.com/international/Masitinib.html	FGFR3|PDGFRA|PDGFRB|KIT|LYN	http://www.lclabs.com/PRODFILE/L-P/M-7007.php4?gclid=CKCJ56KfobwCFatcMgoddHQAtw|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5656|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5656|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5656|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=444643	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|src inhibitor	dermatology	mastocytoma	https://en.wikipedia.org/wiki/Masitinib
CX-4945	CX-4945	Silmitasertib	OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT02128282	HIPK3|DAPK3|CSNK2B|CSNK2A1|CSNK2A2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8126|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8126|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=631068|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8126|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8126	casein kinase inhibitor			
mosapride	mosapride		CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1	Launched	http://www.drugs.com/international/Mosapride.html	HTR3A|HTR4	https://citeline.informa.com/?query=#/drugs/details/12296|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=242	serotonin receptor agonist	gastroenterology|gastroenterology|gastroenterology|gastroenterology	hypertrophic gastritis (GHG)|gastroesophageal reflux disease (GERD)|dyspepsia|irritable bowel syndrome	https://en.wikipedia.org/wiki/Mosapride|https://en.wikipedia.org/wiki/Mosapride|https://en.wikipedia.org/wiki/Mosapride|https://en.wikipedia.org/wiki/Mosapride
ibandronate	ibandronate	boniva|ibandronic acid	CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O	Launched	FDA Orange Book: ibandronate sodium	FDPS	https://www.drugbank.ca/drugs/DB00710	bone resorption inhibitor	orthopedics	osteoporosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9fad4982-95af-d711-f50a-867311835143
bupropion	bupropion	aplenzin|forfivo xl|wellbutrin|wellbutrin sr|wellbutrin xl|zyban	CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1	Launched	FDA Orange Book: bupropion hydrobromide, bupropion hydrochloride	CYP2B6|SLC6A2|SLC6A3|CHRNA3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=119021|https://www.drugbank.ca/drugs/DB01156|https://www.drugbank.ca/drugs/DB01156|https://www.drugbank.ca/drugs/DB01156	dopamine uptake inhibitor	neurology/psychiatry	depression	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39b2d509-1281-4464-9cf1-a94bbc18b84b
reversine	reversine		C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2[nH]cnc12	Preclinical		MAP2K1|ADORA3|INCENP|AURKA|AURKB	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005308|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=413398|https://www.drugbank.ca/drugs/DB07340|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=413398|https://www.drugbank.ca/drugs/DB07340	Aurora kinase inhibitor			
taladegib	taladegib	LY2940680	CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F	Phase 2	https://www.clinicaltrials.gov/show/NCT01722292	SMO|DHH|IHH|PTCH1	http://www.selleckchem.com/products/ly2940680.html|http://www.selleckchem.com/products/ly2940680.html|http://www.selleckchem.com/products/ly2940680.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=718517	smoothened receptor antagonist			
sunitinib	sunitinib	SU-11248|sutent	CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C	Launched	FDA Orange Book: sunitinib malate	KIT|KDR|FLT1|FLT4|FLT3|CSF1R|PDGFRA|PDGFRB|RET|FGFR1	https://www.drugbank.ca/drugs/DB01268|https://www.drugbank.ca/drugs/DB01268|https://www.drugbank.ca/drugs/DB01268|https://www.drugbank.ca/drugs/DB01268|https://www.drugbank.ca/drugs/DB01268|https://www.drugbank.ca/drugs/DB01268|https://www.drugbank.ca/drugs/DB01268|https://www.drugbank.ca/drugs/DB01268|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5713|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5713	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology|oncology|oncology	gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43a4d7f8-48ae-4a63-9108-2fa8e3ea9d9c&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43a4d7f8-48ae-4a63-9108-2fa8e3ea9d9c&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43a4d7f8-48ae-4a63-9108-2fa8e3ea9d9c&audience=consumer
mannitol-D	D-mannitol	Alexitol sodium|Diosmol|E421|aridol kit|d-mannitol|manna sugar|mannite|mannitol|osmitrol|resectisol		Launched	http://en.wikipedia.org/wiki/Mannitol			diuretic	neurology/psychiatry|ophthalmology|gastroenterology	intracranial pressure|intraocular pressure|constipation	https://en.wikipedia.org/wiki/Mannitol#Medical_uses|https://en.wikipedia.org/wiki/Mannitol#Medical_uses|https://en.wikipedia.org/wiki/Mannitol#Medical_uses
nepicastat	nepicastat		NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01704196	DBH	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6630	dopamine beta hydroxylase inhibitor			
etoricoxib	etoricoxib	Algix|Arcoxia|Etosaid|MK-0663|Tauxib	Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O	Launched	http://www.drugs.com/international/etoricoxib.html	PTGS2	https://www.drugbank.ca/drugs/DB01628	cyclooxygenase inhibitor	rheumatology|rheumatology|rheumatology|rheumatology|rheumatology	rheumatoid arthritis|psoriatic arthritis|osteoarthritis|gout|ankylosing spondylitis	https://en.wikipedia.org/wiki/Etoricoxib|https://en.wikipedia.org/wiki/Etoricoxib|https://en.wikipedia.org/wiki/Etoricoxib|https://en.wikipedia.org/wiki/Etoricoxib|https://en.wikipedia.org/wiki/Etoricoxib
rabeprazole	rabeprazole	LY-307640|aciphex|aciphex sprinkle	COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C	Launched	FDA Orange Book: rabeprazole sodium	ATP4A|CYP2C19	https://www.drugbank.ca/drugs/DB01129|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=143151	ATPase inhibitor|gastrin inhibitor	gastroenterology|gastroenterology|gastroenterology	gastroesophageal reflux disease (GERD)|duodenal ulcer disease|Zollinger-Ellison syndrome	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=951caefe-6e18-48ff-9567-beb545b09c25|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=951caefe-6e18-48ff-9567-beb545b09c25|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=951caefe-6e18-48ff-9567-beb545b09c25
ciprofloxacin	ciprofloxacin	BAY Q 3939|BAY-Q-3939|Ciprobay|Velmonit|cetraxal|ciloxan|cipro|otiprio|proquin xr	OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O	Launched	FDA Orange Book: ciprofloxacin, ciprofloxacin hydrochloride	TOP2A	https://www.drugbank.ca/drugs/DB00537	bacterial DNA gyrase inhibitor	otolaryngology	otitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=213b339a-75e0-4b1d-9052-8ee82a65d713
meparfylon	meparfylon	Oblivon|Trusono|dormison|meparfynol|methylparafynol|methylpentynol	CCC(C)(O)C#C	Preclinical							
IRL-2500	IRL-2500		CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1	Preclinical		EDNRB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3887	endothelin receptor antagonist			
HEMADO	HEMADO		CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1	Preclinical		ADORA2B|ADORA2A|ADORA1|ADORA3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5599|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5599|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5599|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5599				
EMD-66684	EMD-66684		CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1	Preclinical		AGTR1	https://www.tocris.com/dispprod.php?ItemId=80444#.VyjZ9WQrImI	angiotensin receptor antagonist			
etofylline	etofylline	beta-hydroxyethyl theophylline|oxyethyltheophylline|oxyphylline	Cn1c2ncn(CCO)c2c(=O)n(C)c1=O	Launched	http://www.drugs.com/international/Etofylline.html	ADORA1	http://www.scbt.com/datasheet-202836-7-b-Hydroxyethyl-theophylline.html	adenosine receptor antagonist	pulmonary|pulmonary	asthma|bronchitis	http://www.drugs.com/international/etofylline.html|http://www.drugs.com/international/etofylline.html
VLX600	VLX600	DNDI1417324	C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02222363	USP14	http://adisinsight.springer.com/drugs/800035207	ubiquitin C-terminal hydrolase inhibitor			
AMG-337	AMG-337		COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02016534	MET	http://meetinglibrary.asco.org/content/138984-158	MET inhibitor			
ML-277	ML-277		COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1	Preclinical		KCNQ1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7666	potassium channel activator			
danazol	danazol	danocrine	C[C@]12CCC3C(CCC4=Cc5oncc5C[C@]34C)C1CC[C@@]2(O)C#C	Launched	FDA Orange Book: danazol	TNF|GNRHR|PGR|AR|CYP2C8|ESR1|GNRHR2|CCL2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091601|https://www.drugbank.ca/drugs/DB01406|https://www.drugbank.ca/drugs/DB01406|https://www.drugbank.ca/drugs/DB01406|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091601|https://www.drugbank.ca/drugs/DB01406|https://www.drugbank.ca/drugs/DB01406|https://www.drugbank.ca/drugs/DB01406	estrogen receptor antagonist|progesterone receptor agonist	obstetrics/gynecology|cardiology	endometriosis|angioedema	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e19acee5-ff33-45a5-bbbf-801756bc59b4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e19acee5-ff33-45a5-bbbf-801756bc59b4
2,4-dinitrochlorobenzene	2,4-dinitrochlorobenzene		[O-][N+](=O)c1ccc(Cl)c(c1)[N+]([O-])=O	Phase 2				thioredoxin inhibitor			
TCID	TCID		Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl	Preclinical							
Ro-08-2750	Ro-08-2750	Ro-0282750	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O	Preclinical		NGFR|NGF	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=771899|http://www.tocris.com/dispprod.php?ItemId=132740				
amineptine	amineptine		OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	SLC6A4|SLC6A2	https://www.drugbank.ca/drugs/DB04836|https://www.drugbank.ca/drugs/DB04836	dopamine receptor agonist			
proxymetacaine	proxymetacaine	Kainair|Paracaine|alcaine|ophthaine|ophthetic|proparacaine	CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC	Launched	FDA Orange Book: proparacaine hydrochloride	SCN10A|SCN9A|SCN5A	https://www.drugbank.ca/drugs/DB00807|https://citeline.informa.com/?query=#/drugs/details/8987|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000513	sodium channel blocker	neurology/psychiatry	anesthetic	https://en.wikipedia.org/wiki/Proxymetacaine
fenspiride	fenspiride		O=C1NCC2(CCN(CCc3ccccc3)CC2)O1	Launched	http://www.drugs.com/international/Fenspiride.html			bronchodilator	pulmonary|otolaryngology|otolaryngology|otolaryngology|otolaryngology	asthma|otitis|sinusitis|rhinopharyngitis|laryngitis	http://www.drugbank.ca/drugs/DB08979|http://www.drugbank.ca/drugs/DB08979|http://www.drugbank.ca/drugs/DB08979|http://www.drugbank.ca/drugs/DB08979|http://www.drugbank.ca/drugs/DB08979
caprylic-acid	caprylic acid	octanoic acid	CCCCCCCC(O)=O	Launched	http://en.wikipedia.org/wiki/Caprylic_acid						
pyrvinium-pamoate	pyrvinium pamoate	povan|pyrvinium		Launched	FDA Orange Book: pyrvinium pamoate	AR	http://www.sigmaaldrich.com/catalog/product/sigma/p0027?lang=en&region=US	androgen receptor antagonist			
vinblastine	vinblastine	velban|vinblastine sulfate	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC	Launched	FDA Orange Book: vinblastine sulfate	JUN|TUBE1|TUBD1|TUBG1|TUBA1A|TUBB	https://www.drugbank.ca/drugs/DB00570|https://www.drugbank.ca/drugs/DB00570|https://www.drugbank.ca/drugs/DB00570|https://www.drugbank.ca/drugs/DB00570|https://www.drugbank.ca/drugs/DB00570|https://www.drugbank.ca/drugs/DB00570	microtubule inhibitor|tubulin polymerization inhibitor	hematologic malignancy|hematologic malignancy|infectious disease|hematologic malignancy|oncology|oncology	Hodgkin's lymphoma|true histiocytic lymphoma (THL)|mycosis|small lymphocytic lymphoma (SLL)|testicular carcinoma|Kaposi sarcoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77
myristyl-nicotinate	myristyl-nicotinate		CCCCCCCCCCCCCCOC(=O)c1cccnc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00619060			topical sunscreen agent			
zileuton	zileuton	A-64077|ABBOTT-64077|zyflo|zyflo cr	CC(N(O)C(N)=O)c1cc2ccccc2s1	Launched	FDA Orange Book: zileuton	ALOX5	ChEMBL	leukotriene synthesis inhibitor|lipoxygenase inhibitor	pulmonary	asthma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aee65202-fddb-497f-9f11-17cc727cb157
isopropamide-iodide	isopropamide iodide	darbid|isopropamide	CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C	Launched	FDA Orange Book: isopropamide iodide	CHRM3|CHRM4	https://www.drugbank.ca/drugs/DB01625|https://www.drugbank.ca/drugs/DB01625	acetylcholine receptor antagonist	gastroenterology|gastroenterology	peptic ulcer disease (PUD)|gastrointestinal acidosis	https://en.wikipedia.org/wiki/Isopropamide|https://en.wikipedia.org/wiki/Isopropamide
broxyquinoline	broxyquinoline	dibromohydroxyquinoline	Oc1c(Br)cc(Br)c2cccnc12	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/3081428			antiprotozoal agent			
tolmetin	tolmetin	MCN-2559|tolectin|tolectin 600|tolectin ds|tolmetin sodium	Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C	Launched	FDA Orange Book: tolmetin sodium	PTGS1|PTGS2	https://www.drugbank.ca/drugs/DB00500|https://www.drugbank.ca/drugs/DB00500	cyclooxygenase inhibitor	rheumatology|rheumatology	rheumatoid arthritis|osteoarthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dbae03d7-b6ab-4139-8e79-29c05924849e&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dbae03d7-b6ab-4139-8e79-29c05924849e&audience=consumer
tenofovir-alafenamide	tenofovir-alafenamide		CC(C)OC(=O)C(C)NP(=O)(COC(C)Cn1cnc2c(N)ncnc12)Oc1ccccc1	Preclinical	FDA Orange Book: tenofovir alafenamide fumarate			nucleoside reverse transcriptase inhibitor			
DDR1-IN-1	DDR1-IN-1		CCN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Oc3ccc4NC(=O)Cc4c3)c2)CC1	Preclinical		DDR1|DDR2	https://www.tocris.com/products/ddr1-in-1-dihydrochloride_5077|https://www.tocris.com/products/ddr1-in-1-dihydrochloride_5077	discoidin domain receptor inhibitor			
melengestrol-acetate	melengestrol acetate		CC(=O)O[C@]1(C(C)=O)C(=C)CC2C3C=C(C)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C	Preclinical				progesterone receptor agonist			
valrocemide	valrocemide	TV-1901	CCCC(CCC)C(=O)NCC(N)=O	Phase 2	http://onlinelibrary.wiley.com/doi/10.1046/j.1528-1157.2001.042007831.x/full						
cyacetacide	cyacetacide		NNC(=O)CC#N	Preclinical							
dacinostat	dacinostat	NVP-LAQ824	OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/18927309	HDAC9|HDAC5|HDAC6|HDAC7|HDAC8|HDAC1|HDAC2|HDAC3|HDAC4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7497|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7497|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7497|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7497|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7497|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7497|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7497|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7497|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7497	HDAC inhibitor			
cortisone-acetate	cortisone acetate	cortisone|cortisone acetate|cortone	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C	Launched	FDA Orange Book: cortisone acetate, fludrocortisone acetate, hydrocortisone acetate	NR3C1	ChEMBL	glucocorticoid receptor agonist	pulmonary|rheumatology|allergy|rheumatology|dermatology|allergy|ophthalmology|gastroenterology|infectious disease	asthma|rheumatoid arthritis|urticaria|osteoarthritis|psoriasis|allergic rhinitis|conjunctivitis|ulcerative colitis|meningitis	http://www.rxlist.com/cortone-drug/indications-dosage.htm|http://www.rxlist.com/cortone-drug/indications-dosage.htm|http://www.rxlist.com/cortone-drug/indications-dosage.htm|http://www.rxlist.com/cortone-drug/indications-dosage.htm|http://www.rxlist.com/cortone-drug/indications-dosage.htm|http://www.rxlist.com/cortone-drug/indications-dosage.htm|http://www.rxlist.com/cortone-drug/indications-dosage.htm|http://www.rxlist.com/cortone-drug/indications-dosage.htm|http://www.rxlist.com/cortone-drug/indications-dosage.htm
taxifolin	taxifolin	(+)-taxifolin	O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1	Phase 2	Integrity	APP|APOB|ADIPOR2|HMGCR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=300382|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=300382|https://en.wikipedia.org/wiki/Taxifolin#Pharmacology|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=300382	opioid receptor antagonist			
fluphenazine-decanoate	fluphenazine decanoate	fluphenazine decanoate|prolixin decanoate	CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	Launched	FDA Orange Book: fluphenazine decanoate	DRD2|HTR4|HTR1B	ChEMBL|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000806|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000806	dopamine receptor antagonist	neurology/psychiatry	schizophrenia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8ba014e-aea0-49bc-8345-4e0a384b484e
isoflurophate	isoflurophate	dyflos|floropryl|fluostigmine	CC(C)OP(F)(=O)OC(C)C	Launched	FDA Orange Book: isoflurophate	ACHE|BCHE	ChEMBL|https://www.drugbank.ca/drugs/DB00677	cholinesterase inhibitor	ophthalmology	glaucoma	http://www.drugbank.ca/drugs/DB00677
norethisterone-enanthate	norethisterone-enanthate		CCCCCCC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C	Launched	https://en.wikipedia.org/wiki/Norethisterone_enanthate			contraceptive agent	endocrinology	contraceptive	https://en.wikipedia.org/wiki/Norethisterone_enanthate
idazoxane	idazoxane		C1CNC(N1)=C1COc2ccccc2O1	Preclinical		ADRA2A|ADRA2C|ADRA2B	https://www.tocris.com/products/idazoxan-hydrochloride_0793|https://www.tocris.com/products/idazoxan-hydrochloride_0793|https://www.tocris.com/products/idazoxan-hydrochloride_0793	adrenergic receptor antagonist			
TAK-285	TAK-285		CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00535522	ERBB2|EGFR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000649|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=470598	EGFR inhibitor			
TTNPB	TTNPB	Ro-137410	C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/3378655	RARA|RARB|RARG	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2646|https://www.drugbank.ca/drugs/DB02877|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2646	retinoid receptor agonist			
colforsin-daproate	colforsin-daproate		CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C	Launched	http://www.drugs.com/international/colforsin-daropate-hydrochloride.html			adenylyl cyclase activator			
fursultiamine	fursultiamine	TTFD|fursultiamine hydrochloride	C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCO)SSCC1CCCO1	Launched	http://www.drugs.com/international/Fursultiamine.html			vitamin B			
hydroxytacrine-maleate-(r,s)	hydroxytacrine-maleate-(r,s)		Nc1c2C(O)CCCc2nc2ccccc12	Preclinical				cholinesterase inhibitor			
dofequidar	dofequidar		OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/17179098	ABCB1|ABCC1	http://www.uniprot.org/uniprot/?query=MDR-1&sort=score|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=204313	MRP inhibitor|P glycoprotein inhibitor			
zoniporide	zoniporide		NC(N)=NC(=O)c1cnn(c1C1CC1)-c1cccc2ncccc12	Phase 3	https://www.ncbi.nlm.nih.gov/pubmed/16202888	AOX1|SLC9A1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=295863|https://www.tocris.com/products/zoniporide-dihydrochloride_2727	sodium/hydrogen exchanger inhibitor			
cefotiam-cilexetil	cefotiam cilexetil		CC(OC(=O)OC1CCCCC1)OC(=O)C1=C(CSc2nnnn2CCN(C)C)CSC2C(NC(=O)Cc3csc(N)n3)C(=O)N12	Launched	http://www.drugs.com/international/cefotiam.html			bacterial cell wall synthesis inhibitor			
acetyl-farnesyl-cysteine	acetyl-farnesyl-cysteine		CC(=O)N[C@@H](CSC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=O	Launched	http://www.news-medical.net/news/20100712/Rohto-launches-AFC-Medirepair-with-Signums-compound-Arazine-in-Japan.aspx	PPARG	http://www.ncbi.nlm.nih.gov/pubmed/21979952	methyltransferase inhibitor	dermatology	acne vulgaris (AV)	http://www.news-medical.net/news/20100712/Rohto-launches-AFC-Medirepair-with-Signums-compound-Arazine-in-Japan.aspx
GZD824	GZD824		CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4[nH]ncc4c3)cc2C(F)(F)F)CC1	Preclinical		BCR|ABL1	http://www.selleckchem.com/products/gzd824.html|http://www.selleckchem.com/products/gzd824.html	Bcr-Abl kinase inhibitor			
4BP-TQS	4BP-TQS		NS(=O)(=O)c1ccc2NC(C3CC=CC3c2c1)c1ccc(Br)cc1	Preclinical		CHRNA7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3962	nicotinic receptor agonist			
BAX-channel-blocker	BAX-channel-blocker		OC(CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12	Preclinical		BAX	http://www.tocris.com/dispprod.php?ItemId=113685	cytochrome C release inhibitor			
GABA-linoleamide	GABA-linoleamide		CCCCC\C=C/C\C=C/CCCCCCCC(=O)NCCCC(O)=O	Phase 2	Pharmaprojects			benzodiazepine receptor agonist			
batimastat	batimastat	BB-94	CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO	Phase 3	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893668/	ADAMTS5|MMP12|MMP16|MMP8|MMP1|MMP2|ADAM28	https://www.drugbank.ca/drugs/DB03880|https://www.drugbank.ca/drugs/DB03880|https://www.drugbank.ca/drugs/DB03880|https://www.drugbank.ca/drugs/DB03880|https://citeline.informa.com/?query=#/drugs/details/2796|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000274|https://www.drugbank.ca/drugs/DB03880	matrix metalloprotease inhibitor			
GSK163090	GSK163090	GSK-163090	Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00896363	HTR1B|HTR1D|HTR1A	https://www.medchemexpress.com/GSK163090.html|https://www.medchemexpress.com/GSK163090.html|https://www.medchemexpress.com/GSK163090.html	serotonin receptor antagonist			
N-acetyltryptamine	N-acetyltryptamine	nb-acetyltryptamine	CC(=O)NCCc1c[nH]c2ccccc12	Preclinical				melatonin receptor agonist			
digitoxigenin	digitoxigenin	Digoxigenin|Uzarigenin	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1	Preclinical		ATP1A1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011988	ATPase inhibitor			
golvatinib	golvatinib	E-7050|E7050	CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1	Phase 2	https://www.clinicaltrials.gov/show/NCT01433991	MET|KDR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7956|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7956	VEGFR inhibitor			
cianidanol	cianidanol	(+)-catechin|cianidol	O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	PTGS1|FASN|SCN5A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013887|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=321630|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=321630	fatty acid synthase inhibitor			
natamycin	natamycin	natacyn	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O	Launched	FDA Orange Book: natamycin			fungal ergosterol inhibitor	ophthalmology|infectious disease|ophthalmology	conjunctivitis|fungal keratosis|blepharitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d262661c-860d-482e-aa8d-3cf1f252b32a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d262661c-860d-482e-aa8d-3cf1f252b32a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d262661c-860d-482e-aa8d-3cf1f252b32a
medetomidine	medetomidine	MPV-1440|dexmedetomidine|dexmedetomidine hydrochloride|precedex	CC(c1c[nH]cn1)c1cccc(C)c1C	Veterinary Launched	https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/554	ADRA1D|ADRA1B|ADRA1A|ADRA2C|ADRA2A|ADRA2B	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004594|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004594|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004594|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004594|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004594|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004594	adrenergic receptor agonist	neurology/psychiatry	sedative	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8fb7886c-7762-4b72-989b-0fe8e963b4b8
LY215490	LY215490	LY-293558|LY293558|NGX424|tezampanel	OC(=O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/9821993	GRIA1|GRIA2|GRIA3|GRIA4|GRIK1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4245|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4245|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4245|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4245|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001099	glutamate receptor antagonist			
viomycin	viomycin		NCCC[C@H](N)CC(=O)N[C@H]1CNC(=O)[C@@H](NC(=O)\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O)=C\NC(N)=O)C1C[C@H](O)N=C(N)N1	Launched	FDA Orange Book: viomycin sulfate			protein synthesis inhibitor	infectious disease	tuberculosis	https://en.wikipedia.org/wiki/Viomycin
U-50488-(-)	(-)-U-50488	(-)-U-50488|(-)-U-50488H	CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	Preclinical		OPRK1	http://www.tocris.com/dispprod.php?ItemId=1949#.VhQBqxNViko	opioid receptor agonist			
etonogestrel	etonogestrel	implanon|nexplanon	CCC12CC(=C)C3C(CCC4=CC(=O)CCC34)C1CC[C@@]2(O)C#C	Launched	FDA Orange Book: etonogestrel	CYP2C19|PGR|ESR1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090420|https://www.drugbank.ca/drugs/DB00294|https://www.drugbank.ca/drugs/DB00294	progesterone receptor agonist	endocrinology	contraceptive	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50ed7e31-b9b7-4f0a-8e36-91ed5af86b81
sodium-gluconate	sodium gluconate	E574|gluconic acid		Launched	FDA Orange Book: sodium gluconate						
minoxidil	minoxidil	Minodyl|Minoxidil (for men)|Minoxidil (for women)|Minoxidil extra strength (for men)|Theroxidil|U-10,858|loniten|men's rogaine|rogaine|rogaine (for men)|rogaine (for women)|rogaine extra strength (for men)|women's rogaine	Nc1cc(nc(N)[n+]1[O-])N1CCCCC1	Launched	FDA Orange Book: minoxidil	REN|KCNJ10|KCNJ11|PTGS1|KCNJ8|KCNJ1|ABCC9	https://citeline.informa.com/?query=#/drugs/details/12114|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000143|ChEMBL|https://www.drugbank.ca/drugs/DB00350|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4254|https://www.drugbank.ca/drugs/DB00350|ChEMBL	KATP activator|Kir6 channel (KATP) activator|vasodilator	endocrinology	androgenetic alopecia	https://en.wikipedia.org/wiki/Minoxidil
coenzyme-a	Coenzyme A	CoASH|Coenzyme A|coenzyme_a	CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)n1cnc2c(N)ncnc12)[C@@H](O)C(=O)NCCC(=O)NCCS	Launched	http://en.wikipedia.org/wiki/Coenzyme_A	KAT2B|KAT2A|HMGCR|CRAT|CS|DBI|KAT5|ACAT2	https://www.drugbank.ca/drugs/DB01992|https://www.drugbank.ca/drugs/DB01992|https://www.drugbank.ca/drugs/DB01992|https://www.drugbank.ca/drugs/DB01992|https://www.drugbank.ca/drugs/DB01992|https://www.drugbank.ca/drugs/DB01992|https://www.drugbank.ca/drugs/DB01992|https://www.drugbank.ca/drugs/DB01992				
perfluorodecalin	perfluorodecalin	perflunafene	FC1(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C1(F)F	Launched	https://www.drugs.com/international/perflunafene.html				dermatology	cosmetic	https://www.truthinaging.com/ingredients/perfluorodecalin
coenzyme-i	coenzyme-i		NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O	Phase 2	Integrity	ALDH3A1|ALDH3A2|ALDH3B1|ALDH3B2|ME3|ME1|ME2|ALDH4A1|HADHA|HMGCR|IDH3A|IDH3B|IDH3G|ALDH5A1|TSTA3|HIBADH|ALDH6A1|ALDH7A1|HADH|ALDH9A1|UGDH|CYB5R3|MTHFD1|MTHFD2|PHGDH|EHHADH|NQO2|NNT|BDH1|MDH2|MDH1|ALDH2|DLD|AASS|DHFR|LDHAL6B|LDHAL6A|GPD1|OGDH|AMT|CDO1|MT-ND4L|HSD11B2|HSD11B1|MT-ND1|MT-ND2|MT-ND5|MT-ND6|MT-ND3|MT-ND4|DHCR7|ADH7|ADH4|ADH5|LDHC|LDHB|LDHA|GSR|H6PD|ALDH1A1|ALDH1A2|ALDH1A3|ALDH1B1|DLAT|NSDHL|NDUFB1|NDUFB5|NDUFB4|NDUFB3|NDUFB2|NDUFB9|NDUFB8|NDUFB7|NDUFB6|NDUFA9|NDUFA4|NDUFA3|NDUFA2|NDUFA1|NDUFA8|NDUFA7|NDUFA6|NDUFA5|NDUFC2|NDUFC1|PDHB|ADH1C|ADH1B|ADH1A|QDPR|MSMO1|NDUFS2|NDUFS1|NDUFV1|NDUFV3|NDUFV2|NDUFS6|NDUFS5|NDUFS4|NDUFS3|NDUFS8|NDUFS7|NDUFA4L2|HSD17B1|HSD17B4|HSD17B3|HSD17B2|HSD17B8|HSD17B7|HPGD|BLVRB|BLVRA|SORD|GAPDHS|ACADS|HSD17B10|HMOX1|HMOX2|TYR|PYCR1|PYCR2|HSD3B2|HSD3B1|CYP17A1|CYP4A11|GLUD2|GLUD1|PDHA2|PDHA1|IMPDH2|IMPDH1|AKR1C2|AKR1C1|AKR1C4|AKR1C3|AKR1B1|NDUFA11|NDUFA10|NDUFA13|NDUFA12|NDUFB10|NDUFAB1|GAPDH|RDH5	https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157|https://www.drugbank.ca/drugs/DB00157				
diroximel-fumarate	diroximel-fumarate		COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02634307	HCAR2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=850997	anti-inflammatory agent			
GSK1904529A	GSK1904529A	GSK-1904529A	CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O	Preclinical		IGF1R|INSR	http://www.selleckchem.com/products/GSK1904529A.html|http://www.selleckchem.com/products/GSK1904529A.html	IGF-1 inhibitor|insulin growth factor receptor inhibitor|insulin receptor ligand			
methocarbamol	methocarbamol	Miolaxin|Neuraxin|delaxin|forbaxin|robaxin|robaxin-750	COc1ccccc1OCC(O)COC(N)=O	Launched	FDA Orange Book: methocarbamol	CA1	ChEMBL	muscle relaxant	neurology/psychiatry	muscle relaxant	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92123cfa-5bd5-4554-8d5d-b877d5cb9c02
doramectin	doramectin		CO[C@H]1C[C@H](OC2[C@H](C)OC(C[C@@H]2OC)O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(C5)O[C@H](C5CCCCC5)[C@@H](C)C=C2)[C@]34O)O[C@@H](C)[C@@H]1O	Veterinary Launched	http://www.drugs.com/international/doramectin.html				infectious disease	gastrointestinal roundworms	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec6ff537-4773-432d-86db-7ba767769c80
methylene-blue	methylene blue	DNDI1417128|methylene blue		Launched	https://clinicaltrials.gov/ct2/show/NCT01386879	ACHE|MAPT	https://www.drugbank.ca/drugs/DB08167|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=309732	guanylyl cyclase inhibitor|nitric oxide production inhibitor	hematology	methemoglobinemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fde64824-2be5-4d85-8d57-5098ca6890bb#
GSK2830371	GSK2830371	GSK-2830371	Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1	Preclinical		PPM1D	https://www.tocris.com/dispprod.php?ItemId=404031#.V-mAdZMrLy8	protein phosphatase inhibitor			
doxycycline-hyclate	doxycycline hyclate	acticlate|acticlate cap|atridox|doryx|doxteric|doxy 100|doxy 200|doxycycline|doxycycline hyclate|periostat|vibra-tabs|vibramycin	CCO.C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12.C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12	Launched	FDA Orange Book: doxycycline hyclate			bacterial 30S ribosomal subunit inhibitor	dental	periodontitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c718fc7-2921-4d02-b273-784e513f8299
sodium-nitroprusside	sodium nitroprusside	nipride|nitropress|sodium nitroprusside	[O-][N+][Fe--](C#N)(C#N)(C#N)(C#N)C#N	Launched	FDA Orange Book: sodium nitroprusside			nitric oxide donor	cardiology|cardiology	hypertension|congestive heart failure	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a44bcac-a0e1-4069-5691-db7b83dbb4b7&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a44bcac-a0e1-4069-5691-db7b83dbb4b7&audience=consumer
GSK-LSD-1	GSK-LSD-1		C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1	Preclinical		KDM1A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8241	histone lysine demethylase inhibitor			
PF-4981517	PF-4981517		Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12	Preclinical		PDE2A|CYP3A5|CYP3A4	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=791555|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=791555|https://www.tocris.com/dispprod.php?ItemId=295167#.VyuIAGQrJZJ	cytochrome P450 inhibitor			
SB-366791	SB-366791		COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1	Preclinical		TRPV1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4309	TRPV antagonist			
articaine	articaine	40 045|HOE-045|Septocaine|carticaine	CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC	Launched	FDA Orange Book: articaine hydrochloride			local anesthetic	neurology/psychiatry	local anesthetic	https://en.wikipedia.org/wiki/Articaine
TTP-22	TTP-22		Cc1ccc(cc1)-c1csc2ncnc(SCCC(O)=O)c12	Preclinical		CSNK2A1	https://www.tocris.com/products/ttp-22_4432	casein kinase inhibitor			
benzbromarone	benzbromarone	L-2214|MJ 10061|benzbromaron	CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1	Launched	http://www.drugs.com/international/Benzbromarone.html	ABCC1|SLC22A12	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000306|https://citeline.informa.com/?query=#/drugs/details/2862	chloride channel blocker	rheumatology	gout	https://en.wikipedia.org/wiki/Benzbromarone
kaempferol	kaempferol	Kempferol|Pelargidenolon|Populnetin|Rhamnolutein|Rhamnolutin|Robigenin|Swartziol|Trifolitin	Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O	Preclinical		ALOX15B|XDH|HSD17B1|UGT3A1|STAT6|ESRRG|ESRRA|CYP1B1|GLO1|AKR1B1|ALOX5|AR|PTGS1|JAK3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006613|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=300444|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006613|https://www.drugbank.ca/drugs/DB01852|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=300444|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=300444|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=300444|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006613|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006613|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006613|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006613|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006613|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=300444|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=300444	bone resorption inhibitor|estrogen-related receptor inverse agonist			
anethole-trithione	Anethole Trithione	Anethole Trithione|anetholtrithion	COc1ccc(cc1)-c1cc(=S)ss1	Launched	http://en.wikipedia.org/wiki/Anethole_trithione			glutathione transferase stimulant			
balapiravir	balapiravir	R04588161|RO4588161	CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-]	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/22166557			RNA polymerase inhibitor			
huperzine-a	huperzine a		C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/21502597	ACHE	https://www.drugbank.ca/drugs/DB01928	acetylcholinesterase inhibitor			
hexestrol	hexestrol			Launched	http://www.drugs.com/international/Hexestrol.html	AKR1C1|ESR1|ESR2	https://www.drugbank.ca/drugs/DB07931|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2823|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012734	synthetic estrogen			
SB-590885	SB-590885	SB590885	CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1	Preclinical		BRAF	http://www.selleckchem.com/products/SB590885.html?gclid=COeS5bq2zLoCFQif4AodFzoAgw	RAF inhibitor			
trolox	trolox		Cc1c(C)c2OC(C)(CCc2c(C)c1O)C(O)=O	Launched	http://en.wikipedia.org/wiki/Trolox			antioxidant			
dihydroergocristine	dihydroergocristine	GNF-Pf-3462	CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	Launched	http://www.drugs.com/international/Dihydroergocristine.html	ADRA1A|HTR2A|HTR3A|HTR1A|HTR5A|HTR4|HTR7|HTR6|ADRB1|DRD1|DRD5|DRD4|DRD3|DRD2	http://www.scbt.com/datasheet-201117-dihydroergocristine-mesylate.html|http://www.scbt.com/datasheet-201117-dihydroergocristine-mesylate.html|http://www.scbt.com/datasheet-201117-dihydroergocristine-mesylate.html|http://www.scbt.com/datasheet-201117-dihydroergocristine-mesylate.html|http://www.scbt.com/datasheet-201117-dihydroergocristine-mesylate.html|http://www.scbt.com/datasheet-201117-dihydroergocristine-mesylate.html|http://www.scbt.com/datasheet-201117-dihydroergocristine-mesylate.html|http://www.scbt.com/datasheet-201117-dihydroergocristine-mesylate.html|http://www.scbt.com/datasheet-201117-dihydroergocristine-mesylate.html|http://www.scbt.com/datasheet-201117-dihydroergocristine-mesylate.html|http://www.scbt.com/datasheet-201117-dihydroergocristine-mesylate.html|http://www.scbt.com/datasheet-201117-dihydroergocristine-mesylate.html|http://www.scbt.com/datasheet-201117-dihydroergocristine-mesylate.html|http://www.scbt.com/datasheet-201117-dihydroergocristine-mesylate.html	adrenergic receptor antagonist|prolactin inhibitor			
norcyclobenzaprine	norcyclobenzaprine		CNCCC=C1c2ccccc2C=Cc2ccccc12	Preclinical				adrenergic receptor agonist|serotonin receptor antagonist			
epirubicin	epirubicin	ellence|epirubicin hydrochloride	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	Launched	FDA Orange Book: epirubicin hydrochloride	TOP2A|CHD1	https://www.drugbank.ca/drugs/DB00445|https://www.drugbank.ca/drugs/DB00445	topoisomerase inhibitor	oncology	breast cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7ec5ec1-fb05-4c78-b821-9aea638cf144
imiquimod	imiquimod	R-837|S-26308|S26308|aldara|zyclara	CC(C)Cn1cnc2c(N)nc3ccccc3c12	Launched	FDA Orange Book: imiquimod	TLR8|TLR7	https://www.drugbank.ca/drugs/DB00724|ChEMBL	interferon inducer|toll-like receptor agonist	dermatology|infectious disease|oncology	actinic keratosis (AK)|genital warts|basal cell carcinoma (BCC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf224c8b-e0a7-b47a-5b7e-a1d161665023|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf224c8b-e0a7-b47a-5b7e-a1d161665023|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf224c8b-e0a7-b47a-5b7e-a1d161665023
cefotiam	cefotiam	ceradon	CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O	Launched	FDA Orange Book: cefotiam hydrochloride			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	bacterial septicemia|bone and joint infections|respiratory tract infections|skin infections|urinary tract infections	https://en.wikipedia.org/wiki/Cefotiam#Indications|https://en.wikipedia.org/wiki/Cefotiam#Indications|https://en.wikipedia.org/wiki/Cefotiam#Indications|https://en.wikipedia.org/wiki/Cefotiam#Indications|https://en.wikipedia.org/wiki/Cefotiam#Indications
indole-3-carbinol	indole-3-carbinol		OCc1c[nH]c2ccccc12	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT00579332	AHR|IDO1	http://www.ncbi.nlm.nih.gov/pubmed/8866829|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=275366	aryl hydrocarbon receptor agonist|indoleamine 2,3-dioxygenase inhibitor			
hydroflumethiazide	hydroflumethiazide	diucardin|saluron	NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F	Launched	FDA Orange Book: hydroflumethiazide	SLC12A3|SLC12A1|KCNMA1|ATP1A1|CA12|CA4|CA2|CA1|CA9	ChEMBL|https://www.drugbank.ca/drugs/DB00774|https://www.drugbank.ca/drugs/DB00774|https://www.drugbank.ca/drugs/DB00774|https://www.drugbank.ca/drugs/DB00774|https://www.drugbank.ca/drugs/DB00774|https://www.drugbank.ca/drugs/DB00774|https://www.drugbank.ca/drugs/DB00774|https://www.drugbank.ca/drugs/DB00774	sodium/potassium/chloride transporter inhibitor	cardiology|cardiology|gastroenterology|rheumatology|nephrology|nephrology|cardiology	edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|chronic renal failure|acute glomerulonephritis (AGN)|hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6153ef9e-77f0-4233-a5bc-3e3d1f732323|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6153ef9e-77f0-4233-a5bc-3e3d1f732323|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6153ef9e-77f0-4233-a5bc-3e3d1f732323|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6153ef9e-77f0-4233-a5bc-3e3d1f732323|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6153ef9e-77f0-4233-a5bc-3e3d1f732323|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6153ef9e-77f0-4233-a5bc-3e3d1f732323|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6153ef9e-77f0-4233-a5bc-3e3d1f732323
tiotropium	tiotropium	spiriva|spiriva respimat	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1	Launched	FDA Orange Book: tiotropium bromide	CHRM2|CHRM1|CHRM3	https://www.drugbank.ca/drugs/DB01409|https://www.drugbank.ca/drugs/DB01409|https://www.drugbank.ca/drugs/DB01409	acetylcholine receptor antagonist	pulmonary|pulmonary|pulmonary	chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=820839ef-e53d-47e8-a3b9-d911ff92e6a9&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=820839ef-e53d-47e8-a3b9-d911ff92e6a9&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=820839ef-e53d-47e8-a3b9-d911ff92e6a9&audience=consumer
fruquintinib	fruquintinib		CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02314819	KDR	http://www.hmplglobal.com/en/fruquintinib/	VEGFR inhibitor			
isoflupredone-acetate	isoflupredone acetate	U-6013|isoflupredone|isoflupredone acetate	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C	Preclinical		NR3C1	http://www.drugs.com/international/isoflupredone.html				
sulfabenzamide	sulfabenzamide	sulfabenzamide (triple sulfa)	Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1	Launched	FDA Orange Book: triple sulfa (sulfabenzamide;sulfacetamide;sulfathiazole)			bacterial antifolate			
mexiletine	mexiletine	mexiletine hydrochloride|mexitil	CC(N)COc1c(C)cccc1C	Launched	FDA Orange Book: mexiletine hydrochloride	SCN4A|SCN5A|AHR|KCNK2|KCNK3|CYP2E1|CYP2B6	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2629|https://www.drugbank.ca/drugs/DB00379|https://www.drugbank.ca/drugs/DB00379|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091522|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091522|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091522|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091522	sodium channel blocker	cardiology|cardiology	ventricular arrhythmias|ventricular tachycardia (VT)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab73778b-6794-441c-b127-610a6d0733ea|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab73778b-6794-441c-b127-610a6d0733ea
moxifloxacin	moxifloxacin	avelox|moxeza|moxifloxacin hydrochloride|vigamox	COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1	Launched	FDA Orange Book: moxifloxacin hydrochloride	TOP2A	https://www.drugbank.ca/drugs/DB00218	bacterial DNA gyrase inhibitor	otolaryngology|pulmonary|infectious disease|infectious disease|infectious disease	sinusitis|bronchitis|pneumonia|skin infections|intra-abdominal infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71b02da1-3175-1db8-192a-c0a8a6cd98a5|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71b02da1-3175-1db8-192a-c0a8a6cd98a5|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71b02da1-3175-1db8-192a-c0a8a6cd98a5|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71b02da1-3175-1db8-192a-c0a8a6cd98a5|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71b02da1-3175-1db8-192a-c0a8a6cd98a5
Ro-28-1675	Ro-28-1675	RO-28-1675|Ro-0281675|Ro-281675	CS(=O)(=O)c1ccc(cc1)[C@@H](CC1CCCC1)C(=O)Nc1nccs1	Preclinical		GCK	http://www.axonmedchem.com/product/1356ro281675.html	glucokinase activator			
epothilone-d	Epothilone D	Epothilone D	C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00077259	TUBB4B|TUBB4A|TUBA4A|TUBA3C|TUBA1A|TUBA1B|TUBA1C|TUBA8|TUBB3|TUBB1|TUBB	https://www.drugbank.ca/drugs/DB01873|https://www.drugbank.ca/drugs/DB01873|https://www.drugbank.ca/drugs/DB01873|https://www.drugbank.ca/drugs/DB01873|https://www.drugbank.ca/drugs/DB01873|https://www.drugbank.ca/drugs/DB01873|https://www.drugbank.ca/drugs/DB01873|https://www.drugbank.ca/drugs/DB01873|https://www.drugbank.ca/drugs/DB01873|https://www.drugbank.ca/drugs/DB01873|https://www.drugbank.ca/drugs/DB01873	microtubule stabilizing agent|tubulin polymerization inhibitor			
CZC24832	CZC24832		CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1	Preclinical		PIK3CG	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6653	PI3K inhibitor			
epothilone-a	epothilone a		C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	Preclinical				microtubule stabilizing agent			
epothilone-b	epothilone b		C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@@H](OC(=O)C[C@@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00262990	TUBB4A|TUBB4B|TUBA4A|TUBA3C|TUBA1B|TUBA1C|TUBA1A|TUBA8|TUBB3|TUBB1|TUBB	https://www.drugbank.ca/drugs/DB03010|https://www.drugbank.ca/drugs/DB03010|https://www.drugbank.ca/drugs/DB03010|https://www.drugbank.ca/drugs/DB03010|https://www.drugbank.ca/drugs/DB03010|https://www.drugbank.ca/drugs/DB03010|https://www.drugbank.ca/drugs/DB03010|https://www.drugbank.ca/drugs/DB03010|https://www.drugbank.ca/drugs/DB03010|https://www.drugbank.ca/drugs/DB03010|https://www.drugbank.ca/drugs/DB03010	microtubule stabilizing agent|tubulin polymerization inhibitor			
SU9516	SU9516	SU-9516|indirubin sulfate	COc1ccc2NC(=O)\C(=C/c3c[nH]cn3)c2c1	Preclinical		CDK4|CDK5|CDK1|CDK2|CCND1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6045|https://www.drugbank.ca/drugs/DB03428|https://www.drugbank.ca/drugs/DB03428|https://www.drugbank.ca/drugs/DB03428|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=287425	CDK inhibitor			
17-alpha-methyltestosterone	17-alpha-methyltestosterone	Android 10|Android 25|Android 5|Methitest|Virilon|metandren|methyltestosterone|oreton|oreton methyl|testred	C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched	https://www.drugs.com/cdi/methyltestosterone.html	CYP19A1|AR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=317732|ChEMBL	aromatase inhibitor			
lamotrigine	lamotrigine	BW 430C|BW-430C|lamictal|lamictal cd|lamictal odt|lamictal xr	Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl	Launched	FDA Orange Book: lamotrigine	SCN4A|SCN3A|SCN5A|SCN1A|SCN2A|SCN8A|SCN9A|SCN7A|SCN10A|SCN11A	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	serotonin receptor antagonist|sodium channel blocker	neurology/psychiatry|neurology/psychiatry	epilepsy|bipolar disorder	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05cba628-b12c-44d8-89a8-3522fe417cc1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05cba628-b12c-44d8-89a8-3522fe417cc1
denatonium-benzoate	denatonium benzoate	denatonium	CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1	Preclinical							
propranolol-(R)	(R)-propranolol	dexpropranolol	CC(C)NC[C@@H](O)COc1cccc2ccccc12	Preclinical		ADRB3|ADRB2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=564|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=564	adrenergic receptor antagonist			
AZD5438	AZD5438	AZD-5438	CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00088790	CCNE1|CCNB1|KCNH2|CDK1|CDK2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=346740|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=346740|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009585|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=346740|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=346740	CDK inhibitor			
KPT-185	KPT-185		COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1	Preclinical		XPO1	http://www.selleckchem.com/products/kpt-185.html	exportin antagonist			
PMPA	PMPA	2-(Phosphonomethyl)Pentanedioic Acid|2-Phosphonomethyl-Pentanedioic Acid	OC(=O)CCC(CP(O)(O)=O)C(O)=O	Preclinical		FOLH1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000053	glutamate receptor antagonist			
butabindide	butabindide		CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC	Preclinical		TPP2	https://www.tocris.com/dispprod.php?ItemId=2007#.Vyex4mQrImI	tripeptidyl peptidase inhibitor			
CP-945,598	CP-945,598		CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O	Phase 3				cannabinoid receptor antagonist			
teriflunomide	teriflunomide	aubagio	CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F	Launched	FDA Orange Book: teriflunomide	CYP1A2|CYP2C8|DHODH|MMP9|MMP2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=178777|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=178777|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6844|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=178777|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=178777	dihydroorotate dehydrogenase inhibitor	neurology/psychiatry	multiple sclerosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4650d12c-b9c8-4525-b07f-a2d773eca155&audience=consumer
aminolevulinic-acid-benzyl-ester	aminolevulinic-acid-benzyl-ester		NCC(=O)CCC(=O)OCc1ccccc1	Phase 1	Integrity						
acefylline	acefylline		Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O	Launched	http://www.drugs.com/international/acefylline-piperazine.html	ADORA1	https://en.wikipedia.org/wiki/Acefylline	adenosine receptor agonist	pulmonary	asthma	https://en.wikipedia.org/wiki/Acefylline
sulisobenzone	sulisobenzone	sungard	COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1	Launched	http://en.wikipedia.org/wiki/Sulisobenzone				dermatology	sunscreen lotion	https://en.wikipedia.org/wiki/Sulisobenzone
sodium-oxybate	sodium oxybate	oxybate|xyrem	OCCCC(O)=O	Launched	FDA Orange Book: sodium oxybate	HCAR1|GABRB1|SLC52A2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4711|https://www.drugbank.ca/drugs/DB01440|https://www.drugbank.ca/drugs/DB01440	benzodiazepine receptor agonist	neurology/psychiatry	narcolepsy	https://en.wikipedia.org/wiki/Sodium_oxybate
isotretinoin	isotretinoin	13 Cis-Retinoic Acid|RO 4-3780|Ro-4-3780|absorica|accutane|amnesteem|claravis|myorisan|sotret	CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C/C(O)=O	Launched	FDA Orange Book: isotretinoin	CYP2C8|CYP2B6|CYP3A5|CYP3A7|CYP2C19|RARB|RARA|RARG	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091113|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091113|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091113|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091113|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091113|ChEMBL|https://www.drugbank.ca/drugs/DB00982|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000114	retinoid receptor agonist	dermatology	acne vulgaris (AV)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d54aab5-3349-4a41-8533-0a566fd7bbaa
benzydamine	benzydamine		CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12	Launched	http://en.wikipedia.org/wiki/Benzydamine			prostanoid receptor antagonist	dental|otolaryngology	mouth inflammation|throat inflammation	https://en.wikipedia.org/wiki/Benzydamine|https://en.wikipedia.org/wiki/Benzydamine
BIX-01294	BIX-01294		COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1	Preclinical		EHMT2|EHMT1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7014|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7014	histone lysine methyltransferase inhibitor			
butylated-hydroxyanisole	butylated hydroxyanisole	E320|butylated hydroxyanisole	COc1ccc(O)c(c1)C(C)(C)C	Preclinical				antioxidant			
tolfenamic-acid	tolfenamic acid	tolfenamic acid	Cc1c(Cl)cccc1Nc1ccccc1C(O)=O	Launched	http://www.drugs.com/international/tolfenamic-acid.html			cyclooxygenase inhibitor|prostanoid receptor antagonist	neurology/psychiatry	migraine headache	https://en.wikipedia.org/wiki/Tolfenamic_acid
testosterone-enanthate	testosterone enanthate	delatestryl|testosterone enanthate|testosterone heptanoate	CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched	FDA Orange Book: testosterone enanthate	AR	ChEMBL	androgen receptor agonist	endocrinology	hypogonadism	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0af5e80-8d01-4aa9-9f33-926735fdd38a&audience=consumer
AS-703026	AS-703026	EMD 1036239 |MSC-1936369B|pimasertib	OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01693068	MAP2K2|MAP2K1	http://www.selleckchem.com/products/AS703026.html|http://www.selleckchem.com/products/AS703026.html	MEK inhibitor			
bicyclol	bicyclol		COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1CO	Launched	http://www.baisainuo.com/en/productinfo.asp?id=1476&big_id=987	HSPB1|HSPA1A	http://www.sigmaaldrich.com/catalog/product/sigma/b3313?lang=en&region=US|http://www.sigmaaldrich.com/catalog/product/sigma/b3313?lang=en&region=US	NFkB pathway inhibitor			
gambogic-acid	gambogic acid		CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/23652044	TOP2A|BCL2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=297016|https://www.tocris.com/dispprod.php?ItemId=230542#.Vyj4p2QrImI	caspase activator			
indirubin	indirubin		O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT01445886	CDK4|CDK5|CDK2|CDK1|GSK3B|GSK3A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090153|http://www.scbt.com/datasheet-201531-Indirubin.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090153|http://www.scbt.com/datasheet-201531-Indirubin.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090153|http://www.scbt.com/datasheet-201531-Indirubin.html	CDK inhibitor|glycogen synthase kinase inhibitor			
NSC-3852	NSC-3852		Oc1ccc([N+][O-])c2cccnc12	Preclinical		HDAC1	http://www.tocris.com/dispprod.php?ItemId=160092	HDAC inhibitor			
diclazuril	diclazuril	R64,433	Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O	Veterinary Launched	http://www.drugs.com/international/Diclazuril.html			antiprotozoal agent	infectious disease	equine protozoal myeloencephalitis (EPM)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=875c461a-e0db-4478-9006-7bd1d006ed3a
JNJ-17203212	JNJ-17203212		FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1	Preclinical		TRPV1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4228	TRPV antagonist			
S-Isopropylisothiourea	S-Isopropylisothiourea	2-Isopropyl-Isothiourea	CC(C)SC(N)=N	Preclinical		NOS3	https://www.drugbank.ca/drugs/DB04018	nitric oxide synthase inhibitor			
A77636	A77636		NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2	Preclinical		CALY|DRD1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000118|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=172282	dopamine receptor agonist			
dexamethasone-acetate	dexamethasone acetate	decadron-la	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O	Launched	FDA Orange Book: dexamethasone acetate	NR3C1	https://citeline.informa.com/?query=#/drugs/details/87008	glucocorticoid receptor agonist	endocrinology|rheumatology|rheumatology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|gastroenterology|rheumatology|dermatology|rheumatology|dermatology	hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=537b424a-3e07-4c81-978c-1ad99014032a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=537b424a-3e07-4c81-978c-1ad99014032a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=537b424a-3e07-4c81-978c-1ad99014032a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=537b424a-3e07-4c81-978c-1ad99014032a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=537b424a-3e07-4c81-978c-1ad99014032a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=537b424a-3e07-4c81-978c-1ad99014032a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=537b424a-3e07-4c81-978c-1ad99014032a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=537b424a-3e07-4c81-978c-1ad99014032a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=537b424a-3e07-4c81-978c-1ad99014032a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=537b424a-3e07-4c81-978c-1ad99014032a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=537b424a-3e07-4c81-978c-1ad99014032a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=537b424a-3e07-4c81-978c-1ad99014032a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=537b424a-3e07-4c81-978c-1ad99014032a
mepazine	mepazine	pecazine	CN1CCCC(CN2c3ccccc3Sc3ccccc23)C1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/13844495	MALT1	http://www.emdmillipore.com/US/en/product/MALT1-Inhibitor-II,-Mepazine-Hydrochloride---CAS-60-89-9---Calbiochem,EMD_BIO-500500	MALT1 inhibitor (JH)			
AZD1208	AZD1208	AZD-1208	N[C@@H]1CCCN(C1)c1c(cccc1-c1ccccc1)\C=C1/SC(=O)NC1=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01489722	PIM3|PIM1|PIM2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7698|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7698|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7698	Pim kinase inhibitor			
NU-2058	NU-2058		Nc1nc(OCC2CCCCC2)c2[nH]cnc2n1	Preclinical		CDK2|CCNA2	https://www.drugbank.ca/drugs/DB02407|https://www.drugbank.ca/drugs/DB02407	cyclin D inhibitor			
isopropyl-myristate	isopropyl myristate	estergel|isopropyl myristate	CCCCCCCCCCCCCC(=O)OC(C)C	Launched	http://en.wikipedia.org/wiki/Isopropyl_myristate				dermatology	cosmetic	https://en.wikipedia.org/wiki/Isopropyl_myristate
GS-143	GS-143		OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O	Preclinical		BTRC|NFKBIA	https://www.tocris.com/products/gs-143_5636|https://www.tocris.com/products/gs-143_5636	ubiquitin ligase inhibitor			
taranabant	taranabant	MK-0364|MK-0634|MK0364	C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00131391	CNR1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000327	cannabinoid receptor inverse agonist			
triflusal	triflusal		CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F	Launched	http://www.drugs.com/international/Triflusal.html	PDE10A|PTGS1|PTGS2|NFKB1|PDE4A|PDE4B|PDE4C|PDE4D|NOS2	http://www.drugbank.ca/drugs/DB08814|http://www.drugbank.ca/drugs/DB08814|https://citeline.informa.com/?query=#/drugs/details/18476|http://www.drugbank.ca/drugs/DB08814|https://citeline.informa.com/?query=#/drugs/details/18476|https://citeline.informa.com/?query=#/drugs/details/18476|https://citeline.informa.com/?query=#/drugs/details/18476|https://citeline.informa.com/?query=#/drugs/details/18476|http://www.drugbank.ca/drugs/DB08814	cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor	neurology/psychiatry|cardiology|cardiology	stroke|myocardial infarction|atrial fibrillation (AF)	https://en.wikipedia.org/wiki/Triflusal|https://en.wikipedia.org/wiki/Triflusal|https://en.wikipedia.org/wiki/Triflusal
resiquimod	resiquimod		CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/24709264	TLR8|TLR7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5051|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5051	toll-like receptor agonist			
CBS-1114	CBS-1114		N=C(NNc1ccccc1)c1ccccc1	Phase 1	Pharmaprojects	ALOX5	https://books.google.com/books?id=2Cn0CAAAQBAJ&lpg=PA198&ots=ay7skPrfv3&dq=CBS-1114%20Chauvin&pg=PA198#v=onepage&q=CBS-1114%20Chauvin&f=false	lipoxygenase inhibitor			
RGB-286638	RGB-286638		COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01168882	MAP3K7|MAPK9|JAK2|CDK5|CDK4|CDK7|CDK6|CDK9|CDK1|CDK3|CDK2|GSK3B|FLT3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7744|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7744|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7744|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7744|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7744|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7744|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7744|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7744|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7744|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7744|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7744|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7744|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7744	CDK inhibitor			
AMG-232	AMG-232		CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT02110355	MDM2	http://www.medchemexpress.com/amg-232.html	MDM inhibitor			
WAY-600	WAY-600		C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1	Preclinical		MTOR	http://www.selleckchem.com/products/way-600.html	mTOR inhibitor			
ZM-336372	ZM-336372		CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1	Preclinical		LCK|BRAF|MAPK14|RAF1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005107|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005107|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005107|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005107	RAF inhibitor			
OC000459	OC000459		Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00890877	PTGDR2	http://www.selleckchem.com/products/oc000459.html?gclid=CPr6zry5w8wCFdhahgodiu8I3w	CRTH receptor antagonist			
estradiol-valerate	estradiol valerate	delestrogen	CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C	Launched	FDA Orange Book: estradiol valerate	ESR1	http://en.wikipedia.org/wiki/Estradiol_valerate	estrogen receptor agonist	oncology|endocrinology|endocrinology|obstetrics/gynecology	prostate cancer|hypoestrogenism|menopause|vaginal atrophy	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d29dc3b-e19a-4924-8ad4-85018f0ab395|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d29dc3b-e19a-4924-8ad4-85018f0ab395|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d29dc3b-e19a-4924-8ad4-85018f0ab395|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d29dc3b-e19a-4924-8ad4-85018f0ab395
XD-14	XD-14		CCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1	Preclinical		BRD4|BRD3|BRD2|BRDT	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7524|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7524|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7524|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7524	bromodomain inhibitor			
fostamatinib	fostamatinib	R-788|R-935788|R788 FREE ACID|R935788 FREE ACID	COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC	Launched	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=21149cc3-049b-43e2-b141-c9499160556c	SYK|FLT3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000211|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=414384	SYK inhibitor	hematology	chronic immune thrombocytopenia (ITP)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=21149cc3-049b-43e2-b141-c9499160556c
pyrithyldione	pyrithyldione		CCC1(CC)C(=O)NC=CC1=O	Withdrawn	http://en.wikipedia.org/wiki/Pyrithyldione			psychoactive drug			
clindamycin	clindamycin	cleocin hydrochloride	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	Launched	FDA Orange Book: clindamycin hydrochloride			protein synthesis inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	respiratory tract infections|pneumonia|skin infections|gynecologic infections|intra-abdominal infections|bacterial septicemia|bone and joint infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5a5be69-f2fa-4f3b-b36e-9d503f35958b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5a5be69-f2fa-4f3b-b36e-9d503f35958b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5a5be69-f2fa-4f3b-b36e-9d503f35958b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5a5be69-f2fa-4f3b-b36e-9d503f35958b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5a5be69-f2fa-4f3b-b36e-9d503f35958b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5a5be69-f2fa-4f3b-b36e-9d503f35958b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5a5be69-f2fa-4f3b-b36e-9d503f35958b
A-366	A-366		COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1	Preclinical		EHMT2|EHMT1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8238|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8238	histone lysine methyltransferase inhibitor			
rizatriptan	rizatriptan	MK-462|maxalt|maxalt-mlt	CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12	Launched	FDA Orange Book: rizatriptan benzoate	HTR1A|HTR1B|HTR1E|HTR1D|HTR1F	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=51|https://www.drugbank.ca/drugs/DB00953|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=51|https://www.drugbank.ca/drugs/DB00953|https://www.drugbank.ca/drugs/DB00953	serotonin receptor agonist	neurology/psychiatry	migraine headache	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53e7e016-1175-45af-a6b7-d44e3d0f92e4
T-0156	T-0156		COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1	Preclinical		PDE5A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5275	phosphodiesterase inhibitor			
bismuth(iii)-trifluoromethanesulfonate	bismuth(iii)-trifluoromethanesulfonate		[Bi].OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F	Preclinical				direct substitution catalyst			
BAY-60-6583	BAY-60-6583		NC(=O)CSc1nc(N)c(C#N)c(-c2ccc(OCC3CC3)cc2)c1C#N	Preclinical		ADORA3|ADORA1|ADORA2B|ADORA2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3289|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3289|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3289|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3289	adenosine receptor agonist			
zimelidine	zimelidine	Normud|Zelmid|zimeldine	CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	SLC6A4|MAOB|MAOA	https://www.drugbank.ca/drugs/DB04832|https://www.drugbank.ca/drugs/DB04832|https://www.drugbank.ca/drugs/DB04832	selective serotonin reuptake inhibitor (SSRI)			
AMPA-(RS)	AMPA-(RS)	(r,s)-ampa	Cc1onc(O)c1CC(N)C(O)=O	Preclinical		GRIN1	http://www.tocris.com/dispprod.php?ItemId=1167#.Ve72tCxVhHw	glutamate receptor agonist			
cadralazine	cadralazine		CCOC(=O)NNc1ccc(nn1)N(CC)CC(C)O	Launched	https://www.drugs.com/international/cadralazine.html	CACNA1C	https://citeline.informa.com/?query=#/drugs/details/4111	adrenergic receptor antagonist	cardiology	hypertension	https://en.wikipedia.org/wiki/Cadralazine
levobunolol-(+/-)	(+/-)-levobunolol		CC(C)(C)NCC(O)COc1cccc2C(=O)CCCc12	Preclinical				adrenergic receptor antagonist			
hexachlorophene	hexachlorophene	dial|e-z scrub|gamophen|germa-medica|germa-medica "mg"|hexa-germ|hexascrub|phiso-scrub|phisohex|pre-op|pre-op ii|scrubteam surgical spongebrush|septi-soft|septisol|soy-dome|turgex	Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl	Launched	FDA Orange Book: hexachlorophene	ENPP2|GLUD1|SDHD	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=338682|https://www.drugbank.ca/drugs/DB00756|https://www.drugbank.ca/drugs/DB00756	potassium channel activator	infectious disease	gram-positive bacterial infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9c6f5b4-8374-491a-9b7c-fe008f20e3d1
PSB-06126	PSB-06126		Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O	Preclinical		ENTPD3	http://www.tocris.com/dispprod.php?ItemId=164448	NTPDase inhibitor			
ciglitazone	ciglitazone	ADD-3878|U-63287	CC1(COc2ccc(CC3SC(=O)NC3=O)cc2)CCCCC1	Phase 2	http://adisinsight.springer.com/drugs/800004145	INS|PPARG	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090178|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2711	PPAR receptor agonist			
Ro-9187	Ro-9187		Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1	Preclinical				HCV inhibitor			
tiratricol	tiratricol	triac	OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1	Launched	http://www.drugs.com/international/Tiratricol.html	THRB|THRA	https://www.drugbank.ca/drugs/DB03604|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2637	thyroid hormone stimulant	endocrinology	Refetoff syndrome	https://en.wikipedia.org/wiki/Tiratricol
paramethadione	paramethadione	isoethadione|paradione	CCC1(C)OC(=O)N(C)C1=O	Launched	FDA Orange Book: paramethadione	CACNA1H|CACNA1I|CACNA1G	ChEMBL|ChEMBL|ChEMBL	anticonvulsant	neurology/psychiatry	seizures	http://www.drugbank.ca/drugs/DB00617
didox	didox	NSC-324360	ONC(=O)c1ccc(O)c(O)c1	Launched	https://www.drugs.com/international/didox.html	RRM1	http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2006.06261.x/full	ribonucleotide reductase inhibitor	oncology	breast cancer	http://www.ndrugs.com/?s=didox
darusentan	darusentan	HMR-4005|LU-135252	COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00389779	EDNRA	https://www.drugbank.ca/drugs/DB04883	endothelin receptor antagonist			
ceritinib	ceritinib	NVP-LDK378-NX|zykadia	CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1	Launched	FDA Orange Book: ceritinib	TSSK1B|FLT3|ALK|INSR|IGF1R	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7397|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7397|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7397|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7397	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fff5d805-4ffd-4e8e-8e63-6f129697563e
cyanocobalamin	cyanocobalamin	berubigen|calomist|nascobal|redisol|rubivite|rubramin pc|vi-twel|vibisone	C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12	Launched	FDA Orange Book: cyanocobalamin, cyanocobalamin co-57, cyanocobalamin co-58, cyanocobalamin co-60	MUT|MTR|MMAA|MTHFR|MTRR|MMACHC	https://www.drugbank.ca/drugs/DB00115|https://www.drugbank.ca/drugs/DB00115|https://www.drugbank.ca/drugs/DB00115|https://www.drugbank.ca/drugs/DB00115|https://www.drugbank.ca/drugs/DB00115|https://www.drugbank.ca/drugs/DB00115	methylmalonyl CoA mutase stimulant|vitamin B	hematology|infectious disease|gastroenterology	anemia|fish tapeworm infestation|celiac disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da925fe7-2051-487f-a9cf-c288249516e7|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da925fe7-2051-487f-a9cf-c288249516e7|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da925fe7-2051-487f-a9cf-c288249516e7
retinaldehyde	retinaldehyde	All-Trans-Retinal|Retinal	CC(\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C)=C/C=O	Launched	http://www.smartskincare.com/treatments/topical/retinaldehyde.html				dermatology	cosmetic	http://www.jenelt.com/Catalog/IngredientHighlights?systemName=Retinaldehyde
BMS-587101	BMS-587101	BMS-688521	CN1C(=O)N(C(=O)[C@]11CN(Cc2cc(cs2)C(O)=O)C[C@H]1c1ccc(cc1)C#N)c1cc(Cl)cc(Cl)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00162253	ITGAL|ITGB2|ICAM1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006934|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006934|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=422821	integrin antagonist			
U-104	U-104	4-{[(4'-Fluorophenyl)Carbamoyl]Amino}Benzenesulfonamide	NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1	Preclinical		CA9|CA2|CA1|CA12	https://www.tocris.com/dispprod.php?ItemId=346572#.VyzFEWQrJZJ|https://www.tocris.com/dispprod.php?ItemId=346572#.VyzFEWQrJZJ|https://www.tocris.com/dispprod.php?ItemId=346572#.VyzFEWQrJZJ|https://www.tocris.com/dispprod.php?ItemId=346572#.VyzFEWQrJZJ	carbonic anhydrase inhibitor			
toloxatone	toloxatone	Humoryl	Cc1cccc(c1)N1CC(CO)OC1=O	Launched	https://www.drugs.com/international/toloxatone.html	MAOA|MAOB	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005392|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005392	monoamine oxidase inhibitor	neurology/psychiatry	depression	https://en.wikipedia.org/wiki/Toloxatone
maribavir	maribavir	1263W94	CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00411645	PYGM	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000372	cytomegalovirus inhibitor|protein kinase inhibitor			
bepridil	bepridil	bepadin|vascor	CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1	Launched	FDA Orange Book: bepridil hydrochloride	ATP1A1|CALM1|TNNC1|CACNA1A|CACNA1C|CACNA1H|SCN5A|PDE1A|PDE1B|CACNA2D2|KCNQ4|KCNQ1	https://www.drugbank.ca/drugs/DB01244|https://www.drugbank.ca/drugs/DB01244|https://www.drugbank.ca/drugs/DB01244|https://www.drugbank.ca/drugs/DB01244|https://citeline.informa.com/?query=#/drugs/details/2888|https://www.drugbank.ca/drugs/DB01244|https://citeline.informa.com/?query=#/drugs/details/2888|https://www.drugbank.ca/drugs/DB01244|https://www.drugbank.ca/drugs/DB01244|https://www.drugbank.ca/drugs/DB01244|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2337|https://www.drugbank.ca/drugs/DB01244	calcium channel blocker	cardiology	angina pectoris	https://en.wikipedia.org/wiki/Bepridil
meluadrine	meluadrine		CC(C)(C)NCC(O)c1ccc(O)cc1Cl	Preclinical							
ONX-0914	ONX-0914		COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@]2(C)CO2)cc1	Preclinical				proteasome inhibitor			
pamidronate	pamidronate	CGP-23339AE|aredia|pamidronate disodium|pamidronic acid	NCCC(O)(P(O)(O)=O)P(O)(O)=O	Launched	FDA Orange Book: pamidronate disodium	FDPS	https://www.drugbank.ca/drugs/DB00282	bone resorption inhibitor	endocrinology|endocrinology|oncology|hematologic malignancy	hypercalcemia|Paget's disease|breast cancer|multiple myeloma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2ca033e-fa5f-4141-b702-11f8b4303da1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2ca033e-fa5f-4141-b702-11f8b4303da1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2ca033e-fa5f-4141-b702-11f8b4303da1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2ca033e-fa5f-4141-b702-11f8b4303da1
DY131	DY131		CCN(CC)c1ccc(cc1)\C=N\NC(=O)c1ccc(O)cc1	Preclinical		ESRRG|ESRRB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2834|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2834	estrogen-related receptor agonist			
IDO5L	IDO5L		Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1	Preclinical		IDO1	https://www.medchemexpress.com/IDO5L.html	indoleamine 2,3-dioxygenase inhibitor			
temazepam	temazepam	Temaz|WY-3917|restoril	CN1c2ccc(Cl)cc2C(=NC(O)C1=O)c1ccccc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	GABRG1|GABRG3|GABRG2|GABRB3|GABRB2|GABRB1|GABRA3|GABRA2|GABRA5|GABRA4|GABRA6|GABRA1|GABRR3|GABRR2|GABRR1|TSPO|GABRQ|GABRP|GABRE|GABRD	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00231|https://www.drugbank.ca/drugs/DB00231|https://www.drugbank.ca/drugs/DB00231|https://www.drugbank.ca/drugs/DB00231|ChEMBL|ChEMBL|ChEMBL|ChEMBL	benzodiazepine receptor agonist			
WP1130	WP1130		CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1	Preclinical		JAK2|USP14|USP9X|SYK|UCHL5|STAT3	http://www.selleckchem.com/products/WP1130.html|http://www.selleckchem.com/products/WP1130.html|http://www.selleckchem.com/products/WP1130.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=423254|http://www.selleckchem.com/products/WP1130.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=423254	deubiquitinase inhibitor			
ER-27319	ER-27319		Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O	Preclinical		SYK	http://www.tocris.com/dispprod.php?ItemId=154944	mediator release inhibitor|SYK inhibitor			
profenamine	profenamine	ethopropazine|parsidol	CCN(CC)C(C)CN1c2ccccc2Sc2ccccc12	Launched	FDA Orange Book: ethopropazine hydrochloride	CHRM1|CHRM2|GRIN3A|BCHE	https://www.drugbank.ca/drugs/DB00392|https://www.drugbank.ca/drugs/DB00392|https://www.drugbank.ca/drugs/DB00392|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=153144	butyrylcholinesterase inhibitor|cholinergic receptor antagonist	neurology/psychiatry	Parkinson's Disease	https://en.wikipedia.org/wiki/Profenamine
PHA-680632	PHA-680632		CCc1cccc(CC)c1NC(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1	Preclinical		AURKC|AURKA|AURKB	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005484|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005484|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005484	Aurora kinase inhibitor			
lixivaptan	lixivaptan	CRTX 080|VPA-985|WAY-VPA-985	Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00876798	AVPR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2238	vasopressin receptor antagonist			
mestranol	mestranol		COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1	Launched	FDA Orange Book: mestranol	ESR1	https://www.drugbank.ca/drugs/DB01357	estrogen receptor agonist	endocrinology	contraceptive	https://en.wikipedia.org/wiki/Mestranol
astaxanthin	astaxanthin	E161j	CC(\C=C\C=C(C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)[C@@H](O)CC1(C)C	Launched	https://clinicaltrials.gov/ct2/show/NCT01647984			antioxidant			
EPZ-5676	EPZ-5676		CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01684150	DOT1L	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7019	histone lysine methyltransferase inhibitor			
Ro-04-5595	Ro-04-5595		COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O	Preclinical		GRIN2B	http://www.tocris.com/dispprod.php?ItemId=93381#.Vg13zGRVhHw				
capsazepine	capsazepine		Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1	Preclinical		TRPV4|TRPV1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004663|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2461	TRPV agonist			
brivanib	brivanib	BMS-540215	C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00825955	FLT4|FLT1|KCNH2|KDR|CYP3A4|FGFR1|FGFR2|FGFR3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=396725|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5671|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006359|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5671|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006359|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5671|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=396725|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=396725	FGFR inhibitor|VEGFR inhibitor			
nitecapone	nitecapone		CC(=O)C(=Cc1cc(O)c(O)c(c1)[N+]([O-])=O)C(C)=O	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/10443596	COMT	https://en.wikipedia.org/wiki/Nitecapone	catechol O methyltransferase inhibitor			
R-1479	R-1479	4'-Azidocytidine	Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)c(=O)n1	Phase 1	http://adisinsight.springer.com/drugs/800018944			HCV inhibitor			
penicillin-v-potassium	penicillin v potassium	Penapar-VK|Veetids|penicillin phenoxymethyl|penicillin v|penicillin v potassium|penicillin-vk|phenomycilline|phenoxymethylpenicillin|v-cillin	CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(O)=O	Launched	FDA Orange Book: penicillin v potassium			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	pneumonia|ear infections|skin infections|throat infections|cholera|scarlet fever	https://www.nlm.nih.gov/medlineplus/druginfo/meds/a685015.html|https://www.nlm.nih.gov/medlineplus/druginfo/meds/a685015.html|https://www.nlm.nih.gov/medlineplus/druginfo/meds/a685015.html|https://www.nlm.nih.gov/medlineplus/druginfo/meds/a685015.html|https://www.nlm.nih.gov/medlineplus/druginfo/meds/a685015.html|https://www.nlm.nih.gov/medlineplus/druginfo/meds/a685015.html
norfluoxetine	norfluoxetine		NCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1	Phase 1	https://en.wikipedia.org/wiki/Seproxetine	HTR2B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=208	selective serotonin reuptake inhibitor (SSRI)			
PG-9	PG-9		CC(C(=O)OC1CC2CCC(C1)N2C)c1ccc(Br)cc1	Preclinical				acetylcholine receptor agonist			
amuvatinib	amuvatinib	HPK-56|MP-470|MP470	S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01357395	PDGFRA|RET|KIT|RAD51|MET|AXL|FLT3|MST1R	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=369450|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=369450|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000171|https://citeline.informa.com/?query=#/drugs/details/32479|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000171|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=369450|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=369450|https://citeline.informa.com/?query=#/drugs/details/32479	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAD51 inhibitor|RET tyrosine kinase inhibitor			
clinofibrate	clinofibrate		CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(OC(C)(CC)C(O)=O)cc1)C(O)=O	Launched	http://www.drugs.com/international/clinofibrate.html	LPL	http://ci.nii.ac.jp/naid/130004883476	lipase clearing factor inhibitor	endocrinology	hypertriglyceridemia	http://www.drugs.com/international/clinofibrate.html
LY456236	LY456236	LY-456236	COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1	Preclinical		GRM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3346	glutamate receptor antagonist			
lomitapide	lomitapide	BMS-201038|BMS-201038-01|juxtapid	FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12	Launched	FDA Orange Book: lomitapide mesylate	CYP2C8|CYP2B6|MTTP|CYP2C19	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=235523|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=235523|https://www.drugbank.ca/drugs/DB08827|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=235523	microsomal trigylceride transfer protein inhibitor	endocrinology	hypercholesterolemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e4c45bb5-15f4-437e-ab98-a649b3676d14
docusate	docusate		CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(O)(=O)=O	Launched	https://clinicaltrials.gov/ct2/show/NCT01773096			laxative	gastroenterology	constipation	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4815b9b8-59bd-4af5-924a-f55bc53b9133
tolazoline	tolazoline	priscoline	C(C1=NCCN1)c1ccccc1	Veterinary Launched	FDA Orange Book: tolazoline hydrochloride	HRH1|HRH2|ADRA2B|ADRA2C|ADRA2A|ADRA1A	https://www.drugbank.ca/drugs/DB00797|https://www.drugbank.ca/drugs/DB00797|https://www.drugbank.ca/drugs/DB00797|https://www.drugbank.ca/drugs/DB00797|https://www.drugbank.ca/drugs/DB00797|https://www.drugbank.ca/drugs/DB00797	adrenergic receptor antagonist	neurology/psychiatry	reverse sedative	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b94baa5-5af2-46e9-8111-519225206a28&audience=consumer
paroxetine	paroxetine	BRL 29060|BRL-29060|brisdelle|paxil|paxil [as hydrochloride]|paxil cr|pexeva	Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1	Launched	FDA Orange Book: paroxetine hydrochloride, paroxetine mesylate	HTR2A|CHRM1|CHRM3|CHRM2|CHRM5|CHRM4|SLC6A2|SLC6A4	https://www.drugbank.ca/drugs/DB00715|https://www.drugbank.ca/drugs/DB00715|https://www.drugbank.ca/drugs/DB00715|https://www.drugbank.ca/drugs/DB00715|https://www.drugbank.ca/drugs/DB00715|https://www.drugbank.ca/drugs/DB00715|https://www.drugbank.ca/drugs/DB00715|https://www.drugbank.ca/drugs/DB00715	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|generalized anxiety disorder (GAD)|panic disorders|posttraumatic stress disorder|social anxiety disorder	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590cd4bb-c1bd-4cf1-893a-1e418621eed4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590cd4bb-c1bd-4cf1-893a-1e418621eed4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590cd4bb-c1bd-4cf1-893a-1e418621eed4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590cd4bb-c1bd-4cf1-893a-1e418621eed4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590cd4bb-c1bd-4cf1-893a-1e418621eed4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=590cd4bb-c1bd-4cf1-893a-1e418621eed4
tranilast	tranilast	MK-341|Rizaben	COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC	Launched	http://www.drugs.com/international/Tranilast.html	TNF|IFNG|IL10|HRH1|SLC22A12|TGFB1|IL2|IL4|HPGDS|IDO1|TRPV2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090998|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090998|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090998|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001531|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090998|https://citeline.informa.com/?query=#/drugs/details/18389|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090998|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090998|https://www.drugbank.ca/drugs/DB07615|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090998|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090998	angiogenesis inhibitor	pulmonary	asthma	https://en.wikipedia.org/wiki/Tranilast
ibutilide	ibutilide	corvert	CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1	Launched	FDA Orange Book: ibutilide fumarate	CACNG1|CACNB1|CACNA2D1|SCN5A|CACNA1C|KCNJ11|KCNH6|KCNH7|KCNH2|KCNK6|KCNK1	https://www.drugbank.ca/drugs/DB00308|https://www.drugbank.ca/drugs/DB00308|https://www.drugbank.ca/drugs/DB00308|https://citeline.informa.com/?query=#/drugs/details/9058|https://www.drugbank.ca/drugs/DB00308|https://www.drugbank.ca/drugs/DB00308|https://www.drugbank.ca/drugs/DB00308|https://www.drugbank.ca/drugs/DB00308|https://www.drugbank.ca/drugs/DB00308|https://www.drugbank.ca/drugs/DB00308|https://www.drugbank.ca/drugs/DB00308	potassium channel blocker	cardiology	atrial fibrillation (AF)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c833457-0409-4fb8-9363-d465bc5ee2fe
VU0155069	VU0155069		C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1	Preclinical		PLD1	http://www.tocris.com/dispprod.php?ItemId=229725#.VhQJ0BNViko	phospholipase inhibitor			
dofetilide	dofetilide	UK-68,798|UK-68798|tikosyn	CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	KCNJ12|KCNH2|KCNH1|KCNK2	https://www.drugbank.ca/drugs/DB00204|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2604|https://www.drugbank.ca/drugs/DB00204	potassium channel blocker			
vismodegib	vismodegib	erivedge	Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O	Launched	FDA Orange Book: vismodegib	CYP2C8|DHH|ABCB1|ABCG2|IHH|CYP2C19|PTCH1|SMO	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=473491|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=473491|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=473491|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=473491|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=473491|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=473491|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=473491|ChEMBL	hedgehog pathway inhibitor|smoothened receptor antagonist	oncology	basal cell carcinoma (BCC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb368bb6-80e3-4df9-8a85-91df0a2ada6a
isamoltane	isamoltane	isamoltan	CC(C)NCC(O)COc1ccccc1-n1cccc1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/8099863	ADRB1|ADRB2|HTR1A|HTR1B	https://citeline.informa.com/?query=#/drugs/details/9668|https://citeline.informa.com/?query=#/drugs/details/9668|https://en.wikipedia.org/wiki/Isamoltane|https://en.wikipedia.org/wiki/Isamoltane	adrenergic receptor antagonist			
ceftizoxim	ceftizoxim	FK-749|cefizox|ceftizoxime	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)c1csc(N)n1	Launched	FDA Orange Book: ceftizoxime sodium			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	respiratory tract infections|urinary tract infections|gonorrhea|pelvic inflammatory disease|intra-abdominal infections|bacterial septicemia|skin infections|bone and joint infections|meningitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3574df06-fec5-4888-8080-3b817addfb02|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3574df06-fec5-4888-8080-3b817addfb02|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3574df06-fec5-4888-8080-3b817addfb02|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3574df06-fec5-4888-8080-3b817addfb02|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3574df06-fec5-4888-8080-3b817addfb02|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3574df06-fec5-4888-8080-3b817addfb02|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3574df06-fec5-4888-8080-3b817addfb02|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3574df06-fec5-4888-8080-3b817addfb02|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3574df06-fec5-4888-8080-3b817addfb02
adrenosterone	adrenosterone	adrenoterone	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O	Preclinical		HSD11B2|HSD11B1	http://www.hmdb.ca/metabolites/HMDB06772|http://www.hmdb.ca/metabolites/HMDB06772	11-beta hydroxysteroid dehydrogenase inhibitor			
nabumetone	nabumetone	BRL 14777|BRL-14777|relafen	COc1ccc2cc(CCC(C)=O)ccc2c1	Launched	FDA Orange Book: nabumetone	PTGS1|PTGS2|CYP2B6|CYP2E1|CYP2C19|AKR1C3	https://www.drugbank.ca/drugs/DB00461|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090098|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090098|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090098|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090098	cyclooxygenase inhibitor	rheumatology|rheumatology	rheumatoid arthritis|osteoarthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e21f89cf-ec07-4b07-9c9b-796b0111df39|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e21f89cf-ec07-4b07-9c9b-796b0111df39
pilocarpine	pilocarpine	isopto carpine|ocusert pilo|ocusert pilo-20|ocusert pilo-40|pilopine hs|salagen	CC[C@H]1[C@@H](Cc2cncn2C)COC1=O	Launched	FDA Orange Book: pilocarpine, pilocarpine hydrochloride	CHRM3|CHRM4|CHRM5|CHRM1|CHRM2	ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=305|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=305|https://www.drugbank.ca/drugs/DB01085|https://www.drugbank.ca/drugs/DB01085	acetylcholine receptor agonist	ophthalmology|cardiology	glaucoma|hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53fa0b7a-f982-48a7-92c4-6f098683c1ed|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53fa0b7a-f982-48a7-92c4-6f098683c1ed
nifekalant	nifekalant		Cn1c(NCCN(CCO)CCCc2ccc(cc2)[N+]([O-])=O)cc(=O)n(C)c1=O	Launched	http://www.drugs.com/international/Nifekalant.html			potassium channel blocker	cardiology|cardiology	ventricular arrhythmias|ventricular tachycardia (VT)	https://en.wikipedia.org/wiki/Nifekalant|https://en.wikipedia.org/wiki/Nifekalant
PF-750	PF-750		O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1	Preclinical		FAAH	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5244	FAAH inhibitor			
O6-Benzylguanine	O6-Benzylguanine	6-O-Benzylguanine	Nc1nc(OCc2ccccc2)c2[nH]cnc2n1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00017147	MGMT	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003646	O6-alkylguanine-DNA alkyltransferase inhibitor			
CH5132799	CH5132799	CH-5132799|PA-799	CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01222546	MTOR|PIK3CD|PIK3CG|PIK3CA|PIK3CB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7743|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7743|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7743|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7743|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7743	PI3K inhibitor			
methylprednisolone-aceponate	methylprednisolone aceponate	methylprednisolone aceponate	CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O	Launched	http://www.medsafe.govt.nz/profs/Datasheet/a/Advantanointcrm.pdf	NR3C1	https://www.drugbank.ca/drugs/DB00959	anti-inflammatory agent|glucocorticoid receptor agonist	endocrinology|endocrinology|endocrinology|rheumatology|rheumatology|infectious disease|allergy|pulmonary|gastroenterology|gastroenterology|rheumatology|dermatology|neurology/psychiatry|hematology	congenital adrenal hyperplasia|thyroiditis|hypercalcemia|rheumatoid arthritis|bursitis|epicondylitis|allergic rhinitis|asthma|ulcerative colitis|enteritis|osteoarthritis|psoriasis|multiple sclerosis|anemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61
cirazoline	cirazoline		C(Oc1ccccc1C1CC1)C1=NCCN1	Preclinical		ADRA1A	http://www.tocris.com/dispprod.php?ItemId=2195#.Ut7GaP30BaE	adrenergic receptor agonist			
methscopolamine	methscopolamine	Methylscopolamine|methscopolamine bromide|pamine|pamine forte		Launched	FDA Orange Book: methscopolamine bromide	HRH1|CHRM3|CHRM1|CHRM2	https://citeline.informa.com/?query=#/drugs/details/33193|https://www.drugbank.ca/drugs/DB00462|https://www.drugbank.ca/drugs/DB00462|https://www.drugbank.ca/drugs/DB00462	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c74bfb0-c80a-4a86-acd1-1e3a1b20255d
atracurium	atracurium	atracurium besylate|atracurium besylate preservative free|nimbex|nimbex preservative free|tracrium|tracrium preservative free	COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC	Launched	FDA Orange Book: atracurium besylate	CHRNA2	https://www.drugbank.ca/drugs/DB00732	acetylcholine receptor antagonist	critical care|neurology/psychiatry	endotracheal intubation|muscle relaxant	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca9e266c-8264-46f4-9df3-8d86a9d8437f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca9e266c-8264-46f4-9df3-8d86a9d8437f
dimpylate	dimpylate	G-24480|diazinon	CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C	Veterinary Launched	http://www.drugs.com/international/dimpylate.html	ACHE	https://en.wikipedia.org/wiki/Diazinon#Metabolism_and_mechanism_of_action	acetylcholinesterase inhibitor			
levodopa	levodopa	bendopa|dopar|larodopa	N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O	Launched	FDA Orange Book: levodopa	DDC|GPR143|DRD3|DRD4|DRD5|DRD1|DRD2	https://citeline.informa.com/?query=#/drugs/details/69353|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639|ChEMBL|https://www.drugbank.ca/drugs/DB01235|https://www.drugbank.ca/drugs/DB01235|https://www.drugbank.ca/drugs/DB01235|https://www.drugbank.ca/drugs/DB01235	dopamine precursor	neurology/psychiatry	Parkinson's Disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a355d5f2-407d-40fa-a374-b3632261ea4a
decoquinate	decoquinate	Deccox|HC 1528|M&B 15497	CCCCCCCCCCOc1cc2c(O)c(cnc2cc1OCC)C(=O)OCC	Veterinary Launched	http://www.drugs.com/international/Decoquinate.html			antiprotozoal agent	infectious disease	coccidiosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ec56702-fb1c-4bd8-8327-6540bffef411
enocitabine	enocitabine		CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1	Launched	http://www.drugs.com/international/Enocitabine.html	POLA1|CMPK1|RRM1|TYMS|POLB	https://citeline.informa.com/?query=#/drugs/details/6374|http://www.drugbank.ca/drugs/DB00441|http://www.drugbank.ca/drugs/DB00441|http://www.drugbank.ca/drugs/DB00441|https://citeline.informa.com/?query=#/drugs/details/6374	DNA synthesis inhibitor			
Org-12962	Org-12962		FC(F)(F)c1ccc(nc1Cl)N1CCNCC1	Phase 2	https://en.wikipedia.org/wiki/Org_12962	HTR2A|HTR2C|HTR2B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=170|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=170|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=170	serotonin receptor agonist			
FH-535	FH-535		Cc1cc(ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl)[N+]([O-])=O	Preclinical		PPARD|PPARG	https://www.tocris.com/products/fh-535_4344|https://www.tocris.com/products/fh-535_4344	PPAR receptor antagonist|WNT signaling inhibitor			
indapamide	indapamide	lozol	CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O	Launched	FDA Orange Book: indapamide	SLC12A3|CA7|KCNQ1|KCNE1	ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091508|https://www.drugbank.ca/drugs/DB00808|https://www.drugbank.ca/drugs/DB00808	thiazide diuretic	cardiology|cardiology	hypertension|congestive heart failure	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fdb20d31-bd0f-4022-84cc-5db97862a7cf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fdb20d31-bd0f-4022-84cc-5db97862a7cf
dinoprost	dinoprost	U-14,583|U-14583|prostin f2 alpha	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O	Launched	FDA Orange Book: dinoprost tromethamine, dinoprostone	PTGIR|PTGFR|PTGDR|TBXA2R|PTGDR2|PTGER3|PTGER4|PTGER1|PTGER2	https://www.drugbank.ca/drugs/DB01160|https://www.drugbank.ca/drugs/DB01160|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884	prostacyclin analog	obstetrics/gynecology	labor induction	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3bc9031-0620-4a50-b440-f661cadfeb1d
ONO-4059	ONO-4059		Nc1ncnc2n(C3CCCN(C3)C(=O)C=C)c(=O)n(-c3ccc(Oc4ccccc4)cc3)c12	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01659255	BTK	http://www.adooq.com/ono-4059.html?gclid=CKCm95TVpNICFQUEaQodnjcJJQ	Bruton's tyrosine kinase (BTK) inhibitor			
BTS-54505	BTS-54505		CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1	Withdrawn	http://www.ncbi.nlm.nih.gov/pubmed/9878996	SLC6A3|SLC6A4|SLC6A2	http://www.drugbank.ca/drugs/DB01105|http://www.drugbank.ca/drugs/DB01105|http://www.drugbank.ca/drugs/DB01105	dopamine reuptake inhibitor			
AZD2014	AZD2014	AZD-2014	CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01793636	MTOR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7699	mTOR inhibitor			
CPP	CPP			Phase 2	Pharmaprojects	GRIN1|GRIN2D|GRIN2A|GRIN2C|GRIN2B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4082|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4082|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4082|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4082|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4082	glutamate receptor antagonist			
AM-24	AM-24	2,4,6-Triiodo-Phenol|2,4,6-Triiodo-Phenol(Tip)|2,4,6-Triiodophenol|Triiodophenol	Oc1c(I)cc(I)cc1I	Phase 2	Pharmaprojects	SELL|ALOX5	https://citeline.informa.com/?query=#/drugs/details/24401|http://www.ncbi.nlm.nih.gov/pubmed/16731748	lipoxygenase inhibitor			
ibrolipim	ibrolipim	NO-1886|OPF 009	CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC	Phase 2	http://adisinsight.springer.com/drugs/800004782	LPL	https://en.wikipedia.org/wiki/Ibrolipim	lipoprotein lipase activator			
sulphadimethoxine	sulphadimethoxine	Albon|Bactrovet|Di-Methox|Theracanzan|madribon|sulfadimethoxine	COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1	Launched	http://en.wikipedia.org/wiki/Sulfadimethoxine			dihydropteroate synthetase inhibitor			
azilsartan-medoxomil	azilsartan medoxomil	azilsartan medoxomil|edarbi	CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1	Launched	http://en.wikipedia.org/wiki/Azilsartan	AGTR2|AGTR1|INS	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000491|https://www.drugbank.ca/drugs/DB08822|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=406532	angiotensin receptor antagonist	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2d6e17b-f14a-463b-a662-03c9387c63dd
DMPS	DMPS		OS(=O)(=O)CC(S)CS	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01059474			chelating agent			
SB-242235	SB-242235		COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1	Phase 1	http://adisinsight.springer.com/drugs/800010787	HSPB1|MAPK14	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009512|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009512	p38 MAPK inhibitor			
RS-102221	RS-102221	RS-102,221	COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O	Preclinical		HTR2C|HTR2B|HTR2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=187|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=187|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=187	serotonin receptor antagonist			
AMG-319	AMG-319		C[C@H](Nc1ncnc2[nH]cnc12)c1cc2ccc(F)cc2nc1-c1ccccn1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02540928	PIK3CD	https://www.medchemexpress.com/amg319.html?gclid=COW7_KOmnM8CFQUmhgodPbIJ5w	PI3K inhibitor			
trometamol	trometamol	tham|tromethamine	NC(CO)(CO)CO	Launched	http://www.drugs.com/international/Trometamol.html	AMD1|NEIL1|DCN|VEGFA|CANT1	https://www.drugbank.ca/drugs/DB03754|https://www.drugbank.ca/drugs/DB03754|https://www.drugbank.ca/drugs/DB03754|https://www.drugbank.ca/drugs/DB03754|https://www.drugbank.ca/drugs/DB03754				
DU-728	DU-728		N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/9542482	ITGB3|ITGA2B	https://www.caymanchem.com/product/15359|https://www.caymanchem.com/product/15359	structural glycoprotein antagonist			
omecamtiv-mecarbil	omecamtiv mecarbil	CK-1827452|omecamtiv mecarbil	COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01077167	MYBPC3	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374655/	cardiac myosin activator			
brivanib-alaninate	brivanib alaninate	BMS-582664|brivanib alaninate	C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00640471	KDR|FGFR1|FGFR3|FLT1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=396728|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=396728|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000358|https://citeline.informa.com/?query=#/drugs/details/33909	FGFR inhibitor|VEGFR inhibitor			
TCS2002	TCS2002		Cc1nnc(o1)-c1ccc2occ(-c3ccc(cc3)S(C)=O)c2c1	Preclinical		GSK3B	https://www.tocris.com/dispprod.php?ItemId=249103#.Vyy2bWQrJZJ	glycogen synthase kinase inhibitor			
ruxolitinib-(S)	(S)-ruxolitinib		N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12	Preclinical		JAK3|JAK2|JAK1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=842985|http://www.selleckchem.com/products/s-ruxolitinib.html|http://www.selleckchem.com/products/s-ruxolitinib.html	JAK inhibitor			
MNS-(3,4-Methylenedioxy-nitrostyrene)	MNS-(3,4-Methylenedioxy-nitrostyrene)		[O-][N+](=O)\C=C\c1ccc2OCOc2c1	Preclinical				src inhibitor|syk inhibitor			
sipatrigine	sipatrigine	619C89	CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/11070372	CACNA1D|CACNA1B|SCN5A|SCN4A|SCN3A|SCN2A|SCN1A|SCN9A|SCN10A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009423|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=164985|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009423|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009423|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009423|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=164985|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009423|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009423|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009423	voltage-gated sodium channel blocker			
fexaramine	fexaramine		COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1	Preclinical		NR1H4	https://www.drugbank.ca/drugs/DB02545	FXR agonist			
parthenolide-(alternate-stereo)	parthenolide-(alternate-stereo)		C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1	Preclinical		RELA|IKBKB	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001093|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001093	NFkB pathway inhibitor			
WZ811	WZ811	WZ-811	C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1	Preclinical		CXCR4	https://www.tocris.com/dispprod.php?ItemId=256069#.VyzM82QrJZJ	CC chemokine receptor antagonist			
TH588	TH588		Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl	Preclinical		NUDT1	http://www.emdmillipore.com/US/en/product/MTH1-Inhibitor%2C-TH588---Calbiochem,EMD_BIO-530916?ReferrerURL=https://www.google.com/&bd=1	MTH1 inhibitor			
talarozole	talarozole	R115866|rambazole	CCC(CC)C(c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00716144	CYP26A1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008926	cytochrome P450 inhibitor			
cisapride	cisapride	propulsid|propulsid quicksolv		Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	HTR2A|HTR3A|KCNH2|HTR4|CYP2B6|CYP2C8|CYP3A5|CYP3A7	https://www.drugbank.ca/drugs/DB00604|https://www.drugbank.ca/drugs/DB00604|https://www.drugbank.ca/drugs/DB00604|https://www.drugbank.ca/drugs/DB00604|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090321|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090321|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090321|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090321	serotonin receptor agonist			
dinoprostone	dinoprostone	U-12,062|U-12062|cervidil|dinoprostone beta-cyclodextrin clathrate|prepidil|prostin e2	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	TBXA2R|CATSPER1|CATSPER2|CATSPER3|CATSPER4|PTGDR|PTGFR|PTGDR2|PTGER4|PTGER3|PTGER2|PTGER1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883|ChEMBL|ChEMBL|ChEMBL|ChEMBL	prostanoid receptor agonist			
trimethobenzamide	trimethobenzamide	tigan	COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1	Launched	FDA Orange Book: trimethobenzamide hydrochloride	DRD2	http://www.amepc.org/apm/article/view/1039/1266	histamine receptor antagonist	gastroenterology|gastroenterology|gastroenterology	vomiting|nausea|gastroenteritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c18073be-d52a-4347-a8d1-6be11bcb7824|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c18073be-d52a-4347-a8d1-6be11bcb7824|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c18073be-d52a-4347-a8d1-6be11bcb7824
cefoxitin	cefoxitin	Cenomycin|Mefoxitin|mefoxin	CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O	Launched	FDA Orange Book: cefoxitin sodium			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	respiratory tract infections|urinary tract infections|intra-abdominal infections|gynecologic infections|bacterial septicemia|bone and joint infections|skin infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b272ef9c-4d83-4ee2-b9cc-477440822cca|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b272ef9c-4d83-4ee2-b9cc-477440822cca|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b272ef9c-4d83-4ee2-b9cc-477440822cca|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b272ef9c-4d83-4ee2-b9cc-477440822cca|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b272ef9c-4d83-4ee2-b9cc-477440822cca|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b272ef9c-4d83-4ee2-b9cc-477440822cca|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b272ef9c-4d83-4ee2-b9cc-477440822cca
SB-743921	SB-743921		CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT00343564	KIF11	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000224	kinesin-like spindle protein inhibitor			
WIN-64338	WIN-64338		CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1	Preclinical		BDKRB2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=677	bradykinin receptor antagonist			
BMS-265246	BMS-265246		CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F	Preclinical		CCNE1|CDK2|CDK1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=286967|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8051|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8051	CDK inhibitor			
HTMT	HTMT		CC(CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1c[nH]cn1	Preclinical		HRH4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1273	histamine receptor agonist			
2-[1-(4-piperonyl)piperazinyl]benzothiazole	2-[1-(4-piperonyl)piperazinyl]benzothiazole		C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1	Preclinical		HTR4	https://www.tocris.com/dispprod.php?ItemId=1797#.VyTeqqMrKCR	serotonin receptor agonist			
polydatin	polydatin	(E)-Piceid|(E)-Polydatin|Piceid|Trans-Piceid	OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01780129	XDH|ICAM1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=326962|http://www.scbt.com/datasheet-203203-polydatin.html	ICAM1 expression inhibitor			
AG-490	AG-490		Oc1ccc(cc1O)\C=C(/C#N)C(=O)NCc1ccccc1	Preclinical		JAK2|JAK3|EGFR|STAT3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000170|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000170|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5916|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=259625	EGFR inhibitor|JAK inhibitor			
RI-1	RI-1		ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1	Preclinical		RAD51|BCL2	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424541/|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=713789				
picartamide	picartamide		CNC(=S)C1(CCCS1)c1ccccn1	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/4006644	ATP4A	https://www.ncbi.nlm.nih.gov/pubmed/4006644	H+/K+-ATPase inhibitor			
atosiban	atosiban		CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)C(NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1	Launched	http://www.drugs.com/international/Atosiban.html	AVPR2|OXTR|OXT|AVPR1A|AVPR1B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2213|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2213|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=140299|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2213|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2213	oxytocin receptor antagonist	neurology/psychiatry|cardiology|cardiology|endocrinology	stroke|angina pectoris|myocardial infarction|hyperlipidemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=901550e6-22be-68c9-eb86-f85a9c9dd998|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=901550e6-22be-68c9-eb86-f85a9c9dd998|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=901550e6-22be-68c9-eb86-f85a9c9dd998|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=901550e6-22be-68c9-eb86-f85a9c9dd998
[sar9,met(o2)11]-substance-p	[sar9,met(o2)11]-substance-p		CC(C)C[C@H](NC(=O)CN(C)C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCS(C)(=O)=O)C(N)=O	Preclinical				tachykinin antagonist			
ixabepilone	ixabepilone	BMS 247550-01|Ixempra|ixempra kit	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	Launched	FDA Orange Book: ixabepilone	TUBB2B|TUBB2A|TUBB4B|TUBB4A|TUBB|TUBA1B|TUBA1C|TUBA1A|TUBA3D|TUBA3E|TUBA3C|TUBA4A|TUBB1|TUBB3|TUBB6|TUBB8	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	microtubule stabilizing agent	oncology	breast cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7992f6b-279b-46a7-b9c3-fea4e17718dc
nizatidine	nizatidine	LY-139037|axid|axid ar	CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O	Launched	FDA Orange Book: nizatidine	HRH2	ChEMBL	histamine receptor antagonist	gastroenterology|gastroenterology|gastroenterology|gastroenterology	duodenal ulcer disease|erosive esophagitis (EE)|ulcerative esophagitis (UE)|gastroesophageal reflux disease (GERD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=faaa7cc4-fda9-d5b8-de2a-71c8744ccb76|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=faaa7cc4-fda9-d5b8-de2a-71c8744ccb76|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=faaa7cc4-fda9-d5b8-de2a-71c8744ccb76|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=faaa7cc4-fda9-d5b8-de2a-71c8744ccb76
TG100-115	TG100-115		Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT00103350	PIK3CG|PIK3CD|PIK3CB|PIK3CA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5715|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5715|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5715|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5715	PI3K inhibitor			
telithromycin	telithromycin	ketek		Launched	FDA Orange Book: telithromycin	SLCO1B3|CYP3A5|CYP3A4|CYP3A7|CYP2D6|CYP1A2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=230662|http://www.drugbank.ca/drugs/DB00976|http://www.drugbank.ca/drugs/DB00976|http://www.drugbank.ca/drugs/DB00976|http://www.drugbank.ca/drugs/DB00976|http://www.drugbank.ca/drugs/DB00976	bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor	infectious disease	pneumonia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4471223e-9023-457e-be2e-8e4e0c2d94d1&audience=consumer
tolrestat	tolrestat	AY-27,773|AY-27773|Alderase|alredase	COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	AKR1B10|AKR1A1|AKR1B1	https://www.drugbank.ca/drugs/DB02383|https://www.drugbank.ca/drugs/DB02383|https://www.drugbank.ca/drugs/DB02383	aldose reductase inhibitor			
RQ-00203078	RQ-00203078		OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1ncc(cc1Cl)C(F)(F)F	Preclinical		TRPM8	https://www.tocris.com/products/rq-00203078_5388	transient receptor potential channel antagonist			
bendroflumethiazide	bendroflumethiazide	bendrofluazide|benzydroflumethiazide|naturetin|naturetin-10|naturetin-2.5|naturetin-5	NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F	Launched	FDA Orange Book: bendroflumethiazide	KCNMA1|SLC12A3|SLC12A1|CA2|CA4|CA1	https://www.drugbank.ca/drugs/DB00436|ChEMBL|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000188|https://www.drugbank.ca/drugs/DB00436|https://www.drugbank.ca/drugs/DB00436|https://www.drugbank.ca/drugs/DB00436	sodium/potassium/chloride transporter inhibitor	cardiology	hypertension	https://en.wikipedia.org/wiki/Bendroflumethiazide
tranexamic-acid	tranexamic acid	CL 65336|CL-65336|cyklokapron|lysteda|tranexamic acid|trans amcha	NC[C@H]1CC[C@@H](CC1)C(O)=O	Launched	FDA Orange Book: tranexamic acid	FGA|FGB|FGG|PLAT|PLG	https://citeline.informa.com/?query=#/drugs/details/18388|https://citeline.informa.com/?query=#/drugs/details/18388|https://citeline.informa.com/?query=#/drugs/details/18388|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=130530|ChEMBL	antifibrinolytic|plasminogen activator inhibitor	hematology	hemophilia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8a45862-2187-49eb-892e-ade1b0cde938&audience=consumer
DBeQ	DBeQ		C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1	Preclinical		CASP3	http://www.sigmaaldrich.com/catalog/product/sigma/sml0031?lang=en&region=US	ATPase inhibitor			
L-Hydroxyproline	L-Hydroxyproline		OC1CNC(C1)C(O)=O	Launched	http://kyowa-usa.com/branded-ingredients/lumistor-l-hydroxyproline						
MDL-11939	MDL-11939	MDL 11,939|glemanserin	OC(C1CCN(CCc2ccccc2)CC1)c1ccccc1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/7714223	HTR2B|HTR2C|HTR2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=186|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=186|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=186	serotonin receptor antagonist			
guanidinoethyldisulfide-bicarbonate	guanidinoethyldisulfide-bicarbonate	Guanidinoethyl Disulfide|Guanidinoethyldisulfide	NC(N)=NCCSSCCN=C(N)N	Phase 2	Cortellis	NOS2	http://www.scbt.com/datasheet-221664-ged-bicarbonate.html	nitric oxide synthase inhibitor			
thiocolchicoside	thiocolchicoside		COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC	Launched	http://www.drugs.com/international/Thiocolchicoside.html	GLRB|GABRB2|GABRA1|GABRG2|GLRA1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013107|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013107|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013107|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013107|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013107	GABA receptor antagonist	neurology/psychiatry	muscle relaxant	http://www.drugs.com/international/thiocolchicoside.html
propiolactone	propiolactone	betaprone	O=C1CCO1	Launched	FDA Orange Book: propiolactone						
zaltoprofen	zaltoprofen		CC(C(O)=O)c1ccc2Sc3ccccc3C(=O)Cc2c1	Launched	http://www.drugs.com/international/Zaltoprofen.html			cyclooxygenase inhibitor	endocrinology|neurology/psychiatry	fever|pain relief	http://www.drugs.com/international/zaltoprofen.html|http://www.drugs.com/international/zaltoprofen.html
thiamine	thiamine	Betaxin|Thiamine (Vit B1)|Vitamin B 1|thiamine hydrochloride	Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N	Launched	FDA Orange Book: thiamine, thiamine hydrochloride	SLC19A3|SLC19A2|TPK1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4628|https://www.drugbank.ca/drugs/DB00152|https://www.drugbank.ca/drugs/DB00152	vitamin B	metabolism	thiamine deficiency	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3c9db74-95d4-487c-90c3-c810786fbaec
FPL-64176	FPL-64176		COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1	Preclinical		CACNA1C|CACNA1S	http://www.tocris.com/dispprod.php?ItemId=1844|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2518	calcium channel activator			
ibuprofen-piconol	ibuprofen piconol	BE-100|U-75630|ibuprofen piconol	CC(C)Cc1ccc(cc1)C(C)C(=O)OCc1ccccn1	Launched	http://www.drugs.com/international/ibuprofen-piconol.html	PTGS1|PTGS2	http://www.genome.jp/dbget-bin/www_bget?D01122|http://www.genome.jp/dbget-bin/www_bget?D01122	cyclooxygenase inhibitor			
gliquidone	gliquidone	ARDF 26	COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C	Launched	http://www.drugs.com/international/Gliquidone.html	KCNJ8|ABCC8|KCNJ10|KCNJ11	https://www.drugbank.ca/drugs/DB01251|https://www.drugbank.ca/drugs/DB01251|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000924|https://citeline.informa.com/?query=#/drugs/details/7975	sulfonylurea	endocrinology	diabetes mellitus	https://en.wikipedia.org/wiki/Gliquidone
exenatide	exenatide	bydureon|bydureon pen|byetta	CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O	Launched	FDA Orange Book: exenatide synthetic	GCG|INS|GLP1R	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=271636|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=271636|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001038	GLP receptor agonist	endocrinology	diabetes mellitus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1c8ee2a-6a76-435e-ad38-8a9c99046ad9
bisoctrizole	bisoctrizole	FAT 75'634|MBBT|tinosorb m	CC(C)(C)CC(C)(C)c1cc(Cc2cc(cc(c2O)-n2nc3ccccc3n2)C(C)(C)CC(C)(C)C)c(O)c(c1)-n1nc2ccccc2n1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00483496						
SU-4312	SU-4312		CN(C)c1ccc(cc1)\C=C1/C(=O)Nc2ccccc12	Preclinical		KDR|PDGFRB	http://www.enzolifesciences.com/BML-EI306/su4312/|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010681	PDGFR tyrosine kinase receptor inhibitor|tyrosine kinase inhibitor|VEGFR inhibitor			
enprofylline	enprofylline	D 4028	CCCn1c2nc[nH]c2c(=O)[nH]c1=O	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/7956392	ADORA2A|ADORA2B|ADORA3|ADORA1|PDE4B|PDE4A	https://www.drugbank.ca/drugs/DB00824|https://www.drugbank.ca/drugs/DB00824|https://www.drugbank.ca/drugs/DB00824|https://www.drugbank.ca/drugs/DB00824|https://www.drugbank.ca/drugs/DB00824|https://www.drugbank.ca/drugs/DB00824	phosphodiesterase inhibitor			
GW-842166	GW-842166	GW-842166X|GW842166|GW842166X	FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00444769	CNR2	https://en.wikipedia.org/wiki/GW-842,166X	cannabinoid receptor agonist			
ursodiol	ursodiol	URSO|actigall|urso 250|urso forte|ursodeoxycholic acid|ursodesoxycholic acid	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched	FDA Orange Book: ursodiol	NR1H4|NFE2L2	ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=122191	nuclear factor erythroid derived|like (NRF2) activator	gastroenterology	gallstones	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a061bb07-a85d-4b08-877f-ce02156f0de7
flurothyl	flurothyl	SK&F 6539|flurotyl|hexafluorodiethyl ether|indoklon	FC(F)(F)COCC(F)(F)F	Preclinical							
chloroquine	chloroquine	NSC-187208|aralen|aralen hydrochloride|chlorochine|chloroquine phosphate	CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12	Launched	FDA Orange Book: chloroquine hydrochloride, chloroquine phosphate, hydroxychloroquine sulfate	CYP2C8|GSTA2|TNF|MRGPRX1|TLR9	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=277862|https://www.drugbank.ca/drugs/DB00608|https://www.drugbank.ca/drugs/DB00608|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5535|https://www.drugbank.ca/drugs/DB00608	antimalarial agent	infectious disease|infectious disease	malaria|amebiasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=638e62df-5bbc-41c3-aa88-eb36781c2af6|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=638e62df-5bbc-41c3-aa88-eb36781c2af6
olopatadine	olopatadine	pataday|patanase|patanol|pazeo	CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12	Launched	FDA Orange Book: olopatadine hydrochloride	S100A1|S100A2|S100B|HRH1|S100A13|S100A12	https://www.drugbank.ca/drugs/DB00768|https://www.drugbank.ca/drugs/DB00768|https://www.drugbank.ca/drugs/DB00768|https://www.drugbank.ca/drugs/DB00768|https://www.drugbank.ca/drugs/DB00768|https://www.drugbank.ca/drugs/DB00768	histamine receptor antagonist	ophthalmology	conjunctivitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2bb05329-c6c7-5a5f-9745-6c4f276bef3c
4-methylhistamine	4-methylhistamine		Cc1nc[nH]c1CCN	Preclinical		HRH4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1269	histamine receptor agonist			
entacapone	entacapone	OR-611|comtan	CCN(CC)C(=O)C(\C#N)=C\c1cc(O)c(O)c(c1)[N+]([O-])=O	Launched	FDA Orange Book: entacapone	COMT	ChEMBL	catechol O methyltransferase inhibitor	neurology/psychiatry	Parkinson's Disease	https://en.wikipedia.org/wiki/Entacapone
embelin	embelin		CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O	Preclinical		XIAP	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004516	HCV inhibitor|XIAP inhibitor			
isoflurane	isoflurane	AErrane|COMPOUND 469|forane	FC(F)OC(Cl)C(F)(F)F	Launched	FDA Orange Book: isoflurane	KCNK18|KCNK10|ATP5D|CALM1|GABRA4|GABRA5|GABRA2|GABRA3|GABRA1|GABRA6|GABRB3|GABRB1|GABRB2|GABRG2|GABRG3|GABRG1|GLRA1|ATP2C1|GLRB|GRIA1|GABRP|GABRQ|GABRD|GABRE|KCNK3|KCNK2|KCNK9|KCNA1	ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00753|https://www.drugbank.ca/drugs/DB00753|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00753|ChEMBL|https://www.drugbank.ca/drugs/DB00753|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00753	inhaled anaesthetic	neurology/psychiatry	general anaesthetic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13c9c37a-0c3d-450a-a61e-d2796818b18f
sari-59-801	sari-59-801		CCc1noc(C)c1-c1[nH]c2ccccc2c1C(O)CN(C)C	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/3424872						
arsanilic-acid	Arsanilic acid	Arsanilic acid|P Aminobenzenearsonic Acid|Pro-Gen|Sodium Arsanilate	Nc1ccc(cc1)[As](O)(O)=O	Phase 1	http://en.wikipedia.org/wiki/Arsanilic_acid	LYZ	https://www.drugbank.ca/drugs/DB03006				
LM11A-31	LM11A-31		CCC(C)C(N)C(=O)NCCN1CCOCC1	Phase 1	https://www.alzdiscovery.org/about-addf/researcher/frank-longo-md-phd	NGFR	http://www.sigmaaldrich.com/catalog/product/sigma/sml0664?lang=en&region=US	neurotrophic agent			
clofedanol	clofedanol	chlophedianol	CN(C)CCC(O)(c1ccccc1)c1ccccc1Cl	Launched	http://www.drugs.com/international/clofedanol.html	HRH1	https://www.drugbank.ca/drugs/DB04837	histamine receptor antagonist	pulmonary	cough suppressant	https://en.wikipedia.org/wiki/Clofedanol
castanospermine	castanospermine		O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00332176?term=celgosivir&rank=1	GAA|GBA	https://www.tocris.com/dispprod.php?ItemId=2129#.Vyez4mQrImI|https://www.tocris.com/dispprod.php?ItemId=2129#.Vyez4mQrImI	glucosidase inhibitor			
setipiprant	setipiprant	ACT-129968|KYTH-105	OC(=O)Cn1c2CCN(Cc2c2cc(F)ccc12)C(=O)c1cccc2ccccc12	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01484119	PTGDR2	http://www.kythera.com/products/kyth-105-setipiprant/	prostaglandin inhibitor			
GGsTop	GGsTop		COP(=O)(CCC(N)C(O)=O)Oc1cccc(CC(O)=O)c1	Preclinical		GGT1	https://www.tocris.com/products/ggstop_4452	gamma glutamyltransferase Inhibitors			
p-dimethylinamyl-benzoate	p-dimethylinamyl benzoate	padimate|padimate a	CCCCCOC(=O)c1ccc(cc1)N(C)C	Preclinical							
parethoxycaine	parethoxycaine		CCOc1ccc(cc1)C(=O)OCCN(CC)CC	Preclinical				local anesthetic			
PRE-084	PRE-084	2-Morpholinoethyl 1-Phenylcyclohexanecarboxylate	O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1	Preclinical		SIGMAR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6678	sigma receptor agonist			
DNQX	DNQX		[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O	Preclinical		GRIA2|GRIA1|GRIN1|GRIK1|GRIN2B|GRIN2A	https://www.drugbank.ca/drugs/DB03759|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011731|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011731|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011731|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011731|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011731	glutamate receptor antagonist			
PF-04418948	PF-04418948		COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01002963	PTGER2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5817	prostaglandin inhibitor			
perfluamine	perfluamine		FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F	Launched	http://en.wikipedia.org/wiki/Fluosol						
tenofovir-disoproxil	tenofovir disoproxil	tenofovir disoproxil|viread	CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C	Launched	FDA Orange Book: tenofovir disoproxil fumarate	CYP1A2|CYP3A4	http://www.drugbank.ca/drugs/DB00300|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=246665	nucleoside reverse transcriptase inhibitor	infectious disease|infectious disease	human immunodeficiency virus (HIV-1)|hepatitis B	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&audience=consumer
rapastinel	rapastinel	GLYX-13	C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O	Phase 2	https://en.wikipedia.org/wiki/Rapastinel			glutamate receptor agonist			
BC-11	BC-11		NC(=N)SCc1ccc(cc1)B(O)O	Preclinical		PLAU	https://www.tocris.com/products/bc-11-hydrobromide_4372	urokinase inhibitor			
S-111	S-111	20(S)-Protopanaxadiol	CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C	Phase 2	Cortellis	PARP1|SLC6A2|SLC6A4	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_id=469877&p_tsearch=A|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=315377|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=315377	PARP inhibitor			
xanomeline	xanomeline		CCCCCCOc1nsnc1C1=CCCN(C)C1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/9876958	HTR2C|HTR2B|HTR2A|HTR1B|HTR1A|HTR1F|HTR1E|HTR1D|HTR7|HTR6|CHRM5|CHRM4|CHRM3|CHRM2|CHRM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=57|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=57|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=57|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=57|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=57|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=57|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=57|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=57|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=57|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=57|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=57|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=57|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=57|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=57|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=57	acetylcholine receptor agonist			
estrone	estrone	Estrogenic substance|Natural estrogenic substance-estrone|oestrone|theelin	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O	Launched	FDA Orange Book: estrone	ESR1|ESR2	ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2818	estrogen receptor agonist|estrogenic hormone			
salicin	salicin		OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/11599656			anti-inflammatory agent			
MK2-IN-1	MK2-IN-1		Clc1ccc(cc1)-c1ccc(o1)C(=O)N(Cc1ccccn1)c1ccc(cc1)N1CCNCC1	Preclinical		MAPKAPK2	https://www.medchemexpress.com/MK2-IN-1.html	MAP kinase inhibitor			
dexfosfoserine	dexfosfoserine	GNF-Pf-1028	N[C@@H](COP(O)(O)=O)C(O)=O	Preclinical		KCNC4|GRM4|GRM7|GRM8|GRM6|CFTR|REG1A|PDPK1|PIM1|TAOK2|PRKACA|RHO|PRKCQ|PYGL|PYGM|SMAD2|SERPINB3	https://www.drugbank.ca/drugs/DB04522|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1411|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1411|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1411|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1411|https://www.drugbank.ca/drugs/DB04522|https://www.drugbank.ca/drugs/DB04522|https://www.drugbank.ca/drugs/DB04522|https://www.drugbank.ca/drugs/DB04522|https://www.drugbank.ca/drugs/DB04522|https://www.drugbank.ca/drugs/DB04522|https://www.drugbank.ca/drugs/DB04522|https://www.drugbank.ca/drugs/DB04522|https://www.drugbank.ca/drugs/DB04522|https://www.drugbank.ca/drugs/DB04522|https://www.drugbank.ca/drugs/DB04522|https://www.drugbank.ca/drugs/DB04522	membrane integrity inhibitor			
pranlukast	pranlukast	ONO-1078|SB 205312	O=C(Nc1cccc2c1oc(cc2=O)-c1nnn[nH]1)c1ccc(OCCCCc2ccccc2)cc1	Launched	http://www.drugs.com/international/pranlukast.html	TNF|MUC2|CYSLTR2|CYSLTR1|RNASE3|NFKB1|IL5	https://www.drugbank.ca/drugs/DB01411|https://www.drugbank.ca/drugs/DB01411|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3634|https://www.drugbank.ca/drugs/DB01411|https://www.drugbank.ca/drugs/DB01411|https://www.drugbank.ca/drugs/DB01411|https://www.drugbank.ca/drugs/DB01411	leukotriene receptor antagonist	pulmonary|pulmonary|pulmonary|pulmonary	bronchospasm|asthma|bronchospasm|asthma	http://www.drugbank.ca/drugs/DB01411|http://www.drugbank.ca/drugs/DB01411|http://www.drugbank.ca/drugs/DB01411|http://www.drugbank.ca/drugs/DB01411
prednisolone-acetate	prednisolone acetate	econopred|flo-pred|meticortelone|omnipred|pred forte|pred mild|prednisolone acetate|sterane		Launched	FDA Orange Book: methylprednisolone acetate, prednisolone acetate	NR3C1	ChEMBL	glucocorticoid receptor agonist	ophthalmology|dermatology|ophthalmology|infectious disease|ophthalmology|ophthalmology	conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d6c3ea4-5189-4f6e-bb6a-c9379f441d7a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d6c3ea4-5189-4f6e-bb6a-c9379f441d7a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d6c3ea4-5189-4f6e-bb6a-c9379f441d7a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d6c3ea4-5189-4f6e-bb6a-c9379f441d7a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d6c3ea4-5189-4f6e-bb6a-c9379f441d7a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d6c3ea4-5189-4f6e-bb6a-c9379f441d7a
A-922500	A-922500		OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1	Preclinical		DGAT1	https://www.tocris.com/products/a-922500_3587	diacylglycerol O acyltransferase inhibitor			
JNJ-10397049	JNJ-10397049		CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@@H](O1)c1ccccc1	Preclinical		HCRTR1|HCRTR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1701|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1701	orexin receptor antagonist			
SP-100030	SP-100030		FC(F)(F)c1cc(NC(=O)c2cnc(Cl)nc2C(F)(F)F)cc(c1)C(F)(F)F	Preclinical		NFKB1|JUN	https://www.tocris.com/products/sp-100030_5309|https://www.tocris.com/products/sp-100030_5309	NFkB pathway inhibitor			
KI-20227	KI-20227		COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1	Preclinical		KIT|KDR|CSF1R|PDGFRB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5690|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5690|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5690|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5690	c-Fms inhibitor			
elemene	elemene		CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C1)C(C)=C	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/22513935			VEGFR inhibitor			
ecamsule-triethanolamine	ecamsule triethanolamine		CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C/c1ccc(cc1)\C=C1\C2CCC(CS(O)(=O)=O)(C1=O)C2(C)C	Launched	http://en.wikipedia.org/wiki/Ecamsule				dermatology|dermatology	skin protectant|sunscreen lotion	https://en.wikipedia.org/wiki/Ecamsule|https://en.wikipedia.org/wiki/Ecamsule
sucralfate	sucralfate	carafate	O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O	Launched	FDA Orange Book: sucralfate	FGF2|EGF|FGG|FGB|FGA	https://www.drugbank.ca/drugs/DB00364|https://www.drugbank.ca/drugs/DB00364|https://www.drugbank.ca/drugs/DB00364|https://www.drugbank.ca/drugs/DB00364|https://www.drugbank.ca/drugs/DB00364	antacid	gastroenterology	duodenal ulcer disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62819787-beb7-408a-9e23-a61b4720e99c&audience=consumer
SAR131675	SAR131675		CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC	Preclinical		FLT4	http://www.ncbi.nlm.nih.gov/pubmed/22584122	VEGFR inhibitor			
CS-110266	CS-110266	BTCP	C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1	Preclinical		SLC6A3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009000	dopamine receptor agonist			
TCS-HDAC6-20b	TCS-HDAC6-20b		CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2	Preclinical		HDAC6	https://www.tocris.com/products/tcs-hdac6-20b_4805	HDAC inhibitor			
dromostanolone-propionate	dromostanolone propionate		CCC(=O)OC1CCC2C3CCC4CC(=O)C(C)CC4(C)C3CCC12C	Launched	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/	AR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6947	androgen receptor modulator	oncology	breast cancer	http://steroid.es/drostanolone.html
penicillamine-(racemic)	DL-penicillamine	Dl-Penicillamine	CC(C)(S)C(N)C(O)=O	Preclinical							
pancuronium	pancuronium	pancuronium bromide|pavulon	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1	Launched	FDA Orange Book: pancuronium bromide	CHRNA1|CHRNA2|CHRM3|CHRM2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4001|https://www.drugbank.ca/drugs/DB01337|https://www.drugbank.ca/drugs/DB01337|https://www.drugbank.ca/drugs/DB01337	acetylcholine receptor antagonist	critical care|neurology/psychiatry	endotracheal intubation|muscle relaxant	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d705382b-8aa0-4893-ed9e-bcf7c7d9d0a2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d705382b-8aa0-4893-ed9e-bcf7c7d9d0a2
cefminox	cefminox	Meicelin|cefminox sodium	CO[C@]1(NC(=O)CSC[C@@H](N)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O	Launched	http://www.drugs.com/international/cefminox.html			bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections	https://en.wikipedia.org/wiki/Cefminox
cefpiramide	cefpiramide	cefpiramide sodium	Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1	Launched	FDA Orange Book: cefpiramide sodium			bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections	http://www.drugbank.ca/drugs/DB00430
idalopirdine	idalopirdine	LU AE58054|LU-AE58054	FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1	Phase 3	https://clinicaltrials.gov/show/NCT02079246	HTR6	http://www.alzforum.org/therapeutics/idalopirdine	serotonin receptor antagonist			
piceatannol	piceatannol	NSC-365798	Oc1cc(O)cc(c1)\C=C\c1ccc(O)c(O)c1	Preclinical		ATP5A1|ATP5C1|SIRT1|ATP5B|IRF3|TYR|SYK|PTGS2	https://www.drugbank.ca/drugs/DB08399|https://www.drugbank.ca/drugs/DB08399|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=172850|https://www.drugbank.ca/drugs/DB08399|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001123|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=172850|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=172850|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=172850	SYK inhibitor			
paromomycin	paromomycin	Aminosidine|Monomycin|paromomycin sulfate	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	Launched	FDA Orange Book: paromomycin sulfate			bacterial 30S ribosomal subunit inhibitor	infectious disease	amebiasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc0f4113-e627-4caf-b2d4-95b4106e57f5
guanidinopropionic-acid	guanidinopropionic acid	3-Guanidino-Propionic Acid|Beta-Guanidinopropionic Acid	NC(N)=NCCC(O)=O	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/25888414	CKM	https://www.ncbi.nlm.nih.gov/pubmed/25888414	creatine kinase inhibitor			
meclofenamic-acid	meclofenamic acid	CI-583|INF 4668|INF-4668|Meclodium|Meclofenamate|meclofenamate sodium|meclofenamic acid|meclomen	Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl	Launched	FDA Orange Book: meclofenamate sodium	CNR1|PTGS1|PTGS2|KCNQ2|KCNQ3|ALOX5	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DPR000027|https://www.drugbank.ca/drugs/DB00939|https://www.drugbank.ca/drugs/DB00939|https://www.drugbank.ca/drugs/DB00939|https://www.drugbank.ca/drugs/DB00939|https://www.drugbank.ca/drugs/DB00939	cyclooxygenase inhibitor|prostanoid receptor antagonist	rheumatology|neurology/psychiatry|rheumatology|endocrinology	joint pain|muscle pain|rheumatoid arthritis|primary dysmenorrhea (PD)	https://en.wikipedia.org/wiki/Meclofenamic_acid|https://en.wikipedia.org/wiki/Meclofenamic_acid|https://en.wikipedia.org/wiki/Meclofenamic_acid|https://en.wikipedia.org/wiki/Meclofenamic_acid
dextromethorphan	dextromethorphan	Dimetane-DX|delsym	COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1	Launched	FDA Orange Book: dextromethorphan hydrobromide, dextromethorphan polistirex	SLC6A2|SLC6A4|GRIN1|GRIN3A|NCF1|NCF2|NCF4|RAC2|RAC1|CYBB|CYBA|OPRM1|OPRD1|OPRK1|PGRMC1|CYP3A5|CHRNB4|CHRNB2|CHRNA7|CHRNA4|CHRNA3|CHRNA2|SIGMAR1	https://www.drugbank.ca/drugs/DB00514|https://www.drugbank.ca/drugs/DB00514|https://citeline.informa.com/?query=#/drugs/details/86170|https://www.drugbank.ca/drugs/DB00514|https://www.drugbank.ca/drugs/DB00514|https://www.drugbank.ca/drugs/DB00514|https://www.drugbank.ca/drugs/DB00514|https://www.drugbank.ca/drugs/DB00514|https://www.drugbank.ca/drugs/DB00514|https://www.drugbank.ca/drugs/DB00514|https://www.drugbank.ca/drugs/DB00514|https://www.drugbank.ca/drugs/DB00514|https://www.drugbank.ca/drugs/DB00514|https://www.drugbank.ca/drugs/DB00514|https://www.drugbank.ca/drugs/DB00514|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=137626|https://www.drugbank.ca/drugs/DB00514|https://www.drugbank.ca/drugs/DB00514|https://www.drugbank.ca/drugs/DB00514|https://www.drugbank.ca/drugs/DB00514|https://www.drugbank.ca/drugs/DB00514|https://www.drugbank.ca/drugs/DB00514|https://www.drugbank.ca/drugs/DB00514	glutamate receptor antagonist|sigma receptor agonist	pulmonary	cough suppressant	https://en.wikipedia.org/wiki/Dextromethorphan
ripasudil	ripasudil		C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12	Launched	http://en.wikipedia.org/wiki/Ripasudil	ROCK2|ROCK1	http://www.medchemexpress.com/k-115-free-base.html|http://www.medchemexpress.com/k-115-free-base.html	rho associated kinase inhibitor	ophthalmology|ophthalmology	glaucoma|ocular hypertension	https://en.wikipedia.org/wiki/Ripasudil|https://en.wikipedia.org/wiki/Ripasudil
AR-12	AR-12	OSU-03012	NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F	Phase 1	https://www.clinicaltrials.gov/show/NCT00978523	PDPK1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8005	phosphoinositide dependent kinase inhibitor			
XL888	XL888		CC[C@@H](C)Nc1cc(C(=O)NC2CC3CCC(C2)N3c2ccc(cn2)C(=O)C2CC2)c(C)cc1C(N)=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00796484			HSP inhibitor			
procysteine	procysteine		OC(=O)[C@@H]1CSC(=O)N1	Phase 3	https://www.thefreelibrary.com/Transcend+Therapeutics+Discontinues+Phase+III+Trial+of+Procysteine...-a020571435			glutathione synthase stimulant			
flunarizine	flunarizine		Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1	Launched	http://www.drugs.com/international/Flunarizine.html	CALM1|CACNA1I|CACNA1G|CACNA1H|CYP2J2|HRH1	https://www.drugbank.ca/drugs/DB04841|https://www.drugbank.ca/drugs/DB04841|https://www.drugbank.ca/drugs/DB04841|https://www.drugbank.ca/drugs/DB04841|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091329|https://www.drugbank.ca/drugs/DB04841	calcium channel blocker	neurology/psychiatry|neurology/psychiatry|cardiology	migraine headache|vertigo|peripheral artery disease (PAD)	https://en.wikipedia.org/wiki/Flunarizine|https://en.wikipedia.org/wiki/Flunarizine|https://en.wikipedia.org/wiki/Flunarizine
1-azakenpaullone	1-azakenpaullone	Azakenpaullone	Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1	Preclinical		CDK5|CDK1|GSK3B|CCNB1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8018|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8018|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8018|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004083	glycogen synthase kinase inhibitor			
tyrphostin-AG-835	tyrphostin-AG-835	Tyrphostin Ag-835	C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1	Preclinical		EGFR	http://www.chemicalbook.com/ChemicalProductProperty_EN_CB2472555.htm	protein tyrosine kinase inhibitor			
triazolam	triazolam	U-33,030|U-33030|halcion	Cc1nnc2CN=C(c3ccccc3Cl)c3cc(Cl)ccc3-n12	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	GABRQ|GABRP|GABRE|GABRD|CYP3A7|CYP3A5|TSPO|GABRA4|GABRA3|GABRA6|GABRA5|GABRA2|GABRA1|GABRB1|GABRB3|GABRB2|GABRR1|GABRR3|GABRR2|GABRG2|GABRG1|GABRG3	ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091340|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091340|https://www.drugbank.ca/drugs/DB00897|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00897|https://www.drugbank.ca/drugs/DB00897|https://www.drugbank.ca/drugs/DB00897|ChEMBL|ChEMBL|ChEMBL	GABA benzodiazepine site receptor agonist			
protirelin	protirelin	thypinone|thyrel trh	NC(=O)C1CCCN1C(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1	Launched	FDA Orange Book: protirelin	TRHR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014804	thyrotropin releasing hormone receptor agonist	radiology	thyroid function diagnostic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af5da799-76bf-415a-9dc7-99c7ddc62bc4
imexon	imexon	amplimexon	N=C1NC(=O)N2CC12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01314014	RRM2|RRM1	https://www.drugbank.ca/drugs/DB05003|https://www.drugbank.ca/drugs/DB05003	apoptosis stimulant|ribonucleotide reductase inhibitor			
GNF-5837	GNF-5837		Cc1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)cc1Nc1ccc2c(NC(=O)\C2=C/c2ccc[nH]2)c1	Preclinical		NTRK1|NTRK2|NTRK3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8071|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8071|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8071	growth factor receptor inhibitor			
TCS-21311	TCS-21311		CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F	Preclinical		JAK3	https://www.tocris.com/search?keywords=TCS-21311	JAK inhibitor			
flosequinan	flosequinan	BTS 49 465	Cn1cc(S(C)=O)c(=O)c2ccc(F)cc12	Withdrawn	http://guceconomics.blogspot.com/2012/03/flosequinan.html	PDE3A	https://citeline.informa.com/?query=#/drugs/details/7333	phosphodiesterase inhibitor			
daltroban	daltroban	BM 13.505|BM-13505|SK&F 96148	OC(=O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1	Phase 3	http://onlinelibrary.wiley.com/store/10.1111/j.1527-3466.1998.tb00358.x/asset/j.1527-3466.1998.tb00358.x.pdf?v=1&t=iuimgvtj&s=628232124771bb0ba4622e5b8d3f1b293bedbb81	TBXA2R	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1986	thromboxane receptor antagonist			
telatinib	telatinib	BAY-57-9352|BAY-579352	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00952497	FLT4|KIT|KDR|PDGFRB	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=303263|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=303263|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000356|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=303263	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor			
URMC-099	URMC-099		CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1	Preclinical		CDKL2|MAP3K11|MAP3K10|MAP3K9|MAP3K2|SRPK2|FLT3|DAPK3|LRRK2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8106|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8106|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8106|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8106|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8106|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8106|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8106|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8106|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8106	mixed lineage kinase inhibitor			
I-CBP-112	I-CBP-112		CCC(=O)N1CCOc2c(C1)cc(cc2OC[C@H]1CCCN(C)C1)-c1ccc(OC)c(OC)c1	Preclinical		EP300|CREBBP	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8236|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8236	bromodomain inhibitor			
eltrombopag	eltrombopag	promacta	CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1	Launched	FDA Orange Book: eltrombopag olamine	CYP2C8|MPL	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=313630|https://www.drugbank.ca/drugs/DB06210	thrombopoietin receptor agonist	hematology|infectious disease|hematology	anemia|hepatitis C|thrombocytopenia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=616224ff-a925-4b38-9ca2-00fbf669380f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=616224ff-a925-4b38-9ca2-00fbf669380f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=616224ff-a925-4b38-9ca2-00fbf669380f
aloe-emodin	aloe emodin	aloe emodin	OCc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	Preclinical		CASP3|CASP8	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=413684|http://www.ncbi.nlm.nih.gov/pubmed/15910415	anticancer agent			
metharbital	metharbital	endiemal|gemonil	CCC1(CC)C(=O)NC(=O)N(C)C1=O	Launched	FDA Orange Book: metharbital	GABRP|GABRQ|GABRD|GABRE|CHRNA7|CHRNA4|GABRB1|GABRA5|GABRA6|GABRA3|GABRA4|GABRA1|GABRA2|GABRB2|GABRB3|GABRG3|GABRG1|GABRG2|GRIK2|GRIA2	ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00463|https://www.drugbank.ca/drugs/DB00463|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00463|https://www.drugbank.ca/drugs/DB00463	GABA receptor modulator	neurology/psychiatry	epilepsy	https://en.wikipedia.org/wiki/Metharbital
N20C	N20C	N-(3,3-Diphenylpropyl)Glycinamide	NC(=O)CNCCC(c1ccccc1)c1ccccc1	Preclinical				glutamate receptor antagonist			
quizartinib	quizartinib	AC-220|AC010220|ASP-2689	CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02039726	RET|PDGFRA|PDGFRB|CSF1R|FLT3|KIT	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5658|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5658|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5658|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5658|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5658|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5658	FLT3 inhibitor			
3,4-DCPG-(S)	(S)-3,4-DCPG		N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O	Preclinical				glutamate receptor agonist			
vandetanib	vandetanib	GNF-Pf-2188|ZD-64|ZD-6474|ZD6474|caprelsa|zactima	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1	Launched	FDA Orange Book: vandetanib	ERBB2|ERBB3|ERBB4|KDR|PTK6|KIT|FLT1|FLT3|FLT4|EGFR|RET|EPHA10|SRC|TEK|VEGFA|EPHB6|EPHB4|EPHB3|EPHB2|EPHB1|EPHA8|EPHA7|EPHA6|EPHA5|EPHA4|EPHA3|EPHA2|EPHA1	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=304792|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=304792|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB05294|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2a87691-c9ad-4753-97a1-311fccfe6515
riodipine	riodipine		COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1OC(F)F)C(=O)OC	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/2097399	CACNA1C	https://citeline.informa.com/?query=#/drugs/details/15706	calcium channel blocker			
PRT4165	PRT4165		O=C1C(=Cc2cccnc2)C(=O)c2ccccc12	Preclinical		PRC1	https://www.tocris.com/dispprod.php?ItemId=393253#.V-6iPJMrLy8	polycomb repressive complex inhibitor			
homoharringtonine	homoharringtonine	CGX-635|omacetaxine mepesuccinate|synribo	COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC	Launched	http://en.wikipedia.org/wiki/Omacetaxine_mepesuccinate	RPL3	https://www.drugbank.ca/drugs/DB04865	protein synthesis inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)	http://www.sigmaaldrich.com/catalog/product/sigma/h0635?lang=en&region=US
phenylacetylglutamine	phenylacetylglutamine		NC(=O)CC[C@H](NC(=O)Cc1ccccc1)C(O)=O	Phase 2	Pharmaprojects			DNA methylase inhibitor|protein synthesis inhibitor			
tropesin	tropesin		COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(C(O)=O)c3ccccc3)c2c1	Launched	http://docslide.us/documents/pp8launch19951997.html	PTGS1|PTGS2	http://www.aidbd.in/drugs.php|http://www.aidbd.in/drugs.php	cyclooxygenase inhibitor			
gramicidin	gramicidin		CC(C)CC(NC(=O)C(C)NC(=O)CNC(=O)C(NC=O)C(C)C)C(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NCCO	Launched	FDA Orange Book: gramicidin			bacterial permeability inducer	infectious disease	first-aid antibiotic	https://en.wikipedia.org/wiki/Gramicidin
dobutamine	dobutamine	COMPOUND 81929|dobutamine hydrochloride|dobutrex	CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1	Launched	FDA Orange Book: dobutamine hydrochloride	ADRB1|ADRB2|ADRA1A	https://www.drugbank.ca/drugs/DB00841|https://www.drugbank.ca/drugs/DB00841|https://citeline.informa.com/?query=#/drugs/details/5799	adrenergic receptor agonist	cardiology	congestive heart failure	https://en.wikipedia.org/wiki/Dobutamine
ethaverine	ethaverine		CCOc1ccc(Cc2nccc3cc(OCC)c(OCC)cc23)cc1OCC	Launched	http://www.drugs.com/international/ethaverine.html			calcium channel blocker	neurology/psychiatry|neurology/psychiatry	muscle relaxant|spasms	http://medical-dictionary.thefreedictionary.com/ethaverine+hydrochloride|http://medical-dictionary.thefreedictionary.com/ethaverine+hydrochloride
BRL-52537	BRL-52537		Clc1ccc(CC(=O)N2CCCCC2CN2CCCC2)cc1Cl	Preclinical		OPRK1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000350	opioid receptor agonist			
rolziracetam	rolziracetam	CI-911	O=C1CCC2CCC(=O)N12	Phase 2	Pharmaprojects						
colistin-b-sulfate	colistin B sulfate		CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O	Launched	http://en.wikipedia.org/wiki/Colistin			bacterial permeability inducer	infectious disease	gram-negative bacterial infections	https://en.wikipedia.org/wiki/Colistin
AH11110	AH11110		OC(COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1	Preclinical		ADRA1B	https://www.tocris.com/dispprod.php?ItemId=1604#.Vyd62mQrImI	adrenergic receptor ligand			
bleomycin	bleomycin	blenoxane|bleomycin sulfate		Launched	FDA Orange Book: bleomycin sulfate	LIG3|LIG1	https://www.drugbank.ca/drugs/DB00290|https://www.drugbank.ca/drugs/DB00290	DNA synthesis inhibitor	hematologic malignancy|hematologic malignancy|pulmonary|oncology|oncology	non-Hodgkin lymphoma (NHL)|Hodgkin's lymphoma|pleural effusion|testicular carcinoma|squamous cell carcinoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5806c40-12ce-48e3-8abd-9f8997ef4428|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5806c40-12ce-48e3-8abd-9f8997ef4428|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5806c40-12ce-48e3-8abd-9f8997ef4428|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5806c40-12ce-48e3-8abd-9f8997ef4428|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5806c40-12ce-48e3-8abd-9f8997ef4428
ONC201	ONC201		Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02525692	TNFSF10|TNFRSF10A	https://www.medchemexpress.com/TIC10.html?gclid=CKax0ovVpNICFZS6wAodVzcGMA|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=765506	AKT inhibitor|MAP kinase inhibitor			
landiolol	landiolol		CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1	Launched	http://www.drugs.com/international/Landiolol.html	ADRB1	https://en.wikipedia.org/wiki/Landiolol	adrenergic receptor antagonist	cardiology	cardiac arrythmia	https://en.wikipedia.org/wiki/Landiolol
barnidipine	barnidipine	barnidipine hydrochloride	COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@H]1CCN(Cc2ccccc2)C1	Launched	http://www.drugs.com/international/Barnidipine.html			calcium channel blocker	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=barnidipine
R-268712	R-268712		Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1	Preclinical		TGFBR1	https://www.tocris.com/products/r-268712_5288	serine/threonine kinase inhibitor			
G007-LK	G007-LK		CS(=O)(=O)c1ccc(nc1)-c1nnc(\C=C\c2nnc(o2)-c2ccc(cc2)C#N)n1-c1ccccc1Cl	Preclinical		TNKS2|TNKS	http://www.adooq.com/g007-lk.html?gclid=COqcp9zSrc8CFYpZhgodfFEBBw|http://www.adooq.com/g007-lk.html?gclid=COqcp9zSrc8CFYpZhgodfFEBBw	tankyrase inhibitor			
sarpogrelate	sarpogrelate	sarpogrelate hydrochloride	COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(O)=O)c1	Launched	http://www.drugs.com/international/Sarpogrelate.html	HTR2C|HTR2B|HTR2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=210|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=210|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=210	serotonin receptor antagonist	endocrinology|cardiology|rheumatology|cardiology|rheumatology	diabetes mellitus|angina pectoris|Raynaud's disease|atherosclerosis|Buerger's disease	https://en.wikipedia.org/wiki/Sarpogrelate|https://en.wikipedia.org/wiki/Sarpogrelate|https://en.wikipedia.org/wiki/Sarpogrelate|https://en.wikipedia.org/wiki/Sarpogrelate|https://en.wikipedia.org/wiki/Sarpogrelate
fosamprenavir	fosamprenavir	lexiva	CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	Launched	FDA Orange Book: fosamprenavir calcium			HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24feb9be-32a6-45fd-a896-f3e202edd8a9
dimetridazole	dimetridazole	Emtryl|RP 8595|Unizole	Cc1ncc(n1C)[N+]([O-])=O	Veterinary Launched	http://www.drugs.com/international/dimetridazole.html			bacterial DNA inhibitor			
ITE	ITE		COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12	Preclinical		AHR	http://www.tocris.com/dispprod.php?ItemId=77799	aryl hydrocarbon receptor agonist			
moxisylyte	moxisylyte	acetoxythymoxamine|moxisylyte hydrochloride|thymoxamine	CC(C)c1cc(OC(C)=O)c(C)cc1OCCN(C)C	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs			adrenergic receptor antagonist			
tetroquinone	tetroquinone		OC1C(=O)C(=O)C(O)C(=O)C1=O	Preclinical							
sulfamethazine	sulfamethazine	SMZ-MED 454|sulfadimidine|sulfamethazine (trisulfapyrimidines)	Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1	Veterinary Launched	FDA Orange Book: trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine)			PABA antagonist	gastroenterology|gastroenterology	enteritis|enteritis	https://en.wikipedia.org/wiki/Sulfadimidine|https://en.wikipedia.org/wiki/Sulfadimidine
MK-0752	MK-0752		OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT00645333			gamma secretase inhibitor			
aloxistatin	aloxistatin		CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/1450492	CTSL|CTSG|CTSH|CTSB	https://citeline.informa.com/?query=#/drugs/details/11070|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008582|https://citeline.informa.com/?query=#/drugs/details/11070|https://citeline.informa.com/?query=#/drugs/details/11070	protease inhibitor			
ethanolamine-oleate	ethanolamine-oleate	ethamolin	NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O	Launched	FDA Orange Book: ethanolamine oleate	FABP4|F12|PLD2|FFAR1|FFAR4	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010898|https://www.drugbank.ca/drugs/DB06689|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054	immunostimulant	gastroenterology	esophageal varices	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9c1d8c5-443e-400e-a42c-16a25fb47231
ESI-09	ESI-09		CC(C)(C)c1cc(no1)C(=O)C(\C#N)=N\Nc1cccc(Cl)c1	Preclinical		RAPGEF3|RAPGEF4	https://medchemexpress.com/esi-09.html?gclid=CPXZ9Pajps8CFVZZhgodijoLIg|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7917	EPAC inhibitor			
teicoplanin-A2-1	teicoplanin A2-1		CCCCC\C=C\CCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(CC4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(OC4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@H](NC1=O)C(O)=O)c5)cc3Cl	Launched	http://en.wikipedia.org/wiki/Teicoplanin			bacterial cell wall synthesis inhibitor			
R306465	R306465		ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00677001			HDAC inhibitor			
dexpanthenol	dexpanthenol	(+)-panthenol|D-PANTHENOL 50|d-panthenol|d-pantothenyl alcohol|ilopan|motilyn|pantothenol		Launched	FDA Orange Book: dexpanthenol				gastroenterology	paralytic ileus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ed47f4b-5182-40b7-a440-9e7b06819d95
A-967079	A-967079		CCC(=N/O)\C(C)=C\c1ccc(F)cc1	Preclinical		TRPA1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6280	transient receptor potential channel antagonist			
AZD8055	AZD8055	AZ-12600000|AZD-8055	COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00731263	MTOR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7714	mTOR inhibitor			
KD025	KD025	KD-025|SLx-2119	CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02106195	ROCK2	https://www.caymanchem.com/product/17055	rho associated kinase inhibitor			
poziotinib	poziotinib	HM-781-36B|NOV-120101	COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01819428	EGFR|ERBB4|ERBB2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7903|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7903|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7903	EGFR inhibitor			
lomeguatrib	lomeguatrib		Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/18475294	MGMT	http://www.sigmaaldrich.com/catalog/product/sigma/sml0586?lang=en&region=US	O6-alkylguanine-DNA alkyltransferase inhibitor			
avridine	avridine	CP-20,961	CCCCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCCCC)CCCN(CCO)CCO	Preclinical				immunostimulant			
droxidopa	droxidopa	DOPS|l-dops|northera	N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O	Launched	FDA Orange Book: droxidopa	ADRB2|ADRB3|ADRB1|PAH|ADRA2B|ADRA2A|ADRA2C|ADRA1D|ADRA1A|ADRA1B	ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB06262|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	norepinephrine precursor	cardiology|neurology/psychiatry	hypertension|Parkinson's Disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2179f02c-48d7-48eb-8007-5ae43d8d16bc|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2179f02c-48d7-48eb-8007-5ae43d8d16bc
6-iodo-nordihydrocapsaicin	6-iodo-nordihydrocapsaicin	6'-Iodononivamide	CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I	Preclinical		TRPV1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4110	TRPV antagonist			
5,7-Dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-2H-chromene-3,4-dione	5,7-Dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-2H-chromene-3,4-dione		COc1ccc(cc1)C1Oc2c(CC=C(C)C)c(O)cc(O)c2C(=O)C1=O	Preclinical							
clorotepine	clorotepine	octoclothepine	CN1CCN(CC1)C1Cc2ccccc2Sc2ccc(Cl)cc12	Launched	https://en.wikipedia.org/wiki/Clorotepine	DRD2|HTR2C|ADRA1B|ADRA1D|ADRA1A|HRH1|HTR6	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004869|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004869|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004869|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004869|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004869|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004869|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004869	dopamine receptor antagonist|adrenergic receptor antagonist	neurology/psychiatry	psychosis	https://en.wikipedia.org/wiki/Clorotepine
desvenlafaxine	desvenlafaxine	O-Desmethylvenlafaxine (Odv)|ODV|khedezla|pristiq	CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1	Launched	FDA Orange Book: desvenlafaxine, desvenlafaxine fumarate, desvenlafaxine succinate	SLC6A2|SLC6A3|SLC6A4	ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7158|ChEMBL	serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=25bdfc41-c7cb-4d16-b6a8-f102f9b8c984
7-methoxytacrine	7-methoxytacrine		COc1ccc2nc3CCCCc3c(N)c2c1	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/8191252	ACHE	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011237	acetylcholinesterase inhibitor			
RU-28318	RU-28318	oxprenoate potassium	CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12	Phase 2	Pharmaprojects	NR3C2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3451	cytochrome P450 inhibitor			
eletriptan	eletriptan	UK-116,044|UK-116,044-04 [AS HYDROBROMIDE)|UK-116044-04|relpax	CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12	Launched	FDA Orange Book: eletriptan hydrobromide	HTR2B|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR7	https://www.drugbank.ca/drugs/DB00216|https://www.drugbank.ca/drugs/DB00216|https://www.drugbank.ca/drugs/DB00216|https://www.drugbank.ca/drugs/DB00216|https://www.drugbank.ca/drugs/DB00216|https://www.drugbank.ca/drugs/DB00216|https://www.drugbank.ca/drugs/DB00216	serotonin receptor agonist	neurology/psychiatry	migraine headache	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=85745375-fcb6-4edc-b6db-a77b4a5f3e8c
NMS-P715	NMS-P715		CCc1cccc(CC)c1NC(=O)c1nn(C)c-2c1CCc1cnc(Nc3ccc(cc3OC(F)(F)F)C(=O)NC3CCN(C)CC3)nc-21	Preclinical		TTK	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=679659	protein kinase inhibitor			
cinanserin	cinanserin		CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1	Preclinical		HTR2A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008884	serotonin receptor antagonist			
sodium-stibogluconate	sodium stibogluconate		OCC(O)C1O[Sb]2(O)(O[Sb]34(O)OC(C(O)CO)C(O3)C(O4)C(O)=O)OC1C(O2)C(O)=O	Launched	https://clinicaltrials.gov/ct2/show/NCT01661296	TOP1|PTPN6	https://www.drugbank.ca/drugs/DB05630|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000001	tyrosine phosphatase inhibitor	infectious disease	leishmaniasis	https://en.wikipedia.org/wiki/Sodium_stibogluconate
SR-1664	SR-1664		C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O	Preclinical		PPARG	https://www.tocris.com/products/sr-1664_4409	PPAR receptor ligand			
NMS-E973	NMS-E973		CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O	Preclinical				HSP inhibitor			
E7449	E7449		O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT01618136	TNKS|TNKS2|PARP1|PARP2	http://www.ncbi.nlm.nih.gov/pubmed/26513298|http://www.ncbi.nlm.nih.gov/pubmed/26513298|http://www.ncbi.nlm.nih.gov/pubmed/26513298|http://www.ncbi.nlm.nih.gov/pubmed/26513298	PARP inhibitor			
chloroxine	chloroxine	capitrol	Oc1c(Cl)cc(Cl)c2cccnc12	Launched	FDA Orange Book: chloroxine	OPRK1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011357	opioid receptor antagonist	gastroenterology|gastroenterology|infectious disease|dermatology	diarrhea|inflammatory bowel disease|giardiasis|dandruff	https://en.wikipedia.org/wiki/Chloroxine|https://en.wikipedia.org/wiki/Chloroxine|https://en.wikipedia.org/wiki/Chloroxine|https://en.wikipedia.org/wiki/Chloroxine
methacycline	methacycline		CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O	Launched	FDA Orange Book: methacycline hydrochloride			protein synthesis inhibitor	pulmonary	bronchitis	http://www.druglib.com/activeingredient/methacycline/
oxyphencyclimine	oxyphencyclimine	daricon	CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)c1ccccc1	Launched	FDA Orange Book: oxyphencyclimine hydrochloride	CHRM3|CHRM2|CHRM1	https://www.drugbank.ca/drugs/DB00383|https://www.drugbank.ca/drugs/DB00383|https://www.drugbank.ca/drugs/DB00383	cholinergic receptor antagonist	gastroenterology	peptic ulcer disease (PUD)	http://www.drugbank.ca/drugs/DB00383
efonidipine-monoethanolate	efonidipine-monoethanolate	efonidipine|efonidipine hydrochloride	CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1	Launched	http://en.wikipedia.org/wiki/Efonidipine	CACNA1C|CACNA1G	http://www.scbt.com/datasheet-364486-CASNumber-111011-76-8.html|http://www.scbt.com/datasheet-364486-CASNumber-111011-76-8.html	L-type calcium channel blocker|T-type calcium channel blocker			
MDMS	MDMS		CS(=O)(=O)OCOS(C)(=O)=O	Phase 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246396/			DNA inhibitor			
propylparaben	propylparaben	E216|propyl parahydroxybenzoate	CCCOC(=O)c1ccc(O)cc1	Launched	http://www.drugs.com/international/propylparaben.html						
deferiprone	deferiprone	APO-066|APO-66|CP20|DN-180-01-AF|ferriprox	Cc1c(O)c(=O)ccn1C	Launched	FDA Orange Book: deferiprone	UGT1A6|CYP4F2	http://www.drugbank.ca/drugs/DB08826|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=135177	chelating agent	hematology|hematology|hematology	transfusional hemosiderosis|thalassemia|iron overload	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc8cbc3d-026c-0db5-42e8-8e93d374dd23|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc8cbc3d-026c-0db5-42e8-8e93d374dd23|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc8cbc3d-026c-0db5-42e8-8e93d374dd23
cypermethrin	cypermethrin	alpha-cypermethrin	CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)c1cccc(Oc2ccccc2)c1	Launched	http://www.drugs.com/international/cypermethrin.html						
gemcitabine	gemcitabine	LY-188011|gemcitabine hydrochloride|gemzar	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1	Launched	FDA Orange Book: gemcitabine hydrochloride	TYMS|RRM1|RRM2|CMPK1	https://www.drugbank.ca/drugs/DB00441|https://www.drugbank.ca/drugs/DB00441|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4793|https://www.drugbank.ca/drugs/DB00441	ribonucleotide reductase inhibitor	oncology|oncology|oncology|oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)|pancreatic cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d16907e7-a8c8-4039-ace4-cf4e24ba68c0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d16907e7-a8c8-4039-ace4-cf4e24ba68c0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d16907e7-a8c8-4039-ace4-cf4e24ba68c0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d16907e7-a8c8-4039-ace4-cf4e24ba68c0
RS-100329	RS-100329		Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O	Preclinical		ADRA1D|ADRA1A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7381|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7381	adrenergic receptor antagonist			
CW-008	CW-008		COc1ccn2ncc(-c3nc4[nH]nc(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1	Preclinical		PRKACA	https://www.tocris.com/products/cw-008_5495	PKA activator			
KU-55933	KU-55933		O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1	Preclinical		ATM|PRKDC	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5928|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007250	ATM kinase inhibitor			
CGP-12177	CGP-12177	CGP12177	CC(C)(C)NCC(O)COc1cccc2[nH]c(O)nc12	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/24765617	ADRB3|ADRB2|ADRB1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=532|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=532|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=532	adrenergic receptor agonist			
lipoamide	lipoamide	thioctic acid amide	NC(=O)CCCCC1CCSS1	Preclinical							
imidafenacin	imidafenacin	KRP-197	Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1	Launched	https://www.drugs.com/international/imidafenacin.html	CHRM1|CHRM3	https://www.ncbi.nlm.nih.gov/pubmed/17396619|https://www.ncbi.nlm.nih.gov/pubmed/17396619	acetylcholine receptor antagonist	neurology/psychiatry|neurology/psychiatry	spasms|spasms	https://en.wikipedia.org/wiki/Imidafenacin|https://en.wikipedia.org/wiki/Imidafenacin
RS-56812	RS-56812		Cn1cc(C(=O)C(=O)N[C@H]2CN3CCC2CC3)c2ccccc12	Preclinical		HTR3A	http://www.tocris.com/dispprod.php?ItemId=2312#.UtgL-P15mf0	serotonin receptor partial agonist			
androstenone	androstenone		CC12CCC3C(CCC4CC(=O)CCC34C)C1CC=C2	Preclinical				steroid			
maropitant	maropitant		COc1ccc(cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1)C(C)(C)C	Launched	https://www.drugs.com/international/maropitant.html	TACR1	https://www.medchemexpress.com/Maropitant.html	neurokinin receptor antagonist	gastroenterology	vomiting	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6aeda328-97c9-4868-8ecb-b3a4dcdbc0a0
ribostamycin	ribostamycin	ribostamycin sulfate		Launched	https://www.drugs.com/international/ribostamycin.html			bacterial 30S ribosomal subunit inhibitor	infectious disease|infectious disease	human immunodeficiency virus (HIV-1)|human immunodeficiency virus (HIV-1)	https://en.wikipedia.org/wiki/Ribostamycin|https://en.wikipedia.org/wiki/Ribostamycin
cresol	cresol	4-Methylphenol|p-cresol|para-cresol	Cc1ccc(O)cc1	Launched	http://www.drugs.com/international/cresol.html						
NHI-2	NHI-2		COC(=O)c1cc2c(cc(cc2n1O)-c1ccccc1)C(F)(F)F	Preclinical		LDHA	https://www.tocris.com/products/nhi-2_5363	lactate dehydrogenase inhibitor			
PHA-665752	PHA-665752	TCMDC-125885	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1	Preclinical		MET	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5700	c-Met inhibitor			
ME-0328	ME-0328		C[C@H](NC(=O)CCc1nc2ccccc2c(=O)[nH]1)c1ccccc1	Preclinical		PARP3	https://www.tocris.com/products/me-0328_5054	PPAR receptor antagonist			
clobetasone-butyrate	clobetasone butyrate	GNF-Pf-1500	CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl	Launched	https://www.drugs.com/uk/eumovate-cream-spc-13606.html	NR3C1	http://www.druginfosys.com/Drug.aspx?drugCode=182&DrugName=Clobetasone%20(Butyrate)&type=1	corticosteroid agonist	dermatology|dermatology|dermatology	eczema|psoriasis|dermatitis	https://en.wikipedia.org/wiki/Clobetasone|https://en.wikipedia.org/wiki/Clobetasone|https://en.wikipedia.org/wiki/Clobetasone
methionine	methionine	dl-methionine|pedameth|racemethionine	CSCCC(N)C(O)=O	Launched	http://www.drugs.com/international/methionine.html	BHMT|METAP2|MTR|BHMT2|MTRR	https://www.drugbank.ca/drugs/DB00134|https://www.drugbank.ca/drugs/DB00134|https://www.drugbank.ca/drugs/DB00134|https://www.drugbank.ca/drugs/DB00134|https://www.drugbank.ca/drugs/DB00134				
UBP-302	UBP-302		N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O	Preclinical		GRIK1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4333	glutamate receptor antagonist			
fluconazole	fluconazole	Triflucan|UK-49,858|UK-49858|diflucan	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	Launched	FDA Orange Book: fluconazole	CYP3A7|CYP3A5|CYP51A1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=108008|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=108008|https://en.wikipedia.org/wiki/Fluconazole	sterol demethylase inhibitor	infectious disease|infectious disease	esophageal candidiasis|meningitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9843b969-33e1-4859-8eae-0055bb71d933|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9843b969-33e1-4859-8eae-0055bb71d933
UNC1999	UNC1999		CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C	Preclinical		EZH1|EZH2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=812236|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8237	histone lysine methyltransferase inhibitor			
raltegravir	raltegravir	MK-0518|isentress	Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C	Launched	FDA Orange Book: raltegravir potassium			HIV integrase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbd3e1af-81f3-44f6-8e45-652deab7a508
WZ-3146	WZ-3146		CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1	Preclinical		EGFR	http://www.selleckchem.com/products/WZ3146.html	EGFR inhibitor			
iodipamide	iodipamide	adipiodone|cholografin|cholografin meglumine|cholografin sodium	OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I	Launched	FDA Orange Book: iodipamide meglumine, iodipamide sodium	ALB	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001226	radiopaque medium	radiology	contrast agent	http://www.drugs.com/mmx/iodipamide-meglumine.html
tecastemizole	tecastemizole	R-43512|norastemizole (trivial name)	Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/11249577	HRH1|KCNH2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=209628|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001035	histamine receptor antagonist			
pleconaril	pleconaril	VP 63843|WIN 63843	Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/12802751						
cefetamet	cefetamet	cefetamet pivoxil hydrochloride	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(O)=O)c1csc(N)n1	Launched	http://www.drugs.com/international/cefetamet.html			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|otolaryngology|otolaryngology|pulmonary|infectious disease	ear infections|pneumonia|otitis|sinusitis|bronchitis|urinary tract infections	https://drug.mynahcare.com/drugs/genericdetail/cefetamet-NDE5|https://drug.mynahcare.com/drugs/genericdetail/cefetamet-NDE5|https://drug.mynahcare.com/drugs/genericdetail/cefetamet-NDE5|https://drug.mynahcare.com/drugs/genericdetail/cefetamet-NDE5|https://drug.mynahcare.com/drugs/genericdetail/cefetamet-NDE5|https://drug.mynahcare.com/drugs/genericdetail/cefetamet-NDE5
sorbitan-monostearate	sorbitan monostearate	SPAN 60|sorbitan monostearate|sorbitan stearate	CCCCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O	Preclinical							
taltirelin	taltirelin		CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O	Launched	http://www.drugs.com/international/taltirelin.html	TRHR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2143	thyrotropin releasing hormone receptor agonist	neurology/psychiatry	spinocerebellar ataxia	https://en.wikipedia.org/wiki/Taltirelin
isobutyramide	isobutyramide		CC(C)C(N)=O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/10772882	HBB|HBG1|HBE1	https://citeline.informa.com/?query=#/drugs/details/18951|http://www.sigmaaldrich.com/catalog/product/aldrich/144436?lang=en&region=US|http://www.sigmaaldrich.com/catalog/product/aldrich/144436?lang=en&region=US	gene expression stimulant			
SD-208	SD-208		Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1	Preclinical		TGFBR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8246	TGF beta receptor inhibitor			
RS-45041-190	RS-45041-190		Clc1cccc2CN(Cc12)C1=NCCN1	Preclinical				imidazoline receptor agonist			
preladenant	preladenant	MK-3814|SCH 420814|SCH-420814	COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01155479	ADORA1|ADORA3|ADORA2A|ADORA2B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5614|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5614|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5614|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5614	adenosine receptor antagonist			
4-P-PDOT	4-P-PDOT		CCC(=O)NC1CC(c2ccccc2)c2ccccc2C1	Preclinical		MTNR1A|MTNR1B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1358|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1358	melatonin receptor antagonist			
doxycycline	doxycycline	monodox|oracea|vibramycin	C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12	Launched	FDA Orange Book: doxycycline, doxycycline calcium, doxycycline hyclate	MMP8|MMP1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6464|https://citeline.informa.com/?query=#/drugs/details/5883	metalloproteinase inhibitor	dental	periodontitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c718fc7-2921-4d02-b273-784e513f8299
navarixin	navarixin	SCH-527123	CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00441701	CXCR2|CXCR1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000980|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000980	CC chemokine receptor antagonist			
diethylcarbamazine	diethylcarbamazine	hetrazan	CCN(CC)C(=O)N1CCN(C)CC1	Launched	FDA Orange Book: diethylcarbamazine citrate	ALOX5|PTGS1	https://www.drugbank.ca/drugs/DB00711|https://www.drugbank.ca/drugs/DB00711	lipoxygenase inhibitor	infectious disease	filariasis	https://en.wikipedia.org/wiki/Diethylcarbamazine
lidoflazine	lidoflazine	MCN-JR-7904|R 7904|angex|clinium	Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	Launched	http://www.drugs.com/international/Lidoflazine.html	SLC29A1|SCN1A|SCN3A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007571|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007571|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007571	calcium channel blocker			
N-oxydiethylenebenzothiazole-2-sulfenamide	N-oxydiethylenebenzothiazole-2-sulfenamide		C1CN(CCO1)Sc1nc2ccccc2s1	Preclinical							
palovarotene	palovarotene	CLM-001|R-667|R03300074|RG-667|RO3300074	CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02190747	RARG	https://en.wikipedia.org/wiki/Palovarotene	retinoid receptor agonist			
tocofersolan	tocofersolan			Launched	https://www.drugs.com/international/tocofersolan.html			antioxidant	cardiology	cerebral cholesterosis	https://en.wikipedia.org/wiki/Tocofersolan
SB-205384	SB-205384		CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N	Preclinical		GABRA3|GABRA6|GABRA5	http://www.tocris.com/dispprod.php?ItemId=28782#.UtgOwv15mf0|http://www.tocris.com/dispprod.php?ItemId=28782#.UtgOwv15mf0|http://www.tocris.com/dispprod.php?ItemId=28782#.UtgOwv15mf0	GABA receptor modulator			
avibactam	avibactam		NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O	Launched	FDA Orange Book: avibactam sodium			beta lactamase inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	intra-abdominal infections|urinary tract infections|pyelonephritis|intra-abdominal infections|urinary tract infections|pyelonephritis|intra-abdominal infections|urinary tract infections|pyelonephritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd
elvitegravir	elvitegravir	GS-9137|JTK-303|vitekta	COc1cc2n(cc(C(O)=O)c(=O)c2cc1Cc1cccc(Cl)c1F)[C@H](CO)C(C)C	Launched	FDA Orange Book: elvitegravir			HIV integrase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be87c3bc-97bb-49cb-8053-9b0c756a1965
triflupromazine	triflupromazine	Nivoman|Vetame|fluopromazine|vesprin	CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F	Launched	FDA Orange Book: triflupromazine, triflupromazine hydrochloride	HTR2B|CHRM2|CHRM1|DRD1|DRD2|CHRNA7	https://www.drugbank.ca/drugs/DB00508|https://www.drugbank.ca/drugs/DB00508|https://www.drugbank.ca/drugs/DB00508|https://www.drugbank.ca/drugs/DB00508|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091402	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|gastroenterology	psychosis|nausea|vomiting	http://www.drugbank.ca/drugs/DB00508|http://www.drugbank.ca/drugs/DB00508|http://www.drugbank.ca/drugs/DB00508
phenylmethylsulfonyl-fluoride	Phenylmethylsulfonyl Fluoride	Phenylmethylsulfonyl Fluoride|phenylmethylsulfonylfluoride	FS(=O)(=O)Cc1ccccc1	Preclinical				serine protease inhibitor			
cefixime	cefixime	CL 284,635|CL-284635|Cefspan|FK 027|FK-027|FR 17027|FR-17027|Oroken|suprax	Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O	Launched	FDA Orange Book: cefixime			bacterial cell wall synthesis inhibitor	infectious disease|otolaryngology|otolaryngology|otolaryngology|infectious disease|pulmonary	urinary tract infections|otitis|pharyngitis|tonsillitis|gonorrhea|bronchitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0fd45bd-7d52-4fa6-a5f7-f46d5651ffa2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0fd45bd-7d52-4fa6-a5f7-f46d5651ffa2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0fd45bd-7d52-4fa6-a5f7-f46d5651ffa2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0fd45bd-7d52-4fa6-a5f7-f46d5651ffa2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0fd45bd-7d52-4fa6-a5f7-f46d5651ffa2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0fd45bd-7d52-4fa6-a5f7-f46d5651ffa2
SPP-86	SPP-86		CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc12	Preclinical		RET	https://www.tocris.com/products/spp-86_5391	receptor tyrosine protein kinase inhibitor			
fenthion	fenthion	pro-spot|spotton|tiguvon	COP(=S)(OC)Oc1ccc(SC)c(C)c1	Launched	http://www.drugs.com/international/fenthion.html			cholinesterase inhibitor			
JQ1-(+)	(+)-JQ1		Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1	Preclinical				bromodomain inhibitor			
talopram	talopram		CNCCCC1(OC(C)(C)c2ccccc12)c1ccccc1	Phase 2	https://books.google.com/books?id=oL_BDAAAQBAJ&pg=PT420&lpg=PT420&dq=Talopram+clinical+trial+-citalopram&source=bl&ots=Gw21L0SWT7&sig=MofOTwS6gCbI0ypU3f9LKi14z_I&hl=en&sa=X&ved=0ahUKEwjDtMHEppHXAhUKEbwKHZUCD3YQ6AEIJjAA#v=onepage&q=Talopram%20clinical%20trial%20-citalopram&f=false	SLC6A2	https://www.tocris.com/products/talopram-hydrochloride_3145	adrenergic inhibitor			
gedunin	gedunin		CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](OC(=O)[C@H]4O[C@@]34[C@]12C)c1ccoc1	Preclinical		HSP90AA1	http://www.tocris.com/dispprod.php?ItemId=220954	HSP inhibitor			
MF-101	MF-101	(2S)-Liquiritigenin|4',7-Dihydroxyflavanone|7,4'-Dihydroxyflavanone|Liquiritigenin|Liquirtigenin	Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1	Phase 3	http://bionovo.com/static/press-releases/201110261638.html	ESR2|CYP19A1|XDH	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=321589|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008191|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008191	estrogen receptor agonist			
BIO-1211	BIO-1211		CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O	Phase 2	http://www.nature.com/leu/journal/v26/n1/fig_tab/leu2011197t4.html	ITGB1|ITGA4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6589|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6589	integrin antagonist			
gadoterate-meglumine	gadoterate-meglumine	DOTA|dotarem|tetraxetan	OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1	Launched	FDA Orange Book: gadoterate meglumine			radiopaque medium	radiology	MRI contrast agent	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2c4a5ac-2df2-4cf4-a2d3-6fbe2d898ebc
econazole	econazole	econazole nitrate|ecoza|spectazole	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1	Launched	FDA Orange Book: econazole nitrate	NPY2R|NPY1R|TRPM2|TRPV5|CYP51A1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011354|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011354|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2446|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2446|https://www.drugbank.ca/drugs/DB07705	lanosterol demethylase inhibitor|sterol demethylase inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	tinea pedis|tinea cruris|tinea corporis|tinea versicolor|cutaneous candidiasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0bb5206-3698-4a6b-9100-40bb86f1a0ca|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0bb5206-3698-4a6b-9100-40bb86f1a0ca|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0bb5206-3698-4a6b-9100-40bb86f1a0ca|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0bb5206-3698-4a6b-9100-40bb86f1a0ca|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0bb5206-3698-4a6b-9100-40bb86f1a0ca
amyleine	amyleine	amylocaine	CCC(C)(CN(C)C)OC(=O)c1ccccc1	Preclinical				local anesthetic			
azosemide	azosemide		NS(=O)(=O)c1cc(-c2nnn[nH]2)c(NCc2cccs2)cc1Cl	Launched	http://www.drugs.com/international/Azosemide.html	SLC12A1|SLC12A2	http://www.genome.jp/dbget-bin/www_bget?hsa:6558+D00247+D00313+D00331+D00382+D01323+D01634+D01895+D04079+D05093+D07999+D08001+D08619+D09772|http://www.genome.jp/dbget-bin/www_bget?hsa:6558+D00247+D00313+D00331+D00382+D01323+D01634+D01895+D04079+D05093+D07999+D08001+D08619+D09772	electrolyte reabsorption inhibitor	cardiology	edema	https://en.wikipedia.org/wiki/Azosemide
indium(iii)-isopropoxide	indium(iii)-isopropoxide		[In].CC(C)O.CC(C)O.CC(C)O	Preclinical							
4-carboxy-3-hydroxyphenylglycine-(S)	(S)-4-carboxy-3-hydroxyphenylglycine		N[C@H](C(O)=O)c1ccc(C(O)=O)c(O)c1	Preclinical		GRM1|GRM2	https://www.rndsystems.com/products/s-4-carboxy-3-hydroxyphenylglycine_0320|https://www.rndsystems.com/products/s-4-carboxy-3-hydroxyphenylglycine_0320	glutamate receptor agonist|glutamate receptor antagonist			
N6-cyclopentyladenosine	N6-cyclopentyladenosine	CCPA|Cyclopentyladenosine	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12	Preclinical		ADORA2A|ADORA2B|SLC29A1|ADORA3|ADORA1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=380|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=380|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003910|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=380|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=380	adenosine receptor agonist			
ergotamine	ergotamine	ergomar|medihaler ergotamine	CN1C[C@@H](C=C2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)C3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	Launched	FDA Orange Book: dihydroergotamine mesylate, ergotamine tartrate	HTR5A|HTR1A|HTR1B|HTR1E|HTR1F|HTR1D|HTR2B|HTR2C|HTR2A|HTR6|ADRA2B|ADRA2A|ADRA1D|ADRA1B|ADRA1A|SLC6A2|DRD1|DRD2|DRD5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=149|https://www.drugbank.ca/drugs/DB00696|https://www.drugbank.ca/drugs/DB00696|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=149|https://www.drugbank.ca/drugs/DB00696|https://www.drugbank.ca/drugs/DB00696|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=149|https://www.drugbank.ca/drugs/DB00696|https://www.drugbank.ca/drugs/DB00696|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=149|https://www.drugbank.ca/drugs/DB00696|https://www.drugbank.ca/drugs/DB00696|https://www.drugbank.ca/drugs/DB00696|https://www.drugbank.ca/drugs/DB00696|https://www.drugbank.ca/drugs/DB00696|https://www.drugbank.ca/drugs/DB00696|https://www.drugbank.ca/drugs/DB00696|https://www.drugbank.ca/drugs/DB00696|https://www.drugbank.ca/drugs/DB00696	adrenergic receptor antagonist	neurology/psychiatry	migraine headache	http://www.drugs.com/cdi/ergotamine.html
docebenone	docebenone	A-61589|AA-861	CC1=C(C)C(=O)C(CCCCC#CCCCC#CCO)=C(C)C1=O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/2111252	ALOX5	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000128	lipoxygenase inhibitor			
enoxacin	enoxacin	AT-2266|CI-919|Flumark|PD 107779|PD-107779|penetrex	CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1	Launched	FDA Orange Book: enoxacin	TOP2A	https://www.drugbank.ca/drugs/DB00467	topoisomerase inhibitor	infectious disease|infectious disease	urinary tract infections|gonorrhea	https://en.wikipedia.org/wiki/Enoxacin|https://en.wikipedia.org/wiki/Enoxacin
nilutamide	nilutamide	Anadron|RU 23908|RU-23908|nilandron	CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	Launched	FDA Orange Book: nilutamide	AR|CYP2C19	ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=100830	androgen receptor antagonist	oncology	prostate cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d2e5c32-3221-4605-955f-37c6bb61aef7
neurodazine	neurodazine		COc1ccc(cc1)-c1nc([nH]c1-c1ccc(OC)cc1)-c1ccc(o1)-c1cccc(Cl)c1	Preclinical				neurogenesis of non-pluripotent C2C12 myoblast inducer			
xylazine	xylazine		Cc1cccc(C)c1NC1=NCCCS1	Veterinary Launched	http://www.drugs.com/international/Xylazine.html	ADRA2B|ADRA2A|ADRA2C	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=523|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=523|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=523	adrenergic receptor agonist	neurology/psychiatry	anesthetic	https://en.wikipedia.org/wiki/Xylazine
lucitanib	lucitanib	AL-3810|CO-3810|E-3810|S 80881	CNC(=O)c1cccc2cc(ccc12)Oc1ccnc2cc(OCC3(N)CC3)c(OC)cc12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02053636	PDGFRB|PDGFRA|FGFR2|FGFR1|KDR|KIT|CSF1R|FLT1|FLT4|RET	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7649|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7649|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=679216|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7649|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7649|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7649|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=679216|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7649|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=679216|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7649	FGFR inhibitor|VEGFR inhibitor			
repsox	repsox	GW786460X	Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1	Preclinical		TGFBR1	https://www.tocris.com/dispprod.php?ItemId=242937#.Vyub9GQrJZJ	TGF beta receptor inhibitor			
KP-1212	KP-1212		NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/22738014						
anguidine	anguidine		CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/455316	SLC5A1	http://www.drug2gene.com/relation/SLC5A1-diacetoxyscirpenol-103694140	protein synthesis inhibitor			
PD-128907	PD-128907	PD128907		Preclinical		DRD2|DRD3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=952|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=952	dopamine receptor agonist			
crizotinib-(S)	(S)-crizotinib		C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl	Preclinical		NUDT1	http://www.apexbt.com/s-crizotinib.html	MTH1 inhibitor			
vindesine	vindesine	COMPOUND 112531	CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O	Launched	https://www.drugs.com/international/vindesine.html	TUBB1|TUBB	https://www.drugbank.ca/drugs/DB00309|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000949	tubulin polymerization inhibitor	oncology|oncology|oncology	breast cancer|non-small cell lung cancer (NSCLC)|melanoma	http://www.macmillan.org.uk/cancerinformation/cancertreatment/treatmenttypes/chemotherapy/individualdrugs/vindesine.aspx|http://www.macmillan.org.uk/cancerinformation/cancertreatment/treatmenttypes/chemotherapy/individualdrugs/vindesine.aspx|http://www.macmillan.org.uk/cancerinformation/cancertreatment/treatmenttypes/chemotherapy/individualdrugs/vindesine.aspx
galantamine	galantamine	galantamine hydrobromide|galanthamine|razadyne|razadyne er|reminyl	COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24	Launched	FDA Orange Book: galantamine hydrobromide	CHRNA6|CHRNA7|CHRNA9|CHRNA1|CHRNA2|CHRNA3|CHRNA4|CHRNA5|CHRNB1|CHRNB2|CHRNB3|CHRNB4|BCHE|ACHE|CHRNG|CHRND|CHRNE|CHRNA10	https://www.drugbank.ca/drugs/DB00674|https://www.drugbank.ca/drugs/DB00674|https://www.drugbank.ca/drugs/DB00674|https://www.drugbank.ca/drugs/DB00674|https://www.drugbank.ca/drugs/DB00674|https://www.drugbank.ca/drugs/DB00674|https://www.drugbank.ca/drugs/DB00674|https://www.drugbank.ca/drugs/DB00674|https://www.drugbank.ca/drugs/DB00674|https://www.drugbank.ca/drugs/DB00674|https://www.drugbank.ca/drugs/DB00674|https://www.drugbank.ca/drugs/DB00674|https://www.drugbank.ca/drugs/DB00674|https://www.drugbank.ca/drugs/DB00674|https://www.drugbank.ca/drugs/DB00674|https://www.drugbank.ca/drugs/DB00674|https://www.drugbank.ca/drugs/DB00674|https://www.drugbank.ca/drugs/DB00674	acetylcholinesterase inhibitor	neurology/psychiatry	senile dementia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bbdaf2f2-14e6-45c4-b807-5b22955444b0
ertapenem	ertapenem	invanz	C[C@@H](O)C1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)Nc3cccc(c3)C(O)=O)=C(N2C1=O)C(O)=O	Launched	FDA Orange Book: ertapenem sodium			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	intra-abdominal infections|skin infections|pneumonia|urinary tract infections|gynecologic infections|postpartum endomyometritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33f3b99b-fa82-42e0-26bf-f49891ae3d22|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33f3b99b-fa82-42e0-26bf-f49891ae3d22|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33f3b99b-fa82-42e0-26bf-f49891ae3d22|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33f3b99b-fa82-42e0-26bf-f49891ae3d22|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33f3b99b-fa82-42e0-26bf-f49891ae3d22|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33f3b99b-fa82-42e0-26bf-f49891ae3d22
LY2584702	LY2584702	LY-2584702	Cn1cc(nc1C1CCN(CC1)c1ncnc2[nH]ncc12)-c1ccc(F)c(c1)C(F)(F)F	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01115803	RPS6KB1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8248	ribosomal protein inhibitor			
tandospirone	tandospirone		O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1	Launched	http://www.drugs.com/international/tandospirone.html	HTR1A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=55	serotonin receptor agonist	neurology/psychiatry|neurology/psychiatry	generalized anxiety disorder (GAD)|dysthymic disorder	https://en.wikipedia.org/wiki/Tandospirone|https://en.wikipedia.org/wiki/Tandospirone
flunisolide	flunisolide	aerobid|aerospan hfa|nasalide|nasarel	CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)C=CC5(C)C4C(O)CC3(C)[C@@]2(O1)C(=O)CO	Launched	FDA Orange Book: flunisolide	NR3C1	https://www.drugbank.ca/drugs/DB00180	cytochrome P450 inhibitor	allergy	allergic rhinitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c72c954-3758-40c3-9977-d03b25d71e0a
GSK9027	GSK9027		Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F	Preclinical		NR3C1	https://www.tocris.com/products/gsk-9027_4116	glucocorticoid receptor agonist			
fluocinonide	fluocinonide	fluocinonide emulsified base|lidex|lidex-e|vanos	CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C	Launched	FDA Orange Book: fluocinonide	SMO|NR3C1|SERPINA6	https://www.drugbank.ca/drugs/DB01047|https://www.drugbank.ca/drugs/DB01047|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000421	glucocorticoid receptor agonist	dermatology|dermatology	seborrheic dermatitis|eczema	https://en.wikipedia.org/wiki/Fluocinonide|https://en.wikipedia.org/wiki/Fluocinonide
debrisoquin	debrisoquin	debrisoquine	NC(=N)N1CCc2ccccc2C1	Launched	http://www.drugbank.ca/drugs/DB04840	SLC6A2	https://www.drugbank.ca/drugs/DB04840	adrenergic neuron blocker	cardiology	hypertension	https://en.wikipedia.org/wiki/Debrisoquine
methyllycaconitine	methyllycaconitine		CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14	Preclinical		CHRNA7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4005	acetylcholine receptor antagonist			
olomoucine	olomoucine	Olomucine	Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12	Preclinical		MAPK1|CDK1|CDK2|CDK5	https://www.drugbank.ca/drugs/DB02116|https://www.drugbank.ca/drugs/DB02116|https://www.drugbank.ca/drugs/DB02116|https://www.drugbank.ca/drugs/DB02116	CDK inhibitor			
ethinyl-estradiol	ethinyl estradiol	Enovid|Enovid-E|Ethynylestradiol|Etinestryl|Follicoral|Ginestrene|Norinyl|Ovulen|Ovulen-21|Ovulen-28|estinyl|ethinyl estradiol|ethinylestradiol|ethinyloestradiol|feminone|lynoral|maxibolin	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C	Launched	FDA Orange Book: ethinyl estradiol	NR1I2|CYP2C8|ESR2|ESR1	https://www.drugbank.ca/drugs/DB00977|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=125559|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7071|ChEMBL	estrogen receptor agonist|estrogenic hormone	endocrinology	contraceptive	https://en.wikipedia.org/wiki/Ethinyl_estradiol
benzylpenicillin	benzylpenicillin	Bicillin|Penicillin G|Penicillin-2|Permapen|Pfizerpen-AS|pfizerpen	CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O	Launched	http://www.drugs.com/international/benzylpenicillin.html			penicillin binding protein inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	celluitis|meningitis|endocarditis|syphilis|pneumonia|bacterial septicemia	https://en.wikipedia.org/wiki/Benzylpenicillin|https://en.wikipedia.org/wiki/Benzylpenicillin|https://en.wikipedia.org/wiki/Benzylpenicillin|https://en.wikipedia.org/wiki/Benzylpenicillin|https://en.wikipedia.org/wiki/Benzylpenicillin|https://en.wikipedia.org/wiki/Benzylpenicillin
MJ-15	MJ-15		Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NCc1cccnc1	Preclinical		CNR1	https://www.tocris.com/products/mj-15_4063	cannabinoid receptor antagonist			
BMS-983970	BMS-983970		NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O	Phase 1	http://cancerres.aacrjournals.org/content/74/19_Supplement/1643			notch signaling inhibitor			
SR-57227A	SR-57227A		NC1CCN(CC1)c1cccc(Cl)n1	Phase 2	Pharmaprojects	HTR3A	http://www.tocris.com/dispprod.php?ItemId=1770#.UuFCDP30BaE	serotonin receptor agonist			
althiazide	althiazide	P-1779|altizide	NS(=O)(=O)c1cc2c(NC(CSCC=C)NS2(=O)=O)cc1Cl	Launched	http://www.drugs.com/international/althiazide.html			diuretic	cardiology	hypertension	http://www.drugs.com/international/althiazide.html
pantothenic-acid	pantothenic acid	Vitamin B 5|pantothenic acid	CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O	Launched	FDA Orange Book: pantothenic acid			coenzyme A precursor			
finasteride	finasteride	propecia|proscar	CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C	Launched	FDA Orange Book: finasteride	AR|SRD5A1|SRD5A2|AKR1D1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=145770|https://www.drugbank.ca/drugs/DB01216|https://www.drugbank.ca/drugs/DB01216|https://www.drugbank.ca/drugs/DB01216	5 alpha reductase inhibitor	endocrinology	androgenetic alopecia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=81b424d3-8418-4497-9395-59eae6755230
PD-407824	PD-407824	PD407824	Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1	Preclinical		WEE1	https://www.drugbank.ca/drugs/DB04608	PKC inhibitor			
alpha-methylserotonin	alpha-methylserotonin		CC(N)Cc1c[nH]c2ccc(O)cc12	Preclinical		HTR4|HTR1D|HTR1F|HTR1E|HTR2A|HTR2C|HTR2B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=152|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=152|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=152|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=152|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=152|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=152|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=152	serotonin receptor agonist			
L-lysine	L-lysine	lysine	NCCCC[C@H](N)C(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01220388	GPRC6A|KARS|SLC7A4|SLC7A3|SLC7A2|SLC7A1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=724|https://www.drugbank.ca/drugs/DB00123|https://www.drugbank.ca/drugs/DB00123|https://www.drugbank.ca/drugs/DB00123|https://www.drugbank.ca/drugs/DB00123|https://www.drugbank.ca/drugs/DB00123	serotonin receptor agonist			
prednisolone	prednisolone	delta-cortef|meti-derm|sterane	C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO	Launched	FDA Orange Book: fluprednisolone, methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, prednisolone, prednisolone acetate, prednisolone sodium phosphate, prednisolone tebutate	SERPINA6|NR3C1|NR3C2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000419|https://www.drugbank.ca/drugs/DB00860|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2866	glucocorticoid receptor agonist	ophthalmology|dermatology|ophthalmology|infectious disease|ophthalmology|ophthalmology	conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d6c3ea4-5189-4f6e-bb6a-c9379f441d7a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d6c3ea4-5189-4f6e-bb6a-c9379f441d7a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d6c3ea4-5189-4f6e-bb6a-c9379f441d7a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d6c3ea4-5189-4f6e-bb6a-c9379f441d7a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d6c3ea4-5189-4f6e-bb6a-c9379f441d7a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d6c3ea4-5189-4f6e-bb6a-c9379f441d7a
flibanserin	flibanserin	BIMT 17|BIMT 17 BS|addyi	FC(F)(F)c1cccc(c1)N1CCN(CCn2c3ccccc3[nH]c2=O)CC1	Launched	FDA Orange Book: flibanserin	HTR2A|HTR1A|DRD4	https://www.drugbank.ca/drugs/DB04908|https://www.drugbank.ca/drugs/DB04908|https://www.drugbank.ca/drugs/DB04908	serotonin receptor agonist	neurology/psychiatry	hypoactive sexual desire disorder	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394
CI-976	CI-976	CL-976	CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC	Phase 1	Pharmaprojects	ACAT1|SOAT1|CES1	http://www.tocris.com/dispprod.php?ItemId=127648|https://citeline.informa.com/?query=#/drugs/details/3656|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000429	ACAT inhibitor			
acexamic-acid	acexamic acid	CY 153|acetaminocaproic acid|acexamic acid	CC(=O)NCCCCCC(O)=O	Launched	http://www.drugs.com/international/acexamic-acid.html	GAST|SRD5A1	http://www.ncbi.nlm.nih.gov/pubmed/1974292|https://citeline.informa.com/?query=#/drugs/details/19704	5 alpha reductase inhibitor	dermatology	wound healing	http://www.drugs.com/international/acexamic-acid.html
osemozotan	osemozotan	MKC-242|MN-305	C(CNC[C@H]1COc2ccccc2O1)COc1ccc2OCOc2c1	Phase 2/Phase 3	http://www.prnewswire.com/news-releases/medicinova-announces-results-from-a-phase-iiiii-generalized-anxiety-disorder-trial-with-mn-305-56074312.html	HTR1A	https://www.drugbank.ca/drugs/DB05339	serotonin receptor agonist			
4-chlorophenylguanidine	4-chlorophenylguanidine	N-(4-Chlorophenyl)Guanidine	NC(=N)Nc1ccc(Cl)cc1	Preclinical		PLAUR	http://www.tocris.com/dispprod.php?ItemId=2170#.VeXyqyxVhHw	urokinase inhibitor			
JNJ-10191584	JNJ-10191584		CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1	Preclinical		HRH4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1277	histamine receptor antagonist			
amezinium	amezinium		COc1cc(N)cn[n+]1-c1ccccc1	Launched	https://www.drugs.com/international/amezinium-metilsulfate.html	ADRB2	https://en.wikipedia.org/wiki/Amezinium_metilsulfate	adrenergic receptor agonist			
YM-976	YM-976		CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1	Phase 1	http://adisinsight.springer.com/drugs/800010783	TNF|PDE4D|PDE4C|PDE4B|PDE4A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=252426|https://citeline.informa.com/?query=#/drugs/details/13823|https://citeline.informa.com/?query=#/drugs/details/13823|https://citeline.informa.com/?query=#/drugs/details/13823|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5292	phosphodiesterase inhibitor			
prednicarbate	prednicarbate	dermatop|dermatop e emollient	CCOC(=O)O[C@@]1(CCC2C3CCC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@]12C)C(=O)COC(=O)CC	Launched	FDA Orange Book: prednicarbate	PLA2G1B|NR3C1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001189|https://www.drugbank.ca/drugs/DB01130	phospholipase activator	dermatology|ophthalmology|neurology/psychiatry	eczema|contact dermatitis|itching	http://www.webmd.com/drugs/2/drug-5985-473/prednicarbate-topical/prednicarbatecream-topical/details|http://www.webmd.com/drugs/2/drug-5985-473/prednicarbate-topical/prednicarbatecream-topical/details|http://www.webmd.com/drugs/2/drug-5985-473/prednicarbate-topical/prednicarbatecream-topical/details
TA-01	TA-01		Fc1ccc(cc1)-c1nc([nH]c1-c1ccncc1)-c1c(F)cccc1F	Preclinical	https://clinicaltrials.gov/ct2/show/NCT00742716	CSNK1E|CSNK1D|MAPK14	http://www.mcchemicals.net/sale-8058047-cas-1784751-18-3-ta-01-ta01-ta-01.html|http://www.mcchemicals.net/sale-8058047-cas-1784751-18-3-ta-01-ta01-ta-01.html|http://www.mcchemicals.net/sale-8058047-cas-1784751-18-3-ta-01-ta01-ta-01.html	casein kinase inhibitor|MAP kinase inhibitor			
cabergoline	cabergoline	FCE 21336|FCE-21336|dostinex	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1	Launched	FDA Orange Book: cabergoline	PRL|DRD1|DRD2|DRD3|DRD4|DRD5|ADRB1|ADRB2|HTR1A|HTR1B|HTR1D|HTR2B|HTR2C|HTR2A|HTR7|ADRA2A|ADRA2B|ADRA2C|ADRA1D|ADRA1A|ADRA1B	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=115048|https://www.drugbank.ca/drugs/DB00248|ChEMBL|https://www.drugbank.ca/drugs/DB00248|https://www.drugbank.ca/drugs/DB00248|https://www.drugbank.ca/drugs/DB00248|https://www.drugbank.ca/drugs/DB00248|https://www.drugbank.ca/drugs/DB00248|https://www.drugbank.ca/drugs/DB00248|https://www.drugbank.ca/drugs/DB00248|https://www.drugbank.ca/drugs/DB00248|https://www.drugbank.ca/drugs/DB00248|https://www.drugbank.ca/drugs/DB00248|https://www.drugbank.ca/drugs/DB00248|https://www.drugbank.ca/drugs/DB00248|https://www.drugbank.ca/drugs/DB00248|https://www.drugbank.ca/drugs/DB00248|https://www.drugbank.ca/drugs/DB00248|https://www.drugbank.ca/drugs/DB00248|https://www.drugbank.ca/drugs/DB00248|https://www.drugbank.ca/drugs/DB00248	dopamine receptor agonist	endocrinology	hyperprolactinemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef345c23-20a8-40d4-bf3c-5650ed81e2f1
imatinib	imatinib	STI-571|gleevec	CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1	Launched	FDA Orange Book: imatinib mesylate	DDR1|CSF1R|ABCG2|BCR|CYP2C8|CYP3A5|PDGFRA|PDGFRB|CYP2C19|RET|ABL1|NTRK1|KIT	https://www.drugbank.ca/drugs/DB00619|https://www.drugbank.ca/drugs/DB00619|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=229058|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=229058|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=229058|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=229058|https://www.drugbank.ca/drugs/DB00619|https://www.drugbank.ca/drugs/DB00619|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=229058|https://www.drugbank.ca/drugs/DB00619|https://www.drugbank.ca/drugs/DB00619|https://www.drugbank.ca/drugs/DB00619|https://www.drugbank.ca/drugs/DB00619	Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy|hematologic malignancy|hematologic malignancy|hematologic malignancy|hematologic malignancy|hematologic malignancy|oncology|oncology	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)|myelodysplastic diseases (MDS)|aggressive systemic mastocytosis (ASM)|hypereosinophilic syndrome (HES)|chronic eosinophilic leukemia (CEL)|dermatofibrosarcoma protuberans (DFSP)|gastrointestinal stromal tumors (GIST)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b
somantadine	somantadine		CC(C)(N)CC12CC3CC(CC(C3)C1)C2	Phase 1	http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.932.3771&rep=rep1&type=pdf			antiviral			
lobendazole	lobendazole	SK&F 24529	CCOC(=O)Nc1nc2ccccc2[nH]1	Preclinical				anthelmintic agent			
G-1	G-1		CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br	Preclinical		GPER1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1014	G protein-coupled receptor agonist			
pirarubicin	pirarubicin		COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	Launched	http://www.drugs.com/international/Pirarubicin.html	TOP2A	http://en.wikipedia.org/wiki/Anthracycline	topoisomerase inhibitor	oncology	breast cancer	http://www.mims.com/India/drug/info/pirarubicin?type=full&mtype=generic
salubrinal	salubrinal		ClC(Cl)(Cl)C(NC(=O)\C=C\c1ccccc1)NC(=S)Nc1cccc2cccnc12	Preclinical		EIF2S1|SLC6A9	http://www.sigmaaldrich.com/catalog/product/sigma/sml0951?lang=en&region=US|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=319312	eukaryotic translation initiation factor inhibitor			
oxiperomide	oxiperomide	R 4714	Oc1nc2ccccc2n1C1CCN(CCOc2ccccc2)CC1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/7373324			dopamine receptor antagonist			
letermovir	letermovir		COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@H](CC(O)=O)N1c1cc(ccc1OC)C(F)(F)F	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02137772			CMV terminase inhibitor			
CP-376395	CP-376395		CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C	Phase 1	http://pubs.acs.org/doi/abs/10.1021/jm070579c	CRHR1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013525	corticosteroid releasing factor receptor antagonist			
OTX015	OTX015		Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT02296476	BRD4|BRD3|BRD2|SELE|VCAM1	https://www.caymanchem.com/product/15947|https://www.caymanchem.com/product/15947|https://www.caymanchem.com/product/15947|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=260008|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=260008	bromodomain inhibitor			
methylatropine-nitrate	methylatropine-nitrate	Methylatropine	C[N+]1(C)C2CCC1CC(C2)OC(=O)C(CO)c1ccccc1	Preclinical		CHRM1	http://www.sigmaaldrich.com/catalog/product/sigma/a0382?lang=en&region=US	acetylcholine receptor antagonist			
pirfenidone	pirfenidone	AMR-69|esbriet	Cc1ccc(=O)n(c1)-c1ccccc1	Launched	FDA Orange Book: pirfenidone	TNFRSF1A|FURIN|TNF|MAPK14	https://citeline.informa.com/?query=#/drugs/details/14499|https://www.drugbank.ca/drugs/DB04951|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000932|https://citeline.informa.com/?query=#/drugs/details/14499	TGF beta receptor inhibitor	pulmonary	idiopathic pulmonary fibrosis (IPF)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e8c3537-36d7-4de5-9b5c-7a624b9a9e6e
limaprost-alfadex	limaprost-alfadex	limaprost|limaprost alpha-cyclodextrin clathrate	CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O	Launched	http://www.drugs.com/international/limaprost-alfadex.html	PTGER1	http://www.drugbank.ca/drugs/DB09211	prostanoid receptor agonist	cardiology	claudication	http://www.drugbank.ca/drugs/DB09211
gimeracil	gimeracil		Oc1cc(=O)[nH]cc1Cl	Launched	http://adisinsight.springer.com/drugs/800004477	DPYD	http://www.abcam.com/gimeracil-ab143274.html	dihydropyrimidine dehydrogenase inhibitor	oncology	gastric adenocarcinoma	https://en.wikipedia.org/wiki/Tegafur/gimeracil/oteracil
AZD3514	AZD3514	CS-1443	CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01162395	AR	http://www.selleckchem.com/products/azd3514.html	androgen receptor modulator			
tandutinib	tandutinib	CT 53518|CT-53518|MLN-0518|MLN-518	COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00408902	PDGFRA|PDGFRB|PDGFD|CSF1R|FLT3|KIT	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=312325|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5695|https://www.drugbank.ca/drugs/DB05465|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5695|https://www.drugbank.ca/drugs/DB05465|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5695	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor			
PD-173212	PD-173212		CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C	Preclinical		CACNA1B	https://www.tocris.com/products/pd-173212_3552	calcium channel blocker			
5-FP	5-FP		Oc1ncc(F)cn1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/12003195	TYMS	https://en.wikipedia.org/wiki/Fluorouracil	thymidylate synthase inhibitor			
fluroxene	fluroxene	fluoromar	FC(F)(F)COC=C	Preclinical				local anesthetic			
SCH-28080	SCH-28080		Cc1nc2c(OCc3ccccc3)cccn2c1CC#N	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/7104515	ATP4A	https://www.biomol.com/product_SCH-28080.html?aRelated=Cay17885	ATPase inhibitor			
TEPP-46	TEPP-46		Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)S(C)=O	Preclinical		PKM	http://www.emdmillipore.com/US/en/product/PKM2-Activator-IV%2C-TEPP-46---Calbiochem,EMD_BIO-505487?ReferrerURL=https://www.google.com/	pyruvate kinase isozyme activator			
6-benzylaminopurine	6-benzylaminopurine	Benzyl Aminopurine	N(Cc1ccccc1)c1ncnc2nc[nH]c12	Preclinical				purinergic receptor activator			
tabimorelin	tabimorelin	NN703	CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/12699438	GHRHR|GHSR|GH1	https://citeline.informa.com/?query=#/drugs/details/12568|https://www.tocris.com/dispprod.php?ItemId=139029#.Vyyx82QrJZI|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=254091	growth hormone secretagogue receptor agonist			
gliclazide	gliclazide	SE 1702	Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1	Launched	http://www.drugs.com/international/Gliclazide.html	VEGFA|KCNJ11|ABCC8	https://www.drugbank.ca/drugs/DB01120|https://citeline.informa.com/?query=#/drugs/details/7959|https://www.drugbank.ca/drugs/DB01120	ATP channel blocker|insulin secretagogue	endocrinology	diabetes mellitus	https://en.wikipedia.org/wiki/Gliclazide
piconol	piconol		OCc1ccccn1	Preclinical							
thiothixene	thiothixene	navane	CN(C)S(=O)(=O)c1ccc2Sc3ccccc3\C(=C/CCN3CCN(C)CC3)c2c1	Launched	FDA Orange Book: thiothixene, thiothixene hydrochloride	DRD2|DRD1|HTR2A|HRH1	https://www.drugbank.ca/drugs/DB01623|https://www.drugbank.ca/drugs/DB01623|https://www.drugbank.ca/drugs/DB01623|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=212	dopamine receptor antagonist	neurology/psychiatry	schizophrenia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13d90931-e9d8-25f3-a045-608d0404cd7a&audience=consumer
pinocembrin	pinocembrin	(2S)-Pinocembrin|NSC-43318	Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02059785	AR|CYP1B1|SRD5A1|SRD5A2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=136700|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011119|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=136700|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=136700	cytochrome P450 inhibitor			
dehydrocholate	dehydrocholate		C[C@H](CCC(O)=O)[C@H]1CCC2C3C(CC(=O)[C@]12C)[C@@]1(C)CCC(=O)CC1CC3=O	Preclinical							
cefepime	cefepime	maxipime	CO\N=C(\C(=O)NC1C2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)c1csc(N)n1	Launched	FDA Orange Book: cefepime hydrochloride			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease|infectious disease	pneumonia|urinary tract infections|skin infections|intra-abdominal infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a02a3bfc-8e79-4e59-953e-361f92a3b3f1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a02a3bfc-8e79-4e59-953e-361f92a3b3f1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a02a3bfc-8e79-4e59-953e-361f92a3b3f1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a02a3bfc-8e79-4e59-953e-361f92a3b3f1
cyclobenzaprine	cyclobenzaprine	amrix|cyclobenzaprine hydrochloride|flexeril	CN(C)CCC=C1c2ccccc2C=Cc2ccccc12	Launched	FDA Orange Book: cyclobenzaprine hydrochloride	HTR2A	https://www.drugbank.ca/drugs/DB00924	adrenergic receptor agonist|serotonin receptor agonist	neurology/psychiatry	spasms	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=229f6824-0d00-411c-9220-4510ba85163d
chicago-sky-blue-6b	chicago-sky-blue-6b	Chicago Sky Blue	COc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1	Preclinical		MIF	http://www.scbt.com/datasheet-361146.html	glutamate inhibitor|macrophage migration inhibiting factor inhibitor			
AMZ30	AMZ30		[O-][N+](=O)c1cccc(c1)S(=O)(=O)n1cccc1\C=C(/C#N)S(=O)(=O)c1ccc(F)cc1	Preclinical				protein phosphatase inhibitor			
zotarolimus	zotarolimus		CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1	Launched	https://clinicaltrials.gov/ct2/show/NCT00611286	FKBP1A|MTOR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7974|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=275709	mTOR inhibitor	cardiology	coronary artery restenosis	https://en.wikipedia.org/wiki/Zotarolimus
PF-05190457	PF-05190457		Cc1cn2cc(CC(=O)N3CCC4(CN(C4)[C@@H]4CCc5cc(ccc45)-c4cc(C)ncn4)CC3)nc2s1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02707055	GHSR	http://www.sigmaaldrich.com/catalog/product/sigma/pz0270?lang=en&region=US	growth hormone secretagogue receptor inverse agonist			
acetazolamide	acetazolamide	acetazolamide sodium|diamox	CC(=O)Nc1nnc(s1)S(N)(=O)=O	Launched	FDA Orange Book: acetazolamide, acetazolamide sodium	CA1|CA2|CA3|CA4|CA6|CA7|CA14|CA13|CA12|AQP1	ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00819|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091457|https://www.drugbank.ca/drugs/DB00819|https://www.drugbank.ca/drugs/DB00819|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091457|ChEMBL|https://www.drugbank.ca/drugs/DB00819	carbonic anhydrase inhibitor	ophthalmology	glaucoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df0f2293-3a46-4eda-ad28-6e713bb6c3a3
pentagastrin	pentagastrin	AY-6608|ICI 50,123|ICI-50123|peptavlon	CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	Launched	FDA Orange Book: pentagastrin	CCKBR	https://www.drugbank.ca/drugs/DB00183	CCK receptor agonist	gastroenterology|gastroenterology|gastroenterology|gastroenterology	anacidity diagnostic|gastric hypersecretion diagnostic|anacidity diagnostic|gastric hypersecretion diagnostic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abc92ef1-f9c3-4eac-a273-9b8705b36c29|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abc92ef1-f9c3-4eac-a273-9b8705b36c29|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abc92ef1-f9c3-4eac-a273-9b8705b36c29|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abc92ef1-f9c3-4eac-a273-9b8705b36c29
uridine	uridine	vistogard|xuriden	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00812058	TYMP|LSM6	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001491|https://www.drugbank.ca/drugs/DB02745	dopamine receptor agonist			
bopindolol	bopindolol	bopindolol malonate	Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1	Launched	http://www.drugbank.ca/drugs/db08807	ADRB1|ADRB3|ADRB2|HTR1B|HTR1A	https://www.drugbank.ca/drugs/DB08807|https://www.drugbank.ca/drugs/DB08807|https://www.drugbank.ca/drugs/DB08807|https://www.drugbank.ca/drugs/DB08807|https://www.drugbank.ca/drugs/DB08807	adrenergic receptor antagonist	cardiology|cardiology	hypertension|coronary artery disease (CAD)	http://www.drugs.com/international/bopindolol.html|http://www.drugs.com/international/bopindolol.html
tucatinib	tucatinib		Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02614794	ERBB2	https://www.medchemexpress.com/Irbinitinib.html	EGFR inhibitor			
terfenadine	terfenadine	RMI 9918|Teldane|Triludan|seldane	CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	KCNH2|KCNH1|HRH1|CHRM1|CHRM3|CHRM2|CHRM5|CHRM4	https://www.drugbank.ca/drugs/DB00342|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2608|https://www.drugbank.ca/drugs/DB00342|https://www.drugbank.ca/drugs/DB00342|https://www.drugbank.ca/drugs/DB00342|https://www.drugbank.ca/drugs/DB00342|https://www.drugbank.ca/drugs/DB00342|https://www.drugbank.ca/drugs/DB00342	histamine receptor antagonist			
chloroxoquinoline	chloroxoquinoline		Oc1ccnc2cc(Cl)ccc12	Launched	Cortellis						
CGP-54626	CGP-54626	CGP54626	C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1	Preclinical		KCTD12|KCTD16|KCTD8|GABBR2|GABBR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1070|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1070|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1070|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1070|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1070	GABA receptor antagonist			
PF-04620110	PF-04620110		Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00799006	DGAT1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7829	diacylglycerol O acyltransferase inhibitor			
AVN-944	AVN-944		CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00493441	IMPDH2|IMPDH1	http://www.drugbank.ca/drugs/DB05500|http://www.drugbank.ca/drugs/DB05500	inosine monophosphate dehydrogenase inhibitor			
metaraminol	metaraminol	aramine|metaraminol bitartrate	C[C@H](N)[C@H](O)c1cccc(O)c1	Launched	FDA Orange Book: metaraminol bitartrate	ADRA1A	https://www.drugbank.ca/drugs/DB00610	adrenergic receptor agonist	cardiology	hypotension	https://en.wikipedia.org/wiki/Metaraminol
delivert	delivert		CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O	Launched	http://www.drugs.com/international/Delivert.html	AGTR2|AGTR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2504|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2504	angiotensin receptor agonist			
amibegron	amibegron	SR58611	CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00825058	ADRB3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=568	adrenergic receptor agonist			
butaclamol	butaclamol	(+)-Butaclamol	CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc([C@H]2C1)c34	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/355181	HTR2A|HTR1A|DRD1|DRD2|DRD3|DRD4|DRD5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=62|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=62|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=62|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=62|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=62|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=62|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=62	dopamine receptor antagonist			
pamabrom	pamabrom		CC(C)(N)CO.Cn1c2nc(Br)[nH]c2c(=O)n(C)c1=O	Launched	http://www.drugs.com/international/pamabrom.html			diuretic	gastroenterology	bloating	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab10451e-ff87-4974-bec4-7ba19c5bbe65
ethoxzolamide	ethoxzolamide	cardrase|ethamide	CCOc1ccc2nc(sc2c1)S(N)(=O)=O	Launched	FDA Orange Book: ethoxzolamide	CA5A|CA5B|CA13|CA14|CA12|CA7|CA6|CA9|CA1|CA3|CA2|CA4	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	carbonic anhydrase inhibitor	ophthalmology|gastroenterology	glaucoma|duodenal ulcer disease	https://en.wikipedia.org/wiki/Ethoxzolamide|https://en.wikipedia.org/wiki/Ethoxzolamide
AZD6738	AZD6738		C[C@@H]1COCCN1c1cc(nc(n1)-c1ccnc2[nH]ccc12)C1(CC1)S(C)(=N)=O	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT02264678	ATR	http://www.selleckchem.com/products/AZD6738.html?gclid=COi1q4eaotICFci1wAodCnIKiQ	ATR kinase inhibitor			
WYE-687	WYE-687		COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(Cc4cccnc4)CC3)c2n1	Preclinical		MTOR	https://www.tocris.com/search?keywords=WYE-687	mTOR inhibitor			
milacemide	milacemide		CCCCCNCC(N)=O	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/8512628	MAOB	https://en.wikipedia.org/wiki/Milacemide	monoamine oxidase inhibitor			
VU-152100	VU-152100		COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1	Preclinical		CHRM4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3263	acetylcholine receptor allosteric modulator			
salicylic-acid	salicylic acid	2-HYDROXY-BENZOIC ACID|advanced pain relief callus removers|advanced pain relief com removers|clear away wart remover|compound w|dr. scholl's callus removers|dr. scholl's corn removers|dr. scholl's wart remover kit|duofilm wart remover|duoplant|freezone|ionil|ionil-plus|parasal|paser|rezipas|salicylic acid|salicylic acid soap|saligel|stri-dex	OC(=O)c1ccccc1O	Launched	FDA Orange Book: aminosalicylic acid, aminosalicylic acid resin complex	PTGS2|PTGS1|AKR1C1	https://www.drugbank.ca/drugs/DB00936|https://www.drugbank.ca/drugs/DB00936|https://www.drugbank.ca/drugs/DB00936	cyclooxygenase inhibitor	dermatology	acne vulgaris (AV)	https://en.wikipedia.org/wiki/Salicylic_acid
picrotoxinin	picrotoxinin		CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C	Preclinical		HTR3A|HTR3B|GLRA3|GLRA1|GLRA2|GLRB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2291|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2291|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2291|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2291|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2291|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2291	GABA receptor antagonist			
PK-THPP	PK-THPP		CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1	Preclinical		KCNK9|KCNK3	https://www.tocris.com/products/pk-thpp_5338|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=762051	potassium channel blocker			
CIQ	CIQ		COc1ccc(OCC2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1	Preclinical		GRIN2D|GRIN2C	https://www.tocris.com/products/ciq_4105|https://www.tocris.com/products/ciq_4105	glutamate receptor potentiator			
A-582941	A-582941		CN1C[C@H]2CN(C[C@H]2C1)c1ccc(nn1)-c1ccccc1	Preclinical		CHRNA7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3995	nicotinic receptor agonist			
suloctidil	suloctidil		CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1	Withdrawn	http://www.fda.gov.ph/issuances-2/pharml-1/155165-administrative-order-no-130-s-1985			adrenergic receptor antagonist			
tavaborole	tavaborole	AN2690|kerydin	OB1OCc2cc(F)ccc12	Launched	FDA Orange Book: tavaborole			leucyl-tRNA synthetase inhibitor	infectious disease	onychomycosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6ba6f49-0055-4285-9e04-67001d4554fd&audience=consumer
valethamate	valethamate		CCC(C)C(C(=O)OCC[N+](C)(CC)CC)c1ccccc1	Launched	https://www.drugs.com/international/valethamate.html	CHRM5|CHRM4|CHRM1	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2107687|https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2107687|https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2107687	acetylcholine receptor antagonist	obstetrics/gynecology	labor induction	https://www.researchgate.net/publication/11802298_Drotaverine_hydrochloride_vs_valethamate_bromide_in_acceleration_of_labor
ziprasidone	ziprasidone	CP-88059|geodon	Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12	Launched	FDA Orange Book: ziprasidone hydrochloride, ziprasidone mesylate	DRD2|DRD1|DRD4|DRD3|DRD5|CHRM2|CHRM1|CHRM5|CHRM4|CHRM3|HTR3A|HTR1A|HTR1E|HTR1D|HTR1B|HTR2A|HTR2C|HTR7|HTR6|HRH1|ADRA1A|ADRA1B|ADRA2B|ADRA2A|ADRA2C|SLC6A4	https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|https://www.drugbank.ca/drugs/DB00246|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=59	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry|neurology/psychiatry	schizophrenia|bipolar disorder	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=315e24c2-2f8c-47d9-b1b1-ce006646098a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=315e24c2-2f8c-47d9-b1b1-ce006646098a
triapine	triapine		NC(=S)N\N=C\c1ncccc1N	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00941070	RRM1|RRM2	http://www.apexbt.com/triapine.html?gclid=CPSegdvqxcwCFQNkhgodakMPKQ|http://www.apexbt.com/triapine.html?gclid=CPSegdvqxcwCFQNkhgodakMPKQ	ribonucleotide reductase inhibitor			
etosalamide	etosalamide	ethosalamide	CCOCCOc1ccccc1C(N)=O	Preclinical				anti-inflammatory agent			
A-769662	A-769662		Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12	Preclinical				AMPK activator			
danirixin	danirixin	GSK1325756|GSK1325756B	Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02130193	CXCR2	https://www.medchemexpress.com/Danirixin.html	CC chemokine receptor antagonist			
TAK-901	TAK-901		CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00807677	AURKB|AURKA	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000657|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=475864	Aurora kinase inhibitor			
pyrvinium	pyrvinium		CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1.CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1	Launched	FDA Orange Book: pyrvinium pamoate	AR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=353190	androgen receptor antagonist			
genz-644282	genz-644282		CNCCn1c2c(cnc3cc4OCOc4cc23)c2cc(OC)c(OC)cc2c1=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00942799	TOP1	http://clincancerres.aacrjournals.org/content/17/9/2777.full.pdf	topoisomerase inhibitor			
SB-399885	SB-399885		COc1ccc(cc1N1CCNCC1)S(=O)(=O)Nc1cc(Cl)cc(Cl)c1OC	Preclinical		HTR6	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3241	serotonin receptor antagonist			
dazoxiben	dazoxiben	UK-37248	OC(=O)c1ccc(OCCn2ccnc2)cc1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/6540986	TBXAS1	https://www.drugbank.ca/drugs/DB03052	thromboxane synthase inhibitor			
WAY-629	WAY-629		C1CCc2c(C1)n1CCNCc3cccc2c13	Preclinical		HTR2C	https://www.tocris.com/dispprod.php?ItemId=114872#.VyzMTmQrJZI	serotonin receptor agonist			
benzoic-acid	benzoic acid	Benzoate|E210|benzoic acid	OC(=O)c1ccccc1	Launched	http://en.wikipedia.org/wiki/Benzoic_acid#Medicinal	HRSP12|PRDX5|RAB9A|DAO	https://www.drugbank.ca/drugs/DB03793|https://www.drugbank.ca/drugs/DB03793|https://www.drugbank.ca/drugs/DB03793|https://www.drugbank.ca/drugs/DB03793	food preservative	infectious disease	tinea pedis	https://en.wikipedia.org/wiki/Whitfield%27s_ointment
ditolylguanidine	ditolylguanidine	Di-o-tolylguanidine	Cc1ccccc1NC(=N)Nc1ccccc1C	Preclinical		GRIN1|GRIN2B|GRIN2A|SIGMAR1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003974|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003974|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003974|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003974	sigma receptor agonist			
telcagepant	telcagepant	MK-0974	Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00443209	CALCA|RAMP1|CALCRL	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=387102|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=703|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=703	calcitonin antagonist			
amygdalin	amygdalin		OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/7033783	CASP3	http://www.ncbi.nlm.nih.gov/pubmed/16880611	caspase activator			
FK-866	FK-866	APO-866	O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00432107	NAMPT|PARP1	https://www.caymanchem.com/app/template/Product.vm/catalog/13287|https://citeline.informa.com/?query=#/drugs/details/28361	niacinamide phosphoribosyltransferase inhibitor			
4-methylgenistein	4-methylgenistein	NSC-123538|biochanin	COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O	Preclinical		SRD5A2|SRD5A1|ESRRB|ESRRA|ESRRG|FASN|CYP19A1|PPARG|PPARA|AR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=201943|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=201943|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2829|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2829|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2829|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005194|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005194|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=201943|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=201943|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=201943	protein tyrosine kinase inhibitor			
metipranolol	metipranolol	BM-01004|BM01.004|VUAB-6453|VUAB6453 (SPOFA)|optipranolol	CC(C)NCC(O)COc1cc(C)c(OC(C)=O)c(C)c1C	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	ADRB2|ADRB1	https://www.drugbank.ca/drugs/DB01214|https://www.drugbank.ca/drugs/DB01214	adrenergic receptor antagonist			
CH55	CH55		CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O	Preclinical		RARB|RARA	http://www.scbt.com/datasheet-203884-ch-55.html|http://www.scbt.com/datasheet-203884-ch-55.html	retinoid receptor binder			
3-anilinopropan-1-ol	3-anilinopropan-1-ol		OCCCNc1ccccc1	Preclinical							
dichloroacetate	dichloroacetate		[Na].OC(=O)C(Cl)Cl	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00004490	PDK1	https://www.drugbank.ca/drugs/DB08809	pyruvate dehydrogenase kinase inhibitor			
anabasine	anabasine	1,2,3,4,5,6-Hexahydro-[2,3']Bipyridinyl|dl-anabasine	C1CCC(NC1)c1cccnc1	Preclinical				acetylcholine receptor agonist			
1-octacosanol	1-octacosanol	Octacosan-1-ol	CCCCCCCCCCCCCCCCCCCCCCCCCCCCO	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/3528918						
SR-95639A	SR-95639A		C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1	Preclinical		CHRM1	http://onlinelibrary.wiley.com/doi/10.1002/ddr.430240109/abstract	acetylcholine receptor agonist			
hyaluronic-acid	hyaluronic acid	hyaluronate	CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1C(O)=O	Launched	https://www.drugs.com/cdi/euflexxa.html	HAPLN1|HAPLN3|HAPLN4|HMMR|ICAM1|C1QBP|HABP2|VCAN|CD44|NCAN	https://www.drugbank.ca/drugs/DB08818|https://www.drugbank.ca/drugs/DB08818|https://www.drugbank.ca/drugs/DB08818|https://www.drugbank.ca/drugs/DB08818|https://www.drugbank.ca/drugs/DB08818|https://www.drugbank.ca/drugs/DB08818|https://www.drugbank.ca/drugs/DB08818|https://www.drugbank.ca/drugs/DB08818|https://www.drugbank.ca/drugs/DB08818|https://www.drugbank.ca/drugs/DB08818		rheumatology|urology	osteoarthritis|interstitial cystitis (IC)	https://www.drugbank.ca/drugs/DB08818#BE0001113|https://www.drugbank.ca/drugs/DB08818#BE0001113
dichlorvos	dichlorvos	Aquagard|DDVP|Herkol|SD 1750|Task|atgard|equigard|equigel|task tabs	COP(=O)(OC)OC=C(Cl)Cl	Launched	http://www.drugs.com/international/dichlorvos.html			acetylcholinesterase inhibitor			
GSK256066	GSK256066	GSK-256066	COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00380354	PDE4C|PDE4B|PDE4D|PDE4A	https://citeline.informa.com/?query=#/drugs/details/35777|https://citeline.informa.com/?query=#/drugs/details/35777|https://citeline.informa.com/?query=#/drugs/details/35777|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000375	phosphodiesterase inhibitor			
APD597	APD597		COc1c(Nc2ccc(nc2C)S(C)(=O)=O)ncnc1OC1CCN(CC1)C(=O)OC(C)C	Phase 1	http://invest.arenapharm.com/releasedetail.cfm?releaseid=527328	GPR119	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5727	glucose dependent insulinotropic receptor agonist			
gallamine-triethiodide	gallamine-triethiodide	flaxedil|gallamine	CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC	Launched	FDA Orange Book: gallamine triethiodide	CHRNA2|CHRNA1|ACHE|CHRM2	https://www.drugbank.ca/drugs/DB00483|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=356|https://www.drugbank.ca/drugs/DB00483|https://www.drugbank.ca/drugs/DB00483	acetylcholine receptor antagonist	neurology/psychiatry	muscle relaxant	https://en.wikipedia.org/wiki/Gallamine_triethiodide
pivmecillinam	pivmecillinam	RO 10-9071|amdinocillin pivoxil|coactabs|pivmecillinam hydrochloride	CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O	Launched	http://www.drugs.com/international/Pivmecillinam.html			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease	urinary tract infections|gram-negative bacterial infections	https://en.wikipedia.org/wiki/Pivmecillinam|https://en.wikipedia.org/wiki/Pivmecillinam
peramivir	peramivir	BCX-1812|rapivab	CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O	Launched	FDA Orange Book: peramivir			neuraminidase inhibitor	infectious disease	influenza A virus infection	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fdedaec-9e53-4a37-a4e4-a301c8a251b8
danusertib	danusertib	PHA-739358	CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00335868	BCR|NTRK1|SLK|RET|FGFR1|AURKB|AURKA|AURKC	https://citeline.informa.com/?query=#/drugs/details/36961|http://www.selleckchem.com/products/PHA-739358%28Danusertib%29.html|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7937|http://www.selleckchem.com/products/PHA-739358%28Danusertib%29.html|http://www.selleckchem.com/products/PHA-739358%28Danusertib%29.html|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7937|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7937|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7937	Aurora kinase inhibitor|growth factor receptor inhibitor			
pentobarbital	pentobarbital	mebubarbital|mebumal|nembutal|nembutal sodium|pentobarbital calcium	CCCC(C)C1(CC)C(=O)NC(=O)NC1=O	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	GRIN1|GRIK2|GRIA2|CHRNA4|CHRNA7|GABRG3|GABRG1|GABRG2|GABRB2|GABRB3|GABRB1|GABRA5|GABRA6|GABRA3|GABRA4|GABRA1|GABRA2|GABRD|GABRE|GABRP|GABRQ|GRIN3B|GRIN3A|GRIN2C|GRIN2B|GRIN2D|GRIN2A	https://www.drugbank.ca/drugs/DB00312|https://www.drugbank.ca/drugs/DB00312|https://www.drugbank.ca/drugs/DB00312|https://www.drugbank.ca/drugs/DB00312|https://www.drugbank.ca/drugs/DB00312|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00312|https://www.drugbank.ca/drugs/DB00312|https://www.drugbank.ca/drugs/DB00312|https://www.drugbank.ca/drugs/DB00312|https://www.drugbank.ca/drugs/DB00312|https://www.drugbank.ca/drugs/DB00312	barbiturate antiepileptic|GABA receptor modulator			
palifosfamide	palifosfamide	Isophosphamide mustard|N,N'-Bis-(2-Chloroethyl)Phosphoric Acid|ZIO-201		Phase 3	https://clinicaltrials.gov/ct2/show/NCT01168791			DNA alkylating agent			
MGCD-265	MGCD-265		Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1	Preclinical		KDR|MET|AXL	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=434522|http://www.mirati.com/programs/mgcd265/|http://www.mirati.com/programs/mgcd265/	VEGFR inhibitor			
TBOA-(DL)	TBOA-(DL)	DL-TBOA	N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O	Preclinical		SLC1A7|SLC1A3|SLC1A6|SLC1A2|SLC1A1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4631|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4631|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4631|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4631|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4631	excitatory amino acid transporter inhibitor			
eucatropine	eucatropine		CC1CC(CC(C)(C)N1C)OC(=O)C(O)c1ccccc1	Preclinical				acetylcholine receptor antagonist			
homochlorcyclizine	homochlorcyclizine	homochlorcyclizine hydrochloride	CN1CCCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1	Launched	http://www.drugs.com/international/Homochlorcyclizine.html	HRH1	http://en.wikipedia.org/wiki/Homochlorcyclizine	antihistamine	allergy	allergic rhinitis	https://en.wikipedia.org/wiki/Homochlorcyclizine
myricetin	myricetin	NSC-407290	Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O	Preclinical		PIK3CG|AR|CYP3A4	https://www.drugbank.ca/drugs/DB02375|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=300446|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=300446	androgen receptor agonist|cytochrome P450 inhibitor			
TC-OT-39	TC-OT-39		CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12	Preclinical		OXTR|OXT|AVPR1A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=376895|https://www.tocris.com/products/tc-ot-39_4625|https://www.tocris.com/products/tc-ot-39_4625	oxytocin receptor agonist|vasopressin receptor agonist			
trigonelline	trigonelline		C[n+]1cccc(c1)C(O)=O	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/19324944?dopt=Abstract						
etafenone	etafenone	etafenone hydrochloride	CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1	Launched	http://drug-info.in/baxanitrat-etafenone-hydrochloride-sanus-austria/			calcium channel blocker			
cytochalasin-b	cytochalasin b		C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C/[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C	Phase 2	Pharmaprojects	ACTB	http://www.sigmaaldrich.com/catalog/product/sigma/c6762?lang=en&region=US	microtubule inhibitor			
AMI-1	AMI-1	NSC-45174	Oc1cc(cc2cc(NC(=O)Nc3ccc4c(O)cc(cc4c3)S(O)(=O)=O)ccc12)S(O)(=O)=O	Preclinical		PRMT1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7028	protein arginine N-methyltransferase inhibitor			
SB-216763	SB-216763		Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12	Preclinical		CCNA2|CDK2|GSK3A|GSK3B	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004157|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004157|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8015|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8015	glycogen synthase kinase inhibitor			
ZAMI-633	ZAMI-633		CCC(=O)NO	Phase 3	Pharmaprojects			urease inhibitor			
PNU-120596	PNU-120596		COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl	Preclinical		CHRNA7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3991	acetylcholine receptor agonist			
gefitinib	gefitinib	ZD-1839|ZD1839|iressa	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1	Launched	FDA Orange Book: gefitinib	CYP2C19|EGFR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=233069|ChEMBL	EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41
bryostatin-1	bryostatin-1		CCC\C=C\C=C\C(=O)O[C@H]1\C(C[C@H]2C[C@@H](OC(=O)C[C@H](O)C[C@H]3C[C@H](OC(C)=O)C(C)(C)[C@](O)(C[C@@H]4C\C(C[C@@H](O4)\C=C/C(C)(C)[C@]1(O)O2)=C\C(=O)OC)O3)[C@@H](C)O)=C\C(=O)OC	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00006081	PRKCE	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000355	protein kinase C inhibitor			
phlorizin	phlorizin		OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@@H](O)[C@@H](O)[C@@H]1O	Preclinical		SLC5A11|SLC5A2|SLC5A3|SLC5A1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4757|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004142|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4757|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004142	sodium/glucose cotransporter inhibitor			
CVT-10216	CVT-10216		CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O	Phase 1	https://guidebook.com/guide/27988/poi/2777638/	ALDH2|ALDH1A2|ALDH7A1|ALDH5A1	https://www.tocris.com/dispprod.php?ItemId=410183#.V-U1rZMrLy8|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=459878|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=459878|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=459878	aldehyde dehydrogenase inhibitor			
dihydroergotamine	dihydroergotamine	d.h.e. 45|migranal	CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	Launched	FDA Orange Book: dihydroergotamine mesylate	DRD2|HTR2B|HTR1F|HTR1B|HTR1D|HTR1E|ADRA2A|HTR7	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000852|https://www.drugbank.ca/drugs/DB00320|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=121|https://www.drugbank.ca/drugs/DB00320|https://www.drugbank.ca/drugs/DB00320|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=121|https://www.drugbank.ca/drugs/DB00320|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=121	serotonin receptor agonist	neurology/psychiatry	migraine headache	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aec0308f-f583-4e27-9bb8-21800bde7faa
4-iodo-6-phenylpyrimidine	4-iodo-6-phenylpyrimidine		Ic1cc(ncn1)-c1ccccc1	Preclinical		MIF	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008701	macrophage migration inhibiting factor inhibitor			
CS-917	CS-917		CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00290940	FBP1	http://www.ncbi.nlm.nih.gov/pubmed/19014931	fructose biphosphate inhibitor			
phenacemide	phenacemide	phenurone	NC(=O)NC(=O)Cc1ccccc1	Launched	FDA Orange Book: phenacemide	SCN10A|SCN11A|SCN7A|SCN8A|SCN9A|SCN2A|SCN3A|SCN4A|SCN5A|SCN1A	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	sodium channel blocker	neurology/psychiatry|neurology/psychiatry	epilepsy|seizures	http://www.drugbank.ca/drugs/DB01121|http://www.drugbank.ca/drugs/DB01121
teneligliptin	teneligliptin		Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1	Launched	https://clinicaltrials.gov/ct2/show/NCT02081599	DPP4	https://en.wikipedia.org/wiki/Teneligliptin	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus	https://en.wikipedia.org/wiki/Teneligliptin
sulbactam-pivoxil	sulbactam pivoxil		CC(C)(C)C(=O)OCOC(=O)C1N2C(CC2=O)S(=O)(=O)C1(C)C	Launched	https://www.drugs.com/international/sulbactam-pivoxil.html			beta lactamase inhibitor	infectious disease	skin infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c68d2338-c43e-4a64-8da4-c93873c5a3c8
evatanepag	evatanepag	CP-533,536|CP-533536	CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1	Phase 2	http://www.pharmacodia.com/yaodu/html/v1/chemicals/99298197cbb50710fee18fb3ec6993b9.html	PTGER2|PTGER4	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000505|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1929	prostaglandin inhibitor			
epalrestat	epalrestat	Kinedak	CC(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1	Launched	http://www.drugs.com/international/Epalrestat.html	AKR1B1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001376	aldose reductase inhibitor	nephrology	diabetic nephropathy	https://en.wikipedia.org/wiki/Epalrestat
GSK2194069	GSK2194069		O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1	Preclinical		FASN	https://www.tocris.com/products/gsk-2194069_5303	fatty acid synthase inhibitor			
ML-297	ML-297		Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1	Preclinical		KCNJ3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7768	inward rectifier potassium channel activator			
cimaterol	cimaterol	AB-A 663|AC 263,780	CC(C)NCC(O)c1ccc(N)c(c1)C#N	Preclinical		ADRB3|ADRB2|ADRB1	http://www.tocris.com/dispprod.php?ItemId=2192#.Vfbkf2TBwXA|http://www.tocris.com/dispprod.php?ItemId=2192#.Vfbkf2TBwXA|http://www.tocris.com/dispprod.php?ItemId=2192#.Vfbkf2TBwXA	adrenergic receptor agonist			
cycloserine-(d)	cycloserine-(d)	cycloserine|seromycin	N[C@@H]1CONC1=O	Launched	https://en.wikipedia.org/wiki/Cycloserine	GRIN1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002628	bacterial cell wall synthesis inhibitor	infectious disease	tuberculosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10727aa8-a03e-4b61-9a80-a024cb4a2d28
niceritrol	niceritrol		O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1	Launched	https://www.drugs.com/international/niceritrol.html	HCAR2	https://citeline.informa.com/?query=#/drugs/details/12950	NAD precursor	endocrinology	hyperlipidemia	https://en.wikipedia.org/wiki/Niceritrol
secnidazole	secnidazole	PM-185184|RP 14539|SYM-1219	CC(O)Cn1c(C)ncc1[N+]([O-])=O	Launched	http://www.drugs.com/international/Secnidazole.html			acetylcholinesterase inhibitor|microtubule inhibitor	infectious disease	protozoan infection	http://www.drugs.com/international/secnidazole.html
mangafodipir	mangafodipir	teslascan		Launched	FDA Orange Book: mangafodipir trisodium			contrast agent	radiology	contrast agent	https://en.wikipedia.org/wiki/Mangafodipir
ML-298	ML-298		Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1	Preclinical		PLD2	https://www.tocris.com/products/ml-298-hydrochloride_4895	phospholipase inhibitor			
rolipram	rolipram	ZK 62 711|ZK-62771	COc1ccc(cc1OC1CCCC1)C1CNC(=O)C1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/1475038			phosphodiesterase inhibitor			
adipic-acid	adipic acid	E355|adipic acid	OC(=O)CCCCC(O)=O	Preclinical		SLC22A6	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013606	solute carrier family member inhibitor			
lersivirine	lersivirine	UK-453,061|UK-453061	CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C#N)C#N	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01254656			non-nucleoside reverse transcriptase inhibitor			
L-ergothioneine	L-ergothioneine		C[N+](C)(C)[C@@H](Cc1c[nH]c(=S)[nH]1)C(O)=O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/22342951			free radical scavenger			
penciclovir	penciclovir	BRL-39123|denavir	Nc1nc(O)c2ncn(CCC(CO)CO)c2n1	Launched	FDA Orange Book: penciclovir sodium			DNA directed DNA polymerase inhibitor	dental	cold sore	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d119057-f299-43ea-b516-e84a09cab890
TC-S-7003	TC-S-7003		CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n2c4ccccc4nc2n(-c2c(C)cccc2C)c3=O)cc1	Preclinical		LCK	https://www.tocris.com/products/tc-s-7003_3567	src inhibitor			
TC-S-7004	TC-S-7004		COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1	Preclinical		DYRK1A|DYRK1B	https://www.tocris.com/products/tc-s-7004_5088|https://www.tocris.com/products/tc-s-7004_5088	DYRK inhibitor			
TC-S-7005	TC-S-7005		C[C@H](Nc1cc2c(noc2cn1)-c1ccc2OCOc2c1)c1ccccc1	Preclinical		PLK2	https://www.tocris.com/products/tc-s-7005_4459	PLK inhibitor			
TC-S-7006	TC-S-7006		Fc1ccc(Nc2c(cnc3cnc(NCc4cccnc4)cc23)C#N)cc1Cl	Preclinical		MAP3K8	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6051	MAP kinase inhibitor			
lapatinib	lapatinib	GW-2016|GW-572016|tykerb	CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1	Launched	FDA Orange Book: lapatinib ditosylate	EGFR|CYP3A5|ERBB2	https://www.drugbank.ca/drugs/DB01259|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=301036|https://www.drugbank.ca/drugs/DB01259	EGFR inhibitor	oncology	breast cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63319b01-cad6-4d0a-c39b-938fa951a808
serdemetan	serdemetan		C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1	Phase 1	https://www.clinicaltrials.gov/ct2/show/NCT00676910	MDM2	http://www.apexbt.com/jnj-26854165-serdemetan.html	MDM inhibitor			
lometrexol	lometrexol		Nc1nc(O)c2C[C@@H](CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2n1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00033722	GART|MTHFD1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006554|https://www.drugbank.ca/drugs/DB04322	glycinamide ribonucleotide formyltransferase inhibitor			
P5091	P5091		CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O	Preclinical		USP7	http://www.apexbt.com/p005091.html	ubiquitin specific protease inhibitor			
SSR128129E	SSR128129E		COc1c(C)c(C(=O)c2ccc(N)c(c2)C(O)=O)n2ccccc12	Preclinical							
acetylcholine	acetylcholine	miochol|miochol-e	CC(=O)OCC[N+](C)(C)C	Launched	FDA Orange Book: acetylcholine chloride	CHRNA2|ACHE|CHRM5|CHRM2|CHRM1|CHRM4|CHRM3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011793|https://www.drugbank.ca/drugs/DB03128|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=294|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=294|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=294|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=294|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=294	acetylcholine receptor agonist	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|gastroenterology|pulmonary	drowsiness|fatigue|headache|indigestion|chest congestion	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7b47350-25a7-4481-9876-6b121c6bd1b7|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7b47350-25a7-4481-9876-6b121c6bd1b7|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7b47350-25a7-4481-9876-6b121c6bd1b7|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7b47350-25a7-4481-9876-6b121c6bd1b7|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7b47350-25a7-4481-9876-6b121c6bd1b7
cyproterone	cyproterone		CC(=O)[C@@]1(O)CCC2C3C=C(Cl)C4=CC(=O)[C@@H]5CC5[C@]4(C)C3CC[C@]12C	Launched	http://www.drugs.com/international/cyproterone.html	ESR1|AR	https://citeline.informa.com/?query=#/drugs/details/6668|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000906	androgen receptor antagonist	oncology	prostate cancer	http://www.macmillan.org.uk/Cancerinformation/Cancertreatment/Treatmenttypes/Hormonaltherapies/Individualhormonaltherapies/Cyproterone.aspx
DMP-543	DMP-543		Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1	Phase 2	http://adisinsight.springer.com/drugs/800009278			acetylcholine release enhancer			
CKD-712	CKD-712		Oc1cc2CCNC(Cc3cccc4ccccc34)c2cc1O	Phase 1	http://adisinsight.springer.com/drugs/800027023	IL6|NFKB1|JAK2|TNF|STAT1	https://citeline.informa.com/?query=#/drugs/details/35702|https://citeline.informa.com/?query=#/drugs/details/35702|http://www.sciencedirect.com/science/article/pii/S0898656808001861|https://citeline.informa.com/?query=#/drugs/details/35702|http://www.sciencedirect.com/science/article/pii/S0898656808001861	NFkB pathway inhibitor			
Calhex-231	Calhex-231		C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12	Preclinical		CASR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=714	calcium sensing receptor negative allosteric modulator			
UNBS-5162	UNBS-5162		CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/23053399			CC chemokine receptor antagonist			
captopril	captopril	Lopril|SQ 14,225|SQ-14225|Tensobon|capoten	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	Launched	FDA Orange Book: captopril	ACE|MMP9|MMP2|LTA4H	ChEMBL|https://www.drugbank.ca/drugs/DB01197|https://www.drugbank.ca/drugs/DB01197|https://www.drugbank.ca/drugs/DB01197	angiotensin converting enzyme inhibitor	cardiology|cardiology|cardiology|endocrinology|nephrology	hypertension|congestive heart failure|myocardial infarction|diabetes mellitus|diabetic nephropathy	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01cca91e-0374-4b89-a25a-be05e8b64346|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01cca91e-0374-4b89-a25a-be05e8b64346|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01cca91e-0374-4b89-a25a-be05e8b64346|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01cca91e-0374-4b89-a25a-be05e8b64346|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01cca91e-0374-4b89-a25a-be05e8b64346
TCS-PIM-1-1	TCS-PIM-1-1		Oc1ccc(Br)cc1-c1cc(-c2ccccc2)c(C#N)c(=O)[nH]1	Preclinical		PIM1	https://www.drugbank.ca/drugs/DB08705	Pim kinase inhibitor			
camphor-(1r)	camphor-(1r)		CC1(C)[C@@H]2CC[C@]1(C)C(=O)C2	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/15342616			TRPV activator			
polyinosine	polyinosine		OC1C(COP(O)(O)=O)OC(C1O)n1cnc2c(O)ncnc12	Preclinical		ADSSL1|IMPDH2|PYGM|HPRT1	https://www.drugbank.ca/drugs/DB04566|https://www.drugbank.ca/drugs/DB04566|https://www.drugbank.ca/drugs/DB04566|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002715	immunostimulant			
latanoprost	latanoprost	PHXA41|XA41|xalatan	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1	Launched	FDA Orange Book: latanoprost	PTGFR	ChEMBL	prostanoid receptor agonist	ophthalmology|ophthalmology	ocular hypertension|glaucoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f44d3f09-fa2d-4f01-831d-71a15bde5e29|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f44d3f09-fa2d-4f01-831d-71a15bde5e29
alcuronium	alcuronium		OC\C=C1/C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1\C1=C\N2C5[C@]6(CC[N@@+]7(CC=C)C\C(=C/CO)[C@H](C[C@@H]67)\C5=C\N(C31)c1ccccc41)c1ccccc21	Launched	http://en.wikipedia.org/wiki/Alcuronium_chloride	CHRNA7|CHRM1|CHRM3|CHRM2|CHRM4	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007589|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=341|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=341|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=341|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=341	muscle relaxant	neurology/psychiatry	muscle relaxant	https://en.wikipedia.org/wiki/Alcuronium_chloride
naftidrofuryl	naftidrofuryl	nafronyl	CCN(CC)CCOC(=O)C(CC1CCCO1)Cc1cccc2ccccc12	Launched	http://www.drugs.com/international/naftidrofuryl.html			adrenergic receptor antagonist	cardiology	claudication	http://www.drugs.com/uk/naftidrofuryl-oxalate-100mg-capsules-leaflet.html
LY2183240	LY2183240	LY-2183240	CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1	Preclinical		FAAH	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009981	FAAH inhibitor|FAAH reuptake inhibitor			
APcK-110	APcK-110		COc1cc(OC)cc(c1)-c1ccc2c(n[nH]c2n1)-c1ccc(F)cc1	Preclinical		STAT3|KIT	https://www.tocris.com/products/apck-110_3704|https://www.tocris.com/products/apck-110_3704	KIT inhibitor			
RG1530	RG1530	R-1530|RG-1530	COc1cc2N=C3NNC(C)=C3N=C(c3ccccc3Cl)c2cc1F	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00493155	CDK2|FLT4|FLT3|FLT1|FGFR1|FGFR2|PDGFRB|KDR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=424715|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=424715|https://citeline.informa.com/?query=#/drugs/details/34248|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=424715|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1980391|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1980391|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=424715|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=424715	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor			
guanosine	guanosine		Nc1nc2n(cnc2c(=O)[nH]1)[C@@H]1O[C@@H](CO)[C@@H](O)[C@H]1O	Preclinical		PNP	https://www.drugbank.ca/drugs/DB02857				
4-tert-butylphenol	4-tert-butylphenol		CC(C)(C)c1ccc(O)cc1	Preclinical							
UNC0737	UNC0737		COc1cc2c(nc(nc2cc1OCCCN1CCCC1)C1CCCCC1)N(C)C1CCN(CC1)C(C)C	Preclinical		EHMT1|EHMT2	http://www.thesgc.org/chemical-probes/UNC0638|http://www.thesgc.org/chemical-probes/UNC0638	histone lysine methyltransferase inhibitor			
testosterone-propionate	testosterone propionate		CCC(=O)O[C@H]1CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C	Veterinary Launched	FDA Orange Book: testosterone propionate	AR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7100	androgen receptor agonist			
CHPG	CHPG		NC(C(O)=O)c1cc(O)ccc1Cl	Preclinical		GRM5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1417	glutamate receptor agonist			
TAK-220	TAK-220		CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1	Phase 1	http://www.takeda.com/news/2007/20070801_3570.html	CCR5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=800	CC chemokine receptor antagonist			
TAK-593	TAK-593		Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00773929	PDGFRA|FLT1|KDR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000654|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=642354|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=642354	VEGFR inhibitor			
letrozole	letrozole	CGS 20267|CGS-20267|femara	N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1	Launched	FDA Orange Book: letrozole	CYP19A1	ChEMBL	aromatase inhibitor	oncology	breast cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02
EPZ005687	EPZ005687		Cc1cc(C)c(CNC(=O)c2cc(cc3n(ncc23)C2CCCC2)-c2ccc(CN3CCOCC3)cc2)c(=O)[nH]1	Preclinical		EZH2	https://www.caymanchem.com/app/template/Product.vm/catalog/13966;jsessionid=44052AD819FD7EC44D5A77257732283B	histone lysine methyltransferase inhibitor			
epinephrine	epinephrine	Ana-Kit|Sus-Phrine|Sus-phrine sulfite-free|Twinject|adrenaclick|adrenalin|adrenaline|auvi-q|bronitin mist|bronkaid mist|epi e z pen jr|epinephrine hydrochloride|epipen|epipen e z pen|epipen jr.|levo-methylaminoethanolcatechol|medihaler-epi|primatene mist|sus-phrine sulfite free|twinject 0.15|twinject 0.3	CNC[C@H](O)c1ccc(O)c(O)c1	Launched	FDA Orange Book: epinephrine, epinephrine bitartrate, epinephrine hydrochloride, norepinephrine bitartrate	TNF|PAH|ADRA2C|ADRA2B|ADRA2A|ADRA1D|ADRA1B|ADRA1A|ADRB1|ADRB2|ADRB3	https://www.drugbank.ca/drugs/DB00668|https://www.drugbank.ca/drugs/DB00668|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	adrenergic receptor agonist|neurotransmitter	cardiology|allergy|pulmonary	cardiac arrest|anaphylactic shock|asthma	https://en.wikipedia.org/wiki/Epinephrine|https://en.wikipedia.org/wiki/Epinephrine|https://en.wikipedia.org/wiki/Epinephrine
PSNCBAM-1	PSNCBAM-1		Clc1ccc(NC(=O)Nc2cccc(c2)-c2cccc(n2)N2CCCC2)cc1	Preclinical		CNR1	https://www.tocris.com/products/psncbam-1_5321	cannabinoid receptor modulator			
AS-77	AS-77	5-(4-Phenoxybutoxy)Psoralen	O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1	Preclinical		KCNN4|KCNA5|KCNA3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008845|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008845|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008845	potassium channel blocker			
puromycin	puromycin		COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)OC([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1	Preclinical		NHP2L1|RSL24D1|RPL26L1|RPL3|RPL8|RPL23A|RPL13A|RPL10L|RPL11|RPL15|RPL19|RPL23|RPL37	https://www.drugbank.ca/drugs/DB08437|https://www.drugbank.ca/drugs/DB08437|https://www.drugbank.ca/drugs/DB08437|https://www.drugbank.ca/drugs/DB08437|https://www.drugbank.ca/drugs/DB08437|https://www.drugbank.ca/drugs/DB08437|https://www.drugbank.ca/drugs/DB08437|https://www.drugbank.ca/drugs/DB08437|https://www.drugbank.ca/drugs/DB08437|https://www.drugbank.ca/drugs/DB08437|https://www.drugbank.ca/drugs/DB08437|https://www.drugbank.ca/drugs/DB08437|https://www.drugbank.ca/drugs/DB08437	protein synthesis inhibitor			
dyclonine	dyclonine	dyclone	CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1	Launched	FDA Orange Book: dyclonine hydrochloride	SCN10A|SCN5A	https://www.drugbank.ca/drugs/DB00645|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000509	sodium channel blocker	neurology/psychiatry	local anesthetic	https://en.wikipedia.org/wiki/Dyclonine
bevantolol	bevantolol		COc1ccc(CCNCC(O)COc2cccc(C)c2)cc1OC	Launched	http://www.drugs.com/international/Bevantolol.html	ADRA1A|ADRB1|ADRB2	https://www.drugbank.ca/drugs/DB01295|https://www.drugbank.ca/drugs/DB01295|https://www.drugbank.ca/drugs/DB01295	adrenergic receptor antagonist	cardiology|cardiology	angina pectoris|hypertension	http://www.drugbank.ca/drugs/DB01295|http://www.drugbank.ca/drugs/DB01295
GSK650394	GSK650394	GSK-650394	OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1	Preclinical		SGK2|SGK1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8040|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8040	serum/glucocorticoid regulated kinase inhibitor			
A-987306	A-987306		Nc1nc(N2CCNCC2)c2CCC3=C([C@@H]4CCCC[C@@H]4O3)c2n1	Preclinical		ADORA1|CCR1|HRH4|AVPR1A|CHRM4|CHRM1|CHRM2|CHRM3|HTR1A|HTR1B|HTR2A|HTR2B|HTR3A|DRD3|TACR2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008996|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008996|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=643792|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008996|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008996|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008996|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008996|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008996|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008996|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008996|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008996|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008996|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008996|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008996|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008996	histamine receptor antagonist			
vanillin	vanillin	vanilline	COc1cc(C=O)ccc1O	Preclinical		ABAT|ALDH5A1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006146|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006146				
bismuth-subgallate	bismuth-subgallate		O[Bi]1Oc2cc(cc(O)c2O1)C(O)=O	Launched	https://en.wikipedia.org/wiki/Bismuth_subgallate	NOS1	http://www.ncbi.nlm.nih.gov/pubmed/14985087	nitric oxide synthase inhibitor			
mequinol	mequinol	4-HYDROXYANISOLE|4-METHOXYPHENOL|BMS-181158|hqmme; hydroxyquinone methyl ether|leucobasal|leucodine b|mechinolum|menthyl anthranilate|novo-dermoquinona|p-guaiacol|p-hydroxyanisole	COc1ccc(O)cc1	Launched	FDA Orange Book: mequinol	TYR	ChEMBL		dermatology	skin depigmentation	https://en.wikipedia.org/wiki/Mequinol
SCH-900776	SCH-900776	MK-8776	Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01870596	CHEK1|CDK2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7943|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7943	CHK inhibitor			
demecarium	demecarium	humorsol	CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C	Launched	FDA Orange Book: demecarium bromide	BCHE|ACHE	https://www.drugbank.ca/drugs/DB00944|https://www.drugbank.ca/drugs/DB00944	acetylcholinesterase inhibitor	ophthalmology|ophthalmology	intraocular pressure|glaucoma	https://en.wikipedia.org/wiki/Demecarium_bromide|https://en.wikipedia.org/wiki/Demecarium_bromide
ofloxacin	ofloxacin	DL-8280|HOE 280|HOE-280|Tarivid|Visiren|floxin|floxin otic|ocuflox|trovan preservative free	CC1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O	Launched	FDA Orange Book: alatrofloxacin mesylate, ciprofloxacin, ciprofloxacin hydrochloride, levofloxacin, ofloxacin	TOP2A	https://www.drugbank.ca/drugs/DB01165	bacterial DNA gyrase inhibitor	infectious disease|otolaryngology|infectious disease|infectious disease|infectious disease|gastroenterology|endocrinology|infectious disease	respiratory tract infections|sinusitis|skin infections|bone and joint infections|intra-abdominal infections|diarrhea|fever|urinary tract infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d54a97d5-3664-4ca5-bffd-8366c7255b73|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d54a97d5-3664-4ca5-bffd-8366c7255b73|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d54a97d5-3664-4ca5-bffd-8366c7255b73|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d54a97d5-3664-4ca5-bffd-8366c7255b73|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d54a97d5-3664-4ca5-bffd-8366c7255b73|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d54a97d5-3664-4ca5-bffd-8366c7255b73|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d54a97d5-3664-4ca5-bffd-8366c7255b73|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d54a97d5-3664-4ca5-bffd-8366c7255b73
praziquantel	praziquantel	Cesol|Cestocur|Droncit|EMBAY 8440|EMBAY-8440|biltricide	O=C(C1CCCCC1)N1CC2N(CCc3ccccc23)C(=O)C1	Launched	FDA Orange Book: praziquantel			anthelmintic agent	infectious disease|infectious disease|infectious disease	gastrointestinal parasites|cystic hydatid disease|schistosomiasis	https://en.wikipedia.org/wiki/Praziquantel|https://en.wikipedia.org/wiki/Praziquantel|https://en.wikipedia.org/wiki/Praziquantel
se-methylselenocysteine	se-methylselenocysteine		C[Se]C[C@H](N)C(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00829205						
sennoside-protonated	sennoside-protonated		OCC1OC(Oc2cccc3c(-c4c5cccc(OC6OC(CO)C(O)C(O)C6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)C(O)C(O)C1O	Preclinical							
trans-4-Methoxycinnamic-acid	trans-4-Methoxycinnamic acid	3-(4-Methoxyphenyl)Acrylic Acid|4-Methoxycinnamic Acid|Para-Methoxycinnamic Acid	COc1ccc(cc1)\C=C\C(O)=O	Preclinical							
2-methylimidazole	2-methylimidazole		Cc1ncc[nH]1	Preclinical				cholesterol inhibitor			
dixanthogen	dixanthogen	NSC-402561|diethyldixanthogen|diexanthogen	CCOC(=S)SSC(=S)OCC	Preclinical							
cetirizine	cetirizine	cetirizine hydrochloride allergy|cetirizine hydrochloride hives relief|children's cetirizine hydrochloride allergy|children's zyrtec allergy|children's zyrtec hives relief|zyrtec|zyrtec allergy|zyrtec hives relief	OC(=O)COCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1	Launched	FDA Orange Book: cetirizine hydrochloride, levocetirizine dihydrochloride	HRH1	https://www.drugbank.ca/drugs/DB00341	histamine receptor antagonist	allergy	allergic rhinitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64c91cbd-9347-4dd2-9d3b-29bbab0728b6
bortezomib	bortezomib	LDP-341|PS-341|velcade	CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O	Launched	FDA Orange Book: bortezomib	CASP3|CYP2C19|RELA|PSMB11|PSMB10|PSMB2|PSMB3|PSMB4|PSMB5|PSMB6|PSMB7|PSMB8|PSMB9|PSMD1|PSMD2|PSMA1|PSMA2|PSMA3|PSMA4|PSMA5|PSMA6|PSMA7|PSMA8|PSMB1|NFKB1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=260757|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=260757|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001157|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00188|https://www.drugbank.ca/drugs/DB00188|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://citeline.informa.com/?query=#/drugs/details/14049	NFkB pathway inhibitor|proteasome inhibitor	hematologic malignancy|hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1521d321-e724-4ffc-adad-34bf4f44fac7|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1521d321-e724-4ffc-adad-34bf4f44fac7
ractopamine	ractopamine		CC(CCc1ccc(O)cc1)NCC(O)c1ccc(O)cc1	Veterinary Launched	http://www.drugs.com/international/ractopamine.html			adrenergic receptor agonist			
flucloxacillin	flucloxacillin		Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(F)cccc1Cl	Launched	https://clinicaltrials.gov/ct2/show/NCT01876628			bacterial cell wall synthesis inhibitor	infectious disease|otolaryngology|otolaryngology|infectious disease|dermatology|infectious disease|infectious disease|gastroenterology|infectious disease	gram-positive bacterial infections|tonsillitis|sinusitis|pneumonia|eczema|endocarditis|meningitis|enteritis|bacterial septicemia	https://en.wikipedia.org/wiki/Flucloxacillin|https://en.wikipedia.org/wiki/Flucloxacillin|https://en.wikipedia.org/wiki/Flucloxacillin|https://en.wikipedia.org/wiki/Flucloxacillin|https://en.wikipedia.org/wiki/Flucloxacillin|https://en.wikipedia.org/wiki/Flucloxacillin|https://en.wikipedia.org/wiki/Flucloxacillin|https://en.wikipedia.org/wiki/Flucloxacillin|https://en.wikipedia.org/wiki/Flucloxacillin
cyclopenthiazide	cyclopenthiazide	SU-8341	NS(=O)(=O)c1cc2c(NC(CC3CCCC3)NS2(=O)=O)cc1Cl	Launched	http://www.drugs.com/international/Cyclopenthiazide.html			thiazide diuretic	cardiology|cardiology	hypertension|congestive heart failure	https://en.wikipedia.org/wiki/Cyclopenthiazide|https://en.wikipedia.org/wiki/Cyclopenthiazide
WYE-354	WYE-354		COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1	Preclinical		MTOR	http://www.selleckchem.com/products/WYE-354.html	mTOR inhibitor			
desoxycortone	desoxycortone	Deoxycortone|Desoxycorticosterone|Dorcostrin|Percorten Pivalate|Undocan	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO	Preclinical		NR3C2|NR3C1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2871|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2871	mineralocorticoid receptor agonist			
fidarestat	fidarestat		NC(=O)C1CC2(NC(=O)NC2=O)c2cc(F)ccc2O1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/11574441	AKR1B1	https://www.drugbank.ca/drugs/DB02021	aldose reductase inhibitor			
AZD7545	AZD7545		CN(C)C(=O)c1ccc(cc1)S(=O)(=O)c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1	Phase 1	http://business.highbeam.com/436989/article-1G1-92793177/azd-7545-astrazeneca-initiates-clinical-trials-europe	PDK1|PDK2	https://www.drugbank.ca/drugs/DB07403|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=283980	pyruvate dehydrogenase kinase inhibitor			
aceglutamide	aceglutamide		CC(=O)N[C@@H](CCC(N)=O)C(O)=O	Launched	http://www.drugs.com/international/aceglutamide.html				gastroenterology	peptic ulcer disease (PUD)	https://en.wikipedia.org/wiki/Aceglutamide
aclarubicin	aclarubicin		CCC1(O)CC(OC2CC(C(OC3CC(O)C(OC4CCC(=O)C(C)O4)C(C)O3)C(C)O2)N(C)C)c2c(cc3C(=O)c4cccc(O)c4C(=O)c3c2O)C1C(=O)OC	Launched	http://www.drugs.com/international/aclarubicin.html	TOP1|TOP2A	http://www.genome.jp/dbget-bin/www_bget?D01911+D02756|http://www.genome.jp/dbget-bin/www_bget?D01911+D02756	topoisomerase inhibitor	hematologic malignancy	acute myeloid leukemia (AML)	http://www.medindia.net/doctors/drug_information/aclarubicin.htm
esmolol	esmolol	brevibloc	COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1	Launched	FDA Orange Book: esmolol hydrochloride	ADRB1	https://www.drugbank.ca/drugs/DB00187	adrenergic receptor antagonist	cardiology|cardiology	ventricular tachycardia (VT)|hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0a56c07-8f0f-4499-8d00-f13a966bf988|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0a56c07-8f0f-4499-8d00-f13a966bf988
metoclopramide	metoclopramide	Clopra|Clopra-"Yellow"|Maxolon|metoclopramide hydrochloride|metozolv odt|reglan|reglan odt	CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC	Launched	FDA Orange Book: metoclopramide hydrochloride	CHRM1|DRD2|HTR4|HTR3A|HTR3B	https://www.drugbank.ca/drugs/DB01233|https://www.drugbank.ca/drugs/DB01233|https://www.drugbank.ca/drugs/DB01233|https://www.drugbank.ca/drugs/DB01233|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=241	dopamine receptor antagonist|serotonin receptor antagonist	gastroenterology|gastroenterology|gastroenterology	gastroparesis|nausea|vomiting	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50a3cf38-66dc-4fa5-8a45-adf959c987ab|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50a3cf38-66dc-4fa5-8a45-adf959c987ab|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50a3cf38-66dc-4fa5-8a45-adf959c987ab
forskolin	forskolin	HL 362|L 75 1362B|boforsin|colforsin	CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C	Launched	http://www.drugs.com/npc/forskolin.html	ADCY5|ADCY2|GNAS	https://www.drugbank.ca/drugs/DB02587|https://www.drugbank.ca/drugs/DB02587|https://www.drugbank.ca/drugs/DB02587	adenylyl cyclase activator			
ICI-118,551	ICI-118,551		CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12	Phase 2				adrenergic receptor antagonist			
omarigliptin	omarigliptin	MK-3102	CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F	Launched	https://en.wikipedia.org/wiki/Omarigliptin	DPP4	https://en.wikipedia.org/wiki/Omarigliptin	dipeptidyl peptidase inhibitor			
memantine	memantine	namenda|namenda xr	CC12CC3CC(C)(C1)CC(N)(C3)C2	Launched	FDA Orange Book: memantine hydrochloride	GRIN1|GRIN2A|GRIN2B|GRIN3A|HTR3A|CYP2E1|CHRFAM7A|DRD2	https://www.drugbank.ca/drugs/DB01043|https://www.drugbank.ca/drugs/DB01043|https://www.drugbank.ca/drugs/DB01043|https://www.drugbank.ca/drugs/DB01043|https://www.drugbank.ca/drugs/DB01043|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091101|https://www.drugbank.ca/drugs/DB01043|https://www.drugbank.ca/drugs/DB01043	glutamate receptor antagonist	neurology/psychiatry|neurology/psychiatry	Alzheimer's disease|senile dementia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c5bef01-2e31-4181-a040-bb5a2fec949d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c5bef01-2e31-4181-a040-bb5a2fec949d
rimantadine	rimantadine	Rimantadin|flumadine	CC(N)C12CC3CC(CC(C3)C1)C2	Launched	FDA Orange Book: rimantadine hydrochloride			antiviral|RNA synthesis inhibitor	infectious disease	influenza A virus infection	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f7d69a-820b-4c75-a31d-b2104c019c12
malotilate	malotilate	NKK-105	CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1	Launched	http://www.drugs.com/international/Malotilate.html			protein synthesis stimulant	gastroenterology	hepatic cirrhosis	http://www.drugs.com/international/malotilate.html
ML-193	ML-193		Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C	Preclinical		GPR55	https://www.tocris.com/products/ml-193_4860	G protein-coupled receptor antagonist			
trichloroacetic-acid	trichloroacetic acid	TCAA|Trichloroethanoic acid|trichloroacetic acid	OC(=O)C(Cl)(Cl)Cl	Launched	https://en.wikipedia.org/wiki/Trichloroacetic_acid				dermatology	warts	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d929f1d6-3234-491c-b084-644c91e61302
spautin-1	spautin-1		Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1	Preclinical		USP13|USP10	https://www.tocris.com/products/spautin-1_5197|https://www.tocris.com/products/spautin-1_5197	deubiquitinase inhibitor			
CD-437	CD-437	O-Demethylated Adapalene	OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2	Preclinical		RARG	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3431	retinoid receptor agonist			
colistin	colistin		CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O	Launched	FDA Orange Book: colistin sulfate			bacterial permeability inducer	infectious disease	gram-negative bacterial infections	http://reference.medscape.com/drug/colistimethate-sodium-coly-mycin-m-colistin-342578
adiporon	adiporon		O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1	Preclinical		ADIPOR2|ADIPOR1	http://www.enzolifesciences.com/ENZ-CHM101/adiporon/|http://www.enzolifesciences.com/ENZ-CHM101/adiporon/	adiponectin receptor agonist			
cefprozil	cefprozil	cefzil	C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O	Launched	FDA Orange Book: cefprozil			bacterial cell wall synthesis inhibitor	otolaryngology|otolaryngology|otolaryngology|otolaryngology|infectious disease|infectious disease|pulmonary	pharyngitis|tonsillitis|otitis|sinusitis|respiratory tract infections|skin infections|bronchitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ec55c0a-1456-412e-972f-352b3135c8f2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ec55c0a-1456-412e-972f-352b3135c8f2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ec55c0a-1456-412e-972f-352b3135c8f2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ec55c0a-1456-412e-972f-352b3135c8f2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ec55c0a-1456-412e-972f-352b3135c8f2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ec55c0a-1456-412e-972f-352b3135c8f2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ec55c0a-1456-412e-972f-352b3135c8f2
aminoguanidine	aminoguanidine	pimagedine|pimagedine hydrochloride	NNC(N)=N	Phase 3	http://en.wikipedia.org/wiki/Pimagedine	NOS2	https://www.drugbank.ca/drugs/DB02533	nitric oxide synthase inhibitor			
MK-8245	MK-8245		OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00846391	SCD	http://www.apexbt.com/mk-8245.html?gclid=CJK3p9-uw8wCFQ9ZhgodXr4MRg	stearoyl-CoA desaturase inhibitor			
SB-239063	SB-239063		COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1	Preclinical		MAPK11|PTGS2|MAPK14|TNF	http://www.sigmaaldrich.com/catalog/product/sigma/s0569?lang=en&region=US|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001288|http://www.sigmaaldrich.com/catalog/product/sigma/s0569?lang=en&region=US|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=254152	p38 MAPK inhibitor			
BETP	BETP		CCS(=O)c1nc(cc(n1)C(F)(F)F)-c1cccc(OCc2ccccc2)c1	Preclinical		GCG|INS|GLP1R	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=761820|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=761820|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7585	glucagon-like peptide receptor positive allosteric modulator			
alvespimycin	alvespimycin		CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00780000	HSP90AA1	https://www.drugbank.ca/drugs/DB03080	HSP inhibitor			
epigallocatechin-gallate-(-)	(-)-epigallocatechin-gallate	(-)-Epigallocatechin Gallate|epigalocatechin gallate	Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT02558933	MMP14|IDO1|MMP2|KDR|FASN|KAT2B|CYP19A1|APP|ELANE|PREP|DYRK1A|SLC5A1|EP300|ENOX2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006617|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=183411|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006617|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=183411|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006617|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7002|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=183411|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=183411|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006617|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=183411|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=183411|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=183411|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7002|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=183411	bacterial DNA gyrase inhibitor			
GS-39783	GS-39783		CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O	Preclinical		GABBR1	http://www.tocris.com/dispprod.php?ItemId=93120	GABA receptor modulator			
palmitoylcarnitine	palmitoylcarnitine		CCCCCCCCCCCCCCCC(=O)OC(CC(O)=O)C[N+](C)(C)C	Preclinical				protein kinase inhibitor			
fosinoprilat	fosinoprilat	SO 27,519	OC(=O)[C@@H]1C[C@H](CN1C(=O)CP(O)(=O)CCCCc1ccccc1)C1CCCCC1	Launched	https://en.wikipedia.org/wiki/Fosinopril	ACE	https://en.wikipedia.org/wiki/Fosinopril	angiotensin converting enzyme inhibitor			
clofibric-acid	clofibric acid	clofibric acid	CC(C)(Oc1ccc(Cl)cc1)C(O)=O	Launched	https://clinicaltrials.gov/ct2/show/NCT01527318	PPARA	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000646	PPAR receptor agonist			
STF-118804	STF-118804		Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1	Preclinical		NAMPT	https://www.tocris.com/dispprod.php?ItemId=416253#.VyuzxWQrJZI	NAMPT inhibitor			
API-1	API-1		NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O	Preclinical		AKT1|AKT2|AKT3	https://www.tocris.com/products/api-1_3897|https://www.tocris.com/products/api-1_3897|https://www.tocris.com/products/api-1_3897	AKT inhibitor			
caspofungin-acetate	caspofungin acetate	cancidas	CC[C@@H](C)C[C@@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@H](O)CCN	Launched	FDA Orange Book: caspofungin acetate			fungal 1,3-beta-D-glucan synthase inhibitor	infectious disease|infectious disease|infectious disease|infectious disease	candidemia|esophageal candidiasis|aspergillosis|peritonitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3bad23a6-09a6-4194-9182-093ed61bc71c|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3bad23a6-09a6-4194-9182-093ed61bc71c|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3bad23a6-09a6-4194-9182-093ed61bc71c|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3bad23a6-09a6-4194-9182-093ed61bc71c
SGI-1776	SGI-1776		CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00848601	FLT3|PIM2|PIM3|PIM1	http://www.selleckchem.com/products/SGI-1776.html|http://www.selleckchem.com/products/SGI-1776.html|http://www.selleckchem.com/products/SGI-1776.html|http://www.selleckchem.com/products/SGI-1776.html	Pim kinase inhibitor			
picrotin	picrotin		CC(C)(O)C1C2OC(=O)C1C1(O)CC3OC33C(=O)OC2C13C	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/18720328	GLRA1|GLRA2|GLRA3|GABRA1|GABRR1|GLRB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4286|https://www.drugbank.ca/drugs/DB00466|https://www.drugbank.ca/drugs/DB00466|https://www.drugbank.ca/drugs/DB00466|https://www.drugbank.ca/drugs/DB00466|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4286	GABA receptor antagonist			
alvocidib	alvocidib	Flavopiridol|HL-275|HMR-1275|L-868275|L86-8275|MDL 107,826A|NSC-649890	CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00083122	BCL2|MCL1|CDK2|CDK1|CDK9|CDK8|CDK7|CDK6|CDK5|CDK4|BIRC5|PYGM|XIAP|EGFR|CCNT1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=166785|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=166785|https://www.drugbank.ca/drugs/DB03496|https://www.drugbank.ca/drugs/DB03496|https://www.drugbank.ca/drugs/DB03496|https://www.drugbank.ca/drugs/DB03496|https://www.drugbank.ca/drugs/DB03496|https://www.drugbank.ca/drugs/DB03496|https://www.drugbank.ca/drugs/DB03496|https://www.drugbank.ca/drugs/DB03496|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=166785|https://www.drugbank.ca/drugs/DB03496|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=166785|https://www.drugbank.ca/drugs/DB03496|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=166785	CDK inhibitor			
OT-R-antagonist-1	OT-R-antagonist-1		CO\N=C1\C[C@H](N(C1)C(=O)c1ccc(cc1)-c1ccccc1C)C(=O)NC[C@@H](O)c1ccccc1	Preclinical		OXTR|OXT|AVPR1A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2192|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=311219|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2192	oxytocin receptor antagonist			
3-MATIDA	3-MATIDA		Cc1cc(sc1C(N)C(O)=O)C(O)=O	Preclinical		GRM1	http://amp.pharm.mssm.edu/Harmonizome/gene_set/3-MATIDA/Guide+to+Pharmacology+Chemical+Ligands+of+Receptors				
VU0364770	VU0364770	N-(3-Chlorophenyl)Picolinamide	Clc1cccc(NC(=O)c2ccccn2)c1	Preclinical		GRM4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6234	glutamate receptor positive allosteric modulator			
bumetanide	bumetanide	Burinex|Lixil|RO 10-6338|Ro-10-6338|bumex	CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O	Launched	FDA Orange Book: bumetanide	SLC12A5|SLC12A1|SLC12A2|SLC12A4|CFTR|GPR35	https://www.drugbank.ca/drugs/DB00887|ChEMBL|https://www.drugbank.ca/drugs/DB00887|https://www.drugbank.ca/drugs/DB00887|https://www.drugbank.ca/drugs/DB00887|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4837	solute carrier family member inhibitor	cardiology|cardiology	edema|congestive heart failure	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5a68154-8003-4b80-81e2-e926524fb72c|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5a68154-8003-4b80-81e2-e926524fb72c
methylphenidate	methylphenidate	aptensio xr|concerta|daytrana|focalin|focalin xr|metadate cd|metadate er|methylin|methylphenidate hydrochloride|quillichew er|quillivant xr|ritalin|ritalin la|ritalin-sr	COC(=O)C(C1CCCCN1)c1ccccc1	Launched	FDA Orange Book: dexmethylphenidate hydrochloride, methylphenidate, methylphenidate hydrochloride	SLC6A3|SLC6A4|SLC6A2	ChEMBL|https://www.drugbank.ca/drugs/DB00422|ChEMBL	dopamine-norepinephrine reuptake inhibitor	neurology/psychiatry|neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)|narcolepsy	https://en.wikipedia.org/wiki/Methylphenidate#Medical|https://en.wikipedia.org/wiki/Methylphenidate#Medical
cabaletta	cabaletta	trehalose	OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02015481			pharmacological chaperone			
MK-571	MK-571		CN(C)C(=O)CCSC(SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1	Phase 2	https://pink.pharmamedtechbi.com/PS019078/MERCK-HAS-FOLLOWUP-LEUKOTRIENE-INHIBITOR-MK571-IN-PHASE-II	ABCC2|CYSLTR1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008918|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6193	leukotriene receptor antagonist			
adenine	adenine		Nc1ncnc2[nH]cnc12	Preclinical		SRPK2|ACP1|ACACB|PECR|APRT|MTAP	https://www.drugbank.ca/drugs/DB00173|https://www.drugbank.ca/drugs/DB00173|https://www.drugbank.ca/drugs/DB00173|https://www.drugbank.ca/drugs/DB00173|https://www.drugbank.ca/drugs/DB00173|https://www.drugbank.ca/drugs/DB00173	protein synthesis stimulant			
U-99194	U-99194	PNU-99194A	CCCN(CCC)C1Cc2cc(OC)c(OC)cc2C1	Preclinical		DRD3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001028	dopamine receptor antagonist			
apatinib	apatinib		O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01287962	RET|KIT|KDR|CYP3A5|CSK	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7648|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7648|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7648|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=413123|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7648	RET tyrosine kinase inhibitor			
AI-10-49	AI-10-49		FC(F)(F)Oc1ccc2nc([nH]c2c1)-c1ccc(OCCOCCOc2ccc(nc2)-c2nc3ccc(OC(F)(F)F)cc3[nH]2)cn1	Preclinical		CBFB	https://en.wikipedia.org/wiki/AI-10-49	core binding factor inhibitor			
carboxypyridine-disulfide	carboxypyridine-disulfide		OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1	Phase 2	Pharmaprojects	DHFR	https://citeline.informa.com/?query=#/drugs/details/3916				
T-62	T-62		Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1	Phase 2	http://adisinsight.springer.com/drugs/800019805	ADORA2A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001009	adenosine receptor modulator			
cilastatin	cilastatin		CC1(C)C[C@@H]1C(=O)N\C(C(O)=O)=C/CCCCSC[C@H](N)C(O)=O	Launched	FDA Orange Book: cilastatin sodium	DPEP1	https://www.drugbank.ca/drugs/DB01597	dehydropeptidase inhibitor			
talabostat	talabostat	Valinyl-L-Boroproline	CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00290017	DPP7|DPP9|DPP8|DPP4|FAP	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=303902|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=303902|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=303902|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007373|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=303902	dipeptidyl peptidase inhibitor|fibroblast activation protein inhibitor			
CP-99994	CP-99994		COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1	Phase 2	https://en.wikipedia.org/wiki/NK1_receptor_antagonist	TACR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2102	tachykinin antagonist			
ZD-7288	ZD-7288		CCN(c1ccccc1)c1cc(NC)[n+](C)c(C)n1	Phase 2	Pharmaprojects	HCN3|HCN2|HCN1|HCN4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2359|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2359|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2359|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2359	HCN channel blocker			
remoxipride	remoxipride	A 33547|FLA 731|Roxiam	CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	SIGMAR1|DRD2|DRD4|DRD3|HTR2A	https://www.drugbank.ca/drugs/DB00409|https://www.drugbank.ca/drugs/DB00409|https://www.drugbank.ca/drugs/DB00409|https://www.drugbank.ca/drugs/DB00409|https://www.drugbank.ca/drugs/DB00409	dopamine receptor antagonist			
rilmenidine	rilmenidine		C1CC1C(NC1=NCCO1)C1CC1	Launched	http://www.drugs.com/international/Rilmenidine.html	ADRA2A	https://en.wikipedia.org/wiki/Rilmenidine	adrenergic receptor agonist|imidazoline receptor agonist	cardiology	hypertension	https://en.wikipedia.org/wiki/Rilmenidine
NCS-382	NCS-382		OC1c2ccccc2CCC\C1=C/C(O)=O	Preclinical		SLC52A2|GABBR1|GABBR2	http://en.wikipedia.org/wiki/NCS-382|http://www.scbt.com/datasheet-203444-NCS-382-Sodium-Salt.html|http://www.scbt.com/datasheet-203444-NCS-382-Sodium-Salt.html	GABA receptor antagonist			
vorinostat	vorinostat	zolinza	ONC(=O)CCCCCCC(=O)Nc1ccccc1	Launched	FDA Orange Book: vorinostat	HDAC11|HDAC10|HDAC1|HDAC9|HDAC8|HDAC6|HDAC5|HDAC3|HDAC2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6852|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6852|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6852|https://www.drugbank.ca/drugs/DB02546|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6852|ChEMBL|ChEMBL	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd86ee78-2781-468b-930c-3c4677bcc092
alizarin	alizarin	athraquinones a	Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O	Preclinical							
asaraldehyde	asaraldehyde		COc1cc(OC)c(C=O)cc1OC	Preclinical		PTGS2	http://www.abcam.com/asaraldehyde-asaronaldehyde-ab143205.html	cyclooxygenase inhibitor			
palosuran	palosuran	ACT-058362	Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/20231521	UTS2R	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3516	urotensin receptor antagonist			
TCS-5861528	TCS-5861528		CCC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1	Preclinical		TRPA1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6276	transient receptor potential channel antagonist			
zometapine	zometapine	CI-781	Cc1nn(C)c2NCCN=C(c12)c1cccc(Cl)c1	Phase 2	Pharmaprojects						
flavin-adenine-dinucleotide	flavin-adenine-dinucleotide		Cc1cc2nc3c(nc(=O)[nH]c3=O)n(CC(O)C(O)C(O)COP(O)(=O)OP(O)(=O)OCC3OC(C(O)C3O)n3cnc4c(N)ncnc34)c2cc1C	Preclinical		MAOA|MAOB|DLD|IL4I1|DAO|FDXR|XDH|GFER|ACAD8|ACADM|ACADS|AIFM1|TXNRD1|POR|GCDH|ERO1LB|IVD|GSR|NOS1|NQO2|NQO1|DPYD|CYB5R1|CYB5R3|ACOX1	https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147|https://www.drugbank.ca/drugs/DB03147				
KI-16425	KI-16425		CC(OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl	Preclinical		LPAR3|LPAR1	https://www.caymanchem.com/product/10012659|https://www.caymanchem.com/product/10012659	lysophosphatidic acid receptor antagonist			
neridronic-acid	neridronic acid	neridronic acid	NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O	Launched	http://en.wikipedia.org/wiki/Neridronic_acid	FDPS	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008434	bone resorption inhibitor	endocrinology|endocrinology	brittle bone disease|Paget's disease	https://en.wikipedia.org/wiki/Neridronic_acid|https://en.wikipedia.org/wiki/Neridronic_acid
ezatiostat	ezatiostat		CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00700206	GSTP1	https://www.drugbank.ca/drugs/DB05460	glutathione transferase inhibitor			
PD-158780	PD-158780		CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1	Preclinical		EGFR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6015	EGFR inhibitor			
flurofamide	flurofamide	EU-4534|flurfamide	NP(N)(=O)NC(=O)c1ccc(F)cc1	Preclinical				urease inhibitor			
TC-I-15	TC-I-15		CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1	Preclinical		ITGB1|ITGA2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6582|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6582	integrin inhibitor			
istaroxime	istaroxime		C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00838253	FXYD2|ATP1A4|ATP1A3|ATP1A2|ATP1A1|ATP1B4|ATP1B3|ATP1B2|ATP1B1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=266338|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=266338|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=266338|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=266338|http://dgidb.genome.wustl.edu/interaction_claims/0015d065-758d-4a0c-b4e1-7480a5ea2989|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=266338|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=266338|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=266338|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=266338	ATPase inhibitor			
darglitazone	darglitazone		Cc1oc(nc1CCC(=O)c1ccc(Cc2sc(O)nc2O)cc1)-c1ccccc1	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/8582540	INS|PPARG	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=154417|https://en.wikipedia.org/wiki/Darglitazone	PPAR receptor antagonist			
N-[2-(Piperidinylamino)ethyl]-4-iodobenzamide	N-[2-(Piperidinylamino)ethyl]-4-iodobenzamide		Ic1ccc(cc1)C(=O)NCCN1CCCCC1	Preclinical				sigma receptor ligand			
CCT137690	CCT137690		CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1	Preclinical		FLT3|AURKA|AURKC|AURKB	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=716386|https://www.tocris.com/dispprod.php?ItemId=300649#.Vye1O2QrImI|https://www.tocris.com/dispprod.php?ItemId=300649#.Vye1O2QrImI|https://www.tocris.com/dispprod.php?ItemId=300649#.Vye1O2QrImI	Aurora kinase inhibitor			
NNC-63-0532	NNC-63-0532		COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O	Preclinical		OPRL1	https://en.wikipedia.org/wiki/NNC_63-0532	opioid receptor agonist			
endoxifen	endoxifen		CC\C(c1ccccc1)=C(/c1ccc(O)cc1)c1ccc(OCCNC)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02311933	ESR1	https://www.pharmgkb.org/pathway/PA145011119	estrogen receptor antagonist			
RHC-80267	RHC-80267		O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1	Preclinical		DAGLA|DAGLB|LIPG|LIPE|LIPC	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5255|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5255|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=286660|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=286660|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=286660	triacylglycerol lipase inhibitor			
PD-98059	PD-98059		COc1cccc(-c2cc(=O)c3ccccc3o2)c1N	Preclinical		MAPK12|MAPK11|MAPK14|RPS6KB1|AKT1|LCK|SGK1|GSK3B|RAF1|CHEK1|ROCK1|PRKCA|MAP2K1|MAP2K2|MAPK1|MAPK8|MAPK3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003791|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003791|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003791|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003791|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003791|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003791|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003791|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003791|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003791|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003791|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003791|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003791|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003791|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=234617|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003791|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003791|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=234617	MEK inhibitor			
strontium-ranelate	strontium ranelate	ranelic acid		Launched	https://clinicaltrials.gov/ct2/show/NCT01222026	CASR	http://www.ncbi.nlm.nih.gov/pubmed/17531955	bone formation stimulant|bone resorption inhibitor	orthopedics|rheumatology	osteoporosis|osteoarthritis	https://en.wikipedia.org/wiki/Strontium_ranelate|https://en.wikipedia.org/wiki/Strontium_ranelate
1-naphthyl-PP1	1-naphthyl-PP1		CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12	Preclinical		SRC|EPHB4	http://www.tocris.com/dispprod.php?ItemId=191870#.VeRxFyxVhHw|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=278774	src inhibitor			
imipramine	imipramine	Pramine|imipramine pamoate|janimine|presamine|tofranil|tofranil-pm	CN(C)CCCN1c2ccccc2CCc2ccccc12	Launched	FDA Orange Book: imipramine hydrochloride, imipramine pamoate	ADRA1B|ADRA1A|ADRA1D|HTR7|HTR6|KCND2|KCND3|KCNH2|KCNH1|HTR1A|HTR2C|HTR2A|SLC6A3|SLC6A4|SLC6A2|CHRM3|CHRM2|CHRM1|CHRM5|CHRM4|DRD1|DRD2|DRD5|CYP2C19|HRH1	https://www.drugbank.ca/drugs/DB00458|https://www.drugbank.ca/drugs/DB00458|https://www.drugbank.ca/drugs/DB00458|https://www.drugbank.ca/drugs/DB00458|https://www.drugbank.ca/drugs/DB00458|https://www.drugbank.ca/drugs/DB00458|https://www.drugbank.ca/drugs/DB00458|https://www.drugbank.ca/drugs/DB00458|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=357|https://www.drugbank.ca/drugs/DB00458|https://www.drugbank.ca/drugs/DB00458|https://www.drugbank.ca/drugs/DB00458|https://www.drugbank.ca/drugs/DB00458|https://www.drugbank.ca/drugs/DB00458|https://www.drugbank.ca/drugs/DB00458|https://www.drugbank.ca/drugs/DB00458|https://www.drugbank.ca/drugs/DB00458|https://www.drugbank.ca/drugs/DB00458|https://www.drugbank.ca/drugs/DB00458|https://www.drugbank.ca/drugs/DB00458|https://www.drugbank.ca/drugs/DB00458|https://www.drugbank.ca/drugs/DB00458|https://www.drugbank.ca/drugs/DB00458|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091382|https://www.drugbank.ca/drugs/DB00458	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	neurology/psychiatry|urology	depression|nocturnal enuresis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f7d5e7f-79aa-4f3a-b9a6-758d9f3ce74d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f7d5e7f-79aa-4f3a-b9a6-758d9f3ce74d
BIX-02188	BIX-02188	BIX02188	CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1	Preclinical		MAP2K5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8064	MEK inhibitor			
BIX-02189	BIX-02189		CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c1	Preclinical		MAPK7|MAP2K5	http://www.tocris.com/dispprod.php?ItemId=373424#.VfBhwSxVhHw|http://www.tocris.com/dispprod.php?ItemId=373424#.VfBhwSxVhHw	MEK inhibitor			
selfotel	selfotel		OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/10657404	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D	https://citeline.informa.com/?query=#/drugs/details/16956|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4155|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4155|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4155|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4155	glutamate receptor antagonist			
L-168049	L-168049		CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1	Preclinical		GCGR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3505	glucagon receptor antagonist			
ceftaroline-fosamil	ceftaroline fosamil		CCO\N=C(\C(=O)N[C@H]1[C@H]2SCC(Sc3nc(cs3)-c3cc[n+](C)cc3)=C(N2C1=O)C(O)=O)c1nsc(NP(O)(O)=O)n1	Launched	http://www.teflaro.com/			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease	skin infections|pneumonia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ecde48b-75a2-4beb-9999-369f3f61bb8a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ecde48b-75a2-4beb-9999-369f3f61bb8a
GW-788388	GW-788388	GW788388	O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1	Preclinical		TGFBR1|LCK|MAPK14	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006358|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006358|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006358	ALK tyrosine kinase receptor inhibitor			
benzalkonium	benzalkonium		CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1	Launched	http://en.wikipedia.org/wiki/Benzalkonium_chloride			Cationic surfactant	dermatology|dermatology	abrasions|superficial cuts	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1284ef9-91f5-47fb-90ef-c4088f6f8a94|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1284ef9-91f5-47fb-90ef-c4088f6f8a94
deflazacort	deflazacort		CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C	Launched	http://www.drugs.com/international/Deflazacort.html	NR3C1	http://www.genome.jp/dbget-bin/www_bget?dr:D03671	glucocorticoid receptor agonist	rheumatology	joint inflammation	http://www.drugs.com/uk/deflazacort-6mg-tablets-leaflet.html
valnemulin	valnemulin		CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@]1(C)[C@H](C)CC3	Veterinary Launched	http://www.drugs.com/international/Valnemulin.html			bacterial 50S ribosomal subunit inhibitor	infectious disease|gastroenterology|infectious disease	dysentry|colitis|pneumonia	https://en.wikipedia.org/wiki/Valnemulin|https://en.wikipedia.org/wiki/Valnemulin|https://en.wikipedia.org/wiki/Valnemulin
cephalosporin-c-zn	cephalosporin-c-zn		CC(=O)OCC1=C2N3C(SC1)[C@H](NC(=O)CCCC(N)C(=O)O[Zn]OC2=O)C3=O	Preclinical				bacterial cell wall synthesis inhibitor			
BMS-626529	BMS-626529	temsavir	COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12	Phase 3	https://clinicaltrials.gov/show/NCT02362503			HIV attachment inhibitor			
dexlansoprazole	dexlansoprazole	Kapidex|T-168390|TAK-390|dexilant|dexilant solutab	Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1	Launched	FDA Orange Book: dexlansoprazole	CYP2C19|ATP4A|ATP4B	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=405414|ChEMBL|ChEMBL	ATPase inhibitor	gastroenterology|gastroenterology	gastroesophageal reflux disease (GERD)|erosive esophagitis (EE)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a957692-7f20-4752-b29a-53cff9325dd2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a957692-7f20-4752-b29a-53cff9325dd2
clidinium	clidinium	quarzan	C[N+]12CCC(CC1)C(C2)OC(=O)C(O)(c1ccccc1)c1ccccc1	Launched	FDA Orange Book: aclidinium bromide, clidinium bromide, umeclidinium bromide	CHRM3|CHRM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=366|https://www.drugbank.ca/drugs/DB00771	acetylcholine receptor antagonist	gastroenterology|gastroenterology|gastroenterology	peptic ulcer disease (PUD)|irritable bowel syndrome|enterocolitis	https://en.wikipedia.org/wiki/Clidinium_bromide|https://en.wikipedia.org/wiki/Clidinium_bromide|https://en.wikipedia.org/wiki/Clidinium_bromide
CGP-57380	CGP-57380		Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12	Preclinical		MKNK2|MKNK1|AURKB|SGK1|LCK	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6010|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6010|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009913|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009913|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009913	MAP kinase inhibitor			
balsalazide	balsalazide	colazal|giazo	OC(=O)CCNC(=O)c1ccc(cc1)N=Nc1ccc(O)c(c1)C(O)=O	Launched	FDA Orange Book: balsalazide disodium	ALOX5|PTGS1|PTGS2|PPARG	https://www.drugbank.ca/drugs/DB01014|https://www.drugbank.ca/drugs/DB01014|https://www.drugbank.ca/drugs/DB01014|https://www.drugbank.ca/drugs/DB01014	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f12ffa32-d14b-e9d9-e957-2ef08b64e8b4
bakuchiol	bakuchiol	(S)-Bakuchiol	CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1	Phase 2	http://www.jaad.org/article/S0190-9622%2810%2901183-7/abstract	HIF1A	http://www.ncbi.nlm.nih.gov/pubmed/18359631	DNA polymerase inhibitor			
alpha-linolenic-acid	alpha-linolenic acid	alpha-lna|linolenate|linolenic acid	CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01764308	SLC8A1|FFAR1|FFAR4|TRPV1|PTGS2|FADS1|FADS2|ELOVL4	https://www.drugbank.ca/drugs/DB00132|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049|https://www.drugbank.ca/drugs/DB00132|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013630|https://www.drugbank.ca/drugs/DB00132|https://www.drugbank.ca/drugs/DB00132|https://www.drugbank.ca/drugs/DB00132	omega 3 fatty acid stimulant			
JIB04	JIB04		Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1	Preclinical		KDM4E	http://www.tocris.com/dispprod.php?ItemId=385325#.VgLZZtNViko	histone lysine demethylase inhibitor			
anthranilic-acid	anthranilic acid		OC(=O)c1ccccc1NC(=O)C12CC3CC(CC(C3)C1)C2	Preclinical							
PFI-1	PFI-1		COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1	Preclinical		BRD4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7523	bromodomain inhibitor			
PFI-3	PFI-3		Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1	Preclinical		PBRM1|SMARCA4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7915|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7915	bromodomain inhibitor			
sodium-picosulfate	sodium picosulfate	picosulfuric acid	OS(=O)(=O)Oc1ccc(cc1)C(c1ccc(OS(O)(=O)=O)cc1)c1ccccn1	Launched	FDA Orange Book: sodium picosulfate				gastroenterology	constipation	https://en.wikipedia.org/wiki/Sodium_picosulfate
ABT-639	ABT-639		Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01345045	CACNA1I|CACNA1H|CACNA1G	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7721|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7721|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7721	calcium channel blocker			
caracemide	caracemide		CNC(=O)ON(C(C)=O)C(=O)NC	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/10638488	RRM1	http://www.medkoo.com/products/7601	ribonucleotide reductase inhibitor			
antimycin-a	antimycin a		CCCCCC[C@@H]1[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)C(NC(=O)c2cccc(NC=O)c2O)[C@@H](C)OC1=O	Preclinical		CYCS	http://en.wikipedia.org/wiki/Antimycin_A	ATP synthase inhibitor			
FK-888	FK-888		CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12	Phase 2	http://adisinsight.springer.com/drugs/800001953	TACR1|TACR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2114|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2114	tachykinin antagonist			
carbamazepine	carbamazepine	G-32883|Tegretol XR|carbatrol|epitol|equetro|tegretol|tegretol-xr|teril	NC(=O)N1c2ccccc2C=Cc2ccccc12	Launched	FDA Orange Book: carbamazepine	CYP1A2|CYP3A4|ABCB1|SCN11A|SCN10A|SCN5A|SCN4A|SCN3A|SCN2A|SCN9A|SCN8A|SCN7A|SCN1A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=168546|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=168546|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=168546|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	carboxamide antiepileptic	neurology/psychiatry	seizures	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c13bc0b8-7900-4ef4-98ed-e1315a08d95d
NADPH	NADPH		NC1CCCCC1.NC1CCCCC1.NC1CCCCC1.NC1CCCCC1.NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](OP(O)(O)=O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O	Preclinical		AASS|DPYD|TXNRD1|GHSR	https://www.drugbank.ca/drugs/DB02338|https://www.drugbank.ca/drugs/DB02338|https://www.drugbank.ca/drugs/DB02338|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DPR000034				
aptiganel	aptiganel		CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/11730442	GRIN1	http://www.genome.jp/dbget-bin/www_bget?dr:D02973	glutamate receptor antagonist			
methazolamide	methazolamide	neptazane	CC(=O)N=c1sc(nn1C)S(N)(=O)=O	Launched	FDA Orange Book: methazolamide	CA14|CA12|INS|CA7|CA1|CA2|CA4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6828|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6828|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=286011|https://www.drugbank.ca/drugs/DB00703|https://www.drugbank.ca/drugs/DB00703|https://www.drugbank.ca/drugs/DB00703|https://www.drugbank.ca/drugs/DB00703	carbonic anhydrase inhibitor	ophthalmology|ophthalmology	glaucoma|intraocular pressure	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c26c8834-961e-4c9c-9ad4-5db2d9419938|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c26c8834-961e-4c9c-9ad4-5db2d9419938
troxipide	troxipide		COc1cc(cc(OC)c1OC)C(=O)NC1CCCNC1	Launched	http://www.drugs.com/international/Troxipide.html			glucosamine synthetase stimulant	gastroenterology	gastroesophageal reflux disease (GERD)	https://en.wikipedia.org/wiki/Troxipide
calcium-gluceptate	calcium gluceptate	calcium gluceptate	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O	Launched	FDA Orange Book: calcium gluceptate						
adaprev	adaprev		OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02377921	M6PR|TGFB1|IGF2R	https://www.drugbank.ca/drugs/DB02900|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=411434|https://www.drugbank.ca/drugs/DB02900	TGF beta receptor inhibitor			
VUF10166	VUF10166		CN1CCN(CC1)c1nc2ccccc2nc1Cl	Preclinical		HTR3A|HTR3B	http://www.tocris.com/dispprod.php?ItemId=345948#.VhQLYRNViko|http://www.tocris.com/dispprod.php?ItemId=345948#.VhQLYRNViko	serotonin receptor antagonist			
ponatinib	ponatinib	AP24534|iclusig	CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1	Launched	FDA Orange Book: ponatinib hydrochloride	FGF2|FLT1|FLT3|SRC|FGFR1|FGFR2|FGFR3|FGFR4|TEK|PDGFRA|KIT|KDR|LCK|LYN|CYP3A5|CYP2C8|RET|BCR|ABL1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=440498|https://citeline.informa.com/?query=#/drugs/details/34938|https://www.drugbank.ca/drugs/DB08901|https://www.drugbank.ca/drugs/DB08901|https://www.drugbank.ca/drugs/DB08901|https://www.drugbank.ca/drugs/DB08901|https://www.drugbank.ca/drugs/DB08901|https://www.drugbank.ca/drugs/DB08901|https://www.drugbank.ca/drugs/DB08901|https://www.drugbank.ca/drugs/DB08901|https://www.drugbank.ca/drugs/DB08901|https://www.drugbank.ca/drugs/DB08901|https://www.drugbank.ca/drugs/DB08901|https://www.drugbank.ca/drugs/DB08901|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=440498|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=440498|https://www.drugbank.ca/drugs/DB08901|https://www.drugbank.ca/drugs/DB08901|https://www.drugbank.ca/drugs/DB08901	Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy|hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=807f988e-117b-4497-934d-73aa78baac71|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=807f988e-117b-4497-934d-73aa78baac71
azathioprine	azathioprine	BW-57-322|azasan|azathioprine sodium|imuran	Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O	Launched	FDA Orange Book: azathioprine, azathioprine sodium	PPAT|IMPDH1|HPRT1	ChEMBL|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000782|https://www.drugbank.ca/drugs/DB00993	dehydrogenase inhibitor	transplant|rheumatology	renal homotransplantation|rheumatoid arthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c49b7cc5-0eed-43b7-b7ad-cbb1b6f0cd2c|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c49b7cc5-0eed-43b7-b7ad-cbb1b6f0cd2c
TMPH	TMPH		CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1	Preclinical							
tebipenem	tebipenem		C[C@@H](O)[C@@H]1[C@@H]2[C@H](C)C(SC3CN(C3)C3=NCCS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C	Launched	http://en.wikipedia.org/wiki/Tebipenem	CNR1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001015	bacterial cell wall synthesis inhibitor	infectious disease|otolaryngology	pneumonia|otitis	http://adisinsight.springer.com/drugs/800010812|http://adisinsight.springer.com/drugs/800010812
GS-9973	GS-9973	entospletinib	C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01796470	SYK	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7889	syk inhibitor			
AC-55541	AC-55541		C\C(=N/NC(=O)C(NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1	Preclinical		PARP2|F2RL1	https://www.tocris.com/dispprod.php?ItemId=220549#.V-AYDZMrLy8|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=440196	PARP inhibitor			
RS-67333	RS-67333		CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1	Preclinical		HTR4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=237	serotonin receptor partial agonist			
rufinamide	rufinamide	60231/4|CGP 33101|E2080|RUF 331|banzel	NC(=O)c1cn(Cc2c(F)cccc2F)nn1	Launched	FDA Orange Book: rufinamide	CYP2E1|CYP3A4|SCN10A|SCN11A|GRM5|SCN9A|SCN3A|SCN4A|SCN1A|SCN2A|SCN7A|SCN8A|SCN5A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=132089|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=132089|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB06201|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	voltage-gated sodium channel blocker	neurology/psychiatry	seizures	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a3fa925-1abd-458a-bd57-4ae780a1ef2d
dihydroxyphenylglycine	dihydroxyphenylglycine		NC(C(O)=O)c1cc(O)cc(O)c1	Preclinical		GRM1|GRM5	https://en.wikipedia.org/wiki/Dihydroxyphenylglycine|https://en.wikipedia.org/wiki/Dihydroxyphenylglycine	glutamate receptor agonist			
PDE10-IN-1	PDE10-IN-1		Cc1c(nc2c3cccnc3ccn12)[C@@H]1C[C@H]1c1nc2c(C)ncc(C)n2n1	Preclinical		PDE10A	https://www.ncbi.nlm.nih.gov/pubmed/26802091	phosphodiesterase inhibitor			
TP-0903	TP-0903		CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl	Preclinical		AXL|AURKA|AURKB	http://www.selleckchem.com/products/tp-0903.html?gclid=CP7pt9C5v88CFYkmhgodotEKJw|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=769930|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=769930	AXL kinase inhibitor			
flupirtine	flupirtine		CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N	Launched	http://www.drugs.com/international/Flupirtine.html	ADRA2A|KCNQ1|KCNQ2|KCNQ3	https://www.drugbank.ca/drugs/DB06623|http://en.wikipedia.org/wiki/Flupirtine|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2598|https://citeline.informa.com/?query=#/drugs/details/7385	glutamate receptor antagonist	neurology/psychiatry	pain relief	http://www.drugs.com/international/flupirtine.html
capreomycin	capreomycin	capastat sulfate		Launched	FDA Orange Book: capreomycin sulfate			protein synthesis inhibitor	infectious disease	tuberculosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=808e4421-2b9c-41e1-a82c-39256b112ae8
arctigenin	arctigenin	(-)-Arctigenin	COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O	Preclinical		AHR|CHUK|ADIPOR1|MAP2K1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=354553|http://www.tocris.com/dispprod.php?ItemId=75119|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=354553|http://www.tocris.com/dispprod.php?ItemId=75119	MEK inhibitor			
tazarotene	tazarotene	AGN 190168|AGN-190168|avage|fabior|tazorac	CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1	Launched	FDA Orange Book: tazarotene	ODC1|RXRB|RARG|RARA|RARB	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=145711|https://www.drugbank.ca/drugs/DB00799|ChEMBL|ChEMBL|ChEMBL	retinoid receptor agonist	dermatology|dermatology	cosmetic|sunscreen lotion	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd8a3be3-8f83-42cf-8752-6fd16da65150&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd8a3be3-8f83-42cf-8752-6fd16da65150&audience=consumer
benfluralin	benfluralin		CCCCN(CC)c1c(cc(cc1[N+]([O-])=O)C(F)(F)F)[N+]([O-])=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00026117	UGT1A1|CYP3A4|CYP1A1|CYP1A2|CYP2B6|ESR1|MMP1|SULT2A1	http://www.t3db.ca/toxins/T3D3796|http://www.t3db.ca/toxins/T3D3796|http://www.t3db.ca/toxins/T3D3796|http://www.t3db.ca/toxins/T3D3796|http://www.t3db.ca/toxins/T3D3796|http://www.t3db.ca/toxins/T3D3796|http://www.t3db.ca/toxins/T3D3796|http://www.t3db.ca/toxins/T3D3796				
C-021	C-021		COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1	Preclinical		CCR4	https://www.tocris.com/products/c-021-dihydrochloride_3581	CC chemokine receptor antagonist			
fenaclon	fenaclon	phenacon	ClCCC(=O)NCCc1ccccc1	Preclinical							
decernotinib	decernotinib	VRT-831509|VX-509|adelatinib	CCC(C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT01830985	JAK2|JAK3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=800050|http://onlinelibrary.wiley.com/doi/10.1002/art.39473/abstract	JAK inhibitor			
cefathiamidine	cefathiamidine		CC(C)N\C(SCC(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)=N/C(C)C	Launched	http://www.drugs.com/international/cefathiamidine.html			bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections	http://www.prnewswire.com/news-releases/investigation-report-on-chinas-cefathiamidine-market-2015-2019-300124863.html
amonafide	amonafide	AS-1413|Quinamed	CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00715637	TOP2A|TOP2B	https://www.drugbank.ca/drugs/DB05022|https://www.drugbank.ca/drugs/DB05022	topoisomerase inhibitor			
zaleplon	zaleplon	CL 284,846|CL-284846|L-846|L846|LJC 10846|LJC-10846|ZAL-846|sonata	CCN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C#N	Launched	FDA Orange Book: zaleplon	AOX1|GABRA1|GABRB1|GABRG2|TSPO	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=132769|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00962	benzodiazepine receptor agonist	neurology/psychiatry	insomnia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f44db39-e1d9-451e-ba31-e4b10366a430
doconexent	doconexent	OMEGA-3 MARINE TRIGLYCERIDES	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O	Launched	http://www.drugs.com/pro/folet-one.html	PTGS2|PTGS1|PPARA|FFAR1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013629|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013629|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=107644|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1051	PPAR receptor agonist			
tranylcypromine	tranylcypromine	parnate		Launched	FDA Orange Book: tranylcypromine sulfate	CYP2A6|KDM1A|MAOB|MAOA	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091431|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5281|https://www.drugbank.ca/drugs/DB00752|https://www.drugbank.ca/drugs/DB00752	monoamine oxidase inhibitor	neurology/psychiatry	depression	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=accef599-6ead-4faa-8208-61e37eab908b&audience=consumer
safflower-yellow	safflower-yellow		OC[C@H]1OC([C@H](O)[C@@H](O)[C@@H]1O)[C@]1(O)C(=O)C(\C=C2/C(=O)C(C(=O)\C=C\c3ccc(O)cc3)C(=O)[C@@](O)(C3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C2=O)C(=O)C(C(=O)\C=C\c2ccc(O)cc2)C1=O	Preclinical				anti-inflammatory agent			
azimilide	azimilide		CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00751738	KCNQ1|KCNE1|KCNH2|KCNA5	https://www.drugbank.ca/drugs/DB04957|https://www.drugbank.ca/drugs/DB04957|https://www.drugbank.ca/drugs/DB04957|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000713	potassium channel blocker			
NTRC-824	NTRC-824		CC(C)C[C@H](NC(=O)Cn1cc(C(=O)C(F)(F)F)c2cc(NS(=O)(=O)c3ccc(C)cc3)ccc12)C(O)=O	Preclinical		NTSR2	https://www.tocris.com/products/ntrc-824_5438	neurotensin receptor antagonist			
cefpirome	cefpirome		CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3cccc4CCCc34)=C(N2C1=O)C(O)=O)c1csc(N)n1	Launched	http://www.drugs.com/international/Cefpirome.html			bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections	https://en.wikipedia.org/wiki/Cefpirome
betahistine	betahistine		CNCCc1ccccn1	Launched	http://www.drugs.com/international/betahistine.html	HRH3|HRH1	https://www.drugbank.ca/drugs/DB06698|https://www.drugbank.ca/drugs/DB06698	histamine receptor agonist|histamine receptor antagonist	neurology/psychiatry	Meniere's disease	https://en.wikipedia.org/wiki/M%C3%A9ni%C3%A8re%27s_disease
zoxazolamine	zoxazolamine		Nc1nc2cc(Cl)ccc2o1	Phase 2	http://jama.jamanetwork.com/article.aspx?articleid=321666			myorelaxant			
R-428	R-428		Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1	Phase 1	http://www.prnewswire.com/news-releases/bergenbio-presents-positive-phase-ia-data-on-bgb324-at-aacr-254563031.html	AXL	http://www.apexbt.com/r428.html	AXL kinase inhibitor			
BMS-299897	BMS-299897		C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/19480557			gamma secretase inhibitor			
ethynodiol-diacetate	ethynodiol diacetate	SC 11800|SC-11800|ethynodiol diacetate|etynodiol|etynodiol acetate	CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1	Launched	FDA Orange Book: ethynodiol diacetate	PGR|ESR1	ChEMBL|https://www.drugbank.ca/drugs/DB00823		endocrinology	contraceptive	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=994cefc2-0724-4b56-a816-ccdabef5492e
bafetinib	bafetinib		CN(C)C1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3ncc(cn3)-c3cncnc3)c2)C1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01144260	BCR|ABL1|FYN|LYN	http://www.selleckchem.com/products/Bafetinib.html|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7906|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=387065|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7906	Bcr-Abl kinase inhibitor|LYN tyrosine kinase inhibitor			
isradipine	isradipine	PN 200-110|PN-200-110|dynacirc|dynacirc cr|isrodipine	COC(=O)C1=C(C)NC(C)=C(C1c1cccc2nonc12)C(=O)OC(C)C	Launched	FDA Orange Book: isradipine	CACNB2|CACNA2D1|CACNA2D2|CACNA1D|CACNA1C|CACNA1S|CACNA1H|CACNA1F	https://www.drugbank.ca/drugs/DB00270|https://www.drugbank.ca/drugs/DB00270|https://www.drugbank.ca/drugs/DB00270|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00270|ChEMBL	calcium channel blocker	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf3425e0-428d-4bdb-ac9a-3b9d483df83a
JTE-013	JTE-013		CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12	Preclinical		P2RY10|S1PR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2917|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2917	lysophospholipid receptor antagonist			
cisplatin	cisplatin	platinol|platinol-aq	N[Pt](N)(Cl)Cl	Launched	FDA Orange Book: cisplatin	SLC22A2|TXNRD1|TXNRD2|XIAP|FASLG	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090894|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090894|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090894|http://www.chemicalbook.com/ChemicalProductProperty_EN_CB9236183.htm|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090894	DNA alkylating agent|DNA synthesis inhibitor	oncology|oncology|oncology	testicular carcinoma|ovarian cancer|bladder cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64975f5d-0eca-4998-8a72-06eec98285eb|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64975f5d-0eca-4998-8a72-06eec98285eb|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64975f5d-0eca-4998-8a72-06eec98285eb
MK-6096	MK-6096	filorexant	C[C@@H]1CC[C@@H](COc2ccc(F)cn2)CN1C(=O)c1cc(C)ccc1-c1ncccn1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01513291	HCRTR2|HCRTR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4460|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4460	orexin receptor antagonist			
thiopental	thiopental	pentothal	CCCC(C)C1(CC)C(=O)NC(S)=NC1=O	Launched	FDA Orange Book: thiopental sodium	GABRA3|GABRA2|GABRA5|GABRA4|GABRA1|GABRA6|FAAH|CHRNA4|CHRNA7|GRIK2|GRIA2	https://www.drugbank.ca/drugs/DB00599|https://www.drugbank.ca/drugs/DB00599|https://www.drugbank.ca/drugs/DB00599|https://www.drugbank.ca/drugs/DB00599|https://www.drugbank.ca/drugs/DB00599|https://www.drugbank.ca/drugs/DB00599|https://www.drugbank.ca/drugs/DB00599|https://www.drugbank.ca/drugs/DB00599|https://www.drugbank.ca/drugs/DB00599|https://www.drugbank.ca/drugs/DB00599|https://www.drugbank.ca/drugs/DB00599	GABA receptor antagonist	neurology/psychiatry	anesthetic	https://en.wikipedia.org/wiki/Sodium_thiopental#Uses
naftifine	naftifine	naftin	CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12	Launched	FDA Orange Book: naftifine hydrochloride	SQLE	https://www.drugbank.ca/drugs/DB00735	fungal squalene epoxidase inhibitor	infectious disease|infectious disease|infectious disease	tinea pedis|tinea cruris|tinea corporis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2bfdef60-3fa9-467f-ba82-8e4870c7d2c1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2bfdef60-3fa9-467f-ba82-8e4870c7d2c1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2bfdef60-3fa9-467f-ba82-8e4870c7d2c1
flurbiprofen-(+/-)	(+/-)-flurbiprofen		CC(C(O)=O)c1ccc(c(F)c1)-c1ccccc1	Launched				cyclooxygenase inhibitor			
suvorexant	suvorexant	MK-4305|belsomra	C[C@@H]1CCN(CCN1C(=O)c1cc(C)ccc1-n1nccn1)c1nc2cc(Cl)ccc2o1	Launched	FDA Orange Book: suvorexant	HCRTR1|HCRTR2	ChEMBL|ChEMBL	orexin receptor antagonist	neurology/psychiatry	insomnia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5b72731-1acb-45b7-9c13-290ad12d3951&audience=consumer
ftaxilide	ftaxilide		Cc1cccc(C)c1NC(=O)c1ccccc1C(O)=O	Preclinical							
lacitol	lacitol		OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO	Launched	http://en.wikipedia.org/wiki/Lactitol			osmosis stimulant	gastroenterology	constipation	https://en.wikipedia.org/wiki/Lactitol
SP-141	SP-141		COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12	Preclinical		MDM2	https://www.tocris.com/products/sp-141_5332	ubiquitin ligase inhibitor			
opipramol	opipramol		OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc23)CC1	Launched	http://www.drugs.com/international/Opipramol.html			sigma receptor agonist	neurology/psychiatry	generalized anxiety disorder (GAD)	https://en.wikipedia.org/wiki/Opipramol
procaine	procaine	Novocain	CCN(CC)CCOC(=O)c1ccc(N)cc1	Launched	FDA Orange Book: chloroprocaine hydrochloride, penicillin g procaine, procaine hydrochloride, procaine merethoxylline	HTR3A|KCNN2|KCNN3|KCNN1|KCNN4|SLC6A3|CHRNA2|SCN10A|HMGCR|RYR1|RYR2|KCNMA1|KCNMB1|KCNMB2|KCNMB3|KCNMB4|MAOA|MAOB|GRIN3A	https://www.drugbank.ca/drugs/DB00721|https://www.drugbank.ca/drugs/DB00721|https://www.drugbank.ca/drugs/DB00721|https://www.drugbank.ca/drugs/DB00721|https://www.drugbank.ca/drugs/DB00721|https://www.drugbank.ca/drugs/DB00721|https://www.drugbank.ca/drugs/DB00721|https://www.drugbank.ca/drugs/DB00721|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091315|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4291|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4291|https://www.drugbank.ca/drugs/DB00721|https://www.drugbank.ca/drugs/DB00721|https://www.drugbank.ca/drugs/DB00721|https://www.drugbank.ca/drugs/DB00721|https://www.drugbank.ca/drugs/DB00721|https://www.drugbank.ca/drugs/DB00721|https://www.drugbank.ca/drugs/DB00721|https://www.drugbank.ca/drugs/DB00721	HMGCR inhibitor	neurology/psychiatry	anesthetic	https://en.wikipedia.org/wiki/Procaine#Pharmacology
SEP-227900	SEP-227900	5-Carboxyfuro[3,2-B]Pyrrole	OC(=O)c1cc2occc2[nH]1	Phase 1	http://adisinsight.springer.com/drugs/800030153	DAO	http://www.biocentury.com/products/sep-227900	D-Amino Acid Oxidase Inhibitor			
saracatinib	saracatinib	AZ-10353926|AZD-0530|AZD0530	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT01196741	LCK|SRC|ABL1|YES1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7731|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7731|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7731|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7731	src inhibitor			
levallorphan	levallorphan	Naloxiphan|lorfan	Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1	Launched	FDA Orange Book: levallorphan tartrate	CHRNA2|OPRM1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000348|https://www.drugbank.ca/drugs/DB00504	opioid antagonist	pulmonary	respiratory depression	http://www.drugs.com/international/levallorphan.html
atazanavir	atazanavir	CGP-73547|reyataz	COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	Launched	FDA Orange Book: atazanavir sulfate			HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=165cff62-b284-4a27-a65d-9ec8a5bfcdd8
pifithrin-cyclic	pifithrin-cyclic		Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1	Preclinical		TP53	https://www.tocris.com/products/cyclic-pifithrin-a-hydrobromide_3843	TP53 inhibitor			
glucosamine	glucosamine		N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O	Launched	http://www.drugs.com/international/glucosamine.html	MMP9|NFKB2|IL1B|TNF|IFNG	https://www.drugbank.ca/drugs/DB01296|https://www.drugbank.ca/drugs/DB01296|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001097|https://www.drugbank.ca/drugs/DB01296|https://www.drugbank.ca/drugs/DB01296	glycosylated protein precursor	neurology/psychiatry|rheumatology|rheumatology|neurology/psychiatry	muscle pain|rheumatoid arthritis|joint pain|backache	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=69c6b560-97b9-43cf-9889-75ff01241854|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=69c6b560-97b9-43cf-9889-75ff01241854|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=69c6b560-97b9-43cf-9889-75ff01241854|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=69c6b560-97b9-43cf-9889-75ff01241854
tagatose	tagatose			Phase 3	https://clinicaltrials.gov/ct2/show/NCT00955747	PYGL	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1186487/	phosphorylase inhibitor			
daucosterol	daucosterol		CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)C	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/24838062			apoptosis stimulant			
methoprene-(s)	methoprene-(s)	methoprene	COC(C)(C)CCC[C@H](C)C\C=C\C(C)=C\C(=O)OC(C)C	Preclinical							
ebselen	ebselen		O=c1n([se]c2ccccc12)-c1ccccc1	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT00762671	ALB|NOX3|LTB4R	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001372|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090700|https://citeline.informa.com/?query=#/drugs/details/6212	cyclooxygenase inhibitor|glutathione peroxidase agonist|H+/K+-ATPase inhibitor|nitric oxide synthase inhibitor			
neomycin	neomycin	neomycin a	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	Launched	FDA Orange Book: neomycin sulfate	CXCR4	https://www.drugbank.ca/drugs/DB00452	bacterial 30S ribosomal subunit inhibitor	gastroenterology|infectious disease	hepatic encephalopathy (HE)|intra-abdominal infections	http://www.webmd.com/drugs/2/drug-8047/neomycin-oral/details|http://www.webmd.com/drugs/2/drug-8047/neomycin-oral/details
TAK-063	TAK-063		COc1cn(nc(-c2ccnn2-c2ccccc2)c1=O)-c1ccc(cc1F)-n1cccn1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02477020	PDE10A	https://www.medchemexpress.com/TAK-063.html?gclid=CKiup_qRv88CFQdkhgodpBIAYQ	phosphodiesterase inhibitor			
BP-554	BP-554		C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1	Preclinical		HTR1A	http://www.tocris.com/dispprod.php?ItemId=1618#.UuFdwf30BaE	serotonin receptor agonist			
luliconazole	luliconazole	NND-502|PR-2699|luzu	Clc1ccc([C@@H]2CS\C(S2)=C(\C#N)n2ccnc2)c(Cl)c1	Launched	FDA Orange Book: luliconazole			sterol demethylase inhibitor	infectious disease|infectious disease|infectious disease	tinea pedis|tinea cruris|tinea corporis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7016010-ce43-4c09-8d21-aeb697ffed31|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7016010-ce43-4c09-8d21-aeb697ffed31|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7016010-ce43-4c09-8d21-aeb697ffed31
6-chloromelatonin	6-chloromelatonin		COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl	Preclinical		MTNR1B|MTNR1A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1346|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1346	melatonin receptor agonist			
CFTRinh-172	CFTRinh-172		OC(=O)c1ccc(cc1)\C=C1\SC(=S)N(C1=O)c1cccc(c1)C(F)(F)F	Preclinical		CFTR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4153	chloride channel blocker			
sanguinarium-chloride	sanguinarium chloride	Sanguinarine|sanguinarium	C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/8537870	CASP3|ACHE	http://www.labnovo.com/CAS/5578-73-4/MFCD00012126|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=118385	apoptosis stimulant			
cephradine	cephradine	velosef|velosef '250'|velosef '500'	CC1=C(N2C(SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O	Launched	FDA Orange Book: cephradine			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease	skin infections|respiratory tract infections|urinary tract infections	http://www.medicinenet.com/cephradine-oral/article.htm|http://www.medicinenet.com/cephradine-oral/article.htm|http://www.medicinenet.com/cephradine-oral/article.htm
orphanin-fq	Orphanin FQ	Nociceptin|Nociceptin/orphanin FQ|Orphanin FQ	CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01198197	OPRL1|OPRM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1681|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004256	opioid receptor agonist			
AT13148	AT13148	AT-13148	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01585701	ROCK2|ROCK1|AKT2|AKT1|AKT3|SGK3	https://us.axonmedchem.com/product/2166/?SID=001d1aa56b204b20810663b57ec24dcb&country_id=US|https://us.axonmedchem.com/product/2166/?SID=001d1aa56b204b20810663b57ec24dcb&country_id=US|https://us.axonmedchem.com/product/2166/?SID=001d1aa56b204b20810663b57ec24dcb&country_id=US|https://us.axonmedchem.com/product/2166/?SID=001d1aa56b204b20810663b57ec24dcb&country_id=US|https://us.axonmedchem.com/product/2166/?SID=001d1aa56b204b20810663b57ec24dcb&country_id=US|https://us.axonmedchem.com/product/2166/?SID=001d1aa56b204b20810663b57ec24dcb&country_id=US	protein kinase inhibitor			
2'-c-methylguanosine	2'-c-methylguanosine	2'-B-METHYL-GUANOSINE|2'-Beta-Methylguanosine|Beta-2'-Methylguanosine	C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(O)nc(N)nc12	Preclinical				HCV inhibitor			
terutroban	terutroban	S18886	Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1	Phase 3	https://www.ncbi.nlm.nih.gov/pubmed/21616527	TBXA2R	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6073	prostanoid receptor antagonist			
tetrahydropapaverine	tetrahydropapaverine		COc1ccc(CC2NCCc3cc(OC)c(OC)cc23)cc1OC	Preclinical							
thiodiglycol	thiodiglycol		OCCSCCO	Preclinical							
5-carboxamidotryptamine	5-carboxamidotryptamine		NCCc1c[nH]c2ccc(cc12)C(N)=O	Preclinical		HTR1B|HTR1A|HTR1F|HTR1D|HTR1E|HTR2C|HTR2A|HTR2B|HTR5A|HTR7|HTR6	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4	serotonin receptor agonist			
2-cyanopyrimidine	2-cyanopyrimidine		N#Cc1ncccn1	Preclinical				cathepsin inhibitor			
VU-0422288	VU-0422288		Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1	Preclinical		GRM3	https://www.tocris.com/products/vu-0422288_5378	glutamate receptor allosteric modulator			
synephrine	synephrine	oxedrine	CNCC(O)c1ccc(O)cc1	Launched	http://en.wikipedia.org/wiki/Synephrine	ADRA1A	http://en.wikipedia.org/wiki/Synephrine	adrenergic receptor agonist			
5-iodo-A-85380	5-iodo-A-85380		Ic1cncc(OC[C@@H]2CCN2)c1	Phase 2	https://clinicaltrials.gov/show/NCT00061789			acetylcholine receptor agonist			
sobrepin	sobrepin		CC1=CC[C@H](C[C@@H]1O)C(C)(C)O	Launched	http://www.drugs.com/international/Sobrepin.html			mucolytic agent	pulmonary	chest congestion	http://www.drugs.com/international/sobrerol.html
N-salicoylaminophenol	N-salicoylaminophenol	L-1718|osalmid	Oc1ccc(NC(=O)c2ccccc2O)cc1	Preclinical				ribonucleotide reductase inhibitor			
timonacic	timonacic		OC(=O)C1CSCN1	Launched	http://www.drugs.com/international/timonacic.html	ANXA5	https://www.drugbank.ca/drugs/DB02846	antioxidant			
WR99210	WR99210	WR-99210	CC1(C)N=C(N)N=C(N)N1OCCCOc1cc(Cl)c(Cl)cc1Cl	Preclinical		TYMS	https://www.drugbank.ca/drugs/DB08734	dihydrofolate reductase inhibitor	infectious disease	malaria	http://www.sigmaaldrich.com/catalog/product/sigma/w1770?lang=en&region=US
sulfanilate-zinc	sulfanilate zinc		Nc1ccc(cc1)S(=O)(=O)O[Zn]OS(=O)(=O)c1ccc(N)cc1	Preclinical							
allylestrenol	allylestrenol		C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)CC=C	Launched	https://www.drugs.com/international/allylestrenol.html	SLC6A9|ESR1|PGR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DPR000085|https://www.drugbank.ca/drugs/DB01431|https://www.drugbank.ca/drugs/DB01431	steroidal progestin	obstetrics/gynecology	premature labor	https://en.wikipedia.org/wiki/Allylestrenol
tenylidone	tenylidone		O=C1\C(CCC\C1=C/c1cccs1)=C\c1cccs1	Preclinical							
homidium	homidium		CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12	Preclinical							
levobetaxolol	levobetaxolol		CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1	Launched	FDA Orange Book: levobetaxolol hydrochloride	ADRB2|ADRB1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8035|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8035	adrenergic receptor antagonist	ophthalmology|ophthalmology	intraocular pressure|glaucoma	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021114_s000_Betaxon.cfm|https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021114_s000_Betaxon.cfm
sal003	sal003		Clc1ccc(cc1)NC(=S)NC(C(Cl)(Cl)Cl)NC(=O)\C=C\c1ccccc1	Preclinical		EIF2A	http://www.tocris.com/dispprod.php?ItemId=236229#.Vg2BCWRVhHw	eukaryotic translation initiation factor inhibitor			
matrine	matrine		O=C1CCC[C@@H]2[C@@H]3CCCN4CCC[C@H](CN12)[C@@H]34	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/23257008	OPRK1	https://en.wikipedia.org/wiki/Matrine	opioid receptor agonist			
PF-3845	PF-3845		FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1	Preclinical		FAAH	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5243	FAAH inhibitor			
temefos	temefos		COP(=S)(OC)Oc1ccc(Sc2ccc(OP(=S)(OC)OC)cc2)cc1	Veterinary Launched	http://www.drugs.com/international/temefos.html			cholinesterase inhibitor			
4,4-pentamethylenepiperidine	4,4-pentamethylenepiperidine		C1CCC2(CC1)CCNCC2	Preclinical				M2 channel blocker			
ioxilan	ioxilan	oxilan|oxilan-300|oxilan-350	CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NCC(O)CO)c1I	Launched	FDA Orange Book: ioxilan			radiopaque medium	radiology	angiography	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae692163-dfbf-4271-87ad-4ed888caa513
desipramine	desipramine	norpramin|pertofrane	CNCCCN1c2ccccc2CCc2ccccc12	Launched	FDA Orange Book: desipramine hydrochloride	HTR1A|HTR2C|HTR2A|HRH1|ADRA1D|ADRA1B|ADRA1A|ADRA2C|ADRA2B|ADRA2A|SMPD1|CHRM1|CHRM4|CHRM5|CHRM2|CHRM3|DRD2|ADRB1|ADRB2|SLC6A2|SLC6A4	https://www.drugbank.ca/drugs/DB01151|https://www.drugbank.ca/drugs/DB01151|https://www.drugbank.ca/drugs/DB01151|https://www.drugbank.ca/drugs/DB01151|https://www.drugbank.ca/drugs/DB01151|https://www.drugbank.ca/drugs/DB01151|https://www.drugbank.ca/drugs/DB01151|https://www.drugbank.ca/drugs/DB01151|https://www.drugbank.ca/drugs/DB01151|https://www.drugbank.ca/drugs/DB01151|https://www.drugbank.ca/drugs/DB01151|https://www.drugbank.ca/drugs/DB01151|https://www.drugbank.ca/drugs/DB01151|https://www.drugbank.ca/drugs/DB01151|https://www.drugbank.ca/drugs/DB01151|https://www.drugbank.ca/drugs/DB01151|https://www.drugbank.ca/drugs/DB01151|https://www.drugbank.ca/drugs/DB01151|https://www.drugbank.ca/drugs/DB01151|https://www.drugbank.ca/drugs/DB01151|https://www.drugbank.ca/drugs/DB01151	tricyclic antidepressant	neurology/psychiatry	depression	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ec5f73f-32b6-48c3-b16e-891d06edf6eb
PD-118057	PD-118057	PD-0118057	OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1	Preclinical		KCNH2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7676	potassium channel activator			
enalapril	enalapril	Lexxel|Vaseretic|epaned kit|vasotec	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O	Launched	FDA Orange Book: enalapril maleate, enalaprilat	ACE	https://www.drugbank.ca/drugs/DB00584	angiotensin converting enzyme inhibitor	cardiology|cardiology|cardiology	hypertension|congestive heart failure|left ventricular systolic dysfunction (LVSD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac0289a6-9533-4f8c-b46c-506dce1b90b5|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac0289a6-9533-4f8c-b46c-506dce1b90b5|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac0289a6-9533-4f8c-b46c-506dce1b90b5
trientine	trientine	syprine	NCCNCCNCCN	Launched	FDA Orange Book: trientine hydrochloride	CA14	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011083	chelating agent	metabolism	Wilson's disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ed52ecf-cda9-4a06-bacc-2c2827cc8967&audience=consumer
priralfinamide	priralfinamide	FCE-26742A|NW-1029|PNU-0154339E|ralfinamide	C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01019824	CACNA1B	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000949	sodium channel blocker			
SC-236	SC-236		NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F	Preclinical		PTGS2	https://www.tocris.com/products/sc-236_3919	cyclooxygenase inhibitor			
PNU-177864	PNU-177864		CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1	Preclinical		DRD3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000934	dopamine receptor antagonist			
ML-179	ML-179		FC(F)(F)c1cccc(c1)N1CCN(CC1)c1cc(=O)n(C2CCCCC2)c(=O)[nH]1	Preclinical		NR5A2	https://www.tocris.com/products/ml-179_4957	liver receptor homolog inverse agonist			
NVP-HSP990	NVP-HSP990		COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1	Phase 1	http://www.selleckchem.com/products/hsp990-nvp-hsp990.html	HSP90AB1|HSP90AA1	https://www.ncbi.nlm.nih.gov/pubmed/22246440|https://www.ncbi.nlm.nih.gov/pubmed/22246440	HSP inhibitor			
bambuterol	bambuterol		CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(c1)C(O)CNC(C)(C)C	Launched	http://www.drugs.com/international/bambuterol.html	CYP2D6|BCHE|ADRB2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090431|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6601|https://www.drugbank.ca/drugs/DB01408	adrenergic receptor agonist	pulmonary	asthma	https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=bambuterol
meldonium	meldonium		C[N+](C)(C)NCCC(O)=O	Launched	https://www.drugs.com/international/meldonium.html	BBOX1	https://en.wikipedia.org/wiki/Meldonium#Pharmacology	gamma butyrobetaine hydroxylase inhibitor	cardiology	coronary artery disease (CAD)	https://en.wikipedia.org/wiki/Meldonium#Medical_use
mizolastine	mizolastine		CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nccc(=O)[nH]1	Launched	http://www.drugs.com/international/Mizolastine.html	HRH1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001403	histamine receptor antagonist	allergy|allergy	urticaria|allergic rhinitis	http://www.drugs.com/uk/mizollen-10mg-modified-release-tablets-leaflet.html|http://www.drugs.com/uk/mizollen-10mg-modified-release-tablets-leaflet.html
gepon	gepon		CC(C)[C@@H](NC(=O)C(NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)C(CCCNC(N)=N)NC(=O)C(CCCCN)NC(=O)[C@@H](CCCCN)NC(=O)C(CCC(O)=O)NC(=O)[C@H](N)C(C)O)C(C)O)C(=O)N[C@H](CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NC(CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O	Phase 1	http://online.liebertpub.com/doi/abs/10.1016/j.jomh.2011.08.030?journalCode=j.jomh						
CNX-2006	CNX-2006		COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F	Preclinical		EGFR	http://www.selleckchem.com/products/cnx-2006.html	EGFR inhibitor			
clemastine	clemastine	HS-592|clemastine fumarate|tavist|tavist-1	CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1	Launched	FDA Orange Book: clemastine fumarate	HRH1	https://www.drugbank.ca/drugs/DB00283	histamine receptor antagonist	allergy|allergy	allergic rhinitis|urticaria	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e403ca1-0c23-4af6-bfac-50187d8d4653|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e403ca1-0c23-4af6-bfac-50187d8d4653
oxyphenbutazone	oxyphenbutazone	oxazolidin|oxiphenbutazone|tandearil	CCCCC1C(=O)N(N(C1=O)c1ccc(O)cc1)c1ccccc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	PTGS2|PTGS1|PLA2G2E	ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB03585	cyclooxygenase inhibitor			
nonoxynol-9	NONOXYNOL 9	EMKO|NONOXINOL 9|NONOXYNOL 9|conceptrol|delfen|gynol ii|intercept|nonylphenoxypolyethoxyethanol|semicid|today|today sponge	CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1	Launched	FDA Orange Book: nonoxynol-9			membrane integrity inhibitor	endocrinology	contraceptive	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5d78ff6-31af-4c46-91b0-b7e5d40c1153
bitoscanate	bitoscanate		S=C=Nc1ccc(cc1)N=C=S	Preclinical				anthelmintic agent			
butylphthalide	butylphthalide	N-Butylphthalide|RAC-3-N-BUTYLPHTHALIDE	CCCCC1OC(=O)c2ccccc12	Launched	https://clinicaltrials.gov/ct2/show/NCT00724724	KCNK2|CYP2B6|CYP2E1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009930/|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=284092|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=284092	potassium channel antagonist	neurology/psychiatry	stroke	https://en.wikipedia.org/wiki/Butylphthalide
pyrithione-zinc	pyrithione zinc	head & shoulders conditioner	O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1	Launched	FDA Orange Book: pyrithione zinc	KCNQ1|KCNQ2|KCNQ4|KCNQ5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2597|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2597|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2597|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2597	ATP synthase inhibitor	dermatology	dandruff	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91f25c4e-297a-4348-802b-3e5dd2507de6
litronesib	litronesib	KF89617|LY2523355	CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01416389	KIF11	https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=661443	kinesin-like spindle protein inhibitor			
N-MPPP	N-MPPP		CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1	Preclinical				opioid receptor agonist			
fmoc-l-leucine	fmoc-l-leucine		CC(C)C[C@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O	Phase 2	http://adisinsight.springer.com/drugs/800001904			PPAR receptor agonist			
ibudilast	ibudilast	AV-411|MN-166	CC(C)C(=O)c1c(nn2ccccc12)C(C)C	Launched	http://www.drugs.com/international/Ibudilast.html	MIF|IL6|PDE5A|PDE4C|PDE4D|PDE4A|PDE4B|PDE3A|IL1B|CYSLTR1|TLR4|PDE10A|PDE11A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=112439|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000838|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7399|https://www.drugbank.ca/drugs/DB05266|https://www.drugbank.ca/drugs/DB05266|https://www.drugbank.ca/drugs/DB05266|https://www.drugbank.ca/drugs/DB05266|https://www.drugbank.ca/drugs/DB05266|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000838|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=112439|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=112439|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=112439|https://citeline.informa.com/?query=#/drugs/details/9018	leukotriene receptor antagonist|phosphodiesterase inhibitor	pulmonary|neurology/psychiatry	asthma|stroke	https://en.wikipedia.org/wiki/Ibudilast|https://en.wikipedia.org/wiki/Ibudilast
levodropropizine	levodropropizine		OC[C@@H](O)CN1CCN(CC1)c1ccccc1	Launched	http://www.drugs.com/international/levodropropizine.html			antitussive	pulmonary	cough suppressant	https://en.wikipedia.org/wiki/Levodropropizine
etoxybamide	etoxybamide		OCCCC(=O)NCCO	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/11417267						
AZD1283	AZD1283		CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1	Preclinical		P2RY12	http://www.nature.com/nature/journal/v509/n7498/fig_tab/nature13083_F2.html	purinergic receptor antagonist			
lypressin	lypressin	diapid	NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O	Launched	FDA Orange Book: lypressin	AVPR2|AVPR1B|AVPR1A	ChEMBL|ChEMBL|ChEMBL	vasopressin receptor agonist			
anisodamine	anisodamine		CN1C2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01929044	TNF|ADRA1A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=312028|https://en.wikipedia.org/wiki/Anisodamine	lipid peroxidase inhibitor			
liothyronine	liothyronine	Euthroid-0.5|Euthroid-1|Euthroid-2|Euthroid-3|Rathyronine|T3 (LIOTRIX)|Tertroxin|Thyrolar-0.25|Thyrolar-0.5|Thyrolar-1|Thyrolar-2|Thyrolar-3|Thyrolar-5|Triiodothyronine (T3 Or Liothyronine, Active) (6-11%)|cytomel|triostat	N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O	Launched	FDA Orange Book: liothyronine sodium	THRA|THRB	ChEMBL|ChEMBL	thyroid hormone stimulant	endocrinology|endocrinology	hypothyroidism|myxedema coma	https://en.wikipedia.org/wiki/Liothyronine|https://en.wikipedia.org/wiki/Liothyronine
AMG-548	AMG-548		Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/16022178	MAPK14|MAPK11|MAPK13|MAPK12|TNF	https://www.tocris.com/dispprod.php?ItemId=254827#.V-BO85MrLy8|https://www.tocris.com/dispprod.php?ItemId=254827#.V-BO85MrLy8|https://www.tocris.com/dispprod.php?ItemId=254827#.V-BO85MrLy8|https://www.tocris.com/dispprod.php?ItemId=254827#.V-BO85MrLy8|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=336991	MAP kinase inhibitor			
cilazapril	cilazapril		CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@@H](N2C1=O)C(O)=O	Launched	http://en.wikipedia.org/wiki/Cilazapril	ACE	https://www.drugbank.ca/drugs/DB01340	angiotensin converting enzyme inhibitor	cardiology|cardiology	hypertension|congestive heart failure	https://en.wikipedia.org/wiki/Cilazapril|https://en.wikipedia.org/wiki/Cilazapril
PIK-75	PIK-75		CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O	Preclinical		PIK3CA|PIK3CG|PIK3CB|PIK3CD|PRKDC	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8012|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8012|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8012|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8012|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8012	DNA protein kinase inhibitor|PI3K inhibitor			
L-760735	L-760735		C[C@@H](O[C@H]1OCCN(Cc2nn[nH]c2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	Preclinical		TACR1	https://www.tocris.com/products/l-760735_4013	tachykinin antagonist			
fanetizole	fanetizole		C(Cc1ccccc1)Nc1nc(cs1)-c1ccccc1	Phase 3	https://www.hindawi.com/journals/isrn/2011/434613/			neutrophil superoxide production			
nebracetam	nebracetam		NCC1CN(Cc2ccccc2)C(=O)C1	Phase 3	http://adisinsight.springer.com/drugs/800001127	CHRM1	https://en.wikipedia.org/wiki/Nebracetam	acetylcholine receptor agonist			
HLCL-61	HLCL-61		CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12	Preclinical		PRMT5	http://www.medkoo.com/products/9397	protein arginine N-methyltransferase inhibitor			
promestriene	promestriene		CCCOc1ccc2[C@H]3CC[C@]4(C)[C@H](CC[C@H]4[C@@H]3CCc2c1)OC	Launched	https://www.drugs.com/international/promestriene.html	ESR1	http://www.genome.jp/dbget-bin/www_bget?dr:D07221	estrogen receptor agonist	endocrinology	androgenetic alopecia	https://en.wikipedia.org/wiki/Promestriene
sophocarpine	sophocarpine		O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34	Phase 3	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002765/						
isoxicam	isoxicam		CN1C(C(=O)Nc2cc(C)on2)C(=O)c2ccccc2S1(=O)=O	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	PTGS2|PTGS1	http://www.ncbi.nlm.nih.gov/pubmed/24425867|http://www.ncbi.nlm.nih.gov/pubmed/24425867	cyclooxygenase inhibitor			
EPPTB	EPPTB		CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1	Preclinical		TAAR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5457	trace amine associated receptor antagonist			
JZL-195	JZL-195		[O-][N+](=O)c1ccc(OC(=O)N2CCN(Cc3cccc(Oc4ccccc4)c3)CC2)cc1	Preclinical		FAAH|MGLL	https://www.tocris.com/products/jzl-195_4715|https://www.tocris.com/products/jzl-195_4715	FAAH inhibitor|monoacylglycerol lipase inhibitor			
SR-3306	SR-3306		Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1	Preclinical		MAPK10|MAPK9|MAPK8	https://www.medchemexpress.com/SR-3306.html?gclid=CJWyj6SEv88CFVRbhgodFVIG0Q|https://www.medchemexpress.com/SR-3306.html?gclid=CJWyj6SEv88CFVRbhgodFVIG0Q|https://www.medchemexpress.com/SR-3306.html?gclid=CJWyj6SEv88CFVRbhgodFVIG0Q	JNK inhibitor			
1,2,3,4,5,6-hexabromocyclohexane	1,2,3,4,5,6-hexabromocyclohexane		BrC1C(Br)C(Br)C(Br)C(Br)C1Br	Preclinical				JAK inhibitor			
IEM1754	IEM1754		NCCCCCNCC12CC3CC(CC(C3)C1)C2	Preclinical		GRIA1	http://www.scbt.com/datasheet-362747.html	glutamate receptor antagonist			
blebbistatin-(+/-)	(+/-)-blebbistatin		Cc1ccc2N=C3N(CCC3(O)C(=O)c2c1)c1ccccc1	Preclinical				ATPase inhibitor			
bisacodyl	bisacodyl	correctol tablets, caplets|dulcolax|feen-a-mint tablets|sk-bisacodyl|theralax	CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1	Launched	FDA Orange Book: bisacodyl			laxative	gastroenterology	constipation	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af84c8aa-02fa-758f-0072-2eedf60e68ae
ethacizin	ethacizin	ethacizine	CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN(CC)CC)c2c1	Launched	https://en.wikipedia.org/wiki/Ethacizine			anticonvulsant	cardiology|cardiology	ventricular tachycardia (VT)|Wolff-Parkinson-White Syndrome (WPW)	https://en.wikipedia.org/wiki/Ethacizine|https://en.wikipedia.org/wiki/Ethacizine
NAN-190	NAN-190		COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1	Preclinical		HTR1A|HTR1F|ADRA1B|ADRA1A|ADRA1D	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=73|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=73|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=73|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=73|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=73	serotonin receptor agonist			
TRV130	TRV130	oliceridine	COc1ccsc1CNCC[C@]1(CCOC2(CCCC2)C1)c1ccccn1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02656875	OPRM1	http://www.adooq.com/trv130-hcl.html?gclid=CIWV7rXIv88CFZJahgodl6cCFg	opioid receptor agonist			
NT157	NT157		Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O	Preclinical		IGF1R	https://www.axonmedchem.com/product/2238	IGF-1 inhibitor			
ornidazole	ornidazole	RO 7-0207	Cc1ncc(n1CC(O)CCl)[N+]([O-])=O	Launched	http://www.drugs.com/international/Ornidazole.html			antiprotozoal agent	infectious disease	protozoan infection	http://www.drugs.com/international/ornidazole.html
acetohexamide	acetohexamide	dymelor	CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	Launched	FDA Orange Book: acetohexamide	KCNJ10|KCNJ11|KCNJ1|ABCC8	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000922|ChEMBL|https://www.drugbank.ca/drugs/DB00414|ChEMBL	ATP channel blocker	endocrinology	diabetes mellitus	https://en.wikipedia.org/wiki/Acetohexamide
AS-1892802	AS-1892802		OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1	Preclinical		ROCK1	https://www.tocris.com/products/as-1892802_4927	rho associated kinase inhibitor			
2-hydroxy-4-((E)-3-(4-hydroxyphenyl)acryloyl)-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)cyclohexane-1,3,5-trione	2-hydroxy-4-((E)-3-(4-hydroxyphenyl)acryloyl)-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)cyclohexane-1,3,5-trione		OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1C(=O)C(C(=O)\C=C\c2ccc(O)cc2)C(=O)C(O)([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C1=O	Preclinical							
L-838417	L-838417		Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F	Preclinical		GABRA2|GABRA3|GABRA1|GABRA5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4241|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4241|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4241|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4241	GABA receptor partial agonist			
tofisopam	tofisopam		CCC1=C(C)NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc12	Launched	https://www.drugs.com/international/tofisopam.html	GABRA2|GABRA3|GABRA1|GABRA5|PDE3A|PDE2A|PDE4A|CYP3A4|PDE10A	https://citeline.informa.com/?query=#/drugs/details/18320|https://citeline.informa.com/?query=#/drugs/details/18320|https://citeline.informa.com/?query=#/drugs/details/18320|https://citeline.informa.com/?query=#/drugs/details/18320|https://www.drugbank.ca/drugs/DB08811|https://www.drugbank.ca/drugs/DB08811|https://www.drugbank.ca/drugs/DB08811|https://en.wikipedia.org/wiki/Tofisopam|https://www.drugbank.ca/drugs/DB08811	phosphodiesterase inhibitor|cytochrome P450 inhibitor	neurology/psychiatry|neurology/psychiatry	anxiety|abstinence from alcohol	https://en.wikipedia.org/wiki/Tofisopam|https://en.wikipedia.org/wiki/Tofisopam
ETP-46464	ETP-46464		CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1	Preclinical				ATR kinase inhibitor			
moclobemide	moclobemide	GNF-Pf-695|RO 11-1163/000	Clc1ccc(cc1)C(=O)NCCN1CCOCC1	Launched	http://www.drugs.com/international/Moclobemide.html	MAOB|MAOA|CYP2C19	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7428|https://www.drugbank.ca/drugs/DB01171|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090662	monoamine oxidase inhibitor	neurology/psychiatry|neurology/psychiatry	depression|anxiety	https://en.wikipedia.org/wiki/Moclobemide|https://en.wikipedia.org/wiki/Moclobemide
pentylenetetrazol	pentylenetetrazol	cardiazol|pentamethylenetetrazol|pentetrazol	C1CCc2nnnn2CC1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs			GABA receptor antagonist			
SP-420	SP-420		COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(O)=O)c(O)c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02274233						
NVP-AEW541	NVP-AEW541		Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1	Preclinical		IGF1R|INSR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8067|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014100	IGF-1 inhibitor			
finafloxacin	finafloxacin	xtoro	OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O	Launched	FDA Orange Book: finafloxacin			bacterial DNA gyrase inhibitor	infectious disease|pulmonary|pulmonary	intra-abdominal infections|chronic obstructive pulmonary disease (COPD)|cystic fibrosis	http://www.merlionpharma.com/?q=node/16|http://www.merlionpharma.com/?q=node/16|http://www.merlionpharma.com/?q=node/16
scriptaid	scriptaid	GNF-Pf-2024|SJ000016636	ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23	Preclinical		HDAC8|HDAC9|HDAC6|HDAC7|HDAC4|HDAC5|HDAC2|HDAC3|HDAC1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7505|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7505|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7505|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7505|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7505|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7505|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7505|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7505|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7505	HDAC inhibitor			
diclofenamide	diclofenamide	daranide|dichlorphenamide|keveyis	NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O	Launched	FDA Orange Book: dichlorphenamide	CA4|CA2|CA1|CA7|CA12	ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB01144|ChEMBL	carbonic anhydrase inhibitor	ophthalmology|neurology/psychiatry	glaucoma|epilepsy	https://en.wikipedia.org/wiki/Diclofenamide|https://en.wikipedia.org/wiki/Diclofenamide
MK-3697	MK-3697		COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC	Phase 2	http://www.sleepdex.org/newdrugs.htm	HCRTR2	http://www.ncbi.nlm.nih.gov/pubmed/25248679	orexin receptor antagonist			
AV-608	AV-608	Spergualin	FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00335660	TACR1	http://www.drugbank.ca/drugs/DB05072	tachykinin antagonist			
myricitrin	myricitrin		C[C@@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2cc(O)c(O)c(O)c2)[C@@H](O)[C@H](O)[C@H]1O	Preclinical		PRKCA|AKR1B1|NOS1	http://www.sigmaaldrich.com/catalog/product/sigma/91255?lang=en&region=US|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=321579|http://www.sigmaaldrich.com/catalog/product/sigma/91255?lang=en&region=US	PKC inhibitor			
AIM-100	AIM-100		C(Nc1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1)[C@@H]1CCCO1	Preclinical		TNK2	https://www.tocris.com/products/aim-100_4946	tyrosine kinase inhibitor			
ZM-447439	ZM-447439	TCMDC-125873	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1	Preclinical		AURKB|AURKA	http://www.selleckchem.com/products/ZM-447439.html|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006943	Aurora kinase inhibitor			
LY288513	LY288513	LY-288513	Brc1ccc(NC(=O)N2NC(=O)[C@H]([C@@H]2c2ccccc2)c2ccccc2)cc1	Preclinical		CCKBR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=902	CCK receptor antagonist			
BI-2536	BI-2536		CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00701766	PLK3|PLK2|PLK1|BRD4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5666|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5666|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5666|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5666	PLK inhibitor			
diphenylguanidine	diphenylguanidine	N,N'-Diphenyl-Guanidine	N=C(Nc1ccccc1)Nc1ccccc1	Preclinical							
GR-103691	GR-103691		COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1	Preclinical		DRD3	http://www.tocris.com/dispprod.php?ItemId=2153#.VgArCWRVhHw	dopamine receptor antagonist			
leflunomide	leflunomide	HWA-486|SU-101|arava|sulol	Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F	Launched	FDA Orange Book: leflunomide	AHR|JAK3|PTK2B|DHODH|CYP2C19|STAT6	https://www.drugbank.ca/drugs/DB01097|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=116061|https://www.drugbank.ca/drugs/DB01097|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=116061|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=116061	dihydroorotate dehydrogenase inhibitor|PDGFR tyrosine kinase receptor inhibitor	rheumatology	rheumatoid arthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=753453c5-8a7a-878e-3ce7-1d1edce718a9
JTE-607	JTE-607		CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O	Phase 2	http://en.pharmacodia.com/web/drug/1_5756.html	IL6|TNF|IL10|IL1B	https://www.tocris.com/dispprod.php?ItemId=413940#.V-qtfpMrLy8|https://www.tocris.com/dispprod.php?ItemId=413940#.V-qtfpMrLy8|https://www.tocris.com/dispprod.php?ItemId=413940#.V-qtfpMrLy8|https://www.tocris.com/dispprod.php?ItemId=413940#.V-qtfpMrLy8	cytokine production inhibitor			
diflorasone-diacetate	diflorasone diacetate	diflorasone diacetate|florone|florone e|psorcon|psorcon e	C[C@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(C)=O)C(=O)COC(C)=O	Launched	FDA Orange Book: diflorasone diacetate	NR3C1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7068	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a44f7c47-1fe7-4f5a-8bef-6df192c3357c
oxymatrine	oxymatrine		[O-][N+]12CCC[C@@H]3CN4[C@H](CCCC4=O)[C@H](CCC1)[C@@H]23	Launched	https://clinicaltrials.gov/ct2/show/NCT02202473						
TG-02	TG-02	SB-1317|TG02	CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01204164	CCNT1|MAPK7|FLT3|CDK9|CDK7|CDK1|CDK2|JAK2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=465977|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=465977|http://www.ncbi.nlm.nih.gov/pubmed/21860433|http://www.ncbi.nlm.nih.gov/pubmed/21860433|http://www.ncbi.nlm.nih.gov/pubmed/21860433|http://www.ncbi.nlm.nih.gov/pubmed/21860433|http://www.ncbi.nlm.nih.gov/pubmed/21860433|http://www.ncbi.nlm.nih.gov/pubmed/21860433	CDK inhibitor|FLT3 inhibitor|JAK inhibitor			
PHA-848125	PHA-848125	Milciclib	CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01011439	NTRK1|CDK5|CDK7|CDK2|CDK1|CDK4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7938|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=459837|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7938|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7938|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=459837|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7938	CDK inhibitor|growth factor receptor inhibitor			
7-hydroxy-DPAT	7-hydroxy-DPAT		CCCN(CCC)C1CCc2ccc(O)cc2C1	Preclinical		DRD3|DRD2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=950|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=950	dopamine receptor agonist			
ethionamide	ethionamide	1314 TH|Trecator-sc|trecator	CCc1cc(ccn1)C(S)=N	Launched	FDA Orange Book: ethionamide			mycolic synthesis inhibitor	infectious disease	tuberculosis	https://en.wikipedia.org/wiki/Ethionamide
17-hydroxyprogesterone-caproate	17-hydroxyprogesterone caproate	delalutin|hydroxyprogesterone caproate|makena	CCCCCC(=O)O[C@@]1(CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C)C(C)=O	Launched	FDA Orange Book: hydroxyprogesterone caproate	AR|CYP1A2|CYP2B6|CYP3A5|PGR|NR3C1|NR1I2|NR1H4|ESR2|ESR1	http://www.t3db.ca/toxins/T3D4792|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=420234|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=420234|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=420234|http://www.t3db.ca/toxins/T3D4792|http://www.t3db.ca/toxins/T3D4792|http://www.t3db.ca/toxins/T3D4792|http://www.t3db.ca/toxins/T3D4792|http://www.t3db.ca/toxins/T3D4792|http://www.t3db.ca/toxins/T3D4792	progesterone receptor agonist			
mirtazapine	mirtazapine	ORG 3770|ORG-3770|remeron|remeron soltab	CN1CCN2C(C1)c1ccccc1Cc1cccnc21	Launched	FDA Orange Book: mirtazapine	DRD2|DRD1|DRD5|DRD3|ADRB2|ADRB1|SLC6A4|SLC6A3|SLC6A2|OPRK1|HTR7|ADRA2C|ADRA2A|ADRA2B|ADRA1B|ADRA1A|ADRA1D|HRH3|HRH1|HTR2B|HTR2A|HTR2C|HTR3A	https://www.drugbank.ca/drugs/DB00370|https://www.drugbank.ca/drugs/DB00370|https://www.drugbank.ca/drugs/DB00370|https://www.drugbank.ca/drugs/DB00370|https://www.drugbank.ca/drugs/DB00370|https://www.drugbank.ca/drugs/DB00370|https://www.drugbank.ca/drugs/DB00370|https://www.drugbank.ca/drugs/DB00370|https://www.drugbank.ca/drugs/DB00370|https://www.drugbank.ca/drugs/DB00370|https://www.drugbank.ca/drugs/DB00370|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00370|https://www.drugbank.ca/drugs/DB00370|https://www.drugbank.ca/drugs/DB00370|https://www.drugbank.ca/drugs/DB00370|https://www.drugbank.ca/drugs/DB00370|https://www.drugbank.ca/drugs/DB00370|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00370	adrenergic receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	depression	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=754ee84c-ad16-4b06-bd1c-6791c758f908
ufenamate	ufenamate		CCCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	Launched	https://www.drugs.com/international/ufenamate.html	PTGS2|PTGS1	http://www.genome.jp/dbget-bin/www_bget?D01823|http://www.genome.jp/dbget-bin/www_bget?D01823	cyclooxygenase inhibitor	dermatology|dermatology	eczema|dermatitis	http://www.ebiochemicals.com/Product/eb000073800.html|http://www.ebiochemicals.com/Product/eb000073800.html
resibufogenin	resibufogenin	bufogenin	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@]11O[C@@H]1C[C@@H]2c1ccc(=O)oc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00837239			Na/K-ATPase inhibitor			
croconazole	croconazole	croconazole hydrochloride	Clc1cccc(COc2ccccc2C(=C)n2ccnc2)c1	Launched	http://www.drugs.com/international/Croconazole.html			bacterial cell wall synthesis inhibitor			
MK-3207	MK-3207	MK3207	Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00712725	RAMP1|CALCRL|CALCA	https://citeline.informa.com/?query=#/drugs/details/39457|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=644217|http://www.apexbt.com/mk-3207.html	calcitonin antagonist			
schisandrol-b	schisandrol b	besigomsin	COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC	Phase 3	http://adisinsight.springer.com/drugs/800003096			lipid peroxidase inhibitor			
inositol	inositol	cyclohexanehexol|meso-inositol	O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O	Launched	http://www.drugs.com/international/inositol.html	CDIPT|GBA	https://www.drugbank.ca/drugs/DB03106|https://www.drugbank.ca/drugs/DB03106	insulin sensitizer			
PF-573228	PF-573228	PF-228	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1	Preclinical		GSK3B|IKBKB|CDK2|CDK1|CDK7	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008520|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008520|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008520|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008520|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008520	focal adhesion kinase inhibitor			
lercanidipine	lercanidipine		COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1	Launched	https://www.drugs.com/international/lercanidipine.html	CACNA2D1|CACNG1|CACNA1C	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001261|https://www.drugbank.ca/drugs/DB00528|https://citeline.informa.com/?query=#/drugs/details/10829	calcium channel blocker	cardiology	hypertension	https://en.wikipedia.org/wiki/Lercanidipine
neohesperidin	neohesperidin		COc1cc(O)cc(c1)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O1	Preclinical							
actinomycin-d	dactinomycin			Launched	https://clinicaltrials.gov/ct2/show/NCT00491946			RNA polymerase inhibitor	oncology|oncology|oncology|oncology	Wilm's tumor|Ewing's sarcoma|rhabdomyosarcoma|testicular carcinoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9914e793-a49c-eb00-1ab7-f606c786fe25|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9914e793-a49c-eb00-1ab7-f606c786fe25|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9914e793-a49c-eb00-1ab7-f606c786fe25|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9914e793-a49c-eb00-1ab7-f606c786fe25
SKF-83566	SKF-83566	SK&F-83566|SK-83566	CN1CCc2cc(Br)c(O)cc2C(C1)c1ccccc1	Preclinical		DRD5|DRD1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=944|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=944	dopamine receptor antagonist			
fludrocortisone-acetate	fludrocortisone acetate	florinef|fludrocortisone acetate	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C	Launched	FDA Orange Book: fludrocortisone acetate	NR3C1|NR3C2|AR	https://www.drugbank.ca/drugs/DB00687|https://www.drugbank.ca/drugs/DB00687|https://www.drugbank.ca/drugs/DB00687		endocrinology|endocrinology	Addison's disease|adrenogenital syndrome	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5cffa20-9a22-43c5-9e89-3225852c2dfa|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5cffa20-9a22-43c5-9e89-3225852c2dfa
guacetisal	guacetisal		COc1ccccc1OC(=O)c1ccccc1OC(C)=O	Launched	https://it.wikipedia.org/wiki/Guacetisal			immunosuppressant			
2,3-DCPE	2,3-DCPE		OCCNCCCOc1cccc(Cl)c1Cl	Preclinical				Bcl-XL downregulator			
NQDI-1	NQDI-1		CCOC(=O)c1c(O)nc2cccc3C(=O)c4ccccc4-c1c23	Preclinical		CASP3|MAP3K5	http://www.sigmaaldrich.com/catalog/product/sigma/sml0185?lang=en&region=US|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=740065	caspase inhibitor			
metixene	metixene	methixene	CN1CCCC(CC2c3ccccc3Sc3ccccc23)C1	Launched	http://www.drugs.com/international/Metixene.html	CHRM4|CHRM5|CHRM2|CHRM3|CHRM1	https://www.drugbank.ca/drugs/DB00340|https://www.drugbank.ca/drugs/DB00340|https://www.drugbank.ca/drugs/DB00340|https://www.drugbank.ca/drugs/DB00340|https://www.drugbank.ca/drugs/DB00340	acetylcholine receptor antagonist	neurology/psychiatry	Parkinson's Disease	https://en.wikipedia.org/wiki/Metixene
acalabrutinib	acalabrutinib		CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02477696	BTK	https://en.wikipedia.org/wiki/Acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitor			
lupanine	lupanine		O=C1CCCC2C3CC(CN12)[C@@H]1CCCCN1C3	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/7810174	INS	http://www.ncbi.nlm.nih.gov/pubmed/26492234	sodium channel blocker			
anastrozole	anastrozole	ICI D1033|ICI-D1033|ZD-1033|ZD1033|arimidex	CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N	Launched	FDA Orange Book: anastrozole	CYP19A1	ChEMBL	aromatase inhibitor	oncology	breast cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03586c40-eb32-45c5-beb7-6762a6b78790
ACT-462206	ACT-462206		COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01954589	HCRTR1|HCRTR2	https://www.tocris.com/dispprod.php?ItemId=429926#.V-AzupMrLy9|https://www.tocris.com/dispprod.php?ItemId=429926#.V-AzupMrLy9	orexin receptor antagonist			
enasidenib	enasidenib		CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F	Launched	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6	IDH1	http://www.medkoo.com/products/6724	isocitrate dehydrogenase inhibitor	hematologic malignancy	acute myeloid leukemia (AML)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6
enoxolone	enoxolone		C[C@]12CC[C@@](C)(C[C@H]1C1=CC(=O)[C@@H]3[C@@]4(C)CC[C@H](O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2)C(O)=O	Launched	http://www.drugs.com/international/Enoxolone.html	HSD11B2|HSD11B1|HSD17B3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=298776|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000609|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=298776	gap junction modulator	gastroenterology|otolaryngology	peptic ulcer disease (PUD)|common cold	https://en.wikipedia.org/wiki/Enoxolone|https://en.wikipedia.org/wiki/Enoxolone
genipin	genipin		COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO	Preclinical				choleretic agent			
3,3'-dichlorobenzaldazine	3,3'-dichlorobenzaldazine		Clc1cccc(c1)\C=N\N=C\c1cccc(Cl)c1	Preclinical				glutamate receptor allosteric ligand			
efaproxiral	efaproxiral	RSR13	Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00005887	HBA1|HBB	https://www.drugbank.ca/drugs/DB08486|https://www.drugbank.ca/drugs/DB08486	haemoglobin oxygen release stimulant			
AEG3482	AEG3482		NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1	Preclinical				HSP inducer			
g-caryophyllene	g-caryophyllene	Beta-Caryophylene|Beta-Caryophyllene	C\C1=C/CCC(=C)[C@H]2CC(C)(C)[C@@H]2CC1	Preclinical		ACHE	https://www.ncbi.nlm.nih.gov/pubmed/25119528	acetylcholinesterase inhibitor			
ACPC	ACPC	1-Amino-Cyclopropanecarboxylic Acid|1-Aminocyclopropane Carboxylic Acid|1-Aminocyclopropanecarboxylic Acid	NC1(CC1)C(O)=O	Phase 1	Pharmaprojects			glutamate receptor antagonist			
pinacidil	pinacidil	pindac	CC(N\C(Nc1ccncc1)=N\C#N)C(C)(C)C	Launched	FDA Orange Book: pinacidil	ABCC8|ABCC9|KCNJ8	http://www.genome.jp/dbget-bin/www_bget?C13729+D05482|http://www.genome.jp/dbget-bin/www_bget?C13729+D05482|https://citeline.informa.com/?query=#/drugs/details/14461	ATP channel activator|potassium channel activator	cardiology	hypertension	https://en.wikipedia.org/wiki/Pinacidil
oxethazaine	oxethazaine	WY-806|oxetacaine	CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1	Launched	http://www.drugs.com/international/oxethazaine.html			local anesthetic	neurology/psychiatry	local anesthetic	https://en.wikipedia.org/wiki/Oxetacaine
alendronate	alendronate	alendronic acid|binosto|fosamax	NCCCC(O)(P(O)(O)=O)P(O)(O)=O	Launched	FDA Orange Book: alendronate sodium	FDPS|ATP6V1A|PTPRS|PTPRE|PTPN4	https://www.drugbank.ca/drugs/DB00630|https://www.drugbank.ca/drugs/DB00630|https://www.drugbank.ca/drugs/DB00630|https://www.drugbank.ca/drugs/DB00630|https://www.drugbank.ca/drugs/DB00630	bone resorption inhibitor	orthopedics	osteoporosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c49d7fc-c76a-40c9-8c43-68b731230f0e
cimetidine	cimetidine	Brumetadina|Valmagen|cimetidine hydrochloride|tagamet|tagamet hb|tagamet hb 200	CN\C(NCCSCc1nc[nH]c1C)=N/C#N	Launched	FDA Orange Book: cimetidine, cimetidine hydrochloride	HRH2|SLC47A2|SLC47A1|SLC29A4	ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1231|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1231|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1231	histamine receptor antagonist	gastroenterology|gastroenterology|gastroenterology|hematologic malignancy|gastroenterology|endocrinology	duodenal ulcer disease|peptic ulcer disease (PUD)|gastroesophageal reflux disease (GERD)|aggressive systemic mastocytosis (ASM)|Zollinger-Ellison syndrome|endocrine adenoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06c0a509-026f-44e0-9975-a94a8de51d43|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06c0a509-026f-44e0-9975-a94a8de51d43|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06c0a509-026f-44e0-9975-a94a8de51d43|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06c0a509-026f-44e0-9975-a94a8de51d43|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06c0a509-026f-44e0-9975-a94a8de51d43|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06c0a509-026f-44e0-9975-a94a8de51d43
vonoprazan	vonoprazan		CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1	Launched	http://www.ncbi.nlm.nih.gov/pubmed/25744862	ATP4A	http://www.selleckchem.com/products/tak-438.html	potassium-competitive acid antagonist	gastroenterology	peptic ulcer disease (PUD)	http://www.ncbi.nlm.nih.gov/pubmed/25744862
acedoben	acedoben		CC(=O)Nc1ccc(cc1)C(O)=O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/6190441						
AM679	AM679	AM-679	COc1cnc(nc1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OC[C@@H]4Cc5ccccc5N4C(C)=O)ccc23)cc1	Preclinical		ALOX5AP|CNR2|CNR1	https://en.wikipedia.org/wiki/AM-679_(cannabinoid)|https://en.wikipedia.org/wiki/AM-679_(FLAP_inhibitor)|https://en.wikipedia.org/wiki/AM-679_(cannabinoid)|https://en.wikipedia.org/wiki/AM-679_(FLAP_inhibitor)|https://en.wikipedia.org/wiki/AM-679_(cannabinoid)|https://en.wikipedia.org/wiki/AM-679_(FLAP_inhibitor)	cannabinoid receptor agonist|lipoxygenase inhibitor			
dantrolene	dantrolene	F-368|dantrium|ryanodex	[O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1	Launched	FDA Orange Book: dantrolene sodium	RYR1|RYR3	https://www.drugbank.ca/drugs/DB01219|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4172	calcium channel blocker	neurology/psychiatry|endocrinology	spasms|malignant hyperthermia (MH)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146f7be7-5cd4-4279-a482-794d0cd554e1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146f7be7-5cd4-4279-a482-794d0cd554e1
indium-tri(2-propanolate)	indium-tri(2-propanolate)		CC(C)O[In](OC(C)C)OC(C)C	Preclinical							
2-ethyl-1,3-hexanediol	2-ethyl-1,3-hexanediol		CCCC(O)C(CC)CO	Preclinical							
oxaliplatin	oxaliplatin	eloxatin	O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O	Launched	FDA Orange Book: oxaliplatin			DNA inhibitor	oncology	colorectal cancer	https://en.wikipedia.org/wiki/Oxaliplatin
ST-91	ST-91		CCc1cccc(CC)c1N=C1NCCN1	Preclinical				adrenergic receptor agonist			
toremifene	toremifene	fareston	CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1	Launched	FDA Orange Book: toremifene citrate	CYP3A5|ESR1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=109868|https://www.drugbank.ca/drugs/DB00539	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	oncology	breast cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6ff9761-7442-4bff-9e50-858c03e27fd0&audience=consumer
iodixanol	iodixanol	2-541O-3A|visipaque|visipaque 270|visipaque 320	CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I	Launched	FDA Orange Book: iodixanol			radiopaque medium	radiology	contrast agent	https://en.wikipedia.org/wiki/Iodixanol
rasagiline	rasagiline	azilect	C#CCN[C@@H]1CCc2ccccc12	Launched	FDA Orange Book: rasagiline mesylate	MAOB|BCL2	https://www.drugbank.ca/drugs/DB01367|https://www.drugbank.ca/drugs/DB01367	monoamine oxidase inhibitor	neurology/psychiatry	Parkinson's Disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a40d0e73-3f9f-4b01-979d-402c9cdaeb60
topiroxostat	topiroxostat		N#Cc1cc(ccn1)-c1n[nH]c(n1)-c1ccncc1	Launched	http://en.wikipedia.org/wiki/Topiroxostat	XDH	https://www.drugbank.ca/drugs/DB01685	xanthine oxidase inhibitor	rheumatology|nephrology	gout|hyperuricemia	https://en.wikipedia.org/wiki/Topiroxostat|https://en.wikipedia.org/wiki/Topiroxostat
DPCPX	DPCPX	1,3-DIPROPYL-8-CYCLOPENTYLXANTHINE [DPCPX]|GNF-Pf-2224	CCCn1c2[nH]c(nc2c(=O)n(CCC)c1=O)C1CCCC1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/11802244	ADORA3|ADORA1|CFTR|ADORA2A|ADORA2B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=386|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=386|https://citeline.informa.com/?query=#/drugs/details/3927|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=386|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=386	adenosine receptor antagonist			
SB-657510	SB-657510		COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1	Preclinical		UTS2R	https://www.tocris.com/dispprod.php?ItemId=229458#.Vyuq_mQrJZI	urotensin receptor antagonist			
benzyldimethyloctylammonium	benzyldimethyloctylammonium		CCCCCCCC[N+](C)(C)Cc1ccccc1	Preclinical							
nisoxetine	nisoxetine	COMPOUND 89218|LY-94939	CNCCC(Oc1ccccc1OC)c1ccccc1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/788744	SLC6A2|SLC6A3|SLC6A4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4637|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008662|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008662	norepinephrine reuptake inhibitor			
lomerizine	lomerizine		COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC	Launched	http://www.drugs.com/international/Lomerizine.html	SCN5A|CACNA1B|ABCB1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007741|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007741|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=130942	calcium channel blocker	neurology/psychiatry	migraine headache	https://en.wikipedia.org/wiki/Lomerizine
ML-3403	ML-3403		CSc1nc(c([nH]1)-c1ccnc(NC(C)c2ccccc2)c1)-c1ccc(F)cc1	Preclinical		CYP3A4|MAPK14|MAPK12|MAPK11|TNF|IL1B	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004092|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004092|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004092|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004092|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=365615|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=365615	MAP kinase inhibitor			
vicriviroc	vicriviroc	SCH-351125	COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00243568	CCR5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=807	CC chemokine receptor antagonist			
terlipressin	terlipressin		NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O	Launched	https://www.drugs.com/international/terlipressin.html	AVPR1A|AVPR1B|AVPR2	https://www.drugbank.ca/drugs/DB02638|https://www.drugbank.ca/drugs/DB02638|https://www.drugbank.ca/drugs/DB02638	vasopressin receptor agonist	cardiology	hypotension	https://en.wikipedia.org/wiki/Terlipressin
vancomycin	vancomycin	Vancoled|Vancor|vancocin hydrochloride|vancomycin hydrochloride	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2	Launched	FDA Orange Book: vancomycin hydrochloride			bacterial cell wall synthesis inhibitor	infectious disease	endocarditis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=622b9406-1c06-4323-8ca2-873cb9112dd4
methiopril	methiopril		CC1CCCC(N1C(=O)CCSC(C)=O)C(O)=O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/8577109	ACE	http://www.ncbi.nlm.nih.gov/pubmed/8577109	angiotensin converting enzyme inhibitor			
CCT128930	CCT128930		NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12	Preclinical		ROCK1|ROCK2|PKIA|PRKACA	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=465058|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=465058|https://www.drugbank.ca/drugs/DB08150|https://www.drugbank.ca/drugs/DB08150	AKT inhibitor			
octadecan-1-ol	octadecan-1-ol	cetostearyl alcohol|stearyl alcohol	CCCCCCCCCCCCCCCCCCO	Preclinical							
4-iodo-L-phenylalanine	4-iodo-L-phenylalanine		N[C@H](Cc1ccc(I)cc1)C(O)=O	Preclinical		DPP4	https://www.drugbank.ca/drugs/DB03660				
mesalazine	mesalazine	apriso|asacol|asacol hd|canasa|delzicol|fisalamine|lialda|mesalamine|pentasa|rowasa|sfrowasa	Nc1ccc(O)c(c1)C(O)=O	Launched	FDA Orange Book: mesalamine	NAT1|IKBKB|ALOX5|PPARG|MPO|PTGS2|PTGS1|CHUK|CTNNB1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=272932|https://www.drugbank.ca/drugs/DB00244|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00244|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00244|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=272932	cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist	gastroenterology|gastroenterology	ulcerative colitis|inflammatory bowel disease	https://en.wikipedia.org/wiki/Mesalazine|https://en.wikipedia.org/wiki/Mesalazine
CH223191	CH223191	CH-223191	Cc1cc(ccc1NC(=O)c1ccnn1C)\N=N\c1ccccc1C	Preclinical		AHR	https://www.tocris.com/dispprod.php?ItemId=248879#.Vye7fWQrImJ	aryl hydrocarbon receptor antagonist			
furamidine	furamidine		NC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=N	Preclinical		PRMT1	https://www.tocris.com/products/furamidine-dihydrochloride_5202	protein arginine N-methyltransferase inhibitor			
DSR-6434	DSR-6434		CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1	Preclinical		TLR7	https://www.tocris.com/products/dsr-6434_4809	toll-like receptor agonist			
mecarbinate	mecarbinate	mecarbine	CCOC(=O)c1c(C)n(C)c2ccc(O)cc12	Preclinical							
iododexetimide	iododexetimide		Ic1ccc(CN2CCC(CC2)C2(CCC(=O)NC2=O)c2ccccc2)cc1	Phase 2	http://jnm.snmjournals.org/content/56/2/317			acetylcholine receptor antagonist			
EGF816	EGF816		CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02323126	EGFR	https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=760001	EGFR inhibitor			
olprinone	olprinone		Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N	Launched	http://www.drugs.com/international/olprinone.html	PDE4C|PDE4B|PDE4A|PDE3A|PDE4D	https://citeline.informa.com/?query=#/drugs/details/11035|https://citeline.informa.com/?query=#/drugs/details/11035|https://citeline.informa.com/?query=#/drugs/details/11035|http://www.ncbi.nlm.nih.gov/pubmed/15127258|https://citeline.informa.com/?query=#/drugs/details/11035	phosphodiesterase inhibitor	cardiology	congestive heart failure	http://www.drugs.com/international/olprinone.html
lerisetron	lerisetron		C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00004219	HTR3A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000864	serotonin receptor antagonist			
thiethylperazine	thiethylperazine	torecan	CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1	Launched	FDA Orange Book: thiethylperazine malate, thiethylperazine maleate	DRD2|DRD4|DRD1	https://www.drugbank.ca/drugs/DB00372|https://www.drugbank.ca/drugs/DB00372|https://www.drugbank.ca/drugs/DB00372	dopamine receptor antagonist	gastroenterology	nausea	http://www.drugs.com/mtm/thiethylperazine.html
T-5601640	T-5601640		Cc1cc(on1)C(=O)Nc1cccc(c1)C(=O)Nc1cccc(c1)C(F)(F)F	Preclinical		LIMK2	https://www.tocris.com/products/t-5601640_5269	LIM kinase inhibitor			
chlorisondamine-diiodide	chlorisondamine-diiodide	chlorisondamine	C[N+](C)(C)CC[N+]1(C)Cc2c(C1)c(Cl)c(Cl)c(Cl)c2Cl	Preclinical		CHRNA1	http://www.tocris.com/dispprod.php?ItemId=2163#.VfL8lWTBwXA	acetylcholine receptor antagonist			
ML-786	ML-786		CC(C)(N)c1cc(cc(c1)C(F)(F)F)C(=O)N[C@@H]1CCc2ccc(OC3=C4CCC(=O)N=C4NC=C3)cc2C1	Preclinical		RAF1|BRAF	https://www.tocris.com/products/ml-786-dihydrochloride_5036|https://www.tocris.com/products/ml-786-dihydrochloride_5036	RAF inhibitor			
alvimopan	alvimopan	ADL 8-2698|entereg	C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1	Launched	FDA Orange Book: alvimopan	OPRK1|OPRM1|OPRD1	https://www.drugbank.ca/drugs/DB06274|ChEMBL|https://www.drugbank.ca/drugs/DB06274	opioid receptor antagonist	gastroenterology	postoperative ileus	https://en.wikipedia.org/wiki/Alvimopan
N-cyanopyrrolidine	N-cyanopyrrolidine	Cyano-Pyrrolidine	N#CN1CCCC1	Preclinical		CTSK	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004972				
montelukast	montelukast	MK-476|singulair	CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1	Launched	FDA Orange Book: montelukast sodium	CYP2C8|ALOX5|CYSLTR1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=205402|https://www.drugbank.ca/drugs/DB00471|https://www.drugbank.ca/drugs/DB00471	leukotriene receptor antagonist	pulmonary|allergy|pulmonary	asthma|allergic rhinitis|exercise-induced bronchoconstriction (EIB)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ccbbf0d6-efd9-4fdd-9e7b-e3d293062609|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ccbbf0d6-efd9-4fdd-9e7b-e3d293062609|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ccbbf0d6-efd9-4fdd-9e7b-e3d293062609
GW-5074	GW-5074	GW5074	Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br	Preclinical		LRRK1|LRRK2|NTRK1|RAF1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=285752|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=285752|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004633|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8072	RAF inhibitor|leucine rich repeat kinase inhibitor			
pyridoxal	pyridoxal		Cc1ncc(CO)c(C=O)c1O	Launched	https://www.drugs.com/international/pyridoxal.html	PDXK	https://www.drugbank.ca/drugs/DB00147		neurology/psychiatry	epilepsy	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1720393/
thioperamide	thioperamide		S=C(NC1CCCCC1)N1CCC(CC1)c1c[nH]cn1	Preclinical		HRH4|HRH3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1267|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1267	histamine receptor antagonist			
butoconazole	butoconazole	butoconazole nitrate|femstat|femstat 3|gynazole-1	Clc1ccc(CCC(Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1	Launched	FDA Orange Book: butoconazole nitrate			bacterial cell wall synthesis inhibitor	infectious disease	vulvovaginal candidiasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5eebfdbb-4800-4f59-9eaa-93e1c02b7b5f
PFK-158	PFK-158		FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02044861	PFKFB3	https://www.axonmedchem.com/product/2542	phosphofructokinase inhibitor			
plinabulin	plinabulin	NPI-2358	CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02504489			tubulin polymerization inhibitor			
NXY-059	NXY-059	disufenton	CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/16467546			free radical scavenger			
putrescine	putrescine		NCCCCN	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/8532768	KCNJ4|ODC1|AMD1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2388|https://www.drugbank.ca/drugs/DB01917|https://www.drugbank.ca/drugs/DB01917	tissue transglutaminase inhibitor			
phentermine	phentermine	Phentermine resin 30|adipex-p|fastin|ionamin|phentermine hydrochloride|phentermine resin complex|pre-sate|suprenza|wilpo	CC(C)(N)Cc1ccccc1	Launched	FDA Orange Book: chlorphentermine hydrochloride, mephentermine sulfate, phentermine hydrochloride, phentermine resin complex	MAOB|MAOA|SLC6A2|SLC6A3|SLC6A4	https://www.drugbank.ca/drugs/DB00191|https://www.drugbank.ca/drugs/DB00191|ChEMBL|https://www.drugbank.ca/drugs/DB00191|https://www.drugbank.ca/drugs/DB00191	dopamine uptake inhibitor|serotonin reuptake inhibitor	endocrinology	weight-loss aid	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abf83fa7-e6e4-421e-940e-f6fec0f1bdf5
doxazosin	doxazosin	cardura|cardura xl	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2ccccc2O1	Launched	FDA Orange Book: doxazosin mesylate	ADRA1D|ADRA1A|ADRA1B|CYP2C19|KCNH7|KCNH6|KCNH2	https://www.drugbank.ca/drugs/DB00590|https://www.drugbank.ca/drugs/DB00590|https://www.drugbank.ca/drugs/DB00590|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090854|https://www.drugbank.ca/drugs/DB00590|https://www.drugbank.ca/drugs/DB00590|https://www.drugbank.ca/drugs/DB00590	adrenergic receptor antagonist	urology|cardiology	benign prostatic hyperplasia (BPH)|hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ed04255-7d9c-464c-bfa6-c355755862d8|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ed04255-7d9c-464c-bfa6-c355755862d8
ribavirin	ribavirin	RibaPak|Ribofluranosyl Carboxamide|Viramid|copegus|rebetol|ribasphere|ribavarin|tribavirin|virazole	NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Launched	FDA Orange Book: ribavirin	IMPDH1|IMPDH2|NT5C2|ENPP1|ADK	ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6842|https://www.drugbank.ca/drugs/DB00811|https://www.drugbank.ca/drugs/DB00811|https://www.drugbank.ca/drugs/DB00811	antiviral	infectious disease	hepatitis C	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35f99f76-f2ef-4a81-91ff-285419664be3
1-acetyl-4-methylpiperazine	1-acetyl-4-methylpiperazine		CN1CCN(CC1)C(C)=O	Preclinical				acetylcholine receptor agonist			
nitromide	nitromide		NC(=O)c1cc(cc(c1)[N+]([O-])=O)[N+]([O-])=O	Launched	http://www.drugs.com/international/nitromide.html						
2-TEDC	2-TEDC		Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O	Preclinical		ALOX12	http://www.biocompare.com/pfu/120065/soids/5843/Inhibitors/ALOX12?vids=103517	lipoxygenase inhibitor			
hemomex-s	hemomex-s		CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C	Launched	http://www.ppginco.com/eng/news/hemomexs.html	PPARG	http://www.ncbi.nlm.nih.gov/pubmed/16394521				
aceclidine	aceclidine	Glaudin|Glaunorm|glaucostat	CC(=O)OC1CN2CCC1CC2	Launched	http://en.wikipedia.org/wiki/Aceclidine	CHRM5|CHRM4|CHRM1|CHRM3|CHRM2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=286|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=286|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=286|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=286|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=286	acetylcholine receptor agonist	ophthalmology	glaucoma	http://www.drugs.com/international/aceclidine.html
AM-1241	AM-1241		CN1CCCCC1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12	Preclinical		CNR2|CNR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3316|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008330	cannabinoid receptor agonist			
indacaterol	indacaterol	QAB149|QABI49|arcapta neohaler	CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12	Launched	FDA Orange Book: indacaterol maleate	ADRB2|ADRB1	https://www.drugbank.ca/drugs/DB05039|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7455	adrenergic receptor agonist	pulmonary	chronic obstructive pulmonary disease (COPD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7d013b1-5ee9-4126-8297-9efd9a5a8344
aldoxorubicin	aldoxorubicin		COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02049905	TOP2A	http://adisinsight.springer.com/drugs/800025015	topoisomerase inhibitor			
SB-225002	SB-225002		Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O	Preclinical		CXCR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=833	CC chemokine receptor antagonist			
chlorotrianisene	chlorotrianisene	chlortrianisestrol|tace|trianisestrol	COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1	Launched	FDA Orange Book: chlorotrianisene	ESR1|ESR2	https://www.drugbank.ca/drugs/DB00269|ChEMBL	estrogenic hormone	endocrinology|oncology	menopause|prostate cancer	https://en.wikipedia.org/wiki/Chlorotrianisene|https://en.wikipedia.org/wiki/Chlorotrianisene
terbinafine	terbinafine	SF 86-327|SF-86-327|lamisil|lamisil at	CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12	Launched	FDA Orange Book: terbinafine, terbinafine hydrochloride	CYP2C8|SQLE|CYP2C19	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090278|https://www.drugbank.ca/drugs/DB00857|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090278	fungal squalene epoxidase inhibitor	infectious disease|infectious disease|infectious disease	tinea pedis|tinea cruris|tinea corporis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7f36b7b-f205-4de5-b083-acea57281871&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7f36b7b-f205-4de5-b083-acea57281871&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7f36b7b-f205-4de5-b083-acea57281871&audience=consumer
tirofiban	tirofiban	L-700462|MK-383|aggrastat	CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O	Launched	FDA Orange Book: tirofiban hydrochloride	ITGB3|ITGA2B	https://www.drugbank.ca/drugs/DB00775|https://www.drugbank.ca/drugs/DB00775	platelet aggregation inhibitor|structural glycoprotein antagonist	cardiology|cardiology	myocardial infarction|refactory angina	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f&audience=consumer
bromindione	bromindione		Brc1ccc(cc1)C1C(=O)c2ccccc2C1=O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/13749480			anticoagulant			
NSC-319726	NSC-319726		C\C(c1ccccn1)=N/NC(=S)N1CCC1	Preclinical				p53 activator			
RX-3117	RX-3117		Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT02030067	DNMT1|CDK2	http://www.activebiochem.com/Product/RX-3117.html|http://www.activebiochem.com/Product/RX-3117.html	DNA synthesis inhibitor|CDK inhibitor			
IC261	IC261		COc1cc(OC)c(\C=C2\C(=O)Nc3ccccc23)c(OC)c1	Preclinical		CSNK1D|CSNK1E|CSNK1G2|CSNK1A1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5985|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5985|https://www.drugbank.ca/drugs/DB03083|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5985	casein kinase inhibitor			
mevastatin	mevastatin		CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12	Preclinical		HMGCR	https://www.drugbank.ca/drugs/DB06693	HMGCR inhibitor			
INCB-024360	INCB-024360	INCB024360|epacadostat	NS(=O)(=O)NCCNc1nonc1\C(Nc1ccc(F)c(Br)c1)=N\O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01685255	IDO1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8221	indoleamine 2,3-dioxygenase inhibitor			
amyl-nitrite	amyl-nitrite		CCCCCO[N+][O-]	Preclinical		NPR1	https://www.drugbank.ca/drugs/DB01612	atrial natriuretic peptide receptor agonist			
Wy-16922	Wy-16922		CCOC(=O)C(=O)Nc1cccc(OC)c1C(N)=O	Phase 1	Pharmaprojects			histamine release inhibitor			
PX-12	PX-12		CCC(C)SSc1ncc[nH]1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00417287	TXN|TXNRD1|TXNRD2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000205|https://www.drugbank.ca/drugs/DB05448|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=287654	thioredoxin inhibitor			
YIL-781	YIL-781		CC(C)N1CCC[C@H](Cn2c(C)nc3ccc(Oc4ccc(F)cc4)cc3c2=O)C1	Preclinical		GHSR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3538	ghrelin receptor antagonist			
bromfenac	bromfenac	bromday|bromfenac sodium|bromsite|prolensa|xibrom	Nc1c(CC(O)=O)cccc1C(=O)c1ccc(Br)cc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	PTGS2|PTGS1	https://www.drugbank.ca/drugs/DB00963|https://www.drugbank.ca/drugs/DB00963	cyclooxygenase inhibitor			
SC-9	SC-9		Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1	Preclinical		PRKCA	http://www.tocris.com/dispprod.php?ItemId=1852#.Vg2QnmRVhHw	protein tyrosine kinase activator			
sisomicin-sulfate	sisomicin sulfate		CN[C@@H]1C(O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	Launched	http://www.drugs.com/international/sisomicin-sulfate.html			bacterial 30S ribosomal subunit inhibitor	infectious disease	gram-negative bacterial infections	http://www.drugs.com/international/sisomicin.html
ritonavir	ritonavir	A-84538|ABBOTT-84538|norvir	CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Launched	FDA Orange Book: ritonavir	CYP2C19|CYP1A2|CYP3A5|CYP3A7|CYP3A4|CYP2C9|CYP2C8|CYP2D6|CYP2B6|CYP2E1	http://www.drugbank.ca/drugs/DB00503|http://www.drugbank.ca/drugs/DB00503|http://www.drugbank.ca/drugs/DB00503|http://www.drugbank.ca/drugs/DB00503|http://www.drugbank.ca/drugs/DB00503|http://www.drugbank.ca/drugs/DB00503|http://www.drugbank.ca/drugs/DB00503|http://www.drugbank.ca/drugs/DB00503|http://www.drugbank.ca/drugs/DB00503|http://www.drugbank.ca/drugs/DB00503	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13b059c6-0c6c-49a5-b985-a4b05caf9ac9
axitinib	axitinib	AG-013736|AG-13736|inlyta	CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1	Launched	FDA Orange Book: axitinib	PLK4|FLT4|FLT1|CYP3A5|KIT|KDR|CSF1|CYP2C19|PDGFRB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5659|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=318296|https://citeline.informa.com/?query=#/drugs/details/29908|ChEMBL|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000353|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=318296|https://citeline.informa.com/?query=#/drugs/details/29908	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	renal cell carcinoma (RCC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84137882-e000-47da-bd5b-fa76ab3c76f9
FIPI	FIPI		Fc1ccc2[nH]c(cc2c1)C(=O)NCCN1CCC(CC1)n1c2ccccc2[nH]c1=O	Preclinical		PLD1|PLD2	https://www.tocris.com/products/fipi_3600|https://www.tocris.com/products/fipi_3600	phospholipase inhibitor			
K-247	K-247		OCC1OC(Nc2ccc(cc2)C(O)=O)C(O)C1O	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/6985188						
anisotropine	anisotropine	valpin 50	CCCC(CCC)C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)C	Launched	FDA Orange Book: anisotropine methylbromide	CHRM1|CHRM2|CHRM3	https://www.drugbank.ca/drugs/DB00517|https://www.drugbank.ca/drugs/DB00517|https://www.drugbank.ca/drugs/DB00517	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)	https://en.wikipedia.org/wiki/Octatropine_methylbromide
iCRT-14	iCRT-14		Cc1cc(\C=C2/SC(=O)N(C2=O)c2ccccc2)c(C)n1-c1cccnc1	Preclinical		CTNNB1|TCF4	https://www.tocris.com/products/icrt-14_4299|https://www.tocris.com/products/icrt-14_4299	WNT signaling inhibitor|beta catenin inhibitor			
GSK2656157	GSK2656157		Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1	Preclinical				PERK inhibitor			
2-iodomelatonin	2-iodomelatonin	Iodomelatonin	COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1	Preclinical		NQO2|MTNR1A|MTNR1B	https://www.drugbank.ca/drugs/DB08190|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1343|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1343	melatonin receptor agonist			
CX-5461	CX-5461		CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O	Phase 1	http://www.aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=598#.VSX3h5TF_Ws			RNA polymerase inhibitor			
AZD7762	AZD7762	AZD-7762	NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00937664	CHEK2|CHEK1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7713|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7713	CHK inhibitor			
CH-170	CH-170		Cc1nc(Cn2cnc3n(C)c(=O)n(C)c(=O)c23)no1	Phase 1	Pharmaprojects						
PCO-400	PCO-400		CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C#N	Phase 1	Pharmaprojects	ABCC9|KCNJ8	https://citeline.informa.com/?query=#/drugs/details/16250|http://www.abcam.com/pco-400-ab141671.html	potassium channel activator			
mevalonic-d,-l-acid-lactone	mevalonic-d,-l-acid-lactone		CC1(O)CCOC(=O)C1	Preclinical							
AT-9283	AT-9283		O=C(NC1CC1)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01145989	STK17A|AURKB|AURKA|BCR|FLT3|RPS6KA6|ABL1|JAK3|JAK2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7949|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7949|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7949|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=430456|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=430456|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7949|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=430456|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7949|https://www.drugbank.ca/drugs/DB08067	Aurora kinase inhibitor|JAK inhibitor			
benzofenac	benzofenac		OC(=O)Cc1ccc(OCc2ccccc2)c(Cl)c1	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/7127389						
5-(4chlorophenyl)-4-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one	5-(4chlorophenyl)-4-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one		CCn1c(O)nnc1-c1ccc(Cl)cc1	Preclinical							
bonaphthone	bonaphthone		Brc1ccc2C(=O)C(=O)C=Cc2c1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/1092074						
lestaurtinib	lestaurtinib		C[C@]12OC(C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00557193	JAK2|NTRK2|NTRK3|NTRK1|FLT3	https://citeline.informa.com/?query=#/drugs/details/22956|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=146816|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=146816|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001395|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5672	FLT3 inhibitor|growth factor receptor inhibitor|JAK inhibitor			
ethoxyquin	ethoxyquin	E324	CCOc1ccc2NC(C)(C)C=C(C)c2c1	Preclinical				antioxidant			
lorglumide	lorglumide	CR-1409	CCCCCN(CCCCC)C(=O)C(CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1	Phase 1	Pharmaprojects	CCKAR|CCKBR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000889|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=891	CCK receptor antagonist			
methoxamine	methoxamine	vasoxyl	COc1ccc(OC)c(c1)C(O)C(C)N	Launched	FDA Orange Book: methoxamine hydrochloride	ADRA1D|ADRA1B|ADRA1A	https://www.drugbank.ca/drugs/DB00723|https://www.drugbank.ca/drugs/DB00723|https://www.drugbank.ca/drugs/DB00723	adrenergic receptor agonist	cardiology	hypotension	http://www.druglib.com/activeingredient/methoxamine/
suplatast	suplatast		CCOCC(O)COc1ccc(NC(=O)CC[S+](C)C)cc1	Launched	http://www.drugs.com/international/suplatast-tosilate.html			histamine release inhibitor|immunoglobulin inhibitor	rheumatology	Kimura's disease	https://en.wikipedia.org/wiki/Kimura%27s_disease
fananserin	fananserin	RP 62203	Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/10080558	DRD4|HTR2A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=163693|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DPR000043	dopamine receptor antagonist|serotonin receptor antagonist			
sulfadoxine	sulfadoxine	RO 4-4393|Ro-4-4393|Sulforthamidine|Sulphormethoxine|fanasil|fanzil	COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC	Launched	FDA Orange Book: sulfadoxine			dihydropteroate synthase inhibitor	infectious disease	malaria	https://en.wikipedia.org/wiki/Sulfadoxine
gentamycin	gentamycin	garamycin|gentamicin sulfate		Launched	http://www.drugs.com/international/Gentamycin.html	LRP2|HSPA8	https://www.drugbank.ca/drugs/DB00798|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000116	bacterial 50S ribosomal subunit inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|critical care	bone and joint infections|endocarditis|pelvic inflammatory disease|meningitis|pneumonia|urinary tract infections|sepsis	https://en.wikipedia.org/wiki/Sepsis|https://en.wikipedia.org/wiki/Sepsis|https://en.wikipedia.org/wiki/Sepsis|https://en.wikipedia.org/wiki/Sepsis|https://en.wikipedia.org/wiki/Sepsis|https://en.wikipedia.org/wiki/Sepsis|https://en.wikipedia.org/wiki/Sepsis
galeterone	galeterone		C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@]34C)C1CC=C2n1cnc2ccccc12	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02438007	CYP17A1|AR	https://en.wikipedia.org/wiki/Galeterone|https://en.wikipedia.org/wiki/Galeterone	androgen receptor modulator			
lumateperone	lumateperone		CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23	Phase 3	http://www.drugbank.ca/drugs/DB06077	HTR2A|DRD2	http://www.drugbank.ca/drugs/DB06077|http://www.drugbank.ca/drugs/DB06077	serotonin receptor antagonist|dopamine receptor modulator			
cefozopran	cefozopran		CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccn4ncccc34)=C(N2C1=O)C(O)=O)c1nsc(N)n1	Launched	http://www.drugs.com/international/cefozopran.html			bacterial cell wall synthesis inhibitor			
BET-BAY-002	BET-BAY-002		Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1	Preclinical		BRD4	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=845187	bromodomain inhibitor			
metrizamide	metrizamide	amipaque	CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)N[C@H]2C(O)O[C@H](CO)[C@@H](O)[C@@H]2O)c1I	Launched	FDA Orange Book: metrizamide			radiopaque medium	radiology	contrast agent	https://en.wikipedia.org/wiki/Metrizamide
ethambutol	ethambutol	myambutol	CC[C@@H](CO)NCCN[C@@H](CC)CO	Launched	FDA Orange Book: ethambutol hydrochloride			bacterial cell wall synthesis inhibitor	infectious disease	tuberculosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c732b415-e1f9-478f-896d-1dc8b6362da4
trans-10,cis-12-Conjugated-linoleic-acid	trans-10,cis-12-Conjugated-linoleic acid		CCCCC\C=C/C=C/CCCCCCCCC(O)=O	Launched							
NS-8593	NS-8593		C1C[C@@H](Nc2nc3ccccc3[nH]2)c2ccccc2C1	Preclinical		KCNN1|KCNN3|KCNN2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2318|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2318|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2318	calcium-activated potassium channel modulator			
lorazepam	lorazepam	Loraz|Lorazepam preservative free|WY-4036|ativan|lorazepam intensol	OC1N=C(c2ccccc2Cl)c2cc(Cl)ccc2NC1=O	Launched	FDA Orange Book: lorazepam	GABRA1|GABRA2|GABRA3|GABRA4|GABRG3|GABRG1|GABRG2|GABRB1|GABRB2|GABRB3|GABRA5|GABRA6|GABRP|GABRQ|GABRD|GABRE|TSPO	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00186	benzodiazepine receptor agonist	neurology/psychiatry	status epilepticus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae274b1f-27c3-483b-99f1-9a9249dc2459
ZM-306416	ZM-306416	CB-676475	COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC	Preclinical		FLT4|FLT1|EGFR|KDR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006010|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8245|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8245|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8245	Abl kinase inhibitor|src inhibitor|VEGFR inhibitor			
salvinorin-a	salvinorin a	salvinorin a	COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00700596	OPRD1|OPRK1|OPRM1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005337|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1666|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005337	opioid receptor agonist			
trimetozine	trimetozine	ABBOTT-22370|PS 2383|trimolide	COc1cc(cc(OC)c1OC)C(=O)N1CCOCC1	Launched	http://www.drugs.com/international/trimetozine.html			sedative	neurology/psychiatry	sedative	https://en.wikipedia.org/wiki/Trimetozine
VER-155008	VER-155008		Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12	Preclinical		HSPA1A	http://www.sigmaaldrich.com/catalog/product/sigma/sml0271?lang=en&region=US	HSP inhibitor			
orphenadrine	orphenadrine	Invagesic|Norgesic|Orphengesic|disipal|norflex|orphenadrine citrate	CN(C)CCOC(c1ccccc1)c1ccccc1C	Launched	FDA Orange Book: orphenadrine citrate, orphenadrine hydrochloride	HRH1|SLC6A2|GRIN2D|GRIN3B|GRIN3A|GRIN1|SCN10A|CYP2B6	https://www.drugbank.ca/drugs/DB01173|https://www.drugbank.ca/drugs/DB01173|https://www.drugbank.ca/drugs/DB01173|https://www.drugbank.ca/drugs/DB01173|https://www.drugbank.ca/drugs/DB01173|https://www.drugbank.ca/drugs/DB01173|https://www.drugbank.ca/drugs/DB01173|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091464	acetylcholine receptor antagonist	neurology/psychiatry	muscle pain	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56bc8e4a-6771-476d-95e8-e4ef2d869cb2
lesinurad	lesinurad	RDEA594|zurampic	OC(=O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12	Launched	http://www.astrazeneca.com/Media/Press-releases/Article/20150122--marketing-authorisation-application-for-gout	SLC22A12	http://www.genome.jp/dbget-bin/www_bget?dr:D09922	uric acid diuretic	rheumatology	gout	http://www.fiercebiotech.com/tags/lesinurad
prednisolone-tebutate	prednisolone tebutate	hydeltra-tba	CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@]12C	Launched	FDA Orange Book: prednisolone tebutate			anti-inflammatory agent			
SR-2211	SR-2211		OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F	Preclinical		RORC	https://www.tocris.com/products/sr-2211_4869	retinoid receptor inverse agonist			
gallopamil	gallopamil		COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC	Launched	http://www.drugs.com/international/gallopamil.html	ATP2A2|CACNA1C	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000672|https://citeline.informa.com/?query=#/drugs/details/7853	L-type calcium channel blocker	cardiology|cardiology	hypertension|cardiac arrythmia	http://www.drugs.com/international/gallopamil.html|http://www.drugs.com/international/gallopamil.html
XMD8-92	XMD8-92		CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1	Preclinical		DCLK2|TNK1|MAPK7|LRRK2|PLK4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8057|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8057|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8057|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=709847|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8057	MAP kinase inhibitor			
VU29	VU29		[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1	Preclinical		GRM5	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013021	glutamate receptor potentiator			
acemetacin	acemetacin		COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1	Launched	http://en.wikipedia.org/wiki/Acemetacin	PTGS1|PTGS2	http://www.genome.jp/dbget-bin/www_bget?D01582|http://www.genome.jp/dbget-bin/www_bget?D01582	cyclooxygenase inhibitor	rheumatology	osteoarthritis	https://en.wikipedia.org/wiki/Acemetacin
vemurafenib	vemurafenib	PLX-4032|RG 7204|RO 5185426|zelboraf	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F	Launched	FDA Orange Book: vemurafenib	BRAF|RAF1|CYP2C19|CYP3A5|CYP3A4	ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5893|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=423462|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=423462|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=423462	RAF inhibitor	oncology	melanoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38eea320-7e0c-485a-bc30-98c3c45e2763
tulobuterol	tulobuterol	tulobuterol hydrochloride	CC(C)(C)NCC(O)c1ccccc1Cl	Launched	http://www.drugs.com/international/tulobuterol.html	ADRB2	https://en.wikipedia.org/wiki/Tulobuterol	adrenergic receptor agonist	pulmonary	asthma	http://www.drugs.com/international/tulobuterol.html
aminothiadiazole	aminothiadiazole		Nc1nncs1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/8677914	ADORA3|IMPDH1	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=39144|http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=39144	inosine monophosphate dehydrogenase inhibitor			
purvalanol-a	Purvalanol A	Piceatannol|Purvalanol A|Purvalanola	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1	Preclinical		CSNK1G3|RPS6KA1|CDK2|CDK1|CDK4|CDK5|SRC|CCNE1|CCND1	https://www.drugbank.ca/drugs/DB04751|https://www.drugbank.ca/drugs/DB04751|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6030|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001165|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6030|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6030|https://www.drugbank.ca/drugs/DB04751|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=273824|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=273824	CDK inhibitor			
chlorphensin-carbamate	chlorphensin-carbamate	U-19,646|U-19646|chlorphenesin|chlorphenesin carbamate|maolate	NC(=O)OCC(O)COc1ccc(Cl)cc1	Preclinical				muscle relaxant			
purvalanol-b	purvalanol b	purvalanol b	CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1	Preclinical		MAPK1|MAPK3|CDK2|CDK5|CDK4|SRPK2	https://www.drugbank.ca/drugs/DB02733|https://www.drugbank.ca/drugs/DB02733|https://www.drugbank.ca/drugs/DB02733|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7806|https://www.drugbank.ca/drugs/DB02733|https://www.drugbank.ca/drugs/DB02733	tyrosine kinase inhibitor			
alfaxalone	alfaxalone	GR 2/234|alphaxalone	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C	Veterinary Launched	http://www.ncbi.nlm.nih.gov/pubmed/25324218	HSD11B1|GABBR1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=457862|https://en.wikipedia.org/wiki/Alfaxalone	chloride channel agonist|benzodiazepine receptor agonist	neurology/psychiatry	general anaesthetic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5d57f72-71e4-46af-b262-673ceabeff04
atropine-oxide	atropine-oxide		C[N+]1([O-])C2CCC1CC(C2)OC(=O)C(CO)c1ccccc1	Preclinical				acetylcholine receptor antagonist			
nikethamide	nikethamide	coramine|nicethamide|nikethyl	CCN(CC)C(=O)c1cccnc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs			immunostimulant			
licochalcone-a	licochalcone a		COc1cc(O)c(cc1C=CC(=O)c1ccc(O)cc1)C(C)(C)C=C	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02173054	PTPN1|TOP1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010160|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=216163	topoisomerase inhibitor			
PD-168393	PD-168393	PD168393	Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1	Preclinical		EGFR|SRC|ERBB2	https://www.drugbank.ca/drugs/DB07662|https://www.drugbank.ca/drugs/DB07662|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004255	EGFR inhibitor			
gastrodin	gastrodin		OC[C@@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/18601850						
clavulanate	clavulanate	BRL 14151|BRL-14151|clavulanic acid	OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O	Launched	FDA Orange Book: clavulanate potassium			beta lactamase inhibitor	otolaryngology	otitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08a35bfc-3945-4f95-948a-8af36cda715c
tacrine	tacrine	cognex	Nc1c2CCCCc2nc2ccccc12	Launched	FDA Orange Book: tacrine hydrochloride	ACHE|BCHE	https://www.drugbank.ca/drugs/DB00382|https://www.drugbank.ca/drugs/DB00382	acetylcholinesterase inhibitor	neurology/psychiatry	Alzheimer's disease	https://en.wikipedia.org/wiki/Tacrine
bromocriptine	bromocriptine	CB-154|bromocriptine mesylate|cycloset|parlodel	CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C	Launched	FDA Orange Book: bromocriptine mesylate	HTR6|HTR7|ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD5|DRD4|DRD1|DRD3|DRD2|PRL|HTR2A|HTR2C|HTR2B|HTR1D|HTR1B|HTR1A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=35|https://www.drugbank.ca/drugs/DB01200|https://www.drugbank.ca/drugs/DB01200|https://www.drugbank.ca/drugs/DB01200|https://www.drugbank.ca/drugs/DB01200|https://www.drugbank.ca/drugs/DB01200|https://www.drugbank.ca/drugs/DB01200|https://www.drugbank.ca/drugs/DB01200|https://www.drugbank.ca/drugs/DB01200|https://www.drugbank.ca/drugs/DB01200|https://www.drugbank.ca/drugs/DB01200|https://www.drugbank.ca/drugs/DB01200|https://www.drugbank.ca/drugs/DB01200|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091466|https://www.drugbank.ca/drugs/DB01200|https://www.drugbank.ca/drugs/DB01200|https://www.drugbank.ca/drugs/DB01200|https://www.drugbank.ca/drugs/DB01200|https://www.drugbank.ca/drugs/DB01200|https://www.drugbank.ca/drugs/DB01200	dopamine receptor agonist	endocrinology|neurology/psychiatry|endocrinology	hyperprolactinemia|Parkinson's Disease|acromegaly	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93a0696b-b261-4262-9e06-f3180b419f8f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93a0696b-b261-4262-9e06-f3180b419f8f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93a0696b-b261-4262-9e06-f3180b419f8f
EED226	EED226		CS(=O)(=O)c1ccc(cc1)-c1cnc(NCc2ccco2)n2cnnc12	Preclinical		EED	http://www.medkoo.com/products/12448	polycomb protein inhibitor			
glutathione	glutathione		N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00979082	HAGH|GGT1|GLRX2|TXNDC12|GLRX|GLO1|HPGDS|GSTZ1|GSTT1|GSTA1|GSTA2|GSTA3|GSTA4|GSTA5|GPX2|GPX3|GPX1|GPX6|GPX7|GPX4|GPX5|GPX8|GSTP1|GSTM1|GSTK1|GSTO1|GSTO2|GSTM2|GSTM3|GSTM4|GSTM5|MGST3|MGST2|MGST1|ESD|GSR|GSS|LTC4S	https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143|https://www.drugbank.ca/drugs/DB00143	antioxidant			
Org-25543	Org-25543		COc1cc(cc(OC)c1OCc1ccccc1)C(=O)NCC1(CCCC1)N(C)C	Preclinical		GLRB|SLC6A5	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014722|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4667	glycine transporter inhibitor			
olvanil	olvanil	NE-19550|TCMDC-124289	CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1	Preclinical		TRPV1|CNR1|GPR119	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2488|http://www.tocris.com/dispprod.php?ItemId=1726|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2488	TRPV agonist			
cyclandelate	cyclandelate	cyclospasmol	CC1CC(CC(C)(C)C1)OC(=O)C(O)c1ccccc1	Launched	http://www.drugs.com/international/Cyclandelate.html	CACNA2D1|CES1	https://www.drugbank.ca/drugs/DB04838|https://www.drugbank.ca/drugs/DB04838	calcium channel blocker	cardiology|cardiology|rheumatology	claudication|arteriosclerosis|Raynaud's disease	https://en.wikipedia.org/wiki/Cyclandelate|https://en.wikipedia.org/wiki/Cyclandelate|https://en.wikipedia.org/wiki/Cyclandelate
BNC105	BNC105		COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01034631			tubulin polymerization inhibitor			
LY3000328	LY3000328	LY-3000328	CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01515358	CTSS	https://www.medchemexpress.com/cathepsin-s-inhibitor.html	cathepsin inhibitor			
sucralose	sucralose		OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl	Launched	http://en.wikipedia.org/wiki/Sucralose						
CP-532623	CP-532623		CC[C@@H]1C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(C)=O)c2cc(ccc2N1C(=O)OC(C)C)C(F)(F)F	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/19455053	CETP	http://www.sigmaaldrich.com/catalog/product/sigma/pz0225?lang=en&region=US	cholesteryl ester transfer protein inhibitor			
MLN9708	MLN9708		CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02406144			proteasome inhibitor			
chloropyramine	chloropyramine	halopyramine	CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1	Launched	http://en.wikipedia.org/wiki/Chloropyramine	HRH1	https://www.drugbank.ca/drugs/DB08800	histamine receptor antagonist	cardiology|ophthalmology|allergy|pulmonary	edema|conjunctivitis|allergic rhinitis|asthma	https://en.wikipedia.org/wiki/Chloropyramine|https://en.wikipedia.org/wiki/Chloropyramine|https://en.wikipedia.org/wiki/Chloropyramine|https://en.wikipedia.org/wiki/Chloropyramine
CF102	CF102	chloro-ib-meca|ci-ib-meca	CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02128958	ADORA2B|ADORA2A|ADORA1|ADORA3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=457|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=457|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=457|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=457	adenosine receptor agonist			
methoxyamine	methoxyamine		CON	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02395692	APEX1	http://www.ncbi.nlm.nih.gov/pubmed/14697759	DNA repair enzyme inhibitor			
KHK-IN-1	KHK-IN-1		CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1	Preclinical		CYP2C19|KHK	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=742627|https://www.medchemexpress.com/KHK-IN-1.html	hexokinase inhibitor			
KG-5	KG-5		CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1	Preclinical		BRAF|PDGFRB|PDGFRA|FLT3|KIT	https://www.tocris.com/products/kg-5_5260|https://www.tocris.com/products/kg-5_5260|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=689793|https://www.tocris.com/products/kg-5_5260|https://www.tocris.com/products/kg-5_5260	RAF inhibitor			
N6022	N6022		Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT01339897	ADH5	http://www.selleckchem.com/products/n6022.html	alcohol dehydrogenase inhibitor			
beta-CCB	beta-CCB		CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21	Launched	http://www.drugs.com/international/?-CCB.html	GABRA1|GABRG2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012697|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012697	benzodiazepine receptor ligand			
CGP-55845	CGP-55845		C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1	Preclinical		KCTD12|KCTD16|KCTD8|GABBR1|GABBR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1088|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1088|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1088|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1088|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1088	GABA receptor antagonist			
madrasin	madrasin		COc1ccc2c(C)nc(Nc3nc(C)c(C)c(O)n3)nc2c1	Preclinical				cell splicing inhibitor			
VUF10460	VUF10460		CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1	Preclinical		HRH4	https://www.tocris.com/products/vuf-10460_4769	histamine receptor agonist			
sitafloxacin	sitafloxacin	DU-6859A	N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F	Launched	http://www.drugs.com/international/sitafloxacin.html			bacterial DNA gyrase inhibitor	infectious disease	buruli ulcer	https://en.wikipedia.org/wiki/Sitafloxacin
conivaptan	conivaptan	vaprisol	Cc1nc2CCN(C(=O)c3ccc(NC(=O)c4ccccc4-c4ccccc4)cc3)c3ccccc3-c2[nH]1	Launched	FDA Orange Book: conivaptan hydrochloride	OXT|AVPR2|OXTR|AVPR1A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=234995|https://www.drugbank.ca/drugs/DB00872|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=234995|https://www.drugbank.ca/drugs/DB00872	vasopressin receptor antagonist	endocrinology	hyponatremia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5150d9d9-01dc-4a52-9858-214c66d8caea
difluprednate	difluprednate	durezol	CCCC(=O)O[C@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)COC(C)=O	Launched	FDA Orange Book: difluprednate	NR3C1	https://www.drugbank.ca/drugs/DB06781	glucocorticoid receptor agonist	ophthalmology	endogenous uveitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d07b65d5-f8e3-4594-a7fb-108218746cec
PF-02545920	PF-02545920		Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01175135	PDE10A	https://www.drugbank.ca/drugs/DB08387	phosphodiesterase inhibitor			
2,5-furandimethanol	2,5-furandimethanol		OCc1ccc(CO)o1	Phase 2				hemoglobin modulator			
trichloroethylene	trichloroethylene	chlorylen	ClC=C(Cl)Cl	Preclinical							
misoprostol	misoprostol	SC-29333|cytotec	CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC	Launched	FDA Orange Book: misoprostol	PTGIR|PTGER4|PTGER2|PTGER3|PTGER1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000358|https://www.drugbank.ca/drugs/DB00929|https://www.drugbank.ca/drugs/DB00929|ChEMBL|https://citeline.informa.com/?query=#/drugs/details/12139	prostanoid receptor agonist	gastroenterology	duodenal ulcer disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a46d05a2-5014-40ff-8f1b-9eca1b0aff3a
lisofylline	lisofylline		CC(O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00464555			interleukin receptor antagonist|STAT inhibitor			
dilazep	dilazep	dilazep dihydrochloride	COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1	Launched	http://www.drugs.com/international/Dilazep.html	SLC29A1|CACNA1C	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4717|https://citeline.informa.com/?query=#/drugs/details/5690	adenosine reuptake inhibitor			
TCS-359	TCS-359		COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O	Preclinical		FLT3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5970	FLT3 inhibitor			
sodium-ascorbate	sodium ascorbate		OC[C@H](O)[C@H]1OC(=O)C(O)C1O	Launched	FDA Orange Book: sodium ascorbate						
AQ-RA741	AQ-RA741		CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1	Preclinical		CHRM2	http://www.tocris.com/dispprod.php?ItemId=138087#.Ve8UuSxVhHw	acetylcholine receptor antagonist			
BAY-61-3606	BAY-61-3606		COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1	Preclinical		SYK	http://www.sigmaaldrich.com/catalog/product/sigma/b9685?lang=en&region=US	syk inhibitor			
tedizolid-phosphate	tedizolid phosphate	TR-701 FA|sivextro|tedizolid phosphate|torezolid phosphate	Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O	Launched	FDA Orange Book: tedizolid phosphate			protein synthesis inhibitor	infectious disease	skin infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75672079-589f-451a-bdbf-eaebcfcc80a9&audience=consumer
imipenem	imipenem		C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O	Launched	FDA Orange Book: imipenem			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	pneumonia|urinary tract infections|intra-abdominal infections|gynecologic infections|bacterial septicemia|bone and joint infections|skin infections|endocarditis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ab0ca9e-9a79-4cab-9f09-470eda06952e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ab0ca9e-9a79-4cab-9f09-470eda06952e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ab0ca9e-9a79-4cab-9f09-470eda06952e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ab0ca9e-9a79-4cab-9f09-470eda06952e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ab0ca9e-9a79-4cab-9f09-470eda06952e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ab0ca9e-9a79-4cab-9f09-470eda06952e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ab0ca9e-9a79-4cab-9f09-470eda06952e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ab0ca9e-9a79-4cab-9f09-470eda06952e
eticlopride	eticlopride	ETQ	CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC	Preclinical		DRD3|DRD4|DRD2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=966|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=966|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=966	dopamine receptor antagonist			
diacerein	diacerein		CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O	Launched	http://www.drugs.com/international/Diacerein.html	IL1B	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000544	interleukin inhibitor	rheumatology	osteoarthritis	https://en.wikipedia.org/wiki/Diacerein
danoprevir	danoprevir		CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1	Phase 2	http://adisinsight.springer.com/drugs/800025457			HCV inhibitor			
PHTPP	PHTPP		Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1	Preclinical		ESR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3461	estrogen receptor antagonist			
tonabersat	tonabersat	SB-220453	CC(=O)c1ccc2OC(C)(C)[C@@H](O)[C@@H](NC(=O)c3ccc(F)c(Cl)c3)c2c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00332007			gap junction modulator|nitric oxide production inhibitor			
aminoglutethimide	aminoglutethimide	cytadren	CCC1(CCC(=O)NC1=O)c1ccc(N)cc1	Launched	FDA Orange Book: aminoglutethimide	NR3C1|CYP11A1|CYP19A1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070408|ChEMBL|ChEMBL	glucocorticoid receptor antagonist	endocrinology|oncology	Cushing's syndrome|breast cancer	https://en.wikipedia.org/wiki/Aminoglutethimide|https://en.wikipedia.org/wiki/Aminoglutethimide
UNC-3230	UNC-3230		NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1	Preclinical		PIP5K1C	https://www.tocris.com/products/unc-3230_5271	phosphatidyl-inositol activator			
methylnaltrexone	methylnaltrexone	relistor	C[N@@+]1(CC2CC2)CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@@]3(O)CCC4=O)ccc5O	Launched	FDA Orange Book: methylnaltrexone bromide	OPRD1|OPRK1|OPRM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7563|https://www.drugbank.ca/drugs/DB06800|https://www.drugbank.ca/drugs/DB06800	opioid receptor antagonist	gastroenterology	constipation	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c488fb7c-0a5b-487c-b452-996809d1cb99
perindopril	perindopril	MCN-A-2833|S-9490|aceon	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC	Launched	FDA Orange Book: perindopril arginine, perindopril erbumine	ACE	https://www.drugbank.ca/drugs/DB00790	angiotensin converting enzyme inhibitor	cardiology|cardiology|cardiology	hypertension|myocardial infarction|coronary artery disease (CAD)	https://en.wikipedia.org/wiki/Perindopril|https://en.wikipedia.org/wiki/Perindopril|https://en.wikipedia.org/wiki/Perindopril
JW-67	JW-67		O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12	Preclinical		GSK3B|APC|AXIN1	https://www.tocris.com/products/jw-67_4651|https://www.tocris.com/products/jw-67_4651|https://www.tocris.com/products/jw-67_4651	Wnt pathway inhibitor			
hexasodium-phytate	hexasodium phytate	E391|fytic acid|phytic acid	OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O	Phase 2	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004313-25						
ozanimod	ozanimod		CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@H](CCc12)NCCO	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02531126	S1PR1	https://www.ncbi.nlm.nih.gov/pubmed/26990079	sphingosine 1 phosphate receptor agonist			
D-limonene	D-limonene		CC(=C)[C@@H]1CCC(C)=CC1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01046929?term=D-limonene&rank=1						
KN-93	KN-93		COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1	Preclinical		CAMK2A	https://www.tocris.com/dispprod.php?ItemId=1492#.Vz9agOeDFHw	calcium/calmodulin dependent protein kinase inhibitor			
anecortave-acetate	anecortave acetate		CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@]12C	Launched	http://invest.alconinc.com/phoenix.zhtml?c=130946&p=irol-newsArticle&ID=795119&highlight=			angiogenesis inhibitor	ophthalmology	macular degeneration	https://en.wikipedia.org/wiki/Anecortave
epitiostanol	epitiostanol	10275-S|epithioandrostanol	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O	Launched	http://en.wikipedia.org/wiki/Epitiostanol	AR	https://en.wikipedia.org/wiki/Epitiostanol	androgen receptor agonist			
cefsulodin	cefsulodin		NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1	Launched	http://en.wikipedia.org/wiki/Cefsulodin			bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections	https://en.wikipedia.org/wiki/Cefsulodin
GKT137831	GKT137831		CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02010242	NOX4|NOX1	https://www.caymanchem.com/product/17764|https://www.caymanchem.com/product/17764	NADPH oxidase inhibitor			
cinepazide	cinepazide	MD 67350 [AS MALEATE]|cinepazide maleate	COc1cc(cc(OC)c1OC)\C=C\C(=O)N1CCN(CC(=O)N2CCCC2)CC1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs			calcium channel activator			
nicaraven	nicaraven		CC(CNC(=O)c1cccnc1)NC(=O)c1cccnc1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/8622153			free radical scavenger			
PF-562271	PF-562271	PF-00562271	CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00666926	PTK2B|PTK2	http://www.selleckchem.com/products/pf-00562271.html|http://www.selleckchem.com/products/pf-00562271.html	focal adhesion kinase inhibitor			
bendazac	bendazac	AF 1934 [LYSINE]|bindazac	OC(=O)COc1nn(Cc2ccccc2)c2ccccc12	Launched	https://www.drugs.com/international/bendazac.html	PTGS2|PTGS1	http://chemicalland21.com/lifescience/UH/BENDAZAC.htm|http://chemicalland21.com/lifescience/UH/BENDAZAC.htm	cyclooxygenase inhibitor	neurology/psychiatry|rheumatology	muscle pain|joint pain	https://en.wikipedia.org/wiki/Bendazac|https://en.wikipedia.org/wiki/Bendazac
D-7193	D-7193		CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O	Phase 2	http://adisinsight.springer.com/drugs/800007192						
tolazamide	tolazamide	U-17835|tolinase	Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1	Launched	FDA Orange Book: tolazamide	KCNJ11|KCNJ10|ABCC8|KCNJ1	ChEMBL|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000919|ChEMBL|https://www.drugbank.ca/drugs/DB00839	ATP channel blocker	endocrinology	diabetes mellitus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f82dcff5-4afa-45d8-bc8c-f0f7c0c96272&audience=consumer
3-indolebutyric-acid	3-indolebutyric acid	Indole-3-Butyric Acid	OC(=O)CCCc1c[nH]c2ccccc12	Preclinical		B2M|TRBC1|HLA-A|TRAC	https://www.drugbank.ca/drugs/DB02740|https://www.drugbank.ca/drugs/DB02740|https://www.drugbank.ca/drugs/DB02740|https://www.drugbank.ca/drugs/DB02740				
isoprenaline	isoprenaline	aerolone|isoproterenol|isoproterenol hydrochloride|isuprel|norisodrine aerotrol|vapo-iso	CC(C)NCC(O)c1ccc(O)c(O)c1	Launched	http://www.drugs.com/international/isoprenaline.html	PIK3R1|PIK3R2|PIK3R3|ADRB2|ADRB1|ADRB3|MAPK1	https://www.drugbank.ca/drugs/DB01064|https://www.drugbank.ca/drugs/DB01064|https://www.drugbank.ca/drugs/DB01064|https://www.drugbank.ca/drugs/DB01064|https://www.drugbank.ca/drugs/DB01064|https://www.drugbank.ca/drugs/DB01064|https://www.drugbank.ca/drugs/DB01064	adrenergic receptor agonist	cardiology|cardiology|pulmonary	bradycardia|heart block|asthma	https://en.wikipedia.org/wiki/Isoprenaline|https://en.wikipedia.org/wiki/Isoprenaline|https://en.wikipedia.org/wiki/Isoprenaline
afloqualone	afloqualone		Cc1ccccc1-n1c(CF)nc2ccc(N)cc2c1=O	Launched	http://www.drugs.com/international/Afloqualone.html			acetylcholine receptor antagonist	neurology/psychiatry	sedative	https://en.wikipedia.org/wiki/Afloqualone
semaxanib	semaxanib	SU-5416|SU5416|Semaxinib	Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00021281	KDR|KIT|PDGFRB|PDGFRA|RET|FGFR1|MET|FLT3|FLT1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5056|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5056|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5056|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004532|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004532|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004532|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=246676|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=246676|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5056	VEGFR inhibitor			
RS-504393	RS-504393		Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1	Preclinical		CCL2|CCR2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DPR000102|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=781	CC chemokine receptor antagonist			
SCH-58261	SCH-58261		Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1	Preclinical		ADORA2B|ADORA2A|ADORA1|ADORA3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=403|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=403|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=403|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=403	adenosine receptor antagonist			
tymazoline	tymazoline		CC(C)c1ccc(C)cc1OC=C1NCCN1	Launched	https://www.drugs.com/international/tymazoline.html				allergy	allergic rhinitis	https://en.wikipedia.org/wiki/Tymazoline
casin	casin		OCCNC1CCCc2c1[nH]c1ccc(cc21)-c1ccccc1	Preclinical		CDC42	https://www.tocris.com/products/casin_5050	GTPase inhibitor			
APY-29	APY-29		C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1	Preclinical		ERN1	https://www.drugbank.ca/drugs/DB07382	serine/threonine kinase inhibitor			
escitalopram	escitalopram	lexapro	CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1	Launched	FDA Orange Book: escitalopram oxalate	SLC6A4|SLC6A2|SLC6A3|CHRM1|ADRA1A|HRH1|CYP2C19	https://www.drugbank.ca/drugs/DB01175|https://www.drugbank.ca/drugs/DB01175|https://www.drugbank.ca/drugs/DB01175|https://www.drugbank.ca/drugs/DB01175|https://www.drugbank.ca/drugs/DB01175|https://www.drugbank.ca/drugs/DB01175|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=157449	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry|neurology/psychiatry	depression|generalized anxiety disorder (GAD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c871d3fe-5ca2-410c-976d-9ec4b72c878f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c871d3fe-5ca2-410c-976d-9ec4b72c878f
heclin	heclin		CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1	Preclinical		WWP1|SMURF2|NEDD4	https://www.tocris.com/products/heclin_5433|https://www.tocris.com/products/heclin_5433|https://www.tocris.com/products/heclin_5433	ubiquitin ligase inhibitor			
meglitinide	meglitinide		COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O	Phase 2	Pharmaprojects	ABCC8|CCR2|KCNJ11	https://citeline.informa.com/?query=#/drugs/details/11801|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000080|https://citeline.informa.com/?query=#/drugs/details/11801	potassium channel blocker			
cefotetan	cefotetan	cefotan	CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)C2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O	Launched	FDA Orange Book: cefotetan disodium			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	urinary tract infections|respiratory tract infections|skin infections|gynecologic infections|chlamydia|intra-abdominal infections|bone and joint infections|surgical prophylaxis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56912a83-4cba-4461-d983-3a0656515458|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56912a83-4cba-4461-d983-3a0656515458|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56912a83-4cba-4461-d983-3a0656515458|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56912a83-4cba-4461-d983-3a0656515458|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56912a83-4cba-4461-d983-3a0656515458|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56912a83-4cba-4461-d983-3a0656515458|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56912a83-4cba-4461-d983-3a0656515458|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56912a83-4cba-4461-d983-3a0656515458
EN460	EN460		OC(=O)c1cc(ccc1Cl)N1N=C(\C(=C\c2ccc(o2)-c2ccccc2)C1=O)C(F)(F)F	Preclinical		ERO1A	http://www.ncbi.nlm.nih.gov/pubmed/20442408	endoplasmic reticulum oxidation inhibitor			
tenovin-1	tenovin-1		CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1	Preclinical		SIRT2|SIRT1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=825429|http://www.sciencedirect.com/science/article/pii/S0968089612000041?np=y	SIRT inhibitor|TP53 activator			
BMS-387032	BMS-387032	SNS-032	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00292864	MCL1|CDK7|CDK9|CDK2	https://citeline.informa.com/?query=#/drugs/details/21691|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000007|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000007|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5670	CDK inhibitor|cell cycle inhibitor|MCL1 inhibitor			
cinepazet	cinepazet		CCOC(=O)CN1CCN(CC1)C(=O)\C=C\c1cc(OC)c(OC)c(OC)c1	Launched	https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA1024&lpg=PA1024&dq=Vascoril&source=bl&ots=N5mvKazTyr&sig=jNyPudDUsiUqKK4obqYQoPrS50s&hl=en&sa=X&ved=0ahUKEwiUifvO5_bQAhVFthoKHRYdCcwQ6AEIXDAO#v=onepage&q=Vascoril&f=false			vasodilator			
tenovin-6	tenovin-6		CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1	Preclinical		SIRT3|SIRT1|SIRT2	http://www.scbt.com/datasheet-224296-tenovin-6.html|http://www.scbt.com/datasheet-224296-tenovin-6.html|http://www.scbt.com/datasheet-224296-tenovin-6.html	SIRT inhibitor			
ML-10302	ML-10302		COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1	Preclinical		HTR3B|HTR3A|HTR4	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005876|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005876|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=235	serotonin receptor partial agonist			
GW-7647	GW-7647	GW7647	CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O	Preclinical		PPARA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2674	PPAR receptor agonist			
L-745870	L-745870		Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1	Preclinical		HTR7|HTR6|HTR1A|HTR2A|DRD4|DRD3|DRD2|DRD1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003799|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003799|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003799|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003799|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3303|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003799|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003799|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003799	dopamine receptor antagonist			
VE-821	VE-821		CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1	Preclinical		ATR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8042	ATR kinase inhibitor			
VE-822	VE-822		CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02627443	ATM|ATR|PIK3CG|MTOR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8003|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8003|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8003|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8003	ATR kinase inhibitor			
betamethasone-dipropionate	betamethasone dipropionate	alphatrex|betamethasone dipropionate|diprolene|diprolene af|diprosone|sernivo	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C	Launched	FDA Orange Book: betamethasone dipropionate			anti-inflammatory agent	dermatology	corticosteroid-responsive dermatoses	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=892bf494-0b95-4314-a253-79350fdd7238
5-HMF	5-HMF	5-HYDROXYMETHYL-FURFURAL	OCc1ccc(C=O)o1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01987908						
CB-839	CB-839		FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT02861300	GLS	http://www.calithera.com/programs/cb-839/	glutaminase inhibitor			
buspirone	buspirone	buspar|buspirone hydrochloride	O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1	Launched	FDA Orange Book: buspirone hydrochloride	HTR1A|DRD2	https://www.drugbank.ca/drugs/DB00490|https://www.drugbank.ca/drugs/DB00490	serotonin receptor agonist	neurology/psychiatry	generalized anxiety disorder (GAD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3fe0ccd-565f-4d0a-a7ba-2fad7a819358
TU-2100	TU-2100		CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC	Phase 2	http://www.tamarkin.co.il/pharmaceutical.asp						
alexidine	alexidine	COMPOUND 904|WIN 21,904	CCCCC(CC)C\N=C(/N)N\C(N)=N\CCCCCC\N=C(/N)N\C(N)=N\CC(CC)CCCC	Preclinical		PTPMT1|CXCR4	http://www.sigmaaldrich.com/catalog/product/sigma/a8986?lang=en&region=US|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=435860	phosphatidylglycerophosphatase inhibitor			
cefodizime	cefodizime		CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(C)c(CC(O)=O)s3)=C(N2C1=O)C(O)=O)c1csc(N)n1	Launched	http://www.drugs.com/international/Cefodizime.html			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease	respiratory tract infections|skin infections|gonorrhea	https://en.wikipedia.org/wiki/Cefodizime|https://en.wikipedia.org/wiki/Cefodizime|https://en.wikipedia.org/wiki/Cefodizime
velneperit	velneperit	S-2367	CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00788528	NPY5R	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001251	neuropeptide receptor antagonist			
AZD5069	AZD5069		C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01233232	CXCR2	http://openinnovation.astrazeneca.com/what-we-offer/compound/azd5069/	CC chemokine receptor antagonist			
oxcarbazepine	oxcarbazepine	GP-47680|KIN-493|oxtellar xr|trileptal	NC(=O)N1c2ccccc2CC(=O)c2ccccc12	Launched	FDA Orange Book: oxcarbazepine	CYP3A4|CYP3A5|CYP2C19|SCN7A|SCN4A|SCN5A|SCN8A|SCN9A|SCN2A|SCN3A|SCN1A|SCN10A|SCN11A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=117845|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=117845|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=117845|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	sodium channel blocker	neurology/psychiatry	seizures	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2515391e-3a88-4226-92e5-f641c8409fe5
raloxifene	raloxifene	evista	Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1	Launched	FDA Orange Book: raloxifene hydrochloride	ESR2|ESR1|ENG|ACVRL1	https://www.drugbank.ca/drugs/DB00481|https://www.drugbank.ca/drugs/DB00481|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090328|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090328	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	orthopedics|oncology	osteoporosis|breast cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9eeef29-f34d-4261-b8c3-499f31365b33|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9eeef29-f34d-4261-b8c3-499f31365b33
tridihexethyl	tridihexethyl	pathilon	CC[N+](CC)(CC)CCC(O)(C1CCCCC1)c1ccccc1	Launched	FDA Orange Book: tridihexethyl chloride	CHRM1|CHRM3|CHRM2	https://www.drugbank.ca/drugs/DB00505|https://www.drugbank.ca/drugs/DB00505|https://www.drugbank.ca/drugs/DB00505	acetylcholine receptor antagonist	gastroenterology|ophthalmology	peptic ulcer disease (PUD)|nystagmus	https://en.wikipedia.org/wiki/Nystagmus|https://en.wikipedia.org/wiki/Nystagmus
KW-3902	KW-3902		CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12CC3CC1CC(C2)C3	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00354458	ADORA3|ADORA1|ADORA2B|ADORA2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5604|https://www.drugbank.ca/drugs/DB05360|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5604|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5604	adenosine receptor antagonist			
altanserin	altanserin		Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1	Phase 2	http://en.wikipedia.org/wiki/Altanserin	HTR2A|HTR2C	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3242|https://citeline.informa.com/?query=#/drugs/details/1396	serotonin receptor antagonist			
AR-A014418	AR-A014418		COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1	Preclinical		GSK3B	https://www.drugbank.ca/drugs/DB01950	glycogen synthase kinase inhibitor			
favipiravir	favipiravir	T-705	NC(=O)c1nc(F)cnc1O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02026349			RNA polymerase inhibitor			
rose-bengal	rose-bengal	robengatope|sodium rose bengal i 131	OC(=O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12	Launched	FDA Orange Book: rose bengal sodium i-131			contrast agent	radiology	diagnostic agent	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=639d9ee5-5c62-4128-b775-1196cdaed45a
phenindamine	phenindamine	Nolahist|Thephorin	CN1CCC2=C(C1)C(c1ccccc21)c1ccccc1	Launched	https://en.wikipedia.org/wiki/Phenindamine	HRH1	https://www.drugbank.ca/drugs/DB01619	histamine receptor antagonist	allergy|otolaryngology	allergic rhinitis|common cold	https://en.wikipedia.org/wiki/Phenindamine|https://en.wikipedia.org/wiki/Phenindamine
diminazene-aceturate	diminazene-aceturate	Babesin|Berenil|Ganasag|diminazene	NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01621789	ACE2|PRDX5|AOC1|PRSS1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=801811|https://www.drugbank.ca/drugs/DB03608|https://www.drugbank.ca/drugs/DB03608|https://www.drugbank.ca/drugs/DB03608	angiotensin converting enzyme activator			
fasudil	fasudil	AT-877|HA-1077|ZK-258594	O=S(=O)(N1CCCNCC1)c1cccc2cnccc12	Launched	http://www.drugs.com/international/Fasudil.html	PKIA|ROCK1|ROCK2|PRKACA	https://www.drugbank.ca/drugs/DB08162|https://www.drugbank.ca/drugs/DB08162|https://www.drugbank.ca/drugs/DB08162|https://www.drugbank.ca/drugs/DB08162	rho associated kinase inhibitor	neurology/psychiatry	cerebral vasospasm	https://en.wikipedia.org/wiki/Fasudil
tolonium	tolonium		CN(C)c1ccc2nc3cc(C)c(N)cc3[s+]c2c1	Launched	http://en.wikipedia.org/wiki/Tolonium_chloride				hematology	methemoglobinemia	http://www.drugs.com/international/tolonium-chloride.html
2-aminobenzenesulfonamide	2-aminobenzenesulfonamide	2-Amino-Benzenesulfonamide	Nc1ccccc1S(N)(=O)=O	Preclinical		CA2|CA9|CA6|CA12|CA14	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004675|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004675|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004675|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004675|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004675	carbonic anhydrase inhibitor			
chlormadinone-acetate	chlormadinone acetate		CC(=O)O[C@@]1(CCC2C3C=C(Cl)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C)C(C)=O	Launched	https://clinicaltrials.gov/ct2/show/NCT01123538	PGR	http://www.sigmaaldrich.com/catalog/product/sigma/c5145?lang=en&region=US	5 alpha reductase inhibitor	endocrinology|endocrinology|endocrinology|endocrinology	hypermenorrhea|amenorrhea|oligomenorrhea|polymenorrhea	https://en.wikipedia.org/wiki/Chlormadinone_acetate|https://en.wikipedia.org/wiki/Chlormadinone_acetate|https://en.wikipedia.org/wiki/Chlormadinone_acetate|https://en.wikipedia.org/wiki/Chlormadinone_acetate
mifepristone	mifepristone	RU 38486|RU 486|RU-38486|RU-486|korlym|mifeprex	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C	Launched	FDA Orange Book: mifepristone	NR3C1|CYP3A5|CYP3A7|CYP2C8|CYP2B6|PGR|NR1I2|AR	ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=125457|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=125457|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=125457|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=125457|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2805|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2805	glucocorticoid receptor antagonist|progesterone receptor antagonist	endocrinology|endocrinology	hyperglycemia|diabetes mellitus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=542f3fae-8bc8-4f00-9228-e4b66c9ad6a9|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=542f3fae-8bc8-4f00-9228-e4b66c9ad6a9
LGK-974	LGK-974		Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT02278133	PORCN	http://www.selleckchem.com/products/lgk-974.html	porcupine inhibitor			
rutaecarpine	rutaecarpine		O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12	Preclinical		PTGS2	http://www.ncbi.nlm.nih.gov/pubmed/10669112	cyclooxygenase inhibitor			
AC-264613	AC-264613		C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1	Preclinical		F2RL1	http://www.apexbt.com/ac-264613.html	PAR agonist			
BIIB021	BIIB021		COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01004081	HSP90AA1|AOX1	http://www.tocris.com/dispprod.php?ItemId=354225|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=415271	HSP inhibitor			
SB-408124	SB-408124		CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1	Preclinical		HCRTR2|HCRTR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1704|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1704	orexin receptor antagonist			
MG-132	MG-132		CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O	Preclinical		PSMB1	http://www.selleckchem.com/products/MG132.html	proteasome inhibitor			
PF-05212384	PF-05212384	PKI-587|gedatolisib	CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01420081	PIK3CA|PIK3CG|MTOR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7940|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=661264|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7940	mTOR inhibitor|PI3K inhibitor			
bicifadine	bicifadine		Cc1ccc(cc1)C12CC1CNC2	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00281645	SLC6A2|SLC6A4|DRD2	https://www.drugbank.ca/drugs/DB04889|https://www.drugbank.ca/drugs/DB04889|https://www.drugbank.ca/drugs/DB04889	serotonin receptor antagonist|dopamine reuptake inhibitor			
dyphylline	dyphylline	Dilor|Dilor-400|diprophylline|glyphylline|lufyllin|neothylline	Cn1c2ncn(CC(O)CO)c2c(=O)n(C)c1=O	Launched	FDA Orange Book: dyphylline	ADORA2A|ADORA1|PDE3A|PDE4D|PDE4C|PDE4B|PDE4A|PDE7B|PDE7A	https://www.drugbank.ca/drugs/DB00651|https://www.drugbank.ca/drugs/DB00651|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00651|https://www.drugbank.ca/drugs/DB00651	adenosine receptor antagonist|phosphodiesterase inhibitor	pulmonary|pulmonary|pulmonary	asthma|bronchitis|emphysema	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d7ed7c0-9646-11de-a404-0002a5d5c51b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d7ed7c0-9646-11de-a404-0002a5d5c51b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d7ed7c0-9646-11de-a404-0002a5d5c51b
SB-452533	SB-452533		CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1	Preclinical		TRPV1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4310	TRPV antagonist			
SB-243213	SB-243213		Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F	Phase 1	http://adisinsight.springer.com/drugs/800010349	HTR6|HTR2A|HTR2B|HTR2C	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009568|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=194|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=194|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=194	serotonin receptor inverse agonist			
naltrexone	naltrexone	Celupan|EN-1639A|EN-1639A [AS HYDROCHLORIDE]|Trexal|Trexan|revia|vivitrol	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	Launched	FDA Orange Book: methylnaltrexone bromide, naltrexone, naltrexone hydrochloride	SIGMAR1|OPRM1|OPRD1|OPRK1	https://www.drugbank.ca/drugs/DB00704|ChEMBL|ChEMBL|ChEMBL	opioid receptor antagonist	neurology/psychiatry	abstinence from alcohol	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49aa3d6d-2270-4615-aafa-b440859ab870
droloxifene	droloxifene	3-HYDROXYTAMOXIFEN|E-Droloxifene|FK-435|K-21060E|K060|K060E	CC\C(=C(\c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1	Phase 3	https://www.ncbi.nlm.nih.gov/pubmed/12088118	ESR1	http://www.drug2gene.com/relation/ESR1-104264735	selective estrogen receptor modulator (SERM)			
doxapram	doxapram	dopram	CCN1CC(CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1	Launched	FDA Orange Book: doxapram hydrochloride	KCNK9|KCNK3	https://www.drugbank.ca/drugs/DB00561|https://www.drugbank.ca/drugs/DB00561	potassium channel blocker	pulmonary|neurology/psychiatry|pulmonary	respiratory depression|central nervous system depression|acute hypercapnia (AHC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8eb330a-a75b-46cb-b694-5be9327ed2eb|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8eb330a-a75b-46cb-b694-5be9327ed2eb|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8eb330a-a75b-46cb-b694-5be9327ed2eb
diphemanil	diphemanil	prantal	C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1	Launched	FDA Orange Book: diphemanil methylsulfate	CHRM3	https://www.drugbank.ca/drugs/DB00729	acetylcholine receptor antagonist	neurology/psychiatry	spasms	http://www.drugs.com/international/diphemanil-metilsulfate.html
cyclophosphamide	cyclophosphamide	Neosar|cytoxan|cytoxan (lyophilized)|lyophilized cytoxan	ClCCN(CCCl)P1(=O)NCCCO1	Launched	FDA Orange Book: cyclophosphamide	CYP3A7|CYP3A5|CYP3A4|CYP2A6|CYP2C9|CYP2C8|CYP2B6|CYP2D6|CYP2C19|CYP2C18|LGALS1|BCL2	http://www.drugbank.ca/drugs/DB00531|http://www.drugbank.ca/drugs/DB00531|http://www.drugbank.ca/drugs/DB00531|http://www.drugbank.ca/drugs/DB00531|http://www.drugbank.ca/drugs/DB00531|http://www.drugbank.ca/drugs/DB00531|http://www.drugbank.ca/drugs/DB00531|http://www.drugbank.ca/drugs/DB00531|http://www.drugbank.ca/drugs/DB00531|http://www.drugbank.ca/drugs/DB00531|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070020|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070020	DNA alkylating agent	hematologic malignancy|hematologic malignancy|oncology|oncology|hematologic malignancy|hematologic malignancy|hematologic malignancy|hematologic malignancy|hematologic malignancy|hematologic malignancy|hematologic malignancy|oncology|oncology	Hodgkin's lymphoma|small lymphocytic lymphoma (SLL)|breast cancer|neuroblastoma|Burkitt's lymphoma|multiple myeloma|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)|true histiocytic lymphoma (THL)|retinoblastoma|ovarian cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8135b917-882f-4b4c-99b7-fa8ea54af4bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8135b917-882f-4b4c-99b7-fa8ea54af4bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8135b917-882f-4b4c-99b7-fa8ea54af4bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8135b917-882f-4b4c-99b7-fa8ea54af4bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8135b917-882f-4b4c-99b7-fa8ea54af4bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8135b917-882f-4b4c-99b7-fa8ea54af4bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8135b917-882f-4b4c-99b7-fa8ea54af4bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8135b917-882f-4b4c-99b7-fa8ea54af4bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8135b917-882f-4b4c-99b7-fa8ea54af4bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8135b917-882f-4b4c-99b7-fa8ea54af4bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8135b917-882f-4b4c-99b7-fa8ea54af4bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8135b917-882f-4b4c-99b7-fa8ea54af4bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8135b917-882f-4b4c-99b7-fa8ea54af4bf
morin	morin	NSC-19801	Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O	Preclinical		MCL1|ESR2|ADORA2A|CYP1A2|FASN|SLC22A12	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006614|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006614|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=411|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=291514|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006614|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006614	cytochrome P450 inhibitor			
SR-59230A	SR-59230A		CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12	Preclinical		ADRB1|ADRB3|ADRB2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=547|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=547|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=547	adrenergic receptor antagonist			
HA-130	HA-130		OB(O)c1cccc(COc2ccc(\C=C3/SC(=O)N(Cc4ccc(F)cc4)C3=O)cc2)c1	Preclinical		ENPP2	https://www.tocris.com/products/ha-130_4196	autotaxin inhibitor			
prazosin	prazosin	CP-12299|minipress|minipress xl	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1	Launched	FDA Orange Book: prazosin hydrochloride	ADRA1D|ADRA1B|ADRA2B|ADRA2A|ADRA2C|ADRA1A|CDK1|KCNH6|KCNH7|KCNH2	https://www.drugbank.ca/drugs/DB00457|https://www.drugbank.ca/drugs/DB00457|https://www.drugbank.ca/drugs/DB00457|https://www.drugbank.ca/drugs/DB00457|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=503|https://www.drugbank.ca/drugs/DB00457|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091503|https://www.drugbank.ca/drugs/DB00457|https://www.drugbank.ca/drugs/DB00457|https://www.drugbank.ca/drugs/DB00457	adrenergic receptor antagonist	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ce90aaf-d075-4617-9a47-e8d922096d23
tramiprosate	tramiprosate	NC-758	NCCCS(O)(=O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00314912	APP	https://www.tocris.com/dispprod.php?ItemId=232275#.VyzBamQrJZI	beta amyloid protein neurotoxicity inhibitor			
oxyquinoline	oxyquinoline		Oc1cccc2cccnc12	Launched	http://www.drugs.com/international/oxyquinoline.html	METAP2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010964	chelating agent	dermatology	cosmetic	http://www.ewg.org/skindeep/ingredient/704378/OXYQUINOLINE/
narlaprevir	narlaprevir	SCH 900518|SCH-900518	CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT00689390			HCV inhibitor			
gossypol	gossypol	(-)-Gossypol	CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O	Phase 2	https://clinicaltrials.gov/show/NCT00561197	MCL1|BCL2|EGF|BCL2L2|BCL2L1|CTGF	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=301647|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000701|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=301647|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=301647|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=301647|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=301647	BCL inhibitor|MCL1 inhibitor			
1,4-butanediol	1,4-butanediol		OCCCCO	Phase 1				benzodiazepine receptor agonist|gamma hydroxybutyric acid agonist			
NPS-2143	NPS-2143	SB-262470	CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N	Preclinical		PTH|CASR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=270642|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=716	calcium receptor antagonist			
halobetasol-propionate	halobetasol propionate	ultravate	CCC(=O)O[C@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)CCl	Launched	FDA Orange Book: halobetasol propionate	PLA2G1B|NR3C1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001186|https://www.drugbank.ca/drugs/DB00596	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f57aaae-8d5f-bfdf-08d6-495b84221311
UNC-926	UNC-926		Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1	Preclinical		L3MBTL1|L3MBTL3	https://www.tocris.com/products/unc-926-hydrochloride_4516|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=755054	MBT inhibitor			
novobiocin	novobiocin	Albamycin|Cathomycin	CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C	Launched	http://www.drugs.com/international/Novobiocin.html			bacterial DNA gyrase inhibitor	obstetrics/gynecology	mastitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dedd8fa7-e5d6-4a90-ab38-d8034f8b66b9
olmesartan-medoxomil	olmesartan medoxomil	CS-866|benicar|olmesartan medoxomil	CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	Launched	FDA Orange Book: olmesartan medoxomil	AGTR1	ChEMBL	angiotensin receptor antagonist	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a9c6e0e-72dd-4ed4-a8bb-8a6aee506681
gentiopicrin	gentiopicrin	Gentiopicroside	OC[C@H]1O[C@@H](O[C@@H]2OC=C3C(=O)OCC=C3[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O	Phase 3	Cortellis	GRIN2B|SRD5A2	www.abcam.com/Gentiopicroside-Gentiopicrin-ab143623.pdf|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=677140	glutamate receptor downregulator			
resminostat	resminostat		CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01037478	HDAC8|HDAC6|HDAC1|HDAC3|HDAC2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7502|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7502|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7502|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7502|https://citeline.informa.com/?query=#/drugs/details/40073	HDAC inhibitor			
LY2606368	LY2606368	prexasertib	COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02203513	CHEK1	http://jco.ascopubs.org/content/early/2016/03/31/JCO.2015.64.5788.abstract	CHK inhibitor			
oxypurinol	oxypurinol	oxipurinol	O=c1[nH]c2n[nH]cc2c(=O)[nH]1	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT00063687	XDH	https://www.drugbank.ca/drugs/DB05262	xanthine oxidase inhibitor			
pifithrin-alpha	pifithrin-alpha		Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N	Preclinical		TP53	http://www.sigmaaldrich.com/catalog/product/sigma/p4359?lang=en&region=US	TP53 inhibitor			
nelarabine	nelarabine	506U|arranon|nelzarabine	COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	Launched	FDA Orange Book: nelarabine	POLA1|ADA	https://www.drugbank.ca/drugs/DB01280|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=229059	DNA synthesis inhibitor|T cell inhibitor	hematologic malignancy|hematologic malignancy	acute lymphoblastic leukemia (ALL)|acute lymphoblastic leukemia (ALL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=893c95d7-d9b6-4064-db97-91dd21ce7e40|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=893c95d7-d9b6-4064-db97-91dd21ce7e40
indole-3-pyrubate	indole-3-pyrubate		OC(=O)C(=O)Cc1c[nH]c2ccccc12	Phase 2	Pharmaprojects			melatonin receptor agonist			
amflutizole	amflutizole		Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/3900392	XDH	https://en.wikipedia.org/wiki/Amflutizole	xanthine oxidase inhibitor			
ramelteon	ramelteon	TAK-375|rozerem	CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12	Launched	FDA Orange Book: ramelteon	MTNR1B|MTNR1A	ChEMBL|ChEMBL	melatonin receptor agonist	neurology/psychiatry	insomnia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a51d289-2013-4d37-adf2-91ea49df7932
micronomicin	micronomicin	micronomicin sulfate	CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1	Launched	http://www.drugs.com/international/micronomicin.html			protein synthesis inhibitor	infectious disease	gram-negative bacterial infections	https://www.goldbio.com/product/3613/micronomicin-sulfate
AMPA-(S)	(S)-AMPA	(s)-ampa|s-ampa	Cc1onc(O)c1C[C@H](N)C(O)=O	Preclinical		GRIN1	http://www.tocris.com/dispprod.php?ItemId=1169#.Ve73JyxVhHw	glutamate receptor agonist			
LM-22A4	LM-22A4		OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO	Preclinical		NTRK2	https://www.tocris.com/products/lm-22a4_4607	tropomyosin receptor kinase inhibitor			
acetylcysteine	acetylcysteine	Mucosil-10|Mucosil-20|acetadote|cetylev|mucomyst|mucosil|n-acetyl-l-cysteine		Launched	FDA Orange Book: acetylcysteine	GRIN1|GRIN3A|GRIN2D|GRIN2B|GRIN2A|RELA|IKBKB|SLC7A11|ACY1|GSS|CHUK	https://www.drugbank.ca/drugs/DB06151|https://www.drugbank.ca/drugs/DB06151|https://www.drugbank.ca/drugs/DB06151|https://www.drugbank.ca/drugs/DB06151|https://www.drugbank.ca/drugs/DB06151|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000981|https://www.drugbank.ca/drugs/DB06151|https://www.drugbank.ca/drugs/DB06151|https://www.drugbank.ca/drugs/DB06151|https://www.drugbank.ca/drugs/DB06151|https://www.drugbank.ca/drugs/DB06151	mucolytic agent	gastroenterology|gastroenterology	acetaminophen overdose|hepatic injury	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d305722-e74f-4f48-8d2c-0daa99144749|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d305722-e74f-4f48-8d2c-0daa99144749
EUK-134	EUK-134		COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12	Preclinical		SOD2|CAT|APP	http://www.selleckchem.com/products/euk-134.html|https://citeline.informa.com/?query=#/drugs/details/6191|http://www.selleckchem.com/products/euk-134.html	catalase stimulant			
cariprazine	cariprazine	RGH-188|vraylar	CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1	Launched	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf	DRD2|DRD3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7671|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7671	dopamine receptor antagonist	neurology/psychiatry	schizophrenia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f
oxacillin	oxacillin	oxacillin sodium|prostaphlin	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1	Launched	FDA Orange Book: oxacillin sodium			bacterial cell wall synthesis inhibitor	infectious disease	staphylococcal infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39453441-db41-4979-9896-51b5eebb5f31
dabigatran-etexilate	dabigatran etexilate	BIBR 1048 BS RS1|BIBR-1048|dabigatran etexilate|pradaxa	CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1	Launched	FDA Orange Book: dabigatran etexilate mesylate	F2	https://www.drugbank.ca/drugs/DB06695	thrombin inhibitor	neurology/psychiatry|hematology|hematology|hematology	stroke|systemic embolism|pulmonary embolism (PE)|deep vein thrombosis (DVT)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9
fenoverine	fenoverine		O=C(CN1CCN(Cc2ccc3OCOc3c2)CC1)N1c2ccccc2Sc2ccccc12	Launched	https://www.drugs.com/international/fenoverine.html	CHRM1|CHRM3|CHRM2|CHRM4	https://citeline.informa.com/?query=#/drugs/details/7229|https://citeline.informa.com/?query=#/drugs/details/7229|https://citeline.informa.com/?query=#/drugs/details/7229|https://citeline.informa.com/?query=#/drugs/details/7229	acetylcholine receptor antagonist	neurology/psychiatry	spasms	http://www.medindia.net/doctors/drug_information/fenoverine.htm
oxiracetam	oxiracetam		NC(=O)CN1C[C@H](O)CC1=O	Launched	http://en.wikipedia.org/wiki/Oxiracetam			acetylcholine receptor agonist			
clorprenaline	clorprenaline		CC(C)NCC(O)c1ccccc1Cl	Launched	http://www.drugs.com/international/clorprenaline.html	ADRB2|ADRB1	http://www.selleckchem.com/products/clorprenaline-hcl.html|http://www.selleckchem.com/products/clorprenaline-hcl.html	adrenergic receptor agonist	pulmonary	asthma	http://www.drugs.com/international/clorprenaline.html
fosfestrol	fosfestrol	diethylstilbestrol diphosphate|stilphostrol	CC\C(c1ccc(OP(O)(O)=O)cc1)=C(\CC)c1ccc(OP(O)(O)=O)cc1	Launched	http://www.drugs.com/international/Fosfestrol.html	ESR1|ESR2	ChEMBL|ChEMBL	synthetic estrogen	oncology	prostate cancer	https://en.wikipedia.org/wiki/Fosfestrol
triamcinolone-acetonide	triamcinolone acetonide	allernaze|azmacort|kenalog|kenalog-10|kenalog-40|nasacort|nasacort allergy 24 hour|nasacort hfa|triamcinolone acetonide|triesence|trivaris	CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	Launched	FDA Orange Book: triamcinolone acetonide	NR3C1|CYP3A7|CYP3A5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2867|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091611|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091611	glucocorticoid receptor agonist|immunosuppressant	dermatology	corticosteroid-responsive dermatoses	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=758a0e7b-8d01-4914-8048-faa0f70c1f69&audience=consumer
siponimod	siponimod	BAF312	CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F	Phase 3	https://www.novartis.com/news/media-releases/novartis-announces-positive-phase-iii-results-showing-efficacy-baf312-patients	S1PR5|S1PR1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=389589|https://en.wikipedia.org/wiki/Siponimod	sphingosine phosphate receptor modulator			
salicylanilide	salicylanilide		Oc1ccccc1C(=O)Nc1ccccc1	Preclinical				other antibiotic			
gabapentin-enacarbil	gabapentin enacarbil	Horizant|XP13512|gabapentin enacarbil	CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1	Launched	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm	CACNA1S|CACNA1I|CACNA1H|CACNA1G|CACNA1F|CACNA1E|CACNA1D|CACNA1C|CACNA1B|CACNA1A|CACNB4|CACNB3|CACNB2|CACNB1|CACNG1|CACNG8|CACNG7|CACNG6|CACNG5|CACNG4|CACNG3|CACNG2|CACNA2D1|CACNA2D2|CACNA2D3|CACNA2D4|SLC22A2	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=332087	adrenergic receptor agonist	neurology/psychiatry|neurology/psychiatry	restless leg syndrome|postherpetic neuralgia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c486fc7-c8c4-4c6c-b30c-366dabaeaadd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c486fc7-c8c4-4c6c-b30c-366dabaeaadd
L-694247	L-694247		CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1	Preclinical		HTR1D|HTR1A|HTR1B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=15|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=15|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=15	serotonin receptor agonist			
pyritinol	pyritinol	pyrithioxine|pyrithioxine hydrochloride	Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O	Launched	http://www.drugs.com/international/pyritinol.html				rheumatology|neurology/psychiatry	rheumatoid arthritis|senile dementia	https://en.wikipedia.org/wiki/Pyritinol|https://en.wikipedia.org/wiki/Pyritinol
ibrutinib	ibrutinib	CRA-032765|PCI-32765|PCI-32765-00|imbruvica	Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C	Launched	FDA Orange Book: ibrutinib	BTK|BMX|BLK	ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6912|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6912	Bruton's tyrosine kinase (BTK) inhibitor	hematologic malignancy|hematologic malignancy|hematologic malignancy	chronic lymphocytic leukemia (CLL)|mantle cell lymphoma (MCL)|Waldenstrom's macroglobulinemia (WM)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44
BIO-5192	BIO-5192		CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O	Preclinical		ITGA4|ITGB1	https://www.tocris.com/products/bio-5192_5051|https://www.tocris.com/products/bio-5192_5051	integrin inhibitor			
NVS-PAK1-1	NVS-PAK1-1		CC(C)NC(=O)N1CC[C@@H](C1)NC1=Nc2cc(F)ccc2N(CC(F)F)c2ccc(Cl)cc12	Preclinical		PAK1	https://www.tocris.com/products/nvs-pak1-1_6132	p21 activated kinase inhibitor			
phenothiazine	phenothiazine	Antiverm|Dibenzothiazine|Helmetina|Lethelmin|nemazine|phenthiazine|thiodiphenylamine	N1c2ccccc2Sc2ccccc12	Preclinical				dopamine receptor antagonist			
bekanamycin	bekanamycin	Kantrex|Klebcil|kanamycin b	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	Launched	http://www.drugs.com/international/bekanamycin.html			bacterial 30S ribosomal subunit inhibitor	infectious disease	gram-negative bacterial infections	http://www.drugs.com/international/bekanamycin.html
terconazole	terconazole	Fungistat|Gyno-Terazol|Panlomyc|R-42,470|R-42470|terazol|terazol 3|terazol 7|triaconazole		Launched	FDA Orange Book: terconazole			sterol demethylase inhibitor	infectious disease	vulvovaginal candidiasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59448bd-f730-46d2-a785-c2d6205579ff&audience=consumer
selinexor	selinexor	KPT-330	FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT02606461	XPO1	http://www.selleckchem.com/products/kpt-330.html	exportin antagonist			
reparixin	reparixin	DF 1681Y|DF-1681Y	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01817959	CXCR2|CXCR1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000955|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000955	CC chemokine receptor antagonist			
RS-23597-190	RS-23597-190		COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1	Preclinical		HTR4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=254	serotonin receptor antagonist			
zaprinast	zaprinast	M&B 22948	CCCOc1ccccc1-c1nc2[nH]nnc2c(=O)[nH]1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/3524648	GPR35|PDE9A|PDE5A|PDE4D|PDE1A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2919|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2919|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2919|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004208|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004208	phosphodiesterase inhibitor			
moracizine	moracizine	EN-313|ethmozine|moricizine	CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1	Launched	FDA Orange Book: moricizine hydrochloride	SCN5A	https://www.drugbank.ca/drugs/DB00680	sodium channel blocker	cardiology	ventricular arrhythmias	https://en.wikipedia.org/wiki/Moracizine
VGX-1027	VGX-1027		OC(=O)CC1CC(=NO1)c1ccccc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00760396	TLR4|TNF	http://www.abcam.com/vgx-1027-git-27-ab145857.html|https://citeline.informa.com/?query=#/drugs/details/35544	tumor necrosis factor receptor antagonist			
SirReal-2	SirReal-2		Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1	Preclinical		SIRT2	https://www.tocris.com/products/sirreal-2_5457	SIRT inhibitor			
levocetirizine	levocetirizine	xyzal	OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1	Launched	FDA Orange Book: levocetirizine dihydrochloride	HRH1|CXCL8	https://en.wikipedia.org/wiki/Levocetirizine|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=269103	histamine receptor antagonist	allergy|allergy	allergic rhinitis|urticaria	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2965ef46-18db-4615-9dce-bfb0f0b3366a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2965ef46-18db-4615-9dce-bfb0f0b3366a
hexaminolevulinate	hexaminolevulinate	cysview kit	CCCCCCOC(=O)CCC(=O)CN	Launched	FDA Orange Book: hexaminolevulinate hydrochloride				radiology	diagnostic agent	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=efe8ac26-e80c-4dc4-89ce-70bd307e3826
Y-39983	Y-39983		C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00846989	ROCK2|ROCK1	http://www.biocentury.com/products/y-39983|http://www.biocentury.com/products/y-39983	rho associated kinase inhibitor			
12-O-tetradecanoylphorbol-13-acetate	12-O-tetradecanoylphorbol-13 acetate	Phorbol Myristate Acetate	CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01009931	CD4|KCNT2|TRPV4	https://citeline.informa.com/?query=#/drugs/details/57443|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2341|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2341	PKC activator			
vildagliptin	vildagliptin	LAF237|NVP-LAF237	OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N	Launched	http://www.drugs.com/international/Vildagliptin.html	DPP4	https://www.drugbank.ca/drugs/DB04876	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus	https://en.wikipedia.org/wiki/Vildagliptin
panobinostat	panobinostat	LBH589|farydak	Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1	Launched	FDA Orange Book: panobinostat	HDAC2|HDAC1|HDAC8|HDAC7|HDAC9|HDAC4|HDAC3|HDAC6	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7489|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7489|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7489|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7489|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7489|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7489|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7489|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7489	HDAC inhibitor	hematologic malignancy	multiple myeloma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7774972a-eeaa-4b9a-9e56-3fc1b968e86a
APY0201	APY0201		Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1	Preclinical		IL12B|IL12A|PIKFYVE	https://www.medchemexpress.com/APY0201.html|https://www.medchemexpress.com/APY0201.html|https://www.medchemexpress.com/APY0201.html	phosphoinositide dependent kinase inhibitor			
CINPA-1	CINPA-1		CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(CC)CC)c2c1	Preclinical		NR1H4|PPARG|NR1I3	https://www.tocris.com/products/cinpa-1_5605|https://www.tocris.com/products/cinpa-1_5605|https://www.tocris.com/products/cinpa-1_5605	CAR antagonist			
trepibutone	trepibutone		CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(O)=O	Launched	https://www.drugs.com/international/trepibutone.html	CHRM2|CHRM3|CHRM1|CHRM4	https://en.wikipedia.org/wiki/Anticholinergic|https://en.wikipedia.org/wiki/Anticholinergic|https://en.wikipedia.org/wiki/Anticholinergic|https://en.wikipedia.org/wiki/Anticholinergic	cholinergic receptor antagonist	gastroenterology	irritable bowel syndrome	http://chealth.canoe.com/Drug/GetDrug/Trimebutine
phenylethyl-alcohol	phenylethyl alcohol	phenethanol|phenethyl alcohol|phenylethanol|phenylethyl alcohol	OCCc1ccccc1	Preclinical							
ocinaplon	ocinaplon	CL 273,547	O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1	Phase 3	http://www.prnewswire.com/news-releases/dov-initiates-pivotal-phase-iii-trial-for-ocinaplon-its-novel-anti-anxiety-drug-candidate-75536232.html	GABRA5|GABRA3|GABRA1|GABRA2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4277|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4277|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4277|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4277	GABA receptor modulator			
carbazochrome	carbazochrome	carbazochrome sulfonic acid	CN1C(CC2=C\C(=N\NC(N)=O)C(=O)C=C12)S(O)(=O)=O	Launched	http://www.drugs.com/international/carbazochrome.html				hematology	hemorrhage	https://en.wikipedia.org/wiki/Carbazochrome
trichlormethiazide	trichlormethiazide	Trichlorex|Trichlormas|metahydrin|naqua	NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C(Cl)Cl)cc1Cl	Launched	FDA Orange Book: trichlormethiazide	CA2|CA1|CA4|SLC12A3|SLC12A1|ATP1A1	https://www.drugbank.ca/drugs/DB01021|https://www.drugbank.ca/drugs/DB01021|https://www.drugbank.ca/drugs/DB01021|ChEMBL|https://www.drugbank.ca/drugs/DB01021|https://www.drugbank.ca/drugs/DB01021	chloride channel blocker	cardiology|cardiology	hypertension|edema	https://en.wikipedia.org/wiki/Trichlormethiazide|https://en.wikipedia.org/wiki/Trichlormethiazide
STA-5326	STA-5326		Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00138840	IL23A|IL12B|IL12A|IL12RB2|IL12RB1	https://citeline.informa.com/?query=#/drugs/details/28837|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=393809|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000235|https://citeline.informa.com/?query=#/drugs/details/28837|https://citeline.informa.com/?query=#/drugs/details/28837	interleukin synthesis inhibitor			
lauric-diethanolamide	lauric-diethanolamide		CCCCCCCCCCCC(=O)N(CCO)CCO	Preclinical							
RU-58841	RU-58841		CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F	Phase 2	Pharmaprojects	AR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008019	androgen receptor antagonist			
WAY-208466	WAY-208466		CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1	Preclinical		HTR6|HTR7|HTR2C|HTR2A|DRD2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010089|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010089|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010089|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010089|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010089	serotonin receptor agonist			
begacestat	begacestat	GSI-953	OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00959881	PSEN1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6979	gamma secretase inhibitor			
PD-166285	PD-166285		CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1	Preclinical		PDGFRB|WEE1|PKMYT1|EGFR|SRC|FGFR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8183|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8183|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8183|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8183|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8183|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8183	src inhibitor			
Y-29794	Y-29794		CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1	Preclinical		PREP	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014320	prolyl endopeptidase inhibitor			
ORY-1001	ORY-1001		NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1	Phase 1/Phase 2	https://www.oryzon.com/en/news/oryzon-initiates-clinical-development-ory-1001-novel-lsd1-inhibitor-patients-acute-myeloid	KDM1A	https://www.caymanchem.com/product/19136	histone lysine demethylase inhibitor			
sulconazole	sulconazole	exelderm	Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1	Launched	FDA Orange Book: sulconazole nitrate			sterol demethylase inhibitor	infectious disease|infectious disease|infectious disease	tinea pedis|tinea cruris|tinea corporis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b963f0d-b041-43be-9434-7161eab49adb&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b963f0d-b041-43be-9434-7161eab49adb&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b963f0d-b041-43be-9434-7161eab49adb&audience=consumer
tioguanine	tioguanine	6-Thioguanosine|thioguanosine	Nc1nc(S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1	Phase 2	http://cancerres.aacrjournals.org/content/21/8/1015.full.pdf			purine antagonist			
briciclib	briciclib	ON 014185|ON-013105	COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02168725	CCND1	https://www.medchemexpress.com/Briciclib.html	cyclin D inhibitor			
GLPG0492	GLPG0492		CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01130818	AR	https://www.ncbi.nlm.nih.gov/pubmed/25185887	androgen receptor modulator			
silver-sulfadiazine	silver sulfadiazine	sildaflo|silvadene|ssd|ssd af|thermazene		Launched	FDA Orange Book: silver sulfadiazine			PABA antagonist	critical care	sepsis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4d6694f-2b0a-4d64-9e05-2fef6d8e60d9&audience=consumer
PS178990	PS178990	BMS-564929	Cc1c(ccc(C#N)c1Cl)N1C(=O)[C@@H]2[C@H](O)CCN2C1=O	Phase 1	http://www.drugs.com/news/pharmacopeia-acquires-selective-androgen-receptor-modulator-sarm-program-bristol-myers-squibb-7027.html	AR	https://www.drugbank.ca/drugs/DB07286	androgen receptor modulator			
phenylbenzimidazole-sulfonic-acid	phenylbenzimidazole sulfonic acid	ensulizole|phenylbenzimidazole sulfonic acid	OS(=O)(=O)c1ccc2[nH]c(nc2c1)-c1ccccc1	Launched	https://en.wikipedia.org/wiki/Phenylbenzimidazole_sulfonic_acid				dermatology	sunscreen lotion	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=607c4a68-477a-47a5-b6b7-fb6ea7db94b7
GW-501516	GW-501516	GW501516	Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00158899	PPARD|PPARA|INS	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2687|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004589|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=299373	PPAR receptor agonist			
hemin	hemin		[Fe+3].Cc1c(CCC(O)=O)c2cc3[nH]c(cc4nc(cc5[nH]c(cc1n2)c(C=C)c5C)c(C=C)c4C)c(C)c3CCC(O)=O	Launched	http://www.drugs.com/international/Hemin.html			enzyme inducer	hematology|cardiology|cardiology	acute intermittent porphyria (AIP)|hypertension|ventricular tachycardia (VT)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d84808a8-d039-6293-6e0d-782327f0a5c0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d84808a8-d039-6293-6e0d-782327f0a5c0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d84808a8-d039-6293-6e0d-782327f0a5c0
bronopol	bronopol		OCC(Br)(CO)[N+]([O-])=O	Launched	http://en.wikipedia.org/wiki/Bronopol						
sacubitril	sacubitril	AHU377	CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O	Launched	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=000dc81d-ab91-450c-8eae-8eb74e72296f	MME	https://en.wikipedia.org/wiki/Valsartan/sacubitril	neprilysin inhibitor	cardiology	congestive heart failure	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=000dc81d-ab91-450c-8eae-8eb74e72296f
otilonium	otilonium		CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC	Launched	http://www.drugs.com/international/otilonium-bromide.html	CACNA1C	http://www.medchemexpress.com/otilonium-bromide.html	acetylcholine receptor antagonist	gastroenterology	irritable bowel syndrome	https://en.wikipedia.org/wiki/Otilonium_bromide
vasopressin	vasopressin	Arginine Vasopressin|Beta-Hypophamine|Leiormone|Vasophysin|pitressin|pitressin tannate|vasostrict	N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O	Launched	FDA Orange Book: vasopressin	OXTR|AVPR2|AVPR1B|AVPR1A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2168|ChEMBL|ChEMBL|ChEMBL	vasopressin receptor agonist	gastroenterology	abdominal distension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ab267f4-9ec9-44fd-8521-f975074667d9
fluspirilene	fluspirilene	IMAP|MCN-JR-6218|R 6218|Redeptin	Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1	Launched	http://de.wikipedia.org/wiki/Fluspirilen	CACNG1|HTR2A|HTR1A|HTR1D|HTR1E|HRH1|DRD2	https://www.drugbank.ca/drugs/DB04842|https://www.drugbank.ca/drugs/DB04842|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=85|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=85|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=85|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=85|https://www.drugbank.ca/drugs/DB04842	dopamine receptor antagonist	neurology/psychiatry	schizophrenia	https://en.wikipedia.org/wiki/Fluspirilene
S4	S4		Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1	Preclinical		CA12|CA9	https://www.tocris.com/products/s4_5577|https://www.tocris.com/products/s4_5577	carbonic anhydrase inhibitor			
azilsartan	azilsartan	TAK-536	CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1	Launched	FDA Orange Book: azilsartan kamedoxomil	AGTR1|AGTR2|INS	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6901|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000490|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=192016	angiotensin receptor antagonist	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=52b27c75-9f5a-4816-bafd-dace9d7d2063
org-27569	org-27569		CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1	Preclinical		CNR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7851	cannabinoid receptor modulator			
faropenem	faropenem		CC(O)C1C2SC(C3CCCO3)=C(N2C1=O)C(O)=O	Launched	http://www.drugs.com/international/faropenem.html			lactamase inhibitor	infectious disease|pulmonary|infectious disease|infectious disease|otolaryngology	pneumonia|bronchitis|skin infections|urinary tract infections|sinusitis	https://en.wikipedia.org/wiki/Faropenem|https://en.wikipedia.org/wiki/Faropenem|https://en.wikipedia.org/wiki/Faropenem|https://en.wikipedia.org/wiki/Faropenem|https://en.wikipedia.org/wiki/Faropenem
triprolidine	triprolidine	Actahist|Actifed|Allerfed|Corphed|Histafed|Myfed|Myidyl|Trilitron|Triphed|actidil	Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1	Launched	http://en.wikipedia.org/wiki/Actifed	HRH1	https://www.drugbank.ca/drugs/DB00427	histamine receptor antagonist	allergy	allergic rhinitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc466d33-cf3e-4f1c-a794-6d3d79903adf
VT-464	VT-464		CC(C)[C@@](O)(c1c[nH]nn1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02130700	CYP17A1	https://en.wikipedia.org/wiki/Seviteronel	cytochrome P450 inhibitor			
tenilsetam	tenilsetam		O=C1NCCNC1c1cccs1	Phase 3	Pharmaprojects			AGE inhibitor			
LDC1267	LDC1267		CCOc1cn(nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1)-c1ccc(F)cc1C	Preclinical		AXL|MET|MERTK|TYRO3|AURKB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8247|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=845541|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8247|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8247|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=845541	protein tyrosine kinase inhibitor			
leucylleucine-methyl-ester	leucylleucine-methyl-ester		COC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00429039						
dapoxetine	dapoxetine		CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1	Launched	http://www.drugs.com/international/Dapoxetine.html	HTR2C|HTR1A|HTR1B|SLC6A4	https://www.drugbank.ca/drugs/DB04884|https://www.drugbank.ca/drugs/DB04884|https://www.drugbank.ca/drugs/DB04884|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7901	selective serotonin reuptake inhibitor (SSRI)	urology	premature ejaculation (PE)	https://en.wikipedia.org/wiki/Dapoxetine
GSK-2837808A	GSK-2837808A		COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(c4)C(O)=O)c(cnc3c2)S(=O)(=O)NC2CC2)c(OC)n1	Preclinical		LDHA	https://www.tocris.com/products/gsk-2837808a_5189	lactate dehydrogenase inhibitor			
ATB-346	ATB-346		COc1ccc2cc(ccc2c1)C(C)C(=O)Oc1ccc(cc1)C(N)=S	Phase 2	http://www.antibethera.com/2016/08/08/antibe-therapeutics-announces-successful-phase-2-trial-of-atb-346-in-osteoarthritis/	PTGER2	http://www.apexbt.com/atb-346.html	cyclooxygenase inhibitor			
daminozide	daminozide		CN(C)NC(=O)CCC(O)=O	Preclinical		PHF8|KDM2A|KDM7A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7025|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7025|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7025	KDM2A inhibitor			
rolipram-R(-)	rolipram-R(-)	(-)-rolipram|(R)-Rolipram|R-Rolipram	COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1	Preclinical		PDE5A|PDE4C|PDE4D|PDE4A|PDE4B	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003593|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5260|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5260|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5260|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5260	phosphodiesterase inhibitor			
cyclovirobuxin-d	cyclovirobuxin-d		CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C	Preclinical				calcium channel modulator			
permethrin	permethrin	elimite|nix	CC1(C)C(C=C(Cl)Cl)C1C(=O)OCc1cccc(Oc2ccccc2)c1	Launched	FDA Orange Book: permethrin	SCN1A	https://www.drugbank.ca/drugs/DB04930		infectious disease	lice	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d757b15-0bae-45c1-8fae-6ebdf0f7d560
pralidoxime-chloride	pralidoxime chloride		C[n+]1ccccc1C[N+][O-]	Launched	https://www.drugs.com/pro/pralidoxime-chloride.html	ACHE|BCHE	http://www.drugbank.ca/drugs/DB00733|http://www.drugbank.ca/drugs/DB00733	acetylcholinesterase inhibitor	pulmonary	respiratory depression	http://www.rxlist.com/protopam-drug/indications-dosage.htm
ilepcimide	ilepcimide		O=C(C=Cc1ccc2OCOc2c1)N1CCCCC1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/2505982			anticonvulsant			
NLG919	NLG919		OC(CC1c2ccccc2-c2cncn12)C1CCCCC1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02048709	IDO1	http://www.selleckchem.com/products/nlg919.html	indoleamine 2,3-dioxygenase inhibitor			
flurizan	flurizan		C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1	Phase 3	https://en.wikipedia.org/wiki/Tarenflurbil	PTGS2|PTGS1|PSEN2|PSEN1|BACE1|APH1B|IKBKG	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4194|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4194|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006444|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006444|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006444|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006444|https://www.drugbank.ca/drugs/DB05289	gamma secretase inhibitor			
colistin-sulfate	colistin sulfate	coly-mycin s		Launched	FDA Orange Book: colistin sulfate			bacterial permeability inducer	infectious disease	gram-negative bacterial infections	https://en.wikipedia.org/wiki/Colistin
noscapine	noscapine			Launched	http://www.drugs.com/international/noscapine.html	SIGMAR1|BDKRB2	http://en.wikipedia.org/wiki/Noscapine|https://citeline.informa.com/?query=#/drugs/details/31920	bradykinin receptor antagonist|tubulin polymerization inhibitor	pulmonary	cough suppressant	https://en.wikipedia.org/wiki/Noscapine
I-BRD9	I-BRD9		CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1	Preclinical		BRD9	https://www.tocris.com/dispprod.php?ItemId=455623#.V-qMBZMrLy8	bromodomain inhibitor			
azeliragon	azeliragon		CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02080364	AGER	http://vtvtherapeutics.com/pipeline/azeliragon	RAGE receptor antagonist			
ganglioside-gm1	ganglioside-gm1		CCCCCCCCCCCCCCCCCC(=O)N[C@@H](COC1OC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(OC4OC(CO)C(O)C(O)C4O)C3NC(C)=O)C(OC3(CC(O)C(NC(C)=O)C(O3)C(O)C(O)CO)C(O)=O)C2O)C(O)C1O)[C@H](O)\C=C\CCCCCCCCCCCCC	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/2041549						
physostigmine-salicylate	physostigmine salicylate		CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1	Phase 3	http://www.aafp.org/afp/1998/1001/p1175.html			acetylcholinesterase inhibitor			
eltoprazine	eltoprazine	DU-28853	C1CN(CCN1)c1cccc2OCCOc12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01266174	HTR1B|HTR1A	https://en.wikipedia.org/wiki/Eltoprazine|https://en.wikipedia.org/wiki/Eltoprazine	serotonin receptor agonist			
PAC-1	PAC-1		Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02355535	CASP3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5238	caspase activator			
benzo[d]thiazole-2(3h)-thione	benzo[d]thiazole-2(3h)-thione	2-Mercaptobenzothiazole|2-Mercaptobenzothioazole|Benzothiazole-2-Thiol	Sc1nc2ccccc2s1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/5342897						
mavoglurant	mavoglurant	AFQ056	COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01813019	CYP2C8|GRM5|CYP2C19	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=342768|https://en.wikipedia.org/wiki/Mavoglurant|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=342768	glutamate receptor antagonist			
anagrelide	anagrelide	Xagrid|agrylin|anagrelide hydrochloride	Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl	Launched	FDA Orange Book: anagrelide hydrochloride	PDE3A	https://www.drugbank.ca/drugs/DB00261	phosphodiesterase inhibitor	hematology|hematologic malignancy	thrombocythemia|myeloproliferative neoplasms	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6727d5d4-e8ec-4a85-bc82-ec70b641eecf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6727d5d4-e8ec-4a85-bc82-ec70b641eecf
bifendate	bifendate		COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1C(=O)OC	Launched	http://www.imm.ac.cn/en/druglist.asp						
trichostatin-a	trichostatin a	GNF-Pf-1011|trichostatin|trichostatin a	C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C	Preclinical		HDAC10|HDAC7|HDAC8|HDAC5|HDAC6|HDAC3|HDAC4|HDAC1|HDAC2|HDAC9	http://en.wikipedia.org/wiki/Trichostatin_A|https://www.drugbank.ca/drugs/DB04297|https://www.drugbank.ca/drugs/DB04297|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7005|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7005|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7005|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7005|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7005|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7005|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7005	HDAC inhibitor			
enilconazole	enilconazole	Clinafarm|Imaverol|Imazalil|R 23,979	Clc1ccc(C(Cn2ccnc2)OCC=C)c(Cl)c1	Veterinary Launched	http://www.drugs.com/international/enilconazole.html	CYP1A2|CYP2C9|CYP2B6|CYP2J2|CYP3A5|CYP3A4|PTGER2|NR1I2|PPARA|CYP19A1	http://www.t3db.ca/toxins/T3D3860#targets|http://www.t3db.ca/toxins/T3D3860#targets|http://www.t3db.ca/toxins/T3D3860#targets|http://www.t3db.ca/toxins/T3D3860#targets|http://www.t3db.ca/toxins/T3D3860#targets|http://www.t3db.ca/toxins/T3D3860#targets|http://www.t3db.ca/toxins/T3D3860#targets|http://www.t3db.ca/toxins/T3D3860#targets|http://www.t3db.ca/toxins/T3D3860#targets|http://www.t3db.ca/toxins/T3D3860#targets	sterol demethylase inhibitor	infectious disease	skin infections	http://www.vetstreet.com/enilconazole-rx
iproniazid	iproniazid	Iproniazide	CC(C)NNC(=O)c1ccncc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	MAOA|MAOB	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008616|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008616	monoamine oxidase inhibitor			
talampanel	talampanel	LY-300164	C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00696332	GRIA2|GRIA1|GRIA4|GRIA3	https://www.drugbank.ca/drugs/DB04982|https://www.drugbank.ca/drugs/DB04982|https://www.drugbank.ca/drugs/DB04982|https://www.drugbank.ca/drugs/DB04982	glutamate receptor antagonist			
chrysophanic-acid	chrysophanic acid	Chrysophanol	Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	Preclinical		KDR|MTOR|FLT1|EGFR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=408822|http://www.selleckchem.com/products/Chrysophanic-acid-Chrysophanol.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=408822|http://www.selleckchem.com/products/Chrysophanic-acid-Chrysophanol.html	EGFR inhibitor			
PLX-4720	PLX-4720		CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F	Preclinical		KDR|BRAF	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5703|https://www.drugbank.ca/drugs/DB06999	RAF inhibitor			
DR-2313	DR-2313		Cc1nc(=O)c2CSCCc2[nH]1	Preclinical		PARP3|PARP1	https://www.drugbank.ca/drugs/DB07677|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002340	PARP inhibitor			
benzyl-isothiocyanate	Benzyl Isothiocyanate	BITC|Benzyl Isothiocyanate|Isothiocyanatomethyl-Benzene	S=C=NCc1ccccc1	Preclinical				methylazoxymethanol acetate inhibitor			
catharanthine	catharanthine	Catharanthine Base	CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC	Preclinical				tubulin polymerization inhibitor			
FPA-124	FPA-124		Cl[Cu]Cl.NC(=S)N\N=C\c1coc2ccccc2c1=O	Preclinical				AKT inhibitor			
TC-F-2	TC-F-2		CCn1c2ccccc2n([C@H]2CCCN(C2)c2nccc(n2)-c2cc3ccccc3o2)c1=O	Preclinical		FAAH	https://www.tocris.com/products/tc-f-2_4355	FAAH inhibitor			
aklomide	aklomide	clomide	NC(=O)c1ccc(cc1Cl)[N+]([O-])=O	Veterinary Launched	http://www.drugs.com/international/aklomide.html				infectious disease	coccidiosis	http://www.drugs.com/international/aklomide.html
SDZ-220-040	SDZ-220-040		N[C@@H](Cc1cc(cc(CP(O)(O)=O)c1O)-c1ccc(Cl)cc1Cl)C(O)=O	Preclinical		GRIN1	http://www.tocris.com/dispprod.php?ItemId=2289#.Vg6bMmRVhHw	glutamate receptor antagonist			
uracil	uracil	BMS-205603-01|SQ-6201|SQ-7726|SQ-8493|uracil mustard	Oc1ccnc(O)n1	Launched	FDA Orange Book: fluorouracil, propylthiouracil, uracil mustard	UCKL1|DPYD	https://www.drugbank.ca/drugs/DB03419|https://www.drugbank.ca/drugs/DB03419				
NBQX	NBQX		NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O	Preclinical		GRIA2|GRIA1|GRIA4|GRIA3|GRIK1|GRIN1|GRIN2A|GRIN2B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4264|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4264|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4264|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4264|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003508|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003508|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003508|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003508	glutamate receptor antagonist			
oxolamine	oxolamine	AF-438 [AS CITRATE]|SKF 9976 [AS CITRATE]	CCN(CC)CCc1nc(no1)-c1ccccc1	Launched	http://www.drugs.com/international/oxolamine.html			antitussive	pulmonary	cough suppressant	http://www.drugs.com/international/oxolamine.html
diazooxonorleucine	diazooxonorleucine		N[C@@H](CCC(=O)C=[N+]=N)C(O)=O	Phase 2	http://en.wikipedia.org/wiki/6-Diazo-5-oxo-L-norleucine#cite_note-Mueller-4			glutamate receptor antagonist			
AJ76-(+)	(+)-AJ76		CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C	Preclinical				dopamine receptor antagonist			
fingolimod	fingolimod	gilenya	CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1	Launched	FDA Orange Book: fingolimod	SPHK1|S1PR3|S1PR4|S1PR1|S1PR5|CYP4F2|CYP2E1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=210392|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=210392|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=210392|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000804|https://www.drugbank.ca/drugs/DB08868|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=210392|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=210392	immunosuppressant|sphingosine phosphate receptor agonist	neurology/psychiatry	multiple sclerosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9
L-798,106	L-798,106		COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1	Preclinical				prostanoid receptor antagonist			
LY2334737	LY2334737	LY-2334737	CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01648764			antitumor agent|ribonucleotide reductase inhibitor			
kinetin	kinetin		C(Nc1ncnc2[nH]cnc12)c1ccco1	Launched	https://clinicaltrials.gov/ct2/show/NCT00492479			cell division inducer	dermatology	sunburn	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af8dd204-add9-4f28-8a27-e40655906456
cyclopentolate	cyclopentolate	cyclogyl	CN(C)CCOC(=O)C(c1ccccc1)C1(O)CCCC1	Launched	FDA Orange Book: cyclopentolate hydrochloride	CHRM1	https://www.drugbank.ca/drugs/DB00979	acetylcholine receptor antagonist	ophthalmology|ophthalmology	mydriasis|cycloplegia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84a02489-2753-4543-9712-0345074e5972|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84a02489-2753-4543-9712-0345074e5972
lisinopril	lisinopril	prinivil|zestril	NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	Launched	FDA Orange Book: lisinopril	ACE2|ACE	https://www.drugbank.ca/drugs/DB00722|https://www.drugbank.ca/drugs/DB00722	angiotensin converting enzyme inhibitor	cardiology|cardiology|endocrinology	hypertension|congestive heart failure|diabetes mellitus	https://en.wikipedia.org/wiki/Lisinopril|https://en.wikipedia.org/wiki/Lisinopril|https://en.wikipedia.org/wiki/Lisinopril
LY450108	LY450108		C[C@@H](CNS(=O)(=O)C(C)C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1	Phase 1	http://www.pharmacodia.com/yaodu/html/v1/chemicals/4458707eaea92785e478122f883f74b7.html			glutamate receptor modulator			
aprindine	aprindine	COMPOUND 99170	CCN(CC)CCCN(C1Cc2ccccc2C1)c1ccccc1	Launched	https://www.drugs.com/international/aprindine.html	CALM1|SCN5A	https://www.drugbank.ca/drugs/DB01429|https://www.drugbank.ca/drugs/DB01429	voltage-gated sodium channel blocker	cardiology	cardiac arrythmia	http://dgidb.genome.wustl.edu/drug_claims/TdgClinicalTrial/APRINDINE
CHF5074	CHF5074		OC(=O)C1(CC1)c1ccc(c(F)c1)-c1ccc(Cl)c(Cl)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01303744	PSEN1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7339	gamma secretase modulator			
oleandrin	oleandrin		CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O	Phase 1	http://jeccr.biomedcentral.com/articles/10.1186/s13046-015-0232-8			Na/K-ATPase inhibitor			
pirquinozol	pirquinozol	SO 13847	OCc1cc2c3ccccc3[nH]c(=O)n2n1	Phase 1	Pharmaprojects			histamine release inhibitor			
niclosamide	niclosamide	BAY 2353|BAY-2353|Ex A Lint|Lintex|Nicloside|Yomesan|niclocide	Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O	Launched	FDA Orange Book: niclosamide	STAT3	http://www.tocris.com/dispprod.php?ItemId=278936#.Utgux_15mf0	DNA replication inhibitor|STAT inhibitor	infectious disease	tapeworm	https://en.wikipedia.org/wiki/Niclosamide
lasofoxifene	lasofoxifene		O[C@@H]([C@H](O)C(O)=O)C(O)=O.Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc(OCCN2CCCC2)cc1	Launched	https://www.drugs.com/international/lasofoxifene.html	ESR2|ESR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7542|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7542	selective estrogen receptor modulator (SERM)	orthopedics|oncology	osteoporosis|breast cancer	https://en.wikipedia.org/wiki/Lasofoxifene|https://en.wikipedia.org/wiki/Lasofoxifene
nTZDpa	nTZDpa		OC(=O)c1n(Cc2ccc(Cl)cc2)c2ccc(Cl)cc2c1Sc1ccccc1	Preclinical		PPARG	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2699	PPAR receptor agonist			
dosulepin	dosulepin	dothiepin	CN(C)CC\C=C1/c2ccccc2CSc2ccccc12	Launched	http://www.drugs.com/international/Dosulepin.html	CHRM3|CHRM2|CHRM5|CHRM4|CHRM1|CYP2C19|SLC6A4|SLC6A2|HRH1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7549|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7549|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7549|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7549|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7549|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091441|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7549|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7549|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7549	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant	neurology/psychiatry	depression	https://en.wikipedia.org/wiki/Dosulepin
carebastine	carebastine		CC(C)(C(O)=O)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/9660043	HRH1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000738	histamine receptor antagonist			
bornyl-acetate	bornyl acetate		CC(=O)OC1CC2CCC1(C)C2(C)C	Preclinical							
umeclidinium	umeclidinium	GSK573719|incruse ellipta 	OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2	Launched	FDA Orange Book: umeclidinium bromide	CHRM2|CHRM3|CHRM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7354|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7354|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7354	acetylcholine receptor antagonist	pulmonary|pulmonary|pulmonary	chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dbb64747-1505-49d7-9a33-99dd402e96d3|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dbb64747-1505-49d7-9a33-99dd402e96d3|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dbb64747-1505-49d7-9a33-99dd402e96d3
10-deacetylbaccatin	10-deacetylbaccatin	10-deacetylbaccatin III|10-deacetylbaccatine III	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C	Preclinical				antitumor agent			
miriplatin	miriplatin			Launched	https://www.drugs.com/international/miriplatin.html			DNA synthesis inhibitor	oncology	hepatocellular carcinoma (HCC)	https://www.ncbi.nlm.nih.gov/pubmed/25132539
ML314	ML314		COc1ccccc1N1CCN(CC1)c1nc(nc2cc(OC)c(OC)cc12)C1CC1	Preclinical		NTSR1	http://www.sigmaaldrich.com/catalog/product/sigma/sml0926?lang=en&region=US	neurotensin agonist			
nimustine	nimustine	nimustine hydrochloride	Cc1ncc(CNC(=O)N(CCCl)[N+][O-])c(N)n1	Launched	http://www.drugs.com/international/nimustine.html			DNA alkylating agent			
GTP-14564	GTP-14564		c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21	Preclinical		KIT|PDGFRB|CSF1R|FLT3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5982|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5982|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5982|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5982	FLT3 inhibitor|tyrosine kinase inhibitor			
chlorobutanol	chlorobutanol	chlorbutol|chloretone|trichlorisobutylalcohol	CC(C)(O)C(Cl)(Cl)Cl	Launched	http://www.drugs.com/international/chlorobutanol.html				neurology/psychiatry|neurology/psychiatry	anesthetic|sedative	https://en.wikipedia.org/wiki/Chlorobutanol|https://en.wikipedia.org/wiki/Chlorobutanol
5-hydroxyectoine	5-hydroxyectoine		O[C@H]1CNC(=C)N[C@@H]1C(O)=O	Preclinical							
PF-03758309	PF-03758309		CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)n[nH]c2C1(C)C)c1ccccc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00932126	PAK4	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=650124	p21 activated kinase inhibitor			
2-chloro-N6-cyclopentyladenosine	2-chloro-N6-cyclopentyladenosine		OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12	Preclinical		ADORA2A|ADORA2B|ADORA1|ADORA3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=374|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=374|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=374|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=374	adenosine receptor agonist			
pexidartinib	pexidartinib		FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1	Phase 3	https://www.clinicaltrials.gov/ct2/show/NCT02371369	KIT|CSF1R|FLT3	http://www.selleckchem.com/products/pexidartinib-plx3397.html|http://www.selleckchem.com/products/pexidartinib-plx3397.html|http://www.selleckchem.com/products/pexidartinib-plx3397.html	tyrosine kinase inhibitor			
gadoteridol	gadoteridol	prohance|prohance multipack		Launched	FDA Orange Book: gadoteridol			radiopaque medium	radiology	MRI contrast agent	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=778aee03-7d4c-481a-be8a-a75db0702f5a
clindamycin-phosphate	clindamycin phosphate	cleocin|cleocin phosphate|cleocin t|clindagel|clindesse|evoclin	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O	Launched	FDA Orange Book: clindamycin phosphate			protein synthesis inhibitor	obstetrics/gynecology	bacterial vaginosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d952e542-d040-42ec-b40e-198195bfe8d0
AGN-194310	AGN-194310		CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O	Phase 3	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100616/	RXRB|RXRA|RXRG	http://www.apexbt.com/agn-194310.html|http://www.apexbt.com/agn-194310.html|http://www.apexbt.com/agn-194310.html	retinoid receptor antagonist			
carbenoxolone	carbenoxolone		CC1(C)[C@H](CC[C@@]2(C)C1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O	Launched	http://www.drugs.com/international/carbenoxolone.html	GJE1|GJB7|GJB2|GJB1|GJB6|GJB5|GJB4|GJB3|GJA9|GJA8|GJA1|GJA5|GJA4|GJA3|GJD4|GJD3|GJD2|GJC3|GJC2|GJC1|PANX3|PANX1|PANX2|HSD11B1|GJA10	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151|https://www.drugbank.ca/drugs/DB02329|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation	https://en.wikipedia.org/wiki/Carbenoxolone|https://en.wikipedia.org/wiki/Carbenoxolone
SB-415286	SB-415286		Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl	Preclinical		GSK3A|GSK3B|RPS6KB1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8019|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8019|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004415	glycogen synthase kinase inhibitor			
propidium-iodide	propidium iodide		CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12	Preclinical		ACHE	https://www.drugbank.ca/drugs/DB02166				
QX-314	QX-314		CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C	Preclinical		MAPK14|TGFBR1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009227|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009227	sodium channel blocker			
MIRA-1	MIRA-1		CCC(=O)OCN1C(=O)C=CC1=O	Preclinical				apoptosis stimulant			
hyperin	hyperin		OCC1OC(Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)C(O)C(O)C1O	Preclinical		ACE|AKR1B1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013595|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013595	aldose reductase inhibitor			
BX-912	BX-912		Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1c[nH]cn1	Preclinical		AKT2|KDR|GSK3B|CDK2|PDPK1|CHEK1|PDK1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=374143|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8007|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8007|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8007|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8007|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8007|http://www.selleckchem.com/products/bx-912.html?gclid=CKyo86qglbwCFedAMgodBgIAVA	pyruvate dehydrogenase kinase inhibitor			
doripenem	doripenem	Finibax|S-4661|doribax	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O	Launched	FDA Orange Book: doripenem	DPEP1	https://docs.google.com/spreadsheets/d/1AjYYAQ_-qbcsgiQj0w9S63eTkEAr8IUsRn_tDHV9HTk/edit#gid=1365307415	bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease	intra-abdominal infections|urinary tract infections|pyelonephritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=974cac49-7d08-4c2a-9c24-ce75f66d9d75|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=974cac49-7d08-4c2a-9c24-ce75f66d9d75|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=974cac49-7d08-4c2a-9c24-ce75f66d9d75
ketorolac	ketorolac	acular|acular ls|acular preservative free|acuvail|ketorolac tromethamine|sprix|toradol	OC(=O)C1CCn2c1ccc2C(=O)c1ccccc1	Launched	FDA Orange Book: ketorolac tromethamine	PTGS2|PTGS1	https://www.drugbank.ca/drugs/DB00465|https://www.drugbank.ca/drugs/DB00465	cyclooxygenase inhibitor			
dimesna	dimesna		OS(=O)(=O)CCSSCCS(O)(=O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00039780			tubulin polymerization inhibitor			
silymarin	silymarin		COc1cc(ccc1O)C1Oc2ccc(cc2OC1CO)C1Oc2cc(O)cc(O)c2C(=O)C1O	Launched	http://www.drugs.com/international/Silymarin.html						
pirenperone	pirenperone	R-47,465	Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1	Preclinical		HTR2A|HTR7	http://www.scbt.com/datasheet-253280-pirenperone.html|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=283	serotonin receptor antagonist			
BAM7	BAM7		CCOc1ccccc1N\N=C1C(=O)N(N=C\1C)c1nc(cs1)-c1ccccc1	Preclinical		BAX	https://www.tocris.com/dispprod.php?ItemId=372040	BAX activator			
nexturastat-a	Nexturastat A	Nexturastat A	CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1	Preclinical		HDAC6|HDAC1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7504|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7504	HDAC inhibitor			
nefiracetam	nefiracetam		Cc1cccc(C)c1NC(=O)CN1CCCC1=O	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/11951055	CHAT|CHRM1	https://citeline.informa.com/?query=#/drugs/details/12851|https://en.wikipedia.org/wiki/Nebracetam	acetylcholine receptor agonist|benzodiazepine receptor agonist			
thymol	thymol		CC(C)c1ccc(C)cc1O	Launched	http://www.drugs.com/international/thymol.html	TRPA1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2499	GABA receptor positive allosteric modulator			
bifemelane	bifemelane	bifemelane hydrochloride	CNCCCCOc1ccccc1Cc1ccccc1	Launched	http://en.wikipedia.org/wiki/Bifemelane	SLC6A2|MAOB|MAOA	https://citeline.informa.com/?query=#/drugs/details/2928|https://en.wikipedia.org/wiki/Bifemelane|https://en.wikipedia.org/wiki/Bifemelane	acetylcholine release enhancer	ophthalmology|neurology/psychiatry	glaucoma|senile dementia	https://en.wikipedia.org/wiki/Bifemelane|https://en.wikipedia.org/wiki/Bifemelane
motolimod	motolimod	VTX-2337|VTX-378	CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT02431559	TLR8	http://www.arraybiopharma.com/product-pipeline/other-compounds/vtx-2337/	toll-like receptor agonist			
propranolol	propranolol	Inderide-40/25|Inderide-80/25|hemangeol|inderal|inderal la|innopran xl|propranolol hydrochloride	CC(C)NCC(O)COc1cccc2ccccc12	Launched	FDA Orange Book: propranolol hydrochloride			adrenergic receptor antagonist	cardiology|cardiology|neurology/psychiatry	hypertension|angina pectoris|migraine headache	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d9d9660-ef3a-4abf-c291-db8d844ff658|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d9d9660-ef3a-4abf-c291-db8d844ff658|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d9d9660-ef3a-4abf-c291-db8d844ff658
McN-5652-(+/-)	(+/-)-McN-5652		CSc1ccc(cc1)[C@H]1CN2CCC[C@H]2c2ccccc12	Preclinical				selective serotonin reuptake inhibitor (SSRI)			
APD668	APD668	JNJ-28630368	CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O	Phase 1	http://adisinsight.springer.com/drugs/800023882	GPR119	https://www.caymanchem.com/product/17642	glucose dependent insulinotropic receptor agonist			
olaparib	olaparib	AZD-2281|AZD2281|lynparza	Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1	Launched	FDA Orange Book: olaparib	PARP1|PARP2|PARP3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7519|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7519|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=417695	PARP inhibitor	oncology	ovarian cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e31a6a9-864f-4aba-8085-37ee1ddcd499
ixazomib	ixazomib	ninlaro	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O	Launched	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf			proteasome inhibitor	hematologic malignancy	multiple myeloma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcef9088-ebab-4bd8-933f-c35f9c8bd50b
lisadimate	lisadimate	glyceryl paba	Nc1ccc(cc1)C(=O)OCC(O)CO	Launched	http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM135688.pdf			topical sunscreen agent	dermatology	sunscreen lotion	https://en.wiktionary.org/wiki/lisadimate
levothyroxine	levothyroxine	levo-t|levolet|levothroid|levothyroxine sodium|levoxyl|novothyrox|synthroid|tirosint|unithroid	N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O	Launched	FDA Orange Book: levothyroxine sodium	THRA|THRB	https://www.drugbank.ca/drugs/DB00451|https://www.drugbank.ca/drugs/DB00451	thyroid hormone stimulant	endocrinology	myxedema coma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce990712-49c1-4f66-9ee4-c770e8ec394c
CCG-1423	CCG-1423		CC(ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1	Preclinical		SRF|RHOC	https://www.tocris.com/products/ccg-1423_5233|https://www.tocris.com/products/ccg-1423_5233	apoptosis stimulant			
OG-L002	OG-L002		N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1	Preclinical		KDM1A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7023	histone lysine demethylase inhibitor			
tapentadol	tapentadol	nucynta|nucynta er		Launched	FDA Orange Book: tapentadol hydrochloride	SLC6A2|SLC6A4|HTR3A|OPRK1|OPRM1|OPRD1|CYP2C19	https://www.drugbank.ca/drugs/DB06204|https://www.drugbank.ca/drugs/DB06204|https://www.drugbank.ca/drugs/DB06204|https://www.drugbank.ca/drugs/DB06204|https://www.drugbank.ca/drugs/DB06204|https://www.drugbank.ca/drugs/DB06204|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=232967	opioid receptor agonist	neurology/psychiatry|neurology/psychiatry	acute pain|muscle pain	https://en.wikipedia.org/wiki/Tapentadol#Medical_use|https://en.wikipedia.org/wiki/Tapentadol#Medical_use
FPH1-(BRD-6125)	FPH1-(BRD-6125)		Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O	Preclinical				hepatocyte function enhancer			
amifostine	amifostine	WR-2721|ethiofos|ethyol|gammaphos	NCCCNCCSP(O)(O)=O	Launched	FDA Orange Book: amifostine	ALPPL2|ENPP1	https://www.drugbank.ca/drugs/DB01143|https://www.drugbank.ca/drugs/DB01143	reducing agent	nephrology	renal toxicity	https://en.wikipedia.org/wiki/Amifostine
chlormidazole	chlormidazole		Cc1nc2ccccc2n1Cc1ccc(Cl)cc1	Launched	http://www.drugs.com/international/chlormidazole.html			fungal lanosterol demethylase inhibitor	infectious disease	fungal infection	http://www.drugs.com/international/chlormidazole.html
nonivamide	nonivamide		CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1	Launched	http://www.drugs.com/international/nonivamide.html	TRPV1	http://www.scbt.com/datasheet-202735-nonivamide.html	TRPV agonist	rheumatology|neurology/psychiatry	rheumatoid arthritis|muscle pain	https://en.wikipedia.org/wiki/Nonivamide|https://en.wikipedia.org/wiki/Nonivamide
MPI-0479605	MPI-0479605		Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1	Preclinical		TTK	http://www.selleckchem.com/products/mpi-0479605.html	mitotic kinase inhibitor			
famprofazone	famprofazone		CC(Cc1ccccc1)N(C)Cc1c(C(C)C)c(=O)n(-c2ccccc2)n1C	Preclinical				cyclooxygenase inhibitor			
org-26576	org-26576		O=C1N2CCC[C@H]2COc2ncccc12	Phase 2	https://clinicaltrials.gov/show/NCT00610649			glutamate receptor modulator			
PA-452	PA-452		CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C	Preclinical		RXRA	https://www.tocris.com/products/pa-452_5086	retinoid receptor antagonist			
levomenol	levomenol	(-)-alpha-bisabolol|Alpha-Bisabolol	CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1	Launched	http://www.drugs.com/international/levomenol.html				neurology/psychiatry|infectious disease	spasms|skin infections	https://www.drugs.com/international/levomenol.html|https://www.drugs.com/international/levomenol.html
colesevalam	colesevalam			Preclinical							
PT-2385	PT-2385		CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02553356	EPAS1	https://www.medchemexpress.com/pt-2385.html?gclid=CLW-i5jRt88CFdZbhgodksMNlQ	hypoxia inducible factor inhibitor			
ANR-94	ANR-94		CCOc1nc2c(N)ncnc2n1CC	Preclinical		ADORA2A	https://www.tocris.com/products/anr-94_3937	A1 adenosine receptor antagonist			
GNTI	GNTI	5'-Guanidinonaltrindole|5'-Guanidinylnaltrindole|5`-Guanidinonaltrindole|C5'-Guanidinyl Naltrindole|Guanidinonaltrindole	NC(=N)Nc1ccc2[nH]c3c(C[C@@]4(O)[C@H]5Cc6ccc(O)c7O[C@@H]3[C@]4(CCN5CC3CC3)c67)c2c1	Preclinical		OPRK1|OPRM1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DPR000053|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DPR000053	opioid receptor antagonist			
cediranib	cediranib	AZD-2171|AZD2171|ZD-2171	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00777153	PDGFRA|PDGFRB|CSF1R|FLT4|FLT3|FLT1|KIT|KDR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5664|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5664|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5664|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5664|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5664|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5664|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5664|https://www.drugbank.ca/drugs/DB04849	KIT inhibitor|VEGFR inhibitor			
emedastine	emedastine	emadine	CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1	Launched	FDA Orange Book: emedastine difumarate	HRH1	https://www.drugbank.ca/drugs/DB01084	histamine receptor antagonist	ophthalmology	conjunctivitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98a010d5-4905-4abf-a9d2-c85a07daa23b
CC-401	CC-401		C(CN1CCCCC1)Oc1cccc(c1)-c1n[nH]c2ccc(cc12)-c1ncn[nH]1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00126893	MAPK8	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000079	JNK inhibitor			
AVE-0991	AVE-0991		CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(C=O)c(OC)nc2-c2ccccc2)cc1	Preclinical		MRGPRX1	http://www.apexbt.com/ave-0991.html?gclid=Cj0KEQjwvIO_BRDt27qG3YX0w4wBEiQAsGu3eZMeJvK7hmDJ0EA8SPE9u2syFI4MomN25ruEFadeN5MaAtee8P8HAQ	angiotensin receptor agonist			
MMPX	MMPX		COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1	Preclinical				phosphodiesterase inhibitor			
ONO-4817	ONO-4817		CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1	Phase 1	http://www.thepharmaletter.com/article/host-of-new-products-revealed-in-ono-pharma-s-r-d-pipeline	MMP8	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6544	matrix metalloprotease inhibitor			
CHIR-124	CHIR-124		Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1	Preclinical		CHEK1	https://www.drugbank.ca/drugs/DB06852	CHK inhibitor			
DC-260126	DC-260126		CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1	Preclinical		FFAR1	https://www.tocris.com/products/dc-260126_5357	free fatty acid receptor antagonist			
naproxen	naproxen	Equiproxen|RS-3540|aleve|anaprox|anaprox ds|ec-naprosyn|naprelan|naprosyn|naproxen sodium	COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O	Launched	FDA Orange Book: naproxen, naproxen sodium	PTGS2|PTGS1	ChEMBL|ChEMBL	cyclooxygenase inhibitor	neurology/psychiatry|rheumatology|neurology/psychiatry|dental|neurology/psychiatry|neurology/psychiatry|otolaryngology|endocrinology	pain relief|rheumatoid arthritis|headache|toothache|backache|muscle pain|common cold|fever	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c76c983e-d680-4908-b79d-968a2e4b1246|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c76c983e-d680-4908-b79d-968a2e4b1246|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c76c983e-d680-4908-b79d-968a2e4b1246|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c76c983e-d680-4908-b79d-968a2e4b1246|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c76c983e-d680-4908-b79d-968a2e4b1246|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c76c983e-d680-4908-b79d-968a2e4b1246|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c76c983e-d680-4908-b79d-968a2e4b1246|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c76c983e-d680-4908-b79d-968a2e4b1246
arecaidine-propargyl-ester	Arecaidine Propargyl Ester	Arecaidine Propargyl Ester	CN1CCC=C(C1)C(=O)OCC#C	Preclinical		CHRM3|CHRM4|CHRM1|CHRM2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=295|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=295|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=295|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=295	acetylcholine receptor agonist			
pinanediol	pinanediol		CC1(C)[C@@H]2C[C@H]1[C@@](C)(O)[C@@H](O)C2	Preclinical							
carbidopa	carbidopa	lodosyn		Launched	FDA Orange Book: carbidopa	DDC	https://www.drugbank.ca/drugs/DB00190	aromatic L-amino acid decarboxylase inhibitor	neurology/psychiatry	Parkinson's Disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5204e5e-10ef-4758-8fc6-cb710048c687
PRT062607	PRT062607	BIIB-057|P505-15|PRT-062607|PRT-2607	N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1	Phase 2	https://www.clinicaltrials.gov/ct2/show/NCT01652937	SYK|MAP3K9|FGR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8070|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8070|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8070	syk inhibitor			
NS-3861	NS-3861		CN1C2CCC1C=C(C2)c1sccc1Br	Preclinical		CHRNB4|CHRNA3	https://www.tocris.com/products/ns-3861_4831|https://www.tocris.com/products/ns-3861_4831	acetylcholine receptor agonist			
EB-47	EB-47		Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1	Preclinical		PARP1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002341	PARP inhibitor			
timofibrate	timofibrate		CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSCC1C(O)=O	Phase 2	Pharmaprojects	LPL	https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA535&lpg=PA535&dq=timofibrate+cholesterol&source=bl&ots=W8j4qltD1H&sig=DV1pWqSrUZRMaJ5teMgVjpqcH0o&hl=en&sa=X&ved=0ahUKEwjTxK7-vtfMAhXD0h4KHbOMBLcQ6AEIIjAB#v=onepage&q=timofibrate%20cholesterol&f=false	cholesterol inhibitor|lipase clearing factor inhibitor			
A922500	A922500		OC(=O)[C@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1	Preclinical		DGAT1	http://www.sigmaaldrich.com/catalog/product/sigma/a1737?lang=en&region=US	diacylglycerol O acyltransferase inhibitor			
ramatroban	ramatroban	BAY U 3405|EN 137774	OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1	Launched	http://www.drugs.com/international/ramatroban.html	CCL2|TBXA2R|PTGDR2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=137774|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1911|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1911	prostanoid receptor antagonist	cardiology|pulmonary	coronary artery disease (CAD)|asthma	https://en.wikipedia.org/wiki/Ramatroban|https://en.wikipedia.org/wiki/Ramatroban
dequalinium	dequalinium		Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12	Launched	https://clinicaltrials.gov/ct2/show/NCT02242695	KCNN3|KCNN1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2313|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2313	PKC inhibitor			
8-bromo-cGMP	8-bromo-cGMP		Nc1nc(O)c2nc(Br)n([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)c2n1	Preclinical		PRKG1	http://www.tocris.com/dispprod.php?ItemId=1988#.VecRc9NViko	PKA activator			
tiaramide	tiaramide		OCCN1CCN(CC1)C(=O)Cn1c2cc(Cl)ccc2sc1=O	Launched	https://www.drugs.com/international/tiaramide.html	ADRB2	https://citeline.informa.com/?query=#/drugs/details/18202	anti-inflammatory agent	pulmonary	asthma	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1427614/
iopodic-acid	iopodic acid	ipodate	CN(C)\C=N\c1c(I)cc(I)c(CCC(O)=O)c1I	Launched	http://www.drugs.com/international/iopodic-acid.html				radiology	contrast agent	http://www.drugs.com/international/iopodic-acid.html
sodium-nitrite	sodium nitrite	sodium nitrite	[O-][N+][O-]	Launched	FDA Orange Book: sodium nitrite			nitric oxide donor	critical care|critical care	poison antidote|cyanide poisoning	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=52f01c6e-172a-47a9-98a6-9eab7651a032&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=52f01c6e-172a-47a9-98a6-9eab7651a032&audience=consumer
fosfructose	fosfructose		O[C@@H]1[C@@H](COP(O)(O)=O)OC(O)(COP(O)(O)=O)[C@H]1O	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/?term=CPC-111	PKLR	https://www.drugbank.ca/drugs/DB04551	fructose diphosphate stimulant			
DBPR108	DBPR108		CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01650324	DPP4	https://www.medchemexpress.com/DBPR108.html	dipeptidyl peptidase inhibitor			
metocurine	metocurine	Dimethyltubocurarine|metubine iodide	COc1ccc2C[C@@H]3c4c(CC[N+]3(C)C)cc(OC)c(OC)c4Oc3ccc(C[C@H]4c5cc(Oc1c2)c(OC)cc5CC[N+]4(C)C)cc3	Launched	FDA Orange Book: metocurine iodide	CHRM2|CHRNA2	https://www.drugbank.ca/drugs/DB01336|https://www.drugbank.ca/drugs/DB01336	acetylcholine receptor antagonist	neurology/psychiatry	muscle relaxant	https://en.wikipedia.org/wiki/Metocurine
AC-55649	AC-55649		CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O	Preclinical		RARA|RARB	http://www.tocris.com/dispprod.php?ItemId=151567#.UuJ-Qv30BaE|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4055	retinoid receptor agonist			
plovamer-acetate	plovamer acetate		NC(Cc1ccc(O)cc1)C(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01963611	YARS2|YARS|TH|TAT	https://www.drugbank.ca/drugs/DB00135|https://www.drugbank.ca/drugs/DB00135|https://www.drugbank.ca/drugs/DB00135|https://www.drugbank.ca/drugs/DB00135				
fagomine	fagomine	D-Fagomine	OC[C@H]1NCC[C@@H](O)[C@@H]1O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01811303	GLB1	http://www.apexbt.com/fagomine.html	glucosidase inhibitor			
NSC-9965	NSC-9965	Dihydro-Beta-Erythroidine	CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1	Preclinical		CHRNA4|CHRNB2	https://www.tocris.com/dispprod.php?ItemId=144245#.Vyt-92QrJZI|https://www.tocris.com/dispprod.php?ItemId=144245#.Vyt-92QrJZI	acetylcholine receptor antagonist			
exisulind	exisulind	Sulindac sulfone	CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)(=O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00085826	PDE2A|PDE5A	https://citeline.informa.com/?query=#/drugs/details/17318|https://en.wikipedia.org/wiki/Exisulind	phosphodiesterase inhibitor			
tiquizium	tiquizium		C[N@+]12CCCC[C@@H]1CCC(C2)=C(c1cccs1)c1cccs1	Launched	http://www.drugs.com/international/tiquizium-bromide.html			acetylcholine receptor antagonist	neurology/psychiatry	spasms	http://www.drugs.com/international/tiquizium-bromide.html
D-Phenylalanine	D-Phenylalanine		N[C@H](Cc1ccccc1)C(O)=O	Preclinical		CRH|HCAR3|CCBL1	https://www.drugbank.ca/drugs/DB02556|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5797|https://www.drugbank.ca/drugs/DB02556	enkephalinase inhibitor			
N-demethylantipyrine	N-demethylantipyrine		Cc1cc(=O)n([nH]1)-c1ccccc1	Preclinical							
frentizole	frentizole	COMPOUND 53616	COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/7006613			immunosuppressant			
neuropathiazol	neuropathiazol		CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1	Preclinical		BMP2|LIF	https://www.tocris.com/products/neuropathiazol_5186|https://www.tocris.com/products/neuropathiazol_5186	neural stem cell inducer			
tubocurarine	tubocurarine	tubocurarine chloride	COc1cc2CCN(C)[C@H]3Cc4ccc(Oc5c(O)c(OC)cc6CC[N+](C)(C)[C@H](Cc7ccc(O)c(Oc1cc23)c7)c56)cc4	Launched	FDA Orange Book: tubocurarine chloride	CHRNA2|ZACN|ACHE|HTR3A|HTR3B|KCNN1|KCNN3|KCNN2	https://www.drugbank.ca/drugs/DB01199|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294|https://www.drugbank.ca/drugs/DB01199|https://www.drugbank.ca/drugs/DB01199|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294	acetylcholine receptor antagonist	neurology/psychiatry	anesthetic	https://en.wikipedia.org/wiki/Tubocurarine_chloride
TGR-1202	TGR-1202		CC(C)Oc1ccc(cc1F)-c1nn([C@@H](C)c2oc3ccc(F)cc3c(=O)c2-c2cccc(F)c2)c2ncnc(N)c12	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02612311	PIK3CD	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=768419	PI3K inhibitor			
SBE-13	SBE-13		COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC	Preclinical		PLK1	https://www.tocris.com/products/sbe-13-hydrochloride_4292	PLK inhibitor			
zolantidine	zolantidine	SK&F-95282	C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1	Preclinical				histamine receptor antagonist			
semustine	semustine	methyl-ccnu	CC1CCC(CC1)NC(=O)N(CCCl)[N+][O-]	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00335075			DNA alkylating agent			
givinostat	givinostat		CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00928707	IL1R2|HDAC1|HDAC2|HDAC5|HDAC6|HDAC3|HDAC4|HDAC9|HDAC7|HDAC8|TNF|IL1B|IL6R	https://citeline.informa.com/?query=#/drugs/details/8997|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7490|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7490|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7490|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7490|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7490|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7490|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7490|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7490|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7490|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=286687|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=286687|https://citeline.informa.com/?query=#/drugs/details/8997	HDAC inhibitor			
A-784168	A-784168		FC(F)(F)c1cccnc1N1CCC(=CC1)C(=O)Nc1ccc(cc1)S(=O)(=O)C(F)(F)F	Preclinical		TRPV1	https://www.tocris.com/products/a-784168_4319	transient receptor potential channel antagonist			
triptan	triptan		CC(C)C(C)(C)C	Phase 1	http://www.vectura.com/news/vectura-group-plc-interim-results-six-months-ended-30-september-20071/	HTR1D|HTR1B	https://livertox.nlm.nih.gov/SerotoninReceptorAgonists.htm|https://livertox.nlm.nih.gov/SerotoninReceptorAgonists.htm	serotonin receptor agonist			
ketanserin	ketanserin	R-41,468	Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1	Launched	http://www.drugs.com/international/Ketanserin.html	ADRA1B|ADRA1A|ADRA1D|HTR5A|HTR2C|HTR2A|HTR2B|HTR1B|HTR1A|HTR1D|HTR7|SLC18A1|SLC18A2|DRD5|DRD1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88	serotonin receptor antagonist	cardiology	hypertension	https://en.wikipedia.org/wiki/Ketanserin
cefoselis	cefoselis		CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1	Launched	http://www.drugs.com/international/cefoselis.html			bacterial cell wall synthesis inhibitor			
ethyl-2-(carbamoyloxy)benzoate	ethyl-2-(carbamoyloxy)benzoate		CCOC(=O)c1ccccc1OC(N)=O	Phase 1	http://www.sciencedirect.com/science/article/pii/000629529090471V/part/first-page-pdf						
ganaxolone	ganaxolone	CCD 1042	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01963208	GABRA4|GABRA5|GABRA6|GABRA1|GABRA2|GABRA3	https://www.drugbank.ca/drugs/DB05087|https://www.drugbank.ca/drugs/DB05087|https://www.drugbank.ca/drugs/DB05087|https://www.drugbank.ca/drugs/DB05087|https://www.drugbank.ca/drugs/DB05087|https://www.drugbank.ca/drugs/DB05087	GABA receptor modulator			
S-Trityl-L-cysteine	S-Trityl-L-cysteine		N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O	Preclinical				mitotic kinesin inhibitor			
ticlopidine	ticlopidine	ticlid|ticlopidine hydrochloride	Clc1ccccc1CN1CCc2sccc2C1	Launched	FDA Orange Book: ticlopidine hydrochloride	P2RY12|CYP2B6|CYP2C19	https://www.drugbank.ca/drugs/DB00208|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091004|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091004	purinergic receptor antagonist	hematology|neurology/psychiatry	thrombosis|stroke	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=707127cb-cdcd-81b0-274d-3c11fefa6824&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=707127cb-cdcd-81b0-274d-3c11fefa6824&audience=consumer
broxuridine	broxuridine		OC[C@H]1O[C@H](C[C@@H]1O)n1cc(Br)c(=O)[nH]c1=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00003832			antimetabolite			
adoprazine	adoprazine	SLV-313	Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1	Phase 2	Pharmaprojects	HTR1A|DRD2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000989|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000989	dopamine receptor antagonist|serotonin receptor agonist			
ezutromid	ezutromid		CCN(CC)c1ccc(cc1)-n1nc2cc(C)c(N)cc2n1	Phase 2	https://globenewswire.com/news-release/2016/04/26/832781/0/en/Summit-s-IND-Cleared-by-FDA-Allowing-Expansion-of-PhaseOut-DMD-a-Phase-2-Clinical-Trial-of-Ezutromid-SMT-C1100-Into-the-US.html	UTRN	https://www.axonmedchem.com/product/2481	utrophin enhancer			
PF-04217903	PF-04217903		OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00706355	MET	http://www.tocris.com/dispprod.php?ItemId=293202	c-Met inhibitor			
cariporide	cariporide	HOE-642	CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/12087349	SLC9A1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008753	sodium/hydrogen exchanger inhibitor			
altinicline	altinicline	SIB-1765F	CN1CCC[C@H]1c1cncc(c1)C#C	Phase 2	https://en.wikipedia.org/wiki/Altinicline	CHRNA4|CHRNB2	https://en.wikipedia.org/wiki/Altinicline|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001325	nicotinic receptor agonist			
phentolamine	phentolamine	oraverse|regitine	Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1	Launched	FDA Orange Book: phentolamine mesylate	ADRA2C|ADRA1A|ADRA2B|ADRA2A|ADRA1D|ADRA1B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=502|https://www.drugbank.ca/drugs/DB00692|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=502|https://www.drugbank.ca/drugs/DB00692|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=502|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=502	adrenergic receptor antagonist	endocrinology|cardiology	pheochromocytoma|hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6db10859-2a3f-4782-ac33-94300463658f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6db10859-2a3f-4782-ac33-94300463658f
CID-5458317	CID-5458317		O=C1c2ccccc2C(NC2CCCCC2)\C1=C/c1ccccc1	Preclinical		DUSP6|MAPK3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=662997|http://www.jbc.org/content/290/2/1129.full	MAP kinase phosphatase inhibitor			
gabazine	gabazine		COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1	Preclinical		GABRG2|GABRA4|GABRA3|GABRA2|GABRA1|GABRA6|GABRA5	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006214|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4197|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4197|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4197|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4197|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4197|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4197	GABA receptor antagonist			
L-755507	L-755507		CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1	Preclinical		ADRB1|ADRB3|ADRB2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003854|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3931|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003854	adrenergic receptor agonist			
clarithromycin	clarithromycin	A-56268|ABBOTT-56268|Biaxin XL Pac|Clarithromycin extended release|Klaricid|Prevpac|TE-031|biaxin|biaxin xl	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC	Launched	FDA Orange Book: clarithromycin	CYP3A7|CYP3A5|CYP3A4|CYP2C19	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=121880|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=121880|https://liferaftgroup.org/long-list-of-inhibitors-and-inducers-of-cyp3a4-and-cyp2d6/|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=121880	bacterial 50S ribosomal subunit inhibitor	otolaryngology|otolaryngology|otolaryngology|pulmonary|infectious disease|infectious disease|otolaryngology	pharyngitis|tonsillitis|sinusitis|bronchitis|pneumonia|skin infections|otitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b98b02bb-2609-49a0-b29f-e5911aa0cbc1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b98b02bb-2609-49a0-b29f-e5911aa0cbc1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b98b02bb-2609-49a0-b29f-e5911aa0cbc1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b98b02bb-2609-49a0-b29f-e5911aa0cbc1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b98b02bb-2609-49a0-b29f-e5911aa0cbc1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b98b02bb-2609-49a0-b29f-e5911aa0cbc1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b98b02bb-2609-49a0-b29f-e5911aa0cbc1
azithromycin	azithromycin	CP-62,993|CP-62993|Sumamed|Sunamed|XZ-450|azasite|azithromycin dihydrate|zithromax|zmax	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	Launched	FDA Orange Book: azithromycin, azithromycin dihydrate	MLNR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6510	bacterial 50S ribosomal subunit inhibitor	infectious disease|infectious disease	pelvic inflammatory disease|pneumonia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=679af699-714d-a3a3-674b-fc9ae4474a9a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=679af699-714d-a3a3-674b-fc9ae4474a9a
rigosertib	rigosertib	ON 01910	COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01928537	PLK1|MCL1	https://en.wikipedia.org/wiki/Rigosertib|https://citeline.informa.com/?query=#/drugs/details/27871	cell cycle inhibitor|PLK inhibitor			
ampyrone	ampyrone	4-Aminoantipyrine	Cc1c(N)c(=O)n(-c2ccccc2)n1C	Preclinical				cyclooxygenase inhibitor			
chlorindione	chlorindione	G-25766|chlophenadione|chlorphenindione|chlorphenylindandione|clorindione	Clc1ccc(cc1)C1C(=O)c2ccccc2C1=O	Preclinical							
TRAM-39	TRAM-39		Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1	Preclinical		KCNN4	https://www.tocris.com/products/tram-39_4952	calcium-activated potassium channel activator			
grazoprevir	grazoprevir		COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C	Launched	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208261Orig1s000lbl.pdf			HCV inhibitor			
TRAM-34	TRAM-34		Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1	Preclinical		KCNN4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2336	potassium channel antagonist			
piracetam	piracetam	Breinox|CL-871|Lucetam|Nootropil	NC(=O)CN1CCCC1=O	Launched	http://www.drugs.com/international/Piracetam.html	GRIA1|GRIA3|GRIA2|GRIA4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4288|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4288|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4288|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4288	acetylcholine receptor agonist	neurology/psychiatry	senile dementia	https://en.wikipedia.org/wiki/Piracetam#Medical_uses
piribedil	piribedil	ET-495|EU-4200	C(N1CCN(CC1)c1ncccn1)c1ccc2OCOc2c1	Launched	http://www.drugs.com/international/Piribedil.html	HTR2B|HTR1A|ADRA2C|ADRA2A|ADRA1A|DRD2|DRD3|DRD4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=49|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=49|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=49|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=49|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=49|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=49|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=49|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=49	dopamine receptor agonist	neurology/psychiatry|neurology/psychiatry	Parkinson's Disease|dizziness	https://en.wikipedia.org/wiki/Piribedil|https://en.wikipedia.org/wiki/Piribedil
histamine	histamine	histamine phosphate	NCCc1c[nH]cn1	Launched	FDA Orange Book: histamine phosphate	HRH1|HRH2|HRH3|HRH4|NOX3	https://www.drugbank.ca/drugs/DB00667|https://www.drugbank.ca/drugs/DB00667|https://www.drugbank.ca/drugs/DB00667|https://www.drugbank.ca/drugs/DB00667|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=240120	histamine receptor agonist	allergy	allergic rhinitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7571a80-9613-45f7-a1a9-fde4943f487e
TMS	TMS	Trans-2,4,3',5'-Tetramethoxystilbene	COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1	Preclinical							
telotristat	telotristat	LP-778902	Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F	Launched	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f11c21f8-f725-445e-b38e-1e4c5b05bcc6	TPH1	http://www.lexpharma.com/pipeline/telotristat-etiprate.html	tryptophan hydroxylase inhibitor			
VX-702	VX-702		NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00205478	MAPK14|MAPK11|MAPK12	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6059|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6059|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000260	p38 MAPK inhibitor			
agmatine	agmatine		NCCCCNC(N)=N	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00405041	CHRNA1|NISCH|PCSK6|PCSK1|GRIN1|KCNJ1|CACNA1B|ADRA2C|ASIC3	https://www.drugbank.ca/drugs/DB08838|https://www.drugbank.ca/drugs/DB08838|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=163406|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=163406|https://www.drugbank.ca/drugs/DB08838|https://www.drugbank.ca/drugs/DB08838|https://www.drugbank.ca/drugs/DB08838|https://www.drugbank.ca/drugs/DB08838|https://www.drugbank.ca/drugs/DB08838	nitric oxide synthase inhibitor			
piroctone-olamine	piroctone-olamine	piroctone	CC(Cc1cc(C)cc(=O)n1O)CC(C)(C)C	Launched	http://en.wikipedia.org/wiki/Piroctone_olamine				infectious disease	fungal infection	https://en.wikipedia.org/wiki/Piroctone_olamine
flutrimazole	flutrimazole	UR-4056	Fc1ccc(cc1)C(c1ccccc1)(c1ccccc1F)n1ccnc1	Launched	http://www.drugs.com/international/Flutrimazole.html			sterol demethylase inhibitor	infectious disease	mycosis	https://en.wikipedia.org/wiki/Flutrimazole
fosbretabulin	fosbretabulin			Phase 3	https://clinicaltrials.gov/ct2/show/NCT01701349	CDH5	http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=4247	tubulin polymerization inhibitor|VE-cadherin antagonist			
mabuterol	mabuterol	ambuterol|mabuterol hydrochloride	CC(C)(C)NCC(O)c1cc(Cl)c(N)c(c1)C(F)(F)F	Launched	https://www.drugs.com/international/mabuterol.html	ADRB2	https://en.wikipedia.org/wiki/Mabuterol	adrenergic receptor agonist			
cetaben	cetaben		CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/26177200	PPARA	https://www.caymanchem.com/product/10007171	cholesterol inhibitor|ACAT inhibitor			
alverine	alverine		CCN(CCCc1ccccc1)CCCc1ccccc1	Launched	https://clinicaltrials.gov/ct2/show/NCT01404923	HTR1A	https://www.drugbank.ca/drugs/DB01616	muscle relaxant	gastroenterology|gastroenterology	irritable bowel syndrome|diverticular disease	https://en.wikipedia.org/wiki/Alverine|https://en.wikipedia.org/wiki/Alverine
mizoribine	mizoribine		NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1O	Launched	http://www.drugs.com/international/Mizoribine.html	IMPDH1	http://www.sigmaaldrich.com/catalog/product/sigma/m3047?lang=en&region=US	immunosuppressant|inosine monophosphate dehydrogenase inhibitor			
ulifloxacin	ulifloxacin		CC1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCNCC1	Launched	https://clinicaltrials.gov/ct2/show/NCT01710488						
dactinomycin	dactinomycin	GNF-Pf-1977|GNF-Pf-2290|actinomycin d|cosmegen	CC(C)[C@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O	Launched	FDA Orange Book: dactinomycin	POLR2A	http://www.metalife.com/Drug2Gene/100143667	RNA polymerase inhibitor	oncology|oncology|oncology|oncology|oncology	testicular carcinoma|Wilm's tumor|rhabdomyosarcoma|Ewing's sarcoma|gestational trophoblastic disease (GTD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9914e793-a49c-eb00-1ab7-f606c786fe25|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9914e793-a49c-eb00-1ab7-f606c786fe25|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9914e793-a49c-eb00-1ab7-f606c786fe25|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9914e793-a49c-eb00-1ab7-f606c786fe25|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9914e793-a49c-eb00-1ab7-f606c786fe25
RS-0481	RS-0481		CC(NC(=O)C1CSCN1C(=O)c1ccccc1)c1ccccc1	Phase 2	Pharmaprojects			immunostimulant			
sulfasalazine	sulfasalazine	Azulfidine EN|S.A.S.|S.a.s.-500|SAS-500|Salazopyrin|azulfidine|azulfidine en-tabs|salazosulfapyridine|salicylazosulfapyridine|sulphasalazine	OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1	Launched	FDA Orange Book: sulfasalazine	PLA2G1B|PTGS1|PTGS2|SLC7A11|IKBKB|SLC46A1|PPARG|TBXAS1|ALOX5|ACAT1|CHUK	https://www.drugbank.ca/drugs/DB00795|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00795|https://www.drugbank.ca/drugs/DB00795|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4840|https://www.drugbank.ca/drugs/DB00795|https://www.drugbank.ca/drugs/DB00795|ChEMBL|https://www.drugbank.ca/drugs/DB00795|https://www.drugbank.ca/drugs/DB00795	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48fbc535-a33a-45ee-85ff-9d1ec9b31d9c&audience=consumer
KHS-101	KHS-101		CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1	Preclinical		TACC3	https://www.tocris.com/products/khs-101-hydrochloride_4888	neural stem cell inducer			
amperozide	amperozide		CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	Veterinary Launched	http://en.wikipedia.org/wiki/Amperozide	DRD2|FAAH|HTR2A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=115089|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010648|https://www.drugbank.ca/drugs/DB08927	dopamine receptor antagonist	neurology/psychiatry	psychosis	https://en.wikipedia.org/wiki/Amperozide
clopidol	clopidol	Clopindol|Coyden|Metichlorpindol	Cc1nc(C)c(Cl)c(O)c1Cl	Veterinary Launched	http://www.drugs.com/international/clopidol.html				infectious disease	coccidiosis	https://en.wikipedia.org/wiki/Clopidol
phenyl-salicylate	phenyl salicylate	phenyl salicylate|salol	Oc1ccccc1C(=O)Oc1ccccc1	Launched	https://www.drugs.com/drp/phenyl-salicylate.html			antiseptic	urology	interstitial cystitis (IC)	https://www.drugs.com/drp/phenyl-salicylate.html
quinpirol-(-)	(-)-quinpirol	quinpirole	CCCN1CCC[C@@H]2Cc3n[nH]cc3C[C@@H]12	Phase 2	Pharmaprojects	DRD3|DRD4|DRD1|DRD2|HTR1A|HTR2C|HTR2A|HTR2B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005427|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2	dopamine receptor agonist			
AFN-1252	AFN-1252		CN(Cc1oc2ccccc2c1C)C(=O)\C=C\C1=CNC2=NC(=O)CCC2=C1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01519492			FABI inhibitor			
ritanserin	ritanserin	R 55,667|tiserton	Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/10069551	ADRA1D|ADRA1A|ADRA1B|HTR6|HTR7|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=97|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=97|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=97|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=97|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=97|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=97|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=97|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=97|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=97|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=97|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=97|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=97	serotonin receptor antagonist			
promethazine	promethazine	Promethacon|Remsed|Zipan-25|Zipan-50|phenergan|promethazine hydrochloride|promethazine hydrochloride plain|promethazine plain|promethegan	CC(CN1c2ccccc2Sc2ccccc12)N(C)C	Launched	FDA Orange Book: promethazine hydrochloride	HTR2A|ADRA1A|HRH1|DRD2|CHRM5|CHRM3|CHRM4|CHRM1|CHRM2|CALM1	https://www.drugbank.ca/drugs/DB01069|https://www.drugbank.ca/drugs/DB01069|https://www.drugbank.ca/drugs/DB01069|https://www.drugbank.ca/drugs/DB01069|https://www.drugbank.ca/drugs/DB01069|https://www.drugbank.ca/drugs/DB01069|https://www.drugbank.ca/drugs/DB01069|https://www.drugbank.ca/drugs/DB01069|https://www.drugbank.ca/drugs/DB01069|https://www.drugbank.ca/drugs/DB01069	histamine receptor antagonist	neurology/psychiatry|allergy	sedative|allergic rhinitis	https://en.wikipedia.org/wiki/Promethazine|https://en.wikipedia.org/wiki/Promethazine
trilostane	trilostane	modrastane	C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)C(C[C@]35C)C#N)[C@@H]1CC[C@@H]2O	Launched	FDA Orange Book: trilostane	NR3C1|HSD3B1|HSD3B2|ESR2|ESR1|JUN	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091049|https://www.drugbank.ca/drugs/DB01108|https://www.drugbank.ca/drugs/DB01108|https://www.drugbank.ca/drugs/DB01108|https://www.drugbank.ca/drugs/DB01108|https://citeline.informa.com/?query=#/drugs/details/18482	3beta-hydroxy-delta5-steroid dehydrogenase inhibitor	endocrinology	Cushing's syndrome	https://en.wikipedia.org/wiki/Trilostane
phenethyl-isothiocyanate	Phenethyl Isothiocyanate	Phenethyl Isothiocyanate|Phenethylisothiocyanate|Phenylethyl Isothiocyanate	S=C=NCCc1ccccc1	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/26951845	CYP2E1	http://www.ncbi.nlm.nih.gov/pubmed/23371965	anticancer agent			
geldanamycin	geldanamycin		CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O	Preclinical		HSP90AA1|HSP90AB1	https://www.drugbank.ca/drugs/DB02424|https://www.drugbank.ca/drugs/DB02424	HSP inhibitor			
cinoxate	cinoxate		CCOCCOC(=O)\C=C\c1ccc(OC)cc1	Launched	http://dermapproved.com/active-ingredients/cinoxate				dermatology	sunscreen lotion	http://dermapproved.com/active-ingredients/cinoxate
SCH-202676	SCH-202676		CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1	Preclinical		DRD1|DRD2|CHRM4|CHRM1|CHRM2	http://www.sigmaaldrich.com/catalog/product/sigma/s4063?lang=en&region=US|http://www.sigmaaldrich.com/catalog/product/sigma/s4063?lang=en&region=US|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=298957|http://www.sigmaaldrich.com/catalog/product/sigma/s4063?lang=en&region=US|http://www.sigmaaldrich.com/catalog/product/sigma/s4063?lang=en&region=US	G protein-coupled receptor modulator			
emoxipin	emoxipin		CCc1nc(C)ccc1O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/13678005						
betamipron	betamipron		OC(=O)CCNC(=O)c1ccccc1	Launched	http://en.wikipedia.org/wiki/Betamipron			panipenem uptake inhibitor	nephrology	renal toxicity	https://en.wikipedia.org/wiki/Betamipron
NKP-1339	NKP-1339			Phase 1	https://clinicaltrials.gov/ct2/show/NCT01415297			HSP inhibitor			
thymol-iodide	thymol iodide	iodothymol|thymol iodide	CC(C)c1cc(c(C)cc1OI)-c1cc(C(C)C)c(OI)cc1C	Preclinical							
KB-SRC-4	KB-SRC-4		Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1	Preclinical		SRC	https://www.tocris.com/products/kb-src-4_4660	src inhibitor			
AZD1446	AZD1446	AZD-1446|TC-6683	Clc1ccc(o1)C(=O)N1CC2CNCC2C1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01012375	CHRNA4|CHRNB2	http://www.alzforum.org/therapeutics/azd1446|http://www.alzforum.org/therapeutics/azd1446	acetylcholine receptor agonist			
TAK-875	TAK-875	fasiglifam	Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01433393	INS|FFAR1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=642642|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6484	insulin secretagogue			
danegaptide	danegaptide	GAP-134	NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)c1ccccc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01977755			gap junction modulator			
latrunculin-b	latrunculin b	NSC-339663|latrunculin b	C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]2CSC(=O)N2)OC(=O)\C=C(C)/CC\C=C/1	Phase 1	https://clinicaltrials.gov/show/NCT00443924	MKL1|ACTA1|SPIRE2	https://www.drugbank.ca/drugs/DB08080|https://www.drugbank.ca/drugs/DB08080|https://www.drugbank.ca/drugs/DB08080	actin polymerization inhibitor			
EI1	EI1		CCC(CC)n1ccc2c(cc(cc12)C#N)C(=O)NCc1c(C)cc(C)[nH]c1=O	Preclinical		EZH2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7013	histone lysine methyltransferase inhibitor			
mitotane	mitotane	CB 313|CB-313|lysodren|o,p'-ddd		Launched	FDA Orange Book: mitotane	ESR1|CYP3A4|FDX1|CYP11A1|CYP11B1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000033|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=357961|https://www.drugbank.ca/drugs/DB00648|ChEMBL|ChEMBL	antineoplastic agent	oncology	adrenal cortical carcinoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9fba7d4-a0ec-4bfa-9b5b-ec97a9710fd3
salicyl-alcohol	salicyl alcohol	salicain|salicyl alcohol|saligenin|saligenol	OCc1ccccc1O	Preclinical							
AM-92016	AM-92016		CN(CCc1ccc(Cl)c(Cl)c1)CC(O)COc1ccc(NS(C)(=O)=O)cc1	Preclinical		GRIN2B|GRIN1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=370891|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013823	potassium channel blocker			
JNJ-26481585	JNJ-26481585	quisinostat	Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01486277	HDAC4|HDAC3|HDAC2|HDAC1|HDAC9|HDAC8|HDAC7|HDAC6|HDAC5|MDM2|HDAC10|HDAC11	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7503|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7503|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7503|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7503|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7503|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7503|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7503|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7503|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7503|http://www.selleckchem.com/products/JNJ-26854165.html|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7503|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7503	HDAC inhibitor			
MLN0128	MLN0128	MLN-0128	CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02091531	MTOR|PIK3CG|PIK3CD|PIK3CA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7933|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7933|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7933|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7933	mTOR inhibitor			
enoximone	enoximone	MDL 17,043|MDL-17043|perfan	CSc1ccc(cc1)C(=O)c1[nH]c(O)nc1C	Launched	https://www.drugs.com/international/enoximone.html	PDE3A	https://www.drugbank.ca/drugs/DB04880	phosphodiesterase inhibitor	cardiology	congestive heart failure	https://en.wikipedia.org/wiki/Enoximone
azelnidipine	azelnidipine		CC(C)OC(=O)C1=C(C)NC(N)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1	Launched	http://www.drugs.com/international/Azelnidipine.html	CACNA1C	www.abcam.com/Azelnidipine-ab145531.pdf	calcium channel blocker	cardiology	hypertension	https://en.wikipedia.org/wiki/Azelnidipine
proxodolol	proxodolol		Cc1noc(COc2ccccc2OCC(O)CNC(C)(C)C)n1	Launched	http://www.drugs.com/international/Proxodolol.html			adrenergic receptor antagonist			
alpha-D-glucopyranose	alpha-D-glucopyranose	Alpha-D-Glucose	OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical							
oleuropein	oleuropein		COC(=O)C1=COC(OC2OC(CO)C(O)C(O)C2O)\C(=C/C)C1CC(=O)OCCc1ccc(O)c(O)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00789425	GPER1	https://en.wikipedia.org/wiki/Oleuropein	estrogen receptor agonist			
fenobam	fenobam		CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/7042771	GRM5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1434	glutamate receptor antagonist			
LY2857785	LY2857785		CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1	Preclinical		CDK9|CDK8	https://www.ncbi.nlm.nih.gov/pubmed/24688048|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=854153	CDK inhibitor			
taurine	taurine	aminoethylsulfonic acid	NCCS(O)(=O)=O	Launched	http://www.drugs.com/international/Taurine.html			antioxidant	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	anxiety|irritability|sleeplessness	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f8a9ba9-e3e2-4910-ae63-5423d2b5dc5b&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f8a9ba9-e3e2-4910-ae63-5423d2b5dc5b&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f8a9ba9-e3e2-4910-ae63-5423d2b5dc5b&audience=consumer
dihydrotestosterone	dihydrotestosterone	5alpha-dihydrotestosterone|androstanolone|neodrol|stanolone	C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O	Launched	https://clinicaltrials.gov/ct2/show/NCT00062790	HSD17B1|AR	https://www.drugbank.ca/drugs/DB02901|https://www.drugbank.ca/drugs/DB02901	androgen receptor agonist	neurology/psychiatry|endocrinology	tetany|hypoparathyroidism	http://www.rxlist.com/dht-drug/indications-dosage.htm|http://www.rxlist.com/dht-drug/indications-dosage.htm
voglibose	voglibose	A-71100|AO-128|basen|glustat	OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O	Launched	http://www.drugs.com/international/Voglibose.html	MGAM|GAA	https://www.drugbank.ca/drugs/DB04878|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=116077	glucosidase inhibitor	endocrinology|endocrinology	diabetes mellitus|hyperglycemia	https://en.wikipedia.org/wiki/Voglibose|https://en.wikipedia.org/wiki/Voglibose
L-732,138	L-732,138		CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F	Preclinical				tachykinin antagonist			
melphalan	melphalan	CB 3025|CB-3025|aikeran|alanine nitrogen mustard|alkeran|evomela|l-sarcolysin|melfalan|phenylalanine mustard	N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O	Launched	FDA Orange Book: melphalan, melphalan hydrochloride			DNA alkylating agent|DNA inhibitor	hematologic malignancy	multiple myeloma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e77d77f3-3e96-4ff3-a42d-8bd67dfcf58b
toyocamycin	toyocamycin	unamycin b	Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/5646857	ERN1	http://www.abcam.com/toyocamycin-ab146171.html	serine/threonine kinase inhibitor			
PIT	PIT		[O-][N+]1=C(C(=O)c2ccccc12)c1ccccn1	Preclinical		P2RY1	http://www.tocris.com/dispprod.php?ItemId=5389	purinergic receptor antagonist			
nedocromil	nedocromil	FPL 59002|FPL-59002|alocril|tilade	CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O	Launched	FDA Orange Book: nedocromil sodium	PTGDR|FPR1|CYSLTR1|CYSLTR2|HSP90AA1	https://www.drugbank.ca/drugs/DB00716|https://www.drugbank.ca/drugs/DB00716|https://www.drugbank.ca/drugs/DB00716|https://www.drugbank.ca/drugs/DB00716|https://www.drugbank.ca/drugs/DB00716	histamine receptor antagonist	neurology/psychiatry|ophthalmology	itching|conjunctivitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5c6b084-f6f8-4c14-a742-48b0f4d9b9a7|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5c6b084-f6f8-4c14-a742-48b0f4d9b9a7
capecitabine	capecitabine	RO 09-1978/000|Ro-09-1978-000|xeloda	CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O	Launched	FDA Orange Book: capecitabine	DPYD|TYMS	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=211639|ChEMBL	DNA synthesis inhibitor|thymidylate synthase inhibitor	oncology|oncology	breast cancer|colorectal cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8345d55e-ad02-4726-a04b-1a46e3337a4b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8345d55e-ad02-4726-a04b-1a46e3337a4b
UB-165	UB-165		Clc1ccc(cn1)C1=CCCC2CCC1N2	Preclinical		CHRNA3|CHRNA4|CHRNB2	http://en.wikipedia.org/wiki/UB-165|http://en.wikipedia.org/wiki/UB-165|http://en.wikipedia.org/wiki/UB-165	acetylcholine receptor agonist			
MK-1775	MK-1775	AZD-1775	CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01164995	WEE1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7702	WEE1 kinase inhibitor			
5-methylfurmethiodide	5-methylfurmethiodide	5-Methylfurmethide	Cc1ccc(C[N+](C)(C)C)o1	Preclinical		CHRM2|CHRM1|CHRM4|CHRM3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=300|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=300|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=300|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=300	acetylcholine receptor agonist			
sorbitol	sorbitol			Launched	FDA Orange Book: sorbitol			mucolytic agent			
AP-18	AP-18		CC(=C/c1ccc(Cl)cc1)\C(C)=N\O	Preclinical		TRPA1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4134	transient receptor potential channel antagonist			
propacetamol	propacetamol		CCN(CC)CC(=O)Oc1ccc(NC(C)=O)cc1	Launched	http://www.drugs.com/international/Propacetamol.html	PTGS1|PTGS2	https://citeline.informa.com/?query=#/drugs/details/14835|http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500785/	cyclooxygenase inhibitor	endocrinology|neurology/psychiatry	fever|pain relief	http://www.drugs.com/international/propacetamol.html|http://www.drugs.com/international/propacetamol.html
L-152804	L-152804		CC1(C)CC(=O)C(C2c3ccccc3OC3=C2C(=O)CC(C)(C)C3)C(=O)C1	Preclinical		NPY5R	https://www.tocris.com/dispprod.php?ItemId=1396#.VykOg2QrImI	neuropeptide receptor antagonist			
probucol	probucol	Bisbid|DH-581|Sinlestal|lorelco	CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	Launched	FDA Orange Book: probucol	CES1|ABCB11|ABCA1	https://www.drugbank.ca/drugs/DB01599|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000916|ChEMBL	atherogenesis inhibitor	cardiology	coronary artery disease (CAD)	https://en.wikipedia.org/wiki/Probucol
CC4	CC4		O=c1cccc2[C@@H]3C[C@@H](CN(CCN4C[C@@H]5C[C@H](C4)c4cccc(=O)n4C5)C3)Cn12	Preclinical		CHRNB2|CHRNA4	https://www.tocris.com/products/cc4_5236|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=415855	nicotinic receptor agonist			
NSC-632839	NSC-632839		Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1	Preclinical		SENP2|USP7|USP1|USP2	http://www.apexbt.com/nsc-632839-hydrochloride.html|http://www.apexbt.com/nsc-632839-hydrochloride.html|http://www.scbt.com/datasheet-204138-nsc-632839-hydrochloride.html|http://www.apexbt.com/nsc-632839-hydrochloride.html	ubiquitin specific protease inhibitor			
UNC0321	UNC0321		COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1	Preclinical		EHMT2	https://www.caymanchem.com/product/10582	histone lysine methyltransferase inhibitor			
tetrabenazine	tetrabenazine	(3S,11Bs)-Tetrabenazine|xenazine	COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC	Launched	FDA Orange Book: tetrabenazine	DRD2|SLC18A2|SLC18A1	https://www.drugbank.ca/drugs/DB04844|https://www.drugbank.ca/drugs/DB04844|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4834	vesicular monoamine transporter inhibitor	infectious disease|neurology/psychiatry	cholera|Huntington's disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5867189c-17bd-4e70-a079-c4730f9950d1&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5867189c-17bd-4e70-a079-c4730f9950d1&audience=consumer
pipenzolate	pipenzolate		CC[N+]1(C)CCCC(C1)OC(=O)C(O)(c1ccccc1)c1ccccc1	Launched	http://www.drugs.com/international/pipenzolate-bromide.html	CHRM1	https://en.wikipedia.org/wiki/Pipenzolate	cholinergic receptor antagonist	neurology/psychiatry	spasms	http://www.drugs.com/international/pipenzolate-bromide.html
INCB-3284	INCB-3284		COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F	Phase 2	https://www.sec.gov/Archives/edgar/data/879169/000119312505094642/dex991.htm	CCR2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000845	CC chemokine receptor antagonist			
WH-4-023	WH-4-023		COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1	Preclinical		LCK|SRC	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8068|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8068	src inhibitor			
metaproterenol	metaproterenol	alupent|metaproterenol sulfate	CC(C)NCC(O)c1cc(O)cc(O)c1	Launched	FDA Orange Book: metaproterenol sulfate	ADRB2	https://www.drugbank.ca/drugs/DB00816	adrenergic receptor agonist	pulmonary|pulmonary|pulmonary|pulmonary	bronchospasm|asthma|bronchitis|emphysema	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66eb4b4d-2388-49d3-8ffa-0b9bca75a28e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66eb4b4d-2388-49d3-8ffa-0b9bca75a28e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66eb4b4d-2388-49d3-8ffa-0b9bca75a28e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66eb4b4d-2388-49d3-8ffa-0b9bca75a28e
R-96544	R-96544		COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1	Preclinical		HTR2A	http://www.tocris.com/dispprod.php?ItemId=68264	serotonin receptor antagonist			
levomequitazine	levomequitazine		C(C1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12	Phase 2	https://clinicaltrials.gov/show/NCT01951222	PDE4A|HRH1|HRH4	https://citeline.informa.com/?query=#/drugs/details/64160|https://www.drugbank.ca/drugs/DB01071|https://citeline.informa.com/?query=#/drugs/details/64160	histamine receptor antagonist			
omega-(4-Iodophenyl)pentadecanoic acid	omega-(4-Iodophenyl)pentadecanoic acid		OC(=O)CCCCCCCCCCCCCCc1ccc(I)cc1	Preclinical							
elinogrel	elinogrel	PRT 060128|PRT060128	CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00751231	P2RY12	http://www.ncbi.nlm.nih.gov/pubmed/20178048	purinergic receptor antagonist			
sulfametopyrazine	sulfametopyrazine	kelfizina|sulfalene|sulfamethopyrazine	COc1nccnc1NS(=O)(=O)c1ccc(N)cc1	Launched	http://www.drugs.com/international/Sulfametopyrazine.html			PABA antagonist	infectious disease|infectious disease|infectious disease	malaria|urinary tract infections|respiratory tract infections	http://www.drugbank.ca/drugs/DB00664|http://www.drugbank.ca/drugs/DB00664|http://www.drugbank.ca/drugs/DB00664
sarafloxacin	sarafloxacin		OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O	Launched	http://www.drugs.com/international/Sarafloxacin.html			bacterial DNA gyrase inhibitor			
methiazole	methiazole		COC(=O)Nc1nc2cc(SC(C)C)ccc2[nH]1	Preclinical				anthelmintic agent			
molindone	molindone	moban|molindone hydrochloride	CCc1c(C)[nH]c2CCC(CN3CCOCC3)C(=O)c12	Launched	FDA Orange Book: molindone hydrochloride	DRD2|DRD5|CHRM1|HTR2A|HTR1A|HRH1	https://www.drugbank.ca/drugs/DB01618|https://citeline.informa.com/?query=#/drugs/details/40170|https://www.drugbank.ca/drugs/DB01618|https://www.drugbank.ca/drugs/DB01618|https://www.drugbank.ca/drugs/DB01618|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=207	dopamine receptor antagonist	neurology/psychiatry	schizophrenia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=138e8ca3-9a12-4c48-95c0-85bd01c79b13
paliperidone	paliperidone	R076477|RO76477|invega|invega sustenna|invega trinza	Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12	Launched	FDA Orange Book: paliperidone, paliperidone palmitate	DRD2|DRD1|DRD4|DRD3|HTR7|HTR1A|HTR1D|HTR2A|HTR2C|CYP3A4|CYP3A5|ADRA1B|ADRA1A|ADRA2C|ADRA2A|ADRA2B|CYP2D6|HRH1	ChEMBL|https://www.drugbank.ca/drugs/DB01267|https://www.drugbank.ca/drugs/DB01267|https://www.drugbank.ca/drugs/DB01267|https://citeline.informa.com/?query=#/drugs/details/32422|https://www.drugbank.ca/drugs/DB01267|https://www.drugbank.ca/drugs/DB01267|ChEMBL|https://www.drugbank.ca/drugs/DB01267|https://www.drugbank.ca/drugs/DB01267|https://www.drugbank.ca/drugs/DB01267|https://www.drugbank.ca/drugs/DB01267|https://www.drugbank.ca/drugs/DB01267|https://www.drugbank.ca/drugs/DB01267|https://www.drugbank.ca/drugs/DB01267|https://www.drugbank.ca/drugs/DB01267|https://www.drugbank.ca/drugs/DB01267|https://www.drugbank.ca/drugs/DB01267	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9089db76-aa50-417d-bf62-3674df161e9a
sulforaphane	sulforaphane	4-(Methylsulfinyl)Butyl Isothiocyanate	CS(=O)CCCCN=C=S	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00982319	NFE2L2	http://genatlas.medecine.univ-paris5.fr/fiche.php?symbol=NFE2L2	anticancer agent|aryl hydrocarbon receptor antagonist			
KH-CB19	KH-CB19		CCOC(=O)c1c(\C(=C/N)C#N)c2ccc(Cl)c(Cl)c2n1C	Preclinical		CLK1|CLK3|DYRK1A	https://www.drugbank.ca/drugs/DB08691|https://www.drugbank.ca/drugs/DB08691|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8055	CDC inhibitor			
WAY-161503	WAY-161503		Clc1cc2NC(=O)C3CNCCN3c2cc1Cl	Preclinical		HTR2C	https://en.wikipedia.org/wiki/WAY-161503	serotonin receptor agonist			
Teijin-compound-1	Teijin-compound-1		FC(F)(F)c1cccc(c1)C(=O)NCC(=O)N[C@@H]1CCN(Cc2ccc(Cl)cc2)C1	Preclinical		CCR2	https://www.tocris.com/products/teijin-compound-1_3664	CC chemokine receptor antagonist			
sulmazole	sulmazole		COc1cc(ccc1-c1nc2ncccc2[nH]1)S(C)=O	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/6395955			adenosine receptor antagonist			
nalbuphine	nalbuphine	nalbuphine hydrochloride|nubain	O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45	Launched	FDA Orange Book: nalbuphine hydrochloride	OPRM1|OPRK1|OPRD1	https://www.drugbank.ca/drugs/DB00844|https://www.drugbank.ca/drugs/DB00844|https://www.drugbank.ca/drugs/DB00844	opioid receptor agonist|opioid receptor antagonist	neurology/psychiatry	pain relief	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6025e8d4-5083-4c3a-58a0-050e7b0b6150
paeonol	paeonol		COc1ccc(C(C)=O)c(O)c1	Preclinical				anti-inflammatory agent			
flavoxate	flavoxate	flavoxate hydrochloride|urispas	Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1	Launched	FDA Orange Book: flavoxate hydrochloride	CHRM1|CHRM2	https://www.drugbank.ca/drugs/DB01148|https://www.drugbank.ca/drugs/DB01148	acetylcholine receptor antagonist	urology|urology|urology|urology	urinary incontinence|interstitial cystitis (IC)|urethritis|prostatitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4260d7e-2ab3-49f6-aa57-bae19a23d82a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4260d7e-2ab3-49f6-aa57-bae19a23d82a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4260d7e-2ab3-49f6-aa57-bae19a23d82a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4260d7e-2ab3-49f6-aa57-bae19a23d82a
clofarabine	clofarabine	clolar	Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F	Launched	FDA Orange Book: clofarabine	POLD1|POLA1|RRM2B|SLC22A8|POLE|RRM1|RRM2	ChEMBL|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=154861|ChEMBL|ChEMBL|ChEMBL	ribonucleotide reductase inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c35903cd-e9eb-4841-93d1-fc14249d1e9f
olmutinib	olmutinib		CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1	Launched	https://www.boehringer-ingelheim.com/press-release/south-korea-first-approve-next-generation-lung-cancer	JAK3|ITK|EGFR|BTK	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=758347|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=758347|http://www.selleckchem.com/products/olmutinib-hm61713-bi-1482694.html?gclid=CJy84NSUtc8CFVFZhgodk4YIJA|http://www.selleckchem.com/products/olmutinib-hm61713-bi-1482694.html?gclid=CJy84NSUtc8CFVFZhgodk4YIJA	EGFR inhibitor|Bruton's tyrosine kinase (BTK) inhibitor			
veliparib	veliparib		C[C@]1(CCCN1)c1nc2c(cccc2[nH]1)C(N)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02032277	PARP1|PARP2	https://www.drugbank.ca/drugs/DB07232|https://www.drugbank.ca/drugs/DB07232	PARP inhibitor			
acepromazine	acepromazine	Acezine 2|Atravet	CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O	Veterinary Launched	http://www.drugs.com/international/acepromazine.html	ADRA1A|ADRA1B|DRD1|DRD2|HTR2A|HTR1A	https://www.drugbank.ca/drugs/DB01614|https://www.drugbank.ca/drugs/DB01614|https://www.drugbank.ca/drugs/DB01614|https://www.drugbank.ca/drugs/DB01614|https://www.drugbank.ca/drugs/DB01614|https://www.drugbank.ca/drugs/DB01614	dopamine receptor antagonist	neurology/psychiatry	sedative	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a7ad9ed-c955-48bd-82f9-f9265ea4242c
venetoclax	venetoclax	ABT-199|venclexta	CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1	Launched	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf	BCL2	https://en.wikipedia.org/wiki/Venetoclax	BCL inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b118a40d-6b56-cee3-10f6-ded821a97018
everolimus	everolimus	afinitor|afinitor disperz|zortress	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO	Launched	FDA Orange Book: everolimus	MTOR|FKBP1A|CYP3A5	https://www.drugbank.ca/drugs/DB01590|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=210424|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=210424	mTOR inhibitor	oncology|oncology|oncology|neurology/psychiatry|genetics|urology	breast cancer|neuroendocrine tumors of pancreatic origin (PNET)|renal cell carcinoma (RCC)|subependymal giant cell astrocytoma (SEGA)|tuberous sclerosis complex (TSC)|renal angiomyolipoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2150f73a-179b-4afc-b8ce-67c85cc72f04|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2150f73a-179b-4afc-b8ce-67c85cc72f04|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2150f73a-179b-4afc-b8ce-67c85cc72f04|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2150f73a-179b-4afc-b8ce-67c85cc72f04|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2150f73a-179b-4afc-b8ce-67c85cc72f04|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2150f73a-179b-4afc-b8ce-67c85cc72f04
S-Sulfo-L-cysteine-sodium-salt	S-Sulfo-L-cysteine-sodium-salt		N[C@@H](CSS(O)(=O)=O)C(O)=O	Preclinical				glutamate receptor agonist			
anisindione	anisindione	miradon	COc1ccc(cc1)C1C(=O)c2ccccc2C1=O	Launched	FDA Orange Book: anisindione	GGCX	ChEMBL	vitamin K antagonist	hematology	deep vein thrombosis (DVT)	http://www.rxlist.com/miradon-drug.htm
SIS3	SIS3		COc1cc2CCN(Cc2cc1OC)C(=O)\C=C\c1c(-c2ccccc2)n(C)c2ncccc12	Preclinical		SMAD3|TGFBR1	https://www.tocris.com/products/sis3_5291|https://www.tocris.com/products/sis3_5291	serine/threonine kinase inhibitor			
AZD8186	AZD8186	AZD-8186	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01884285	PIK3CD|PIK3CB	http://openinnovation.astrazeneca.com/what-we-offer/compound/azd8186/|http://openinnovation.astrazeneca.com/what-we-offer/compound/azd8186/	PI3K inhibitor			
almorexant	almorexant		CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00608985	HCRTR2|HCRTR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2886|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2886	orexin receptor antagonist			
LY303511	LY303511	LY-303511	O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1	Preclinical		CSNK2B|CSNK2A2|CSNK2A1|BRD3|BRD4|BRD2|MTOR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=402785|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=402785|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=402785|http://www.abcam.com/ly-303511-ab145193.html|http://www.abcam.com/ly-303511-ab145193.html|http://www.abcam.com/ly-303511-ab145193.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=402785	casein kinase inhibitor|mTOR inhibitor|PI3K inhibitor			
laquinimod	laquinimod		CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00988052	CXCL2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000860	immunosuppressant			
GSK2190915	GSK2190915		CCOc1ccc(cn1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OCc4ccc(C)cn4)ccc23)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00748306	ALOX5AP	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000413	lipoxygenase inhibitor			
SLV-319-(+/-)	(+/-)-SLV-319		C\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1CC(C(=N1)c1ccc(Cl)cc1)c1ccccc1	Phase 2				cannabinoid receptor antagonist			
isoleucine	isoleucine		CCC(C)C(N)C(O)=O	Launched	http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM135688.pdf	BCAT1|BCAT2|IARS2|IARS|ACADSB	https://www.drugbank.ca/drugs/DB00167|https://www.drugbank.ca/drugs/DB00167|https://www.drugbank.ca/drugs/DB00167|https://www.drugbank.ca/drugs/DB00167|https://www.drugbank.ca/drugs/DB00167				
BI-224436	BI-224436		Cc1nc2ccccc2c(-c2ccc3OCCc4ccnc2c34)c1[C@H](OC(C)(C)C)C(O)=O	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/24663024			HIV integrase inhibitor			
trimethylolpropane-triacrylate	trimethylolpropane-triacrylate		CCC(COC(=O)C=C)(COC(=O)C=C)COC(=O)C=C	Preclinical							
xibenolol	xibenolol		Cc1cccc(OCC(O)CNC(C)(C)C)c1C	Phase 3				adrenergic receptor antagonist			
CBS,-N-Cyclohexyl-2-benzothiazolesulfenamide	CBS,-N-Cyclohexyl-2-benzothiazolesulfenamide		C1CCC(CC1)NSc1nc2ccccc2s1	Preclinical							
sodium-tetradecyl-sulfate	sodium tetradecyl sulfate	Tetradecyl sulfate|sotradecol|tetradecyl sulfuric acid		Launched	FDA Orange Book: sodium tetradecyl sulfate	PROC|PROS1	https://www.drugbank.ca/drugs/DB00464|https://www.drugbank.ca/drugs/DB00464		dermatology|dermatology	varicose veins|varicose veins	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4749ba52-52d4-431b-8e86-14dcbeec7220&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4749ba52-52d4-431b-8e86-14dcbeec7220&audience=consumer
ZLN-024	ZLN-024		Cc1ccc(OCCSc2ncccn2)c(Br)c1	Preclinical		PRKAA1|PRKAB1|PRKAG1	https://www.tocris.com/products/zln-024-hydrochloride_5285|https://www.tocris.com/products/zln-024-hydrochloride_5285|https://www.tocris.com/products/zln-024-hydrochloride_5285	AMPK activator			
trimeprazine	trimeprazine		CC(CN(C)C)CN1c2ccccc2Sc2ccccc12.CC(CN(C)C)CN1c2ccccc2Sc2ccccc12	Launched	FDA Orange Book: trimeprazine tartrate	HRH1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001077	histamine receptor ligand|histamine receptor antagonist	allergy|neurology/psychiatry|pulmonary	urticaria|itching|cough suppressant	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9de07d0d-44df-47da-b4b7-24f5fc803b46|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9de07d0d-44df-47da-b4b7-24f5fc803b46|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9de07d0d-44df-47da-b4b7-24f5fc803b46
remodelin	remodelin		N#Cc1ccc(cc1)-c1csc(NN=C2CCCC2)n1	Preclinical		NAT10	https://www.tocris.com/products/remodelin_5193	transferase inhibitor			
promazine	promazine	sparine	CN(C)CCCN1c2ccccc2Sc2ccccc12	Launched	FDA Orange Book: chlorpromazine, chlorpromazine hydrochloride, levomepromazine, promazine hydrochloride, triflupromazine, triflupromazine hydrochloride	CHRM3|CHRM2|CHRM5|CHRM4|CHRM1|DRD3|DRD2|DRD1|DRD4|ADRA1D|ADRA1A|ADRA1B|HRH1|HTR2C|HTR2A	https://www.drugbank.ca/drugs/DB00420|https://www.drugbank.ca/drugs/DB00420|https://www.drugbank.ca/drugs/DB00420|https://www.drugbank.ca/drugs/DB00420|https://www.drugbank.ca/drugs/DB00420|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7281|https://www.drugbank.ca/drugs/DB00420|https://www.drugbank.ca/drugs/DB00420|https://www.drugbank.ca/drugs/DB00420|https://www.drugbank.ca/drugs/DB00420|https://www.drugbank.ca/drugs/DB00420|https://www.drugbank.ca/drugs/DB00420|https://www.drugbank.ca/drugs/DB00420|https://www.drugbank.ca/drugs/DB00420|https://www.drugbank.ca/drugs/DB00420	dopamine receptor antagonist	neurology/psychiatry	schizophrenia	https://en.wikipedia.org/wiki/Promazine
tryptophan	tryptophan	l-tryptophan	N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O	Launched	http://www.drugs.com/international/tryptophan.html	IDO1|WARS2|CASR|WARS|SLC36A1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001316|https://www.drugbank.ca/drugs/DB00150|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717|https://www.drugbank.ca/drugs/DB00150|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717	serotonin receptor partial agonist	neurology/psychiatry|gastroenterology|gastroenterology|neurology/psychiatry|neurology/psychiatry	anxiety|bloating|constipation|fatigue|sleeplessness	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f37c4f6d-ee0c-4a81-a463-a7c3edffa225|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f37c4f6d-ee0c-4a81-a463-a7c3edffa225|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f37c4f6d-ee0c-4a81-a463-a7c3edffa225|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f37c4f6d-ee0c-4a81-a463-a7c3edffa225|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f37c4f6d-ee0c-4a81-a463-a7c3edffa225
prilocaine	prilocaine	citanest|citanest plain|citanest plain dental|prilocaine hydrochloride	CCCNC(C)C(=O)Nc1ccccc1C	Launched	FDA Orange Book: prilocaine, prilocaine hydrochloride	SCN1A|SCN2A|SCN9A|SCN7A|SCN8A|SCN5A|SCN3A|SCN4A|SCN11A|SCN10A	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	local anesthetic	neurology/psychiatry	anesthetic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1972d657-2d5a-4697-bba9-80caffc2f2d7
2-thiouracil	2-thiouracil	thiouracil	Oc1ccnc(S)n1	Preclinical							
PIK-294	PIK-294		Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O	Preclinical		PIK3CG|PIK3CD|PIK3CB	http://www.scbt.com/datasheet-364586-CASNumber-900185-02-6.html|http://www.scbt.com/datasheet-364586-CASNumber-900185-02-6.html|http://www.scbt.com/datasheet-364586-CASNumber-900185-02-6.html	PI3K inhibitor			
EMD-1214063	EMD-1214063	MSC-2156119|MSC-2156119J|Tepotinib	CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01014936	MET	http://www.selleckchem.com/products/emd-1214063.html	hepatocyte growth factor receptor inhibitor			
PIK-293	PIK-293		Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O	Preclinical		PIK3CG|PIK3CB|PIK3CD|PIK3CA	http://www.scbt.com/datasheet-364585-CASNumber-900185-01-5.html|http://www.scbt.com/datasheet-364585-CASNumber-900185-01-5.html|http://www.scbt.com/datasheet-364585-CASNumber-900185-01-5.html|http://www.scbt.com/datasheet-364585-CASNumber-900185-01-5.html	PI3K inhibitor			
etretinate	etretinate	RO 10-9359|Ro-10-9359|tegison	CCOC(=O)\C=C(C)\C=C\C=C(C)\C=C\c1c(C)cc(OC)c(C)c1C	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	RXRG|RXRB|RXRA|RARB|RARA|RARG	ChEMBL|https://www.drugbank.ca/drugs/DB00926|https://www.drugbank.ca/drugs/DB00926|https://www.drugbank.ca/drugs/DB00926|ChEMBL|https://www.drugbank.ca/drugs/DB00926	protein synthesis inhibitor			
etacrynic-acid	etacrynic acid	MK-595|edecrin|etacrynic acid|ethacrynic acid	CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl	Launched	FDA Orange Book: ethacrynic acid	SLC12A2|SLC12A1|ATP1A1	https://citeline.informa.com/?query=#/drugs/details/6662|ChEMBL|https://www.drugbank.ca/drugs/DB00903	sodium/potassium/chloride transporter inhibitor	cardiology|cardiology|cardiology|gastroenterology|nephrology|rheumatology	hypertension|congestive heart failure|edema|hepatic cirrhosis|chronic renal failure|nephrotic syndrome	https://en.wikipedia.org/wiki/Etacrynic_acid|https://en.wikipedia.org/wiki/Etacrynic_acid|https://en.wikipedia.org/wiki/Etacrynic_acid|https://en.wikipedia.org/wiki/Etacrynic_acid|https://en.wikipedia.org/wiki/Etacrynic_acid|https://en.wikipedia.org/wiki/Etacrynic_acid
ONO-8130	ONO-8130		CC(C)CN(c1cc2CCCc2cc1OCc1ccc(cc1)C(O)=O)S(=O)(=O)c1nc(C)cs1	Preclinical		PTGER1	https://www.tocris.com/products/ono-8130_5406	prostanoid receptor antagonist			
GR-113808	GR-113808		Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12	Preclinical		HTR4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=247	serotonin receptor antagonist			
firocoxib	firocoxib	ML-1,785,713|equioxx	CC1(C)OC(=O)C(OCC2CC2)=C1c1ccc(cc1)S(C)(=O)=O	Veterinary Launched	http://www.drugs.com/international/firocoxib.html	PTGS2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004467	cyclooxygenase inhibitor	rheumatology	osteoarthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7125c03-46dc-4e18-9383-810036d7edfd
sinomenine	sinomenine		COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O	Preclinical				angiogenesis inhibitor			
avagacestat	avagacestat	BMS-708163|BMS-708163-01	NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00890890	PSEN1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6489	gamma secretase inhibitor			
tacrolimus	tacrolimus	astagraf xl|envarsus xr|prograf|protopic	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC	Launched	FDA Orange Book: tacrolimus	CYP3A5|CYP3A7|FKBP1A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=124071|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=124071|https://www.drugbank.ca/drugs/DB00864	calcineurin inhibitor	transplant	organ rejection	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd447ffa-9196-4c3c-accf-5adf29b84665&audience=consumer
acitazanolast	acitazanolast		OC(=O)C(=O)Nc1cccc(c1)-c1nnn[nH]1	Launched	http://www.drugs.com/international/acitazanolast.html			mediator release inhibitor	allergy	allergic rhinitis	http://www.adooq.com/acitazanolast.html
3-alpha-Hydroxy-5-beta-androstan-17-one	3-alpha-Hydroxy-5-beta-androstan-17-one		C[C@]12CCC3[C@@H](CC[C@@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O	Preclinical							
lansoprazole	lansoprazole	A-65006|AG-1749|Prevacid Delayed Release|Prevacid SoluTab|prevacid|prevacid 24 hr|prevacid iv	Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1	Launched	FDA Orange Book: dexlansoprazole, lansoprazole	CYP3A4|CYP3A5|ATP4A|ATP4B|CYP2C19	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=123065|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=123065|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=123065	ATPase inhibitor	gastroenterology	heartburn	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8da40a40-6a46-4bc1-843a-09d942c5d039
MN-64	MN-64		CC(C)c1ccc(cc1)-c1cc(=O)c2ccccc2o1	Preclinical		TNKS	https://www.tocris.com/dispprod.php?ItemId=400037	tankyrase inhibitor			
SID-7969543	SID-7969543		CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O	Preclinical		NR5A1	https://www.tocris.com/dispprod.php?ItemId=222684#.VyuvDWQrJZJ	steroidogenic factor antagonist			
1400W	1400W		CC(=N)NCc1cccc(CN)c1	Preclinical		NOS2|NOS1|NOS3	https://www.drugbank.ca/drugs/DB02044|https://www.drugbank.ca/drugs/DB02044|https://www.drugbank.ca/drugs/DB02044	nitric oxide synthase inhibitor			
GDC-0152	GDC-0152		CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00977067	BIRC2|BIRC3|BIRC7|XIAP	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7733|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7733|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7733|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7733	XIAP inhibitor			
imidapril	imidapril		CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O	Launched	http://www.drugs.com/international/Imidapril.html	ACE	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6377	angiotensin converting enzyme inhibitor	cardiology|cardiology	hypertension|congestive heart failure	https://en.wikipedia.org/wiki/Imidapril|https://en.wikipedia.org/wiki/Imidapril
octreotide	octreotide	octreotide acetate|octreotide acetate (preservative free)|sandostatin|sandostatin lar	CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(N)Cc2ccccc2)C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1	Launched	FDA Orange Book: octreotide acetate	SST|GH1|SSTR3|SSTR5|SSTR1|SSTR2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=120090|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=120090|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2055|https://www.drugbank.ca/drugs/DB00104|https://www.drugbank.ca/drugs/DB00104|https://www.drugbank.ca/drugs/DB00104	somatostatin receptor agonist	gastroenterology|endocrinology|oncology	diarrhea|acromegaly|carcinoid tumors	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f278f0d8-4062-420a-97c3-3a8b88253a08|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f278f0d8-4062-420a-97c3-3a8b88253a08|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f278f0d8-4062-420a-97c3-3a8b88253a08
volasertib	volasertib	BI 6727|BI-6727	CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01721876	PLK1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7947	PLK inhibitor			
basimglurant	basimglurant	RG7090|RO-4917523|RO4917523	Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01750957	GRM5	https://en.wikipedia.org/wiki/Basimglurant	glutamate receptor antagonist			
levobunolol	levobunolol	betagan	CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12	Launched	FDA Orange Book: levobunolol hydrochloride	ADRB3|ADRB1|ADRB2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=570|https://www.drugbank.ca/drugs/DB01210|https://www.drugbank.ca/drugs/DB01210	adrenergic receptor antagonist	ophthalmology|ophthalmology	glaucoma|ocular hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0bf8746-2264-408a-98b1-3583ac0f975f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0bf8746-2264-408a-98b1-3583ac0f975f
BQU57	BQU57		Cc1nn(C)c2OC(N)=C(C#N)C(c12)c1ccc(cc1)C(F)(F)F	Preclinical		RALB|RALA	http://www.sigmaaldrich.com/catalog/product/sigma/sml1268?lang=en&region=US|http://www.sigmaaldrich.com/catalog/product/sigma/sml1268?lang=en&region=US	Ras GTPase inhibitor			
AMG-487	AMG-487		CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/18442035	CXCR3	https://citeline.informa.com/?query=#/drugs/details/26261	CC chemokine receptor antagonist			
mirabegron	mirabegron	YM178|myrbetriq	Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1	Launched	FDA Orange Book: mirabegron	ADRB2|ADRB3|ADRB1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7445|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7445	adrenergic receptor agonist	urology	urinary incontinence	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba9e9e15-e666-4c56-9271-2e24739cfa2d
NBI-27914	NBI-27914		CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl	Preclinical		CRHR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3512	corticosteroid releasing factor receptor antagonist			
trans-4-[8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexanecarboxylic-acid	trans-4-[8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexanecarboxylic acid		OC(=O)C1CCC(CC1)c1cc2cccnc2c(n1)-c1cccc(F)c1	Preclinical							
hexylcaine	hexylcaine	cyclaine	CC(CNC1CCCCC1)OC(=O)c1ccccc1	Launched	FDA Orange Book: hexylcaine hydrochloride	SCN5A|SCN10A	https://www.drugbank.ca/drugs/DB00473|https://www.drugbank.ca/drugs/DB00473	sodium channel blocker	neurology/psychiatry	local anesthetic	https://en.wikipedia.org/wiki/Hexylcaine
zidovudine	zidovudine	AZT|BW A509U|BW-A-509U|BWA509U|azidothymidine|compound s|retrovir		Launched	FDA Orange Book: zidovudine	TERT	https://www.drugbank.ca/drugs/DB00495	nucleoside reverse transcriptase inhibitor	infectious disease|infectious disease	human immunodeficiency virus (HIV-1)|acquired immunodeficiency syndrome (AIDS)	https://en.wikipedia.org/wiki/Zidovudine|https://en.wikipedia.org/wiki/Zidovudine
ibotenic-acid	ibotenic acid	(+/-)-Ibotenic Acid	NC(C(O)=O)c1cc(O)no1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00005925	GRIN1	https://en.wikipedia.org/wiki/Ibotenic_acid#Mechanism_of_action	glutamate receptor agonist			
CGP-74514	CGP-74514		CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12	Preclinical		CDK1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5945	CDK inhibitor			
TC-I-2014	TC-I-2014		FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F	Preclinical		TRPM8	https://www.tocris.com/products/tc-i-2014_5410	transient receptor potential channel antagonist			
5-hydroxymethyl-tolterodine	5-hydroxymethyl-tolterodine		CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01566760	CHRM3	http://www.drugbank.ca/drugs/DB01036	acetylcholine receptor antagonist			
aminocaproic-acid	aminocaproic acid	177 J.D|177 J.D.|Aminocaproic|CL 10304|CL-10304|CY-116|EACA|amicar|aminocaproic acid|epsilon-aminocaproic acid	NCCCCCC(O)=O	Launched	FDA Orange Book: aminocaproic acid	LPA|PLAT|PLG	https://www.drugbank.ca/drugs/DB00513|ChEMBL|ChEMBL	plasminogen activator inhibitor	hematology	fibrinolytic bleeding	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4f65667-c349-420b-b7b7-f20f3a4e4d4e
flucytosine	flucytosine	Alcobon|Ancoban|Flourocytosine|Fluorocytosine|RO 2-9915|Ro-2-9915|ancobon	Nc1nc(=O)[nH]cc1F	Launched	FDA Orange Book: flucytosine	DNMT1	https://www.drugbank.ca/drugs/DB01099	other antifungal	infectious disease|infectious disease|infectious disease|infectious disease	bacterial septicemia|endocarditis|urinary tract infections|meningitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58189ec7-118b-458a-8e4f-7867a97cfcbd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58189ec7-118b-458a-8e4f-7867a97cfcbd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58189ec7-118b-458a-8e4f-7867a97cfcbd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58189ec7-118b-458a-8e4f-7867a97cfcbd
triciribine	triciribine	NSC-154020	Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT01697293	AKT1|AKT2|AKT3	http://www.emdmillipore.com/life-science-research/akt-inhibitor-v-triciribine/EMD_BIO-124012/p_1P.b.s1Ls8oAAAEWxmEfVhTm|http://www.emdmillipore.com/life-science-research/akt-inhibitor-v-triciribine/EMD_BIO-124012/p_1P.b.s1Ls8oAAAEWxmEfVhTm|http://www.emdmillipore.com/life-science-research/akt-inhibitor-v-triciribine/EMD_BIO-124012/p_1P.b.s1Ls8oAAAEWxmEfVhTm	AKT inhibitor			
metazosin	metazosin		COC(C)C(=O)N1CCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/7489576	ADRA1A	https://www.ncbi.nlm.nih.gov/pubmed/1981860	adrenergic receptor antagonist			
OPC-21268	OPC-21268	OPC-1268	CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/8385161	AVPR1A|AVPR1B|OXTR|AVPR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2196|https://citeline.informa.com/?query=#/drugs/details/13274|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2196|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2196	vasopressin receptor antagonist			
selegiline	selegiline	eldepryl|emsam|selegiline hydrochloride|zelapar	CC(Cc1ccccc1)N(C)CC#C	Launched	FDA Orange Book: selegiline, selegiline hydrochloride	CYP2C19|MAOB|MAOA|CYP2B6	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=140055|https://www.drugbank.ca/drugs/DB01037|https://www.drugbank.ca/drugs/DB01037|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=140055	monoamine oxidase inhibitor	neurology/psychiatry	Parkinson's Disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2aa9f8ee-6a86-6cf1-bec7-6a1ffa5e1ae2&audience=consumer
meglumine	meglumine	cardiografin|cholovue|conray|conray 30|conray 43|cysto-conray ii|cystografin|cystografin dilute|diatrizoate meglumine|hypaque|hypaque-cysto|magnevist|multihance|multihance multipack|reno-30|reno-60|reno-dip|renovue-65|renovue-dip	CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	Launched	FDA Orange Book: diatrizoate meglumine, fosaprepitant dimeglumine, gadobenate dimeglumine, gadopentetate dimeglumine, gadoterate meglumine, iodamide meglumine, iodipamide meglumine, iodoxamate meglumine, iothalamate meglumine, ioxaglate meglumine, meglumine, meglumine metrizoate			excipient			
guanfacine	guanfacine	intuniv|tenex	NC(=N)NC(=O)Cc1c(Cl)cccc1Cl	Launched	FDA Orange Book: guanfacine hydrochloride	ADRA2C|ADRA2B|ADRA2A|CYP3A5|HCN4|HCN3|HCN2|HCN1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=522|https://www.drugbank.ca/drugs/DB01018|https://www.drugbank.ca/drugs/DB01018|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091510|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091510|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091510|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091510|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091510	adrenergic receptor agonist	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6fdcebac-0a5a-4858-b0e6-87f77ba53bf1
proglumetacin	proglumetacin	proglumetacin maleate	CCCN(CCC)C(=O)C(CCC(=O)OCCCN1CCN(CCOC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OC)cc23)CC1)NC(=O)c1ccccc1	Launched	http://www.drugs.com/international/Proglumetacin.html	PTGS2|PTGS1	http://www.genome.jp/dbget-bin/www_bget?D01765|http://www.genome.jp/dbget-bin/www_bget?D01765	cyclooxygenase inhibitor	neurology/psychiatry	pain relief	http://www.drugs.com/international/proglumetacin.html
hydrocortisone-butyrate	hydrocortisone butyrate	locoid|locoid lipocream	CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO	Launched	FDA Orange Book: hydrocortisone butyrate	NR3C1	http://dgidb.genome.wustl.edu/interaction_claims/8ae2535f-4ddc-4acf-94a9-93b0bd94dc9d	glucocorticoid receptor agonist	dermatology|dermatology	corticosteroid-responsive dermatoses|eczema	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a45634ce-f697-4e4c-880d-9217e11e3ae7|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a45634ce-f697-4e4c-880d-9217e11e3ae7
rufloxacin	rufloxacin	MF 934|Qari	CN1CCN(CC1)c1c(F)cc2c3c1SCCn3cc(C(O)=O)c2=O	Launched	http://www.drugs.com/international/rufloxacin.html			bacterial DNA gyrase inhibitor	infectious disease	gram-negative bacterial infections	http://www.drugs.com/international/rufloxacin.html
MK-5108	MK-5108		OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00543387	AURKC|AURKB|AURKA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8061|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8061|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8061	Aurora kinase inhibitor			
naringin-dihydrochalcone	naringin-dihydrochalcone		C[C@@H]1O[C@@H](O[C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c(C(=O)CCc3ccc(O)cc3)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	Preclinical				cytochrome P450 inhibitor			
SB-218078	SB-218078		O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13	Preclinical		CHEK1	https://www.drugbank.ca/drugs/DB08683	CHK inhibitor			
cyclosporine	cyclosporine		CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	Launched	FDA Orange Book: cyclosporine	CAMLG|SLC10A1|PPID|PPIF|PPIA|FPR1|SLCO1B1|SLCO1B3|PPP3R2|CYP3A7|CYP3A5|ABCB11	https://www.drugbank.ca/drugs/DB00091|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1024|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091277|https://www.drugbank.ca/drugs/DB00091|https://www.drugbank.ca/drugs/DB00091|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1024|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1024|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1024|https://www.drugbank.ca/drugs/DB00091|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091277|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091277|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000503	calcineurin inhibitor	transplant|rheumatology|dermatology	organ rejection|rheumatoid arthritis|psoriasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94461af3-11f1-4670-95d4-2965b9538ae3|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94461af3-11f1-4670-95d4-2965b9538ae3|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94461af3-11f1-4670-95d4-2965b9538ae3
pyrazinoylguanidine	pyrazinoylguanidine		NC(=N)NC(=O)c1cnccn1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/9925970			diuretic			
voriconazole	voriconazole	UK-109,496|UK-109496|vfend	C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	Launched	FDA Orange Book: voriconazole	PTGS1|CYP2C19|CYP2C9|CYP51A1|CYP3A4|CYP3A5	http://www.drugbank.ca/drugs/DB00582|http://www.drugbank.ca/drugs/DB00582|http://www.drugbank.ca/drugs/DB00582|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=179738|http://www.drugbank.ca/drugs/DB00582|http://www.drugbank.ca/drugs/DB00582	cytochrome P450 inhibitor	infectious disease|infectious disease|infectious disease	esophageal candidiasis|aspergillosis|skin infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74f51144-c228-440e-8043-c3ec9cb1b42e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74f51144-c228-440e-8043-c3ec9cb1b42e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74f51144-c228-440e-8043-c3ec9cb1b42e
colforsin	colforsin		CC(=O)O[C@H]1[C@@H](O)C2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/16749416	ADCY5|ADCY2	http://en.wikipedia.org/wiki/Colforsin|http://en.wikipedia.org/wiki/Colforsin	adenylyl cyclase activator			
rupatadine	rupatadine		Cc1cncc(CN2CCC(CC2)=C2c3ccc(Cl)cc3CCc3cccnc23)c1	Launched	http://www.drugs.com/international/Rupatadine.html	HRH1|PTAFR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005871|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005871	histamine receptor antagonist|platelet activating factor receptor antagonist	allergy|allergy	allergic rhinitis|urticaria	https://en.wikipedia.org/wiki/Rupatadine|https://en.wikipedia.org/wiki/Rupatadine
ephedrine-(racemic)	racephedrine		CNC(C)C(O)c1ccccc1	Launched	http://en.wikipedia.org/wiki/Ephedrine	ADRA1A|ADRA2A	https://en.wikipedia.org/wiki/Racemic_epinephrine|https://en.wikipedia.org/wiki/Racemic_epinephrine	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity	https://en.wikipedia.org/wiki/Ephedrine|https://en.wikipedia.org/wiki/Ephedrine|https://en.wikipedia.org/wiki/Ephedrine|https://en.wikipedia.org/wiki/Ephedrine
chloroprocaine	chloroprocaine	nesacaine|nesacaine-mpf	CCN(CC)CCOC(=O)c1ccc(N)cc1Cl	Launched	FDA Orange Book: chloroprocaine hydrochloride	SCN10A|HTR3A|GRIN3A|CHRNA10|ATP1A1|SLC6A3	https://www.drugbank.ca/drugs/DB01161|https://www.drugbank.ca/drugs/DB01161|https://www.drugbank.ca/drugs/DB01161|https://www.drugbank.ca/drugs/DB01161|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000131|https://www.drugbank.ca/drugs/DB01161	sodium channel blocker	neurology/psychiatry	local anesthetic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec4ab877-878f-4b0e-3eb6-106a606479ad
levo-phencynonate	levo-phencynonate		CN1CC2CCCC(C1)C2OC(=O)C(O)(C1CCCC1)c1ccccc1	Launched	http://www.drugs.com/international/phencynonate-hydrochloride.html	CHRM1	http://adisinsight.springer.com/drugs/800041719	acetylcholine receptor antagonist			
etomoxir	etomoxir		CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/17319797	CPT1B|CPT1A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=100320|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000630	carnitine palmitoyltransferase inhibitor			
perhexiline	perhexiline		C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1	Launched	http://www.drugs.com/international/perhexiline.html	CPT2|CPT1A	https://www.drugbank.ca/drugs/DB01074|https://www.drugbank.ca/drugs/DB01074	carnitine palmitoyltransferase inhibitor	cardiology	angina pectoris	https://en.wikipedia.org/wiki/Perhexiline
clorsulon	clorsulon	MK-401	Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O	Veterinary Launched	http://www.drugs.com/international/Clorsulon.html			glycolysis inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	gastrointestinal roundworms|lungworms|liver flukes|lice|mites	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e68bf871-4c05-4965-959e-aa0f550b8751|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e68bf871-4c05-4965-959e-aa0f550b8751|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e68bf871-4c05-4965-959e-aa0f550b8751|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e68bf871-4c05-4965-959e-aa0f550b8751|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e68bf871-4c05-4965-959e-aa0f550b8751
iodophenpropit	iodophenpropit		Ic1ccc(CCNC(=N)SCCCc2c[nH]cn2)cc1	Preclinical		HRH3|HRH4|GRIN2B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1266|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1266|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=716959	histamine receptor antagonist			
acadesine	acadesine	GP-1-110	NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00872001			AMPK activator			
SB-222200	SB-222200		CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1	Preclinical		TACR3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2131	tachykinin antagonist			
methylprednisolone-sodium-succinate	methylprednisolone sodium succinate	solu-medrol	C[C@H]1CC2C3CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]3(C)C[C@H](O)C2[C@@]2(C)C=CC(=O)C=C12	Launched	FDA Orange Book: methylprednisolone sodium succinate			glucocorticoid receptor agonist	endocrinology|endocrinology|rheumatology|rheumatology|dermatology|pulmonary|allergy|infectious disease|ophthalmology|gastroenterology|gastroenterology|hematology|neurology/psychiatry|infectious disease	hypercalcemia|thyroiditis|osteoarthritis|rheumatoid arthritis|seborrheic dermatitis|asthma|allergic rhinitis|shingles|conjunctivitis|ulcerative colitis|enteritis|anemia|multiple sclerosis|mycosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84399711-2358-4e27-b66f-c856e85e47bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84399711-2358-4e27-b66f-c856e85e47bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84399711-2358-4e27-b66f-c856e85e47bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84399711-2358-4e27-b66f-c856e85e47bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84399711-2358-4e27-b66f-c856e85e47bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84399711-2358-4e27-b66f-c856e85e47bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84399711-2358-4e27-b66f-c856e85e47bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84399711-2358-4e27-b66f-c856e85e47bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84399711-2358-4e27-b66f-c856e85e47bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84399711-2358-4e27-b66f-c856e85e47bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84399711-2358-4e27-b66f-c856e85e47bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84399711-2358-4e27-b66f-c856e85e47bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84399711-2358-4e27-b66f-c856e85e47bf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84399711-2358-4e27-b66f-c856e85e47bf
abiraterone-acetate	abiraterone acetate	CB7630|abiraterone acetate|zytiga	CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1	Launched	FDA Orange Book: abiraterone acetate	CYP2C19|CYP2C8|CYP3A5|CYP17A1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=217053|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=217053|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=217053|ChEMBL	androgen biosynthesis inhibitor	oncology	prostate cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513
fenoxaprop-p-ethyl	fenoxaprop-p-ethyl		CCOC(=O)[C@@H](C)Oc1ccc(Oc2nc3ccc(Cl)cc3o2)cc1	Preclinical		NOS3|NOS2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000030|https://www.drugbank.ca/drugs/DB05252				
dicycloverine	dicycloverine	bentyl|bentyl preservative free|dicyclomine|dicyclomine hydrochloride	CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1	Launched	FDA Orange Book: dicyclomine hydrochloride	CHRM3|CHRM1|CHRM2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=355|https://www.drugbank.ca/drugs/DB00804|https://www.drugbank.ca/drugs/DB00804	acetylcholine receptor antagonist	gastroenterology	irritable bowel syndrome	https://en.wikipedia.org/wiki/Dicycloverine
AGI-5198	AGI-5198		Cc1nccn1CC(=O)N(C(C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1	Preclinical		IDH1	http://www.apexbt.com/agi-5198.html	isocitrate dehydrogenase inhibitor			
pruvanserin	pruvanserin	EMD 390920|EMD-281014|LSN-2422347|LSN2422347|LY2422347	Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1	Phase 2	https://en.wikipedia.org/wiki/Pruvanserin	HTR2C|HTR2A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011099|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011099	serotonin receptor antagonist			
carzenide	carzenide	para-carboxybenzenesulfonamide (weak carbonic anhydrase inhibitor)	NS(=O)(=O)c1ccc(cc1)C(O)=O	Preclinical		CA9|CA6|CA1|CA2|CA14|CA12	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004667|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004667|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004667|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004667|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004667|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004667				
LB42708	LB42708		Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1	Preclinical				farnesyltransferase inhibitor			
fluorometholone-acetate	fluorometholone acetate	U-17,323|U-17323|flarex|fluorometholone acetate	C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12	Launched	FDA Orange Book: fluorometholone acetate	NR3C1	ChEMBL		ophthalmology	eye inflammation	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=545776fe-63df-44ab-ace3-f3d73d2e0092
meropenem	meropenem	ICI 194,660|ICI-194660|Merrem i.v.|SM-7338|merrem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O	Launched	FDA Orange Book: meropenem			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease	skin infections|intra-abdominal infections|meningitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3b952a55-6ef7-45c8-be21-16eefe37ec2e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3b952a55-6ef7-45c8-be21-16eefe37ec2e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3b952a55-6ef7-45c8-be21-16eefe37ec2e
idarubicin	idarubicin	idamycin|idamycin pfs	C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O	Launched	FDA Orange Book: idarubicin hydrochloride	TOP2A	https://www.drugbank.ca/drugs/DB01177	topoisomerase inhibitor	hematologic malignancy	acute myeloid leukemia (AML)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31c9691c-aa14-426d-b67f-f8d25e7200ce
SRT2104	SRT2104		Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00937326	SIRT1	http://www.selleckchem.com/products/srt2104-gsk2245840.html?gclid=CNKot7OEv88CFQ1ahgodWNwD_w	SIRT activator			
PNU-74654	PNU-74654		Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1	Preclinical		CTNNB1|TCF4	http://www.tocris.com/dispprod.php?ItemId=225597|http://www.tocris.com/dispprod.php?ItemId=225597	beta-catenin inhibitor			
hesperetin	hesperetin	NSC-57654	COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1	Launched	http://www.drugbank.ca/drugs/DB01094	DGAT1|CYP1B1|SOAT2|SOAT1|MTTP	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001306|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=346572|https://www.drugbank.ca/drugs/DB01094|https://www.drugbank.ca/drugs/DB01094|https://www.drugbank.ca/drugs/DB01094	ACAT inhibitor			
L-778123	L-778123		Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00004057	PGGT1B|FNTB|FNTA	https://www.drugbank.ca/drugs/DB07227|https://www.drugbank.ca/drugs/DB07227|https://www.drugbank.ca/drugs/DB07227	farnesyltransferase inhibitor			
thiorphan	thiorphan		OC(=O)CNC(=O)C(CS)Cc1ccccc1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/8735864	MME	https://www.drugbank.ca/drugs/DB08626	membrane metalloendopeptidase inhibitor			
VU0360172	VU0360172		Fc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1	Preclinical		GRM5	https://www.tocris.com/products/vu-0360172-hydrochloride_4323	glutamate receptor positive allosteric modulator			
ricinoleic-acid	ricinoleic acid		CCCCCC[C@@H](O)C\C=C/CCCCCCCC(O)=O	Launched	http://en.wikipedia.org/wiki/Ricinoleic_acid	PTGER3	https://en.wikipedia.org/wiki/Ricinoleic_acid	prostanoid receptor agonist			
cepharanthine	cepharanthine	(+)-Cepharanthine	COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/21602589			NFkB pathway inhibitor			
riboflavin-5-phosphate-sodium	riboflavin 5'-phosphate sodium			Launched	http://en.wikipedia.org/wiki/Flavin_mononucleotide	RPS6KA4|MT-ND1|PNPO|BLVRB|HAO2|HAO1|PPCDC|RFK|SGK1|DPYD|NOS1|DHODH|POR	https://www.drugbank.ca/drugs/DB03247|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002494|https://www.drugbank.ca/drugs/DB03247|https://www.drugbank.ca/drugs/DB03247|https://www.drugbank.ca/drugs/DB03247|https://www.drugbank.ca/drugs/DB03247|https://www.drugbank.ca/drugs/DB03247|https://www.drugbank.ca/drugs/DB03247|https://www.drugbank.ca/drugs/DB03247|https://www.drugbank.ca/drugs/DB03247|https://www.drugbank.ca/drugs/DB03247|https://www.drugbank.ca/drugs/DB03247|https://www.drugbank.ca/drugs/DB03247				
albuterol	albuterol	Combivent|Duoneb|Proventil HFA|accuneb|albuterol sulfate|proair hfa|proair respiclick|proventil|proventil-hfa|salbutamol|ventolin|ventolin hfa|ventolin rotacaps|volmax|vospire er	CC(C)(C)NCC(O)c1ccc(O)c(CO)c1	Launched	FDA Orange Book: albuterol, albuterol sulfate, levalbuterol hydrochloride, levalbuterol tartrate	ADRB1|ADRB2	https://www.drugbank.ca/drugs/DB01001|ChEMBL	adrenergic receptor agonist	pulmonary	asthma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f422539-5708-46fd-944d-c88a12fc5ec3
nibentan	nibentan		CCN(CC)CCCCC(NC(=O)c1ccc(cc1)[N+]([O-])=O)c1ccccc1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/9889704			potassium channel blocker			
estradiol-benzoate	estradiol benzoate		C[C@]12CCC3C(CCc4cc(OC(=O)c5ccccc5)ccc34)C1CC[C@@H]2O	Preclinical		ESR1	https://www.caymanchem.com/app/template/Product.vm/catalog/10006487	contraceptive agent			
SB-200646	SB-200646		Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12	Preclinical		HTR2C|HTR2B	http://www.tocris.com/dispprod.php?ItemId=1765|http://www.tocris.com/dispprod.php?ItemId=1765	serotonin receptor antagonist			
ravuconazole	ravuconazole	BMS-207147|ER-30346	C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01489228			sterol demethylase inhibitor			
CR8-(R)	(R)-CR8		CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1	Preclinical		CCNH|CDK2|CDK1|CDK7|CDK5|CDK9|CCNT1|CCNE1|CCNA2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=652274|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=652274|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=652274|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=652274|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=652274|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=652274|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=652274|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=652274|https://www.drugbank.ca/drugs/DB08463	CDK inhibitor			
skepinone-l	skepinone-l		OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1	Preclinical		MAPK14|TNF	http://www.selleckchem.com/products/skepinone-l.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=781120	p38 MAPK inhibitor			
arbutin	arbutin		OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT00717652	TYR	https://en.wikipedia.org/wiki/Arbutin	melanin inhibitor			
ethisterone	ethisterone	anhydrohydroxyprogesterone|ora-lutin|pranone|pregneninolone|syngestrotabs|trosinone		Launched	https://clinicaltrials.gov/ct2/show/NCT00732693	TYR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013429	progestogen hormone			
iguratimod	iguratimod		CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1	Launched	https://clinicaltrials.gov/ct2/show/NCT01554917	PTGS2	http://www.ncbi.nlm.nih.gov/pubmed/23032798	cyclooxygenase inhibitor|NFkB pathway inhibitor	rheumatology	rheumatoid arthritis	https://en.wikipedia.org/wiki/Iguratimod
PF-03084014	PF-03084014	PF-3084014|nirogacestat	CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02109445			gamma secretase inhibitor			
rifamycin-sv	rifamycin-sv		CO[C@H]1C=CO[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C\[C@@H](C)[C@@H](O)[C@@H](C)[C@H](O)[C@H](C)[C@H]([C@H]1C)C(=O)OC)c(O)c2c(O)c3C	Phase 3	http://www.cosmopharmaceuticals.com/activities/pipeline/rifamycin.aspx			RNA synthesis inhibitor			
lovastatin	lovastatin	MK-803|altoprev|mevacor|mevinolin	CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12	Launched	FDA Orange Book: lovastatin	ITGAL|HDAC2|CYP3A5|HMGCR|NR1I2	https://www.drugbank.ca/drugs/DB00227|https://www.drugbank.ca/drugs/DB00227|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090077|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2739	HMGCR inhibitor	cardiology|cardiology|endocrinology	coronary heart disease|myocardial infarction|hypercholesterolemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a694c480-76f3-42c3-bb67-bed50e12c1ae|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a694c480-76f3-42c3-bb67-bed50e12c1ae|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a694c480-76f3-42c3-bb67-bed50e12c1ae
ciaftalan-zinc	ciaftalan zinc	(phthalocyaninato)zinc(ii)	[Zn]1n2c3\N=C4/N=C(c5ccccc45)/N=c4\n1\c(=N/C1=N/C(c5ccccc15)=N\c2c1ccccc31)c1ccccc41	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/18815617			reactive oxygen species stimulant			
tylosin	tylosin	E713|Tylon|tylan	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC	Veterinary Launched	http://www.drugs.com/international/tylosin.html			protein synthesis inhibitor	infectious disease|gastroenterology	gram-positive bacterial infections|colitis	https://en.wikipedia.org/wiki/Tylosin|https://en.wikipedia.org/wiki/Tylosin
paricalcitol	paricalcitol	COMPOUND 49510|zemplar	C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1C[C@@H](O)C[C@H](O)C1	Launched	FDA Orange Book: paricalcitol	PTH|VDR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=248876|ChEMBL	vitamin D receptor agonist	nephrology|endocrinology	chronic kidney disease (CKD)|hyperthyroidism	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18d7da0b-d715-4257-bdb3-d35fd9d02a74|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18d7da0b-d715-4257-bdb3-d35fd9d02a74
CEP-33779	CEP-33779		CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1	Preclinical		JAK2	http://www.selleckchem.com/products/cep33779.html	JAK inhibitor			
bazedoxifene	bazedoxifene		Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12	Launched	FDA Orange Book: bazedoxifene acetate	ESR1|ESR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7355|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7355	selective estrogen receptor modulator (SERM)	orthopedics|endocrinology	osteoporosis|menopause	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16705d8-4472-4f83-96ac-69fa2be066cb|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16705d8-4472-4f83-96ac-69fa2be066cb
dapagliflozin	dapagliflozin	BMS-512148|farxiga	CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1	Launched	FDA Orange Book: dapagliflozin	SLC5A2|SLC5A1	ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4594	sodium/glucose cotransporter inhibitor	endocrinology	diabetes mellitus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc6ae30e-868b-4ac9-b69d-900922503998
MDL-73005EF	MDL-73005EF	binospirone	O=C1CC2(CCCC2)CC(=O)N1CCNCC1COc2ccccc2O1	Phase 1	http://link.springer.com/chapter/10.1007/978-3-0348-7259-1_47	HTR1A	http://www.ncbi.nlm.nih.gov/pubmed/1970269	serotonin receptor antagonist			
2-Oleoylglycerol	2-Oleoylglycerol		CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01043445	GPR119	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5112	glucose dependent insulinotropic receptor ligand			
camptothecin	camptothecin	NSC-94600	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00063141	HIF1A|TOP1	https://citeline.informa.com/?query=#/drugs/details/29981|https://www.drugbank.ca/drugs/DB04690	topoisomerase inhibitor			
chlormezanone	chlormezanone	chlormethazanone|trancopal	CN1C(c2ccc(Cl)cc2)S(=O)(=O)CCC1=O	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	GABRA1|TSPO	http://www.tocris.com/dispprod.php?ItemId=2148#.VfL-WmTBwXA|https://www.drugbank.ca/drugs/DB01178	GABA receptor modulator			
geniposide	geniposide		COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO	Preclinical		GLP1R	http://www.abcam.com/geniposide-ab141934.html	GLP receptor agonist			
Mps-BAY-2a	Mps-BAY-2a		CC(C)CNc1nc(cn2c(cnc12)-c1ccc(cc1)C(=O)NC1CC1)-c1cccc2ncccc12	Preclinical		TTK	https://www.tocris.com/products/mps-bay-2a_5562	monopolar spindle 1 kinase inhibitor			
uridine-triacetate	uridine triacetate	uridine triacetate	CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)n1ccc(=O)[nH]c1=O	Launched	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208159s000lbl.pdf				nephrology	orotic aciduria	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40606ca9-4f14-45b7-8632-fc2d17d11a2e
digoxin	digoxin	lanoxicaps|lanoxin|lanoxin pediatric	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C	Launched	FDA Orange Book: digoxin	SLCO1B3|RORC|ABCB1|ATP1A1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=272916|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=272916|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=272916|https://www.drugbank.ca/drugs/DB00390	ATPase inhibitor	cardiology|cardiology	congestive heart failure|atrial fibrillation (AF)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3933b07f-5857-4a80-b502-e3214bdf9330|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3933b07f-5857-4a80-b502-e3214bdf9330
ABT-751	ABT-751	E-7010	COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00063102	TUBB	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014662	tubulin polymerization inhibitor			
ABT-202	ABT-202		NC1CCN(C1)c1cccnc1	Phase 1	http://media.corporate-ir.net/media_files/nys/abt/rdday/PharmDev.pdf			acetylcholine receptor agonist			
aminopentamide	aminopentamide	Centrine|aminopentamide sulfate|dimevamide	CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C	Veterinary Launched	http://www.drugs.com/vet/centrine-tablets.html	CHRM1	http://www.drugs.com/vet/centrine-tablets.html	acetylcholine receptor antagonist	gastroenterology|gastroenterology|gastroenterology	acute abdominal visceral spasm|hypertrophic gastritis (GHG)|nausea	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=361308e8-9eb1-4037-a7c5-5633d528496d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=361308e8-9eb1-4037-a7c5-5633d528496d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=361308e8-9eb1-4037-a7c5-5633d528496d
bindarit	bindarit	AF 2838	CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01109212	CCL2|CCL7|CCL8	http://www.abcam.com/bindarit-ab143292.html|http://www.abcam.com/bindarit-ab143292.html|http://www.abcam.com/bindarit-ab143292.html	NFkB pathway inhibitor			
tiagabine	tiagabine	A-70569-1|ABBOTT-70569|ABBOTT-70569-1|ABT-569|NNC-05-0328|NO-05-0328|gabitril	Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C	Launched	FDA Orange Book: tiagabine hydrochloride	CYP2C19|SLC6A1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=139181|https://www.drugbank.ca/drugs/DB00906	GABA uptake inhibitor	neurology/psychiatry	seizures	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=25225511-70b8-4377-ad4f-6629025ac75f&audience=consumer
CO-101244	CO-101244		Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1	Preclinical		GRIN2B	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000459	glutamate receptor antagonist			
etofibrate	etofibrate		CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCOC(=O)c1cccnc1	Launched	http://www.drugs.com/international/Etofibrate.html	LPL|PPARA	https://citeline.informa.com/?query=#/drugs/details/6699|http://www.genome.jp/dbget-bin/www_bget?D07187	PPAR receptor agonist	endocrinology	hypertriglyceridemia	http://www.drugs.com/international/etofibrate.html
ronidazole	ronidazole	Dugro|Nitro Imidazole|Ridzol	Cn1c(COC(N)=O)ncc1[N+]([O-])=O	Veterinary Launched	FDA Orange Book: metronidazole, metronidazole hydrochloride			antiprotozoal agent	infectious disease|infectious disease	histomoniasis|dysentry	https://en.wikipedia.org/wiki/Ronidazole|https://en.wikipedia.org/wiki/Ronidazole
satraplatin	satraplatin			Phase 3	https://clinicaltrials.gov/ct2/show/NCT00069745			DNA alkylating agent			
phthalylsulfathiazole	phthalylsulfathiazole	Intestiazol|Sulfathalidine|Thalazole|phthalylsulphathiazole|sulfaphtalylthiazol	OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	Launched	http://www.drugs.com/international/phthalylsulfathiazole.html			dihydropteroate synthetase inhibitor	infectious disease|gastroenterology	dysentry|colitis	https://en.wikipedia.org/wiki/Phthalylsulfathiazole|https://en.wikipedia.org/wiki/Phthalylsulfathiazole
oxymetazoline	oxymetazoline	ocuclear|visine l.r.	Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C	Launched	FDA Orange Book: oxymetazoline hydrochloride	HTR1D|HTR1B|HTR2C|CYP2C19|ADRA2C|ADRA2B|ADRA2A|ADRA1D|ADRA1B|ADRA1A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=124|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=124|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=124|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070114|https://www.drugbank.ca/drugs/DB00935|https://www.drugbank.ca/drugs/DB00935|https://www.drugbank.ca/drugs/DB00935|https://www.drugbank.ca/drugs/DB00935|https://www.drugbank.ca/drugs/DB00935|https://www.drugbank.ca/drugs/DB00935	adrenergic receptor agonist	otolaryngology	nasal congestion	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1103cd8-344b-4a65-8a60-3c7be86d01a6
VX-765	VX-765		CCO[C@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01048255	CASP1|IL18R1	http://www.selleckchem.com/products/VX-765.html?gclid=CLSV3dH0xcwCFQhkhgod6tUKKA|https://citeline.informa.com/?query=#/drugs/details/24197	caspase inhibitor			
NG-nitro-arginine	NG-nitro-arginine	L-N-Nitroarginine|L-Nitroarginine|L-Nw-Nitroarginine|n (g)-nitro-l-arginine	N[C@@H](CCCNC(=N)N[N+]([O-])=O)C(O)=O	Phase 1	https://www.clinicaltrials.gov/ct2/show/NCT01324115	NOS3|NOS1|NOS2	https://www.drugbank.ca/drugs/DB04223|https://www.drugbank.ca/drugs/DB04223|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008851	nitric oxide synthase inhibitor			
CX-516	CX-516	CX516	O=C(N1CCCCC1)c1ccc2OCOc2c1	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT00235352			glutamate receptor modulator			
cyamemazine	cyamemazine	RP 7204|cyamepromazine|kyamepromazin	CC(CN(C)C)CN1c2ccccc2Sc2ccc(cc12)C#N	Launched	https://www.drugs.com/international/cyamemazine.html	HTR2A|HTR2C|HTR1A|HTR7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=84|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=84|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=84|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=84	serotonin receptor antagonist	neurology/psychiatry|neurology/psychiatry	schizophrenia|anxiety	https://en.wikipedia.org/wiki/Cyamemazine|https://en.wikipedia.org/wiki/Cyamemazine
ALX-5407	ALX-5407		CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O	Phase 1	http://www.nature.com/mp/journal/v12/n10/fig_tab/4002062t1.html	SLC6A9	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4618	Glycine transporter 1 inhibitor			
titanocene-dichloride	titanocene-dichloride		Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1	Phase 2	http://www.karger.com/Article/PDF/27075			apoptosis stimulant			
thiostrepton	thiostrepton			Veterinary Launched	http://www.drugs.com/international/thiostrepton.html	FOXM1	http://www.ncbi.nlm.nih.gov/pubmed/21860463	FOXM1 inhibitor|protein synthesis inhibitor	obstetrics/gynecology	mastitis	https://en.wikipedia.org/wiki/Thiostrepton
captamine	captamine		CN(C)CCS	Preclinical							
mepyramine	mepyramine	pyrilamine	COc1ccc(cc1)CN(CCN(C)C)c1ccccn1	Launched	FDA Orange Book: pyrilamine maleate	HRH1	https://www.drugbank.ca/drugs/DB06691	histamine receptor antagonist	otolaryngology|obstetrics/gynecology	common cold|menstrual pain	https://en.wikipedia.org/wiki/Mepyramine|https://en.wikipedia.org/wiki/Mepyramine
diiodothyropropionic-acid	diiodothyropropionic acid		OC(=O)CCc1cc(I)c(Oc2ccc(O)cc2)c(I)c1	Phase 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513545/			thyroid hormone stimulant			
prednisolone-sodium-phosphate	prednisolone sodium phosphate	hydeltrasol|orapred odt|pediapred|prednisolone sodium phosphate	C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COP(O)(O)=O	Launched	FDA Orange Book: prednisolone sodium phosphate	NR3C1	http://dgidb.genome.wustl.edu/interaction_claims/2bdd65c4-7d2a-4999-b6c9-e7fbb2c6e88b	glucocorticoid receptor agonist	allergy|pulmonary|ophthalmology|infectious disease|rheumatology|endocrinology|endocrinology|endocrinology|neurology/psychiatry|gastroenterology|gastroenterology|hematology|infectious disease|pulmonary|infectious disease|rheumatology|rheumatology	allergic rhinitis|asthma|contact dermatitis|mycosis|lupus|hypercalcemia|thyroiditis|congenital adrenal hyperplasia|multiple sclerosis|ulcerative colitis|enteritis|thrombocythemia|pneumonia|asthma|meningitis|psoriatic arthritis|rheumatoid arthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d46d10-00b9-45d5-81f9-e9b31083ae89|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d46d10-00b9-45d5-81f9-e9b31083ae89|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d46d10-00b9-45d5-81f9-e9b31083ae89|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d46d10-00b9-45d5-81f9-e9b31083ae89|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d46d10-00b9-45d5-81f9-e9b31083ae89|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d46d10-00b9-45d5-81f9-e9b31083ae89|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d46d10-00b9-45d5-81f9-e9b31083ae89|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d46d10-00b9-45d5-81f9-e9b31083ae89|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d46d10-00b9-45d5-81f9-e9b31083ae89|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d46d10-00b9-45d5-81f9-e9b31083ae89|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d46d10-00b9-45d5-81f9-e9b31083ae89|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d46d10-00b9-45d5-81f9-e9b31083ae89|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d46d10-00b9-45d5-81f9-e9b31083ae89|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d46d10-00b9-45d5-81f9-e9b31083ae89|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d46d10-00b9-45d5-81f9-e9b31083ae89|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d46d10-00b9-45d5-81f9-e9b31083ae89|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d46d10-00b9-45d5-81f9-e9b31083ae89
cortodoxone	cortodoxone	11-Deoxycortisol|Cortexolone|SK&F 3050		Phase 3	https://clinicaltrials.gov/ct2/show/NCT02682264	AR	https://sapienza.pure.elsevier.com/en/publications/biological-profile-of-cortexolone-17%CE%B1-propionate-cb-03-01-a-new-t	androgen receptor antagonist			
isometheptene-mucate	isometheptene-mucate	isometheptene	CNC(C)CCC=C(C)C	Launched	http://www.drugs.com/ppa/isometheptene-mucate-dichloralphenazone-acetaminophen.html	SLC18A2|ADRA1A	https://www.drugbank.ca/drugs/DB06706|https://www.drugbank.ca/drugs/DB06706		neurology/psychiatry	headache	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c82c7ea9-0941-4462-ae44-dbc60e76f92c
1-EBIO	1-EBIO		CCn1c2ccccc2[nH]c1=O	Preclinical		KCNN4|KCNN3|KCNN2|KCNN1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2314|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2314|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2314|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2314	potassium channel activator			
D-alpha-tocopheryl-succinate	D-alpha-tocopheryl-succinate	(+)-alpha-tocopheryl succinate|Alpha-Tocopheryl Succinate	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(O)=O)c(C)c(C)c2O1	Launched	http://en.wikipedia.org/wiki/Tocopherol						
carboxyamidotriazole	carboxyamidotriazole		NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00003869	CXCL8	https://books.google.com/books?id=2WUPzLlx0x0C&pg=PA31&lpg=PA31&dq=carboxyamidotriazole+CXCL8&source=bl&ots=MUqYO-NW3P&sig=XXpfdVjhE19eLww5PNeVxYNK5Go&hl=en&sa=X&ved=0ahUKEwj91vDqq6PPAhXD8x4KHXjIAnMQ6AEIHDAA#v=onepage&q=carboxyamidotriazole%20CXCL8&f=false	calcium channel blocker			
bropirimine	bropirimine	U-54,461	Nc1nc(-c2ccccc2)c(Br)c(=O)[nH]1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/10559611			interferon inducer			
enalaprilat	enalaprilat	MK-421|vasotec	C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	Launched	FDA Orange Book: enalaprilat	ACE	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6332	angiotensin converting enzyme inhibitor	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=895c7f90-2c53-43c3-ae4d-31d858e11eff
phensuximide	phensuximide	milontin	CN1C(=O)CC(C1=O)c1ccccc1	Launched	http://www.drugs.com/ingredient/phensuximide.html	CACNA1I|CACNA1H|CACNA1G	ChEMBL|ChEMBL|ChEMBL	succinimide antiepileptic	neurology/psychiatry	seizures	http://www.drugbank.ca/drugs/DB00832
2,3-cis/exo-pinanediol	pinanediol		CC1(C)C2CC1[C@](C)(O)[C@H](O)C2	Phase 1							
MK-0354	MK-0354		C1Cc2[nH]nc(-c3nnn[nH]3)c2C1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00337415	HCAR2|HCAR3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5784|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008666	niacin receptor agonist			
aliskiren-hemifumarate	aliskiren-hemifumarate	tekturna	COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC	Launched	FDA Orange Book: aliskiren hemifumarate	REN	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4812	renin inhibitor	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=833c7a0b-5f64-4363-94d5-9a179049113a
SB-218795	SB-218795		COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1	Preclinical		TACR3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5764	tachykinin antagonist			
TC-E-5002	TC-E-5002		ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1	Preclinical		KDM7A|KDM4A|KDM2A|KDM6A|KDM5A|KDM4C|PHF8	https://www.tocris.com/products/tc-e-5002_5089|https://www.tocris.com/products/tc-e-5002_5089|https://www.tocris.com/products/tc-e-5002_5089|https://www.tocris.com/products/tc-e-5002_5089|https://www.tocris.com/products/tc-e-5002_5089|https://www.tocris.com/products/tc-e-5002_5089|https://www.tocris.com/products/tc-e-5002_5089	histone demethylase inhibitor			
TC-E-5006	TC-E-5006		CC(C(O)=O)c1ccc(C(N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F	Preclinical		APP	https://www.tocris.com/products/tc-e-5006_4898	gamma secretase modulator			
golgicide-a	golgicide a		Fc1cc(F)c2NC([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1	Preclinical		GBF1	http://www.sigmaaldrich.com/catalog/product/sigma/g0923?lang=en&region=US	ARF inhibitor			
octamethyltrisiloxane	octamethyltrisiloxane		C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C	Preclinical							
isoniazid	isoniazid	Dow-isoniazid|Hyzyd|Laniazid|Stanozide|isonicotinylhydrazine|nydrazid|rimifon	NNC(=O)c1ccncc1	Launched	FDA Orange Book: isoniazid	CYP1A2|CYP2E1|CYP2C8|CYP3A4|CYP2C19	http://www.drugbank.ca/drugs/DB00951|http://www.drugbank.ca/drugs/DB00951|http://www.drugbank.ca/drugs/DB00951|http://www.drugbank.ca/drugs/DB00951|http://www.drugbank.ca/drugs/DB00951	FABI inhibitor	infectious disease	tuberculosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77795c31-1cdf-4a20-b4a1-cd15f5b310f1
dimethicone	dimethicone		C[Si](C)(C)O[Si](C)(C)C	Launched	http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM135688.pdf				dermatology	cosmetic	https://www.ewg.org/skindeep/ingredient/702011/DIMETHICONE/
ellagic-acid	ellagic acid	benzoaric acid|ellagic acid	Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00455416	BACE1|AKR1B1|PRKACA|PRKCB|PRKCA|SYK|CSNK2A1|GSK3B|CA14|CA12|CA5A|CA5B|SQLE|CA2|CA3|CA4|CA6|CA7|CA9|CA1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=113581|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=113581|https://www.drugbank.ca/drugs/DB08846|https://www.drugbank.ca/drugs/DB08846|https://www.drugbank.ca/drugs/DB08846|https://www.drugbank.ca/drugs/DB08846|https://www.drugbank.ca/drugs/DB08846|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006412|https://www.drugbank.ca/drugs/DB08846|https://www.drugbank.ca/drugs/DB08846|https://www.drugbank.ca/drugs/DB08846|https://www.drugbank.ca/drugs/DB08846|https://www.drugbank.ca/drugs/DB08846|https://www.drugbank.ca/drugs/DB08846|https://www.drugbank.ca/drugs/DB08846|https://www.drugbank.ca/drugs/DB08846|https://www.drugbank.ca/drugs/DB08846|https://www.drugbank.ca/drugs/DB08846|https://www.drugbank.ca/drugs/DB08846|https://www.drugbank.ca/drugs/DB08846	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor			
ferrostatin-1	ferrostatin-1		CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1	Preclinical				ferroptosis inhibitor			
fdcyd	fdcyd		Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00978250			DNA methyltransferase inhibitor			
degarelix	degarelix	FE200486 (AS ACETATE SALT)|firmagon	CC(C)CC(NC(=O)C(Cc1ccc(NC(N)=O)cc1)NC(=O)C(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)NC(=O)C(CO)NC(=O)C(Cc1cccnc1)NC(=O)C(Cc1ccc(Cl)cc1)NC(=O)C(Cc1ccc2ccccc2c1)NC(C)=O)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O	Launched	FDA Orange Book: degarelix acetate	GNRH1|GNRHR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=274806|https://www.drugbank.ca/drugs/DB06699	gonadotropin releasing factor hormone receptor antagonist	oncology	prostate cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab11dd8a-0fd9-4013-89ab-e114557c7e4b
MDL-27531	MDL-27531		Cn1c(nnc1S(C)(=O)=O)-c1ccccc1	Preclinical				glycine receptor agonist			
sparteine-sulfate	sparteine sulfate		C1CCN2C[C@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1	Launched	http://www.drugs.com/international/sparteine.html						
cladribine	cladribine	RWJ 26251|RWJ-26251|cladaribine|leustatin	Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1	Launched	FDA Orange Book: cladribine	POLE|RRM2B|RRM1|RRM2|ADA|POLE4|POLE2|POLE3|POLA1|PNP	https://www.drugbank.ca/drugs/DB00242|https://www.drugbank.ca/drugs/DB00242|https://www.drugbank.ca/drugs/DB00242|https://www.drugbank.ca/drugs/DB00242|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000565|https://www.drugbank.ca/drugs/DB00242|https://www.drugbank.ca/drugs/DB00242|https://www.drugbank.ca/drugs/DB00242|https://www.drugbank.ca/drugs/DB00242|https://www.drugbank.ca/drugs/DB00242	adenosine deaminase inhibitor|ribonucleotide reductase inhibitor	hematologic malignancy	hairy cell leukemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2592a9b-bca6-4a5a-89c2-855a0634d5fe
brexpiprazole	brexpiprazole	OPC-34712|rexulti	O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1	Launched	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850	HTR1A|HTR2A|DRD2|DRD3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=676533|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=676533|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7672|https://citeline.informa.com/?query=#/drugs/details/42637	dopamine receptor partial agonist	neurology/psychiatry|neurology/psychiatry	depression|schizophrenia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850
RU-SKI-43	RU-SKI-43		CCC(C)CNCC(=O)N1CCc2sccc2C1COc1cccc(C)c1	Preclinical		HHAT	https://www.tocris.com/products/ru-ski-43-hydrochloride_4886	hedgehog pathway inhibitor			
hydroxytoluic-acid	hydroxytoluic acid	3 MS|hydroxytoluic acid	Cc1cccc(C(O)=O)c1O	Preclinical							
boceprevir	boceprevir	SCH 503034|SCH-503034|victrelis	CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C	Launched	FDA Orange Book: boceprevir	CMA1|CTSF|CTSK|CTSA|CTSL|CTSS|CYP3A5|AKR1C3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011192|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011192|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011192|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7876|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011192|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011192|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=405424|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=405424	HCV inhibitor	infectious disease	hepatitis C	https://en.wikipedia.org/wiki/Boceprevir
kenpaullone	kenpaullone		Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1	Preclinical		CCNB1|GSK3B|CDK5|CDK2|CDK1|LCK	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004072|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6000|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004072|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=274528|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004072|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=274528	CDK inhibitor|glycogen synthase kinase inhibitor			
ozagrel	ozagrel	ozagrel sodium	OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1	Launched	http://www.drugs.com/international/Ozagrel.html	TBXAS1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001083	thromboxane synthase inhibitor	neurology/psychiatry	stroke	https://clinicaltrials.gov/ct2/show/NCT00200356
sorbic-acid	sorbic acid		CC=CC=CC(O)=O	Preclinical							
isobutamben	isobutamben		CC(C)COC(=O)c1ccc(N)cc1	Preclinical				local anesthetic			
guvacine	guvacine		OC(=O)C1=CCCNC1	Preclinical		SLC6A13|SLC6A12|SLC6A11|SLC6A1	https://www.drugbank.ca/drugs/DB08848|https://www.drugbank.ca/drugs/DB08848|https://www.drugbank.ca/drugs/DB08848|https://www.drugbank.ca/drugs/DB08848	GABA uptake inhibitor			
loreclezole	loreclezole	R 72063	Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/1909240	GABRB2|GABRB3	http://www.tocris.com/dispprod.php?ItemId=2253#.UthJpv15mf0|http://www.tocris.com/dispprod.php?ItemId=2253#.UthJpv15mf0	benzodiazepine receptor agonist			
norgestrel	norgestrel	ovrette	CC[C@]12CCC3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	Launched	FDA Orange Book: levonorgestrel, norgestrel	PGR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001208	progesterone receptor agonist	endocrinology	contraceptive	https://en.wikipedia.org/wiki/Norgestrel
acetriazoic-acid	acetriazoic acid	Acetrizoate|acetrizoic acid	CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I	Preclinical							
bisindolylmaleimide-ix	bisindolylmaleimide ix	Ro-31-8220|bisindolylmaleimide ix	Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12	Preclinical		MAPK14|MAPK12|MAPK11|LCK|AKT1|LRRK2|SIRT2|SIRT1|GSK3B|RPS6KB1|ROCK1|PRKCA|MAPK8|MAPK1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007005|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=158495|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=158495|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007005|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007005	PKC inhibitor			
L-368899	L-368899		Cc1ccccc1N1CCN(CC1)S(=O)(=O)CC12CCC(C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C	Phase 1	Pharmaprojects	AVPR2|OXT|OXTR|AVPR1A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009533|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=197239|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2249|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009533	oxytocin receptor antagonist			
CP-471474	CP-471474		CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO	Preclinical		MMP13|MMP1|MMP9|MMP3|MMP2	https://www.tocris.com/products/cp-471474_3780|https://www.tocris.com/products/cp-471474_3780|https://www.tocris.com/products/cp-471474_3780|https://www.tocris.com/products/cp-471474_3780|https://www.tocris.com/products/cp-471474_3780	matrix metalloprotease inhibitor			
travoprost	travoprost	AL-6221|izba|travatan|travatan z	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F	Launched	FDA Orange Book: travoprost	PTGFR	ChEMBL	prostanoid receptor agonist	ophthalmology|ophthalmology	ocular hypertension|glaucoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db08d5f3-6713-4372-a66c-fad3018ef5c6&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db08d5f3-6713-4372-a66c-fad3018ef5c6&audience=consumer
tretazicar	tretazicar	CB-1954	NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00746590	NQO2	https://www.drugbank.ca/drugs/DB04253	DNA replication inhibitor			
acenocoumarol	acenocoumarol	acenocoumarin|nicoumalone	CC(=O)CC(c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O	Launched	http://www.drugs.com/international/acenocoumarol.html	VKORC1	https://www.drugbank.ca/drugs/DB01418	vitamin K antagonist	hematology	deep vein thrombosis (DVT)	https://en.wikipedia.org/wiki/Acenocoumarol
imidurea	imidurea		OCN1C(NC(=O)NCNC(=O)NC2N(CO)C(=O)NC2=O)C(=O)NC1=O	Preclinical				other antibiotic			
meclizine	meclizine	antivert|meclozine	Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1	Launched	FDA Orange Book: meclizine hydrochloride	HRH1|NR1I3	https://www.drugbank.ca/drugs/DB00737|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2757	constitutive androstane receptor (CAR) agonist	gastroenterology|gastroenterology|neurology/psychiatry	nausea|vomiting|motion sickness	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d592399-3930-4d59-bdce-b6fa8ad21358|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d592399-3930-4d59-bdce-b6fa8ad21358|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d592399-3930-4d59-bdce-b6fa8ad21358
tyrphostin-AG-494	tyrphostin-AG-494	AG-494	Oc1ccc(cc1O)\C=C(/C#N)C(=O)Nc1ccccc1	Preclinical		EGFR	http://www.enzolifesciences.com/BML-EI228/ag-494/	EGFR inhibitor			
7-methylxanthine	7-methylxanthine	NSC-7861	Cn1cnc2nc(O)nc(O)c12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00263471			adenosine receptor antagonist			
phenazone	phenazone	Analgesine|Antipyrin|Phenazon|antipyrine	Cc1cc(=O)n(-c2ccccc2)n1C	Launched	http://en.wikipedia.org/wiki/Phenazone	PTGS1|PTGS2	https://www.drugbank.ca/drugs/DB01435|https://www.drugbank.ca/drugs/DB01435	cyclooxygenase inhibitor	neurology/psychiatry	pain relief	https://en.wikipedia.org/wiki/Phenazone
A-674563	A-674563		Cc1n[nH]c2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1	Preclinical		AKT1|PKIA|PRKACA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5655|https://www.drugbank.ca/drugs/DB08568|https://www.drugbank.ca/drugs/DB08568	AKT inhibitor			
clomipramine	clomipramine	anafranil	CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12	Launched	FDA Orange Book: clomipramine hydrochloride	GSTP1|HTR2C|HTR2B|HTR2A|CYP2C19|SLC6A3|SLC6A2|SLC6A4	https://www.drugbank.ca/drugs/DB01242|https://www.drugbank.ca/drugs/DB01242|https://www.drugbank.ca/drugs/DB01242|https://www.drugbank.ca/drugs/DB01242|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091440|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2398|https://www.drugbank.ca/drugs/DB01242|https://www.drugbank.ca/drugs/DB01242	serotonin transporter (SERT) inhibitor	neurology/psychiatry	obsessive compulsive disorder (OCD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7cee3fa-d05c-4702-8f75-f446627bdb49
clebopride	clebopride	LAS 9273|clebopride malate|cleboril	COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1	Launched	http://www.drugs.com/international/clebopride.html	ACHE|DRD2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011919|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011919	dopamine receptor antagonist	gastroenterology	nausea	http://www.drugs.com/international/clebopride.html
meclinertant	meclinertant		COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT00290953	NTSR1|NTSR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1582|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1582	neurotensin receptor antagonist			
eprodisate	eprodisate		OS(=O)(=O)CCCS(O)(=O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01215747	SAA1	http://www.selleckchem.com/products/eprodisate-disodium.html?gclid=CMyh04nmxs8CFYOFaQodnxINJQ	antiamyloidogenic agent|amyloid protein inhibitor			
flumatinib	flumatinib	HHGV-678	CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02204644	BCR|ABL1|PDGFRB	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=702641|http://www.medchemexpress.com/flumatinib-mesylate.html|http://www.medchemexpress.com/flumatinib-mesylate.html	Bcr-Abl kinase inhibitor			
LY2090314	LY2090314	LY-2090314	Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01214603	GSK3B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7958	glycogen synthase kinase inhibitor			
SKF-91488	SKF-91488		CN(C)CCCCSC(N)=N	Preclinical		HNMT	https://www.drugbank.ca/drugs/DB07106	histamine N-methyltransferase inhibitor			
phenprobamate	phenprobamate	MH-532	NC(=O)OCCCc1ccccc1	Launched	http://www.drugs.com/international/Phenprobamate.html			muscle relaxant	neurology/psychiatry|neurology/psychiatry	anxiety|muscle relaxant	http://www.drugs.com/international/phenprobamate.html|http://www.drugs.com/international/phenprobamate.html
trimethadione	trimethadione	tridione|troxidone	CN1C(=O)OC(C)(C)C1=O	Launched	FDA Orange Book: trimethadione	CACNA1H|CACNA1G|CACNA1I	ChEMBL|ChEMBL|ChEMBL	oxazolidine antiepileptic	neurology/psychiatry	seizures	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9322f58-ffcc-4831-5381-93a535b49a09
RRx-001	RRx-001		[O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02096354	G6PD	https://www.medchemexpress.com/rrx-001.html?gclid=CJ2Rmqf1vs8CFUgmhgodoMgBGA	glucose 6-phosphate dehydrogenase inhibitor			
mycophenolate-mofetil	mycophenolate mofetil	RS-61443|cellcept|mycophenolate mofetil	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1	Launched	FDA Orange Book: mycophenolate mofetil, mycophenolate mofetil hydrochloride	IMPDH2|IMPDH1|HCAR2	ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=144096	dehydrogenase inhibitor|inositol monophosphatase inhibitor	transplant	organ rejection	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=209efe01-7908-46e4-a964-0665078c0acd
dexmedetomidine	dexmedetomidine		C[C@H](c1cnc[nH]1)c1cccc(C)c1C	Launched	FDA Orange Book: dexmedetomidine hydrochloride	ADRA2B|ADRA2C|ADRA2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=521|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=521|https://www.drugbank.ca/drugs/DB00633	adrenergic receptor agonist			
chlorhexidine	chlorhexidine	Avagard|bioscrub|chg scrub|chlorhexidine gluconate|cida-stat|dyna-hex|exidine|hibiclens|hibistat|peridex|periochip|pharmaseal scrub care	Clc1ccc(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)cc1	Launched	FDA Orange Book: chlorhexidine gluconate			membrane integrity inhibitor	dermatology|infectious disease|dental	cosmetic|skin infections|gingivitis	https://en.wikipedia.org/wiki/Chlorhexidine|https://en.wikipedia.org/wiki/Chlorhexidine|https://en.wikipedia.org/wiki/Chlorhexidine
alfacalcidol	alfacalcidol		CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	Launched	http://www.drugs.com/international/Alfacalcidol.html	CYP27B1|VDR	https://www.drugbank.ca/drugs/DB01436|https://www.drugbank.ca/drugs/DB01436	vitamin D receptor agonist	endocrinology	vitamin D deficiency	https://en.wikipedia.org/wiki/Alfacalcidol
Ro-4987655	Ro-4987655	CH-4987655	OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00817518	MAP2K1	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=633506	MEK inhibitor			
talnetant	talnetant	SB-2234|SB-223412	CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00049946	TACR3|TACR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2132|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2132	tachykinin antagonist			
malathion	malathion	Cythion|Organoderm|Prioderm|ovide	CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC	Launched	FDA Orange Book: malathion	ACHE|BCHE	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000895|https://www.drugbank.ca/drugs/DB00772	cholinesterase inhibitor	infectious disease	lice	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d792c1cb-ec9b-4942-8096-101d01293cea
oxantel	oxantel		CN1CCCN=C1\C=C\c1cccc(O)c1	Phase 3	http://www.nejm.org/doi/full/10.1056/NEJMoa1301956			anthelmintic agent			
EDTMP	EDTMP		OP(O)(=O)CN(CCN(CP(O)(O)=O)CP(O)(O)=O)CP(O)(O)=O	Preclinical				chelating agent			
SDZ-WAG-994	SDZ-WAG-994		CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/10383546	ADORA1	https://www.tocris.com/dispprod.php?ItemId=154424#.VyutnGQrJZI	adenosine receptor agonist			
adefovir	adefovir	GS-0393	Nc1ncnc2n(CCOCP(O)(O)=O)cnc12	Launched	FDA Orange Book: adefovir dipivoxil			DNA polymerase inhibitor	infectious disease	hepatitis B	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e047f3b2-feae-4c5e-9d07-1fefb4c0ec25
homosalate	homosalate	heliophan|homomenthyl salicylate	CC1CC(CC(C)(C)C1)OC(=O)c1ccccc1O	Preclinical				HSP inducer			
proguanil	proguanil	chloroguanide	CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1	Launched	http://en.wikipedia.org/wiki/Proguanil	DHFR|CYP2C19	https://www.drugbank.ca/drugs/DB01131|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=258517	dihydrofolate reductase inhibitor	infectious disease	malaria	https://en.wikipedia.org/wiki/Proguanil
A-1070722	A-1070722		COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1	Preclinical		PTGER2|GSK3A|GSK3B	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=761866|http://www.sigmaaldrich.com/catalog/product/sigma/sml0863?lang=en&region=US|http://www.sigmaaldrich.com/catalog/product/sigma/sml0863?lang=en&region=US	glycogen synthase kinase inhibitor			
NVP-BSK805	NVP-BSK805		Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1	Preclinical		JAK2	http://www.selleckchem.com/products/nvp-bsk805.html	JAK inhibitor			
pelitinib	pelitinib	EKB-569|WAY-EKB-569	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00067548	ERBB2|EGFR	https://citeline.informa.com/?query=#/drugs/details/24961|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7644	EGFR inhibitor			
L-Quisqualic-acid	L-Quisqualic acid	Quisqualate|quisqualic acid	N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O	Preclinical		GRIK1|GRIK2|GRIA2|GRM8|GRM7|GRM3|GRM5|GRM2|GRM1|FOLH1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007532|https://www.drugbank.ca/drugs/DB02999|https://www.drugbank.ca/drugs/DB02999|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007532|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007532|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007532|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007532|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007532|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007532|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007532	glutamate receptor agonist			
zibotentan	zibotentan	ZD-4054|ZD4054	COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00626548	EDNRA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3539	endothelin receptor antagonist			
Ro-3306	Ro-3306		O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1	Preclinical		CDK1	https://www.tocris.com/products/ro-3306_4181	CDK inhibitor			
salazodine	salazodine		COc1ccc(NS(=O)(=O)c2ccc(cc2)N=Nc2ccc(O)c(c2)C(O)=O)nn1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/441953						
cloxyquin	cloxyquin	cloxiquine	Oc1ccc(Cl)c2cccnc12	Preclinical		KCNK18	http://www.ncbi.nlm.nih.gov/pubmed/24513205	potassium channel activator			
perchlozone	perchlozone		NC(=S)NN=Cc1ccncc1	Launched	http://www.ncbi.nlm.nih.gov/pubmed/25704063				infectious disease	tuberculosis	http://en.perchlozone.info/
benzyldimethylhexadecylammonium	benzyldimethylhexadecylammonium	cetalkonium	CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1	Preclinical				cationic surfactant			
propafenone	propafenone	GNF-Pf-4594|rythmol|rythmol sr	CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1	Launched	FDA Orange Book: propafenone hydrochloride	SCN5A|ADRB2|ADRB1|KCNH2|KCNK3|KCNK2|KCNA5	https://www.drugbank.ca/drugs/DB01182|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2561|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2561|https://www.drugbank.ca/drugs/DB01182|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091524|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091524|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2561	antiarrhythmic	cardiology|cardiology|cardiology	atrial fibrillation (AF)|ventricular tachycardia (VT)|ventricular arrhythmias	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a313c111-e539-47bc-9d57-c3767f74bcca|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a313c111-e539-47bc-9d57-c3767f74bcca|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a313c111-e539-47bc-9d57-c3767f74bcca
levomenthol	levomenthol	Leavo-menthol|l-menthol		Launched	http://www.drugs.com/international/levomenthol.html	TRPA1|TRPM8|TRPV3|OPRK1	https://www.drugbank.ca/drugs/DB00825|https://www.drugbank.ca/drugs/DB00825|https://www.drugbank.ca/drugs/DB00825|https://www.drugbank.ca/drugs/DB00825		neurology/psychiatry	pain relief	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f34872c9-91b9-49db-8e41-5b54a069284a
lobenzarit	lobenzarit		OC(=O)c1ccccc1Nc1cc(Cl)ccc1C(O)=O	Launched	http://www.drugs.com/international/Lobenzarit.html			immunosuppressant	rheumatology	rheumatoid arthritis	https://en.wikipedia.org/wiki/Lobenzarit
brivaracetam	brivaracetam	UCB 34714|briviact	CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1	Launched	FDA Orange Book: brivaracetam	SV2A|SLC8A1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000730|https://citeline.informa.com/?query=#/drugs/details/27812	voltage-gated sodium channel blocker	neurology/psychiatry	seizures	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3cf2f439-0e97-443e-8e33-25ecef616f6c
ligustilide	ligustilide	(Z)-Ligustilide	CCC\C=C1OC(=O)C2=C/1CCC=C2	Preclinical		TNF	https://www.ncbi.nlm.nih.gov/pubmed/24560902	tumor necrosis factor production inhibitor			
7-nitroindazole	7-nitroindazole		[O-][N+](=O)c1cccc2cn[nH]c12	Preclinical		NOS2|NOS1|NOS3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002417|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5127|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002417	nitric oxide synthase inhibitor			
saquinavir	saquinavir	fortovase|invirase		Launched	FDA Orange Book: saquinavir, saquinavir mesylate	CYP3A4|CYP3A5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4813|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=162315	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09f4482d-75a8-4c98-bd00-08108da675c8
P276-00	P276-00		CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00835419	CDK1|CDK4|CDK9	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7934|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7934|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7934	CDK inhibitor			
1,5-dicaffeoylquinic-acid	1,5-dicaffeoylquinic acid		O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)\C=C\c1ccc(O)c(O)c1)C(O)=O	Phase 1							
cephalomannine	cephalomannine		C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1	Preclinical				DNA polymerase inhibitor			
ectoine-zwitterion	ectoine-zwitterion		OC(=O)[C@@H]1CCNC(=C)N1	Preclinical							
C646	C646		CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O	Preclinical		EP300	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7004	histone acetyltransferase inhibitor			
benzoclidine	benzoclidine		O=C(OC1CN2CCC1CC2)c1ccccc1	Preclinical							
CGP-53353	CGP-53353		Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1	Preclinical		PRKCB|EGFR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5163|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003638	EGFR inhibitor|PKC inhibitor			
16,16-dimethylprostaglandin-e2	16,16-dimethylprostaglandin-e2		CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O	Phase 2				prostanoid receptor agonist			
ritodrine	ritodrine	yutopar		Launched	FDA Orange Book: ritodrine hydrochloride	ADRB2	https://www.drugbank.ca/drugs/DB00867	adrenergic receptor agonist	obstetrics/gynecology	premature labor	https://en.wikipedia.org/wiki/Ritodrine
trovafloxacin	trovafloxacin	trovan	N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	TOP2A	https://www.drugbank.ca/drugs/DB00685	bacterial DNA gyrase inhibitor			
liranaftate	liranaftate		COc1cccc(n1)N(C)C(=S)Oc1ccc2CCCCc2c1	Launched	http://www.drugs.com/international/Liranaftate.html			fungal squalene epoxidase inhibitor	infectious disease	fungal infection	http://www.drugs.com/international/liranaftate.html
dydrogesterone	dydrogesterone	gynorest|isopregnenone	CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C	Launched	FDA Orange Book: dydrogesterone	PGR	ChEMBL	progesterone receptor agonist	obstetrics/gynecology	infertility	https://en.wikipedia.org/wiki/Dydrogesterone
A-804598	A-804598		C[C@H](\N=C(\NC#N)Nc1cccc2ncccc12)c1ccccc1	Preclinical		P2RX7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4121	purinergic receptor antagonist			
amthamine	amthamine		Cc1nc(N)sc1CCN	Preclinical		HRH2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4025	histamine receptor agonist			
GS-9620	GS-9620		CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02166047	TLR7	http://medchemexpress.com/GS-9620.html?gclid=CPmGn7TTvswCFVZahgodviMFMQ	toll-like receptor agonist			
pidolic-acid	pidolic acid	pyroglutamic acid	OC(=O)[C@@H]1CCC(=O)N1	Launched	http://en.wikipedia.org/wiki/Pyroglutamic_acid	TFF2|HCRT|VEGFA|AMY2A|AMY2B|AMY1A|ADAM28|ANG|CCL8|IGLC1|KRTAP5-2	https://www.drugbank.ca/drugs/DB03088|https://www.drugbank.ca/drugs/DB03088|https://www.drugbank.ca/drugs/DB03088|https://www.drugbank.ca/drugs/DB03088|https://www.drugbank.ca/drugs/DB03088|https://www.drugbank.ca/drugs/DB03088|https://www.drugbank.ca/drugs/DB03088|https://www.drugbank.ca/drugs/DB03088|https://www.drugbank.ca/drugs/DB03088|https://www.drugbank.ca/drugs/DB03088|https://www.drugbank.ca/drugs/DB03088		dermatology	xerosis cutis	https://en.wikipedia.org/wiki/Pyroglutamic_acid
BU-239	BU-239		C1CN=C(N1)c1cnc2ccccc2n1	Preclinical				imidazoline receptor ligand|imidazoline receptor agonist			
kanamycin	kanamycin	kanamycin sulfate	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	Launched	FDA Orange Book: kanamycin sulfate			bacterial 30S ribosomal subunit inhibitor	infectious disease	gram-negative bacterial infections	https://en.wikipedia.org/wiki/Kanamycin#Medical_uses
AMG-208	AMG-208		COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00813384	MET	https://www.drugbank.ca/drugs/DB08079	tyrosine kinase inhibitor			
nifurtimox	nifurtimox		CC1CS(=O)(=O)CCN1N=Cc1ccc(o1)[N+]([O-])=O	Launched	http://www.drugs.com/international/Nifurtimox.html			DNA inhibitor	infectious disease|infectious disease	Chagas disease|African trypanosomiasis	https://en.wikipedia.org/wiki/Nifurtimox#Medical_uses|https://en.wikipedia.org/wiki/Nifurtimox#Medical_uses
clemizole	clemizole	AL 20 [AS HYDROCHLORIDE]|clemizole hydrochloride	Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1	Launched	http://www.drugs.com/international/clemizole-penicillin.html			HCV inhibitor	allergy	allergic rhinitis	https://en.wikipedia.org/wiki/Clemizole
amfenac	amfenac		Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1	Launched	http://www.drugs.com/international/amfenac.html	PTGS1|PTGS2	http://www.ebi.ac.uk/chebi/searchId.do;jsessionid=7DDAA8921FDFCC38658ABFD22C33A288?chebiId=CHEBI%3A75915|http://www.ebi.ac.uk/chebi/searchId.do;jsessionid=7DDAA8921FDFCC38658ABFD22C33A288?chebiId=CHEBI%3A75915	cyclooxygenase inhibitor	neurology/psychiatry	pain relief	https://en.wikipedia.org/wiki/Amfenac
sanazole	sanazole		COCCNC(=O)Cn1cnc(n1)[N+]([O-])=O	Phase 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2943094/						
selexipag	selexipag	ACT-293987|ACT-293987; NS-304|NS-304|uptravi	CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01106014	PTGIR	https://www.tocris.com/dispprod.php?ItemId=219987#.V-1SYZMrLy8	platelet aggregation inhibitor|IP1 prostacyclin receptor agonist			
naltriben	naltriben		Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1oc2ccccc2c1C[C@@]35O	Preclinical		OPRM1|OPRK1|OPRD1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1640|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1640|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1640	opioid receptor antagonist			
alpha-tochopherol	alpha-tochopherol		CC(C)CCCC(C)CCCC(C)CCCC1(C)CCc2c(C)c(O)c(C)c(C)c2O1	Launched	http://en.wikipedia.org/wiki/Alpha-Tocopherol			antioxidant	endocrinology	vitamin E deficiency	https://en.wikipedia.org/wiki/Alpha-Tocopherol
fendiline	fendiline		CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1	Preclinical		HTR2B	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011273	calcium channel blocker			
canagliflozin	canagliflozin	invokana	Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	Launched	FDA Orange Book: canagliflozin	CYP2C8|CYP2B6|SLC5A1|SLC5A2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=455923|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=455923|https://www.drugbank.ca/drugs/DB08907|https://www.drugbank.ca/drugs/DB08907	sodium/glucose cotransporter inhibitor	endocrinology	diabetes mellitus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9057d3b-b104-4f09-8a61-c61ef9d4a3f3
cicloprofen	cicloprofen	SQ 20824	CC(C(O)=O)c1ccc-2c(Cc3ccccc-23)c1	Preclinical		PTGS2|PTGS1	http://www.genome.jp/dbget-bin/www_bget?drug+D03489|http://www.genome.jp/dbget-bin/www_bget?drug+D03489	cyclooxygenase inhibitor			
zopolrestat	zopolrestat		OC(=O)C=C1NN(Cc2nc3cc(ccc3s2)C(F)(F)F)C(=O)c2ccccc12	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/14747227						
L-threonine	L-threonine	l-threonine|threonine	C[C@@H](O)[C@H](N)C(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02145949	TARS|THNSL1|TARS2	https://www.drugbank.ca/drugs/DB00156|https://www.drugbank.ca/drugs/DB00156|https://www.drugbank.ca/drugs/DB00156				
piboserod	piboserod	SB-207266	CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00421746	HTR2B|HTR4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=225|https://www.drugbank.ca/drugs/DB04873	serotonin receptor antagonist			
PI4KIII-beta-inhibitor-1	PI4KIII-beta-inhibitor-1		COc1ccc(cc1S(=O)(=O)Nc1ccc(O)cc1)-c1sc(NC(=O)C(C)(C)C)nc1C	Preclinical		PI4K2B	https://www.medchemexpress.com/PI4KIIIbeta-IN-10.html	PI4K inhibitor			
falecalcitriol	falecalcitriol	flocalcitriol	C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	Launched	http://www.drugs.com/international/Falecalcitriol.html	VDR	https://docs.google.com/spreadsheets/d/1AjYYAQ_-qbcsgiQj0w9S63eTkEAr8IUsRn_tDHV9HTk/edit#gid=1365307415	vitamin D receptor agonist	endocrinology	hyperparathyroidism	http://www.drugs.com/international/falecalcitriol.html
algestone-acetophenide	algestone acetophenide	SO 15,101|algestone acetophenide|deladroxone|dihydroxyprogesterone acetophenide|droxone	CC(=O)[C@@]12OC(C)(O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]21C)c1ccccc1	Launched	http://www.drugs.com/international/algestone-acetophenide.html				endocrinology	contraceptive	https://en.wikipedia.org/wiki/Algestone_acetophenide
3-amino-benzamide	3-amino-benzamide	3-Aminobenzamide|3-Aminobenzaminde	NC(=O)c1cccc(N)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00271167	PARP1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000058	PARP inhibitor			
carbinoxamine	carbinoxamine	Palgic|carbinoxamine maleate|clistin|karbinal er	CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1	Launched	FDA Orange Book: carbinoxamine maleate	HRH1	https://www.drugbank.ca/drugs/DB00748	histamine receptor antagonist	allergy|ophthalmology|otolaryngology|dermatology	allergic rhinitis|conjunctivitis|vasomotor rhinitis|dermatographism	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1741b4f2-af49-43fe-8319-7b8a38fa25d2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1741b4f2-af49-43fe-8319-7b8a38fa25d2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1741b4f2-af49-43fe-8319-7b8a38fa25d2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1741b4f2-af49-43fe-8319-7b8a38fa25d2
acedapsone	acedapsone	CI 556|CN-1883|PAM-MR-1165|dadds|hansolar	CC(=O)Nc1ccc(cc1)S(=O)(=O)c1ccc(NC(C)=O)cc1	Launched	http://en.wikipedia.org/wiki/Acedapsone				infectious disease	leprosy	https://en.wikipedia.org/wiki/Acedapsone
kakonein	kakonein		OCC1OC(C(O)C(O)C1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/22883272			GABA receptor antagonist|serotonin receptor antagonist			
donepezil	donepezil	E-2020|aricept|aricept odt	COc1cc2CC(CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC	Launched	FDA Orange Book: donepezil hydrochloride	HTR2A|ACHE	https://www.drugbank.ca/drugs/DB00843|https://www.drugbank.ca/drugs/DB00843	acetylcholinesterase inhibitor	neurology/psychiatry	Alzheimer's disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b1b7b5f-2f20-418c-b1ac-794c2ef1ce5e
formononetin	formononetin	NSC-93360	COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O	Preclinical		ADH1C|SLC5A2	http://www.scbt.com/datasheet-202614.html|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007648	alcohol dehydrogenase inhibitor			
2-pyridylethylamine	2-pyridylethylamine	2-(2-Aminoethyl)Pyridine	NCCc1ccccn1	Preclinical		HRH1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1197	histamine receptor agonist			
deferoxamine-mesylate	deferoxamine mesylate	deferoxamine|desferal|desferrioxamine	CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN	Launched	FDA Orange Book: deferoxamine mesylate			chelating agent	hematology|hematology	acute iron intoxication|iron overload	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9ab6b1c-98d0-4373-0e9b-b10cb4a67543|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9ab6b1c-98d0-4373-0e9b-b10cb4a67543
propantheline	propantheline	pro-banthine|propantheline bromide	CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C	Launched	FDA Orange Book: propantheline bromide	CHRM1|CHRM2|CHRM3|CHRM4	https://www.drugbank.ca/drugs/DB00782|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=329|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=329|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=329	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84a920c8-b637-4741-b9b2-fc607e245ce0
piketoprofen	piketoprofen		CC(C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1	Launched	http://www.drugs.com/international/piketoprofen.html			cyclooxygenase inhibitor	neurology/psychiatry	pain relief	http://www.drugs.com/international/piketoprofen.html
IEM1460	IEM1460		C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2	Preclinical		GRIA2	http://www.tocris.com/dispprod.php?ItemId=56829#.VgGwc2RVhHw	glutamate receptor antagonist			
PR-619	PR-619		Nc1nc(N)c(SC#N)cc1SC#N	Preclinical				DUB inhibitor			
mazindol	mazindol	42-548|mazanor|sanorex	OC1(N2CCN=C2c2ccccc12)c1ccc(Cl)cc1	Launched	FDA Orange Book: mazindol	SLC6A2|SLC6A3|SLC6A4	ChEMBL|ChEMBL|ChEMBL	dopamine reuptake inhibitor|selective serotonin reuptake inhibitor (SSRI)	genetics	duchenne muscular dystrophy (DMD)	https://en.wikipedia.org/wiki/Mazindol
glasdegib	glasdegib	PF-04449913|PF-4449913	CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N	Phase 2	https://clinicaltrials.gov/show/NCT02367456	SMO|IHH|DHH	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8201|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=675843|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=675843	hedgehog pathway inhibitor			
dihydrotachysterol	dihydrotachysterol		CC(C)C(C)\C=C\C(C)C1CCC2C1(C)CCC\C2=C/C=C1\CC(O)CCC1C	Launched	http://www.drugs.com/dihydrotachysterol.html	VDR	https://www.drugbank.ca/drugs/DB01070	vitamin analog	orthopedics|endocrinology|endocrinology	rickets|hypocalcemia|osteomalacia	https://www.drugbank.ca/drugs/DB01070|https://www.drugbank.ca/drugs/DB01070|https://www.drugbank.ca/drugs/DB01070
clobutinol	clobutinol	KAT 256 [AS HYDROCHLORIDE]|clobutinol hydrochloride	CC(CN(C)C)C(C)(O)Cc1ccc(Cl)cc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs			antitussive			
aceclofenac	aceclofenac		OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl	Launched	http://www.drugs.com/international/aceclofenac.html	PTGS2	http://www.genome.jp/dbget-bin/www_bget?dr:D01545	prostanoid receptor antagonist	rheumatology|rheumatology|rheumatology|rheumatology|rheumatology|rheumatology	rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|periarthritis|lumbago|ischiadynia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a023942-01e8-4849-aa3c-1a640ffc7fd3|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a023942-01e8-4849-aa3c-1a640ffc7fd3|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a023942-01e8-4849-aa3c-1a640ffc7fd3|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a023942-01e8-4849-aa3c-1a640ffc7fd3|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a023942-01e8-4849-aa3c-1a640ffc7fd3|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a023942-01e8-4849-aa3c-1a640ffc7fd3
WAY-170523	WAY-170523		Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO	Preclinical		MMP13	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5288	metalloproteinase inhibitor			
alibendol	alibendol	H 3774	COc1cc(CC=C)cc(C(=O)NCCO)c1O	Launched	http://www.drugs.com/international/Alibendol.html			antispasmodic	gastroenterology	bile stimulation	http://www.drugs.com/international/alibendol.html
TC-FPR-43	TC-FPR-43		CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C	Preclinical		FPR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5831	formyl peptide receptor agonist			
valrubicin	valrubicin	AD 32|AD-32|valstar|valstar preservative free	CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1	Launched	FDA Orange Book: valrubicin	TOP2A	ChEMBL	DNA inhibitor|topoisomerase inhibitor	oncology	bladder cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e96f30a0-6662-11de-8f80-0002a5d5c51b
furazolidone	furazolidone	Furall|furoxone|nifurazolidone	[O-][N+](=O)c1ccc(\C=N\N2CCOC2=O)o1	Launched	FDA Orange Book: furazolidone			bacterial DNA inhibitor	gastroenterology|gastroenterology|infectious disease	diarrhea|enteritis|cholera	https://en.wikipedia.org/wiki/Furazolidone|https://en.wikipedia.org/wiki/Furazolidone|https://en.wikipedia.org/wiki/Furazolidone
meclofenoxate	meclofenoxate	centrophenoxine|clophenoxate|meclofenoxate hydrochloride	CN(C)CCOC(=O)COc1ccc(Cl)cc1	Launched	http://www.drugs.com/international/meclofenoxate.html			nootropic agent	neurology/psychiatry|neurology/psychiatry	senile dementia|Alzheimer's disease	https://en.wikipedia.org/wiki/Meclofenoxate|https://en.wikipedia.org/wiki/Meclofenoxate
GR125487	GR125487	GR-125487	COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1	Preclinical		HTR4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=248	serotonin receptor antagonist			
sarcosine	sarcosine	Methylamino-Acetic Acid	CNCC(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00977353	SLC6A9	http://molpharm.aspetjournals.org/content/74/6/1705.full	Glycine transporter 1 inhibitor			
linagliptin	linagliptin	BI 1356 BS|BI-1356|BS 1356 BS|Trajenta|tradjenta	CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1	Launched	FDA Orange Book: linagliptin	DPP4	ChEMBL	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6dd9b86-0d18-95d4-2bc7-05591bfdd597
BADGE	BADGE		CC(C)(c1ccc(OCC2CO2)cc1)c1ccc(OCC2CO2)cc1	Preclinical		PPARG	http://www.scbt.com/datasheet-202487-badge.html	PPAR receptor antagonist			
U-0521	U-0521		CC(C)C(=O)c1ccc(O)c(O)c1	Preclinical		COMT	http://www.abcam.com/u-0521-ab141565.html	catechol O methyltransferase inhibitor			
L-670596	L-670596		CS(=O)(=O)c1ccc(Cn2c3C(CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1	Preclinical				prostanoid receptor antagonist			
chlorophyllin	chlorophyllin		CCc1c(C)c2cc3[nH]c(cc4nc([C@@H](CCC(O)=O)[C@@H]4C)c(CC(O)=O)c4nc(cc1[nH]2)c(C)c4C(O)=O)c(C)c3C=C	Preclinical					urology	urinary incontinence	https://en.wikipedia.org/wiki/Chlorophyllin
ropinirole	ropinirole	SK&F 101468|requip|requip xl	CCCN(CCC)CCc1cccc2NC(=O)Cc12	Launched	FDA Orange Book: ropinirole hydrochloride	DRD1|DRD2|DRD3|DRD4|DRD5|HTR2A|HTR2B|HTR2C|HTR1D|HTR1A|HTR1B|ADRA2C|ADRA2B|ADRA2A	https://www.drugbank.ca/drugs/DB00268|https://www.drugbank.ca/drugs/DB00268|https://www.drugbank.ca/drugs/DB00268|https://www.drugbank.ca/drugs/DB00268|https://www.drugbank.ca/drugs/DB00268|https://www.drugbank.ca/drugs/DB00268|https://www.drugbank.ca/drugs/DB00268|https://www.drugbank.ca/drugs/DB00268|https://www.drugbank.ca/drugs/DB00268|https://www.drugbank.ca/drugs/DB00268|https://www.drugbank.ca/drugs/DB00268|https://www.drugbank.ca/drugs/DB00268|https://www.drugbank.ca/drugs/DB00268|https://www.drugbank.ca/drugs/DB00268	dopamine receptor agonist	neurology/psychiatry|neurology/psychiatry	Parkinson's Disease|restless leg syndrome	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5ce07b9-ad0d-4b72-9daf-8662775af093|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5ce07b9-ad0d-4b72-9daf-8662775af093
lorlatinib	lorlatinib	PF-06463922	C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02927340	ALK	https://jhoonline.biomedcentral.com/articles/10.1186/s13045-016-0251-8	ALK tyrosine kinase receptor inhibitor			
detomidine	detomidine		Cc1cccc(Cc2c[nH]cn2)c1C	Launched	https://clinicaltrials.gov/ct2/show/NCT00932386	ADRA2A	https://en.wikipedia.org/wiki/Detomidine	adrenergic receptor agonist	neurology/psychiatry	sedative	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8fb7886c-7762-4b72-989b-0fe8e963b4b8
GP2a	GP2a		Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1	Preclinical		CNR2	https://www.tocris.com/dispprod.php?ItemId=5209#.Vyj9VWQrImI	cannabinoid receptor agonist			
metaphit	metaphit	methaphit	S=C=Nc1cccc(c1)C1(CCCCC1)N1CCCCC1	Preclinical				phencyclidine receptor acylator			
flumecinol	flumecinol		CCC(O)(c1ccccc1)c1cccc(c1)C(F)(F)F	Launched	Pharmaprojects						
clobenpropit	clobenpropit		Clc1ccc(CNC(=N)SCCCc2c[nH]cn2)cc1	Preclinical		HRH2|HRH3|HRH1|HRH4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1223|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1223|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1223|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1223	histamine receptor antagonist			
3-alpha-bis-(4-fluorophenyl)-methoxytropane	3-alpha-bis-(4-fluorophenyl)-methoxytropane	difluorobenztropine	CN1C2CCC1CC(C2)OC(c1ccc(F)cc1)c1ccc(F)cc1	Preclinical		SLC6A2|SLC6A3|SLC6A4|CHRM1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005986|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005986|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005986|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005986	dopamine uptake inhibitor			
sirolimus	sirolimus	AY-22989|WY-090217|rapamune|rapamycin		Launched	FDA Orange Book: sirolimus, temsirolimus	CCR5|FGF2|FKBP1A|MTOR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=175652|https://www.drugbank.ca/drugs/DB00877|ChEMBL|https://www.drugbank.ca/drugs/DB00877	mTOR inhibitor	transplant|pulmonary	organ rejection|lymphangioleiomyomatosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3275b824-3f82-4151-2ab2-0036a9ba0acc|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3275b824-3f82-4151-2ab2-0036a9ba0acc
PIM-1-Inhibitor-2	PIM-1-Inhibitor-2		Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1	Preclinical		PIM1	https://www.drugbank.ca/drugs/DB08707	Pim kinase inhibitor			
tracazolate	tracazolate	ICI 136,753	CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12	Phase 2	Pharmaprojects	GABRA1	http://www.tocris.com/dispprod.php?ItemId=44570#.UuFol_30BaE	GABA receptor modulator			
PPT	PPT	Propylpyrazoletriol	CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1	Preclinical		ESR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2819	estrogen receptor agonist			
dexniguldipine	dexniguldipine	niguldipine	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1	Phase 2	http://adisinsight.springer.com/drugs/800002528	CALM1|ADORA3|PRKCA	https://citeline.informa.com/?query=#/drugs/details/5531|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=463|https://citeline.informa.com/?query=#/drugs/details/5531	calmodulin antagonist			
RG7112	RG7112	RG-7112	CCOc1cc(ccc1C1=NC(C)(c2ccc(Cl)cc2)C(C)(N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1)c1ccc(Cl)cc1)C(C)(C)C	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00559533	MDM2	https://www.medchemexpress.com/RG7112.html?gclid=CI-Jt4TYpNICFZGLaQodgsMDwQ	MDM inhibitor			
dolastatin-10	dolastatin-10		CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00005579	TUBB	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006861	tubulin polymerization inhibitor			
LY2228820	LY2228820	LY-2228820|LY22288220|ralimetinib	CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1[nH]c(nc1-c1ccc(F)cc1)C(C)(C)C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02322853	MAPK14	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7959	p38 MAPK inhibitor			
idoxuridine	idoxuridine	5IUDR|ALLERGAN 211|Allergan-211|IDU|SK&F 14287|SK&F-14287|dendrid|herplex|stoxil	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O	Launched	FDA Orange Book: idoxuridine			DNA directed DNA polymerase inhibitor	infectious disease	virus herpes simplex (HSV)	https://en.wikipedia.org/wiki/Idoxuridine#Clinical_use
MTPG	MTPG		CC(N)(C(O)=O)c1ccc(cc1)-c1nnn[nH]1	Preclinical		GRM3|GRM2	http://www.tocris.com/dispprod.php?ItemId=1669#.VglmEWRVhHw|http://www.tocris.com/dispprod.php?ItemId=1669#.VglmEWRVhHw	glutamate receptor antagonist			
roscovitine	roscovitine	AL-39256|CYC-202|seliciclib	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02160730	CDK7|CDK9|CDK2|CDK5|CDK1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=309808|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6035|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6035|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=309808|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=309808	CDK inhibitor			
pimecrolimus	pimecrolimus	elidel	CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC	Launched	FDA Orange Book: pimecrolimus	MTOR|FKBP1A|CYP3A5	https://www.drugbank.ca/drugs/DB00337|https://www.drugbank.ca/drugs/DB00337|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=175619	calcineurin inhibitor	dermatology	eczema	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e4027e5a-0f9b-4070-b196-f60172f45c4c
ondansetron	ondansetron	Desmethylondansetron|GR-38032|GR-38032F|zofran|zofran odt|zofran preservative free|zuplenz	Cc1nccn1CC1CCc2c(C1=O)c1ccccc1n2C	Launched	FDA Orange Book: ondansetron, ondansetron hydrochloride	OPRM1|CYP2D6|CYP3A5|HTR1B|HTR1A|HTR3B|HTR3A|HTR4	https://www.drugbank.ca/drugs/DB00904|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=130944|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=130944|https://www.drugbank.ca/drugs/DB00904|https://www.drugbank.ca/drugs/DB00904|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2290|ChEMBL|https://www.drugbank.ca/drugs/DB00904	serotonin receptor antagonist	gastroenterology|gastroenterology	nausea|vomiting	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0050959-c14c-41b6-9a92-fadc5f6feff3|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0050959-c14c-41b6-9a92-fadc5f6feff3
PU-H71	PU-H71		CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01393509	HSP90AA1	http://www.tocris.com/dispprod.php?ItemId=206850	HSP inhibitor			
celiprolol	celiprolol	Cardem|Celipres|Celipro|Celol|Cordiax|Dilanorm|Selectol	CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(c1)C(C)=O	Launched	http://en.wikipedia.org/wiki/Celiprolol	ADRA2A|ADRB1|ADRB2	https://en.wikipedia.org/wiki/Celiprolol|https://en.wikipedia.org/wiki/Celiprolol|https://en.wikipedia.org/wiki/Celiprolol	adrenergic receptor antagonist	genetics	Ehlers-Danlos syndrome (EDS)	https://en.wikipedia.org/wiki/Ehlers%E2%80%93Danlos_syndrome
EBPC	EBPC		CCOC(=O)C1CN(Cc2ccccc2)C(=O)C1=O	Preclinical		AKR1B1	http://drug2gene.info/relation/102213059	aldose reductase inhibitor			
gepefrine	gepefrine		CC(N)Cc1cccc(O)c1	Launched	https://en.wikipedia.org/wiki/Gepefrine			adrenergic receptor agonist	cardiology	hypotension	https://en.wikipedia.org/wiki/Gepefrine
oxfendazole	oxfendazole	Benzelmin|Equi-Cide|RS-8858|Synanthic|Systamex	COC(=O)Nc1nc2ccc(cc2[nH]1)S(=O)c1ccccc1	Veterinary Launched	http://www.drugs.com/international/Oxfendazole.html			anthelmintic agent	infectious disease|infectious disease|infectious disease	lungworms|tapeworm|gastrointestinal roundworms	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d005dd90-73ca-42de-9e95-96fecccdd04a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d005dd90-73ca-42de-9e95-96fecccdd04a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d005dd90-73ca-42de-9e95-96fecccdd04a
SB-221284	SB-221284		CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F	Preclinical		HTR2A|HTR2C|HTR2B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=191|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=191|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=191	serotonin receptor antagonist			
lidamidine	lidamidine		CNC(=N)NC(=O)Nc1c(C)cccc1C	Launched	http://www.drugs.com/international/Lidamidine.html			adrenergic receptor agonist	gastroenterology	diarrhea	http://www.drugs.com/international/lidamidine.html
crizotinib	crizotinib	PF-2341066|xalkori	C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl	Launched	FDA Orange Book: crizotinib	ROS1|ALK|MET|CYP2B6|CYP3A5|MST1R	https://citeline.informa.com/?query=#/drugs/details/36489|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=421155|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=421155|https://citeline.informa.com/?query=#/drugs/details/36489	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7
INCB-003284	INCB-003284		COc1ccc(cn1)C1(O)CCC(CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F	Phase 2	Pharmaprojects			CC chemokine receptor antagonist			
hydroquinone	hydroquinone	black and white bleaching cream|eldopaque forte|eldoquin forte|solaquin forte	Oc1ccc(O)cc1	Launched	FDA Orange Book: hydroquinone	TYR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000750	melanin inhibitor	dermatology	dyschromia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62c05873-cdf8-4a4a-9744-e4dbe3e822ff
eplerenone	eplerenone	SC-66110|SC-6611O|inspra	COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13	Launched	FDA Orange Book: eplerenone	NR3C2|CYP3A5	ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=261466	cytochrome P450 inhibitor	cardiology|cardiology	congestive heart failure|hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59e27acd-3877-babf-341b-b65968a8a607|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59e27acd-3877-babf-341b-b65968a8a607
YM-244769	YM-244769		Nc1cccc(CNC(=O)c2ccc(Oc3ccc(OCc4cccc(F)c4)cc3)nc2)c1	Preclinical				sodium/calcium exchange inhibitor			
IB-MECA	IB-MECA	CF101	CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01235234	ADORA3|ADORA1|ADORA2B|ADORA2A	https://www.drugbank.ca/drugs/DB05511|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=422|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=422|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=422	adenosine receptor agonist			
gluconolactone	gluconolactone		OC[C@@H]1OC(=O)[C@@H](O)[C@H](O)[C@H]1O	Launched	FDA Orange Book: gluconolactone	LCT	https://www.drugbank.ca/drugs/DB04564				
pipotiazine-palmitate	pipotiazine palmitate	IL-19552|RP 19552|pipotiazine|pipotiazine palmitate	CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(cc23)S(=O)(=O)N(C)C)CC1	Launched	https://www.drugs.com/uk/piportil-depot-50-mg-ml-solution-for-injection-leaflet.html	HTR1A|HTR2A|DRD1|DRD2	http://www.drugbank.ca/drugs/DB01621|http://www.drugbank.ca/drugs/DB01621|http://www.drugbank.ca/drugs/DB01621|http://www.drugbank.ca/drugs/DB01621	dopamine receptor antagonist|serotonin receptor antagonist			
octocrylene	octocrylene		CCCC[C@@H](CC)COC(=O)C(C#N)=C(c1ccccc1)c1ccccc1	Launched	FDA Orange Book: octocrylene				dermatology	sunscreen lotion	https://en.wikipedia.org/wiki/Octocrylene
ampicillin	ampicillin	AY-6108|Alpha-Aminobenzylpenicillin|BRL-1341|Omnipen|Omnipen-N|P-50|Polycillin-Prb|Principen|Probampacin|Totacillin-N|amcill|aminobenzylpenicillin|ampicillin sodium|ampicillin trihydrate|ampicillin/ampicillin trihydrate|omnipen (ampicillin)|penbritin|penbritin-s|pfizerpen-a|polycillin|polycillin-n|principen '250'|principen '500'|totacillin	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O	Launched	FDA Orange Book: ampicillin sodium, ampicillin/ampicillin trihydrate, bacampicillin hydrochloride			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	respiratory tract infections|meningitis|bacterial septicemia|endocarditis|urinary tract infections|gastrointestinal infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da8da9c0-fa46-40d3-82c6-1a18ffa1b585|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da8da9c0-fa46-40d3-82c6-1a18ffa1b585|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da8da9c0-fa46-40d3-82c6-1a18ffa1b585|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da8da9c0-fa46-40d3-82c6-1a18ffa1b585|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da8da9c0-fa46-40d3-82c6-1a18ffa1b585|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da8da9c0-fa46-40d3-82c6-1a18ffa1b585
delamanid	delamanid	OPC-67683	C[C@]1(COc2ccc(cc2)N2CCC(CC2)Oc2ccc(OC(F)(F)F)cc2)Cn2cc(nc2O1)[N+]([O-])=O	Launched	https://www.drugs.com/international/delamanid.html			bacterial cell wall synthesis inhibitor	infectious disease	tuberculosis	https://en.wikipedia.org/wiki/Delamanid
anamorelin	anamorelin		CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01387269	GHSR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000049	growth hormone secretagogue receptor agonist			
cinflumide	cinflumide	BW 532U	Fc1cccc(c1)\C=C\C(=O)NC1CC1	Phase 2	Pharmaprojects			muscle relaxant			
alprenolol	alprenolol		CC(C)NCC(O)COc1ccccc1CC=C	Launched	http://en.wikipedia.org/wiki/Alprenolol	ADRB1|ADRB2|HTR1A	https://www.drugbank.ca/drugs/DB00866|https://www.drugbank.ca/drugs/DB00866|https://www.drugbank.ca/drugs/DB00866	adrenergic receptor antagonist	cardiology	angina pectoris	https://en.wikipedia.org/wiki/Alprenolol
nadide	nadide		NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O	Launched	http://www.drugs.com/international/nadide.html	BLVRA|SORD|DHPS|P2RY11|AKR1A1|HMGCR|TRPM2|IMPDH2|GALE|HSD17B4|HSD17B1|DLD|MGAM|ALDH2|AHCY	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002947|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002947|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002947|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002947|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002947|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002947|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002947|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002947|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002947|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002947|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002947|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002947|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002947	electron acceptor			
trihexyphenidyl	trihexyphenidyl	artane|trihexyphenidyl hydrochloride	OC(CCN1CCCCC1)(C1CCCCC1)c1ccccc1	Launched	FDA Orange Book: trihexyphenidyl hydrochloride	CHRM5|CHRM4|CHRM3|CHRM2|CHRM1	https://www.drugbank.ca/drugs/DB00376|https://www.drugbank.ca/drugs/DB00376|https://www.drugbank.ca/drugs/DB00376|https://www.drugbank.ca/drugs/DB00376|https://www.drugbank.ca/drugs/DB00376	acetylcholine receptor antagonist	neurology/psychiatry	parkinsonism	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7e4200c-feff-4537-aad1-cf9989fd8c14&audience=consumer
zeatin	zeatin	Trans-Zeatin	C\C(CO)=C/CNc1[nH]cnc2ncnc12	Phase 1	http://www.prnewswire.com/news-releases/senetek-plc-announces-successful-completion-of-zeatin-pre-clinical-studies-clinical-trials-underway-54406902.html						
buflomedil	buflomedil		COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1	Launched	http://en.wikipedia.org/wiki/Buflomedil	CACNA1C|ADRA1A	https://citeline.informa.com/?query=#/drugs/details/3098|http://www.ncbi.nlm.nih.gov/pubmed/15331158	adrenergic receptor antagonist|calcium channel blocker	cardiology	peripheral artery disease (PAD)	https://en.wikipedia.org/wiki/Peripheral_artery_disease
vinburnine	vinburnine		CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41	Launched	http://www.drugs.com/international/vinburnine.html	CHRM4|CHRM3|CHRM2|CHRM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=345|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=345|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=345|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=345	adrenergic receptor antagonist	neurology/psychiatry	stroke	http://www.drugs.com/international/vinburnine.html
mephenytoin	mephenytoin	mesantoin|methoin	CCC1(NC(=O)N(C)C1=O)c1ccccc1	Launched	FDA Orange Book: mephenytoin	CYP2C19|SCN8A|SCN9A|SCN2A|SCN3A|SCN1A|SCN7A|SCN4A|SCN5A|SCN10A|SCN11A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091453|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	hydantoin antiepileptic	neurology/psychiatry	seizures	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9370d8e6-7db4-452d-9792-9093e7b4f4bd
mdivi-1	mdivi-1		COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O	Preclinical		DNM1	http://www.sigmaaldrich.com/catalog/product/sigma/m0199?lang=en&region=US	dynamin inhibitor			
azodicarbonamide	azodicarbonamide	E927a|NSC-674447	NC(=O)\N=N\C(N)=O	Phase 2	https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000950-30/ES			DNA synthesis inhibitor			
IMREG-1	IMREG-1	Tyr-Gly-Gly	N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(O)=O	Phase 3	Pharmaprojects						
AH-7614	AH-7614		Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12	Preclinical		FFAR4	https://www.tocris.com/products/ah-7614_5256	free fatty acid receptor antagonist			
A66	A66		Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C	Preclinical		PIK3CA	http://www.biocompare.com/11119-Chemicals-and-Reagents/5799433-A66/?vpim=2&ppim=5799433_0_0&ncatid=19394	PI3K inhibitor			
GBR-12783	GBR-12783		C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1	Preclinical				dopamine uptake inhibitor			
stattic	stattic		[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1	Preclinical							
VX-745	VX-745		Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/11892915	MAPK12|MAPK14|MAPK11	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000261|https://www.drugbank.ca/drugs/DB07138|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5719	p38 MAPK inhibitor			
4-phenolsulfonic-acid	4-phenolsulfonic acid		Oc1ccc(cc1)S(O)(=O)=O	Preclinical							
hydrocortisone	hydrocortisone	cort-dome|cortef|cortenema|cortril|hydrocortone|texacort	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	Launched	FDA Orange Book: hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone cypionate, hydrocortisone probutate, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydrocortisone valerate	NR3C1	https://citeline.informa.com/?query=#/drugs/details/8690	glucocorticoid receptor agonist	dermatology|dermatology|dermatology|neurology/psychiatry	eczema|psoriasis|seborrheic dermatitis|itching	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b5091e1-1800-4f48-9efc-c045222f8885|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b5091e1-1800-4f48-9efc-c045222f8885|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b5091e1-1800-4f48-9efc-c045222f8885|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b5091e1-1800-4f48-9efc-c045222f8885
zalcitabine	zalcitabine	RO 24-2027/000|Ro-24-2027-000|dideoxycytidine|hivid	Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1	Launched	FDA Orange Book: zalcitabine			nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://en.wikipedia.org/wiki/Zalcitabine
cordycepin	cordycepin	3'-Deoxyadenosine	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT00709215			DNA inhibitor			
2,6-dimethylpiperidine	2,6-dimethylpiperidine		CC1CCCC(C)N1	Preclinical							
oleamide	oleamide	Octadec-9-Enoic Acid Amide	CCCCCCCC\C=C/CCCCCCCC(N)=O	Preclinical		CNR1|PLA2G2A|HTR7	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070520|https://www.drugbank.ca/drugs/DB03784|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=284	cannabinoid receptor agonist			
SSR-180711	SSR-180711		Brc1ccc(OC(=O)N2CCN3CCC2CC3)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00602680	CHRNA7	https://www.tocris.com/products/ssr-180711-hydrochloride_5559	acetylcholine receptor agonist			
khellin	khellin	ammivin|khelloyd	COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/14693493			vasodilator			
GW-542573X	GW-542573X		COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C	Preclinical		KCNN1	https://www.tocris.com/products/gw-542573x_4311	calcium channel activator			
3-deazaadenosine	3-deazaadenosine		Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)C(O)C1O	Phase 2	Pharmaprojects	AHCY	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5115	adenosylhomocysteinase inhibitor			
SNS-314	SNS-314		Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00519662	AURKC|AURKB|AURKA	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000006|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000006|https://www.drugbank.ca/drugs/DB07361	Aurora kinase inhibitor			
2-iodohippuric-acid	2-iodohippuric acid	iodohippurate	OC(=O)CNC(=O)c1ccccc1I	Preclinical							
pimavanserin	pimavanserin	nuplazid	CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1	Launched	https://clinicaltrials.gov/ct2/show/NCT01174004	DRD2|HTR2A	https://www.drugbank.ca/drugs/DB05316|https://www.drugbank.ca/drugs/DB05316	serotonin receptor inverse agonist			
tilmicosin	tilmicosin		CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC	Veterinary Launched	http://www.drugs.com/international/Tilmicosin.html			bacterial 50S ribosomal subunit inhibitor	pulmonary	bovine respiratory disease (BRD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd2e3864-6b8f-48aa-b6ab-5cf0170cbd2e&audience=consumer
dienogest	dienogest		C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N	Launched	FDA Orange Book: dienogest	PGR	https://en.wikipedia.org/wiki/Dienogest	progesterone receptor agonist	endocrinology|obstetrics/gynecology	contraceptive|endometriosis	https://en.wikipedia.org/wiki/Dienogest|https://en.wikipedia.org/wiki/Dienogest
V-51	V-51		COc1cc(CN2CCN(CC2)c2ccc(F)cc2)cc(OC)c1OC	Phase 1	Pharmaprojects			adrenergic receptor antagonist			
chlortetracycline	chlortetracycline	aureomycin	CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O	Launched	FDA Orange Book: chlortetracycline hydrochloride			protein synthesis inhibitor	ophthalmology	conjunctivitis	https://en.wikipedia.org/wiki/Chlortetracycline
3-deazaneplanocin-A	3-deazaneplanocin-A		Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O	Preclinical		EZH2|AHCY	http://www.stemcell.com/en/Products/All-Products/3Deazaneplanocin-A.aspx|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=126585	histone lysine methyltransferase inhibitor			
XL228	XL228	XL-228	CC(C)c1cc(CNc2nc(Nc3cc([nH]n3)C3CC3)cc(n2)N2CCN(C)CC2)on1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00464113	SRC|FGF2|AURKA|IGF1R	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=549001|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=416744|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=416744|http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=549001	Abl kinase inhibitor|insulin growth factor receptor inhibitor|src inhibitor			
olmesartan	olmesartan	RNH-6270	CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O	Launched	FDA Orange Book: olmesartan medoxomil	AGTR1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000907	angiotensin receptor antagonist	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a9c6e0e-72dd-4ed4-a8bb-8a6aee506681
beta-elemene	beta-elemene		CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@@H](C1)C(C)=C	Launched	http://www.gtjas.com.hk/wwwarchive/UploadFiles/gtja_Report/2013/05/1093%20CR%2015May%202013.pdf	MMP2|MMP9	http://www.abcam.com/beta-elemene-ab145171.html|http://www.abcam.com/beta-elemene-ab145171.html	apoptosis stimulant			
pyrimethamine	pyrimethamine	Chloridin|GNF-Pf-5586|Malacide|TCMDC-123831|TCMDC-125860|daraprim	CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1	Launched	FDA Orange Book: pyrimethamine	DHFRP1|HEXA|STAT3|SLC47A1|DHFR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070197|https://citeline.informa.com/?query=#/drugs/details/72013|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070197|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4800|https://www.drugbank.ca/drugs/DB00205	dihydrofolate reductase inhibitor	infectious disease	malaria	https://en.wikipedia.org/wiki/Pyrimethamine
prasugrel	prasugrel	effient	CC(=O)Oc1cc2CN(CCc2s1)C(C(=O)C1CC1)c1ccccc1F	Launched	FDA Orange Book: prasugrel hydrochloride	CYP2C19|CYP2B6|P2RY12|CYP3A5	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=273686|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=273686|https://www.drugbank.ca/drugs/DB06209|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=273686	purinergic receptor antagonist	cardiology|cardiology	myocardial infarction|acute coronary syndrome (ACS)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fe9c118-c44b-48d7-a142-9668ae3df0c6|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fe9c118-c44b-48d7-a142-9668ae3df0c6
efavirenz	efavirenz	sustiva	FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1	Launched	FDA Orange Book: efavirenz	CYP2C19|CYP1A2|CYP2B6|CYP2D6|CYP2C8|CYP2C9|CYP3A4|CYP3A5	http://www.drugbank.ca/drugs/DB00625|http://www.drugbank.ca/drugs/DB00625|http://www.drugbank.ca/drugs/DB00625|http://www.drugbank.ca/drugs/DB00625|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=207217|http://www.drugbank.ca/drugs/DB00625|http://www.drugbank.ca/drugs/DB00625|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=207217	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32d6371e-ba56-4294-b732-6d43627c5c47
gynostemma-extract	gynostemma-extract		CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C	Preclinical				calcium channel modulator			
JNJ-27141491	JNJ-27141491		CC[C@@H](c1ccc(F)c(F)c1)n1c(C(=O)OC)c([nH]c1=S)-c1ccno1	Preclinical		CCR2	https://www.tocris.com/products/jnj-27141491_5176	CC chemokine receptor antagonist			
duloxetine	duloxetine	cymbalta	CNCC[C@H](Oc1cccc2ccccc12)c1cccs1	Launched	FDA Orange Book: duloxetine hydrochloride	HTR2C|HTR2A|SLC6A2|SLC6A4|SLC6A3|HTR6	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=202|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=202|https://www.drugbank.ca/drugs/DB00476|https://www.drugbank.ca/drugs/DB00476|https://www.drugbank.ca/drugs/DB00476|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=202	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	depression|generalized anxiety disorder (GAD)|muscle pain|peripheral neuropathy	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a541d20-5466-433b-a104-40a7b2296076|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a541d20-5466-433b-a104-40a7b2296076|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a541d20-5466-433b-a104-40a7b2296076|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a541d20-5466-433b-a104-40a7b2296076
PHCCC	PHCCC		O\N=C1/C2CC2(Oc2ccccc12)C(=O)Nc1ccccc1	Preclinical		GRM4|GRM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1416|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1416	glutamate receptor agonist			
nerbacadol	nerbacadol		Cc1oncc1C(=O)N1CCCCC1	Phase 3	Pharmaprojects			cyclooxygenase inhibitor			
tozasertib	tozasertib	MK-045|MK-0457|VX-68|VX-680	CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00290550?term=NCT00290550&rank=1	BCR|FLT3|DDR2|LCK|JAK2|ABL1|AURKA|AURKB|AURKC	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=330736|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=330736|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=330736|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000259|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=330736|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=330736|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5718|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5718|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5718	Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor			
RS-127445	RS-127445		CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/?term=MT-500%5Bti%5D	HTR2B|HTR2C|HTR2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=188|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=188|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=188	serotonin receptor antagonist			
volinanserin	volinanserin	M100907|MDL-100907|MDL100.907	COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00788515	KCNH2|HTR2C|HTR2B|HTR2A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003903|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=185|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=185|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=185	serotonin receptor antagonist			
7-hydroxy-PIPAT	7-hydroxy-PIPAT		CCCN(C\C=C\I)C1CCc2ccc(O)cc2C1	Preclinical		DRD3	http://www.tocris.com/dispprod.php?ItemId=1467#.VecPE9NVikp	dopamine receptor ligand			
rifaximin	rifaximin	xifaxan	CO[C@H]1C=CO[C@@]2(C)Oc3c(C2=O)c2c4nc5cc(C)ccn5c4c(NC(=O)\C(C)=C/C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C	Launched	FDA Orange Book: rifaximin	NR1I2|CYP3A4	https://www.drugbank.ca/drugs/DB01220|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090171	RNA synthesis inhibitor	gastroenterology|gastroenterology|gastroenterology	diarrhea|irritable bowel syndrome|hepatic encephalopathy (HE)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5e8e2fd-7087-4b78-9181-cc259c0be2f1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5e8e2fd-7087-4b78-9181-cc259c0be2f1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5e8e2fd-7087-4b78-9181-cc259c0be2f1
AZD1480	AZD1480	AZD-1480	C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00910728	JAK1|JAK2|JAK3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5933|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5933|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5933	JAK inhibitor			
L-161982	L-161982		CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C	Preclinical		PTGER4	http://www.tocris.com/dispprod.php?ItemId=159902#.UtgvHP15mf0	prostanoid receptor antagonist			
C106	C106		CN1CCCC1c1cccnc1.Cc1ccc(cc1)C(=O)OC(C(OC(=O)c1ccc(C)cc1)C(O)=O)C(O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02047734						
quazinone	quazinone		Cc1c(O)nc2Nc3cccc(Cl)c3Cn12	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/4003296	PDE3A|PDE3B	https://en.wikipedia.org/wiki/Quazinone|https://en.wikipedia.org/wiki/Quazinone	phosphodiesterase inhibitor			
niguldipine-(S)-(+)	(S)-(+)-niguldipine		COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1	Preclinical				adrenergic receptor antagonist			
veliflapon	veliflapon	BAY X 1005|BAY-X-005|DG-031	OC(=O)[C@H](C1CCCC1)c1ccc(OCc2ccc3ccccc3n2)cc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00353067	ALOX5AP	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000104	leukotriene synthesis inhibitor			
triamterene	triamterene	SK&F 8542|SK&F-8542|SK-8542|dyrenium	Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1	Launched	FDA Orange Book: triamterene	SCNN1G|SCNN1B|SCNN1D|SCNN1A	ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00384|ChEMBL	sodium channel blocker	endocrinology|cardiology|cardiology	hypokalemia|hypertension|edema	https://www.google.com/search?q=hypokalemia&oq=hypokalemia&aqs=chrome..69i57j0l5.254j0j4&sourceid=chrome&es_sm=91&ie=UTF-8|https://www.google.com/search?q=hypokalemia&oq=hypokalemia&aqs=chrome..69i57j0l5.254j0j4&sourceid=chrome&es_sm=91&ie=UTF-8|https://www.google.com/search?q=hypokalemia&oq=hypokalemia&aqs=chrome..69i57j0l5.254j0j4&sourceid=chrome&es_sm=91&ie=UTF-8
NKY-80	NKY-80		Nc1ncc2C(=O)CC(Cc2n1)c1ccco1	Preclinical		ADCY5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5233	adenylyl cyclase inhibitor			
difloxacin	difloxacin		CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1	Veterinary Launched	http://www.drugs.com/international/Difloxacin.html			bacterial DNA gyrase inhibitor	infectious disease|infectious disease	skin infections|urinary tract infections	https://en.wikipedia.org/wiki/Difloxacin|https://en.wikipedia.org/wiki/Difloxacin
etifoxine	etifoxine	36-801|HOE 36801	CCNC1=Nc2ccc(Cl)cc2C(C)(O1)c1ccccc1	Launched	http://www.drugs.com/international/etifoxine.html	GABRA5|GABRA1|GABRA2|GABRA3	https://www.tocris.com/dispprod.php?ItemId=207711|https://www.tocris.com/dispprod.php?ItemId=207711|https://www.tocris.com/dispprod.php?ItemId=207711|https://www.tocris.com/dispprod.php?ItemId=207711	GABA receptor modulator	neurology/psychiatry	anxiety	https://en.wikipedia.org/wiki/Etifoxine
L-asparagine-n-hydroxy	L-asparagine-n-hydroxy		N[C@@H](CC(=O)NO)C(O)=O	Preclinical							
isopropyl-palmitate	isopropyl palmitate	isopropyl palmitate	CCCCCCCCCCCCCCCC(=O)OC(C)C	Launched	http://en.wikipedia.org/wiki/Isopropyl_palmitate			cosmetic moisturizer	dermatology	cosmetic	http://www.ewg.org/skindeep/ingredient/703207/ISOPROPYL_PALMITATE/
parthenolide	parthenolide		C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/15122077			NFkB pathway inhibitor			
amrinone	amrinone	WIN 40680|amrinone lactate|inamrinone|inocor	Nc1cc(c[nH]c1=O)-c1ccncc1	Launched	FDA Orange Book: inamrinone lactate	TNF|PDE3B|PDE3A|PDE4B	https://www.drugbank.ca/drugs/DB01427|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7202|https://www.drugbank.ca/drugs/DB01427|https://www.drugbank.ca/drugs/DB01427	phosphodiesterase inhibitor	cardiology	congestive heart failure	https://en.wikipedia.org/wiki/Amrinone
tadalafil	tadalafil	IC-351|IC351|adcirca|cialis	CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O	Launched	FDA Orange Book: tadalafil	PDE5A|PDE11A	ChEMBL|https://www.drugbank.ca/drugs/DB00820	phosphodiesterase inhibitor	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff61b237-be8e-461b-8114-78c52a8ad0ae&audience=consumer
SC-10	SC-10		CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12	Preclinical		PRKCA	http://www.tocris.com/dispprod.php?ItemId=1853#.Vg2N7WRVhHw	protein kinase activator			
cefotaxime	cefotaxime	claforan	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1	Launched	FDA Orange Book: cefotaxime sodium			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	respiratory tract infections|bone and joint infections|pelvic inflammatory disease|intra-abdominal infections|skin infections|bone and joint infections|meningitis|urinary tract infections|bacterial septicemia|gynecologic infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef1a6dc6-bc3d-4f09-8f92-7ff328f56561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef1a6dc6-bc3d-4f09-8f92-7ff328f56561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef1a6dc6-bc3d-4f09-8f92-7ff328f56561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef1a6dc6-bc3d-4f09-8f92-7ff328f56561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef1a6dc6-bc3d-4f09-8f92-7ff328f56561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef1a6dc6-bc3d-4f09-8f92-7ff328f56561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef1a6dc6-bc3d-4f09-8f92-7ff328f56561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef1a6dc6-bc3d-4f09-8f92-7ff328f56561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef1a6dc6-bc3d-4f09-8f92-7ff328f56561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef1a6dc6-bc3d-4f09-8f92-7ff328f56561
kevetrin	kevetrin		NC(=N)SCCCC#N	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01664000			p53 activator			
OF-1	OF-1		COc1cc2n(C)c(=O)n(C)c2cc1NS(=O)(=O)c1ccc(Br)cc1C	Preclinical		BRD1	https://www.tocris.com/products/of-1_5289	bromodomain inhibitor			
trimetazidine	trimetazidine	trimetazidine hydrochloride	COc1ccc(CN2CCNCC2)c(OC)c1OC	Launched	http://www.drugs.com/international/trimetazidine.html	ACAA2	https://en.wikipedia.org/wiki/Trimetazidine#Mechanism_of_action	3-ketoacyl CoA thiolase inhibitor	cardiology	angina pectoris	https://en.wikipedia.org/wiki/Trimetazidine
simvastatin	simvastatin	MK-733|Simvastatin hydroxy acid|synvinolin|zocor	CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12	Launched	FDA Orange Book: simvastatin	CYP3A4|CYP3A5|CYP2C8|ITGB2|HMGCR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=122234|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=122234|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=122234|https://www.drugbank.ca/drugs/DB00641|ChEMBL	HMGCR inhibitor	endocrinology|cardiology|cardiology|neurology/psychiatry|endocrinology	hypercholesterolemia|coronary heart disease|myocardial infarction|stroke|hyperlipidemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff4a8eab-17d5-caf4-efba-7e7688202bf5&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff4a8eab-17d5-caf4-efba-7e7688202bf5&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff4a8eab-17d5-caf4-efba-7e7688202bf5&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff4a8eab-17d5-caf4-efba-7e7688202bf5&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff4a8eab-17d5-caf4-efba-7e7688202bf5&audience=consumer
ICI-63197	ICI-63197		CCCn1c2nc(N)nn2cc(C)c1=O	Preclinical				phosphodiesterase inhibitor			
GSK2256294A	GSK2256294A		CNc1nc(C)nc(N[C@H]2CCC[C@H](C2)C(=O)NCc2ccc(cc2C(F)(F)F)C#N)n1	Phase 1	https://newdrugapprovals.org/2015/03/18/gsk-2256294/	EPHX2	https://www.ncbi.nlm.nih.gov/pubmed/23434473	epoxide hydolase inhibitor			
SU014813	SU014813		Cc1[nH]c(\C=C2\C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00322517	FLT3|KDR|PDGFRA|PDGFRB	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=362360|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000357|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=362360|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=362360	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor			
daphnetin	daphnetin	TCMDC-125839	Oc1ccc2ccc(=O)oc2c1O	Preclinical				protein kinase inhibitor			
MK-2206	MK-2206		NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01042379	AKT2|AKT3|AKT1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7945|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7945|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7945	AKT inhibitor			
lurasidone	lurasidone	latuda	O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12	Launched	FDA Orange Book: lurasidone hydrochloride	HTR2A|HTR1A|HTR7|ADRA2C|ADRA2A|DRD2	https://www.drugbank.ca/drugs/DB08815|https://www.drugbank.ca/drugs/DB08815|https://www.drugbank.ca/drugs/DB08815|https://www.drugbank.ca/drugs/DB08815|https://www.drugbank.ca/drugs/DB08815|https://www.drugbank.ca/drugs/DB08815	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88a244d1-eddb-499c-bee2-e1f49056e78f
cobicistat	cobicistat	tybost	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Launched	FDA Orange Book: cobicistat	CYP3A7|CYP3A5|CYP3A4|SLCO1B3|CYP3A43	ChEMBL|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=644627|ChEMBL	cytochrome P450 inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3784c35c-e87f-410c-900b-8fd6313c6010
avanafil	avanafil	TA-1790|stendra	COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl	Launched	FDA Orange Book: avanafil	PDE5A	ChEMBL	phosphodiesterase inhibitor	urology	erectile dysfunction	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5172788-e1ab-45f9-99fa-878ee42cf91d
dovitinib	dovitinib	CHIR-258|GFKI-258|NVP-TKI258|TKI-258	CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01223027	INSR|EGFR|FLT4|FLT3|FLT1|CSF1R|KDR|KIT|PDGFRA|PDGFRB|FGFR2|FGFR3|FGFR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5962|http://www.selleckchem.com/products/CHIR-258.html|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5962	EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor			
DMP-777	DMP-777	L-694458	CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1	Phase 2	http://erj.ersjournals.com/content/32/3/783.full	PI3|MPO	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=226522|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000471	elastase inhibitor			
CGP-37849	CGP-37849		C\C(CP(O)(O)=O)=C/C(N)C(O)=O	Phase 1	http://adisinsight.springer.com/drugs/800001494	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D	https://citeline.informa.com/?query=#/drugs/details/3459|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4154|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4154|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4154|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4154	glutamate receptor antagonist			
rostafuroxine	rostafuroxine		C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1	Phase 2	http://de.wikipedia.org/wiki/Rostafuroxin	ATP1A1	http://www.ncbi.nlm.nih.gov/pubmed/20083196	ATPase inhibitor			
istradefylline	istradefylline	KW-6002	CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O	Launched	http://www.ncbi.nlm.nih.gov/pubmed/23700273	ADORA2B|ADORA2A|ADORA1|ADORA3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5608|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5608|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5608|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5608	adenosine receptor antagonist	neurology/psychiatry|neurology/psychiatry	Parkinson's Disease|dyskinesia	https://en.wikipedia.org/wiki/Istradefylline|https://en.wikipedia.org/wiki/Istradefylline
pirodavir	pirodavir	R 77975	CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/7726484						
fentiazac	fentiazac	WY-21,894	OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1	Launched	http://www.drugs.com/international/Fentiazac.html	PTGS1|PTGS2	http://download.springer.com/static/pdf/833/art%253A10.1186%252F2046-4053-3-79.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1186%2F2046-4053-3-79&token2=exp=1463070582~acl=%2Fstatic%2Fpdf%2F833%2Fart%25253A10.1186%25252F2046-4053-3-79.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1186%252F2046-4053-3-79*~hmac=9bbeb8c517534f6b8f49d2549c6e63ab2e7dd1e5e39c7454f7919acc5d3cb8cc|http://download.springer.com/static/pdf/833/art%253A10.1186%252F2046-4053-3-79.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1186%2F2046-4053-3-79&token2=exp=1463070582~acl=%2Fstatic%2Fpdf%2F833%2Fart%25253A10.1186%25252F2046-4053-3-79.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1186%252F2046-4053-3-79*~hmac=9bbeb8c517534f6b8f49d2549c6e63ab2e7dd1e5e39c7454f7919acc5d3cb8cc	cyclooxygenase inhibitor	neurology/psychiatry|rheumatology	muscle pain|joint pain	https://en.wikipedia.org/wiki/Fentiazac|https://en.wikipedia.org/wiki/Fentiazac
sitagliptin	sitagliptin	MK-0431|januvia	N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F	Launched	FDA Orange Book: sitagliptin phosphate	DPP4|CYP2C8|HMGCR|FASLG|SLC22A8	https://www.drugbank.ca/drugs/DB01261|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=333966|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=333966|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=333966|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=333966	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus	https://en.wikipedia.org/wiki/Sitagliptin
dimaprit	dimaprit		CN(C)CCCSC(N)=N	Preclinical		HRH2|HRH4|HRH3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000564|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1248|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1248	histamine receptor agonist			
NH125	NH125		CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C	Preclinical				eukaryotic translation elongation factor 2 inhibitor			
dithranol	dithranol		Oc1cccc2cc3cccc(O)c3c(O)c12	Launched	https://www.drugs.com/international/dithranol.html			DNA synthesis inhibitor	dermatology	psoriasis	https://en.wikipedia.org/wiki/Dithranol
blebbistatin-(-)	(-)-blebbistatin		Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1	Preclinical				ATPase inhibitor			
lincomycin	lincomycin	lincocin		Launched	FDA Orange Book: lincomycin hydrochloride			bacterial 30S ribosomal subunit inhibitor	gastroenterology	enteritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7866c530-8cb9-4e99-922c-f217a4047ab1
cyclovalone	cyclovalone		COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1	Launched	http://www.drugs.com/international/Cyclovalone.html	ABCG2|ABCC1	http://www.ncbi.nlm.nih.gov/pubmed/25543853|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=473558	breast cancer resistance protein inhibitor	gastroenterology	bile stimulation	http://www.drugs.com/international/cyclovalone.html
clomesone	clomesone		CS(=O)(=O)CS(=O)(=O)OCCCl	Phase 1	http://www.newmedinc.com/pdfs/Future_Oncology.Vol.1.No.4.pdf			DNA inhibitor			
lofepramine	lofepramine		CN(CCCN1c2ccccc2CCc2ccccc12)CC(=O)c1ccc(Cl)cc1	Launched	http://www.drugs.com/international/Lofepramine.html	SLC6A4|SLC6A2|HTR1A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7551|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7551|https://www.ncbi.nlm.nih.gov/pubmed/8254146	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression	https://en.wikipedia.org/wiki/Lofepramine
baicalin	baicalin		O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O	Launched	http://en.wikipedia.org/wiki/Baicalin	PREP|GUSB	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009519|https://citeline.informa.com/?query=#/drugs/details/17678	beta glucuronidase inhibitor			
salsolinol-1-carboxylic-acid	salsolinol-1-carboxylic acid		CC1(NCCc2cc(O)c(O)cc12)C(O)=O	Preclinical							
procarbazine	procarbazine	matulane	CNNCc1ccc(cc1)C(=O)NC(C)C	Launched	FDA Orange Book: procarbazine hydrochloride			monoamine oxidase inhibitor	hematologic malignancy	Hodgkin's lymphoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de1c8271-64d8-4ea5-85e8-871faa4d7632
rhodamine-123	rhodamine-123		COC(=O)c1ccccc1-c1c2ccc(N)cc2[o+]c2cc(N)ccc12	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/16167524						
bicuculline-(+)	(+)-bicuculline		CN1CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21	Preclinical				GABA receptor antagonist			
protriptyline	protriptyline	vivactil	CNCCCC1c2ccccc2C=Cc2ccccc12	Launched	FDA Orange Book: protriptyline hydrochloride	SLC6A2|SLC6A4	https://www.drugbank.ca/drugs/DB00344|https://www.drugbank.ca/drugs/DB00344	tricyclic antidepressant	neurology/psychiatry	depression	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=700abc58-9362-4ef5-9d7a-dd3c4d364d0a
cholesterol	cholesterol		CC(C)CCCC(C)[C@H]1CCC2C3CC=C4C[C@@H](O)CC[C@]4(C)C3CC[C@]12C	Preclinical		RORA	https://www.drugbank.ca/drugs/DB04540				
WWL-113	WWL-113		CCOC(=O)c1ccc(cc1)-c1ccc(OC(=O)N(C)Cc2cccc(c2)-c2ccncc2)cc1	Preclinical		CES3	https://www.tocris.com/products/wwl-113_5259	carboxylesterase inhibitor			
zuclopenthixol	zuclopenthixol	AY-62021|N-746|chlorpenthixol|clopenthixol	OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1	Launched	http://www.drugs.com/international/Zuclopenthixol.html	HRH1|HTR2A|DRD1|DRD2|DRD5|ADRA2A|ADRA1A	https://www.drugbank.ca/drugs/DB01624|https://www.drugbank.ca/drugs/DB01624|https://www.drugbank.ca/drugs/DB01624|https://www.drugbank.ca/drugs/DB01624|https://www.drugbank.ca/drugs/DB01624|https://www.drugbank.ca/drugs/DB01624|https://www.drugbank.ca/drugs/DB01624	dopamine receptor antagonist	neurology/psychiatry|neurology/psychiatry	schizophrenia|bipolar disorder	https://en.wikipedia.org/wiki/Zuclopenthixol|https://en.wikipedia.org/wiki/Zuclopenthixol
rolitetracycline	rolitetracycline		CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(=O)NCN2CCCC2)C1=O	Launched	http://www.drugs.com/international/rolitetracycline.html			bacterial 30S ribosomal subunit inhibitor			
bremelanotide	bremelanotide	PT-141	CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02338960	MC5R|MC4R|MC3R|MC2R|MC1R	https://en.wikipedia.org/wiki/Bremelanotide|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000074|https://en.wikipedia.org/wiki/Bremelanotide|https://en.wikipedia.org/wiki/Bremelanotide|https://en.wikipedia.org/wiki/Bremelanotide	melanocortin receptor agonist			
PKI-179	PKI-179		O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1C2CCC1COC2	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00997360	MTOR	http://www.emdmillipore.com/US/en/product/PI-3-KmTOR-Inhibitor-III,-PKI-179---CAS-1197160-28-3---Calbiochem,EMD_BIO-526561	mTOR inhibitor|PI3K inhibitor			
GSK2126458	GSK2126458	GSK-2126458|omipalisib	COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00972686	PIK3CB|PIK3CD|PIK3CA|PIK3CG|MTOR	http://www.selleckchem.com/products/gsk2126458.html|http://www.selleckchem.com/products/gsk2126458.html|http://www.selleckchem.com/products/gsk2126458.html|http://www.selleckchem.com/products/gsk2126458.html|http://www.selleckchem.com/products/gsk2126458.html	mTOR inhibitor|PI3K inhibitor			
7,8,9,10-tetrahydroazepino[2,1-b]quinazolin-12(6H)-one	7,8,9,10-tetrahydroazepino[2,1-b]quinazolin-12(6H)-one		O=C1N2CCCCC=C2Nc2ccccc12	Preclinical							
lomustine	lomustine	CCNU|ceenu|gleostine	[O-][N+]N(CCCl)C(=O)NC1CCCCC1	Launched	FDA Orange Book: lomustine	STMN4	https://www.drugbank.ca/drugs/DB01206	DNA synthesis inhibitor	hematologic malignancy|oncology	Hodgkin's lymphoma|brain tumors	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17893de9-7d54-448c-9fca-d10642046d14|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17893de9-7d54-448c-9fca-d10642046d14
cebranopadol	cebranopadol	GRT6005	CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02031432	OPRL1|OPRM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8866|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8866	opioid receptor agonist			
cintriamide	cintriamide	cintramide	COc1cc(cc(OC)c1OC)\C=C\C(N)=O	Preclinical							
halofuginone	halofuginone	rel-Halofuginone	O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O	Launched	http://www.drugs.com/international/Halofuginone.html	MMP2|COL1A1	https://www.drugbank.ca/drugs/DB04866|https://www.drugbank.ca/drugs/DB04866	collagenase inhibitor	rheumatology	scleroderma	https://en.wikipedia.org/wiki/Halofuginone
eseroline-(-)	(-)-eseroline	(-)-Eseroline	CN1CC[C@]2(C)[C@H]1N(C)c1ccc(O)cc21	Preclinical		ACHE|OPRD1|OPRM1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=102919|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013739|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013739	acetylcholinesterase inhibitor			
Gue-1654	Gue-1654		CSc1nc2ccc3nc(NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1	Preclinical		OXER1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6173	oxoeicosanoid receptor modulator			
linopirdine	linopirdine	DUP 996	O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/9164692	KCNQ5|KCNQ4|KCNQ3|KCNQ2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2599|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2599|http://en.wikipedia.org/wiki/Linopirdine|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2599	potassium channel blocker			
metenkephalin	metenkephalin		CSCCC(NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)C(N)Cc1ccc(O)cc1)C(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00109941	OPRD1|OGFR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000931|https://citeline.informa.com/?query=#/drugs/details/11914	immunostimulant			
CEP-32496	CEP-32496		COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT01877811	EGFR|BRAF|RAF1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=674841|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7880|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7880	RAF inhibitor			
oxyphenonium	oxyphenonium	antrenyl	CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)c1ccccc1	Launched	FDA Orange Book: oxyphenonium bromide	CHRM1	https://www.drugbank.ca/drugs/DB00219	cholinergic receptor antagonist	gastroenterology	peptic ulcer disease (PUD)	http://www.drugs.com/international/oxyphenonium-bromide.html
phenylbutyrate	phenylbutyrate	buphenyl|phenylbutanoic acid	OC(=O)CCCc1ccccc1	Launched	FDA Orange Book: sodium phenylbutyrate	CYP3A5|HDAC1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=222462|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000929	HDAC inhibitor	metabolism	urea cycle disorders	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463a36fa-3eb2-4326-8bd0-c8c7a11bca3a
RS-17053	RS-17053		CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1	Preclinical		ADRA1A|ADRA1D	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=495|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=495	adrenergic receptor antagonist			
MRS3777	MRS3777		C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2[nH]cnc12	Preclinical		ADORA3|ADORA2A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=402535|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005313	adenosine receptor antagonist			
dioxybenzone	dioxybenzone		COc1ccc(C(=O)c2ccccc2O)c(O)c1	Preclinical				topical sunscreen agent			
BW-B70C	BW-B70C		CC(\C=C\c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O	Preclinical		ALOX5	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000366	lipoxygenase inhibitor			
EC-144	EC-144		COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C	Preclinical		HSP90AB1|HSP90AA1	https://www.tocris.com/products/ec-144_4701|https://www.tocris.com/products/ec-144_4701	HSP inhibitor			
hydroxystilbamidine	hydroxystilbamidine	hydroxystilbamidine isethionate	NC(=N)c1ccc(cc1)\C=C\c1ccc(cc1O)C(N)=N	Launched	FDA Orange Book: hydroxystilbamidine isethionate						
faropenem-medoxomil	faropenem medoxomil	A0026|faropenem medoxomil	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C	Launched	http://www.drugs.com/international/Faropenem.html			lactamase inhibitor	otolaryngology|infectious disease|pulmonary|infectious disease|infectious disease	sinusitis|pneumonia|bronchitis|skin infections|urinary tract infections	https://en.wikipedia.org/wiki/Faropenem|https://en.wikipedia.org/wiki/Faropenem|https://en.wikipedia.org/wiki/Faropenem|https://en.wikipedia.org/wiki/Faropenem|https://en.wikipedia.org/wiki/Faropenem
TNP-470	TNP-470		CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00038701			methionine aminopeptidase inhibitor			
L-701324	L-701324		Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12	Preclinical		GRIN2D|GRIN2C|GRIN2B|GRIN2A|GRIN1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4240|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4240|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4240|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4240|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4240	glutamate receptor antagonist			
2-PMDQ	2-PMDQ		O=C1Nc2ccccc2C2=NC(CN3CCN(CC3)c3ccccc3)CN12	Preclinical		ADRA1A	http://www.tocris.com/dispprod.php?ItemId=1756#.VeSyhyxVhHw	adrenergic receptor antagonist			
clonidine	clonidine	Clorpres|Combipres|ST-155-BS|ST-155BS|catapres|catapres-tts-1|catapres-tts-2|catapres-tts-3|duraclon|jenloga|kapvay	Clc1cccc(Cl)c1N=C1NCCN1	Launched	FDA Orange Book: apraclonidine hydrochloride, clonidine, clonidine hydrochloride	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	https://www.drugbank.ca/drugs/DB00575|https://www.drugbank.ca/drugs/DB00575|https://www.drugbank.ca/drugs/DB00575|ChEMBL|ChEMBL|ChEMBL	adrenergic receptor agonist	cardiology|neurology/psychiatry	hypertension|attention-deficit/hyperactivity disorder (ADHD)	http://www.drugs.com/clonidine.html|http://www.drugs.com/clonidine.html
streptozotocin	streptozotocin	STZ|U-9889|streptozocin|zanosar		Launched	http://en.wikipedia.org/wiki/Streptozotocin	SLC2A2	https://www.drugbank.ca/drugs/DB00428	DNA alkylating agent	oncology	pancreatic cancer	https://en.wikipedia.org/wiki/Streptozotocin
quinidine	quinidine	cardioquin|duraquin|quinaglute|quinidex|quinidine gluconate|quinidine sulfate	COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1	Launched	FDA Orange Book: quinidine gluconate, quinidine polygalacturonate, quinidine sulfate	SCN5A|KCNA7|KCNA5|KCNH5|KCNH1|KCNH2|KCNK1|KCNK6|ABCB1|CYP2D6|SLC29A4	https://www.drugbank.ca/drugs/DB00908|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2342|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2342|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2342|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2342|https://www.drugbank.ca/drugs/DB00908|https://www.drugbank.ca/drugs/DB00908|https://www.drugbank.ca/drugs/DB00908|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=134271|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=134271|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2342	sodium channel blocker	infectious disease|cardiology|cardiology	malaria|atrial fibrillation (AF)|ventricular arrhythmias	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11d14362-8f69-4c30-b487-5d05f6462bd7|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11d14362-8f69-4c30-b487-5d05f6462bd7|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11d14362-8f69-4c30-b487-5d05f6462bd7
curcumol	curcumol		CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00542711	JAK3|JAK2|JAK1	http://www.selleckchem.com/products/Curcumol.html|http://www.selleckchem.com/products/Curcumol.html|http://www.selleckchem.com/products/Curcumol.html	JAK inhibitor			
ombitasvir	ombitasvir	ABT-267	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)Nc1ccc(cc1)[C@@H]1CC[C@H](N1c1ccc(cc1)C(C)(C)C)c1ccc(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)cc1	Launched	FDA Orange Book: ombitasvir			HCV inhibitor	infectious disease	hepatitis C	https://en.wikipedia.org/wiki/Ombitasvir
fimasartan	fimasartan		CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1	Launched	https://clinicaltrials.gov/ct2/show/NCT01384747	AGTR1	https://en.wikipedia.org/wiki/Fimasartan	angiotensin receptor antagonist	cardiology|cardiology|cardiology|cardiology	hypertension|congestive heart failure|hypertension|congestive heart failure	https://en.wikipedia.org/wiki/Fimasartan#Pharmacology|https://en.wikipedia.org/wiki/Fimasartan#Pharmacology|https://en.wikipedia.org/wiki/Fimasartan#Pharmacology|https://en.wikipedia.org/wiki/Fimasartan#Pharmacology
beclomethasone-dipropionate	beclomethasone dipropionate	SCH 18020W|SCH-18020W|beclometasone|beclometasone dipropionate|beclomethasone|beclomethasone dipropionate|beclomethasone dipropionate monohydrate|beclovent|beconase|beconase aq|qnasl|qvar 40|qvar 80|vancenase|vancenase aq|vanceril|vanceril double strength	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C	Launched	FDA Orange Book: beclomethasone dipropionate, beclomethasone dipropionate monohydrate	GPR97|CYP3A5|NR3C1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5894|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091480|ChEMBL	glucocorticoid receptor agonist	allergy	allergic rhinitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3be74938-3281-4586-a57c-2501e8a06960
GSK503	GSK503		CC(C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCN(C)CC1)C(=O)NCc1c(C)cc(C)[nH]c1=O	Preclinical		EZH2	https://www.caymanchem.com/product/18531	histone lysine methyltransferase inhibitor			
CPSI-1306-(+/-)	(+/-)-CPSI-1306		Fc1ccc(C2=NOC(CC(=O)N3CCOCC3)C2)c(F)c1	Preclinical				macrophage migration inhibiting factor inhibitor			
acetyl-l-leucine	acetyl-l-leucine		CC(C)C[C@H](NC(C)=O)C(O)=O	Launched	http://www.ncbi.nlm.nih.gov/pubmed/11207808				neurology/psychiatry	vertigo	http://www.ncbi.nlm.nih.gov/pubmed/11207808
PNU-282987	PNU-282987		Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2	Preclinical		CHRNA7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3988	cholinergic receptor agonist			
ciprofibrate	ciprofibrate	WIN 35833	CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O	Launched	http://www.drugs.com/international/Ciprofibrate.html	PPARA|LPL	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3438|https://citeline.informa.com/?query=#/drugs/details/4668	PPAR receptor agonist	endocrinology	hyperlipidemia	http://patient.info/medicine/ciprofibrate-for-hyperlipidaemia
talazoparib	talazoparib	BMN 673	Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01945775	PARP1|PARP2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=685984|http://www.selleckchem.com/products/bmn-673.html?gclid=CMSo8LXexcwCFc9ahgodgisLCQ	PARP inhibitor			
VU591	VU591		[O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1	Preclinical		KCNJ1	http://www.uniprot.org/uniprot/?query=Kir1.1&sort=score	potassium channel blocker			
propranolol-(S)	(S)-propranolol	(-)-propanolol|Propanolol	CC(C)NC[C@H](O)COc1cccc2ccccc12	Preclinical		SLC10A1|CYP2C19|HTR5A|HTR1B|HTR1A|ADRB2|ADRB1|ADRB3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=63|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091327|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=63|https://www.drugbank.ca/drugs/DB00571|https://www.drugbank.ca/drugs/DB00571|https://www.drugbank.ca/drugs/DB00571|https://www.drugbank.ca/drugs/DB00571|https://www.drugbank.ca/drugs/DB00571	adrenergic receptor antagonist			
biotin	biotin		OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12	Launched	FDA Orange Book: biotin	SLC5A6|ACACA|ACACB|PCCB|PCCA|HLCS|PC|MCCC2|MCCC1	https://www.drugbank.ca/drugs/DB00121|https://www.drugbank.ca/drugs/DB00121|https://www.drugbank.ca/drugs/DB00121|https://www.drugbank.ca/drugs/DB00121|https://www.drugbank.ca/drugs/DB00121|https://www.drugbank.ca/drugs/DB00121|https://www.drugbank.ca/drugs/DB00121|https://www.drugbank.ca/drugs/DB00121|https://www.drugbank.ca/drugs/DB00121	vitamin B			
CYM-50260	CYM-50260		FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1	Preclinical		S1PR4	https://www.tocris.com/products/cym-50260_4677	sphingosine 1 phosphate receptor agonist			
CD-1530	CD-1530		OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2	Preclinical		RARG	http://www.tocris.com/dispprod.php?ItemId=162835#.UuFhCf30BaE	retinoid receptor agonist			
dicloralurea	dicloralurea	SK&F 1995	OC(NC(=O)NC(O)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl	Preclinical							
ICA-110381	ICA-110381		Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1	Preclinical		KCNQ2	https://www.tocris.com/products/ica-110381_4950	voltage-gated potassium channel activator			
ticarcillin	ticarcillin	ticar		Launched	FDA Orange Book: ticarcillin disodium			lactamase inhibitor	infectious disease	gram-negative bacterial infections	https://en.wikipedia.org/wiki/Ticarcillin
chlorzoxazone	chlorzoxazone	Parafon Forte|Parafon-Forte|Strifon forte dsc|paraflex|parafon|parafon forte dsc|strifon	Clc1ccc2oc(=O)[nH]c2c1	Launched	FDA Orange Book: chlorzoxazone	KCNMA1|KCNN4	https://www.drugbank.ca/drugs/DB00356|ChEMBL	bacterial 30S ribosomal subunit inhibitor	neurology/psychiatry	muscle relaxant	https://en.wikipedia.org/wiki/Chlorzoxazone
LB-100	LB-100			Phase 1	https://clinicaltrials.gov/ct2/show/NCT01837667			protein phosphatase inhibitor			
NO-ASA	NO-ASA		CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+]([O-])=O)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01256775	IKBKB|INS|PTGS1|PTGS2	https://citeline.informa.com/?query=#/drugs/details/12453|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=252036|https://citeline.informa.com/?query=#/drugs/details/12453|http://www.ncbi.nlm.nih.gov/pubmed/9753266	cyclooxygenase inhibitor			
daptomycin	daptomycin	cubicin	CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)c2ccccc2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@@H](C)CC(O)=O	Launched	FDA Orange Book: daptomycin			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease	skin infections|endocarditis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e33053a5-38cd-4a34-8566-208f94f55714|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e33053a5-38cd-4a34-8566-208f94f55714
VU-0364739	VU-0364739		Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1	Preclinical		PLD2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5287	phospholipase inhibitor			
quetiapine	quetiapine	seroquel|seroquel xr	OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12	Launched	FDA Orange Book: quetiapine fumarate	HTR7|HTR6|HTR3A|HTR2A|HTR2C|HTR1F|HTR1E|HTR1B|HTR1A|HTR1D|HRH1|ADRA2C|ADRA2B|ADRA2A|ADRA1D|ADRA1B|ADRA1A|SLC6A2|CHRM3|CHRM2|CHRM5|CHRM4|CHRM1|DRD3|DRD2|DRD1|DRD5|DRD4	https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=50|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=50|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224|https://www.drugbank.ca/drugs/DB01224	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry|neurology/psychiatry	schizophrenia|bipolar disorder	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=904f80af-44b6-d964-1680-ac9e6b61327b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=904f80af-44b6-d964-1680-ac9e6b61327b
deptropine	deptropine		CN1[C@H]2CC[C@@H]1CC(C2)OC1c2ccccc2CCc2ccccc12	Preclinical		HRH1	http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI%3A50190	histamine receptor antagonist			
SR-3677	SR-3677		CN(C)CCOc1cc(ccc1NC(=O)C1COc2ccccc2O1)-c1cn[nH]c1	Preclinical		ROCK2	https://www.tocris.com/products/sr-3677-dihydrochloride_3667	rho associated kinase inhibitor			
allantoin	allantoin		NC(=O)NC1NC(=O)NC1=O	Launched	http://www.drugs.com/international/allantoin.html			cosmetic	dermatology	skin protectant	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3333c1b0-3fc2-4cf1-a7f0-b5e4c84ae8bb
CB-10-277	CB-10-277	CB-10-277-(free-acid)	CN(C)\N=N\c1ccc(cc1)C(O)=O	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/?term=CB-10-277%5Bti%5D			DNA synthesis inhibitor			
balicatib	balicatib		CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00371670	CTSK	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7861	cathepsin inhibitor			
choline	choline	choline c-11	C[N+](C)(C)CCO	Phase 3	Pharmaprojects	PHOSPHO1|CHRNA2|PLD2|PLD1|PCYT1B|PCYT1A|ACHE|BCHE	https://www.drugbank.ca/drugs/DB00122|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011828|https://www.drugbank.ca/drugs/DB00122|https://www.drugbank.ca/drugs/DB00122|https://www.drugbank.ca/drugs/DB00122|https://www.drugbank.ca/drugs/DB00122|https://www.drugbank.ca/drugs/DB00122|https://www.drugbank.ca/drugs/DB00122	acetylcholine precursor			
talniflumate	talniflumate	BA 7602-06|somalgen	FC(F)(F)c1cccc(Nc2ncccc2C(=O)OC2OC(=O)c3ccccc23)c1	Launched	http://www.drugs.com/international/Talniflumate.html	CLCA1	http://www.tocris.com/dispprod.php?ItemId=159450	cyclooxygenase inhibitor	neurology/psychiatry	pain relief	http://www.drugs.com/international/talniflumate.html
floctafenine	floctafenine	R 4318|RU 15750|idarac	OCC(O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F	Launched	https://www.drugs.com/international/floctafenine.html	PTGS1|PTGS2	http://www.genome.jp/dbget-bin/www_bget?dr:D01267|http://www.genome.jp/dbget-bin/www_bget?dr:D01267	cyclooxygenase inhibitor	neurology/psychiatry	pain relief	https://myhealth.alberta.ca/Health/medications/Pages/conditions.aspx?hwid=fdb1186
SHP099	SHP099		CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl	Preclinical		PTPN11	https://www.caymanchem.com/product/20000	protein tyrosine kinase inhibitor			
gatifloxacin	gatifloxacin	AM-1155|BMS-206584-01|tequin|zymar|zymaxid	COc1c(N2CCNC(C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs			bacterial DNA gyrase inhibitor			
pipemidic-acid	pipemidic acid	pipemidic acid|pipemidic acid trihydrate	CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCNCC1	Launched	http://www.drugs.com/international/pipemidic-acid.html			topoisomerase inhibitor	infectious disease	gram-negative bacterial infections	http://www.drugs.com/international/pipemidic-acid.html
bemegride	bemegride	megimide|methetharimide	CCC1(C)CC(=O)NC(=O)C1	Launched	http://www.drugs.com/international/bemegride.html	GABRA1	http://www.ncbi.nlm.nih.gov/pubmed/2160252	chemoreceptor agonist	critical care	poison antidote	https://en.wikipedia.org/wiki/Bemegride
chloralose	chloralose		OCC(O)[C@H]1O[C@@H]2O[C@@H](O[C@@H]2[C@H]1O)C(Cl)(Cl)Cl	Preclinical							
dibenzepine	dibenzepine	dibenzepin	CN(C)CCN1c2ccccc2N(C)c2ccccc2C1=O	Preclinical				norepinephrine reputake inhibitor			
LY2157299	LY2157299	LY-2157299|galunisertib	Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT02008318	TGFBR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7797	TGF beta receptor inhibitor			
calcitriol	calcitriol	1ALPHA,25-DIHYDROXYCHOLECALCIFEROL|1ALPHA,25-DIHYDROXYVITAMIN D3|Dihydroxycholecalciferol|Dihydroxyvitamin D 3|RO 21-5535|Ro-21-5535|Topitriol|calcijex|rocaltrol|vectical	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	Launched	FDA Orange Book: calcitriol	VDR|CYP3A5	ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070044	vitamin D receptor agonist	endocrinology|endocrinology|orthopedics	hypocalcemia|hypoparathyroidism|osteoporosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdcaffc6-e14e-4607-b77b-fc78a8382f60|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdcaffc6-e14e-4607-b77b-fc78a8382f60|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdcaffc6-e14e-4607-b77b-fc78a8382f60
LY2801653	LY2801653	LY-2801653|merestinib	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1	Phase 2	http://www.lilly.com/SiteCollectionDocuments/Pipeline/Clinical%20Development%20Pipeline/index.html	MST1R|MET	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=689871|http://www.apexbt.com/ly2801653.html	MET inhibitor			
birinapant	birinapant	TL32711	CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01681368	BIRC2|BIRC3|XIAP	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7432|https://citeline.informa.com/?query=#/drugs/details/42169|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7432	XIAP inhibitor			
BINA	BINA		Cc1c2C(=O)C(Cc2cc(OCc2cccc(c2)-c2ccc(cc2)C(O)=O)c1C)C1CCCC1	Preclinical		GRM2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3954	glutamate receptor positive allosteric modulator			
triacetin	triacetin	E1518|eastman triacetin|enzactin|glyceryl triacetate	CC(=O)OCC(COC(C)=O)OC(C)=O	Launched	http://www.drugs.com/international/triacetin.html						
SB-269970	SB-269970		CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1	Preclinical		HTR7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3233	serotonin receptor antagonist			
GSK1070916	GSK1070916	GSK-1070916	CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01118611	CYP2D6|CYP3A4|AURKB|AURKA|AURKC	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010677|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010677|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010677|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010677|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010677	Aurora kinase inhibitor			
HC-030031	HC-030031		CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1	Phase 1	http://www.biospace.com/News/cubist-pharmaceuticals-inc-and-hydra-biosciences/245862	TRPA1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4211	TRPA1 channel blocker			
SB-612111	SB-612111		Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12	Preclinical		OPRL1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1693	nociceptin/orphanin FQ (NOP) receptor antagonist			
sibutramine	sibutramine	meridia	CC(C)CC(N(C)C)C1(CCC1)c1ccc(Cl)cc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	CYP2B6|CYP3A5|CYP2C19|SLC6A2|SLC6A4|SLC6A3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=125655|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=125655|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=125655|https://www.drugbank.ca/drugs/DB01105|https://www.drugbank.ca/drugs/DB01105|https://www.drugbank.ca/drugs/DB01105	serotoninnorepinephrine reuptake inhibitor (SNRI)			
AY-9944	AY-9944		Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1	Preclinical				hedgehog pathway modulator			
cefoperazone	cefoperazone	cefobid	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O	Launched	FDA Orange Book: cefoperazone sodium			bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections	https://en.wikipedia.org/wiki/Cefoperazone
MRS1845	MRS1845	MRS-1845	CCOC(=O)C1=C(C)N(CC#C)C(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC	Preclinical				calcium channel blocker			
celecoxib	celecoxib	Celebra|Onsenal|SC-58635|celebrex	Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F	Launched	FDA Orange Book: celecoxib	CYP2C19|PDPK1|CASP3|CA12|PTGS2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=228583|https://www.drugbank.ca/drugs/DB00482|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=228583|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2892|ChEMBL	cyclooxygenase inhibitor	rheumatology|rheumatology|rheumatology|endocrinology	osteoarthritis|rheumatoid arthritis|ankylosing spondylitis|primary dysmenorrhea (PD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=457eb10a-1188-4c43-a147-d258517342e8|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=457eb10a-1188-4c43-a147-d258517342e8|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=457eb10a-1188-4c43-a147-d258517342e8|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=457eb10a-1188-4c43-a147-d258517342e8
gabexate	gabexate	gabexate mesilate	CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1	Launched	http://www.drugs.com/international/Gabexate.html	TPSAB1|PRSS1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7863|www.tocris.com/dispprod.php?ItemId=77651	serine protease inhibitor	gastroenterology	pancreatitis	https://en.wikipedia.org/wiki/Gabexate
glycerol-monolaurate	Glycerol Monolaurate	Glycerol Monolaurate	CCCCCCCCCCCC(=O)OCC(O)CO	Launched	https://en.wikipedia.org/wiki/Monolaurin			beta lactamase inhibitor			
sulbutiamine	sulbutiamine		CC(C)C(=O)OCC\C(SS\C(CCOC(=O)C(C)C)=C(/C)N(Cc1cnc(C)nc1N)C=O)=C(\C)N(Cc1cnc(C)nc1N)C=O	Launched	http://www.drugs.com/international/Sulbutiamine.html			acetylcholine receptor antagonist	neurology/psychiatry	asthenia	https://en.wikipedia.org/wiki/Sulbutiamine
VU0361737	VU0361737		COc1cc(NC(=O)c2ccccn2)ccc1Cl	Preclinical		GRM4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3956	glutamate receptor positive allosteric modulator			
pyrethrins	pyrethrins		CC(C)=C[C@@H]1[C@@H](C(=O)O[C@H]2CC(=O)C(C\C=C/C=C)=C2)C1(C)C	Launched	FDA Orange Book: pyrethrins						
CGP-13501	CGP-13501		CC(C)(Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)C=O	Preclinical		GABBR1	http://www.tocris.com/dispprod.php?ItemId=34269#.Utakh_15mf0	GABA receptor modulator			
DR-4485	DR-4485		Clc1ccc(cc1)C1=CCN(CCCCC23CCCc4c2c(NC3=O)ccc4Cl)CC1	Preclinical		HTR7	https://www.tocris.com/products/dr-4485-hydrochloride_5005	serotonin receptor antagonist			
SNAP	SNAP	snap (s-nitroso-n-acetylpenicillamine)	CC(=O)NC(C(O)=O)C(C)(C)S[N+][O-]	Phase 2	Pharmaprojects	PTPN1	http://www.ncbi.nlm.nih.gov/pubmed/12117721	nitric oxide donor			
dimenhydrinate	dimenhydrinate	chloranautine|dramamine	Cn1c2nc(Cl)[nH]c2c(=O)n(C)c1=O.CN(C)CCOC(c1ccccc1)c1ccccc1	Launched	FDA Orange Book: dimenhydrinate	HRH1	ChEMBL	histamine receptor antagonist	neurology/psychiatry|gastroenterology|gastroenterology	motion sickness|nausea|vomiting	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4e1e0e9-a7cf-4c10-9e1b-0f4110be0767|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4e1e0e9-a7cf-4c10-9e1b-0f4110be0767|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4e1e0e9-a7cf-4c10-9e1b-0f4110be0767
GSK2330672	GSK2330672		CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01899703	SLC10A2	http://pubs.acs.org/doi/abs/10.1021/jm400459m	bile acid transporter inhibitor			
cot-inhibitor-2	cot-inhibitor-2		CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1	Preclinical		MAP3K8|TNF	http://www.apexbt.com/cot-inhibitor-2.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=667355	MAPK-interacting kinase inhibitor			
cot-inhibitor-1	cot-inhibitor-1		Fc1ccc(Nc2c(cnc3c(Cl)cc(NCc4cn(CCN5CCCCCC5)nn4)cc23)C#N)cc1Cl	Preclinical		MAP3K8|TNF	https://www.medchemexpress.com/Cot-inhibitor-1.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=434319	MAPK-interacting kinase inhibitor			
acalisib	acalisib		C[C@H](Nc1ncnc2[nH]cnc12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01705847	PIK3CD|PIK3CB	http://www.medkoo.com/products/5030|http://www.medkoo.com/products/5030	PI3K inhibitor			
resatorvid	resatorvid	TAK-242	CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00143611	TLR4	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000620	toll-like receptor antagonist			
aurothioglucose	aurothioglucose		OC[C@H]1OC(S[Au])[C@H](O)[C@@H](O)[C@@H]1O	Launched	http://en.wikipedia.org/wiki/Aurothioglucose	PRKCI	http://www.sigmaaldrich.com/catalog/product/sigma/a0606?lang=en&region=US	PKC inhibitor	rheumatology	rheumatoid arthritis	http://www.medicinenet.com/aurothioglucose/article.htm
GK921	GK921		C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1	Preclinical		TGM2	https://www.medchemexpress.com/gk921.html	transglutaminase inhibitor			
AMG-925	AMG-925		C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12	Phase 1	http://www.flxbio.com/initiation-of-phase-1-trial-of-flx925	FLT3|CDK4|CDK6	http://www.apexbt.com/amg-925.html|http://www.apexbt.com/amg-925.html|http://www.apexbt.com/amg-925.html	CDK inhibitor|FLT3 inhibitor			
compound-w	compound-w		OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1	Preclinical		BACE1	http://www.tocris.com/dispprod.php?ItemId=5187#.VfgtoGRVhHw	beta-secretase inhibitor			
cefradine	cefradine	Ecosporina|SK&F D-39304|SK-D-39304|SQ 11436|SQ 22022 [DIHYDRATE]|SQ-11436|SQ-22022|Velosef '125'|Velosef '250'|Velosef '500'|anspor|cephradine|velosef	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O	Launched	https://www.drugs.com/international/cefradine.html	CYP3A4	http://www.drugbank.ca/drugs/DB01333	bacterial cell wall synthesis inhibitor	infectious disease|otolaryngology|infectious disease|infectious disease|otolaryngology|otolaryngology|infectious disease	respiratory tract infections|otitis|skin infections|urinary tract infections|tonsillitis|pharyngitis|pneumonia	https://en.wikipedia.org/wiki/Cefradine|https://en.wikipedia.org/wiki/Cefradine|https://en.wikipedia.org/wiki/Cefradine|https://en.wikipedia.org/wiki/Cefradine|https://en.wikipedia.org/wiki/Cefradine|https://en.wikipedia.org/wiki/Cefradine|https://en.wikipedia.org/wiki/Cefradine
arofylline	arofylline	LAS 31025	CCCn1c(=O)n(-c2ccc(Cl)cc2)c2[nH]cnc2c1=O	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/18046869	PDE4A|PDE4B|PDE4C|PDE4D	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000700|https://citeline.informa.com/?query=#/drugs/details/1968|https://citeline.informa.com/?query=#/drugs/details/1968|https://citeline.informa.com/?query=#/drugs/details/1968	phosphodiesterase inhibitor			
PF-04691502	PF-04691502		COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01430585	MTOR|PIK3CG|PIK3CD|PIK3CA|PIK3CB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7936|https://citeline.informa.com/?query=#/drugs/details/62521|https://citeline.informa.com/?query=#/drugs/details/62521|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7936|https://citeline.informa.com/?query=#/drugs/details/62521	mTOR inhibitor|PI3K inhibitor			
SRC-kinase-inhibitor-I	SRC-kinase-inhibitor-I		COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC	Preclinical		LCK|CSK|RIPK2	http://www.scbt.com/datasheet-204303-src-kinase-inhibitor-i.html|http://www.scbt.com/datasheet-204303-src-kinase-inhibitor-i.html|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6042	src inhibitor			
ML167	ML167		Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1	Preclinical		DYRK1B|CLK1|CLK4	http://www.sigmaaldrich.com/catalog/product/sigma/sml0924?lang=en&region=US|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=726474|http://www.sigmaaldrich.com/catalog/product/sigma/sml0924?lang=en&region=US	CLK inhibitor|DYRK inhibitor			
ML161	ML161		CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1	Preclinical				protease-activated receptor inhibitor			
halothane	halothane	Rhidialothan|fluothane	FC(F)(F)C(Cl)Br	Launched	FDA Orange Book: halothane	ATP5D|GABRG3|GABRG2|GABRG1|GABRA6|GABRA1|GABRA5|GABRA4|GABRA3|GABRA2|GABRB2|GABRB1|GABRB3|GLRA1|ATP2C1|NPSR1|MT-ND1|RHO|KCNMA1|KCNK10|KCNK12|KCNK13|KCNK15|KCNK18|GABRE|GABRD|GABRP|GABRQ|KCNN4|KCNJ3|KCNJ6|KCNK2|KCNK3|KCNK9|GRIN2A|GNG2|CYP2E1|GRIN3B|GRIN3A|GLRB	https://www.drugbank.ca/drugs/DB01159|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB01159|https://www.drugbank.ca/drugs/DB01159|https://www.drugbank.ca/drugs/DB01159|https://www.drugbank.ca/drugs/DB01159|https://www.drugbank.ca/drugs/DB01159|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2401|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2401|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2401|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB01159|https://www.drugbank.ca/drugs/DB01159|https://www.drugbank.ca/drugs/DB01159|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB01159|https://www.drugbank.ca/drugs/DB01159|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091316|https://www.drugbank.ca/drugs/DB01159|https://www.drugbank.ca/drugs/DB01159|ChEMBL	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic	http://www.drugs.com/pro/halothane.html
morinidazole	morinidazole		Cc1ncc(n1CC(O)CN1CCOCC1)[N+]([O-])=O	Launched	http://aac.asm.org/content/58/10/5987.short	CYP51A1	http://www.drugbank.ca/drugs/DB00916	other antibiotic			
ammonium-lactate	ammonium lactate	BMS-186091|E328|ammonium lactate|lac-hydrin	N.CC(O)C(O)=O	Launched	FDA Orange Book: ammonium lactate	HCAR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2932		dermatology|dermatology	xerosis cutis|ichthyosis vulgaris	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34d21510-062e-40ab-b074-ae3a0dc65e68|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34d21510-062e-40ab-b074-ae3a0dc65e68
goserelin-acetate	goserelin acetate	ICI 118,630|ICI-118630|goserelin|zoladex	CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O	Launched	FDA Orange Book: goserelin acetate	LHCGR|GNRH1|GNRHR	https://www.drugbank.ca/drugs/DB00014|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090110|https://www.drugbank.ca/drugs/DB00014	gonadotropin releasing factor hormone receptor agonist	oncology|oncology|obstetrics/gynecology	prostate cancer|breast cancer|endometriosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6bd94a89-f18a-45e5-d0a4-b343a4f0f03d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6bd94a89-f18a-45e5-d0a4-b343a4f0f03d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6bd94a89-f18a-45e5-d0a4-b343a4f0f03d
dehydrocorydaline	dehydrocorydaline		COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4c(C)c3-c2cc1OC	Phase 3	https://www.ncbi.nlm.nih.gov/pubmed/4597775	AKR1B1|ACHE	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=151126|http://www.abcam.com/dehydrocorydaline-chloride-ab145576.html	acetylcholinesterase inhibitor			
metaxalone	metaxalone	AHR-438|skelaxin	Cc1cc(C)cc(OCC2CNC(=O)O2)c1	Launched	FDA Orange Book: metaxalone			muscle relaxant	neurology/psychiatry	muscle pain	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f06f2b96-3684-483c-89f7-6c9201fd4664
lithocholic-acid	lithocholic acid		C[C@H](CCC(O)=O)[C@@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Preclinical		GPBAR1|MDM2|MDM4|NR1I2|NR1H4|PTPN1|VDR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=611|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=796660|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=796660|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=611|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000880|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=796660|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=611	FXR antagonist|vitamin D receptor agonist			
bergapten	bergapten		COc1c2ccoc2cc2oc(=O)ccc12	Preclinical							
UF-010	UF-010		CCCCNNC(=O)c1ccc(Br)cc1	Preclinical		HDAC8|HDAC1|HDAC2|HDAC3	https://www.tocris.com/products/uf-010_5588|https://www.tocris.com/products/uf-010_5588|https://www.tocris.com/products/uf-010_5588|https://www.tocris.com/products/uf-010_5588	HDAC inhibitor			
CE3F4	CE3F4		CC1CCc2c(cc(Br)c(F)c2Br)N1C=O	Preclinical		RAPGEF3	https://www.tocris.com/products/ce3f4_4793	rap guanine nucleotide exchange factor inhibitor			
eliprodil	eliprodil		OC(CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/24502346	GRIN2B|GRIN1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011295|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011295	glutamate receptor antagonist			
hexamethylenebisacetamide	hexamethylenebisacetamide		CC(=O)NCCCCCCNC(C)=O	Phase 2	http://www.bloodjournal.org/content/bloodjournal/80/10/2604.full.pdf?sso-checked=true	AKT1	https://www.ncbi.nlm.nih.gov/pubmed/19029824	AKT inhibitor|differentiation inducer|NFKB pathway inhibitor			
tanaproget	tanaproget	NSP-989	Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/17046384	PGR	https://www.drugbank.ca/drugs/DB04787	progesterone receptor agonist			
3-methyladenine	3-methyladenine		Cn1cnc(=N)c2nc[nH]c12	Preclinical		PI3	http://www.ncbi.nlm.nih.gov/gene/?term=PI3K	PI3K inhibitor			
SB-525334	SB-525334		Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C	Preclinical		TGFBR1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010927	TGF beta receptor inhibitor			
3'-fluorobenzylspiperone	3'-fluorobenzylspiperone		Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1	Preclinical		DRD2	http://www.scbt.com/datasheet-361079.html	dopamine receptor ligand			
HKI-357	HKI-357		CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00550381	EGFR	https://www.tocris.com/dispprod.php?ItemId=230170#.V-mVspMrLy8	EGFR inhibitor			
fosphenytoin	fosphenytoin	cerebyx|fosphenytoin sodium	OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1	Launched	FDA Orange Book: fosphenytoin sodium	CYP2C19|SCN5A|SCN3A|SCN1A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=126926|https://www.drugbank.ca/drugs/DB01320|https://citeline.informa.com/?query=#/drugs/details/7469|https://citeline.informa.com/?query=#/drugs/details/7469	sodium channel blocker	neurology/psychiatry|neurology/psychiatry	epilepsy|seizures	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b60c9c82-e5c7-4e05-98c7-5bbba4af04b2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b60c9c82-e5c7-4e05-98c7-5bbba4af04b2
endo-IWR-1	endo-IWR-1		O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O	Preclinical		TNKS|TNKS2	https://www.emdmillipore.com/US/en/product/Wnt-Antagonist-I%2C-IWR-1-endo---Calbiochem,EMD_BIO-681669|https://www.emdmillipore.com/US/en/product/Wnt-Antagonist-I%2C-IWR-1-endo---Calbiochem,EMD_BIO-681669	PARP inhibitor			
GPI-1046	GPI-1046		CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCc1cccnc1	Preclinical		FKBP1A	https://www.drugbank.ca/drugs/DB01951	FKBP inhibitor			
SR-11302	SR-11302		CC(\C=C\C=C(\C=C\C1=C(C)CCCC1(C)C)c1ccc(C)cc1)=C/C(O)=O	Preclinical							
vinorelbine	vinorelbine	Vinorelbine Base|navelbine		Launched	FDA Orange Book: vinorelbine, vinorelbine tartrate	TUBB1|TUBB8|TUBB6|TUBB3|TUBA1B|TUBA1A|TUBA1C|TUBA3D|TUBA3C|TUBA3E|TUBA4A|TUBB2B|TUBB2A|TUBB4B|TUBB4A|TUBB	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	tubulin polymerization inhibitor	oncology	non-small cell lung cancer (NSCLC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd3dcc9a-e40c-4677-9ee6-f318e7c7d835
RS-39604	RS-39604		COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1	Preclinical		HTR4	http://www.tocris.com/dispprod.php?ItemId=1038#.UufJnKX0CMI	serotonin receptor antagonist			
ABC-294640	ABC-294640		Clc1ccc(cc1)C12CC3CC(CC(C3)(C1)C(=O)NCc1ccncc1)C2	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT02229981	SPHK2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624	sphingosine kinase inhibitor			
PRIMA1	PRIMA1		OCC1(CO)N2CCC(CC2)C1=O	Preclinical		ACHE	http://en.wikipedia.org/wiki/PRIMA1	TP53 inhibitor			
PCI-29732	PCI-29732		Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)C1CCCC1	Preclinical		BTK	https://www.tocris.com/products/pci-29732_5012	Bruton's tyrosine kinase (BTK) inhibitor			
TRIM	TRIM	1-[2-(Trifluoromethyl)Phenyl]Imidazole	FC(F)(F)c1ccccc1-n1ccnc1	Preclinical							
pozanicline	pozanicline	A-87089.0|ABT-089	Cc1ncccc1OC[C@@H]1CCCN1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01756053	CHRNA4|CHRNB2	https://www.drugbank.ca/drugs/DB05458|https://www.drugbank.ca/drugs/DB05458	acetylcholine receptor antagonist			
diphencyprone	diphencyprone		O=c1c(c1-c1ccccc1)-c1ccccc1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/25653027			immunostimulant			
spirobromin	spirobromin	dibrospidium	BrCCC(=O)N1CC[N+]2(CC1)CC[N+]1(CCN(CC1)C(=O)CCBr)CC2	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/3678800						
risperidone	risperidone	R 64 766|R-64-766|R-64766|Risperdal Consta Long Acting|Risperdal M|risperdal|risperdal consta|risperdal m-tab	Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12	Launched	FDA Orange Book: risperidone	HTR7|HTR6|CYP3A5|HRH1|ADRA2C|ADRA2A|ADRA2B|ADRA1D|ADRA1B|ADRA1A|DRD3|DRD4|DRD1|DRD2|HTR2A|HTR2C|HTR1D|HTR1E|HTR1F|HTR1A|HTR1B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=96|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=96|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=127142|https://www.drugbank.ca/drugs/DB00734|https://www.drugbank.ca/drugs/DB00734|https://www.drugbank.ca/drugs/DB00734|https://www.drugbank.ca/drugs/DB00734|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=96|https://www.drugbank.ca/drugs/DB00734|https://www.drugbank.ca/drugs/DB00734|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00734|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00734|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=96|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=96|https://www.drugbank.ca/drugs/DB00734|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=96	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	schizophrenia|bipolar disorder|irritability	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c3250f3-d291-4280-97d5-da3bb171e2b6|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c3250f3-d291-4280-97d5-da3bb171e2b6|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c3250f3-d291-4280-97d5-da3bb171e2b6
ribostamycin-sulfate	ribostamycin sulfate		NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)C2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	Launched	http://www.drugs.com/international/ribostamycin-sulfate.html	P4HB	https://www.drugbank.ca/drugs/DB03615	bacterial 30S ribosomal subunit inhibitor	infectious disease	gram-negative bacterial infections	http://www.drugs.com/international/ribostamycin.html
ceftriaxone	ceftriaxone	rocephin	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1	Launched	FDA Orange Book: ceftriaxone sodium			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|otolaryngology|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	gonorrhea|pneumonia|otitis|skin infections|urinary tract infections|pelvic inflammatory disease|bacterial septicemia|bone and joint infections|intra-abdominal infections|meningitis|surgical prophylaxis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73acbe07-ba46-42c4-8634-b024a44c3bf1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73acbe07-ba46-42c4-8634-b024a44c3bf1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73acbe07-ba46-42c4-8634-b024a44c3bf1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73acbe07-ba46-42c4-8634-b024a44c3bf1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73acbe07-ba46-42c4-8634-b024a44c3bf1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73acbe07-ba46-42c4-8634-b024a44c3bf1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73acbe07-ba46-42c4-8634-b024a44c3bf1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73acbe07-ba46-42c4-8634-b024a44c3bf1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73acbe07-ba46-42c4-8634-b024a44c3bf1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73acbe07-ba46-42c4-8634-b024a44c3bf1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73acbe07-ba46-42c4-8634-b024a44c3bf1
NAV-26	NAV-26		FC(F)(F)Oc1ccc(CNC(=O)C2N(C3CCOCC3)C(=O)c3ccccc23)cc1	Preclinical		SCN9A	https://www.tocris.com/products/nav-26_4691	voltage-gated sodium channel blocker			
citicoline	citicoline		C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O	Launched	http://www.drugs.com/international/citicoline.html	SLC1A2|ACHE	https://en.wikipedia.org/wiki/Citicoline#Mechanism_of_action|https://en.wikipedia.org/wiki/Citicoline	membrane permeability enhancer|glutathione transferase stimulant	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|ophthalmology	stroke|Alzheimer's disease|senile dementia|Parkinson's Disease|attention-deficit/hyperactivity disorder (ADHD)|glaucoma	http://www.webmd.com/vitamins-supplements/ingredientmono-1090-citicoline.aspx?activeingredientid=1090&activeingredientname=citicoline|http://www.webmd.com/vitamins-supplements/ingredientmono-1090-citicoline.aspx?activeingredientid=1090&activeingredientname=citicoline|http://www.webmd.com/vitamins-supplements/ingredientmono-1090-citicoline.aspx?activeingredientid=1090&activeingredientname=citicoline|http://www.webmd.com/vitamins-supplements/ingredientmono-1090-citicoline.aspx?activeingredientid=1090&activeingredientname=citicoline|http://www.webmd.com/vitamins-supplements/ingredientmono-1090-citicoline.aspx?activeingredientid=1090&activeingredientname=citicoline|http://www.webmd.com/vitamins-supplements/ingredientmono-1090-citicoline.aspx?activeingredientid=1090&activeingredientname=citicoline
m-THP	m-THP		Oc1cccc(c1)-c1c2ccc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2	Phase 1	Integrity						
doconexent-ethyl-ester	doconexent-ethyl-ester		CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC	Launched	http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=52869			omega 3 fatty acid stimulant			
EVP4593	EVP4593		Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1	Preclinical				NFkB pathway inhibitor			
ammonium-perfluorocaprylate	ammonium-perfluorocaprylate	2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-Pentadecafluoro-Octanoic Acid	OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	Phase 1	http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=9443	PIM1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.exec_form_pro_pr?p_par_pro=PRO_DRUG_NAME&p_val_pro=ammonium-perfluorocaprylate&p_origen=PROD&p_oper_pro=AND&p_par_tar=&p_val_tar=&p_oper_tar=AND&p_par_ref=&p_val_ref=&p_oper_ref=AND&p_par_pat=&p_val_pat=&p_oper_pat=AND	Pim kinase inhibitor			
lirimilast	lirimilast		CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(oc2c1)C(=O)c1ccc(Cl)cc1Cl	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/14580925			phosphodiesterase inhibitor			
A740003	A740003	A-740003	COc1ccc(CC(=O)NC(N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC	Preclinical		P2RX7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4119	purinergic receptor antagonist			
norgestimate	norgestimate		CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C	Launched	FDA Orange Book: norgestimate	PGR|ESR1	https://www.drugbank.ca/drugs/DB00957|https://www.drugbank.ca/drugs/DB00957	progesterone receptor agonist	endocrinology	contraceptive	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=beabee48-1912-47bf-a9b5-d5c426c4fcc2
VU10010	VU10010		Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1	Preclinical		CHRM4	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014424	acetylcholine receptor allosteric modulator			
oxiconazole	oxiconazole	Oxizole|oxistat	Clc1ccc(CO\N=C(/Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	Launched	FDA Orange Book: oxiconazole nitrate			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease	tinea pedis|tinea cruris|tinea corporis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=094d5b1e-ccf6-4384-b208-fd70360ffda2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=094d5b1e-ccf6-4384-b208-fd70360ffda2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=094d5b1e-ccf6-4384-b208-fd70360ffda2
desoxycorticosterone-pivalate	desoxycorticosterone pivalate	desoxycorticosterone pivalate|percorten	CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	Veterinary Launched	http://www.drugbank.ca/drugs/DB01134	NR3C2	ChEMBL	corticosteroid agonist	endocrinology	Addison's disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c9b766a-c36b-44aa-bbd8-24fab24ca97c
sulfachlorpyridazine	sulfachlorpyridazine	Sulfachloropyridazine|nefrosul|sonilyn|sulphachlorpyridazine	Nc1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)nn1	Launched	http://www.drugs.com/international/sulfachlorpyridazine.html			bacterial antifolate	infectious disease	urinary tract infections	http://www.drugs.com/international/sulfachlorpyridazine.html
clonazepam	clonazepam	RO 5-4023|Ro-5-4023|klonopin|klonopin rapidly disintegrating	[O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1	Launched	FDA Orange Book: clonazepam	GABRG1|GABRG2|GABRG3|GABRB3|GABRB1|GABRB2|GABRA2|GABRA3|GABRA4|GABRA5|GABRA1|GABRA6|GABRQ|GABRD|GABRE|GABRP|TSPO	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB01068	GABA benzodiazepine site receptor agonist	neurology/psychiatry|neurology/psychiatry	seizures|panic disorders	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acbce0e8-5098-4785-943b-8bdb5ff17fab|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acbce0e8-5098-4785-943b-8bdb5ff17fab
pexmetinib	pexmetinib		Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/25480830	MAPK14|TEK	http://www.selleckchem.com/products/pexmetinib-arry-614.html|http://www.selleckchem.com/products/pexmetinib-arry-614.html	TIE tyrosine kinase inhibitor|MAP kinase inhibitor			
norepinephrine	norepinephrine	R-norepinephrine|levophed	NC[C@H](O)c1ccc(O)c(O)c1	Launched	FDA Orange Book: norepinephrine bitartrate	SLC18A2|SLC18A1|ADRB3|ADRB2|ADRB1|PAH|ADRA1D|ADRA1B|ADRA1A|ADRA2C|ADRA2A|ADRA2B	https://www.drugbank.ca/drugs/DB00368|https://www.drugbank.ca/drugs/DB00368|https://www.drugbank.ca/drugs/DB00368|https://www.drugbank.ca/drugs/DB00368|https://www.drugbank.ca/drugs/DB00368|https://www.drugbank.ca/drugs/DB00368|https://www.drugbank.ca/drugs/DB00368|https://www.drugbank.ca/drugs/DB00368|https://www.drugbank.ca/drugs/DB00368|https://www.drugbank.ca/drugs/DB00368|https://www.drugbank.ca/drugs/DB00368|https://www.drugbank.ca/drugs/DB00368	adrenergic receptor agonist	cardiology|allergy|neurology/psychiatry|neurology/psychiatry	hypertension|urticaria|headache|seasonal affective disorder	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28f82bb6-1769-490d-ba28-2b382b6e6aca|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28f82bb6-1769-490d-ba28-2b382b6e6aca|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28f82bb6-1769-490d-ba28-2b382b6e6aca|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28f82bb6-1769-490d-ba28-2b382b6e6aca
flumexadol	flumexadol		FC(F)(F)c1cccc(c1)C1CNCCO1	Preclinical							
vorapaxar	vorapaxar	SCH-530348|zontivity	CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1	Launched	FDA Orange Book: vorapaxar sulfate	F2R	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4047	thrombin receptor antagonist	cardiology|cardiology	myocardial infarction|peripheral artery disease (PAD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45d79217-53cf-4240-9c43-19ee54a1dc3a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45d79217-53cf-4240-9c43-19ee54a1dc3a
pyridoxal-isonicotinoyl-hydrazone	Pyridoxal Isonicotinoyl Hydrazone	Pyridoxal Isonicotinoyl Hydrazone|Pyridoxalisonicotinoyl Hydrazone	Cc1ncc(CO)c(\C=N\NC(=O)c2ccncc2)c1O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00000588			apoptosis stimulant			
YM-201636	YM-201636		Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1	Preclinical				PI3K inhibitor			
methacholine	methacholine	provocholine	CC(C[N+](C)(C)C)OC(C)=O	Launched	FDA Orange Book: methacholine chloride	CHRM2|CHRM3|CHRM4	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004591|https://www.drugbank.ca/drugs/DB06709|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004591	acetylcholine receptor agonist	pulmonary	bronchial hyperresponsiveness diagnostic	https://en.wikipedia.org/wiki/Methacholine
bay-60-7550	bay-60-7550		COc1ccc(Cc2nn3c(nc(C)c3c(=O)[nH]2)[C@@H](CCCc2ccccc2)[C@@H](C)O)cc1OC	Preclinical		PDE2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5147	phosphodiesterase inhibitor			
butamben	butamben	butesin|butyl aminobenzoate	CCCCOC(=O)c1ccc(N)cc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs			sodium channel blocker			
relcovaptan	relcovaptan	SR-49059|TDI 0134	COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/15823830	AVPR1B|AVPR1A|OXTR|AVPR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2200|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2200|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2200|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2200	vasopressin receptor antagonist			
firategrast	firategrast	SB-683699	CCOCc1cc(OC)c(-c2ccc(C[C@H](NC(=O)c3c(F)cccc3F)C(O)=O)cc2)c(OC)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00395317	ITGB1|ITGB7|ITGA4	https://citeline.informa.com/?query=#/drugs/details/23742|https://citeline.informa.com/?query=#/drugs/details/23742|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000528	integrin antagonist			
HJC-0350	HJC-0350		Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C	Preclinical		RAPGEF4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6556	GTPase inhibitor			
omega-3-acid-esters	omega-3-acid-esters	AMR101|ethyl icosapentate|icosapent ethyl|vascepa	CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC	Launched	http://www.rxlist.com/lovaza-drug.htm			cholesterol inhibitor			
fludarabine-phosphate	fludarabine phosphate	fludara|fludarabine|fludarabine phosphate|oforta	Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O	Launched	FDA Orange Book: fludarabine phosphate	DCK|RRM2|RRM1|POLE|POLD1|POLA1|RRM2B	https://www.drugbank.ca/drugs/DB01073|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	ribonucleotide reductase inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1ffd18c-9f6b-4479-94b9-6890bc730ecc
oxytetracycline	oxytetracycline	terramycin		Launched	FDA Orange Book: oxytetracycline, oxytetracycline calcium, oxytetracycline hydrochloride			bacterial 30S ribosomal subunit inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|urology|infectious disease	chlamydia|urinary tract infections|skin infections|ear infections|gonorrhea|urethritis|Lyme disease	https://en.wikipedia.org/wiki/Oxytetracycline|https://en.wikipedia.org/wiki/Oxytetracycline|https://en.wikipedia.org/wiki/Oxytetracycline|https://en.wikipedia.org/wiki/Oxytetracycline|https://en.wikipedia.org/wiki/Oxytetracycline|https://en.wikipedia.org/wiki/Oxytetracycline|https://en.wikipedia.org/wiki/Oxytetracycline
tartaric-acid	tartaric acid	tartrate	O[C@H]([C@@H](O)C(O)=O)C(O)=O	Launched	FDA Orange Book: tartaric acid	DDX6|ATP6V1C1|TREM1|HIF1AN|B3GAT1	https://www.drugbank.ca/drugs/DB01694|https://www.drugbank.ca/drugs/DB01694|https://www.drugbank.ca/drugs/DB01694|https://www.drugbank.ca/drugs/DB01694|https://www.drugbank.ca/drugs/DB01694	antioxidant			
fotemustine	fotemustine	Muphoran|S 10036	CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)[N+][O-]	Launched	https://www.drugs.com/international/fotemustine.html	TXNRD1	https://www.drugbank.ca/drugs/DB04106	thioredoxin inhibitor	oncology	melanoma	https://en.wikipedia.org/wiki/Fotemustine
BAY-41-2272	BAY-41-2272		Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12	Preclinical		GUCY1A3|GUCY1B3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5146|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5146	guanylyl cyclase activator			
tipranavir	tipranavir	aptivus	CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1	Launched	FDA Orange Book: tipranavir			HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08982e49-d2eb-4b25-b01a-1be52fd669ef&audience=consumer
N-methyl-(-)ephedrine-[1r,2s]	N-methyl-(-)ephedrine-[1r,2s]		C[C@@H]([C@H](O)c1ccccc1)N(C)C	Preclinical							
EHop-016	EHop-016		CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12	Preclinical		RAC3|RAC1	http://www.sigmaaldrich.com/catalog/product/sigma/sml0526?lang=en&region=US|http://www.sigmaaldrich.com/catalog/product/sigma/sml0526?lang=en&region=US	Ras GTPase inhibitor			
amorolfine	amorolfine	RO 14-4767/000|amorolfine hydrochloride|loceryl	CCC(C)(C)c1ccc(CC(C)CN2C[C@H](C)O[C@H](C)C2)cc1	Launched	http://www.drugs.com/international/Amorolfine.html			membrane integrity inhibitor	infectious disease	onychomycosis	https://en.wikipedia.org/wiki/Amorolfine
papaverine	papaverine		COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC	Launched	http://www.drugs.com/international/papaverine.html	PDE5A|PDE4B|PDE10A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000959|https://www.drugbank.ca/drugs/DB01113|https://www.drugbank.ca/drugs/DB01113	phosphodiesterase inhibitor	cardiology|cardiology|hematology|gastroenterology|cardiology	myocardial infarction|angina pectoris|pulmonary embolism (PE)|colitis|vascular spasm	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e5e2ce4-7a57-4c61-a826-64c8d11d038e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e5e2ce4-7a57-4c61-a826-64c8d11d038e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e5e2ce4-7a57-4c61-a826-64c8d11d038e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e5e2ce4-7a57-4c61-a826-64c8d11d038e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e5e2ce4-7a57-4c61-a826-64c8d11d038e
K-858	K-858		CC(=O)NC1=NN(C(C)=O)C(C)(S1)c1ccccc1	Preclinical		KIF11	http://www.sigmaaldrich.com/catalog/product/sigma/k3644?lang=en&region=US	kinesin-like spindle protein inhibitor			
LY2979165	LY2979165		C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01248052	GRM2	http://www.medchemexpress.com/ly2979165.html	glutamate receptor agonist			
vincristine	vincristine	marqibo kit|oncovin|vincristine sulfate pfs	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC	Launched	FDA Orange Book: vincristine sulfate	TUBB|TUBA4A	https://www.drugbank.ca/drugs/DB00541|https://www.drugbank.ca/drugs/DB00541	tubulin polymerization inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1869e23-b93b-4407-843b-4b830319d82e
avasimibe	avasimibe	CI-1011	CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/15533865	SOAT1|ABCB1|CES1	https://citeline.informa.com/?query=#/drugs/details/2071|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=217771|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000265	ACAT inhibitor			
trimethoquinol	trimethoquinol	AQ-110|tretoquinol|trimetoquinol hydrochloride	COc1cc(CC2NCCc3cc(O)c(O)cc23)cc(OC)c1OC	Launched	https://www.drugs.com/international/inolin.html	ADRB2|ADRB3	https://www.ncbi.nlm.nih.gov/pubmed/5682242|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001470	adrenergic receptor antagonist			
verinurad	verinurad		CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(O)=O	Phase 2	http://www.pharmacodia.com/yaodu/html/v1/chemicals/df5192a28088ba286c78665fd53c8d40.html	SLC22A12	http://www.medkoo.com/products/9576	urate transporter inhibitor			
liarozole	liarozole		Clc1cccc(c1)C(c1ccc2nc[nH]c2c1)n1ccnc1	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT00282724	CYP26A1|CYP17A1|CYP19A1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008925|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=141393|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008925	cytochrome P450 inhibitor			
resveratrol	resveratrol	(E)-resveratrol|3,5,4'-Trihydroxy-trans-stilbene	Oc1ccc(cc1)\C=C\c1cc(O)cc(O)c1	Launched	http://www.drugs.com/Resveratrol.html	MAOA|XDH|SCN5A|NQO2|CSNK2A1|TXNRD2|TXNRD1|BACE1|PTGS1|PTGS2|APOA1|SIRT1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=245646|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=245646|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=245646|https://www.drugbank.ca/drugs/DB02709|https://www.drugbank.ca/drugs/DB02709|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=245646|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=245646|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=245646|https://www.drugbank.ca/drugs/DB02709|https://www.drugbank.ca/drugs/DB02709|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=245646|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=245646	cytochrome P450 inhibitor|SIRT activator			
SB-705498	SB-705498	GSK705498	FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01424514	TRPV1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4311	TRPV antagonist			
probenecid	probenecid	Probalan|Probampicin|Probecid|benemid	CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O	Launched	FDA Orange Book: probenecid	SLC22A8|SLC22A6|ABCC1|SLC22A11|SLCO1C1|PANX1|TRPV2	ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=278982|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4357|https://www.drugbank.ca/drugs/DB01032|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=278982	uricosuric blocker	nephrology|rheumatology	hyperuricemia|gout	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab497fd8-00c3-4364-b003-b39d21fbdf38|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab497fd8-00c3-4364-b003-b39d21fbdf38
BTB06584	BTB06584		[O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1	Preclinical		ATP5F1	http://www.selleckchem.com/products/btb06584.html	ATPase inhibitor			
vanitiolide	vanitiolide		COc1cc(ccc1O)C(=S)N1CCOCC1	Preclinical							
diflunisal	diflunisal	dolobid	OC(=O)c1cc(ccc1O)-c1ccc(F)cc1F	Launched	FDA Orange Book: diflunisal	PTGS2|PTGS1	ChEMBL|ChEMBL	prostanoid receptor antagonist	rheumatology|rheumatology	rheumatoid arthritis|osteoarthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e110f879-98e6-49cb-a3b0-68805cdf602a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e110f879-98e6-49cb-a3b0-68805cdf602a
naringin	naringin		C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O	Preclinical		SLCO1A2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4738	cytochrome P450 inhibitor			
L-monomethylarginine	L-monomethylarginine	N-Methyl-L-Arginine|l-monomethylarginine	CN[C@@H](CCCNC(N)=N)C(O)=O	Phase 3	https://www.ncbi.nlm.nih.gov/pubmed/17387132	NOS1|NOS2	https://www.scbt.com/scbt/product/l-ng-monomethylarginine-acetate-salt-l-nmma-53308-83-1|https://www.scbt.com/scbt/product/l-ng-monomethylarginine-acetate-salt-l-nmma-53308-83-1	nitric oxide synthase inhibitor			
dazmegrel	dazmegrel	UK-38,485|UK-38485	Cc1c(Cn2ccnc2)c2ccccc2n1CCC(O)=O	Phase 2	Pharmaprojects	TBXAS1	http://www.ncbi.nlm.nih.gov/pubmed/2622975	thromboxane synthase inhibitor			
ODM-201	ODM-201		C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc([nH]n1)C(C)O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02200614	AR	http://www.selleckchem.com/products/ODM-201.html?gclid=COSpkPSTtc8CFRJbhgodWHMCEw	androgen receptor antagonist			
clonixin-lysinate	clonixin-lysinate		NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O	Launched	http://www.drugs.com/international/clonixin.html			cyclooxygenase inhibitor	neurology/psychiatry	pain relief	http://www.drugs.com/international/clonixin.html
P7C3	P7C3		OC(CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12	Preclinical		NAMPT	https://www.tocris.com/products/p7c3_4076	NAMPT inhibitor			
omeprazole	omeprazole	omeprazole magnesium|prilosec|prilosec otc	COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C	Launched	FDA Orange Book: omeprazole, omeprazole magnesium	CLCN2|CYP1A2|CYP2C19|ATP4A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4279|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090859|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090859|https://www.drugbank.ca/drugs/DB00338	ATPase inhibitor	gastroenterology	heartburn	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99f76e43-fa34-42a6-8bbb-e55467b852aa
pivagabine	pivagabine		CC(C)(C)C(=O)NCCCC(O)=O	Launched	http://en.wikipedia.org/wiki/Pivagabine	CRHR2|CRHR1|UCN	https://en.wikipedia.org/wiki/Pivagabine|https://en.wikipedia.org/wiki/Pivagabine|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=186739	corticosteroid releasing factor receptor antagonist	neurology/psychiatry	depression	https://en.wikipedia.org/wiki/Pivagabine
dalcetrapib	dalcetrapib	R04607381|RO4607381	CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01059682	CETP	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000513	cholesteryl ester transfer protein inhibitor			
oxaloacetate	oxaloacetate		OC(=O)CC(=O)C(O)=O	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT01741701	CS|SPR	https://www.drugbank.ca/drugs/DB02637|https://www.drugbank.ca/drugs/DB02637	glutamate release inhibitor			
miconazole	miconazole	Conofite|Dermazole|Micatin|Monistat-3|Vusion|miconazole nitrate|monistat|monistat 1 combination pack|monistat 3|monistat 3 combination pack|monistat 3 combination pack (prefilled)|monistat 5|monistat 7|monistat 7 combination pack|monistat-derm|oravig	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	Launched	FDA Orange Book: miconazole, miconazole nitrate	NOS2|NOS3|TRPM2|TRPV5|KCNMB4|KCNMB3|KCNMA1|KCNMB2|KCNMB1|KCNH2|KCNH6|KCNH7|KCNN1|KCNN2|KCNN3|KCNN4|CYP19A1	https://www.drugbank.ca/drugs/DB01110|https://www.drugbank.ca/drugs/DB01110|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2449|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2449|https://www.drugbank.ca/drugs/DB01110|https://www.drugbank.ca/drugs/DB01110|https://www.drugbank.ca/drugs/DB01110|https://www.drugbank.ca/drugs/DB01110|https://www.drugbank.ca/drugs/DB01110|https://www.drugbank.ca/drugs/DB01110|https://www.drugbank.ca/drugs/DB01110|https://www.drugbank.ca/drugs/DB01110|https://www.drugbank.ca/drugs/DB01110|https://www.drugbank.ca/drugs/DB01110|https://www.drugbank.ca/drugs/DB01110|https://www.drugbank.ca/drugs/DB01110|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=120420	bacterial cell wall synthesis inhibitor	infectious disease|neurology/psychiatry	yeast infection|itching	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf7391ef-bcca-45c6-882f-033fd7970596|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf7391ef-bcca-45c6-882f-033fd7970596
hyoscyamine	hyoscyamine		CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1	Launched	http://www.drugs.com/international/hyoscyamine.html	CHRM1|CHRM3|CHRM2|CHRM4	https://www.drugbank.ca/drugs/DB00424|https://www.drugbank.ca/drugs/DB00424|https://www.drugbank.ca/drugs/DB00424|https://www.drugbank.ca/drugs/DB00424	acetylcholine receptor antagonist	gastroenterology|gastroenterology|gastroenterology|urology|gastroenterology|gastroenterology|neurology/psychiatry|allergy	peptic ulcer disease (PUD)|acute abdominal visceral spasm|ulcerative colitis|interstitial cystitis (IC)|enterocolitis|irritable bowel syndrome|tremors|allergic rhinitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=422fe1f6-43d6-4580-8788-b92f8527e10a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=422fe1f6-43d6-4580-8788-b92f8527e10a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=422fe1f6-43d6-4580-8788-b92f8527e10a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=422fe1f6-43d6-4580-8788-b92f8527e10a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=422fe1f6-43d6-4580-8788-b92f8527e10a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=422fe1f6-43d6-4580-8788-b92f8527e10a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=422fe1f6-43d6-4580-8788-b92f8527e10a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=422fe1f6-43d6-4580-8788-b92f8527e10a
SB-683698	SB-683698	TR-14035	COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/14643165	ITGB7|ITGAV|ITGB1|ITGA4	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004593|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004593|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004593|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004593	integrin antagonist			
epinephrine-(racemic)	racepinephrine	racepinefrine|racepinephrine|vaponefrin	CNCC(O)c1ccc(O)c(O)c1	Launched	http://en.wikipedia.org/wiki/Epinephrine			carbonic anhydrase activator	cardiology|allergy|pulmonary	cardiac arrest|anaphylactic shock|asthma	https://en.wikipedia.org/wiki/Epinephrine|https://en.wikipedia.org/wiki/Epinephrine|https://en.wikipedia.org/wiki/Epinephrine
allopurinol	allopurinol	BW 56-158|BW-56-158|aloprim|lopurin|zyloprim	O=c1[nH]cnc2[nH]ncc12	Launched	FDA Orange Book: allopurinol, allopurinol sodium	XDH	ChEMBL	xanthine oxidase inhibitor	rheumatology|urology	gout|kidney stones	http://www.drugs.com/allopurinol.html|http://www.drugs.com/allopurinol.html
arotinolol	arotinolol	arotinolol hydrochloride	CC(C)(C)NCC(O)CSc1nc(cs1)-c1ccc(s1)C(N)=O	Launched	http://www.drugs.com/international/Arotinolol.html	ADRB3|ADRB2|ADRB1	https://en.wikipedia.org/wiki/Arotinolol|https://citeline.informa.com/?query=#/drugs/details/1973|https://citeline.informa.com/?query=#/drugs/details/1973	adrenergic receptor antagonist	cardiology|neurology/psychiatry	hypertension|tremors	https://en.wikipedia.org/wiki/Arotinolol|https://en.wikipedia.org/wiki/Arotinolol
fluorescein	fluorescein	ak-fluor 10%|ak-fluor 25%|fluorescite|funduscein-25	Oc1ccc2c(Oc3cc(O)ccc3C22OC(=O)c3ccccc23)c1	Launched	FDA Orange Book: fluorescein sodium	SLC22A6	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013608		ophthalmology	ophthalmology diagnostic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c5a620f-7083-4fee-99e2-c9380541c368
RN-1734	RN-1734		CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl	Preclinical		TRPV4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4294	TRPV antagonist			
CZC-54252	CZC-54252		COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1	Preclinical		LRRK2	https://www.tocris.com/products/czc-54252-hydrochloride_4534	leucine rich repeat kinase inhibitor			
BMS-986020	BMS-986020		C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01766817	LPAR1	http://www.biocentury.com/products/bms-986020	lysophosphatidic acid receptor antagonist			
maraviroc	maraviroc	selzentry	CC(C)c1nnc(C)n1C1CC2CCC(C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1	Launched	FDA Orange Book: maraviroc	CCR5|CYP3A5	https://www.drugbank.ca/drugs/DB04835|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=313738	CC chemokine receptor antagonist	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a94a9a2b-337b-4c13-8622-fc392194dc21
triptorelin	triptorelin	CL 118,532|trelstar	CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	Launched	FDA Orange Book: triptorelin pamoate	GNRH1|GNRHR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090485|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1177	gonadotropin releasing factor hormone receptor agonist	oncology|oncology|endocrinology|obstetrics/gynecology|obstetrics/gynecology|endocrinology	prostate cancer|breast cancer|precocious puberty|endometriosis|myoma|gender dysphoria	https://en.wikipedia.org/wiki/Triptorelin|https://en.wikipedia.org/wiki/Triptorelin|https://en.wikipedia.org/wiki/Triptorelin|https://en.wikipedia.org/wiki/Triptorelin|https://en.wikipedia.org/wiki/Triptorelin|https://en.wikipedia.org/wiki/Triptorelin
palonosetron	palonosetron	Aurothioglucose|aloxi|palonosetron hydrochloride	O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]1CN2CCC1CC2	Launched	FDA Orange Book: palonosetron hydrochloride	HTR3A	https://www.drugbank.ca/drugs/DB00377	serotonin receptor antagonist	gastroenterology|gastroenterology	nausea|vomiting	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4216772-6c37-4ff0-a575-f758390656e3|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4216772-6c37-4ff0-a575-f758390656e3
BW-A4C	BW-A4C		CC(=O)N(O)C\C=C\c1cccc(Oc2ccccc2)c1	Phase 1	Pharmaprojects	ALOX5	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000364	lipoxygenase inhibitor			
ON123300	ON123300		CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1	Preclinical		RET|FGFR2|FGFR1|PDGFRB|CCNT1|NUAK1|FYN|LCK|LYN|FLT4|FLT3|CDK4|CDK6|CDK9	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=763054|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=763054|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=763054|http://www.selleckchem.com/products/on123300.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=763054|http://www.selleckchem.com/products/on123300.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=763054|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=763054|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=763054|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=763054|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=763054|http://www.selleckchem.com/products/on123300.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=763054|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=763054	CDK inhibitor			
ibutamoren	ibutamoren	MK-677	CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/21067829	GH1|GHR|GHSR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=226508|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001483|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5867	growth hormone secretagogue receptor agonist			
xamoterol	xamoterol		OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/2893916	ADRB1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=538	adrenergic receptor agonist			
ENMD-2076	ENMD-2076		CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(\C=C\c2ccccc2)n1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01104675	FGFR2|FGFR3|FGFR1|SRC|PDGFRA|EPHA1|AURKA|KDR|KIT|PTK2|CSF1R|FLT4|FLT3	https://citeline.informa.com/?query=#/drugs/details/33975|https://citeline.informa.com/?query=#/drugs/details/33975|https://citeline.informa.com/?query=#/drugs/details/33975|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7885|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7885|https://citeline.informa.com/?query=#/drugs/details/33975|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7885|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7885|https://citeline.informa.com/?query=#/drugs/details/33975|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7885|https://citeline.informa.com/?query=#/drugs/details/33975|https://citeline.informa.com/?query=#/drugs/details/33975|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7885	Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor			
2-phenylmelatonin	2-phenylmelatonin		COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1	Preclinical		MTNR1A|MTNR1B	http://www.tocris.com/dispprod.php?ItemId=1754#.VeSxqyxVhHw|http://www.tocris.com/dispprod.php?ItemId=1754#.VeSxqyxVhHw	melatonin receptor agonist			
AN2718	AN2718		OB1OCc2cc(Cl)ccc12	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00781664			leucyl-tRNA synthetase inhibitor			
malic-acid	malic acid	E296|malic acid	OC(CC(O)=O)C(O)=O	Launched	https://en.wikipedia.org/wiki/Malic_acid#Malic_acid_in_food	PKD2L1|ME2|CS	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2480|https://www.drugbank.ca/drugs/DB03499|https://www.drugbank.ca/drugs/DB03499				
pimozide	pimozide	MCN-JR-6238|R 6238|R-6238|orap	Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1	Launched	FDA Orange Book: pimozide	CACNA1I|CALM1|HRH1|HTR1A|HTR2A|KCNH2|KCNA10|DRD5|DRD4|DRD1|DRD3|DRD2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=90|https://www.drugbank.ca/drugs/DB01100|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=90|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=90|ChEMBL|https://www.drugbank.ca/drugs/DB01100|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=90|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	dopamine receptor antagonist	neurology/psychiatry	Tourette's disorder	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280
blonanserin	blonanserin		CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1	Launched	http://en.wikipedia.org/wiki/Blonanserin	HTR2A|DRD2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7670|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7670	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia	https://en.wikipedia.org/wiki/Blonanserin
tropisetron	tropisetron		CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12	Launched	http://www.drugs.com/international/Tropisetron.html	GLRB|GLRA1|GLRA2|HTR4|HTR3A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=260|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=260|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=260|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=260|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=260	serotonin receptor antagonist	gastroenterology|gastroenterology|gastroenterology|gastroenterology	nausea|vomiting|nausea|vomiting	https://en.wikipedia.org/wiki/Tropisetron|https://en.wikipedia.org/wiki/Tropisetron|https://en.wikipedia.org/wiki/Tropisetron|https://en.wikipedia.org/wiki/Tropisetron
perzinfotel	perzinfotel		OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O	Phase 2	http://www.pharmacodia.com/yaodu/html/v1/chemicals/fc0cfd2341703ede70ebfa6a0968adcf.html	GRIN1|GRIN2B|GRIN2A	http://www.kegg.jp/kegg-bin/ddi_list?drug=D00777|http://www.kegg.jp/kegg-bin/ddi_list?drug=D00777|http://www.kegg.jp/kegg-bin/ddi_list?drug=D00777	glutamate receptor antagonist			
lofexidine	lofexidine		CC(Oc1c(Cl)cccc1Cl)C1=NCCN1	Launched	FDA Orange Book: lofexidine	ADRA2A	https://www.drugbank.ca/drugs/DB04948	adrenergic receptor agonist	neurology/psychiatry	opioid withdrawal	http://www.usworldmeds.com/lofexidine.asp
desloratadine	desloratadine	SCH 34117|SCH-34117|clarinex	Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1	Launched	FDA Orange Book: desloratadine	HRH1	ChEMBL	histamine receptor antagonist	allergy|allergy	allergic rhinitis|urticaria	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dbb8e695-f00b-4c67-bd49-09a1ae5bb669|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dbb8e695-f00b-4c67-bd49-09a1ae5bb669
BIBN4096	BIBN4096	BIBN-4096BS|olcegepant	NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02198339	CALCA|CALCRL|RAMP1	https://www.drugbank.ca/drugs/DB04869|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=702|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=702	calcitonin antagonist			
MK-2461	MK-2461		CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT00496353	NTRK1|NTRK2|MST1R|MET|KDR|MERTK|FGFR1|FGFR2|FGFR3|PDGFRB|FLT1|FLT4|FLT3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7962|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7962	FGFR inhibitor|VEGFR inhibitor			
equol	equol	(S)-Equol|AUS-131	Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1	Launched	http://en.wikipedia.org/wiki/Equol	ESR2|ESR1	https://en.wikipedia.org/wiki/Equol|https://en.wikipedia.org/wiki/Equol	estrogen receptor agonist			
curcumin	curcumin		COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1	Launched	https://clinicaltrials.gov/ct2/show/NCT01052597	CYP3A4|PTGS2|PTGS1|CA6|CA9|CA4|CA2|CA1|G6PC|MMP9|NOS2|DNMT1|MMP13|CCND1|XDH|CA12|CA14|EP300|APP|MAPT|DNMT3B	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006900|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006900|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006900|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006900|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006900|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006900|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006900|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006900|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=119974|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006900|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006900|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=119974|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006900|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=119974|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006900|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006900|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006900|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7000|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006900|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=119974|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006900	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor			
etilefrine	etilefrine	etilefrine hydrochloride	CCNCC(O)c1cccc(O)c1	Launched	http://www.drugs.com/international/Etilefrine.html	ADRB1|ADRA1A	http://en.wikipedia.org/wiki/Etilefrine|http://en.wikipedia.org/wiki/Etilefrine	adrenergic receptor agonist	neurology/psychiatry|otolaryngology|endocrinology|pulmonary|otolaryngology	headache|nasal congestion|fever|cough suppressant|common cold	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db8c036d-1403-4646-8878-6252c0740fb5|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db8c036d-1403-4646-8878-6252c0740fb5|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db8c036d-1403-4646-8878-6252c0740fb5|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db8c036d-1403-4646-8878-6252c0740fb5|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db8c036d-1403-4646-8878-6252c0740fb5
domperidone	domperidone	R 33,812|motilium	Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1	Launched	http://www.drugs.com/international/Domperidone.html	DRD3|DRD2|ABCG2|CYP3A5	https://www.drugbank.ca/drugs/DB01184|https://www.drugbank.ca/drugs/DB01184|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091089|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091089	dopamine receptor antagonist	infectious disease	fescue toxicosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e55d075e-2fe2-4405-b57a-59b85067e0c0
megestrol-acetate	megestrol acetate	BDH 1298|BDH-1298|Ovaban|SC 10363|SC-10363|megace|megace es|megestrol|megestrol acetate		Launched	FDA Orange Book: megestrol acetate	NR3C1|PGR	https://www.drugbank.ca/drugs/DB00351|ChEMBL	progesterone receptor agonist	neurology/psychiatry|endocrinology	anorexia|cachexia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2dc921d5-e423-4379-a345-151e87d13651|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2dc921d5-e423-4379-a345-151e87d13651
sodium-butyrate	sodium butyrate	Butanoic acid	CCCC(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00800930	HDAC8|HDAC3|HDAC2|HDAC1|FFAR2|FFAR3|BCHE	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1059|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1059|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1059|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1059|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1059|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1059|https://www.drugbank.ca/drugs/DB03568	HDAC inhibitor			
neo-gilurytmal	neo-gilurytmal		CCC[N+]12[C@H]3C[C@]45C(O)C3[C@@H](CC1[C@@H]4N(C)c1ccccc51)[C@H](CC)[C@H]2O	Launched	http://www.drugs.com/international/Neo-Gilurytmal.html						
BMS-182874	BMS-182874		CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C	Phase 2	http://adisinsight.springer.com/drugs/800004811	EDNRA	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003707	endothelin receptor antagonist			
erteberel	erteberel	LY500307	Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01874756	ESR1|ESR2	https://www.drugbank.ca/drugs/DB07933|https://www.drugbank.ca/drugs/DB07933	estrogen receptor agonist			
verapamil	verapamil	CP-16,533-1|CP-16533-1|D-365|Tarka|calan|calan sr|covera-hs|iproveratril|isoptin|verapamil hydrochloride|verelan|verelan pm	COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC	Launched	FDA Orange Book: verapamil hydrochloride	SLC6A4|CYP2E1|CYP2C8|KCNA10|CYP3A5|CYP3A4|CYP3A7|KCNA7|KCNH2|NALCN|SLC29A4|CACNA1G|CACNA1F|CACNA1C|CACNA1D|CACNA1A|CACNA1B|CACNA1I|CACNA1S|KCNJ11|SCN5A|CACNB2|CACNB1|CACNB4|CACNB3|DRD2	https://www.drugbank.ca/drugs/DB00661|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=115395|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=115395|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2406|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=115395|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2406|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=115395|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2406|https://www.drugbank.ca/drugs/DB00661|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2406|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2406|https://www.drugbank.ca/drugs/DB00661|https://www.drugbank.ca/drugs/DB00661|https://www.drugbank.ca/drugs/DB00661|https://www.drugbank.ca/drugs/DB00661|https://www.drugbank.ca/drugs/DB00661|https://www.drugbank.ca/drugs/DB00661|https://www.drugbank.ca/drugs/DB00661|https://www.drugbank.ca/drugs/DB00661|https://www.drugbank.ca/drugs/DB00661|https://www.drugbank.ca/drugs/DB00661|https://www.drugbank.ca/drugs/DB00661|https://www.drugbank.ca/drugs/DB00661|https://www.drugbank.ca/drugs/DB00661|https://www.drugbank.ca/drugs/DB00661|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=115395	calcium channel blocker	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ae13cb4-0316-40d1-9216-c7d5556aaed3
GW-1100	GW-1100		CCOC(=O)c1ccc(cc1)-n1cc(Cc2cnc(OCC)nc2)c(=O)nc1SCc1ccc(F)cc1	Preclinical		FFAR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1057	G protein-coupled receptor agonist			
chlorazanil	chlorazanil		Nc1ncnc(Nc2ccc(Cl)cc2)n1	Preclinical							
RS-79948	RS-79948		CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12	Preclinical		ADRA2A	http://www.tocris.com/dispprod.php?ItemId=2282#.Vg19bmRVhHw	adrenergic receptor antagonist			
hydroxyfasudil	hydroxyfasudil	Hydroxy-Fasudil	Oc1nccc2c(cccc12)S(=O)(=O)N1CCCNCC1	Preclinical		PKIA|PRKACA|ROCK1|ROCK2	https://www.drugbank.ca/drugs/DB04707|https://www.drugbank.ca/drugs/DB04707|https://www.drugbank.ca/drugs/DB04707|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=286870	rho associated kinase inhibitor			
netupitant	netupitant	RO 67-3189/000	CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1	Launched	FDA Orange Book: netupitant	TACR1	ChEMBL	tachykinin antagonist	gastroenterology|gastroenterology	nausea|vomiting	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2daa0c22-3051-4f12-a860-e5404c862760|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2daa0c22-3051-4f12-a860-e5404c862760
NS-9283	NS-9283		N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1	Preclinical		CHRNA4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3993	acetylcholine receptor allosteric modulator			
AL-8697	AL-8697		Cc1c(F)cc(cc1-c1c(F)cn2c(nnc2c1F)C(C)(C)C)C(=O)NC1CC1	Preclinical		TNF|RET|MAPK14	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=774800|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=774800|https://www.tocris.com/products/al-8697_4753	p38 MAPK inhibitor			
indeloxazine	indeloxazine		C(Oc1cccc2C=CCc12)C1CNCCO1	Withdrawn	https://en.wikipedia.org/wiki/Indeloxazine	SLC6A4	https://citeline.informa.com/?query=#/drugs/details/9172	norepinephrine reuptake inhibitor|serotonin reuptake inhibitor			
fosfosal	fosfosal		OC(=O)c1ccccc1OP(O)(O)=O	Launched	Pharmaprojects	PTGS1|PTGS2|PDE4C|PDE4D|PDE4A|PDE4B	http://database.idrb.cqu.edu.cn/TTD/ZFTTDDetail.asp?ID=TTDS00039|http://database.idrb.cqu.edu.cn/TTD/ZFTTDDetail.asp?ID=TTDS00039|https://citeline.informa.com/?query=#/drugs/details/7462|https://citeline.informa.com/?query=#/drugs/details/7462|https://citeline.informa.com/?query=#/drugs/details/7462|https://citeline.informa.com/?query=#/drugs/details/7462	phosphodiesterase inhibitor			
xipamide	xipamide	BE-1293|MJF 10,938	Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O	Launched	http://www.drugs.com/international/Xipamide.html	SLC12A3	http://www.ncbi.nlm.nih.gov/pubmed/3440481	carbonic anhydrase inhibitor	cardiology|cardiology	edema|hypertension	https://en.wikipedia.org/wiki/Xipamide|https://en.wikipedia.org/wiki/Xipamide
STF-083010	STF-083010		Oc1ccc2ccccc2c1\C=N\S(=O)(=O)c1cccs1	Preclinical		ERN1	https://www.emdmillipore.com/US/en/product/IRE1-Inhibitor-I,-STF-083010---Calbiochem,EMD_BIO-412510	serine/threonine kinase inhibitor			
benzoyl-peroxide	benzoyl peroxide	E928|acne-aid cream|benoxyl|benzac|benzac w|benzoyl peroxide|brevoxyl|clear by design|dry and clear|epi-clear|fostex bpo bar, gel, and wash|loroxide|panoxyl|persa-gel|vanoxide	O=C(OOC(=O)c1ccccc1)c1ccccc1	Launched	FDA Orange Book: benzoyl peroxide			oxidizing agent	dermatology	acne vulgaris (AV)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8cb19ffe-f7c0-4500-a56d-234fd8871f87
GSK2879552	GSK2879552		OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02034123	KDM1A	https://www.caymanchem.com/product/19403	histone lysine demethylase inhibitor			
3-bromo-7-nitroindazole	3-bromo-7-nitroindazole		[O-][N+](=O)c1cccc2c(Br)n[nH]c12	Preclinical		NOS1|NOS2|NOS3	https://www.drugbank.ca/drugs/DB01997|https://www.drugbank.ca/drugs/DB01997|https://www.drugbank.ca/drugs/DB01997	nitric oxide synthase inhibitor			
rimexolone	rimexolone	ORG 6216|ORG-6216|vexol	CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C	Launched	FDA Orange Book: rimexolone	NR3C1|SERPINA6	ChEMBL|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000420	glucocorticoid receptor agonist	ophthalmology	anterior uveitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1699f4e-40d5-49d0-ab80-1c8cc68e80a4
phenoxybenzamine	phenoxybenzamine	dibenzyline	CC(COc1ccccc1)N(CCCl)Cc1ccccc1	Launched	FDA Orange Book: phenoxybenzamine hydrochloride	ADRB2|ADRA2A|ADRA2B|ADRA2C|ADRA1D|ADRA1A|ADRA1B|CALM1	https://www.drugbank.ca/drugs/DB00925|https://www.drugbank.ca/drugs/DB00925|https://www.drugbank.ca/drugs/DB00925|https://www.drugbank.ca/drugs/DB00925|https://www.drugbank.ca/drugs/DB00925|https://www.drugbank.ca/drugs/DB00925|https://www.drugbank.ca/drugs/DB00925|https://www.drugbank.ca/drugs/DB00925	adrenergic receptor antagonist	cardiology|endocrinology	hypertension|pheochromocytoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29ddb739-0f8e-4c41-ab4b-a6331ae2d508|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29ddb739-0f8e-4c41-ab4b-a6331ae2d508
pilsicainide	pilsicainide	pilsicainide hydrochloride	Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2	Launched	http://www.drugs.com/international/Pilsicainide.html	SCN5A	https://en.wikipedia.org/wiki/Pilsicainide	sodium channel blocker	cardiology	cardiac arrythmia	https://en.wikipedia.org/wiki/Pilsicainide
dicoumarol	dicoumarol	bishydroxycoumarin|dicumarol	Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc2ccccc12	Launched	FDA Orange Book: dicumarol	CRYZ|NQO1|VKORC1	https://www.drugbank.ca/drugs/DB00266|https://www.drugbank.ca/drugs/DB00266|ChEMBL	NADPH inhibitor	hematology	deep vein thrombosis (DVT)	https://en.wikipedia.org/wiki/Dicoumarol
felodipine	felodipine	H 154/82|H-154/82|plendil	CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(Cl)c1Cl)C(=O)OC	Launched	FDA Orange Book: felodipine	CACNA2D2|CACNA2D1|CACNA1F|CACNA1C|CACNA1D|CACNA1H|CACNA1S|CALM1|TNNC1|TNNC2|PDE1A|PDE1B|CACNB2|NR3C2|CFTR	https://www.drugbank.ca/drugs/DB01023|https://www.drugbank.ca/drugs/DB01023|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB01023|ChEMBL|https://www.drugbank.ca/drugs/DB01023|https://www.drugbank.ca/drugs/DB01023|https://www.drugbank.ca/drugs/DB01023|https://www.drugbank.ca/drugs/DB01023|https://www.drugbank.ca/drugs/DB01023|https://www.drugbank.ca/drugs/DB01023|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4190	calcium channel blocker	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55637724-8757-11de-8a39-0800200c9a66
PLX8394	PLX8394		F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT02012231	BRAF	http://www.medkoo.com/products/5760	serine/threonine kinase inhibitor			
camostat-mesilate	camostat mesilate	Foipan|camostat|camostat mesilate	CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1	Launched	http://www.drugs.com/international/camostat.html	KLK3|PLG|PRSS1|PRSS3|PRSS2|F10|F2	https://citeline.informa.com/?query=#/drugs/details/4191|https://citeline.informa.com/?query=#/drugs/details/4191|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6432|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=115084|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=115084|https://citeline.informa.com/?query=#/drugs/details/4191|https://citeline.informa.com/?query=#/drugs/details/4191	protease inhibitor	gastroenterology	pancreatitis	https://en.wikipedia.org/wiki/Camostat
PH-797804	PH-797804	PHA-797804	CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01102660	MAPK14|MAPK11	https://www.drugbank.ca/drugs/DB07941|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7818	p38 MAPK inhibitor			
S1P1-agonist-III	S1P1-agonist-III		COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F	Preclinical		S1PR1	https://www.medchemexpress.com/s1p1-agonist-iii.html	sphingosine kinase inhibitor			
tasimelteon	tasimelteon	BMS-214778|VEC-162|hetlioz	CCC(=O)NC[C@@H]1C[C@H]1c1cccc2OCCc12	Launched	FDA Orange Book: tasimelteon	MTNR1A|MTNR1B	ChEMBL|ChEMBL	melatonin receptor agonist	neurology/psychiatry	Non-24-Hour Sleep-Wake Disorder	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca4a9b63-708e-49e9-8f9b-010625443b90
apabetalone	apabetalone		COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02586155	BRD4|BRD3|APOA1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=636328|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7034|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=636328	apolipoprotein expression enhancer			
LCZ696	LCZ696		CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O.CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1)[C@@H](C(C)C)C(O)=O	Launched	https://clinicaltrials.gov/ct2/show/NCT02554890			angiotensin receptor antagonist	cardiology|cardiology	angioedema|hypotension	https://en.wikipedia.org/wiki/Valsartan/sacubitril|https://en.wikipedia.org/wiki/Valsartan/sacubitril
1-deoxymannojirimycin	1-deoxymannojirimycin	Deoxymannojirimycin	OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O	Preclinical		MAN2A1	http://www.tocris.com/dispprod.php?ItemId=2081#.VeRpzSxVhHw	alpha mannosidase inhibitor			
zaldaride	zaldaride		CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/8574720	CALM1	http://www.tocris.com/dispprod.php?ItemId=132008	calmodulin antagonist			
4-mu-8C	4-mu-8C		Cc1cc(=O)oc2c(C=O)c(O)ccc12	Preclinical		ERN1	http://www.tocris.com/dispprod.php?ItemId=336106#.VeX8NCxVhHw	IRE1 inhibitor			
bretylium	bretylium	bretylium tosylate|bretylol	CC[N+](C)(C)Cc1ccccc1Br	Launched	FDA Orange Book: bretylium tosylate	ATP1A1	https://www.drugbank.ca/drugs/DB01158	norepinephrine inhibitor	cardiology|cardiology|cardiology	ventricular arrhythmias|ventricular fibrillation (VF)|ventricular tachycardia (VT)	https://en.wikipedia.org/wiki/Bretylium|https://en.wikipedia.org/wiki/Bretylium|https://en.wikipedia.org/wiki/Bretylium
exifone	exifone		Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	TYR	http://www.ncbi.nlm.nih.gov/pubmed/20939763?dopt=Abstract	nootropic agent			
GW-803430	GW-803430	GW-3430	COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1	Phase 1	Pharmaprojects	MCHR1|KCNH2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4033|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009122	melanin inhibitor			
daprodustat	daprodustat	GSK1278863	OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02879305?term=daprodustat&rank=1	EGLN1	http://www.medkoo.com/products/6720	hypoxia inducible factor inhibitor			
co-102862	co-102862	V-102862	NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1	Phase 1	Pharmaprojects	SCN2A|SCN4A|SCN9A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=246696|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004241|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004241				
tuaminoheptane	tuaminoheptane		CCCCCC(C)N	Launched	http://www.drugs.com/international/tuaminoheptane.html				otolaryngology	nasal congestion	https://en.wikipedia.org/wiki/Tuaminoheptane
CP-93129	CP-93129		O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1	Preclinical		HTR1B|HTR1A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=161734|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11	serotonin receptor agonist			
revaprazan	revaprazan		CC1N(CCc2ccccc12)c1nc(Nc2ccc(F)cc2)nc(C)c1C	Launched	http://www.drugs.com/international/revaprazan.html	ATP4A	https://en.wikipedia.org/wiki/Revaprazan	potassium-competitive acid antagonist	gastroenterology	gastritis	https://en.wikipedia.org/wiki/Revaprazan
evans-blue	evans blue	evans blue	Cc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(c(C)c1)\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O	Launched	FDA Orange Book: evans blue	PTPN1|GRIA1|ENPP2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004420|https://en.wikipedia.org/wiki/Evans_Blue_(dye)|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=389100	glutamate receptor negative allosteric modulator			
VU1545	VU1545		[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1	Preclinical		GRM5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4059	glutamate receptor positive allosteric modulator			
securinine	securinine		O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31	Preclinical		GABRA1	http://www.sigmaaldrich.com/catalog/product/sigma/sml0055?lang=en&region=US	GABA receptor antagonist|TP53 activator			
phenethicillin	phenethicillin	pheneticillin	CC(Oc1ccccc1)C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	Launched	http://www.drugs.com/international/Phenethicillin.html			bacterial cell wall synthesis inhibitor			
esaprazole	esaprazole		O=C(CN1CCNCC1)NC1CCCCC1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/8447149						
potassium-canrenoate	potassium-canrenoate	canrenoate|canrenoic acid	C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O	Launched	http://en.wikipedia.org/wiki/Potassium_canrenoate	NR3C2	http://www.genome.jp/dbget-bin/www_bget?drug:D01943	mineralocorticoid receptor antagonist	cardiology	edema	http://www.drugs.com/international/potassium-canrenoate.html
gavestinel	gavestinel	GV 150526X	OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/16340185	GLRB	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000678	glutamate receptor antagonist			
gemcadiol	gemcadiol	CI-720	CC(C)(CO)CCCCCCC(C)(C)CO	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/834121			antilipemic			
SGC-CBP30	SGC-CBP30		COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl	Preclinical		CREBBP|EP300	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7529|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7529	bromodomain inhibitor			
AZD3264	AZD3264		Cc1noc(C)c1-c1ccc(-c2cc(C(N)=O)c(NC(N)=O)s2)c(O[C@H]2CCNC2)c1	Preclinical		IKBKB	http://www.selleckchem.com/products/azd3264.html	IKK inhibitor			
AZD4547	AZD4547		COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)n[nH]2)cc(OC)c1	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT02154490	IGF1R|FGF2|FGFR3|FGFR4|FGFR1|FGFR2|KDR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7707|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=678357|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7707|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7707|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7707|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7707|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7707	FGFR inhibitor			
emetine	emetine	GNF-Pf-196|TCMDC-125531		Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/4603136	RPS2	http://en.wikipedia.org/wiki/Emetine	protein synthesis inhibitor			
pralidoxime	pralidoxime	Atnaa|Duodote|pralidoxime chloride|protopam chloride	C[n+]1ccccc1\C=N\O	Launched	FDA Orange Book: pralidoxime chloride	ACHE|BCHE	https://www.drugbank.ca/drugs/DB00733|https://www.drugbank.ca/drugs/DB00733	acetylcholinesterase inhibitor	critical care	organophosphate poisoning	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a16ac225-bb32-4b27-bb66-9e152cf065eb
APTO-253	APTO-253		Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02267863	KLF4	http://aptose.com/apto-253/	krppel-like factor expression enhancer			
EMD-386088	EMD-386088		Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1	Preclinical		HTR6	http://www.tocris.com/dispprod.php?ItemId=144639#.UufrTv30BaE	serotonin receptor agonist			
cyt387	cyt387	CYT-11387|CYT-387|GS-0387|momelotinib	O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01969838	JAK1|JAK2|JAK3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7791|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7791|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7791				
lonafarnib	lonafarnib	SCH 66336|SCH-66336	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00050336	NRAS|KRAS|FNTA|HRAS	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8024|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8024|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000152|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8024	farnesyltransferase inhibitor			
benzotript	benzotript		OC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1	Phase 1	Pharmaprojects	CCKAR|CCKBR	http://www.sigmaaldrich.com/technical-documents/articles/biology/rbi-handbook/peptide-receptors-and-peptide-metabolism/cholecystokinin-and-gastrin-receptors.html|http://www.sigmaaldrich.com/technical-documents/articles/biology/rbi-handbook/peptide-receptors-and-peptide-metabolism/cholecystokinin-and-gastrin-receptors.html	CCK receptor antagonist			
atipamezole	atipamezole	MPV-1248|antisedan	CCC1(Cc2ccccc2C1)c1cnc[nH]1	Veterinary Launched	http://www.drugs.com/vet/antisedan-can.html			adrenergic receptor antagonist	neurology/psychiatry	reverse sedative	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7c8327f-c99d-4347-a89d-61172837d4b7
betrixaban	betrixaban	PRT054021	COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1	Launched	FDA Orange Book: betrixaban	F10|KCNH2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=390678|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009421	coagulation factor inhibitor	hematology	deep vein thrombosis (DVT)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ebaa2dd9-257e-4a68-ab6a-fb2791bb62ce
antioxine	antioxine	Carvacrol	CC(C)c1ccc(C)c(O)c1	Launched	http://en.wikipedia.org/wiki/Carvacrol						
equilin	equilin		CC12CCC3C(=CCc4cc(O)ccc34)C1CCC2=O	Preclinical		HSD17B1	https://www.drugbank.ca/drugs/DB02187	estrogen receptor agonist			
PCI-34051	PCI-34051		COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1	Preclinical		HDAC10|IL1B|HDAC1|HDAC8|HDAC6	http://www.selleckchem.com/products/pci-34051.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=462020|http://www.selleckchem.com/products/pci-34051.html|http://www.selleckchem.com/products/pci-34051.html|http://www.selleckchem.com/products/pci-34051.html	HDAC inhibitor			
erythritol	erythritol	E968	OC[C@H](O)[C@H](O)CO	Launched	https://clinicaltrials.gov/ct2/show/NCT02023840						
itopride	itopride		COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1	Launched	http://www.drugs.com/international/itopride.html	ACHE|DRD2|CHRM3	https://citeline.informa.com/?query=#/drugs/details/9753|https://www.drugbank.ca/drugs/DB04924|https://www.drugbank.ca/drugs/DB04924	dopamine receptor antagonist	gastroenterology|gastroenterology|gastroenterology|gastroenterology|gastroenterology|neurology/psychiatry	dyspepsia|gastroparesis|heartburn|nausea|vomiting|anorexia	https://en.wikipedia.org/wiki/Itopride#Clinical_use|https://en.wikipedia.org/wiki/Itopride#Clinical_use|https://en.wikipedia.org/wiki/Itopride#Clinical_use|https://en.wikipedia.org/wiki/Itopride#Clinical_use|https://en.wikipedia.org/wiki/Itopride#Clinical_use|https://en.wikipedia.org/wiki/Itopride#Clinical_use
nitrofurazone	nitrofurazone	Furazone|actin-n|furacilin|furacin|nitrofural	NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	Launched	FDA Orange Book: nitrofurazone			bacterial DNA inhibitor	infectious disease	first-aid antibiotic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00a70c72-5009-439a-9e1d-0491090e4b93
ABT-737	ABT-737		CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT02070094	BCL2|BCL2L2|BCL2L1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007115|http://www.selleckchem.com/products/ABT-737.html|http://www.selleckchem.com/products/ABT-737.html	BCL inhibitor			
editol	editol	edetol|neutrol te|quadrol	CC(O)CN(CCN(CC(C)O)CC(C)O)CC(C)O	Preclinical							
o-3M3FBS	o-3M3FBS		Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F	Preclinical				phospholipase activator			
alosetron	alosetron	lotronex	Cc1[nH]cnc1CN1CCc2c(C1=O)c1ccccc1n2C	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	HTR3A	https://www.drugbank.ca/drugs/DB00969	serotonin receptor antagonist			
oxprenolol	oxprenolol	trasicor	CC(C)NCC(O)COc1ccccc1OCC=C	Launched	FDA Orange Book: oxprenolol hydrochloride	ADRB2|ADRB1	https://www.drugbank.ca/drugs/DB01580|https://www.drugbank.ca/drugs/DB01580	adrenergic receptor antagonist	cardiology|cardiology|cardiology	angina pectoris|hypertension|cardiac arrythmia	https://en.wikipedia.org/wiki/Oxprenolol|https://en.wikipedia.org/wiki/Oxprenolol|https://en.wikipedia.org/wiki/Oxprenolol
Ro-15-4513	Ro-15-4513	Ro-154513	CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-]	Preclinical		GABRG2|GABRA1|GABRB2|GABRA6|GABRA5|GABRA4|GABRA3|GABRA2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003516|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4296|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003516|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4296|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4296|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4296|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4296|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4296				
ZSTK-474	ZSTK-474	TCMDC-137004	FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT01682473	PIK3CG|PIK3CB|PIK3CA|PIK3CD	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7965|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7965|https://citeline.informa.com/?query=#/drugs/details/33566|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7965	PI3K inhibitor			
quinaprilat	quinaprilat	CI-928	C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O	Launched	http://en.wikipedia.org/wiki/Quinaprilat	ACE	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6352	angiotensin converting enzyme inhibitor	cardiology|cardiology	hypertension|angioedema	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=383ecaa6-29c8-4280-a442-c47f101d7c88|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=383ecaa6-29c8-4280-a442-c47f101d7c88
HMN-214	HMN-214		COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/16951237	PLK1	https://www.ncbi.nlm.nih.gov/pubmed/16951237	PLK inhibitor			
butalbital	butalbital	alisobumal|allylbarbituric acid|itobarbital|sandoptal|tetrallobarbital	CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O	Launched	FDA Orange Book: butalbital	GRIA2|GRIK2|CHRNA7|CHRNA4|GABRG2|GABRG3|GABRG1|GABRB1|GABRB2|GABRB3|GABRA1|GABRA6|GABRA4|GABRA5|GABRA2|GABRA3|GABRE|GABRP|GABRQ|GABRD	https://www.drugbank.ca/drugs/DB00241|https://www.drugbank.ca/drugs/DB00241|https://www.drugbank.ca/drugs/DB00241|https://www.drugbank.ca/drugs/DB00241|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	GABA receptor antagonist	neurology/psychiatry|neurology/psychiatry	headache|muscle relaxant	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ad8bd05-c133-45f5-9100-11660ec40043|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ad8bd05-c133-45f5-9100-11660ec40043
biperiden	biperiden	akineton	OC(CCN1CCCCC1)(C1CC2CC1C=C2)c1ccccc1	Launched	FDA Orange Book: biperiden hydrochloride, biperiden lactate	CHRNA2|CHRM2|CHRM1|CHRM4|CHRM3|CHRM5	https://www.drugbank.ca/drugs/DB00810|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7128|https://www.drugbank.ca/drugs/DB00810|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7128|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7128|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7128	acetylcholine receptor antagonist	neurology/psychiatry	Parkinson's Disease	https://en.wikipedia.org/wiki/Biperiden
mometasone-furoate	mometasone-furoate	asmanex hfa|asmanex twisthaler|elocon|nasonex	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl	Launched	FDA Orange Book: mometasone furoate, mometasone furoate monohydrate	NR3C1	http://dgidb.genome.wustl.edu/interaction_claims/cd060818-a28d-49d1-a57b-0aef171ba990	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f69603aa-a5a6-b8f3-c9ed-2d0abc9f4d92
sclareolide	sclareolide	(3aR)-(+)-Sclareolide	C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2	Launched	http://en.wikipedia.org/wiki/Sclareolide			other antifungal			
cinchonine	cinchonine		O[C@@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12	Preclinical		CYP2D6	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003892	P glycoprotein inhibitor			
NVP-DPP728	NVP-DPP728		O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/11978683	DPP4	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005423	dipeptidyl peptidase inhibitor			
AS-2444697	AS-2444697		Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1	Preclinical		IRAK4	https://www.tocris.com/products/as-2444697_5430	interleukin inhibitor			
MRK-560	MRK-560		Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1	Preclinical		APP	https://www.tocris.com/products/mrk-560_4000	gamma secretase inhibitor			
acetanilide	acetanilide	antifebrin	CC(=O)Nc1ccccc1	Preclinical				hydrogen peroxide decomposition inhibitor			
chlorthalidone	chlorthalidone	G-33182|chlortalidone|hygroton|thalitone	NS(=O)(=O)c1cc(ccc1Cl)C1(O)NC(=O)c2ccccc12	Launched	FDA Orange Book: chlorthalidone	SLC12A3|SLC12A1|CA1|CA4|CA7|CA14|CA12	ChEMBL|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000521|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7147|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7147|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7147|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7147|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7147	carbonic anhydrase inhibitor	cardiology|cardiology|cardiology|gastroenterology|rheumatology|nephrology|nephrology	hypertension|edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=193c85ba-43c2-4be2-82cf-7b394a83390e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=193c85ba-43c2-4be2-82cf-7b394a83390e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=193c85ba-43c2-4be2-82cf-7b394a83390e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=193c85ba-43c2-4be2-82cf-7b394a83390e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=193c85ba-43c2-4be2-82cf-7b394a83390e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=193c85ba-43c2-4be2-82cf-7b394a83390e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=193c85ba-43c2-4be2-82cf-7b394a83390e
APR-246	APR-246		COCC1(CO)N2CCC(CC2)C1=O	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT02098343	TP53	https://www.tocris.com/dispprod.php?ItemId=239334#.V-FV95MrKYU	p53 activator			
LMI070	LMI070		CC1(C)CC(CC(C)(C)N1)Oc1ccc(nn1)-c1ccc(cc1O)-c1cn[nH]c1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT02268552	SMN1	http://en.pharmacodia.com/web/drug/1_1606.html	survival motor neuron protein modulator			
adatanserin	adatanserin		O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2	Phase 2	https://books.google.com/books?id=uR-J27FHr94C&pg=PA547&lpg=PA547&dq=adatanserin+phase+II	HTR1A|HTR2A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000680|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000680	serotonin receptor agonist|serotonin receptor antagonist			
CL-225385	CL-225385		O=C(CC#N)c1ccccc1	Phase 2	https://books.google.com/books?id=anRzslvfcUwC&pg=PA873&lpg=PA873&dq=CL-225385&source=bl&ots=R8zl_G8kZf&sig=uYkkhtJISsKsfPlVhBELeO6uqs4&hl=en&sa=X&ved=0ahUKEwjH9c6o5qHRAhWHyoMKHQRjCxwQ6AEIHDAA#v=onepage&q=CL-225385&f=false						
isoxsuprine	isoxsuprine		CC(COc1ccccc1)NC(C)[C@H](O)c1ccc(O)cc1	Launched	http://www.drugs.com/international/isoxsuprine.html	ADRB2	http://en.wikipedia.org/wiki/Isoxsuprine	adrenergic receptor agonist	rheumatology|cardiology|rheumatology	Raynaud's disease|arteriosclerosis|Buerger's disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47134a96-77d0-4211-90b8-e2a857586d7b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47134a96-77d0-4211-90b8-e2a857586d7b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47134a96-77d0-4211-90b8-e2a857586d7b
nefopam	nefopam		CN1CCOC(c2ccccc2)c2ccccc2C1	Launched	http://www.drugs.com/international/Nefopam.html			cyclooxygenase inhibitor	neurology/psychiatry	pain relief	https://en.wikipedia.org/wiki/Nefopam
cefalonium	cefalonium		NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)Cc2cccs2)C3=O)C(O)=O)cc1	Veterinary Launched	http://www.drugs.com/international/cefalonium.html			bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections	http://www.drugs.com/international/cefalonium.html
fludroxycortide	fludroxycortide	cordran|cordran sp	CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)CC[C@]5(C)C4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	Launched	FDA Orange Book: flurandrenolide	NR3C1|SERPINA6	https://www.drugbank.ca/drugs/DB00846|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000418	glucocorticoid receptor agonist	infectious disease|dermatology	skin infections|psoriasis	http://drugs.webmd.boots.com/drugs/drug-203-.aspx?drugid=203&drugname=|http://drugs.webmd.boots.com/drugs/drug-203-.aspx?drugid=203&drugname=
KB-R7943	KB-R7943		NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1	Preclinical		SLC8A1|TRPC3|TRPC6|TRPC5	http://www.tocris.com/dispprod.php?ItemId=1380|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4232|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4232|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4232	sodium/calcium exchange inhibitor			
PF-429242	PF-429242		CCN(CC)Cc1ccc(cc1)C(=O)N(CCc1ccccc1OC)[C@@H]1CCNC1	Preclinical		MBTPS1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007770	SREBP inhibitor			
AC-710	AC-710		CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1	Preclinical		PDGFRA|PDGFRB|KIT|CSF1R|FLT3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8095|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8095|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8095|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8095|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8095	PDGFR tyrosine kinase receptor inhibitor			
SK&F-10047-(+)	(+)-SK&F-10047		C[C@H]1C2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C	Phase 1				sigma receptor agonist			
chlorpromazine	chlorpromazine	Elmarin|Largactil|Megaphen|Sonazine|chlorpromazine hibenzate|chlorpromazine hydrochloride|chlorpromazine phenolphthalinate|chlorpromazine tannate|thorazine	CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12	Launched	FDA Orange Book: chlorpromazine, chlorpromazine hydrochloride	ADRA1D|ADRA1B|ADRA1A|ADRA2C|ADRA2B|ADRA2A|DRD2|DRD3|DRD4|DRD5|DRD1|ORM1|ORM2|CHRM3|CHRM1|KIF11|HRH4|HRH1|HTR2B|HTR2C|HTR2A|HTR1A|KCNH2|HTR6|HTR7|SMPD1|CALM1|TRPC5	https://www.drugbank.ca/drugs/DB00477|https://www.drugbank.ca/drugs/DB00477|https://www.drugbank.ca/drugs/DB00477|https://www.drugbank.ca/drugs/DB00477|https://www.drugbank.ca/drugs/DB00477|https://www.drugbank.ca/drugs/DB00477|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00477|https://www.drugbank.ca/drugs/DB00477|https://www.drugbank.ca/drugs/DB00477|https://www.drugbank.ca/drugs/DB00477|https://www.drugbank.ca/drugs/DB00477|https://www.drugbank.ca/drugs/DB00477|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=163701|https://www.drugbank.ca/drugs/DB00477|https://www.drugbank.ca/drugs/DB00477|https://www.drugbank.ca/drugs/DB00477|https://www.drugbank.ca/drugs/DB00477|ChEMBL|https://www.drugbank.ca/drugs/DB00477|https://www.drugbank.ca/drugs/DB00477|https://www.drugbank.ca/drugs/DB00477|https://www.drugbank.ca/drugs/DB00477|https://www.drugbank.ca/drugs/DB00477|https://www.drugbank.ca/drugs/DB00477|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=83	dopamine receptor antagonist	neurology/psychiatry|gastroenterology|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0
triamcinolone	triamcinolone	Aristocort A|Kenalog|aristocort|fluoxiprednisolone|kenacort	C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO	Launched	FDA Orange Book: triamcinolone, triamcinolone acetonide, triamcinolone diacetate, triamcinolone hexacetonide	SERPINA6|NR3C1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000417|ChEMBL	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=758a0e7b-8d01-4914-8048-faa0f70c1f69&audience=consumer
10058-F4	10058-F4		CCc1ccc(cc1)\C=C1\SC(=S)NC1=O	Preclinical				c-Myc inhibitor			
trimipramine	trimipramine	7162 RP|IL 6001|IL-6001|surmontil|trimeproprimine	CC(CN(C)C)CN1c2ccccc2CCc2ccccc12	Launched	FDA Orange Book: trimipramine maleate	HRH1|ADRA2B|ADRA2A|ADRA1B|ADRA1A|CHRM1|CHRM4|CHRM5|CHRM2|CHRM3|ADRB1|ADRB2|ADRB3|HTR3A|HTR2C|HTR2A|HTR1D|HTR1A|SLC6A2|SLC6A3|SLC6A4|DRD1|DRD2|DRD5	https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726|https://www.drugbank.ca/drugs/DB00726	norepinephrine reputake inhibitor|tricyclic antidepressant	neurology/psychiatry	depression	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e1e4157-bc15-4e2a-bb2a-ff41b2a8f905
oltipraz	oltipraz		Cc1c(ssc1=S)-c1cnccn1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02068339	ANG|CYP2B6|NFE2L2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001060|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090895|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090895	nuclear factor erythroid derived|like (NRF2) activator			
moroxydine	moroxydine	ABOB|SKF 8898-A	NC(=N)NC(=N)N1CCOCC1	Launched	http://www.drugs.com/international/Moroxydine.html			antiviral	infectious disease	influenza A virus infection	http://www.drugs.com/international/moroxydine.html
erdafitinib	erdafitinib	JNJ-42756493	COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02699606	FGFR4|FGFR3|FGFR2|FGFR1	https://www.medchemexpress.com/Erdafitinib.html|https://www.medchemexpress.com/Erdafitinib.html|https://www.medchemexpress.com/Erdafitinib.html|https://www.medchemexpress.com/Erdafitinib.html	FGFR inhibitor			
CCG-50014	CCG-50014		Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O	Preclinical		RGS8|RGS4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7784|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7784	G protein signaling inhibitor			
R-1485	R-1485		Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1	Phase 1	http://en.pharmacodia.com/web/drug/1_14010.html	HTR6	https://www.tocris.com/products/r-1485-dihydrochloride_4964	serotonin receptor antagonist			
solamargine	solamargine		CC1C2C(CC3C4CC=C5CC(CCC5(C)C4CCC23C)OC2OC(CO)C(OC3OC(C)C(O)C(O)C3O)C(O)C2OC2OC(C)C(O)C(O)C2O)OC11CCC(C)CN1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01493921			apoptosis inhibitor			
cilomilast	cilomilast		COc1ccc(cc1OC1CCCC1)C1(CCC(CC1)C(O)=O)C#N	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00103922	IL12B|IL12A|PDE4A|PDE4B|PDE4C|PDE4D|IL1B|TNF	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=204973|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=204973|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000752|https://www.drugbank.ca/drugs/DB03849|https://citeline.informa.com/?query=#/drugs/details/15986|https://www.drugbank.ca/drugs/DB03849|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=204973|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=204973	phosphodiesterase inhibitor			
3-carboxy-4-hydroxyphenylglycine-(S)	(S)-3-carboxy-4-hydroxyphenylglycine		N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O	Preclinical		GRM1|GRM5	http://www.tocris.com/dispprod.php?ItemId=2115#.VeXTQixVhHw|http://www.tocris.com/dispprod.php?ItemId=2115#.VeXTQixVhHw	glutamate receptor antagonist			
clenbuterol	clenbuterol	NAB 365|Planipart|Spiropent|Ventipulmin|clenbuterol hydrochloride	CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1	Launched	http://en.wikipedia.org/wiki/Clenbuterol	NGF|ADRB2|ADRB1|ADRB3|TNF	https://www.drugbank.ca/drugs/DB01407|https://www.drugbank.ca/drugs/DB01407|https://www.drugbank.ca/drugs/DB01407|https://www.drugbank.ca/drugs/DB01407|https://www.drugbank.ca/drugs/DB01407	adrenergic receptor agonist	pulmonary|pulmonary	chronic obstructive pulmonary disease (COPD)|asthma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=691e6c6a-0ac6-4cc2-bd87-954bf6716735|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=691e6c6a-0ac6-4cc2-bd87-954bf6716735
pyrazolanthrone	pyrazolanthrone		O=C1c2ccccc2-c2n[nH]c3cccc1c23	Preclinical		MAPK10|MAPK8IP1|LRRK2|TTK|MAPK8|MAPK9	https://www.drugbank.ca/drugs/DB01782|https://www.drugbank.ca/drugs/DB01782|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=301539|https://www.drugbank.ca/drugs/DB01782|https://www.drugbank.ca/drugs/DB01782|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5273	JNK inhibitor			
CGS-21680	CGS-21680	CGS21680	CCNC(=O)[C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1cnc2c(N)nc(NCCc3ccc(CCC(O)=O)cc3)nc12	Preclinical		ADORA3|ADORA1|ADORA2B|ADORA2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=375|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=375|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=375|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=375	adenosine receptor agonist			
A-1120	A-1120		OC(=O)c1ccccc1NC(=O)N1CCC(CC1)c1ccccc1C(F)(F)F	Preclinical		RBP4	https://www.tocris.com/products/a-1120_3793	retinoid receptor ligand			
phenolphthalein	phenolphthalein	ex-lax|prulet	Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	UGT1A9	https://www.drugbank.ca/drugs/DB04824	indicator dye			
PHA-793887	PHA-793887		CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00996255	CCND1|CCNE1|CDK1|CDK2|CDK4|CDK5|CDK7|CDK9	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=687948|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=687948|http://www.selleckchem.com/products/PHA-793887.html|http://www.selleckchem.com/products/PHA-793887.html|http://www.selleckchem.com/products/PHA-793887.html|http://www.selleckchem.com/products/PHA-793887.html|http://www.selleckchem.com/products/PHA-793887.html|http://www.selleckchem.com/products/PHA-793887.html	CDK inhibitor			
FPL-12495	FPL-12495		CC(N)(Cc1ccccc1)c1ccccc1	Phase 1	http://en.pharmacodia.com/yaodu/html/v1/chemicals/0a7dbcd63eed483217fa9fe55ead3b9a.html			glutamate receptor antagonist			
mitoxantrone	mitoxantrone	mitoxantrone hydrochloride|novantrone	OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12	Launched	FDA Orange Book: mitoxantrone hydrochloride	PIM1|TOP2A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091234|https://www.drugbank.ca/drugs/DB01204	topoisomerase inhibitor	neurology/psychiatry|oncology|hematologic malignancy	multiple sclerosis|prostate cancer|acute myeloid leukemia (AML)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c101cb05-faaa-44cb-9666-c8214628c844|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c101cb05-faaa-44cb-9666-c8214628c844|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c101cb05-faaa-44cb-9666-c8214628c844
PIK-93	PIK-93		CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO	Preclinical		PIK3CG|PIK3C3|PI4KB	https://www.drugbank.ca/drugs/DB06836|https://www.drugbank.ca/drugs/DB06836|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6062	PI3K inhibitor			
AZD3463	AZD3463		COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1	Preclinical		IGF1R|ALK	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7706|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7706	ALK tyrosine kinase receptor inhibitor|insulin growth factor receptor inhibitor			
vanoxerine	vanoxerine	GBR-12909	Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02454283	SLC6A3|MAOB|MAOA	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001032|https://citeline.informa.com/?query=#/drugs/details/7548|https://citeline.informa.com/?query=#/drugs/details/7548	dopamine uptake inhibitor			
picolinic-acid	picolinic acid	2-PICOLINIC ACID|NSC-89		Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/17300246			chelating agent			
ML-228	ML-228		C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1	Preclinical		HIF1A	https://www.tocris.com/products/ml-228_4565	hypoxia inducible factor activator			
buthionine-sulfoximine	buthionine-sulfoximine	buthionine sulfoxime	CCCCS(=N)(=O)CC[C@H](N)C(O)=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00005835	GCLM	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000357	glutathione transferase inhibitor			
CNQX	CNQX		[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N	Phase 1	Pharmaprojects	GRIA4|GRIA3|GRIA2|GRIA1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4081|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4081|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4081|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4081	glutamate receptor antagonist			
bupicomide	bupicomide	SCH 10595	CCCCc1ccc(nc1)C(N)=O	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/875465	ADRB1	https://aobious.com/aobious/g-protein-coupled-receptor-ligands/1030-bupicomide.html	adrenergic receptor antagonist			
oxotremorine-m	oxotremorine-m		C[N+](C)(C)CC#CCN1CCCC1=O	Preclinical		CHRM1|CHRM3|CHRM2|CHRM4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=303|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=303|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=303|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=303	acetylcholine receptor agonist			
spiperone	spiperone	R 5147|spiroperidol|spiropitan	Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1	Launched	http://www.drugs.com/international/Spiperone.html	ADRA1B|ADRA1A|ADRA1D|HTR7|HTR6|HTR2A|HTR2C|HTR2B|HTR1D|HTR1A|DRD1|DRD5|DRD4|DRD3|DRD2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=99|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=99|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=99|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=99|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003591|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=99|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=99|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=99|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=99|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=99|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=99|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=99|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=99|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=99|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003591	dopamine receptor antagonist	neurology/psychiatry	schizophrenia	https://en.wikipedia.org/wiki/Spiperone
Y-27632	Y-27632		C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1	Preclinical		PRKCE|PRKACA|ROCK1|ROCK2|LRRK2|PKIA|PKN2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5290|https://www.drugbank.ca/drugs/DB08756|https://www.drugbank.ca/drugs/DB08756|https://www.drugbank.ca/drugs/DB08756|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=256939|https://www.drugbank.ca/drugs/DB08756|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5290	rho associated kinase inhibitor			
NNC-05-2090	NNC-05-2090		COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1	Preclinical		SLC6A11|SLC6A12|SLC6A13	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=254374|http://www.tocris.com/dispprod.php?ItemId=5268#.UtRS2KWBNhM|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=254374	GABA uptake inhibitor|GAT inhibitor			
lithium-citrate	lithium citrate	lithium citrate|lithonate	[Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O	Launched	FDA Orange Book: lithium citrate				neurology/psychiatry|neurology/psychiatry	bipolar disorder|depression	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7dc9c6d2-6d9a-49e4-a8ab-437b0ed5f84e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7dc9c6d2-6d9a-49e4-a8ab-437b0ed5f84e
mofegiline	mofegiline		NC\C(CCc1ccc(F)cc1)=C\F	Phase 1	https://www.researchgate.net/publication/15643826_Pharmacokinetics_and_pharmacodynamics_of_the_monoamine_oxidase_B_inhibitor_mofegiline_assessed_during_a_phase_I_dose_tolerance_trial	MAOB|MAOA	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009632|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009632	monoamine oxidase inhibitor			
MRS-1220	MRS-1220		Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1	Preclinical		ADORA2B|ADORA3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=448|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=448	adenosine receptor antagonist			
K145	K145		CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1	Preclinical		SPHK2	https://www.medchemexpress.com/k145-hydrochloride.html	sphingosine kinase inhibitor			
ifosfamide	ifosfamide	Ifsofamide|MJF 9325|MJF-9325|Z-4942|Z4942|ifex	ClCCNP1(=O)OCCCN1CCCl	Launched	FDA Orange Book: ifosfamide	CYP2C18|CYP2C19|PTGS1|CYP2C9|CYP2C8|CYP2B6|CYP2A6|CYP3A7|CYP3A4|CYP3A5	http://www.drugbank.ca/drugs/DB01181|http://www.drugbank.ca/drugs/DB01181|http://www.drugbank.ca/drugs/DB01181|http://www.drugbank.ca/drugs/DB01181|http://www.drugbank.ca/drugs/DB01181|http://www.drugbank.ca/drugs/DB01181|http://www.drugbank.ca/drugs/DB01181|http://www.drugbank.ca/drugs/DB01181|http://www.drugbank.ca/drugs/DB01181|http://www.drugbank.ca/drugs/DB01181	DNA alkylating agent	oncology|urology	testicular carcinoma|hemorrhagic cystitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91e433a9-6800-43a6-ac13-a49a04a5aecd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91e433a9-6800-43a6-ac13-a49a04a5aecd
FIT	FIT		CCC(=O)N(C1CCN(CCc2ccc(cc2)N=C=S)CC1)c1ccccc1	Preclinical		OPRD1	http://www.tocris.com/dispprod.php?ItemId=1234	opioid receptor agonist			
cholecalciferol	cholecalciferol	7-DEHYDROCHOLESTEROL, ACTIVATED|Dihydrocholesterol|Vitamin D 3|colecalciferol|vitamin d	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	Launched	FDA Orange Book: cholecalciferol	VDR|CYP2J2	ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=390460		endocrinology	vitamin D deficiency	https://en.wikipedia.org/wiki/Cholecalciferol
presatovir	presatovir	GS-5806	Cc1cn2nc(cc2nc1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(C)(=O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02135614			RSV fusion inhibitor			
vesamicol	vesamicol	(+/-)-Vesamicol|(-)-Vesamicol	O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1	Preclinical		SLC18A3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4759	acetylcholinesterase inhibitor			
riluzole	riluzole	RP 54274|RP-54274|rilutek	Nc1nc2ccc(OC(F)(F)F)cc2s1	Launched	FDA Orange Book: riluzole	KCNK10|SCN3A|SCN2A|SCN1A|SCN5A|SCN4A|SCN7A|SCN9A|SCN8A|SLC7A11|SCN11A|SCN10A|KCNK2|KCNK4|KCND3|KCNN4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2326|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00740|ChEMBL|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2326|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2326|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=111447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2326	glutamate inhibitor	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba1f7351-76cd-a872-c9e0-57db929e84de
maltobionic-acid	maltobionic acid		OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O	Launched	http://www.neostratapro.com/images/neostratapro/en_us/local/landing/maltobionic_acid_powerful.pdf			matrix metalloprotease inhibitor	dermatology	cosmetic	https://www.neostratapro.com/images/neostratapro/en_us/local/landing/maltobionic_acid_powerful.pdf
3,4-DCPG-(+/-)	(+/-)-3,4-DCPG		NC(C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O	Preclinical				glutamate receptor agonist			
TC-S-7009	TC-S-7009		[O-][N+](=O)c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12	Preclinical		EPAS1	https://www.tocris.com/products/tc-s-7009_5243	hypoxia inducible factor inhibitor			
rolipram-S(+)	rolipram-S(+)		COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1	Preclinical				phosphodiesterase inhibitor			
diphenidol	diphenidol	SK&F 478|SK&F-478|SK-478|difenidol|difenidol hydrochloride|vontrol	OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1	Launched	FDA Orange Book: diphenidol hydrochloride	CHRM4|CHRM3|CHRM2|CHRM1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001133|https://www.drugbank.ca/drugs/DB01231|https://www.drugbank.ca/drugs/DB01231|https://www.drugbank.ca/drugs/DB01231	acetylcholine receptor agonist	neurology/psychiatry	vertigo	https://en.wikipedia.org/wiki/Diphenidol
iniparib	iniparib		NC(=O)c1ccc(I)c(c1)[N+]([O-])=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00938652	PARP1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000500	PARP inhibitor			
4,5,6,7-tetrabromobenzotriazole	4,5,6,7-tetrabromobenzotriazole		Brc1c(Br)c(Br)c2[nH]nnc2c1Br	Preclinical				casein kinase inhibitor			
ZM-39923	ZM-39923		CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1	Preclinical		JAK1|JAK3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5994|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5994	JAK inhibitor			
anidulafungin	anidulafungin	eraxis	CCCCCOc1ccc(cc1)-c1ccc(cc1)-c1ccc(cc1)C(=O)NC1CC(O)C(O)NC(=O)C2C(O)C(C)CN2C(=O)C(NC(=O)C(NC(=O)C2CC(O)CN2C(=O)C(NC1=O)C(C)O)C(O)C(O)c1ccc(O)cc1)C(C)O	Launched	FDA Orange Book: anidulafungin			fungal 1,3-beta-D-glucan synthase inhibitor	infectious disease|infectious disease|infectious disease	candidemia|fungal infection|esophageal candidiasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a88d9010-55fb-4a02-baff-042cd27688ea|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a88d9010-55fb-4a02-baff-042cd27688ea|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a88d9010-55fb-4a02-baff-042cd27688ea
dizocilpine-(-)	(-)-dizocilpine		C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21	Phase 1	http://stroke.ahajournals.org/content/26/3/503.full			glutamate receptor antagonist			
AEE788	AEE788	AEE-788|GNF-Pf-5343|NVP-AEE788	CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT00107237	FGFR3|FGFR2|KDR|ERBB2|ERBB4|FLT1|EGFR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000361|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000361|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7643|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7643|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7643|https://citeline.informa.com/?query=#/drugs/details/30735|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7643	EGFR inhibitor|VEGFR inhibitor			
NSC-23766	NSC-23766		CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1	Preclinical				Ras GTPase inhibitor			
fenbufen	fenbufen	CL 82,204|Cepal|Cinopal|Cybufen|Lederfen|Reugast	OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1	Launched	http://www.drugs.com/international/fenbufen.html	PTGS2|PTGS1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014108|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014108	cyclooxygenase inhibitor			
carmoxirole	carmoxirole		OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1	Phase 2	http://adisinsight.springer.com/drugs/800002269	DRD2	https://www.tocris.com/dispprod.php?ItemId=121708#.VyezwGQrImI	dopamine receptor agonist			
triclosan	triclosan	CH 3565|CH-3565|DNDI1246774|cloxifenol|stri-dex cleansing bar|stri-dex face wash	Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl	Launched	FDA Orange Book: triclosan	DNMT1	http://www.ncbi.nlm.nih.gov/pubmed/22939515	antibacterial agent			
SJ-172550	SJ-172550		CCOc1cc(\C=C2C(=O)N(N=C\2C)c2ccccc2)cc(Cl)c1OCC(=O)OC	Preclinical		MDM4	http://www.tocris.com/dispprod.php?ItemId=254928	MDM inhibitor			
TG-100801	TG-100801	TG100-801	Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00509548	KDR|FGFR1|EPHB4|FLT1|SRC	http://medchemexpress.com/TG-100801.html?gclid=CJXdoObkxcwCFZdZhgodC1wAIA|http://medchemexpress.com/TG-100801.html?gclid=CJXdoObkxcwCFZdZhgodC1wAIA|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=440879|http://medchemexpress.com/TG-100801.html?gclid=CJXdoObkxcwCFZdZhgodC1wAIA|http://medchemexpress.com/TG-100801.html?gclid=CJXdoObkxcwCFZdZhgodC1wAIA	src inhibitor|VEGFR inhibitor			
netilmicin	netilmicin	netromycin	CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1OC1OC[C@](C)(O)[C@H](NC)[C@H]1O	Launched	FDA Orange Book: netilmicin sulfate			protein synthesis inhibitor	infectious disease	gram-negative bacterial infections	https://en.wikipedia.org/wiki/Netilmicin
usniacin-(+)	(+)-usniacin		CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O	Preclinical				MAP kinase activator			
ISX-9	ISX-9		O=C(NC1CC1)c1cc(on1)-c1cccs1	Preclinical		NEUROD1	https://www.tocris.com/products/isx-9_4439	neural stem cell inducer			
isovaleramide	isovaleramide	NFS1776	CC(C)CC(N)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00172094			alcohol dehydrogenase inhibitor			
L-693403	L-693403		C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1	Preclinical		DRD2|SIGMAR1	http://www.chemicalbook.com/ProductChemicalPropertiesCB5253009_EN.htm|http://www.tocris.com/dispprod.php?ItemId=2015	sigma receptor agonist|sigma receptor antagonist			
pirlindole	pirlindole	Pirazidol	Cc1ccc2n3CCNC4CCCc(c34)c2c1	Launched	http://www.drugs.com/international/Pirlindole.html	MAOA|SLC6A4|SLC6A2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6638|https://citeline.informa.com/?query=#/drugs/details/14512|https://citeline.informa.com/?query=#/drugs/details/14512	monoamine oxidase inhibitor	neurology/psychiatry	depression	https://en.wikipedia.org/wiki/Pirlindole
indocyanine-green	indocyanine green	ic-green|indocyanine green	CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12	Launched	FDA Orange Book: indocyanine green	SLCO1B1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4844	contrast agent			
genistein	genistein	NSC-36586	Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT00355953	CFTR|ESR2|ESR1|EGFR|NCOA2|NCOA1|ESRRG|ESRRA|ESRRB|TOP2A|PTK2B|TRPC5|PPARG	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2826|https://www.drugbank.ca/drugs/DB01645|https://www.drugbank.ca/drugs/DB01645|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=122175|https://www.drugbank.ca/drugs/DB01645|https://www.drugbank.ca/drugs/DB01645|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2826|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2826|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2826|https://www.drugbank.ca/drugs/DB01645|https://www.drugbank.ca/drugs/DB01645|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2826|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000330	tyrosine kinase inhibitor			
GDC-0879	GDC-0879		OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1	Preclinical		BRAF	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5681	RAF inhibitor			
sparfosate	sparfosate	sparfosic acid	OC(=O)CC(NC(=O)CP(O)(O)=O)C(O)=O	Phase 3	http://adisinsight.springer.com/drugs/800002096	CA2|CAD|CA4	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004922|https://www.drugbank.ca/drugs/DB03459|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004922	aspartate carbamoyltransferase inhibitor			
sodium-orthovanadate	sodium orthovanadate	Orthovanadate	O[V](O)(O)=O	Preclinical							
aspirin	aspirin	8-hour bayer|Acetosalic Acid|Ecotrin|Equi-Prin|Salicylic Acid Acetate|acetylsalicylic acid|bayer extra strength aspirin for migraine pain|durlaza|measurin	CC(=O)Oc1ccccc1C(O)=O	Launched	https://clinicaltrials.gov/ct2/show/NCT00915733	AKR1C1|EDNRA|RPS6KA3|NFKBIA|ASIC3|IKBKB|PRKAA1|PRKAA2|PRKAB1|PRKAB2|PRKAG1|PRKAG2|PRKAG3|TP53|HSPA5|PTGS2|PTGS1|NFKB1|NFKB2	https://www.drugbank.ca/drugs/DB00945|https://www.drugbank.ca/drugs/DB00945|https://www.drugbank.ca/drugs/DB00945|https://www.drugbank.ca/drugs/DB00945|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4139|https://www.drugbank.ca/drugs/DB00945|https://www.drugbank.ca/drugs/DB00945|https://www.drugbank.ca/drugs/DB00945|https://www.drugbank.ca/drugs/DB00945|https://www.drugbank.ca/drugs/DB00945|https://www.drugbank.ca/drugs/DB00945|https://www.drugbank.ca/drugs/DB00945|https://www.drugbank.ca/drugs/DB00945|https://www.drugbank.ca/drugs/DB00945|https://www.drugbank.ca/drugs/DB00945|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00945|https://www.drugbank.ca/drugs/DB00945	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology|dental|neurology/psychiatry	headache|fever|toothache|muscle pain	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b694189-6e16-4814-a797-ce3fb4d41dcd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b694189-6e16-4814-a797-ce3fb4d41dcd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b694189-6e16-4814-a797-ce3fb4d41dcd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b694189-6e16-4814-a797-ce3fb4d41dcd
palmitoylethanolamide	palmitoylethanolamide	palmidrol	CCCCCCCCCCCCCCCC(=O)NCCO	Launched	https://clinicaltrials.gov/ct2/show/NCT01742247	CNR2|GPR55|GPR119	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001092|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3622|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3622	cannabinoid receptor agonist			
erbstatin-analog	erbstatin-analog	Methyl 2,5-Dihydroxycinnamate|Methyl 3-(2,5-Dihydroxyphenyl)Acrylate	COC(=O)\C=C\c1cc(O)ccc1O	Preclinical		EGFR	http://www.tocris.com/dispprod.php?ItemId=1615	EGFR inhibitor|tyrosine kinase inhibitor			
esculin	esculin		OC[C@H]1O[C@@H](Oc2cc3ccc(=O)oc3cc2O)[C@@H](O)[C@@H](O)[C@@H]1O	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/21211224			antioxidant			
FG-2216	FG-2216		OC(=O)CNC(=O)c1nc(Cl)c2ccccc2c1O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00456053	HIF1A|EGLN1|EGLN2	https://www.drugbank.ca/drugs/DB08687|https://www.drugbank.ca/drugs/DB08687|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000111	hypoxia inducible factor prolyl hydroxylase inhibitor			
CPI-0610	CPI-0610		Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01949883	BRD4	http://www.dcchemicals.com/products_Show.asp?id=5239	bromodomain inhibitor			
haloperidol-decanoate	haloperidol decanoate	Haldol Dec|R-13,672|R-13672|haldol|haloperidol decanoate	CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1	Launched	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm	DRD3|DRD4|DRD2|HTR2A|CYP3A7|CYP3A4|CYP2D6|CYP1A1|CYP1A2	ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=120019|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=120019|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=120019|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=120019|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=120019	psychoactive drug	neurology/psychiatry	schizophrenia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f7e8cf1-7ae9-480c-b1d2-117cf176afa8
sodium-salicylate	sodium salicylate		OC(=O)c1ccccc1O	Launched	https://clinicaltrials.gov/ct2/show/NCT00339833	ASIC3|PTGS1|PTGS2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4306|https://www.drugbank.ca/drugs/DB01398|https://www.drugbank.ca/drugs/DB01398	prostanoid receptor antagonist	endocrinology|neurology/psychiatry	fever|pain relief	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f31976b-cf71-4ae0-a153-0ee242430931&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f31976b-cf71-4ae0-a153-0ee242430931&audience=consumer
etofenamate	etofenamate	BAY D 1107|TVX485|WHR-5020	OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	Launched	http://www.drugs.com/international/Etofenamate.html	PTGS1|PTGS2	http://www.genome.jp/dbget-bin/www_bget?dr:D04102|http://www.genome.jp/dbget-bin/www_bget?dr:D04102	cyclooxygenase inhibitor	neurology/psychiatry|rheumatology	muscle pain|joint pain	https://en.wikipedia.org/wiki/Etofenamate|https://en.wikipedia.org/wiki/Etofenamate
amitifadine	amitifadine	DOV-216303|DOV-21947|DOV-2947	Clc1ccc(cc1Cl)C12CC1CNC2	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01318434	SLC6A2|SLC6A4|SLC6A3	http://www.genome.jp/dbget-bin/www_bget?dr:D10088|http://www.genome.jp/dbget-bin/www_bget?dr:D10088|http://www.genome.jp/dbget-bin/www_bget?dr:D10088	serotonin transporter (SERT) inhibitor			
GSK-2193874	GSK-2193874		FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1	Preclinical		TRPV4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6465	transient receptor potential channel antagonist			
saxagliptin	saxagliptin	onglyza	N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2	Launched	FDA Orange Book: saxagliptin hydrochloride	DPP4|CYP3A5	https://www.drugbank.ca/drugs/DB06335|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=310379	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5116390-e0fe-4969-94cb-e9de5165fbab
PNU-37883	PNU-37883	U-37883A	C1CCC(CC1)N\C(N1CCOCC1)=N\C12CC3CC(CC(C3)C1)C2	Preclinical				ATP-sensitive potassium channel antagonist			
rotundine	rotundine	(-)-Tetrahydropalmatine|L-Tetrahydropalmatine|Tetrahydropalmatine	COc1cc2CCN3Cc4c(C[C@H]3c2cc1OC)ccc(OC)c4OC	Launched	http://en.wikipedia.org/wiki/Tetrahydropalmatine	HTR4|HTR7|HTR1D|HTR1A|DRD2|DRD1|DRD3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=431086|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=431086|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=431086|http://www.abcam.com/rotundine-ab143130.html|http://www.abcam.com/rotundine-ab143130.html|http://www.abcam.com/rotundine-ab143130.html|http://www.abcam.com/rotundine-ab143130.html	serotonin receptor agonist			
butofilolol	butofilolol		CCCC(=O)c1cc(F)ccc1OCC(O)CNC(C)(C)C	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/6412614	ADRB2|ADRB1	https://citeline.informa.com/?query=#/drugs/details/3169|https://citeline.informa.com/?query=#/drugs/details/3169	adrenergic receptor antagonist			
apigenin	apigenin	NSC-83244	Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1	Preclinical		CFTR|AKR1B1|CDK6|MAOA|AR|CYP19A1|HSD17B1|XDH|ODC1|CYP1B1|CYP1A2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4136|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004714|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004714|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=162478|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004714|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004714|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004714|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=162478|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=162478|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004714|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=162478	casein kinase inhibitor|cell proliferation inhibitor			
L-Cystine	L-Cystine	cysteine hydrochloride		Launched	http://www.drugs.com/international/L-Cystine.html	SLC3A1|SLC7A9|SLC7A11|CTNS	https://www.drugbank.ca/drugs/DB00138|https://www.drugbank.ca/drugs/DB00138|https://www.drugbank.ca/drugs/DB00138|https://www.drugbank.ca/drugs/DB00138				
flufenamic-acid	flufenamic acid	CI 440|CN-27,554|INF-1837|arlef|flufenamic acid	OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	Preclinical		PANX3|PANX2|PANX1|GJA10|PTGS2|PTGS1|TRPM2|TRPM5|TRPC5|AR|GJB1|GJB2|GJB3|GJB4|GJB5|GJB6|GJB7|GJA9|GJA1|GJA3|GJA4|GJA5|GJA8|GJE1|GJD2|GJD3|GJD4|GJC1|GJC2|GJC3|PKD2L1|AKR1C3|ANO1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|https://www.drugbank.ca/drugs/DB02266|https://www.drugbank.ca/drugs/DB02266|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|https://www.drugbank.ca/drugs/DB02266|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447|https://www.drugbank.ca/drugs/DB02266|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447	chloride channel blocker			
LCL-161	LCL-161		CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02098161	XIAP|BIRC2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7912|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7912	XIAP inhibitor			
rebastinib	rebastinib	DCC-2036|DP-1919	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00827138	HCK|ABL1|FGR|LYN|KDR|SRC|TEK|BCR|FLT3	http://www.selleckchem.com/products/dcc-2036.html|http://www.apexbt.com/dcc-2036-rebastinib.html?gclid=COv7htDSw8wCFVZahgodHLoBFw|http://www.selleckchem.com/products/dcc-2036.html|http://www.selleckchem.com/products/dcc-2036.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=466966|http://www.selleckchem.com/products/dcc-2036.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=466966|http://www.selleckchem.com/products/dcc-2036.html|http://www.apexbt.com/dcc-2036-rebastinib.html?gclid=COv7htDSw8wCFVZahgodHLoBFw	Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor			
bleomycetin	bleomycetin		C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)C(NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](O[C@H]1O[C@H](CO)[C@H](O)[C@@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1)C(=O)NCCc1nc(cs1)-c1nc(cs1)C(=O)NCCCNCCCCN	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/6187278			EGFR expression inhibitor			
cyproterone-acetate	cyproterone acetate		CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O	Launched	https://clinicaltrials.gov/ct2/show/NCT00752635	AR|ADORA1	https://www.drugbank.ca/drugs/DB04839|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011884	androgen receptor antagonist	oncology	prostate cancer	http://www.macmillan.org.uk/Cancerinformation/Cancertreatment/Treatmenttypes/Hormonaltherapies/Individualhormonaltherapies/Cyproterone.aspx
emtricitabine	emtricitabine	(-)-FTC|524W91|BW-524W91|FTC|FTC-(-)|emtriva	Nc1nc(=O)n(cc1F)[C@@H]1CS[C@H](CO)O1	Launched	FDA Orange Book: emtricitabine			nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=946b680e-34e2-4789-8a9f-c00f851ad033
20-hydroxyecdysone	20-hydroxyecdysone		CC(C)(O)CC[C@@H](O)[C@](C)(O)[C@@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@@H]3CC[C@]12C	Preclinical				ecdysone receptor modulator			
sulfanitran	sulfanitran		CC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)[N+]([O-])=O	Veterinary Launched	http://www.drugs.com/international/sulfanitran.html						
omadacycline	omadacycline		CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(cc(CNCC(C)(C)C)c(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00865280			bacterial 30S ribosomal subunit inhibitor			
SB-756050	SB-756050		COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00733577	GPBAR1	https://www.dovepress.com/tgr5-ligands-as-potential-therapeutics-in-inflammatory-diseases-peer-reviewed-fulltext-article-IJICMR	G protein-coupled receptor agonist			
estropipate	estropipate	ogen 2.5	C[C@]12CCC3C(CCc4cc(OS(O)(=O)=O)ccc34)C1CCC2=O	Launched	FDA Orange Book: estropipate	ESR2|ESR1	https://www.drugbank.ca/drugs/DB04574|https://www.drugbank.ca/drugs/DB04574	estrogen receptor agonist	orthopedics|endocrinology|obstetrics/gynecology|endocrinology	osteoporosis|menopause|vaginal atrophy|hypoestrogenism	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4252d631-03d0-4b37-8a0e-c7dc8fc5438a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4252d631-03d0-4b37-8a0e-c7dc8fc5438a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4252d631-03d0-4b37-8a0e-c7dc8fc5438a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4252d631-03d0-4b37-8a0e-c7dc8fc5438a
isavuconazole	isavuconazole		C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)C(O)(Cn1cncn1)c1cc(F)ccc1F	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00413218	CYP3A4	https://en.wikipedia.org/wiki/Isavuconazole	cytochrome P450 inhibitor			
minaprine	minaprine	AGR-1240|Brantur|CB-30038|cantor	Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	MAOA|SLC6A4|HTR2C|HTR2B|HTR2A|ACHE|DRD2|DRD1|CHRM1	https://www.drugbank.ca/drugs/DB00805|https://www.drugbank.ca/drugs/DB00805|https://www.drugbank.ca/drugs/DB00805|https://www.drugbank.ca/drugs/DB00805|https://www.drugbank.ca/drugs/DB00805|https://www.drugbank.ca/drugs/DB00805|https://www.drugbank.ca/drugs/DB00805|https://www.drugbank.ca/drugs/DB00805|https://www.drugbank.ca/drugs/DB00805	serotonin reuptake inhibitor			
cyclopiazonic-acid	cyclopiazonic acid		CC(=O)C1C(=O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O	Preclinical		ATP2A1	http://en.wikipedia.org/wiki/Cyclopiazonic_acid	ATPase inhibitor			
talc	talc	sclerosol	O=[Mg].O=[Mg].O=[Mg].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O	Launched	FDA Orange Book: talc						
GW-0742	GW-0742		Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F	Preclinical		PPARD|INS	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2686|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=339842	PPAR receptor agonist			
GR-235	GR-235	(Z)-Gugglesterone|Guggulsterone	C\C=C1/C(=O)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched	http://en.wikipedia.org/wiki/Guggulsterone	NR1I2|NR1H4|PGR|ESR1|IKBKB	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=140689|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2745|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=140689|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=140689|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=140689	estrogen receptor agonist|FXR antagonist|progesterone receptor agonist			
mianserin	mianserin		CN1CCN2C(C1)c1ccccc1Cc1ccccc21	Launched	http://www.drugs.com/international/Mianserin.html	HTR2C|HTR2A|HTR2B|HTR1F|HTR1A|ADRA2B|ADRA2A|ADRA2C|ADRA1A|ADRA1D|ADRA1B|HRH4|HRH1|HRH2|HTR7|HTR6|OPRK1|DRD1|DRD2|DRD3|DRD5|SLC6A2|SLC6A3|SLC6A4	https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011946|https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148|https://www.drugbank.ca/drugs/DB06148	serotonin receptor antagonist	neurology/psychiatry	depression	https://en.wikipedia.org/wiki/Mianserin
retinyl-palmitate	retinyl palmitate	Afaxin|Alphalin|Aquasol a|Del-vi-a|Vi-dom-a|vitamin a palmitate	CCCCCCCCCCCCCCCC(=O)OC\C=C(C)\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C	Launched	https://clinicaltrials.gov/ct2/show/NCT01225289						
SM-21	SM-21		CCC(Oc1ccc(Cl)cc1)C(=O)OC1CC2CCC(C1)N2C	Preclinical		PGRMC1	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064612/	sigma receptor antagonist			
apraclonidine	apraclonidine	iopidine	Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1	Launched	FDA Orange Book: apraclonidine hydrochloride	ADRA1A|ADRA2B|ADRA2C|ADRA2A	https://www.drugbank.ca/drugs/DB00964|https://www.drugbank.ca/drugs/DB00964|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7117|https://www.drugbank.ca/drugs/DB00964	adrenergic receptor agonist	ophthalmology|ophthalmology	glaucoma|intraocular pressure	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a6c44a6-e415-467f-bf3b-3e7f2c7dc714|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a6c44a6-e415-467f-bf3b-3e7f2c7dc714
puerarin	puerarin		OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00854724			serotonin receptor antagonist			
CMPD-1	CMPD-1		Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1	Preclinical		GNRHR|MAPK14	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1179|http://www.rndsystems.com/Products/2186	p38 MAPK inhibitor			
indobufen	indobufen		CCC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O	Launched	http://www.drugs.com/international/Indobufen.html	PTGS1|PTGS2	http://www.genome.jp/dbget-bin/www_bget?dr:D07141|http://www.genome.jp/dbget-bin/www_bget?dr:D07141	cyclooxygenase inhibitor|platelet aggregation inhibitor	hematology	thrombosis	http://www.mims.com/India/drug/info/indobufen/?type=full&mtype=generic
ARQ-092	ARQ-092		Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02476955	AKT2	http://www.medkoo.com/products/5241	AKT inhibitor			
JAK3-inhibitor-V	JAK3-inhibitor-V	ZM-449829	C=CC(=O)c1ccc2ccccc2c1	Preclinical		JAK3	http://www.scbt.com/datasheet-295218.html	JAK inhibitor			
pivampicillin	pivampicillin		CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O	Launched	http://www.drugs.com/international/Pivampicillin.html			bacterial cell wall synthesis inhibitor	pulmonary|infectious disease|infectious disease	bronchitis|pneumonia|gynecologic infections	http://www.drugbank.ca/drugs/DB01604|http://www.drugbank.ca/drugs/DB01604|http://www.drugbank.ca/drugs/DB01604
ilomastat	ilomastat		CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO	Phase 3	Pharmaprojects	MMP12|MMP13|MMP14|MMP8|MMP9|MMP3|MMP1|MMP2|ACAN|ADAM28	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003714|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003714|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003714|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003714|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003714|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003714|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003714|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003714|https://www.drugbank.ca/drugs/DB02255|https://www.drugbank.ca/drugs/DB02255	matrix metalloprotease inhibitor			
metronidazole	metronidazole	BAY-5360|BAYER 5360|Flagyl 375|Metric 21|Metro IV|Metrolyl|Metromidol|RP 8823|RP-8823|Satric|flagyl|flagyl er|flagyl i.v.|metro i.v.|metrocream|metrogel|metrogel-vaginal|metrolotion|noritate|nuvessa|protostat|vandazole	Cc1ncc(n1CCO)[N+]([O-])=O	Launched	FDA Orange Book: metronidazole, metronidazole hydrochloride	CYP2C9|CYP2C8|CYP2E1|CYP3A7|CYP3A4|CYP3A5	https://en.wikipedia.org/wiki/Metronidazole|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070005|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070005|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070005|https://en.wikipedia.org/wiki/Metronidazole|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070005	DNA inhibitor	dermatology	rosacea	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de4cb39f-cc6e-98fb-05e5-103f3aca2dad#
GW-2580	GW-2580	GW2580|GW632580X	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1	Preclinical		CSF1R	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5685	cFMS kinase inhibitor			
protoporphyrin-ix	protoporphyrin-ix		Cc1c(CCC(O)=O)c2cc3[nH]c(cc4nc(cc5[nH]c(cc1n2)c(C)c5C=C)c(C)c4C=C)c(C)c3CCC(O)=O	Preclinical		HMOX1	http://www.ncbi.nlm.nih.gov/pubmed/16027238	heme oxygenase inhibitor			
PAOPA	PAOPA		NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O	Preclinical		DRD2	https://www.tocris.com/products/paopa_5041	dopamine receptor modulator			
GSK690693	GSK690693	GSK-690693	CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00493818	PRKG1|PRKCQ|AKT2|AKT1|AKT3|PAK7|PAK6|PAK4|PRKX	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5196|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5196|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5196|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5196|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5196|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5196|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5196|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5196|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5196	AKT inhibitor			
eperezolid	eperezolid	U-100,592|U-100592	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/9327249			bacterial 30S ribosomal subunit inhibitor			
IPA-3	IPA-3		Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12	Preclinical		PAK1	https://www.tocris.com/dispprod.php?ItemId=232389#.VykIvWQrImJ	p21 activated kinase inhibitor			
butylated-hydroxytoluene	butylated hydroxytoluene	BHT|Butylhydroxytoluene|E321|butylated hydroxytoluene	Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02220673	CA2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009127	carbonic anhydrase inhibitor			
NVP-BEZ235	NVP-BEZ235	BEZ-235|NVP-BEZ235-NX|dactolisib	Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01288092	ATR|MTOR|PIK3CD|PIK3CG|PIK3CA|PIK3CB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=440710	mTOR inhibitor|PI3K inhibitor			
SUN-11602	SUN-11602		CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C	Preclinical		FGFR1	https://www.tocris.com/products/sun-11602_4826	fibroblast growth factor mimetic			
granisetron	granisetron	BRL 43694|BRL-43694|LY-278584|granisetron hydrochloride|granisetron hydrochloride preservative free|kytril|sancuso	CN1C2CCCC1CC(C2)NC(=O)c1nn(C)c2ccccc12	Launched	FDA Orange Book: granisetron, granisetron hydrochloride	HTR3A|CYP3A5	ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=130362	serotonin receptor antagonist	gastroenterology|gastroenterology	nausea|vomiting	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dddc8714-383f-4bc5-a468-ae89dbc802b4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dddc8714-383f-4bc5-a468-ae89dbc802b4
diarylpropionitrile	diarylpropionitrile	2,3-Bis(4-Hydroxyphenyl)Propanenitrile	Oc1ccc(CC(C#N)c2ccc(O)cc2)cc1	Preclinical		ESR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2825	estrogen receptor agonist			
CGH2466	CGH2466		Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1	Preclinical		ADORA2B|ADORA1|ADORA3	https://www.tocris.com/dispprod.php?ItemId=143720#.Vye6Q2QrImJ|https://www.tocris.com/dispprod.php?ItemId=143720#.Vye6Q2QrImJ|https://www.tocris.com/dispprod.php?ItemId=143720#.Vye6Q2QrImJ	adenosine receptor antagonist			
cyclic-AMP	cyclic-AMP		Nc1ncnc2n(cnc12)C1OC2COP(O)(=O)OC2C1O	Preclinical		TRPM7|CNGA3|HCN2|PRKAR2B|PRKAR1A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352|https://www.drugbank.ca/drugs/DB02527|https://www.drugbank.ca/drugs/DB02527|https://www.drugbank.ca/drugs/DB02527				
SB-271046	SB-271046		COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1	Phase 1	http://adisinsight.springer.com/drugs/800011590	HTR6	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=276	serotonin receptor antagonist			
ICI-162846	ICI-162846		NC(=O)CCCCn1ccc(n1)\N=C(/N)NCC(F)(F)F	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/2874823	HRH2	https://www.tocris.com/dispprod.php?ItemId=1502#.VykBeGQrImI	histamine receptor antagonist			
17-PA	17-PA		C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC=C2c1ccccc1	Preclinical				glucocorticoid receptor agonist			
acitretin	acitretin	RO 10-1670/000|Ro-10-1670-000|etretin|soriatane	COc1cc(C)c(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)c(C)c1C	Launched	FDA Orange Book: acitretin	RARG|RARB|RARA|RBP1|STAT3|RXRA|RXRB|RXRG	https://www.drugbank.ca/drugs/DB00459|https://www.drugbank.ca/drugs/DB00459|ChEMBL|https://www.drugbank.ca/drugs/DB00459|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000743|https://www.drugbank.ca/drugs/DB00459|https://www.drugbank.ca/drugs/DB00459|ChEMBL	retinoid receptor agonist	dermatology	psoriasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2955439-fca4-4614-bfcf-dd0855b86185
XE-991	XE-991		O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12	Preclinical		KCNQ3|KCNQ4|KCNQ5|KCNQ1|KCNQ2	http://www.tocris.com/dispprod.php?ItemId=5482|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2596|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2596|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2596|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2596	potassium channel blocker			
famciclovir	famciclovir	BRL-42810|famvir	CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O	Launched	FDA Orange Book: famciclovir			DNA polymerase inhibitor	dental|infectious disease|infectious disease	cold sore|genitial herpes|shingles	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eeeee9c4-8566-4100-8ca4-3df936a3365d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eeeee9c4-8566-4100-8ca4-3df936a3365d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eeeee9c4-8566-4100-8ca4-3df936a3365d
CGP-60474	CGP-60474	GNF-Pf-88	OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1	Preclinical		CDK2|CDK1	https://www.tocris.com/products/cgp-60474_5471|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004640	CDK inhibitor			
C-751	C-751		CCOC(=O)c1c[nH]cn1	Preclinical							
NSI-189	NSI-189		CC(C)CCNc1ncccc1C(=O)N1CCN(Cc2ccccc2)CC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02695472			neurotrophic agent			
cryptotanshinone	cryptotanshinone		C[C@H]1COC2=C1C(=O)C(=O)c1c2ccc2c1CCCC2(C)C	Preclinical		STAT3|PTGS2|ACHE|AKR1B1	https://www.tocris.com/dispprod.php?ItemId=239511#.Vyi202QrImI|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=347594|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=347594|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=347594	acetylcholinesterase inhibitor|STAT inhibitor			
nocodazole	nocodazole	R 17,934	COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1	Preclinical		HPGDS	https://www.drugbank.ca/drugs/DB08313	tubulin polymerization inhibitor			
exalamide	exalamide		CCCCCCOc1ccccc1C(N)=O	Launched	http://www.kegg.jp/entry/D01585			membrane permeability inhibitor			
asenapine	asenapine	saphris		Launched	FDA Orange Book: asenapine maleate	HTR6|HTR7|ADRA1A|ADRA2C|ADRA2B|ADRA2A|HRH2|HRH1|HTR2B|HTR2A|HTR2C|HTR1E|HTR1D|HTR1A|HTR1B|HTR5A|DRD2|DRD1|DRD4|DRD3|ADRB2|ADRB1	https://www.drugbank.ca/drugs/DB06216|https://www.drugbank.ca/drugs/DB06216|https://www.drugbank.ca/drugs/DB06216|https://www.drugbank.ca/drugs/DB06216|https://www.drugbank.ca/drugs/DB06216|https://www.drugbank.ca/drugs/DB06216|https://www.drugbank.ca/drugs/DB06216|https://www.drugbank.ca/drugs/DB06216|https://www.drugbank.ca/drugs/DB06216|https://www.drugbank.ca/drugs/DB06216|https://www.drugbank.ca/drugs/DB06216|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=22|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=22|https://www.drugbank.ca/drugs/DB06216|https://www.drugbank.ca/drugs/DB06216|https://www.drugbank.ca/drugs/DB06216|https://www.drugbank.ca/drugs/DB06216|https://www.drugbank.ca/drugs/DB06216|https://www.drugbank.ca/drugs/DB06216|https://www.drugbank.ca/drugs/DB06216|https://www.drugbank.ca/drugs/DB06216|https://www.drugbank.ca/drugs/DB06216	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry|neurology/psychiatry	schizophrenia|bipolar disorder	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8
XL019	XL019		O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00595829	JAK1|JAK2|JAK3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7971|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7971|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7971	JAK inhibitor			
felbinac	felbinac	CL 83,544|LJC 10,141|dolinac|felbinac ethyl|flexfree|napageln|target|traxam	OC(=O)Cc1ccc(cc1)-c1ccccc1	Launched	http://www.drugs.com/international/felbinac.html	CTSL	https://www.drugbank.ca/drugs/DB07477	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	rheumatoid arthritis|muscle pain	https://en.wikipedia.org/wiki/Felbinac|https://en.wikipedia.org/wiki/Felbinac
5-fluoro-3-pyridyl-methanol	5-fluoro-3-pyridyl-methanol		OCc1cncc(F)c1	Preclinical							
2,4-dinitrophenol	2,4-dinitrophenol		Oc1ccc(cc1[N+]([O-])=O)[N+]([O-])=O	Preclinical				ATP synthase inhibitor			
isoxepac	isoxepac	HP 549|P 720549|artil	OC(=O)Cc1ccc2OCc3ccccc3C(=O)c2c1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/7040500			anti-inflammatory agent			
BMS-777607	BMS-777607		CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT00605618	MERTK|MET|MST1R|FLT3|AXL|TYRO3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7953|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7953|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7953|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=477986|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7953|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7953	AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor			
pimonidazole	pimonidazole	RO 03-8799	OC(CN1CCCCC1)Cn1ccnc1[N+]([O-])=O	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/8465022						
metolazone	metolazone	SR 720-22|SR-720-22|diulo|mykrox|zaroxolyn	CC1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O	Launched	FDA Orange Book: metolazone	CA2|CA7|SLC12A3	https://citeline.informa.com/?query=#/drugs/details/11994|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=125455|ChEMBL	carbonic anhydrase inhibitor	cardiology|cardiology	edema|hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b619826-2567-49d7-8972-b6da5e4467df|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b619826-2567-49d7-8972-b6da5e4467df
vitamin-E	vitamin e	Alpha Tocopherol|E307|Tocopherol (Vit E)|alpha-tocopherol|aquasol e|eprolin|natopherol|tocopherol|tocopheryl acetate, d-alpha|tocopheryl acetate, dl-alpha|tocopheryl acid succinate, d-alpha|vitamin e	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT01749371?term=Vitamin+E&rank=1	PRKCA|PRKCB|ALOX5|SEC14L2|SEC14L4|SEC14L3|DGKA|PPP2CB|PPP2CA|NR1I2	https://www.drugbank.ca/drugs/DB00163|https://www.drugbank.ca/drugs/DB00163|https://www.drugbank.ca/drugs/DB00163|https://www.drugbank.ca/drugs/DB00163|https://www.drugbank.ca/drugs/DB00163|https://www.drugbank.ca/drugs/DB00163|https://www.drugbank.ca/drugs/DB00163|https://www.drugbank.ca/drugs/DB00163|https://www.drugbank.ca/drugs/DB00163|https://www.drugbank.ca/drugs/DB00163	PKC inhibitor|LDL oxidation inhibitor			
L-Aspartic-Acid	L-Aspartic-Acid	aspartic acid|l-aspartic acid	N[C@@H](CC(O)=O)C(O)=O	Launched	https://www.clinicaltrials.gov/ct2/show/NCT02158182	PAICS|CAD|GRIN2B|GRIN2A|GRIN2D|GRIN2C|ASRGL1|DARS2|ADSS|ACY1|ACY3|DARS|GRIN1|SLC1A1|GOT1|GOT2|RNASE1|ADSSL1|ASNS|ASPH|ASPA|ASS1|SLC25A12|SLC25A13|LYZ	https://www.drugbank.ca/drugs/DB00128|https://www.drugbank.ca/drugs/DB00128|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4237|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4237|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4237|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4237|https://www.drugbank.ca/drugs/DB00128|https://www.drugbank.ca/drugs/DB00128|https://www.drugbank.ca/drugs/DB00128|https://www.drugbank.ca/drugs/DB00128|https://www.drugbank.ca/drugs/DB00128|https://www.drugbank.ca/drugs/DB00128|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4237|https://www.drugbank.ca/drugs/DB00128|https://www.drugbank.ca/drugs/DB00128|https://www.drugbank.ca/drugs/DB00128|https://www.drugbank.ca/drugs/DB00128|https://www.drugbank.ca/drugs/DB00128|https://www.drugbank.ca/drugs/DB00128|https://www.drugbank.ca/drugs/DB00128|https://www.drugbank.ca/drugs/DB00128|https://www.drugbank.ca/drugs/DB00128|https://www.drugbank.ca/drugs/DB00128|https://www.drugbank.ca/drugs/DB00128|https://www.drugbank.ca/drugs/DB00128	metallic radical formation stimulant			
sulfameter	sulfameter	AHR-857|Bayrena|Ultrax|sulfametin|sulfametoxydiazine|sulla|sulphamethoxydiazine	COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1	Launched	FDA Orange Book: sulfameter	DHFR	http://www.sigmaaldrich.com/catalog/product/sigma/s0383?lang=en&region=US	dihydrofolate reductase inhibitor	infectious disease	urinary tract infections	http://www.sigmaaldrich.com/catalog/product/sigma/s0383?lang=en&region=US
gaboxadol	gaboxadol	LU 02-030|LU-02030|MK-0928	Oc1noc2CNCCc12	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00094666	GABRD|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRR1|GABRR2|GABRR3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322	benzodiazepine receptor agonist			
eliglustat	eliglustat	cerdelga	CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1	Launched	FDA Orange Book: eliglustat tartrate	UGCG	https://en.wikipedia.org/wiki/Eliglustat	Glycosyl transferase inhibitor	hematology|hematology	Gaucher disease|Gaucher disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819f828a-b888-4e46-83fc-94d774a28a83|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819f828a-b888-4e46-83fc-94d774a28a83
RKI-1447	RKI-1447		Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1	Preclinical		LIMK1|MYLK|PAK1|ROCK1|ROCK2|CDC42BPA|PKN1|DMPK	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8152|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8152|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8152|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8152|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8152|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8152|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8152|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8152	rho associated kinase inhibitor			
tribenoside	tribenoside	21401-BA	CCOC1O[C@H]([C@@H](COCc2ccccc2)OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1O	Launched	http://www.drugs.com/international/Tribenoside.html			anti-inflammatory agent|capillary stabilizing agent			
meprobamate	meprobamate	Amosene|Bamate|equanil|mepriam|meprospan|miltown|neuramate|tranmep	CCCC(C)(COC(N)=O)COC(N)=O	Launched	FDA Orange Book: meprobamate	GABRQ|GABRP|GABRE|GABRD|GABRG2|GABRG1|GABRG3|GABRA4|GABRA3|GABRA6|GABRA5|GABRA2|GABRA1|GABRB1|GABRB3|GABRB2	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL		neurology/psychiatry	anxiety	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3b255bcd-0218-44f8-830b-971f5ec45276
UNC0646	UNC0646		COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C	Preclinical		EHMT2	https://www.tocris.com/dispprod.php?ItemId=305310	histone lysine methyltransferase inhibitor			
UNC0642	UNC0642		COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1	Preclinical		EHMT1|EHMT2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7017|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7017	histone lysine methyltransferase inhibitor			
preclamol	preclamol		CCCN1CCC[C@@H](C1)c1cccc(O)c1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/9377590	DRD2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010450	dopamine receptor agonist			
SA-47	SA-47		CNC(=O)COC(=O)NCCC1CCN(CC1)c1cccc(C)n1	Preclinical		FAAH	https://www.tocris.com/products/sa-47_4785	FAAH inhibitor			
chenodeoxycholic-acid	chenodeoxycholic acid	Chenodeoxycholate|chenic acid|chenix|chenodeoxycholic acid|chenodiol	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched	FDA Orange Book: chenodiol	HSD11B1|NR1H4	https://www.biomol.com/product_Chenodeoxycholic-acid.html?aRelated=AG-CN2-0410|ChEMBL	11-beta hydroxysteroid dehydrogenase inhibitor|FXR agonist	cardiology|gastroenterology	cerebral cholesterosis|gallstones	https://en.wikipedia.org/wiki/Chenodeoxycholic_acid|https://en.wikipedia.org/wiki/Chenodeoxycholic_acid
CGP-71683	CGP-71683	CGP-71683A|CGP71683	Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12	Preclinical		NPY5R	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000083	neuropeptide receptor antagonist			
ambroxol	ambroxol	ambroxol hydrochloride	Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1	Launched	http://en.wikipedia.org/wiki/Ambroxol	GBA|CYP3A4	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=133797|http://www.drugbank.ca/drugs/DB06742	sodium channel blocker	pulmonary	bronchitis	http://www.drugs.com/ambroxol.html
isoquinoline,-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro,	isoquinoline,-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro,		COc1cc2CCNC(C)c2cc1OC	Preclinical							
phytosphingosine	phytosphingosine		CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/20179727						
cinaciguat	cinaciguat		OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01067859	GUCY1A3|GUCY1B3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5168|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5168	guanylate cyclase activator			
biapenem	biapenem		C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O	Launched	http://en.wikipedia.org/wiki/Biapenem			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease	bacterial septicemia|pneumonia|urinary tract infections	http://www.mims.com/Thailand/drug/info/Omegacin/?type=full|http://www.mims.com/Thailand/drug/info/Omegacin/?type=full|http://www.mims.com/Thailand/drug/info/Omegacin/?type=full
silodosin	silodosin	rapaflo	C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F	Launched	FDA Orange Book: silodosin	ADRA1A|ADRA1B|ADRA1D	ChEMBL|https://www.drugbank.ca/drugs/DB06207|https://www.drugbank.ca/drugs/DB06207	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a21163d6-e1b9-4490-bce3-751e0823797c&audience=consumer
domiphen	domiphen		CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1	Preclinical							
ambrisentan	ambrisentan	letairis	COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1	Launched	FDA Orange Book: ambrisentan	CYP3A5|CYP3A4|SLCO1B3|EDNRA|EDNRB|CYP2C19	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=282368|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=282368|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=282368|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=282368	endothelin receptor antagonist	pulmonary	pulmonary arterial hypertension (PAH)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=725d4e73-6c83-477a-adc6-0ae4a133a844
DAA-1106	DAA-1106		COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1	Preclinical		TSPO	https://en.wikipedia.org/wiki/DAA-1106	benzodiazepine receptor agonist			
rivaroxaban	rivaroxaban	BAY 59-7939|BAY-59-7939|xarelto	Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O	Launched	FDA Orange Book: rivaroxaban	CYP2J2|F10|CYP3A5	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=307796|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=307796	coagulation factor inhibitor	neurology/psychiatry|hematology|cardiology|hematology|hematology	stroke|systemic embolism|atrial fibrillation (AF)|deep vein thrombosis (DVT)|pulmonary embolism (PE)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0e105f6-28f3-45ee-83bd-7d458835242b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0e105f6-28f3-45ee-83bd-7d458835242b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0e105f6-28f3-45ee-83bd-7d458835242b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0e105f6-28f3-45ee-83bd-7d458835242b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0e105f6-28f3-45ee-83bd-7d458835242b
NMS-873	NMS-873		Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O	Preclinical		VCP	https://www.caymanchem.com/Product.vm/catalog/17674;jsessionid=BAE3F7786AC5090B802B3F5F55638BA8	ATPase inhibitor			
nifedipine	nifedipine	Afeditab cr|BAY A 1040|BAY-A-1040|adalat|adalat cc|procardia|procardia xl	COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC	Launched	FDA Orange Book: nifedipine	CACNA1H|CACNA1S|CACNA1F|CACNA1D|CACNA1C|CALM1|CACNB2|GLRB|NR1I2|TRPM3|GLRA1|GLRA3|CYP3A5|CACNA2D1|KCNA5|KCNA1	https://www.drugbank.ca/drugs/DB01115|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB01115|https://www.drugbank.ca/drugs/DB01115|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2514|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2514|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2514|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2514|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2514|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=133799|https://www.drugbank.ca/drugs/DB01115|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2514|https://www.drugbank.ca/drugs/DB01115	calcium channel blocker	cardiology|cardiology	vasospastic angina|chronic stable angina	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0cc236dc-95fa-49cc-aeb8-6590de157585|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0cc236dc-95fa-49cc-aeb8-6590de157585
UK-5099	UK-5099		OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N	Preclinical		SLC16A1	https://www.tocris.com/products/uk-5099_4186	monocarboxylate transporter inhibitor			
flumazenil	flumazenil	Anexate|Mazicon|RO 15-1788/000|Ro-15-1788|flumazepil|romazicon	CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21	Launched	FDA Orange Book: flumazenil	GABRG2|GABRG1|GABRG3|GABRB3|GABRB2|GABRB1|GABRA4|GABRA3|GABRA2|GABRA1|GABRA6|GABRA5|GABRQ|GABRP|GABRE|GABRD	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	benzodiazepine receptor antagonist	neurology/psychiatry	sedative	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11882e93-aa62-4d24-895c-6f01d97fc730
methyl-aminolevulinate	methyl aminolevulinate	methyl aminolevulinate|metvixia	COC(=O)CCC(=O)CN	Launched	FDA Orange Book: methyl aminolevulinate hydrochloride	FECH|FCGR1A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001024|https://www.drugbank.ca/drugs/DB00992	oxidizing agent	dermatology	actinic keratosis (AK)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d02af310-d097-4886-86e5-adcf6bca0533
SB-2343	SB-2343		CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1	Phase 1	https://clinicaltrials.gov/show/NCT02372227	PIK3CG|PIK3CA|PIK3CB|PIK3CD|MTOR	http://www.apexbt.com/vs-5584.html|http://www.apexbt.com/vs-5584.html|http://www.apexbt.com/vs-5584.html|http://www.apexbt.com/vs-5584.html|http://www.apexbt.com/vs-5584.html	mTOR inhibitor|PI3K inhibitor			
terbutaline	terbutaline	brethaire|brethine|bricanyl|terbutaline sulfate	CC(C)(C)NCC(O)c1cc(O)cc(O)c1	Launched	http://en.wikipedia.org/wiki/Terbutaline	ADRB2	https://www.drugbank.ca/drugs/DB00871	adrenergic receptor agonist	pulmonary|pulmonary|pulmonary	bronchospasm|bronchitis|emphysema	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ae8fb3d-9df3-4948-bb07-6e4169521f15&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ae8fb3d-9df3-4948-bb07-6e4169521f15&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ae8fb3d-9df3-4948-bb07-6e4169521f15&audience=consumer
irbesartan	irbesartan	BMS-186295|SR 47436|SR-47436|avapro	CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1	Launched	FDA Orange Book: irbesartan	AGTR1|SLC10A1|JUN	ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=589|https://www.drugbank.ca/drugs/DB01029	angiotensin receptor antagonist	cardiology|nephrology	hypertension|diabetic nephropathy	http://www.rxlist.com/avapro-drug/indications-dosage.htm|http://www.rxlist.com/avapro-drug/indications-dosage.htm
carfilzomib	carfilzomib	PR-171|kyprolis	CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1	Launched	FDA Orange Book: carfilzomib	PSMB11|PSMB10|PSMB7|PSMB8|PSMB9|PSMB3|PSMB4|PSMB5|PSMB6|PSMA1|PSMB1|PSMB2|PSMA6|PSMA7|PSMA8|PSMA2|PSMA3|PSMA4|PSMA5	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	proteasome inhibitor	hematologic malignancy	multiple myeloma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea66eb30-e665-4693-99a1-a9d3b4bbe2d6
5'-Chloro-5'-deoxy-ENBA-(+/-)	(+/-)-5'-Chloro-5'-deoxy-ENBA		O[C@@H]1[C@@H](CCl)O[C@H]([C@@H]1O)n1cnc2c(NC3CC4CCC3C4)ncnc12	Preclinical				adenosine receptor agonist			
diphenylpyraline	diphenylpyraline	hispril	CN1CCC(CC1)OC(c1ccccc1)c1ccccc1	Launched	FDA Orange Book: diphenylpyraline hydrochloride	SLC6A3|HRH1	https://www.drugbank.ca/drugs/DB01146|https://www.drugbank.ca/drugs/DB01146	dopamine uptake inhibitor	allergy	allergic rhinitis	https://en.wikipedia.org/wiki/Diphenylpyraline
estramustine-phosphate	estramustine phosphate	emcyt|estramustine phosphate	C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O	Launched	FDA Orange Book: estramustine phosphate sodium	MAP2|ESR1|ESR2|MAP1A	http://www.drugbank.ca/drugs/DB01196|http://www.drugbank.ca/drugs/DB01196|http://www.drugbank.ca/drugs/DB01196|http://www.drugbank.ca/drugs/DB01196	DNA synthesis inhibitor|microtubule inhibitor	oncology	prostate cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9b01bc6-95ac-46f9-befa-d845a74d53c1
levofloxacin	levofloxacin	DR-3355|Floxacin|RWJ-25213|iquix|levaquin|quixin	C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O	Launched	FDA Orange Book: levofloxacin	TOP2A	https://www.drugbank.ca/drugs/DB01137	bacterial DNA gyrase inhibitor	infectious disease|otolaryngology|pulmonary|infectious disease|urology|infectious disease|infectious disease|infectious disease|infectious disease	pneumonia|sinusitis|bronchitis|skin infections|prostatitis|urinary tract infections|pyelonephritis|anthrax|plague	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=111ad6f9-170d-4a14-a4e2-ff86f60521cd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=111ad6f9-170d-4a14-a4e2-ff86f60521cd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=111ad6f9-170d-4a14-a4e2-ff86f60521cd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=111ad6f9-170d-4a14-a4e2-ff86f60521cd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=111ad6f9-170d-4a14-a4e2-ff86f60521cd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=111ad6f9-170d-4a14-a4e2-ff86f60521cd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=111ad6f9-170d-4a14-a4e2-ff86f60521cd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=111ad6f9-170d-4a14-a4e2-ff86f60521cd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=111ad6f9-170d-4a14-a4e2-ff86f60521cd
WAY-207024	WAY-207024		CC(C)(C)c1ccc(cc1)-c1nc2cccc(N3CCN(Cc4ccc5nccnc5c4)CC3)c2[nH]1	Preclinical		TACR2|HRH2|GNRHR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008790|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008790|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5582	gonadotropin releasing factor hormone receptor antagonist			
MKT-077	MKT-077		CCn1\c(=C/c2cccc[n+]2CC)s\c(=C2\Sc3ccccc3N2C)c1=O	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/10509153			HSP inhibitor			
etravirine	etravirine	TMC 125|TMC-125|intelence	Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N	Launched	FDA Orange Book: etravirine	CYP3A4|CYP2C19|CYP2C9	http://www.genome.jp/dbget-bin/www_bget?D04112|http://www.genome.jp/dbget-bin/www_bget?D04112|http://www.genome.jp/dbget-bin/www_bget?D04112	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b5a2dc7-0570-4977-876d-88b4176844a1
amantadine	amantadine	Symadine|TCMDC-125869|amantadine hydrochloride|symmetrel	NC12CC3CC(CC(C3)C1)C2	Launched	FDA Orange Book: amantadine hydrochloride	DRD2|GRIN1|GRIN3A|GRIN2D|GRIN2C|GRIN2B|GRIN2A	https://www.drugbank.ca/drugs/DB00915|https://citeline.informa.com/?query=#/drugs/details/62119|https://www.drugbank.ca/drugs/DB00915|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4128|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4128|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4128|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4128	glutamate receptor antagonist	infectious disease|neurology/psychiatry	influenza A virus infection|Parkinson's Disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6e6e111-38da-43a2-b6c4-15e69b720495|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6e6e111-38da-43a2-b6c4-15e69b720495
stavudine	stavudine	BMY-27857|d4T|zerit|zerit xr	Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O	Launched	FDA Orange Book: stavudine			DNA directed DNA polymerase inhibitor|nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d19c57bd-56f8-4640-b891-18f9c365e372&audience=consumer
genz-123346	genz-123346		CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1	Preclinical		UGCG	https://www.linkedin.com/pulse/glucosylceramide-synthase-inhibitor-genz-123346-qingqi-chen-ph-d-	glucosylceramidase inhibitor			
YM-90709	YM-90709		COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC	Preclinical		IL5RA|CSF2RB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5090|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5090	IL5 inhibitor			
PHT-427	PHT-427		CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1	Preclinical		AKT2|PDPK1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8009|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8009	AKT inhibitor|pyruvate dehydrogenase inhibitor			
CTEP	CTEP		Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1	Preclinical		GRM5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6409	glutamate receptor antagonist			
TMC647055	TMC647055		COc1ccc2-c3c(C4CCCCC4)c4ccc5cc4n3CC(=Cc2c1)C(=O)N(C)CCOCCN(C)S(=O)(=O)NC5=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01724086			RNA polymerase inhibitor			
N-acetyl-tyrosine	N-acetyl-tyrosine		CC(=O)NC(Cc1ccc(O)cc1)C(O)=O	Launched	http://www.webmd.com/vitamins-supplements/ingredientmono-1037-tyrosine.aspx?activeingredientid=1037&						
NIDA-41020	NIDA-41020		COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	Preclinical		CNR1	https://www.tocris.com/products/nida-41020_3921	cannabinoid receptor antagonist			
honokiol	honokiol		Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00966953	PTGS2|PTGS1|ALOX5	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009851|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009851|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009851	AKT inhibitor			
WZ8040	WZ8040		CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1	Preclinical		EGFR	http://www.selleckchem.com/products/WZ8040.html	EGFR inhibitor			
albendazole	albendazole	Eskazole|SK&F 62979|SK&F-62979|Valbazen|Zental|albenza	CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1	Launched	FDA Orange Book: albendazole	TUBB4B|TUBA1A|TUBB|CYP2J2|CYP1A2	https://www.drugbank.ca/drugs/DB00518|https://www.drugbank.ca/drugs/DB00518|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000951|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=129625|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=129625	tubulin polymerization inhibitor	infectious disease|infectious disease	cystic hydatid disease|parenchymal neurocysticercosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845
GW-311616	GW-311616	GW311616	CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O	Phase 1	https://books.google.com/books?id=JRSdVwX-K6wC&pg=PA193&lpg=PA193&dq=GW311616+phase+I&source=bl&ots=jsBTgSBAPb&sig=7tqaiNtuoEFKhPpcxRBt4gkiNlk&hl=en&sa=X&ved=0ahUKEwic4fPJgurPAhWQCD4KHZpxCP0Q6AEIIjAB#v=onepage&q=GW311616%20phase%20I&f=false	ELANE	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000714	leukocyte elastase inhibitor|elastase inhibitor			
miglustat	miglustat	OGT 918|OGT-918|zavesca	CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	Launched	FDA Orange Book: miglustat	UGCG|GAA|SLC5A4	ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=155014|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=155014	Glycosyl transferase inhibitor	hematology	Gaucher disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=817892d1-ee12-4632-85fc-57ccdf16d7b8
butein	butein	3,4,2',4'-Tetrahydroxychalone	Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1	Preclinical		TNF|CXCL8|ACE|SRD5A2|SRD5A1|SIRT1|IL6	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=175912|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=175912|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007119|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=175912|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=175912|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=175912|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=175912	EGFR inhibitor|src inhibitor			
SQ-109	SQ-109		CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2	Phase 3	http://en.wikipedia.org/wiki/SQ109	FDFT1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7997	bacterial cell wall synthesis inhibitor			
pilaralisib	pilaralisib	SAR-245408|SAR245408|XL-147	COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/25528496			PI3K inhibitor			
BVT-948	BVT-948			Preclinical		PTPN1|PTPN2|PTPN11	http://www.abcam.com/bvt-948-ab141304.html|http://www.abcam.com/bvt-948-ab141304.html|http://www.abcam.com/bvt-948-ab141304.html	tyrosine phosphatase inhibitor			
carsalam	carsalam	oxyphenhydrazine	O=c1[nH]c(=O)c2ccccc2o1	Preclinical				analgesic agent			
telbivudine	telbivudine	NV-02B|Sebivo|tyzeka	Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O	Launched	FDA Orange Book: telbivudine	TK2	https://www.drugbank.ca/drugs/DB04485	DNA polymerase inhibitor	infectious disease	hepatitis B	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0664309d-1342-4a63-ba5f-4b899cdf3bec&audience=consumer
ARC-239	ARC-239		COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1	Preclinical		ADRA2A|ADRA2C|ADRA2B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=524|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=524|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=524	adrenergic receptor antagonist			
sotagliflozin	sotagliflozin	LP-802034|LX-4211|LX4211	CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02384941	SLC5A1|SLC5A2	http://www.lexpharma.com/pipeline/lx4211.html|http://www.lexpharma.com/pipeline/lx4211.html	sodium/glucose cotransporter inhibitor			
KU-60019	KU-60019		C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1	Preclinical		ATM	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8041	ATM kinase inhibitor			
BCTC	BCTC		CC(C)(C)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2Cl)cc1	Preclinical		TRPM8|TRPV1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=327580|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2460	TRPV antagonist			
CaCCinh-A01	CaCCinh-A01		CC(C)(C)C1CCc2c(C1)sc(NC(=O)c1ccco1)c2C(O)=O	Preclinical		CLCA1	http://www.genecards.org/cgi-bin/carddisp.pl?gene=CLCA1	calcium-activated chloride channel inhibitor			
OMDM-2	OMDM-2		CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1	Preclinical		GPR119	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5720	FAAH inhibitor			
raltitrexed	raltitrexed	ZD-16|ZD-1694|ZD1694|tomudex	CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	Launched	http://www.drugs.com/international/Raltitrexed.html	FPGS|TYMS	https://www.drugbank.ca/drugs/DB00293|https://www.drugbank.ca/drugs/DB00293	thymidylate synthase inhibitor	oncology	mesothelioma	https://en.wikipedia.org/wiki/Raltitrexed
suramin	suramin	Germanin	Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O	Launched	http://www.drugs.com/international/Suramin.html	P2RY11|P2RY13|HPSE|P2RY1|P2RY2|FSHR|F2|SIRT5|PLA2G2A|RYR2|RYR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1728|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1728|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=116051|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1728|https://www.drugbank.ca/drugs/DB04786|https://www.drugbank.ca/drugs/DB04786|https://www.drugbank.ca/drugs/DB04786|https://www.drugbank.ca/drugs/DB04786|https://www.drugbank.ca/drugs/DB04786|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1728|https://www.drugbank.ca/drugs/DB04786	DNA synthesis inhibitor	infectious disease|infectious disease	African trypanosomiasis|onchocerciasis	https://en.wikipedia.org/wiki/Onchocerciasis|https://en.wikipedia.org/wiki/Onchocerciasis
zofenopril-calcium	zofenopril-calcium	zofenopril	C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1	Launched	http://en.wikipedia.org/wiki/Zofenopril	ACE	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6462	angiotensin converting enzyme inhibitor	cardiology	hypertension	https://en.wikipedia.org/wiki/Zofenopril
ATN-161	ATN-161		CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00131651	ITGA5|ITGAV|ITGB5|ITGB3|ITGB1	http://www.drugbank.ca/drugs/DB05491|http://www.drugbank.ca/drugs/DB05491|https://citeline.informa.com/?query=#/drugs/details/26918|http://www.drugbank.ca/drugs/DB05491|http://www.drugbank.ca/drugs/DB05491	integrin antagonist			
wiskostatin	wiskostatin		CN(C)CC(O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12	Preclinical		WASL|WAS	http://www.sigmaaldrich.com/catalog/product/sigma/w2270?lang=en&region=US|https://www.drugbank.ca/drugs/DB01731	neural Wiskott-Aldrich syndrome protein inhibitor|actin related protein inhibitor			
idebenone	idebenone		COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O	Launched	http://www.drugs.com/international/Idebenone.html			calcium channel modulator	neurology/psychiatry|neurology/psychiatry|ophthalmology	Alzheimer's disease|Friedreich's ataxia|Leber hereditary optic neuropathy (LHON)	http://www.webmd.com/vitamins-supplements/ingredientmono-1078-idebenone.aspx?activeingredientid=1078&activeingredientname=idebenone|http://www.webmd.com/vitamins-supplements/ingredientmono-1078-idebenone.aspx?activeingredientid=1078&activeingredientname=idebenone|http://www.webmd.com/vitamins-supplements/ingredientmono-1078-idebenone.aspx?activeingredientid=1078&activeingredientname=idebenone
mozavaptan	mozavaptan		CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12	Launched	http://www.drugs.com/international/Mozavaptan.html	AVPR1A|AVPR1B|AVPR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2197|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2197|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2197	vasopressin receptor antagonist	endocrinology	hyponatremia	https://en.wikipedia.org/wiki/Mozavaptan
A-317491	A-317491		OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12	Preclinical		P2RX3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4115	purinergic receptor antagonist			
TW-37	TW-37		CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O	Preclinical		BCL2L1|BCL2|MCL1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006894|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006894|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006894	BCL inhibitor			
UCL-2077	UCL-2077		C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1	Preclinical				slow afterhyperpolarization channel blocker			
S-methylcysteine	S-methylcysteine		CSC[C@H](N)C(O)=O	Phase 1	Integrity	MGMT|CTSD	https://www.drugbank.ca/drugs/DB02216|https://www.drugbank.ca/drugs/DB02216				
ADX-47273	ADX-47273		Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1	Preclinical		GRM5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1420	glutamate receptor modulator			
UNC1215	UNC1215		O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1	Preclinical		L3MBTL3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8232	L3MBTL antagonist			
pralatrexate	pralatrexate	folotyn	Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1	Launched	FDA Orange Book: pralatrexate	SLC19A1|DHFR|TYMS	https://citeline.informa.com/?query=#/drugs/details/28975|ChEMBL|https://www.drugbank.ca/drugs/DB06813	dihydrofolate reductase inhibitor	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e4cf15b-bf7b-4b83-863e-e9ef27741a51
glipizide	glipizide	CP-28,720|CP-28720|K 4024|K-4024|glucotrol|glucotrol xl	Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	Launched	FDA Orange Book: glipizide	ABCC8|PPARG|KCNJ10|KCNJ11	ChEMBL|https://www.drugbank.ca/drugs/DB01067|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000920|ChEMBL	sulfonylurea	endocrinology|endocrinology	diabetes mellitus|hyperglycemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37a18bd1-034f-4366-8323-ec4e1c52ac1e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37a18bd1-034f-4366-8323-ec4e1c52ac1e
ftorafur	ftorafur		Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O	Launched	http://www.drugs.com/international/Ftorafur.html	TYMS	http://www.genome.jp/dbget-bin/www_bget?D01244+C12673	thymidylate synthase inhibitor	oncology	colorectal cancer	https://en.wikipedia.org/wiki/Tegafur/uracil
HC-067047	HC-067047		Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F	Preclinical		TRPV4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4213	transient receptor potential channel antagonist			
alpelisib	alpelisib	BYL-719|NVP-BYL719	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02437318	PIK3CG|PIK3CD|PIK3CB|PIK3CA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7955|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7955|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7955|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7955	PI3K inhibitor			
EPZ011989	EPZ011989		CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1	Preclinical		EZH2	http://www.uniprot.org/uniprot/?query=EZH2&sort=score	histone lysine methyltransferase inhibitor			
perindoprilat	perindoprilat	S-9780	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(O)=O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/8387806	ACE	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6373	angiotensin converting enzyme inhibitor			
anthraquinone	anthraquinone	9,10-Anthraquinone|Anthracene-9,10-Dione	O=C1c2ccccc2C(=O)c2ccccc12	Preclinical		CDC25B	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009075	CDC inhibitor			
iodoantipyrine	iodoantipyrine		Cc1c(I)c(=O)n(-c2ccccc2)n1C	Preclinical							
leuprolide	leuprolide	eligard|leuprolide acetate|leuprorelin|lupron|lupron depot|lupron depot-ped|viadur	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1	Launched	FDA Orange Book: leuprolide acetate	GNRHR|GNRH1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1175|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=115073	gonadotropin releasing factor hormone receptor agonist	oncology	prostate cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe3228a7-a5e4-40e4-9fe6-b35db60a71ce
nebivolol	nebivolol	R65,824|bystolic		Launched	FDA Orange Book: nebivolol hydrochloride	ADRB2|ADRB1	https://www.drugbank.ca/drugs/DB04861|https://www.drugbank.ca/drugs/DB04861	adrenergic receptor antagonist	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f98d499-f68f-4148-8ec3-8c66ef184a83
vilazodone	vilazodone	EMD 515259|viibryd	NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1	Launched	FDA Orange Book: vilazodone hydrochloride	DRD2|DRD3|HRH1|HTR1A|HTR4|CYP2E1|SLC6A4|CYP2C19	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7427|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7427|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7427|https://www.drugbank.ca/drugs/DB06684|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7427|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=226940|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7427|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=226940	serotonin reuptake inhibitor	neurology/psychiatry	depression	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64b61582-48b4-49fe-9d55-d7131b3683d8
BVD-523	BVD-523		CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT01781429			MAP kinase inhibitor			
dapsone	dapsone	aczone|diaminodiphenylsulfone|diaphenylsulfone	Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1	Launched	FDA Orange Book: dapsone	DHFR	http://www.drugbank.ca/drugs/DB00250	bacterial antifolate	dermatology|infectious disease	dermatitis herpetiformis (DH)|leprosy	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f111dc5a-ea05-4d67-9550-41060442441f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f111dc5a-ea05-4d67-9550-41060442441f
WWL-123	WWL-123		CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O	Preclinical		ABHD6	https://www.tocris.com/products/wwl-123_5317	monoacylglycerol lipase inhibitor			
AR-42	AR-42		CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01129193	AKT1|HDAC1|HDAC2	https://citeline.informa.com/?query=#/drugs/details/37218|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DPR000141|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=403161	HDAC inhibitor			
icatibant-acetate	icatibant acetate	HOE-140|firazyr|icatibant	N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O	Launched	FDA Orange Book: icatibant acetate	BDKRB2|ANPEP	https://www.drugbank.ca/drugs/DB06196|https://www.drugbank.ca/drugs/DB06196	bradykinin receptor antagonist	cardiology	angioedema	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed6657ca-ab68-477a-9968-e12dc928b540
SNAP-5089	SNAP-5089		COC(=O)C1=C(C)NC(C)=C(C1c1ccc(cc1)[N+]([O-])=O)C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1	Preclinical		ADRA2A|ADRA2C|ADRA2B|ADRA1D|ADRA1B|ADRA1A|CACNA1D|CACNA1C	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003939|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003939|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003939|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003939|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003939|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=498|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003939|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003939	adrenergic receptor antagonist			
alfuzosin	alfuzosin	uroxatral	COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)C1CCCO1	Launched	FDA Orange Book: alfuzosin hydrochloride	ADRA1D|ADRA1A|ADRA1B|KCNH2	https://www.drugbank.ca/drugs/DB00346|https://www.drugbank.ca/drugs/DB00346|https://www.drugbank.ca/drugs/DB00346|https://www.drugbank.ca/drugs/DB00346	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f075a897-7bef-4799-b7e2-7e051c461443
schisandrin-b	schisandrin b		COc1cc2C[C@H](C)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC	Preclinical		GSR|ATR|ABCB1|ABCC1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=405206|http://www.selleckchem.com/products/schisandrin-b.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=405206|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=405206	antioxidant			
bergenin	bergenin		COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O	Preclinical		PTPN1|TNF|IL1B	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=309293|http://www.sigmaaldrich.com/catalog/product/sigma/smb00073?lang=en&region=US|http://www.sigmaaldrich.com/catalog/product/sigma/smb00073?lang=en&region=US	interleukin inhibitor			
T-0070907	T-0070907		[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1	Preclinical		PPARG	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3444	PPAR receptor antagonist			
sivelestat	sivelestat	ONO-5046	CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O	Launched	http://www.drugs.com/international/Sivelestat.html	CELA1|ELANE	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001333|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6441	elastase inhibitor	pulmonary	acute lung injury	https://www.dovepress.com/clinical-utility-of-the-neutrophil-elastase-inhibitor-sivelestat-for-t-peer-reviewed-article-TCRM
frovatriptan	frovatriptan	frova	CN[C@@H]1CCc2[nH]c3ccc(cc3c2C1)C(N)=O	Launched	FDA Orange Book: frovatriptan succinate	HTR1D|HTR1A|HTR1B	https://www.drugbank.ca/drugs/DB00998|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7191|https://www.drugbank.ca/drugs/DB00998	serotonin receptor agonist	neurology/psychiatry	migraine headache	https://www.drugs.com/cdi/frovatriptan.html
indirubin-3-monoxime	indirubin-3-monoxime		O\N=C1c2ccccc2NC/1=C1\C(=O)Nc2ccccc12	Preclinical		LCK|GSK3B|CCNE1|CDK5R1|LRRK1|LRRK2|CDK2|CDK4|CDK5|CDK9|CDK1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=306293|https://www.drugbank.ca/drugs/DB02052|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=306293|https://www.drugbank.ca/drugs/DB02052|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=306293|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=306293|https://www.drugbank.ca/drugs/DB02052|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=306293|https://www.drugbank.ca/drugs/DB02052|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=306293|https://www.drugbank.ca/drugs/DB02052	CDK inhibitor|glycogen synthase kinase inhibitor			
IKK-2-inhibitor-V	IKK-2-inhibitor-V	IMD-0354|TCMDC-125465	Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F	Phase 1	Pharmaprojects	IKBKB	http://www.emdmillipore.com/life-science-research/ikk-2-inhibitor-v/EMD_BIO-401482/p_6Cub.s1LUxkAAAEWxWEfVhTm?PortalCatalogID=merck4biosciences&CountryName=United+States+of+America	IKK inhibitor|NFkB pathway inhibitor			
flecainide	flecainide	flecainide acetate|tambocor	FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1	Launched	FDA Orange Book: flecainide acetate	KCNA5|KCNA7|SCN4A|SCN5A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2560|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2560|https://www.drugbank.ca/drugs/DB01195|https://www.drugbank.ca/drugs/DB01195	sodium channel blocker	cardiology|cardiology|cardiology	ventricular tachycardia (VT)|atrial fibrillation (AF)|ventricular arrhythmias	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e
MM-11253	MM-11253		CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O	Preclinical		RARG	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4062	retinoid receptor antagonist			
dizocilpine-(+)	(+)-dizocilpine		C[C@]12N[C@H](Cc3ccccc13)c1ccccc21	Preclinical				glutamate receptor antagonist			
mometasone	mometasone		C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl	Launched	FDA Orange Book: mometasone furoate	NR3C1	https://www.drugbank.ca/drugs/DB00764	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f69603aa-a5a6-b8f3-c9ed-2d0abc9f4d92
tirapazamine	tirapazamine	WIN 59075	Nc1n[n+]([O-])c2ccccc2[n+]1[O-]	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00006484			DNA inhibitor			
benurestat	benurestat	EU-2826	ONC(=O)CNC(=O)c1ccc(Cl)cc1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/1089613			urease inhibitor			
ambenonium	ambenonium	mytelase	CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl	Launched	FDA Orange Book: ambenonium chloride	ACHE	https://www.drugbank.ca/drugs/DB01122	cholinesterase inhibitor	neurology/psychiatry	myasthenia gravis	https://en.wikipedia.org/wiki/Ambenonium_chloride
azapropazone	azapropazone	AHR-3018|MI-85|apazone|cinnopropazone	CCCC1C(=O)N2N(C1=O)c1cc(C)ccc1N=C2N(C)C	Withdrawn	http://en.wikipedia.org/wiki/Azapropazone	XDH|PTGS2|PTGS1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091924|http://www.drugbank.ca/drugs/DB07402|https://citeline.informa.com/?query=#/drugs/details/2093	cyclooxygenase inhibitor			
afalanine	afalanine		CC(=O)N[C@@H](Cc1ccccc1)C(O)=O	Phase 3	Pharmaprojects	SLC6A3|DRD2	https://citeline.informa.com/?query=#/drugs/details/11578|https://books.google.com/books?id=NYIECAAAQBAJ&pg=PA133&lpg=PA133&dq=MR-708+dopamine&source=bl&ots=y9YUK5AKY5&sig=yir35P7Sa4egCEFb3cMXLYwruEA&hl=en&sa=X&ved=0ahUKEwjtptaLr9LMAhXLKx4KHaUkAe8Q6AEIHDAA#v=onepage&q=MR-708%20dopamine&f=false	dopamine receptor agonist			
testolactone	testolactone	SQ 9538|SQ-9538|teslac	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CCC(=O)O2	Launched	FDA Orange Book: testolactone	CYP19A1	ChEMBL	aromatase inhibitor	oncology	breast cancer	https://en.wikipedia.org/wiki/Testolactone
guanadrel	guanadrel	hylorel	NC(=N)NCC1COC2(CCCCC2)O1	Launched	FDA Orange Book: guanadrel sulfate	SLC6A2	https://www.drugbank.ca/drugs/DB00226	adrenergic inhibitor	cardiology	hypertension	https://en.wikipedia.org/wiki/Guanadrel
pixantrone	pixantrone		NCCNc1ccc(NCCN)c2C(=O)c3cnccc3C(=O)c12	Launched	http://en.wikipedia.org/wiki/Pixantrone	TOP2A	https://en.wikipedia.org/wiki/Pixantrone	topoisomerase inhibitor	hematologic malignancy	non-Hodgkin lymphoma (NHL)	http://www.ctibiopharma.com/pipeline/pixantrone/
harringtonine	harringtonine		COC(=O)C[C@@](O)(CCC(C)(C)O)C(=O)O[C@H]1[C@@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00004933			protein synthesis inhibitor			
spironolactone	spironolactone	aldactone	CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12	Launched	FDA Orange Book: spironolactone	CACNA2D1|CACNA2D2|CACNA2D3|CACNA1S|CACNA1G|CACNA1F|CACNA1I|CACNA1H|CACNA1A|CACNA1C|CACNA1B|CACNA1D|KCND3|KCNA5|SCNN1A|AR|CYP11B2|PGR|SHBG|NR3C2|NR3C1|CACNG1|CACNB1|CACNB2|CACNB3|CACNB4	https://www.drugbank.ca/drugs/DB00421|https://www.drugbank.ca/drugs/DB00421|https://www.drugbank.ca/drugs/DB00421|https://www.drugbank.ca/drugs/DB00421|https://www.drugbank.ca/drugs/DB00421|https://www.drugbank.ca/drugs/DB00421|https://www.drugbank.ca/drugs/DB00421|https://www.drugbank.ca/drugs/DB00421|https://www.drugbank.ca/drugs/DB00421|https://www.drugbank.ca/drugs/DB00421|https://www.drugbank.ca/drugs/DB00421|https://www.drugbank.ca/drugs/DB00421|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=112456|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=112456|https://citeline.informa.com/?query=#/drugs/details/22970|https://www.drugbank.ca/drugs/DB00421|https://www.drugbank.ca/drugs/DB00421|https://www.drugbank.ca/drugs/DB00421|https://www.drugbank.ca/drugs/DB00421|ChEMBL|https://www.drugbank.ca/drugs/DB00421|https://www.drugbank.ca/drugs/DB00421|https://www.drugbank.ca/drugs/DB00421|https://www.drugbank.ca/drugs/DB00421|https://www.drugbank.ca/drugs/DB00421|https://www.drugbank.ca/drugs/DB00421	mineralocorticoid receptor antagonist	endocrinology|cardiology|gastroenterology|rheumatology|cardiology|endocrinology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7510768-8a52-4230-6aa0-b0d92d82588f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7510768-8a52-4230-6aa0-b0d92d82588f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7510768-8a52-4230-6aa0-b0d92d82588f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7510768-8a52-4230-6aa0-b0d92d82588f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7510768-8a52-4230-6aa0-b0d92d82588f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7510768-8a52-4230-6aa0-b0d92d82588f
ACY-1215	ACY-1215	ACY-1215; ACY-63|ACY-63|ricolinostat	ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT01323751	HDAC6|HDAC1|HDAC2|HDAC3|HDAC8	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7010|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7010|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7010|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7010|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7010	HDAC inhibitor			
GMX1778	GMX1778		Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT00724841	NAMPT	https://www.medchemexpress.com/GMX1778.html?gclid=CJPw6eblrc8CFYMehgodx-EOKQ	NAMPT inhibitor			
bacitracin	bacitracin			Launched	FDA Orange Book: bacitracin, bacitracin zinc	A2M|IDE	https://www.drugbank.ca/drugs/DB00626|https://www.drugbank.ca/drugs/DB00626	bacterial cell wall synthesis inhibitor	infectious disease	first-aid antibiotic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=630e0841-baf2-e9fa-b309-ad1a5f95da3b
cefmetazole	cefmetazole	zefazone	CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O	Launched	FDA Orange Book: cefmetazole sodium			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease	urinary tract infections|skin infections	https://en.wikipedia.org/wiki/Cefmetazole|https://en.wikipedia.org/wiki/Cefmetazole
miltefosine	miltefosine	impavido	CCCCCCCCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C	Launched	FDA Orange Book: miltefosine	PLA2G1B	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DPR000076	membrane integrity inhibitor	infectious disease	leishmaniasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6658aeb-7bc1-4eef-ad0d-0a873ddbecf5
BMS-817378	BMS-817378		Nc1nccc(Oc2ccc(NC(=O)c3cn(COP(O)(O)=O)cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00792558	KDR|MET	https://www.medchemexpress.com/c-Met-inhibitor-2.html|https://www.medchemexpress.com/c-Met-inhibitor-2.html	c-Met inhibitor|VEGFR inhibitor			
ADL5859	ADL5859		CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00979953	OPRD1	http://www.axonmedchem.com/product/1751	opioid receptor agonist			
5-fluorouracil	5-fluorouracil	5-FU|RO 2-9757|Ro-2-9757|adrucil|carac|efudex|fluoroplex|fluorouracil|fluracil|tolak	Fc1c[nH]c(=O)[nH]c1=O	Launched	http://www.drugs.com/international/5-Fluorouracil.html	DPYD|TYMS|CD44	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000085|ChEMBL|https://citeline.informa.com/?query=#/drugs/details/246	thymidylate synthase inhibitor	oncology|oncology|oncology|oncology	colorectal cancer|breast cancer|pancreatic cancer|gastric adenocarcinoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e301c810-0edc-4d21-8ccd-ec9653249019|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e301c810-0edc-4d21-8ccd-ec9653249019|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e301c810-0edc-4d21-8ccd-ec9653249019|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e301c810-0edc-4d21-8ccd-ec9653249019
thiomersal	thiomersal		CC[Hg]Sc1ccccc1C(O)=O	Launched	http://www.drugs.com/international/thimerosal.html	OXCT1	https://www.drugbank.ca/drugs/DB02731	other antibiotic			
desonide	desonide	D-2083|D2083|desonate|desowen|verdeso	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	Launched	FDA Orange Book: desonide	NR3C1|PLA2G1B	ChEMBL|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001188	glucocorticoid receptor agonist	gastroenterology	Crohn's disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c73928d-2b96-42f5-1fb9-90965c214c21
pyrazoloacridine	pyrazoloacridine	NSC-627168	COc1ccc2[nH]c3c(ccc4n(CCCN(C)C)nc(c34)c2c1)[N+]([O-])=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00005976	TOP1|TOP2A	https://www.ncbi.nlm.nih.gov/pubmed/9533538|https://www.ncbi.nlm.nih.gov/pubmed/9533538	topoisomerase inhibitor			
amphotericin-b	amphotericin b	Fungilin|abelcet|ambisome|amophotericin b|amphotec|amphotercin b|amphotericin|amphotericin b|amphotericine b|amphotericitin b|amphotreicin b|ampotericin b|fungizone	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O	Launched	FDA Orange Book: amphotericin b			membrane permeability enhancer	infectious disease	fungal infection	https://en.wikipedia.org/wiki/Amphotericin_B#Antifungal
bifonazole	bifonazole	BAY H 4502|mycospor	c1cn(cn1)C(c1ccccc1)c1ccc(cc1)-c1ccccc1	Launched	http://en.wikipedia.org/wiki/Bifonazole	CYP2B6	https://www.drugbank.ca/drugs/DB04794	sterol demethylase inhibitor	infectious disease|infectious disease	tinea pedis|tinea cruris	https://en.wikipedia.org/wiki/Bifonazole|https://en.wikipedia.org/wiki/Bifonazole
eflornithine	eflornithine	ornidyl|vaniqa	NCCCC(N)(C(F)F)C(O)=O	Launched	FDA Orange Book: eflornithine hydrochloride	ARG2|ODC1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000558|https://www.drugbank.ca/drugs/DB03856	ornithine decarboxylase inhibitor	dermatology	facial hair reduction	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e872db73-7cd7-4886-9b0f-6710700e3765
AMG900	AMG900	AMG-900	Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01380756	AURKC|AURKB|AURKA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8060|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8060|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8060	Aurora kinase inhibitor			
BTB1	BTB1		[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1	Preclinical		KIF18A	https://www.tocris.com/products/btb1_5399	mitotic kinesin inhibitor			
EPZ015666	EPZ015666		O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1	Preclinical		PRMT5	https://www.caymanchem.com/product/17285	protein arginine N-methyltransferase inhibitor			
dibenzothiophene	dibenzothiophene		c1ccc2c(c1)sc1ccccc21	Preclinical							
TBA-354	TBA-354		[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(nc1)-c1ccc(OC(F)(F)F)cc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02288481						
NSC-95397	NSC-95397		OCCSC1=C(SCCO)C(=O)c2ccccc2C1=O	Preclinical		CDC25A|CDC25B|CASP3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007961|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007961|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=302485	CDC inhibitor			
kainic-acid	kainic acid	kainic acid	CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O	Preclinical		GRIK2|GRIK1|GRIK4|GRIK3|GRIK5|GRIA1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4231|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4231|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4231|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4231|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4231|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004378	kainate receptor agonist			
sulindac	sulindac	clinoril	CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)=O	Launched	FDA Orange Book: sulindac	MAPK3|AKR1B1|PPARD|PTGDR2|PTGS1|PTGS2	https://www.drugbank.ca/drugs/DB00605|https://www.drugbank.ca/drugs/DB00605|https://www.drugbank.ca/drugs/DB00605|https://www.drugbank.ca/drugs/DB00605|ChEMBL|ChEMBL	cyclooxygenase inhibitor	rheumatology|rheumatology|rheumatology	osteoarthritis|rheumatoid arthritis|ankylosing spondylitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96c73bd2-4577-487d-a642-bd8f91e94c3a&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96c73bd2-4577-487d-a642-bd8f91e94c3a&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96c73bd2-4577-487d-a642-bd8f91e94c3a&audience=consumer
ketotifen	ketotifen	(R)-Ketotifen|alaway|zaditor	CN1CCC(CC1)=C1c2ccsc2C(=O)Cc2ccccc12	Launched	FDA Orange Book: ketotifen fumarate	HRH1|PGD|PDE8B|PDE8A|PDE7B|PDE7A|PDE4D|PDE4C|PDE4B|PDE4A	https://www.drugbank.ca/drugs/DB00920|https://www.drugbank.ca/drugs/DB00920|https://www.drugbank.ca/drugs/DB00920|https://www.drugbank.ca/drugs/DB00920|https://www.drugbank.ca/drugs/DB00920|https://www.drugbank.ca/drugs/DB00920|https://www.drugbank.ca/drugs/DB00920|https://www.drugbank.ca/drugs/DB00920|https://www.drugbank.ca/drugs/DB00920|https://www.drugbank.ca/drugs/DB00920	histamine receptor agonist|leukotriene receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry	itching	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39856d6d-31ed-4184-9831-b40efdf4dcf4
thiotepa	thiotepa	thioplex	S=P(N1CC1)(N1CC1)N1CC1	Launched	FDA Orange Book: thiotepa	CYP2B6|CYP3A4	http://www.drugbank.ca/drugs/DB04572|http://www.drugbank.ca/drugs/DB04572	cytochrome P450 inhibitor	oncology|oncology|oncology	breast cancer|ovarian cancer|bladder cancer	https://en.wikipedia.org/wiki/ThioTEPA|https://en.wikipedia.org/wiki/ThioTEPA|https://en.wikipedia.org/wiki/ThioTEPA
itacitinib	itacitinib		Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12	Phase 2	http://medkoo.com/products/5532	JAK1	https://www.medchemexpress.com/Itacitinib.html	JAK inhibitor			
benproperine	benproperine	ASA 158/5 [AS PHOSPHATE]|benproperine phosphate	CC(COc1ccccc1Cc1ccccc1)N1CCCCC1	Launched	https://www.drugs.com/international/benproperine.html	SCN5A	http://www.drugbank.ca/drugs/DB00868	antitussive	pulmonary	cough suppressant	https://en.wikipedia.org/wiki/Benproperine
fisetin	fisetin	NSC-407010	Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O	Preclinical		FASN|AURKB|SIRT1|AKR1B1|CDK6	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004713|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=275737|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=275737|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=275737|https://www.drugbank.ca/drugs/DB07795	Aurora kinase inhibitor			
azatadine	azatadine	Trinalin|optimine	CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12	Launched	FDA Orange Book: azatadine maleate	HRH1	https://www.drugbank.ca/drugs/DB00719	histamine receptor antagonist	allergy	allergic rhinitis	http://www.drugs.com/mtm/azatadine.html
cinchophen	cinchophen	phenylcinchoninic acid	OC(=O)c1cc(nc2ccccc12)-c1ccccc1	Launched	http://www.drugs.com/international/Cinchophen.html			analgesic agent	rheumatology	gout	http://www.drugs.com/international/cinchophen.html
glyburide	glyburide	Glynase PresTab|HB 419|HB-419|U-26,452|U-26452|diabeta|glibenclamide|glyburide (micronized)|glynase|micronase	COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	Launched	FDA Orange Book: glyburide	CFTR|ABCB11|TRPA1|KCNJ11|CPT1A|SLCO2B1|ABCC8|ABCC9|ABCA1|KCNJ5|KCNJ8|KCNJ1	https://www.drugbank.ca/drugs/DB01016|https://www.drugbank.ca/drugs/DB01016|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091577|ChEMBL|https://www.drugbank.ca/drugs/DB01016|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2414|ChEMBL|https://www.drugbank.ca/drugs/DB01016|https://www.drugbank.ca/drugs/DB01016|https://www.drugbank.ca/drugs/DB01016|https://www.drugbank.ca/drugs/DB01016|https://www.drugbank.ca/drugs/DB01016	ATP channel blocker|insulin secretagogue|sulfonylurea	endocrinology|endocrinology	diabetes mellitus|hyperglycemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d367e16-fc74-4a63-ac6d-85e038164de5|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d367e16-fc74-4a63-ac6d-85e038164de5
arcyriaflavin-a	arcyriaflavin a	arcyiaflavin a|staurosporine aglycon	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21	Preclinical		CCND1|CCNE1|CDK4|CDK2	https://www.tocris.com/dispprod.php?ItemId=154014#.VyeETGQrImI|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=351924|https://www.tocris.com/dispprod.php?ItemId=154014#.VyeETGQrImI|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=351924	CDK inhibitor			
PF-06447475	PF-06447475		N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12	Preclinical		LRRK2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8054	serine/threonine kinase inhibitor			
sodium-dodecyl-sulfate	sodium dodecyl sulfate		[Na].CCCCCCCCCCCCOS(O)(=O)=O	Preclinical		LYZ|ALB	https://www.drugbank.ca/drugs/DB03967|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001227				
peficitinib	peficitinib			Phase 3	http://www.pharmacodia.com/web/drug/1_753.html	JAK1|JAK2|JAK3	https://www.medchemexpress.com/peficitinib.html?gclid=CLPJs_Oytc8CFQtZhgodFwUNzA|https://www.medchemexpress.com/peficitinib.html?gclid=CLPJs_Oytc8CFQtZhgodFwUNzA|https://www.medchemexpress.com/peficitinib.html?gclid=CLPJs_Oytc8CFQtZhgodFwUNzA	JAK inhibitor			
levopropoxyphene	levopropoxyphene	novrad	CCC(=O)OC(Cc1ccccc1)(C(C)CN(C)C)c1ccccc1	Launched	FDA Orange Book: levopropoxyphene napsylate anhydrous	OPRM1|OPRK1|OPRD1	https://www.drugbank.ca/drugs/DB00647|https://www.drugbank.ca/drugs/DB00647|https://www.drugbank.ca/drugs/DB00647	antitussive	pulmonary	cough suppressant	https://en.wikipedia.org/wiki/Levopropoxyphene
fleroxacin	fleroxacin	AM-833|Quinodis|RO 23-6240/000|Ro-236240|megalone	CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O	Launched	http://www.drugs.com/international/Fleroxacin.html			topoisomerase inhibitor	infectious disease|gastroenterology|gastroenterology|infectious disease	gonorrhea|enteritis|diarrhea|respiratory tract infections	https://en.wikipedia.org/wiki/Fleroxacin|https://en.wikipedia.org/wiki/Fleroxacin|https://en.wikipedia.org/wiki/Fleroxacin|https://en.wikipedia.org/wiki/Fleroxacin
napabucasin	napabucasin	2-ACETYL FURANONAPTHOQUINONE|2-Acetylfuranonaphthoquinone|BBI608	CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02178956	STAT3	http://www.selleckchem.com/products/napabucasin.html?gclid=CIHjzYuEtc8CFcEehgodEWUH_Q	STAT inhibitor			
niraparib	niraparib	MK-4827	NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1	Launched	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fe9d533-67a9-4981-978a-1e84755ae30b	PARP1|PARP2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000571|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=643931	PARP inhibitor	oncology	primary peritoneal cancer (PPC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fe9d533-67a9-4981-978a-1e84755ae30b
budipine	budipine		CC(C)(C)N1CCC(CC1)(c1ccccc1)c1ccccc1	Launched	http://www.drugs.com/international/Budipine.html	GRIN1	https://en.wikipedia.org/wiki/Budipine	glutamate receptor antagonist	neurology/psychiatry	Parkinson's Disease	https://en.wikipedia.org/wiki/Budipine
oxazepam	oxazepam	WY-3498|oxozepam|serax|zaxopam	OC1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O	Launched	FDA Orange Book: oxazepam	GABRR3|GABRR2|GABRR1|GABRB3|GABRB2|GABRB1|GABRA2|GABRA1|GABRA6|GABRA5|GABRA4|GABRA3|GABRG3|GABRG2|GABRG1|GABRQ|GABRP|GABRE|GABRD	https://www.drugbank.ca/drugs/DB00842|https://www.drugbank.ca/drugs/DB00842|https://www.drugbank.ca/drugs/DB00842|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	GABA benzodiazepine site receptor agonist	neurology/psychiatry	anxiety	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=140d8f61-912b-449a-9c34-b52e08b3d819
DS2-(806622)	DS2-(806622)		Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1	Preclinical							
broxaldine	broxaldine	brobenzoxaldine	Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1	Preclinical							
ergosterol	ergosterol	Ergosterol D	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Preclinical				vitamin D precursor			
valdecoxib	valdecoxib	SC-65872|bextra	Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	PTGS2|CYP2C19|CA12	ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=241522|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2894	cyclooxygenase inhibitor			
RTA-408	RTA-408		CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02065375	NFE2L2	https://en.wikipedia.org/wiki/NFE2L2	nitric oxide production inhibitor			
CYT-997	CYT-997	CYT997|lexibulin	CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00664378	TUBB	http://www.ncbi.nlm.nih.gov/pubmed/21917561	tubulin polymerization inhibitor			
arecaidine-but-2-ynyl-ester	arecaidine-but-2-ynyl-ester	ARECAIDINE BUT-2-YNYL ESTER	CC#CCOC(=O)C1=CCCN(C)C1	Preclinical		CHRM2	http://www.abcam.com/arecaidine-but-2-ynyl-ester-tosylate-ab141318.html	acetylcholine receptor agonist			
troxerutin	troxerutin	VITAMIN P4|Z 6000|flavonoid|trioxyethylrutin	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	Launched	http://www.drugs.com/international/Troxerutin.html			antioxidant			
CL316243	CL316243	CL-316243	C[C@H](Cc1ccc2OC(Oc2c1)(C(O)=O)C(O)=O)NC[C@H](O)c1cccc(Cl)c1	Phase 2	http://adisinsight.springer.com/drugs/800002967	ADRB3|UCP3|UCP2|UCP1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3462|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000443|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000443|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000443	adrenergic receptor agonist			
bivalirudin	bivalirudin	angiomax		Launched	FDA Orange Book: bivalirudin	F2	https://www.drugbank.ca/drugs/DB02351	thrombin inhibitor	cardiology	angina pectoris	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f3b2717-056e-4edb-a9b0-a63efa008d2b
ON-01500	ON-01500		COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(N)c2)c(OC)c1	Preclinical				apoptosis stimulant			
alcaftadine	alcaftadine	R 89674|lastacaft	CN1CCC(CC1)=C1c2ncc(C=O)n2CCc2ccccc12	Launched	FDA Orange Book: alcaftadine	HRH1	ChEMBL	histamine receptor antagonist	allergy	allergic conjunctivitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17d37e8d-7825-424b-b6ca-0a85d0bf4694
posaconazole	posaconazole	SCH 56592|noxafil	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O	Launched	FDA Orange Book: posaconazole	CYP3A4|CYP51A1	http://www.drugbank.ca/drugs/DB01263|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=226562	sterol demethylase inhibitor	infectious disease	oropharyngeal candidiasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b073b082-7b57-4423-8c06-4fd4263d6f84
XL388	XL388		Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O	Preclinical		MTOR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7973	mTOR inhibitor			
colfosceril-palmitate	colfosceril palmitate		CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC	Launched	FDA Orange Book: colfosceril palmitate			pulmonary surfactant	pulmonary	respiratory distress syndrome (RDS)	http://www.drugs.com/mmx/colfosceril-palmitate.html
PF-3274167	PF-3274167		COCc1nnc(N2CC(C2)Oc2ccc(F)cc2Cl)n1-c1ccc(OC)nc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02232425	AVPR1A|OXTR|OXT	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010247|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010247|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=440907	oxytocin receptor antagonist			
entinostat	entinostat	MS-275|SNDX-275	Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02115282	HDAC9|HDAC3|HDAC2|HDAC1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7007|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7007|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7007|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7007	HDAC inhibitor			
almitrine	almitrine		Fc1ccc(cc1)C(N1CCN(CC1)c1nc(NCC=C)nc(NCC=C)n1)c1ccc(F)cc1	Launched	http://www.drugs.com/international/Almitrine.html	ATP1A1	https://www.drugbank.ca/drugs/DB01430	neurotransmitter agonist	pulmonary	chronic obstructive pulmonary disease (COPD)	https://en.wikipedia.org/wiki/Almitrine
radafaxine	radafaxine		C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00057226	SLC6A3|SLC6A2|CHRNB2|CHRNA4	https://en.wikipedia.org/wiki/Radafaxine|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=318095|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=318095|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=318095	dopamine-norepinephrine reuptake inhibitor			
pramoxine	pramoxine	pramocaine	CCCCOc1ccc(OCCCN2CCOCC2)cc1	Launched	FDA Orange Book: pramoxine hydrochloride			topical anesthetic	dermatology	corticosteroid-responsive dermatoses	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0792a1a2-d935-4d06-b9d6-26dbf02092a6
GW-438014A	GW-438014A		O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1	Preclinical		NPY5R	https://www.tocris.com/products/gw-438014a_4669	neuropeptide receptor antagonist			
riodoxol	riodoxol		Oc1c(I)cc(I)c(O)c1I	Launched	http://www.rlsnet.ru/tn_index_id_5083.htm			other antibiotic			
LY310762	LY310762		CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12	Preclinical		HTR1D	https://www.tocris.com/dispprod.php?ItemId=192174#.V-rUSZMrLy8	serotonin receptor antagonist			
deferasirox	deferasirox	ICL670A|exjade|jadenu	OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O	Launched	FDA Orange Book: deferasirox	CYP2C8|CYP3A4|CYP2C19	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=280627|http://www.drugbank.ca/drugs/DB01609|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=280627	chelating agent	hematology|hematology|hematology	transfusional hemosiderosis|thalassemia|iron overload	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fee89140-fff1-4443-9f42-24ac004fcda1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fee89140-fff1-4443-9f42-24ac004fcda1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fee89140-fff1-4443-9f42-24ac004fcda1
asiatic-acid	Asiatic acid	Asiatic acid	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O	Preclinical		PYGM	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013814	apoptosis stimulant			
spectinomycin	spectinomycin	trobicin	CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O	Launched	FDA Orange Book: spectinomycin hydrochloride			bacterial 30S ribosomal subunit inhibitor	pulmonary|pulmonary	airsacculitis|chronic respiratory disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03974f03-924f-44e6-bb88-8850f4d9a211&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03974f03-924f-44e6-bb88-8850f4d9a211&audience=consumer
trelagliptin	trelagliptin		Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2cc(F)ccc2C#N)c1=O	Launched	http://www.takeda.com/news/2015/20150528_6997.html	DPP4	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000647	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus	https://en.wikipedia.org/wiki/Trelagliptin
N-methylformamide	N-methylformamide	N-Methyl-Formamide	CNC=O	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/3719579						
zolpidem	zolpidem	ambien|ambien cr|edluar|intermezzo|tovalt odt|zolpimist	CN(C)C(=O)Cc1c(nc2ccc(C)cn12)-c1ccc(C)cc1	Launched	FDA Orange Book: zolpidem tartrate	GABRA1|GABRA3|GABRA2	https://www.drugbank.ca/drugs/DB00425|https://www.drugbank.ca/drugs/DB00425|https://www.drugbank.ca/drugs/DB00425	benzodiazepine receptor agonist	neurology/psychiatry	insomnia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de965605-268a-4479-86f7-84de949cf36f
levcromakalim	levcromakalim	BRL-38227	CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N	Phase 3	Pharmaprojects	KCNJ8|KCNJ5|ABCC9	https://citeline.informa.com/?query=#/drugs/details/10862|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000874|https://citeline.informa.com/?query=#/drugs/details/10862	potassium channel activator			
bisoprolol	bisoprolol	CL-297939|EMD 33 512|EMD-33-512|Ziac|zebeta	CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1	Launched	FDA Orange Book: bisoprolol fumarate	ADRB2|ADRB1	https://www.drugbank.ca/drugs/DB00612|https://www.drugbank.ca/drugs/DB00612	adrenergic receptor antagonist	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9ee689a-ea12-435d-b01c-70d45891e62f
osthol	osthol	Osthole	COc1ccc2ccc(=O)oc2c1CC=C(C)C	Preclinical				calcium channel blocker			
TIC10	TIC10			Phase 2	https://clinicaltrials.gov/ct2/show/NCT02525692	AKT1|MAPK1	http://www.selleckchem.com/products/TIC-10.html?gclid=COqCvsbnxcwCFRNZhgodj28AbA|http://www.selleckchem.com/products/TIC-10.html?gclid=COqCvsbnxcwCFRNZhgodj28AbA	AKT inhibitor|TRAIL modulator			
JNJ-37822681	JNJ-37822681		Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00728195	DRD2	https://www.ncbi.nlm.nih.gov/pubmed/22490380	dopamine receptor antagonist			
GSK2334470	GSK2334470		CNc1nc(cc(n1)-c1ccc2c(N)n[nH]c2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1	Preclinical		PDPK1|AURKB|AURKA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8008|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8008|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8008	phosphoinositide dependent kinase inhibitor			
nadolol	nadolol	SQ 11725|SQ-11725|corgard	CC(C)(C)NCC(O)COc1cccc2C[C@@H](O)[C@@H](O)Cc12	Launched	FDA Orange Book: nadolol	ADRB2|ADRB1|ADRB3	ChEMBL|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=554	adrenergic receptor antagonist	cardiology|cardiology	angina pectoris|hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0152dffb-6575-4d15-9d67-019efa6ae5f6|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0152dffb-6575-4d15-9d67-019efa6ae5f6
propyl-benzoate	propyl benzoate		CCCOC(=O)c1ccccc1	Launched	https://en.wikipedia.org/wiki/Propyl_benzoate						
doxorubicin	doxorubicin	Adriamycin|Doxil|Hydroxydaunorubicin|Rubex|adriblastina|doxil (liposomal)|doxorubicin hydrochloride|doxorubicin hydrochloride (liposomal)	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	Launched	FDA Orange Book: doxorubicin hydrochloride	TOP2A	https://www.drugbank.ca/drugs/DB00997	topoisomerase inhibitor	hematologic malignancy|hematologic malignancy|oncology|oncology|oncology|hematologic malignancy|oncology|hematologic malignancy	acute lymphoblastic leukemia (ALL)|acute myeloid leukemia (AML)|Wilm's tumor|breast cancer|ovarian cancer|Hodgkin's lymphoma|bladder cancer|multiple myeloma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=939cfd5f-a496-43b3-a883-dbf4651310d4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=939cfd5f-a496-43b3-a883-dbf4651310d4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=939cfd5f-a496-43b3-a883-dbf4651310d4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=939cfd5f-a496-43b3-a883-dbf4651310d4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=939cfd5f-a496-43b3-a883-dbf4651310d4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=939cfd5f-a496-43b3-a883-dbf4651310d4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=939cfd5f-a496-43b3-a883-dbf4651310d4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=939cfd5f-a496-43b3-a883-dbf4651310d4
ONO-AE3-208	ONO-AE3-208		CC(C(=O)Nc1cc(ccc1CCCC(O)=O)C#N)c1ccc(F)c2ccccc12	Preclinical		PTGER4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1942	prostanoid receptor antagonist			
dehydroepiandrosterone-sulfate	dehydroepiandrosterone sulfate	prasterone sulfuric acid	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@H](CC[C@]34C)OS(O)(=O)=O)[C@@H]1CCC2=O	Launched	https://en.wikipedia.org/wiki/Dehydroepiandrosterone_sulfate	ESR2|ESR1|AR	https://en.wikipedia.org/wiki/Dehydroepiandrosterone#Mechanism_of_action|https://en.wikipedia.org/wiki/Dehydroepiandrosterone#Mechanism_of_action|https://en.wikipedia.org/wiki/Dehydroepiandrosterone#Mechanism_of_action	androgen receptor agonist|estrogen receptor agonist	endocrinology	menopause	https://www.drugs.com/npp/dehydroepiandrosterone.html
loxapine	loxapine	CL 62,362|CL-62362|Loxapac|SUM 3170|SUM-3170|adasuve|loxapine succinate|loxitane|loxitane c|loxitane im|loxitane intramuscular [as hydrochloride]|loxitane-c oral suspension [as hydrochloride]	CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12	Launched	FDA Orange Book: loxapine succinate	HRH1|HRH2|HRH4|HTR5A|HTR3A|HTR2C|HTR2A|HTR1B|HTR1D|HTR1E|HTR1A|ADRA1B|ADRA1A|ADRA2C|ADRA2A|ADRA2B|HTR6|HTR7|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|ADRB1|SLC6A4|SLC6A3|SLC6A2|DRD5|DRD3|DRD4|DRD1|DRD2	https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|https://www.drugbank.ca/drugs/DB00408|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00408|ChEMBL	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dee2537b-1bd8-42f6-990f-62359e646822
haloperidol	haloperidol	Keselen|MCN-JR-1625|R-1625|Serenace|haldol|haldol solutab	OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1	Launched	FDA Orange Book: haloperidol, haloperidol decanoate, haloperidol lactate	HRH1|GRIN2B|HTR2A|HTR2B|HTR1D|HTR1A|KCNH1|DRD1|DRD5|DRD4|DRD3|DRD2|HTR7|CYP3A7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=86|https://www.drugbank.ca/drugs/DB00502|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=86|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=86|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=86|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=86|https://www.drugbank.ca/drugs/DB00502|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=86|ChEMBL|ChEMBL|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=86|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091385	dopamine receptor antagonist	neurology/psychiatry|neurology/psychiatry	schizophrenia|Tourette's disorder	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1ad2abd-a9d6-44e3-957b-36a73260f4f5|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1ad2abd-a9d6-44e3-957b-36a73260f4f5
hygromycin-b	hygromycin b		CN[C@H]1C[C@@H](N)[C@H](O)[C@@H](O[C@@H]2O[C@H](CO)[C@@H]3OC4(O[C@@H]3[C@@H]2O)O[C@H](C(N)CO)[C@H](O)[C@H](O)[C@H]4O)[C@@H]1O	Preclinical				polypeptide synthesis inhibitor			
AZD1981	AZD1981	AZD-1981	CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00766415	PTGDR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7680	CRTH receptor antagonist			
melatonin	melatonin	N-(2-(5-METHOXY-1H-INDOL-3-YL)ETHYL)ACETAMIDE|N-ACETYL-5-METHOXYTRYPTAMINE	COc1ccc2[nH]cc(CCNC(C)=O)c2c1	Launched	http://www.drugs.com/Melatonin.html	CALR|CALM1|ASMT|ESR1|NQO2|MPO|HTR2B|RORB|MTNR1B|MTNR1A|EPX|TH	https://www.drugbank.ca/drugs/DB01065|https://www.drugbank.ca/drugs/DB01065|https://www.drugbank.ca/drugs/DB01065|https://www.drugbank.ca/drugs/DB01065|https://www.drugbank.ca/drugs/DB01065|https://www.drugbank.ca/drugs/DB01065|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=224|https://www.drugbank.ca/drugs/DB01065|https://www.drugbank.ca/drugs/DB01065|https://www.drugbank.ca/drugs/DB01065|https://www.drugbank.ca/drugs/DB01065|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=238255	melatonin receptor agonist|nitric oxide synthase inhibitor	neurology/psychiatry	sleep cycle support	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5a9ba4c-85f0-4c95-b9ba-6e4bebebe657
LY2109761	LY2109761		C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c(nn2CCCc12)-c1ccccn1	Preclinical		TGFBR1|TGFBR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8075|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8075	TGF beta receptor inhibitor			
OR-486	OR-486	3,5-DINITROCATECHOL (OR-486)|3,5-Dinitrocatechol	Oc1cc(cc(c1O)[N+]([O-])=O)[N+]([O-])=O	Preclinical		COMT	https://www.drugbank.ca/drugs/DB02105	catechol O methyltransferase inhibitor			
fosaprepitant-dimeglumine	fosaprepitant-dimeglumine	emend|fosaprepitant	C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	Launched	FDA Orange Book: fosaprepitant dimeglumine	TACR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7623	tachykinin antagonist	gastroenterology|gastroenterology	nausea|vomiting	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44f634f4-b794-4d55-8ab7-037fdef8ff0f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44f634f4-b794-4d55-8ab7-037fdef8ff0f
irsogladine	irsogladine	irsogladine maleate	Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl	Launched	http://www.drugs.com/international/Irsogladine.html	PDE4A	http://www.tocris.com/dispprod.php?ItemId=159296#.Utl-1v30DmE	phosphodiesterase inhibitor	gastroenterology	peptic ulcer disease (PUD)	http://www.drugs.com/international/irsogladine.html
doxylamine	doxylamine	Doxy-Sleep-Aid|decapryn|unisom	CN(C)CCOC(C)(c1ccccc1)c1ccccn1	Launched	FDA Orange Book: doxylamine succinate	CHRM1|HRH1	https://www.drugbank.ca/drugs/DB00366|https://www.drugbank.ca/drugs/DB00366	histamine receptor antagonist	neurology/psychiatry	sedative	https://en.wikipedia.org/wiki/Doxylamine
dibekacin	dibekacin	dibekacin sulfate	NC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)O1	Launched	http://www.drugs.com/international/dibekacin.html			bacterial 30S ribosomal subunit inhibitor	infectious disease	gram-negative bacterial infections	http://www.drugs.com/international/dibekacin.html
chloramine-t	chloramine-t		Cc1ccc(cc1)S(=O)(=O)NCl	Veterinary Launched	http://www.drugs.com/international/chloramine-t.html				infectious disease	bacterial gill disease	https://books.google.com/books?id=VkXrCAAAQBAJ&pg=PA172&lpg=PA172&dq=chloramine-t+trihydrate+indication&source=bl&ots=oil_i20LjY&sig=Elk4OWCcsllBceJBetCn-nV4K5A&hl=en&sa=X&ved=0ahUKEwjCt8Hp3ebMAhXFcD4KHU9fCgoQ6AEIWTAH#v=onepage&q=chloramine-t%20trihydrate%20indication&f=false
JNJ-1661010	JNJ-1661010		O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1	Preclinical		FAAH	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5206	FAAH inhibitor			
GANT-61	GANT-61		CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1	Preclinical		GLI1|GLI2|DHH|IHH	https://www.tocris.com/dispprod.php?ItemId=210479#.Vz9Vt-eDFHw|https://www.tocris.com/dispprod.php?ItemId=210479#.Vz9Vt-eDFHw|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=452349|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=452349	GLI antagonist			
BCX-1470	BCX-1470		NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1	Phase 1	http://investor.shareholder.com/biocryst/releasedetail.cfm?releaseid=25542	CFD	https://www.medchemexpress.com/bcx-1470.html	serine protease inhibitor|complement inhibitor			
propatylnitrate	propatylnitrate	ETTN|WIN 9317|etrynit|propatyl nitrate	CCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O	Launched	https://www.drugs.com/international/propatylnitrate.html				cardiology	angina pectoris	https://en.wikipedia.org/wiki/Propatylnitrate
eupatilin	eupatilin		COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1	Launched	http://www.drugs.com/international/eupatilin.html			mucus protecting agent			
troventol	troventol		CCC(CO)(C(=O)OC1CC2CCC(C1)[N+]2(C)C)c1ccccc1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/2588524						
lutein	lutein	E161b	CC(\C=C\C=C(C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C	Launched	https://clinicaltrials.gov/ct2/show/NCT01339299			antioxidant	ophthalmology|ophthalmology|ophthalmology	macular degeneration|cataracts|retinitis pigmentosa (RP)	http://www.webmd.com/vitamins-supplements/ingredientmono-754-lutein.aspx?activeingredientid=754&|http://www.webmd.com/vitamins-supplements/ingredientmono-754-lutein.aspx?activeingredientid=754&|http://www.webmd.com/vitamins-supplements/ingredientmono-754-lutein.aspx?activeingredientid=754&
bexarotene	bexarotene	LG-100069|LG100069|LGD-1069|LGD1069|Targretine|targretin	Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C	Launched	FDA Orange Book: bexarotene	CYP3A4|CYP2C8|RXRA|RXRB|RXRG|ABCA1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=214151|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=214151|ChEMBL|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=214151	retinoid receptor agonist	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d1eb4bd-51f9-4c9b-9fb1-0be5e30a3dc5
lumiracoxib	lumiracoxib	COX-189	Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	PTGS2|PTGS1	https://www.drugbank.ca/drugs/DB01283|https://www.drugbank.ca/drugs/DB01283	cyclooxygenase inhibitor			
decamethoxine	decamethoxine		CC(C)C1CCC(C)CC1OC(=O)C[N+](C)(C)CCCCCCCCCC[N+](C)(C)CC(=O)OC1CC(C)CCC1C(C)C	Phase 2	http://www.ifp.kiev.ua/doc/journals/aa/15/pdf15-3/eng/23_en.pdf			antiseptic			
muscimol	muscimol		NCc1cc(O)no1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00005925	GABRA6|GABRA5|GABRA4|GABRA3|GABRA2|GABRA1|GABRR3|GABRR2|GABRR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4259|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4259|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4259|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4259|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4259|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4259|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4259|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4259|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4259	benzodiazepine receptor agonist			
ergonovine	ergonovine		CC(CO)NC(=O)C1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34	Launched	http://en.wikipedia.org/wiki/Ergometrine	ADRA1A|HTR1E	https://www.drugbank.ca/drugs/DB01253|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=148	adrenergic receptor agonist|serotonin receptor agonist	hematology	postpartum hemorrhage (PPH)	https://en.wikipedia.org/wiki/Ergometrine
oxybutynin	oxybutynin	anturol|ditropan|ditropan xl|gelnique|oxybutynin chloride|oxytrol|oxytrol for women	CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c1ccccc1	Launched	FDA Orange Book: oxybutynin, oxybutynin chloride	CHRM2|CHRM3|CHRM4|CHRM1	ChEMBL|ChEMBL|https://citeline.informa.com/?query=#/drugs/details/13565|https://www.drugbank.ca/drugs/DB01062	acetylcholine receptor antagonist	urology	urinary incontinence	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce850693-bc70-41e8-8af8-426898631f42
hexylene-glycol	hexylene glycol	hexylene glycol	CC(O)CC(C)(C)O	Preclinical		PGF|PTPN1|HSP90AA1|NOS3|PLA2G1B|CTPS1|DLG4|AKR1C3|SELP	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002435|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002435|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002435|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002435|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002435|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002435|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002435|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002435|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002435				
teroxirone	teroxirone	alphatgi	O=c1n(CC2CO2)c(=O)n(CC2CO2)c(=O)n1CC1CO1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/3567975			DNA inhibitor			
vilanterol	vilanterol	GW642444M|vilanterol trifenatate	OC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc1c(Cl)cccc1Cl	Launched	FDA Orange Book: vilanterol trifenatate	ADRB2	ChEMBL	adrenergic receptor agonist	pulmonary	chronic obstructive pulmonary disease (COPD)	https://en.wikipedia.org/wiki/Vilanterol
nitrofurantoin	nitrofurantoin	Dantafur|Furalan|Macrobid|Nitrofurantoin (monohydrate/macrocrystals)|Nitrofurantoin macrocrystalline|furadantin|ivadantin|macrodantin|nitrofurantoin, macrocrystalline	[O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1	Launched	FDA Orange Book: nitrofurantoin, nitrofurantoin sodium, nitrofurantoin, macrocrystalline			DNA inhibitor	infectious disease|infectious disease	urinary tract infections|pyelonephritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=944c0e5f-88ff-4a46-95ef-2ea7d55063ce|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=944c0e5f-88ff-4a46-95ef-2ea7d55063ce
tasquinimod	tasquinimod		COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01234311	S100A9|HDAC4	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=285383|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8098	angiogenesis inhibitor|S100A9 inhibitor			
terodiline	terodiline		CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C	Phase 3	https://www.ncbi.nlm.nih.gov/pubmed/8058236	CHRM4|CHRM3|CHRM2|CHRM1	https://citeline.informa.com/?query=#/drugs/details/18016|https://citeline.informa.com/?query=#/drugs/details/18016|https://citeline.informa.com/?query=#/drugs/details/18016|https://citeline.informa.com/?query=#/drugs/details/18016	cholinergic receptor antagonist			
niacin	niacin	Niacin TD|Niaspan ER|Nicolar|Nicotinate|Simcor|niacor|niaspan|niaspan titration starter pack|nicotinic acid|wampocap	OC(=O)c1cccnc1	Launched	FDA Orange Book: niacin, niacinamide	NNMT|HCAR2|HCAR1|HCAR3|DGAT2|QPRT	https://www.drugbank.ca/drugs/DB00627|https://www.drugbank.ca/drugs/DB00627|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1588|https://www.drugbank.ca/drugs/DB00627|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001546|https://www.drugbank.ca/drugs/DB00627	NAD precursor|vitamin B	endocrinology	hypertriglyceridemia	https://en.wikipedia.org/wiki/Niacin
IT1t	IT1t		CC1(C)CN2C(CS\C(NC3CCCCC3)=N\C3CCCCC3)=CSC2=N1	Preclinical		CXCR4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2899	CC chemokine receptor antagonist			
ATPA	ATPA		CC(C)(C)c1onc(O)c1CC(N)C(O)=O	Preclinical		GRIK1|GRIA2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4140|https://www.drugbank.ca/drugs/DB03319	glutamate receptor agonist			
epiandrosterone	epiandrosterone		C[C@]12CC[C@@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O	Preclinical		G6PD	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009675	steroid			
YS-035	YS-035		COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC	Preclinical				calcium channel blocker			
mitiglinide	mitiglinide	Glufast	OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1	Launched	https://clinicaltrials.gov/ct2/show/NCT02143765	KCNJ11|KCNJ10|INS|PPARG|ABCC8	https://citeline.informa.com/?query=#/drugs/details/12142|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000917|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=189711|https://www.drugbank.ca/drugs/DB01252|https://www.drugbank.ca/drugs/DB01252	insulin secretagogue	endocrinology	diabetes mellitus	https://en.wikipedia.org/wiki/Mitiglinide
oxtriphylline	oxtriphylline	choledyl|choledyl sa	Cn1c2nc[nH]c2c(=O)n(C)c1=O	Launched	FDA Orange Book: oxtriphylline	ADORA1|ADORA3|PDE3A|PDE5A|PDE4A|PDE4B|HDAC2|CYP2E1|CYP3A4|ADORA2B|ADORA2A|CHIA	https://www.drugbank.ca/drugs/DB00277|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=413|https://www.drugbank.ca/drugs/DB00277|https://www.drugbank.ca/drugs/DB00277|https://www.drugbank.ca/drugs/DB00277|https://www.drugbank.ca/drugs/DB00277|https://www.drugbank.ca/drugs/DB00277|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=133798|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=133798|https://www.drugbank.ca/drugs/DB00277|https://www.drugbank.ca/drugs/DB00277|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=133798	adenosine receptor antagonist	pulmonary|pulmonary|pulmonary	asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm	http://www.drugbank.ca/drugs/DB01303|http://www.drugbank.ca/drugs/DB01303|http://www.drugbank.ca/drugs/DB01303
SAR407899	SAR407899	SAR-407899	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00914277	ROCK1|ROCK2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000638|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=444394	rho associated kinase inhibitor			
BMS-309403	BMS-309403		CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1	Preclinical		FABP4	https://www.tocris.com/products/bms-309403_5258	fatty acid binding protein inhibitor			
beta-amyloid-synthesis-inhibitor	beta-amyloid-synthesis-inhibitor		Oc1cccc(Nc2ccc(Nc3cccc(O)c3)nn2)c1	Preclinical		APP	https://www.researchgate.net/publication/264984949_Amyloid-beta_Precursor_Protein_Synthesis_Inhibitors_for_Alzheimer's_Disease_Treatment	beta amyloid synthesis inhibitor			
SC-19220	SC-19220		CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12	Preclinical		PTGER1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1922	prostanoid receptor antagonist			
gallic-acid	gallic acid	Gallate|gallic acid	OC(=O)c1cc(O)c(O)c(O)c1	Preclinical		SELP|CA14|CA12|APP|CA4|CA6|CA9|CA1|CA2|PPARG	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007143|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007143|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007143|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=285260|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007143|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007143|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007143|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5549|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007143|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=285260	beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist			
progesterone	progesterone	crinone|endometrin|progestasert|prometrium	CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched	FDA Orange Book: hydroxyprogesterone caproate, medroxyprogesterone acetate, progesterone	ESR1|CYP2C19|OPRK1|CYP17A1|NR3C2|CATSPER1|CATSPER2|CATSPER3|CATSPER4|PGR|TRPC5	https://www.drugbank.ca/drugs/DB00396|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=231565|https://www.drugbank.ca/drugs/DB00396|https://www.drugbank.ca/drugs/DB00396|https://www.drugbank.ca/drugs/DB00396|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377|https://www.drugbank.ca/drugs/DB00396|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377	progesterone receptor agonist	obstetrics/gynecology|endocrinology	infertility|amenorrhea	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c8ffbd2-6b7a-42c7-b29e-e4de69dad9e6|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c8ffbd2-6b7a-42c7-b29e-e4de69dad9e6
clozapine	clozapine	HF 1854|HF-1854|clozaril|fazaclo|fazaclo odt|versacloz	CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12	Launched	FDA Orange Book: clozapine	CYP2C19|CALY|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD4|DRD5|DRD2|DRD3|DRD1|ADRA1B|ADRA1A|ADRA1D|ADRA2A|ADRA2C|ADRA2B|HRH1|HRH4|HTR6|HTR7|HTR5A|HTR2A|HTR2B|HTR2C|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR3A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091414|https://www.drugbank.ca/drugs/DB00363|https://www.drugbank.ca/drugs/DB00363|https://www.drugbank.ca/drugs/DB00363|https://www.drugbank.ca/drugs/DB00363|https://www.drugbank.ca/drugs/DB00363|https://www.drugbank.ca/drugs/DB00363|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=38|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00363|https://www.drugbank.ca/drugs/DB00363|https://www.drugbank.ca/drugs/DB00363|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=38|https://www.drugbank.ca/drugs/DB00363|https://www.drugbank.ca/drugs/DB00363|https://www.drugbank.ca/drugs/DB00363|https://www.drugbank.ca/drugs/DB00363|https://www.drugbank.ca/drugs/DB00363|https://www.drugbank.ca/drugs/DB00363|https://www.drugbank.ca/drugs/DB00363|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=38|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=38|https://www.drugbank.ca/drugs/DB00363|https://www.drugbank.ca/drugs/DB00363|https://www.drugbank.ca/drugs/DB00363|https://www.drugbank.ca/drugs/DB00363|https://www.drugbank.ca/drugs/DB00363|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=38|https://www.drugbank.ca/drugs/DB00363	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=339eedf1-6c19-46e0-be8f-3a58ea4d49d3
ivacaftor	ivacaftor	VX-770|kalydeco	CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C	Launched	FDA Orange Book: ivacaftor	CYP3A7|CYP3A5|CFTR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=418632|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=418632|ChEMBL	CFTR channel potentiator	pulmonary	cystic fibrosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25
prochlorperazine	prochlorperazine	Compro|compazine|prochlorperazine edisylate|prochlorperazine maleate|prochlorperazine mesilate	CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1	Launched	FDA Orange Book: prochlorperazine, prochlorperazine edisylate, prochlorperazine maleate	DRD1|DRD2|DRD3|DRD4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7279|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7279|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7279	dopamine receptor antagonist	gastroenterology|gastroenterology	nausea|vomiting	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9595346e-76e5-e155-341b-ffaaafb885ab|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9595346e-76e5-e155-341b-ffaaafb885ab
spaglumic-acid	spaglumic acid	N-Acetylaspartylglutamate|isospaglumic acid	CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O	Launched	http://en.wikipedia.org/wiki/N-Acetylaspartylglutamic_acid	GRM3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1405	glutamate receptor antagonist	allergy|allergy	allergic conjunctivitis|allergic rhinitis	http://www.drugbank.ca/drugs/DB08835|https://en.wikipedia.org/wiki/N-Acetylaspartylglutamic_acid
mebeverine	mebeverine		CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)C(C)Cc1ccc(OC)cc1	Launched	http://www.drugs.com/international/mebeverine.html	CHRM4|CHRM3|CHRM2|CHRM1	https://citeline.informa.com/?query=#/drugs/details/11779|https://citeline.informa.com/?query=#/drugs/details/11779|https://citeline.informa.com/?query=#/drugs/details/11779|http://en.wikipedia.org/wiki/Mebeverine	acetylcholine receptor antagonist	gastroenterology	irritable bowel syndrome	https://en.wikipedia.org/wiki/Mebeverine
levalbuterol	levalbuterol	levosalbutamol|xopenex|xopenex hfa	CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1	Launched	FDA Orange Book: albuterol, albuterol sulfate, levalbuterol hydrochloride, levalbuterol tartrate	ADRB2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000873	adrenergic receptor agonist	pulmonary	bronchospasm	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91b2b443-bdc7-4045-bb94-906199125f49
imiloxan	imiloxan		CCn1ccnc1CC1COc2ccccc2O1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/20446913	ADRA2B|ADRA2A	https://www.tocris.com/dispprod.php?ItemId=2263#.VykEoWQrImI|https://www.tocris.com/dispprod.php?ItemId=2263#.VykEoWQrImI	adrenergic receptor antagonist			
pyrantel	pyrantel		OC(=O)c1cc2ccccc2c(Cc2c(O)c(cc3ccccc23)C(O)=O)c1O	Launched	https://www.drugs.com/mtm/pyrantel.html			nicotinic receptor agonist	infectious disease|infectious disease	gastrointestinal roundworms|gastrointestinal roundworms	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9c4ba67-cab0-4cf8-9ae0-0094cb09c297|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9c4ba67-cab0-4cf8-9ae0-0094cb09c297
mepiroxol	mepiroxol		OCc1ccc[n+]([O-])c1	Preclinical							
KBG	KBG		OC1O[C@@H]2COC(O[C@H]2[C@H](O)[C@H]1O)c1ccccc1	Phase 2	Pharmaprojects	MME	http://www.google.com/patents/EP0166443A3?cl=en	neprilysin inhibitor			
A12B4C3	A12B4C3		CCCCCCCCCCC(O)C1C=CC2C(N1Nc1ccc(cc1)[N+]([O-])=O)C(=O)N(C2=O)c1ccccc1	Preclinical		PNKP	https://www.tocris.com/products/a12b4c3_5097	polynucleotide kinase/phosphatase inhibitor			
casanthranol-variant	casanthranol		OC[C@H]1O[C@@H](O[C@@H]2c3cccc(O)c3C(=O)c3c(O)cc(CO)cc23)[C@H](O)[C@H](O)[C@H]1O	Launched	http://www.drugs.com/international/casanthranol.html						
MBX-2982	MBX-2982		CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01035879	GPR119	http://www.cymabay.com/pipeline_mbx2982.html	glucose dependent insulinotropic receptor agonist			
YM-511	YM-511		Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/12926103	CYP19A1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004040	aromatase inhibitor			
L-cysteine	L-cysteine	(r)-cysteine|Cysteine Hydrochloride|E920|E921|cysteine|l-cysteine	N[C@@H](CS)C(O)=O	Launched	https://clinicaltrials.gov/ct2/show/NCT01241513	SLC19A3|CSAD|GOT1|CDO1|CBS|CTH|NFS1|GSS|MGMT|CARS2|CARS|CDO-1|GCLC|GCLM	https://www.drugbank.ca/drugs/DB00151|https://www.drugbank.ca/drugs/DB00151|https://www.drugbank.ca/drugs/DB00151|https://www.drugbank.ca/drugs/DB00151|https://www.drugbank.ca/drugs/DB00151|https://www.drugbank.ca/drugs/DB00151|https://www.drugbank.ca/drugs/DB00151|https://www.drugbank.ca/drugs/DB00151|https://www.drugbank.ca/drugs/DB00151|https://www.drugbank.ca/drugs/DB00151|https://www.drugbank.ca/drugs/DB00151|https://www.drugbank.ca/drugs/DB00151|https://www.drugbank.ca/drugs/DB00151|https://www.drugbank.ca/drugs/DB00151				
oxyfedrine	oxyfedrine	oxyfedrine hydrochloride	COc1cccc(c1)C(=O)CCN[C@@H](C)[C@H](O)c1ccccc1	Launched	https://www.drugs.com/international/oxyfedrine.html			adrenergic receptor agonist	cardiology	angina pectoris	http://www.medindia.net/doctors/drug_information/oxyfedrine.htm
phosphatidylcholine	phosphatidylcholine		CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC	Launched	https://clinicaltrials.gov/ct2/show/NCT01436539	PCTP	https://www.drugbank.ca/drugs/DB02306		infectious disease|infectious disease|dermatology|gastroenterology|cardiology|obstetrics/gynecology	hepatitis B|hepatitis C|eczema|gallbladder disease|cholesterol|premenstrual syndrome	http://www.webmd.com/vitamins-supplements/ingredientmono-501-phosphatidylcholine.aspx?activeingredientid=501&activeingredientname=phosphatidylcholine|http://www.webmd.com/vitamins-supplements/ingredientmono-501-phosphatidylcholine.aspx?activeingredientid=501&activeingredientname=phosphatidylcholine|http://www.webmd.com/vitamins-supplements/ingredientmono-501-phosphatidylcholine.aspx?activeingredientid=501&activeingredientname=phosphatidylcholine|http://www.webmd.com/vitamins-supplements/ingredientmono-501-phosphatidylcholine.aspx?activeingredientid=501&activeingredientname=phosphatidylcholine|http://www.webmd.com/vitamins-supplements/ingredientmono-501-phosphatidylcholine.aspx?activeingredientid=501&activeingredientname=phosphatidylcholine|http://www.webmd.com/vitamins-supplements/ingredientmono-501-phosphatidylcholine.aspx?activeingredientid=501&activeingredientname=phosphatidylcholine
oseltamivir-carboxylate	oseltamivir-carboxylate	Oseltamivir|Oseltamivir acid|Tamiflu|oseltamivir carboxylic acid	CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O	Launched	http://www.ncbi.nlm.nih.gov/pubmed/20056566			neuraminidase inhibitor	infectious disease	influenza A virus infection	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee3c9555-60f2-4f82-a760-11983c86e97b
UC-112	UC-112		Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12	Preclinical		XIAP	https://www.tocris.com/products/uc-112_5251	XIAP inhibitor			
candesartan-cilextil	candesartan-cilextil	TCV-116|atacand|candesartan|candesartan cilexetil	CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1	Launched	FDA Orange Book: candesartan cilexetil	AGTR1|AGTR2	ChEMBL|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001442	angiotensin receptor antagonist	cardiology|cardiology	hypertension|congestive heart failure	http://www.rxlist.com/atacand-drug/indications-dosage.htm|http://www.rxlist.com/atacand-drug/indications-dosage.htm
GW-405833	GW-405833	L-768242	COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1	Preclinical		CNR2	http://www.tocris.com/dispprod.php?ItemId=144481#.Uufwmf30BaE	cannabinoid receptor agonist			
tiludronate	tiludronate	SR 41319|SR-41319|skelid|tiludronic acid	OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O	Launched	FDA Orange Book: tiludronate disodium	ATP6V1A|MMP2|PTPN1	https://www.drugbank.ca/drugs/DB01133|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7604|https://www.drugbank.ca/drugs/DB01133	bone resorption inhibitor|osteoclast inhibitor	orthopedics	navicular syndrome	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b441b911-015c-4a05-9319-d85382d8fcc0&audience=consumer
GSK269962	GSK269962		CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N	Preclinical		ROCK1|ROCK2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8037|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8037	rho associated kinase inhibitor			
MY-5445	MY-5445		Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1	Preclinical		PDE5A	http://www.tocris.com/dispprod.php?ItemId=1671	phosphodiesterase inhibitor|platelet aggregation inhibitor			
tiracizine	tiracizine		CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(C)C)c2c1	Withdrawn	Pharmaprojects	SCN5A	https://www.researchgate.net/publication/14673786_Tiracizine_disposition_in_healthy_volunteers_with_reference_to_the_debrisoquine_oxidation_phenotype	sodium channel blocker			
SC-51089	SC-51089		Clc1ccc2Oc3ccccc3CN(C(=O)NNC(=O)CCc3ccncc3)c2c1	Preclinical		PTGER1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1923	prostanoid receptor antagonist			
trofinetide	trofinetide	Gly-Pro-Glu	NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02715115	TNF|IFNG|IL6	http://www.medkoo.com/products/7800|http://www.medkoo.com/products/7800|http://www.medkoo.com/products/7800	cytokine production inhibitor			
resorcinol-monoacetate	resorcinol-monoacetate		CC(=O)Oc1cccc(O)c1	Launched	https://us.vwr.com/store/product/21573469/spcmr1723			antiseptic			
SKLB1002	SKLB1002		COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC	Preclinical		KDR	http://www.sigmaaldrich.com/catalog/product/sigma/sml1164?lang=en&region=US	VEGFR inhibitor			
sertindole	sertindole	Serdolect|serlect	Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	HRH1|HTR6|ADRA1D|ADRA1B|ADRA1A|KCNH2|HTR2C|HTR2A|HTR1E|HTR1F|HTR1D|HTR1A|HTR1B|DRD2|DRD3|DRD4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=98|https://www.drugbank.ca/drugs/DB06144|https://www.drugbank.ca/drugs/DB06144|https://www.drugbank.ca/drugs/DB06144|https://www.drugbank.ca/drugs/DB06144|https://www.drugbank.ca/drugs/DB06144|https://www.drugbank.ca/drugs/DB06144|https://www.drugbank.ca/drugs/DB06144|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=98|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=98|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=98|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=98|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=98|https://www.drugbank.ca/drugs/DB06144|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=98|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=98	dopamine receptor antagonist|serotonin receptor antagonist			
methyl-salicylate	methyl salicylate	Rhodiaflor|betula oil|birch oil, sweet|gaultheria oil|methyl salicylate|sweet birch oil|teaberry oil|wintergreen oil	COC(=O)c1ccccc1O	Launched	http://www.drugs.com/international/methyl-salicylate.html				endocrinology|neurology/psychiatry	fever|pain relief	http://www.drugs.com/international/methyl-salicylate.html|http://www.drugs.com/international/methyl-salicylate.html
nornicotine	nornicotine		C1CNC(C1)c1cccnc1	Preclinical				acetylcholine receptor agonist			
carteolol	carteolol	cartrol|ocupress	CC(C)(C)NCC(O)COc1cccc2NC(=O)CCc12	Launched	FDA Orange Book: carteolol hydrochloride	ADRB1|ADRB2	https://www.drugbank.ca/drugs/DB00521|https://www.drugbank.ca/drugs/DB00521	adrenergic receptor antagonist	ophthalmology|ophthalmology|ophthalmology	intraocular pressure|glaucoma|ocular hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=571fe550-399d-4296-835c-37aa1ab9b409|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=571fe550-399d-4296-835c-37aa1ab9b409|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=571fe550-399d-4296-835c-37aa1ab9b409
6,_7-dehydro-17-acetoxy-progesterone	6,_7-dehydro-17-acetoxy-progesterone		CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O	Preclinical				steroidal progestin			
methsuximide	methsuximide	celontin|mesuximide	CN1C(=O)CC(C)(C1=O)c1ccccc1	Launched	FDA Orange Book: methsuximide	CACNA1G|CACNA1I|CACNA1H	ChEMBL|ChEMBL|ChEMBL	T-type calcium channel binder	neurology/psychiatry	seizures	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64a6ee88-c6b1-4e13-8208-b6772ef65a74
peretinoin	peretinoin		CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(C)=C\C(O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01640808	RXRA	http://adisinsight.springer.com/drugs/800028422	retinoid receptor agonist			
phenyl-aminosalicylate	phenyl aminosalicylate	fenamisal|pheny-pas-tebamin|phenyl aminosalicylate	Nc1ccc(C(=O)Oc2ccccc2)c(O)c1	Launched	FDA Orange Book: phenyl aminosalicylate				infectious disease	tuberculosis	http://www.drugs.com/dict/phenyl-aminosalicylate.html
LTA	LTA		N=C(Nc1ccccc1)c1cccs1	Phase 2	Pharmaprojects						
betamethasone-acetate	betamethasone acetate		C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O	Launched	http://www.drugs.com/international/betamethasone-acetate.html	NR3C1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7061	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e63c73d-30b2-4f47-a817-0313a08281c1
piperazine	piperazine	Bryel|Hexahydropyrazine|Pipcide|Pipfuge Pedatabs|Pipzine|Wormelix|antepar|bryrel|multifuge	C1CNCCN1	Launched	FDA Orange Book: piperazine citrate	GABRB3	https://www.drugbank.ca/drugs/DB00592	benzodiazepine receptor agonist	infectious disease	gastrointestinal roundworms	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e31e576a-d2d5-46b2-b281-547cc443323c
NVP-BVU972	NVP-BVU972		Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1	Preclinical		MET	http://www.selleckchem.com/products/nvp-bvu972.html	MET inhibitor			
RBC8	RBC8		COc1ccc(OC)c(c1)C1c2c(OC(N)=C1C#N)[nH]nc2-c1ccc2ccccc2c1	Preclinical		RALA|RALB	https://www.tocris.com/dispprod.php?ItemId=438961#.V-6rHJMrLy9|https://www.tocris.com/dispprod.php?ItemId=438961#.V-6rHJMrLy9	Ral GTPase inhibitor			
CJ-033466	CJ-033466		CC(C)CN1CCC(CNC(=O)c2cc(Cl)c(N)n3cc(C)nc23)CC1	Preclinical		HTR4	https://www.tocris.com/products/cj-033466_3089	serotonin receptor agonist			
pincainide	pincainide		Cc1cccc(C)c1NC(=O)CN1CCCCCC1	Phase 1	Pharmaprojects	SCN5A	https://citeline.informa.com/?query=#/drugs/details/14466	antiarrhythmic			
tianeptine	tianeptine		CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O	Launched	http://www.drugs.com/international/Tianeptine.html	SLC6A4|OPRD1|OPRK1|OPRM1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090995|https://en.wikipedia.org/wiki/Tianeptine#Mechanism_of_action|https://en.wikipedia.org/wiki/Tianeptine#Mechanism_of_action|https://en.wikipedia.org/wiki/Tianeptine#Mechanism_of_action	selective serotonin reuptake enhancer (SSRE)	neurology/psychiatry|pulmonary|gastroenterology	depression|asthma|irritable bowel syndrome	https://en.wikipedia.org/wiki/Tianeptine|https://en.wikipedia.org/wiki/Tianeptine|https://en.wikipedia.org/wiki/Tianeptine
teicoplanin-a2-3	teicoplanin A2-3			Launched	https://en.wikipedia.org/wiki/Teicoplanin			bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections	https://en.wikipedia.org/wiki/Teicoplanin
fenticonazole	fenticonazole	Lomexin	Clc1ccc(C(Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1	Launched	http://www.drugs.com/international/Fenticonazole.html			bacterial cell wall synthesis inhibitor	infectious disease	vulvovaginal candidiasis	https://en.wikipedia.org/wiki/Fenticonazole
ubenimex	ubenimex	Bestatin	CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O	Launched	http://www.drugs.com/international/Ubenimex.html	LTA4H|ANPEP|RNPEP	https://www.drugbank.ca/drugs/DB03424|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090702|http://www.selleckchem.com/products/Ubenimex%28Bestatin%29.html	leukotriene synthesis inhibitor	hematologic malignancy	acute myeloid leukemia (AML)	https://en.wikipedia.org/wiki/Ubenimex
dehydroacetic-acid	dehydroacetic acid	E265|dehydroacetic acid	CC(=O)C1C(=O)OC(C)=CC1=O	Preclinical							
UPF-1069	UPF-1069		O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1	Preclinical		PARP2	http://www.tocris.com/dispprod.php?ItemId=241269#.VhQEqRNViko	PARP inhibitor			
ponesimod	ponesimod	ACT-128800	CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02425644	S1PR1	https://en.wikipedia.org/wiki/Ponesimod	sphingosine 1 phosphate receptor agonist			
alantolactone	alantolactone		C[C@H]1CCC[C@]2(C)C[C@H]3OC(=O)C(=C)[C@H]3C=C12	Preclinical		STAT3|ACHE	https://www.ncbi.nlm.nih.gov/pubmed/25434800|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=299809	apoptosis stimulant|STAT inhibitor			
P22077	P22077		CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O	Preclinical		USP7	http://www.tocris.com/dispprod.php?ItemId=337649#.Vgrx6WRVhHw	ubiquitin specific protease inhibitor			
fluoxetine	fluoxetine	Symbyax|fluoxetine hydrochloride|prozac|prozac weekly|sarafem	CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1	Launched	FDA Orange Book: fluoxetine hydrochloride	ANO1|SLC6A4|HTR2B|CYP2C19	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=203|https://www.drugbank.ca/drugs/DB00472|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=203|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=131699	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|bulimia nervosa|panic disorders|bipolar disorder	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59de2889-c3d3-4ebf-8826-13f30a3fa439|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59de2889-c3d3-4ebf-8826-13f30a3fa439|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59de2889-c3d3-4ebf-8826-13f30a3fa439|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59de2889-c3d3-4ebf-8826-13f30a3fa439|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59de2889-c3d3-4ebf-8826-13f30a3fa439
erlotinib	erlotinib	OSI-774|R-1415|RG-1415|Ro-508231|tarceva	COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC	Launched	FDA Orange Book: erlotinib hydrochloride	NR1I2|EGFR	https://www.drugbank.ca/drugs/DB00530|https://www.drugbank.ca/drugs/DB00530	EGFR inhibitor	oncology|oncology	non-small cell lung cancer (NSCLC)|pancreatic cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20
kartogenin	kartogenin		OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)-c1ccccc1	Preclinical		FLNA	https://www.ncbi.nlm.nih.gov/pubmed/22491093	chondrocyte differentiation stimulator			
exemestane	exemestane	aromasin	C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O	Launched	FDA Orange Book: exemestane	CYP19A1	https://www.drugbank.ca/drugs/DB00990	aromatase inhibitor	oncology	breast cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61d86c55-9946-273f-4f22-42d3fc33d143
ICI-192605	ICI-192605		OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/1838424	TBXA2R	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6072	thromboxane receptor antagonist			
roflumilast	roflumilast	B9302-107|BY217|BYK20869|daliresp	FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl	Launched	FDA Orange Book: roflumilast	PDE4A|PDE4D|PDE4C|PDE4B|CYP2C19|CYP2B6	ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=224324|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=224324	phosphodiesterase inhibitor	pulmonary|pulmonary	chronic obstructive pulmonary disease (COPD)|bronchitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9a1d0a8-581f-4f91-a2b8-f419192d0ebf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9a1d0a8-581f-4f91-a2b8-f419192d0ebf
valnoctamide	valnoctamide	MCN-X-181|axiquel	CCC(C)C(CC)C(N)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00140179			arachidonic acid acylation inhibitor|benzodiazepine receptor agonist			
2-chloroadenosine	2-chloroadenosine		Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Preclinical		ADORA1|ADORA2B|ADORA2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=372|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=372|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=372	adenosine receptor agonist			
WIN-18446	WIN-18446		ClC(Cl)C(=O)NCCCCCCCCNC(=O)C(Cl)Cl	Preclinical		ALDH1A2	https://www.tocris.com/dispprod.php?ItemId=365511#.V_P0dZMrLy8	aldehyde dehydrogenase inhibitor			
PHP-501	PHP-501		On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1	Preclinical		GABRA1|GABRB2|GABRG2	https://www.tocris.com/products/php-501-trifluoroacetate_4466|https://www.tocris.com/products/php-501-trifluoroacetate_4466|https://www.tocris.com/products/php-501-trifluoroacetate_4466	GABA receptor antagonist			
barbital	barbital	barbitone|diemal|diethylbarbituric acid	CCC1(CC)C(=O)NC(=O)NC1=O	Launched	http://en.wikipedia.org/wiki/Barbital	GABRA5|GABRA6|GABRA3|GABRA4|GABRA1|GABRA2|CHRNA4|CHRNA7|GRIK2|GRIA2	https://www.drugbank.ca/drugs/DB01483|https://www.drugbank.ca/drugs/DB01483|https://www.drugbank.ca/drugs/DB01483|https://www.drugbank.ca/drugs/DB01483|https://www.drugbank.ca/drugs/DB01483|https://www.drugbank.ca/drugs/DB01483|https://www.drugbank.ca/drugs/DB01483|https://www.drugbank.ca/drugs/DB01483|https://www.drugbank.ca/drugs/DB01483|https://www.drugbank.ca/drugs/DB01483	sedative	neurology/psychiatry|neurology/psychiatry	sedative|seizures	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=069b92ce-0061-4724-8c25-08d8596770a2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=069b92ce-0061-4724-8c25-08d8596770a2
DMSO	DMSO	Domoso|Infiltrina|RIMSO-50|Rimso 50|SQ 9453|SQ-9453|Syntexan|dimethyl sulfoxide	CS(C)=O.CS(C)=O	Preclinical				control vehicle			
chlorproguanil	chlorproguanil		CC(C)NC(=N)NC(=N)Nc1ccc(Cl)c(Cl)c1	Launched	https://clinicaltrials.gov/ct2/show/NCT00164359	DHFR	http://www.antimicrobe.org/drugpopup/chlorproguanil.htm	dihydrofolate reductase inhibitor	infectious disease	malaria	https://en.wikipedia.org/wiki/Chlorproguanil
OTS514	OTS514		C[C@@H](CN)c1ccc(cc1)-c1c(O)cc(C)c2[nH]c(=O)c3sccc3c12	Preclinical		PBK	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=748720	TOPK inhibitor			
lithium-acetoacetate	lithium-acetoacetate	acetoacetic acid	CC(=O)CC(O)=O	Preclinical							
delavirdine	delavirdine	U-90152|rescriptor	CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1	Launched	FDA Orange Book: delavirdine mesylate	CYP2C19|CYP3A4	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=196540|https://en.wikipedia.org/wiki/Delavirdine	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb28dcd2-c457-4137-9eec-00062e5a601b
flunixin-meglumin	flunixin-meglumin	SCH 14714|flunixin	Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F	Veterinary Launched	veterinary use			prostanoid receptor antagonist			
GDC-0834	GDC-0834		CN1CCN(C)C(=O)C1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/25701252	BTK	http://www.ncbi.nlm.nih.gov/pubmed/25701252	Bruton's tyrosine kinase (BTK) inhibitor			
chlorophyllin-copper	chlorophyllin-copper		CCC1=C(C)\C2=C\c3c(C=C)c(C)c4\C=C5/N=C(C(CCC(O)=O)C5C)/C(CC(O)=O)=c5/c(C(O)=O)c(C)/c(=C/C1=N/2)n5[Cu]n34	Phase 1	https://www.clinicaltrials.gov/ct2/show/NCT00340743			cytochrome P450 inhibitor			
integrin-antagonist-1	integrin-antagonist-1		Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCC2=CC=C3CCCN=C3N2)C1)CC(O)=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02612051	ITGB6|ITGAV	https://www.medchemexpress.com/Integrin-Antagonist-1-hydrochloride.html|https://www.medchemexpress.com/Integrin-Antagonist-1-hydrochloride.html	integrin antagonist			
yohimbine	yohimbine		COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12	Veterinary Launched	http://www.drugs.com/international/Yohimbine.html	DRD2|DRD3|ADRA2C|ADRA2B|ADRA2A|KCNJ11|KCNJ10|KCNJ12|KCNJ15|KCNJ14|HTR2C|HTR2B|HTR2A|HTR1F|HTR1E|HTR1D|HTR1B|HTR1A|HTR7|HTR5A|KCNJ1|KCNJ8	https://www.drugbank.ca/drugs/DB01392|https://www.drugbank.ca/drugs/DB01392|https://www.drugbank.ca/drugs/DB01392|https://www.drugbank.ca/drugs/DB01392|https://www.drugbank.ca/drugs/DB01392|https://www.drugbank.ca/drugs/DB01392|https://www.drugbank.ca/drugs/DB01392|https://www.drugbank.ca/drugs/DB01392|https://www.drugbank.ca/drugs/DB01392|https://www.drugbank.ca/drugs/DB01392|https://www.drugbank.ca/drugs/DB01392|https://www.drugbank.ca/drugs/DB01392|https://www.drugbank.ca/drugs/DB01392|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=102|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=102|https://www.drugbank.ca/drugs/DB01392|https://www.drugbank.ca/drugs/DB01392|https://www.drugbank.ca/drugs/DB01392|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=102|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=102|https://www.drugbank.ca/drugs/DB01392|https://www.drugbank.ca/drugs/DB01392	adrenergic receptor antagonist	cardiology|cardiology	cardiac arrythmia|bradycardia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73e593c2-0838-48aa-8e60-dce4193b9caa|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73e593c2-0838-48aa-8e60-dce4193b9caa
caspofungin	caspofungin		CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@@H](O)[C@H](O)c1ccc(O)cc1)[C@H](O)CCN	Launched	FDA Orange Book: caspofungin acetate			fungal 1,3-beta-D-glucan synthase inhibitor|bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease|infectious disease	candidemia|esophageal candidiasis|aspergillosis|fungal infection	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3bad23a6-09a6-4194-9182-093ed61bc71c|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3bad23a6-09a6-4194-9182-093ed61bc71c|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3bad23a6-09a6-4194-9182-093ed61bc71c|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3bad23a6-09a6-4194-9182-093ed61bc71c
choline-alfoscerate	choline-alfoscerate		C[N+](C)(C)CCOP(O)(=O)OC[C@H](O)CO	Launched	https://clinicaltrials.gov/ct2/show/NCT01363648	GM2A	https://www.drugbank.ca/drugs/DB04660	acetylcholine precursor			
4E1RCat	4E1RCat		OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O	Preclinical		EIF4G1|EIF4E	http://www.sigmaaldrich.com/catalog/product/sigma/sml0197?lang=en&region=US|http://www.sigmaaldrich.com/catalog/product/sigma/sml0197?lang=en&region=US	protein synthesis inhibitor			
meclocycline-sulfosalicylate	meclocycline sulfosalicylate	meclan	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)ccc(Cl)c4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O	Launched	FDA Orange Book: meclocycline sulfosalicylate			bacterial 50S ribosomal subunit inhibitor	dermatology|infectious disease	acne vulgaris (AV)|skin infections	http://www.healthcare.com/medications/meclocycline-sulfosalicylate-topical-14302.php|http://www.healthcare.com/medications/meclocycline-sulfosalicylate-topical-14302.php
CP-316819	CP-316819		CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1	Preclinical		PYGL	https://www.tocris.com/products/cp-316819_3542	glycogen phosphorylase inhibitor			
enflurane	enflurane	ANESTHETIC COMPOUND NO. 347|ethrane	FC(F)OC(F)(F)C(F)Cl	Launched	FDA Orange Book: enflurane	GABRQ|GABRP|GABRE|GABRD|GLRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRA1|GABRB3|GABRB1|GABRB2|GABRG1|GABRG2|GABRG3|KCNK10|KCNK18|ATP2C1|GLRB|GRIA1|ATP5D|CYP2E1|KCNA1|KCNN4|KCNK3|KCNK2|KCNK9	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00228|ChEMBL|https://www.drugbank.ca/drugs/DB00228|https://www.drugbank.ca/drugs/DB00228|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091312|https://www.drugbank.ca/drugs/DB00228|https://www.drugbank.ca/drugs/DB00228|ChEMBL|ChEMBL|ChEMBL	membrane permeability inhibitor			
andarine	andarine		CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1	Phase 1	http://adisinsight.springer.com/drugs/800019485	AR	https://www.drugbank.ca/drugs/DB07423	androgen receptor modulator			
PSN-375963	PSN-375963		CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1	Preclinical		GPR119	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3318	glucose dependent insulinotropic receptor agonist			
afobazole	afobazole		CCOc1ccc2[nH]c(SCCN3CCOCC3)nc2c1	Launched	http://en.ibcgenerium.ru/upload/medialibrary/7e1/Generium_Afobazole_2012June.pdf			anxiolytic	neurology/psychiatry	anxiety	https://en.wikipedia.org/wiki/Fabomotizole
clodronic-acid	clodronic acid	Bonefos|Clodron|Loron|clodronic acid	OP(O)(=O)C(Cl)(Cl)P(O)(O)=O	Launched	http://en.wikipedia.org/wiki/Clodronic_acid	SLC25A4|SLC25A5|SLC25A6	https://www.drugbank.ca/drugs/DB00720|https://www.drugbank.ca/drugs/DB00720|https://www.drugbank.ca/drugs/DB00720	bone resorption inhibitor	orthopedics|endocrinology|endocrinology|hematologic malignancy	osteoporosis|hyperparathyroidism|hypercalcemia|multiple myeloma	https://en.wikipedia.org/wiki/Clodronic_acid|https://en.wikipedia.org/wiki/Clodronic_acid|https://en.wikipedia.org/wiki/Clodronic_acid|https://en.wikipedia.org/wiki/Clodronic_acid
LY2874455	LY2874455		C[C@@H](Oc1ccc2[nH]nc(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01212107	KDR|FGFR3|FGFR2|FGFR1|FGFR4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8104|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8104|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8104|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8104|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8104	FGFR antagonist			
thiamylal	thiamylal	surital	CCCC(C)C1(CC=C)C(=O)NC(S)=NC1=O	Launched	FDA Orange Book: thiamylal sodium	KCNJ11|GABRA1|KCNJ8	https://www.drugbank.ca/drugs/DB01154|https://www.drugbank.ca/drugs/DB01154|https://www.drugbank.ca/drugs/DB01154	glutamate receptor antagonist	neurology/psychiatry	sedative	https://en.wikipedia.org/wiki/Thiamylal
2-octyldodecan-1-ol	2-octyldodecan-1-ol	octyldodecanol	CCCCCCCCCCC(CO)CCCCCCCC	Preclinical							
moxidectin	moxidectin		CO\N=C1\C[C@]2(C[C@@H]3C[C@@H](C\C=C(C)\C[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\C)=C\C(C)C	Veterinary Launched	http://www.drugs.com/international/moxidectin.html			chloride channel antagonist	infectious disease	gastrointestinal parasites	https://en.wikipedia.org/wiki/Moxidectin
ZLN005	ZLN005		CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1	Preclinical							
prolylleucylglycinamide	prolylleucylglycinamide		CC(C)CC(NC(=O)C1CCCN1)C(=O)NCC(N)=O	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/3244794			melanocyte-stimulating hormone release inhibitor			
WAY-200070	WAY-200070		Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1	Preclinical		ESR2|ERBB4|ERBB3|ERBB2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4052|http://www.tocris.com/dispprod.php?ItemId=220540#.VhQLlBNViko|http://www.tocris.com/dispprod.php?ItemId=220540#.VhQLlBNViko|http://www.tocris.com/dispprod.php?ItemId=220540#.VhQLlBNViko	estrogen receptor agonist			
Ro-61-8048	Ro-61-8048		COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O	Preclinical		KMO	https://www.tocris.com/dispprod.php?ItemId=214932#.V_JzJJMrLy8	kynurenine 3-monooxygenase inhibitor			
tyrphostin-AG-1296	tyrphostin-AG-1296	AG-1296	COc1cc2ncc(nc2cc1OC)-c1ccccc1	Preclinical		FLT3	https://www.caymanchem.com/product/10010592	FLT3 inhibitor			
methysergide	methysergide	sansert	CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34	Launched	FDA Orange Book: methysergide maleate	HTR6|HTR7|HTR2C|HTR2B|HTR2A|HTR1F|HTR1E|HTR1D|HTR1B|HTR1A|HTR5A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=134|https://www.drugbank.ca/drugs/DB00247|https://www.drugbank.ca/drugs/DB00247|https://www.drugbank.ca/drugs/DB00247|https://www.drugbank.ca/drugs/DB00247|https://www.drugbank.ca/drugs/DB00247|https://www.drugbank.ca/drugs/DB00247|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=134|https://www.drugbank.ca/drugs/DB00247|https://www.drugbank.ca/drugs/DB00247|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=134	serotonin receptor antagonist	neurology/psychiatry	headache	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fae28ee-700e-4d4f-a040-02ef01a2aeb4
BRD-9876	BRD-9876		CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N	Preclinical		KIF11	https://www.tocris.com/products/brd-9876_5454	kinesin inhibitor			
NVP-BHG712	NVP-BHG712		Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F	Preclinical		EPHB4	http://www.tocris.com/dispprod.php?ItemId=324774#.Vgq7sWRVhHw	ephrin inhibitor			
taurocholate	taurocholate	Cholaic acid|Cholic acid taurine conjugate|N-Choloyltaurine	C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	Phase 1	http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID=79550	FABP6|SLCO1C1|CEL	https://www.drugbank.ca/drugs/DB04348|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4547|https://www.drugbank.ca/drugs/DB04348	G protein-coupled receptor agonist			
gadopentetic-acid	gadopentetic acid		OC(=O)CN1CCN2CCN(CC(O)=O)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2	Launched	https://en.wikipedia.org/wiki/Gadopentetic_acid			contrast agent	radiology	contrast agent	https://en.wikipedia.org/wiki/Gadopentetic_acid
pyridoxamine	pyridoxamine		Cc1ncc(CO)c(CN)c1O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02156843			AGE inhibitor			
hycanthone	hycanthone	WIN 24,933	CCN(CC)CCNc1ccc(CO)c2sc3ccccc3c(=O)c12	Launched	http://en.wikipedia.org/wiki/Hycanthone			RNA synthesis inhibitor	infectious disease	schistosomiasis	https://en.wikipedia.org/wiki/Hycanthone
phenothrin	phenothrin	S-2539F|Sumithrin	CC(C)=CC1C(C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C	Launched	http://www.drugs.com/international/phenothrin.html				infectious disease	lice	https://en.wikipedia.org/wiki/Phenothrin
bicalutamide	bicalutamide	Calutide|Cosudex|ICI 176,334|Kalumid|casodex	CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F	Launched	FDA Orange Book: bicalutamide	CYP2C19|AR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=130910|ChEMBL	androgen receptor antagonist	oncology	prostate cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c295b64-ec39-42ec-9f02-da5b42e775e1
LX7101	LX7101		CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT01528111	LIMK2|ROCK1|ROCK2	http://www.apexbt.com/lx7101-hcl.html|http://www.apexbt.com/lx7101-hcl.html|http://www.apexbt.com/lx7101-hcl.html	LIM kinase inhibitor|rho associated kinase inhibitor			
eszopiclone	eszopiclone	(s)-zopiclone|lunesta	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)c2nccnc12)c1ccc(Cl)cn1	Launched	FDA Orange Book: eszopiclone	GABRQ|GABRP|GABRE|GABRD|TSPO|CYP2E1|GABRG2|GABRG1|GABRG3|GABRB1|GABRB3|GABRB2|GABRA2|GABRA1|GABRA4|GABRA3|GABRA6|GABRA5	ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00402|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=283666|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	benzodiazepine receptor agonist	neurology/psychiatry	insomnia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f71eb4-15ca-42e2-b62b-7963cc8ef115
moxaverine	moxaverine		CCc1cc2cc(OC)c(OC)cc2c(Cc2ccccc2)n1	Launched	https://www.drugs.com/international/moxaverine.html			phosphodiesterase inhibitor	neurology/psychiatry	spasms	https://www.drugs.com/international/moxaverine.html
benznidazole	benznidazole	Radanil|Rochagan	[O-][N+](=O)c1nccn1CC(=O)NCc1ccccc1	Launched	http://www.drugs.com/international/Benznidazole.html			DNA synthesis inhibitor	infectious disease	Chagas disease	https://en.wikipedia.org/wiki/Benznidazole
YZ9	YZ9		CCOC(=O)c1cc2ccc(O)cc2oc1=O	Preclinical		PFKFB3|MIF	https://www.tocris.com/products/yz9_5048|https://www.drugbank.ca/drugs/DB02728	phosphofructokinase inhibitor			
PGL5001	PGL5001	AS-602801|Bentamapimod|PGL-5001	N#CC(c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01630252	MAPK9|MAPK8|MAPK10	https://us.axonmedchem.com/product/2002/?SID=14ae04753ed34ed385d112112966b6d9&country_id=US|https://us.axonmedchem.com/product/2002/?SID=14ae04753ed34ed385d112112966b6d9&country_id=US|https://us.axonmedchem.com/product/2002/?SID=14ae04753ed34ed385d112112966b6d9&country_id=US	JNK inhibitor			
piperacillin	piperacillin	pipracil		Launched	FDA Orange Book: piperacillin sodium			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease|infectious disease	intra-abdominal infections|skin infections|pelvic inflammatory disease|pneumonia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cfa6723-175b-4c4d-8212-266844b07610|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cfa6723-175b-4c4d-8212-266844b07610|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cfa6723-175b-4c4d-8212-266844b07610|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cfa6723-175b-4c4d-8212-266844b07610
candesartan	candesartan	CV-11974	CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1	Launched	FDA Orange Book: candesartan cilexetil	AGTR1	https://www.drugbank.ca/drugs/DB00796	angiotensin receptor antagonist	cardiology|cardiology	hypertension|congestive heart failure	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be36901a-b2fe-5834-755b-9a44e6748890|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be36901a-b2fe-5834-755b-9a44e6748890
LFM-A13	LFM-A13		CC(=O)C(C#N)C(=O)Nc1cc(Br)ccc1Br	Preclinical		BTK	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008393	Bruton's tyrosine kinase (BTK) inhibitor			
L-655240	L-655240		Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12	Phase 1	Pharmaprojects	PTGES	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014756	thromboxane receptor antagonist			
pirinixic-acid	pirinixic acid	pirinixic acid	Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C	Preclinical		PPARA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2666	PPAR receptor agonist			
ropivacaine	ropivacaine	naropin	CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C	Launched	FDA Orange Book: ropivacaine hydrochloride	SCN10A|SCN9A	https://www.drugbank.ca/drugs/DB00296|https://citeline.informa.com/?query=#/drugs/details/15762	sodium channel blocker	neurology/psychiatry	anesthetic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb8b926d-cf66-bc7e-c940-e820fd4e877c
ceftibuten	ceftibuten	7432-S|SCH 39720|SCH-39720|Seftem|cedax|ceftibuten dihydrate	Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O	Launched	FDA Orange Book: ceftibuten dihydrate			bacterial cell wall synthesis inhibitor	pulmonary|otolaryngology|otolaryngology|otolaryngology	bronchitis|otitis|pharyngitis|tonsillitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2dd58c88-142f-41ad-bc31-0a4fff074970|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2dd58c88-142f-41ad-bc31-0a4fff074970|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2dd58c88-142f-41ad-bc31-0a4fff074970|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2dd58c88-142f-41ad-bc31-0a4fff074970
cinalukast	cinalukast	RO 24-5913|Ro-24-5913	CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/9042047	CYSLTR1	https://www.drugbank.ca/drugs/DB00587	leukotriene receptor antagonist			
crisaborole	crisaborole	AN2728	OB1OCc2cc(Oc3ccc(cc3)C#N)ccc12	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02118766	IL1B|TNF|PDE4A|PDE4B|PDE4C|PDE4D|IFNG|CXCL8|IL2|IL6	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=424112|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=424112|https://citeline.informa.com/?query=#/drugs/details/36954|https://en.wikipedia.org/wiki/Crisaborole|https://citeline.informa.com/?query=#/drugs/details/36954|https://citeline.informa.com/?query=#/drugs/details/36954|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=424112|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=424112|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=424112|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=424112	phosphodiesterase inhibitor			
4,4'-DDT	4,4'-DDT		Clc1ccc(cc1)C(c1ccc(Cl)cc1)C(Cl)(Cl)Cl	Preclinical							
JLK-6	JLK-6		COc1oc(=O)c2cc(N)ccc2c1Cl	Preclinical		PSEN1	http://www.scbt.com/datasheet-203612-jlk-6.html	gamma secretase inhibitor			
QX-222	QX-222		Cc1cccc(C)c1NC(=O)C[N+](C)(C)C	Preclinical				sodium channel blocker			
TG-101209	TG-101209		CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1	Preclinical		JAK3|JAK2	https://www.caymanchem.com/Product.vm/catalog/14696|https://www.caymanchem.com/Product.vm/catalog/14696	JAK inhibitor			
dabrafenib	dabrafenib	GSK2118436A|tafinlar	CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F	Launched	FDA Orange Book: dabrafenib mesylate	LIMK1|CYP2B6|CYP2C8|CYP3A4|CYP2C19|SIK1|RAF1|NEK11|BRAF	https://www.drugbank.ca/drugs/DB08912|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=679978|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=679978|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=679978|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=679978|https://www.drugbank.ca/drugs/DB08912|https://www.drugbank.ca/drugs/DB08912|https://www.drugbank.ca/drugs/DB08912|https://www.drugbank.ca/drugs/DB08912	RAF inhibitor	oncology	melanoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=803beaaa-33f9-48cc-9a95-c2e887e095b4
nifursol	nifursol		Oc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	Veterinary Launched	http://www.ncbi.nlm.nih.gov/pubmed/22515034			bacterial DNA inhibitor			
scopine	scopine		CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21	Launched	http://www.drugs.com/international/scopine.html						
alogliptin	alogliptin	nesina		Launched	FDA Orange Book: alogliptin benzoate	DPP4	https://www.drugbank.ca/drugs/DB06203	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3768c7e-aa4c-44d3-bc53-43bb7346c0b0
SDZ-SER-082	SDZ-SER-082		CN1CC[C@@H]2CN3CCc4cccc([C@@H]2C1)c34	Preclinical		HTR2A|HTR2C|HTR2B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=195|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=195|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=195	serotonin receptor antagonist			
CI-923	CI-923		CCNC(C)CN1CCc2c(C1)c(=O)oc1ccccc21	Phase 1	Pharmaprojects			acetylcholine receptor antagonist			
hydrocortisone-phosphate	hydrocortisone phosphate	hydrocortone	CC12C[C@H](O)C3C(CCC4=CC(=O)CCC34C)C1CC[C@]2(O)C(=O)COP(O)(O)=O	Launched	http://www.drugs.com/uk/efcortesol-injection-leaflet.html	ANXA1|NR3C1|NOS2	https://www.drugbank.ca/drugs/DB00741|https://www.drugbank.ca/drugs/DB00741|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000718		pulmonary|gastroenterology|gastroenterology|hematologic malignancy|ophthalmology|gastroenterology|gastroenterology	asthma|nausea|vomiting|multiple myeloma|contact dermatitis|enteritis|colitis	http://www.rxlist.com/solu-cortef-drug/indications-dosage.htm|http://www.rxlist.com/solu-cortef-drug/indications-dosage.htm|http://www.rxlist.com/solu-cortef-drug/indications-dosage.htm|http://www.rxlist.com/solu-cortef-drug/indications-dosage.htm|http://www.rxlist.com/solu-cortef-drug/indications-dosage.htm|http://www.rxlist.com/solu-cortef-drug/indications-dosage.htm|http://www.rxlist.com/solu-cortef-drug/indications-dosage.htm
N-acetylmannosamine	N-acetylmannosamine		CC(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01634750	CHIT1	https://www.drugbank.ca/drugs/DB03109				
octenidine	octenidine		CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1	Launched	http://www.drugs.com/international/Octenidine.html			membrane integrity inhibitor			
trovirdine	trovirdine	LY-300046	Brc1ccc(NC(=S)NCCc2ccccn2)nc1	Phase 1	https://www.wikigenes.org/e/chem/e/3000870.html			non-nucleoside reverse transcriptase inhibitor			
nadifloxacin	nadifloxacin	OPC-7251	CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O	Launched	http://www.drugs.com/international/Nadifloxacin.html			bacterial DNA gyrase inhibitor	dermatology|infectious disease	acne vulgaris (AV)|skin infections	https://en.wikipedia.org/wiki/Nadifloxacin|https://en.wikipedia.org/wiki/Nadifloxacin
isaxonine	isaxonine		CC(C)Nc1ncccn1	Withdrawn	Pharmaprojects			nerve growth factor agonist			
lynestrenol	lynestrenol	lynoestrenol	C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	Launched	http://www.drugs.com/international/Lynestrenol.html			progestogen hormone	endocrinology	contraceptive	http://www.drugs.com/international/lynestrenol.html
GBR-12935	GBR-12935		C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1	Preclinical		AGTR1|SLC6A3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000679|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4639	dopamine uptake inhibitor			
levonordefrin	levonordefrin	Nordefrin|corbadrine|neo-cobefrin	C[C@H](N)[C@H](O)c1ccc(O)c(O)c1	Launched	FDA Orange Book: levonordefrin	SLC6A2|ADRA2A|ADRA2C|ADRA2B|ADRA1B|ADRA1A|ADRA1D	https://www.drugbank.ca/drugs/DB06707|ChEMBL|ChEMBL|ChEMBL|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012645|https://www.drugbank.ca/drugs/DB06707|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=508	vasodilator	hematology	hemorrhage	http://www.drugbank.ca/drugs/DB06707
YC-1	YC-1		OCc1ccc(o1)-c1nn(Cc2ccccc2)c2ccccc12	Preclinical		HIF1A|GUCY1B3|GUCY1A2|GUCY1A3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008047|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5291|http://www.tocris.com/dispprod.php?ItemId=302097|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5291	guanylyl cyclase activator			
prenylamine	prenylamine	B-436|Segontin|prenylamine lactate	CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	CALM1|MYLK2	https://www.drugbank.ca/drugs/DB04825|https://www.drugbank.ca/drugs/DB04825	calcium channel blocker			
oxatomide	oxatomide	R 35,443	O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1	Launched	http://www.drugs.com/international/oxatomide.html	HRH1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001414	histamine receptor antagonist	allergy	allergic rhinitis	http://www.drugs.com/international/oxatomide.html
forodesine	forodesine	fodosine	OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00095381	PNP	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000117	purinergic receptor antagonist			
ethotoin	ethotoin	peganone	CCN1C(=O)NC(C1=O)c1ccccc1	Launched	FDA Orange Book: ethotoin	SCN11A|SCN10A|SCN9A|SCN7A|SCN8A|SCN1A|SCN2A|SCN5A|SCN3A|SCN4A	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	hydantoin antiepileptic	neurology/psychiatry	seizures	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afcb9d60-3668-3890-5fed-f0794a12509d
rilpivirine	rilpivirine	R 278474|R-278474|TMC-278|edurant	Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1	Launched	FDA Orange Book: rilpivirine hydrochloride	CYP2C19|CYP3A5|SCN10A|NR1I2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=336587|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=336587|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000968|https://www.drugbank.ca/drugs/DB08864	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03880372-2c68-45c6-a53a-f420c49541d6
NAB-2	NAB-2		Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl	Preclinical		NEDD4	https://www.tocris.com/products/nab-2_5131	ubiquitin ligase transport promoter			
ME0328	ME0328		CC(NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1	Preclinical		PARP1|PARP3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=826101|http://www.tocris.com/dispprod.php?ItemId=393743#.VgQrItNViko	PARP inhibitor			
tretinoin	tretinoin	Tretin-X|atralin|avita|panretin|renova|retin-a|retin-a micro|retin-a-micro|vesanoid	CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(O)=O	Launched	FDA Orange Book: alitretinoin, isotretinoin, tretinoin	NR0B1|ALDH1A2|ALDH1A1|GPRC5A|PPARD|NR2C2|RXRG|RXRB|RARRES1|RORC|RORB|RARG|RARB|RARA	https://www.drugbank.ca/drugs/DB00755|https://www.drugbank.ca/drugs/DB00755|https://www.drugbank.ca/drugs/DB00755|https://www.drugbank.ca/drugs/DB00755|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644|https://www.drugbank.ca/drugs/DB00755|https://www.drugbank.ca/drugs/DB00755|https://www.drugbank.ca/drugs/DB00755|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644|ChEMBL|ChEMBL|ChEMBL	retinoid receptor agonist|retinoid receptor ligand	hematologic malignancy	acute promyelocytic leukemia (APL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f81f505-a962-414e-8612-c3ef3b159e9a&audience=consumer
nifuroxazide	nifuroxazide	RC-27109|SJ000287313	Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	Launched	http://www.drugs.com/international/Nifuroxazide.html			bacterial DNA inhibitor	gastroenterology|gastroenterology	colitis|diarrhea	https://en.wikipedia.org/wiki/Colitis|https://en.wikipedia.org/wiki/Colitis
M-25	M-25		CCCC(CCC)C(=O)NCc1ccc2n(ncc2c1)-c1ccccc1OC	Preclinical		SMO|PTCH1|DHH|IHH	https://www.tocris.com/products/m-25_4917|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=671031|https://www.tocris.com/products/m-25_4917|https://www.tocris.com/products/m-25_4917	smoothened receptor antagonist			
A-939572	A-939572		CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1	Preclinical		SCD	https://www.tocris.com/products/a-939572_4845	stearoyl-CoA desaturase inhibitor			
raclopride	raclopride		CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC	Launched	https://clinicaltrials.gov/ct2/show/NCT02020408	DRD3|DRD2|HTR1A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=94|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=94|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=94	dopamine receptor antagonist			
tolbutamide	tolbutamide	orinase|orinase diagnostic	CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1	Launched	FDA Orange Book: tolbutamide, tolbutamide sodium	KCNJ1|KCNJ8|ABCC8|CYP2B6|CYP2C8|CYP2C19|KCNJ11	https://www.drugbank.ca/drugs/DB01124|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6848|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070448|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070448|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070448|ChEMBL	ATP channel blocker	endocrinology	diabetes mellitus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3995eed8-39ec-ce5e-8cc2-062f93445c8d&audience=consumer
ouabain	ouabain		C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O	Launched	http://www.drugbank.ca/drugs/DB01092	ATP1A1|ATP1A2|ATP1A3|ATP1A4|FXYD2|ATP1B1|ATP1B2|ATP1B3|ATP1B4	https://www.drugbank.ca/drugs/DB01092|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=280497|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=280497|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=280497|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=280497|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=280497|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=280497|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=280497|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=280497	ATPase inhibitor	cardiology|cardiology	hypertension|cardiac arrythmia	https://en.wikipedia.org/wiki/Ouabain#Medical_uses|https://en.wikipedia.org/wiki/Ouabain#Medical_uses
desmethylclozapine	desmethylclozapine	N-Demethylclozapine|Norclozapine|n-desmethylclozapine	Clc1ccc2Nc3ccccc3C(=Nc2c1)N1CCNCC1	Phase 2	https://www.clinicaltrials.gov/ct2/show/NCT00490516	DRD3|DRD2|HTR2C|HTR2A|CHRM1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=272499|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=272499|https://www.tocris.com/dispprod.php?ItemId=1303#.VyjH_mQrImI|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=272499|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=272499	acetylcholine receptor agonist			
ETP-45658	ETP-45658		Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1	Preclinical		PIK3CB|PIK3CA|PIK3CD|PIK3CG	https://www.tocris.com/products/etp-45658_4702|https://www.tocris.com/products/etp-45658_4702|https://www.tocris.com/products/etp-45658_4702|https://www.tocris.com/products/etp-45658_4702	PI3K inhibitor			
ST-1859	ST-1859		Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/16952488			antiamyloidogenic agent			
medronic-acid	medronic acid	medronic acid	OP(O)(=O)CP(O)(O)=O	Launched	https://www.drugs.com/pro/technetium-tc-99m-medronate.html			bone resorption inhibitor	radiology	skeletal imaging agent	https://www.drugs.com/mmx/technetium-tc-99m-medronate.html
lenalidomide	lenalidomide	CC-5013|CDC-501|revlimid	Nc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O	Launched	FDA Orange Book: lenalidomide	PTGS2|CRBN|TNF|TNFSF11|CDH5	https://www.drugbank.ca/drugs/DB00480|https://www.drugbank.ca/drugs/DB00480|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001255|https://www.drugbank.ca/drugs/DB00480|https://www.drugbank.ca/drugs/DB00480	anticancer agent	hematologic malignancy|hematologic malignancy|hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)|myelodysplastic diseases (MDS)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be
balaglitazone	balaglitazone	DRF-2593	Cn1c(COc2ccc(CC3SC(=O)NC3=O)cc2)nc2ccccc2c1=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00515632	PPARG|INS	http://www.apexbt.com/balaglitazone.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=274471	insulin sensitizer|PPAR receptor partial agonist			
cefonicid	cefonicid	monocid	O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1	Launched	FDA Orange Book: cefonicid sodium			bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections	http://www.drugbank.ca/drugs/DB01328
SYM-2081	SYM-2081	2S,4R-4-METHYLGLUTAMATE	C[C@H](C[C@H](N)C(O)=O)C(O)=O	Preclinical		GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|SLC1A2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4317|https://www.drugbank.ca/drugs/DB03425|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4317|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4317|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4317|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4317	kainate receptor antagonist			
alda-1	alda-1		Clc1cccc(Cl)c1C(=O)NCc1ccc2OCOc2c1	Preclinical		ALDH2	http://www.tocris.com/dispprod.php?ItemId=271579#.UuFIdP30BaE	aldehyde dehydrogenase activator			
CBiPES	CBiPES		CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N	Preclinical		GRM2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3372	glutamate receptor positive allosteric modulator			
MLN-8054	MLN-8054		OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00249301	AURKA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5696	Aurora kinase inhibitor			
racecadotril	racecadotril		CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1	Launched	http://www.drugs.com/international/Racecadotril.html	MME	http://www.genome.jp/dbget-bin/www_bget?dr:D08464	enkephalinase inhibitor	gastroenterology	diarrhea	https://en.wikipedia.org/wiki/Racecadotril
potassium-iodide	potassium iodide	iosat|potassium iodide|thyro-block|thyrosafe|thyroshield	[K].I	Launched	FDA Orange Book: potassium iodide				pulmonary|pulmonary|pulmonary	asthma|bronchitis|emphysema	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce81b927-49e8-4680-b5a9-8b3c09b1a2a7|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce81b927-49e8-4680-b5a9-8b3c09b1a2a7|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce81b927-49e8-4680-b5a9-8b3c09b1a2a7
phenolsulfonphthalein	phenolsulfonphthalein	phenol red|phenolsulphonphthalein|phenosulfophthalein	Oc1ccc(cc1)C1(OS(=O)(=O)c2ccccc12)c1ccc(O)cc1	Launched	http://www.drugs.com/international/phenolsulfonphthalein.html						
tofogliflozin	tofogliflozin		CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1	Launched	https://www.drugs.com/international/tofogliflozin.html	GCK|SLC5A2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000614|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=432224	sodium/glucose cotransporter inhibitor	endocrinology|endocrinology	diabetes mellitus|diabetes mellitus	https://en.wikipedia.org/wiki/Tofogliflozin|https://en.wikipedia.org/wiki/Tofogliflozin
isodibut	isodibut	4-NAPHTHALIMIDOBUTYRIC ACID	OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/8926708			aldehyde reductase inhibitor			
allopregnanolone	allopregnanolone		CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01673828	GABRA6|GABRB2|GABRA1|GABRA3|GABRA2|GABRA5|GABRA4|GABRG2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4108|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012876|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4108|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4108|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4108|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4108|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4108|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012876	GABA receptor positive allosteric modulator			
marbofloxacin	marbofloxacin		CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O	Veterinary Launched	http://www.drugs.com/international/Marbofloxacin.html			bacterial DNA gyrase inhibitor	infectious disease	gram-negative bacterial infections	https://en.wikipedia.org/wiki/Marbofloxacin
budesonide	budesonide	Rhinocort Aqua|S-1320|entocort ec|pulmicort|pulmicort flexhaler|pulmicort respules|rhinocort|rhinocort allergy|uceris		Launched	FDA Orange Book: budesonide	CYP3A7|CYP3A5|NR3C1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091057|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091057|ChEMBL	glucocorticoid receptor agonist	gastroenterology	Crohn's disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a578d93-087e-42f7-a258-a49afef41dea
quinagolide	quinagolide	Norprolac	CCCN1C[C@H](C[C@@H]2Cc3c(O)cccc3C[C@@H]12)NS(=O)(=O)N(CC)CC	Launched	https://www.drugs.com/international/quinagolide.html	DRD2|PRL	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001420|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=100826	dopamine receptor agonist	endocrinology	hyperprolactinemia	https://en.wikipedia.org/wiki/Quinagolide
cefamandole	cefamandole		Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](O)c1ccccc1)C2=O)C(O)=O	Launched	FDA Orange Book: cefamandole nafate			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease	skin infections|urinary tract infections|respiratory tract infections	https://en.wikipedia.org/wiki/Cefamandole|https://en.wikipedia.org/wiki/Cefamandole|https://en.wikipedia.org/wiki/Cefamandole
monoctanoin	monoctanoin	moctanin|monoctanoin component a	CCCCCCCC(=O)OCC(O)CO	Launched	FDA Orange Book: monoctanoin				gastroenterology	gallstones	https://en.wikipedia.org/wiki/Monoctanoin
NSC-4644	NSC-4644	Betulin	CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12	Phase 2	Integrity	SOAT1|PYGM	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=383816|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013813	ACAT inhibitor|sterol regulatory element binding protein (SREBP) inhibitor			
COR-170	COR-170		CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(ccc12)-c1ccccc1	Preclinical		CNR2	https://www.tocris.com/products/cor-170_4756	cannabinoid receptor inverse agonist			
ELN-441958	ELN-441958		Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1	Preclinical		BDKRB1	http://www.apexbt.com/eln441958.html	bradykinin receptor antagonist			
kifunensine	kifunensine		OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12	Phase 1	Pharmaprojects	MAN2A1|MAN1B1	https://www.drugbank.ca/drugs/DB02742|https://www.drugbank.ca/drugs/DB02742	mannosidase inhibitor			
brimonidine	brimonidine	UK-14304|alphagan|alphagan p|brimonidine tartrate|mirvaso|qoliana	Brc1c(NC2=NCCN2)ccc2nccnc12	Launched	FDA Orange Book: brimonidine tartrate	AOX1|ADRA2C|ADRA2A|ADRA2B	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090969|https://www.drugbank.ca/drugs/DB00484|https://www.drugbank.ca/drugs/DB00484|https://www.drugbank.ca/drugs/DB00484	adrenergic receptor agonist	ophthalmology|ophthalmology|ophthalmology	intraocular pressure|glaucoma|ocular hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ce6d79a-32c1-44dc-b50c-ada8848f39c3|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ce6d79a-32c1-44dc-b50c-ada8848f39c3|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ce6d79a-32c1-44dc-b50c-ada8848f39c3
plurisin-#1	plurisin-#1		O=C(NNc1ccccc1)c1ccncc1	Preclinical				stearoyl-CoA desaturase inhibitor			
SU-11274	SU-11274		CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1	Preclinical		MET	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5057	hepatocyte growth factor receptor inhibitor|tyrosine kinase inhibitor			
phenserine	phenserine		CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/23227991	ACHE|BCHE|APP	https://www.drugbank.ca/drugs/DB04892|https://www.drugbank.ca/drugs/DB04892|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=330103	acetylcholinesterase inhibitor|beta amyloid synthesis inhibitor			
CAY10505	CAY10505		Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1	Preclinical		PIK3CG	https://www.caymanchem.com/product/10009078	PI3K inhibitor			
KW-2449	KW-2449		O=C(N1CCNCC1)c1ccc(cc1)\C=C\c1n[nH]c2ccccc12	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00779480	AURKA|AURKB|FGFR1|ABL1|FLT3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5691|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5691|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=468664|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5691|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5691	Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor			
thiamine-pyrophosphate	thiamine-pyrophosphate	cocarboxylase	Cc1c(CCOP(O)(=O)OP(O)(O)=O)sc[n+]1Cc1cnc(C)nc1N	Launched	http://en.wikipedia.org/wiki/Thiamine_pyrophosphate						
LE-135	LE-135		CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C	Preclinical		RARB	https://www.caymanchem.com/app/template/Product.vm/catalog/14415/promo/emolecules	retinoid receptor agonist			
CH-5183284	CH-5183284		Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01948297	FGFR3|FGFR2|FGFR1	https://www.caymanchem.com/product/17120|https://www.caymanchem.com/product/17120|https://www.caymanchem.com/product/17120	fibroblast growth factor inhibitor			
eperisone	eperisone	eperisone hydrochloride	CCc1ccc(cc1)C(=O)C(C)CN1CCCCC1	Launched	http://www.drugs.com/international/Eperisone.html	CYP2J2	http://topics.sciencedirect.com/topics/page/Eperisone	acetylcholine receptor antagonist	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	amyotrophic lateral sclerosis (ALS)|spasms|head injury|spinal injury	https://drugs-pharmaceuticals.knoji.com/myonal-eperisone-50mg/|https://drugs-pharmaceuticals.knoji.com/myonal-eperisone-50mg/|https://drugs-pharmaceuticals.knoji.com/myonal-eperisone-50mg/|https://drugs-pharmaceuticals.knoji.com/myonal-eperisone-50mg/
bardoxolone	bardoxolone	2-CYANO-3,12-DIOXOOLEANA-1,9(11)-DIEN-28-OIC ACID|CDDO|RTA 401	CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O	Phase 1	http://adisinsight.springer.com/drugs/800011617	PPARG|NOS2|NFE2L2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2717|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005679|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=273031	nuclear factor erythroid derived|like (NRF2) activator			
carprofen	carprofen	RO 20-5720/000|Ro-20-5720-000|rimadyl	CC(C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21	Veterinary Launched	FDA Orange Book: carprofen	PTGS2|PTGS1	ChEMBL|https://www.drugbank.ca/drugs/DB00821	cyclooxygenase inhibitor	rheumatology	osteoarthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b17c13de-9141-4a87-b83a-74a19f9aad86
mCPP	mCPP	1-M-Chlorophenyl Piperazine Metabolite|chlorophenylpiperazine	Clc1cccc(c1)N1CCNCC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00605904	HTR6|HTR2B|HTR2A|HTR2C|HTR1E|HTR1D|HTR1A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003584|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=142|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=142|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=142|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=142|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=142|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003584	serotonin receptor agonist			
benzonatate	benzonatate	tessalon	CCCCNc1ccc(cc1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC	Launched	FDA Orange Book: benzonatate	SCN5A	https://www.drugbank.ca/drugs/DB00868	local anesthetic	pulmonary	cough suppressant	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abb4360a-4c52-45b6-9b80-df3c1bfc4c59
bephenium-hydroxynaphthoate	bephenium-hydroxynaphthoate	bephenium	C[N+](C)(CCOc1ccccc1)Cc1ccccc1	Launched	http://en.wikipedia.org/wiki/Bephenium_hydroxynaphthoate			anthelmintic agent	infectious disease	ascariasis	https://en.wikipedia.org/wiki/Bephenium_hydroxynaphthoate
MK-0893	MK-0893		COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02004886	GCGR	http://www.apexbt.com/mk-0893.html	glucagon receptor antagonist			
rimcazole	rimcazole		C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1	Phase 1	http://adisinsight.springer.com/drugs/800001129	SIGMAR1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DPR000097	sigma receptor antagonist			
cilostazol	cilostazol	OPC-13013|OPC-21|pletal	O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1	Launched	FDA Orange Book: cilostazol	PDE3B|PDE3A|CYP3A5|CYP2C19	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7148|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090133|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090133	phosphodiesterase inhibitor	cardiology	claudication	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ada307f1-b6b1-4b64-a060-5c254b1948f2
TC1	TC1		OC12C3C4C5C3C(C3C5CC4C13)N2CCc1cccc(F)c1	Preclinical		BACE1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.exec_form_pro_pr?p_par_pro=PRO_DRUG_NAME&p_val_pro=TC1&p_origen=PROD&p_oper_pro=AND&p_par_tar=&p_val_tar=&p_oper_tar=AND&p_par_ref=&p_val_ref=&p_oper_ref=AND&p_par_pat=&p_val_pat=&p_oper_pat=AND	beta-secretase inhibitor			
CDPPB	CDPPB		O=C(Nc1cc(nn1-c1ccccc1)-c1ccccc1)c1cccc(c1)C#N	Preclinical		GRM5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1422	glutamate receptor positive allosteric modulator			
D-4476	D-4476		NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1	Preclinical		CSNK1A1|CSNK1D|TGFB1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5940|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5940|http://www.tocris.com/dispprod.php?ItemId=5415#.UuFlDf30BaE	TGF beta receptor inhibitor			
GR-127935	GR-127935		COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1	Preclinical		HTR1D|HTR1A|HTR1B|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=14|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=14|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=14|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=14|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=14|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=14|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=14|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=14|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=14	serotonin receptor antagonist			
ipratropium	ipratropium	atrovent|atrovent hfa|ipratropium bromide	CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)c1ccccc1	Launched	FDA Orange Book: ipratropium bromide	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	https://www.drugbank.ca/drugs/DB00332|https://www.drugbank.ca/drugs/DB00332|https://www.drugbank.ca/drugs/DB00332|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=325|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=325	acetylcholine receptor antagonist	pulmonary|pulmonary|pulmonary|pulmonary	bronchospasm|chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=lf69f100f-c766-490f-9143-5e8e0c8cb7c9|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=lf69f100f-c766-490f-9143-5e8e0c8cb7c9|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=lf69f100f-c766-490f-9143-5e8e0c8cb7c9|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=lf69f100f-c766-490f-9143-5e8e0c8cb7c9
lenvatinib	lenvatinib	ER-203492-00|lenvima	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O	Launched	FDA Orange Book: lenvatinib mesylate	RET|FLT1|FLT4|PDGFRB|FGFR3|FGFR2|FGFR4|FGFR1|PDGFB|KIT|KDR	https://citeline.informa.com/?query=#/drugs/details/29926|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=343663|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7426|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=343663|https://citeline.informa.com/?query=#/drugs/details/29926|https://citeline.informa.com/?query=#/drugs/details/29926|https://citeline.informa.com/?query=#/drugs/details/29926|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=343663|https://citeline.informa.com/?query=#/drugs/details/29926|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=343663|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7426	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology	thyroid cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4bedd21-efde-44c6-9d9c-b48b78d7ed1e
methyclothiazide	methyclothiazide	aquatensen|enduron	CN1C(CCl)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O	Launched	FDA Orange Book: methyclothiazide	SLC12A1|SLC12A3|CA2|CA4|CA1	https://www.drugbank.ca/drugs/DB00232|ChEMBL|https://www.drugbank.ca/drugs/DB00232|https://www.drugbank.ca/drugs/DB00232|https://www.drugbank.ca/drugs/DB00232	chloride reabsorption inhibitor	cardiology|cardiology	hypertension|edema	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4910dad2-c533-4232-85bf-e6b0235379c2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4910dad2-c533-4232-85bf-e6b0235379c2
idramantone	idramantone		OC12CC3CC(C1)C(=O)C(C3)C2	Preclinical							
1s,2r-phenylpropanolamine	1s,2r-phenylpropanolamine		C[C@@H](N)[C@@H](O)c1ccccc1	Withdrawn				adrenergic receptor agonist			
tiotidine	tiotidine	ICI 125,211	CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N	Phase 2	Pharmaprojects	HRH2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3959	histamine receptor antagonist			
tempol	tempol	4-Hydroxy-Tempo	CC1(C)CC(O)CC(C)(C)N1O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00713154			free radical scavenger			
nuclomedone	nuclomedone		Clc1ccc(CC2C(=O)N=C3SCCN3C2=O)cc1	Phase 3	http://www.chemdrug.com/article/8/3284/16419374.html			immunosuppressant			
2-methyl-5-hydroxytryptamine	2-methyl-5-hydroxytryptamine		Cc1[nH]c2ccc(O)cc2c1CCN	Preclinical		HTR3B|HTR3A|HTR1F|HTR1E|HTR1D|HTR1B|HTR6	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=218|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=218|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=218|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=218|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=218|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=218|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003577	serotonin receptor agonist			
BMY-7378	BMY-7378		COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1	Preclinical		ADRA1A|ADRA1D|ADRA1B|HTR1A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9	adrenergic receptor antagonist|serotonin receptor antagonist			
GR-79236	GR-79236		OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12	Phase 1	Pharmaprojects	ADORA2A|ADORA1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3288|http://www.tocris.com/dispprod.php?ItemId=87264#.UtgrNf15mf0	adenosine receptor agonist			
astemizole	astemizole	GNF-Pf-2461|R 43,512|hismanal	COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	KCNH2|KCNH1|CYP2J2|HRH1|CYP3A5	https://www.drugbank.ca/drugs/DB00637|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2603|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091095|https://www.drugbank.ca/drugs/DB00637|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091095	histamine receptor antagonist			
naringeninic-acid	naringeninic acid	P-Coumaric Acid|coumaric acid	OC(=O)\C=C\c1ccc(O)cc1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/21198798	HCAR2|PTGR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5787|https://www.drugbank.ca/drugs/DB04066				
HA-966-(S)-(-)	(S)-(-)-HA-966		N[C@H]1CCN(O)C1=O	Preclinical		GRIA1	http://www.scbt.com/datasheet-361328.html	glutamate receptor antagonist			
SKA-31	SKA-31		Nc1nc2c(ccc3ccccc23)s1	Preclinical		KCNN4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2335	potassium channel activator			
rifabutin	rifabutin	mycobutin	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(c(O)c3C)c(O)c(NC(=O)\C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c1=NC3(CCN(CC(C)C)CC3)N=c21	Launched	FDA Orange Book: rifabutin	HSP90B1|CYP3A4|HSP90AA1	https://www.drugbank.ca/drugs/DB00615|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090506|https://www.drugbank.ca/drugs/DB00615	protein synthesis inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2026b67-4755-4236-96b6-a6b5e7399707
antimony-potassium	antimony-potassium		OC(=O)C1O[Sb]2OC(C(O[Sb]3OC1C(=O)O3)C(O)=O)C(=O)O2	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01380301						
NU-7026	NU-7026	LY-293646	O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1	Preclinical		PRKDC	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5959	DNA dependent protein kinase inhibitor|mTOR inhibitor|PI3K inhibitor			
OSI-420	OSI-420		COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO	Preclinical		EGFR	http://www.scbt.com/datasheet-212485-osi-420-free-base-desmethyl-erlotinib.html	EGFR inhibitor			
I-BZA	I-BZA		CCN(CC)CCNC(=O)c1ccc(I)cc1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/8326382						
phenacaine	phenacaine		CCOc1ccc(NC(C)=Nc2ccc(OCC)cc2)cc1	Launched	http://www.drugs.com/international/phenacaine.html			local anesthetic	neurology/psychiatry	local anesthetic	https://en.wikipedia.org/wiki/Phenacaine
VUF11207	VUF11207		COc1cc(cc(OC)c1OC)C(=O)N(CCC1CCCN1C)C\C(C)=C\c1ccccc1F	Preclinical		ACKR3	https://www.tocris.com/products/vuf-11207-fumarate_4780	CC chemokine receptor agonist			
AZD8330	AZD8330	ARRY-424704|ARRY-704|AZD-8330	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00454090			MEK inhibitor			
GW-6471	GW-6471	GW6471	CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F	Preclinical		PPARA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3440	PPAR receptor antagonist			
epomediol	epomediol		CC1(C)OC2(C)C(O)CC1CC2O	Launched	https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA1240&lpg=PA1240&dq=Clesidren&source=bl&ots=ephnhEuf7A&sig=Gwn9hlo9Gh0VxuoIfO2g8-5ttwU&hl=en&sa=X&ved=0ahUKEwjkq5j05_bQAhWKVxoKHVpWBQ4Q6AEI6QEwJA#v=onepage&q=Clesidren&f=false	CYP7A1	http://www.drug2gene.com/relation/CYP7A1-epomediol-100006528	cholesterol inhibitor			
orlistat	orlistat	RO 18-0647/002|Ro-18-0647-002|alli|lipstatin|orlipastat|tetrahydrolipstatin|xenical		Launched	FDA Orange Book: orlistat	DAGLB|DAGLA|FASN|PNLIP|LIPF|CNR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5277|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5277|ChEMBL|ChEMBL|ChEMBL|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009290	lipase inhibitor	endocrinology	weight-loss aid	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2d3bd73-f3af-4ea5-a57c-66b0004cfe4f
ascorbic-acid	ascorbic acid		OC[C@H](O)[C@H]1OC(=O)C(=O)C1O	Launched	FDA Orange Book: ascorbic acid	LCT|P3H1|P3H3|P3H2|ALKBH2|ALKBH3|P4HTM|PLOD3|PLOD2|PLOD1|DBH|P4HA1|KDM5D|PHYH|AKR1B1|OGFOD1|OGFOD2|TMLHE|BBOX1|EGLN3|EGLN1|EGLN2|SLC23A2|SLC23A1|PAM	https://www.drugbank.ca/drugs/DB00126|https://www.drugbank.ca/drugs/DB00126|https://www.drugbank.ca/drugs/DB00126|https://www.drugbank.ca/drugs/DB00126|https://www.drugbank.ca/drugs/DB00126|https://www.drugbank.ca/drugs/DB00126|https://www.drugbank.ca/drugs/DB00126|https://www.drugbank.ca/drugs/DB00126|https://www.drugbank.ca/drugs/DB00126|https://www.drugbank.ca/drugs/DB00126|https://www.drugbank.ca/drugs/DB00126|https://www.drugbank.ca/drugs/DB00126|https://www.drugbank.ca/drugs/DB00126|https://www.drugbank.ca/drugs/DB00126|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=274718|https://www.drugbank.ca/drugs/DB00126|https://www.drugbank.ca/drugs/DB00126|https://www.drugbank.ca/drugs/DB00126|https://www.drugbank.ca/drugs/DB00126|https://www.drugbank.ca/drugs/DB00126|https://www.drugbank.ca/drugs/DB00126|https://www.drugbank.ca/drugs/DB00126|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4532|https://www.drugbank.ca/drugs/DB00126|https://www.drugbank.ca/drugs/DB00126	antioxidant	endocrinology	scurvy	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdc0522c-57f0-488d-b4bb-1a3c35631949
amlodipine	amlodipine	amlodipine besylate|amvaz|norvasc	CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC	Launched	FDA Orange Book: amlodipine, amlodipine besylate, amlodipine maleate	CA1|CACNA2D3|CACNA2D1|ABCG2|CACNA1B|CACNA1C|CACNA1F|CACNA1D|CACNA1S|SMPD1|CACNB2|CACNB1	https://www.drugbank.ca/drugs/DB00381|https://www.drugbank.ca/drugs/DB00381|https://www.drugbank.ca/drugs/DB00381|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=109067|https://www.drugbank.ca/drugs/DB00381|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00381|https://www.drugbank.ca/drugs/DB00381|https://www.drugbank.ca/drugs/DB00381	calcium channel blocker	cardiology|cardiology|cardiology|cardiology	hypertension|chronic stable angina|vasospastic angina|coronary artery disease (CAD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cec7a02-b7a5-49e1-ab64-3a4dab4149d2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cec7a02-b7a5-49e1-ab64-3a4dab4149d2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cec7a02-b7a5-49e1-ab64-3a4dab4149d2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cec7a02-b7a5-49e1-ab64-3a4dab4149d2
ZD-2079	ZD-2079	talibegron	O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1	Phase 2	Pharmaprojects	ADRB3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001534	adrenergic receptor agonist			
propoxur	propoxur	Baygon	CNC(=O)Oc1ccccc1OC(C)C	Veterinary Launched	http://www.drugs.com/international/propoxur.html						
liraglutide	liraglutide	Ethane|Venoterpine|saxenda|victoza	CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(Cc1ccccc1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O	Launched	FDA Orange Book: liraglutide recombinant	GLP1R|INS|GCG	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1133|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=288055|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=288055	GLP receptor agonist	endocrinology|endocrinology	weight-loss aid|diabetes mellitus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4
foscarnet	foscarnet	Dihydroxyphosphinecarboxylic Acid Oxide|foscavir	OC(=O)P(O)(O)=O	Launched	FDA Orange Book: foscarnet sodium			DNA polymerase inhibitor	infectious disease|infectious disease|infectious disease	cytomegalovirus retinitis|acquired immunodeficiency syndrome (AIDS)|virus herpes simplex (HSV)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e177c228-33e1-4074-3e98-7d484c370e58|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e177c228-33e1-4074-3e98-7d484c370e58|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e177c228-33e1-4074-3e98-7d484c370e58
hydrocortisone-acetate	hydrocortisone acetate	GNF-Pf-4997|cortef acetate|cortifoam|cortril|hydrocortisone acetate|hydrocortone	CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3[C@@H](O)C[C@]12C	Launched	FDA Orange Book: hydrocortisone acetate	NR3C1|NR3C2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2868|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2868	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14dc356d-6c29-4d91-b78e-f5222cd163c0
PCI-24781	PCI-24781	S78454|abexinostat	CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT00724984	HDAC10|HDAC6|HDAC8|HDAC2|HDAC3|HDAC1	https://citeline.informa.com/?query=#/drugs/details/29190|http://www.selleckchem.com/products/PCI-24781.html|https://citeline.informa.com/?query=#/drugs/details/29190|http://www.selleckchem.com/products/PCI-24781.html|http://www.selleckchem.com/products/PCI-24781.html|http://www.selleckchem.com/products/PCI-24781.html	HDAC inhibitor			
ioversol	ioversol	MP 328|MP-328|optiray|optiray 160|optiray 240|optiray 300|optiray 320|optiray 350	OCCN(C(=O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I	Launched	FDA Orange Book: ioversol			radiopaque medium	radiology	contrast agent	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=549d38db-d4ed-4708-8f76-7cdaa157063f
cutamesine	cutamesine	[11C]SA4503	COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00551109	SIGMAR1	http://www.ncbi.nlm.nih.gov/pubmed/25270629	sigma receptor agonist			
molsidomine	molsidomine		CCOC(=O)Nc1c[n+](no1)N1CCOCC1	Launched	http://www.drugs.com/international/molsidomine.html	GUCY1A3	http://www.molbio.gu.se/courses/drug/imming.pdf	guanylate cyclase stimulant	cardiology	coronary artery disease (CAD)	http://www.drugs.com/international/molsidomine.html
tiprenolol	tiprenolol		CSc1ccccc1OCC(O)CNC(C)C	Phase 2	https://www.mysciencework.com/publication/show/4cdfba588cf15a96d2cef804996e0b90	ADRB1|ADRB2|ADRB3	http://www.genome.jp/dbget-bin/www_bget?dr:D06162|http://www.genome.jp/dbget-bin/www_bget?dr:D06162|http://www.genome.jp/dbget-bin/www_bget?dr:D06162	adrenergic receptor antagonist			
3,3'-diindolylmethane	3,3'-diindolylmethane		C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12	Phase 3				CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor			
BD-1008	BD-1008		CN(CCN1CCCC1)CCc1ccc(Cl)c(Cl)c1	Preclinical				sigma receptor antagonist			
mofezolac	mofezolac		COc1ccc(cc1)-c1noc(CC(O)=O)c1-c1ccc(OC)cc1	Launched	https://www.drugs.com/international/mofezolac.html	PTGS1	http://www.genome.jp/dbget-bin/www_bget?D01718	cyclooxygenase inhibitor	rheumatology|orthopedics	rheumatoid arthritis|osteoporosis	http://www.sciencedirect.com/topics/page/Mofezolac|http://www.sciencedirect.com/topics/page/Mofezolac
A-61603	A-61603		CS(=O)(=O)Nc1c(O)ccc2C(CCCc12)=C1NCCN1	Preclinical		ADRA1D|ADRA1A|ADRA1B	https://www.tocris.com/products/a-61603-hydrobromide_1052|https://www.tocris.com/products/a-61603-hydrobromide_1052|https://www.tocris.com/products/a-61603-hydrobromide_1052	adrenergic receptor agonist			
pridinol	pridinol	C-238|pridinol mesilate	OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1	Launched	http://www.drugs.com/international/pridinol.html			muscle relaxant	neurology/psychiatry	muscle relaxant	https://en.wikipedia.org/wiki/Pridinol
flopropione	flopropione	phloropropiophenone	CCC(=O)c1c(O)cc(O)cc1O	Launched	http://www.drugs.com/international/Flopropione.html	HTR1A	https://en.wikipedia.org/wiki/Flopropione	serotonin receptor antagonist	neurology/psychiatry	spasms	http://www.drugs.com/international/flopropione.html
basic-fuchsin	basic-fuchsin		CC1=CC(C=CC1=N)=C(c1ccc(N)cc1)c1ccc(N)cc1	Preclinical							
actinoquinol	actinoquinol		CCOc1ccc(c2cccnc12)S(O)(=O)=O	Preclinical							
camphor-(+)	(+)-camphor		CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2	Phase 2							
ganetespib	ganetespib	STA-9090	CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01798485	HSP90AA1|WT1	http://www.genome.jp/dbget-bin/www_bget?dr:D10126|https://citeline.informa.com/?query=#/drugs/details/34754	HSP inhibitor			
N-methylquipazine	N-methylquipazine	n-methylquipazine	CN1CCN(CC1)c1ccc2ccccc2n1	Preclinical		SLC6A4|HTR6|HTR3B|HTR3A|HTR2C|HTR2B|HTR2A|HTR1A|HTR1D	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003554|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003554|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=173|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=173|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=173|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=173|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=173|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003554|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003554	serotonin receptor agonist			
F-11440	F-11440	eptapirone	Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O	Phase 2	http://en.pharmacodia.com/web/drug/1_5748.html	HTR1A	https://en.wikipedia.org/wiki/Eptapirone	serotonin receptor agonist			
roxithromycin	roxithromycin	RU 28965|RU 965|Rulid|rulide	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	Launched	http://www.drugs.com/international/Roxithromycin.html	MLNR|ABCB1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1465|https://www.drugbank.ca/drugs/DB00778	bacterial 50S ribosomal subunit inhibitor	infectious disease|infectious disease|infectious disease	respiratory tract infections|urinary tract infections|skin infections	https://en.wikipedia.org/wiki/Roxithromycin|https://en.wikipedia.org/wiki/Roxithromycin|https://en.wikipedia.org/wiki/Roxithromycin
moxonidine	moxonidine	BDF5896|BE5895|CYNT|Physiotens|norcynt|nucynt	COc1nc(C)nc(Cl)c1NC1=NCCN1	Launched	http://www.drugs.com/international/Moxonidine.html	ADRA2B|ADRA2A|ADRA2C|NISCH	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004144|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004144|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004144|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090787	imidazoline receptor agonist	cardiology	hypertension	https://en.wikipedia.org/wiki/Moxonidine
amlexanox	amlexanox	AA-673|CHX 3673|CHX-3673|aphthasol	CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O	Launched	FDA Orange Book: amlexanox	IL3|S100A13|S100A12|FGF1|PDE4A|PDE4B|PDE4C|PDE4D	https://www.drugbank.ca/drugs/DB01025|https://www.drugbank.ca/drugs/DB01025|https://www.drugbank.ca/drugs/DB01025|https://www.drugbank.ca/drugs/DB01025|ChEMBL|ChEMBL|ChEMBL|ChEMBL	histamine receptor modulator	dental|pulmonary|ophthalmology|allergy	aphthous ulcers|asthma|conjunctivitis|allergic rhinitis	https://en.wikipedia.org/wiki/Amlexanox|https://en.wikipedia.org/wiki/Amlexanox|https://en.wikipedia.org/wiki/Amlexanox|https://en.wikipedia.org/wiki/Amlexanox
suritozole	suritozole	MDL 26,479	Cn1nc(-c2cccc(F)c2)n(C)c1=S	Phase 2	http://www.chemdrug.com/article/8/3285/16420450.html	ADORA1|GABBR1	https://citeline.informa.com/?query=#/drugs/details/17397|https://en.wikipedia.org/wiki/Suritozole	GABA receptor inverse agonist			
amiodarone	amiodarone	L-3428|Pacerone|SKF 33134-A|amiodarone hydrochloride|cordarone|nexterone	CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1	Launched	FDA Orange Book: amiodarone hydrochloride	CACNA2D2|KCNH2|KCNA7|CACNA1H|CYP2C8|SCN5A|CHRM3|ADRB1	https://www.drugbank.ca/drugs/DB01118|https://www.drugbank.ca/drugs/DB01118|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2566|https://www.drugbank.ca/drugs/DB01118|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091520|https://citeline.informa.com/?query=#/drugs/details/1460|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091520|https://www.drugbank.ca/drugs/DB01118	potassium channel blocker	cardiology	ventricular arrhythmias	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08641e51-abca-4c1c-ba19-d24435332018
dexchlorpheniramine	dexchlorpheniramine	dexchlorpheniramine maleate	CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1	Launched	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1950f4d6-7fc2-44cd-9f7d-1359315353fc			histamine receptor antagonist	allergy|allergy|allergy|cardiology	allergic conjunctivitis|allergic rhinitis|urticaria|angioedema	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1950f4d6-7fc2-44cd-9f7d-1359315353fc|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1950f4d6-7fc2-44cd-9f7d-1359315353fc|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1950f4d6-7fc2-44cd-9f7d-1359315353fc|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1950f4d6-7fc2-44cd-9f7d-1359315353fc
SB-772077B	SB-772077B		CCn1c(nc2cncc(C(=O)N3CC[C@H](N)C3)c12)-c1nonc1N	Preclinical		ROCK2|ROCK1	https://www.tocris.com/products/sb-772077b-dihydrochloride_4118|https://www.tocris.com/products/sb-772077b-dihydrochloride_4118	rho associated kinase inhibitor			
hesperidin	hesperidin		COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1	Launched	http://www.drugs.com/international/Hesperidin.html	CACNA1B	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011359	flavanone glycoside			
diphenyleneiodonium	diphenyleneiodonium		[I+]1c2ccccc2-c2ccccc12	Preclinical		ALDH7A1|XDH|ALDH5A1|ALDH1A2|ALDH2|NOX3|NOS2|NOS3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=393378|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=393378|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=393378|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=393378|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=393378|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=393378|https://www.caymanchem.com/product/81050|https://www.caymanchem.com/product/81050	nitric oxide synthase inhibitor			
olanzapine	olanzapine	LY-170053|zyprexa|zyprexa relprevv|zyprexa zydis	CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12	Launched	FDA Orange Book: olanzapine, olanzapine pamoate	GABRG2|GABRG1|GABRG3|GABRB1|GABRB3|GABRB2|GABRA2|GABRA1|GABRA4|GABRA3|GABRA6|GABRA5|HTR6|HTR7|HTR1D|HTR1E|HTR1F|HTR1A|HTR1B|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|ADRA2B|ADRA2C|ADRA2A|ADRA1A|ADRA1B|CYP2C8|HRH1|HRH2|HRH4|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD4|DRD5|DRD2|DRD3|DRD1|GABRQ|GABRP|GABRE|GABRD	https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=47|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|ChEMBL|https://www.drugbank.ca/drugs/DB00334|ChEMBL|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=177756|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|ChEMBL|https://www.drugbank.ca/drugs/DB00334|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334|https://www.drugbank.ca/drugs/DB00334	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry|neurology/psychiatry	schizophrenia|bipolar disorder	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=676ace4e-7706-742d-cab0-430dd1f83408|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=676ace4e-7706-742d-cab0-430dd1f83408
amfepramone	amfepramone	diethylpropion	CCN(CC)C(C)C(=O)c1ccccc1	Launched	http://en.wikipedia.org/wiki/Amfepramone	SLC6A3|SLC6A2	https://www.drugbank.ca/drugs/DB00937|https://www.drugbank.ca/drugs/DB00937	adrenergic receptor agonist	endocrinology	obesity	https://en.wikipedia.org/wiki/Amfepramone
farnesyl-thiosalicylic-acid-amide	farnesyl-thiosalicylic-acid-amide	S-Trans,Trans-Farnesylthiosalicylamide	CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00867230	HRAS	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401632/	Ras GTPase inhibitor			
sapropterin	sapropterin	daproterin|kuvan	C[C@H](O)[C@H](O)[C@H]1CNc2nc(N)nc(O)c2N1	Launched	FDA Orange Book: sapropterin dihydrochloride	NOS3|PAH|TPH1|DBH|TH	https://www.drugbank.ca/drugs/DB00360|https://www.drugbank.ca/drugs/DB00360|https://www.drugbank.ca/drugs/DB00360|https://citeline.informa.com/?query=#/drugs/details/16880|https://www.drugbank.ca/drugs/DB00360	phenylalanine 4-hydroxylase stimulant	metabolism	hyperphenylalaninemia (HPA)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af38711e-8873-4790-a92d-4d583e23fb89
dorzolamide	dorzolamide	trusopt	CCN[C@@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O	Launched	FDA Orange Book: dorzolamide hydrochloride	CA12|CA14|CA4|CA7|CA2|CA1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6810|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6810|https://www.drugbank.ca/drugs/DB00869|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6810|https://www.drugbank.ca/drugs/DB00869|https://www.drugbank.ca/drugs/DB00869	carbonic anhydrase inhibitor	ophthalmology|ophthalmology	intraocular pressure|glaucoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f00ee361-51ed-48aa-bf34-2df0af2e2ac3|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f00ee361-51ed-48aa-bf34-2df0af2e2ac3
NDT-9513727	NDT-9513727		CCCCn1c(CN(Cc2ccc3OCOc3c2)Cc2ccc3OCOc3c2)c(nc1-c1ccccc1)-c1ccccc1	Preclinical		C5AR1	https://www.tocris.com/products/ndt-9513727_3333	complement antagonist			
propiverine	propiverine	propiverine hydrochloride	CCCOC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1	Launched	https://www.drugs.com/international/propiverine.html	CHRM4|CHRM2|CHRM3|CHRM1|CACNA1C	https://citeline.informa.com/?query=#/drugs/details/14844|https://citeline.informa.com/?query=#/drugs/details/14844|https://citeline.informa.com/?query=#/drugs/details/14844|http://www.genome.jp/kegg-bin/ddi_list?drug=D08838|https://citeline.informa.com/?query=#/drugs/details/14844	acetylcholine receptor antagonist	urology	urinary incontinence	https://en.wikipedia.org/wiki/Propiverine
carbetapentane	carbetapentane	pentoxyverine	CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1	Launched	http://en.wikipedia.org/wiki/Pentoxyverine	CHRM2	https://en.wikipedia.org/wiki/Pentoxyverine#Mechanism_of_action	acetylcholine receptor antagonist	otolaryngology|otolaryngology|pulmonary	common cold|nasal congestion|bronchitis	https://en.wikipedia.org/wiki/Pentoxyverine|https://en.wikipedia.org/wiki/Pentoxyverine|https://en.wikipedia.org/wiki/Pentoxyverine
mebicar	mebicar		CN1C2C(N(C)C1=O)N(C)C(=O)N2C	Launched	http://en.wikipedia.org/wiki/Mebicar			anxiolytic	neurology/psychiatry	anxiety	http://rupharma.com/adaptol/
necrostatin-2	necrostatin-2		CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O	Preclinical		KRR1|RIPK2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=407826|http://www.apexbt.com/necrostatin-2.html	necroptosis inhibitor|RIPK inhibitor			
buphenine	buphenine	nylidrin	CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1	Launched	http://www.drugs.com/mmx/nylidrin-hydrochloride.html	ADRB2	http://en.wikipedia.org/wiki/Buphenine	adrenergic receptor agonist	rheumatology	Raynaud's disease	http://www.drugs.com/international/buphenine.html
S-Nitrosoglutathione	S-Nitrosoglutathione		N[C@@H](CCC(=O)N[C@@H](CS[N+][O-])C(=O)NCC(O)=O)C(O)=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01746784	PTPN1	http://www.ncbi.nlm.nih.gov/pubmed/10486138	nitric oxide stimulant			
necrostatin-1	necrostatin-1	Necrostatin	CN1C(=S)NC(Cc2c[nH]c3ccccc23)C1=O	Preclinical		KRR1|RIPK1|IDO1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=393468|http://www.tocris.com/dispprod.php?ItemId=141558#.Unfe0SRLEa0|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=393468	RIPK inhibitor			
adrafinil	adrafinil		ONC(=O)CS(=O)C(c1ccccc1)c1ccccc1	Launched	http://en.wikipedia.org/wiki/Adrafinil			adrenergic receptor agonist	neurology/psychiatry	fatigue	https://en.wikipedia.org/wiki/Adrafinil
fluticasone-propionate	fluticasone propionate	CCI 18781|CCI-18781|cutivate|flonase|flonase allergy relief|flovent|flovent diskus 100|flovent diskus 250|flovent diskus 50|flovent hfa|fluticasone|fluticasone propionate		Launched	FDA Orange Book: fluticasone propionate	PLA2G4A|CYP3A5|CYP3A7|PGR|NR3C2|NR3C1	https://www.drugbank.ca/drugs/DB00588|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=167983|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=167983|ChEMBL|https://www.drugbank.ca/drugs/DB00588|ChEMBL	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14c8d082-b301-8f09-a509-950459ae0a28
HQK-1001	HQK-1001	2,2-Dimethyl-Butyric Acid	CCC(C)(C)C(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01322269						
eprazinone	eprazinone	eprazinone hydrochloride	CCOC(CN1CCN(CC(C)C(=O)c2ccccc2)CC1)c1ccccc1	Launched	http://www.drugs.com/international/Eprazinone.html			mucolytic agent	pulmonary	bronchospasm	https://en.wikipedia.org/wiki/Bronchospasm
glutamine-(l)	glutamine-(l)	glutamine|l-glutamine|levoglutamide|nutrestore	N[C@@H](CCC(N)=O)C(O)=O	Launched	https://clinicaltrials.gov/ct2/show/NCT00647036	GPRC6A|CTPS1|PPAT|GLUL	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=723|https://www.drugbank.ca/drugs/DB00130|https://www.drugbank.ca/drugs/DB00130|https://www.drugbank.ca/drugs/DB00130		gastroenterology|dental|neurology/psychiatry|rheumatology|gastroenterology|gastroenterology|gastroenterology|neurology/psychiatry|neurology/psychiatry	diarrhea|mucositis|muscle pain|joint pain|peptic ulcer disease (PUD)|ulcerative colitis|Crohn's disease|anxiety|insomnia	http://www.webmd.com/vitamins-supplements/ingredientmono-878-glutamine.aspx?activeingredientid=878&|http://www.webmd.com/vitamins-supplements/ingredientmono-878-glutamine.aspx?activeingredientid=878&|http://www.webmd.com/vitamins-supplements/ingredientmono-878-glutamine.aspx?activeingredientid=878&|http://www.webmd.com/vitamins-supplements/ingredientmono-878-glutamine.aspx?activeingredientid=878&|http://www.webmd.com/vitamins-supplements/ingredientmono-878-glutamine.aspx?activeingredientid=878&|http://www.webmd.com/vitamins-supplements/ingredientmono-878-glutamine.aspx?activeingredientid=878&|http://www.webmd.com/vitamins-supplements/ingredientmono-878-glutamine.aspx?activeingredientid=878&|http://www.webmd.com/vitamins-supplements/ingredientmono-878-glutamine.aspx?activeingredientid=878&|http://www.webmd.com/vitamins-supplements/ingredientmono-878-glutamine.aspx?activeingredientid=878&
ampalex	ampalex	CX-516	O=C(N1CCCCC1)c1ccc2nccnc2c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00040443	GRIA4|GRIA1|GRIA2|GRIA3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4165|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4165|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4165|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4165	glutamate receptor agonist			
cis-exo-camphanediol-2,3	cis-exo-camphanediol-2,3		CC1(C)[C@H]2CC[C@]1(C)[C@@H](O)[C@H]2O	Phase 1				nitric oxide stimulant			
2-methoxyestradiol	2-methoxyestradiol		COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00328497	TNFRSF10B|CYP1B1|CYP1A1|TUBB|CASP3|HIF1A|CYP19A1|COMT	https://citeline.informa.com/?query=#/drugs/details/166|https://www.drugbank.ca/drugs/DB02342|https://www.drugbank.ca/drugs/DB02342|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000670|https://citeline.informa.com/?query=#/drugs/details/166|https://www.drugbank.ca/drugs/DB02342|https://www.drugbank.ca/drugs/DB02342|https://www.drugbank.ca/drugs/DB02342	hypoxia inducible factor inhibitor			
NS-11021	NS-11021		FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nnn[nH]2)cc(c1)C(F)(F)F	Preclinical		KCNMA1	https://www.tocris.com/products/ns-11021_4788	calcium-activated potassium channel activator			
butenafine	butenafine	lotrimin ultra|mentax|mentax-tc	CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12	Launched	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=167ecefd-4553-41b8-8160-81a48dbca076	SQLE	https://www.drugbank.ca/drugs/DB01091	fungal squalene epoxidase inhibitor	infectious disease|infectious disease|infectious disease	tinea pedis|tinea cruris|tinea corporis	https://en.wikipedia.org/wiki/Butenafine|https://en.wikipedia.org/wiki/Butenafine|https://en.wikipedia.org/wiki/Butenafine
perflubron	perflubron	PFOB|imagent|perfluorooctylbromide	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br	Launched	FDA Orange Book: perflubron			contrast agent	radiology	contrast agent	https://en.wikipedia.org/wiki/Perflubron
ethylnorepinephrine	ethylnorepinephrine		CCC(N)C(O)c1ccc(O)c(O)c1	Preclinical				bronchodilator			
ripazepam	ripazepam	CL-683	CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/780378	GABRA3|GABRA5|GABRA1|GABRA2	https://citeline.informa.com/?query=#/drugs/details/15713|https://citeline.informa.com/?query=#/drugs/details/15713|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012269|https://citeline.informa.com/?query=#/drugs/details/15713	benzodiazepine receptor agonist			
GDC-0810	GDC-0810		CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01823835	ESR1	https://elifesciences.org/content/5/e15828v1	selective estrogen receptor destabilizer			
lodoxamide	lodoxamide	alomide	OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N	Launched	FDA Orange Book: lodoxamide tromethamine			histamine receptor antagonist	ophthalmology	vernal keratoconjunctivitis (VKC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b97597f-f2e7-4574-81a8-f35b769c957a
D609	D609		SC(=S)OC1CC2CC1C1CCCC21	Preclinical				phospholipase inhibitor			
CP-775146	CP-775146		CC(C)c1ccc(CC(=O)N2CCC[C@H](C2)c2cccc(OC(C)(C)C(O)=O)c2)cc1	Preclinical		PPARA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6691	PPAR receptor agonist			
SR-2640	SR-2640		OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/1928658	CYSLTR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3329	leukotriene receptor antagonist			
obatoclax	obatoclax		COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01563601	MCL1|BCL2|BCL2L1	https://citeline.informa.com/?query=#/drugs/details/23933|http://www.selleckchem.com/products/Obatoclax-Mesylate.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=390240	BCL inhibitor			
radezolid	radezolid	RX-01_667	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cnn[nH]2)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00646958			bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor			
isocarboxazid	isocarboxazid	marplan	Cc1cc(no1)C(=O)NNCc1ccccc1	Launched	FDA Orange Book: isocarboxazid	MAOB|MAOA	ChEMBL|ChEMBL	monoamine oxidase inhibitor	neurology/psychiatry	depression	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac387aa0-3f04-4865-a913-db6ed6f4fdc5
fenoprofen	fenoprofen	fenoprofen calcium|nalfon	CC(C(O)=O)c1cccc(Oc2ccccc2)c1	Launched	FDA Orange Book: fenoprofen calcium	SLC5A8|PTGS1|PTGS2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4820|https://www.drugbank.ca/drugs/DB00573|https://www.drugbank.ca/drugs/DB00573	prostaglandin inhibitor	rheumatology|rheumatology	rheumatoid arthritis|osteoarthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef59e72f-6218-4f42-8f00-d10a6a14223a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef59e72f-6218-4f42-8f00-d10a6a14223a
indisulam	indisulam	E7070	NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00014625	CA14|CA12|CA5B|TP53|TOP2A|CDKN1A|CA6|CA7|CA1|CA2|CA4|CA9	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004666|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7046|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=234241|https://citeline.informa.com/?query=#/drugs/details/5999|https://citeline.informa.com/?query=#/drugs/details/5999|https://citeline.informa.com/?query=#/drugs/details/5999|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004666|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7046|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7046|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004666|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=234241|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004666	CDK inhibitor			
imetit	imetit		NC(=N)SCCc1c[nH]cn1	Preclinical		HRH3|HRH4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1250|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1250	histamine receptor agonist			
cefaclor	cefaclor	Cefaclor hydrate|ceclor|ceclor cd	N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1	Launched	FDA Orange Book: cefaclor			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|otolaryngology|otolaryngology	pneumonia|skin infections|urinary tract infections|respiratory tract infections|tonsillitis|pharyngitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=447da05c-c90f-40eb-a8d9-3e8c69e19c00|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=447da05c-c90f-40eb-a8d9-3e8c69e19c00|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=447da05c-c90f-40eb-a8d9-3e8c69e19c00|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=447da05c-c90f-40eb-a8d9-3e8c69e19c00|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=447da05c-c90f-40eb-a8d9-3e8c69e19c00|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=447da05c-c90f-40eb-a8d9-3e8c69e19c00
bemesetron	bemesetron		CN1C2CCC1CC(C2)OC(=O)c1cc(Cl)cc(Cl)c1	Phase 3	Adis	HTR3B|HTR3A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005712|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005712	serotonin receptor antagonist			
3-bromopyruvate	3-bromopyruvate	Bromopyruvic Acid|bromopyruvate		Preclinical		HK2	http://www.ncbi.nlm.nih.gov/pubmed/22382780	hexokinase inhibitor			
amprolium	amprolium		CCCc1ncc(C[n+]2ccccc2C)c(N)n1	Veterinary Launched	http://www.drugs.com/international/Amprolium.html			thiamine uptake blocker	infectious disease	coccidiosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49295a3c-eb73-4832-a8a3-5c1967accb4d
ARV-825	ARV-825		Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(OCCOCCOCCOCCNc3cccc4C(=O)N(C5CCC(=O)NC5=O)C(=O)c34)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1	Preclinical		BRD4	https://www.medchemexpress.com/ARV-825.html	bromodomain inhibitor			
SDM25N	SDM25N		CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(CC1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O	Preclinical		OPRD1	http://www.tocris.com/dispprod.php?ItemId=2024	opioid receptor antagonist			
cardionogen-1	cardionogen-1		C1CCC(CC1)c1nn2c(nnc2s1)-c1ccco1	Preclinical		CTNNB1	http://www.genecards.org/cgi-bin/carddisp.pl?gene=CTNNB1	WNT signaling inhibitor			
para-toluenesulfonamide	para-toluenesulfonamide	Paratoulene sulfonamide|p-toluenesulfonamide	Cc1ccc(cc1)S(N)(=O)=O	Phase 3	http://www.chictr.org/en/proj/show.aspx?proj=3665	CA3|CA2|CA6|CA9|CA12	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=333310|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004885|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004885|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004885|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004885				
simeprevir	simeprevir	olysio	COc1ccc2c(O[C@@H]3C[C@@H]4C(C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C	Launched	FDA Orange Book: simeprevir sodium	CYP3A4|CYP2C8|CYP1A2|SLCO1B3|CYP2C19	http://www.drugbank.ca/drugs/DB06290|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=445010|http://www.drugbank.ca/drugs/DB06290|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=445010|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=445010	HCV inhibitor	infectious disease	hepatitis C	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1816fd68-0ed7-4a37-84bb-e298c5ab6e28&audience=consumer
tetrahydrouridine	tetrahydrouridine		OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(O)NC1=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00978250	CDA	http://www.biovision.com/tetrahydrouridine-3011.html	cytidine deaminase inhibitor			
TGX-221	TGX-221		CC(Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1	Preclinical		PIK3CB|PIK3CD	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8244|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8244	PI3K inhibitor			
BMS-CCR2-22	BMS-CCR2-22		CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F	Preclinical		CCR2	https://www.tocris.com/products/bms-ccr2-22_3129	CC chemokine receptor antagonist			
phenacetin	phenacetin	acetophenetidin|acetphenetidin	CCOc1ccc(NC(C)=O)cc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	PTGS1	https://www.drugbank.ca/drugs/DB03783	cyclooxygenase inhibitor			
trimebutine	trimebutine	trimebutine maleate	CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1	Launched	http://www.drugs.com/international/Trimebutine.html	OPRD1|OPRM1|OPRK1|CHRM4|CHRM3|CHRM2|CHRM1	http://www.apexbt.com/trimebutine-28890.html|http://www.apexbt.com/trimebutine-28890.html|http://www.apexbt.com/trimebutine-28890.html|https://citeline.informa.com/?query=#/drugs/details/18486|https://citeline.informa.com/?query=#/drugs/details/18486|https://citeline.informa.com/?query=#/drugs/details/18486|https://citeline.informa.com/?query=#/drugs/details/18486	opioid receptor agonist	gastroenterology	irritable bowel syndrome	https://en.wikipedia.org/wiki/Trimebutine
N-alpha-Methylhistamine-dihydrochloride	N-alpha-Methylhistamine-dihydrochloride	N-Alpha-Methylhistamine|Nalpha-Methylhistamine	CNCCc1cnc[nH]1	Phase 3	Integrity	HRH4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1239	histamine receptor agonist			
indibulin	indibulin	D-24851|ZIO-301	Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT00726687			tubulin polymerization inhibitor			
CPI-169	CPI-169		CCS(=O)(=O)N1CCC(CC1)[C@@H](C)n1c(C)c(C(=O)NCc2c(OC)cc(C)[nH]c2=O)c2ccccc12	Preclinical		EZH2	http://www.apexbt.com/cpi-169.html	histone lysine methyltransferase inhibitor			
spiroxatrine	spiroxatrine	R 5188|spiroxamide	O=C1NCN(c2ccccc2)C11CCN(CC2COc3ccccc3O2)CC1	Preclinical		HTR1A|HTR2B|ADRA2C|ADRA2B|ADRA2A|ADRA1B|ADRA1D|ADRA1A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=53|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=53|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=53|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=53|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=53|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=53|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=53|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=53	serotonin receptor antagonist			
linsitinib	linsitinib	ASP-7487|OSI-906|OSI-906AA	C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00924989	IGF1R|INSRR|INSR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7423|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7423|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7423	IGF-1 inhibitor			
azaperone	azaperone	R 1929|stresnil|suicalm	Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1	Veterinary Launched	http://en.wikipedia.org/wiki/Azaperone	DRD2|DRD3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004148|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004148	dopamine receptor antagonist	neurology/psychiatry	sedative	https://en.wikipedia.org/wiki/Azaperone
corticosterone	corticosterone	11-b,21-Dihydroxypregn-3,20-dione|17-Deoxycortisol|Corticosteron|Preg-4-ene-3,20-dione,11-b,21-dihydroxy-	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO	Preclinical		HSD11B1|NR3C2|NCOA1	https://www.drugbank.ca/drugs/DB04652|https://www.drugbank.ca/drugs/DB04652|https://www.drugbank.ca/drugs/DB04652	mineralocorticoid receptor agonist			
SB-747651A	SB-747651A		CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N	Preclinical		AKT1|AKT3|ROCK1|RPS6KA4|RPS6KA5|RPS6KB1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005279|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005279|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005279|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=402814|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8130|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005279	kinase inhibitor			
VTP-27999	VTP-27999		CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01217736	REN	http://www.ncbi.nlm.nih.gov/pubmed/23460288	renin inhibitor			
PF-06463922	PF-06463922		CC1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01970865	ROS1|ALK|FES	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7476|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7476|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7476	ALK tyrosine kinase receptor inhibitor			
PF-03049423	PF-03049423		CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01208233	PDE5A	https://www.ncbi.nlm.nih.gov/pubmed/26738812	phosphodiesterase inhibitor			
2-Chloropyrazine	2-Chloropyrazine		Clc1cnccn1	Preclinical							
chlorindanol	chlorindanol	clorindanol	Oc1ccc(Cl)c2CCCc12	Preclinical							
thiazovivin	thiazovivin		O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1	Preclinical				rho associated kinase inhibitor			
8-M-PDOT	8-M-PDOT		CCC(=O)NC1CCc2cccc(OC)c2C1	Preclinical		MTNR1A|MTNR1B	http://www.tocris.com/dispprod.php?ItemId=2313#.VecTrdNViko|http://www.tocris.com/dispprod.php?ItemId=2313#.VecTrdNViko	melatonin receptor agonist			
isosteviol	isosteviol		C[C@]12C[C@@]3(CC1=O)CC[C@H]1[C@@](C)(CCC[C@@]1(C)C(O)=O)C3CC2	Phase 2	http://adisinsight.springer.com/drugs/800035468						
pentacosanoic-acid	pentacosanoic acid		CCCCCCCCCCCCCCCCCCCCCCCCC(O)=O	Preclinical							
methoxyphenamine	methoxyphenamine		CNC(C)Cc1ccccc1OC	Launched	http://www.drugs.com/international/methoxyphenamine.html			adrenergic receptor agonist	pulmonary	asthma	http://www.drugs.com/international/asthma.html
NE-100	NE-100		CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1	Phase 2	http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.1996.tb00299.x/abstract	SIGMAR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6679	sigma receptor antagonist			
Ro-10-5824	Ro-10-5824		Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1	Preclinical		DRD4	https://www.tocris.com/dispprod.php?ItemId=141942#.VyuhIWQrJZI	dopamine receptor agonist			
sulfaguanidine	sulfaguanidine	Ganidan|Resulfon|Suganyl|Sulfanilylguanidine|sulphaguanidine	NC(=N)NS(=O)(=O)c1ccc(N)cc1	Launched	http://www.drugs.com/international/Sulfaguanidine.html			bacterial antifolate	infectious disease	urinary tract infections	http://www.drugs.com/international/sulfaguanidine.html
tafamidis-meglumine	tafamidis-meglumine	FX-1006|tafamidis	OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1	Launched	http://en.wikipedia.org/wiki/Tafamidis	TTR	https://en.wikipedia.org/wiki/Tafamidis	transthyretin amyloid inhibitor	neurology/psychiatry	familial amyloid polyneuropathy (FAP)	https://en.wikipedia.org/wiki/Transthyretin-related_hereditary_amyloidosis
NVP-AUY922	NVP-AUY922	NVP-AUY922-NX|VER-52296|luminespib	CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01084330	HSP90AA1|HSP90AB1	https://en.wikipedia.org/wiki/NVP-AUY922|https://en.wikipedia.org/wiki/NVP-AUY922	HSP inhibitor			
alpha-tochopheryl-acetate	alpha-tochopheryl acetate	alpha-tochopheryl acetate	CC(C)CCCC(C)CCCC(C)CCCC1(C)CCc2c(C)c(OC(C)=O)c(C)c(C)c2O1	Launched	http://en.wikipedia.org/wiki/Alpha-Tocopherol			antioxidant	endocrinology	vitamin E deficiency	https://en.wikipedia.org/wiki/Alpha-Tocopherol
procodazole	procodazole		OC(=O)CCc1nc2ccccc2[nH]1	Preclinical				immunostimulant			
bis(maltolato)oxovanadium(IV)	bis(maltolato)oxovanadium(IV)		Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/19162329	PTPN1	http://www.enzolifesciences.com/BML-PR131/bmov/	tyrosine phosphatase inhibitor			
stepronin	stepronin	tiofacic	CC(SC(=O)c1cccs1)C(=O)NCC(O)=O	Launched	http://www.ndrugs.com/?s=broncoplus			mucolytic agent			
chiniofon	chiniofon		Oc1c(I)cc(c2cccnc12)S(O)(=O)=O	Launched	http://www.drugs.com/international/chiniofon.html			antiprotozoal agent	infectious disease	amebiasis	http://www.drugs.com/dict/chiniofon.html
GBR-13069	GBR-13069		Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1	Preclinical		SLC6A3	http://www.scbt.com/datasheet-203966-gbr-13069-dihydrochloride.html	dopamine uptake inhibitor			
apocynin	apocynin	Acetovanillone	COc1cc(ccc1O)C(C)=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00992667	NOX3|NOX4	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=351858|http://www.mdpi.com/1420-3049/18/3/2821	NADPH oxidase inhibitor			
diacetamate	diacetamate		CC(=O)Nc1ccc(OC(C)=O)cc1	Preclinical							
GW-3965	GW-3965		OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1	Preclinical		ABCA1|NR1H2|NR1H3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=317876|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2754|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2754	LXR agonist			
E-2012	E-2012			Phase 1	http://www.eisai.com/news/news200818.html	PSENEN|APP|APH1A|APH1B	https://www.drugbank.ca/drugs/DB05171|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=425832|https://www.drugbank.ca/drugs/DB05171|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000107	gamma secretase modulator			
7-aminocephalosporanic-acid	7-aminocephalosporanic acid		CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O	Preclinical				beta lactamase inhibitor			
dichlorisone-acetate	dichlorisone acetate	dichlorisone|dichlorisone acetate|diloderm	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/14052165						
4SC-202	4SC-202		Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01344707	HDAC1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DPR000166	HDAC inhibitor			
fenigam	fenigam		NCC(CC(O)=O)c1ccccc1	Launched	http://en.wikipedia.org/wiki/Phenibut	GABBR1|GABBR2	https://en.wikipedia.org/wiki/Phenibut|https://en.wikipedia.org/wiki/Phenibut	benzodiazepine receptor agonist	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	posttraumatic stress disorder|anxiety|depression	https://en.wikipedia.org/wiki/Phenibut|https://en.wikipedia.org/wiki/Phenibut|https://en.wikipedia.org/wiki/Phenibut
zotepine	zotepine	Lodopin|Losizopilon|Nipolept|Setous	CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12	Launched	http://www.drugs.com/international/Zotepine.html	HTR2A|HTR2C|HTR1E|HTR1D|HTR1A|HTR1B|HTR6|HTR7|ADRA2B|HRH1|SLC6A4|SLC6A2|DRD2|DRD4|DRD3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=103|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=103|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=103|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=103|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=103|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=103|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=103|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=103|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=103|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=103|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=103|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=103|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=103|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=103|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=103	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry	schizophrenia	https://en.wikipedia.org/wiki/Zotepine
sulfamethoxazole	sulfamethoxazole	RO 4-2130|Ro-4-2130|Sinomin|Suphamethoxazole|Urobak|acetylsulfamethoxazole|gantanol|gantanol-ds|sulfamethoxazole sodium|sulphamethoxazole	Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1	Launched	FDA Orange Book: sulfamethoxazole			PABA antagonist	infectious disease|gastroenterology|infectious disease	pneumonia|enteritis|urinary tract infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b89b5502-ce87-45a6-a43c-9891da3cfca4&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b89b5502-ce87-45a6-a43c-9891da3cfca4&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b89b5502-ce87-45a6-a43c-9891da3cfca4&audience=consumer
tocainide	tocainide	W-36095|tonocard	CC(N)C(=O)Nc1c(C)cccc1C	Launched	FDA Orange Book: tocainide hydrochloride	SCN5A	https://www.drugbank.ca/drugs/DB01056	sodium channel blocker	cardiology	cardiac arrythmia	http://www.drugs.com/mtm/tocainide.html
oxacyclohexadecan-2-one	oxacyclohexadecan-2-one		O=C1CCCCCCCCCCCCCCO1	Preclinical				protein kinase inhibitor			
SKF-81297	SKF-81297		Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1	Preclinical		DRD1|DRD5	http://en.wikipedia.org/wiki/SKF-81,297|http://en.wikipedia.org/wiki/SKF-81,297	dopamine receptor agonist			
cortisone	cortisone		C[C@]12CC(=O)C3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@]2(O)C(=O)CO	Launched	FDA Orange Book: cortisone acetate, fludrocortisone acetate, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone cypionate, hydrocortisone probutate, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydrocortisone valerate	NR3C1	http://en.wikipedia.org/wiki/Cortisone	glucocorticoid receptor agonist	gastroenterology|rheumatology|dermatology|rheumatology|dermatology	ulcerative colitis|rheumatoid arthritis|psoriasis|joint inflammation|eczema	https://en.wikipedia.org/wiki/Cortisone|https://en.wikipedia.org/wiki/Cortisone|https://en.wikipedia.org/wiki/Cortisone|https://en.wikipedia.org/wiki/Cortisone|https://en.wikipedia.org/wiki/Cortisone
ambazone	ambazone		NC(=N)N=Nc1ccc(NNC(S)=N)cc1	Phase 1	Pharmaprojects			DNA damage inducer			
diclofensine	diclofensine		COc1ccc2C(CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/3725890?dopt=Abstract	DRD1|MAOA|MAOB|SLC6A3	https://www.caymanchem.com/product/15355|https://www.caymanchem.com/product/15355|https://www.caymanchem.com/product/15355|https://citeline.informa.com/?query=#/drugs/details/5622	dopamine reuptake inhibitor			
cephalothin	cephalothin	Seffin|cefalotin|keflin	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1cccs1)C2=O)C(O)=O	Launched	FDA Orange Book: cephalothin sodium			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease	skin infections|surgical prophylaxis	http://www.drugs.com/ingredient/cephalothin.html|http://www.drugs.com/ingredient/cephalothin.html
retapamulin	retapamulin	altabax	C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C	Launched	FDA Orange Book: retapamulin			protein synthesis inhibitor	infectious disease	impetigo	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7acc17e7-7041-46bf-f2b2-a615cbf99da6
tyrphostin-AG-825	tyrphostin-AG-825		COc1cc(\C=C(/C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O	Preclinical		ERBB2	https://www.caymanchem.com/app/template/Product.vm/catalog/10010243	protein tyrosine kinase inhibitor			
talipexole	talipexole		Nc1nc2CCN(CC=C)CCc2s1	Launched	http://www.drugs.com/international/Talipexole.html	HTR3A|DRD2|ADRA2A	https://www.tocris.com/dispprod.php?ItemId=5360#.V-GHZJMrKYU|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001406|https://www.tocris.com/dispprod.php?ItemId=5360#.V-GHZJMrKYU	adrenergic receptor agonist|dopamine receptor agonist	infectious disease	genitial herpes	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7758c9c7-b4c7-3c7c-e0d9-0a78e9c276ff
GSK2578215A	GSK2578215A		Fc1cc(ccn1)-c1ccc(OCc2ccccc2)c(c1)C(=O)Nc1cccnc1	Preclinical		LRRK2	https://www.tocris.com/products/gsk2578215a_4629	leucine rich repeat kinase inhibitor			
tyrphostin-A9	Tyrphostin A9	Tyrphostin A9	CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C	Preclinical				protein tyrosine kinase inhibitor|tyrosine kinase inhibitor			
methimazole	methimazole	tapazole|thiamazole	Cn1cc[nH]c1=S	Launched	FDA Orange Book: methimazole	TPO	ChEMBL	antithyroid agent	endocrinology	hyperthyroidism	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc92f45f-8d27-4dcb-b72d-6b8b04c6f0ce
robalzotan	robalzotan		NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/11249580	HTR1A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=72	serotonin receptor antagonist			
penfluridol	penfluridol	MCN-JR-16,341|Micefal|R 16,341|semap	OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F	Launched	http://www.drugs.com/international/Penfluridol.html	CACNA1G|DRD2|DRD1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001108|https://citeline.informa.com/?query=#/drugs/details/14245|https://citeline.informa.com/?query=#/drugs/details/14245	T-type calcium channel blocker	neurology/psychiatry	schizophrenia	http://www.medindia.net/doctors/drug_information/penfluridol.htm
droxinostat	droxinostat		Cc1cc(Cl)ccc1OCCCC(=O)NO	Preclinical		HDAC8|HDAC6	http://www.selleckchem.com/products/Droxinostat.html?gclid=CPHgpJ2l47oCFag7OgodEykAEQ|http://www.selleckchem.com/products/Droxinostat.html?gclid=CPHgpJ2l47oCFag7OgodEykAEQ	HDAC inhibitor			
GPBAR-A	GPBAR-A		Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12	Preclinical		GPBAR1	https://www.tocris.com/products/gpbar-a_4478	G protein coupled receptor agonist			
trans-2-Undecenoic-acid	trans-2-Undecenoic acid		CCCCCCCC\C=C\C(O)=O	Preclinical							
halazone	halazone		OC(=O)c1ccc(cc1)S(=O)(=O)N(Cl)Cl	Launched	http://www.drugs.com/international/halazone.html						
voxtalisib	voxtalisib	SAR-245409|XL-765|XL765	CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O	Phase 2	https://www.clinicaltrials.gov/ct2/show/NCT01403636	MTOR|PIK3CA	http://www.selleckchem.com/products/XL765(SAR245409).html?gclid=CLuP9JH0xcwCFUokhgodHGIO6w|http://www.selleckchem.com/products/XL765(SAR245409).html?gclid=CLuP9JH0xcwCFUokhgodHGIO6w	mTOR inhibitor|PI3K inhibitor			
cytochlor	cytochlor		Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00077051						
AT13387	AT13387	ATI13387X|onalespib	CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01294202	HSP90AA1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000057	HSP antagonist			
citric-acid	citric acid	E330|Urologic G|citric acid	OC(=O)CC(O)(CC(O)=O)C(O)=O	Preclinical		RNASE1|RNASE3|PDE5A|APRT|PLEKHA1|LSM6|PKD2L1|CPB1|MIF|UCK2|HS3ST3A1|SRC|MDH2|IL4I1|CS|CA4|C8G|BHMT|HGS|TNFSF13B|AKR1B1|CTDSP1|GNMT|ITPA|ANG	https://www.drugbank.ca/drugs/DB04272|https://www.drugbank.ca/drugs/DB04272|https://www.drugbank.ca/drugs/DB04272|https://www.drugbank.ca/drugs/DB04272|https://www.drugbank.ca/drugs/DB04272|https://www.drugbank.ca/drugs/DB04272|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2478|https://www.drugbank.ca/drugs/DB04272|https://www.drugbank.ca/drugs/DB04272|https://www.drugbank.ca/drugs/DB04272|https://www.drugbank.ca/drugs/DB04272|https://www.drugbank.ca/drugs/DB04272|https://www.drugbank.ca/drugs/DB04272|https://www.drugbank.ca/drugs/DB04272|https://www.drugbank.ca/drugs/DB04272|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004954|https://www.drugbank.ca/drugs/DB04272|https://www.drugbank.ca/drugs/DB04272|https://www.drugbank.ca/drugs/DB04272|https://www.drugbank.ca/drugs/DB04272|https://www.drugbank.ca/drugs/DB04272|https://www.drugbank.ca/drugs/DB04272|https://www.drugbank.ca/drugs/DB04272|https://www.drugbank.ca/drugs/DB04272|https://www.drugbank.ca/drugs/DB04272	coagulation factor inhibitor			
setiptiline	setiptiline	setiptiline maleate	CN1CCC2=C(C1)c1ccccc1Cc1ccccc21	Launched	http://www.drugs.com/international/Setiptiline.html	HTR2A|HTR2C|HRH1	https://en.wikipedia.org/wiki/Setiptiline|https://en.wikipedia.org/wiki/Setiptiline|https://en.wikipedia.org/wiki/Setiptiline	adrenergic receptor antagonist	neurology/psychiatry	depression	https://en.wikipedia.org/wiki/Setiptiline
KRN-633	KRN-633		CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl	Preclinical		KDR|FLT1|FLT4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6057|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6057|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6057	VEGFR inhibitor			
SM-164	SM-164		CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@@H]4CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1	Preclinical		XIAP|BIRC2|BIRC3|CASP9|CASP3	http://www.medkoo.com/products/6998|http://www.medkoo.com/products/6998|http://www.medkoo.com/products/6998|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=434356|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=434356	XIAP inhibitor			
epacadostat	epacadostat		NS(=O)(=O)NCCNc1nonc1\C(Nc1ccc(F)c(Br)c1)=N\O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02752074	IDO1	https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=685310	indoleamine 2,3-dioxygenase inhibitor			
barasertib-HQPA	barasertib-HQPA	AZD-1152-HQPA|Barasertib	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT00952588	AURKB|AURKC	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5663|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=426270	Aurora kinase inhibitor			
GR46611	GR46611	GR-4661	COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1	Preclinical		HTR1D	https://www.tocris.com/dispprod.php?ItemId=1430#.Vyj9bWQrImI	serotonin receptor agonist			
rosoxacin	rosoxacin	Eradacil|WIN 35,213|acrosoxacin|roxadyl	CCn1cc(C(O)=O)c(=O)c2ccc(cc12)-c1ccncc1	Launched	https://www.drugs.com/international/rosoxacin.html			topoisomerase inhibitor	infectious disease	urinary tract infections	https://en.wikipedia.org/wiki/Rosoxacin
azomycin-(2-nitroimidazole)	azomycin-(2-nitroimidazole)	Azomycin	[O-][N+](=O)c1ncc[nH]1	Preclinical				protein synthesis inhibitor			
IU1	IU1		Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1	Preclinical		USP14	http://www.sigmaaldrich.com/catalog/product/sigma/i1911?lang=en&region=US	ubiquitin C-terminal hydrolase inhibitor			
erastin	erastin		CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1	Preclinical		VDAC2	http://www.axonmedchem.com/product/1825erastin.html	ion channel antagonist			
droperidol	droperidol	Dridol|Droleptan|MCN-JR-4749|R-4749|inapsine	Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O	Launched	FDA Orange Book: droperidol	HTR2A|ADRA1A|DRD3|DRD4|DRD2	ChEMBL|https://www.drugbank.ca/drugs/DB00450|ChEMBL|ChEMBL|ChEMBL	dopamine receptor antagonist	gastroenterology|gastroenterology	nausea|vomiting	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b99a44df-ff38-4602-68ab-9bef1ff3af83|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b99a44df-ff38-4602-68ab-9bef1ff3af83
aloin	aloin	Aloin A	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12	Preclinical				angiogenesis inhibitor			
abacavir	abacavir	Epzicom|ziagen	Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1	Launched	FDA Orange Book: abacavir sulfate			nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80c1702a-973c-436a-90f8-69b29674dca0
7-chlorokynurenic-acid	7-chlorokynurenic acid	7-Chlorokynurenic Acid	OC(=O)c1cc(O)c2ccc(Cl)cc2n1	Preclinical		GRIN1|GRIN2C|GRIN2B|GRIN2A	http://www.tocris.com/dispprod.php?ItemId=2157#.VecNktNViko|http://www.tocris.com/dispprod.php?ItemId=2157#.VecNktNViko|http://www.tocris.com/dispprod.php?ItemId=2157#.VecNktNViko|http://www.tocris.com/dispprod.php?ItemId=2157#.VecNktNViko	glutamate receptor antagonist			
nafadotride	nafadotride		CCCCN1CCCC1CNC(=O)c1cc(C#N)c2ccccc2c1OC	Preclinical		HTR1A|DRD3|DRD2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=44|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=44|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=44	dopamine receptor antagonist			
tyloxapol	tyloxapol			Launched	FDA Orange Book: tyloxapol	LPL|NFKB2	https://www.drugbank.ca/drugs/DB06439|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000254	NFkB pathway inhibitor			
sobetirome	sobetirome	GC-1|QRX-431	CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01787578	THRB|THRA	https://www.drugbank.ca/drugs/DB07425|https://www.drugbank.ca/drugs/DB07425	thyroid hormone receptor agonist			
tideglusib	tideglusib	NP-031112|NP-12	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01350362	GSK3B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6929	glycogen synthase kinase inhibitor			
10-hydroxycamptothecin	10-hydroxycamptothecin	10-Hydroxy Camptothecin|10-Hydroxy-Camptothecin|10-Hydroxycamptothecine|Hydroxycamptothecin	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O	Preclinical		TOP1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000028	topoisomerase inhibitor			
TWS-119	TWS-119		Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1	Preclinical		GSK3B|JUN|MYC	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5980|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014447|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014447	glycogen synthase kinase inhibitor			
bucladesine	bucladesine	bucladesine sodium		Launched	http://www.drugs.com/international/bucladesine.html	PRKACA	http://www.selleckchem.com/products/bucladesine-sodium-salt.html	adenosine receptor agonist|cAMP stimulant	dermatology	skin ulcer	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332354/
PHA-767491	PHA-767491		O=C1NCCc2[nH]c(cc12)-c1ccncc1	Preclinical		CDK1|RPS6KB1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007421|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007421	CDC inhibitor			
PD-0325901	PD-0325901		OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F	Phase 2	https://www.clinicaltrials.gov/ct2/show/NCT02096471	MAP2K2|MAP2K1	https://citeline.informa.com/?query=#/drugs/details/34738|https://www.drugbank.ca/drugs/DB07101	MEK inhibitor			
BMS-927711	BMS-927711	rimegepant	N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01430442	CALCRL|CALCA	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=729510|http://www.apexbt.com/bms-927711.html	calcitonin antagonist			
ingenol-mebutate	ingenol mebutate	PEP-005|ingenol mebutate|picato	C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C	Launched	FDA Orange Book: ingenol mebutate	PRKCG|PRKCB|PRKCA|PRKCE|PRKCD	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7443|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7443|https://www.drugbank.ca/drugs/DB05013|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7443|https://www.drugbank.ca/drugs/DB05013	PKC activator	dermatology	actinic keratosis (AK)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5accc7a5-8209-4680-b0ae-2a6963500419
eugenol	eugenol		COc1cc(CC=C)ccc1O	Launched	http://www.drugs.com/international/eugenol.html	AR|MAOA	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010687|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=296404	androgen receptor antagonist	dental	toothache	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=138e7e95-0865-4b4d-bbdb-1e9700db4aa0
NVP-BGJ398	NVP-BGJ398	BGJ-398|infigratinib	CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01820364	FGFR2|FGFR3|FGFR4|FGFR1|KDR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7877|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7877|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7877|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7877|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7877	FGFR inhibitor			
nimodipine	nimodipine	BAY E 9736|BAY-E-9736|nimotop|nymalize	COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C	Launched	FDA Orange Book: nimodipine	NR3C2|CFTR|AHR|CACNA1S|CACNA1D|CACNA1C|CACNA1F|CACNB3|CACNB2|CACNB4|CACNB1	ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2523|https://www.drugbank.ca/drugs/DB00393|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00393|https://www.drugbank.ca/drugs/DB00393|https://www.drugbank.ca/drugs/DB00393|https://www.drugbank.ca/drugs/DB00393	calcium channel blocker	hematology	hemorrhage	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83e0df20-c3b1-4139-9679-f7c7661f5caa
oseltamivir-phosphate	oseltamivir phosphate	Oseltamivir Carboxylate|RO 640796|oseltamivir|tamiflu	CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1	Launched	FDA Orange Book: oseltamivir phosphate	NEU1|NEU2|CES1	https://www.drugbank.ca/drugs/DB00198|https://www.drugbank.ca/drugs/DB00198|https://www.drugbank.ca/drugs/DB00198	neuraminidase inhibitor	infectious disease	influenza A virus infection	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=644ddc43-b2fa-44bd-aeb7-2547defb85e0
demeclocycline	demeclocycline	declomycin|demeclocycline hydrochloride	CN(C)[C@H]1[C@@H]2C[C@@H]3[C@H](O)c4c(Cl)ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O	Launched	FDA Orange Book: demeclocycline hydrochloride			bacterial 30S ribosomal subunit inhibitor	endocrinology|infectious disease|infectious disease|infectious disease|ophthalmology|urology|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	fever|respiratory tract infections|psittacosis|trachoma|conjunctivitis|urethritis|chancroid|cholera|syphilis|listeria|anthrax|actinomycosis|tularemia|brucellosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b
efloxate	efloxate		CCOC(=O)COc1ccc2c(c1)oc(cc2=O)-c1ccccc1	Preclinical				vasodilator			
butylscopolamine-bromide	butylscopolamine bromide		CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@@H](CO)c1ccccc1	Launched	http://en.wikipedia.org/wiki/Butylscopolamine			cholinergic receptor antagonist	gastroenterology	abdominal pain	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=858926e9-457e-47c2-b7c4-2d1c6bb13ea8
ISO-1	ISO-1		COC(=O)CC1CC(=NO1)c1ccc(O)cc1	Preclinical		MIF	https://www.drugbank.ca/drugs/DB07888	macrophage migration inhibiting factor inhibitor			
indatraline	indatraline	(r,s)-indatraline	CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1	Preclinical		SLC6A2|SLC6A3|SLC6A4|MAOB|MAOA	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=106538|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=106538|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=106538|https://en.wikipedia.org/wiki/Indatraline|https://en.wikipedia.org/wiki/Indatraline	norepinephrine transporter inhibitor			
efinaconazole	efinaconazole	KP-103|jublia	C[C@@H](N1CCC(=C)CC1)C(O)(Cn1cncn1)c1ccc(F)cc1F	Launched	FDA Orange Book: efinaconazole	CYP51A1	https://en.wikipedia.org/wiki/Lanosterol_14_alpha-demethylase	lanosterol demethylase inhibitor	infectious disease	onychomycosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=922d4d25-c530-11e1-9b21-0800200c9a66
N6-methyladenosine	N6-methyladenosine	6-Methylaminopurine Riboside	CNc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Preclinical							
NTNCB	NTNCB		[O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNCC2CCc3ccccc3C2)CC1	Preclinical		NPY5R	http://www.tocris.com/dispprod.php?ItemId=113643#.UnhEZxaBNhM	neuropeptide receptor antagonist			
tosedostat	tosedostat	CHR-2797	CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00780598	NPEPPS|LAP3|ANPEP	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000085|http://www.tocris.com/dispprod.php?ItemId=230685|http://www.tocris.com/dispprod.php?ItemId=230685	peptidase inhibitor			
DFB	DFB	1,2-Bis(3-Fluorobenzylidene)Hydrazine	Fc1cccc(c1)\C=N\N=C\c1cccc(F)c1	Preclinical		GRM5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1424	glutamate receptor agonist			
ticagrelor	ticagrelor	brilinta	CCCSc1nc(N[C@@H]2C[C@@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@H](O)[C@H]3O)c2n1	Launched	FDA Orange Book: ticagrelor	CYP3A5|P2RY12	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=283279|https://www.drugbank.ca/drugs/DB08816	purinergic receptor antagonist	cardiology|cardiology	acute coronary syndrome (ACS)|myocardial infarction	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8&audience=consumer
TCN201	TCN201		Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1	Preclinical		GRIN2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7846	glutamate receptor antagonist			
LDN-57444	LDN-57444		CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12	Preclinical				ubiquitin C-terminal hydrolase inhibitor			
tamibarotene	tamibarotene	Amnoid	CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12	Launched	http://www.drugs.com/international/Tamibarotene.html	RARB|RARA	https://www.drugbank.ca/drugs/DB04942|https://www.drugbank.ca/drugs/DB04942	retinoid receptor agonist	hematologic malignancy	acute promyelocytic leukemia (APL)	http://www.drugbank.ca/drugs/DB04942
CKI-7	CKI-7		NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12	Preclinical		CSNK1G2	https://www.drugbank.ca/drugs/DB03693	casein kinase inhibitor			
acetyl-11-keto-beta-boswellic-acid	acetyl-11-keto-beta-boswellic acid		C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)C4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)(C5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/19918712	HSD11B1|HSD11B2|ABCB1|ALOX5	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010341|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010341|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=150518|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=150518	lipoxygenase inhibitor			
OCO-1112	OCO-1112		CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O	Phase 2	Pharmaprojects			cholesterol inhibitor			
atglistatin	atglistatin		CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C	Preclinical				adipose triglyceride lipase inhibitor			
AZD9668	AZD9668		Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00703391	ELANE	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6476	elastase inhibitor			
ADD-233089	ADD-233089		Clc1ccc(cc1)N1CC(=NC1=O)N1CCOCC1	Phase 1	http://ec.europa.eu/health/documents/community-register/2013/20130225125304/anx_125304_en.pdf			benzodiazepine receptor agonist			
berberine	berberine		COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT02084004	ACHE|LDLR|CYP2E1|CYP2C19|PTPN1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070019|http://www.ncbi.nlm.nih.gov/pubmed/17767919|http://www.sciencedirect.com/science/article/pii/S1002007109002883|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070019|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070019|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070019	LDL receptor activator			
nutlin-3	nutlin-3	Rac-Nutlin-3		Preclinical		MDM2|TP53	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006637|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006637	MDM inhibitor			
pipobroman	pipobroman	A-8103|vercyte	BrCCC(=O)N1CCN(CC1)C(=O)CCBr	Launched	FDA Orange Book: pipobroman			DNA alkylating agent	hematology|hematology	polycythemia vera|thrombocythemia	http://www.ncbi.nlm.nih.gov/pubmed/14565648|http://www.ncbi.nlm.nih.gov/pubmed/14565648
bretazenil	bretazenil	RO 16-6028/000	CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/8905533	GABRA1|GABRA4|GABRA5|GABRA2|GABRA3|GABRA6	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4146|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4146|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4146|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4146|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4146|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4146	GABA benzodiazepine site receptor partial agonist			
ITX3	ITX3		Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1	Preclinical		TRIO	https://www.medchemexpress.com/itx3.html	GEF inhibitor			
BVT-2733	BVT-2733		CN1CCN(CC1)C(=O)Cc1csc(NS(=O)(=O)c2cccc(Cl)c2C)n1	Preclinical		HSD17B1|HSD11B1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009534|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=321182	11-beta hydroxysteroid dehydrogenase inhibitor			
ketoconazole	ketoconazole	extina|nizoral|nizoral a-d|xolegel		Launched	FDA Orange Book: ketoconazole	KCNA10|AR|CYP21A2|CYP19A1|CYP3A7|CYP3A5|CYP2C19	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2568|https://www.drugbank.ca/drugs/DB01026|https://www.drugbank.ca/drugs/DB01026|https://www.drugbank.ca/drugs/DB01026|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=116505|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=116505|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=116505	sterol demethylase inhibitor	dermatology	seborrheic dermatitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b65f632-a98d-400e-9ec3-84dea581d6a3
PhiKan-083	PhiKan-083		CCn1c2ccccc2c2cc(CNC)ccc12	Preclinical		TP53	https://www.drugbank.ca/drugs/DB08363	p53 stabilizing agent			
TMN-355	TMN-355		Fc1cccc(Cl)c1C(=O)NC(=O)NC1c2ccccc2-c2ccccc12	Preclinical		PPIA	https://www.tocris.com/products/tmn-355_4152	cyclophilin inhibitor			
perifosine	perifosine		CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01002248	AKT1|PIK3CA	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000194|https://citeline.informa.com/?query=#/drugs/details/14311	AKT inhibitor			
U-54494A	U-54494A		CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1	Preclinical		OPRK1	http://www.tocris.com/dispprod.php?ItemId=1956#.VhQCaRNViko	opioid receptor agonist			
OSI-027	OSI-027		COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00698243	MTOR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001095	mTOR inhibitor			
sorafenib	sorafenib	BAY 43-9006|BAY-43-9006|nexavar	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1	Launched	FDA Orange Book: sorafenib tosylate	FLT4|FLT3|FLT1|DDR2|KIT|KDR|BRAF|RET|PDGFRB|SLCO1B3|RAF1|FGFR1|PDGFB|CYP3A5|CYP2C8|CYP2B6	https://www.drugbank.ca/drugs/DB00398|https://www.drugbank.ca/drugs/DB00398|https://www.drugbank.ca/drugs/DB00398|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5711|https://www.drugbank.ca/drugs/DB00398|https://www.drugbank.ca/drugs/DB00398|https://www.drugbank.ca/drugs/DB00398|https://www.drugbank.ca/drugs/DB00398|https://www.drugbank.ca/drugs/DB00398|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=301618|https://www.drugbank.ca/drugs/DB00398|https://www.drugbank.ca/drugs/DB00398|https://citeline.informa.com/?query=#/drugs/details/15581|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=301618|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=301618|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=301618	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology|oncology|oncology	renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0&audience=consumer
tezacaftor	tezacaftor	VX-661	CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO	Launched	FDA Orange Book: tezacaftor	CFTR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=695945	CFTR channel agonist	pulmonary	cystic fibrosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=302ae804-37db-44fd-ac2f-3dbdeda9aa4b
BHQ	BHQ	Di-Tert-Butylhydroquinone	CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C	Preclinical		ATP2A1	https://www.drugbank.ca/drugs/DB04638	ATPase inhibitor			
acrylate	acrylate		[Na].OC(=O)C=C	Phase 3	Pharmaprojects			mucus protecting agent			
nizofenone	nizofenone	nizofenone fumarate	CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O	Launched	http://www.drugs.com/international/Nizofenone fumarate.html			ion channel antagonist	neurology/psychiatry	stroke	https://en.wikipedia.org/wiki/Nizofenone
dexloxiglumide	dexloxiglumide		CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00220090	CCKAR	https://www.drugbank.ca/drugs/DB04856	CCK receptor antagonist			
SB-742457	SB-742457	GSK742457|RVT-101|intepirdine	O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02586909	HTR6	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000391	serotonin receptor antagonist			
PK-11195	PK-11195		CCC(C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00205595	TSPO|NR1I3|NR1I2	https://www.tocris.com/dispprod.php?ItemId=1804#.VyuUBmQrJZI|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=284279|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=284279	benzodiazepine receptor antagonist			
MK-5046	MK-5046		O[C@@](Cc1nc(CC2(CC2)C(F)(F)F)c[nH]1)(c1ccc(cc1)-n1cccn1)C(F)(F)F	Preclinical		NMBR|BRS3|GRPR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6170|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6170|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6170	bombesin receptor agonist			
cefuroxime-axetil	cefuroxime-axetil	ceftin	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OC(C)OC(C)=O)c1ccco1	Launched	FDA Orange Book: cefuroxime axetil			bacterial cell wall synthesis inhibitor	otolaryngology|otolaryngology|otolaryngology|otolaryngology	pharyngitis|tonsillitis|otitis|sinusitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=faef39e9-d793-4191-a728-310f6fab759d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=faef39e9-d793-4191-a728-310f6fab759d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=faef39e9-d793-4191-a728-310f6fab759d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=faef39e9-d793-4191-a728-310f6fab759d
WZ4003	WZ4003		CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1	Preclinical		NUAK1|NUAK2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8047|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8047	AMPK inhibitor			
eprosartan	eprosartan	SK&F 108566|SK&F-108566|SK-108566|teveten	CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O	Launched	FDA Orange Book: eprosartan mesylate	AGTR1	https://www.drugbank.ca/drugs/DB00876	angiotensin receptor antagonist	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64fbc500-3b77-4c9c-8576-b3ec5f6655a5
noretynodrel	noretynodrel		C[C@]12CCC3C(CCC4=C3CCC(=O)C4)C1CC[C@@]2(O)C#C	Launched	FDA Orange Book: norethynodrel	PGR	http://en.wikipedia.org/wiki/Norethynodrel	progestogen hormone	endocrinology	contraceptive	https://en.wikipedia.org/wiki/Noretynodrel
chlorothymol	chlorothymol	monochlorothymol	CC(C)c1cc(Cl)c(C)cc1O	Launched	http://www.drugs.com/international/chlorothymol.html						
florfenicol	florfenicol	Fluorothiamphenicol|SCH 25298		Veterinary Launched	http://www.drugs.com/international/Florfenicol.html			protein synthesis inhibitor	pulmonary	bovine respiratory disease (BRD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=edb7a8d8-21d1-4279-892c-8e2ae5425bbe
PD-156707	PD-156707		COc1ccc(cc1)C(=O)C(\Cc1cc(OC)c(OC)c(OC)c1)=C(/C(O)=O)c1ccc2OCOc2c1	Preclinical		EDNRB|EDNRA	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004349|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=999	endothelin receptor antagonist			
1,3-dipropyl-8-phenylxanthine	1,3-dipropyl-8-phenylxanthine		CCCn1c2[nH]c(nc2c(=O)n(CCC)c1=O)-c1ccccc1	Preclinical				adenosine receptor antagonist			
talmapimod	talmapimod	SCIO 469|SCIO-469	C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C	Phase 2	https://www.clinicaltrials.gov/show/NCT00095680	MAPK11|MAPK14	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7817|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7817	p38 MAPK inhibitor			
pyrazinamide	pyrazinamide	pyrazinecarboxamide	NC(=O)c1cnccn1	Launched	FDA Orange Book: pyrazinamide	FASN	https://en.wikipedia.org/wiki/Pyrazinamide	fatty acid synthase inhibitor	infectious disease	tuberculosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257bd8cf-74d7-45db-bf25-354a8d26634e
doxifluridine	doxifluridine		C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O	Launched	http://www.drugs.com/international/Doxifluridine.html	TYMS	https://www.caymanchem.com/product/10253	thymidylate synthase inhibitor	oncology	colorectal cancer	http://www.drugs.com/international/doxifluridine.html
eniluracil	eniluracil	776C85	Oc1ncc(C#C)c(O)n1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00003873	DPYD|AOX1|XDH	https://www.drugbank.ca/drugs/DB03516|https://www.drugbank.ca/drugs/DB03516|https://www.drugbank.ca/drugs/DB03516	dihydropyrimidine dehydrogenase inhibitor			
ID-1101	ID-1101	4-Hydroxy Isoleucine	C[C@H](O)[C@H](C)[C@H](N)C(O)=O	Phase 1	http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=160603	INSR|INS	https://citeline.informa.com/?query=#/drugs/details/26151|http://prodinra.inra.fr/?locale=fr#!ConsultNotice:73643	insulin sensitizer			
pantethine	pantethine			Launched	http://www.drugs.com/international/pantethine.html			coenzyme A precursor			
naringenin	naringenin	NSC-11855	Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01091077	ESR2|HSD17B1|CYP19A1|CYP1B1|GLO1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007019|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007019|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007019|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007019|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007019	aromatase inhibitor|TRPV antagonist			
LY2452473	LY2452473	LY-2452473	CC(C)OC(=O)N[C@@H]1Cc2c(C1)c1cc(ccc1n2Cc1ccccn1)C#N	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01160289	AR	https://www.ncbi.nlm.nih.gov/pubmed/22961682	androgen receptor modulator			
saroglitazar	saroglitazar		CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02265276	PPARG|PPARA	https://en.wikipedia.org/wiki/Saroglitazar|https://en.wikipedia.org/wiki/Saroglitazar	PPAR receptor agonist			
UBP-310	UBP-310		Cc1cn(C[C@H](N)C(O)=O)c(=O)n(Cc2ccsc2C(O)=O)c1=O	Preclinical		GRIK1|GRIK5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4334|https://www.tocris.com/products/ubp-310_3621	glutamate receptor antagonist			
palmitoleic-acid	Palmitoleic Acid	Palmitoleic Acid|Palmitoleicacid	CCCCCC\C=C/CCCCCCCC(O)=O	Preclinical		ACE2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=697750				
dipraglurant	dipraglurant	ADX48621	Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01336088	GRM5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6452	glutamate receptor negative allosteric modulator			
hydroxyprogesterone-acetate	hydroxyprogesterone acetate		CC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O	Launched	https://en.wikipedia.org/wiki/Hydroxyprogesterone_acetate	SRD5A2|SRD5A1|PGR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=671121|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=671121|https://en.wikipedia.org/wiki/Hydroxyprogesterone_acetate	progesterone receptor agonist			
tolnaftate	tolnaftate	SCH 10144|aftate|dr. scholl's athlete's foot spray|tinactin|tritin	CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1	Launched	http://www.drugs.com/international/Tolnaftate.html			fungal squalene epoxidase inhibitor	infectious disease|infectious disease	tinea pedis|tinea corporis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4e306cb-c65a-4620-ada7-44db88de98f8&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4e306cb-c65a-4620-ada7-44db88de98f8&audience=consumer
butyl-paraben	butyl-paraben	butyl p-hydroxybenzoate|butyl parahydroxybenzoate|butylparaben	CCCCOC(=O)c1ccc(O)cc1	Preclinical				DNA synthesis inhibitor			
artesunate	artesunate		C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	Launched	http://www.drugs.com/international/Artesunate.html			DNA synthesis inhibitor	infectious disease	malaria	https://en.wikipedia.org/wiki/Artesunate
LDN-212854	LDN-212854		C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12	Preclinical		ACVRL1|RIPK2|ACVR1|ABL1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=822277|http://www.sigmaaldrich.com/catalog/product/sigma/sml0965?lang=en&region=US|http://www.sigmaaldrich.com/catalog/product/sigma/sml0965?lang=en&region=US|http://www.sigmaaldrich.com/catalog/product/sigma/sml0965?lang=en&region=US	bone morphogenic protein inhibitor			
LRRK2-IN-1	LRRK2-IN-1		COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1	Preclinical		LRRK2	https://www.tocris.com/dispprod.php?ItemId=298334#.V-rQa5MrLy8	leucine rich repeat kinase inhibitor			
sparfloxacin	sparfloxacin	AT-4140|CI-978|Spara|zagam	C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	TOP2A	https://www.drugbank.ca/drugs/DB01208	bacterial DNA gyrase inhibitor			
PSB-603	PSB-603		CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1	Preclinical		ADORA2A|ADORA2B|ADORA1|ADORA3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3284|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3284|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3284|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3284	adenosine receptor antagonist			
dapivirine	dapivirine	AIDS-105293|R-147681|TMC-120	Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01337570	CYP2C19|CYP2B6|CYP2C8|CYP3A5|CYP3A4	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=281553|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=281553|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=281553|http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807636/figure/F10/|http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807636/figure/F10/	non-nucleoside reverse transcriptase inhibitor			
SX-011	SX-011		CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1	Preclinical		MAPK14	https://www.tocris.com/dispprod.php?ItemId=235472#.VyyxxmQrJZI	MAP kinase inhibitor			
targinine	targinine		CNC(=N)NCCC[C@H](N)C(O)=O	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/14707556	NOS2|NOS3	https://citeline.informa.com/?query=#/drugs/details/17911|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000151	nitric oxide synthase inhibitor			
josamycin	josamycin		CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC(=O)CC(C)C)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O	Launched	http://www.drugs.com/international/Josamycin.html			bacterial 50S ribosomal subunit inhibitor	pulmonary	bronchitis	https://en.wikipedia.org/wiki/Josamycin
bromhexine	bromhexine		CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1	Launched	http://en.wikipedia.org/wiki/Bromhexine			mucolytic agent	pulmonary	chest congestion	https://en.wikipedia.org/wiki/Bromhexine
LY266097	LY266097		COc1ccc(CC2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC	Preclinical		HTR2B	https://www.tocris.com/products/ly-266097-hydrochloride_4081	serotonin receptor antagonist			
BIBU-1361	BIBU-1361		CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1	Preclinical		EGFR	http://www.tocris.com/dispprod.php?ItemId=149465#.UngakhaBNhM	EGFR inhibitor			
bupranolol	bupranolol	B 1312 [AS HYDROCHLORIDE]|KL-255 [AS HYDROCHLORIDE]|bupranol|bupranolol hydrochloride	Cc1ccc(Cl)c(OCC(O)CNC(C)(C)C)c1	Launched	http://en.wikipedia.org/wiki/Bupranolol	ADRB1|ADRB2|ADRB3	https://www.drugbank.ca/drugs/DB08808|https://www.drugbank.ca/drugs/DB08808|https://www.drugbank.ca/drugs/DB08808	adrenergic receptor antagonist	cardiology|ophthalmology	hypertension|glaucoma	https://en.wikipedia.org/wiki/Bupranolol|https://en.wikipedia.org/wiki/Bupranolol
stiripentol	stiripentol	BCX 2600	CC(C)(C)C(O)\C=C\c1ccc2OCOc2c1	Launched	https://www.drugs.com/international/stiripentol.html	GABRA3|SCN3A|SCN1A|ABAT	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652007/|https://citeline.informa.com/?query=#/drugs/details/17252|https://citeline.informa.com/?query=#/drugs/details/17252|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090358	GABA uptake inhibitor	neurology/psychiatry	epilepsy	https://en.wikipedia.org/wiki/Stiripentol
AZD3759	AZD3759		COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02228369	EGFR	http://www.selleckchem.com/products/azd3759.html	EGFR inhibitor			
aminohydroxybutyric-acid	aminohydroxybutyric acid	gamma-amino-beta-hydroxybutyric acid	NCC(O)CC(O)=O	Launched	http://en.wikipedia.org/wiki/Gamma-Amino-beta-hydroxybutyric_acid				neurology/psychiatry	epilepsy	https://en.wikipedia.org/wiki/Gamma-Amino-beta-hydroxybutyric_acid
ditiocarb-sodium-trihydrate	ditiocarb-sodium-trihydrate	Diethyldithiocarbamate|ditiocarb	CCN(CC)C(S)=S	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/8094001	CYP2E1|CA1|CA2|CA4	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090807|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009118|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009118|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009118	immunostimulant			
rosmarinic-acid	Rosmarinic acid	Rosmarinic acid	OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1	Launched	https://clinicaltrials.gov/ct2/show/NCT01380015	MCL1|TYR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011370|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011370	GABA transaminase inhibitor			
BF2.649	BF2.649	Pitolisant|Tiprolisant	Clc1ccc(CCCOCCCN2CCCCC2)cc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01036139	HRH3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009090	histamine receptor antagonist			
ulipristal	ulipristal	ella	CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12	Launched	FDA Orange Book: ulipristal acetate	PGR	https://www.drugbank.ca/drugs/DB05366	progesterone receptor antagonist	endocrinology	contraceptive	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=052bfe45-c485-49e5-8fc4-51990b2efba4
azlocillin	azlocillin	azlin		Launched	FDA Orange Book: azlocillin sodium			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease	gram-positive bacterial infections|gram-negative bacterial infections	https://en.wikipedia.org/wiki/Azlocillin|https://en.wikipedia.org/wiki/Azlocillin
roquinimex	roquinimex	FCF 89|LS 2616|Linomide	CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/10849523			angiogenesis inhibitor|tumor necrosis factor production inhibitor			
brompheniramine	brompheniramine	BPN|Bromfed|Bromfenex|Dimetapp|Lodrane|dimetane|dimetane-ten	CN(C)CCC(c1ccc(Br)cc1)c1ccccn1	Launched	FDA Orange Book: brompheniramine maleate, dexbrompheniramine maleate	CHRM5|CHRM3|CHRM4|CHRM1|CHRM2|HRH1	https://www.drugbank.ca/drugs/DB00835|https://www.drugbank.ca/drugs/DB00835|https://www.drugbank.ca/drugs/DB00835|https://www.drugbank.ca/drugs/DB00835|https://www.drugbank.ca/drugs/DB00835|https://www.drugbank.ca/drugs/DB00835	histamine receptor antagonist	allergy|otolaryngology	allergic rhinitis|common cold	https://en.wikipedia.org/wiki/Brompheniramine|https://en.wikipedia.org/wiki/Brompheniramine
naratriptan	naratriptan	amerge	CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1	Launched	FDA Orange Book: naratriptan hydrochloride	HTR1E|HTR1D|HTR1F|HTR1A|HTR1B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=45|https://www.drugbank.ca/drugs/DB00952|https://www.drugbank.ca/drugs/DB00952|https://www.drugbank.ca/drugs/DB00952|https://www.drugbank.ca/drugs/DB00952	serotonin receptor agonist	neurology/psychiatry	migraine headache	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1524990-2757-44bb-a044-dbe92ff9caaa
SR-1078	SR-1078		OC(C(F)(F)F)(C(F)(F)F)c1ccc(cc1)NC(=O)c1ccc(cc1)C(F)(F)F	Preclinical		RORC|RORA	https://www.tocris.com/products/sr-1078_4874|https://www.tocris.com/products/sr-1078_4874	retinoid receptor agonist			
FK-3311	FK-3311		CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1	Phase 2	Pharmaprojects	PTGS2	https://www.tocris.com/dispprod.php?ItemId=64004#.Vyj0HGQrImI	cyclooxygenase inhibitor			
temozolomide	temozolomide	CCRG-81045|M&B 39831|M&B-39831|M-39831|SCH 52365|SCH-52365|Temodal|temodar	Cn1nnc2c(ncn2c1=O)C(N)=O	Launched	FDA Orange Book: temozolomide	TOP2A|MGMT	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=108485|https://en.wikipedia.org/wiki/Temozolomide	DNA alkylating agent	oncology|oncology	glioblastoma|astrocytoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c8529ec-8936-4fec-a1a5-2b285c7e4859&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c8529ec-8936-4fec-a1a5-2b285c7e4859&audience=consumer
cisatracurium	cisatracurium		COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC	Launched	FDA Orange Book: cisatracurium besylate	CHRNA2	https://www.drugbank.ca/drugs/DB00565	acetylcholine receptor antagonist	neurology/psychiatry|critical care	muscle relaxant|endotracheal intubation	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f78a07e2-0d3b-4460-b29e-8c10c90afbda|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f78a07e2-0d3b-4460-b29e-8c10c90afbda
PF-04136309	PF-04136309		O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01226797			CC chemokine receptor antagonist			
CDK1-5-inhibitor	CDK1-5-inhibitor	Quinoxaline1	Nc1n[nH]c2nc3ccccc3nc12	Preclinical		GSK3B|CDK5|CDK1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5947|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5947|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5947	CDK inhibitor|glycogen synthase kinase inhibitor			
orteronel	orteronel		CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01809691	CYP17A1	https://en.wikipedia.org/wiki/Orteronel	androgen biosynthesis inhibitor|androgen receptor antagonist|cytochrome P450 inhibitor			
CDBA	CDBA		OCC1OC2OC3C(CO)OC(OC4C(CO)OC(OC5C(CO)OC(OC6C(CO)OC(OC7C(CO)OC(OC8C(CO)OC(OC1C(O)C2O)C(O)C8O)C(O)C7O)C(O)C6O)C(O)C5O)C(O)C4O)C(O)C3O	Phase 3	Pharmaprojects						
tosufloxacin	tosufloxacin	ABBOTT-61827|Ozex|tosufloxacin tosilate	NC1CCN(C1)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F	Launched	http://www.drugs.com/international/Tosufloxacin.html			bacterial DNA gyrase inhibitor	infectious disease	gram-negative bacterial infections	http://www.drugs.com/international/tosufloxacin.html
lanatoside-c	lanatoside c		C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)C(CCC3C2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	Preclinical				cardiac glycoside			
benzyl-alcohol	benzyl alcohol	E1519|benzyl alcohol|phenylcarbinol|ulesfia	OCc1ccccc1	Launched	FDA Orange Book: benzyl alcohol			local anesthetic	infectious disease	virus herpes simplex (HSV)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f86b5de9-8e44-4d06-890e-75f7e71c79e4
ursolic-acid	ursolic acid		C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O	Phase 1	http://www.chictr.org/en/proj/show.aspx?proj=3231	CASP3|PTPN1|HSD11B1|PYGM|STS|ACHE|PLA2G1B	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=277911|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007423|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007423|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007423|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=277911|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=277911|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007423	ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor			
lauric-acid	Lauric Acid	Dodecanoic Acid|Dodecanoic Acid Anion|Lauric Acid|dodecanoate	CCCCCCCCCCCC(O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00004690	LTF|GPR84|HNF4A|LY96|PLA2G2A|TLR4	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002438|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5534|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002438|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002438|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002438|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002438	bacterial permeability inducer			
fenipentol	fenipentol		CCCCC(O)c1ccccc1	Launched	http://www.drugs.com/international/fenipentol.html			choleretic agent	gastroenterology	bile stimulation	http://www.drugs.com/international/fenipentol.html
linifanib	linifanib	ABT-869|AL-39324|RG-3635	Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1	Phase 3	https://www.clinicaltrials.gov/show/NCT01009593	RET|TEK|PDGFRB|PDGFRA|KIT|KDR|CSF1|FLT3|FLT4|FLT1|CSF1R	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5657|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5657|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5657|https://citeline.informa.com/?query=#/drugs/details/33513|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5657|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5657|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000029|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5657|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5657|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5657|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5657	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor			
BCI-540	BCI-540	coluracetam	Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00621270			glutamate receptor agonist			
ORE1001	ORE1001	MLN-4760	CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT01039597	ACE2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7866	angiotensin converting enzyme inhibitor			
N-acetylglycyl-D-glutamic-acid	N-acetylglycyl-D-glutamic acid		CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O	Preclinical				glutamate receptor agonist			
oxotremorine-sesquifumarate	oxotremorine-sesquifumarate	oxotremorine	O=C1CCCN1CC#CCN1CCCC1	Preclinical		CHRM1|CHRM4|CHRM3|CHRM2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=302|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=302|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=302|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=302	cholinergic receptor agonist			
ADX-10059	ADX-10059		Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00810485	GRM5	https://www.tocris.com/products/adx-10059-hydrochloride_4416	glutamate receptor negative allosteric modulator			
methicillin	methicillin	meticillin|staphcillin	COc1cccc(OC)c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	Launched	FDA Orange Book: methicillin sodium			bacterial cell wall synthesis inhibitor			
DRF053-(R)	(R)-DRF053		CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1	Preclinical		CSNK1A1	http://www.tocris.com/dispprod.php?ItemId=232061#.Vfm1jNNViko	CDK inhibitor			
SEN-1269	SEN-1269		CN(C)c1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1	Preclinical		APP	https://www.tocris.com/products/sen-1269_4699	beta amyloid inhibitor			
BRL-44408	BRL-44408		CC1N(CC2=NCCN2)Cc2ccccc12	Preclinical		ADRA2C|ADRA2B|ADRA2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=525|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=525|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=525	adrenergic receptor antagonist			
LY225910	LY225910	LY-225910	CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O	Preclinical		CCKBR	https://www.tocris.com/dispprod.php?ItemId=2301#.Vytp4GQrJZI	CCK receptor antagonist			
fenbendazole	fenbendazole	HOE 881Y|Safe Guard|Safe-Guard|panacur	COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1	Veterinary Launched	http://www.drugs.com/international/Fenbendazole.html	TUBB|CYP2C19|CYP3A4|CYP2J2|CYP2D6	http://en.wikipedia.org/wiki/Fenbendazole|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=716025|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=716025|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=716025|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=716025	tubulin polymerization inhibitor	infectious disease|infectious disease	gastrointestinal parasites|gastrointestinal roundworms	https://en.wikipedia.org/wiki/Fenbendazole|https://en.wikipedia.org/wiki/Fenbendazole
I-BET151	I-BET151	GSK-1210151A	COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C	Preclinical		BRD2|BRD3|BRD4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7518|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7518|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7518	bromodomain inhibitor			
selenomethionine	selenomethionine	selenomethionine se 75|sethotope		Launched	FDA Orange Book: selenomethionine se-75						
pevonedistat	pevonedistat	MLN4924	NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02610777	NAE1|UBA3	http://www.selleckchem.com/products/mln-4924.html?gclid=CPPm55au47oCFRFo7Aod-WYASw|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000576	nedd activating enzyme inhibitor			
lornoxicam	lornoxicam		CN1C(C(=O)Nc2ccccn2)C(=O)c2sc(Cl)cc2S1(=O)=O	Launched	http://www.drugs.com/international/Lornoxicam.html	PTGS1|PTGS2	https://www.drugbank.ca/drugs/DB06725|https://www.drugbank.ca/drugs/DB06725	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	osteoarthritis|sciata	https://en.wikipedia.org/wiki/Lornoxicam|https://en.wikipedia.org/wiki/Lornoxicam
prednisone	prednisone	Cortan|Delta-dome|Fernisone|Liquid pred|Prednicen-M|Sterapred|deltasone|meticorten|orasone|paracort|prednisone intensol|rayos	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	Launched	FDA Orange Book: meprednisone, prednisone	NR3C1|HSD11B1	ChEMBL|https://www.drugbank.ca/drugs/DB00635	glucocorticoid receptor agonist	endocrinology|endocrinology|rheumatology|rheumatology|rheumatology|rheumatology|rheumatology|infectious disease|rheumatology|dermatology|infectious disease|ophthalmology|hematology|gastroenterology|gastroenterology|neurology/psychiatry|infectious disease	congenital adrenal hyperplasia|hypercalcemia|rheumatoid arthritis|psoriatic arthritis|ankylosing spondylitis|bursitis|osteoarthritis|epicondylitis|dermatomyositis|psoriasis|mycosis|conjunctivitis|anemia|ulcerative colitis|enteritis|multiple sclerosis|meningitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3400d26a-41cb-40e4-99b4-780e1e0ec561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3400d26a-41cb-40e4-99b4-780e1e0ec561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3400d26a-41cb-40e4-99b4-780e1e0ec561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3400d26a-41cb-40e4-99b4-780e1e0ec561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3400d26a-41cb-40e4-99b4-780e1e0ec561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3400d26a-41cb-40e4-99b4-780e1e0ec561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3400d26a-41cb-40e4-99b4-780e1e0ec561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3400d26a-41cb-40e4-99b4-780e1e0ec561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3400d26a-41cb-40e4-99b4-780e1e0ec561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3400d26a-41cb-40e4-99b4-780e1e0ec561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3400d26a-41cb-40e4-99b4-780e1e0ec561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3400d26a-41cb-40e4-99b4-780e1e0ec561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3400d26a-41cb-40e4-99b4-780e1e0ec561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3400d26a-41cb-40e4-99b4-780e1e0ec561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3400d26a-41cb-40e4-99b4-780e1e0ec561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3400d26a-41cb-40e4-99b4-780e1e0ec561|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3400d26a-41cb-40e4-99b4-780e1e0ec561
AZD3988	AZD3988		OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(NC(=O)c2nnc(Nc3ccc(F)c(F)c3)o2)cc1	Preclinical		DGAT1	https://www.tocris.com/products/azd-3988_4837	diacylglycerol kinase inhibitor			
troglitazone	troglitazone	CI-991|CS-045|GR-92132X|GR92132X|prelay|rezulin	Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	CYP3A4|SLC29A1|INS|SERPINE1|AKR1B1|CCL2|ESRRA|ESRRG|ACSL4|PPARG|TRPM3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=105806|https://www.drugbank.ca/drugs/DB00197|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=105806|https://www.drugbank.ca/drugs/DB00197|https://citeline.informa.com/?query=#/drugs/details/18521|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=105806|https://www.drugbank.ca/drugs/DB00197|https://www.drugbank.ca/drugs/DB00197|https://www.drugbank.ca/drugs/DB00197|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2693	insulin sensitizer|PPAR receptor agonist			
acarbose	acarbose	BAY G 5421|Glucobay|precose	C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O	Launched	FDA Orange Book: acarbose	MGAM|GAA|SI|AMY2A	ChEMBL|https://www.drugbank.ca/drugs/DB00284|https://www.drugbank.ca/drugs/DB00284|ChEMBL	glucosidase inhibitor	endocrinology	diabetes mellitus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b56f1c19-b798-46d2-9ad1-73816ed86ef3
CID-16020046	CID-16020046		Cc1ccc(cc1)-c1[nH]nc2C(=O)N(C(c12)c1cccc(O)c1)c1ccc(cc1)C(O)=O	Preclinical		GPR55	https://www.tocris.com/products/cid-16020046_4959	G protein-coupled receptor antagonist			
AZD9272	AZD9272		Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N	Preclinical		GRM5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6439	glutamate receptor antagonist			
2-hydroxyflutamide	2-hydroxyflutamide	Hydroxyflutamide	CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT00913263	AR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2862	androgen receptor antagonist			
semagacestat	semagacestat		CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1c2ccccc2CCN(C)C1=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01035138	PSEN1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6978	gamma secretase inhibitor			
GSK1292263	GSK1292263		CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01128621	GPR119|GRPR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=646040|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000407	glucose dependent insulinotropic receptor agonist			
befuraline	befuraline		O=C(N1CCN(Cc2ccccc2)CC1)c1cc2ccccc2o1	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/341906						
foretinib	foretinib	EXEL-2880|GSK-089|GSK-1363089|GSK1363089G|XL-880	COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00726323	KIT|KDR|MST1R|MET|TEK|FLT3|FLT4|FLT1|AXL	https://citeline.informa.com/?query=#/drugs/details/31893|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5679|https://citeline.informa.com/?query=#/drugs/details/31893|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5679|https://citeline.informa.com/?query=#/drugs/details/31893|https://citeline.informa.com/?query=#/drugs/details/31893|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5679|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5679|https://citeline.informa.com/?query=#/drugs/details/31893	VEGFR inhibitor			
trametinib	trametinib	GSK1120212|mekinist	CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O	Launched	FDA Orange Book: trametinib dimethyl sulfoxide	CYP2C8|CYP3A4|MAP2K1|MAP2K2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=415494|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=415494|https://www.drugbank.ca/drugs/DB08911|https://www.drugbank.ca/drugs/DB08911	MEK inhibitor	oncology	melanoma	https://en.wikipedia.org/wiki/Trametinib
enzalutamide	enzalutamide	MDV3100|xtandi	CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F	Launched	FDA Orange Book: enzalutamide	CYP2C19|AR|CYP3A4|CYP2C8	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=438422|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=438422|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=438422	androgen receptor antagonist	oncology	prostate cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf
CI-966	CI-966		OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1	Phase 1	http://adisinsight.springer.com/drugs/800007911	SLC6A1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4612	GAT inhibitor			
exherin	exherin		CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00264433	CDH2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000110	cadherin antagonist			
8-hydroxy-DPAT	8-hydroxy-DPAT	8-OH-DPAT	CCCN(CCC)C1CCc2cccc(O)c2C1	Preclinical		MAPK14|LCK|PDPK1|CDK1|HTR7|HTR5A|GSK3B|MARK1|CHEK1|CHEK2|PRKCG|PRKCE|PRKCD|PRKCA|PRKCB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907|http://www.tocris.com/dispprod.php?ItemId=1468#.VecSitNViko|http://www.tocris.com/dispprod.php?ItemId=1468#.VecSitNViko|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907	serotonin receptor agonist			
tolterodine	tolterodine	KABI 2234|KABI-2234|detrol|detrol la	CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C	Launched	FDA Orange Book: tolterodine tartrate	CHRM1|CHRM4|CHRM5|CHRM2|CHRM3	https://www.drugbank.ca/drugs/DB01036|https://www.drugbank.ca/drugs/DB01036|https://www.drugbank.ca/drugs/DB01036|https://www.drugbank.ca/drugs/DB01036|https://www.drugbank.ca/drugs/DB01036	acetylcholine receptor antagonist	urology|urology	urinary incontinence|urinary frequency	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db6e0b6d-0ce5-41d7-881f-881c11f530a4&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db6e0b6d-0ce5-41d7-881f-881c11f530a4&audience=consumer
tioxolone	tioxolone	thioxolone	Oc1ccc2sc(=O)oc2c1	Preclinical		CA1|CA2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=638196|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009264	carbonic anhydrase inhibitor			
CCT129202	CCT129202		CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1	Preclinical		AURKB|AURKC|AURKA	http://www.selleckchem.com/products/CCT129202.html|http://www.selleckchem.com/products/CCT129202.html|http://www.selleckchem.com/products/CCT129202.html	Aurora kinase inhibitor			
LY344864	LY344864	LY-344864	CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1	Preclinical		HTR7|HTR1B|HTR1D|HTR1E|HTR1F|HTR1A|HTR2C|HTR2A|HTR2B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=21|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=21|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=21|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=21|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=21|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=21|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=21|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=21|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=21	serotonin receptor agonist			
sulfapyridine	sulfapyridine	Coccoclase|Eubasin|Piridazol|Sulfanilamidopyridine|sulphapyridine	Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1	Launched	FDA Orange Book: sulfapyridine			PABA antagonist			
pemirolast	pemirolast	alamast	Cc1cccn2c1ncc(-c1nnn[nH]1)c2=O	Launched	FDA Orange Book: pemirolast potassium	HRH1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001064	mediator release inhibitor	pulmonary	asthma	https://en.wikipedia.org/wiki/Pemirolast
fluorometholone	fluorometholone	fml|fml forte|oxylone	C[C@H]1CC2C3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)C2(C)C=CC(=O)C=C12	Launched	FDA Orange Book: fluorometholone, fluorometholone acetate	NR3C1	https://www.drugbank.ca/drugs/DB00324	glucocorticoid receptor agonist	ophthalmology	eye inflammation	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=545776fe-63df-44ab-ace3-f3d73d2e0092
linalool	linalool		CC(C)=CCCC(C)(O)C=C	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/15238993			anticonvulsant			
GW-9508	GW-9508	GW9508	OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1	Preclinical		FFAR4|FFAR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1050|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1050	free fatty acid receptor agonist|G protein-coupled receptor agonist			
PF-431396	PF-431396		CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O	Preclinical		PTK2B|PTK2	https://www.tocris.com/products/pf-431396_4278|https://www.tocris.com/products/pf-431396_4278	focal adhesion kinase inhibitor			
physostigmine	physostigmine	eserine	CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1	Launched	http://www.drugs.com/international/physostigmine.html	ACHE|BCHE	https://www.drugbank.ca/drugs/DB00981|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6598	cholinesterase inhibitor	cardiology|neurology/psychiatry|ophthalmology|gastroenterology	hypotension|Alzheimer's disease|glaucoma|gastroparesis	https://en.wikipedia.org/wiki/Physostigmine#Bioactivity|https://en.wikipedia.org/wiki/Physostigmine#Bioactivity|https://en.wikipedia.org/wiki/Physostigmine#Bioactivity|https://en.wikipedia.org/wiki/Physostigmine#Bioactivity
MRS2578	MRS2578		S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1	Preclinical		P2RY6	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1753	purinergic receptor antagonist			
benethamine	benethamine		C(Cc1ccccc1)NCc1ccccc1	Preclinical							
AZD9496	AZD9496		C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02248090	ESR1	http://www.ncbi.nlm.nih.gov/pubmed/27020862	estrogen receptor agonist			
thiophanate	thiophanate	Thiophanate Methyl|Thiophanate-Methyl	COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC	Preclinical							
bitopertin	bitopertin		C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01192880	SLC6A5|SLC6A9	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7546|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7546	glycine transporter inhibitor|GlyT-1 inhibitor			
edaravone	edaravone	MCI-186|Radicut	CC1=NN(C(=O)C1)c1ccccc1	Launched	http://www.drugs.com/international/Edaravone.html	BCL2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000877	nootropic agent	neurology/psychiatry	stroke	https://en.wikipedia.org/wiki/Edaravone
GW-9662	GW-9662		[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1	Preclinical		NCOA2|PPARG|RXRA	https://www.drugbank.ca/drugs/DB07863|https://www.drugbank.ca/drugs/DB07863|https://www.drugbank.ca/drugs/DB07863	PPAR receptor antagonist			
limonin	limonin		CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1	Preclinical				HIV protease inhibitor			
gabapentin	gabapentin	CI-945|GOE 3450|GOE-3450|gralise|horizant|neurontin	NCC1(CC(O)=O)CCCCC1	Launched	FDA Orange Book: gabapentin, gabapentin enacarbil	CACNG6|CACNG7|CACNG8|CACNG2|CACNG3|CACNG4|CACNG5|CACNG1|CACNB1|CACNB2|CACNB3|CACNB4|CACNA1S|CACNA1F|CACNA1E|CACNA1H|CACNA1G|CACNA1B|CACNA1A|CACNA1D|CACNA1C|CACNA1I|CACNA2D4|CACNA2D2|CACNA2D3|CACNA2D1|ADORA1|GRIN2A|GRIN2D|GRIN2B|GRIN2C|GRIN3A|GRIN3B|GRIN1	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00996|https://www.drugbank.ca/drugs/DB00996|https://www.drugbank.ca/drugs/DB00996|https://www.drugbank.ca/drugs/DB00996|https://www.drugbank.ca/drugs/DB00996|https://www.drugbank.ca/drugs/DB00996|https://www.drugbank.ca/drugs/DB00996|https://www.drugbank.ca/drugs/DB00996	calcium channel blocker	infectious disease|infectious disease|neurology/psychiatry|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome	http://www.drugs.com/gabapentin.html|http://www.drugs.com/gabapentin.html|http://www.drugs.com/gabapentin.html|http://www.drugs.com/gabapentin.html
4-pyrimidinecarbonitrile	4-pyrimidinecarbonitrile		N#Cc1ccncn1	Preclinical							
4-HQN	4-HQN	4-quinazolone|Quinazolin-4-ol|quinazolinone	Oc1ncnc2ccccc12	Preclinical		PARP1	http://www.tocris.com/dispprod.php?ItemId=121538#.VeXzaCxVhHw	PARP inhibitor			
iobenguane	iobenguane	adreview|iobenguane sulfate i 131	NC(=N)NCc1cccc(I)c1	Launched	FDA Orange Book: iobenguane sulfate i-123, iobenguane sulfate i-131			antineoplastic agent	oncology|cardiology|endocrinology	neuroblastoma|congestive heart failure|pheochromocytoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c89d3ecc-4f4c-4566-8808-79152344194d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c89d3ecc-4f4c-4566-8808-79152344194d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c89d3ecc-4f4c-4566-8808-79152344194d
SB-202190	SB-202190		Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1	Preclinical		PRKCA|ALOX5|AKT1|LCK|GSK3B|MAPK8|MAPK1|SGK1|RPS6KB1|ROCK1|CHEK1|MAPK12|MAPK11|MAPK14	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004280|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004280|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004280|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004280|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004280|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004280|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004280|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004280|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004280|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004280|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004280|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004280|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004280|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4307	p38 MAPK inhibitor			
PYR-41	PYR-41		CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O	Preclinical				ubiquitin activating enzyme inhibitor			
amsacrine	amsacrine	Amsakrin|CI-880|NCI-249992|amsidyl|m-amsa	COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12	Launched	http://www.drugs.com/international/amsacrine.html	TOP2A|KCNH2	https://www.drugbank.ca/drugs/DB00276|https://www.drugbank.ca/drugs/DB00276	topoisomerase inhibitor	hematologic malignancy|hematologic malignancy	acute lymphoblastic leukemia (ALL)|acute lymphoblastic leukemia (ALL)	https://en.wikipedia.org/wiki/Amsacrine|https://en.wikipedia.org/wiki/Amsacrine
higenamine	higenamine		Oc1ccc(CC2NCCc3cc(O)c(O)cc23)cc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01451229	ADRB2	https://en.wikipedia.org/wiki/Higenamine	adrenergic receptor agonist			
atenolol-(+/-)	(+/-)-atenolol		CC(C)NCC(O)COc1ccc(CC(N)=O)cc1	Launched				adrenergic receptor antagonist			
PD-102807	PD-102807		CCOC(=O)c1c(C)[nH]c2ccc3OC4N(CCc5cc(OC)ccc45)Cc3c12	Preclinical		CHRM4	https://www.tocris.com/dispprod.php?ItemId=61839#.VyuGw2QrJZI	acetylcholine receptor antagonist			
NSC-663284	NSC-663284		ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O	Preclinical		CDC25A|CDC25B|CDC25C	http://www.tocris.com/dispprod.php?ItemId=83018#.Utb-CPaGZ3c|http://www.tocris.com/dispprod.php?ItemId=83018#.Utb-CPaGZ3c|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006028	CDC inhibitor			
BW-616U	BW-616U		CNC(=O)c1ccc2C(=O)c3ccccc3S(=O)(=O)c2c1	Preclinical		MAOA	https://www.google.com/patents/US5792799	monoamine oxidase inhibitor			
piricapiron	piricapiron		CC1(C)C2CCC1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O	Phase 2	Integrity	HTR1A|HTR2A|DRD2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=227533|http://zhanglab.ccmb.med.umich.edu/GLASS/assoc.cgi?id=219940|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=227533	dopamine receptor antagonist|serotonin receptor antagonist			
Y-27152	Y-27152		CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/8739023	KCNJ8	https://www.tocris.com/dispprod.php?ItemId=103302#.VyzPXGQrJZI	potassium channel activator			
m-3M3FBS	m-3M3FBS		Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F	Preclinical		PLCB3|PLCB2|PLCG2|PLCG1|PLCD1	http://www.millipore.com/catalogue/item/525185-10mg|http://www.millipore.com/catalogue/item/525185-10mg|http://www.millipore.com/catalogue/item/525185-10mg|http://www.millipore.com/catalogue/item/525185-10mg|http://www.millipore.com/catalogue/item/525185-10mg				
aspartame	aspartame	E951|SC-18862	COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O	Launched	http://en.wikipedia.org/wiki/Aspartame	TRPV1|TAS1R2	https://www.drugbank.ca/drugs/DB00168|https://www.drugbank.ca/drugs/DB00168				
AMG-517	AMG-517		CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/?term=18337008	TRPV1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4129	TRPV antagonist			
fipronil	fipronil	MB 46030|RM 1601	Nc1c(c(nn1-c1c(Cl)cc(cc1Cl)C(F)(F)F)C#N)S(=O)C(F)(F)F	Veterinary Launched	http://www.drugs.com/international/fipronil.html			chloride channel blocker|GABA gated chloride channel blocker			
methylergometrine	methylergometrine	methergine|methylergonovine|methylergonovine maleate	CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34	Launched	FDA Orange Book: methylergonovine maleate	DRD1|HTR2A|HTR2B|HTR2C|HTR1E|HTR1F	https://www.drugbank.ca/drugs/DB00353|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=150|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=150|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=150|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=150|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=150	dopamine receptor antagonist|serotonin receptor antagonist	hematology|neurology/psychiatry	postpartum hemorrhage (PPH)|migraine headache	https://en.wikipedia.org/wiki/Methylergometrine|https://en.wikipedia.org/wiki/Methylergometrine
BML-190	BML-190	Indomethacin Morpholinylamide	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1	Preclinical		CNR2	https://www.tocris.com/dispprod.php?ItemId=1762#.VyetWWQrImI	cannabinoid receptor inverse agonist			
leucomethylene-blue	Leucomethylene Blue	Leucomethylene Blue	CN(C)c1ccc2Nc3ccc(cc3Sc2c1)N(C)C	Phase 3	http://taurx.com/taurx-reports-first-phase-3-results-for-lmtx.pdf	MAPT	http://www.mpasmb-hamburg.mpg.de/mand-pdf/Schirmer__Mandelkow_2011_NeurobiolAging_MethyleneBlue.pdf	nitric oxide production inhibitor|tau aggregation inhibitor			
triptolide	triptolide		CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02115659	CYP2C19|RELA	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090968|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001473	RNA polymerase inhibitor			
evodiamine	evodiamine		CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12	Preclinical		TRPV1	http://www.scbt.com/datasheet-201479-evodiamine.html	ATPase inhibitor|TRPV agonist			
retinol	retinol	Vitamin A 1|Vitamin a solubilized|aquasol a|oleovitamin a|retinol acetate|retinol palmitate|vitamin a|vitamin a oil	CC(\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C)=C/CO	Launched	http://www.drugs.com/international/retinol.html	ALDH1A2|ALDH1A1|ALDH1A3|RXRG|RXRB|RXRA|RLBP1|RDH11|RDH12|RDH13|RDH14|RDH8|RDH5|LRAT|RBP1|RBP3|DHRS4|DHRS3|RHO|NR2C2|RETSAT	https://www.drugbank.ca/drugs/DB00162|https://www.drugbank.ca/drugs/DB00162|https://www.drugbank.ca/drugs/DB00162|http://www.biocentury.com/targets/retinoid_x_receptor|http://www.biocentury.com/targets/retinoid_x_receptor|http://www.biocentury.com/targets/retinoid_x_receptor|https://www.drugbank.ca/drugs/DB00162|https://www.drugbank.ca/drugs/DB00162|https://www.drugbank.ca/drugs/DB00162|https://www.drugbank.ca/drugs/DB00162|https://www.drugbank.ca/drugs/DB00162|https://www.drugbank.ca/drugs/DB00162|https://www.drugbank.ca/drugs/DB00162|https://www.drugbank.ca/drugs/DB00162|https://www.drugbank.ca/drugs/DB00162|https://www.drugbank.ca/drugs/DB00162|https://www.drugbank.ca/drugs/DB00162|https://www.drugbank.ca/drugs/DB00162|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001498|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4053|https://www.drugbank.ca/drugs/DB00162	retinoid receptor ligand	dermatology|dermatology|dermatology	cosmetic|acne vulgaris (AV)|keratosis	https://en.wikipedia.org/wiki/Retinol|https://en.wikipedia.org/wiki/Retinol|https://en.wikipedia.org/wiki/Retinol
PF-4800567	PF-4800567		Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1	Preclinical		CSNK1E|CSNK1D	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8050|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8050	casein kinase inhibitor			
PF-477736	PF-477736		Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00437203	CHEK2|CHEK1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8043|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8043	CHK inhibitor			
homoquinolinic-acid	homoquinolinic acid		OC(=O)Cc1cccnc1C(O)=O	Preclinical		GRIN1|GRIN2C|GRIN2D|GRIN2A|GRIN2B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4216|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4216|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4216|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4216|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4216	glutamate receptor agonist			
merimepodib	merimepodib	VI-21,497|VX-497	COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00088504	IMPDH1	http://www.drugbank.ca/drugs/DB04862	inosine monophosphate dehydrogenase inhibitor			
8-bromo-cAMP	8-bromo-cAMP		Nc1ncnc2n([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)c(Br)nc12	Preclinical				PKA activator			
copper-histidine	copper-histidine	D-His|D-Histamine|D-Histidine	N[C@H](Cc1c[nH]cn1)C(O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00811785	HARS|HDC|HAL|SLC15A4|SLC15A3|SLC38A5|SLC38A3	https://www.drugbank.ca/drugs/DB00117|https://www.drugbank.ca/drugs/DB00117|https://www.drugbank.ca/drugs/DB00117|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4623|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4623|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4623|https://www.drugbank.ca/drugs/DB00117				
3,4-DCPG-(R)	(R)-3,4-DCPG		N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O	Preclinical				glutamate receptor antagonist			
timolol	timolol	betimol|blocadren|istalol|timolol maleate|timoptic|timoptic-xe		Launched	FDA Orange Book: timolol, timolol maleate	ADRB1|ADRB2	ChEMBL|ChEMBL	adrenergic receptor antagonist	ophthalmology|ophthalmology	ocular hypertension|glaucoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00f62dd1-dad2-4892-8a5d-21e5e54509ce&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00f62dd1-dad2-4892-8a5d-21e5e54509ce&audience=consumer
betazole	betazole	histalog	NCCc1cc[nH]n1	Launched	FDA Orange Book: betazole hydrochloride	HRH2	https://www.drugbank.ca/drugs/DB00272	histamine receptor agonist	gastroenterology	gastric hypersecretion diagnostic	https://en.wikipedia.org/wiki/Betazole
levocarnitine	levocarnitine	carnitor|carnitor sf|dextrocarnitine	C[N+](C)(C)C[C@H](O)CC(O)=O	Launched	FDA Orange Book: levocarnitine				endocrinology	carnitine deficiency	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0423ba8e-6377-4a26-baf2-c2d035671eed
indoprofen	indoprofen	K 4277	CC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	CXCR2|CXCR1|PTGS1|PTGS2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005383|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005383|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005383|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005383	cyclooxygenase inhibitor|prostanoid receptor antagonist			
palomid-529	palomid-529	P-529	COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)C(C)O)cc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01033721	MTOR|FGF2	http://www.selleckchem.com/products/Palomid-529-P529.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=460870	AKT inhibitor|mTOR inhibitor			
MK-2048	MK-2048		CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O	Preclinical				HIV integrase inhibitor			
PNU-22394	PNU-22394		Cn1c2CCNCCc2c2ccccc12	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/4965508	MAOB|MAOA|HTR2C|HTR2A|HTR2B	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011654|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011654|http://www.tocris.com/dispprod.php?ItemId=123700#.Vgw269NViko|http://www.tocris.com/dispprod.php?ItemId=123700#.Vgw269NViko|http://www.tocris.com/dispprod.php?ItemId=123700#.Vgw269NViko	serotonin receptor agonist			
telmesteine	telmesteine		CCOC(=O)N1CSCC1C(O)=O	Launched	http://www.ndrugs.com/?s=muconorm			mucolytic agent			
JTE-907	JTE-907		CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12	Phase 1	http://adisinsight.springer.com/drugs/800018164	CNR2	http://www.tocris.com/dispprod.php?ItemId=156543#.Unk6yiRLn48	cannabinoid receptor inverse agonist			
levetiracetam	levetiracetam	UCB 22059|UCB L059|UCB-22059|UCB-L059|keppra|keppra xr|spritam	CC[C@H](N1CCCC1=O)C(N)=O	Launched	FDA Orange Book: levetiracetam	CACNA1B|SCN1A|SV2A	ChEMBL|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000502|ChEMBL	calcium channel blocker	neurology/psychiatry	seizures	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e26d49b-f0ba-4fd1-b863-4bd68e65ee88
GDC-0994	GDC-0994		Cn1nccc1Nc1nccc(n1)-c1ccn(C(CO)c2ccc(Cl)c(F)c2)c(=O)c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01875705	MAPK1|MAPK3	http://www.selleckchem.com/products/gdc-0994.html?gclid=CPOooO_BpNICFZKHaQodJKwMcw|http://www.selleckchem.com/products/gdc-0994.html?gclid=CPOooO_BpNICFZKHaQodJKwMcw	MAP kinase inhibitor			
SAR405	SAR405		C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F	Preclinical		PIK3C3	https://www.medchemexpress.com/SAR405.html	PI3K inhibitor			
cromakalim	cromakalim	BRL 34915	CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/1975334	KCNJ8|ABCC9	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2413|https://citeline.informa.com/?query=#/drugs/details/4929				
nemonapride	nemonapride		CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C	Launched	http://www.drugs.com/international/Nemonapride.html	DRD2|DRD4|DRD3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001497|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=983|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=983	dopamine receptor antagonist	neurology/psychiatry	schizophrenia	https://en.wikipedia.org/wiki/Nemonapride
spermidine	spermidine		NCCCCNCCCN	Preclinical		KCNJ4|TXNRD1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2390|https://www.drugbank.ca/drugs/DB03566	glutamate receptor modulator			
A-412997	A-412997		Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1	Preclinical		DRD4	https://www.tocris.com/products/a-412997-dihydrochloride_4552	dopamine receptor agonist			
indinavir	indinavir	L-735524|MK-639|crixivan	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12	Launched	FDA Orange Book: indinavir sulfate	CYP3A7|CYP3A5|CYP3A4	http://www.genome.jp/dbget-bin/www_bget?dr:D03833|http://www.genome.jp/dbget-bin/www_bget?dr:D03833|http://www.genome.jp/dbget-bin/www_bget?dr:D03833	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f
regadenoson	regadenoson	lexiscan	CNC(=O)c1cnn(c1)-c1nc(N)c2ncn([C@@H]3O[C@H](CO)C(O)C3O)c2n1	Launched	FDA Orange Book: regadenoson	ADORA1|ADORA3|ADORA2A|ADORA2B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5596|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5596|https://www.drugbank.ca/drugs/DB06213|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5596	adenosine receptor agonist	radiology	myocardial perfusion imaging (MPI)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=057289f4-2e18-4c1e-bed4-6c1858e2ef16
mebhydroline-1,5-naphtalenedisulfonate	mebhydroline-1,5-naphtalenedisulfonate		CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1	Preclinical							
uracil-mustard	uracil mustard	U-8344|uracil mustard|uramustine	Oc1ncc(N(CCCl)CCCl)c(O)n1	Launched	http://www.drugbank.ca/drugs/DB00791			DNA synthesis inhibitor	hematologic malignancy	non-Hodgkin lymphoma (NHL)	https://en.wikipedia.org/wiki/Uramustine
spermine	spermine		NCCCNCCCCNCCCN	Preclinical		ODC1|CASR|GRIN2A|SMOX|CA14|GRIN1|SMS|TRPM5|TRPM4|NOS2|CA4|CA6|CA9|KCNJ4	https://www.drugbank.ca/drugs/DB00127|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=710|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010766|https://www.drugbank.ca/drugs/DB00127|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010766|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010766|https://www.drugbank.ca/drugs/DB00127|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=710|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=710|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=393803|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010766|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010766|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010766|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=710				
oxiniacic-acid	oxiniacic acid	oxiniacic acid	OC(=O)c1ccc[n+]([O-])c1	Preclinical							
quinelorane	quinelorane		CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@@H]12	Phase 3	https://www.pharmamedtechbi.com/publications/the-pink-sheet/50/051/lillys-quinelorane-phase-iiiii-clinical-trial-for-treatment-of-sexual-dysfunction-will-require-3000patient	DRD2|DRD3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=954|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=954	dopamine receptor agonist			
cefamandole-nafate	cefamandole-nafate	NSC-299588|mandol	Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](OC=O)c1ccccc1)C2=O)C(O)=O	Launched	FDA Orange Book: cefamandole nafate			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease	skin infections|urinary tract infections|respiratory tract infections	https://en.wikipedia.org/wiki/Cefamandole|https://en.wikipedia.org/wiki/Cefamandole|https://en.wikipedia.org/wiki/Cefamandole
substance-p	substance p	substance p	CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O	Phase 1	http://cureresearch4type1diabetes.blogspot.com/2016/09/substance-p-starts-phase-i-clinical.html	TACR1|TACR2|TACR3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2098|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2098|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2098	neurokinin receptor antagonist			
buparlisib	buparlisib	BKM-120|BKM120-NX|NVP-BKM120	Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01610284	PIK3CG|PIK3CA	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001087|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7878	PI3K inhibitor			
pempidine	pempidine		CN1C(C)(C)CCCC1(C)C	Launched	http://www.ncbi.nlm.nih.gov/pubmed/13756469			ganglionic blocker	cardiology	hypertension	https://en.wikipedia.org/wiki/Pempidine
lappaconite	lappaconite		CCN1C[C@@]2(CC[C@@H](OC)[C@@]34[C@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@H](C[C@H]23)C14)OC(=O)c1ccccc1NC(C)=O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/25702400			sodium channel blocker			
LY223982	LY223982	LY-223982|LY-333982	COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1	Phase 2	http://adisinsight.springer.com/drugs/800002326	LTB4R	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3415	leukotriene receptor antagonist			
KX2-391	KX2-391		O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01074138	SRC	http://www.selleckchem.com/products/kx2-391.html	src inhibitor|tubulin polymerization inhibitor			
NECA	NECA	5'-N-Ethylcarboxamidoadenosine	CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	Launched	FDA Orange Book: sinecatechins	ADORA1|ADORA3|HSP90B1|ADORA2B|ADORA2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=377|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=377|https://www.drugbank.ca/drugs/DB03719|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=377|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=377	adenosine receptor agonist			
selamectin	selamectin		CO[C@H]1CC(O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4C(=N/O)\C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(CC[C@H](C)[C@H](O2)C2CCCCC2)C5)[C@]34O)O[C@@H](C)C1O	Veterinary Launched	http://www.drugs.com/international/selamectin.html			nematocide	infectious disease	flea control	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c8cb87ca-841c-4800-a8e4-a593e31d2efb
nolatrexed	nolatrexed		Cc1ccc2nc(N)nc(O)c2c1Sc1ccncc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00012324	TYMS	https://en.wikipedia.org/wiki/Nolatrexed	thymidylate synthase inhibitor			
dipivefrine	dipivefrine	dipivalyl epinephrine|dipivefrin|propine	CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1	Launched	FDA Orange Book: dipivefrin hydrochloride	ACHE|ADRA1A|ADRA2A|BCHE|ADRB2	https://www.drugbank.ca/drugs/DB00449|https://www.drugbank.ca/drugs/DB00449|https://www.drugbank.ca/drugs/DB00449|https://www.drugbank.ca/drugs/DB00449|https://www.drugbank.ca/drugs/DB00449	adrenergic receptor agonist	ophthalmology|ophthalmology	glaucoma|intraocular pressure	https://en.wikipedia.org/wiki/Dipivefrine|https://en.wikipedia.org/wiki/Dipivefrine
benzamil	benzamil		NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/10543294	ASIC1|SCNN1D|SCNN1B|SCNN1A|SCNN1G|SLC8A1|PKD2L1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4145|http://www.tocris.com/dispprod.php?ItemId=220898#.UufMd6X0CMI|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4145|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4145|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4145|http://www.tocris.com/dispprod.php?ItemId=220898#.UufMd6X0CMI|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4145	sodium channel blocker			
MRS1334	MRS1334		CCOC(=O)C1=C(C)NC(c2ccccc2)=C(C1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O	Preclinical		ADORA3	http://www.tocris.com/dispprod.php?ItemId=1785#.Vgli_WRVhHw	adenosine receptor antagonist			
balofloxacin	balofloxacin		CNC1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1	Launched	http://en.wikipedia.org/wiki/Balofloxacin			bacterial DNA gyrase inhibitor	infectious disease	gram-negative bacterial infections	https://en.wikipedia.org/wiki/Balofloxacin
disopyramide	disopyramide	SC-7031|norpace|norpace cr	CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C	Launched	FDA Orange Book: disopyramide phosphate	CHRM3|CHRM1|CHRM2|SCN5A|KCNH2|KCND3|KCND2	https://www.drugbank.ca/drugs/DB00280|https://www.drugbank.ca/drugs/DB00280|https://www.drugbank.ca/drugs/DB00280|https://www.drugbank.ca/drugs/DB00280|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7167|https://www.drugbank.ca/drugs/DB00280|https://www.drugbank.ca/drugs/DB00280	sodium channel blocker	cardiology|cardiology	ventricular tachycardia (VT)|ventricular arrhythmias	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11a68e26-d2e4-48f6-ba0f-9bdd5778f25a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11a68e26-d2e4-48f6-ba0f-9bdd5778f25a
dimethisoquin	dimethisoquin	quinisocaine	CCCCc1cc2ccccc2c(OCCN(C)C)n1	Launched	http://www.drugs.com/international/Dimethisoquin.html			local anesthetic	neurology/psychiatry	local anesthetic	https://en.wikipedia.org/wiki/Quinisocaine
nifenazone	nifenazone		Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C	Launched	http://www.drugs.com/international/nifenazone.html			analgesic agent	neurology/psychiatry	pain relief	http://www.drugs.com/international/nifenazone.html
U-0124	U-0124		CS\C(N)=C(C#N)\C(C#N)=C(/N)SC	Preclinical				MEK inhibitor			
trans-4-Hydroxycrotonic-acid	trans-4-Hydroxycrotonic acid	Trans-4-Hydroxycrotonic Acid	OC\C=C\C(O)=O	Preclinical				gamma hydroxybutyric acid ligand			
minocycline	minocycline	arestin|minocin|minocycline hydrochloride|solodyn|ximino	CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C	Launched	FDA Orange Book: minocycline hydrochloride	CASP1|CASP3|VEGFA|CYCS|IL1B|ALOX5|MMP9|PARP1	https://www.drugbank.ca/drugs/DB01017|https://www.drugbank.ca/drugs/DB01017|https://www.drugbank.ca/drugs/DB01017|https://www.drugbank.ca/drugs/DB01017|https://www.drugbank.ca/drugs/DB01017|https://www.drugbank.ca/drugs/DB01017|https://www.drugbank.ca/drugs/DB01017|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070094	bacterial 30S ribosomal subunit inhibitor	endocrinology|infectious disease|infectious disease|infectious disease|ophthalmology|urology|infectious disease|infectious disease|infectious disease|infectious disease	fever|respiratory tract infections|psittacosis|trachoma|conjunctivitis|urethritis|chancroid|tularemia|cholera|brucellosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c69d40-e716-4347-9351-f8d8e1e65085|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c69d40-e716-4347-9351-f8d8e1e65085|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c69d40-e716-4347-9351-f8d8e1e65085|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c69d40-e716-4347-9351-f8d8e1e65085|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c69d40-e716-4347-9351-f8d8e1e65085|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c69d40-e716-4347-9351-f8d8e1e65085|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c69d40-e716-4347-9351-f8d8e1e65085|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c69d40-e716-4347-9351-f8d8e1e65085|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c69d40-e716-4347-9351-f8d8e1e65085|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c69d40-e716-4347-9351-f8d8e1e65085
prednisolone-hemisuccinate	prednisolone-hemisuccinate		C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O	Preclinical		NR3C1	http://www.genome.jp/dbget-bin/www_bget?dr:D02156	glucocorticoid receptor agonist			
ursodeoxycholyltaurine	ursodeoxycholyltaurine	Ursodeoxy Cholic Acid|tauroursodeoxycholate	C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/12191671			cholesterol inhibitor			
uprosertib	uprosertib	GSK-2141795|GSK2141795C	Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01907815	AKT2|AKT3|AKT1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7902|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7902|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7902	AKT inhibitor			
SC-144	SC-144		Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21	Preclinical				P glycoprotein inhibitor			
PSB-11	PSB-11		CC[C@@H]1CN2C(=N1)c1[nH]c(nc1N(C)C2=O)-c1ccccc1	Preclinical		ADORA2A|ADORA3|ADORA1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5620|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5620|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5620	adenosine receptor antagonist			
tolimidone	tolimidone	CP-26,154	Cc1cccc(Oc2cnc(=O)[nH]c2)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02317796	LYN|SRC	http://www.sigmaaldrich.com/catalog/product/sigma/sml0371?lang=en&region=US|http://www.sigmaaldrich.com/catalog/product/sigma/sml0371?lang=en&region=US	src activator			
GTS21	GTS21	3-(2,4-Dimethoxybenzylidene)Anabaseine	COc1ccc(\C=C2CCCN=C/2c2cccnc2)c(OC)c1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT00419445	CHRNA7	https://www.drugbank.ca/drugs/DB05708	cholinergic receptor agonist			
moexipril	moexipril	Uniretic|univasc	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O	Launched	FDA Orange Book: moexipril hydrochloride	ACE|ACE2	https://www.drugbank.ca/drugs/DB00691|https://www.drugbank.ca/drugs/DB00691	angiotensin converting enzyme inhibitor	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d18108f5-98ca-1220-d145-bcf4e71ceaee
PD-166793	PD-166793	PD166793	CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O	Preclinical		MMP13|MMP3|MMP2	http://www.scbt.com/datasheet-202709-PD166793.html|http://www.scbt.com/datasheet-202709-PD166793.html|http://www.scbt.com/datasheet-202709-PD166793.html	collagenase inhibitor|metalloproteinase inhibitor			
AS-604850	AS-604850		FC1(F)Oc2ccc(cc2O1)\C=C1/SC(=O)NC1=O	Preclinical		PIK3CA|PIK3CG	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6024|https://www.drugbank.ca/drugs/DB07503	PI3K inhibitor			
iothalamic-acid-d3	iothalamic-acid-d3	MI-216|iotalamic acid|iothalamic acid	CNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	Preclinical				radiopaque medium			
benserazide	benserazide	RO 4-4602|benserazide hydrochloride	NC(CO)C(=O)NNCc1ccc(O)c(O)c1O	Launched	http://www.drugs.com/international/Benserazide.html	DDC	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5150	DOPA decarboxylase inhibitor	neurology/psychiatry	Parkinson's Disease	https://en.wikipedia.org/wiki/Benserazide
zafirlukast	zafirlukast	ICI 204,219|ICI-204219|accolate	COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C	Launched	FDA Orange Book: zafirlukast	CYSLTR2|CYSLTR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3322|ChEMBL	leukotriene receptor antagonist	pulmonary	asthma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0262e192-94f4-423d-a58e-bb374dc106fe
dimethyl-isosorbide	dimethyl-isosorbide		COC1COC2C(COC12)OC	Preclinical				cosmetic moisturizer			
loperamide	loperamide	imodium|imodium a-d|imodium a-d ez chews|loperamide hydrochloride	CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1	Launched	FDA Orange Book: loperamide hydrochloride	OPRD1|OPRM1|OPRK1|CACNA1A|CALM1|CYP2C8|CYP2B6|POMC|NPR2	https://www.drugbank.ca/drugs/DB00836|https://www.drugbank.ca/drugs/DB00836|https://www.drugbank.ca/drugs/DB00836|https://www.drugbank.ca/drugs/DB00836|https://www.drugbank.ca/drugs/DB00836|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091568|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091568|https://www.drugbank.ca/drugs/DB00836|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091568	opioid receptor agonist	gastroenterology	diarrhea	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40204b82-b7c6-447a-89b0-3571bfa83ff7
valpromide	valpromide		CCCC(CCC)C(N)=O	Launched	https://www.drugs.com/international/valpromide.html			epoxide hydolase inhibitor	neurology/psychiatry	epilepsy	https://en.wikipedia.org/wiki/Valpromide
NNC-55-0396	NNC-55-0396		CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1	Preclinical		CATSPER1|CATSPER4|CATSPER3|CATSPER2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4269|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4269|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4269|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4269	T-type calcium channel blocker			
R-59022	R-59022		Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1	Preclinical		DGKA	http://www.tocris.com/dispprod.php?ItemId=121709#.Utakaf15mf1	diacylglycerol kinase inhibitor|protein kinase inhibitor			
arundic-acid	arundic acid		CCCCCC[C@@H](CCC)C(O)=O	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT00229177	APP|PTGS2|S100B	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=258543|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000905|https://www.drugbank.ca/drugs/DB05343	astrocyte modulating agent			
2-oxopropanoate	2-oxopropanoate	pyruvate	CC(=O)C(O)=O	Preclinical		PKM|ABAT|PC|AGXT2|PDHB|SLC16A4|SLC16A3|SLC16A6|SLC16A5|SLC16A2|SLC16A1|SLC16A8|SLC16A7|PKLR	https://www.drugbank.ca/drugs/DB00119|https://www.drugbank.ca/drugs/DB00119|https://www.drugbank.ca/drugs/DB00119|https://www.drugbank.ca/drugs/DB00119|https://www.drugbank.ca/drugs/DB00119|https://www.drugbank.ca/drugs/DB00119|https://www.drugbank.ca/drugs/DB00119|https://www.drugbank.ca/drugs/DB00119|https://www.drugbank.ca/drugs/DB00119|https://www.drugbank.ca/drugs/DB00119|https://www.drugbank.ca/drugs/DB00119|https://www.drugbank.ca/drugs/DB00119|https://www.drugbank.ca/drugs/DB00119|https://www.drugbank.ca/drugs/DB00119	pyruvate dehydrogenase kinase inhibitor			
cardiogenol-c	Cardiogenol C	Cardiogenol C	COc1ccc(Nc2nccc(NCCO)n2)cc1	Preclinical				cardiomyogenesis inducer			
gonadorelin	gonadorelin	Human gonadoliberin-i|factrel|lutrepulse kit	CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	Launched	FDA Orange Book: gonadorelin acetate, gonadorelin hydrochloride	GNRH1|GNRHR|GNRHR2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=107457|https://www.drugbank.ca/drugs/DB00644|https://www.drugbank.ca/drugs/DB00644	gonadotropin releasing factor hormone receptor agonist	obstetrics/gynecology|obstetrics/gynecology	cystic ovaries|reproductive synchrony	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b4cad4e-df2a-4192-aee1-5d75c756632a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b4cad4e-df2a-4192-aee1-5d75c756632a
oridonin	oridonin		O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C	Preclinical		NFE2L2|BCL2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=387097|http://www.ncbi.nlm.nih.gov/pubmed/15132839	BCL inhibitor			
osimertinib	osimertinib	AZD-9291|AZD9291|tagrisso	COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12	Launched	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf	EGFR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7719	EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7
alisertib	alisertib	MLN-8237|MLN8237	COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01482962	AURKA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7790	Aurora kinase inhibitor			
fadrozole	fadrozole	Afema|CGS-16949A	N#Cc1ccc(cc1)C1CCCc2cncn12	Launched	https://en.wikipedia.org/wiki/Fadrozole	CYP11B1|CYP19A1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003938|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003938	aromatase inhibitor	oncology	breast cancer	https://en.wikipedia.org/wiki/Fadrozole
macelignan	macelignan	Austrobailignan 6	COc1cc(C[C@H](C)[C@H](C)Cc2ccc3OCOc3c2)ccc1O	Preclinical		PPARG|PPARA	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=431714|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=431714	antioxidant|antiinflammatory agent			
stobadine	stobadine	dicarbine		Phase 2	Pharmaprojects	ADRA1A	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798857/	adrenergic receptor antagonist			
deslanoside	deslanoside	cedilanid-d|desacetyl-lanatoside c	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	Launched	FDA Orange Book: deslanoside	ATP1B2|ATP1B3|ATP1B1|ATP1A3|ATP1A4|ATP1A1|ATP1A2|FXYD2	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	Na/K-ATPase inhibitor	cardiology|cardiology	congestive heart failure|cardiac arrythmia	https://en.wikipedia.org/wiki/Deslanoside|https://en.wikipedia.org/wiki/Deslanoside
obidoxime	obidoxime		O\N=C\c1cc[n+](COC[n+]2ccc(cc2)\C=N\O)cc1	Launched	http://en.wikipedia.org/wiki/Obidoxime	ACHE	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012927	cholinesterase reactivator	critical care|neurology/psychiatry	poison antidote|nerve gas poisoning	https://en.wikipedia.org/wiki/Obidoxime|https://en.wikipedia.org/wiki/Obidoxime
rucaparib	rucaparib	AG-014699|AG-14447	CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01968213	PARP2|PARP1	http://www.clovisoncology.com/products-companion-diagnostics/rucaparib/|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7736	PARP inhibitor			
pravadoline	pravadoline		COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2ccccc12	Preclinical		CNR2|CNR1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012804|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012804	cyclooxygenase inhibitor			
tedizolid	tedizolid	TR-700|torezolid	Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O	Launched	FDA Orange Book: tedizolid phosphate			bacterial 50S ribosomal subunit inhibitor	infectious disease	skin infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75672079-589f-451a-bdbf-eaebcfcc80a9&audience=consumer
BD-1047	BD-1047		CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1	Preclinical		SIGMAR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6680	adrenergic receptor antagonist			
meglutol	meglutol	CB-337	CC(O)(CC(O)=O)CC(O)=O	Launched	Pharmaprojects	HMGCR	https://www.drugbank.ca/drugs/DB04377	HMGCR inhibitor			
acebutolol	acebutolol	sectral	CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O	Launched	FDA Orange Book: acebutolol hydrochloride	ADRB2|ADRB1	https://www.drugbank.ca/drugs/DB01193|https://www.drugbank.ca/drugs/DB01193	adrenergic receptor antagonist	cardiology|cardiology	hypertension|ventricular arrhythmias	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6bfb00a0-c057-4dfb-9ae3-e5b7d782cd24|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6bfb00a0-c057-4dfb-9ae3-e5b7d782cd24
thioridazine	thioridazine	TP-21|mellaril|mellaril-s|thioridazine hydrochloride	CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	HTR6|HTR7|HTR1A|HTR2A|HTR2C|KCNH2|HRH1|ADRA1B|ADRA1A|MALT1|DRD3|DRD4|DRD1|DRD2|DRD5|CHRNA7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=100|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=100|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=100|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00679|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=100|https://www.drugbank.ca/drugs/DB00679|https://www.drugbank.ca/drugs/DB00679|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091404|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00679|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=100|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091404	dopamine receptor antagonist			
propofol	propofol	Disoprivan|ICI 35,868|ICI-35868|Rapinovet|diprivan|disoprofol|lusedra	CC(C)c1cccc(C(C)C)c1O	Launched	FDA Orange Book: fospropofol disodium, propofol	GABRP|GABRQ|GABRD|GABRE|CYP2B6|TRPV1|FAAH|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRG3|GABRG1|GABRG2|SCN2A|SCN4A	ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090057|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090057|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000662|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00818|https://www.drugbank.ca/drugs/DB00818	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0403897-79f5-4086-94b7-56c0cb7ee65c
tivantinib	tivantinib	ARQ 197|ARQ-197	O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01244191	MET	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7948	tyrosine kinase inhibitor			
arglabin	arglabin		CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13	Launched	http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI%3A73228	NFKB1|FNTA	http://www.hellobio.com/arglabin-6425.html|http://www.hellobio.com/arglabin-6425.html	farnesyltransferase inhibitor			
carmofur	carmofur	Mifurol	CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O	Launched	http://www.drugs.com/international/carmofur.html	TYMS	http://www.genome.jp/dbget-bin/www_bget?dr:D01784	thymidylate synthase inhibitor	oncology|oncology	breast cancer|colorectal cancer	https://en.wikipedia.org/wiki/Carmofur|https://en.wikipedia.org/wiki/Carmofur
estradiol	estradiol	Alfatradiol|Aquagen|Climara Pro|Depo-Estradiol|E-Cypionate|Gynodiol|Gynogen|Vagifem 18|Vagifem 8|agofollin|alora|climara|destradiol|dihydrotheelin|dihydroxyestrin|divigel|elestrim|elestrin|esclim|estrace|estraderm|estradiol hemihydrate|estrasorb|estring|estrogel|evamist|fempatch|gvnodiol|gynergon|gynoestryl|innofem|menostar|minivelle|oestradiol|vagifem|vivelle|vivelle-dot	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O	Launched	FDA Orange Book: estradiol, estradiol acetate, estradiol cypionate, estradiol hemihydrate, estradiol valerate, ethinyl estradiol, polyestradiol phosphate	GPER1|ESR2|ESR1|CYP3A7|CYP3A5|CYP2B6|CYP2C8|CYP2E1|NR1I2|KCNMA1|CYP2C19	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1013|https://www.drugbank.ca/drugs/DB00783|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070490|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070490|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070490|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070490|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070490|https://www.drugbank.ca/drugs/DB00783|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1013|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070490	estrogen receptor agonist	endocrinology	contraceptive	https://en.wikipedia.org/wiki/Estradiol#Medical_uses
itraconazole	itraconazole	R 51,211|R-51211|Sporanos|onmel|sporanox	CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O	Launched	FDA Orange Book: itraconazole	KDR|CYP3A5|CYP3A7|CYP51A1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090519|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090519|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090519|https://www.drugbank.ca/drugs/DB01167	cytochrome P450 inhibitor	infectious disease|infectious disease|infectious disease|infectious disease	onychomycosis|histoplasmosis|blastomycosis|aspergillosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=599dcdd0-df9b-41e2-a767-b1f44f466fbd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=599dcdd0-df9b-41e2-a767-b1f44f466fbd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=599dcdd0-df9b-41e2-a767-b1f44f466fbd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=599dcdd0-df9b-41e2-a767-b1f44f466fbd
GNF-7	GNF-7		CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C	Preclinical		GCK|ABL1|BCR|TNK2	https://www.tocris.com/products/gnf-7_5607|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=705126|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=705126|https://www.tocris.com/products/gnf-7_5607	protein kinase inhibitor|glucokinase inhibitor			
tarafenacin	tarafenacin	SVT-40776	Fc1cccc(c1)N(Cc1cc(F)c(F)c(F)c1)C(=O)O[C@H]1CN2CCC1CC2	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01458197	CHRM3	http://www.apexbt.com/tarafenacin.html	acetylcholine receptor antagonist			
liothyronine-(isomer)	liothyronine-(isomer)	DT-3|detrothyronine|dextrothyronine	N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O	Preclinical							
opicapone	opicapone		Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01851850	COMT	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853535/	catechol O methyltransferase inhibitor			
azelaic-acid	azelaic acid	ZK 62498|ZK-62498|azelaic acid|azelex|finacea|finacea 	OC(=O)CCCCCCCC(O)=O	Launched	FDA Orange Book: azelaic acid	SRD5A2|TXNRD2|TXNRD1|TYR|AKR1D1	https://www.drugbank.ca/drugs/DB00548|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090898|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090898|https://www.drugbank.ca/drugs/DB00548|https://www.drugbank.ca/drugs/DB00548	tyrosinase inhibitor	dermatology	rosacea	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc81df32-d949-4aac-9757-e1175005732a
hemoglobin-modulators-1	hemoglobin-modulators-1		CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O	Phase 3	http://ir.globalbloodtx.com/phoenix.zhtml?c=254105&p=irol-newsArticle&ID=2238100			hemoglobin modulator			
hydroxyprogesterone	hydroxyprogesterone		CC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C	Launched	FDA Orange Book: hydroxyprogesterone caproate	PGR	https://en.wikipedia.org/wiki/17-Hydroxyprogesterone	progesterone receptor agonist	obstetrics/gynecology	spontaneous preterm birth	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1998c1d-8337-4f00-8dcb-af3b54d39b77
proadifen	proadifen		CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1	Preclinical		NOS1	http://www.scbt.com/datasheet-200492.html	nitric oxide synthase inhibitor			
CYC116	CYC116	CYC-116	Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00560716	AURKC|AURKB|AURKA|KDR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=372230|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000010|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000010|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000010	Aurora kinase inhibitor			
GSK2801	GSK2801		CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O	Preclinical		BAZ2B|BAZ2A|ZNF215	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8233|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8233|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=823351	bromodomain inhibitor			
aminopurvalanol-a	aminopurvalanol a	aminopurvalanol	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1	Preclinical		CDK2|CDK1|CDK6|CDK5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5927|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5927|https://www.drugbank.ca/drugs/DB07379|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5927	CDK inhibitor|tyrosine kinase inhibitor			
ML-281	ML-281		CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O	Preclinical		STK33	https://www.tocris.com/products/ml-281_4880	serine/threonine kinase inhibitor			
SGI-1027	SGI-1027		Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1	Preclinical		DNMT1|DNMT3A|DNMT3B	https://www.tocris.com/dispprod.php?ItemId=405876#.VyuugWQrJZJ|https://www.tocris.com/dispprod.php?ItemId=405876#.VyuugWQrJZJ|https://www.tocris.com/dispprod.php?ItemId=405876#.VyuugWQrJZJ	DNA methyltransferase inhibitor			
3,5-DHPG-(S)	(S)-3,5-DHPG		N[C@H](C(O)=O)c1cc(O)cc(O)c1	Preclinical				glutamate receptor agonist			
rocuronium	rocuronium	rocuronium bromide|zemuron	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1	Launched	FDA Orange Book: rocuronium bromide	CHRNA2|CHRM2|HTR3A	https://www.drugbank.ca/drugs/DB00728|https://www.drugbank.ca/drugs/DB00728|https://www.drugbank.ca/drugs/DB00728	acetylcholine receptor antagonist	neurology/psychiatry	anesthetic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1933332-1ae0-4dc1-be4c-694849e6c9f9
SKF-38393	SKF-38393	NCG-C00093856-01|SK&F-38393|SK&F-383933|SK-38393|SK-383933	Oc1cc2CCNCC(c3ccccc3)c2cc1O	Preclinical		CALY|DRD1|DRD5	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001339|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=935|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=935	dopamine receptor agonist			
TMC-353121	TMC-353121		Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1	Phase 2	https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003439-53/BE			RSV fusion inhibitor			
cresopirine	cresopirine		CC(=O)Oc1c(C)cccc1C(O)=O	Preclinical							
pazufloxacin	pazufloxacin	Pasil	C[C@H]1COc2c(c(F)cc3c2n1cc(C(O)=O)c3=O)C1(N)CC1	Launched	http://www.drugs.com/international/pazufloxacin.html			topoisomerase inhibitor	infectious disease|infectious disease|infectious disease	pneumonia|peritonitis|bacterial septicemia	https://www.mims.com/India/drug/info/PAZUBID/PAZUBID%20infusion|https://www.mims.com/India/drug/info/PAZUBID/PAZUBID%20infusion|https://www.mims.com/India/drug/info/PAZUBID/PAZUBID%20infusion
piperazinedione	piperazinedione	Piperazine-2,5-Dione|diketopiperazine	O=C1CNC(=O)CN1	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/3755650			DNA synthesis inhibitor			
hypoxanthine	hypoxanthine		O=c1[nH]cnc2nc[nH]c12	Preclinical		PNP	https://www.drugbank.ca/drugs/DB04076	PARP inhibitor			
icilin	icilin	Icillin	Oc1ccccc1N1CC=C(NC1=O)c1cccc(c1)[N+]([O-])=O	Phase 1	http://www.medicaljournals.se/acta/content/download.php?doi=10.2340/00015555-1244	TRPM8|TRPA1	https://www.tocris.com/dispprod.php?ItemId=38283#.VykBiGQrImI|https://www.tocris.com/dispprod.php?ItemId=38283#.VykBiGQrImI	TRPV agonist			
PDP-EA	PDP-EA		CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1	Preclinical		FAAH	https://www.tocris.com/products/pdp-ea_5210	FAAH activator			
go-6983	go-6983	Go-6893	COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1	Preclinical		PRKCZ|PRKCD|PRKCG|PRKCA|PRKCB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192	protein kinase inhibitor			
URB597	URB597		NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00916201	FAAH2|FAAH|TRPA1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4339|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4339|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4339	FAAH inhibitor			
PFI-4	PFI-4		COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1	Preclinical		BRPF1	https://www.tocris.com/products/pfi-4_5576	bromodomain inhibitor			
dextroamphetamine	dextroamphetamine	Dexampex|Dextrostat|Ferndex|d-Amphetamine|dexamfetamine|dexamphetamine|dexedrine|dextroamphetamine resin complex|dextroamphetamine sulfate	C[C@H](N)Cc1ccccc1	Launched	FDA Orange Book: dextroamphetamine adipate, dextroamphetamine resin complex, dextroamphetamine saccharate, dextroamphetamine sulfate	SLC18A2|ADRA1B|ADRA1A|SLC6A2|SLC6A3|TAAR1	ChEMBL|https://www.drugbank.ca/drugs/DB01576|https://www.drugbank.ca/drugs/DB01576|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB01576	monoamine oxidase inhibitor	neurology/psychiatry|neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)|narcolepsy	https://en.wikipedia.org/wiki/Dextroamphetamine|https://en.wikipedia.org/wiki/Dextroamphetamine
azaguanine-8	azaguanine-8	8-Azaguanine	Nc1nc2[nH]nnc2c(=O)[nH]1	Preclinical		PNP	https://www.drugbank.ca/drugs/DB01667	purine antagonist			
XL-647	XL-647	KD-019|KD-020|tesevatinib	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01487174	FLT4|EGFR|EPHB4|SRC|ERBB2|KDR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7944|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7944|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7944|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=345084|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7944|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7944	EGFR inhibitor|VEGFR inhibitor			
bupivacaine	bupivacaine	Anekain|SKY0402|bupivacaine hydrochloride|bupivacaine hydrochloride kit|exparel|marcaine|marcaine hydrochloride|marcaine hydrochloride preservative free|sensorcaine	CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C	Launched	FDA Orange Book: bupivacaine, bupivacaine hydrochloride, levobupivacaine hydrochloride	SCN10A|KCNA5|PTGER1|SCN9A|SCN4A	https://www.drugbank.ca/drugs/DB00297|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2397|https://www.drugbank.ca/drugs/DB00297|https://citeline.informa.com/?query=#/drugs/details/27817|ChEMBL	sodium channel blocker	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	peripheral nerve block|caudal epidural block|lumbar epidural block	https://en.wikipedia.org/wiki/Bupivacaine|https://en.wikipedia.org/wiki/Bupivacaine|https://en.wikipedia.org/wiki/Bupivacaine
PD-184352	PD-184352	CI-1040|PD-18435	Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00033384	MAP3K2|MAP3K1|MAP2K1|MAP2K2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001105|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001105|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5676|https://citeline.informa.com/?query=#/drugs/details/23074	MEK inhibitor			
PD-168077	PD-168077	PD-168,077	Cc1cccc(c1)C(=O)NCN1CCN(CC1)c1ccccc1C#N	Preclinical		DRD4|DRD2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=298982|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012281	dopamine receptor agonist			
cytarabine	cytarabine	Tarabine PFS|U-19,920|U-19920|ara-cytidine|arabinosyl cytosine|cytosar-u|depocyt	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1	Launched	FDA Orange Book: cytarabine	POLB|POLE|POLA1|POLD1	https://www.drugbank.ca/drugs/DB00987|ChEMBL|ChEMBL|ChEMBL	ribonucleotide reductase inhibitor	hematologic malignancy|hematologic malignancy|hematologic malignancy|hematologic malignancy	acute lymphoblastic leukemia (ALL)|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|non-Hodgkin lymphoma (NHL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b48842dd-c5c9-484c-a3f5-cb883919b418|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b48842dd-c5c9-484c-a3f5-cb883919b418|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b48842dd-c5c9-484c-a3f5-cb883919b418|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b48842dd-c5c9-484c-a3f5-cb883919b418
pramiracetam	pramiracetam		CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C	Launched	http://www.drugs.com/international/Pramiracetam.html			acetylcholine receptor agonist			
CG-400549	CG-400549	CG-400459|CG400549	Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01593761			FABI inhibitor			
isofloxythepin	isofloxythepin		CC(C)c1ccc2Sc3cc(F)ccc3CC(N3CCN(CCO)CC3)c2c1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/2571218			dopamine receptor antagonist			
4-propylbenzoic-acid	4-propylbenzoic acid	4-Propyl-Benzoic Acid|4-Propylbenzoic Acid	CCCc1ccc(cc1)C(O)=O	Preclinical							
romidepsin	romidepsin	depsipeptide|istodax	C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C	Launched	FDA Orange Book: romidepsin	CYP2C19|HDAC8|HDAC7|HDAC9|HDAC4|HDAC3|HDAC6|HDAC5|HDAC2|HDAC1|CYP3A5|CYP2B6	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=158963|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7006|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7006|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7006|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7006|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7006|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7006|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7006|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7006|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7006|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=158963|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=158963	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6005c345-ccf9-4fff-8660-3fd73485b0d9
amylene-hydrate	amylene hydrate	Tertiary Amyl Alcohol|Tertiary Pentyl Alchol|amylene hydrate	CCC(C)(C)O	Preclinical				local anesthetic			
atizoram	atizoram		COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1	Phase 2	https://books.google.com/books?id=tbUvRs_qr2IC&pg=PA93&lpg=PA93&dq=atizoram+clinical+trial&source=bl&ots=x9jsXdpf8z&sig=7loB8skTVuWNdgUYTUOa0uOPLAY&hl=en&sa=X&ved=0ahUKEwibjbiO5-fPAhXBqR4KHcjbAGMQ6AEILDAC#v=onepage&q=atizoram%20clinical%20trial&f=false	PDE4A|PDE4B|PDE4C|PDE4D	https://en.wikipedia.org/wiki/Atizoram|https://en.wikipedia.org/wiki/Atizoram|https://en.wikipedia.org/wiki/Atizoram|https://en.wikipedia.org/wiki/Atizoram	phosphodiesterase inhibitor			
evacetrapib	evacetrapib	LY2484595	Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01687998	CETP	https://en.wikipedia.org/wiki/Evacetrapib	cholesteryl ester transfer protein inhibitor			
pafuramidine	pafuramidine		CONC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(=N)NOC	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00302341			DNA synthesis inhibitor			
nomifensine	nomifensine	Alival|Merital	CN1CC(c2ccccc2)c2cccc(N)c2C1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	DRD2|MPO|MAOB|MAOA|SLC6A2|SLC6A3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000339|https://www.drugbank.ca/drugs/DB04821|https://www.drugbank.ca/drugs/DB04821|https://www.drugbank.ca/drugs/DB04821|https://www.drugbank.ca/drugs/DB04821|https://www.drugbank.ca/drugs/DB04821	dopamine uptake inhibitor|noradrenaline uptake inhibitor			
NS-3623	NS-3623		FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nnn[nH]2)c1	Preclinical		KCNH2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7660	voltage-gated potassium channel activator			
peruvoside	peruvoside		CO[C@H]1[C@@H](O)C(C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)C1O	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/4919553			cardiac glycoside			
aztreonam	aztreonam	SO 26776|SQ-26776|azactam|cayston	C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O	Launched	FDA Orange Book: aztreonam			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	urinary tract infections|respiratory tract infections|bacterial septicemia|skin infections|intra-abdominal infections|gynecologic infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=302fd27d-0a22-44ea-91fb-1b1ffcf17a1f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=302fd27d-0a22-44ea-91fb-1b1ffcf17a1f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=302fd27d-0a22-44ea-91fb-1b1ffcf17a1f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=302fd27d-0a22-44ea-91fb-1b1ffcf17a1f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=302fd27d-0a22-44ea-91fb-1b1ffcf17a1f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=302fd27d-0a22-44ea-91fb-1b1ffcf17a1f
calcipotriol	calcipotriol	MC 903|MC-903|calcipotriene|calcipotriene hydrate|dovonex|sorilux	C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	Launched	FDA Orange Book: calcipotriene, calcipotriene hydrate	VDR	ChEMBL	vitamin D receptor agonist	dermatology	psoriasis	https://en.wikipedia.org/wiki/Calcipotriol
artemotil	artemotil		CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3	Launched	http://www.drugs.com/international/Artemotil.html				infectious disease	malaria	https://en.wikipedia.org/wiki/Artemotil
atovaquone	atovaquone	mepron	Clc1ccc(cc1)[C@H]1CC[C@@H](CC1)C1C(=O)C(=O)c2ccccc2C1=O	Launched	FDA Orange Book: atovaquone	DHODH	https://www.drugbank.ca/drugs/DB01117	mitochondrial electron transport inhibitor	infectious disease	pneumonia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55eb29e3-6c28-4274-8330-9ace09f6659e
dimetindene	dimetindene	dimethindene	CC(C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1	Launched	https://www.drugs.com/international/dimetindene.html	HRH1|CHRM2	https://www.drugbank.ca/drugs/DB08801|https://www.drugbank.ca/drugs/DB08801	histamine receptor antagonist|cholinergic receptor antagonist	allergy	allergic rhinitis	https://www.drugs.com/international/dimetindene.html
betaxolol	betaxolol	Kerledex|betaxolol hydrochloride|betoptic|betoptic s|kerlone		Launched	FDA Orange Book: betaxolol hydrochloride	ADRB2|ADRB1	https://www.drugbank.ca/drugs/DB00195|https://www.drugbank.ca/drugs/DB00195	adrenergic receptor antagonist	ophthalmology|ophthalmology|ophthalmology	intraocular pressure|glaucoma|ocular hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fc0a413-4e6b-4ed7-9957-ace4c8cfab55|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fc0a413-4e6b-4ed7-9957-ace4c8cfab55|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fc0a413-4e6b-4ed7-9957-ace4c8cfab55
isosorbide-mononitrate	isosorbide mononitrate	AHR-4698|BM 22.145|BM-22-145|IS 5-MN|IS-5-MN|imdur|ismo|isosorbide mononitrate|monoket	O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O	Launched	FDA Orange Book: isosorbide mononitrate	GUCY1A3|GUCY1A2|GUCY1B2|GUCY1B3	ChEMBL|ChEMBL|ChEMBL|ChEMBL	nitric oxide stimulant	cardiology|cardiology	angina pectoris|coronary artery disease (CAD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec09ab1c-52fa-4f41-bf65-a632dce8f097|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec09ab1c-52fa-4f41-bf65-a632dce8f097
SNC-80	SNC-80		CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1	Preclinical		OPRD1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1611				
dimethadione	dimethadione	AC 1198|BAX 1400Z	CC1(C)OC(=O)NC1=O	Preclinical				oxazolidine antiepileptic			
AZ20	AZ20		C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O	Preclinical		ATR|MTOR	https://www.tocris.com/dispprod.php?ItemId=415746#.VyeOFGQrImJ|https://www.tocris.com/dispprod.php?ItemId=415746#.VyeOFGQrImJ	ATR kinase inhibitor			
L-NIL	L-NIL		CC(=N)NCCCC[C@H](N)C(O)=O	Preclinical		NOS3|NOS2|NOS1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008173|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5231|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008173	nitric oxide synthase inhibitor			
nicotinyl-alcohol-tartrate	nicotinyl alcohol tartrate	NU-2121|Nicotinyl Alcohol (Pyridylcarbinol)|RO 1-5155|nicotinyl alcohol|nicotinyl alcohol tartrate|pyridylcarbinol|pyridylmethanol|roniacol	OCc1cccnc1	Launched	http://www.drugs.com/international/nicotinyl-alcohol-tartrate.html						
mexeneone	mexeneone	mexenone	COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1	Preclinical							
dalfampridine	dalfampridine	Ampyra Extended Release|EL-970|ampyra|fampridine|neurelan	Nc1ccncc1	Launched	FDA Orange Book: dalfampridine	KCNV1|KCNV2|KCNS2|KCNS3|KCNS1|KCNQ4|KCNQ5|KCNQ2|KCNQ3|KCNQ1|KCNA10|KCNG2|KCNG3|KCNG1|KCNG4|KCNF1|KCND3|KCND1|KCND2|KCNJ5|KCNH3|KCNH4|KCNH1|KCNH2|KCNH7|KCNH8|KCNH5|KCNH6|KCNC4|KCNC2|KCNC3|KCNC1|KCNB1|KCNB2|KCNA4|KCNA5|KCNA2|KCNA3|KCNA6|KCNA7|KCNA1|KCNJ13	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001551|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416	potassium channel blocker	neurology/psychiatry	multiple sclerosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=550eb76a-e4a6-4fa1-ad65-c0fd8b0ce783
pantoprazole	pantoprazole	BY 1023|BY-1023|SK&F 96022|SK&F-96022|SK-96022|protonix|protonix iv	COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC	Launched	FDA Orange Book: pantoprazole sodium	ATP4A|CYP3A4|CYP2C19	https://www.drugbank.ca/drugs/DB00213|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=163674|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=163674	ATPase inhibitor	gastroenterology|gastroenterology|gastroenterology	gastroesophageal reflux disease (GERD)|erosive esophagitis (EE)|Zollinger-Ellison syndrome	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eda64039-771b-41d7-b9c4-970cfbf5fbb9|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eda64039-771b-41d7-b9c4-970cfbf5fbb9|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eda64039-771b-41d7-b9c4-970cfbf5fbb9
minerval	minerval		CCCCCCCC\C=C/CCCCCCC(O)C(O)=O	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT01792310	FAAH	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=407338	FAAH inhibitor			
cefmenoxime	cefmenoxime	cefmax	CO\N=C(\C(=O)NC1C2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1	Launched	FDA Orange Book: cefmenoxime hydrochloride			bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections	http://www.drugbank.ca/drugs/DB00267
procaterol	procaterol		CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12	Launched	http://www.drugs.com/international/Procaterol.html	ADRB2	https://www.drugbank.ca/drugs/DB01366	adrenergic receptor agonist	pulmonary	asthma	https://en.wikipedia.org/wiki/Procaterol
TXA127	TXA127		CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N1CCC[C@H]1C(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00771810			angiotensin receptor agonist			
citalopram	citalopram	celexa|citalopram hydrobromide	CN(C)CCCC1(OCc2cc(ccc12)C#N)c1ccc(F)cc1	Launched	FDA Orange Book: citalopram hydrobromide, escitalopram oxalate	SLC6A4|SLC6A2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7547|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7547	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2632b547-2e13-447f-ac85-c774e437d6a8
L-Arginine	L-Arginine	D-Arginine|r-gene 10	N[C@H](CCCNC(N)=N)C(O)=O	Launched	https://clinicaltrials.gov/ct2/show/NCT00777075	GPRC6A|ASS1|ARG2|ASL|AZIN2|SLC7A3|SLC7A4|SLC7A1|NOS3|NOS2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721|https://www.drugbank.ca/drugs/DB00125|https://www.drugbank.ca/drugs/DB00125|https://www.drugbank.ca/drugs/DB00125|https://www.drugbank.ca/drugs/DB00125|https://www.drugbank.ca/drugs/DB00125|https://www.drugbank.ca/drugs/DB00125|https://www.drugbank.ca/drugs/DB00125|https://www.drugbank.ca/drugs/DB00125|https://www.drugbank.ca/drugs/DB00125	nitric oxide precursor	cardiology|cardiology|cardiology|cardiology|neurology/psychiatry|urology|obstetrics/gynecology|otolaryngology	congestive heart failure|hypertension|coronary artery disease (CAD)|claudication|senile dementia|erectile dysfunction|infertility|common cold	http://www.webmd.com/vitamins-supplements/ingredientmono-875-l-arginine.aspx?activeingredientid=875&activeingredientname=l-arginine|http://www.webmd.com/vitamins-supplements/ingredientmono-875-l-arginine.aspx?activeingredientid=875&activeingredientname=l-arginine|http://www.webmd.com/vitamins-supplements/ingredientmono-875-l-arginine.aspx?activeingredientid=875&activeingredientname=l-arginine|http://www.webmd.com/vitamins-supplements/ingredientmono-875-l-arginine.aspx?activeingredientid=875&activeingredientname=l-arginine|http://www.webmd.com/vitamins-supplements/ingredientmono-875-l-arginine.aspx?activeingredientid=875&activeingredientname=l-arginine|http://www.webmd.com/vitamins-supplements/ingredientmono-875-l-arginine.aspx?activeingredientid=875&activeingredientname=l-arginine|http://www.webmd.com/vitamins-supplements/ingredientmono-875-l-arginine.aspx?activeingredientid=875&activeingredientname=l-arginine|http://www.webmd.com/vitamins-supplements/ingredientmono-875-l-arginine.aspx?activeingredientid=875&activeingredientname=l-arginine
methoxsalen	methoxsalen	8-METHOXYPSORALEN|8-mop|oxsoralen|oxsoralen-ultra|uvadex|xanthotoxin	COc1c2occc2cc2ccc(=O)oc12	Launched	FDA Orange Book: methoxsalen	CYP2A13|CYP1A2|CYP1A1|CYP2A6|ACHE|CYP3A4	http://www.drugbank.ca/drugs/DB00553|http://www.drugbank.ca/drugs/DB00553|http://www.drugbank.ca/drugs/DB00553|http://www.drugbank.ca/drugs/DB00553|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=206597|http://www.drugbank.ca/drugs/DB00553	DNA synthesis inhibitor	dermatology	psoriasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6432c42-e53d-4077-bf7b-f33349349de6
AZD4282	AZD4282	aminoacetic acid|glycine|glycocoll|glycolixir	NCC(O)=O	Phase 1	http://adisinsight.springer.com/drugs/800016835	GARS|GATM|GLRA3|GLRA2|GLRA1|GCAT|SLC6A9|GCSH|SLC6A5|SLC32A1|PIPOX|AGXT|GPRC6A|AGXT2|GSS|GPR18|ALAS1|ALAS2|SHMT2|SHMT1|SLC36A1|GNMT|BAAT|GRIN1|GLYAT|GLYATL1|GLYATL2|GRIN2D|GRIN3B|GRIN2A|GRIN2C|GRIN2B|GLDC|GLRB	https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727|https://www.drugbank.ca/drugs/DB00145|https://www.drugbank.ca/drugs/DB00145	glutamate receptor antagonist			
MRK-409	MRK-409		Cn1ncnc1COc1nn2c(nnc2cc1C1CCC1)-c1c(F)cccc1F	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/21309116			benzodiazepine receptor agonist			
cetrimonium	cetrimonium		CCCCCCCCCCCCCCCC[N+](C)(C)C	Launched	http://www.drugs.com/international/Cetrimonium.html				dermatology	cosmetic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa72ab8d-3883-408b-8602-a4417d3acd1b
CUDC-101	CUDC-101		COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00728793	EGFR|ERBB2	https://www.caymanchem.com/product/16426|https://www.caymanchem.com/product/16426	EGFR inhibitor			
C-1	C-1		O=S(=O)(N1CCNCC1)c1cccc2cnccc12	Preclinical		PRKCA	http://www.tocris.com/dispprod.php?ItemId=2087#.VfGahCxVhHw	protein kinase inhibitor			
GW-1929	GW-1929		CN(CCOc1ccc(CC(Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1	Preclinical		PPARG|INS	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2703|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=278223	PPAR receptor agonist			
fluprazine	fluprazine		NC(=O)NCCN1CCN(CC1)c1cccc(c1)C(F)(F)F	Phase 1	Pharmaprojects	HTR1A|HTR1B	https://en.wikipedia.org/wiki/Fluprazine|https://en.wikipedia.org/wiki/Fluprazine	serotonin receptor agonist			
azalomycin-b	azalomycin b		CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@@H]1OC(=O)\C=C\C=C\[C@@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1	Preclinical				bacterial 50S ribosomal subunit inhibitor			
mabuprofen	mabuprofen		CC(C)Cc1ccc(cc1)C(C)C(=O)NCCO	Launched	https://www.drugs.com/international/mabuprofen.html			cyclooxygenase inhibitor	neurology/psychiatry	pain relief	http://druginfosys.com/Drug.aspx?drugCode=795&drugName=Aminoprofen&type=7
lylamine	lylamine		CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1	Preclinical		CNR1	http://www.tocris.com/dispprod.php?ItemId=109462#.Ut_lav30BaE	cannabinoid receptor agonist			
ceftiofur	ceftiofur		CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1	Veterinary Launched	http://en.wikipedia.org/wiki/Ceftiofur			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease	pneumonia|respiratory tract infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19416c94-4aab-49a9-9195-0d65f945d532|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19416c94-4aab-49a9-9195-0d65f945d532
midodrine	midodrine	midodrine hydrochloride|proamatine	COc1ccc(OC)c(c1)C(O)CNC(=O)CN	Launched	FDA Orange Book: midodrine hydrochloride	ADRA1D|ADRA1B|ADRA1A	https://www.drugbank.ca/drugs/DB00211|https://www.drugbank.ca/drugs/DB00211|https://www.drugbank.ca/drugs/DB00211	adrenergic receptor agonist	cardiology	hypotension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=937e679e-1e86-48de-a69f-83ed7a98e76e
ledipasvir	ledipasvir	GS-5885	COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1ncc([nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C	Launched	FDA Orange Book: ledipasvir			HCV inhibitor	infectious disease	hepatitis C	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4ec77e4-bae8-4db0-b3d5-bde09c5fa075
hexetidine	hexetidine	hexopyrimidine|sterisil	CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1	Launched	http://www.drugs.com/international/hexetidine.html			local anesthetic	otolaryngology|infectious disease|otolaryngology|dental|gastroenterology	pharyngitis|meningitis|laryngitis|gingivitis|ulcerative colitis	https://en.wikipedia.org/wiki/Hexetidine|https://en.wikipedia.org/wiki/Hexetidine|https://en.wikipedia.org/wiki/Hexetidine|https://en.wikipedia.org/wiki/Hexetidine|https://en.wikipedia.org/wiki/Hexetidine
tigecycline	tigecycline	tygacil	CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(cc(NC(=O)CNC(C)(C)C)c(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C	Launched	FDA Orange Book: tigecycline			bacterial 30S ribosomal subunit inhibitor	infectious disease|infectious disease|infectious disease	skin infections|pneumonia|intra-abdominal infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ccdb48e-c14a-4eeb-348c-4920ccfd7465&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ccdb48e-c14a-4eeb-348c-4920ccfd7465&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ccdb48e-c14a-4eeb-348c-4920ccfd7465&audience=consumer
selumetinib	selumetinib	ARRY-142886|ARRY-886|AZD-6244|AZD6244	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01933932	MAP2K2|MAP2K1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=355417|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5665	MEK inhibitor			
beta-lapachone	beta-lapachone	Lapachone, Beta-	CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00102700	E2F1|IDO1|TDO2|TOP1	https://citeline.informa.com/?query=#/drugs/details/25690|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=282732|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=282732|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000494	topoisomerase inhibitor			
2-Deoxy-2-{[methyl(nitroso)carbamoyl]amino}hexose	2-Deoxy-2-{[methyl(nitroso)carbamoyl]amino}hexose		CN([N+][O-])C(=O)NC(C=O)C(O)C(O)C(O)CO	Preclinical					oncology|endocrinology	pancreatic cancer|hypoglycemia	https://en.wikipedia.org/wiki/Streptozotocin|https://en.wikipedia.org/wiki/Streptozotocin
vesnarinone	vesnarinone	OPC-8212|arkin	COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1	Launched	https://www.drugs.com/international/vesnarinone.html	KCNA3|KCNH2|PDE3A|VCP|IL6R	https://citeline.informa.com/?query=#/drugs/details/19041|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003894|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003894|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090576|https://citeline.informa.com/?query=#/drugs/details/19041	phosphodiesterase inhibitor	cardiology	congestive heart failure	https://en.wikipedia.org/wiki/Vesnarinone
MDL-72832	MDL-72832		O=C1CC2(CCCC2)CC(=O)N1CCCCNCC1COc2ccccc2O1	Preclinical		HTR1A	https://www.tocris.com/dispprod.php?ItemId=1573#.VytsPWQrJZI	serotonin receptor agonist			
levosulpiride	levosulpiride		CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O	Launched	http://www.drugs.com/international/levosulpiride.html	DRD2|DRD3|CA12|CA7|CA1	https://www.drugbank.ca/drugs/DB00391|https://www.drugbank.ca/drugs/DB00391|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5501|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5501|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5501	dopamine receptor antagonist	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|gastroenterology|gastroenterology|urology	schizophrenia|psychosis|anxiety|vertigo|dyspepsia|irritable bowel syndrome|premature ejaculation (PE)	https://en.wikipedia.org/wiki/Levosulpiride|https://en.wikipedia.org/wiki/Levosulpiride|https://en.wikipedia.org/wiki/Levosulpiride|https://en.wikipedia.org/wiki/Levosulpiride|https://en.wikipedia.org/wiki/Levosulpiride|https://en.wikipedia.org/wiki/Levosulpiride|https://en.wikipedia.org/wiki/Levosulpiride
arsenic-trioxide	arsenic trioxide	trisenox	O[AsH]O[AsH]O	Launched	FDA Orange Book: arsenic trioxide	JUN|AKT1|TXNRD1|MAPK3|MAPK1|CCND1|IKBKB	https://www.drugbank.ca/drugs/DB01169|https://www.drugbank.ca/drugs/DB01169|https://www.drugbank.ca/drugs/DB01169|https://www.drugbank.ca/drugs/DB01169|https://www.drugbank.ca/drugs/DB01169|https://www.drugbank.ca/drugs/DB01169|https://www.drugbank.ca/drugs/DB01169	apoptosis stimulant	gastroenterology	diarrhea	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3f40f9b-2553-4926-9ae7-0659792d84a5
AMG458	AMG458	AMG-458	COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1	Preclinical		MET	http://www.scbt.com/datasheet-364400-CASNumber-913376-83-7.html	MET inhibitor			
MK-8033	MK-8033		Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00559182	MST1R|MET	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=470348|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000574	c-Met inhibitor			
AGI-6780	AGI-6780		FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1	Preclinical		IDH2	http://www.apexbt.com/agi-6780.html	isocitrate dehydrogenase inhibitor			
E-64	E-64		CC(C)C[C@H](NC(=O)[C@@H]1O[C@H]1C(O)=O)C(=O)NCCCCN=C(N)N	Preclinical		CTSS	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000588	cysteine protease inhibitor|calpain inhibitor			
darifenacin	darifenacin	UK-88525|enablex	NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1	Launched	FDA Orange Book: darifenacin hydrobromide	CHRM5|CHRM1|CHRM2|CHRM3|CHRM4	https://www.drugbank.ca/drugs/DB00496|https://www.drugbank.ca/drugs/DB00496|https://www.drugbank.ca/drugs/DB00496|https://www.drugbank.ca/drugs/DB00496|https://www.drugbank.ca/drugs/DB00496	acetylcholine receptor antagonist	urology	urinary incontinence	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a293cece-e97a-4e67-be72-b187568e3b11
SB-334867	SB-334867		Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1	Preclinical		HCRTR1|HCRTR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1703|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1703	orexin receptor antagonist			
alagebrium	alagebrium		Cc1sc[n+](CC(=O)c2ccccc2)c1C	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT01417663			glycosylation inhibitor			
corosolic-acid	Corosolic Acid	Corosolic Acid	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/12787964	PTPN1|HSD11B1	http://www.nature.com/articles/srep26854|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010347	PKC inhibitor|protein tyrosine kinase inhibitor			
pibenzimol	pibenzimol	HOE-33258|HOECHST 33258		Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/1709154			DNA inhibitor			
BTT-3033	BTT-3033		CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1	Preclinical		ITGB1|ITGA2	https://www.tocris.com/products/btt-3033_4724|https://www.tocris.com/products/btt-3033_4724	integrin inhibitor			
TG-100713	TG-100713		Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1	Preclinical				PI3K inhibitor			
tanespimycin	tanespimycin	BMS-722782	CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00546780	HSP90AA1|CHEK1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000242|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=231090	HSP inhibitor			
cefuroxime	cefuroxime	zinacef	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1	Launched	FDA Orange Book: cefuroxime axetil, cefuroxime sodium			bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections	https://en.wikipedia.org/wiki/Cefpirome
SDZ-21009	SDZ-21009	carpindolol	CC(C)OC(=O)c1cc2c(OCC(O)CNC(C)(C)C)cccc2[nH]1	Preclinical		HTR1A|HTR1B	http://www.tocris.com/dispprod.php?ItemId=34271#.Vg6a-mRVhHw|http://www.tocris.com/dispprod.php?ItemId=34271#.Vg6a-mRVhHw	adrenergic receptor antagonist|serotonin receptor antagonist			
xylometazoline	xylometazoline		Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C	Launched	http://www.drugs.com/international/Xylometazoline.html	ADRA2C|ADRA2A|ADRA2B|ADRA1D|ADRA1B|ADRA1A	https://www.drugbank.ca/drugs/DB06694|https://www.drugbank.ca/drugs/DB06694|https://www.drugbank.ca/drugs/DB06694|https://www.drugbank.ca/drugs/DB06694|https://www.drugbank.ca/drugs/DB06694|https://www.drugbank.ca/drugs/DB06694	adrenergic receptor agonist	otolaryngology|allergy	nasal congestion|allergic rhinitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b70ba985-2894-493f-a4cf-c9102fe36d97|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b70ba985-2894-493f-a4cf-c9102fe36d97
IDRA-21	IDRA-21		CC1Nc2ccc(Cl)cc2S(=O)(=O)N1	Preclinical		GRIA3|GRIA2|GRIA1|GRIA4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4219|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4219|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4219|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4219	glutamate receptor positive allosteric modulator			
BGT226	BGT226	BGT-226|NVP-BGT226	COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT00600275	MTOR|PIK3CG|PIK3CA|PIK3CB	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001086|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7951|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7951|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7951	PI3K inhibitor			
RN-1	RN-1		CN1CCN(CC1)C(=O)CN[C@@H]1C[C@H]1c1ccc(OCc2ccccc2)cc1	Preclinical		KDM1A	https://www.tocris.com/products/rn-1-dihydrochloride_4977	histone demethylase inhibitor			
sisomicin	sisomicin	sissomicin	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	Launched	https://www.drugs.com/international/sisomicin.html			protein synthesis inhibitor	ophthalmology|ophthalmology|ophthalmology|ophthalmology	conjunctivitis|punctate keratitis|conjunctivitis|punctate keratitis	http://www.medindia.net/doctors/drug_information/sisomicin.htm|http://www.medindia.net/doctors/drug_information/sisomicin.htm|http://www.medindia.net/doctors/drug_information/sisomicin.htm|http://www.medindia.net/doctors/drug_information/sisomicin.htm
GSK429286A	GSK429286A	GSK-429286A	CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F	Preclinical		ROCK1	https://www.stemgent.com/products/show/187	rho associated kinase inhibitor			
ML-348	ML-348		FC(F)(F)c1ccc(Cl)c(NC(=O)CN2CCN(CC2)C(=O)c2ccco2)c1	Preclinical		LYPLA1	https://www.tocris.com/products/ml-348_5345	lysophospholipase inhibitor			
AZ-10606120	AZ-10606120		OCCNCCNc1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2n1	Preclinical		P2RX7	https://www.tocris.com/products/az-10606120-dihydrochloride_3323	purinergic receptor antagonist			
bosentan	bosentan	RO 47-0203/029|Ro-47-0203-029|tracleer	COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1	Launched	FDA Orange Book: bosentan	EDNRB|EDNRA|CYP2C19|ABCB1|CYP3A4	ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=203927|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=203927|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=203927	endothelin receptor antagonist	pulmonary	pulmonary arterial hypertension (PAH)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=749e42fb-2fe0-45dd-9268-b43bb3f4081c
CY208-243	CY208-243	CY-208243	CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/1535688	CALY|DRD1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000799|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=111845	dopamine receptor agonist			
VX-222	VX-222		C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01080222			HCV inhibitor			
leucovorin	leucovorin	fusilev|leucovorin calcium|leucovorin calcium preservative free|levoleucovorin calcium|wellcovorin	Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1	Launched	FDA Orange Book: leucovorin calcium, levoleucovorin calcium	TYMS	https://www.drugbank.ca/drugs/DB00650	folate receptor ligand	oncology	osteosarcoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d0e5356-ff39-4a8e-944c-e808a21ef4b2
isopentyl-4-methoxycinnamate	isopentyl-4-methoxycinnamate	E-1000|amiloxate|isoamyl methoxycinnamate	COc1ccc(cc1)\C=C\C(=O)OCCC(C)C	Launched	https://en.wikipedia.org/wiki/Amiloxate				dermatology	sunscreen lotion	https://en.wikipedia.org/wiki/Amiloxate
fenoldopam	fenoldopam	SK&F-82526|SK-82526|corlopam	Oc1ccc(cc1)C1CNCCc2c(Cl)c(O)c(O)cc12	Launched	FDA Orange Book: fenoldopam mesylate	DRD5|DRD4|DRD1|ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	https://www.drugbank.ca/drugs/DB00800|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=939|https://www.drugbank.ca/drugs/DB00800|https://www.drugbank.ca/drugs/DB00800|https://www.drugbank.ca/drugs/DB00800|https://www.drugbank.ca/drugs/DB00800|https://www.drugbank.ca/drugs/DB00800|https://www.drugbank.ca/drugs/DB00800|https://www.drugbank.ca/drugs/DB00800	dopamine receptor agonist	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7a060fa-0b7d-45eb-ecae-a4abfb16b548
Ro-1138452	Ro-1138452		CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1	Preclinical		PTGIR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1969	prostanoid receptor antagonist			
niflumic-acid	niflumic acid	UP 83|niflumic acid	OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F	Launched	http://www.drugs.com/international/niflumic-acid.html	KCNQ1|CLCNKA|CLCNKB|ANO1|UGT1A9|CLCN1|PTGS2|PTGS1|PLA2G4A|PLA2G1B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2439|https://www.drugbank.ca/drugs/DB04552|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2439|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2439|https://www.drugbank.ca/drugs/DB04552|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2439|https://www.drugbank.ca/drugs/DB04552|https://www.drugbank.ca/drugs/DB04552|https://www.drugbank.ca/drugs/DB04552|https://www.drugbank.ca/drugs/DB04552	cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	joint pain|muscle pain	https://en.wikipedia.org/wiki/Niflumic_acid|https://en.wikipedia.org/wiki/Niflumic_acid
reserpine	reserpine	hiserpia|rau-sed|sandril|serpalan|serpanray|serpasil|serpate|serpivite	CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1	Launched	FDA Orange Book: reserpine	SLC18A1|SLC18A2	https://www.drugbank.ca/drugs/DB00206|ChEMBL	vesicular monoamine transporter inhibitor	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462
2,3-cis/exo-camphanediol	2,3-cis/exo-camphanediol		CC1(C)[C@@H]2CC[C@@]1(C)[C@H](O)[C@@H]2O	Phase 1							
adarotene	adarotene		OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/22365912	RARG|RARA|RARB	http://www.apexbt.com/adarotene.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=333941|http://www.apexbt.com/adarotene.html	retinoid receptor agonist			
nifenalol	nifenalol	isophenethanol	CC(C)NCC(O)c1ccc(cc1)[N+]([O-])=O	Launched	Pharmaprojects	ADRB1|ADRB2	https://en.wikipedia.org/wiki/Nifenalol|https://en.wikipedia.org/wiki/Nifenalol	adrenergic receptor antagonist			
tegaserod	tegaserod	SDZ-HTF-919|zelmac|zelnorm	CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	HTR4|HTR2A|HTR2B|HTR2C	https://www.drugbank.ca/drugs/DB01079|https://www.drugbank.ca/drugs/DB01079|https://www.drugbank.ca/drugs/DB01079|https://www.drugbank.ca/drugs/DB01079	serotonin receptor partial agonist			
chromocarb	chromocarb		OC(=O)c1cc(=O)c2ccccc2o1	Launched	http://www.drugs.com/international/Chromocarb.html			antispasmodic			
azasetron	azasetron	azasetron hydrochloride	CN1C(=O)COc2c1cc(Cl)cc2C(=O)NC1CN2CCC1CC2	Launched	http://www.drugs.com/international/azasetron.html	HTR3B|HTR3A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2285|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2285	serotonin receptor antagonist	infectious disease	genitial herpes	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2376d17-68e2-4443-a81e-10ffcfb53ec0
medrysone	medrysone	hms		Launched	FDA Orange Book: medrysone	NR3C1	https://www.drugbank.ca/drugs/DB00253	glucocorticoid receptor agonist	ophthalmology|ophthalmology	conjunctivitis|episcleritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1612d931-d86e-4dba-bbd7-0aac3eaee131|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1612d931-d86e-4dba-bbd7-0aac3eaee131
sucrose	sucrose		OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O	Launched	https://www.drugs.com/inactive/sucrose-74.html	ATOX1|C22orf28|LYZ|ACTA1	https://www.drugbank.ca/drugs/DB02772|https://www.drugbank.ca/drugs/DB02772|https://www.drugbank.ca/drugs/DB02772|https://www.drugbank.ca/drugs/DB02772				
pacritinib	pacritinib	ONX-0803|SB-1518|SB1518	C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01773187	JAK1|JAK3|JAK2|CDK2|FLT3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7793|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7793|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7793|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=453356|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7793	FLT3 inhibitor|JAK inhibitor			
pravastatin	pravastatin	pravachol		Launched	FDA Orange Book: pravastatin sodium	HMGCR|SLCO1B1	https://www.drugbank.ca/drugs/DB00175|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2953	HMGCR inhibitor	endocrinology|cardiology|endocrinology	hypercholesterolemia|myocardial infarction|hyperlipidemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9736d9b1-9dca-36a3-5324-3bbeda537aca|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9736d9b1-9dca-36a3-5324-3bbeda537aca|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9736d9b1-9dca-36a3-5324-3bbeda537aca
deoxyepinephrine	deoxyepinephrine	deoxiepinephrine	CNCCc1ccc(O)c(O)c1	Preclinical		ADRA1A|DRD2|DRD1	http://www.sigmaaldrich.com/catalog/product/sigma/d5886?lang=en&region=US|http://www.sigmaaldrich.com/catalog/product/sigma/d5886?lang=en&region=US|http://www.sigmaaldrich.com/catalog/product/sigma/d5886?lang=en&region=US	adrenergic receptor agonist|dopamine receptor agonist			
Ro-90-7501	Ro-90-7501	GNF-Pf-5510	Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1	Preclinical		APP	https://www.tocris.com/dispprod.php?ItemId=148391#.VyuhYGQrJZJ				
5-methylhydantoin-(D)	5-methylhydantoin-(D)		C[C@H]1NC(=O)NC1=O	Preclinical							
tivozanib	tivozanib	ASP-4130|KIL8951|KRN-951|Kil-8951	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01030783	PDGFRA|PDGFRB|KDR|KIT|FLT1|FLT4	http://www.selleckchem.com/products/AV-951.html|http://www.selleckchem.com/products/AV-951.html|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6058|http://www.selleckchem.com/products/AV-951.html|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6058|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6058	VEGFR inhibitor			
fludarabine	fludarabine	2-Fluoro-Ara-A	Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	Launched	FDA Orange Book: fludarabine phosphate	RRM1|RRM2|ADA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4802|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4802|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000567	ribonucleotide reductase inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1ffd18c-9f6b-4479-94b9-6890bc730ecc
PD-153035	PD-153035	PD153035	COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/24335566	KDR|EGFR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003889|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003889	EGFR inhibitor			
furaltadone	furaltadone	nitrofurmethone	[O-][N+](=O)c1ccc(\C=N\N2CC(CN3CCOCC3)OC2=O)o1	Veterinary Launched	http://www.drugs.com/international/furaltadone.html			bacterial DNA inhibitor			
cinchonidine	cinchonidine	TCMDC-123934	O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/11187897	ABCB1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=189453	P glycoprotein inhibitor			
RU-24969	RU-24969		COc1ccc2[nH]cc(C3=CCNCC3)c2c1	Phase 1	Pharmaprojects	HTR6|HTR5A|HTR1D|HTR1B|HTR1A|HTR2C|HTR2B|HTR2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=23|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=23|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=23|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=23|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=23|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=23|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=23|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=23	serotonin receptor agonist			
zilpaterol	zilpaterol		CC(C)N[C@H]1CCn2c(O)nc3cccc([C@@H]1O)c23	Launched	https://www.drugs.com/international/zilpaterol.html	ADRB2	https://en.wikipedia.org/wiki/Zilpaterol	adrenergic receptor agonist	endocrinology	weight-gain aid	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dff70a14-40f0-4d99-8ee8-1b49e10c274f
delanzomib	delanzomib	CEP-18770	CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT01023880	CTSG|CYP3A4|ELANE|CMA1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008299|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008299|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008299|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008299	proteasome inhibitor			
GSK-J5	GSK-J5		CCOC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1	Preclinical				histone demethylase control			
proquazone	proquazone	43-715|arthrex	CC(C)n1c2cc(C)ccc2c(nc1=O)-c1ccccc1	Launched	http://www.ilacprospektusu.com/ilac/127/biarison-200-mg-30-kapsul	PTGS1|PTGS2	http://www.merckvetmanual.com/mvm/pharmacology/anti-inflammatory_agents/nonsteroidal_anti-inflammatory_drugs.html|http://www.merckvetmanual.com/mvm/pharmacology/anti-inflammatory_agents/nonsteroidal_anti-inflammatory_drugs.html	cyclooxygenase inhibitor			
adefovir-dipivoxil	adefovir dipivoxil	GS-0840|adefovir dipivoxil|hepsera	CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C	Launched	FDA Orange Book: adefovir dipivoxil			DNA polymerase inhibitor	infectious disease	hepatitis B	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e047f3b2-feae-4c5e-9d07-1fefb4c0ec25
edelfosine	edelfosine		CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC	Phase 2	http://en.wikipedia.org/wiki/Edelfosine			phospholipase inhibitor			
salidroside	salidroside		OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical		APP	http://www.ncbi.nlm.nih.gov/pubmed/20615444	beta amyloid protein neurotoxicity inhibitor			
etamsylate	etamsylate	dobesilic acid	Oc1ccc(O)c(c1)S(O)(=O)=O	Launched	http://www.drugs.com/international/Ethamsylate.html			haemostatic agent	hematology	hemorrhage	https://en.wikipedia.org/wiki/Etamsylate
mercaptopurine	mercaptopurine	Mercaptopurine anhydrous|purinethol|purixan	S=c1[nH]cnc2nc[nH]c12	Launched	FDA Orange Book: mercaptopurine	IMPDH2|IMPDH1|HPRT1|PPAT	https://www.drugbank.ca/drugs/DB01033|https://www.drugbank.ca/drugs/DB01033|https://www.drugbank.ca/drugs/DB01033|https://www.drugbank.ca/drugs/DB01033	immunosuppressant|protein synthesis inhibitor|purine antagonist	hematologic malignancy	acute lymphoblastic leukemia (ALL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15904472-4c32-4224-95d3-eb131a7ff9c8
KML29	KML29		OC(C1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)(c1ccc2OCOc2c1)c1ccc2OCOc2c1	Preclinical		MGLL	https://www.tocris.com/dispprod.php?ItemId=374979#.V-qvyZMrLy8	monoacylglucerol lipase inhibitor			
griseofulvin	griseofulvin	Fulvicin|Fulvicin p/g|Fulvicin p/g 165|Fulvicin p/g 330|Grifulvin|Grisactin ultra|Grivate|Ultragris-165|Ultragris-330|fulvicin-p/g|fulvicin-u/f|grifulvin v|gris-peg|grisactin|griseofulvin, microcrystalline|griseofulvin, microsize|griseofulvin, ultramicrocrystalline|griseofulvin, ultramicrosize|griseofulvin,ultramicrosize	COc1cc(OC)c(Cl)c2O[C@]3([C@H](C)CC(=O)C=C3OC)C(=O)c12	Launched	FDA Orange Book: griseofulvin, microcrystalline, griseofulvin, microsize, griseofulvin, ultramicrocrystalline, griseofulvin, ultramicrosize	KRT12	https://www.drugbank.ca/drugs/DB00400	tubulin polymerization inhibitor	infectious disease|infectious disease	ringworm|tinea pedis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b394ee74-53e5-493a-8ed9-95d3e8a10e88|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b394ee74-53e5-493a-8ed9-95d3e8a10e88
sodium-monofluorophosphate	sodium monofluorophosphate	extra-strength aim	OP(O)(F)=O	Launched	FDA Orange Book: sodium monofluorophosphate	PYGM	https://www.drugbank.ca/drugs/DB02348		dental	cavities	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=594d5fbc-a134-45ac-a8a7-d4d49d753ac7&audience=consumer
aceneuramic-acid	aceneuramic acid		CC(=O)N[C@@H]1[C@@H](O)C[C@](O)(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02736188	MBL2|CES1|SIGLEC1|SELE|SELP|REG1A|AZGP1	https://www.drugbank.ca/drugs/DB03721|https://www.drugbank.ca/drugs/DB03721|https://www.drugbank.ca/drugs/DB03721|https://www.drugbank.ca/drugs/DB03721|https://www.drugbank.ca/drugs/DB03721|https://www.drugbank.ca/drugs/DB03721|https://www.drugbank.ca/drugs/DB03721				
escin	escin		C\C=C(\C)C(=O)O[C@@H]1[C@H](OC(C)=O)[C@]2(CO)[C@H](O)C[C@]3(C)C(=CCC4[C@@]5(C)CC[C@H](O[C@@H]6O[C@@H]([C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(O)=O)[C@](C)(CO)C5CC[C@@]34C)C2CC1(C)C	Launched	http://www.drugs.com/international/escin.html			nitric oxide synthase stimulant	dermatology	varicose veins	http://www.webmd.com/skin-problems-and-treatments/guide/varicose-spider-veins
linsidomine	linsidomine		Nc1c[n+](no1)N1CCOCC1	Launched	http://www.drugs.com/international/linsidomine.html			nitric oxide donor	urology	erectile dysfunction	http://www.drugs.com/international/linsidomine.html
amifampridine	amifampridine	3,4-Diammoniopyridinium|4-DAP|Pyridine-3,4-Diamine	Nc1ccncc1N	Launched	http://en.wikipedia.org/wiki/3,4-Diaminopyridine			potassium channel blocker	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	http://www.netag.nhs.uk/files/appraisal-reports/Firdapse%20-%20NETAG%20appraisal%20report%20-%20Nov%202011%20-WEB%20VERSION.pdf
medica-16	medica-16	3,3,14,14-Tetramethyl-Hexadecanedioic Acid|3,3,14,14-Tetramethylhexadecanedioic Acid	CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O	Phase 2	Pharmaprojects	FFAR1|ACLY	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1053|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=149244	ATP citrase lyase inhibitor			
meticrane	meticrane	SD 17102	Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O	Launched	http://www.drugs.com/international/meticrane.html			diuretic	cardiology	edema	http://www.drugs.com/international/meticrane.html
chlorprothixene	chlorprothixene	N-714|RO 4-0403|Ro-4-0403|taractan	CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12	Launched	FDA Orange Book: chlorprothixene	CHRM5|CHRM2|CHRM1|CHRM4|CHRM3|HRH1|DRD3|DRD2|DRD1|HTR2B|HTR2A|HTR2C	https://www.drugbank.ca/drugs/DB01239|https://www.drugbank.ca/drugs/DB01239|https://www.drugbank.ca/drugs/DB01239|https://www.drugbank.ca/drugs/DB01239|https://www.drugbank.ca/drugs/DB01239|https://www.drugbank.ca/drugs/DB01239|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB01239|https://www.drugbank.ca/drugs/DB01239|ChEMBL|ChEMBL	dopamine receptor antagonist	neurology/psychiatry|neurology/psychiatry	schizophrenia|bipolar disorder	https://en.wikipedia.org/wiki/Chlorprothixene#Indications|https://en.wikipedia.org/wiki/Chlorprothixene#Indications
DH-97	DH-97		CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12	Preclinical		MTNR1B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3366	melatonin receptor antagonist			
L-alanine	L-alanine	l-alanine	C[C@H](N)C(O)=O	Launched	https://clinicaltrials.gov/ct2/show/NCT01944059						
TPCA-1	TPCA-1		NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1	Preclinical		IKBKB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5986	IKK inhibitor			
lanoconazole	lanoconazole		Clc1ccccc1C1CS\C(S1)=C(\C#N)n1ccnc1	Launched	http://www.drugs.com/international/Lanoconazole.html			sterol demethylase inhibitor	infectious disease	fungal infection	http://www.drugs.com/international/lanoconazole.html
AZ-10417808	AZ-10417808		[O-][N+](=O)c1cc(C(=O)NCC=C)c2nc(Nc3ccc(Cl)c(Cl)c3)[nH]c(=O)c2c1	Preclinical		CASP3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5143	caspase inhibitor			
pargyline	pargyline	Eutron|eutonyl	CN(CC#C)Cc1ccccc1	Launched	FDA Orange Book: pargyline hydrochloride	MAOB|MAOA	https://www.drugbank.ca/drugs/DB01626|https://www.drugbank.ca/drugs/DB01626	monoamine oxidase inhibitor	cardiology	hypertension	https://en.wikipedia.org/wiki/Pargyline
XBD173	XBD173	AC-5216|emapunil	CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00108836	TSPO	https://en.wikipedia.org/wiki/Emapunil	benzodiazepine receptor ligand			
SAG	SAG		CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl	Preclinical		DHH|PTCH1|IHH|TRPC6|SMO	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=417914|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=417914|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=417914|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2437|https://www.tocris.com/products/sag_4366	smoothened receptor agonist			
roxarsone	roxarsone		Oc1ccc(cc1[N+]([O-])=O)[As](O)(O)=O	Veterinary Launched	http://www.drugs.com/international/roxarsone.html			antiprotozoal agent	endocrinology	weight-gain aid	https://en.wikipedia.org/wiki/Roxarsone
bipenamol	bipenamol		NCc1ccccc1Sc1ccccc1CO	Phase 2	Pharmaprojects	CTSC	http://www.trc-canada.com/product-detail/?B397805	dipeptidyl peptidase inhibitor			
CHC	CHC		OC(=O)C(\C#N)=C\c1ccc(O)cc1	Preclinical		SLC16A1	https://www.tocris.com/products/chc_5029	monocarboxylate transporter inhibitor			
bardoxolone-methyl	bardoxolone-methyl		COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01351675	PPARG|HMOX1|HMOX2|STAT3|BCL2|NFE2L2|CHUK|GSR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3443|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=284395|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=284395|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000217|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=284395|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=284395|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=284395|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=284395	nuclear factor erythroid derived|like (NRF2) activator			
PSB-36	PSB-36		CCCCn1c(=O)n(CCCO)c2nc([nH]c2c1=O)C12CC3CC1CC(C2)C3	Preclinical		ADORA2A|ADORA2B|ADORA3|ADORA1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3285|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3285|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3285|http://www.tocris.com/dispprod.php?ItemId=95401#.Uuc8UqX0CMI	adenosine receptor antagonist			
GSK-37647	GSK-37647		COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C	Preclinical		FFAR4	https://www.tocris.com/products/gsk-137647_5257	free fatty acid receptor agonist			
olesoxime	olesoxime			Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT00868166			apoptosis stimulant			
splitomycin	splitomycin	splitomicin	O=C1CCc2c(O1)ccc1ccccc21	Preclinical		SIRT1|SIRT2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8101|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=313483	SIRT inhibitor			
FERb-033	FERb-033		O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O	Preclinical		ERBB2	http://www.scbt.com/datasheet-294590.html	EGFR inhibitor			
eact	eact		COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(cs1)-c1ccccc1	Preclinical		ANO1	https://www.tocris.com/products/eact_4876	calcium-activated chloride channel inhibitor			
NGD-98-2	NGD-98-2		CCC(CC)Nc1nc(C)c(nc1OC)-c1ccc(OC(F)(F)F)cc1OC	Preclinical		CRHR1	https://www.tocris.com/products/ngd-98-2-hydrochloride_4315	corticosteroid releasing factor receptor antagonist			
bavisant	bavisant	JNJ-31001074	O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01362699	HRH3	https://www.mrc.ac.uk/funding/browse/mrc-industry-asset-sharing-initiative/compounds-list/histamine-type-3-receptor-antagonist/	histamine receptor antagonist			
SIB-1757	SIB-1757		Cc1ccc(O)c(N=Nc2ccccc2)n1	Preclinical		GRM5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1431	glutamate receptor antagonist			
flubendazole	flubendazole	Biovermin|Flubenol|Flumoxal|Flutelmium|R 17,889	COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1	Veterinary Launched	http://www.drugs.com/international/Flubendazole.html	TUBB	http://www.ncbi.nlm.nih.gov/pubmed/20348394	tubulin polymerization inhibitor	infectious disease	gastrointestinal parasites	https://en.wikipedia.org/wiki/Flubendazole
enciprazine	enciprazine		COc1ccccc1N1CCN(CC(O)COc2cc(OC)c(OC)c(OC)c2)CC1	Phase 3	http://en.pharmacodia.com/web/drug/1_8158.html	GABRA1	http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI%3A31413	GABA receptor modulator			
dolasetron	dolasetron	anzemet	O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12	Launched	FDA Orange Book: dolasetron mesylate	HTR3A	https://www.drugbank.ca/drugs/DB00757	serotonin receptor antagonist	gastroenterology|gastroenterology	nausea|vomiting	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6600dfea-fcf2-4f89-ab45-66282dee969f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6600dfea-fcf2-4f89-ab45-66282dee969f
UNC2025	UNC2025		CCCCNc1ncc2c(cn([C@H]3CC[C@H](O)CC3)c2n1)-c1ccc(CN2CCN(C)CC2)cc1	Preclinical		MERTK|TYRO3|AXL|FLT3	https://www.caymanchem.com/product/16613|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=847062|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=847062|https://www.caymanchem.com/product/16613	MER tyrosine kinase inhibitor|FLT3 inhibitor			
CCT018159	CCT018159		CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O	Preclinical		HSP90AB1|HSP90AA1	https://www.drugbank.ca/drugs/DB07594|https://www.drugbank.ca/drugs/DB07594	HSP inhibitor			
SCH-51344	SCH-51344		COc1ccc2[nH]c3nnc(C)c3c(NCCOCCO)c2c1	Preclinical		NUDT1	https://www.tocris.com/products/sch-51344_5280	MTH1 inhibitor			
pardoprunox	pardoprunox	DU 126891|SLV 308	CN1CCN(CC1)c1cccc2[nH]c(=O)oc12	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00407095	DRD2|DRD4|DRD3|HTR1A|HTR7	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000915|https://en.wikipedia.org/wiki/Pardoprunox|https://en.wikipedia.org/wiki/Pardoprunox|https://en.wikipedia.org/wiki/Pardoprunox|https://en.wikipedia.org/wiki/Pardoprunox	serotonin receptor agonist|dopamine receptor agonist			
ginsenoside-c-k	ginsenoside-c-k		CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C	Preclinical		PTGS2|NR3C1|CASP3	http://www.chemfaces.com/natural/Compound-K-CFN99756.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=104031|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=104031	NFkB pathway inhibitor|nitric oxide synthase inhibitor			
palbociclib	palbociclib	PD-0332991|ibrance	CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O	Launched	FDA Orange Book: palbociclib	CDK4|CDK6|CCND3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7380|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7380|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=345543	CDK inhibitor	oncology	breast cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0e6412f-50b4-4fd4-9364-62818d121a07
ozolinone	ozolinone		CN1C(=O)C(S\C1=C/C(O)=O)N1CCCCC1	Phase 3	Pharmaprojects			diuretic			
idazoxan	idazoxan	RX-781094	C1CN=C(N1)C1COc2ccccc2O1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00294944	ADRA2A|NISCH	https://en.wikipedia.org/wiki/Idazoxan|https://citeline.informa.com/?query=#/drugs/details/9067	adrenergic receptor antagonist			
chlorogenic-acid	chlorogenic acid	NSC-407296|chlorogenic acid	O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O	Launched	http://en.wikipedia.org/wiki/Chlorogenic_acid	SLC37A4	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000424	antioxidant	neurology/psychiatry|pulmonary|allergy	headache|chest congestion|allergic rhinitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92b04d08-40f1-41bf-81dc-ead63bf811f3|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92b04d08-40f1-41bf-81dc-ead63bf811f3|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92b04d08-40f1-41bf-81dc-ead63bf811f3
exatecan-mesylate	exatecan mesylate	exatecan	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00023972	TOP1	http://clincancerres.aacrjournals.org/content/7/12/3963.full	topoisomerase inhibitor			
seratrodast	seratrodast	A-73001|AA-2414|ABBOTT-73001|ABT-001	CC1=C(C)C(=O)C(C(CCCCCC(O)=O)c2ccccc2)=C(C)C1=O	Launched	http://www.drugs.com/international/seratrodast.html	TBXA2R	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000326	prostanoid receptor antagonist	pulmonary	asthma	https://en.wikipedia.org/wiki/Seratrodast#Clinical_experience
NOV-002	NOV-002		N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00347412	GSR|GSTM2	https://www.drugbank.ca/drugs/DB03310|https://www.drugbank.ca/drugs/DB03310				
butibufen	butibufen		CCC(C(O)=O)c1ccc(CC(C)C)cc1	Withdrawn	http://adisinsight.springer.com/drugs/800000939			cyclooxygenase inhibitor			
azacitidine	azacitidine	U-18,496|U-18496|ladakamycin|vidaza	Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1	Launched	FDA Orange Book: azacitidine	DNMT1|DNMT3A	ChEMBL|ChEMBL	DNA methyltransferase inhibitor	hematologic malignancy|hematology|hematologic malignancy	myelodysplastic diseases (MDS)|anemia|chronic myelomonocytic leukemia (CMMoL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55915b5d-0e85-4ede-ad4f-ac89670d8973|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55915b5d-0e85-4ede-ad4f-ac89670d8973|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55915b5d-0e85-4ede-ad4f-ac89670d8973
penbutolol	penbutolol	levatol	CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1	Launched	FDA Orange Book: penbutolol sulfate	HTR1B|HTR1A|ADRB1|ADRB2	https://www.drugbank.ca/drugs/DB01359|https://www.drugbank.ca/drugs/DB01359|https://www.drugbank.ca/drugs/DB01359|https://www.drugbank.ca/drugs/DB01359	adrenergic receptor antagonist	cardiology	hypertension	https://en.wikipedia.org/wiki/Penbutolol
BTS	BTS		Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1	Preclinical							
AV-412	AV-412	MP-412	CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00381654	EGFR|ERBB2	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=513167|http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=513167	protein tyrosine kinase inhibitor			
LY231617	LY231617	LY-231617	CCNCc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	Preclinical				lipid peroxidase inhibitor			
tofacitinib	tofacitinib	xeljanz|xeljanz xr	C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N	Launched	FDA Orange Book: tofacitinib citrate	TYK2|CYP2C19|JAK1|JAK2|JAK3	https://www.drugbank.ca/drugs/DB08183|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=306518|https://www.drugbank.ca/drugs/DB08183|https://www.drugbank.ca/drugs/DB08183|https://www.drugbank.ca/drugs/DB08183	JAK inhibitor	rheumatology	rheumatoid arthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf74ba2f-afc5-4baa-8594-979c889a5831&audience=consumer
ZK-200775	ZK-200775	fanapanel	OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/16131799			kainate receptor antagonist			
ER-50891	ER-50891		CC(C)c1cccc2c(cc(nc12)-c1ccc([nH]1)-c1ccc(cc1)C(O)=O)-c1ccccc1	Preclinical		RARA	https://www.tocris.com/products/er-50891_3823	retinoid receptor antagonist			
epicatechin-gallate-(-)	(-)-epicatechin-gallate	(-)-Epicatechin Gallate|Epicatechin Gallate	Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02015312	APP|SLC5A1|FASN|BACE1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=300449|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=300449|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004629|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004629	bacterial DNA gyrase inhibitor			
primaquine	primaquine		COc1cc(NC(C)CCCN)c2ncccc2c1	Launched	FDA Orange Book: primaquine phosphate	KRT7|NQO2	https://www.drugbank.ca/drugs/DB01087|https://www.drugbank.ca/drugs/DB01087	antimalarial agent|DNA inhibitor	infectious disease	malaria	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c8c2bc6-428b-40b6-8114-6df80290878d
AZD8931	AZD8931	AZD-8931|Sapitinib	CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01151215	ERBB3|ERBB2|EGFR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7717|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7717|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7717	EGFR inhibitor			
2-ethoxybenzoic-acid	2-ethoxybenzoic acid		CCOc1ccccc1C(O)=O	Phase 1	Pharmaprojects	PTGS2|PTGS1	https://citeline.informa.com/?query=#/drugs/details/25412|https://citeline.informa.com/?query=#/drugs/details/25412	analgesic agent			
GPR120-modulator-1	GPR120-modulator-1		Cc1cc(OCc2nc(cs2)-c2ccccc2Cl)ccc1OCC(O)=O	Preclinical		FFAR4	https://www.medchemexpress.com/gpr120-modulator-1.html	G protein-coupled receptor modulator			
mimosine	mimosine	L-Mimosine	N[C@@H](Cn1ccc(=O)c(O)c1)C(O)=O	Preclinical		TYR|SHMT1|SHMT2|CCL2	https://www.drugbank.ca/drugs/DB01055|https://www.drugbank.ca/drugs/DB01055|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000947|https://www.drugbank.ca/drugs/DB01055	DNA replication inhibitor			
fenretinide	fenretinide	4-HPR|MCN-R-1967	CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01479192	RARA|RARG|CYP2C8|CYP3A5	http://www.genome.jp/dbget-bin/www_bget?dr:D04162|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090670|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090670|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090670	apoptosis stimulant|retinoid receptor agonist			
boronophenylalanine	boronophenylalanine		N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00085059						
AM-580	AM-580	AM580	CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O	Preclinical		RARA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2647	retinoid receptor agonist			
SMER-28	SMER-28		Brc1ccc2ncnc(NCC=C)c2c1	Preclinical		SNCA	https://www.tocris.com/products/smer-28_4297	autophagy inducer			
geranyl-farnesylacetate	geranyl-farnesylacetate	DA 688|gefarnate	CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/1103273			mucin production enhancer			
BAY-87-2243	BAY-87-2243		Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01297530	HIF1A	http://www.selleckchem.com/products/bay-87-2243.html	hypoxia inducible factor inhibitor			
sulbentine	sulbentine	D 47|dibenzathione|dibenzthion	S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1	Preclinical				other antifungal			
CV-1808	CV-1808		Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Preclinical		ADORA2B|ADORA2A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090897|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=420	adenosine receptor agonist			
CUDC-907	CUDC-907		COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02674750	PIK3R1|HDAC2	http://medchemexpress.com/CUDC-907.html?gclid=Cj0KEQjwg9-vBRCK7L7wmO2u0JcBEiQA_tzoaKLyXcNww6nu675J-Y6zLPb80yhb5GyuES-sUdYxtg8aAiO38P8HAQ|http://medchemexpress.com/CUDC-907.html?gclid=Cj0KEQjwg9-vBRCK7L7wmO2u0JcBEiQA_tzoaKLyXcNww6nu675J-Y6zLPb80yhb5GyuES-sUdYxtg8aAiO38P8HAQ	PI3K inhibitor			
xilobam	xilobam		CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/7975729						
SKF-89976A	SKF-89976A	SKF-89976	OC(=O)C1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1	Preclinical		SLC6A1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4705	GABA uptake inhibitor			
BD-1063	BD-1063		CN1CCN(CCc2ccc(Cl)c(Cl)c2)CC1	Preclinical		SIGMAR1	http://www.tocris.com/dispprod.php?ItemId=1997#.Ut_w3f30BaE	sigma receptor antagonist			
carazolol	carazolol	BM 51052|Conducton|Suacron	CC(C)NCC(O)COc1cccc2[nH]c3ccccc3c12	Launched	https://www.drugs.com/international/carazolol.html	ADRB2|ADRB1|ADRB3	https://www.drugbank.ca/drugs/DB07543|https://www.ncbi.nlm.nih.gov/pubmed/8719421|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=569	adrenergic receptor antagonist	cardiology|cardiology|cardiology|cardiology	angina pectoris|cardiac arrythmia|hypertension|myocardial infarction	http://www.ndrugs.com/?s=carazolol|http://www.ndrugs.com/?s=carazolol|http://www.ndrugs.com/?s=carazolol|http://www.ndrugs.com/?s=carazolol
eprobemide	eprobemide		Clc1ccc(cc1)C(=O)NCCCN1CCOCC1	Launched	http://en.wikipedia.org/wiki/Eprobemide	MAOA	https://en.wikipedia.org/wiki/Eprobemide	monoamine oxidase inhibitor	neurology/psychiatry	depression	http://adisinsight.springer.com/drugs/800007855
ademetionine	ademetionine		C[S+](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	Launched	http://www.drugs.com/international/Ademetionine.html	CBS|GNMT|PDE4B|MAT1A|MAT2A|COMT|AMD1	https://www.drugbank.ca/drugs/DB00118|https://www.drugbank.ca/drugs/DB00118|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=284419|https://www.drugbank.ca/drugs/DB00118|https://www.drugbank.ca/drugs/DB00118|https://www.drugbank.ca/drugs/DB00118|https://www.drugbank.ca/drugs/DB00118	methyltransferase stimulant|phosphodiesterase inhibitor	neurology/psychiatry|neurology/psychiatry	depression|attention-deficit/hyperactivity disorder (ADHD)	http://www.mayoclinic.org/drugs-supplements/same/dosing/hrb-20059935|http://www.mayoclinic.org/drugs-supplements/same/dosing/hrb-20059935
BTZ043-racemate	BTZ043-racemate		CC1COC2(CCN(CC2)c2nc(=O)c3cc(cc([N+]([O-])=O)c3s2)C(F)(F)F)O1	Preclinical				DPRE1 inhibitor			
bevirimat-dimeglumine	bevirimat-dimeglumine	PA-457|bevirimat	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00967187			HIV capsid assembly inhibitor			
amitraz	amitraz	Mitaban|Taktic|Triatix|U-36,059	CN(\C=N\c1ccc(C)cc1C)\C=N\c1ccc(C)cc1C	Veterinary Launched	http://www.drugs.com/international/amitraz.html	ADRA2A|ADRA1A	https://en.wikipedia.org/wiki/Amitraz#Mechanism_of_action|https://en.wikipedia.org/wiki/Amitraz#Mechanism_of_action	adrenergic receptor agonist	infectious disease	generalized demodicosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1c04eff-dc24-49cf-a5b5-17434dc77503
beta-carotene	beta carotene	beta carotene|betacarotene|betavit|lucaratin|solatene	CC(\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C	Launched	FDA Orange Book: beta carotene						
ranirestat	ranirestat		Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00101426	AKR1B1	https://www.drugbank.ca/drugs/DB05327	aldose reductase inhibitor			
NVP-TAE684	NVP-TAE684	TAE-684	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1	Preclinical		INSR|ALK	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013651|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5714	ALK tyrosine kinase receptor inhibitor			
CHR-6494	CHR-6494		CCCNc1ccc2ncc(-c3ccc4[nH]ncc4c3)n2n1	Preclinical		GSG2	https://www.tocris.com/dispprod.php?ItemId=431345#.V-QwNZMrLy8	serine/threonine kinase inhibitor			
dropropizine	dropropizine	UCB 1967	OCC(O)CN1CCN(CC1)c1ccccc1	Launched	http://www.drugs.com/international/dropropizine.html			antitussive	pulmonary	cough suppressant	https://en.wikipedia.org/wiki/Dropropizine
linezolid	linezolid	U-100,766|U-100766|zyvox	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1	Launched	FDA Orange Book: linezolid	MAOB|MAOA	http://www.drugbank.ca/drugs/DB00601|http://www.drugbank.ca/drugs/DB00601	bacterial 50S ribosomal subunit inhibitor	infectious disease|infectious disease	pneumonia|skin infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c401f1a8-cc37-461b-bfef-f2e156629bf8|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c401f1a8-cc37-461b-bfef-f2e156629bf8
anagliptin	anagliptin		Cc1cc2ncc(cn2n1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N	Launched	https://clinicaltrials.gov/ct2/show/NCT02330406	SLC22A8|DPP4	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=426247|https://clinicaltrials.gov/ct2/show/NCT02330406	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus	https://en.wikipedia.org/wiki/Anagliptin
SU3327	SU3327		Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1	Preclinical		MAPK8	https://www.tocris.com/dispprod.php?ItemId=231683#.Vyyw_WQrJZI	JNK inhibitor			
droxicam	droxicam		CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O	Launched	http://en.wikipedia.org/wiki/Droxicam	PTGS2|PTGS1	https://citeline.informa.com/?query=#/drugs/details/5902|http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_76133	cyclooxygenase inhibitor	rheumatology|rheumatology	rheumatoid arthritis|osteoarthritis	https://en.wikipedia.org/wiki/Droxicam|https://en.wikipedia.org/wiki/Droxicam
divalproex-sodium	divalproex-sodium	depakene|depakote|depakote cp|depakote er|stavzor|valproic acid	CCCC(CCC)C(O)=O	Launched	FDA Orange Book: divalproex sodium	ALDH5A1	ChEMBL	benzodiazepine receptor agonist	neurology/psychiatry|neurology/psychiatry	epilepsy|seizures	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f911748c-fb3a-fe1a-ab2a-4b40455e05ef|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f911748c-fb3a-fe1a-ab2a-4b40455e05ef
WYE-125132	WYE-125132		CNC(=O)Nc1ccc(cc1)-c1nc(N2CC3CCC(C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1	Preclinical		MTOR|PIK3CA	http://www.apexbt.com/wye-125132-wye-132.html?gclid=CLHp5rH1xcwCFcNahgodPAEMDg|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=670053	mTOR inhibitor			
diadenosine-tetraphosphate	diadenosine-tetraphosphate		Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H](C(O)C2O)n2cnc3c(N)ncnc23)C(O)C1O	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/9926194	P2RY2|P2RY13	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1732|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1732	adenosine kinase inhibitor			
cinchocaine	cinchocaine	dibucaine|heavy solution nupercaine|nupercainal	CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1	Launched	FDA Orange Book: dibucaine hydrochloride	CALM1|SCN5A|SCN10A	https://www.drugbank.ca/drugs/DB00527|https://www.drugbank.ca/drugs/DB00527|https://www.drugbank.ca/drugs/DB00527	sodium channel blocker	neurology/psychiatry	local anesthetic	https://en.wikipedia.org/wiki/Cinchocaine
mupirocin	mupirocin	BRL 4910A|BRL-4910A|bactroban|centany|pseudomonic acid	C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O	Launched	FDA Orange Book: mupirocin, mupirocin calcium			isoleucyl-tRNA synthetase inhibitor	infectious disease	impetigo	https://www.google.com/search?q=impetigo&rlz=1C5CHFA_enUS546US546&oq=impetigo&aqs=chrome..69i57.1560j0j4&sourceid=chrome&es_sm=119&ie=UTF-8
L-165041	L-165041		CCCc1c(OCCCOc2ccc(OCC(O)=O)cc2)ccc(C(C)=O)c1O	Preclinical		PPARD	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2691	PPAR receptor agonist			
abiraterone	abiraterone		C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1	Launched	FDA Orange Book: abiraterone acetate	CYP17A1|CYP11B1	https://www.drugbank.ca/drugs/DB05812|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003575	androgen biosynthesis inhibitor	oncology	prostate cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513
caffeine	caffeine	cafcit|coffeine|methyltheobromine|nodoz caplets and chewable tablets|theine	Cn1cnc2n(C)c(=O)n(C)c(=O)c12	Launched	FDA Orange Book: caffeine, caffeine citrate	ADORA1|ADORA3|PDE11A|PDE10A|PDE8A|PDE8B|PDE9A|PDE6C|PDE6A|PDE6B|PDE7A|PDE7B|PDE4C|PDE4D|PDE4A|PDE4B|PDE5A|PDE2A|PDE3B|PDE3A|PDE1B|PDE1C|PDE1A|PRKDC|PIK3CD|PIK3CB|PIK3CA|ITPR3|ITPR2|ITPR1|RYR3|RYR1|RYR2|ATR|ATM|ADORA2B|ADORA2A	ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=407|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|https://www.drugbank.ca/drugs/DB00201|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=407|https://www.drugbank.ca/drugs/DB00201|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=407|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070317|https://www.drugbank.ca/drugs/DB00201|ChEMBL|ChEMBL	adenosine receptor antagonist|phosphodiesterase inhibitor	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	fatigue|drowsiness|fatigue|drowsiness	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d221f66d-06bb-44e8-a01b-f5919f5c52d2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d221f66d-06bb-44e8-a01b-f5919f5c52d2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d221f66d-06bb-44e8-a01b-f5919f5c52d2|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d221f66d-06bb-44e8-a01b-f5919f5c52d2
4-acetyl-1,1-dimethylpiperazinium	4-acetyl-1,1-dimethylpiperazinium		CC(=O)N1CC[N+](C)(C)CC1	Preclinical				acetylcholine receptor agonist			
artemether	artemether		CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3	Launched	FDA Orange Book: artemether	ATP1A1|CYP2C19|CYP3A5|CYP2B6	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001453|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090712|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090712|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090712	antimalarial agent	infectious disease	malaria	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7866ec19-dfac-47d4-a53f-511a12643cbf
cefetamet-pivoxil	cefetamet pivoxil		CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1	Launched	http://www.drugs.com/international/cefetamet.html			bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections	https://en.wikipedia.org/wiki/Cefetamet
BMS-754807	BMS-754807		C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01225172	AKT1|IGF1R	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014870|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7952	IGF-1 inhibitor			
primidone	primidone	Lepsiral|Neurosyn|mysoline	CCC1(C(=O)NCNC1=O)c1ccccc1	Launched	FDA Orange Book: primidone	GABRP|GABRQ|GABRD|GABRE|SCN11A|SCN10A|SCN9A|SCN5A|SCN7A|SCN8A|SCN1A|SCN2A|SCN3A|SCN4A|GABRG3|GABRG2|GABRG1|GABRB3|GABRB2|GABRB1|GABRA6|GABRA5|GABRA4|GABRA3|GABRA2|GABRA1|CHRNA4|CHRNA7|GRIA2|GRIK2	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00794|https://www.drugbank.ca/drugs/DB00794|https://www.drugbank.ca/drugs/DB00794|https://www.drugbank.ca/drugs/DB00794	GABA receptor antagonist	neurology/psychiatry	seizures	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02ba0182-0870-4c0d-a814-a1dc427d47b8
tetraethylenepentamine	tetraethylenepentamine		NCCNCCNCCNCCN	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT00469729	SOD1|SOD2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.exec_form_pro_pr?p_par_pro=PRO_DRUG_NAME&p_val_pro=tetraethylenepentamine&p_origen=PROD&p_oper_pro=AND&p_par_tar=&p_val_tar=&p_oper_tar=AND&p_par_ref=&p_val_ref=&p_oper_ref=AND&p_par_pat=&p_val_pat=&p_oper_pat=AND|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.exec_form_pro_pr?p_par_pro=PRO_DRUG_NAME&p_val_pro=tetraethylenepentamine&p_origen=PROD&p_oper_pro=AND&p_par_tar=&p_val_tar=&p_oper_tar=AND&p_par_ref=&p_val_ref=&p_oper_ref=AND&p_par_pat=&p_val_pat=&p_oper_pat=AND	superoxide dismutase inhibitor			
BW-180C	BW-180C		CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O	Phase 2	Pharmaprojects	OPRD1|OPRM1|SLC6A2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1607|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1607|https://citeline.informa.com/?query=#/drugs/details/2719	opioid receptor agonist			
mepacrine	mepacrine	GNF-Pf-5448|quinacrine	CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12	Launched	http://en.wikipedia.org/wiki/Mepacrine	PLA2G6|PLCL1|TP53|MTOR|AKT1|PLA2G4A|PLA2G1B|PLA2G2A|PLA2G2D|NFKB1	https://www.drugbank.ca/drugs/DB01103|https://www.drugbank.ca/drugs/DB01103|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=102168|https://citeline.informa.com/?query=#/drugs/details/35748|https://citeline.informa.com/?query=#/drugs/details/35748|https://www.drugbank.ca/drugs/DB01103|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000925|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=102168|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=102168|https://citeline.informa.com/?query=#/drugs/details/35748	cytokine production inhibitor|NFkB pathway inhibitor|TP53 activator	infectious disease	giardiasis	https://en.wikipedia.org/wiki/Mepacrine#Medical_uses
guanidine	guanidine	guanidine hydrochloride	NC(N)=N	Launched	FDA Orange Book: guanidine hydrochloride	RNASE1|GAMT|ALDH2|DLG4	https://www.drugbank.ca/drugs/DB00536|https://www.drugbank.ca/drugs/DB00536|https://www.drugbank.ca/drugs/DB00536|https://www.drugbank.ca/drugs/DB00536	HSP inhibitor	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593
diethylstilbestrol	diethylstilbestrol	NEW-ESTRANOL 1|Stilboesterol|cyren a|estrobene|estrogenine|estromenin|fonatol|palestrol|stilbestroform|stilbestrol|stilbetin|stilboestrol|stilphostrol|synestrin|synthestrin	CC\C(c1ccc(O)cc1)=C(\CC)c1ccc(O)cc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	ESR1|ESR2|ESRRG|ESRRB	ChEMBL|https://www.drugbank.ca/drugs/DB00255|https://www.drugbank.ca/drugs/DB00255|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2801	estrogen receptor agonist			
podophyllotoxin	podophyllotoxin	condylox|podofilox	COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12	Launched	FDA Orange Book: podofilox	IGF1R|TUBB|TUBA4A|TOP2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7873|https://www.drugbank.ca/drugs/DB01179|https://www.drugbank.ca/drugs/DB01179|https://www.drugbank.ca/drugs/DB01179	microtubule inhibitor|tubulin polymerization inhibitor	infectious disease	genital warts	https://en.wikipedia.org/wiki/Podophyllotoxin#Uses
gidazepam	gidazepam		NNC(=O)CN1c2ccc(Br)cc2C(=NCC1=O)c1ccccc1	Launched	https://drugs-forum.com/forum/showwiki.php?title=Gidazepam			GABA benzodiazepine site receptor agonist			
succinylcholine-chloride	succinylcholine chloride	Succinylcholine|anectine|quelicin|quelicin preservative free|sucostrin|suxamethonium	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	Launched	FDA Orange Book: succinylcholine chloride	CHRNA1|CHRM3|CHRM2|CHRM1|CHRNA10|CHRFAM7A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4004|https://www.drugbank.ca/drugs/DB00202|https://www.drugbank.ca/drugs/DB00202|https://www.drugbank.ca/drugs/DB00202|https://www.drugbank.ca/drugs/DB00202|https://www.drugbank.ca/drugs/DB00202		neurology/psychiatry	muscle relaxant	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=579ff759-3099-45f5-befe-c4b79106c87e&audience=consumer
ethyl-paraben	ethyl-paraben	E214|ethyl hydroxybenzoate|ethyl parahydroxybenzoate|ethylparaben	CCOC(=O)c1ccc(O)cc1	Preclinical							
norelgestromin	norelgestromin	EVRA|RWJ-10553|ortho evra	CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(O)C#C	Launched	FDA Orange Book: norelgestromin	PGR	ChEMBL		endocrinology	contraceptive	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8e8a69e-a018-469a-af56-e20f61fe4e06
S-14506	S-14506		COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1	Preclinical		HTR2C|HTR1A|DRD2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=185541|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=24|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=185541	serotonin receptor agonist			
valsartan	valsartan	CGP 48933|CGP-48933|Exforge|diovan	CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O	Launched	FDA Orange Book: valsartan	AGTR1	ChEMBL	angiotensin receptor antagonist	cardiology|cardiology	hypertension|congestive heart failure	http://www.rxlist.com/diovan-drug/indications-dosage.htm|http://www.rxlist.com/diovan-drug/indications-dosage.htm
AMG-9810	AMG-9810		CC(C)(C)c1ccc(cc1)\C=C\C(=O)Nc1ccc2OCCOc2c1	Preclinical		TRPV1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6347	TRPV antagonist			
carbendazim	carbendazim	Bavistin	COC(=O)Nc1nc2ccccc2[nH]1	Launched	https://www.drugs.com/international/carbendazim.html	TUBB|TP53	http://www.t3db.ca/toxins/T3D0942|http://www.t3db.ca/toxins/T3D0942	microtubule inhibitor|tubulin polymerization inhibitor	infectious disease	fungicide	https://en.wikipedia.org/wiki/Carbendazim
YO-01027	YO-01027		C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O	Preclinical				gamma secretase inhibitor			
M-344	M-344		CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO	Preclinical				HDAC inhibitor			
zindotrine	zindotrine	MDL 257	Cc1cc(nn2cnnc12)N1CCCCC1	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/3229340			phosphodiesterase inhibitor			
rociletinib	rociletinib	AVL-301|CNX-419|CO-1686	COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02322281	EGFR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7966	EGFR inhibitor			
SB-258585	SB-258585		COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1	Preclinical		HTR6	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3232	serotonin receptor antagonist			
proxyphylline	proxyphylline		CC(O)Cn1cnc2n(C)c(=O)n(C)c(=O)c12	Launched	http://www.drugs.com/international/proxyphylline.html				pulmonary	asthma	http://www.drugs.com/international/proxyphylline.html
SR-27897	SR-27897	lintitript	OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/?term=lintitript%5Bti%5D	CCKAR	https://www.drugbank.ca/drugs/DB04867	CCK receptor antagonist			
chlorphenamine	chlorphenamine	Antagonate|Isoclor|Kloromin|Phenetron|chlor-trimeton|chlorpheniramine|efidac 24 chlorpheniramine maleate|teldrin	CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1	Launched	FDA Orange Book: chlorpheniramine maleate, chlorpheniramine polistirex, dexchlorpheniramine maleate	HRH1|SLC6A4|SLC6A3|SLC6A2	https://www.drugbank.ca/drugs/DB01114|https://www.drugbank.ca/drugs/DB01114|https://www.drugbank.ca/drugs/DB01114|https://www.drugbank.ca/drugs/DB01114	histamine receptor antagonist	allergy|allergy	allergic rhinitis|urticaria	https://en.wikipedia.org/wiki/Chlorphenamine|https://en.wikipedia.org/wiki/Chlorphenamine
safranal	safranal		CC1=C(C=O)C(C)(C)CC=C1	Phase 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643654/	GABBR1	https://en.wikipedia.org/wiki/Safranal	benzodiazepine receptor agonist			
AZD1080	AZD1080	AZ-11548415|AZD-1080	Oc1[nH]c2ccc(cc2c1-c1ccc(CN2CCOCC2)cn1)C#N	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/23410232	GSK3B|GSK3A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7819|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7819	glycogen synthase kinase inhibitor			
tryptanthrin	tryptanthrin	GNF-Pf-2691|TCMDC-125859	O=C1c2ccccc2-n2c1nc1ccccc1c2=O	Preclinical		PTGS2|HGF|ALOX5|IDO1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=400617|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=400617|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=400617|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8224	cyclooxygenase inhibitor			
taselisib	taselisib	GDC-0032|RG-7604	CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02340221	PIK3CG|PIK3CD|PIK3CA|PIK3CB	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=726262|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=726262|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7794|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=726262	PI3K inhibitor			
CP-673451	CP-673451		COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1	Preclinical		PDGFRA|PDGFRB|KIT	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8069|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8069|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8069	PDGFR tyrosine kinase receptor inhibitor			
CTS-1027	CTS-1027	RS-130830	ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00925990	MMP8|MMP9|MMP1|MMP2|MMP3|MMP14|MMP13|MMP12	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=256579|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004074|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004074|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004074|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004074|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=256579|https://www.drugbank.ca/drugs/DB08490|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=256579	metalloproteinase inhibitor			
CB-5083	CB-5083		Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02223598	VCP	https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=764238	valosin-containing protein inhibitor			
amoxicillin	amoxicillin	Amoxi-Inject|Amoxi-Tabs|Amoxicillin pediatric|Aquacil|BRL 2333|BRL-2333|Biomox|Polymox|Robamox|Sumox|Utimox|Vetremox|Wymox|amoxicilline|amoxil|amoxycillin|dispermox|larotid|moxatag|trimox	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O	Launched	FDA Orange Book: amoxicillin	SLC15A1|SLC15A2|CYP2C19|SLC22A6	http://www.drugbank.ca/drugs/DB01060|http://www.drugbank.ca/drugs/DB01060|http://www.drugbank.ca/drugs/DB01060|http://www.drugbank.ca/drugs/DB01060	penicillin binding protein inhibitor	infectious disease|gastroenterology|infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	skin infections|duodenal ulcer disease|gonorrhea|ear infections|throat infections|genitourinary tract infections|respiratory tract infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de8990a6-f3b6-478f-acbe-eda961b6da4b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de8990a6-f3b6-478f-acbe-eda961b6da4b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de8990a6-f3b6-478f-acbe-eda961b6da4b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de8990a6-f3b6-478f-acbe-eda961b6da4b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de8990a6-f3b6-478f-acbe-eda961b6da4b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de8990a6-f3b6-478f-acbe-eda961b6da4b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de8990a6-f3b6-478f-acbe-eda961b6da4b
O4I1	O4I1		COc1ccc(COc2ccc(CC#N)cc2)cc1	Preclinical		POU5F1	https://www.tocris.com/products/o4i1_5639	Oct inducer			
CUR-61414	CUR-61414		COc1cccc(CN([C@H]2C[C@H](N(Cc3ccc4OCOc4c3)C2)C(=O)N2CCNCC2)C(=O)CC(C)(C)C)c1	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/21558397	SMO|PTCH1|DHH|IHH	http://www.pnas.org/content/100/8/4616.full.pdf|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=305810|http://www.pnas.org/content/100/8/4616.full.pdf|http://www.pnas.org/content/100/8/4616.full.pdf	smoothened receptor antagonist			
phenylephrine	phenylephrine	Cyclomydril|Duo-Medihaler|phenylephrine hydrochloride|vazculep	CNC[C@H](O)c1cccc(O)c1	Launched	FDA Orange Book: phenylephrine bitartrate, phenylephrine hydrochloride	ADRA1D|ADRA1B|ADRA1A	https://www.drugbank.ca/drugs/DB00388|https://www.drugbank.ca/drugs/DB00388|https://www.drugbank.ca/drugs/DB00388	adrenergic receptor agonist	otolaryngology|gastroenterology|cardiology	nasal congestion|hemorrhoids|hypotension	https://en.wikipedia.org/wiki/Phenylephrine#Medical_uses|https://en.wikipedia.org/wiki/Phenylephrine#Medical_uses|https://en.wikipedia.org/wiki/Phenylephrine#Medical_uses
lafutidine	lafutidine		O=C(CS(=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1	Launched	http://www.drugs.com/international/Lafutidine.html	HRH2	https://en.wikipedia.org/wiki/Lafutidine	histamine receptor antagonist	gastroenterology|gastroenterology	duodenal ulcer disease|peptic ulcer disease (PUD)	https://en.wikipedia.org/wiki/Lafutidine|https://en.wikipedia.org/wiki/Lafutidine
mubritinib	mubritinib	TAK-165	FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00034281	ERBB2|EGFR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6011|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000347	protein tyrosine kinase inhibitor			
lomefloxacin	lomefloxacin	SC-47111A|maxaquin	CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12	Launched	FDA Orange Book: lomefloxacin hydrochloride	TOP2A	https://www.drugbank.ca/drugs/DB00978	bacterial DNA gyrase inhibitor	infectious disease|infectious disease	respiratory tract infections|urinary tract infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=173018f5-fd76-4480-90f8-4b7efe328444|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=173018f5-fd76-4480-90f8-4b7efe328444
tetracaine	tetracaine	Dicaine|amethocaine|medihaler-tetracaine|metraspray|pontocaine|tetracaine hydrochloride	CCCCNc1ccc(cc1)C(=O)OCCN(C)C	Launched	FDA Orange Book: tetracaine	SCN10A|SCN11A|SCN1A|SCN4A|SCN5A|SCN2A|SCN3A|SCN8A|SCN9A|SCN7A	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	membrane integrity inhibitor	neurology/psychiatry	anesthetic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b29124f7-c238-4961-b810-f4e7fabe4bb1&audience=consumer
busulfan	busulfan	busulfex|myelosan|myleran|sulphabutin	CS(=O)(=O)OCCCCOS(C)(=O)=O	Launched	FDA Orange Book: busulfan			DNA inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03dc50f9-c7bd-4c0c-8bbb-c1216ec90c95
Mps1-IN-1	Mps1-IN-1		COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1	Preclinical		TTK|ALK	https://www.tocris.com/products/mps1-in-1-dihydrochloride_5142|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=655689	monopolar spindle 1 kinase inhibitor			
Mps1-IN-5	Mps1-IN-5		COc1cc(ccc1Nc1nc2ccc(cn2n1)-c1ccc(NC(=O)[C@H](C)c2ccc(F)cc2)cc1)S(C)(=O)=O	Preclinical		TTK	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=817700	protein kinase inhibitor			
chlorcyclizine	chlorcyclizine	Di-Paralene|Mantadil|Pruresidine|Trihistan	CN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1	Launched	http://en.wikipedia.org/wiki/Chlorcyclizine	HRH1	https://www.drugbank.ca/drugs/DB08936	histamine receptor antagonist	allergy	allergic rhinitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d50b5154-20a3-4c5b-ad7b-08c081340b12
mephenesin	mephenesin	cresoxydiol|tolserol	Cc1ccccc1OCC(O)CO	Launched	http://www.drugs.com/international/mephenesin.html			muscle relaxant	neurology/psychiatry	muscle relaxant	https://en.wikipedia.org/wiki/Mephenesin
OICR-9429	OICR-9429		CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1	Preclinical		WDR5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8231	WDR5/MLL interaction inhibitor			
deltarasin	deltarasin		C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1	Preclinical		KRAS	https://www.tocris.com/products/deltarasin_5424	phosphodiesterase inhibitor			
copanlisib	copanlisib	BAY 80-6946|BAY-80-6946	COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12	Launched	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ade50241-2c10-4038-b4e9-72f6bf905f03	PIK3CG|PIK3CD|PIK3CB|PIK3CA	http://www.selleckchem.com/products/bay80-6946.html?gclid=CIaijPnO2s8CFQotaQodTQcPIw|http://www.raredr.com/conferences/asco2015/Biomarkers-Copanlisib|http://www.selleckchem.com/products/bay80-6946.html?gclid=CIaijPnO2s8CFQotaQodTQcPIw|http://www.raredr.com/conferences/asco2015/Biomarkers-Copanlisib	PI3K inhibitor	hematologic malignancy	follicular lymphoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ade50241-2c10-4038-b4e9-72f6bf905f03
etifenin	etifenin		CCc1cccc(CC)c1NC(=O)CN(CC(O)=O)CC(O)=O	Preclinical				renal function diagnostic agent			
aminomethyltransferase	aminomethyltransferase		CC1CCN=C(N)S1	Preclinical		NOS2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013705	nitric oxide synthase inhibitor			
carglumic-acid	carglumic acid	OE 312 (LABORATORY CODE DESIGNATION)|carbaglu|carglumic acid	NC(=O)N[C@@H](CCC(O)=O)C(O)=O	Launched	FDA Orange Book: carglumic acid	CPS1	ChEMBL	carbamoyl phosphate synthase activator	metabolism	hyperammonemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10175e73-5172-4dde-a508-8a88b7afc0a1
mirodenafil	mirodenafil		CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1	Launched	http://www.drugs.com/international/mirodenafil.html	PDE5A	https://en.wikipedia.org/wiki/Mirodenafil	phosphodiesterase inhibitor	urology	erectile dysfunction	https://en.wikipedia.org/wiki/Mirodenafil
olsalazine	olsalazine	dipentum	OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O	Launched	FDA Orange Book: olsalazine sodium	IFNG|TPMT|PTGS2|PTGS1	https://www.drugbank.ca/drugs/DB01250|https://www.drugbank.ca/drugs/DB01250|https://citeline.informa.com/?query=#/drugs/details/13434|https://citeline.informa.com/?query=#/drugs/details/13434	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75a96561-6f52-4c11-a105-391fbbfe4827
elagolix	elagolix	NBI-56418	COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01620528	GNRHR|GNRH1	http://www.neurocrine.com/pipeline/elagolix-gnrh-antagonist/|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=395035	gonadotropin releasing factor hormone receptor antagonist			
GDC-0623	GDC-0623	RG-7420	OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01106599			MEK inhibitor			
oligomycin-a	oligomycin a		CCC1CCC2OC3(CC[C@@H](C)C(C[C@H](C)O)O3)[C@H](C)C(OC(=O)\C=C\[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@@](C)(O)[C@H](O)[C@@H](C)C\C=C\C=C\1)[C@H]2C	Preclinical		ATP5A1	http://www.scbt.com/datasheet-201551-oligomycin-a.html	ATP synthase inhibitor|ATPase inhibitor			
indalpine	indalpine	LM-5008|Upstene	C(Cc1c[nH]c2ccccc12)C1CCNCC1	Withdrawn	https://pubchem.ncbi.nlm.nih.gov/compound/indalpine	SLC6A4	http://www.bindingdb.org/MonoNames?name=Indalpine_50029150	selective serotonin reuptake inhibitor (SSRI)			
irinotecan	irinotecan	camptosar|irinotecan hydrochloride|onivyde	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12	Launched	FDA Orange Book: irinotecan hydrochloride	TOP1MT|CYP3A5|TOP1	https://www.drugbank.ca/drugs/DB00762|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=103766|https://www.drugbank.ca/drugs/DB00762	topoisomerase inhibitor	oncology	colorectal cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80f3b79c-a399-45b3-b755-8535457719af
salinomycin	salinomycin		CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O	Veterinary Launched	http://www.drugs.com/international/Salinomycin.html				infectious disease	coccidiosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b55d5494-6ef2-4c68-be0c-2168fa325edc
sennoside-a	sennoside a		OC[C@H]1O[C@H](Oc2cccc3C([C@H]4c5cccc(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)c5C(=O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4C(=O)c23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O	Launched	https://clinicaltrials.gov/ct2/show/NCT01140295			glycoside agonist	gastroenterology	constipation	https://en.wikipedia.org/wiki/Senna_glycoside
siguazodan	siguazodan	SK&F 94836|SKF-94836	CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)CC1C	Phase 1	Pharmaprojects	PDE3A	https://www.tocris.com/dispprod.php?ItemId=2142#.Vyuvg2QrJZI	phosphodiesterase inhibitor			
TH-302	TH-302	evofosfamide	Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01440088			DNA alkylating agent			
ML-365	ML-365		COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1	Preclinical		KCNK9|KCNK3	https://www.tocris.com/products/ml-365_5337|https://www.tocris.com/products/ml-365_5337	potassium channel blocker			
caffeic-acid-phenethyl-ester	Caffeic Acid Phenethyl Ester	Caffeic Acid Phenethyl Ester|Phenethyl 3-(3,4-Dihydroxyphenyl)Acrylate|Phenethyl Caffeate|trans-caffeic acid phenethyl ester	Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O	Preclinical		RELA	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000379	HIV integrase inhibitor			
KU14R	KU14R		CCC1(Cc2ccccc2O1)c1ncc[nH]1	Preclinical				imidazoline receptor antagonist			
amiflamine	amiflamine		CC(N)Cc1ccc(cc1C)N(C)C	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/3720180	MAOA|MAOB|SLC6A2	https://en.wikipedia.org/wiki/Amiflamine|https://citeline.informa.com/?query=#/drugs/details/1431|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011518	monoamine oxidase inhibitor			
PD-160170	PD-160170		CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O	Preclinical		NPY1R	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DPR000090	neuropeptide receptor antagonist			
GSK-J4	GSK-J4		CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1	Preclinical		KDM6A|KDM6B|TNF	http://www.chemicalprobes.org/GSK-J4/overview|http://www.chemicalprobes.org/GSK-J4/overview|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=835307	histone lysine demethylase inhibitor			
pentamidine	pentamidine	GNF-Pf-3680|MB 800 [AS ISETHIONATE]|MB-800|PENTAM 300 [AS ISETHIONATE]|RP 2512 [AS ISETHIONATE)|RP-2512|nebupent|nebupent [as isethionate]|pentacarinat [as isethionate]|pentam|pentamidine isetionate	NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1	Launched	FDA Orange Book: pentamidine isethionate	TRDMT1	https://www.drugbank.ca/drugs/DB00738	anti-pneumocystis agent	infectious disease	pneumonia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb
GSK-J2	GSK-J2		OC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1	Preclinical				histone demethylase inhibitor			
GSK-J1	GSK-J1		OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1	Preclinical		KDM6B|KDM6A|TNF	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7027|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=786135|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=786135	histone demethylase inhibitor			
WEHI-345-analog	WEHI-345-analog		Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)CNC(=O)c1ncccc1C	Preclinical				src inhibitor			
NSC636819	NSC636819		[O-][N+](=O)c1cc(c(\C=C\c2ccc(Cl)c(Cl)c2)cc1\C=C\c1ccc(Cl)c(Cl)c1)[N+]([O-])=O	Preclinical		KDM4B|KDM4A	https://www.tocris.com/products/nsc-636819_5287|https://www.tocris.com/products/nsc-636819_5287	histone demethylase inhibitor			
bismuth-subcitrate-potassium	bismuth subcitrate potassium		OC(=O)CC(O)(CC(=O)O[Bi]1OC(=O)CC(O)(CC(O)=O)C(=O)O1)C(O)=O	Launched	FDA Orange Book: bismuth subcitrate potassium				gastroenterology	duodenal ulcer disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a762e164-b390-4e8c-bd46-bf6c31eeb486
dexfenfluramine	dexfenfluramine		CCN[C@@H](C)Cc1cccc(c1)C(F)(F)F	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	HTR2C|SLC6A4	https://www.drugbank.ca/drugs/DB01191|https://www.drugbank.ca/drugs/DB01191	serotonin receptor agonist			
sulfathiazole	sulfathiazole	sulfathiazole (triple sulfa)|sulphathiazole	Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	Launched	FDA Orange Book: triple sulfa (sulfabenzamide;sulfacetamide;sulfathiazole)			dihydropteroate synthase inhibitor			
CCT-031374	CCT-031374		O=C(CN1C2=NCCN2c2ccccc12)c1ccc(cc1)-c1ccccc1	Preclinical		CTNNB1	https://www.tocris.com/products/cct-031374-hydrobromide_4675	WNT signaling inhibitor			
INT-747	INT-747	DSP-1747|obeticholic acid	CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01473524	NR1H4	https://citeline.informa.com/?query=#/drugs/details/32228	FXR agonist			
SQ-22536	SQ-22536		Nc1ncnc2n(cnc12)C1CCCO1	Preclinical		ADCY5|ADCY1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=290988|http://www.tocris.com/dispprod.php?ItemId=1217	adenylyl cyclase inhibitor			
polymyxin-b-sulfate	polymyxin b sulfate	polymyxin b sulfate	CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(Cc2ccccc2)NC(=O)C(CCN)NC1=O)C(C)O	Launched	FDA Orange Book: polymyxin b sulfate			bacterial permeability inducer	ophthalmology	eye infection	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b317249-30eb-4415-8a1c-cfedb4ba3549
BMS-470539	BMS-470539		CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](N)Cc1cncn1C)c1ccccc1	Preclinical		MC1R	https://www.tocris.com/products/bms-470539-dihydrochloride_4053	melanocortin receptor agonist			
closantel	closantel	Flukiver|R 31,520|Seponver	Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O	Veterinary Launched	http://www.drugs.com/international/Closantel.html			chitinase inhibitor|NFkB pathway inhibitor	infectious disease	liver flukes	http://parasitipedia.net/index.php?option=com_content&view=article&id=2505&Itemid=2778
pizotifen	pizotifen	BC-105|pizotyline|sandomigran	CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12	Launched	http://www.drugs.com/international/Pizotifen.html	HTR1A|HTR2C|HTR2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=93|http://en.wikipedia.org/wiki/Pizotifen|http://en.wikipedia.org/wiki/Pizotifen	serotonin receptor antagonist	neurology/psychiatry	migraine headache	https://en.wikipedia.org/wiki/Pizotifen
tanshinone-i	Tanshinone I	Tanshinone I	Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01452477	IFNG|AHR	http://www.scbt.com/datasheet-205850-tanshinone-i.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=347593	AP inhibitor			
L-733060	L-733060		FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F	Preclinical		TACR1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004178	tachykinin antagonist			
tafenoquine	tafenoquine	SB-252263-AAB|WR 238605	COc1cc(C)c2c(Oc3cccc(c3)C(F)(F)F)c(OC)cc(NC(C)CCCN)c2n1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02216123			antimalarial agent			
flurbiprofen-(S)-(+)	(S)-(+)-flurbiprofen		C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1	Launched				cyclooxygenase inhibitor			
isoconazole	isoconazole	R-15,454 [AS NITRATE SALT]|isoconazole nitrate	Clc1ccc(C(Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1	Launched	http://www.drugs.com/international/isoconazole.html	CYP17A1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004441	fungal lanosterol demethylase inhibitor	infectious disease	gram-positive bacterial infections	https://en.wikipedia.org/wiki/Isoconazole
clorgiline	clorgiline	M&B 9302|clorgyline	CN(CCCOc1ccc(Cl)cc1Cl)CC#C	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/6342562	MAOA	https://www.drugbank.ca/drugs/DB04017	monoamine oxidase inhibitor			
cyclamic-acid	cyclamic acid	cyclamic acid|hexamic acid	OS(=O)(=O)NC1CCCCC1	Preclinical							
methylbenzethonium-chloride	methylbenzethonium chloride	methylbenzethonium	Cc1cc(ccc1OCCOCC[N+](C)(C)Cc1ccccc1)C(C)(C)CC(C)(C)C	Preclinical				other antibiotic			
JZL-184	JZL-184		OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1	Preclinical		MGLL	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5207	monoacylglucerol lipase inhibitor			
tiabendazole	tiabendazole	E233|Equizole|MK-360|Omnizole|mintezol|thiabendazole	c1nc(cs1)-c1nc2ccccc2[nH]1	Launched	FDA Orange Book: thiabendazole			angiogenesis inhibitor	infectious disease|infectious disease	gastrointestinal roundworms|hookworm	https://en.wikipedia.org/wiki/Tiabendazole|https://en.wikipedia.org/wiki/Tiabendazole
BI-78D3	BI-78D3		Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1	Preclinical		MAPK8	http://www.tocris.com/dispprod.php?ItemId=218553	JNK inhibitor			
dopamine	dopamine	Carbilev|Parcopa|Sinemet|dopamine hydrochloride|intropin	NCCc1ccc(O)c(O)c1	Launched	FDA Orange Book: dopamine hydrochloride	DBH|HTR1A|DRD3|DRD2|DRD1|DRD5|DRD4|SLC6A4|SLC6A3|SLC6A2|HTR7	https://www.drugbank.ca/drugs/DB00988|https://www.drugbank.ca/drugs/DB00988|https://www.drugbank.ca/drugs/DB00988|https://www.drugbank.ca/drugs/DB00988|https://www.drugbank.ca/drugs/DB00988|https://www.drugbank.ca/drugs/DB00988|https://www.drugbank.ca/drugs/DB00988|https://www.drugbank.ca/drugs/DB00988|https://www.drugbank.ca/drugs/DB00988|https://www.drugbank.ca/drugs/DB00988|https://www.drugbank.ca/drugs/DB00988	dopamine receptor agonist	cardiology|neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	ventricular arrhythmias|depression|headache|tremors	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64d8e280-2801-4450-a23b-8ffe5980a456|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64d8e280-2801-4450-a23b-8ffe5980a456|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64d8e280-2801-4450-a23b-8ffe5980a456|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64d8e280-2801-4450-a23b-8ffe5980a456
combretastatin-A-4	combretastatin-A-4	COMBRETASTATIN A4|Combrestatin A4|NSC-613729	COc1ccc(cc1O)\C=C/c1cc(OC)c(OC)c(OC)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01423149			tubulin polymerization inhibitor			
2-(3-mercaptopropyl)pentanedioic acid	2-(3-mercaptopropyl)pentanedioic acid		OC(=O)CCC(CCCS)C(O)=O	Phase 1				glutamate carboxypeptidase inhibitor			
azelastine	azelastine	astelin|astepro|optivar	CN1CCCC(CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O	Launched	FDA Orange Book: azelastine hydrochloride	HRH1|CYP2C19	https://www.drugbank.ca/drugs/DB00972|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090028	histamine receptor antagonist	ophthalmology	conjunctivitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77a33738-ffcf-221c-1562-780418882e5d
AZD6765	AZD6765	lanicemine	NC(Cc1ccccn1)c1ccccc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00781742	GRIN1	http://www.sigmaaldrich.com/catalog/product/sigma/sml0635?lang=en&region=US	glutamate receptor antagonist			
ST-2825	ST-2825		NC(=O)[C@H]1CCS[C@@H]2C[C@]3(CCCN3C(=O)Cc3ccc(NC(=O)COc4ccc(Cl)cc4Cl)cc3)C(=O)N12	Preclinical		MYD88	https://medchemexpress.com/ST-2825.html?gclid=COq8wsGEv88CFYQkhgod2HEFjg	myeloid differentiation primary response inhibitor			
deoxycorticosterone-acetate	deoxycorticosterone acetate	DOCA|deoxycorticosterone acetate|deoxycortone|desoxycorticosterone acetate|desoxycortone|percorten	CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	Preclinical		NR3C2	ChEMBL	progestogen hormone			
harmane	harmane	harman	Cc1nccc2c3ccccc3[nH]c12	Preclinical		MAOA|MAOB	https://en.wikipedia.org/wiki/Harmane|https://en.wikipedia.org/wiki/Harmane	monoamine oxidase inhibitor			
dehydroepiandrosterone	dehydroepiandrosterone		C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O	Launched	https://clinicaltrials.gov/ct2/show/NCT00543166	SIGMAR1|SULT2B1|SULT2A1|GRIN1|HSD17B1|GABRB3|GABRB2|GABRB1|GABRA6|GABRA5|GABRA2|GABRA1|GABRA4|GABRA3|GABRG3|GABRG2|GABRG1|NR1I3|NR1I2|PPARA|ESR1|ESR2|GABRQ|GABRP|GABRE|GABRD|G6PD|AR|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|CYP3A5	https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001146|https://citeline.informa.com/?query=#/drugs/details/5122|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://www.drugbank.ca/drugs/DB01708|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=213244	protein synthesis stimulant			
CHIR-98014	CHIR-98014		Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O	Preclinical		GSK3B|GSK3A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8016|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8016	glycogen synthase kinase inhibitor			
NPC-01	NPC-01		C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00902746			steroid			
icotinib	icotinib	BPI-2009H	C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1	Launched	https://clinicaltrials.gov/ct2/show/NCT01465243	EGFR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7641	EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)	https://en.wikipedia.org/wiki/Icotinib
mirin	mirin		NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1	Preclinical		MRE11A	http://www.sigmaaldrich.com/catalog/product/sigma/m9948?lang=en&region=US	MRE11A exonuclease inhibitor			
nobiletin	nobiletin	NSC-76751	COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1	Preclinical		MAP2K1|TYR|ABCB1	http://www.scbt.com/datasheet-202733-nobiletin.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=285344|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=285344	MEK inhibitor			
GS-6201	GS 6201	CVT-6883|GS 6201	CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1	Phase 1	https://www.inknowvation.com/sbir/techseekers/gilead-sciences-inc	ADORA1|ADORA3|ADORA2A|ADORA2B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5615|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5615|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5615|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5615	adenosine receptor antagonist			
dihydroartemisinin	dihydroartemisinin		C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	Launched	http://www.drugs.com/international/Dihydroartemisinin.html			antimalarial agent	infectious disease	malaria	https://en.wikipedia.org/wiki/Dihydroartemisinin
FRAX486	FRAX486		CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O	Preclinical		PAK2|PAK3|PAK1|PAK4	https://www.tocris.com/dispprod.php?ItemId=415470#.V-lk8pMrLy8|https://www.tocris.com/dispprod.php?ItemId=415470#.V-lk8pMrLy8|https://www.tocris.com/dispprod.php?ItemId=415470#.V-lk8pMrLy8|https://www.tocris.com/dispprod.php?ItemId=415470#.V-lk8pMrLy8	serine/threonine kinase inhibitor			
alafosfalin	alafosfalin		C[C@H](N)C(=O)N[C@@H](C)P(O)(O)=O	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/7406481			bacterial cell wall synthesis inhibitor			
risedronate	risedronate	NE-58095|actonel|atelvia|risedronic acid	OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O	Launched	FDA Orange Book: risedronate sodium	FDPS	https://www.drugbank.ca/drugs/DB00884	osteoclast inhibitor	orthopedics|endocrinology	osteoporosis|Paget's disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=563c6d6d-56df-43a7-a7aa-709c5ea3cdbe|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=563c6d6d-56df-43a7-a7aa-709c5ea3cdbe
etilevodopa	etilevodopa	TV-1203	CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/16476809	DRD3|DDC	https://www.ebi.ac.uk/chembl/target/inspect/CHEMBL234|https://citeline.informa.com/?query=#/drugs/details/17831	dopamine receptor agonist			
EC-23	EC-23		CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O	Preclinical		RARA|RARB|RARG	https://www.stemcell.com/ec23.html|https://www.stemcell.com/ec23.html|https://www.stemcell.com/ec23.html	retinoid receptor agonist			
exo-IWR-1	exo-IWR-1		O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@H]3C[C@H](C=C3)[C@H]2C1=O	Preclinical		TNKS	https://www.tocris.com/products/exo-iwr-1_3947	WNT signaling inhibitor negative control			
MK-0812	MK-0812		CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00239655	CCR2	http://www.medchemexpress.com/mk-0812.html	CC chemokine receptor antagonist			
BAY-11-7085	BAY-11-7085	BAY-117085	CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N	Preclinical		NFKBIA	https://www.caymanchem.com/app/template/Product.vm/catalog/14795	NFkB pathway inhibitor			
BAY-11-7082	BAY-11-7082		Cc1ccc(cc1)S(=O)(=O)\C=C\C#N	Preclinical		RELA	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008174	NFkB pathway inhibitor			
KN-62	KN-62		CN(C(Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(CC1)c1ccccc1)S(=O)(=O)c1cccc2cnccc12	Preclinical		LCK|MAPK11|MAPK12|MAPK14|AKT1|PRKCA|P2RX7|SGK1|MAPK8|MAPK1|CAMK2A|ROCK1|CHEK1|RPS6KB1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008115|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008115|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008115|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008115|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008115|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008115|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4235|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008115|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008115|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008115|http://www.tocris.com/dispprod.php?ItemId=1490#.UuEypv30BaE|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008115|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008115|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008115	calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist			
hydroxyurea	hydroxyurea	SQ 1089|SQ-1089|droxia|hydrea|hydroxycarbamide	NC(=O)NO	Launched	FDA Orange Book: hydroxyurea	RRM1|RRM2|RRM2B	ChEMBL|ChEMBL|ChEMBL	ribonucleotide reductase inhibitor	hematologic malignancy|oncology	chronic myeloid leukemia (CML)|head and neck squamous cell carcinoma (HNSCC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9514ae5-79ae-4cc2-9d7f-c8f7806d1694|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9514ae5-79ae-4cc2-9d7f-c8f7806d1694
NMS-1286937	NMS-1286937		CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01014429	PLK2|PLK1|PLK3|FLT3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7918|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7918|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7918|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7918	PLK inhibitor			
SCS	SCS	Salicylaldehyde2-Hydroxybenzoylhydrazone	Oc1ccccc1\C=N\NC(=O)c1ccccc1O	Preclinical							
homoveratrylamine	homoveratrylamine	2-(3,4-Dimethoxyphenyl)Ethanamine	COc1ccc(CCN)cc1OC	Preclinical				dopamine analog			
GSK1838705A	GSK1838705A	GSK-1838705A	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12	Preclinical		RPS6KA1|INSR|ALK|IGF1R	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5683|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5683|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5683|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5683	insulin growth factor receptor inhibitor			
tariquidar	tariquidar	XR-9576|XR9576	COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00042315	ABCB1	http://www.apexbt.com/tariquidar.html?gclid=CNXOkc3fxcwCFQUmhgodj9IEvA	P glycoprotein inhibitor			
ICI-185,282	ICI-185,282		OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F	Phase 1				thromboxane receptor antagonist			
costunolide	costunolide	Melampolide	C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1	Preclinical				telomerase inhibitor			
tazobactam	tazobactam		C[C@]1(Cn2ccnn2)C(N2C(CC2=O)S1(=O)=O)C(O)=O	Launched	FDA Orange Book: tazobactam sodium			beta lactamase inhibitor	infectious disease	pneumonia	https://en.wikipedia.org/wiki/Tazobactam
tioconazole	tioconazole	Trosyl|UK-20,349|UK-20349|tz-3|vagistat|vagistat-1	Clc1sccc1COC(Cn1ccnc1)c1ccc(Cl)cc1Cl	Launched	FDA Orange Book: tioconazole	CYP51A1	https://www.drugbank.ca/drugs/DB01007	sterol demethylase inhibitor	infectious disease	yeast infection	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b3ee10a-d945-41f4-bbb5-ff2e2fdcd22c&audience=consumer
benzoin	benzoin	benzoin tincture	OC(C(=O)c1ccccc1)c1ccccc1	Preclinical		CES1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005432				
dacarbazine	dacarbazine	DIC|DTIC|dtic-dome	CN(C)\N=N\c1[nH]cnc1C(N)=O	Launched	FDA Orange Book: dacarbazine	POLA2|PGD	https://www.drugbank.ca/drugs/DB00851|https://www.drugbank.ca/drugs/DB00851	DNA alkylating agent	oncology|hematologic malignancy	melanoma|Hodgkin's lymphoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6b97e41-5f15-498c-abfb-d8443ea4d216|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6b97e41-5f15-498c-abfb-d8443ea4d216
fenofibrate	fenofibrate	antara|antara (micronized)|fenofibrate (micronized)|fenoglide|lipidil|lipofen|tricor|tricor (micronized)|triglide|trilipix	CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1	Launched	FDA Orange Book: choline fenofibrate, fenofibrate	MMP25|PPARA|CYP2C19|APOA1|CYP2C8	https://www.drugbank.ca/drugs/DB01039|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=276065|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=276065|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=276065	PPAR receptor agonist	endocrinology|endocrinology	hypercholesterolemia|hypertriglyceridemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68024459-987a-9cf4-f539-4959093bc9f0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68024459-987a-9cf4-f539-4959093bc9f0
BAY-85-8050	BAY-85-8050		NC(CC(F)C(O)=O)C(O)=O	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/23877631						
homatropine-methylbromide	homatropine methylbromide		C[N+]1(C)C2CC[C@H]1C[C@H](C2)OC(=O)C(O)c1ccccc1	Launched	FDA Orange Book: homatropine methylbromide	CHRM5|CHRM3|CHRM4|CHRM1|CHRM2	https://www.drugbank.ca/drugs/DB00725|https://www.drugbank.ca/drugs/DB00725|https://www.drugbank.ca/drugs/DB00725|https://www.drugbank.ca/drugs/DB00725|https://www.drugbank.ca/drugs/DB00725	acetylcholine receptor antagonist	ophthalmology	uveal tract inflammation	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=538ef499-28cb-a4d1-5f16-6e87ac4e07ac
artemisinin	artemisinin		C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	Launched	http://www.drugs.com/international/Artemisinin.html	CYP2B6	http://www.ncbi.nlm.nih.gov/pubmed/23506555	DNA synthesis inhibitor	infectious disease	malaria	https://en.wikipedia.org/wiki/Artemisinin
lactulose	lactulose	E966|cephulac|chronulac|constulose|enulose|lactitol	OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O	Launched	FDA Orange Book: lactulose			laxative	gastroenterology	portal-systemic encephalopathy (PSE)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9b8bc93-af0f-44e6-a5f2-ff001542a81f
prasterone-acetate	prasterone acetate		CC(=O)O[C@H]1CC[C@]2(C)C3CC[C@@]4(C)C(CCC4=O)C3CC=C2C1	Preclinical							
carbachol	carbachol	Carbastat|carbachol chloride|miostat	C[N+](C)(C)CCOC(N)=O	Launched	FDA Orange Book: carbachol	CHRNA2|CHRM5|CHRM4|CHRM1|CHRM3|CHRM2	https://www.drugbank.ca/drugs/DB00411|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=298|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=298|https://www.drugbank.ca/drugs/DB00411|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=298|https://www.drugbank.ca/drugs/DB00411	cholinergic receptor agonist	ophthalmology	intraocular pressure	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=048af9c6-4866-4500-9914-cd7071a19b63
levobunolol-(+)	(+)-levobunolol		CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12	Preclinical				adrenergic receptor antagonist			
estramustine	estramustine		C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O	Launched	FDA Orange Book: estramustine phosphate sodium	MAP1A|ESR2|ESR1|MAP2	https://www.drugbank.ca/drugs/DB01196|https://www.drugbank.ca/drugs/DB01196|https://www.drugbank.ca/drugs/DB01196|https://www.drugbank.ca/drugs/DB01196	DNA alkylating agent	oncology	prostate cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9b01bc6-95ac-46f9-befa-d845a74d53c1
colchicine	colchicine	colcrys|mitigare	COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC	Launched	FDA Orange Book: colchicine	TUBA4A|TUBA3D|TUBA3C|TUBA3E|TUBA1B|TUBA1A|TUBA1C|TUBB2B|TUBB2A|TUBB4B|TUBB4A|TUBB|GLRA2|GLRA1|TUBB6|TUBB8|TUBB1|TUBB3	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2367|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2367|ChEMBL|ChEMBL|ChEMBL|ChEMBL	microtubule inhibitor	rheumatology|endocrinology	gout|fever	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=153f5af8-827e-4a58-a0bd-5aafcb3b5444|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=153f5af8-827e-4a58-a0bd-5aafcb3b5444
bemotrizinol	bemotrizinol	BEMT|FAT 70'884|tinosorb s	CCCCC(CC)COc1ccc(c(O)c1)-c1nc(nc(n1)-c1ccc(OCC(CC)CCCC)cc1O)-c1ccc(OC)cc1	Launched	http://en.wikipedia.org/wiki/Bemotrizinol				dermatology	sunscreen lotion	https://en.wikipedia.org/wiki/Bemotrizinol
clobetasol-propionate	clobetasol propionate	clobetasol propionate|clobetasol propionate (emollient)|clobex|cormax|embeline|olux|olux e|temovate|temovate e	CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl	Launched	FDA Orange Book: clobetasol propionate	PLA2G1B|NR3C1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001183|https://www.drugbank.ca/drugs/DB01013	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a188664a-8fa1-479f-9493-0da4a6c592f7
oxidopamine	oxidopamine		NCCc1cc(O)c(O)cc1O	Preclinical				neurotoxin			
asymmetrical-dimethylarginine	asymmetrical-dimethylarginine		CN(C)C(=N)NCCC[C@H](N)C(O)=O	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/14662708	NOS2|NOS3	https://www.drugbank.ca/drugs/DB01686|https://www.drugbank.ca/drugs/DB01686	nitric oxide synthase inhibitor			
treosulfan	treosulfan		CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O	Launched	https://www.drugs.com/international/treosulfan.html			DNA synthesis inhibitor	oncology	ovarian cancer	http://www.macmillan.org.uk/cancerinformation/cancertreatment/treatmenttypes/chemotherapy/individualdrugs/treosulfan.aspx
NS-018	NS-018		C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT01423851	JAK3|JAK2|JAK1|TYK2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7839|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7839|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7839|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7839	JAK inhibitor			
cyclothiazide	cyclothiazide	anhydron|fluidil	NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C2CC3CC2C=C3)cc1Cl	Launched	FDA Orange Book: cyclothiazide	FXYD2|GRIA1|GRIA3|GRIA2|GRIA4|SLC12A3|CA4|CA2|CA1	https://www.drugbank.ca/drugs/DB00606|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4167|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4167|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4167|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4167|ChEMBL|https://www.drugbank.ca/drugs/DB00606|https://www.drugbank.ca/drugs/DB00606|https://www.drugbank.ca/drugs/DB00606	glutamate receptor modulator	cardiology	hypertension	https://en.wikipedia.org/wiki/Cyclothiazide
thioctic-acid	thioctic acid	lipoic acid, alpha|thioctic acid	OC(=O)CCCCC1CCSS1	Launched	https://clinicaltrials.gov/ct2/show/NCT01056497	LIAS|ACHE|LIPT1|SLC5A6|ALDH2|PTGS2	https://www.drugbank.ca/drugs/DB00166|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008121|https://www.drugbank.ca/drugs/DB00166|https://www.drugbank.ca/drugs/DB00166|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=172618|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008121	reducing agent			
ML347	ML347		COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12	Preclinical		ACVR1|BMPR1A|ACVRL1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8121|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8121|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8121	ALK tyrosine kinase receptor inhibitor			
ephedrine	ephedrine	Ephetonin|Isofedrol|Racephedrine|afrinol|akovaz|novafed|pseudo-12|sudafed 12 hour|sudafed 24 hour	CN[C@@H](C)[C@H](O)c1ccccc1	Launched	http://en.wikipedia.org/wiki/Ephedrine	SLC18A2|ADRA1A|SLC6A2|ACHE|ADRB2	https://www.drugbank.ca/drugs/DB01364|https://www.drugbank.ca/drugs/DB01364|https://www.drugbank.ca/drugs/DB01364|https://www.drugbank.ca/drugs/DB01364|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=556	adrenergic receptor agonist	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity	https://en.wikipedia.org/wiki/Ephedrine|https://en.wikipedia.org/wiki/Ephedrine|https://en.wikipedia.org/wiki/Ephedrine|https://en.wikipedia.org/wiki/Ephedrine
docetaxel	docetaxel	docefrez|taxotere	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C	Launched	FDA Orange Book: docetaxel	TUBB1|TUBB|BCL2|MAPT|MAP2|MAP4|NR1I2	https://www.drugbank.ca/drugs/DB01248|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6809|https://www.drugbank.ca/drugs/DB01248|https://www.drugbank.ca/drugs/DB01248|https://www.drugbank.ca/drugs/DB01248|https://www.drugbank.ca/drugs/DB01248|https://www.drugbank.ca/drugs/DB01248	tubulin polymerization inhibitor	oncology|oncology|oncology|oncology|oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f
BIBX-1382	BIBX-1382	falnidamol	CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00003980	EGFR|ERBB2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7646|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7646	EGFR inhibitor			
INH1	INH1		Cc1ccc(c(C)c1)-c1csc(NC(=O)c2ccccc2)n1	Preclinical		CFTR|NDC80	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=401237|https://www.tocris.com/dispprod.php?ItemId=226844#.VzTH12QrJZJ	Hec1 inhibitor			
meprednisone	meprednisone	SCH 4358|SCH-4358|betapar		Launched	FDA Orange Book: meprednisone	NR3C1	ChEMBL				
elbasvir	elbasvir		COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc2-c3cc4cc(ccc4n3[C@@H](Oc2c1)c1ccccc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C	Launched	FDA Orange Book: elbasvir			HCV inhibitor	infectious disease	hepatitis C	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=164dc02a-9180-426a-b8b5-04ab39d2bbd4
adenosine	adenosine	SR 96225|SR-96225|adenocard|adenoscan	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Launched	http://en.wikipedia.org/wiki/Adenosine	ADORA2A|ADORA2B|TRPM4|ADORA1|ADORA3|PI4K2A|PI4K2B	ChEMBL|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844|ChEMBL|https://www.drugbank.ca/drugs/DB00640|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844	adenosine receptor agonist	cardiology	Wolff-Parkinson-White Syndrome (WPW)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a55b45d-9cee-4c0c-9e44-021dbf70a018
baricitinib	baricitinib	INCB-28050|INCB028050|LY-3009104|LY3009104	CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01711359	JAK2|JAK1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7792|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7792	JAK inhibitor			
TG-101348	TG-101348	SAR-302503|SAR302503|SAR302503; TG101348|TG101348|fedratinib	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C	Phase 3	https://www.clinicaltrials.gov/show/NCT01437787	RET|BRD4|JAK1|JAK3|JAK2|TYK2|FLT3	https://citeline.informa.com/?query=#/drugs/details/36703|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5716|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5716|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5716|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5716|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5716|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=441519	FLT3 inhibitor|JAK inhibitor			
SCMC-Lys	SCMC-Lys	AHR-3053|LJ 206|carbocistein|carbocisteine|carbocysteine|loviscol|mucofan	N[C@@H](CSCC(O)=O)C(O)=O	Launched	http://www.drugs.com/international/carbocisteine.html	GSTP1	https://www.drugbank.ca/drugs/DB04339	mucolytic agent			
defactinib	defactinib	PF-04554878|VS-6063	CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01870609	PTK2	http://www.verastem.com/attachments/WCLC-2015-Meso_Pachter.pdf	focal adhesion kinase inhibitor			
zacopride	zacopride		COc1cc(N)c(Cl)cc1C(=O)NC1CN2CCC1CC2	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/1514881	HTR3A|HTR3B|HTR5A|HTR4	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003562|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003562|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003562|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=245	serotonin receptor antagonist			
dacomitinib	dacomitinib		COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01360554	EGFR|ERBB2|ERBB4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7422|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7422|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7422	EGFR inhibitor			
creatinine	creatinine		CN1CC(=O)NC1=N	Preclinical							
enisamium-iodide	enisamium iodide		C[n+]1ccc(cc1)C(=O)NCc1ccccc1	Launched	http://farmak.ua/en/news/795						
FK-33-824	FK-33-824		C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CCS(C)=O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/6739537	OGFR|OPRM1	https://citeline.informa.com/?query=#/drugs/details/6990|http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693002/	opioid receptor agonist			
antazoline	antazoline	Vasocon-A	C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1	Launched	FDA Orange Book: antazoline phosphate	HRH1	https://www.drugbank.ca/drugs/DB08799	antihistamine	ophthalmology|otolaryngology	conjunctivitis|nasal congestion	https://en.wikipedia.org/wiki/Antazoline|https://en.wikipedia.org/wiki/Antazoline
daidzein	daidzein	dihydroxyflavone	Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00669656	TRPC5|ESRRG|ESRRA|ESRRB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2828|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2828|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2828|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2828	estrogen receptor agonist			
pepstatin	pepstatin	pepstatin a	CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O	Preclinical		CTSL|CTSB|CTSD|REN	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004306|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004306|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004306|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004306	aspartic protease inhibitor			
I-BET-762	I-BET-762	GSK-525762A	CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12	Phase 2	https://www.clinicaltrials.gov/show/NCT01943851	APOA1|BRD4|BRD2|BRD3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=720296|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7033|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7033|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7033	bromodomain inhibitor			
ITI214	ITI214		CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O	Phase 1	http://ir.intracellulartherapies.com/releasedetail.cfm?releaseid=847565	PDE1A	https://www.ncbi.nlm.nih.gov/pubmed/27342643	phosphodiesterase inhibitor			
torin-2	torin-2		Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1	Preclinical		MTOR	http://www.selleckchem.com/products/torin-2.html?gclid=CPz455mIoLwCFctcMgodJ2oAoQ	mTOR inhibitor			
torin-1	torin-1	Torin1	CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1	Preclinical		PIK3CA|MTOR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=717842|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8004	mTOR inhibitor			
DCEBIO	DCEBIO		CCn1c(O)nc2cc(Cl)c(Cl)cc12	Preclinical		KCNN2|KCNN3|KCNN4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2324|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2324|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2324	potassium channel activator			
LMK-235	LMK-235		Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO	Preclinical		HDAC4|HDAC5	https://www.tocris.com/products/lmk-235_4830|https://www.tocris.com/products/lmk-235_4830	HDAC inhibitor			
icomucret	icomucret	AL-12959	CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O	Phase 3	http://library.corporate-ir.net/library/13/130/130946/items/151995/Alcon_04_AR_R3.pdf	LTB4R2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3401	mucin production enhancer			
FG-7142	FG-7142		CNC(=O)c1cc2c(cn1)[nH]c1ccccc21	Preclinical				GABA benzodiazepine site receptor inverse agonist			
medorinone	medorinone	WIN 49,016	Cc1nccc2[nH]c(=O)ccc12	Phase 1	Pharmaprojects						
darunavir	darunavir	MC-114|TMC 114|TMC-114|UIC-940T|prezista	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1	Launched	FDA Orange Book: darunavir ethanolate	CYP3A4|CYP3A5	http://www.drugbank.ca/drugs/DB01264|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=310828	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=814301f9-c990-46a5-b481-2879a521a16f
denotivir	denotivir		Cc1nsc(NC(=O)c2ccccc2)c1C(=O)Nc1ccc(Cl)cc1	Launched	https://www.drugs.com/international/denotivir.html			antiviral	infectious disease|infectious disease	virus herpes simplex (HSV)|skin infections	http://www.ndrugs.com/?s=denotivir|http://www.ndrugs.com/?s=denotivir
urethane	urethane	ethyl carbamate|urethan	CCOC(N)=O	Preclinical				local anesthetic			
MD-920	MD-920	(+)-Gibberellic Acid|GIBBERELLIN A3	C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O	Phase 1	http://adisinsight.springer.com/drugs/800022566	AADACL2	https://www.drugbank.ca/drugs/DB07814	NFkB pathway inhibitor			
mesoridazine	mesoridazine	NC-123|TPS-23|lidanar|serentil	CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O	Launched	FDA Orange Book: mesoridazine besylate	HTR2A|DRD2	https://www.drugbank.ca/drugs/DB00933|https://www.drugbank.ca/drugs/DB00933	dopamine receptor antagonist	neurology/psychiatry	schizophrenia	https://en.wikipedia.org/wiki/Mesoridazine
pentostatin	pentostatin	nipent		Launched	FDA Orange Book: pentostatin	ADA	https://www.drugbank.ca/drugs/DB00552	adenosine deaminase inhibitor|ribonucleotide reductase inhibitor	hematologic malignancy	hairy cell leukemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=151c6d2e-1af1-4c13-96ec-de3228c6efb3
tamoxifen	tamoxifen	ICI-46474|nolvadex|soltamox|tamoxifen citrate	CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1	Launched	FDA Orange Book: tamoxifen citrate	ESR1|ESR2|PRKCB|PRKCA|PRKCG|PRKCE|PRKCD|PRKCZ|PRKCI|PRKCQ|EBP|GPER1|CYP3A5	https://www.drugbank.ca/drugs/DB00675|https://www.drugbank.ca/drugs/DB00675|https://www.drugbank.ca/drugs/DB00675|https://www.drugbank.ca/drugs/DB00675|https://www.drugbank.ca/drugs/DB00675|https://www.drugbank.ca/drugs/DB00675|https://www.drugbank.ca/drugs/DB00675|https://www.drugbank.ca/drugs/DB00675|https://www.drugbank.ca/drugs/DB00675|https://www.drugbank.ca/drugs/DB00675|https://www.drugbank.ca/drugs/DB00675|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1016|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=276979	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	oncology	breast cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=063fa789-4570-4715-c3bd-1bad0449fb26&audience=consumer
halcinonide	halcinonide	halog|halog-e		Launched	FDA Orange Book: halcinonide	NR3C1	http://en.wikipedia.org/wiki/Halcinonide	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e60d0691-0628-4c98-9a17-f4a89822baf2
OXA-06	OXA-06		Fc1ccccc1CNCc1ccc(cc1)-c1ccnc2[nH]ccc12	Preclinical		ROCK1|ROCK2	https://www.tocris.com/products/oxa-06-dihydrochloride_5182|https://www.tocris.com/products/oxa-06-dihydrochloride_5182	rho associated kinase inhibitor			
lubiprostone	lubiprostone	amitiza	CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	Launched	FDA Orange Book: lubiprostone	CLCN2	https://www.drugbank.ca/drugs/DB01046	chloride channel activator	gastroenterology|gastroenterology	constipation|irritable bowel syndrome	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=222817c2-d4a6-43d0-8cbb-215f19acb198|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=222817c2-d4a6-43d0-8cbb-215f19acb198
modafinil	modafinil	CEP 1538|CEP-1538|CRL 40476|CRL-40476|provigil	NC(=O)CS(=O)C(c1ccccc1)c1ccccc1	Launched	FDA Orange Book: armodafinil, modafinil	CYP2C19|CYP2B6|ADRA1B|CYP1A2|CYP3A4|CYP3A5|SLC6A3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=129674|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=129674|https://www.drugbank.ca/drugs/DB00745|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=129674|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=129674|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=129674|ChEMBL	adrenergic receptor agonist	pulmonary|neurology/psychiatry	obstructive sleep apnea|shift work disorder (SWD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5bc33938-2717-471b-b066-c6c67317d4e0|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5bc33938-2717-471b-b066-c6c67317d4e0
teprenone	teprenone		CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C	Launched	http://www.drugs.com/international/Teprenone.html			mucus protecting agent	dermatology	cosmetic	http://www.paulaschoice.com/cosmetic-ingredient-dictionary/definition/teprenone
mebhydrolin	mebhydrolin	mebhydrolin napadisylate	CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1	Launched	http://www.drugs.com/international/mebhydrolin.html			antihistamine	allergy|allergy	allergic rhinitis|urticaria	http://druginfosys.com/Drug.aspx?drugCode=439&drugName=&type=1|http://druginfosys.com/Drug.aspx?drugCode=439&drugName=&type=1
piperidolate	piperidolate		CCN1CCCC(C1)OC(=O)C(c1ccccc1)c1ccccc1	Launched	http://www.drugs.com/international/piperidolate.html	CHRM1	http://en.wikipedia.org/wiki/Piperidolate	acetylcholine receptor antagonist	neurology/psychiatry	spasms	http://www.drugs.com/international/piperidolate.html
pyrantel-pamoate	pyrantel-pamoate	pyrantel	CN1CCCN=C1\C=C\c1cccs1	Veterinary Launched	https://clinicaltrials.gov/ct2/show/NCT01327469			neuromuscular blocker	infectious disease|infectious disease	hookworm|tapeworm	https://en.wikipedia.org/wiki/Pyrantel_pamoate|https://en.wikipedia.org/wiki/Pyrantel_pamoate
octisalate	octisalate		CCCC[C@@H](CC)COC(=O)c1ccccc1O	Launched	http://en.wikipedia.org/wiki/Octyl_salicylate				dermatology	sunscreen lotion	http://www.ewg.org/skindeep/ingredient/704204/OCTISALATE/
pritelivir	pritelivir		CN(C(=O)Cc1ccc(cc1)-c1ccccn1)c1nc(C)c(s1)S(N)(=O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01047540			helicase primase inhibitor			
benzthiazide	benzthiazide	aquatag|exna|fovane|urese	NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O	Launched	FDA Orange Book: benzthiazide	SLC12A3|CA9|CA4|CA1|CA2|CA12	ChEMBL|https://www.drugbank.ca/drugs/DB00562|https://www.drugbank.ca/drugs/DB00562|https://www.drugbank.ca/drugs/DB00562|https://www.drugbank.ca/drugs/DB00562|https://www.drugbank.ca/drugs/DB00562	carbonic anhydrase inhibitor	cardiology|cardiology	hypertension|edema	https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=benzthiazide|https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=benzthiazide
emorfazone	emorfazone		CCOc1c(cnn(C)c1=O)N1CCOCC1	Launched	https://www.drugs.com/international/emorfazone.html			antiinflammatory agent|cyclooxygenase inhibitor	dental	mouth inflammation	https://www.jstage.jst.go.jp/article/jjoms1967/32/12/32_12_2443/_article
barium-6-O-phosphonato-D-glucose	barium-6-O-phosphonato-D-glucose		O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H](O)C=O	Preclinical		TGFBR2|TGFB1|GPI	https://citeline.informa.com/?query=#/drugs/details/26978|https://citeline.informa.com/?query=#/drugs/details/26978|https://www.drugbank.ca/drugs/DB03581				
SB-328437	SB-328437		COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12	Preclinical				CCR antagonist			
KD-023	KD-023		CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O	Phase 2	Pharmaprojects	CHAT|ACACA|ACACB	https://citeline.informa.com/?query=#/drugs/details/73185|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5280|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5280	ACAT inhibitor			
parbendazole	parbendazole	SK&F 29044|TCMDC-131798	CCCCc1ccc2[nH]c(NC(=O)OC)nc2c1	Preclinical		TUBB	http://www.ncbi.nlm.nih.gov/pubmed/7031071	tubulin polymerization inhibitor			
LY2811376	LY2811376		C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00838084	BACE1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6936	beta-secretase inhibitor			
SM-108	SM-108		NC(=O)c1[nH]cnc1O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/2643392						
CTS21166	CTS21166	OM99-2	CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00621010	BACE1	http://www.drugbank.ca/drugs/DB06073	beta-secretase inhibitor			
AZ505	AZ505		Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12	Preclinical		SMYD2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7021	histone lysine methyltransferase inhibitor			
A61603	A61603		CS(=O)(=O)Nc1c(O)ccc2C(CCCc12)C1=NCCN1	Preclinical		ADRA1A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=480	adrenergic receptor agonist			
fluoxymesterone	fluoxymesterone	Android-f|Androxy|fluoximesterone|halotestin|ora-testryl	C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C	Launched	FDA Orange Book: fluoxymesterone	AR|PRLR|ESR1|NR3C1	ChEMBL|https://www.drugbank.ca/drugs/DB01185|https://www.drugbank.ca/drugs/DB01185|https://www.drugbank.ca/drugs/DB01185	androgen receptor modulator	endocrinology	hypogonadism	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09bafc2d-1893-4618-86dc-e9403407cd41
urapidil	urapidil		COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1	Launched	http://www.drugs.com/international/Urapidil.html	HTR1A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001490	adrenergic receptor antagonist	cardiology	hypertension	https://en.wikipedia.org/wiki/Urapidil
CGP-20712A	CGP-20712A		Cn1cc(nc1-c1ccc(OCC(O)CNCCOc2ccc(O)c(c2)C(N)=O)cc1)C(F)(F)F	Preclinical		ADRB1|ADRB3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=541|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=541	adrenergic receptor antagonist			
SRT1720	SRT1720	SRT-1720	O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1	Preclinical		SIRT1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7703	SIRT activator			
etizolam	etizolam		CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl	Launched	http://www.drugs.com/international/Etizolam.html	GABRA5|GABRA3|GABRA2|GABRA1|PTAFR	https://citeline.informa.com/?query=#/drugs/details/6694|https://citeline.informa.com/?query=#/drugs/details/6694|https://citeline.informa.com/?query=#/drugs/details/6694|http://www.genome.jp/dbget-bin/www_bget?D01514|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090825	benzodiazepine receptor agonist	neurology/psychiatry|neurology/psychiatry	insomnia|anxiety	https://en.wikipedia.org/wiki/Etizolam#Indications|https://en.wikipedia.org/wiki/Etizolam#Indications
JTC-801	JTC-801		CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/18670432	OPRL1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1692	opioid receptor antagonist			
shikimic-acid	shikimic acid		O[C@@H]1CC(=CC(O)C1O)C(O)=O	Preclinical							
leteprinim	leteprinim		OC(=O)c1ccc(NC(=O)CCn2cnc3c(O)ncnc23)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00041795			nerve growth factor agonist			
WDR5-0103	WDR5-0103		COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1	Preclinical		WDR5	https://www.tocris.com/products/wdr5-0103_5323	histone lysine methyltransferase inhibitor			
Ro-5126766	Ro-5126766	CKI-27|RG-7304|ro-5126766	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00773526	MAP2K2|MAP2K1|RAF1|BRAF	http://www.apexbt.com/ro5126766-ch5126766.html|http://www.apexbt.com/ro5126766-ch5126766.html|http://www.apexbt.com/ro5126766-ch5126766.html|http://www.apexbt.com/ro5126766-ch5126766.html	RAF inhibitor|MEK inhibitor			
ostarine	ostarine	GTX-024|MK-2866|enobosarm	C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01355497	AR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DPR000088	androgen receptor modulator			
pazopanib	pazopanib	GW-786034|votrient	CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1	Launched	FDA Orange Book: pazopanib hydrochloride	FGF1|CSF1R|DDR2|FLT1|FLT4|ITK|KIT|KDR|SH2B3|CYP2B6|CYP2C8|CYP2E1|BRAF|FGFR3|FGFR1|PDGFRB|PDGFRA	https://www.drugbank.ca/drugs/DB06589|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5698|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=334209|https://www.drugbank.ca/drugs/DB06589|https://www.drugbank.ca/drugs/DB06589|https://www.drugbank.ca/drugs/DB06589|https://www.drugbank.ca/drugs/DB06589|https://www.drugbank.ca/drugs/DB06589|https://www.drugbank.ca/drugs/DB06589|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=334209|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=334209|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=334209|https://citeline.informa.com/?query=#/drugs/details/25936|https://www.drugbank.ca/drugs/DB06589|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5698|https://www.drugbank.ca/drugs/DB06589|https://www.drugbank.ca/drugs/DB06589	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	oncology|oncology	renal cell carcinoma (RCC)|soft tissue sarcoma (STS)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5b7b3a4-c3a4-4722-8ca5-8f6a5c622553|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5b7b3a4-c3a4-4722-8ca5-8f6a5c622553
VBY-825	VBY-825		CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1	Preclinical		CTSL|CTSS|CTSB	https://www.medchemexpress.com/VBY-825.html|https://www.medchemexpress.com/VBY-825.html|https://www.medchemexpress.com/VBY-825.html	cathepsin inhibitor			
NSC-405020	NSC-405020		CCCC(C)NC(=O)c1ccc(Cl)c(Cl)c1	Preclinical		MMP1	http://www.tocris.com/dispprod.php?ItemId=378044#.Vgq4-GRVhHw	matrix metalloprotease inhibitor			
tienilic-acid	tienilic acid	SK&F 62698|selacryn|ticrynafen|tienilic acid	OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl	Withdrawn	https://en.wikipedia.org/wiki/Tienilic_acid	SLC12A1|CYP2C9|SLC22A12	http://en.wikipedia.org/wiki/Tienilic_acid|http://en.wikipedia.org/wiki/Tienilic_acid|https://citeline.informa.com/?query=#/drugs/details/18220	sodium/potassium/chloride transporter inhibitor|cytochrome P450 inhibitor			
INC-280	INC-280	Capmatinib|INC280|INCB-28060|NVP-INC280	CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01610336	MET	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7904	c-Met inhibitor			
CGM097	CGM097		COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01760525	MDM2|TP53	http://www.medchemexpress.com/nvp-cgm097.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=737818	MDM inhibitor			
ecabet	ecabet	ecabet sodium	CC(C)c1cc2CC[C@H]3[C@@](C)(CCC[C@]3(C)c2cc1S(O)(=O)=O)C(O)=O	Launched	http://www.drugs.com/international/Ecabet.html	NOXO1|GAST|CCKBR	https://www.drugbank.ca/drugs/DB05265|https://citeline.informa.com/?query=#/drugs/details/6214|https://citeline.informa.com/?query=#/drugs/details/6214	gastrin inhibitor|urease inhibitor	ophthalmology	dry eye syndrome	http://www.drugbank.ca/drugs/DB05265
ICG-001	ICG-001		Oc1ccc(C[C@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1	Preclinical		CTNNB1	http://www.tocris.com/dispprod.php?ItemId=341069#.VgGk92RVhHw	beta-catenin inhibitor			
PF-670462	PF-670462		Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1	Preclinical		CSNK1D|CSNK1E	https://www.tocris.com/dispprod.php?ItemId=218698#.V-1-Z5MrLy8|https://www.tocris.com/dispprod.php?ItemId=218698#.V-1-Z5MrLy8	casein kinase inhibitor			
drotaverine	drotaverine		CCOc1ccc(\C=C2\NCCc3cc(OCC)c(OCC)cc23)cc1OCC	Launched	http://www.drugs.com/international/Drotaverine.html	PDE4A|CACNA1C	https://www.drugbank.ca/drugs/DB06751|https://www.drugbank.ca/drugs/DB06751	phosphodiesterase inhibitor	obstetrics/gynecology	labor induction	https://en.wikipedia.org/wiki/Drotaverine
brequinar	brequinar		Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/8256771	DHODH	https://www.drugbank.ca/drugs/DB03523	dihydroorotate dehydrogenase inhibitor			
TC-N-1752	TC-N-1752		CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C	Preclinical		SCN9A	https://www.tocris.com/products/tc-n-1752_4435	sodium channel blocker			
oxfenicine	oxfenicine			Phase 1	Pharmaprojects	CPT1A|CPT1B	http://www.genome.jp/dbget-bin/www_bget?dr:D05292|http://www.genome.jp/dbget-bin/www_bget?dr:D05292	carnitine palmitoyltransferase inhibitor			
rhein	rhein		OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	Phase 1	Cortellis	HSP90AA1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011351				
CU-T12-9	CU-T12-9		CNc1ccc(cc1-n1cnc(c1)-c1ccc(cc1)C(F)(F)F)[N+]([O-])=O	Preclinical		TLR2|TLR1	https://www.tocris.com/products/cu-t12-9_5414|https://www.tocris.com/products/cu-t12-9_5414	toll-like receptor agonist			
dimemorfan	dimemorfan	dimemorfan phosphate	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31	Launched	https://www.drugs.com/international/dimemorfan.html	SIGMAR1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000565	sigma receptor agonist	pulmonary	cough suppressant	https://en.wikipedia.org/wiki/Dimemorfan
PSB-1115	PSB-1115		CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O	Preclinical		ADORA1|ADORA3|ADORA2B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3286|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3286|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3286	adenosine receptor antagonist			
andrographolide	andrographolide		C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H](C\C=C3/[C@H](O)COC3=O)C(=C)CCC12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01993472	NFKB1|TNF	https://en.wikipedia.org/wiki/Andrographolide|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=383472	tumor necrosis factor production inhibitor			
PPY-A	PPY-A		COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C	Preclinical		BCR|ABL1	https://www.tocris.com/products/ppy-a_4730|https://www.drugbank.ca/drugs/DB08350	Abl kinase inhibitor			
nialamide	nialamide		O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	COMT|MAOA|MAOB	https://www.drugbank.ca/drugs/DB04820|https://www.drugbank.ca/drugs/DB04820|https://www.drugbank.ca/drugs/DB04820	monoamine oxidase inhibitor			
L-741742	L-741742		Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1	Preclinical		DRD4|DRD3|SCN1A|SCN3A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3302|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004182|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004182|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004182	dopamine receptor antagonist			
LY2365109	LY2365109		CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O	Preclinical		SLC6A9	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4712	Glycine transporter 1 inhibitor			
iloprost	iloprost	ZK 00036374|ciloprost|ventavis	CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O	Launched	FDA Orange Book: iloprost	PTGER3|PTGER4|PTGER1|PTGER2|PDE4A|PDE4B|PDE4C|PDE4D|PLAT|TBXA2R|PTGFR|PTGIR|PTGDR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1895|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1895|https://www.drugbank.ca/drugs/DB01088|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1895|https://www.drugbank.ca/drugs/DB01088|https://www.drugbank.ca/drugs/DB01088|https://www.drugbank.ca/drugs/DB01088|https://www.drugbank.ca/drugs/DB01088|https://www.drugbank.ca/drugs/DB01088|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1895|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1895|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1895	platelet aggregation inhibitor|prostanoid receptor agonist	pulmonary	pulmonary arterial hypertension (PAH)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3bebc1c-f032-402a-bbc9-aff024276ed1
pregabalin	pregabalin	CI-1008|PD-144723|lyrica	CC(C)C[C@H](CN)CC(O)=O	Launched	FDA Orange Book: pregabalin	CACNA1I|CACNA1F|CACNA1E|CACNA1H|CACNA1G|CACNA1B|CACNA1A|CACNA1D|CACNA1C|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|CACNG6|CACNG7|CACNG8|CACNG2|CACNG3|CACNG4|CACNG5|CACNG1|CACNA2D4|CACNA2D2|CACNA2D3|CACNA2D1	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	voltage-gated calcium channel ligand	neurology/psychiatry|neurology/psychiatry|rheumatology|neurology/psychiatry	peripheral neuropathy|seizures|fibromyalgia|postherpetic neuralgia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed2a7ed8-25e0-48cc-af01-9ad0956023da|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed2a7ed8-25e0-48cc-af01-9ad0956023da|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed2a7ed8-25e0-48cc-af01-9ad0956023da|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed2a7ed8-25e0-48cc-af01-9ad0956023da
picolamine	picolamine		NCc1cccnc1	Preclinical							
mibefradil	mibefradil	Posicor	COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	CACNA1I|CACNA1S|CACNA1D|CACNA1C|CACNA1H|CACNA1G|CACNA1F|CACNB4|CACNB3|CACNB2|CACNB1|CATSPER4|CATSPER1|CATSPER2|CATSPER3|SCN5A|SCN9A|ANO1|SCN2A|SCN4A	https://www.drugbank.ca/drugs/DB01388|https://www.drugbank.ca/drugs/DB01388|https://www.drugbank.ca/drugs/DB01388|https://www.drugbank.ca/drugs/DB01388|https://www.drugbank.ca/drugs/DB01388|https://www.drugbank.ca/drugs/DB01388|https://www.drugbank.ca/drugs/DB01388|https://www.drugbank.ca/drugs/DB01388|https://www.drugbank.ca/drugs/DB01388|https://www.drugbank.ca/drugs/DB01388|https://www.drugbank.ca/drugs/DB01388|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2522|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2522|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2522|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2522|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=143135|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=143135|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2522|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=143135|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=143135	T-type calcium channel blocker			
AM-281	AM-281		Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1	Preclinical		GPR55|CNR2|CNR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=741|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009072|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009072	cannabinoid receptor antagonist			
amtolmetin-guacil	amtolmetin guacil	amtolmetin guacil	COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C	Launched	http://www.drugs.com/international/Amtolmetin guacil.html	PTGS1|PTGS2	http://www.ncbi.nlm.nih.gov/pubmed/16396699|http://www.ncbi.nlm.nih.gov/pubmed/16396699	cyclooxygenase inhibitor	rheumatology|rheumatology	rheumatoid arthritis|osteoarthritis	https://en.wikipedia.org/wiki/Amtolmetin_guacil|https://en.wikipedia.org/wiki/Amtolmetin_guacil
TC-H-106	TC-H-106		Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1	Preclinical		HDAC1|HDAC2|HDAC3|HDAC8	https://www.tocris.com/products/tc-h-106_4270|https://www.tocris.com/products/tc-h-106_4270|https://www.tocris.com/products/tc-h-106_4270|https://www.tocris.com/products/tc-h-106_4270	HDAC inhibitor			
bendamustine	bendamustine	bendeka|treanda	Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl	Launched	FDA Orange Book: bendamustine hydrochloride			DNA inhibitor	hematologic malignancy|hematologic malignancy	chronic lymphocytic leukemia (CLL)|non-Hodgkin lymphoma (NHL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ace9a43b-f9bd-4896-abfe-0ef4fec67ddf|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ace9a43b-f9bd-4896-abfe-0ef4fec67ddf
ZK-93423	ZK-93423		CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/10653203	GABRA3|GABRA1|GABRA2|GABRA5|GABRB2|GABRG2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4346|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4346|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4346|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4346|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011521|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011521	benzodiazepine receptor agonist			
ZK-93426	ZK-93426		CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/2890423	GABRA5|GABRA2|GABRA3|GABRA1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4347|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4347|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4347|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4347	benzodiazepine receptor antagonist			
anpirtoline	anpirtoline		Clc1cccc(SC2CCNCC2)n1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/8018453	HTR1B|HTR3A	http://www.tocris.com/dispprod.php?ItemId=1173#.Ut6oUf30DmE|https://citeline.informa.com/?query=#/drugs/details/1604	serotonin receptor agonist			
ampiroxicam	ampiroxicam	CP-65703	CCOC(=O)OC(C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1	Launched	http://www.drugs.com/international/ampiroxicam.html	PTGS1|PTGS2	http://www.selleckchem.com/products/ampiroxicam.html|http://www.selleckchem.com/products/ampiroxicam.html	cyclooxygenase inhibitor	neurology/psychiatry	pain relief	https://en.wikipedia.org/wiki/Ampiroxicam
I-BZA2	I-BZA2		CCN(CC)CCNC(=O)c1ccccc1I	Phase 3	http://www.snmmi.org/files/images/Publications/jnm123554_v2.pdf						
androsterone	androsterone		C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O	Preclinical				androgen receptor agonist			
methylthiouracil	methylthiouracil		Cc1cc(=O)[nH]c(=S)[nH]1	Launched	http://www.drugs.com/international/Methylthiouracil.html				endocrinology	hyperthyroidism	https://en.wikipedia.org/wiki/Methylthiouracil
PD-161570	PD-161570	PD161570	CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl	Preclinical		FGFR1	http://www.tocris.com/dispprod.php?ItemId=241117#.Vgv8VtNViko	FGFR inhibitor			
benzoylpas	benzoylpas		OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O	Preclinical							
SAR-245409	SAR-245409		COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT01082068	MTOR|PIK3CG	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000264|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000264	PI3K inhibitor			
CC-930	CC-930	JNK-930|tanzisertib	O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01203943			JNK inhibitor			
mocetinostat	mocetinostat	MGCD-0103|MGCD0103	Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02236195	HDAC2|HDAC1|HDAC3|HDAC11	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7008|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7008|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7008|http://www.selleckchem.com/products/MGCD0103(Mocetinostat).html?gclid=CMqlx-6KhrwCFaxr7AodgnMANA	HDAC inhibitor			
ardeparin	ardeparin	normiflo	CC(=O)NC1C(O)OC(COS(O)(=O)=O)C(OC2OC(C(OC3OC(CO)C(OC4OC(C(O)C(O)C4OS(O)(=O)=O)C(O)=O)C(OS(O)(=O)=O)C3NS(O)(=O)=O)C(O)C2OS(O)(=O)=O)C(O)=O)C1O	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	SERPIND1|SERPINC1	https://www.drugbank.ca/drugs/DB00407|https://www.drugbank.ca/drugs/DB00407	thrombin inhibitor			
idronoxil	idronoxil	NV-06	Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00382811	TOP2A|ENOX2|XIAP|CFLAR|SRD5A1|SPHK1	https://citeline.informa.com/?query=#/drugs/details/12723|https://www.drugbank.ca/drugs/DB04915|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=273285|https://citeline.informa.com/?query=#/drugs/details/12723|https://citeline.informa.com/?query=#/drugs/details/12723|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000196	XIAP inhibitor			
nitenpyram	nitenpyram		CCN(Cc1ccc(Cl)nc1)C(\NC)=C\[N+]([O-])=O	Launched	http://www.drugs.com/international/nitenpyram.html				infectious disease	flea control	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5411a966-0e1f-4533-9f31-076d81050705
RU-42173	RU-42173	Zilpaterol	CC(C)N[C@@H]1CCn2c3c(cccc3[nH]c2=O)[C@H]1O	Phase 2	Pharmaprojects	ADRB2	https://www.caymanchem.com/product/16484	adrenergic receptor agonist			
zamifenacin	zamifenacin	UK-76654-2 [AS FUMARATE]	C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1	Phase 3	https://www.pharmamedtechbi.com/publications/the-pink-sheet/55/017/pfizer-zamifenacin-trials-include-costeffectiveness-study-of-sick-days-firm-tells-shareholders-irritable	CHRM3	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001531	acetylcholine receptor antagonist			
zinc-undecylenate	zinc undecylenate		C=CCCCCCCCCC(=O)O[Zn]OC(=O)CCCCCCCCC=C	Launched	http://www.drugs.com/cdi/undecylenic-acid-zinc-undecylenate-powder.html			other antifungal	infectious disease	tinea pedis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0129d801-90f6-49fd-857f-27d6ba9fc66c
SLV-320	SLV-320		O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00744341	ADORA3|ADORA1|ADORA2A|ADORA2B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3281|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3281|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3281|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3281	adenosine receptor antagonist			
cephapirin	cephapirin	cefadyl|cefapirin	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O	Launched	FDA Orange Book: cephapirin sodium			bacterial cell wall synthesis inhibitor	obstetrics/gynecology	mastitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c32e2442-74c1-4a7d-8a45-88923522c7e5
2-CMDO	2-CMDO		CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12	Preclinical		DRD4|DRD2	http://www.tocris.com/dispprod.php?ItemId=2159#.VeSTnSxVhHw|http://www.tocris.com/dispprod.php?ItemId=2159#.VeSTnSxVhHw	dopamine receptor antagonist			
merbarone	merbarone		O=C(Nc1ccccc1)C1C(=O)NC(=S)NC1=O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/9468039	TOP2A	http://www.sigmaaldrich.com/catalog/product/sigma/m2070?lang=en&region=US	topoisomerase inhibitor			
valaciclovir	valaciclovir	valacyclovir|valtrex	CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1nc(N)[nH]c2=O	Launched	http://www.drugs.com/international/Valaciclovir.html			DNA polymerase inhibitor	infectious disease|infectious disease	shingles|virus herpes simplex (HSV)	https://en.wikipedia.org/wiki/Valaciclovir|https://en.wikipedia.org/wiki/Valaciclovir
spiramycin	spiramycin		CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1OC1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C	Launched	http://www.drugs.com/international/Spiramycin.html			bacterial 50S ribosomal subunit inhibitor	infectious disease|infectious disease	toxoplasmosis|soft tissue infection	https://en.wikipedia.org/wiki/Spiramycin|https://en.wikipedia.org/wiki/Spiramycin
clinafloxacin	clinafloxacin		NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/11760164			bacterial DNA gyrase inhibitor			
AC-261066	AC-261066		CCCCOCCOc1nc(sc1C)-c1ccc(C(O)=O)c(F)c1	Preclinical		RARB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4054	retinoid receptor agonist			
BRL-54443	BRL-54443		CN1CCC(CC1)c1c[nH]c2ccc(O)cc12	Preclinical		HTR1E|HTR1F	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3927|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3927	serotonin receptor agonist			
phloroglucin	phloroglucin	phloroglucinol	Oc1cc(O)cc(O)c1	Launched	https://clinicaltrials.gov/ct2/show/NCT01842932						
irosustat	irosustat	667 COUMATE|BN-83495|BN83495|STX-64|STX64	NS(=O)(=O)Oc1ccc2c3CCCCCc3c(=O)oc2c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01662726	STS|CA2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000238|https://www.drugbank.ca/drugs/DB02292	steroid sulfatase inhibitor			
dynole-34-2	dynole-34-2		CCCCCCCCNC(=O)C(=C\c1cn(CCCN(C)C)c2ccccc12)\C#N	Preclinical		DNM1	https://www.tocris.com/products/dynole-34-2_4222	dynamin inhibitor			
JW-642	JW-642		FC(F)(F)C(OC(=O)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1)C(F)(F)F	Preclinical		MGLL	https://www.tocris.com/products/jw-642_4906	monoacylglycerol lipase inhibitor			
tiplaxtinin	tiplaxtinin	PAI-039|tiplasinin	OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1	Phase 1	http://www.synovellab.com/product/tiplaxtinin	SERPINE1	http://www.selleckchem.com/products/tiplaxtinin-pai-039.html	plasminogen activator inhibitor			
clopidogrel	clopidogrel	plavix	COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl	Launched	FDA Orange Book: clopidogrel, clopidogrel bisulfate	P2RY12|CYP2C19|CYP2B6|CYP3A5	ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=142672|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=142672|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=142672	purinergic receptor antagonist	cardiology|neurology/psychiatry|cardiology|cardiology	myocardial infarction|stroke|peripheral artery disease (PAD)|acute coronary syndrome (ACS)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=edae8df1-caf9-ff72-1304-5ae8b355f8e7|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=edae8df1-caf9-ff72-1304-5ae8b355f8e7|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=edae8df1-caf9-ff72-1304-5ae8b355f8e7|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=edae8df1-caf9-ff72-1304-5ae8b355f8e7
tiapride	tiapride	tiapride hydrochloride	CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O	Launched	http://www.drugs.com/international/tiapride.html	DRD2|DRD3	https://en.wikipedia.org/wiki/Tiapride|https://en.wikipedia.org/wiki/Tiapride	dopamine receptor antagonist	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	dyskinesia|abstinence from alcohol|psychosis	https://en.wikipedia.org/wiki/Tiapride|https://en.wikipedia.org/wiki/Tiapride|https://en.wikipedia.org/wiki/Tiapride
thaliblastine	thaliblastine	Thalicarpine	COc1cc(C[C@@H]2N(C)CCc3cc(OC)c(OC)cc23)c(Oc2cc3C[C@@H]4N(C)CCc5cc(OC)c(OC)c(-c3cc2OC)c45)cc1OC	Phase 2	http://www.cancer.gov/clinicaltrials/search/view?cdrid=64672&version=HealthProfessional&protocolsearchid=11552376			DNA inhibitor			
chuanxiongzine	chuanxiongzine	2,3,5,6-Tetramethyl-Pyrazine|2,3,5,6-Tetramethylpyrazine|Ligustrazine|Tetramethylpyrazine	Cc1nc(C)c(C)nc1C	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/21163116						
PD1-PDL-inhibitor-1	PD1-PDL-inhibitor-1		COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CN1CCCC[C@H]1C(O)=O	Preclinical		CD274	http://www.biovision.com/pd-1-pd-l1-inhibitor-1-12437.html	programmed death ligand inhibitor			
troleandomycin	troleandomycin	tao	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](OC3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	Launched	FDA Orange Book: troleandomycin			protein synthesis inhibitor	infectious disease|pulmonary|otolaryngology|otolaryngology	pneumonia|bronchitis|tonsillitis|sinusitis	http://www.drugs.com/mtm/troleandomycin.html|http://www.drugs.com/mtm/troleandomycin.html|http://www.drugs.com/mtm/troleandomycin.html|http://www.drugs.com/mtm/troleandomycin.html
paracetamol	paracetamol	APAP|Datril|Phenaphen|Tylenol (caplet)|Tylenol (geltab)|acephen|acetaminophen|infants' feverall|injectapap|neopap|ofirmev|tylenol|tylenol 	CC(=O)Nc1ccc(O)cc1	Launched	FDA Orange Book: acetaminophen	CYP2E1|PTGS1|PTGS2|FAAH|TRPV1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=080000|ChEMBL|ChEMBL|ChEMBL|ChEMBL	cyclooxygenase inhibitor	neurology/psychiatry|endocrinology	pain relief|fever	http://www.drugs.com/paracetamol.html|http://www.drugs.com/paracetamol.html
psoralen	psoralen		O=c1ccc2cc3ccoc3cc2o1	Launched	http://en.wikipedia.org/wiki/Psoralen	MAOA|MAOB	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001160|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001160		dermatology|dermatology|dermatology	psoriasis|eczema|vitiligo	https://en.wikipedia.org/wiki/Psoralen|https://en.wikipedia.org/wiki/Psoralen|https://en.wikipedia.org/wiki/Psoralen
wnt-c59	wnt-c59		Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1	Preclinical		PORCN	http://www.tocris.com/dispprod.php?ItemId=404784#.VhQMhRNViko	porcupine inhibitor			
abamectin	abamectin		CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C	Launched	http://www.drugs.com/international/abamectin.html	GABBR2|GABBR1	http://parasitipedia.net/index.php?option=com_content&view=article&id=2675&Itemid=2959|http://parasitipedia.net/index.php?option=com_content&view=article&id=2675&Itemid=2959	benzodiazepine receptor agonist	infectious disease	gastrointestinal parasites	https://en.wikipedia.org/wiki/Abamectin
pikamilone	pikamilone		OC(=O)CCCNC(=O)c1cccnc1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/?term=pikamilone%5Bti%5D						
vinpocetine	vinpocetine	AY-27,255	CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41	Launched	http://www.drugs.com/international/Vinpocetine.html	SCN10A|PDE1C|PDE1A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=136806|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5285|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5285	phosphodiesterase inhibitor|sodium channel blocker			
sucrose-octaacetate	sucrose octaacetate	sucrose octaacetate	CC(=O)OC[C@H]1O[C@@](COC(C)=O)(O[C@H]2O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]2OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O	Preclinical							
pyridoxine	pyridoxine	Hexa-Betalin|M.V.I.-12|Pyridoxine (Vit B6)|Vitamin B6|pyridoxine hydrochloride	Cc1ncc(CO)c(CO)c1O	Launched	FDA Orange Book: pyridoxine, pyridoxine hydrochloride	DDC|PDXK	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000869|https://www.drugbank.ca/drugs/DB00165	vitamin B	metabolism	vitamin B6 deficiency	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a56d11c0-b033-4201-85ff-fc710506481a
LDN-209929	LDN-209929		COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1	Preclinical		GSG2	https://www.tocris.com/products/ldn-209929-dihydrochloride_4828	haspin kinase inhibitor			
INT-767	INT-767		CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12	Phase 1	http://ir.interceptpharma.com/releasedetail.cfm?releaseid=944736	GPBAR1|NR1H4	https://www.medchemexpress.com/int-767.html?gclid=CKG-gO-CsM8CFUlahgoddeMEoQ|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=645154	FXR agonist			
ZCL-278	ZCL-278		Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1	Preclinical		CDC42	http://www.tocris.com/dispprod.php?ItemId=370452#.VhQQDhNViko	CDC inhibitor			
narasin	narasin		CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O	Veterinary Launched	http://www.drugs.com/international/narasin.html			antiprotozoal agent	infectious disease	coccidiosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea075806-8fd6-4d62-aa79-ebc20661e890
clioquinol	clioquinol	domeform-hc|iodochlorhydroxyquin|quin-o-creme|vioform	Oc1c(I)cc(Cl)c2cccnc12	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	OPRK1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011356	chelating agent			
epoprostenol	epoprostenol	PG-I2|PGI2|PROSTAGLANDIN I2|U-53,217|U-53217|flolan|prostacyclin|prostaglandin x|veletri	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O	Launched	FDA Orange Book: epoprostenol sodium	PTGIR|PTGIS|PTGER4|PTGER1|P2RY12	https://www.drugbank.ca/drugs/DB01240|https://www.drugbank.ca/drugs/DB01240|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915|https://www.drugbank.ca/drugs/DB01240	prostacyclin analog	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df502787-46ec-4dd1-a2c0-be90f6d95a5d
Lu-AA-47070	Lu-AA-47070		CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O	Phase 2	https://books.google.com/books?id=eQzLBQAAQBAJ&lpg=PA882&ots=W9m6RFDD6S&dq=Lu-AA-47070%20phase&pg=PA882#v=onepage&q=Lu-AA-47070%20phase&f=false	ADORA2A	https://www.tocris.com/search?keywords=Lu-AA-47070	adenosine receptor antagonist			
gramine	gramine		CN(C)Cc1c[nH]c2ccccc12	Preclinical				norepinephrine reputake inhibitor			
paclitaxel	paclitaxel	abraxane|taxol	CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1	Launched	FDA Orange Book: paclitaxel	ABCB1|TUBB|BCL2|CYP2C8|MAPT|MAP4|MAP2|NR1I2|TUBB1|TLR4	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=101438|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2770|https://www.drugbank.ca/drugs/DB01229|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=101438|https://www.drugbank.ca/drugs/DB01229|https://www.drugbank.ca/drugs/DB01229|https://www.drugbank.ca/drugs/DB01229|https://www.drugbank.ca/drugs/DB01229|https://www.drugbank.ca/drugs/DB01229|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2770	tubulin polymerization inhibitor	oncology|oncology|oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ffd3e34-537f-4f65-b00e-57c25bab3b01|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ffd3e34-537f-4f65-b00e-57c25bab3b01|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ffd3e34-537f-4f65-b00e-57c25bab3b01
LGX818	LGX818		COC(=O)NC(C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01909453	BRAF	http://www.arraybiopharma.com/product-pipeline/encorafenib-lgx818/	RAF inhibitor			
dinaciclib	dinaciclib	MK-7965|SCH 727965|SCH-727965	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01580228	CCNT1|CDK2|CDK1|CDK5|CDK9	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=428087|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7379|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7379|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7379|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7379	CDK inhibitor			
ibuproxam	ibuproxam		CC(C)Cc1ccc(cc1)C(C)C(=O)NO	Launched	https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA540&lpg=PA540&dq=Nialen+ibuproxam&source=bl&ots=eqambIrf1z&sig=gNlFjggDpm_phiikXAb_TOFA6rg&hl=en&sa=X&ved=0ahUKEwjd2Zfht7LXAhUmw4MKHbP1C94Q6AEIMzAD#v=onepage&q=Nialen%20ibuproxam&f=false	PTGS1|PTGS2|ALOX5	https://citeline.informa.com/?query=#/drugs/details/9056|https://citeline.informa.com/?query=#/drugs/details/9056|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011692	cyclooxygenase inhibitor|prostaglandin inhibitor	endocrinology|rheumatology|neurology/psychiatry	fever|joint inflammation|pain relief	https://www.ndrugs.com/?s=ibuproxam|https://www.ndrugs.com/?s=ibuproxam|https://www.ndrugs.com/?s=ibuproxam
U-18666A	U-18666A		CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1	Preclinical				oxidosqualene cyclase inhibitor			
quipazine	quipazine		C1CN(CCN1)c1ccc2ccccc2n1	Preclinical		HTR2A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070181	serotonin receptor agonist			
3-hydroxy-3-phenylpentanamide	3-hydroxy-3-phenylpentanamide		CCC(O)(CC(N)=O)c1ccccc1	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/9872340			GABA receptor modulator			
metatinib	metatinib		Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02004548	MET|KDR|BCR|ABL1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=667932|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=667932|http://www.biocentury.com/products/bl001|http://www.biocentury.com/products/bl001	Bcr-Abl kinase inhibitor			
RG2833	RG2833		Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N	Phase 1	http://www.neurology.org/content/82/10_Supplement/PL1.003.short	HDAC1|HDAC3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7501|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7501	HDAC inhibitor			
cilengitide	cilengitide	EMD-12192|EMD-121974	CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00689221	ITGAV|ITGB5|ITGB3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6597|https://citeline.informa.com/?query=#/drugs/details/6078|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6597	integrin antagonist			
CYM-50358	CYM-50358		Cc1cc(CN)cc(C)c1NC(=O)c1ccc(o1)-c1cc(Cl)ccc1Cl	Preclinical		S1PR4	https://www.tocris.com/products/cym-50358-hydrochloride_4679	sphingosine 1-phosphate receptor antagonist			
ameltolide	ameltolide		Cc1cccc(C)c1NC(=O)c1ccc(N)cc1	Preclinical				anticonvulsant			
vernakalant	vernakalant		COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC	Launched	http://www.drugs.com/international/Vernakalant.html	KCNA5|KCNJ5|KCNJ3|SCN5A	http://www.ncbi.nlm.nih.gov/pubmed/21903653|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=299039|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=299039|https://citeline.informa.com/?query=#/drugs/details/25653	potassium channel blocker	cardiology	atrial fibrillation (AF)	https://en.wikipedia.org/wiki/Vernakalant
glycopyrrolate	glycopyrrolate	cuvposa|glycopyrronium|robinul|robinul forte|seebri	C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)c1ccccc1	Launched	FDA Orange Book: glycopyrrolate	CHRM2|CHRM1|CHRM4|CHRM3|CHRM5	https://www.drugbank.ca/drugs/DB00986|https://www.drugbank.ca/drugs/DB00986|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7459|https://www.drugbank.ca/drugs/DB00986|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7459	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61767a0d-c94c-44d8-b35c-316a5731a275
2-iminobiotin	2-iminobiotin		OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=N)N[C@H]12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01626924	NOS1|NOS2	http://www.enzolifesciences.com/ALX-430-008/2-iminobiotin/|http://www.enzolifesciences.com/ALX-430-008/2-iminobiotin/	nitric oxide synthase inhibitor			
nomegestrol-acetate	nomegestrol acetate	ORG 10486-0|TX 066|nomegestrol acetate	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O	Launched	http://en.wikipedia.org/wiki/Nomegestrol_acetate	PGR	https://en.wikipedia.org/wiki/Nomegestrol_acetate	progesterone receptor agonist	endocrinology	contraceptive	https://en.wikipedia.org/wiki/Nomegestrol_acetate
benidipine	benidipine		COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1	Launched	http://www.drugs.com/international/Benidipine.html	CACNA1C|CACNA1G|CYP3A5	http://www.alomone.com/p/benidipine_hydrochloride/b-120/7|http://www.alomone.com/p/benidipine_hydrochloride/b-120/7|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090489	calcium channel blocker	cardiology	hypertension	https://en.wikipedia.org/wiki/Benidipine
piroximone	piroximone	MDL 19,205|MDL-19205	CCc1[nH]c(O)nc1C(=O)c1ccncc1	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/2447409	PDE3A	http://www.sciencedirect.com/science/article/pii/S0049384897002211	phosphodiesterase inhibitor			
BQ-788	BQ-788		CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00427232	EDNRB	http://www.sigmaaldrich.com/catalog/product/sigma/b157?lang=en&region=US	endothelin receptor antagonist			
methyldopa	methyldopa	MK-351|Methyldopa (Levorotatory)|aldomet|alpha-methyldopa	C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O	Launched	FDA Orange Book: methyldopa, methyldopate hydrochloride	ADRA2B|ADRA2C|ADRA2A|DDC	ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00968	adrenergic receptor agonist	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb1c7c3f-9e6f-4d0e-aea1-6974558659ef
sulfacetamide	sulfacetamide	Bleph-30|Cetamide|FML-S|Ocusulf-10|Ocusulf-30|SULF-10|SULF-15|Sulfacel-15|Sulfair-15|Sulster|Sulten-10|bleph-10|klaron|sodium sulamyd|sulfacetamide (triple sulfa)|sulfacetamide sodium|sulphacetamide	CC(=O)NS(=O)(=O)c1ccc(N)cc1	Launched	FDA Orange Book: sulfacetamide sodium, triple sulfa (sulfabenzamide;sulfacetamide;sulfathiazole)			PABA antagonist	ophthalmology	conjunctivitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ac30a78-6633-4d8d-919e-39f665eb3fdb&audience=consumer
picotamide	picotamide		COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1	Launched	http://www.drugs.com/international/Picotamide.html	TBXA2R|TBXAS1	http://www.ncbi.nlm.nih.gov/pubmed/15474700|https://citeline.informa.com/?query=#/drugs/details/14428	thromboxane receptor antagonist|thromboxane synthase inhibitor	hematology	thrombosis	http://www.drugs.com/international/picotamide.html
rifapentine	rifapentine	priftin	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C	Launched	FDA Orange Book: rifapentine	CYP3A4|CYP2C9|CYP2C8	https://en.wikipedia.org/wiki/Rifapentine|https://en.wikipedia.org/wiki/Rifapentine|https://en.wikipedia.org/wiki/Rifapentine	RNA polymerase inhibitor	infectious disease	tuberculosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f768e337-a948-420a-9fbe-9be359c7a170
hippuric-acid	hippuric acid	hippuric acid	OC(=O)CNC(=O)c1ccccc1	Preclinical							
mitomycin-c	mitomycin c	mitomycin|mitosol|mitozytrex|mutamycin	CO[C@@]12[C@@H]3NC3CN1C1=C([C@@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O	Launched	https://clinicaltrials.gov/ct2/show/NCT02199327			DNA alkylating agent|DNA synthesis inhibitor	oncology|oncology	pancreatic cancer|gastric adenocarcinoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d80c6dc0-5f26-4d7a-a0f7-7698ab4f249a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d80c6dc0-5f26-4d7a-a0f7-7698ab4f249a
minodronic-acid	minodronic acid	minodronic acid	OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O	Launched	http://www.drugs.com/international/Minodronic acid.html	FDPS|GGPS1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3164|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3164	bone resorption inhibitor	orthopedics	osteoporosis	https://en.wikipedia.org/wiki/Minodronic_acid
BML-284	BML-284		COc1cccc(c1)-c1cc(NCc2ccc3OCOc3c2)nc(N)n1	Preclinical				WNT agonist			
AZ191	AZ191		COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1	Preclinical		DYRK1A|DYRK1B	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=830333|http://www.sigmaaldrich.com/catalog/product/sigma/sml1089?lang=en&region=US	DYRK inhibitor			
apoptosis-activator-II	apoptosis-activator-II		Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl	Preclinical		CES1|BCHE	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007179|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007179	carboxylesterase inhibitor			
sulfamerazine	sulfamerazine	Mesulfa|Methypyrimal|Sulfamethyldiazine|Sumedin|sulfamerazine (trisulfapyrimidines)	Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1	Veterinary Launched	FDA Orange Book: sulfamerazine, trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine)			bacterial antifolate	infectious disease|infectious disease	coccidiosis|cholera	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ed8f868-aabd-45ca-a409-cdbaebfdaae6&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ed8f868-aabd-45ca-a409-cdbaebfdaae6&audience=consumer
OTS167	OTS167		CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01910545	MELK	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=751983	maternal embryonic leucine zipper kinase inhibitor			
EPZ004777	EPZ004777		CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12	Preclinical		DOT1L	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7377	histone lysine methyltransferase inhibitor			
cathepsin-inhibitor-1	cathepsin-inhibitor-1		Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C	Preclinical		CTSV|CTSL|CTSB	http://www.selleckchem.com/products/cathepsin-Inhibitor-1.html|http://www.selleckchem.com/products/cathepsin-Inhibitor-1.html|http://www.selleckchem.com/products/cathepsin-Inhibitor-1.html	cathepsin inhibitor			
gadodiamide	gadodiamide	omniscan	CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2	Launched	FDA Orange Book: gadodiamide			radiopaque medium	radiology	MRI contrast agent	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d539c8b2-13fe-4ba2-994e-b4d0ee1ef490
aurora-a-inhibitor-i	aurora-a-inhibitor-i		CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1	Preclinical		AURKA	http://www.selleckchem.com/products/Aurora-A-Inhibitor-I.html	Aurora kinase inhibitor			
dasabuvir	dasabuvir	ABT-333	COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1	Launched	FDA Orange Book: dasabuvir sodium 			HCV inhibitor	infectious disease	hepatitis C	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab74e474-9fd6-902c-9bd9-16dc9541edd0
beclamide	beclamide	benzchlorpropamide|benzylamide	ClCCC(=O)NCc1ccccc1	Launched	http://en.wikipedia.org/wiki/Beclamide			anticonvulsant	neurology/psychiatry|neurology/psychiatry	sedative|seizures	https://en.wikipedia.org/wiki/Beclamide|https://en.wikipedia.org/wiki/Beclamide
carbaril	carbaril	ENT-23969|Sevin|carbaryl	CNC(=O)Oc1cccc2ccccc12	Veterinary Launched	http://www.drugs.com/international/carbaril.html			acetylcholinesterase inhibitor			
gestrinone	gestrinone	A 46 745|R 2323|RU 2323	CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C	Launched	http://www.drugs.com/international/Gestrinone.html	AR|PGR|ESR1	https://www.caymanchem.com/app/template/Product.vm/catalog/10006488|https://en.wikipedia.org/wiki/Gestrinone|https://www.caymanchem.com/app/template/Product.vm/catalog/10006488	progesterone receptor antagonist	obstetrics/gynecology	endometriosis	https://en.wikipedia.org/wiki/Gestrinone
esomeprazole	esomeprazole	esomeprazole strontium|nexium|nexium 24hr|nexium iv	COc1ccc2[nH]c(nc2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C	Launched	FDA Orange Book: esomeprazole magnesium, esomeprazole sodium, esomeprazole strontium	ATP4A|CYP2C19|CYP3A4	https://www.drugbank.ca/drugs/DB00736|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=272598|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=272598	ATPase inhibitor	gastroenterology|gastroenterology|gastroenterology	gastroesophageal reflux disease (GERD)|Zollinger-Ellison syndrome|peptic ulcer disease (PUD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e04e7c84-59c8-4a1d-8dfc-d72588b97b59|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e04e7c84-59c8-4a1d-8dfc-d72588b97b59|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e04e7c84-59c8-4a1d-8dfc-d72588b97b59
oxybenzone	oxybenzone	UVINUL M40	COc1ccc(C(=O)c2ccccc2)c(O)c1	Launched	FDA Orange Book: oxybenzone	LIPE	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014822	lipase inhibitor	dermatology	sunscreen lotion	https://en.wikipedia.org/wiki/Oxybenzone
beta-glycerophosphoric-acid	beta-glycerophosphoric acid	glycerophosphoric acid	OCC(CO)OP(O)(O)=O	Preclinical							
fexofenadine	fexofenadine	allegra|allegra allergy|allegra hives|children's allegra allergy|children's allegra hives	CC(C)(C(O)=O)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1	Launched	FDA Orange Book: fexofenadine hydrochloride	HRH1	https://www.drugbank.ca/drugs/DB00950	histamine receptor antagonist	allergy|allergy	allergic rhinitis|urticaria	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac0c0247-3b20-445a-84c0-cb7f3939c823|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac0c0247-3b20-445a-84c0-cb7f3939c823
benfotiamine	benfotiamine	8088 C.B|benzoylthiaminmonophosphat		Launched	http://www.drugs.com/international/benfotiamine.html	AGER	http://www.ncbi.nlm.nih.gov/pubmed/22792314	antioxidant	rheumatology	lumbago	https://en.wikipedia.org/wiki/Benfotiamine
CCG-63808	CCG-63808		Cc1cccn2c1nc(Oc1ccc(F)cc1)c(\C=C(/C#N)c1nc3ccccc3s1)c2=O	Preclinical		RGS4	https://www.medchemexpress.com/ccg-63808.html	G protein signaling inhibitor			
lorediplon	lorediplon		CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1	Phase 2	http://www.ergomedplc.com/ergomed-completes-recruitment-of-phase-iia-clinical-trial-of-lorediplon-in-insomnia-in-collaboration-with-co-development-partner-ferrer/	GABRA1	https://www.researchgate.net/publication/281890289_Lorediplon_A_New_GABAA_Modulator_Drug_for_Treatment_of_Insomnia	GABA receptor modulator			
NVP-231	NVP-231		O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1	Preclinical		CERK	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6668	ceramidase inhibitor			
YM-298198	YM-298198	YM-268198	CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C	Preclinical		GRM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1389	glutamate receptor antagonist			
deoxycholic-acid	deoxycholic acid	ATX-101|Deoxycholate|deoxycholic acid|kybella	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	Launched	https://clinicaltrials.gov/ct2/show/NCT01141322	FPR1|GPBAR1|EFTUD1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=610|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=610|https://www.drugbank.ca/drugs/DB07690	biliverdin reductase A activator|G protein-coupled receptor agonist	endocrinology	submental fat	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe431ed4-ea6f-4e99-b4bc-ec25ae7b8553
isoliquiritigenin	isoliquiritigenin		Oc1ccc(cc1)\C=C\C(=O)c1ccc(O)cc1O	Preclinical		HRH2|SIRT1|GABBR1|AKR1B1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=139347|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=139347|https://en.wikipedia.org/wiki/Isoliquiritigenin|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=139347	guanylate cyclase activator			
N-acetyl-D-glucosamine	N-acetyl-D-glucosamine		CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT01893606	RENBP|B4GALT2|B4GALT1|B4GALT4|B4GALT3|NAGK|NAGLU|NAGPA	https://www.drugbank.ca/drugs/DB00141|https://www.drugbank.ca/drugs/DB00141|https://www.drugbank.ca/drugs/DB00141|https://www.drugbank.ca/drugs/DB00141|https://www.drugbank.ca/drugs/DB00141|https://www.drugbank.ca/drugs/DB00141|https://www.drugbank.ca/drugs/DB00141|https://www.drugbank.ca/drugs/DB00141				
L-Citrulline	L-Citrulline		NC(CCCNC(N)=O)C(O)=O	Launched	http://www.drugs.com/international/L-Citrulline.html	PADI6|PADI1|PADI2|PADI3|PADI4|ASS1|OTC|DDAH1|DDAH2|NOS3|NOS1|NOS2|GPRC6A	https://www.drugbank.ca/drugs/DB00155|https://www.drugbank.ca/drugs/DB00155|https://www.drugbank.ca/drugs/DB00155|https://www.drugbank.ca/drugs/DB00155|https://www.drugbank.ca/drugs/DB00155|https://www.drugbank.ca/drugs/DB00155|https://www.drugbank.ca/drugs/DB00155|https://www.drugbank.ca/drugs/DB00155|https://www.drugbank.ca/drugs/DB00155|https://www.drugbank.ca/drugs/DB00155|https://www.drugbank.ca/drugs/DB00155|https://www.drugbank.ca/drugs/DB00155|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722	nitric oxide stimulant	cardiology|urology	hypertension|erectile dysfunction	http://www.webmd.com/vitamins-and-supplements/l-citrulline-uses-and-risks|http://www.webmd.com/vitamins-and-supplements/l-citrulline-uses-and-risks
nitazoxanide	nitazoxanide	PH 5776|alinia	CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O	Launched	FDA Orange Book: nitazoxanide			pyruvate ferredoxin oxidoreductase inhibitor	gastroenterology	diarrhea	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e90f98d9-3c9b-4e75-ba18-5517283eadf0
dextrose	dextrose		OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O	Launched	FDA Orange Book: dextrose				endocrinology	hypoglycemia	http://www.drugs.com/cdi/dextrose.html
TCS-2314	TCS-2314		Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1	Preclinical		ITGB1|ITGA4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6590|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6590	integrin inhibitor			
nalfurafine	nalfurafine		CN([C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45)C(=O)\C=C\c1ccoc1	Launched	https://www.drugs.com/international/nalfurafine.html	OPRM1|OPRK1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014434|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1651	opioid receptor agonist	nephrology	uremic pruritus	https://en.wikipedia.org/wiki/Nalfurafine
bucetin	bucetin		CCOc1ccc(NC(=O)CC(C)O)cc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs			analgesic agent			
pyrintegrin	pyrintegrin		Oc1ccc2N(CCCc2c1)c1ccnc(Nc2ccc(cc2)S(=O)(=O)NCC2CC2)n1	Preclinical				integrin signaling activator			
PYM50028	PYM50028	Sarsasapogenin	C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@H](C)CO1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01060878			neurotrophic agent			
pregnenolone	pregnenolone		CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched	http://www.drugs.com/international/Pregnenolone.html	CYP17A1|SULT2B1|PGR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001147|https://www.drugbank.ca/drugs/DB02789|https://citeline.informa.com/?query=#/drugs/details/61633	glutamate receptor modulator			
norethindrone	norethindrone		C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	Launched	FDA Orange Book: norethindrone, norethindrone acetate	PGR	https://www.drugbank.ca/drugs/DB00717	progesterone receptor agonist	obstetrics/gynecology	endometriosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64cb920c-36e8-4d62-9d08-3ddf3989d313
T-5224	T-5224		OC(=O)CCc1cc(ccc1OCc1ccc2c(O)noc2c1)C(=O)c1ccc(OC2CCCC2)cc1O	Phase 2	http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-101359	JUN	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000240	AP inhibitor			
sumatriptan	sumatriptan	alsuma|imitrex|imitrex statdose|onzetra xsail|sumavel dosepro|zecuity|zembrace symtouch	CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1	Launched	FDA Orange Book: sumatriptan succinate	HTR7|HTR6|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR5A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=54|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=54|https://www.drugbank.ca/drugs/DB00669|ChEMBL|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=54|https://www.drugbank.ca/drugs/DB00669|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=54	serotonin receptor agonist	neurology/psychiatry	migraine headache	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd288b01-b95c-6398-fdff-b9ead9f324fa&audience=consumer
metirosine	metirosine	L-588357-0|MK-781|demser|metyrosine	C[C@](N)(Cc1ccc(O)cc1)C(O)=O	Launched	http://www.webmd.com/drugs/2/drug-9117/demser-oral/details	TH	ChEMBL	tyrosine hydroxylase inhibitor	cardiology	hypertension	https://en.wikipedia.org/wiki/Metirosine
safingol	safingol	DL-erythro-Dihydrosphingosine|Dihydrospingosine	CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01553071	TRPM3|PRKCA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453|https://citeline.informa.com/?query=#/drugs/details/16816	PKC inhibitor			
centazolone	centazolone		Nn1cnc2cc3ccccc3cc2c1=O	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/614203			monoamine oxidase inhibitor			
MK-2295	MK-2295		FC(F)(F)c1ccc(Nc2ncnc3cc(ccc23)-c2ncccc2C(F)(F)F)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00387140	TRPV1	http://www.medkoo.com/products/7896	TRPV antagonist			
piperine	piperine		O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1	Phase 1	http://www.ukctg.nihr.ac.uk/trialdetails/NCT01331382	TRPV1|MAOA|MAOB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2489|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014176|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014176	monoamine oxidase inhibitor			
o-acetyl-L-serine	o-acetyl-L-serine		CC(=O)OC[C@H](N)C(O)=O	Preclinical		PTGS1	https://www.drugbank.ca/drugs/DB01837				
4-galactosyllactose	4-galactosyllactose		OC[C@H]1O[C@@H](O[C@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O	Preclinical		AMY2B	https://www.drugbank.ca/drugs/DB03277				
alaproclate	alaproclate	GEA 654	CC(N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/3883697	SLC6A4	http://en.wikipedia.org/wiki/Alaproclate	serotonin receptor antagonist			
GSK2110183	GSK2110183	GSK-2110183|GSK2110183C|afuresertib	Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01395004	AKT1|AKT3|AKT2	http://www.medchemexpress.com/gsk2110183.html|http://www.medchemexpress.com/gsk2110183.html|http://www.medchemexpress.com/gsk2110183.html	AKT inhibitor			
ML324	ML324		CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1	Preclinical		KDM4A|KDM4E	https://www.ncbi.nlm.nih.gov/books/NBK169450/|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=799870	histone lysine demethylase inhibitor			
parthenolide-(-)	(-)-parthenolide		C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1	Preclinical		HDAC1|ADIPOR2	https://en.wikipedia.org/wiki/Parthenolide|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=124002	NFkB pathway inhibitor			
tomelukast	tomelukast	LY-171833|LY-171883	CCCc1c(OCCCCc2nnn[nH]2)ccc(C(C)=O)c1O	Phase 3	http://www.researchgate.net/profile/R_Jason_Herr/publication/11176547_5-Substituted-1H-tetrazoles_as_carboxylic_acid_isosteres_medicinal_chemistry_and_synthetic_methods/links/0deec5346ad071e537000000.pdf	CYSLTR1	http://www.genome.jp/dbget-bin/www_bget?dr:D02851	leukotriene receptor antagonist			
AM-630	AM-630		COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12	Preclinical		CNR1|CNR2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004939|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=750	cannabinoid receptor antagonist			
hydrastinine	hydrastinine		CN1CCc2cc3OCOc3cc2C1O	Preclinical				haemostatic agent			
buramate	buramate	AC-601	OCCOC(=O)NCc1ccccc1	Preclinical				antiepileptic			
H-89	H-89		Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1	Preclinical		PRKACA|PKIA|GSG2|KCNA5|KCNA2|KCNA3|KCNE1|KCNE2|KCNE3|KCNE4|KCNC1|KCNC2|KCNC3|KCNH1|KCNH2|KCNAB2|KCNQ5|KCNQ1|KCNQ2|KCNQ3|KCNS3	https://www.drugbank.ca/drugs/DB07995|https://www.drugbank.ca/drugs/DB07995|https://www.drugbank.ca/drugs/DB07995|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=238977|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=238977|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=238977|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=238977|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=238977|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=238977|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=238977|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=238977|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=238977|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=238977|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=238977|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=238977|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=238977|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=238977|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=238977|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=238977|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=238977|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=238977	PKA inhibitor			
orbifloxacin	orbifloxacin	orbax	C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	Veterinary Launched	http://www.drugs.com/international/Orbifloxacin.html			bacterial DNA gyrase inhibitor	infectious disease	urinary tract infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a4cabca-caa0-4df3-bc46-963f0804b54a
tizanidine	tizanidine	zanaflex	Clc1ccc2nsnc2c1NC1=NCCN1	Launched	FDA Orange Book: tizanidine hydrochloride	ADRA2A|ADRA2C|ADRA2B|CYP1A2|NISCH	https://www.drugbank.ca/drugs/DB00697|https://www.drugbank.ca/drugs/DB00697|https://www.drugbank.ca/drugs/DB00697|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091135|https://www.drugbank.ca/drugs/DB00697	adrenergic receptor agonist	neurology/psychiatry	spasms	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0132fe9-b145-4324-9f41-a86fe6ac2b85&audience=consumer
fipexide	fipexide		Clc1ccc(OCC(=O)N2CCN(Cc3ccc4OCOc4c3)CC2)cc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs			psychoactive drug			
mandelic-acid	mandelic acid	mandelic acid	OC(C(O)=O)c1ccccc1	Launched	https://en.wikipedia.org/wiki/Mandelic_acid						
coenzyme-q10	coenzyme-q10	ubidecarenone	COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O	Launched	https://clinicaltrials.gov/ct2/show/NCT02115581						
brilliant-green	brilliant-green		CCN(CC)c1ccc(cc1)C(c1ccccc1)=C1C=CC(C=C1)=[N+](CC)CC	Launched	http://en.wikipedia.org/wiki/Brilliant_Green_%28dye%29						
chlorquinaldol	chlorquinaldol	clorquinaldol	Cc1ccc2c(Cl)cc(Cl)c(O)c2n1	Launched	http://www.drugs.com/international/Chlorquinaldol.html			other antibiotic	infectious disease	fungal infection	http://www.drugs.com/international/chlorquinaldol.html
sulfamethoxypyridazine	sulfamethoxypyridazine	midicel|sulfamethoxy pyridazine|sulphamethoxypyridazine	COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs			bacterial antifolate			
CI-844	CI-844	3-Phenoxy-Pyridine	O(c1ccccc1)c1cccnc1	Phase 2	Pharmaprojects						
bromperidol	bromperidol	R 11,333	OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1	Launched	http://en.wikipedia.org/wiki/Bromperidol	DRD2	http://www.scbt.com/datasheet-210966-bromperidol.html	dopamine receptor antagonist	neurology/psychiatry	schizophrenia	https://en.wikipedia.org/wiki/Bromperidol
meta-cresyl-acetate	meta-cresyl acetate	3-Methylphenyl Acetate	CC(=O)Oc1cccc(C)c1	Preclinical							
toceranib	toceranib	PHA-291639	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1	Launched	https://www.drugs.com/international/toceranib.html	PDGFRB|PDGFRA|FGF2|FLT1|FLT3|KDR	http://www.genome.jp/dbget-bin/www_bget?dr:D08503|http://www.genome.jp/dbget-bin/www_bget?dr:D08503|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=311900|http://www.genome.jp/dbget-bin/www_bget?dr:D08503|http://www.genome.jp/dbget-bin/www_bget?dr:D08503|http://www.genome.jp/dbget-bin/www_bget?dr:D08503	protein tyrosine kinase inhibitor	oncology|oncology	cutaneous mast cell tumors|cutaneous mast cell tumors	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae09ae83-0812-4ddc-92e3-730f7a1ae449|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae09ae83-0812-4ddc-92e3-730f7a1ae449
sudan-iv	sudan-iv		Cc1ccccc1N=Nc1ccc(N=Nc2c(O)ccc3ccccc23)c(C)c1	Preclinical							
LTB4	LTB4	LEUKOTRIENE_B4|Leukotriene B4	CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00251537	LTB4R|LTB4R2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2487|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2487	leukocyte activator			
SUN-B-8155	SUN-B-8155		C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O	Preclinical		CALCR|CALCA	http://www.tocris.com/dispprod.php?ItemId=162513|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=312813	calcitonin agonist			
mivobulin	mivobulin		CCOC(=O)Nc1cc2NC(C)=C(Nc2c(N)n1)c1ccccc1	Preclinical				microtubule inhibitor			
EG00229	EG00229		NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O	Preclinical		NRP1	https://www.tocris.com/dispprod.php?ItemId=381533#.V-V4upMrLy8	neuropilin receptor antagonist			
thiamet-g	thiamet-g		CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1	Preclinical		MGEA5	https://www.tocris.com/dispprod.php?ItemId=323849#.Vyy70mQrJZJ	GLCNAC phosphotransferase inhibitor			
ACTB-1003	ACTB-1003		COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1	Phase 1	http://www.businesswire.com/news/home/20100121007080/en/ACT-BIOTECH-Announces-FDA-Acceptance-IND-ACTB1003	FGF2|RPS6KA1|RPS6KB1|KDR|TEK	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=671292|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=671292|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=671292|http://www.medkoo.com/products/4822|http://www.medkoo.com/products/4822	FGFR inhibitor|VEGFR inhibitor			
PP-121	PP-121		C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12	Preclinical		KDR|PRKDC|PDGFRA|SRC|PIK3CG|PIK3CD|PIK3CB|PIK3CA|MTOR|EGFR|ABL1|HCK	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013|https://www.drugbank.ca/drugs/DB08052|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013	protein tyrosine kinase inhibitor			
cinoxacin	cinoxacin	cinobac	CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12	Launched	FDA Orange Book: cinoxacin			topoisomerase inhibitor	infectious disease	urinary tract infections	https://en.wikipedia.org/wiki/Cinoxacin
nateglinide	nateglinide	A-4166|AY-4166|AY4166|DJN 608|DJN-608|SDZ DJN 608|SDZ-DJN-608|Starsis|starlix		Launched	FDA Orange Book: nateglinide	KCNJ10|KCNJ11|INS|PPARG|CYP3A4|ABCC8	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000918|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=127137|https://www.drugbank.ca/drugs/DB00731|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=127137|ChEMBL	insulin secretagogue	endocrinology	diabetes mellitus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b28951-76d2-cabd-64a1-b74aa225c6e9
cefcapene-pivoxil	cefcapene pivoxil		CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1	Launched	http://www.drugs.com/international/cefcapene.html			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease	skin infections|pneumonia|urinary tract infections	http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=32939|http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=32939|http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=32939
brivudine	brivudine		OC[C@H]1O[C@H](CC1O)n1cc(\C=C\Br)c(=O)[nH]c1=O	Launched	http://www.drugs.com/international/Brivudine.html			DNA directed DNA polymerase inhibitor	infectious disease	shingles	https://en.wikipedia.org/wiki/Brivudine
VU0364439	VU0364439		Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl	Preclinical		GRM4	http://www.tocris.com/dispprod.php?ItemId=321615#.VhQLJBNViko	glutamate receptor positive allosteric modulator			
LY2608204	LY2608204		O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01408095	GCK	http://www.apexbt.com/ly2608204.html	glucokinase activator			
mefenamic-acid	mefenamic acid	CI-473|CN-35355|INF-3355|mefenamic acid|ponstel	Cc1cccc(Nc2ccccc2C(O)=O)c1C	Launched	FDA Orange Book: mefenamic acid	PTGS2|PTGS1|TRPM3|KCNQ1	ChEMBL|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2593|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2593	cyclooxygenase inhibitor	endocrinology	primary dysmenorrhea (PD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c275df4-f044-4867-8498-f46d34103bbb
felbinac-ethyl	felbinac-ethyl		CCOC(=O)Cc1ccc(cc1)-c1ccccc1	Launched	http://adisinsight.springer.com/drugs/800008296	PTGS1|PTGS2	http://togodb.biosciencedbc.jp/togodb/show/kegg_medicus_drug_en/D01841|http://togodb.biosciencedbc.jp/togodb/show/kegg_medicus_drug_en/D01841	cyclooxygenase inhibitor			
LY294002	LY294002	LY-294002	O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1	Preclinical		LCK|PIK3CD|PIK3CG|PIK3CB|PIK3CA|PDE2A|MTOR|PRKCA|PRKDC|MAPK14|MAPK12|MAPK11|AKT1|CHEK1|GSK3B|MAPK1|MAPK8|SGK1|PLK1|RPS6KB1|ROCK1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003512|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6004|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6004|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6004|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6004|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=209179|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003512|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003512|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003512|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003512|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003512|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003512|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003512|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003512|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003512|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003512|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003512|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003512|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003512|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003512|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003512	mTOR inhibitor|PI3K inhibitor|DNA dependent protein kinase inhibitor|phosphodiesterase inhibitor|PLK inhibitor			
VER-49009	VER-49009		CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O	Preclinical		HSP90AA1	https://www.drugbank.ca/drugs/DB07495	HSP inhibitor			
isosorbide	isosorbide	AT-101|ismotic	O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12	Launched	FDA Orange Book: isosorbide, isosorbide dinitrate, isosorbide mononitrate			nitric oxide stimulant	cardiology|cardiology	angina pectoris|coronary artery disease (CAD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a4cd065-a1dd-4b88-9f7a-7ba93502f972|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a4cd065-a1dd-4b88-9f7a-7ba93502f972
C34	C34		CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O	Preclinical		TLR4	https://www.tocris.com/products/c34_5373	toll-like receptor inhibitor			
thonzylamine	thonzylamine		COc1ccc(CN(CCN(C)C)c2ncccn2)cc1	Launched	http://www.drugs.com/international/thonzylamine.html			antihistamine	neurology/psychiatry	itching	https://en.wikipedia.org/wiki/Thonzylamine
BMS-191011	BMS-191011		Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F	Preclinical		KCNMA1	http://www.tocris.com/dispprod.php?ItemId=5194	potassium channel activator			
wortmannin	wortmannin		COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O	Preclinical		ATM|ATR|PLK1|PLK3|PI4KB|PIK3CA|PIK3CG|PIK3CD|PIK3R1|PI4KA|MTOR|PRKDC	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=162313|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=162313|https://www.drugbank.ca/drugs/DB08059|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=162313|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6060|https://www.drugbank.ca/drugs/DB08059|https://www.drugbank.ca/drugs/DB08059|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001514|https://www.drugbank.ca/drugs/DB08059|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6060|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=162313|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6060	PI3K inhibitor			
autotaxin-modulator-1	autotaxin-modulator-1		C[C@@H](N1C2CCC1CC(C2)C(O)=O)c1ccc2ccc(O[C@H]3CC[C@H](CC3)C(F)(F)F)c(c2c1)C(F)(F)F	Preclinical		ENPP2	https://www.medchemexpress.com/Autotaxin-modulator-1.html	autotaxin inhibitor			
afatinib	afatinib	BIBW-2992|BIBW2992|gilotrif	CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1	Launched	FDA Orange Book: afatinib dimaleate	ERBB4|ERBB2|EGFR	https://www.drugbank.ca/drugs/DB08916|https://www.drugbank.ca/drugs/DB08916|https://www.drugbank.ca/drugs/DB08916	EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387
practolol	practolol	AY-21,011|I.C.I. 50,172|[3-(4-ACETYLAMINO-PHENOXY)-2-HYDROXY-PROPYL]-ISOPROPYL-AMMONIUM	CC(C)NCC(O)COc1ccc(NC(C)=O)cc1	Withdrawn	http://en.wikipedia.org/wiki/Practolol	ADRB1	https://www.drugbank.ca/drugs/DB01297	adrenergic receptor antagonist			
NU-7441	NU-7441	NU-7432	O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1	Preclinical		PRKDC|ABCB1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8010|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=365102	DNA dependent protein kinase inhibitor			
caroverine	caroverine		CCN(CC)CCN1C(=O)C(Nc2ccccc12)=Cc1ccc(OC)cc1	Launched	https://www.drugs.com/international/caroverine.html			glutamate receptor antagonist|calcium channel blocker	neurology/psychiatry	tinnitus	https://en.wikipedia.org/wiki/Caroverine
cantharidin	cantharidin		C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O	Launched	http://www.webmd.com/skin-problems-and-treatments/cantharidin-for-wart-treatment			protein phosphatase inhibitor	dermatology	blisters	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=85b6b393-9795-40f7-87ff-96b5f3268d36
NPPB	NPPB	5-NITRO-2-PHENYLPROPYLAMINOBENZOIC ACID [NPPB]	OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O	Preclinical		TRPA1|ANO1|CLCN2|CLCN7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4270|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4270|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4270|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4270	chloride channel blocker			
isoguvacine	isoguvacine		OC(=O)C1=CCNCC1	Preclinical		GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRR1|GABRR2|GABRR3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4226|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4226|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4226|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4226|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4226|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4226|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4226|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4226|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4226	benzodiazepine receptor agonist			
mestinon	mestinon	pyridostigmine|pyridostigmine bromide|regonol	CN(C)C(=O)Oc1ccc[n+](C)c1	Launched	FDA Orange Book: pyridostigmine bromide	ACHE|BCHE	https://www.drugbank.ca/drugs/DB00545|https://www.drugbank.ca/drugs/DB00545	cholinesterase inhibitor	neurology/psychiatry	myasthenia gravis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a851795e-b7a8-40c3-9922-5e79d3eb4d92
orantinib	orantinib	SU-6668|TSU-68	Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01465464	EGFR|KDR|FGFR1|FGFR2|TBK1|AURKA|AURKB|PDGFRA|PDGFRB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7816|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7816|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7816|http://www.cancer.gov/drugdictionary?cdrid=38421|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=283644|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000342|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000342|http://www.cancer.gov/drugdictionary?cdrid=38421|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7816	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor			
trifluridine	trifluridine	viroptic	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F	Launched	FDA Orange Book: trifluridine	TYMS	https://www.drugbank.ca/drugs/DB00432	DNA directed DNA polymerase inhibitor|thymidylate synthase inhibitor	infectious disease	virus herpes simplex (HSV)	https://en.wikipedia.org/wiki/Trifluridine
carboplatin	carboplatin	paraplatin	N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1	Launched	FDA Orange Book: carboplatin			DNA alkylating agent|DNA inhibitor	oncology	ovarian cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=806736d3-215a-4df5-8187-97f2161e5a53
rutin	rutin	NSC-115918|rutoside	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	Launched	http://www.drugs.com/international/Rutin.html	AKR1C3|AKR1B1	https://www.drugbank.ca/drugs/DB01698|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=321569	antioxidant|capillary stabilizing agent|nitric oxide scavenger	rheumatology|otolaryngology|gastroenterology|neurology/psychiatry|allergy	joint pain|nasal congestion|constipation|irritability|allergic rhinitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8713a3e7-d78a-4246-b576-52f00aa81133|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8713a3e7-d78a-4246-b576-52f00aa81133|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8713a3e7-d78a-4246-b576-52f00aa81133|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8713a3e7-d78a-4246-b576-52f00aa81133|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8713a3e7-d78a-4246-b576-52f00aa81133
venlafaxine	venlafaxine	effexor|effexor xr|venlafaxine hydrochloride	COc1ccc(cc1)C(CN(C)C)C1(O)CCCCC1	Launched	FDA Orange Book: desvenlafaxine, desvenlafaxine fumarate, desvenlafaxine succinate, venlafaxine hydrochloride	SLC6A3|SLC6A4|SLC6A2|CYP2C19	https://www.drugbank.ca/drugs/DB00285|https://www.drugbank.ca/drugs/DB00285|https://www.drugbank.ca/drugs/DB00285|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=100721	adrenergic inhibitor|norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	depression|generalized anxiety disorder (GAD)|panic disorders|social anxiety disorder	https://en.wikipedia.org/wiki/Venlafaxine|https://en.wikipedia.org/wiki/Venlafaxine|https://en.wikipedia.org/wiki/Venlafaxine|https://en.wikipedia.org/wiki/Venlafaxine
pemetrexed	pemetrexed	alimta	Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1	Launched	FDA Orange Book: pemetrexed disodium	DHFR|ATIC|SLC22A8|GART|TYMS	https://www.drugbank.ca/drugs/DB00642|https://www.drugbank.ca/drugs/DB00642|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=173565|https://www.drugbank.ca/drugs/DB00642|https://www.drugbank.ca/drugs/DB00642	dihydrofolate reductase inhibitor|thymidylate synthase inhibitor	oncology|oncology	non-small cell lung cancer (NSCLC)|mesothelioma	https://en.wikipedia.org/wiki/Mesothelioma|https://en.wikipedia.org/wiki/Mesothelioma
inimur	inimur	macmiror|magmilor|nifuratel|polmiror|tydantil	CSCC1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1	Launched	http://www.drugs.com/international/Inimur.html			other antifungal			
chlorpyrifos	chlorpyrifos		CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl	Launched	http://www.drugs.com/international/chlorpyrifos.html	ACHE	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012929	acetylcholinesterase inhibitor			
tributyrin	tributyrin		CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00002677			HDAC inhibitor			
beta-hydroxy-beta-methylbutyrate	beta-hydroxy-beta-methylbutyrate		CC(C)(O)CC(O)=O.CC(C)(O)CC(O)=O	Phase 2/Phase 3	https://www.clinicaltrials.gov/ct2/show/NCT02773771	MTOR	https://www.clinicaltrials.gov/ct2/show/NCT02773771	protein synthesis stimulant			
DVD-111	DVD-111		CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/22500312						
MRS-3777	MRS-3777		C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2[nH]cnc12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2[nH]cnc12	Preclinical		ADORA2B|ADORA2A|ADORA3|ADORA1	https://www.tocris.com/products/mrs-3777-hemioxalate_2403|https://www.tocris.com/products/mrs-3777-hemioxalate_2403|https://www.tocris.com/products/mrs-3777-hemioxalate_2403|https://www.tocris.com/products/mrs-3777-hemioxalate_2403	adenosine receptor antagonist			
reboxetine	reboxetine			Launched	http://www.drugs.com/international/Reboxetine.html	SLC6A2	https://www.drugbank.ca/drugs/DB00234	adrenergic receptor antagonist	neurology/psychiatry	depression	https://en.wikipedia.org/wiki/Reboxetine
alclofenac	alclofenac	W 7320|mervan	OC(=O)Cc1ccc(OCC=C)c(Cl)c1	Launched	https://www.drugs.com/international/mervan.html	PTGS1|PTGS2	https://www.ncbi.nlm.nih.gov/pubmed/11318639|https://citeline.informa.com/?query=#/drugs/details/1321	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis	https://www.ncbi.nlm.nih.gov/pubmed/21068
masoprocol	masoprocol	CHX-100|Nordihydroguaiaretic acid|actinex|meso-ndga|meso-nordihydroguaiaretic acid	CC(Cc1ccc(O)c(O)c1)C(C)Cc1ccc(O)c(O)c1	Launched	FDA Orange Book: masoprocol	IGF1R|ALOX5	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=164329|https://www.drugbank.ca/drugs/DB00179	lipoxygenase inhibitor	dermatology	actinic keratosis (AK)	http://www.drugs.com/mmx/masoprocol.html
mepenzolate	mepenzolate	cantil	C[N+]1(C)CCCC(C1)OC(=O)C(O)(c1ccccc1)c1ccccc1	Launched	FDA Orange Book: mepenzolate bromide	CHRM1|CHRM3	https://www.drugbank.ca/drugs/DB04843|https://www.drugbank.ca/drugs/DB04843	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71b7afe6-4625-4467-adb7-510769da2b17
AG-1024	AG-1024		CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O	Preclinical		EGFR|IGF1R	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=302449|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5912	insulin growth factor receptor inhibitor			
quinine	quinine	GNF-Pf-180|qualaquin		Launched	FDA Orange Book: quinine sulfate	KCNN4|KCNB2|GP9|SLC29A4	https://www.drugbank.ca/drugs/DB00468|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2510|https://www.drugbank.ca/drugs/DB00468|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2510	hemozoin biocrystallization inhibitor	infectious disease	malaria	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b796723-cb13-4a6e-9719-487e8563190f
estradiol-cypionate	estradiol cypionate	depo-estradiol	C[C@]12CCC3C(CCc4cc(O)ccc34)C1CC[C@@H]2OC(=O)CCC1CCCC1	Launched	FDA Orange Book: estradiol cypionate	ESR1	http://www.selleckchem.com/products/estradiol-cypionate.html	estrogen receptor agonist	endocrinology|endocrinology	hypoestrogenism|menopause	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9a4229fd-fecd-4ac1-9c4f-6d442533457f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9a4229fd-fecd-4ac1-9c4f-6d442533457f
benzocaine	benzocaine	Amercaine|Anesthesin|Cetacaine|americaine|baby anbesol|ethyl aminobenzoate	CCOC(=O)c1ccc(N)cc1	Launched	http://www.drugs.com/international/Benzocaine.html	SCN9A|SCN10A	https://citeline.informa.com/?query=#/drugs/details/85667|https://www.drugbank.ca/drugs/DB01086	sodium channel blocker	infectious disease	first-aid antiseptic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=466fe24d-ad54-4854-a49e-9cc7e231b14f
dexamethasone-sodium-phosphate	dexamethasone sodium phosphate	decadron|dexacort|dexamethasone sodium phosphate|dexamethasone sodium phosphate preservative free|hexadrol		Launched	FDA Orange Book: dexamethasone sodium phosphate	NR3C1	http://dgidb.genome.wustl.edu/interaction_claims/4686f839-a988-481b-9e67-6905a7eff104	glucocorticoid receptor agonist	endocrinology|rheumatology|rheumatology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|gastroenterology|rheumatology|dermatology|rheumatology|dermatology	hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0277cc0a-2fd4-4605-a310-b613be84ee26|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0277cc0a-2fd4-4605-a310-b613be84ee26|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0277cc0a-2fd4-4605-a310-b613be84ee26|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0277cc0a-2fd4-4605-a310-b613be84ee26|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0277cc0a-2fd4-4605-a310-b613be84ee26|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0277cc0a-2fd4-4605-a310-b613be84ee26|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0277cc0a-2fd4-4605-a310-b613be84ee26|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0277cc0a-2fd4-4605-a310-b613be84ee26|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0277cc0a-2fd4-4605-a310-b613be84ee26|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0277cc0a-2fd4-4605-a310-b613be84ee26|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0277cc0a-2fd4-4605-a310-b613be84ee26|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0277cc0a-2fd4-4605-a310-b613be84ee26|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0277cc0a-2fd4-4605-a310-b613be84ee26
haloprogin	haloprogin	M-1028|halotex	Clc1cc(Cl)c(OCC#CI)cc1Cl	Launched	FDA Orange Book: haloprogin			other antifungal	infectious disease	tinea pedis	https://en.wikipedia.org/wiki/Haloprogin
suxibuzone	suxibuzone		CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	Veterinary Launched	http://www.drugs.com/international/suxibuzone.html			cyclooxygenase inhibitor	rheumatology|neurology/psychiatry	joint pain|muscle pain	https://en.wikipedia.org/wiki/Suxibuzone|https://en.wikipedia.org/wiki/Suxibuzone
vecuronium	vecuronium	norcuron|vecuronium bromide	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1	Launched	FDA Orange Book: vecuronium bromide	CHRNA2	https://www.drugbank.ca/drugs/DB01339	acetylcholine receptor antagonist	neurology/psychiatry	muscle relaxant	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3b851af-f8e9-4375-bbbe-7132e66ee0d0
desoximetasone	desoximetasone	topicort|topicort lp	C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO	Launched	FDA Orange Book: desoximetasone	NR3C1|PLA2G1B	https://www.drugbank.ca/drugs/DB00547|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001185	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37eb1205-1743-4480-8631-b0bbcaeb8359
TC-G-1008	TC-G-1008		CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(n1)-c1ccccn1	Preclinical		GPR39	https://www.tocris.com/products/tc-g-1008_5355	G protein-coupled receptor agonist			
pioglitazone	pioglitazone	Duetact|actos	CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1	Launched	FDA Orange Book: pioglitazone hydrochloride	TRPM3|PPARG|INS	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2694|https://www.drugbank.ca/drugs/DB01132|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=126029	insulin sensitizer|PPAR receptor agonist	endocrinology	diabetes mellitus	https://en.wikipedia.org/wiki/Pioglitazone#Medical_uses
TC-G-1000	TC-G-1000		Cc1sc(C)c2c1CCC=C2c1c[nH]cn1	Preclinical		ADRA2B|ADRA2C|ADRA2A	https://www.tocris.com/products/tc-g-1000_5021|https://www.tocris.com/products/tc-g-1000_5021|https://www.tocris.com/products/tc-g-1000_5021	adrenergic receptor agonist			
UNC-2327	UNC-2327		O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1	Preclinical		PRMT3	https://www.tocris.com/products/unc-2327_5057	protein arginine N-methyltransferase inhibitor			
TC-G-1004	TC-G-1004		COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C	Preclinical		ADORA2A	https://www.tocris.com/products/tc-g-1004_4407	adenosine receptor antagonist			
TC-G-1005	TC-G-1005		Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc23)c1	Preclinical		GPBAR1	https://www.tocris.com/products/tc-g-1005_5129	G protein-coupled receptor agonist			
hydrastine-(1r,-9s)	hydrastine-(1r,-9s)		COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12	Preclinical				tyrosine hydroxylase inhibitor			
sertaconazole	sertaconazole	Demofix|ertaczo	Clc1ccc(C(Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1	Launched	FDA Orange Book: sertaconazole nitrate			sterol demethylase inhibitor	infectious disease	tinea pedis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=821073f7-33f6-464d-baed-f66d97987d6d&audience=consumer
hydroxypropyl-beta-cyclodextrin	hydroxypropyl-beta-cyclodextrin		CC(O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COCC(C)O)O[C@H](O[C@@H]4[C@@H](COCC(C)O)O[C@H](O[C@@H]5[C@@H](COCC(C)O)O[C@H](O[C@@H]6[C@@H](COCC(C)O)O[C@H](O[C@@H]7[C@@H](COCC(C)O)O[C@H](O[C@@H]8[C@@H](COCC(C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00914745						
acyclovir	acyclovir	Acycloguanosine|Cyclovir|aciclovir|acyclovir sodium|sitavig|zovirax	Nc1nc2n(COCCO)cnc2c(=O)[nH]1	Launched	FDA Orange Book: acyclovir, acyclovir sodium, valacyclovir hydrochloride	PNP	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000157	DNA polymerase inhibitor	infectious disease|infectious disease|infectious disease	genitial herpes|shingles|chicken pox	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7008d09b-c551-4851-b131-cf1e785c944e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7008d09b-c551-4851-b131-cf1e785c944e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7008d09b-c551-4851-b131-cf1e785c944e
cerulenin	cerulenin		C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O	Launched	http://www.drugbank.ca/drugs/DB01034	FASN	https://www.drugbank.ca/drugs/DB01034	fatty acid synthase inhibitor	infectious disease	fungal infection	https://en.wikipedia.org/wiki/Cerulenin
SKF-77434	SKF-77434		Oc1cc2CCN(CC=C)CC(c3ccccc3)c2cc1O	Preclinical		DRD1	http://en.wikipedia.org/wiki/SKF-77,434	dopamine receptor agonist			
nanchangmycin	nanchangmycin		CO[C@H]1CCC(O[C@H]2CC(O[C@]3(O[C@H](C[C@@H]3C)C3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C	Preclinical				other antibiotic			
BMY-45778	BMY-45778		OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1	Preclinical		PTGIR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1963	IP1 prostacyclin receptor agonist			
sildenafil	sildenafil	UK-92480|revatio|viagra	CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1	Launched	FDA Orange Book: sildenafil citrate	SLCO1B3|SLCO1B1|PDE5A|PDE6G|PDE6H	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4743|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4743|https://www.drugbank.ca/drugs/DB00203|https://www.drugbank.ca/drugs/DB00203|https://www.drugbank.ca/drugs/DB00203	phosphodiesterase inhibitor	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb92d686-a81e-4b91-8048-693af0534cb3&audience=consumer
cidofovir	cidofovir	GS-0504|vistide	Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1	Launched	FDA Orange Book: cidofovir			DNA polymerase inhibitor	infectious disease|infectious disease	acquired immunodeficiency syndrome (AIDS)|cytomegalovirus retinitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90639fc6-0295-4115-98f0-054b783850ce|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90639fc6-0295-4115-98f0-054b783850ce
BL-5583	BL-5583	Benzo[B]Thiophene-2-Carboxylic Acid	OC(=O)c1cc2ccccc2s1	Preclinical				hypercalcaemic agent			
pyronaridine	pyronaridine		COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00403260			antimalarial agent			
belinostat	belinostat	PXD101|beleodaq	ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1	Launched	FDA Orange Book: belinostat	HDAC10|HDAC11|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9|HDAC1	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	HDAC inhibitor	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84b2e16e-f0d1-4757-8da8-79dfa83aab79
alarelin	alarelin		CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1	Launched	Cortellis	GNRH1	http://www.apexbt.com/alarelin-acetate.html	gonadotropin releasing factor hormone receptor antagonist			
inositol-hexanicotinate	inositol hexanicotinate	WIN 9154|hexopal|inositol hexanicotinate|inositol niacinate|inositol nicotinate|linodil|palohex	O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H]1OC(=O)c1cccnc1)c1cccnc1	Launched	http://en.wikipedia.org/wiki/Niacin				dermatology|cardiology|rheumatology|cardiology|neurology/psychiatry|cardiology|neurology/psychiatry|neurology/psychiatry|dermatology|dermatology	statis dermatitis|claudication|Raynaud's disease|hypertension|insomnia|atherosclerosis|restless leg syndrome|schizophrenia|psoriasis|acne vulgaris (AV)	http://www.webmd.com/vitamins-supplements/ingredientmono-742-inositol%20nicotinate.aspx?activeingredientid=742&activeingredientname=inositol%20nicotinate|http://www.webmd.com/vitamins-supplements/ingredientmono-742-inositol%20nicotinate.aspx?activeingredientid=742&activeingredientname=inositol%20nicotinate|http://www.webmd.com/vitamins-supplements/ingredientmono-742-inositol%20nicotinate.aspx?activeingredientid=742&activeingredientname=inositol%20nicotinate|http://www.webmd.com/vitamins-supplements/ingredientmono-742-inositol%20nicotinate.aspx?activeingredientid=742&activeingredientname=inositol%20nicotinate|http://www.webmd.com/vitamins-supplements/ingredientmono-742-inositol%20nicotinate.aspx?activeingredientid=742&activeingredientname=inositol%20nicotinate|http://www.webmd.com/vitamins-supplements/ingredientmono-742-inositol%20nicotinate.aspx?activeingredientid=742&activeingredientname=inositol%20nicotinate|http://www.webmd.com/vitamins-supplements/ingredientmono-742-inositol%20nicotinate.aspx?activeingredientid=742&activeingredientname=inositol%20nicotinate|http://www.webmd.com/vitamins-supplements/ingredientmono-742-inositol%20nicotinate.aspx?activeingredientid=742&activeingredientname=inositol%20nicotinate|http://www.webmd.com/vitamins-supplements/ingredientmono-742-inositol%20nicotinate.aspx?activeingredientid=742&activeingredientname=inositol%20nicotinate|http://www.webmd.com/vitamins-supplements/ingredientmono-742-inositol%20nicotinate.aspx?activeingredientid=742&activeingredientname=inositol%20nicotinate
DUP-697	DUP-697		CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/7858707	PTGS2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000581	cyclooxygenase inhibitor			
BMS-707035	BMS-707035		Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00397566			HIV integrase inhibitor			
UNC669	UNC669		Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1	Preclinical		L3MBTL3|L3MBTL1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=739446|http://www.abcam.com/unc669-ab144568.html	L3MBTL antagonist			
TC-NTR1-17	TC-NTR1-17		COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)N[C@@H](CC(C)C)C(O)=O	Preclinical		NTSR1	https://www.tocris.com/products/tc-ntr1-17_5087	neurotensin agonist			
L-proline	L-proline	Pyrrolidine-2-Carboxylic Acid|l-proline|proline	OC(=O)[C@@H]1CCCN1	Launched	https://www.drugbank.ca/drugs/DB00172	L3HYPDH|SLC6A14|PARS2|EPRS|P4HA1|P4HA2|PPIA|PPIC|PPIB|PPIG|PPIF|PPIH|SLC6A7|P3H1|P3H3|P3H2|PYCRL|PYCR2|PYCR1|PROSC|PRODH	https://www.drugbank.ca/drugs/DB00172|https://www.drugbank.ca/drugs/DB00172|https://www.drugbank.ca/drugs/DB00172|https://www.drugbank.ca/drugs/DB00172|https://www.drugbank.ca/drugs/DB00172|https://www.drugbank.ca/drugs/DB00172|https://www.drugbank.ca/drugs/DB00172|https://www.drugbank.ca/drugs/DB00172|https://www.drugbank.ca/drugs/DB00172|https://www.drugbank.ca/drugs/DB00172|https://www.drugbank.ca/drugs/DB00172|https://www.drugbank.ca/drugs/DB00172|https://www.drugbank.ca/drugs/DB00172|https://www.drugbank.ca/drugs/DB00172|https://www.drugbank.ca/drugs/DB00172|https://www.drugbank.ca/drugs/DB00172|https://www.drugbank.ca/drugs/DB00172|https://www.drugbank.ca/drugs/DB00172|https://www.drugbank.ca/drugs/DB00172|https://www.drugbank.ca/drugs/DB00172|https://www.drugbank.ca/drugs/DB00172	glutamate receptor agonist			
SB-505124	SB-505124		Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2OCOc2c1)C(C)(C)C	Preclinical		ACVR1B|ACVR1C|TGFBR1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=363712|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=363712|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6049	ALK tyrosine kinase receptor inhibitor			
dioscin	dioscin		C[C@@H]1[C@@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](CC[C@]5(C)[C@@H]4CC[C@]23C)O[C@@H]2O[C@@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1	Preclinical		CXCR3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=840	apoptosis stimulant			
icosapent	icosapent	OMEGA-3 MARINE TRIGLYCERIDES|eicosapentaenoic acid|vascepa	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	Launched	FDA Orange Book: icosapent ethyl	PPARD|PPARG|TRPV1|ACSL3|ACSL4|FFAR1|SLC8A1|FADS1|PTGS2|PTGS1	https://www.drugbank.ca/drugs/DB00159|https://www.drugbank.ca/drugs/DB00159|https://www.drugbank.ca/drugs/DB00159|https://www.drugbank.ca/drugs/DB00159|https://www.drugbank.ca/drugs/DB00159|https://www.drugbank.ca/drugs/DB00159|https://www.drugbank.ca/drugs/DB00159|https://www.drugbank.ca/drugs/DB00159|https://www.drugbank.ca/drugs/DB00159|https://www.drugbank.ca/drugs/DB00159	platelet aggregation inhibitor	endocrinology	hypertriglyceridemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c1a2828-1583-4414-ab22-a60480e8e508
TC-O-9311	TC-O-9311		COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12	Preclinical		GPR139	https://www.tocris.com/products/tc-o-9311_4255	G protein-coupled receptor agonist			
SR-3576	SR-3576		COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC	Preclinical		MAPK10	https://www.tocris.com/products/sr-3576_5044	JNK inhibitor			
suprofen	suprofen	R-25,061|R-25061|profenal|sutoprofen	CC(C(O)=O)c1ccc(cc1)C(=O)c1cccs1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	PTGS1|PTGS2	ChEMBL|ChEMBL	cyclooxygenase inhibitor			
OXF-BD-02	OXF-BD-02		Cc1noc(C)c1-c1cc(O)cc(c1)C(O)c1ccccc1	Preclinical		CREB1|BRD4	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=792361|https://www.tocris.com/products/oxf-bd-02_4928	bromodomain inhibitor			
DPPE	DPPE	tesmilifene	CCN(CC)CCOc1ccc(Cc2ccccc2)cc1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/14722035	HRH1|ABCB1	https://www.drugbank.ca/drugs/DB04905|https://www.drugbank.ca/drugs/DB04905	histamine receptor antagonist			
chlorothiazide	chlorothiazide	chlorthiazide|diuril	NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O	Launched	FDA Orange Book: chlorothiazide, chlorothiazide sodium, hydrochlorothiazide	CA1|CA4|CA2|SLC12A3	https://www.drugbank.ca/drugs/DB00880|https://www.drugbank.ca/drugs/DB00880|https://www.drugbank.ca/drugs/DB00880|ChEMBL	diuretic	cardiology	hypertension	http://www.drugs.com/cdi/chlorothiazide.html
JNJ-63533054	JNJ-63533054		C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1	Preclinical		GPR139	https://www.tocris.com/dispprod.php?ItemId=463467#.V-qs1pMrLy8	G protein-coupled receptor agonist			
lobeline	lobeline	(-)-Lobeline|Alpha-Lobeline|Alpha-Lobeline Hydrochloride		Launched	http://www.drugs.com/international/Lobeline.html	CHRNA4|CHRNB2|CHRNA9|OPRM1|SLC18A2|CHRNA10	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=272129|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=272129|https://www.drugbank.ca/drugs/DB05137|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=272129|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002402|https://www.drugbank.ca/drugs/DB05137	acetylcholine receptor antagonist	neurology/psychiatry	smoking cessation	http://www.drugs.com/international/lobeline.html
LY2784544	LY2784544	LY-2784544|gandotinib	Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01594723	JAK3|JAK2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7909|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7909	JAK inhibitor			
propylene-glycol	propylene glycol	E1520|E490|propylene glycol|propylene glycol cefatrizine|sentry propylene glycol|sirlene	CC(O)CO	Launched	https://www.drugs.com/ingredient/propylene-glycol.html	F13A1	https://www.drugbank.ca/drugs/DB01839				
tyrphostin-AG-1478	tyrphostin-AG-1478	AG-1478|TYRPHOSTIN AG-1478	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC	Preclinical		MAPK14|EGFR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005110|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4862	EGFR inhibitor			
propoxycaine	propoxycaine		CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC	Launched	FDA Orange Book: propoxycaine hydrochloride			local anesthetic	neurology/psychiatry	anesthetic	https://en.wikipedia.org/wiki/Propoxycaine
GSK2606414	GSK2606414	GSK-2606414	Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12	Preclinical		MYLK2|EIF2AK3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6740|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6740	protein kinase inhibitor			
carnitine-(D/L)	carnitine-(D/L)		C[N+](C)(C)CC(O)CC(O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00322322?term=carnitine&rank=4						
WAY-316606	WAY-316606		FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1	Preclinical		SFRP1	https://www.tocris.com/dispprod.php?ItemId=369372#.V_Pzn5MrLy8	secreted frizzled related protein inhibitor			
glimepiride	glimepiride	HOE 490|amaryl	CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O	Launched	FDA Orange Book: glimepiride	KCNJ1|ABCC8|KCNJ11	https://www.drugbank.ca/drugs/DB00222|ChEMBL|ChEMBL	insulin secretagogue	endocrinology	diabetes mellitus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b74fbac-9e04-4927-9981-1e3dace89c6d
BI-D1870	BI-D1870		CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12	Preclinical		RPS6KA3|RPS6KA2|RPS6KA1|RPS6KA6	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8038|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8038|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8038|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8038	ribosomal protein inhibitor			
streptomycin	streptomycin	streptomycin sulfate		Launched	FDA Orange Book: streptomycin sulfate			bacterial 30S ribosomal subunit inhibitor	infectious disease	tuberculosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abd1f64e-4283-4370-aae8-3666316aa36e&audience=consumer
SKI-II	SKI-II		Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1	Preclinical		VCP|SPHK1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=373616|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6041	sphingosine kinase inhibitor			
efaroxan	efaroxan		CCC1(Cc2ccccc2O1)C1=NCCN1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/9686773	ADORA2A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000771	adrenergic receptor antagonist			
tetrindole	tetrindole		C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1	Phase 3	Pharmaprojects	MAOA	http://www.tocris.com/dispprod.php?ItemId=1900#.UufPO6X0CMI	monoamine oxidase inhibitor			
nastorazepide	nastorazepide		CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1	Phase 2	http://en.pharmacodia.com/web/drug/1_1566.html	CCKBR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=907	CCK receptor antagonist			
isepamicin	isepamicin	Isepacin|SCH 21420|isepamicin sulfate	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O	Launched	https://www.drugs.com/international/isepamicin.html			protein synthesis inhibitor	infectious disease|infectious disease	pneumonia|peritonitis	http://factmed.com/study-ISEPAMICIN-causing-ORAL%20INTAKE%20REDUCED.php|http://factmed.com/study-ISEPAMICIN-causing-ORAL%20INTAKE%20REDUCED.php
3-AQC	3-AQC		C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N	Preclinical		HTR3A	http://www.tocris.com/dispprod.php?ItemId=1056#.VeXQ3ixVhHw	serotonin receptor agonist			
formoterol	formoterol	brovana|foradil|foradil certihaler|perforomist	COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1	Launched	FDA Orange Book: arformoterol tartrate, formoterol fumarate, formoterol fumarate dihydrate	ADRB2|CYP2C19	https://www.drugbank.ca/drugs/DB00983|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=125563	adrenergic receptor agonist	pulmonary|pulmonary|pulmonary	asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b9da867-04ad-4ace-a889-9f4ff8bec47b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b9da867-04ad-4ace-a889-9f4ff8bec47b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b9da867-04ad-4ace-a889-9f4ff8bec47b
ibuprofen-(s)	ibuprofen-(s)	Neoprofen|Rufen|dexibuprofen|ibu-tab	CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O	Preclinical		ASIC1|THBD|PPARG|PTGS2|PTGS1|FABP2|SLC5A8|BCL2|CFTR|PLAT	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2713|https://www.drugbank.ca/drugs/DB01050|https://www.drugbank.ca/drugs/DB01050|https://www.drugbank.ca/drugs/DB01050|https://www.drugbank.ca/drugs/DB01050|https://www.drugbank.ca/drugs/DB01050|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2713|https://www.drugbank.ca/drugs/DB01050|https://www.drugbank.ca/drugs/DB01050|https://www.drugbank.ca/drugs/DB01050	cyclooxygenase inhibitor			
JNJ-40411813	JNJ-40411813		CCCCn1ccc(N2CCC(CC2)c2ccccc2)c(Cl)c1=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01323205	GRM2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317228/	glutamate receptor positive allosteric modulator			
formestane	formestane		C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O	Launched	http://www.drugs.com/international/Formestane.html	CYP19A1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004204	aromatase inhibitor	oncology	breast cancer	https://en.wikipedia.org/wiki/Formestane
chlorambucil	chlorambucil	chlorbutin|leukeran	OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl	Launched	FDA Orange Book: chlorambucil			DNA inhibitor	hematologic malignancy|hematologic malignancy	chronic lymphocytic leukemia (CLL)|Hodgkin's lymphoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=967ed3ff-d99b-41e8-b768-dfb586d3d9a6|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=967ed3ff-d99b-41e8-b768-dfb586d3d9a6
aminopterin	aminopterin		Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01420679	DHFR|SLC46A1	http://www.drugbank.ca/drugs/DB08878|http://www.drugbank.ca/drugs/DB08878	dihydrofolate reductase inhibitor			
mitoflaxone	mitoflaxone	NSC-347512	OC(=O)Cc1cccc2c1oc(cc2=O)-c1ccccc1	Phase 2	http://adisinsight.springer.com/drugs/800000745	VWF	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000652	antitumor agent			
AM-404	AM-404		CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1	Preclinical		TRPV1|CNR1|CNR2|FAAH	http://www.tocris.com/dispprod.php?ItemId=2199|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006015|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006015|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006015	cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist			
FG-4592	FG-4592	ASP1517|roxadustat	Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01750190	EGLN2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000112	hypoxia inducible factor prolyl hydroxylase inhibitor			
A-33903	A-33903		CC(=O)NC1C(=O)Nc2ccccc2C(=N1)c1ccccc1	Phase 2	Pharmaprojects						
4-aminohippuric-acid	4-aminohippuric acid	PAHA|aminohippurate sodium|aminohippuric acid|para-aminohippuric acid	Nc1ccc(cc1)C(=O)NCC(O)=O	Launched	https://en.wikipedia.org/wiki/Aminohippuric_acid	SLC22A6	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013609				
tropanyl-3,5-dimethylbenzoate	tropanyl-3,5-dimethylbenzoate		CN1C2CCC1CC(C2)OC(=O)c1cc(C)cc(C)c1	Preclinical				serotonin receptor antagonist			
pranidipine	pranidipine		COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/8723171	CACNA1C	http://www.ncbi.nlm.nih.gov/pubmed/9546618	calcium channel blocker			
medroxyprogesterone-acetate	medroxyprogesterone acetate	depo-provera|depo-subq provera 104|provera	C[C@H]1CC2C3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CCC2[C@@]2(C)CCC(=O)C=C12	Launched	FDA Orange Book: medroxyprogesterone acetate			progesterone receptor agonist	endocrinology	contraceptive	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=428481bb-b7cf-4d76-b57d-0d6bfa2b6ac3
NSC-697923	NSC-697923		Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O	Preclinical		UBE2N	http://www.tocris.com/dispprod.php?ItemId=374319#.Vgq6JGRVhHw	ubiquitin-conjugating enzyme inhibitor			
verteporfin	verteporfin	visudyne	COC(=O)CCc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC	Launched	FDA Orange Book: verteporfin			photosensitizing agent	ophthalmology	macular degeneration	https://en.wikipedia.org/wiki/Verteporfin
abametapir	abametapir	HA44	Cc1ccc(nc1)-c1ccc(C)cn1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02062060	MMP2|MMP9|MMP8	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=733793|http://www.biovision.com/manuals/9665.pdf|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=733793	metalloproteinase inhibitor			
2-methyl-5-nitrophenol	2-methyl-5-nitrophenol		Cc1ccc(cc1O)[N+]([O-])=O	Preclinical							
digoxigenin	digoxigenin		C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1	Preclinical				steroid			
CPI-613	CPI-613		OC(=O)CCCCC(CCSCc1ccccc1)SCc1ccccc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01520805	OGDH|PDHA1	https://citeline.informa.com/?query=#/drugs/details/41376|http://dgidb.genome.wustl.edu/interaction_claims/87efdf3b-e853-4cd8-8cec-410b1d8c1f73	pyruvate dehydrogenase inhibitor			
RWJ-67657	RWJ-67657		OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/12723461	IL1B|PTGS2|MAPK14|TNF	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=270783|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001245|https://www.tocris.com/dispprod.php?ItemId=5467#.V_J2fpMrLy8|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=270783	MAP kinase inhibitor			
TCN-238	TCN-238		Nc1nccc(\C=C\c2ccccc2)n1	Preclinical		GRM4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6235	glutamate receptor positive allosteric modulator			
gilteritinib	gilteritinib	ASP-2215|ASP2215	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02927262	FLT3	http://meetinglibrary.asco.org/content/165082-176	FLT3 inhibitor			
ibuprofen	ibuprofen	Aches-n-pain|Cap-profen|Children's ibuprofen|Ibu-tab|Ibu-tab 200|Ibuprin|Ibuprohm|Junior strength ibuprofen|Medipren|Profen|Tab-profen|U-18,573|U-18573|advil|advil liqui-gels|advil migraine liqui-gels|caldolor|children's advil|children's advil-flavored|children's elixsure|children's motrin|ibu|junior strength advil|junior strength motrin|midol|midol liquid gels|motrin|motrin ib|motrin migraine pain|nuprin|pediatric advil|rufen	CC(C)Cc1ccc(cc1)C(C)C(O)=O	Launched	FDA Orange Book: ibuprofen, ibuprofen lysine, ibuprofen sodium	PTGS1|PTGS2	ChEMBL|ChEMBL	cyclooxygenase inhibitor	neurology/psychiatry|neurology/psychiatry|rheumatology|neurology/psychiatry|otolaryngology|obstetrics/gynecology|endocrinology|dental	headache|muscle pain|rheumatoid arthritis|backache|common cold|menstrual pain|fever|toothache	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66e2a92c-2827-413f-9349-898cc7dc009a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66e2a92c-2827-413f-9349-898cc7dc009a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66e2a92c-2827-413f-9349-898cc7dc009a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66e2a92c-2827-413f-9349-898cc7dc009a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66e2a92c-2827-413f-9349-898cc7dc009a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66e2a92c-2827-413f-9349-898cc7dc009a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66e2a92c-2827-413f-9349-898cc7dc009a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66e2a92c-2827-413f-9349-898cc7dc009a
GSK2636771	GSK2636771	GSK-2636771	Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O	Phase 2	https://www.clinicaltrials.gov/show/NCT01458067	PIK3CB	http://www.axonmedchem.com/product/1912	PI3K inhibitor			
acipimox	acipimox		Cc1cnc(c[n+]1[O-])C(O)=O	Launched	http://en.wikipedia.org/wiki/Acipimox	HCAR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1596	cholesterol inhibitor	endocrinology	hyperlipidemia	https://en.wikipedia.org/wiki/Acipimox
ipragliflozin-l-proline	ipragliflozin-l-proline		OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1	Launched	http://www.ncbi.nlm.nih.gov/pubmed/24668021	SLC5A2	http://www.genome.jp/dbget-bin/www_bget?D10196+D10200	sodium/glucose cotransporter inhibitor	endocrinology	diabetes mellitus	http://www.pharmacodia.com/yaodu/html/v1/chemicals/8a56257ea05c74018291954fc56fc448.html
bentiromide	bentiromide	E-2663|btpaba, pft|chymex	OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1	Launched	FDA Orange Book: bentiromide	HPN	https://www.drugbank.ca/drugs/DB00522		gastroenterology	pancreas diagnostic agent	https://en.wikipedia.org/wiki/Bentiromide
beta-naphthol	beta-naphthol	betanaphthol	Oc1ccc2ccccc2c1	Preclinical							
MLN1117	MLN1117		Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT02393209	PIK3CA	https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=714372	PI3K inhibitor			
ramifenazone	ramifenazone		CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O	Veterinary Launched	http://www.drugs.com/international/ramifenazone.html			cyclooxygenase inhibitor	neurology/psychiatry|endocrinology	pain relief|fever	http://www.drugs.com/international/ramifenazone.html|http://www.drugs.com/international/ramifenazone.html
PF-04885614	PF-04885614		CC(C)(N)c1nc(c[nH]1)-c1ccc(OC(F)(F)F)cc1	Preclinical		SCN10A	https://www.tocris.com/products/pf-04885614_4916	voltage-gated sodium channel blocker			
cis-urocanic acid	cis-urocanic acid		OC(=O)\C=C/c1c[nH]cn1	Phase 2				serotonin receptor agonist			
ML-141	ML-141		COc1ccc(cc1)C1CC(=NN1c1ccc(cc1)S(N)(=O)=O)c1ccccc1	Preclinical		CDC42	https://www.tocris.com/products/ml-141_4266	GTPase inhibitor			
PX-478	PX-478		NC(Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00522652	HIF1A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=323448	hypoxia inducible factor inhibitor			
A-7	A-7		NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12	Preclinical				calmodulin antagonist			
heptaminol	heptaminol		CC(N)CCCC(C)(C)O	Launched	http://www.drugs.com/international/heptaminol.html			vasoconstrictor	cardiology	hypotension	https://en.wikipedia.org/wiki/Heptaminol
secoisolariciresinol-diglucoside	secoisolariciresinol-diglucoside		COc1cc(C[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)Cc2ccc(O)c(OC)c2)ccc1O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01234506			antioxidant			
acifran	acifran	AY-25,712|reductol	CC1(OC(=CC1=O)C(O)=O)c1ccccc1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/4028627	HCAR2|HCAR3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1595|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1595	cholesterol inhibitor			
TAS-103	TAS-103		CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/11283142	TOP1|TOP2A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001410|https://citeline.informa.com/?query=#/drugs/details/17530	topoisomerase inhibitor			
pipecuronium	pipecuronium	arduan	CC(=O)OC1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1	Launched	FDA Orange Book: pipecuronium bromide	CHRNA2|CHRM2|CHRM3	https://www.drugbank.ca/drugs/DB01338|https://www.drugbank.ca/drugs/DB01338|https://www.drugbank.ca/drugs/DB01338	neuromuscular blocker	neurology/psychiatry	anesthetic	https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=49779
amiprilose	amiprilose		CN(C)CCCO[C@H]1[C@H](O[C@@H]2OC(C)(C)O[C@H]12)[C@H](O)CO	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/19078443			CD antagonist			
benzenemethanol,-2,5-dimethyl-[[(1-methylethyl)amino]methyl]	benzenemethanol,-2,5-dimethyl-[[(1-methylethyl)amino]methyl]		CC(C)NCC(O)c1cc(C)ccc1C	Preclinical							
pimobendan	pimobendan	Acardi|Pimobendane|UDCG-115|Vetmedin	COc1ccc(cc1)-c1nc2cc(ccc2[nH]1)C1=NNC(=O)CC1C	Veterinary Launched	http://www.drugs.com/international/Pimobendan.html	PDE3A	https://en.wikipedia.org/wiki/Pimobendan	calcium sensitizer|phosphodiesterase inhibitor	cardiology	congestive heart failure	https://en.wikipedia.org/wiki/Pimobendan
ketoprofen	ketoprofen	R.P. 19,583|RP-19583|actron|nexcede|orudis|orudis kt|oruvail	CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1	Launched	FDA Orange Book: ketoprofen	CXCR1|SLC5A8|PTGS1|PTGS2	https://www.drugbank.ca/drugs/DB01009|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4795|ChEMBL|ChEMBL	cyclooxygenase inhibitor	rheumatology|rheumatology	rheumatoid arthritis|osteoarthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=198a4140-f4c0-4478-9157-ee1d68d0bb96|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=198a4140-f4c0-4478-9157-ee1d68d0bb96
ML-323	ML-323		CC(C)c1ccccc1-c1ncc(C)c(NCc2ccc(cc2)-n2ccnn2)n1	Preclinical		USP1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7898	ubiquitin specific protease inhibitor			
WHI-P154	WHI-P154		COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC	Preclinical		EGFR|ALK|JAK1|JAK2|JAK3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5993|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=266241|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5993|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5993|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5993	JAK inhibitor			
ifenprodil	ifenprodil	RC 61-91|ifenprodil tartrate	CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1	Launched	http://www.drugs.com/international/Ifenprodil.html	GRIN2B|GRIN1	https://www.drugbank.ca/drugs/DB08954|https://www.drugbank.ca/drugs/DB08954	adrenergic receptor antagonist|glutamate receptor antagonist			
DMAB-anabaseine	DMAB-anabaseine	3-(4-Dimethylaminobenzylidene)Anabaseine	CN(C)c1ccc(cc1)\C=C1CCCN=C/1c1cccnc1	Preclinical		CHRNA7	http://www.tocris.com/dispprod.php?ItemId=129870#.UtatoP15mf0	adrenergic receptor agonist			
trichlormethine	trichlormethine	trimustine	ClCCN(CCCl)CCCl	Preclinical				DNA alkylating agent			
canrenone	canrenone		C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]21CCC(=O)O1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	NR3C2	http://www.genome.jp/dbget-bin/www_bget?dr:D03363	mineralocorticoid receptor antagonist			
sitosterol	sitosterol	b-Sitosterol|beta-Sitosterol	CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C	Preclinical							
CU-CPT-4a	CU-CPT-4a		OC(=O)[C@@H](Cc1ccccc1)NC(=O)c1sc2cc(F)ccc2c1Cl	Preclinical		TLR3	https://www.tocris.com/products/cu-cpt-4a_4883	toll-like receptor inhibitor			
drospirenone	drospirenone	Angeliq|ZK 30595|ZK-30595	C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1	Launched	FDA Orange Book: drospirenone	AR|PGR|NR3C2	https://www.drugbank.ca/drugs/DB01395|ChEMBL|ChEMBL	mineralocorticoid receptor antagonist	endocrinology	contraceptive	https://en.wikipedia.org/wiki/Drospirenone
KT-433	KT-433		CCc1oc2ccccc2c1C(=O)c1ccc(OCC(O)=O)cc1	Phase 2	http://www.jhasim.com/files/articlefiles/pdf/ASIM_Master_5_4_p183_194.pdf	SLC22A12	https://citeline.informa.com/?query=#/drugs/details/10047	uricosuric agent			
aminothiazole	aminothiazole	RP 2921	Nc1nccs1	Preclinical		NOS2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC013786	cyclin D inhibitor			
ODQ	ODQ		O=c1onc2cnc3ccccc3n12	Preclinical		GUCY1B3|GUCY1A3|GUCY1A2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5234|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5234|https://www.caymanchem.com/app/template/Product.vm/catalog/81410	guanylyl cyclase inhibitor			
RSV604	RSV604	RSV-604	Fc1ccccc1NC(=O)N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O	Phase 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2043207/			RSV replication inhibitor			
IWP-L6	IWP-L6		O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1	Preclinical		PORCN	http://www.tocris.com/dispprod.php?ItemId=387300#.VgLZLdNViko	porcupine inhibitor			
ki16198	ki16198		COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)OC(C)c1ccccc1Cl	Preclinical		LPA	http://www.apexbt.com/ki16198.html	lipoprotein antagonist			
piroxicam	piroxicam	feldene	CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O	Launched	FDA Orange Book: piroxicam	PTGS1|PTGS2	https://www.drugbank.ca/drugs/DB00554|https://www.drugbank.ca/drugs/DB00554	cyclooxygenase inhibitor	rheumatology|rheumatology	osteoarthritis|rheumatoid arthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d3e528b-a748-4bc5-b604-e7e9c5ab9183|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d3e528b-a748-4bc5-b604-e7e9c5ab9183
5-BDBD	5-BDBD		Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21	Preclinical		P2RX4	https://www.tocris.com/dispprod.php?ItemId=230094#.VydwDWQrImI	purinergic receptor antagonist			
brefeldin-a	brefeldin a	brefeldin a	C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1	Preclinical		GBF1|ARF1|ARFGEF2|ARFGEF1|CYTH2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=203054|https://www.drugbank.ca/drugs/DB07348|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=203054|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=203054|https://www.drugbank.ca/drugs/DB07348	protein synthesis inhibitor			
bepotastine	bepotastine	bepreve	OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1	Launched	FDA Orange Book: bepotastine besilate	HRH1	https://www.drugbank.ca/drugs/DB04890	histamine receptor antagonist	ophthalmology	conjunctivitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68bbf6a0-c4b5-47c1-8a1c-08220fbdbce6
L-365260	L-365260	LY-365260	CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/7786960	CCKBR|CCKAR|KCNQ1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=879|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005790|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005790	CCK receptor antagonist			
1-ethyl-2-pyrrolidone	1-ethyl-2-pyrrolidone		CCN1CCCC1=O	Preclinical				transdermal absorption-enhancing compound			
aniracetam	aniracetam	Ampamet|Draganon|Memodrin|RO 13-5057|Sarpul	COc1ccc(cc1)C(=O)N1CCCC1=O	Launched	http://en.wikipedia.org/wiki/Aniracetam	DRD2|HTR2A|GRIA3|GRIA4|GRIA1|GRIA2	https://www.drugbank.ca/drugs/DB04599|https://www.drugbank.ca/drugs/DB04599|https://www.drugbank.ca/drugs/DB04599|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4133|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4133|https://www.drugbank.ca/drugs/DB04599	glutamate receptor agonist			
sulfisoxazole-acetyl	sulfisoxazole acetyl	acetylsulfisoxazole|gantrisin|gantrisin pediatric|lipo gantrisin|sulfisoxazole acetyl	CC(=O)N(c1onc(C)c1C)S(=O)(=O)c1ccc(N)cc1	Launched	FDA Orange Book: sulfisoxazole acetyl			folic acid antagonist	infectious disease|infectious disease|otolaryngology|infectious disease	meningitis|urinary tract infections|otitis|trachoma	http://www.rxlist.com/gantrisin-drug/indications-dosage.htm|http://www.rxlist.com/gantrisin-drug/indications-dosage.htm|http://www.rxlist.com/gantrisin-drug/indications-dosage.htm|http://www.rxlist.com/gantrisin-drug/indications-dosage.htm
temocapril	temocapril		CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1	Launched	http://www.drugs.com/international/Temocapril.html	ACE	https://www.drugbank.ca/drugs/DB08836	angiotensin converting enzyme inhibitor	cardiology|cardiology|nephrology|cardiology	hypertension|congestive heart failure|diabetic nephropathy|coronary artery disease (CAD)	http://www.drugbank.ca/drugs/DB08836|http://www.drugbank.ca/drugs/DB08836|http://www.drugbank.ca/drugs/DB08836|http://www.drugbank.ca/drugs/DB08836
terreic-acid-(-)	(-)-terreic-acid		CC1C(=O)[C@H]2O[C@H]2C(=O)C1=O	Preclinical		BTK	http://www.tocris.com/dispprod.php?ItemId=1879#.UtWtePaGZ3c	Bruton's tyrosine kinase (BTK) inhibitor			
deforolimus	deforolimus	AP23573|MK-8669|ridaforolimus	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00538239	MTOR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7884	mTOR inhibitor			
fosfomycin	fosfomycin	monurol		Launched	FDA Orange Book: fosfomycin tromethamine			bacterial cell wall synthesis inhibitor	infectious disease	urinary tract infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad155d62-9b49-4a50-a2ae-d3aad8155936
brucine	brucine		COc1cc2N3C4[C@@H]5C(CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC	Preclinical		CHRM5|CHRM4|CHRM3|CHRM2|CHRM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=342|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=342|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=342|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=342|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=342	glycine receptor antagonist			
SDZ-220-581	SDZ-220-581		N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O	Preclinical		GRIN1	http://www.tocris.com/dispprod.php?ItemId=2288#.Vg6cQWRVhHw	glutamate receptor antagonist			
theobromine	theobromine		Cn1cnc2n(C)c(=O)[nH]c(=O)c12	Launched	http://www.drugs.com/international/theobromine-sodium-salicylate.html	ADORA1|PDE4B|ADORA2A	https://www.drugbank.ca/drugs/DB01412|https://www.drugbank.ca/drugs/DB01412|https://www.drugbank.ca/drugs/DB01412	phosphodiesterase inhibitor			
OLDA	OLDA	N-Oleoyl-Dopamine|N-Oleoyldopamine|Oleoyl Dopamine	CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1	Preclinical		GPR119	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5552	TRPV agonist			
ispinesib	ispinesib		CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00085813	KIF11	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000139	kinesin inhibitor			
etebenecid	etebenecid	ethebenecid	CCN(CC)S(=O)(=O)c1ccc(cc1)C(O)=O	Preclinical				uricosuric blocker			
ataluren	ataluren	PTC124	OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F	Launched	http://en.wikipedia.org/wiki/Ataluren	CFTR|DMD|F8|F9	https://citeline.informa.com/?query=#/drugs/details/25708|http://quest.mda.org/news/dmd-dystrophin-levels-increased-after-ataluren-treatment|https://citeline.informa.com/?query=#/drugs/details/25708|https://citeline.informa.com/?query=#/drugs/details/25708	CFTR channel agonist|dystrophin stimulant	genetics|pulmonary	duchenne muscular dystrophy (DMD)|cystic fibrosis	http://www.ptcbio.com/en/pipeline/ataluren-translarna/|http://www.ptcbio.com/en/pipeline/ataluren-translarna/
neostigmine	neostigmine	bloxiverz|neostigmine methylsulfate	CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C	Launched	FDA Orange Book: neostigmine methylsulfate	ACHE	https://www.drugbank.ca/drugs/DB01400	acetylcholinesterase inhibitor	neurology/psychiatry	myasthenia gravis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c3a7e99-cbde-43a8-acb9-6b414820cd46
theophylline	theophylline	elixophyllin|synophylate|theo-24	Cn1c2nc[nH]c2c(=O)n(C)c1=O	Launched	http://en.wikipedia.org/wiki/Theophylline			adenosine receptor antagonist	pulmonary|pulmonary|pulmonary	asthma|emphysema|bronchitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3829d74e-b3ab-46df-a08b-f0327b63304e&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3829d74e-b3ab-46df-a08b-f0327b63304e&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3829d74e-b3ab-46df-a08b-f0327b63304e&audience=consumer
otenzepad	otenzepad		CCN(CC)CC1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12	Phase 3	Pharmaprojects	CHRM4|CHRM3|CHRM2|CHRM1|CHRM5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=309|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=309|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=309|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=309|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=309	acetylcholine receptor antagonist			
JW-74	JW-74		COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1	Preclinical		TNKS2|TNKS	https://www.caymanchem.com/product/19124|https://www.caymanchem.com/product/19124	WNT signaling inhibitor|tankyrase inhibitor			
nitrendipine	nitrendipine	BAY E 5009|baypress	CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC	Launched	http://www.drugs.com/international/Nitrendipine.html	KCNN4|CACNA2D1|CACNA2D2|CACNG1|CACNB2|CACNA1S|CACNA1H|CACNA1C|CACNA1D	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2334|https://www.drugbank.ca/drugs/DB01054|https://www.drugbank.ca/drugs/DB01054|https://www.drugbank.ca/drugs/DB01054|https://www.drugbank.ca/drugs/DB01054|https://www.drugbank.ca/drugs/DB01054|https://www.drugbank.ca/drugs/DB01054|https://www.drugbank.ca/drugs/DB01054|https://www.drugbank.ca/drugs/DB01054	calcium channel blocker	cardiology	hypertension	https://en.wikipedia.org/wiki/Nitrendipine
LPA2-antagonist-1	LPA2-antagonist-1		C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12	Preclinical		LPAR2	https://www.medchemexpress.com/LPA2-antagonist-1.html	lysophosphatidic acid receptor antagonist			
hydralazine	hydralazine	apresoline|hydralazine hydrochloride	NNc1nncc2ccccc12	Launched	FDA Orange Book: hydralazine hydrochloride	P4HA1|AOC3	https://www.drugbank.ca/drugs/DB01275|https://www.drugbank.ca/drugs/DB01275	vasodilator	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=638a511d-cb51-49b5-b917-ffe8192cc270
aphidicolin	aphidicolin		C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/1886148			RNA synthesis inhibitor			
empagliflozin	empagliflozin	jardiance	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1	Launched	FDA Orange Book: empagliflozin	SLC5A2|SLC5A1	ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4754	sodium/glucose cotransporter inhibitor	endocrinology	diabetes mellitus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565
mebendazole	mebendazole	Mebenvet|R 17,635|R-17635|Telmin|Telmintic|vermox	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1	Launched	FDA Orange Book: mebendazole	TUBA1A|TUBB4B|TUBB	https://www.drugbank.ca/drugs/DB00643|https://www.drugbank.ca/drugs/DB00643|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000950	tubulin polymerization inhibitor	infectious disease|infectious disease|infectious disease|infectious disease	pinworm|whipworm|hookworm|ascariasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c338415f-41e0-071d-8c51-a80a02ebf2cd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c338415f-41e0-071d-8c51-a80a02ebf2cd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c338415f-41e0-071d-8c51-a80a02ebf2cd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c338415f-41e0-071d-8c51-a80a02ebf2cd
atropine	atropine	Atroject|Atrophate|Isopto Atropine|atropen|atropine sulfate|atropine sulfate ansyr plastic syringe	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)c1ccccc1	Launched	FDA Orange Book: atropine, atropine sulfate, homatropine methylbromide	CHRM3|CHRM4|CHRM5|CHRM1|CHRM2	ChEMBL|https://www.drugbank.ca/drugs/DB00572|https://www.drugbank.ca/drugs/DB00572|ChEMBL|ChEMBL	acetylcholine receptor antagonist	ophthalmology|ophthalmology|ophthalmology	cycloplegia|mydriasis|amblyopia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b40bf1-3063-4849-a5a0-0ac5d0d1e72a
vitamin-b12	vitamin B12		C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2[N+]3=C1C(C)=C1[C@@H](CCC(N)=O)C(C)(C)C4=[N+]1[Co]31(C#N)N3C([C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@]23C)=C(C)C2=[N+]1C(=C4)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12	Launched	http://www.drugs.com/international/Vitamin B12.html				hematology	megaloblastic anemia	https://en.wikipedia.org/wiki/Vitamin_B12
proxyfan	proxyfan	proxifan	C(COCc1ccccc1)Cc1cnc[nH]1	Preclinical		HRH3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1255	histamine receptor modulator			
tetracycline	tetracycline	achromycin|achromycin v|actisite|tetrex|topicycline	CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O	Launched	FDA Orange Book: tetracycline, tetracycline hydrochloride, tetracycline phosphate complex	PRNP	https://www.drugbank.ca/drugs/DB00759	bacterial 30S ribosomal subunit inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|dermatology|infectious disease|infectious disease	respiratory tract infections|pneumonia|skin infections|urinary tract infections|acne vulgaris (AV)|plague|psittacosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac85703a-17a2-4f0b-87f4-78f1756d2f85|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac85703a-17a2-4f0b-87f4-78f1756d2f85|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac85703a-17a2-4f0b-87f4-78f1756d2f85|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac85703a-17a2-4f0b-87f4-78f1756d2f85|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac85703a-17a2-4f0b-87f4-78f1756d2f85|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac85703a-17a2-4f0b-87f4-78f1756d2f85|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac85703a-17a2-4f0b-87f4-78f1756d2f85
LY2886721	LY2886721		NC1=N[C@]2(COC[C@@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT01561430	BACE1|BACE2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6475|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=720275	beta-secretase inhibitor			
SKF-96365	SKF-96365	SK&F-96365|SK-96365	COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1	Preclinical		TRPC1|TRPC4|TRPC5|TRPC3|TRPV2|PKD2|CYP3A4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2441|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2441|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2441|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2441|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2441|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2441|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008331	calcium channel blocker			
ACT-132577	ACT-132577		NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	Launched	http://en.wikipedia.org/wiki/Macitentan	EDNRA|EDNRB	http://www.apexbt.com/act-132577.html|http://www.apexbt.com/act-132577.html	endothelin receptor antagonist	pulmonary	pulmonary arterial hypertension (PAH)	https://en.wikipedia.org/wiki/Macitentan
D-delta-Tocopherol	D-delta-Tocopherol	E309	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2cc(O)cc(C)c2O1	Launched	http://en.wikipedia.org/wiki/Delta-Tocopherol						
alimemazine	alimemazine	Trimeprazine|methylpromazine|temaril	CC(CN(C)C)CN1c2ccccc2Sc2ccccc12	Launched	FDA Orange Book: trimeprazine tartrate	HRH1	https://www.drugbank.ca/drugs/DB01246	histamine receptor agonist	neurology/psychiatry	sedative	https://en.wikipedia.org/wiki/Alimemazine
XMD17-109	XMD17-109		CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1	Preclinical		LRRK2|MAPK7	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=821571|https://www.medchemexpress.com/xmd17-109.html	MAP kinase inhibitor			
RP67580	RP67580		COc1ccccc1C=C(N)N1C[C@H]2[C@@H](C1)C(CCC2=O)(c1ccccc1)c1ccccc1	Preclinical							
NSC5844	NSC5844		C(CNc1ccnc2cc(Cl)ccc12)Nc1ccnc2cc(Cl)ccc12	Preclinical		CCR1	http://www.adooq.com/nsc5844.html	CC chemokine receptor agonist			
GSK-3-inhibitor-IX	GSK-3-inhibitor-IX		O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12	Preclinical		ALOX5|GSK3A|GSK3B	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=372484|http://www.scbt.com/datasheet-202634-gsk-3-inhibitor-ix.html|https://www.drugbank.ca/drugs/DB03444	glycogen synthase kinase inhibitor|lipoxygenase inhibitor			
pindolol-(-)	(-)-pindolol	S(-)-Pindolol	CC(C)NC[C@H](O)COc1cccc2[nH]ccc12	Preclinical		HTR1A	https://en.wikipedia.org/wiki/Pindolol#Pharmacology	adrenergic receptor antagonist|serotonin receptor antagonist			
hydrocortisone-hemisuccinate	hydrocortisone-hemisuccinate	solu-cortef	C[C@]12C[C@H](O)C3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT01817153						
bosutinib	bosutinib	SKI-606|bosulif|bosutinib monohydrate	COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl	Launched	FDA Orange Book: bosutinib monohydrate	TNK2|MAP3K2|MAP4K5|SRC|TXK|MAP2K2|MAP2K1|CAMK1D|CAMK2G|LYN|ABL1|FRK|FYN|HCK|CDK2|STK4|BCR|STK24|STK10	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5710|https://www.drugbank.ca/drugs/DB06616|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5710|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5710|https://www.drugbank.ca/drugs/DB06616|https://www.drugbank.ca/drugs/DB06616|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5710|https://www.drugbank.ca/drugs/DB06616|ChEMBL|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5710|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5710|ChEMBL|https://www.drugbank.ca/drugs/DB06616|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5710|https://www.drugbank.ca/drugs/DB06616|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5710|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5710	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|src inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adc84ad5-a04d-4fee-9ba8-91f7abd928e3
coumophos	coumophos	BAYER 21199|baymix|coumafos|coumaphos|meldane	CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1	Preclinical				cholinesterase inhibitor			
GSK2816126	GSK2816126		CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02082977	EZH2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7012	histone lysine methyltransferase inhibitor			
licarbazepine	licarbazepine	10-hydroxy-carbamazepine	NC(=O)N1c2ccccc2CC(O)c2ccccc12	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00107926	SCN1A|SCN3A|SCN5A	https://citeline.informa.com/?query=#/drugs/details/30790|https://citeline.informa.com/?query=#/drugs/details/30790|http://dgidb.genome.wustl.edu/interaction_claims/dfd75666-4ea1-456e-b467-91bb2e9a7fd8	voltage-gated sodium channel blocker			
metyrapone	metyrapone	metopirone	CC(C)(C(=O)c1cccnc1)c1cccnc1	Launched	FDA Orange Book: metyrapone	NR3C2|CYP11B1|HSD11B1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091541|https://www.drugbank.ca/drugs/DB01011|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091541	cytochrome P450 inhibitor	nephrology	adrenal diagnostic agent	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a27d0ef-83a7-4e1c-9430-46a3326ee8d8
secalciferol	secalciferol	24, 25-DIHYDROXYCHOLECALCIFEROL|osteo d	C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C	Launched	https://books.google.com/books?id=jcvh_okaAk8C&pg=PA1407&lpg=PA1407&dq=secalciferol+teva	VDR	http://www.medchemexpress.com/secalciferol.html	vitamin D receptor agonist	critical care	bone fracture	http://www.apexbt.com/secalciferol.html
terguride	terguride	R(+)-Terguride	CCN(CC)C(=O)N[C@H]1CC2C(Cc3c[nH]c4cccc2c34)N(C)C1	Launched	http://www.drugs.com/international/terguride.html	HTR2A|HTR2C|HTR2B|HTR1D|HTR1B|HTR1A|DRD4|DRD3|DRD2|PRL|ADRA1A|ADRA2C|ADRA2B|ADRA2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=56|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=56|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=56|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=56|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=56|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=56|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=56|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=56|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=56|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=115397|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=56|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=56|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=56|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=56	dopamine receptor agonist|serotonin receptor antagonist			
urea	urea	E927b|breathtek ubt for h-pylori|helicosol|meretek ubt kit (w/ pranactin)|pylori-chek breath test|sterile urea|ureaphil	NC(N)=O	Launched	FDA Orange Book: urea	CA2|CTNNB1|ARG1	https://www.drugbank.ca/drugs/DB03904|https://www.drugbank.ca/drugs/DB03904|https://www.drugbank.ca/drugs/DB03904	hydroxy radical formation stimulant	dermatology|dermatology|dermatology|dermatology|dermatology|dermatology	psoriasis|xerosis cutis|ichthyosis vulgaris|eczema|keratosis|dermatitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=697b1730-b716-444f-8671-934f47ae21bd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=697b1730-b716-444f-8671-934f47ae21bd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=697b1730-b716-444f-8671-934f47ae21bd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=697b1730-b716-444f-8671-934f47ae21bd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=697b1730-b716-444f-8671-934f47ae21bd|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=697b1730-b716-444f-8671-934f47ae21bd
alpha-Asarone	alpha-Asarone	Trans-Asarone	COc1cc(OC)c(\C=C\C)cc1OC	Preclinical		ACHE|HMGCR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=294947|https://www.caymanchem.com/product/11681	cytochrome P450 inhibitor|HMGCR inhibitor			
ecabapide	ecabapide		CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1	Phase 3	Pharmaprojects						
MRK-016	MRK-016		Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C	Phase 1	http://sinoipro.com/en/jishuall.aspx?id=64&cid=166	GABRA1|GABRA2|GABRA3|GABRA5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4257|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4257|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4257|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4257	GABA receptor inverse agonist			
erdosteine	erdosteine		OC(=O)CSCC(=O)NC1CCSC1=O	Launched	http://www.drugs.com/international/Erdosteine.html			mucolytic agent	pulmonary|pulmonary|pulmonary|infectious disease	bronchitis|cough suppressant|chronic obstructive pulmonary disease (COPD)|respiratory tract infections	http://www.erdosteine.net/|http://www.erdosteine.net/|http://www.erdosteine.net/|http://www.erdosteine.net/
DAU-5884	DAU-5884		CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O	Preclinical		CHRM1|CHRM3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=188522|http://www.tocris.com/dispprod.php?ItemId=107360#.UuJ0a_30BaE	acetylcholine receptor antagonist			
anacetrapib	anacetrapib		COc1cc(F)c(cc1-c1ccc(cc1CN1[C@H](C)[C@H](OC1=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01252953	CETP	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000048	cholesteryl ester transfer protein inhibitor			
imidacloprid	imidacloprid		[O-][N+](=O)NC1=NCCN1Cc1ccc(Cl)nc1	Launched	http://www.drugs.com/international/Imidacloprid.html	CHRFAM7A	https://www.drugbank.ca/drugs/DB07980	acetylcholine receptor antagonist			
terazosin	terazosin	hytrin|terazosin hydrochloride	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1	Launched	FDA Orange Book: terazosin hydrochloride	KCNH2|KCNH7|KCNH6|ADRA1D|ADRA1A|ADRA1B	https://www.drugbank.ca/drugs/DB01162|https://www.drugbank.ca/drugs/DB01162|https://www.drugbank.ca/drugs/DB01162|https://www.drugbank.ca/drugs/DB01162|https://www.drugbank.ca/drugs/DB01162|https://www.drugbank.ca/drugs/DB01162	adrenergic receptor antagonist	urology|cardiology	benign prostatic hyperplasia (BPH)|hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43e92495-2cf2-46dd-a80c-f0c3c88c7b73&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43e92495-2cf2-46dd-a80c-f0c3c88c7b73&audience=consumer
dorsomorphin	dorsomorphin		C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1	Preclinical		BMPR1A|BMPR1B|KDR|LCK|SRC|ACVR1|MKNK1|FKBP1A|EPHA2|PRKAA1|FLT3|FLT1|RPS6KA1	http://www.tocris.com/dispprod.php?ItemId=206557|http://www.tocris.com/dispprod.php?ItemId=206557|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4907|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4907|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4907|https://www.drugbank.ca/drugs/DB08597|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4907|https://www.drugbank.ca/drugs/DB08597|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4907|http://www.tocris.com/dispprod.php?ItemId=206557|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4907|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4907|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4907	AMPK inhibitor			
nicotinamide	nicotinamide	niacinamide|nicotinic acid amide|nicotylamide	NC(=O)c1cccnc1	Launched	http://www.drugs.com/international/Nicotinamide.html	SIRT5|CYP2E1|PARP1|LDHA|BST1|AOX1	https://www.drugbank.ca/drugs/DB02701|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091300|https://www.drugbank.ca/drugs/DB02701|https://www.drugbank.ca/drugs/DB02701|https://www.drugbank.ca/drugs/DB02701|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091300	protein synthesis stimulant	dermatology	acne vulgaris (AV)	https://www.drugs.com/drp/nicotinamide.html
SF-11	SF-11		CCOc1ccc(cc1)NC(=S)N1CCC(CC1)C(O)(c1ccccc1)c1ccccc1	Preclinical		MCOLN3|NPY2R	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6404|https://www.tocris.com/products/sf-11_3898	neuropeptide receptor antagonist			
flupentixol	flupentixol	LC 44|N-7009	OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	Launched	http://www.drugs.com/international/Flupentixol.html	CHRM1|DRD5|DRD3|DRD1|DRD2|ADRA1A|HTR2A	https://www.drugbank.ca/drugs/DB00875|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=948|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=948|https://www.drugbank.ca/drugs/DB00875|https://www.drugbank.ca/drugs/DB00875|https://www.drugbank.ca/drugs/DB00875|https://www.drugbank.ca/drugs/DB00875	dopamine receptor antagonist	neurology/psychiatry|neurology/psychiatry	schizophrenia|depression	https://en.wikipedia.org/wiki/Flupentixol|https://en.wikipedia.org/wiki/Flupentixol
almotriptan	almotriptan	LAS 31416|LAS-31416|axert	CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12	Launched	FDA Orange Book: almotriptan malate	HTR1F|HTR1D|HTR1B	https://citeline.informa.com/?query=#/drugs/details/1364|https://www.drugbank.ca/drugs/DB00918|https://www.drugbank.ca/drugs/DB00918	serotonin receptor agonist	neurology/psychiatry	migraine headache	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9129bb95-7846-4ed7-bd03-0c17d8963447
thioguanine	thioguanine	Tabloid|tioguanine	Nc1nc2nc[nH]c2c(=S)[nH]1	Launched	FDA Orange Book: thioguanine	IMPDH2|IMPDH1	ChEMBL|ChEMBL	purine antagonist	hematologic malignancy	acute myeloid leukemia (AML)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4490128b-e73f-4849-9d6e-e8591639d771&audience=consumer
sevoflurane	sevoflurane	MR6S4|MR_6S4|sojourn|ultane	FCOC(C(F)(F)F)C(F)(F)F	Launched	FDA Orange Book: sevoflurane	GRIA1|ATP2C1|ATP5D|MT-ND1|CYP2E1|KCNK2|KCNK3|KCNK9|KCNA1|GLRB|GABRP|GABRQ|GABRD|GABRE|GLRA1|GABRA5|GABRA4|GABRA6|GABRA1|GABRA3|GABRA2|GABRB2|GABRB1|GABRB3|GABRG3|GABRG2|GABRG1|KCNK18|KCNK10	https://www.drugbank.ca/drugs/DB01236|https://www.drugbank.ca/drugs/DB01236|https://www.drugbank.ca/drugs/DB01236|https://www.drugbank.ca/drugs/DB01236|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090235|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB01236|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	membrane integrity inhibitor	neurology/psychiatry	anesthetic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e79b33ec-b9b6-46ea-9f67-f1bf6a79a4c6&audience=consumer
acrisorcin	acrisorcin	SCH 7056|SCH-7056|akrinol	CCCCCCc1ccc(O)cc1O.Nc1c2ccccc2nc2ccccc12	Launched	FDA Orange Book: acrisorcin			other antifungal	infectious disease	fungal infection	https://en.wikipedia.org/wiki/Acrisorcin
Y-320	Y-320		Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N	Preclinical		TNF|IL17A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=454726|https://en.wikipedia.org/wiki/Y-320	interleukin inhibitor			
toltrazuril	toltrazuril	BAY VI 9142	Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O	Veterinary Launched	http://www.drugs.com/international/Toltrazuril.html			antiprotozoal agent	infectious disease	coccidiosis	https://en.wikipedia.org/wiki/Toltrazuril
YM-58483	YM-58483		Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F	Preclinical		TRPM4|TRPC5|TRPC3|IL2|IL4|IL5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2438|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2438|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2438|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=307208|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=307208|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=307208	calcium channel blocker			
proflavine-hemisulfate	proflavine-hemisulfate	proflavine	Nc1ccc2cc3ccc(N)cc3nc2c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02029937	F2	https://www.drugbank.ca/drugs/DB01123	topical anesthetic			
quinapril	quinapril	CI-906|accupril	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O	Launched	FDA Orange Book: quinapril hydrochloride	ACE	https://www.drugbank.ca/drugs/DB00881	angiotensin converting enzyme inhibitor	cardiology|cardiology|cardiology	hypertension|congestive heart failure|angioedema	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93e6e668-5306-4f26-81d8-cbc3a7a5e787|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93e6e668-5306-4f26-81d8-cbc3a7a5e787|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93e6e668-5306-4f26-81d8-cbc3a7a5e787
FR-180204	FR-180204		Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1	Preclinical		MAPK1|MAPK3	https://www.drugbank.ca/drugs/DB07794|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5966	MAP kinase inhibitor			
allylthiourea	allylthiourea	tiosinamine	NC(S)=NCC=C	Preclinical				nitrification inhibitor			
UNC2250	UNC2250		CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1	Preclinical		MERTK	http://www.selleckchem.com/products/unc2250.html	MER tyrosine kinase inhibitor			
calcifediol	calcifediol	25-HYDROXYCHOLECALCIFEROL|25-Hydroxycholecalciferol (Calcifediol)|calderol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C	Launched	FDA Orange Book: calcifediol	VDR	https://www.drugbank.ca/drugs/DB00146	vitamin D receptor agonist			
varenicline	varenicline	chantix	C1C2CNCC1c1cc3nccnc3cc21	Launched	FDA Orange Book: varenicline tartrate	CHRNB2|CHRNA3|CHRNA4|CHRNA7|CHRNA6	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=301545|https://www.drugbank.ca/drugs/DB01273|https://www.drugbank.ca/drugs/DB01273|https://www.drugbank.ca/drugs/DB01273|https://www.drugbank.ca/drugs/DB01273	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d52bc40b-db7b-4243-888c-9ee95bbc6545
camicinal	camicinal	GSK-962040|GSK962040|GSK962040B	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02210000	MLNR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4035	motilin receptor agonist			
SD-169	SD-169		NC(=O)c1ccc2[nH]ccc2c1	Preclinical		MAPK14	http://www.creative-enzymes.com/product/SD169_3065.html	p38 MAPK inhibitor			
GR-144053	GR-144053	GR-144053F	NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1	Preclinical		ITGB3|ITGA2B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6587|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6587	integrin antagonist			
ertugliflozin	ertugliflozin		CCOc1ccc(Cc2cc(ccc2Cl)[C@@]23OC[C@@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)cc1	Launched	FDA Orange Book: ertugliflozin	SLC5A2	https://clinicaltrials.gov/ct2/show/NCT02226003	sodium/glucose cotransporter inhibitor	endocrinology	diabetes mellitus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6f3e718-bb99-48f1-ab94-b9f0af05fed6
L-Ascorbyl-6-palmitate	L-Ascorbyl-6 palmitate		CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)C1O	Preclinical							
hesperadin	hesperadin	TCMDC-135395	CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1	Preclinical		AURKB	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006942	Aurora kinase inhibitor			
hydroquinidine	hydroquinidine		CC[C@H]1CN2CCC1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12	Launched	http://www.drugs.com/international/hydroquinidine.html			antiarrhythmic	cardiology	cardiac arrythmia	http://www.drugs.com/international/hydroquinidine.html
valproic-acid	valproic acid	depacon|depakene|stavzor	CCCC(CCC)C(O)=O	Launched	http://www.drugs.com/international/valproic-acid.html	ABAT|OGDH|HDAC9|HDAC2|HDAC1|ALDH5A1|SCN10A|SCN11A|ACADSB|SCN2A|SCN2B|SCN1B|SCN1A|SCN8A|SCN7A|SCN9A|SCN4A|SCN4B|SCN3B|SCN3A|SCN5A	https://www.drugbank.ca/drugs/DB00313|https://www.drugbank.ca/drugs/DB00313|https://www.drugbank.ca/drugs/DB00313|https://www.drugbank.ca/drugs/DB00313|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7009|https://www.drugbank.ca/drugs/DB00313|https://www.drugbank.ca/drugs/DB00313|https://www.drugbank.ca/drugs/DB00313|https://www.drugbank.ca/drugs/DB00313|https://www.drugbank.ca/drugs/DB00313|https://www.drugbank.ca/drugs/DB00313|https://www.drugbank.ca/drugs/DB00313|https://www.drugbank.ca/drugs/DB00313|https://www.drugbank.ca/drugs/DB00313|https://www.drugbank.ca/drugs/DB00313|https://www.drugbank.ca/drugs/DB00313|https://www.drugbank.ca/drugs/DB00313|https://www.drugbank.ca/drugs/DB00313|https://www.drugbank.ca/drugs/DB00313|https://www.drugbank.ca/drugs/DB00313|https://www.drugbank.ca/drugs/DB00313	HDAC inhibitor	neurology/psychiatry	seizures	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c932e019-1808-4d11-acf5-a859fae93060
k-strophanthidin	k-strophanthidin		C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/1864667	ATP1A1|ATP1A2|ATP1A3|ATP1A4|ATP1B1|ATP1B2|ATP1B3|ATP1B4|FXYD2	https://en.wikipedia.org/wiki/K-Strophanthidin|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=357701|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=357701|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=357701|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=357701|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=357701|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=357701|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=357701|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=357701	ATPase inhibitor			
JNJ-42165279	JNJ-42165279		FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02432703	FAAH	https://en.wikipedia.org/wiki/JNJ-42165279	FAAH inhibitor			
geniposidic-acid	Geniposidic Acid	Geniposidic Acid	OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical				cyclooxygenase inhibitor			
gemifloxacin	gemifloxacin	factive	CO\N=C1/CN(CC1CN)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1	Launched	FDA Orange Book: gemifloxacin mesylate			bacterial DNA gyrase inhibitor	pulmonary|infectious disease	bronchitis|pneumonia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a51dc88f-c298-402e-b204-618609a4721c|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a51dc88f-c298-402e-b204-618609a4721c
dutasteride	dutasteride	avodart	C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F	Launched	FDA Orange Book: dutasteride	SRD5A1|SRD5A2|CYP3A5	https://www.drugbank.ca/drugs/DB01126|https://www.drugbank.ca/drugs/DB01126|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=222406	5 alpha reductase inhibitor	urology	benign prostatic hyperplasia (BPH)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7502cc8b-b282-4454-94a2-f86302d54a47
pterostilbene	pterostilbene		COc1cc(OC)cc(C=Cc2ccc(O)cc2)c1	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT01267227	FAAH|PTGS1|PTGS2|PPARA	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=326963|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=326963|http://www.ncbi.nlm.nih.gov/pubmed/18551458|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=326963	cyclooxygenase inhibitor|PPAR receptor agonist			
eprinomectin	eprinomectin		CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C	Veterinary Launched	http://www.drugs.com/international/eprinomectin.html			benzodiazepine receptor agonist	infectious disease|infectious disease	gastrointestinal roundworms|lungworms	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e1757d1-c6e3-4353-bb14-ae4cee6f0418|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e1757d1-c6e3-4353-bb14-ae4cee6f0418
nicergoline	nicergoline	sermion	CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13	Launched	http://www.drugs.com/international/nicergoline.html	ADRA1A	https://www.drugbank.ca/drugs/DB00699	adrenergic receptor antagonist	rheumatology|neurology/psychiatry|cardiology|hematology|rheumatology|neurology/psychiatry|cardiology|hematology	Raynaud's disease|migraine headache|atherosclerosis|thrombosis|Raynaud's disease|migraine headache|atherosclerosis|thrombosis	https://en.wikipedia.org/wiki/Nicergoline|https://en.wikipedia.org/wiki/Nicergoline|https://en.wikipedia.org/wiki/Nicergoline|https://en.wikipedia.org/wiki/Nicergoline|https://en.wikipedia.org/wiki/Nicergoline|https://en.wikipedia.org/wiki/Nicergoline|https://en.wikipedia.org/wiki/Nicergoline|https://en.wikipedia.org/wiki/Nicergoline
JNJ-26990990	JNJ-26990990		NS(=O)(=O)NCc1csc2ccccc12	Phase 2	https://en.wikipedia.org/wiki/JNJ-26990990			anticonvulsant			
SB-297006	SB-297006		CCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1ccccc1	Preclinical		CCR3	https://www.tocris.com/products/sb-297006_4213	CC chemokine receptor antagonist			
oglemilast	oglemilast		CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00859404			phosphodiesterase inhibitor			
safinamide	safinamide		C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O	Launched	http://www.parkinsons.org.uk/news/13-january-2015/new-parkinsons-drug-safinamide-wins-eu-approval	SLC6A3|MAOB	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=169540|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000972	dopamine uptake inhibitor|glutamate inhibitor|monoamine oxidase inhibitor	neurology/psychiatry	Parkinson's Disease	https://en.wikipedia.org/wiki/Safinamide
immethridine	immethridine		C(c1cnc[nH]1)c1ccncc1	Phase 1	https://clinicaltrials.gov/show/NCT01965301	HRH3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4024	histamine receptor agonist			
sulfamonomethoxine	sulfamonomethoxine	Sulfamethoxine	COc1cc(NS(=O)(=O)c2ccc(N)cc2)ncn1	Launched	http://www.drugs.com/international/sulfamonomethoxine.html			bacterial antifolate	infectious disease	urinary tract infections	http://www.drugs.com/international/sulfamonomethoxine.html
epirizole	epirizole	DA-398|mepirizole|methopyrimazole	COc1cc(C)nn1-c1nc(C)cc(OC)n1	Launched	http://www.drugs.com/international/Epirizole.html	PTGS2|PTGS1	http://en.wikipedia.org/wiki/Epirizole|http://en.wikipedia.org/wiki/Epirizole	cyclooxygenase inhibitor	neurology/psychiatry	pain relief	http://www.drugs.com/international/epirizole.html
cefpodoxime	cefpodoxime	banan|cefpodoxime proxetil|vantin	COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\c1csc(N)n1)C2=O)C(=O)OC(C)OC(=O)OC(C)C	Launched	FDA Orange Book: cefpodoxime proxetil			bacterial cell wall synthesis inhibitor	otolaryngology|infectious disease|pulmonary|infectious disease|infectious disease|infectious disease|otolaryngology|otolaryngology	pharyngitis|pneumonia|bronchitis|gonorrhea|skin infections|urinary tract infections|sinusitis|tonsillitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63777889-d306-4fc3-88da-b24859040ef4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63777889-d306-4fc3-88da-b24859040ef4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63777889-d306-4fc3-88da-b24859040ef4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63777889-d306-4fc3-88da-b24859040ef4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63777889-d306-4fc3-88da-b24859040ef4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63777889-d306-4fc3-88da-b24859040ef4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63777889-d306-4fc3-88da-b24859040ef4|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63777889-d306-4fc3-88da-b24859040ef4
AZ-12080282	AZ-12080282		Cc1ccc(cc1NC(=O)c1ccc(OCc2ccccn2)cc1)-c1ncc[nH]1	Preclinical		IHH|DHH	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=783809|http://www.freepatentsonline.com/y2017/0290849.html	hedgehog pathway inhibitor			
ciclopirox	ciclopirox	HOE 296B|loprox|penlac	Cc1cc(C2CCCCC2)n(O)c(=O)c1	Launched	FDA Orange Book: ciclopirox	ATP1A1	https://www.drugbank.ca/drugs/DB01188	membrane integrity inhibitor	infectious disease	onychomycosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ef301b7-c40a-0635-4a76-185141473dba
KF-38789	KF-38789		COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1	Preclinical		SELP	http://www.tocris.com/dispprod.php?ItemId=52750	P selectin inhibitor			
ornithine	ornithine	ornithine aketoglutarate	NCCCC(N)C(O)=O	Launched	FDA Orange Book: eflornithine hydrochloride	OAZ3|OAZ2|OAZ1|SLC7A3|SLC7A4|SLC7A1|SLC7A2|SLC25A15|OTC|OAT|SLC25A2|GATM|ARG1|ARG2|GPRC6A	https://www.drugbank.ca/drugs/DB00129|https://www.drugbank.ca/drugs/DB00129|https://www.drugbank.ca/drugs/DB00129|https://www.drugbank.ca/drugs/DB00129|https://www.drugbank.ca/drugs/DB00129|https://www.drugbank.ca/drugs/DB00129|https://www.drugbank.ca/drugs/DB00129|https://www.drugbank.ca/drugs/DB00129|https://www.drugbank.ca/drugs/DB00129|https://www.drugbank.ca/drugs/DB00129|https://www.drugbank.ca/drugs/DB00129|https://www.drugbank.ca/drugs/DB00129|https://www.drugbank.ca/drugs/DB00129|https://www.drugbank.ca/drugs/DB00129|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=725	NFkB pathway modulator			
hypoestoxide	hypoestoxide		CC(=O)O[C@H]1CC2(C)OC2CCC2(C)OC2CC2CC(=O)C(=C)C1C2(C)C	Phase 1	Cortellis	IL1B|TNF|IL6|IKBKB	http://www.scbt.com/datasheet-221735.html|http://www.scbt.com/datasheet-221735.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=425583|http://www.scbt.com/datasheet-221735.html	IKK inhibitor			
midostaurin	midostaurin	CGP 41251|NVP-PKC412|PKC 412|PKC-412	CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1	Launched	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11fa3fc9-6776-49a6-b1c1-653f627c3e58	FLT1|FLT3|KIT|KDR|VEGFA|PRKCA|PRKCG|CCNB1|PDGFRB	https://citeline.informa.com/?query=#/drugs/details/12081|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5702|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=158003|https://citeline.informa.com/?query=#/drugs/details/12081|https://citeline.informa.com/?query=#/drugs/details/12081|https://citeline.informa.com/?query=#/drugs/details/12081|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000165|https://citeline.informa.com/?query=#/drugs/details/12081|https://citeline.informa.com/?query=#/drugs/details/12081	FLT3 inhibitor|KIT inhibitor|PKC inhibitor	hematologic malignancy	acute myeloid leukemia (AML)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11fa3fc9-6776-49a6-b1c1-653f627c3e58
alpidem	alpidem	SL 80.0342-00	CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1	Withdrawn	https://en.wikipedia.org/wiki/Alpidem	GABRA1	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1995685/	benzodiazepine receptor agonist			
nandrolone-decanoate	nandrolone decanoate	deca-durabolin|durabolin|nandrolone decanoate	CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	Phase 1	http://www.organext.com/news/promising-clinical-results-of-organext-recovery-booster-therapy-for-older-patients/	AR	ChEMBL	androgenic steroid			
examorelin	examorelin		C[C@H](NC(=O)[C@@H](Cc1c(C)[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	Phase 2	https://en.wikipedia.org/wiki/Examorelin	GH1|GHRHR|GHSR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=222476|https://en.wikipedia.org/wiki/Examorelin|https://en.wikipedia.org/wiki/Examorelin	growth hormone releasing factor agonist			
quinestrol	quinestrol	estrovis	C[C@]12CCC3C(CCc4cc(OC5CCCC5)ccc34)C1CC[C@@]2(O)C#C	Launched	FDA Orange Book: quinestrol	ESR1	https://www.drugbank.ca/drugs/DB04575	estrogen receptor agonist	endocrinology	menopause	https://en.wikipedia.org/wiki/Quinestrol
etoposide-phosphate	etoposide phosphate	BMY 40481|BMY-40481|etopophos|etoposide phosphate	COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12	Launched	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e28c05f0-081f-406d-8bfb-9160a6908307	TOP2A	ChEMBL	topoisomerase inhibitor	oncology|oncology	testicular carcinoma|small cell lung cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e28c05f0-081f-406d-8bfb-9160a6908307|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e28c05f0-081f-406d-8bfb-9160a6908307
triclabendazole	triclabendazole		CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1	Launched	http://www.drugs.com/international/Triclabendazole.html	DNMT1	http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0078752	microtubule inhibitor	infectious disease	tapeworm	https://en.wikipedia.org/wiki/Triclabendazole
STAT3-inhibitor-VI	STAT3-inhibitor-VI	NSC-74859	Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1	Preclinical		STAT3	http://www.millipore.com/catalogue/item/573102-10MG&cid=BIOS-A-LINS-1212-1204-RC	STAT inhibitor			
lemborexant	lemborexant	E2006	Cc1ncc(OC[C@]2(C[C@H]2C(=O)Nc2ccc(F)cn2)c2cccc(F)c2)c(C)n1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02783729	HCRTR1|HCRTR2	https://en.wikipedia.org/wiki/Lemborexant|https://en.wikipedia.org/wiki/Lemborexant	orexin receptor antagonist			
sulfamethizole	sulfamethizole	Methazol|Microsul|Proklar|Sulphamethylthiadiazole|Tetracid|sulphamethizole|thiosulfil	Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1	Launched	FDA Orange Book: sulfamethizole			bacterial antifolate	infectious disease	urinary tract infections	http://www.drugbank.ca/drugs/DB00576
ansamitocin-p-3	ansamitocin-p-3		CO[C@@H]1C=C\C=C(C)/Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2	Preclinical				apoptosis stimulant			
4-PPBP	4-PPBP		C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1	Preclinical		SIGMAR1	http://www.ncbi.nlm.nih.gov/pubmed/25111531	sigma receptor ligand			
maprotiline	maprotiline	BA-34,276 [AS HYDROCHLORIDE]|ludiomil|maprotiline hydrochloride	CNCCCC12CCC(c3ccccc13)c1ccccc21	Launched	FDA Orange Book: maprotiline hydrochloride	ADRA2C|ADRA2B|ADRA2A|ADRA1B|ADRA1A|ADRA1D|HRH1|HTR2A|HTR2C|HTR7|SLC6A2|DRD2|CHRM5|CHRM2|CHRM1|CHRM4|CHRM3	https://www.drugbank.ca/drugs/DB00934|https://www.drugbank.ca/drugs/DB00934|https://www.drugbank.ca/drugs/DB00934|https://www.drugbank.ca/drugs/DB00934|https://www.drugbank.ca/drugs/DB00934|https://www.drugbank.ca/drugs/DB00934|https://www.drugbank.ca/drugs/DB00934|https://www.drugbank.ca/drugs/DB00934|https://www.drugbank.ca/drugs/DB00934|https://www.drugbank.ca/drugs/DB00934|https://www.drugbank.ca/drugs/DB00934|https://www.drugbank.ca/drugs/DB00934|https://www.drugbank.ca/drugs/DB00934|https://www.drugbank.ca/drugs/DB00934|https://www.drugbank.ca/drugs/DB00934|https://www.drugbank.ca/drugs/DB00934|https://www.drugbank.ca/drugs/DB00934	norepinephrine reputake inhibitor|tricyclic antidepressant	neurology/psychiatry|neurology/psychiatry	depression|dysthymic disorder	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87
OAC1	OAC1		O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1	Preclinical				Oct activator			
OAC2	OAC2		O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1	Preclinical		POU5F1	https://www.caymanchem.com/product/14103	Oct activator			
altretamine	altretamine	hexalen|hexamethylmelamine	CN(C)c1nc(nc(n1)N(C)C)N(C)C	Launched	FDA Orange Book: altretamine			DNA synthesis inhibitor	oncology	ovarian cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90a5e59a-bee8-404a-ad69-fabddeaf27f9
SR-33805	SR-33805		COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC	Phase 1	http://adisinsight.springer.com/drugs/800002436			calcium channel blocker			
naftopidil	naftopidil		COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1	Launched	http://www.drugs.com/international/naftopidil.html	ADRA1D|ADRA1A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=105012|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004943	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)	https://en.wikipedia.org/wiki/Naftopidil
sulfacarbamide	sulfacarbamide	sulphaurea	NC(=O)NS(=O)(=O)c1ccc(N)cc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs						
dicloxacillin	dicloxacillin	BRL-1702|Dycill|R-13423|dicloxacillin sodium|dynapen|pathocil	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl	Launched	FDA Orange Book: dicloxacillin sodium			bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections	https://en.wikipedia.org/wiki/Dicloxacillin
eptifibatide	eptifibatide	integrilin	NC(=N)NCCCCC1NC(=O)CCSSCC(NC(=O)C2CCCN2C(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CC(O)=O)NC(=O)CNC1=O)C(N)=O	Launched	FDA Orange Book: eptifibatide	ITGB3|ITGA2B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6585|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6585	platelet aggregation inhibitor	cardiology|cardiology	acute coronary syndrome (ACS)|percutaneous coronary intervention (PCI)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1de8006b-6b11-46a8-b8e8-c6c07b9c9555|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1de8006b-6b11-46a8-b8e8-c6c07b9c9555
silibinin	silibinin		COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O	Launched	http://www.drugs.com/international/Silibinin.html	ALOX5	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001331	cytochrome P450 inhibitor	gastroenterology	hepatic cirrhosis	https://www.google.com/webhp?sourceid=chrome-instant&ion=1&espv=2&ie=UTF-8#q=herpatic+Cirrhosis
tasisulam	tasisulam		Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01006252			apoptosis stimulant			
WP1066	WP1066		C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01904123	STAT3	http://www.scbt.com/datasheet-203282-stat3-inhibitor-iii-wp1066.html	STAT inhibitor			
chromanol-(+/-)	(+/-)-chromanol		CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N.CCS(=O)(=O)N(C)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	Preclinical				potassium channel blocker			
SN-6	SN-6		CCOC(=O)C1CSC(N1)Cc1ccc(OCc2ccc([N+]([O-])=O)cc2)cc1	Preclinical				sodium/calcium exchange inhibitor			
creatinol-phosphate	creatinol phosphate	creatinolfosfate	CN(CCOP(O)(O)=O)C(N)=N	Launched	Pharmaprojects						
SN-2	SN-2		Cc1cc(C)c(C2=NOC3C4CCC(C4)C23)c(C)c1	Preclinical		MCOLN3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6402	transient receptor potential channel agonist			
sufentanil	sufentanil	R 30,730|R-30730|sufenta preservative free	CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1	Launched	FDA Orange Book: sufentanil citrate	OPRD1|OPRK1|OPRM1	https://www.drugbank.ca/drugs/DB00708|https://www.drugbank.ca/drugs/DB00708|https://www.drugbank.ca/drugs/DB00708	opioid receptor modulator	neurology/psychiatry	anesthetic	https://en.wikipedia.org/wiki/Sufentanil
amodiaquine	amodiaquine	camoquin hydrochloride	CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O	Launched	FDA Orange Book: amodiaquine hydrochloride	HNMT|CYP2C8	https://www.drugbank.ca/drugs/DB00613|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070201	histamine receptor agonist	infectious disease	malaria	https://en.wikipedia.org/wiki/Amodiaquine
fenoterol	fenoterol	TH 1165A [AS HYDROBROMIDE SALT]|berotec [as hydrobromide]|fenoterol hydrobromide	CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	ADRB2|ADRB3|ADRB1	https://www.drugbank.ca/drugs/DB01288|https://www.drugbank.ca/drugs/DB01288|https://www.drugbank.ca/drugs/DB01288	adrenergic receptor agonist			
DPI-201106	DPI-201106	SDZ-201106	OC(COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/3318371	ADRB2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009288	sodium channel activator			
neratinib	neratinib	CDP-820|HKI-272|WAY-179272	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00878709	EGFR|ERBB2|ERBB4|KDR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5686|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5686|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=343722|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004815	EGFR inhibitor			
armodafinil	armodafinil	CEP-10953|nuvigil	NC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1	Launched	FDA Orange Book: armodafinil	CYP2C19|ABCB1|CYP3A5|CYP1A2|SLC6A3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=135643|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=135643|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=135643|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=135643|ChEMBL	adrenergic receptor agonist	pulmonary|neurology/psychiatry|neurology/psychiatry	obstructive sleep apnea|narcolepsy|shift work disorder (SWD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c824d4c-2309-4e2a-bc74-aa8d80a5c454|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c824d4c-2309-4e2a-bc74-aa8d80a5c454|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c824d4c-2309-4e2a-bc74-aa8d80a5c454
2-BFI	2-BFI		C1CN=C(N1)c1cc2ccccc2o1	Preclinical		ADRA2C|ADRA2B|ADRA2A|MAOB|MAOA	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012203|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012203|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012203|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012203|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012203	imidazoline receptor ligand			
JDTic	JDTic		CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01431586	OPRK1	https://en.wikipedia.org/wiki/JDTic	opioid receptor antagonist			
SU-16f	SU-16f		Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O	Preclinical		PDGFRB	https://www.tocris.com/products/su-16f_3304	PDGFR tyrosine kinase receptor inhibitor			
API-001	API-001		Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1	Phase 2	https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000398-21/ES	SIGMAR1	https://en.wikipedia.org/wiki/S1RA	sigma receptor antagonist			
cafestol	cafestol		C[C@@]12CCc3occc3[C@H]1CC[C@@]13C[C@@H](CC[C@@H]21)[C@@](O)(CO)C3	Launched	http://en.wikipedia.org/wiki/Cafestol			pregnane X receptor agonist			
Y-134	Y-134		CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1	Preclinical		ESR2|ESR1	http://www.tocris.com/dispprod.php?ItemId=78754#.Utmn-6X0DAI|http://www.tocris.com/dispprod.php?ItemId=78754#.Utmn-6X0DAI	estrogen receptor antagonist			
manidipine	manidipine	MANIDIPINE 6300|manidipine hydrochloride	COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1	Launched	http://www.drugs.com/international/Manidipine.html	CACNA1D|CACNA1C	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011942|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011942	calcium channel blocker	cardiology	hypertension	https://en.wikipedia.org/wiki/Manidipine
GDC-0941	GDC-0941	RG-7321|pictilisib	CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01437566	PIK3CA|PIK3CB|PIK3CD|PIK3CG	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682	PI3K inhibitor			
pyroxamide	pyroxamide	Octanedioic acid hydroxyamide pyridin-3-ylamide	ONC(=O)CCCCCCC(=O)Nc1cccnc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00042900	HDAC1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001119	HDAC inhibitor			
cobimetinib	cobimetinib	GDC-0973|RG 7420|RG 7420; GDC-0973|RG-7421|XL-518|cotellic	OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1	Launched	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c387579e-cee0-4334-bd1e-73f93ac1bde6			MEK inhibitor	oncology	melanoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c387579e-cee0-4334-bd1e-73f93ac1bde6
AC1NDSS5	AC1NDSS5		CCCCCCCCCCCCCCCCCC[S+](CCC)c1ccccc1C(=O)OCC	Phase 1	Pharmaprojects						
piromidic-acid	piromidic acid	PD-93|piromidic acid	CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/7029845			bacterial DNA gyrase inhibitor			
nicotine	nicotine	Nicotrol Inhaler|Nicotrol NS|commit|habitrol|nicoderm|nicoderm cq|nicorette|nicorette (mint)|nicotrol|prostep		Launched	FDA Orange Book: nicotine, nicotine polacrilex	CHAT|CHRNA10|CYP19A1|AOX1|TBXAS1|TRPA1|CHRNB4|CHRNB3|CHRNB2|CHRNA5|CHRNA4|CHRNA3|CHRNA2|CHRNA9|CHRNA7|CHRNA6|CYP2B6	https://www.drugbank.ca/drugs/DB00184|https://www.drugbank.ca/drugs/DB00184|https://www.drugbank.ca/drugs/DB00184|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070191|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004080|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2585|https://www.drugbank.ca/drugs/DB00184|https://www.drugbank.ca/drugs/DB00184|ChEMBL|https://www.drugbank.ca/drugs/DB00184|ChEMBL|https://www.drugbank.ca/drugs/DB00184|https://www.drugbank.ca/drugs/DB00184|https://www.drugbank.ca/drugs/DB00184|https://www.drugbank.ca/drugs/DB00184|https://www.drugbank.ca/drugs/DB00184|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070191	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=815a7c24-8e2a-4e3f-8127-a59ee4336fd9
MEK162	MEK162	ARRY-162|ARRY-438162|MEK-162|NVP-MEK162|binimetinib	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01763164	TNFRSF1A|MAP2K2|MAP2K1|IL1R2|IL6R	https://citeline.informa.com/?query=#/drugs/details/35353|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7921|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7921|https://citeline.informa.com/?query=#/drugs/details/35353|https://citeline.informa.com/?query=#/drugs/details/35353	MEK inhibitor			
dalbavancin	dalbavancin	A-A-1|BI397|MDL 64,397|VERO001|Zeven|dalvance	CN[C@@H]1c2ccc(O)c(Oc3cc(O)c(Cl)c(c3)[C@@H]3NC(=O)[C@@H](Cc4ccc(Oc5cc6cc(Oc7ccc(cc7Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]6NC3=O)c3ccc(O)c(c3)-c3c(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)cc(O)cc3[C@H](NC7=O)C(=O)NCCCN(C)C)c5O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)C(O)=O)cc4)NC1=O)c2	Launched	FDA Orange Book: dalbavancin hydrochloride	PNLIP	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000512	bacterial cell wall synthesis inhibitor	infectious disease	skin infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b4674d8-4d1e-4728-8465-d42ada33fa5c
acamprosate	acamprosate	acamprosate calcium|campral	CC(=O)NCCCS(O)(=O)=O	Launched	FDA Orange Book: acamprosate calcium	GABRP|GABRQ|GABRD|GABRE|GRM5|GRIN3A|GRIN3B|GRIN2C|GRIN2D|GRIN2A|GRIN2B|GRIN1|GABRA1|GABRA3|GABRA2|GABRA5|GABRA4|GABRA6|GABRB2|GABRB1|GABRB3|GABRG3|GABRG2|GABRG1	https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659|https://www.drugbank.ca/drugs/DB00659	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75ddfd10-55b2-426e-bc74-3413cd0d7c94
PD-318088	PD-318088	PD318088	OCC(O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F	Preclinical		MAP2K1	https://www.drugbank.ca/drugs/DB03115	MEK inhibitor			
CPCCOEt	CPCCOEt		CCOC(=O)C12CC1\C(=N/O)c1ccccc1O2	Preclinical		GRM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1382	glutamate receptor antagonist			
K-Ras(G12C)-inhibitor-12	K-Ras(G12C)-inhibitor-12		Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C	Preclinical		KRAS	http://www.nature.com/nature/journal/v503/n7477/full/nature12796.html	K-ras inhibitor			
NGD-94-1	NGD-94-1	[3H]NGD-941	C(N1CCN(CC1)c1ncccn1)c1cnc([nH]1)-c1ccccc1	Phase 1	https://books.google.com/books?id=HEzPBAAAQBAJ&pg=PA29&lpg=PA29&dq=NGD-94-1+phase+I&source=bl&ots=Bvu9zpXdCi&sig=0Tanv99RO_x5e2bB4jj9xaqxDO0&hl=en&sa=X&ved=0ahUKEwjxxuPqtuzPAhWMFz4KHVkxCrsQ6AEINzAE#v=onepage&q=NGD-94-1%20phase%20I&f=false	DRD4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3297	dopamine receptor antagonist			
candicidin	candicidin		CC(CC(C)C1OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)CC(=O)CC(O)C(C(O)CC(O[C@@H]2O[C@H](C)[C@H](O)[C@@H](O)[C@@H]2N)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C1C)C(O)=O)C(O)CC(=O)c1ccc(N)cc1	Launched	FDA Orange Book: candicidin			fungal ergosterol inhibitor	infectious disease	vulvovaginal candidiasis	https://en.wikipedia.org/wiki/Candicidin
TC-A-2317	TC-A-2317		CC(CCCC(C)(C)O)Nc1nc(Nc2cc(C)[nH]n2)cc(C)c1C#N	Preclinical		AURKA|AURKB	https://www.tocris.com/products/tc-a-2317-hydrochloride_4066|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=477632	Aurora kinase inhibitor			
1,12-Besm	1,12-Besm		CCNCCCNCCCCNCCCNCC	Phase 2				polyamine biosynthesis inhibitor			
BTS-72664	BTS-72664		CC(Oc1ccc(Cl)cc1)c1ccnc2ncnn12	Phase 1	http://adisinsight.springer.com/drugs/800008391	GABBR1	http://onlinelibrary.wiley.com/store/10.1111/j.1527-3458.2001.tb00193.x/asset/j.1527-3458.2001.tb00193.x.pdf;jsessionid=6A52A4D6C70CD006F1E7716EEB4FE9A5.f03t02?v=1&t=itdc8zbh&s=b97b60b2158ffee5488403b66926a300d1d8d72b	GABA receptor antagonist			
PF-03882845	PF-03882845		OC(=O)c1ccc2C3=C(CCc2c1)[C@H](C1CCCC1)N(N3)c1ccc(C#N)c(Cl)c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00971802						
DG-172	DG-172		CN1CCN(CC1)c1ccc(cc1)\C=C(/C#N)c1ccccc1Br	Preclinical		PPARD	https://www.tocris.com/products/dg-172-dihydrochloride_5566	PPAR receptor inverse agonist			
SCP-1	SCP-1		Oc1ccc(NC(=O)CN2C(=O)c3ccccc3S2(=O)=O)cc1	Phase 1	http://adisinsight.springer.com/drugs/800011117|https://www.sbir.gov/sbirsearch/detail/316862			analgesic agent			
laropiprant	laropiprant	MK-0524	CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12	Launched	http://www.drugs.com/international/laropiprant.html	PTGDR2|PTGER3|PTGER2|PTGER1|PTGFR|PTGIR|PTGDR|TBXA2R	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007125|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007125|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007125|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007125|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007125|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007125|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007125|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007125	prostanoid receptor antagonist	cardiology	cholesterol	https://en.wikipedia.org/wiki/Laropiprant
milnacipran	milnacipran	fetzima|midalcipran|savella		Launched	FDA Orange Book: levomilnacipran hydrochloride, milnacipran hydrochloride	GRIN1|SLC6A4|SLC6A2|GRIN2B|GRIN2A|GRIN2D|GRIN2C|GRIN3B|GRIN3A	https://www.drugbank.ca/drugs/DB04896|https://www.drugbank.ca/drugs/DB04896|https://www.drugbank.ca/drugs/DB04896|https://www.drugbank.ca/drugs/DB04896|https://www.drugbank.ca/drugs/DB04896|https://www.drugbank.ca/drugs/DB04896|https://www.drugbank.ca/drugs/DB04896|https://www.drugbank.ca/drugs/DB04896|https://www.drugbank.ca/drugs/DB04896	serotoninnorepinephrine reuptake inhibitor (SNRI)	rheumatology	fibromyalgia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16a4a314-f97e-4e91-95e9-576a3773d284
DHBP	DHBP		CCCCCCC[n+]1ccc(cc1)-c1cc[n+](CCCCCCC)cc1	Preclinical				ryanodine receptor blocker			
RX-821002	RX-821002		COC1(COc2ccccc2O1)C1=NCCN1	Preclinical		ADRA2B|ADRA2A|ADRA2C|ADRA1A|ADRA1B|ADRA1D	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=526|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=526|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=526|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012444|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012444|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012444	adrenergic receptor antagonist			
tannic-acid	tannic acid		Oc1cc(cc(O)c1O)C(=O)Oc1cc(cc(O)c1O)C(=O)OC[C@H]1O[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1	Launched	FDA Orange Book: tannic acid	PARG|ANO1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=372314|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4319	PARG inhibitor	gastroenterology	constipation	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92362431-9618-4aef-9b8a-a79809a0cb96&audience=consumer
dodecyl-sulfate	dodecyl sulfate		CCCCCCCCCCCCOS(O)(=O)=O	Preclinical		LYZ	http://www.drugbank.ca/drugs/DB03967				
dexamethasone	dexamethasone	decaderm|decadron|decaspray|dexamethasone intensol|hexadrol|maxidex|ozurdex		Launched	FDA Orange Book: dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate	CYP3A4|CYP3A5|NOS2|ANXA1|NR3C1|NR3C2|NR0B1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070529|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070529|https://www.drugbank.ca/drugs/DB01234|https://www.drugbank.ca/drugs/DB01234|https://www.drugbank.ca/drugs/DB01234|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2768|https://www.drugbank.ca/drugs/DB01234	glucocorticoid receptor agonist	endocrinology|rheumatology|rheumatology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|gastroenterology|rheumatology|dermatology|rheumatology|dermatology	hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b15200fb-1826-472b-a907-e677a272513b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b15200fb-1826-472b-a907-e677a272513b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b15200fb-1826-472b-a907-e677a272513b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b15200fb-1826-472b-a907-e677a272513b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b15200fb-1826-472b-a907-e677a272513b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b15200fb-1826-472b-a907-e677a272513b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b15200fb-1826-472b-a907-e677a272513b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b15200fb-1826-472b-a907-e677a272513b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b15200fb-1826-472b-a907-e677a272513b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b15200fb-1826-472b-a907-e677a272513b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b15200fb-1826-472b-a907-e677a272513b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b15200fb-1826-472b-a907-e677a272513b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b15200fb-1826-472b-a907-e677a272513b
oprozomib	oprozomib		COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)C1(C)CO1	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT01416428			proteasome inhibitor			
halopemide	halopemide	R 34,301	Oc1nc2cc(Cl)ccc2n1C1CCN(CCNC(=O)c2ccc(F)cc2)CC1	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/6398861	PLD2|PLD1	https://www.caymanchem.com/product/13205|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008843	phospholipase inhibitor			
oncrasin-1	oncrasin-1		Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1	Preclinical				apoptosis stimulant			
LCQ908	LCQ908	LCQ908-NXA|pradigastat	OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01514461	DGAT1	http://www.lipidjournal.com/article/S1933-2874(12)00118-3/abstract	diacylglycerol O acyltransferase inhibitor			
delapril	delapril		CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1	Launched	http://www.drugs.com/international/Delapril.html	ACE	http://www.drugs.com/international/delapril.html	angiotensin converting enzyme inhibitor	cardiology	hypertension	https://en.wikipedia.org/wiki/Delapril
JHW-007	JHW-007		CCCCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1	Preclinical		SLC6A3	https://www.tocris.com/products/jhw-007-hydrochloride_4351	dopamine uptake inhibitor			
CPA-inhibitor	CPA-inhibitor		ON(CC(Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1	Preclinical		CPA1|CPA2	https://www3.scbt.com/scbt/browse/chemicals-Protein-Interacting-Inhibitors-Activators-Substrates-Protein-Inhibitors-CPA-Inhibitors/_/N-sixmoj|https://www3.scbt.com/scbt/browse/chemicals-Protein-Interacting-Inhibitors-Activators-Substrates-Protein-Inhibitors-CPA-Inhibitors/_/N-sixmoj	carboxypeptidase inhibitor			
succinylsulfathiazole	succinylsulfathiazole		OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	Phase 2	http://archsurg.jamanetwork.com/article.aspx?articleid=545580	DHFR	http://www.sigmaaldrich.com/catalog/product/sigma/s8752?lang=en&region=US	dihydrofolate reductase inhibitor			
tacedinaline	tacedinaline	CI-994|GOE 5549|PD 123654	CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00005093	HDAC1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001122	HDAC inhibitor			
sulfadiazine	sulfadiazine	Adiazine|Diazyl|SSD|Sildaflo|Silvadene|Sulfapyrimidine|Sulfolex|Thermazene|coco-diazine|sulfacombin|sulfadiazine (trisulfapyrimidines)|sulfadiazine sodium|sulphadiazine	Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1	Launched	FDA Orange Book: silver sulfadiazine, sulfadiazine, sulfadiazine sodium, trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine)			bacterial antifolate	infectious disease|infectious disease|infectious disease|ophthalmology|infectious disease|infectious disease	malaria|meningitis|urinary tract infections|conjunctivitis|trachoma|chancroid	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10549cba-9c15-4d2e-a68c-5afbc178591d&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10549cba-9c15-4d2e-a68c-5afbc178591d&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10549cba-9c15-4d2e-a68c-5afbc178591d&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10549cba-9c15-4d2e-a68c-5afbc178591d&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10549cba-9c15-4d2e-a68c-5afbc178591d&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10549cba-9c15-4d2e-a68c-5afbc178591d&audience=consumer
aminosalicylate	aminosalicylate	Rezipas|aminosalicylic acid|aminosalicylic acid resin complex|para-aminosalicylic acid|parasal|parasal sodium|paser|paskalium|teebacin	Nc1ccc(C(O)=O)c(O)c1	Launched	FDA Orange Book: aminosalicylate sodium, phenyl aminosalicylate, potassium aminosalicylate	PTGS1|PTGS2|CHUK|ALOX5|PLA2G2E	ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00233|https://www.drugbank.ca/drugs/DB00233|https://www.drugbank.ca/drugs/DB00233	cyclooxygenase inhibitor	gastroenterology|gastroenterology	inflammatory bowel disease|ulcerative colitis	https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=aminosalicylate|https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=aminosalicylate
80841-78-7	80841-78-7		Cc1oc(=O)oc1CCl	Preclinical							
pramipexole	pramipexole	SUD919CL2Y|U-98528E|U-98528E; SUD919CL2Y|mirapex|mirapex er	CCCN[C@H]1CCc2nc(N)sc2C1	Launched	FDA Orange Book: pramipexole dihydrochloride	ADRA2C|ADRA2A|ADRA2B|HTR2B|HTR2A|HTR2C|HTR1A|HTR1D|HTR1B|DRD5|DRD2|DRD1|DRD4|DRD3	https://www.drugbank.ca/drugs/DB00413|https://www.drugbank.ca/drugs/DB00413|https://www.drugbank.ca/drugs/DB00413|https://www.drugbank.ca/drugs/DB00413|https://www.drugbank.ca/drugs/DB00413|https://www.drugbank.ca/drugs/DB00413|https://www.drugbank.ca/drugs/DB00413|https://www.drugbank.ca/drugs/DB00413|https://www.drugbank.ca/drugs/DB00413|https://www.drugbank.ca/drugs/DB00413|https://www.drugbank.ca/drugs/DB00413|https://www.drugbank.ca/drugs/DB00413|https://www.drugbank.ca/drugs/DB00413|https://www.drugbank.ca/drugs/DB00413	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f90971a-e005-4dd3-bb93-b09125ada3c8
serotonin	serotonin	5-HT|5-HYDROXYTRYPTAMINE	NCCc1c[nH]c2ccc(O)cc12	Launched	http://www.drugs.com/international/Serotonin.html	HTR7|HTR6|HTR4|SLC36A1|DRD1|DRD5|HTR2C|HTR2B|HTR2A|HTR1F|HTR1E|HTR1D|HTR1B|HTR1A|HTR5A|HTR3B|HTR3A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5	growth factor receptor activator	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	anxiety|depression|sleeplessness	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3110db40-0209-48ca-be5e-0f77b27506f8&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3110db40-0209-48ca-be5e-0f77b27506f8&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3110db40-0209-48ca-be5e-0f77b27506f8&audience=consumer
CYM-5541	CYM-5541		O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1	Preclinical		S1PR3	https://www.tocris.com/products/cym-5541_4897	sphingosine 1 phosphate receptor agonist			
regorafenib	regorafenib	BAY 73-4506|BAY 73-4506 MONOHYDRATE|stivarga	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1	Launched	FDA Orange Book: regorafenib	TEK|FGF2|RET|DDR2|FLT1|FLT4|KIT|KDR|ABL1|FRK|NTRK1|MAPK11|CYP2C8|CYP2B6|CYP2C19|BRAF|RAF1|FGFR2|FGFR1|EPHA2|PDGFRA|PDGFRB	ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=395674|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB08896|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=395674|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=395674|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=395674|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB08896|ChEMBL|ChEMBL	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology|oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=824f19c9-0546-4a8a-8d8f-c4055c04f7c7|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=824f19c9-0546-4a8a-8d8f-c4055c04f7c7
hydrocortisone-valerate	hydrocortisone valerate	hydrocortisone valerate|westcort	CCCCC(=O)O[C@@]1(CCC2C3CCC4=CC(=O)CC[C@]4(C)C3[C@@H](O)C[C@]12C)C(=O)CO	Launched	FDA Orange Book: hydrocortisone valerate			glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3c91e05-8a76-4743-aaf6-0eb421c03b42
talinolol	talinolol		CC(C)(C)NCC(O)COc1ccc(NC(=O)NC2CCCCC2)cc1	Launched	http://www.drugs.com/international/Talinolol.html	ADRB1	https://www.caymanchem.com/product/16116	adrenergic receptor antagonist	cardiology	hypertension	http://www.drugs.com/international/talinolol.html
CPI-1189	CPI-1189		CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00002414	TNF	http://www.ncbi.nlm.nih.gov/pubmed/12528314	tumor necrosis factor release inhibitor			
HA-1004	HA-1004	H-1004	NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12	Phase 2	Integrity			calcium channel blocker			
etanidazole	etanidazole	SR 2508|radinyl	OCCNC(=O)Cn1ccnc1[N+]([O-])=O	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/1826961			bacterial cell wall synthesis inhibitor			
succinic-acid	succinic acid	E363|succinic acid	OC(=O)CCC(O)=O	Launched	http://en.wikipedia.org/wiki/Succinic_acid	ALDH5A1|P3H3|P3H2|P3H1|SUCLA2|HSD17B6|SLC13A3|SLC13A2|SLC13A1|SUCLG2|SUCLG1|TMLHE|SUCNR1|OXCT1|OXCT2|SDHB|SDHA|SDHD|SDHC|SLC25A10|BBOX1|ASPH|PLOD1|PLOD3|P4HA1|P4HA2	https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139|https://www.drugbank.ca/drugs/DB00139				
TAME	TAME		COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1	Preclinical							
AMG-PERK-44	AMG-PERK-44		Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N	Preclinical		EIF2AK4	https://www.tocris.com/products/amg-perk-44_5517	PERK inhibitor			
L-mimosine	L-mimosine		N[C@@H](CN1CC(=O)C(=O)C=C1)C(O)=O	Preclinical		EIF5A|DBH	https://www.scbt.com/scbt/product/l-mimosine-500-44-7|https://www.scbt.com/scbt/product/l-mimosine-500-44-7	dopamine beta hydroxylase inhibitor|eukaryotic translation initiation factor inhibitor			
cefditoren-pivoxil	cefditoren pivoxil	ME1207|cdtr-pi|cefditoren|cefditoren pivoxil|meiact|spectracef	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1	Launched	FDA Orange Book: cefditoren pivoxil			bacterial cell wall synthesis inhibitor	infectious disease|pulmonary|infectious disease|otolaryngology|otolaryngology	pneumonia|bronchitis|skin infections|tonsillitis|pharyngitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5050d0e-81d1-4707-a38a-e80de2aebf09|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5050d0e-81d1-4707-a38a-e80de2aebf09|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5050d0e-81d1-4707-a38a-e80de2aebf09|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5050d0e-81d1-4707-a38a-e80de2aebf09|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5050d0e-81d1-4707-a38a-e80de2aebf09
solcitinib	solcitinib	G154578|GLPG-0778|GLPG-0788|GLPG0778|GSK-2586184|GSK2586184A	CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01953835	JAK1	http://www.medkoo.com/products/5848	JAK inhibitor			
phenindione	phenindione	hedulin|phenylindanedione	O=C1C(C(=O)c2ccccc12)c1ccccc1	Launched	FDA Orange Book: phenindione	VKORC1	ChEMBL	vitamin K antagonist	hematology	deep vein thrombosis (DVT)	http://www.drugs.com/international/phenindione.html
iopromide	iopromide	ZK 35760|ZK-35760|ultravist|ultravist (pharmacy bulk)|ultravist 150|ultravist 240|ultravist 300|ultravist 370	COCC(=O)Nc1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)N(C)CC(O)CO)c1I	Launched	FDA Orange Book: iopromide			radiopaque medium	radiology	contrast agent	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df917c3a-59a2-4ed1-8470-8a5394c73325
nisoldipine	nisoldipine	BAY K 5552|BAY-K-5552|sular	COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C	Launched	FDA Orange Book: nisoldipine	CACNB2|CACNA2D1|CYP3A5|CACNA1F|CACNA1C|CACNA1D|CACNA1S	https://www.drugbank.ca/drugs/DB00401|https://www.drugbank.ca/drugs/DB00401|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090251|ChEMBL|ChEMBL|ChEMBL|ChEMBL	calcium channel blocker	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00d506a4-74d6-4838-b008-3f9e7c017e08
lymecycline	lymecycline		CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)C1=O	Launched	http://www.drugs.com/international/Lymecycline.html			bacterial 50S ribosomal subunit inhibitor	dermatology	acne vulgaris (AV)	http://patient.info/medicine/lymecycline-capsules
nemorubicin	nemorubicin		CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O	Phase 2	https://www.clinicaltrialsregister.eu/ctr-search/search?query=Nemorubicin	TOP1|TOP2A	http://www.medkoo.com/products/5672|http://www.medkoo.com/products/5672	topoisomerase inhibitor			
cyclizine	cyclizine	marezine	CN1CCN(CC1)C(c1ccccc1)c1ccccc1	Launched	FDA Orange Book: cyclizine lactate	SULT1E1|HRH1	https://www.drugbank.ca/drugs/DB01176|https://www.drugbank.ca/drugs/DB01176	histamine receptor modulator	gastroenterology|gastroenterology|neurology/psychiatry|neurology/psychiatry	nausea|vomiting|vertigo|motion sickness	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d06a3473-d76f-4c91-b992-a6ae6b222810|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d06a3473-d76f-4c91-b992-a6ae6b222810|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d06a3473-d76f-4c91-b992-a6ae6b222810|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d06a3473-d76f-4c91-b992-a6ae6b222810
NU6027	NU6027	NU-6027	Nc1nc(N)c([N+][O-])c(OCC2CCCCC2)n1	Preclinical		ATR|CDK2|CDK1|CCNA2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=274670|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004110|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=274670|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004110	CDK inhibitor			
clobazam	clobazam	H 4723|HR 376|LM 2717|onfi|urbanyl	CN1c2ccc(Cl)cc2N(c2ccccc2)C(=O)CC1=O	Launched	FDA Orange Book: clobazam	CYP2C19|GABRE|GABRD|GABRQ|GABRP|GABRA6|GABRA5|GABRA4|GABRA3|GABRA2|GABRA1|GABRG3|GABRG2|GABRG1|GABRB3|GABRB2|GABRB1|CYP3A4|CYP2B6	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091395|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091395|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091395	GABA benzodiazepine site receptor agonist	neurology/psychiatry	seizures	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de03bd69-2dca-459c-93b4-541fd3e9571c
stemregenin-1	stemregenin-1		CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12	Preclinical		AHR	http://www.stemcell.com/en/Products/All-Products/StemRegenin-1.aspx	aryl hydrocarbon receptor antagonist			
ebrotidine	ebrotidine		NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	HRH2	https://en.wikipedia.org/wiki/Ebrotidine	histamine receptor antagonist			
GW-843682X	GW-843682X	GW843682X	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC	Preclinical		PLK1|PLK3	http://www.tocris.com/dispprod.php?ItemId=5442|http://www.tocris.com/dispprod.php?ItemId=5442	PLK inhibitor			
proscillaridin-a	proscillaridin a		C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)C4CC[C@]5(C)[C@H](CC[C@]5(O)C4CCC3=C2)c2ccc(=O)oc2)C(O)C(O)[C@H]1O	Launched	http://www.drugs.com/international/proscillaridin.html				cardiology|cardiology	congestive heart failure|cardiac arrythmia	https://en.wikipedia.org/wiki/Proscillaridin|https://en.wikipedia.org/wiki/Proscillaridin
JNJ-47965567	JNJ-47965567		O=C(NCC1(CCOCC1)N1CCN(CC1)c1ccccc1)c1cccnc1Sc1ccccc1	Preclinical		IL1B|P2RX7	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=809247|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7538	purinergic receptor antagonist			
3-methyl-GABA	3-methyl-GABA		CC(CN)CC(O)=O	Preclinical		ABAT	http://www.tocris.com/dispprod.php?ItemId=1622#.VeXcoixVhHw	GABA aminotransferase activator			
nefazodone	nefazodone	nefazodone hydrochloride|serzone	CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	ADRA2A|ADRA1B|ADRA1A|CYP3A4|CYP3A5|CYP3A7|HTR2C|HTR2A|HTR1A|SLC6A2|SLC6A3|SLC6A4	https://www.drugbank.ca/drugs/DB01149|https://www.drugbank.ca/drugs/DB01149|https://www.drugbank.ca/drugs/DB01149|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7247|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090786|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090786|https://www.drugbank.ca/drugs/DB01149|https://www.drugbank.ca/drugs/DB01149|https://www.drugbank.ca/drugs/DB01149|https://www.drugbank.ca/drugs/DB01149|https://www.drugbank.ca/drugs/DB01149|https://www.drugbank.ca/drugs/DB01149	adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor			
meisoindigo	meisoindigo		CN1C(=O)\C(c2ccccc12)=C1\C(=O)Nc2ccccc12	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/11122126	STAT3	http://onlinelibrary.wiley.com/store/10.1002/eji.200939566/asset/460_ftp.pdf?v=1&t=io4olpjo&s=c9c568c4cd372aeee8adb7266c22ac93ea875709&systemMessage=Wiley+Online+Library+will+be+unavailable+on+Saturday+14th+May+11%3A00-14%3A00+BST+%2F+06%3A00-09%3A00+EDT+%2F+18%3A00-21%3A00+SGT+for+essential+maintenance.Apologies+for+the+inconvenience.	STAT inhibitor			
5-methylhydantoin-(L)	5-methylhydantoin-(L)		C[C@@H]1NC(=O)NC1=O	Preclinical							
mercaptosuccinic-acid	mercaptosuccinic acid		OC(=O)CC(S)C(O)=O	Launched	http://en.wikipedia.org/wiki/Dimercaptosuccinic_acid						
azacyclonol	azacyclonol	Ataractan|Calmeran|Frenoton|Frenquel|Psychosan|gamma-Pipradol	OC(C1CCNCC1)(c1ccccc1)c1ccccc1	Preclinical		HRH1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010157	histamine receptor antagonist			
indomethacin	indomethacin	Indo-lemmon|indocin|indocin sr|indometacin|indometacin farnesil|tivorbex	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1	Launched	FDA Orange Book: indomethacin, indomethacin sodium	PTGS1|PTGR2|PTGS2|PLA2G2A|PPARG|PPARA|PTGDR2|SLC46A1|GLO1	ChEMBL|https://www.drugbank.ca/drugs/DB00328|ChEMBL|https://www.drugbank.ca/drugs/DB00328|https://www.drugbank.ca/drugs/DB00328|https://www.drugbank.ca/drugs/DB00328|https://www.drugbank.ca/drugs/DB00328|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1909|https://www.drugbank.ca/drugs/DB00328	cyclooxygenase inhibitor	rheumatology|rheumatology|rheumatology|rheumatology|orthopedics	rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|bursitis|tendinitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12f62bae-5fc0-4f8d-a8b4-446524bd53d1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12f62bae-5fc0-4f8d-a8b4-446524bd53d1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12f62bae-5fc0-4f8d-a8b4-446524bd53d1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12f62bae-5fc0-4f8d-a8b4-446524bd53d1|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12f62bae-5fc0-4f8d-a8b4-446524bd53d1
clofazimine	clofazimine	G 30320|G-30320|lamprene	CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1	Launched	FDA Orange Book: clofazimine			GK0582 inhibitor	infectious disease	leprosy	http://www.drugs.com/cons/clofazimine.html
SPP301	SPP301		COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00120328	EDNRA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8260	endothelin receptor antagonist			
RAF265	RAF265	CHIR-265|NVP-RAF265|RAF-265	Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00304525	PDGFRB|BRAF|RAF1|KIT|KDR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=409804|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5674|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=409804|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=409804|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=409804	RAF inhibitor|VEGFR inhibitor			
repaglinide	repaglinide	AG-EE 623 ZW|AGEE-623ZW|prandin	CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O	Launched	FDA Orange Book: repaglinide	INS|KCNJ11|PPARG|ABCC8|CYP3A5|CYP2C8	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=178930|ChEMBL|https://www.drugbank.ca/drugs/DB00912|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=178930|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=178930	insulin secretagogue	endocrinology	diabetes mellitus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68064989-47ea-4ed5-a20e-43c4ef6ec271
acesulfame-potassium	acesulfame-potassium	acesulfame	CC1=CC(=O)NS(=O)(=O)O1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00796354						
flumethasone-pivalate	flumethasone pivalate		C[C@@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C	Launched	FDA Orange Book: flumethasone pivalate	SERPINA6|NR3C1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000814|https://www.drugbank.ca/drugs/DB00663	glucocorticoid receptor agonist			
vardenafil	vardenafil	levitra|staxyn	CCCc1nc(C)c2n1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1	Launched	FDA Orange Book: vardenafil hydrochloride	CYP2C19|PDE6G|PDE6H|PDE5A|CYP3A5|CYP2C8	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=276900|https://www.drugbank.ca/drugs/DB00862|https://www.drugbank.ca/drugs/DB00862|https://www.drugbank.ca/drugs/DB00862|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=276900|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=276900	phosphodiesterase inhibitor	urology	erectile dysfunction	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a01def95-c0ef-43b9-bd9e-5565b2385ad3
G-15	G-15		Brc1cc2OCOc2cc1[C@H]1Nc2ccccc2[C@H]2C=CC[C@@H]12.Brc1cc2OCOc2cc1[C@@H]1Nc2ccccc2[C@@H]2C=CC[C@H]12	Preclinical		GPER1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3320	estrogen receptor antagonist			
furegrelate	furegrelate		OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1	Phase 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401873/	TBXAS1	https://www.ncbi.nlm.nih.gov/pubmed/22837860	thromboxane synthase inhibitor			
anthralin	anthralin	anthra-derm|dithranol|drithocreme|drithoscalp|lasan	Oc1cccc2Cc3cccc(O)c3C(=O)c12	Launched	http://en.wikipedia.org/wiki/Dithranol			DNA synthesis inhibitor	dermatology	psoriasis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d624774-3618-423c-89bd-492f4795ad19
2-oxoglutaric-acid	2-oxoglutaric acid	2-Oxoglutarate|2-Oxopentanedioic Acid|Alpha-Ketoglutarate|alpha-ketoglutaric acid	OC(=O)CCC(=O)C(O)=O	Preclinical		OXGR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3636				
crenolanib	crenolanib	ARO-002|CP-868596	CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01229644	FLT3|CSF1R|PDGFRB|PDGFRA|KIT	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7882|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7882|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7882|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7882|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7882	PDGFR tyrosine kinase receptor inhibitor			
zanamivir	zanamivir	GG167|GR 121167X|GR-121167|relenza	CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O	Launched	FDA Orange Book: zanamivir	NEU2	https://www.drugbank.ca/drugs/DB00558	neuraminidase inhibitor	infectious disease	influenza A virus infection	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12ff22f6-20b5-4fa8-9028-58f87e169ff5
threo-2-methylisocitrate-(DL)	threo-2-methylisocitrate-(DL)	DL-threo-2-methylisocitrate	CC(O)([C@@H](CC(O)=O)C(O)=O)C(O)=O.CC(O)([C@H](CC(O)=O)C(O)=O)C(O)=O	Preclinical				isocitrate lyase substrate			
GYKI-52466	GYKI-52466		CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1	Preclinical		GRIA4|GRIA1|GRIA3|GRIA2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4210|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4210|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4210|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4210	glutamate receptor antagonist			
sangivamycin	sangivamycin		NC(=O)c1cn(C2OC(CO)[C@H](O)[C@@H]2O)c2ncnc(N)c12	Phase 1	http://deepblue.lib.umich.edu/bitstream/handle/2027.42/31387/0000?sequence=1			DNA inhibitor			
JW-55	JW-55		COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1	Preclinical		TNKS2|TNKS	https://www.tocris.com/products/jw-55_4514|https://www.tocris.com/products/jw-55_4514	tankyrase inhibitor			
BMS-566419	BMS-566419		CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F	Preclinical		IMPDH2|IMPDH1	https://www.tocris.com/products/bms-566419_5492|https://www.tocris.com/products/bms-566419_5492	inosine monophosphate dehydrogenase inhibitor			
apafant	apafant	WEB 2086 BS|WEB-2086	Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl	Phase 3	Pharmaprojects	PTAFR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1860	platelet activating factor receptor antagonist			
DPC-681	DPC-681		CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNCc1cccc(F)c1)C(C)(C)C)S(=O)(=O)c1cccc(N)c1	Phase 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90777/			HIV protease inhibitor			
alanine	alanine	E639|l-alanine	CC(N)C(O)=O	Launched	http://www.drugs.com/alanine.html	AARS2|GPRC6A|PHYKPL|NFS1|SLC36A1|AARS|GPT2|KYNU|SLC1A4|AGXT|GPT|AGXT2|ABAT|SLC7A8	https://www.drugbank.ca/drugs/DB00160|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=720|https://www.drugbank.ca/drugs/DB00160|https://www.drugbank.ca/drugs/DB00160|https://www.drugbank.ca/drugs/DB00160|https://www.drugbank.ca/drugs/DB00160|https://www.drugbank.ca/drugs/DB00160|https://www.drugbank.ca/drugs/DB00160|https://www.drugbank.ca/drugs/DB00160|https://www.drugbank.ca/drugs/DB00160|https://www.drugbank.ca/drugs/DB00160|https://www.drugbank.ca/drugs/DB00160|https://www.drugbank.ca/drugs/DB00160|https://www.drugbank.ca/drugs/DB00160				
diftalone	diftalone	L-5418	O=C1N2Cc3ccccc3C(=O)N2Cc2ccccc12	Launched	Pharmaprojects			cyclooxygenase inhibitor	endocrinology	thyroiditis	https://www.ncbi.nlm.nih.gov/pubmed/913862
kuromanin	kuromanin		OC[C@H]1O[C@@H](Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical		CD38|INS	https://www.caymanchem.com/product/16406|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=392793	ribosyl cyclase inhibitor			
cloprostenol-(+/-)	(+/-)-cloprostenol		O[C@@H](COc1cccc(Cl)c1)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O	Launched				prostaglandin receptor agonist			
mepivacaine	mepivacaine	Polocaine|Polocaine-Mpf|carbocaine|isocaine hydrochloride|scandonest plain	CN1CCCCC1C(=O)Nc1c(C)cccc1C	Launched	FDA Orange Book: mepivacaine hydrochloride	SCN10A|SCN9A	https://www.drugbank.ca/drugs/DB00961|https://citeline.informa.com/?query=#/drugs/details/27324	potassium channel blocker|sodium channel blocker	neurology/psychiatry	local anesthetic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92e262ff-9c22-4aca-48b3-a753487d5d21
1-phenylbiguanide	1-phenylbiguanide	N-Phenylimidodicarbonimidic Diamide|Phenyl Biguanide	NC(=N)NC(=N)Nc1ccccc1	Preclinical		HTR3A|HTR3B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2284|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2284	serotonin receptor agonist			
tripelennamine	tripelennamine	pbz|pbz-sr	CN(C)CCN(Cc1ccccc1)c1ccccn1	Launched	FDA Orange Book: tripelennamine citrate, tripelennamine hydrochloride	HRH1	https://www.drugbank.ca/drugs/DB00792	histamine receptor antagonist	pulmonary|allergy|allergy	asthma|allergic rhinitis|urticaria	https://en.wikipedia.org/wiki/Tripelennamine|https://en.wikipedia.org/wiki/Tripelennamine|https://en.wikipedia.org/wiki/Tripelennamine
orotic-acid	orotic acid	orotic acid	OC(=O)c1cc(=O)[nH]c(=O)[nH]1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01620268	DHODH	https://www.drugbank.ca/drugs/DB02262				
secoisolariciresinol-(-)	(-)-secoisolariciresinol	(-)-secoisolariciresinol	COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O	Preclinical							
F351	F351		Cc1ccc(=O)n(c1)-c1ccc(O)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02499562	TGFB1	http://www.gnipharma.com/english/rd/product/f351.shtml	TGF beta receptor inhibitor			
levocarnitine-propionate	levocarnitine propionate	levocarnitine propionate	CCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C	Launched	https://www.drugs.com/international/levocarnitine.html	CRAT	https://www.caymanchem.com/product/9001873	carnitine palmitoyltransferase inhibitor	neurology/psychiatry|endocrinology	peripheral neuropathy|carnitine deficiency	https://www.drugs.com/international/levocarnitine.html|https://www.drugs.com/international/levocarnitine.html
GW-4064	GW-4064		CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl	Preclinical		NR1H4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2743	FXR agonist			
creatine	creatine		CN(CC(O)=O)C(N)=N	Launched	http://www.drugs.com/Creatine.html	GAMT|CKM|CKB|CKMT1A|SLC6A8|CKMT2	https://www.drugbank.ca/drugs/DB00148|https://www.drugbank.ca/drugs/DB00148|https://www.drugbank.ca/drugs/DB00148|https://www.drugbank.ca/drugs/DB00148|https://www.drugbank.ca/drugs/DB00148|https://www.drugbank.ca/drugs/DB00148				
fidaxomicin	fidaxomicin	dificid	CC[C@H]1\C=C(C)/[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)c3c(O)c(Cl)c(O)c(Cl)c3CC)[C@H](O)[C@@H]2OC)\C(=O)O[C@H](C\C=C(C)\C=C(C)[C@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@H]1O)[C@@H](C)O	Launched	FDA Orange Book: fidaxomicin			RNA polymerase inhibitor	gastroenterology	diarrhea	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd966338-c820-4270-b704-09ef75fa3ceb
ramosetron	ramosetron		Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12	Launched	http://www.drugs.com/international/ramosetron.html	HTR3A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2301	serotonin receptor antagonist	gastroenterology|gastroenterology|gastroenterology	nausea|vomiting|irritable bowel syndrome	https://en.wikipedia.org/wiki/Ramosetron|https://en.wikipedia.org/wiki/Ramosetron|https://en.wikipedia.org/wiki/Ramosetron
nafamostat	nafamostat		NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N	Launched	http://www.drugs.com/international/Nafamostat.html	C1R|TPSAB1|TRPM7|ASIC3|ASIC2|ASIC1|PRSS1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262	serine protease inhibitor			
BMS-345541	BMS-345541		Cc1cnc2c(NCCN)nc3ccc(C)cc3n12	Preclinical		CHUK|IKBKB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5669|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5669	IKK inhibitor			
menbutone	menbutone	SC 1749 [AS SODIUM SALT]|methonaphthone	COc1ccc(C(=O)CCC(O)=O)c2ccccc12	Launched	http://www.drugs.com/international/menbutone.html				gastroenterology	bile stimulation	http://www.drugs.com/international/menbutone.html
O-1918	O-1918		COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C	Preclinical				cannabinoid receptor antagonist			
MC-1	MC-1	pyridoxal phosphate	Cc1ncc(COP(O)(O)=O)c(C=O)c1O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00402506	PROSC|GCAT|THNSL1|PHYKPL|GLDC|PDXDC1|PDXP|KYNU|ODC1|MOCOS|GPT2|ALAS1|BCAT2|BCAT1|GOT2|GOT1|SHMT2|SHMT1|SPTLC3|SPTLC2|SPTLC1|CBS|CTH|NFS1|AZIN2|ABAT|PNPO|PSAT1|AGXT2|DDC|GPT|FTCD|AADAT|IGSF10|HDC|SEPSECS|GADL1|SGPL1|CCBL2|CCBL1|AGXT|PYGB|PYGL|PYGM|CSAD|OAT|GAD2|GAD1|TAT|SDSL|SDS|SCLY|SRR	https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114|https://www.drugbank.ca/drugs/DB00114				
BAY-K-8644-(s)-(-)	(-)-BAY-K-8644-(s)		COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O	Preclinical		CACNA1C	http://www.tocris.com/dispprod.php?ItemId=5180	L-type calcium channel activator			
thioproperazine	thioproperazine		CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1	Launched	http://www.drugs.com/international/Thioproperazine.html	DRD1|DRD2|HTR2A|HTR1A|ADRA1B|ADRA1A	https://www.drugbank.ca/drugs/DB01622|https://www.drugbank.ca/drugs/DB01622|https://www.drugbank.ca/drugs/DB01622|https://www.drugbank.ca/drugs/DB01622|https://www.drugbank.ca/drugs/DB01622|https://www.drugbank.ca/drugs/DB01622	dopamine receptor antagonist	neurology/psychiatry	schizophrenia	http://www.drugbank.ca/drugs/DB01622
topiramate	topiramate	MCN-4853|RWJ-17021|qudexy xr|topamax|topamax sprinkle|trokendi xr	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	Launched	FDA Orange Book: topiramate	SCN5A|SCN9A|SCN8A|SCN7A|SCN2A|SCN1A|SCN4A|SCN3A|GRIK2|GRIK3|GRIK1|GRIK4|GRIK5|GRIA4|GRIA2|GRIA3|GRIA1|GABRG2|GABRG3|GABRG1|GABRA6|GABRA1|GABRA4|GABRA5|GABRA2|GABRA3|GABRB1|GABRB2|GABRB3|CYP2C19|SCN11A|SCN10A|CA1|CA2|CA4|CA7|CA12|CYP3A4|GABRE|GABRD|GABRP|GABRQ	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=105605|ChEMBL|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6849|ChEMBL|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6849|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6849|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=105605|ChEMBL|ChEMBL|ChEMBL|ChEMBL	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	neurology/psychiatry|neurology/psychiatry	epilepsy|migraine headache	http://www.webmd.com/drugs/2/drug-14494-6019/topamax-oral/topiramate-oral/details|http://www.webmd.com/drugs/2/drug-14494-6019/topamax-oral/topiramate-oral/details
ETC-1002	ETC-1002	ESP-55016|bempedoic acid	CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02666664	ACLY	http://www.apexbt.com/etc-1002.html?gclid=CPjJ5peirc8CFQpehgodnXEE2A	AMPK inhibitor			
AMN-082	AMN-082		C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1	Preclinical		GRM7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1441	glutamate receptor modulator			
AGN-192403	AGN-192403		CC(C)[C@@H]1C2CCC(C2)[C@H]1N	Preclinical		NISCH	http://www.scbt.com/datasheet-203501-agn-192403-hydrochloride.html	imidazoline receptor ligand			
lasalocid	lasalocid		CC[C@H](C1OC(CC)(C[C@@H]1C)C1CC[C@](O)(CC)[C@H](C)O1)C(=O)C(C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O	Veterinary Launched	http://www.drugs.com/international/lasalocid.html			bacterial permeability inducer	infectious disease	coccidiosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2f30e27-2627-4e5e-a3fd-6e6f633329e7
pentoxifylline	pentoxifylline	BL 191|BL-191|oxpentifylline|pentoxil|trental	CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O	Launched	FDA Orange Book: pentoxifylline	PDE10A|ACHE|ADORA1|CHIA|ADRA2B|TNF|NT5E|ADORA2A|ADORA2B|PDE1A|PDE1B|PDE1C|PDE5A|PDE4A|PDE4D|PDE4B|PDE4C|PDE3A|PDE3B|PDE2A|PDE9A|PDE8A|PDE8B|PDE7A|PDE7B|PDE6B|PDE6C|PDE6A|PDE6G|PDE6D|PDE6H	ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=143975|https://www.drugbank.ca/drugs/DB00806|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=143975|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7095|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000048|https://www.drugbank.ca/drugs/DB00806|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	phosphodiesterase inhibitor	cardiology	claudication	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40ae2d9a-0d95-640d-0640-f76e7e1a13cb
cabozantinib	cabozantinib	BMS-907351|XL-184|cabometyx|cometriq	COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC	Launched	FDA Orange Book: cabozantinib s-malate	MET|KDR|KIT|TEK|RET|CYP2C19|FLT3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5887|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5887|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=379934|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=379934|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=379934|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=379934|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=379934	RET tyrosine kinase inhibitor|VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a0c3bea-c87b-4d25-bb44-5f0174da6b34
EPZ020411	EPZ020411		CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1	Preclinical		PRMT6	https://www.medchemexpress.com/EPZ020411.html	protein arginine N-methyltransferase inhibitor			
GKA-50	GKA-50		COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O	Preclinical		GCK	https://www.tocris.com/products/gka-50_5133	glucokinase activator			
tepoxalin	tepoxalin	ORF 20485|RWJ 20485	COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1	Veterinary Launched	http://www.drugs.com/international/tepoxalin.html	ALOX5	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001423	cyclooxygenase inhibitor|lipoxygenase inhibitor	rheumatology|orthopedics	rheumatoid arthritis|hip dysplasia	https://en.wikipedia.org/wiki/Tepoxalin|https://en.wikipedia.org/wiki/Tepoxalin
AGN-195183	AGN-195183		CC1(C)CCC(C)(C)c2c(Cl)c(O)c(cc12)C(=O)Nc1cc(F)c(C(O)=O)c(F)c1	Phase 1/Phase 2	https://www.medchemexpress.com/agn-195183.html	RARA	https://medchemexpress.com/AGN-195183.html	retinoid receptor agonist			
stetaderm	stetaderm	RP-49356	CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@H](O)C[C@]12C	Launched	Pharmaprojects	AR	https://citeline.informa.com/?query=#/drugs/details/16735				
eterobarb	eterobarb	EX 12-095|RMI 16,238|antilon	CCC1(C(=O)N(COC)C(=O)N(COC)C1=O)c1ccccc1	Phase 2	http://www.neurology.org/content/25/5/399			anticonvulsant			
chloroxylenol	chloroxylenol		Cc1cc(O)cc(C)c1Cl	Launched	http://www.drugs.com/international/chloroxylenol.html			ATP synthase inhibitor	infectious disease	skin infections	http://www.rxwiki.com/chloroxylenol
terpene	terpene	terpin	CC(C)(O)C1CCC(C)(O)CC1	Preclinical							
morantel	morantel		CN1CCCN=C1\C=C\c1sccc1C	Veterinary Launched	http://www.drugs.com/international/morantel.html			acetylcholine receptor agonist	infectious disease	tapeworm	http://www.drugs.com/pro/rumatel.html
octodrine	octodrine	SK&F 51	CC(C)CCCC(C)N	Preclinical				antitumor agent			
diazoxide	diazoxide	Eudimine|Mutabase|SCH 6783|SCH-6783|SRG 95213|SRG-95213|hyperstat|proglycem	CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1	Launched	FDA Orange Book: diazoxide	KCNJ8|CA2|CA1|KCNJ11|SLC12A3|KCNMA1|ATP1A1	ChEMBL|https://www.drugbank.ca/drugs/DB01119|https://www.drugbank.ca/drugs/DB01119|ChEMBL|https://www.drugbank.ca/drugs/DB01119|https://www.drugbank.ca/drugs/DB01119|https://www.drugbank.ca/drugs/DB01119	potassium channel activator	endocrinology	hypoglycemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b16c7832-2fd9-49af-b923-1dc0d91fd6e2
MI-14	MI-14		CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)nc2c(NCCNC(C)=O)cc(Cl)nn12	Preclinical		PI4KB	https://www.tocris.com/products/mi-14_5604	PI4K inhibitor			
YM-155	YM-155	sepantronium	COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00818480	BIRC5	http://www.selleckchem.com/products/YM155.html?gclid=CKmSxZ3-lLwCFcVFMgodbysAWA	survivin inhibitor			
benzoxiquine	benzoxiquine	dioxyline|oxyquinoline benzoate	O=C(Oc1cccc2cccnc12)c1ccccc1	Preclinical				antiinfective drug			
PQ-401	PQ-401	TCMDC-125497	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12	Preclinical		IGF1R	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5048	IGF-1 inhibitor			
AKBA	AKBA		C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C	Phase 3	https://www.ncbi.nlm.nih.gov/pubmed/18667054	ALOX5	http://www.antibodies-online.com/abstract/Arachidonate+5-Lipoxygenase+(ALOX5)+Antibody/	lipoxygenase inhibitor			
VLX-600	VLX-600		Cc1cccc2c1[nH]c1nc(NNC(=C)c3ccccn3)nnc21	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02222363	TP53	https://www.caymanchem.com/product/17192	antitumor agent			
cefdinir	cefdinir	CI-983|Cefzon|FK 482|FK-482|omnicef	Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O	Launched	FDA Orange Book: cefdinir	MPO	https://www.drugbank.ca/drugs/DB00535	bacterial cell wall synthesis inhibitor	infectious disease|otolaryngology|otolaryngology|pulmonary|infectious disease|otolaryngology|otolaryngology	pneumonia|tonsillitis|pharyngitis|bronchitis|skin infections|otitis|sinusitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb7366ce-1778-451f-aba5-65cf73c9b87a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb7366ce-1778-451f-aba5-65cf73c9b87a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb7366ce-1778-451f-aba5-65cf73c9b87a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb7366ce-1778-451f-aba5-65cf73c9b87a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb7366ce-1778-451f-aba5-65cf73c9b87a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb7366ce-1778-451f-aba5-65cf73c9b87a|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb7366ce-1778-451f-aba5-65cf73c9b87a
MDL-29951	MDL-29951		OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O	Preclinical		FBP1|GPR17	https://www.drugbank.ca/drugs/DB04175|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=169679	glutamate receptor antagonist			
potassium-p-aminobenzoate	potassium-p-aminobenzoate	4-Aminobenzoic Acid|PABA|Paraminobenzoic Acid|Vitamin Bx|aminobenzoic acid|para-aminobenzoic acid|rvpaba lipstick	Nc1ccc(cc1)C(O)=O	Launched	http://www.drugs.com/mmx/potassium-para-aminobenzoate.html				rheumatology|rheumatology|urology	scleroderma|dermatomyositis|Peyronie's disease	http://www.medicinenet.com/potassium_para-aminobenzoate-oral/article.htm|http://www.medicinenet.com/potassium_para-aminobenzoate-oral/article.htm|http://www.medicinenet.com/potassium_para-aminobenzoate-oral/article.htm
N-hydroxynicotinamide	N-hydroxynicotinamide	n-hydroxynicotinamide|nicoxamat	ONC(=O)c1cccnc1	Preclinical							
moprolol	moprolol		COc1ccccc1OCC(O)CNC(C)C	Launched	http://en.wikipedia.org/wiki/Levomoprolol			adrenergic receptor antagonist	cardiology|ophthalmology|neurology/psychiatry	hypertension|glaucoma|anxiety	https://en.wikipedia.org/wiki/Moprolol|https://en.wikipedia.org/wiki/Moprolol|https://en.wikipedia.org/wiki/Moprolol
glycitein	glycitein		COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01463436	IL1B|TNF|APP	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=321627|http://womenhealth-phytochemicals.blogspot.com/2011/12/phytochemicals-in-foods-13-health_01.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=321627	tumor necrosis factor release inhibitor			
TC-I-2000	TC-I-2000		Fc1ccc(NC(=O)N2CCc3ccccc3C2c2ccc(cc2)C(F)(F)F)cc1	Preclinical		TRPM8	https://www.tocris.com/products/tc-i-2000_4632	transient receptor potential channel antagonist			
ASP-2535	ASP-2535		CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12	Phase 1	https://www.researchgate.net/publication/224866438_A_novel_glycine_transporter-1_GlyT1_inhibitor_ASP2535_4-3-isopropyl-5-6-phenyl-3-pyridyl-4H-124-triazol-4-yl-213-benzoxadiazole_improves_cognition_in_animal_models_of_cognitive_impairment_in_schizophr	SLC6A9	https://www.tocris.com/dispprod.php?ItemId=429197#.V-FkJJMrKYU	glycine transporter inhibitor			
brinzolamide	brinzolamide	AL-4862|azopt	CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O	Launched	FDA Orange Book: brinzolamide	CYP2B6|CYP2C8|CA1|CA2|CA4|CA7|CA5A|CA14|CA12	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=256930|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=256930|https://www.drugbank.ca/drugs/DB01194|ChEMBL|https://www.drugbank.ca/drugs/DB01194|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6797|https://www.drugbank.ca/drugs/DB01194|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6797|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6797	carbonic anhydrase inhibitor	ophthalmology|ophthalmology|ophthalmology	intraocular pressure|glaucoma|ocular hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9ea2ae7-1b98-4034-9fba-8ce2225e0145|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9ea2ae7-1b98-4034-9fba-8ce2225e0145|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9ea2ae7-1b98-4034-9fba-8ce2225e0145
K02288	K02288		COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1	Preclinical		BMP1|LCK|PTK6|MAP4K4|ACVR1|ABL1|ABL2|ACVRL1|BMPR1A|HCK	http://www.tocris.com/dispprod.php?ItemId=387191#.VgLdbNNViko|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=825638|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=825638|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=825638|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=825638|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=825638|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=825638|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=825638|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=825638|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=825638	bone morphogenic protein inhibitor			
PRT062070	PRT062070		CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01994382	SYK	https://ash.confex.com/ash/2015/webprogram/Paper84721.html	JAK inhibitor|syk inhibitor			
dimethyl-fumarate	dimethyl fumarate	AZL 0 211089|dimethyl fumarate|tecfidera	COC(=O)\C=C\C(=O)OC	Launched	FDA Orange Book: dimethyl fumarate	KEAP1|NFE2L2	ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=306774	nuclear factor erythroid derived|like (NRF2) activator	neurology/psychiatry	multiple sclerosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151
ICA-121431	ICA-121431		O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1	Preclinical		SCN3A|SCN1A	https://www.tocris.com/products/ica-121431_5066|https://www.tocris.com/products/ica-121431_5066	sodium channel blocker			
amprenavir	amprenavir	141 W94|141W94|KVX-478|VX-478|agenerase	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	Launched	FDA Orange Book: amprenavir, fosamprenavir calcium			HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://en.wikipedia.org/wiki/Amprenavir
CFM-2	CFM-2		COc1cc2CC(=O)NN=C(c3ccc(N)cc3)c2cc1OC	Preclinical				glutamate receptor antagonist			
KS-176	KS-176		OCCc1ccc(NC(=O)c2ccccc2NC(=O)c2ccc(cc2)[N+]([O-])=O)cc1	Preclinical		ABCG2	https://www.tocris.com/products/ks-176_4169	BCRP inhibitor			
WZ-4002	WZ-4002		COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1	Preclinical		ERBB2|EGFR	http://www.selleckchem.com/products/WZ4002.html|http://www.selleckchem.com/products/WZ4002.html	EGFR inhibitor			
uridine-5'-triphosphate	uridine-5'-triphosphate	UTP|Uridine triphosphate	O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O	Launched	https://www.drugs.com/international/uridine-5-triphosphate.html	P2RY6|P2RY4|P2RY2|P2RY11|UCK2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1734|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1734|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1734|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1734|https://www.drugbank.ca/drugs/DB04005	purinergic receptor activator			
iodoquinol	iodoquinol	Amebaquin|Floraquin|diiodohydroxyquin|diiodohydroxyquinoline|ioquin|quinadome|yodoxin	Oc1c(I)cc(I)c2cccnc12	Launched	http://www.drugs.com/international/iodoquinol.html			antiseptic	infectious disease	amebiasis	https://en.wikipedia.org/wiki/Diiodohydroxyquinoline
tasuldine	tasuldine		C(Sc1ncccn1)c1cccnc1	Phase 3	Pharmaprojects			mucolytic agent			
ethopabate	ethopabate		CCOc1cc(NC(C)=O)ccc1C(=O)OC	Veterinary Launched	http://www.drugs.com/international/ethopabate.html			antiprotozoal agent	infectious disease	coccidiosis	https://en.wikipedia.org/wiki/Ethopabate
PD-81723	PD-81723	PD81723	Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C	Preclinical		ADORA1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004139	adenosine receptor agonist			
salvianolic-acid-B	salvianolic-acid-B		OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/12174378	MMP9|APP	http://www.sigmaaldrich.com/catalog/product/sigma/sml0048?lang=en&region=US|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=291310	metalloproteinase inhibitor|EGFR inhibitor			
pirenzepine	pirenzepine	Gastrozepin	CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1	Launched	http://www.drugs.com/international/pirenzepine.html	CHRM4|CHRM5|CHRM2|CHRM3|CHRM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=328|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=328|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=328|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=328|https://www.drugbank.ca/drugs/DB00670	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)	https://en.wikipedia.org/wiki/Pirenzepine
APC-100	APC-100		Cc1c(C)c2OC(C)(C)CCc2c(C)c1O	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT01436214	AR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001148	anti-inflammatory agent|androgen receptor antagonist			
latrepirdine	latrepirdine		CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00954590	GRIN2B|HRH1|HTR6	https://citeline.informa.com/?query=#/drugs/details/34470|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010278|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010278	glutamate receptor antagonist			
A0001	A0001	Alpha-Tocopherylquinone	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01035671						
solithromycin	solithromycin		CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(nn3)-c3cccc(N)c3)C(=O)O[C@]12C)OC	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01756339			protein synthesis inhibitor			
AMG-487-(+/-)	(+/-)-AMG-487		CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)C(C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Phase 2				CC chemokine receptor antagonist			
ICI-199441	ICI-199441	ICI-199,441	CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1	Preclinical		CYP2D6|OPRM1|OPRK1|OPRD1|UTS2R	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004906|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004906|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004906|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004906|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004906	opioid receptor agonist			
AR-C155858	AR-C155858		CC(C)Cn1c2sc(Cc3c(C)n[nH]c3C)c(C(=O)N3C[C@H](O)CO3)c2c(=O)n(C)c1=O	Preclinical		SLC16A7|SLC16A1	https://www.tocris.com/dispprod.php?ItemId=384713#.V-FcP5MrKYU|https://www.tocris.com/dispprod.php?ItemId=384713#.V-FcP5MrKYU	monocarboxylate transporter inhibitor			
sulfaquinoxaline	sulfaquinoxaline		Nc1ccc(cc1)S(=O)(=O)Nc1cnc2ccccc2n1	Veterinary Launched	http://www.drugs.com/international/sulfaquinoxaline.html			vitamin K antagonist	infectious disease	coccidiosis	https://en.wikipedia.org/wiki/Sulfaquinoxaline
fosinopril	fosinopril	fosinopril sodium|monopril	CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C	Launched	FDA Orange Book: fosinopril sodium	ABCG2|ACE	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=105657|https://www.drugbank.ca/drugs/DB00492	angiotensin converting enzyme inhibitor	cardiology|cardiology	hypertension|congestive heart failure	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eaa753e8-9fda-af0b-9d54-bdf0d1674832|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eaa753e8-9fda-af0b-9d54-bdf0d1674832
vipadenant	vipadenant	BIIB014|V2006	Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N	Phase 1	http://www.medkoo.com/products/8047	ADORA2B|ADORA2A|ADORA3|ADORA1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5612|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5612|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5612|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5612	adenosine receptor antagonist			
etoposide	etoposide	Toposar|VP-16-213|etopophos preservative free|vepesid	COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12	Launched	FDA Orange Book: etoposide, etoposide phosphate	TOP2A|TOP2B|CYP3A5|CYP2E1	ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090999|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090999	topoisomerase inhibitor	oncology	non-small cell lung cancer (NSCLC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=508a418e-985f-4208-9324-2230655bb5c2
anisomycin	anisomycin	Flagecidin|GNF-Pf-4549|TCMDC-125504	COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1	Preclinical		RPL37|RPL11|RPL15|RPL19|RPL23|RPL23A|RPL3|RPL8|RPL13A|RPL10L|RPL26L1|RSL24D1|NHP2L1	https://www.drugbank.ca/drugs/DB07374|https://www.drugbank.ca/drugs/DB07374|https://www.drugbank.ca/drugs/DB07374|https://www.drugbank.ca/drugs/DB07374|https://www.drugbank.ca/drugs/DB07374|https://www.drugbank.ca/drugs/DB07374|https://www.drugbank.ca/drugs/DB07374|https://www.drugbank.ca/drugs/DB07374|https://www.drugbank.ca/drugs/DB07374|https://www.drugbank.ca/drugs/DB07374|https://www.drugbank.ca/drugs/DB07374|https://www.drugbank.ca/drugs/DB07374|https://www.drugbank.ca/drugs/DB07374	DNA synthesis inhibitor			
procyanidin-b-2	procyanidin-b-2	Procyanidin B1	O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/19659873						
CGS-20625	CGS-20625		COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/8576841	GABRA3|GABRA4|GABRA5|GABRA6|GABRA1|GABRA2	https://www.tocris.com/dispprod.php?ItemId=154449#.Vye632QrImI|https://www.tocris.com/dispprod.php?ItemId=154449#.Vye632QrImI|https://www.tocris.com/dispprod.php?ItemId=154449#.Vye632QrImI|https://www.tocris.com/dispprod.php?ItemId=154449#.Vye632QrImI|https://www.tocris.com/dispprod.php?ItemId=154449#.Vye632QrImI|https://www.tocris.com/dispprod.php?ItemId=154449#.Vye632QrImI	benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist			
paeoniflorin	paeoniflorin		C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	Preclinical				anticonvulsant			
sodium-danshensu	sodium danshensu		OC(Cc1ccc(O)c(O)c1)C(O)=O	Preclinical							
etazolate	etazolate	EHT-0202|SQ-20009	CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00880412	PDE4A|GABRB3	http://www.tocris.com/dispprod.php?ItemId=1372#.UuWJnP30BaE|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7336	phosphodiesterase inhibitor			
elesclomol	elesclomol	STA-4783	CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00522834	TOP2A|HSPA1A	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=343476|http://www.selleckchem.com/products/Elesclomol.html	oxidative stress inducer			
CGP-37157	CGP-37157		Clc1ccc2NC(=O)CSC(c3ccccc3Cl)c2c1	Preclinical		SLC8A1	http://www.tocris.com/dispprod.php?ItemId=2169	mitochondrial Na+/Ca2+ exchanger antagonist|sodium/calcium exchange inhibitor			
fluoromethylcholine	fluoromethylcholine		C[N+](C)(CF)CCO	Launched	http://www.iason.eu/en/kernkompetenzen/pharmazeutische-kompetenz.html						
telenzepine	telenzepine		CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/2658396	CHRM1	https://www.tocris.com/dispprod.php?ItemId=2233#.Vyy2gGQrJZI	acetylcholine receptor antagonist			
K-MAP	K-MAP		OCC1OC(Nc2ccc(cc2)C(O)=O)C(O)C(O)C1O	Phase 2	Pharmaprojects						
NSC-625987	NSC-625987		COc1ccc(OC)c2c1[nH]c1ccccc1c2=S	Preclinical		CDK4|CDK2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5951|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5951	CDK inhibitor			
methylparaben	methylparaben	E218|Methyl Parasept|Methylhydroxybenzoate|Nipagin|Tegosept|methyl p-hydroxybenzoate|methyl parahydroxybenzoate	COC(=O)c1ccc(O)cc1	Launched	https://en.wikipedia.org/wiki/Methylparaben			other antifungal	dermatology	cosmetic	https://en.wikipedia.org/wiki/Methylparaben
BP-897	BP-897		COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1	Phase 2	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678839/|http://adisinsight.springer.com/drugs/800012397	DRD3|DRD2|DRD1|DRD4|HTR1A|HTR2B|ADRA1D|ADRA1A|ADRA2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7625|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005570|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005570|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005570|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005570|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005570|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005570|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005570|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005570	dopamine receptor agonist			
imeglimin	imeglimin		C[C@@H]1N=C(N)NC(=N1)N(C)C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01951235			gluconeogenesis inhibitor			
mephentermine	mephentermine	wyamine sulfate	CNC(C)(C)Cc1ccccc1	Launched	FDA Orange Book: mephentermine sulfate	ADRB3|ADRB1|ADRB2|ADRA1B|ADRA1A|ADRA1D|ADRA2C|ADRA2B|ADRA2A	https://www.drugbank.ca/drugs/DB01365|https://www.drugbank.ca/drugs/DB01365|https://www.drugbank.ca/drugs/DB01365|https://www.drugbank.ca/drugs/DB01365|https://www.drugbank.ca/drugs/DB01365|https://www.drugbank.ca/drugs/DB01365|https://www.drugbank.ca/drugs/DB01365|https://www.drugbank.ca/drugs/DB01365|https://www.drugbank.ca/drugs/DB01365	adrenergic receptor agonist	cardiology	hypotension	https://en.wikipedia.org/wiki/Mephentermine#Indication_.26_Dosage
MCC950	MCC950		CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12	Preclinical		NLRP3|IL1B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8228|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=775271	NOD like receptor inhibitor			
KI-8751	KI-8751		COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC	Preclinical		KDR	http://www.scbt.com/datasheet-203090-ki-8751.html	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor			
TY-52156	TY-52156		CC(C)(C)C(=O)C(\NNc1ccc(Cl)cc1)=N\c1ccc(Cl)cc1	Preclinical		S1PR3	https://www.tocris.com/dispprod.php?ItemId=431347#.V_LMH5MrLy8	sphingosine 1-phosphate receptor antagonist			
diclofenac	diclofenac	Arthrotec|Voltaren Ophthalmic|Voltaren XR|cambia|cataflam|diclofenac potassium|diclofenac sodium|dyloject|flector|pennsaid|solaraze|voltaren|voltaren-xr|zipsor|zorvolex	OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl	Launched	FDA Orange Book: diclofenac, diclofenac epolamine, diclofenac potassium, diclofenac sodium	ASIC3|ASIC1|ALOX5|PPARG|SCN4A|CYP2C8|AKR1C3|PLA2G2A|PTGS1|PTGS2|KCNQ2|KCNQ3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2714|https://www.drugbank.ca/drugs/DB00586|https://www.drugbank.ca/drugs/DB00586|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2714|https://www.drugbank.ca/drugs/DB00586|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091353|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005898|https://www.drugbank.ca/drugs/DB00586|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00586|https://www.drugbank.ca/drugs/DB00586	cyclooxygenase inhibitor	rheumatology|rheumatology|neurology/psychiatry	rheumatoid arthritis|osteoarthritis|migraine headache	http://www.drugs.com/diclofenac.html|http://www.drugs.com/diclofenac.html|http://www.drugs.com/diclofenac.html
SNG-1153	SNG-1153		CC(C)=CCc1c(O)cc(O)c2c1oc(-c1ccc(cc1)C(F)(F)F)c(O)c2=O	Preclinical		ESR1	http://www.dcchemicals.com/products_Show.asp?id=5715	selective estrogen receptor modulator (SERM)			
nilotinib	nilotinib	AMN 107|tasigna	Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F	Launched	FDA Orange Book: nilotinib hydrochloride monohydrate	PDGFRA|KIT|DDR1|DDR2|ABL1|CYP2B6|CYP2C8|BCR	https://citeline.informa.com/?query=#/drugs/details/32907|https://www.drugbank.ca/drugs/DB04868|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=386178|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=386178|https://www.drugbank.ca/drugs/DB04868|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=386178|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=386178|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=386178	Abl kinase inhibitor|Bcr-Abl kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6093952a-5248-45cb-ad17-33716a411146
ethosuximide	ethosuximide	CI-366|CN-10,395|CN-10395|PM-671|zarontin	CCC1(C)CC(=O)NC1=O	Launched	FDA Orange Book: ethosuximide	CACNA1I|CACNA1H|CACNA1G	ChEMBL|ChEMBL|ChEMBL	succinimide antiepileptic	neurology/psychiatry	epilepsy	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b61118d-1046-4510-b327-0f8d41acd156
enrofloxacin	enrofloxacin	BAY VP 2674|baytril	CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1	Veterinary Launched	http://www.drugs.com/international/Enrofloxacin.html			bacterial DNA gyrase inhibitor	infectious disease|infectious disease	gram-negative bacterial infections|gram-negative bacterial infections	https://en.wikipedia.org/wiki/Enrofloxacin|https://en.wikipedia.org/wiki/Enrofloxacin
HTH-01-015	HTH-01-015		CN1c2cc3ccccc3cc2C(=O)N(C)c2c(C)nc(Nc3cnn(c3)C3CCNCC3)nc12	Preclinical		NUAK1	https://www.tocris.com/products/hth-01-015_5622	protein kinase inhibitor			
BI-847325	BI-847325		CCNC(=O)C#Cc1ccc2c(NC(=O)\C2=C(\Nc2ccc(CN(C)C)cc2)c2ccccc2)c1	Phase 1	http://www.pharmacodia.com/yaodu/html/v1/chemicals/0378944aa0da95a0e9bf1edcf0f447ee.html	MAP2K2|MAP2K1|AURKC|AURKB|AURKA	http://www.selleckchem.com/products/bi-847325.html|http://www.selleckchem.com/products/bi-847325.html|http://www.selleckchem.com/products/bi-847325.html|http://www.selleckchem.com/products/bi-847325.html|http://www.selleckchem.com/products/bi-847325.html	MEK inhibitor|Aurora kinase inhibitor			
oxelaidin	oxelaidin	oxeladin|oxeladin citrate|oxeladin tannate	CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1	Launched	http://en.wikipedia.org/wiki/Oxeladin			antitussive	pulmonary	cough suppressant	https://en.wikipedia.org/wiki/Oxeladin#Indications
AG-556	AG-556		Oc1ccc(\C=C(/C#N)C(=O)NCCCCc2ccccc2)cc1O	Preclinical				tyrosine kinase inhibitor			
AG-555	AG-555		Oc1ccc(\C=C(/C#N)C(=O)NCCCc2ccccc2)cc1O	Preclinical		CDK2	http://www.abcam.com/ag-555-tyrphostin-b46-ab145877.html	tyrosine kinase inhibitor			
tibolone	tibolone		C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)C12	Launched	http://www.drugs.com/international/Tibolone.html	AR|ESR1|STS|PGR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=115398|http://en.wikipedia.org/wiki/Tibolone|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=115398|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=115398	androgen receptor agonist|estrogen receptor agonist|progesterone receptor agonist	obstetrics/gynecology	endometriosis	https://en.wikipedia.org/wiki/Tibolone
5-Amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione	5-Amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione		Nc1nc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(=O)sc2c(=O)[nH]1	Preclinical							
cilnidipine	cilnidipine		COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1	Launched	http://www.drugs.com/international/Cilnidipine.html	CACNA1C|CACNA1B	https://citeline.informa.com/?query=#/drugs/details/4637|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000288	calcium channel blocker	cardiology	hypertension	https://en.wikipedia.org/wiki/Cilnidipine#Medical_uses
chromanol-293B-(-)-[3R,4S]	chromanol-293B-(-)-[3R,4S]		CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N	Preclinical				potassium channel blocker			
bimatoprost	bimatoprost	latisse|lumigan	CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(O)CCc1ccccc1	Launched	FDA Orange Book: bimatoprost	PTGER3|PTGER1|AKR1C3|PTGFR	https://www.drugbank.ca/drugs/DB00905|https://www.drugbank.ca/drugs/DB00905|https://www.drugbank.ca/drugs/DB00905|https://www.drugbank.ca/drugs/DB00905	prostanoid receptor agonist	ophthalmology|ophthalmology|ophthalmology	intraocular pressure|glaucoma|ocular hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac853f64-50bd-4bff-9cbe-aac93ef5550f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac853f64-50bd-4bff-9cbe-aac93ef5550f|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac853f64-50bd-4bff-9cbe-aac93ef5550f
carmustine	carmustine	BCNU|bicnu|gliadel	[O-][N+]N(CCCl)C(=O)NCCCl	Launched	FDA Orange Book: carmustine	TXNRD2|TXNRD1|GSR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091365|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091365|ChEMBL	DNA alkylating agent|DNA inhibitor	hematologic malignancy|hematologic malignancy|hematologic malignancy|oncology|oncology|oncology|oncology|oncology	non-Hodgkin lymphoma (NHL)|Hodgkin's lymphoma|multiple myeloma|glioblastoma|brainstem glioma|medulloblastoma|astrocytoma|ependymoma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6cbb63c-e0b1-43ee-ad6f-408da0772079|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6cbb63c-e0b1-43ee-ad6f-408da0772079|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6cbb63c-e0b1-43ee-ad6f-408da0772079|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6cbb63c-e0b1-43ee-ad6f-408da0772079|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6cbb63c-e0b1-43ee-ad6f-408da0772079|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6cbb63c-e0b1-43ee-ad6f-408da0772079|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6cbb63c-e0b1-43ee-ad6f-408da0772079|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6cbb63c-e0b1-43ee-ad6f-408da0772079
ZAPA	ZAPA	3-Carbamimidoylsulfanyl-Acrylic Acid	NC(=N)S\C=C/C(O)=O	Preclinical							
scopolamine	scopolamine	transderm scop		Launched	FDA Orange Book: methscopolamine bromide, scopolamine	CHRM1|CHRM2|CHRM3|CHRM4	https://citeline.informa.com/?query=#/drugs/details/16927|https://citeline.informa.com/?query=#/drugs/details/16927|https://citeline.informa.com/?query=#/drugs/details/16927|https://citeline.informa.com/?query=#/drugs/details/16927	acetylcholine receptor antagonist	neurology/psychiatry|gastroenterology|gastroenterology	motion sickness|vomiting|nausea	https://en.wikipedia.org/wiki/Hyoscine_hydrobromide|https://en.wikipedia.org/wiki/Hyoscine_hydrobromide|https://en.wikipedia.org/wiki/Hyoscine_hydrobromide
telaprevir	telaprevir	MP-424|VRT-111950|VX-950|incivek	CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1	Launched	FDA Orange Book: telaprevir	CTSA|PGR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7871|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001419	HCV inhibitor	infectious disease	hepatitis C	https://en.wikipedia.org/wiki/Telaprevir
clocortolone-pivalate	clocortolone pivalate	SH 863|SH-863|clocortolone pivalate|cloderm	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C	Launched	FDA Orange Book: clocortolone pivalate	NR3C1|PLA2G1B	ChEMBL|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001190	steroid	dermatology	corticosteroid-responsive dermatoses	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1eae193c-5cfd-5db1-344a-c951e2c9eff8
AZD7687	AZD7687		Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01046357	DGAT1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7827	diacylglycerol O acyltransferase inhibitor			
m-Chlorophenylbiguanide	m-Chlorophenylbiguanide	3-Chloro-Phenyl Biguanide|M-Chlorophenylbiguanidine|N-(3-Chlorophenyl)Imidodicarbonimidic Diamide	NC(=N)NC(=N)Nc1cccc(Cl)c1	Preclinical		HTR3A|HTR3B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2287|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2287				
luteolin	luteolin	Digitoflavone|Flacitran|Luteoline|Luteolol	Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/23688534	GAA|MAOA|AKR1B1|TOP1|XDH	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=244028|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=244028|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=244028|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000896|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=244028	glucosidase inhibitor			
ethyl-pyruvate	ethyl-pyruvate	2-Oxo-Propionic Acid Ethyl Ester	CCOC(=O)C(C)=O	Phase 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891599/	HMGB1|TNF	https://www.drugbank.ca/drugs/DB05869|https://www.drugbank.ca/drugs/DB05869	tumor necrosis factor production inhibitor			
nortriptyline	nortriptyline	aventyl |aventyl hydrochloride|nortriptyline hydrochloride|pamelor	CNCCC=C1c2ccccc2CCc2ccccc12	Launched	FDA Orange Book: nortriptyline hydrochloride	ADRA2A|ADRA2B|ADRA2C|ADRA1D|ADRA1A|ADRA1B|HTR1A|HTR2A|HTR2C|HRH1|PGRMC1|HTR6|PIK3CD|CYP2C19|DRD2|KCNJ10|SLC6A2|SLC6A4|SIGMAR1|ADRB3|ADRB2|ADRB1|CHRM3|CHRM2|CHRM5|CHRM4|CHRM1	https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091435|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091435|https://www.drugbank.ca/drugs/DB00540|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2404|https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540|https://www.drugbank.ca/drugs/DB00540	tricyclic antidepressant	neurology/psychiatry	depression	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ced93eb0-e8b6-44b8-9d2c-e2afa92500f7
nitroxoline	nitroxoline	A-82|nitrohydroxyquinoline	Oc1ccc([N+]([O-])=O)c2cccnc12	Launched	http://www.drugs.com/international/nitroxoline.html	METAP2|METAP1|SIRT1|CTSB	https://www.drugbank.ca/drugs/DB01422|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=657491|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=657491|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=657491	cathepsin inhibitor	infectious disease	urinary tract infections	http://www.drugbank.ca/drugs/DB01422
TCS-OX2-29	TCS-OX2-29		COc1cc2CCN(Cc2cc1OC)C(=O)[C@@H](NCc1ccncc1)C(C)(C)C	Preclinical		HCRTR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4038	orexin receptor antagonist			
BAN-ORL-24	BAN-ORL-24		O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1	Preclinical		OPRL1	http://www.tocris.com/dispprod.php?ItemId=236281#.Ve8dWSxVhHw	nociceptin/orphanin FQ receptor antagonist			
gly-gln	gly-gln		NCC(=O)N[C@@H](CCC(N)=O)C(O)=O	Phase 2	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1513970/						
C11-Acetate	C11-Acetate		[Y+3]	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01777061	SOD1|AKR1C3|ABAT|CA2|ACE|NOS3|NOS1|HPRT1|FFAR3|FFAR2|PTPN1|ESR2|MMP12|TXN|PLA2G1B|LTA4H|CELA1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002498|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002498|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002498|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002498|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002498|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002498|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002498|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002498|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1058|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1058|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002498|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002498|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002498|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002498|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002498|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002498|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002498				
verubulin	verubulin	MX-128495	COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01285414	TUBB	http://www.genome.jp/dbget-bin/www_bget?dr:D10029	tubulin polymerization inhibitor			
eslicarbazepine-acetate	eslicarbazepine acetate	BIA 2-093|SEP - 0002093|aptiom|erelib|eslicarbazepine acetate|pazzul|stedesa	CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12	Launched	FDA Orange Book: eslicarbazepine acetate	CYP2C19|SCN10A|SCN11A|SCN9A|SCN8A|SCN7A|SCN5A|SCN4A|SCN3A|SCN2A|SCN1A|CYP3A4	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=278670|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=278670	sodium channel blocker	neurology/psychiatry	seizures	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3
avatrombopag	avatrombopag	E5501	OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1	Launched	FDA Orange Book: avatrombopag	MPL	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000686	thrombopoietin receptor agonist	hematology	thrombocytopenia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2d5960d-6c18-46cc-86bd-089222b09852
valganciclovir	valganciclovir	valcyte	CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c1nc(N)[nH]c2=O	Launched	FDA Orange Book: valganciclovir hydrochloride			DNA synthesis inhibitor	infectious disease	cytomegalovirus (CMV)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37b7a5d8-9a2c-40b1-a414-71ecc47e567d
amdinocillin	amdinocillin	coactin	CC1(C)S[C@@H]2[C@H](\N=C\N3CCCCCC3)C(=O)N2[C@H]1C(O)=O	Launched	FDA Orange Book: amdinocillin			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease	urinary tract infections|gram-negative bacterial infections	https://en.wikipedia.org/wiki/Mecillinam|https://en.wikipedia.org/wiki/Mecillinam
odanacatib	odanacatib	MK-0822	CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00729183	CTSK	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6478	cathepsin inhibitor			
SB-228357	SB-228357		COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F	Preclinical		HTR2B|HTR2C|HTR2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=192|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=192|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=192	serotonin receptor antagonist			
BIRT-377	BIRT-377		CN1C(=O)N(C(=O)[C@@]1(C)Cc1ccc(Br)cc1)c1cc(Cl)cc(Cl)c1	Preclinical		ICAM1	https://www.tocris.com/products/birt-377_4776	lymphocyte function-associated antigen negative modulator			
cilostamide	cilostamide		CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1	Preclinical		PDE3A|PDE3B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5167|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5167	phosphodiesterase inhibitor			
hexamethonium	hexamethonium		C[N+](C)(C)CCCCCC[N+](C)(C)C	Preclinical		CHRNA2|CHRNA4|CHRNA3|CHRNA6	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3963|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3963|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3963|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3963	cholinergic receptor antagonist			
BMS-536924	BMS-536924		Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1	Preclinical		INSR|IGF1R|ERBB2|AKT1|MET|LCK|KDR|CCNE1|PDGFRA|PDGFRB|MAPK1|CDK2|CYP3A4	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=394129|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005781|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005781|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005781|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005781|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005781|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005781|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005781|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005781|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005781|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005781|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005781|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005781	IGF-1 inhibitor			
LY2140023	LY2140023	LY-2140023|LY-404039|LY404039	N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01307800	GRM2|GRM3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=252861|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000159	glutamate receptor agonist			
3-MPPI	3-MPPI		COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1	Preclinical		ADRA1A	http://www.scbt.kr/datasheet-361078.html	adrenergic receptor ligand			
loxoprofen	loxoprofen	Loxomac|Loxonin|Oxeno|loxoprofen sodium	CC(C(O)=O)c1ccc(CC2CCCC2=O)cc1	Launched	http://www.drugs.com/international/loxoprofen.html	PTGS2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011270	cyclooxygenase inhibitor|prostanoid receptor antagonist	neurology/psychiatry	pain relief	http://www.drugs.com/international/loxoprofen.html
PD-123319	PD-123319	PD123319	CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/16470490	AGTR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=597	angiotensin antagonist			
ivosidenib	ivosidenib		Fc1cncc(c1)N([C@H](C(=O)NC1CC(F)(F)C1)c1ccccc1Cl)C(=O)[C@@H]1CCC(=O)N1c1cc(ccn1)C#N	Launched	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b6d8ae8-bac8-4e1b-b1b4-7f9665e62de5	IDH1	http://www.chemietek.com/ag-120--ivosidenib-details.aspx	isocitrate dehydrogenase inhibitor	hematologic malignancy	acute myeloid leukemia (AML)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b6d8ae8-bac8-4e1b-b1b4-7f9665e62de5
zatebradine	zatebradine		COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/9165168	HCN2|HCN1|HCN4|HCN3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2358|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2358|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2358|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2358	HCN channel blocker			
ABT-239	ABT-239		C[C@@H]1CCCN1CCc1cc2cc(ccc2o1)-c1ccc(cc1)C#N	Phase 1	http://media.corporate-ir.net/media_files/nys/abt/rdday/PharmDev.pdf	HRH1|HRH2|HRH3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1218|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1218|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1218	histamine receptor antagonist			
SN-38	SN-38	7-Ethyl-10-Hydroxy-Camptothecin	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12	Launched	http://en.wikipedia.org/wiki/SN-38	TOP1	https://www.drugbank.ca/drugs/DB05482	topoisomerase inhibitor	oncology	colorectal cancer	https://en.wikipedia.org/wiki/SN-38
FGIN-1-27	FGIN-1-27		CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1	Preclinical		TSPO	https://en.wikipedia.org/wiki/FGIN-127	inositol monophosphatase inhibitor			
chlorfenson	chlorfenson		Clc1ccc(OS(=O)(=O)c2ccc(Cl)cc2)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01180491			other antifungal			
ochromycinone	ochromycinone		C[C@@H]1CC(=O)c2c(C1)ccc1C(=O)c3c(O)cccc3C(=O)c21	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/20811392	STAT3	www.abcam.com/STA-21-Ochromycinone-ab145648.pdf	STAT inhibitor			
5,7-dichlorokynurenic-acid	5,7-dichlorokynurenic acid		OC(=O)c1cc(O)c2c(Cl)cc(Cl)cc2n1	Preclinical				glutamate receptor antagonist			
L-glutamic-acid	L-glutamic acid	E620|L-Glutamate|glutamic acid	N[C@@H](CCC(O)=O)C(O)=O	Launched	http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM135688.pdf	GCLC|GCLM|ASNS|NADSYN1|GLUD2|GLUD1|SLC1A7|SLC1A6|SLC1A3|SLC1A2|SLC1A1|GGCX|ALDH18A1|GATB|TAT|GAD1|GAD2|OPLAH|GLS2|GLUL|PFAS|GMPS|NAGS|PGCP|SLC25A18|SLC25A22|GOT1|GOT2|GRIN3A|GRIN3B|GRIN2D|GRIN2A|GRIN2B|GRIN2C|DNPEP|GRIN1|GRIK4|GRIK3|GRIK5|GRIK2|GRIK1|GRID1|GRID2|GRIA2|GRIA1|GRIA4|GRIA3|ABAT|PSAT1|AADAT|GPT|EPRS|GLS|FTCD|GPT2|ENPEP|BCAT1|BCAT2|SLC7A11|FOLH1|GRM1|GRM2|GRM3|GRM4|GRM6|GRM7|GRM8|AASS|FPGS|EARS2|LGSN|CCBL2	https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369|https://www.drugbank.ca/drugs/DB00142|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142|https://www.drugbank.ca/drugs/DB00142	glutamate receptor agonist			
BIBR-1532	BIBR-1532		C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1	Preclinical		TERT	http://www.medchemexpress.com/BIBR-1532.html	telomerase inhibitor			
rebamipide	rebamipide		OC(=O)C(Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1	Launched	http://www.drugs.com/international/Rebamipide.html	FPR1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001200	free radical scavenger	gastroenterology|gastroenterology	peptic ulcer disease (PUD)|gastritis	https://en.wikipedia.org/wiki/Rebamipide|https://en.wikipedia.org/wiki/Rebamipide
VS-4718	VS-4718		CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02651727			focal adhesion kinase inhibitor			
BMS-649	BMS-649	SR-11237	CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O	Preclinical		ABCA1|RXRA	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=218851|https://www.tocris.com/dispprod.php?ItemId=222007#.VyeucGQrImI	retinoid receptor agonist			
UBP-296	UBP-296		NC(Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O	Preclinical		GRIK1	https://www.rndsystems.com/products/ubp-296_2078	glutamate receptor antagonist			
lisuride	lisuride	lisuride maleate|lysuride	CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34	Launched	http://www.drugs.com/international/Lisuride.html	DRD1|DRD3|DRD2|DRD5|DRD4|HTR2C|HTR2B|HTR1D|HTR1B|HTR1A|HTR2A|HTR6|ADRA1A|ADRA2C|ADRA2B|ADRA2A	https://www.drugbank.ca/drugs/DB00589|https://www.drugbank.ca/drugs/DB00589|https://www.drugbank.ca/drugs/DB00589|https://www.drugbank.ca/drugs/DB00589|https://www.drugbank.ca/drugs/DB00589|https://www.drugbank.ca/drugs/DB00589|https://www.drugbank.ca/drugs/DB00589|https://www.drugbank.ca/drugs/DB00589|https://www.drugbank.ca/drugs/DB00589|https://www.drugbank.ca/drugs/DB00589|https://www.drugbank.ca/drugs/DB00589|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=43|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=43|https://www.drugbank.ca/drugs/DB00589|https://www.drugbank.ca/drugs/DB00589|https://www.drugbank.ca/drugs/DB00589	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease	https://en.wikipedia.org/wiki/Lisuride
miglitol	miglitol	glyset		Launched	FDA Orange Book: miglitol	SLC5A4|MGAM|GAA|GANAB|GANC	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=102773|https://www.drugbank.ca/drugs/DB00491|https://www.drugbank.ca/drugs/DB00491|https://www.drugbank.ca/drugs/DB00491|https://www.drugbank.ca/drugs/DB00491	glucosidase inhibitor	endocrinology	diabetes mellitus	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=192e6ed7-9e8c-4772-9e3b-5912a1c63a31
AZD5363	AZD5363	AZD-5363	NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02077569	AKT1|AKT2|AKT3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7709|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7709|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7709	AKT inhibitor			
NI-57	NI-57		COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N	Preclinical		BRPF1|BRPF3|BRD1	https://www.sigmaaldrich.com/catalog/product/sigma/sml1486?lang=en&region=US|https://www.sigmaaldrich.com/catalog/product/sigma/sml1486?lang=en&region=US|https://www.sigmaaldrich.com/catalog/product/sigma/sml1486?lang=en&region=US	bromodomain inhibitor			
elacridar	elacridar		COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/17545533	ABCB1	https://www.drugbank.ca/drugs/DB04881	P glycoprotein inhibitor			
BMY-14802	BMY-14802		OC(CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/7910021	SIGMAR1|HTR1A	https://citeline.informa.com/?query=#/drugs/details/2446|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8	sigma receptor antagonist			
iopamidol	iopamidol	IOPAMIDOL-200|IOPAMIDOL-250|IOPAMIDOL-300|IOPAMIDOL-370|SCANLUX-300|SCANLUX-370|SQ 13,396|SQ-13396|isovue|isovue-128|isovue-200|isovue-250|isovue-300|isovue-370|isovue-m 200|isovue-m 300	C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I	Launched	FDA Orange Book: iopamidol			radiopaque medium	radiology	contrast agent	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae8c18c9-3e7d-4515-b980-120025a88fc1
hypericin	hypericin		Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00000792?term=hypericin&rank=2			tyrosine kinase inhibitor			
saclofen	saclofen		NCC(CS(O)(=O)=O)c1ccc(Cl)cc1	Preclinical		KCTD12|KCTD16|KCTD8|GABBR1|GABBR2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1078|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1078|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1078|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1078|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1078	GABA receptor antagonist			
S26948	S26948		COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC	Preclinical		INS|PPARG	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=308378|https://www.tocris.com/dispprod.php?ItemId=238063#.VyujzWQrJZJ	PPAR receptor agonist			
EW-7197	EW-7197		Cc1cccc(n1)-c1[nH]c(CNc2ccccc2F)nc1-c1ccc2ncnn2c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02160106	TGFBR1|ACVR1B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8107|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8107	TGF beta receptor inhibitor			
o-mercapto-benzoic-acid	o-mercapto-benzoic acid	2-Mercapto-Benzoic Acid|thiosalicylic acid	OC(=O)c1ccccc1S	Preclinical							
L-methionine	L-methionine	Meonine|Methilanin|Nestone|Racemethionine|l-methionine|methionine	CSCC[C@H](N)C(O)=O	Launched	https://clinicaltrials.gov/ct2/show/NCT02557360			voltage-gated calcium channel ligand			
Z160	Z160	MK6721|NMED-160|NP-118809	O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01655849	CACNA1B|CACNA2D1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=346687|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014272	N-type calcium channel blocker			
bufexamac	bufexamac	CP 1044 J3|anderm|butoxyphenylacethydroxamic acid|paraderm|parfenac	CCCCOc1ccc(CC(=O)NO)cc1	Withdrawn	http://en.wikipedia.org/wiki/Bufexamac	HDAC10|HDAC6	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7498|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7498	cyclooxygenase inhibitor			
ciproxifan	ciproxifan		O=C(C1CC1)c1ccc(OCCCc2c[nH]cn2)cc1	Preclinical		ADRA2A|ADRA2C|HRH3|HRH4|HTR3A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002338|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002338|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1265|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1265|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC002338	histamine receptor antagonist			
LSN-2463359	LSN-2463359		CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1	Preclinical		GRM5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6394	glutamate receptor positive allosteric modulator			
CUDC-427	CUDC-427		CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01908413	XIAP	http://www.medkoo.com/products/5485	apoptosis inhibitor			
sutezolid	sutezolid	PNU-100480|U-100480	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCSCC2)c(F)c1	Phase 2	http://www.treatmentactiongroup.org/tb/drugs-advocacy/sutezolid			protein synthesis inhibitor			
XAV-939	XAV-939		Oc1nc(nc2CCSCc12)-c1ccc(cc1)C(F)(F)F	Preclinical		TNKS|TNKS2	http://www.selleckchem.com/products/XAV-939.html?gclid=CPfg98LQobwCFe1cMgodjXkASw|http://www.selleckchem.com/products/XAV-939.html?gclid=CPfg98LQobwCFe1cMgodjXkASw	tankyrase inhibitor			
cabotegravir	cabotegravir		C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT02720094			HIV integrase inhibitor			
ipriflavone	ipriflavone		CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O	Launched	http://www.drugs.com/international/Ipriflavone.html			bone resorption inhibitor	orthopedics	osteoporosis	https://en.wikipedia.org/wiki/Ipriflavone
tazemetostat	tazemetostat		CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02601950	EZH2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7011	histone lysine methyltransferase inhibitor			
STF-62247	STF-62247		Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1	Preclinical				autophagy inducer			
dinitolmide	dinitolmide	dinitrotoluamide|methyldinitrobenzamide	Cc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(N)=O	Veterinary Launched	http://www.drugs.com/international/dinitolmide.html				infectious disease	coccidiosis	http://www.drugs.com/international/dinitolmide.html
penicillamine-(D)	penicillamine-(D)	D Mercaptovaline|D Penicillamine|Trolovol|cuprimine|depen|dimethylcysteine|penicillamine	CC(C)(S)[C@@H](N)C(O)=O	Launched	http://en.wikipedia.org/wiki/Penicillamine			chelating agent	metabolism|rheumatology|nephrology	Wilson's disease|rheumatoid arthritis|cystinuria	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f8ae60-b354-11de-8a39-0800200c9a66|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f8ae60-b354-11de-8a39-0800200c9a66|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f8ae60-b354-11de-8a39-0800200c9a66
danofloxacin	danofloxacin		CN1C[C@@H]2C[C@H]1CN2c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1	Veterinary Launched	http://www.drugs.com/international/Danofloxacin.html			bacterial DNA gyrase inhibitor	pulmonary	bovine respiratory disease (BRD)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d22c22fc-d530-423c-8d78-ca95fe195ba1
baclofen-(R)	(R)-baclofen	STX209|arbaclofen	NC[C@H](CC(O)=O)c1ccc(Cl)cc1	Preclinical		GABBR1|GABBR2	http://www.abcam.com/r-baclofen-ab120325.html|http://www.abcam.com/r-baclofen-ab120325.html	benzodiazepine receptor agonist			
auranofin	auranofin	ridaura		Launched	FDA Orange Book: auranofin	PRDX5|TRPA1|TXNRD2|TXNRD1|IKBKB	https://www.drugbank.ca/drugs/DB00995|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6306|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=271613|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=271613|https://www.drugbank.ca/drugs/DB00995	NFkB pathway inhibitor	rheumatology	rheumatoid arthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05c34ddf-a0f7-4267-83f5-d02be3defc37
ginkgolide-a	ginkgolide a		C[C@@H]1C(=O)O[C@H]2CC34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	Preclinical		APP|GLRB|GLRA1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=411556|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007171|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007171	GABA receptor antagonist			
ginkgolide-b	ginkgolide b			Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/17516700	PTAFR|HTR3A|HTR3B|GLRB|GLRA1|GLRA2|GLRA3	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=113515|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1862|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1862|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1862|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1862|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1862|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1862	platelet activating factor receptor antagonist			
zaltidine	zaltidine		Cc1ncc([nH]1)-c1csc(NC(N)=N)n1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/2902681	HRH2	http://www.ncbi.nlm.nih.gov/pubmed/2902681	histamine receptor antagonist			
tetradecylthioacetic-acid	Tetradecylthioacetic Acid	Tetradecylsulfanyl-Acetic Acid|Tetradecylthioacetic Acid	CCCCCCCCCCCCCCSCC(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00605787			lipid peroxidase inhibitor			
phytonadione	phytonadione	Phylloquinone|Vitamin K 1|aquamephyton|konakion|mephyton|phytomenadione|vitamin k1	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O	Launched	FDA Orange Book: phytonadione	BGLAP|GGCX	https://www.drugbank.ca/drugs/DB01022|https://www.drugbank.ca/drugs/DB01022		hematology|hematology	vitamin K deficiency|anticoagulation reversal	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab569c0b-d35c-49ca-942b-98e2558b79c5|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab569c0b-d35c-49ca-942b-98e2558b79c5
N-acetylcarnosine	N-acetylcarnosine		CC(=O)NCCC(=O)N[C@@H](Cc1c[nH]cn1)C(O)=O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/12001824						
pentetic-acid	pentetic acid	DTPA|Pentetate|pentetic acid	OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00001575	PGD	https://www.drugbank.ca/drugs/DB00789	chelating agent			
ramipril	ramipril	HOE 498|HOE-498|altace	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O	Launched	FDA Orange Book: ramipril	ACE	ChEMBL	angiotensin converting enzyme inhibitor	cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b59207a-ea5c-4697-a8b6-94c3015a00de
anlotinib	anlotinib		COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT02029209	PDGFRB|KDR	https://clinicaltrials.gov/ct2/show/NCT01924195|https://clinicaltrials.gov/ct2/show/NCT01924195	VEGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor			
tolcapone	tolcapone	RO 40-7592|Ro-40-7592|tasmar	Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	COMT|TTR	ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=163695	catechol O methyltransferase inhibitor			
ajmaline	ajmaline		CC[C@H]1C2CC3[C@@H]4N(C)c5ccccc5[C@]44C[C@@H](C2C4O)N3[C@@H]1O	Launched	http://www.drugs.com/international/ajmaline.html	SCN5A	https://www.drugbank.ca/drugs/DB01426	sodium channel blocker	cardiology	Wolff-Parkinson-White Syndrome (WPW)	https://en.wikipedia.org/wiki/Ajmaline
pomalidomide	pomalidomide	CC-4047|IMID 3|pomalyst	Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12	Launched	FDA Orange Book: pomalidomide	PTGS2|CYP2C19|TNF|CRBN	https://www.drugbank.ca/drugs/DB08910|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=269739|https://www.drugbank.ca/drugs/DB08910|https://www.drugbank.ca/drugs/DB08910	angiogenesis inhibitor|tumor necrosis factor production inhibitor	hematologic malignancy	multiple myeloma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66
LXR-623	LXR-623	WAY-252623	Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00385489	ABCA1|AR|NR3C1|NR1I2|NR1H3|NR1H2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=459563|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008994|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008994|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008994|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008994|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008994	LXR agonist			
clotiapine	clotiapine	HF-2159|clothiapine	CN1CCN(CC1)C1=Nc2ccccc2Sc2ccc(Cl)cc12	Launched	http://www.drugs.com/international/Clotiapine.html				neurology/psychiatry	psychosis	https://en.wikipedia.org/wiki/Clotiapine
somatostatin	somatostatin	Aminopan|Modustatina|SRIF|SRIF-14|gh-rif	C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC1=O)[C@@H](C)O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N	Launched	https://www.drugs.com/international/somatostatin.html	OPRD1|OPRM1|SSTR5|SSTR4|SSTR3|SSTR2|SSTR1|GHR|GH1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004375|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004375|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004375|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004375|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004375|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004375|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004375|https://citeline.informa.com/?query=#/drugs/details/17126|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=107753	somatostatin receptor agonist	hematology	hemorrhage	http://www.medindia.net/doctors/drug_information/somatostatin.htm
grapiprant	grapiprant	AAT-007|CJ-023|MR10A7|RQ-00000007|RQ-7	CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1	Veterinary Launched	http://www.aratana.com/therapeutics/osteoarthritis-pain/	PTGER4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5858	prostaglandin inhibitor	rheumatology	osteoarthritis	http://www.aratana.com/therapeutics/osteoarthritis-pain/
KL-001	KL-001		CS(=O)(=O)N(CC(O)Cn1c2ccccc2c2ccccc12)Cc1ccco1	Preclinical		CRY2|CRY1	https://www.tocris.com/products/kl-001_4685|https://www.tocris.com/products/kl-001_4685	proteasome inhibitor			
sphingosylphosphorylcholine	sphingosylphosphorylcholine		CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(=O)OCC[N+](C)(C)C	Preclinical		GPR12	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4032	gene expression stimulant			
barasertib	barasertib	AZD-1152	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT00952588	AURKA|AURKB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7332|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7332	Aurora kinase inhibitor			
RP-001	RP-001		CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2C(CCc12)NCCC(O)=O	Preclinical		S1PR1	https://www.tocris.com/products/rp-001-hydrochloride_4289	sphingosine 1 phosphate receptor agonist			
betamethasone	betamethasone	celestone|uticort		Launched	FDA Orange Book: dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate	NR3C1	https://www.drugbank.ca/drugs/DB00443	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87700e94-70e3-4cd1-8432-0faaee306d00
LDN-27219	LDN-27219		NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1	Preclinical		TGM2	https://www.tocris.com/products/ldn-27219_4602	tissue transglutaminase inhibitor			
metoxibutropate	metoxibutropate		COc1ccccc1OC(=O)C(C)c1ccc(CC(C)C)cc1	Launched	http://www.ncbi.nlm.nih.gov/pubmed/9446076	PTGS2|PTGS1	http://www.chemdrug.com/article/8/3284/16419839.html|http://www.chemdrug.com/article/8/3284/16419839.html	cyclooxygenase inhibitor			
foxy-5	foxy-5		CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02020291	WNT5A	http://www.wntresearch.com/pipeline/foxy-5.aspx	WNT5a peptide mimetic			
lazabemide	lazabemide	RO 19-6327/000|Ro-19-6327	NCCNC(=O)c1ccc(Cl)cn1	Phase 3	http://www.forbes.com/forbes/2000/0320/6507094a.html	MAOB	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6640	monoamine oxidase inhibitor			
cyclocreatine	cyclocreatine		OC(=O)CN1CCNC1=N	Phase 1	http://cancerres.aacrjournals.org/content/canres/54/19/5160.full.pdf			creatine kinase substrate			
aminophylline	aminophylline	Accurbron|Aerolate|Aerolate iii|Aerolate jr|Aerolate sr|Aquaphyllin|Bronkodyl|Duraphyl|Elixicon|Elixomin|Elixophyllin sr|Labid|Lanophyllin|Quibron|Quibron-t|Quibron-t/sr|Respbid|Slo-bid|Slo-phyllin|Somophyllin-crt|Somophyllin-t|Sustaire|T-phyl|THEO-24|Theo-Dur|Theobid|Theobid jr.|Theocin|Theoclear l.a.-130|Theoclear l.a.-260|Theoclear-100|Theoclear-200|Theoclear-80|Theolair|Theolair-sr|Theolixir|Theophyl|Theophyl-225|Theophyl-sr|Theophylline-sr|Theovent|Uni-dur|aminophyllin|dimethylxanthine|elixophyllin|somophyllin|theochron|theophylline|uniphyl	Cn1c2nc[nH]c2c(=O)n(C)c1=O	Launched	FDA Orange Book: aminophylline	ADORA2A|ADORA2B|PDE4D|PDE4C|PDE4B|PDE4A|PDE3B|PDE3A|ADORA3|ADORA1|HDAC2	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB01223|ChEMBL|https://www.drugbank.ca/drugs/DB01223	adenosine receptor antagonist	pulmonary|pulmonary|pulmonary	asthma|bronchitis|emphysema	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bc5d8ca-58de-4683-a27a-3e216b20e82b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bc5d8ca-58de-4683-a27a-3e216b20e82b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bc5d8ca-58de-4683-a27a-3e216b20e82b
MLN2480	MLN2480	MLN-2480	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(s1)C(=O)Nc1cc(c(Cl)cn1)C(F)(F)F	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01425008			RAF inhibitor			
adelmidrol	adelmidrol		OCCNC(=O)CCCCCCCC(=O)NCCO	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT01420510			anti-inflammatory agent			
TAK-715	TAK-715		CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00760864	MAPK14|TNF	http://www.selleckchem.com/products/tak-715.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=384416	p38 MAPK inhibitor			
retigabine	retigabine	AWD21-360|D-23129|GKE-841|GW582892X|WAY-143841|ezogabine|potiga	CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N	Launched	http://en.wikipedia.org/wiki/Retigabine	ABAT|KCNQ3|KCNQ2|KCNQ5|KCNQ4|KCNQ1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=227505|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	potassium channel activator	neurology/psychiatry	epilepsy	https://en.wikipedia.org/wiki/Retigabine
sulpiride	sulpiride	Bosnyl|Dogmatil|Dolmatil|Eglonyl|Espiride|Meresa|Modal|dogmatyl	CCN1CCCC1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O	Launched	http://www.drugs.com/international/sulpiride.html	DRD2|CA7	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091411|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091411	dopamine receptor antagonist	neurology/psychiatry|neurology/psychiatry	schizophrenia|schizophrenia	https://www.medicines.org.uk/emc/medicine/18936|https://www.medicines.org.uk/emc/medicine/18936
LY320135	LY320135	LY-320135	COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N	Preclinical		CNR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=742	cannabinoid receptor antagonist			
ICI-215,001	ICI-215,001		O[C@@H](CNCCOc1ccc(OCC(O)=O)cc1)COc1ccccc1	Preclinical				adrenergic receptor agonist			
tanshinone-iia	Tanshinone IIA	Tanshinone IIA	Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c1CCCC2(C)C	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT01637675	IL1B|NR1I2|TNF	http://www.scbt.com/datasheet-200932-tanshinone-iia.html|http://www.scbt.com/datasheet-200932-tanshinone-iia.html|http://www.scbt.com/datasheet-200932-tanshinone-iia.html	anti-inflammatory agent|interleukin inhibitor			
trap-101	trap-101		CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O	Preclinical		OPRL1	http://www.tocris.com/dispprod.php?ItemId=159329	nociceptin/orphanin FQ receptor antagonist|opioid receptor antagonist			
tolamolol	tolamolol		Cc1ccccc1OCC(O)CNCCOc1ccc(cc1)C(N)=O	Phase 3	https://www.ncbi.nlm.nih.gov/pubmed/804952	ADRB3|ADRB1|ADRB2	http://www.genome.jp/dbget-bin/www_bget?dr:D06176|http://www.genome.jp/dbget-bin/www_bget?dr:D06176|http://www.genome.jp/dbget-bin/www_bget?dr:D06176	adrenergic receptor antagonist			
2-deoxyglucose	2-deoxyglucose		OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00001568	SLC2A1|SLC2A4|SLC2A3|SLC2A2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4643|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4643|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4643|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4643	glycolysis inhibitor			
crotamiton	crotamiton	crotan|eurax	CCN(C(=O)\C=C\C)c1ccccc1C	Launched	FDA Orange Book: crotamiton			antipruritic	infectious disease	scabies	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56465446-7f78-4ad1-acb3-08a4d60e5715
spiradoline	spiradoline	U-62066	CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	Phase 2	http://adisinsight.springer.com/drugs/800002115	OPRK1	https://en.wikipedia.org/wiki/Spiradoline	opioid receptor agonist			
isbufylline	isbufylline		CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12	Phase 2	http://adisinsight.springer.com/drugs/800000109			phosphodiesterase inhibitor			
coumarin	coumarin	2H-CHROMEN-2-ONE	O=c1ccc2ccccc2o1	Launched	http://www.drugs.com/international/Coumarin.html	CA14|CA12|CYP2A6|CA9|CA1|CA2|CA4|CA6	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010059|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010059|https://www.drugbank.ca/drugs/DB04665|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010059|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010059|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010059|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010059|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010059	vitamin K antagonist	gastroenterology|pulmonary|gastroenterology	ulcerative colitis|asthma|celiac disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=638f5a02-0f10-4cbc-87f8-5b5d4fef209b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=638f5a02-0f10-4cbc-87f8-5b5d4fef209b|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=638f5a02-0f10-4cbc-87f8-5b5d4fef209b
emodin	emodin		Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1	Preclinical		CSNK2A1|CSNK2A2|PTP4A3|CSNK2B|IL6	https://www.drugbank.ca/drugs/DB07715|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=237157|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=237157|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=237157|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=237157	11-beta hydroxysteroid dehydrogenase inhibitor			
zolimidine	zolimidine	zoliridine	CS(=O)(=O)c1ccc(cc1)-c1cn2ccccc2n1	Launched	https://en.wikipedia.org/wiki/Zolimidine			mucus protecting agent			
tenofovir	tenofovir	Atripla|GS-1278|PMPA|Truvada	C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O	Launched	FDA Orange Book: tenofovir disoproxil fumarate			HIV integrase inhibitor|nucleoside reverse transcriptase inhibitor	infectious disease|infectious disease	human immunodeficiency virus (HIV-1)|hepatitis B	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&audience=consumer
CP-640186	CP-640186		O=C([C@@H]1CCCN(C1)C1CCN(CC1)C(=O)c1c2ccccc2cc2ccccc12)N1CCOCC1	Preclinical		ACACB|ACACA	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006686|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC006686	acetyl-CoA carboxylase inhibitor			
tipifarnib	tipifarnib	R-11577|R-115777|R115777|Zarnestra	Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00093470	FNTB|FNTA	https://www.drugbank.ca/drugs/DB04960|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000266	farnesyltransferase inhibitor			
torasemide	torasemide	AC-4464|AC4464|BM-02015|BM02.015|demadex|torsemide	CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1	Launched	FDA Orange Book: torsemide	CYP2C8|SLC12A1|SLC12A2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090063|ChEMBL|https://citeline.informa.com/?query=#/drugs/details/18363	electrolyte reabsorption inhibitor|thromboxane receptor antagonist	cardiology|cardiology|cardiology	edema|congestive heart failure|hypertension	https://en.wikipedia.org/wiki/Torasemide|https://en.wikipedia.org/wiki/Torasemide|https://en.wikipedia.org/wiki/Torasemide
napirimus	napirimus		Cn1cc(cc1C(O)=O)C(=O)c1cccc2ccccc12	Phase 1	Pharmaprojects			immunosuppressant			
benperidol	benperidol	MCN-JR-4584|R-4584	Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O	Launched	http://en.wikipedia.org/wiki/Benperidol	DRD2	http://www.ncbi.nlm.nih.gov/pubmed/2148346	dopamine receptor antagonist	neurology/psychiatry	schizophrenia	https://en.wikipedia.org/wiki/Benperidol
GLPG0492-R-enantiomer	GLPG0492-R-enantiomer		CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01130818	AR	https://www.medchemexpress.com/glpg0492-r-enantiomer.html	androgen receptor modulator			
BRL-15572	BRL-15572	BRL-15,572	OC(CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1	Preclinical		HTR1F|HTR1E|HTR2A|HTR2C|HTR2B|HTR1D|HTR1B|HTR1A|HTR6	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10	serotonin receptor antagonist			
testosterone	testosterone	androderm|androgel|aveed|axiron|depo-testosterone|fortesta|natesto|striant|testim|testoderm|testoderm tts|testopel|vogelxo	C[C@]12CCC3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@@H]2O	Launched	FDA Orange Book: testosterone	CYP2C19|CYP3A5|AR|CYP2C8	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=080002|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=080002|https://www.drugbank.ca/drugs/DB00624|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=080002	androgen receptor agonist	endocrinology	hypogonadism	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cfbb53d4-b868-4a28-8436-f9112eb01c39&audience=consumer
disodium sebacate	disodium sebacate		OC(=O)CCCCCCCCC(O)=O	Phase 1							
BRL-37344	BRL-37344		C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1	Phase 2	Pharmaprojects	ADRB2|ADRB3|ADRB1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003984|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=567|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003984	adrenergic receptor agonist			
palmatine-chloride	palmatine chloride	palmitine	COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC	Preclinical		ACHE|CYP3A4	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=389681|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008080	dopamine synthesis inhibitor			
procyclidine	procyclidine	kemadrin	OC(CCN1CCCC1)(C1CCCCC1)c1ccccc1	Launched	FDA Orange Book: procyclidine hydrochloride	CHRM4|CHRM2|CHRM3|CHRM1	https://www.drugbank.ca/drugs/DB00387|https://www.drugbank.ca/drugs/DB00387|https://www.drugbank.ca/drugs/DB00387|https://www.drugbank.ca/drugs/DB00387	acetylcholine receptor antagonist	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	parkinsonism|Parkinson's Disease|akathisia|dystonia	https://en.wikipedia.org/wiki/Procyclidine|https://en.wikipedia.org/wiki/Procyclidine|https://en.wikipedia.org/wiki/Procyclidine|https://en.wikipedia.org/wiki/Procyclidine
perampanel	perampanel	E-2007|E2007|ER-155055-90|fycompa	O=c1c(cc(cn1-c1ccccc1)-c1ccccn1)-c1ccccc1C#N	Launched	FDA Orange Book: perampanel	CYP3A5|GRIA3|GRIA4|GRIA1|GRIA2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=314603|ChEMBL|ChEMBL|ChEMBL|ChEMBL	glutamate receptor antagonist	neurology/psychiatry	seizures	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71cf3309-e182-473c-8b0b-280cabd0e122
ipsapirone	ipsapirone		O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/9690691	HTR1A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=42	serotonin receptor agonist			
alrestatin	alrestatin	AY-22284	OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23	Preclinical		AKR1B1	https://www.drugbank.ca/drugs/DB02020	aldose reductase inhibitor			
amoxapine	amoxapine	CL 67,772|CL-67772|asendin	Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1	Launched	FDA Orange Book: amoxapine	GABRQ|GABRP|GABRE|GABRD|CHRM4|CHRM3|CHRM5|CHRM2|CHRM1|HTR3A|HTR1B|HTR1A|HTR2C|HTR2B|HTR2A|HTR6|HTR7|HRH1|HRH4|ADRA1A|ADRA1D|ADRA1B|ADRA2A|ADRA2B|ADRA2C|GABRB3|SLC6A4|SLC6A3|SLC6A2|GABRA1|GABRA4|GABRA5|GABRA2|GABRA3|GABRA6|GABRB1|GABRB2|GABRG2|GABRG3|GABRG1|DRD5|DRD4|DRD3|DRD2|DRD1	https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|ChEMBL|https://www.drugbank.ca/drugs/DB00543|ChEMBL|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|https://www.drugbank.ca/drugs/DB00543|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL	norepinephrine reputake inhibitor	neurology/psychiatry	depression	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a16297df-3158-48db-85e5-5cd506885556
GSK-0660	GSK-0660	GSK0660	COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC	Preclinical		PPARD	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3441	PPAR receptor antagonist			
lofemizole	lofemizole		Cc1nc[nH]c1-c1ccc(Cl)cc1	Phase 3	Pharmaprojects			cyclooxygenase inhibitor			
allicin	allicin	Diallyl Thiosulfinate	C=CCSS(=O)CC=C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00455416	TRPA1|TRPV1|CTSB|CTSL	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2419|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2419|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=147782|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=147782	cytokine production inhibitor			
CGP-7930	CGP-7930		CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	Preclinical		GABBR1	http://en.wikipedia.org/wiki/CGP-7930	GABA receptor modulator			
ICA-069673	ICA-069673		Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1	Preclinical		KCNQ2|KCNQ3	https://www.tocris.com/products/ica-069673_4305|https://www.tocris.com/products/ica-069673_4305	voltage-gated potassium channel activator			
KPT-276	KPT-276		FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(n1)\C=C/C(=O)N1CC(F)(F)C1	Preclinical		XPO1	http://www.selleckchem.com/products/kpt-276.html	exportin antagonist			
OSI-930	OSI-930		FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00513851	PDGFRB|PDGFB|KDR|KIT	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=377652|https://citeline.informa.com/?query=#/drugs/details/32120|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000352|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000352	KIT inhibitor|VEGFR inhibitor			
ANA-12	ANA-12		O=C(Nc1ccccc1C(=O)NC1CCCCNC1=O)c1cc2ccccc2s1	Preclinical		NTRK2	https://www.tocris.com/products/ana-12_4781	tropomyosin receptor kinase inhibitor			
diloxanide	diloxanide	diloxanide furoate	CN(C(=O)C(Cl)Cl)c1ccc(OC(=O)c2ccco2)cc1	Launched	http://www.drugs.com/international/diloxanide.html			protein synthesis inhibitor	infectious disease	amebiasis	https://en.wikipedia.org/wiki/Diloxanide_furoate
relebactam	relebactam		OS(=O)(=O)ON1[C@H]2CN([C@@H](CC2)C(=O)NC2CCNCC2)C1=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02452047			beta lactamase inhibitor			
AMG319	AMG319		CC(Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1	Phase 2	https://www.clinicaltrials.gov/ct2/show/NCT02540928	PIK3CD	http://www.selleckchem.com/products/AMG319.html?gclid=COO1q9aUotICFZWCaQod9n8Gmw	PI3K inhibitor			
pelanserin	pelanserin		O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(CC1)c1ccccc1	Phase 2	Pharmaprojects	HTR2A	https://en.wikipedia.org/wiki/Pelanserin	serotonin receptor antagonist			
apramycin	apramycin		CN[C@H]1[C@@H](O)[C@H]2O[C@@H](O[C@@H]3[C@@H](N)C[C@@H](N)[C@H](O)[C@H]3O)[C@H](N)C[C@@H]2O[C@@H]1O[C@H]1O[C@H](CO)[C@@H](N)[C@H](O)[C@H]1O	Veterinary Launched	http://en.wikipedia.org/wiki/Apramycin			bacterial 30S ribosomal subunit inhibitor	infectious disease	gram-negative bacterial infections	https://en.wikipedia.org/wiki/Apramycin
NPY-5RA972	NPY-5RA972		CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12	Preclinical		NPY5R	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DPR000082	neuropeptide receptor antagonist			
chrysin	chrysin	NSC-407436	Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/16003560	ABCG2|AKR1B1|CDK6|CYP1B1|CYP19A1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=282437|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004715|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004715|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004715|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004715	breast cancer resistance protein inhibitor			
nesbuvir	nesbuvir	HCV 796|HCV-796	CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1	Phase 2	https://www.clinicaltrials.gov/ct2/show/NCT00367887			RNA polymerase inhibitor			
oleanolic-acid	oleanolic acid	NSC-114945|oleanolic_acid	CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O	Preclinical		GPBAR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3306	G protein-coupled receptor agonist			
TG-003	TG-003		CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O	Preclinical		DYRK1A|DYRK1B|CLK1|CLK4	https://www.tocris.com/dispprod.php?ItemId=304768#.Vyy6RmQrJZJ|https://www.tocris.com/dispprod.php?ItemId=304768#.Vyy6RmQrJZJ|https://www.tocris.com/dispprod.php?ItemId=304768#.Vyy6RmQrJZJ|https://www.tocris.com/dispprod.php?ItemId=304768#.Vyy6RmQrJZJ	CLK inhibitor			
doramapimod	doramapimod	BIRB-796	Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02209753	DDR2|MAPK11|MAPK13|MAPK12|MAPK14	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=292897|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5668|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5668|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5668|https://www.drugbank.ca/drugs/DB03044	p38 MAPK inhibitor			
marimastat	marimastat	BB-2516	CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00002911	MMP1|MMP7|MMP9|MMP8|MMP3|MMP2|MMP15|MMP16|MMP13|MMP14|MMP19|MMP17|MMP20|MMP21|MMP26|MMP27|MMP24|MMP25|MMP28|MMP11|MMP12|MMP10|MMP23A	https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786|https://www.drugbank.ca/drugs/DB00786	matrix metalloprotease inhibitor			
CP-91149	CP-91149		CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1	Preclinical		PYGL	http://www.sigmaaldrich.com/catalog/product/sigma/pz0104?lang=en&region=US	glycogen phosphorylase inhibitor			
cinromide	cinromide		CCNC(=O)\C=C\c1cccc(Br)c1	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/6409599						
macitentan	macitentan	ACT-064992|opsumit	CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	Launched	FDA Orange Book: macitentan	EDNRB|EDNRA	ChEMBL|ChEMBL	endothelin receptor antagonist	endocrinology	contraceptive	http://www.medindia.net/doctors/drug_information/lynestrenol.htm
ascomycin	ascomycin		CCC1\C=C(C)\CC(C)CC(OC)C2OC(O)(C(C)CC2OC)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)C(O)CC1=O)C(\C)=C\C1CCC(O)C(C1)OC	Preclinical		FKBP1A	http://www.hellobio.com/ascomycin.html	calcineurin inhibitor			
GGTI-298	GGTI-298		COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12	Preclinical		CDKN1A	http://www.ncbi.nlm.nih.gov/pubmed/9341167	GGTase inhibitor			
chlorphenesin	chlorphenesin	maolate	OCC(O)COc1ccc(Cl)cc1	Launched	FDA Orange Book: chlorphenesin carbamate			muscle relaxant	neurology/psychiatry|neurology/psychiatry	muscle relaxant|sedative	https://en.wikipedia.org/wiki/Chlorphenesin|https://en.wikipedia.org/wiki/Chlorphenesin
RO-3	RO-3		COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C	Preclinical		P2RX3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4298	purinergic receptor antagonist			
lindane	lindane	Gamma Benzene Hydrochloride|Gammallin|Gammaxene|Gexane|Quellada|benzene hexachloride, gamma|gamene|gamma-Hexachlorocyclohexane|hexachlorane|hexicide|kwell|scabene		Launched	FDA Orange Book: lindane	GABRB1|GLRA1|GLRA3|GLRA2|GLRB	https://www.drugbank.ca/drugs/DB00431|https://www.drugbank.ca/drugs/DB00431|https://www.drugbank.ca/drugs/DB00431|https://www.drugbank.ca/drugs/DB00431|https://www.drugbank.ca/drugs/DB00431		infectious disease	scabies	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=770415b2-4555-4abc-b5d6-c67dfb07ab30
AS-2034178	AS-2034178		OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F	Preclinical		FFAR1|INS	https://www.tocris.com/products/as-2034178_5035|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=629347	free fatty acid receptor agonist			
propentofylline	propentofylline	HWA 285	CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12	Veterinary Launched	http://www.drugs.com/international/Propentofylline.html	PDE1A|ACHE	http://www.genome.jp/dbget-bin/www_bget?dr:D01630|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090664	adenosine reuptake inhibitor|phosphodiesterase inhibitor	neurology/psychiatry	stroke	http://www.drugs.com/international/propentofylline.html
retaspimycin	retaspimycin		CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00688766	HSP90AA1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000137	HSP inhibitor			
darapladib	darapladib	SB-480848	CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00799903	PLA2G7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6696	phospholipase inhibitor			
cromoglicic-acid	cromoglicic acid	cromoglicic acid|cromolyn	OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O	Launched	http://en.wikipedia.org/wiki/Cromoglicic_acid	S100P|KCNMA1	https://www.drugbank.ca/drugs/DB01003|https://www.drugbank.ca/drugs/DB01003	immunosuppressant	pulmonary|ophthalmology|allergy|gastroenterology	asthma|conjunctivitis|urticaria|ulcerative colitis	https://en.wikipedia.org/wiki/Cromoglicic_acid|https://en.wikipedia.org/wiki/Cromoglicic_acid|https://en.wikipedia.org/wiki/Cromoglicic_acid|https://en.wikipedia.org/wiki/Cromoglicic_acid
acetarsol	acetarsol	Stovarsol	CC(=O)Nc1cc(ccc1O)[As](O)(O)=O	Launched	http://www.drugs.com/international/acetarsol.html				gastroenterology	diarrhea	http://www.drugs.com/international/acetarsol.html
todralazine	todralazine	BT 621 [AS HYDROCHLORIDE]|ceph [as hydrochloride]|ecarazine hydrochloride|todralazine hydrochloride	CCOC(=O)NNc1nncc2ccccc12	Launched	http://www.drugs.com/international/todralazine.html			antihypertensive agent			
rimonabant	rimonabant	SR-14171|SR-141716|SR-141716A|SR141716|acomplia	Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	GPR55|IL6|CNR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=743|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=217004|https://www.drugbank.ca/drugs/DB06155	cannabinoid receptor antagonist			
metacresol	metacresol		Cc1cccc(O)c1	Launched	http://www.drugs.com/international/metacresol.html	INS	https://www.drugbank.ca/drugs/DB01776				
L-(+)-Rhamnose-Monohydrate	L-(+)-Rhamnose-Monohydrate		C[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O	Preclinical							
perospirone	perospirone		O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12	Launched	http://www.drugs.com/international/Perospirone.html	DRD3|DRD4|DRD2|HTR2A|HTR2C	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7556|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7556|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7556|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=161247|https://citeline.informa.com/?query=#/drugs/details/14319	dopamine receptor antagonist|serotonin receptor antagonist	neurology/psychiatry|neurology/psychiatry	schizophrenia|bipolar disorder	https://en.wikipedia.org/wiki/Perospirone|https://en.wikipedia.org/wiki/Perospirone
THZ1-R	THZ1-R		CN(C)CCCC(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1	Preclinical		CDK7	http://www.cell.com/cms/attachment/2025134816/2044786487/mmc1.pdf	CDK inhibitor			
benzyl-benzoate	benzyl benzoate	Mange Treatment|Scabanca|Vanzoate|benzyl benzoate	O=C(OCc1ccccc1)c1ccccc1	Launched	FDA Orange Book: benzyl benzoate	LIPE	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014821	lipase inhibitor	allergy	sweet itch	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba27041b-0253-43a3-a1d6-4fb0ddee5ecb
GDC-0349	GDC-0349	RG-7603	CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01356173	PIK3CA|PIM3	http://www.selleckchem.com/products/gdc-0349.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=741097	Pim kinase inhibitor			
SYM-2206	SYM-2206		CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1C	Preclinical		GRIA1|GRIA3|GRIA2|GRIA4	http://www.tocris.com/dispprod.php?ItemId=1890#.VhKecmRVhHw|http://www.tocris.com/dispprod.php?ItemId=1890#.VhKecmRVhHw|http://www.tocris.com/dispprod.php?ItemId=1890#.VhKecmRVhHw|http://www.tocris.com/dispprod.php?ItemId=1890#.VhKecmRVhHw	glutamate receptor antagonist			
neomycin-sulfate	neomycin sulfate	mycifradin|neo-fradin|neomycin sulfate	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	Launched	FDA Orange Book: neomycin sulfate			bacterial 30S ribosomal subunit inhibitor	infectious disease	first-aid antibiotic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=650d1b78-005c-41eb-9df4-67a5d576c02b
rifamycin	rifamycin	Rifamycin Sv|rifomycin	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C	Launched	http://www.drugs.com/international/rifamycin.html	SLCO1A2|SLCO1B3|SLCO1B1|SLCO2B1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4570|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4570|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4570|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4570	DNA directed RNA polymerase inhibitor	infectious disease|infectious disease	tuberculosis|leprosy	https://en.wikipedia.org/wiki/Rifamycin#Mechanism_of_action|https://en.wikipedia.org/wiki/Rifamycin#Mechanism_of_action
NS-5806	NS-5806		FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nnn[nH]2)cc(c1)C(F)(F)F	Preclinical		KCND3	https://www.tocris.com/products/ns-5806_4166	voltage-gated potassium channel activator			
BU-224	BU-224		C1CN=C(N1)c1ccc2ccccc2n1	Preclinical		MAOA|MAOB	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014061|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC014061	imidazoline receptor ligand			
drofenine	drofenine		CCN(CC)CCOC(=O)C(C1CCCCC1)c1ccccc1	Launched	http://www.drugs.com/international/drofenine.html				neurology/psychiatry	spasms	http://www.drugs.com/international/drofenine.html
ACDPP	ACDPP		CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1	Preclinical		GRM5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3388	glutamate receptor antagonist			
A-438079	A-438079		Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl	Preclinical		P2RX7	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4118	purinergic receptor antagonist			
clofilium	clofilium		CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/9024749	KCNA5|KCND2|KCNH1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2507|https://citeline.informa.com/?query=#/drugs/details/4760|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2507	potassium channel blocker			
cabazitaxel	cabazitaxel	jevtana kit	CO[C@@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@@H](OC(=O)c3ccccc3)[C@@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C	Launched	FDA Orange Book: cabazitaxel	TUBB1|TUBB|TUBA4A|CYP3A5|CYP2C8|SLCO1B3	https://www.drugbank.ca/drugs/DB06772|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6798|https://www.drugbank.ca/drugs/DB06772|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=287186|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=287186|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=287186	microtubule inhibitor	oncology	prostate cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa
tolonidine	tolonidine	ST 375	Cc1ccc(NC2=NCCN2)c(Cl)c1	Launched	https://books.google.com/books?id=2HBPHmclMWIC&lpg=PA460&ots=VTFYXAiJ_l&dq=Euctan%20tolonidine&pg=PA460#v=onepage&q=Euctan%20tolonidine&f=false	ADRA2A	https://www.ncbi.nlm.nih.gov/pubmed/3186	adrenergic receptor antagonist			
sinefungin	sinefungin	COMPOUND 57926	N[C@@H](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	Preclinical		CARM1	http://www.epizyme.com/wp-content/uploads/2015/04/Boriack-Sjodin_CARM1peptides_Poster_v7.pdf	DNA methyltransferase inhibitor|RNA synthesis inhibitor			
clopamide	clopamide	DT-327|aquex|chlosudimeprimylum	CC1CCCC(C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O	Launched	http://www.drugs.com/international/clopamide.html			sodium/chloride cotransporter inhibitor	cardiology	hypertension	http://www.drugs.com/international/clopamide.html
dolutegravir	dolutegravir	tivicay	C[C@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12	Launched	FDA Orange Book: dolutegravir sodium	POU2F2|SLC22A2|UGT1A1|CYP3A7|CYP3A5|CYP3A4	http://www.drugbank.ca/drugs/DB08930|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=466915|http://www.drugbank.ca/drugs/DB08930|http://www.drugbank.ca/drugs/DB08930|http://www.drugbank.ca/drugs/DB08930|http://www.drugbank.ca/drugs/DB08930	HIV integrase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63df5af3-b8ac-4e76-9830-2dbb340af922
dimercaprol	dimercaprol	Anti-Lewisite|Sulfactin|bal	OCC(S)CS	Launched	FDA Orange Book: dimercaprol			chelating agent	neurology/psychiatry	metal toxicity	https://en.wikipedia.org/wiki/Dimercaprol
undecylenic-acid	undecylenic acid	undecylenic acid	OC(=O)CCCCCCCCC=C	Launched	http://www.drugs.com/cdi/undecylenic-acid-liquid.html			other antifungal	infectious disease|infectious disease	tinea pedis|tinea corporis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7b39ecf-d009-4ec8-b4c7-fc6a8b4820c3|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7b39ecf-d009-4ec8-b4c7-fc6a8b4820c3
ID-8	ID-8		COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12	Preclinical							
UK-383367	UK-383367		NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO	Phase 1	Pharmaprojects	BMP1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC007549	Procollagen C-Endopeptidase Inhibitors			
AS-1269574	AS-1269574		Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1	Preclinical		GPR119	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4027	glucose dependent insulinotropic receptor agonist			
AZD6482	AZD6482	AZD-6482	C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00853450	PIK3CG|PIK3CD|PIK3CB|PIK3CA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8059|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8059|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8059|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8059	PI3K inhibitor			
igmesine	igmesine		CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1	Phase 2	https://books.google.com/books?id=3XJ8PXFCXq4C&pg=PA251&lpg=PA251&dq=igmesine+phase+2&source=bl&ots=IzdIbTC-k2&sig=9v0X-Bnwy9YulG8r93ujfzLH9gY&hl=en&sa=X&ved=0ahUKEwjjk6ykmcjRAhVp9IMKHXDEAV8Q6AEINDAE#v=onepage&q=igmesine%20phase%202&f=false	SIGMAR1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000782	sigma receptor agonist			
tegobuvir	tegobuvir		Fc1ccccc1-c1nc2ccn(Cc3ccc(nn3)-c3ccc(cc3C(F)(F)F)C(F)(F)F)cc2n1	Phase 3	https://www.clinicaltrialsregister.eu/ctr-search/search?query=+2009-013442-86			HCV inhibitor|protease inhibitor			
phenazopyridine	phenazopyridine		Nc1ccc(\N=N\c2ccccc2)c(N)n1	Launched	FDA Orange Book: phenazopyridine hydrochloride	SCN1A	https://www.drugbank.ca/drugs/DB01438	local anesthetic	infectious disease	urinary tract infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47185181-607e-4bbe-8850-726af1973cf1
plicamycin	plicamycin	mithracin	CO[C@@H]([C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O	Launched	FDA Orange Book: plicamycin			alcohol dehydrogenase inhibitor	oncology|endocrinology|endocrinology	testicular carcinoma|Paget's disease|hypercalcemia	https://en.wikipedia.org/wiki/Plicamycin|https://en.wikipedia.org/wiki/Plicamycin|https://en.wikipedia.org/wiki/Plicamycin
naloxone	naloxone	Nalone|Narcanti|Suboxone|evzio|naloxone hydrochloride|narcan	Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	Launched	FDA Orange Book: naloxone hydrochloride	OPRM1|OPRK1|OPRD1|CREB1|TLR4|ESR1	https://www.drugbank.ca/drugs/DB01183|https://www.drugbank.ca/drugs/DB01183|https://www.drugbank.ca/drugs/DB01183|https://www.drugbank.ca/drugs/DB01183|https://www.drugbank.ca/drugs/DB01183|https://www.drugbank.ca/drugs/DB01183	opioid receptor antagonist	pulmonary	respiratory depression	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76f7eee1-d524-43a4-a868-ffa9f29638a6
adenosine-triphosphate	Adenosine triphosphate	Adenosine triphosphate	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O	Phase 2	https://www.clinicaltrials.gov/ct2/show/NCT02279511	ACSL1|ACSS1|ACSS2|CDK15|RYR3|RYR2|RYR1|TRPM7|TRPM4|ACVR1|GPR17|AKT1|NT5C2|ARAF|SLC25A4|P2RY4|P2RY1|P2RY2|PRKAA1|APAF1|ASS1|ASNS|TNK2|P2RY11|P2RY13|ASNA1|NAE1|ACVR1B|ADCY1|ACVRL1|AFG3L2|AMHR2|ABCB11|ALK|ADRBK2|ADRBK1|ITPR1|ABCC9|ABCC8|ABCC2|ABCB1|ABCG1|ABCA1|ABL1|ABL2	https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713|https://www.drugbank.ca/drugs/DB00171|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171|https://www.drugbank.ca/drugs/DB00171	adenosine receptor agonist			
cis-ACPD	cis-ACPD		N[C@]1(CC[C@@H](C1)C(O)=O)C(O)=O.N[C@@]1(CC[C@H](C1)C(O)=O)C(O)=O	Preclinical		GRM6|GRM3|GRM2|GRM7|GRM8	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1365|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1365|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1365|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1365|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1365	glutamate receptor agonist			
abemaciclib	abemaciclib	LY2835219	CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1	Launched	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be4bc0de-0fdc-4d46-8d25-be43c79e6a06	CDK6|CDK4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7382|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7382	CDK inhibitor	oncology	breast cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be4bc0de-0fdc-4d46-8d25-be43c79e6a06
ebastine	ebastine	LAS W-090|RP 64305|kestine	CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1	Launched	http://www.drugs.com/international/Ebastine.html	HRH1|CYP2J2|CYP3A4	https://en.wikipedia.org/wiki/Ebastine|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=135187|https://en.wikipedia.org/wiki/Ebastine	histamine receptor antagonist	allergy|allergy	allergic rhinitis|urticaria	https://en.wikipedia.org/wiki/Ebastine|https://en.wikipedia.org/wiki/Ebastine
estetrol	estetrol		C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02817841	ESR1	https://en.wikipedia.org/wiki/Estetrol	selective estrogen receptor modulator (SERM)			
AS-1949490	AS-1949490		C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1	Preclinical		INPP5D	https://www.tocris.com/dispprod.php?ItemId=240535#.VyeJZGQrImI	SHIP2 phosphatase inhibitor			
proglumide	proglumide	W-5219|nulsa	CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)c1ccccc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	CCKAR|CCKBR	https://en.wikipedia.org/wiki/Proglumide|https://en.wikipedia.org/wiki/Proglumide	CCK receptor antagonist			
AT-1015	AT-1015		O=CN1CCC(CC1)C(=O)NCCN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12	Preclinical		HTR2A	https://www.tocris.com/products/at-1015_4468	serotonin receptor antagonist			
PSI-6130	PSI-6130	PS-6130	C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O	Phase 1	http://en.wikipedia.org/wiki/PSI-6130			RNA polymerase inhibitor			
6-aminopenicillanic-acid	6-aminopenicillanic acid		CC1(C)S[C@@H]2[C@H](N)C(=O)N2[C@H]1C(O)=O	Preclinical							
DAPT	DAPT		C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1	Preclinical				gamma secretase inhibitor			
ribociclib	ribociclib	LEE-011|NVP-LEE011	CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1	Launched	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8	CDK6|CDK4|JAK3	http://www.selleckchem.com/products/lee011.html?gclid=COHy_4PVw8wCFQxahgodPkkCIw|http://www.selleckchem.com/products/lee011.html?gclid=COHy_4PVw8wCFQxahgodPkkCIw|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=743529	CDK inhibitor	oncology	breast cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8
nelfinavir	nelfinavir	viracept	Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C	Launched	FDA Orange Book: nelfinavir mesylate	CYP3A7|CYP3A5|CYP3A4|CYP2D6|CYP2C9|CYP2B6|CYP1A2|CYP2C19	http://www.drugbank.ca/drugs/DB00220|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=211732|http://www.drugbank.ca/drugs/DB00220|http://www.drugbank.ca/drugs/DB00220|http://www.drugbank.ca/drugs/DB00220|http://www.drugbank.ca/drugs/DB00220|http://www.drugbank.ca/drugs/DB00220|http://www.drugbank.ca/drugs/DB00220	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b370904-d2cd-4585-bc48-a8110621c8bd
methanesulfonyl-fluoride	methanesulfonyl-fluoride		CS(F)(=O)=O	Phase 2	https://en.wikipedia.org/wiki/Methanesulfonyl_fluoride	ACHE	https://en.wikipedia.org/wiki/Methanesulfonyl_fluoride	acetylcholinesterase inhibitor			
methenamine	methenamine	E239|hexamethylenamine|hexamethylenetetramine|hexamine|hiprex|urex|uritone|urotropin	C1N2CN3CN1CN(C2)C3	Launched	FDA Orange Book: methenamine hippurate			bacterial DNA inhibitor	infectious disease	urinary tract infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad741dc5-816c-4ab2-9273-9b1a586149bc
piperaquine-phosphate	piperaquine phosphate	Piperaquine	Clc1ccc2c(ccnc2c1)N1CCN(CCCN2CCN(CC2)c2ccnc3cc(Cl)ccc23)CC1	Launched	https://clinicaltrials.gov/ct2/show/NCT01930331			antimalarial agent	infectious disease	malaria	https://en.wikipedia.org/wiki/Piperaquine
canertinib	canertinib	CI-1033	Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00362986	EGFR|AKT1|ERBB2|ERBB4	https://www.drugbank.ca/drugs/DB05424|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000086|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5675|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000086	EGFR inhibitor			
pifithrin-mu	pifithrin-mu		NS(=O)(=O)C#Cc1ccccc1	Preclinical		TP53|HSPA1A	http://www.scbt.com/datasheet-203195-pifithrin-mu.html|http://www.scbt.com/datasheet-203195-pifithrin-mu.html	HSP inhibitor			
chlorocresol	chlorocresol		Cc1cc(O)ccc1Cl	Launched	http://www.drugs.com/international/Chlorocresol.html			ryanodine receptor activator	infectious disease	first-aid antiseptic	https://en.wikipedia.org/wiki/P-Chlorocresol
carbetocin	carbetocin		CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O	Launched	https://www.drugs.com/international/carbetocin.html	OXTR	https://www.drugbank.ca/drugs/DB01282	oxytocin receptor agonist	hematology	hemorrhage	https://en.wikipedia.org/wiki/Carbetocin#Medical_uses
bacitracin-zinc	bacitracin zinc			Launched	FDA Orange Book: bacitracin zinc			bacterial cell wall synthesis inhibitor	infectious disease	first-aid antibiotic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73cbb154-d543-4b63-ad72-5b580123d5d6
RG108	RG108	RG-108	OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O	Preclinical		DNMT1|DNMT3B	http://www.tocris.com/dispprod.php?ItemId=216684|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010387	DNA methyltransferase inhibitor			
GSK461364	GSK461364	GSK-461364|GSK-461364A	C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00536835	PLK1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5684	PLK inhibitor			
HA-966-(R)-(+)	(R)-(+)-HA-966		N[C@@H]1CCN(O)C1=O	Preclinical				glutamate receptor agonist			
pronethalol	pronethalol	AY 6204 [AS HYDROCHLORIDE]|GNF-Pf-2670|ICI 38174 [AS HYDROCHLORIDE]|nethalide|pronetalol	CC(C)NCC(O)c1ccc2ccccc2c1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs			adrenergic receptor antagonist			
maytansinol-isobutyrate	maytansinol-isobutyrate		CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2	Preclinical							
1-hexadecanol	1-hexadecanol	cetanol|cetyl alcohol|hexadecanol	CCCCCCCCCCCCCCCCO	Launched	http://en.wikipedia.org/wiki/Cetyl_alcohol				dermatology	cosmetic	https://en.wikipedia.org/wiki/Cetyl_alcohol
fomepizole	fomepizole	4-METHYLPYRAZOLE|4-MP|antizol	Cc1cn[nH]c1	Launched	FDA Orange Book: fomepizole	AKR1A1|CAT|ADH1C|ADH1B|ADH1A	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000568|https://www.drugbank.ca/drugs/DB01213|ChEMBL|ChEMBL|ChEMBL	alcohol dehydrogenase inhibitor	critical care	poison antidote	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c045b5a8-b220-4f0a-a831-155b29c19454
ibuprofen-lysine	ibuprofen lysine	ibuprofen lysine|neoprofen	NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)C(C)C(O)=O	Launched	FDA Orange Book: ibuprofen lysine	CYP2C8|PTGS2|PTGS1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=133198|ChEMBL|ChEMBL	cyclooxygenase inhibitor	cardiology	patent ductus arteriosus (PDA)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f5ede6f-b0b7-4fc8-969e-652f60ead047
cysteamine	cysteamine	L-1573|MEA|cystagon|cystaran|mercaptamine|procysbi		Launched	FDA Orange Book: cysteamine bitartrate, cysteamine hydrochloride	SST|TGM2|NPY2R	https://www.drugbank.ca/drugs/DB00847|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=233811|https://www.drugbank.ca/drugs/DB00847	tissue transglutaminase inhibitor	metabolism	cystinosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b98ee838-ed23-42a9-93b5-72579e490fba
difenpiramide	difenpiramide		O=C(Cc1ccc(cc1)-c1ccccc1)Nc1ccccn1	Launched	https://books.google.com/books?id=anRzslvfcUwC&pg=PA878&lpg=PA878&dq=difenpyramide&source=bl&ots=R8zl-NaoZn&sig=87g-TQ0KlH4DekB9DKF71hh4JI8&hl=en&sa=X&ved=0ahUKEwjwpoXL6KbRAhUq4IMKHR6lAVQQ6AEIMTAE#v=onepage&q=difenpyramide&f=false			cyclooxygenase inhibitor|prostaglandin inhibitor			
fluocinolone-acetonide	fluocinolone acetonide	capex|derma-smoothe/fs|dermotic|iluvien|retisert|synalar|synalar-hp		Launched	FDA Orange Book: fluocinolone acetonide	SERPINA6|NR3C1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000813|https://www.drugbank.ca/drugs/DB00591	glucocorticoid receptor agonist	dermatology	seborrheic dermatitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a52763d0-7024-48a8-9cca-3127333dfb01
phloretin	phloretin	2',4,4',6'-Tetrahydroxy-Dihydrochalcone|2',4,4',6'-Tetrahydroxydihydrochalcone	Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1	Launched	http://www.skinceuticals.com/phloretin-cf-635494328004.html	SLC23A1|AQP9|CLCN3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4285|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4285|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4285	sodium/glucose cotransporter inhibitor			
xanthone	xanthone		O=c1c2ccccc2oc2ccccc12	Preclinical				antimalarial agent			
hymecromone	hymecromone	LM-94|cantabiline	Cc1cc(=O)oc2cc(O)ccc12	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00225537	MAOA|MAOB	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12208|https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12208	monoamine oxidase inhibitor			
LY3023414	LY3023414		CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02549989	AKT1|MTOR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=783199|https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=738090	PI3K inhibitor|mTOR inhibitor			
SIB-1893	SIB-1893		Cc1cccc(\C=C\c2ccccc2)n1	Preclinical		GRM4|GRM5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1432|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1432	glutamate receptor antagonist			
BS-181	BS-181		CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12	Preclinical		CDK7	http://www.selleckchem.com/products/BS-181.html	CDK inhibitor			
tiopronin	tiopronin	thiola	CC(S)C(=O)NCC(O)=O	Launched	FDA Orange Book: tiopronin			chelating agent|reducing agent	urology	kidney stones	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=494a714e-923c-cd57-df6c-12886afb265a&audience=consumer
LIMKi-3	LIMKi-3		CC(C)C(=O)Nc1ncc(s1)-c1cc(nn1-c1c(Cl)cccc1Cl)C(F)F	Preclinical		LIMK1	https://www.tocris.com/products/limki-3_4745	LIM kinase inhibitor			
GW-627368	GW-627368		CCOc1c2CN(C(=O)c2c(OCC)c2ccccc12)c1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1	Preclinical		PTGER4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1953	prostanoid receptor antagonist			
MK-8745	MK-8745		Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1	Preclinical		AURKA	http://www.selleckchem.com/products/mk-8745.html	Aurora kinase inhibitor			
SDZ-NKT-343	SDZ-NKT-343		CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O	Phase 1	http://adisinsight.springer.com/drugs/800010524	TACR1	http://www.tocris.com/dispprod.php?ItemId=147429#.UuJ80v30BaE	tachykinin antagonist			
diazepam	diazepam	Apozepam|E-Pam|Paxel|Q-pam|RO 5-2807|Relanium|Scriptopam|Serenack|Stesolid|Tranimul|Vivol|WY-3467|diastat|diastat acudial|diazepam intensol|dizac|la iii|valium|valrelease	CN1c2ccc(Cl)cc2C(=NCC1=O)c1ccccc1	Launched	FDA Orange Book: diazepam	GABRB1|GABRB3|GABRB2|GABRA2|GABRA1|GABRA4|GABRA3|GABRA6|GABRA5|GABRG2|GABRG1|GABRG3|GABRR1|GABRR3|GABRR2|ADRA1A|GABRE|GABRD|GABRQ|GABRP|CYP2C19|TSPO	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00829|https://www.drugbank.ca/drugs/DB00829|https://www.drugbank.ca/drugs/DB00829|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3364|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091323|https://www.drugbank.ca/drugs/DB00829	benzodiazepine receptor agonist	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	generalized anxiety disorder (GAD)|abstinence from alcohol|hallucinosis|tremors	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa352464-14c8-49e9-b8b7-5a968b1cfa93|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa352464-14c8-49e9-b8b7-5a968b1cfa93|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa352464-14c8-49e9-b8b7-5a968b1cfa93|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa352464-14c8-49e9-b8b7-5a968b1cfa93
L-690330	L-690330		CC(Oc1ccc(O)cc1)(P(O)(O)=O)P(O)(O)=O	Preclinical		IMPA1	http://www.tocris.com/dispprod.php?ItemId=1542	inositol monophosphatase inhibitor			
PP242	PP242		CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12	Preclinical		MTOR|PASK	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5704|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5704	mTOR inhibitor			
losmapimod	losmapimod	GW-856553|GW856553X|gsk-ahab	Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02145468	MAPK14	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7835	p38 MAPK inhibitor			
benzethonium	benzethonium		CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1	Launched	http://en.wikipedia.org/wiki/Benzethonium_chloride	SCN10A|SCN9A	http://www.drugbank.ca/drugs/DB01086|https://citeline.informa.com/?query=#/drugs/details/923	sodium channel blocker	infectious disease	first-aid antiseptic	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37a75879-accb-4a6a-b8dd-558b94450fc4
AZD3965	AZD3965		CC(C)n1c2sc(Cc3c(C)[nH]nc3C(F)(F)F)c(C(=O)N3C[C@](C)(O)CO3)c2c(=O)n(C)c1=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT01791595	SLC16A7|SLC16A1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=768966|http://www.selleckchem.com/products/azd3965.html?gclid=Cj0KEQjwvIO_BRDt27qG3YX0w4wBEiQAsGu3eSh51RhVH6EBf4mW1m5mTjVfhK2P8NsfUSYp_evVUHoaAtW08P8HAQ	monocarboxylate transporter inhibitor			
acivicin	acivicin		N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/8192104	CTPS1|CAD|GGT1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000149|https://citeline.informa.com/?query=#/drugs/details/1196|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090116	gamma glutamyltransferase Inhibitors			
monosodium-alpha-luminol	monosodium-alpha-luminol		Nc1cccc2c1c(=O)[nH][nH]c2=O	Launched	http://bachpharma.com/pipeline.php						
rosamicin	rosamicin		CCC1OC(=O)CC(O)C(C)C(OC2OC(C)CC(C2O)N(C)C)C(CC=O)CC(C)C(=O)\C=C\C2(C)OC2C1C	Phase 2	https://www.ncbi.nlm.nih.gov/pubmed/7039760			protein synthesis inhibitor			
NS-19504	NS-19504		Nc1ncc(Cc2ccc(Br)cc2)s1	Preclinical		KCNMA1	https://www.tocris.com/products/ns-19504_5276	calcium-activated potassium channel activator			
etodolac	etodolac	AY-24,236|AY-24236|etodolic acid|lodine|lodine xl	CCc1cccc2c3CCOC(CC)(CC(O)=O)c3[nH]c12	Launched	FDA Orange Book: etodolac	TRPV1|PTGS1|PTGS2|RXRA	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090094|https://www.drugbank.ca/drugs/DB00749|ChEMBL|https://www.drugbank.ca/drugs/DB00749	cyclooxygenase inhibitor	rheumatology|rheumatology	osteoarthritis|rheumatoid arthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=420c7b62-3bea-4d6b-82e0-ab1c176c7f1e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=420c7b62-3bea-4d6b-82e0-ab1c176c7f1e
gestodene	gestodene		CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C	Launched	http://www.drugs.com/international/Gestodene.html			contraceptive agent	endocrinology	contraceptive	https://en.wikipedia.org/wiki/Gestodene
bilastine	bilastine		CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1	Launched	http://www.drugs.com/international/Bilastine.html	HRH1	https://en.wikipedia.org/wiki/Bilastine	histamine receptor antagonist	ophthalmology	conjunctivitis	https://en.wikipedia.org/wiki/Bilastine
NS-1643	NS-1643		Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F	Preclinical		KCNMA1|KCNH2|KCNH6	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2308|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2308|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2308	voltage-gated potassium channel activator			
lidocaine	lidocaine	Anestacon|Embolex|Iontocaine|Lidocaton|Lignocaine HCl|Lignostab|Octocaine|akten|alphacaine|dentipatch|lidocaine hydrochloride|lidocaine hydrochloride preservative free|lidoderm|lidopen|lignocaine|xylocaine|xylocaine dental|xylocaine preservative free|xylocaine viscous|zingo	CCN(CC)CC(=O)Nc1c(C)cccc1C	Launched	FDA Orange Book: lidocaine, lidocaine hydrochloride	SCN10A|SCN11A|SCN9A|SCN8A|SCN7A|SCN5A|SCN4A|SCN3A|SCN2A|SCN1A|EGFR	ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00281	histamine receptor agonist	neurology/psychiatry|dermatology|hematology	itching|eczema|hemorrhage	http://www.webmd.com/drugs/2/drug-76896/lidocaine-hc-topical/details|http://www.webmd.com/drugs/2/drug-76896/lidocaine-hc-topical/details|http://www.webmd.com/drugs/2/drug-76896/lidocaine-hc-topical/details
mesna	mesna	2-MERCAPTOETHANE|mesnex	OS(=O)(=O)CCS	Launched	FDA Orange Book: mesna			antioxidant	urology	hemorrhagic cystitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c79a07d-32cc-4fe7-9a74-152c169f1c4f
CGK-733	CGK-733		[O-][N+](=O)c1cc(NC(=S)NC(NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F	Preclinical		ATM|ATR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5929|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5929	ATM kinase inhibitor|ATR kinase inhibitor			
tiletamine	tiletamine		CCNC1(CCCCC1=O)c1cccs1	Veterinary Launched	http://www.drugs.com/international/tiletamine.html			glutamate receptor antagonist	neurology/psychiatry	anesthetic	https://en.wikipedia.org/wiki/Tiletamine
vortioxetine	vortioxetine	brintellix	Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1	Launched	FDA Orange Book: vortioxetine hydrobromide	CYP2C19|CYP2C8|CYP2B6|HTR7|HTR6|CYP3A5|SLC6A4|HTR5A|HTR1A|HTR1B|HTR3A|HTR2A|HTR2C|HTR1D	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=355504|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=355504|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=355504|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7351|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7351|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=355504|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7351|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7351|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7351|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7351|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7351|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7351|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7351|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=355504	serotonin receptor agonist|serotonin receptor antagonist	neurology/psychiatry	depression	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b0700c9-b417-4c3a-b36f-de461e125bd3
PNU-89843	PNU-89843		Cc1cc2c(nc(nc2n1C)N1CCCC1)N1CCCC1	Preclinical		GABBR1	https://en.wikipedia.org/wiki/GABAA_receptor	benzodiazepine receptor agonist			
elactocin	elactocin		CCC(\C=C\[C@H]1OC(=O)C=C[C@@H]1C)=C\[C@H](C)C\C=C\C(C)=C\[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C\C(C)=C\C(O)=O	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/8761384	XPO1	http://www.bloodjournal.org/content/120/23/4621	exportin antagonist			
estradiol-acetate	estradiol acetate	ESTRADIOL-3-ACETATE|estradiol acetate|femring|femtrace	CC(=O)Oc1ccc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2c1	Launched	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/	ESR1	ChEMBL	estrogen receptor agonist	endocrinology|obstetrics/gynecology	menopause|vaginal atrophy	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86b90d68-bfb6-47f6-aa5b-a6642391ff13|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86b90d68-bfb6-47f6-aa5b-a6642391ff13
compound-401	compound-401		O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1	Preclinical		PRKDC|MTOR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004793|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004793	DNA dependent protein kinase inhibitor			
eltanolone	eltanolone	Allopregnanolone	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/9303287	GABRB2|GABRA1|GABRG2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012877|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012877|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC012877	membrane integrity inhibitor			
motesanib	motesanib	AMG-706	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12	Phase 3	http://www.ncbi.nlm.nih.gov/pubmed/24419239	RET|PDGFRA|FLT4|FLT1|KIT|KDR	https://citeline.informa.com/?query=#/drugs/details/31493|https://citeline.informa.com/?query=#/drugs/details/31493|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5660|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5660|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000578|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5660	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor			
SB-206553	SB-206553		Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1	Preclinical		HTR1A|HTR2A|HTR2C|HTR2B	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=209946|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=189|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=189|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=189	serotonin receptor antagonist			
monobenzone	monobenzone	benoquin|monobenzyl ether of hydroquinone|p-benzyloxyphenol	Oc1ccc(OCc2ccccc2)cc1	Launched	FDA Orange Book: monobenzone	TYR	ChEMBL	melanin inhibitor	dermatology	skin depigmentation	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=addb5a47-6693-4f77-8622-c2631c17a119
levonorgestrel	levonorgestrel	Norplant ii|Norplant system|WY-5104|jadelle|liletta|mirena|norplant|plan b|plan b one-step|skyla	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	Launched	FDA Orange Book: levonorgestrel	AR|ESR1|SRD5A1|CYP2E1|PGR	https://www.drugbank.ca/drugs/DB00367|https://www.drugbank.ca/drugs/DB00367|https://www.drugbank.ca/drugs/DB00367|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=125558|ChEMBL	estrogen receptor agonist|glucocorticoid receptor antagonist|progesterone receptor agonist|progesterone receptor antagonist	endocrinology	contraceptive	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=efa6c9a7-ed87-4c86-ba37-534d55127755
garenoxacin	garenoxacin		C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1	Launched	https://www.drugs.com/international/garenoxacin.html	TOP2A	https://www.ncbi.nlm.nih.gov/pubmed/12384338	topoisomerase inhibitor	infectious disease	respiratory tract infections	http://www.taisho.co.jp/en/company/release/2007/2007100401-e.html
FGIN-1-43	FGIN-1-43		CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1	Preclinical		TSPO	https://en.wikipedia.org/wiki/FGIN-143	benzodiazepine receptor agonist			
beclomethasone	beclomethasone		CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(Cl)C(O)CC2(C)C1(O)C(=O)CO	Launched	FDA Orange Book: beclomethasone dipropionate, beclomethasone dipropionate monohydrate	SERPINA6|NR3C1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000416|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7059	glucocorticoid receptor agonist	allergy	allergic rhinitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a44782cf-4ab5-4c8a-79b7-221f21e40a34
NGB-2904	NGB-2904		Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl	Preclinical		DRD3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6674	dopamine receptor antagonist			
dihydromyricetin	dihydromyricetin		O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1	Preclinical							
daunorubicin	daunorubicin	cerubidine|daunorubicin hydrochloride|daunoxome	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O	Launched	FDA Orange Book: daunorubicin citrate, daunorubicin hydrochloride	TOP2B|TOP2A	https://www.drugbank.ca/drugs/DB00694|https://www.drugbank.ca/drugs/DB00694	RNA synthesis inhibitor|topoisomerase inhibitor	hematologic malignancy|hematologic malignancy	acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29fe455e-f177-4b0e-99fb-60a53016db72|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29fe455e-f177-4b0e-99fb-60a53016db72
TC-SP-14	TC-SP-14		OC(=O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1	Preclinical		S1PR1	https://www.tocris.com/products/tc-sp-14_4363	sphingosine 1 phosphate receptor agonist			
ML130	ML130		Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12	Preclinical				NOD1 inhibitor			
dienestrol	dienestrol	estraguard	C\C=C(c1ccc(O)cc1)\C(c1ccc(O)cc1)=C\C	Launched	FDA Orange Book: dienestrol	ESR1	ChEMBL	estrogen receptor agonist	endocrinology	menopause	https://en.wikipedia.org/wiki/Dienestrol
ML133	ML133		COc1ccc(CNCc2cccc3ccccc23)cc1	Preclinical				potassium channel blocker			
IOWH032	IOWH032		Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT02111304	CFTR	http://www.ncbi.nlm.nih.gov/pubmed/21859305	CFTR channel antagonist			
voreloxin	voreloxin	SNS-595|vosaroxin	CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1	Phase 3	https://clinicaltrials.gov/ct2/show/NCT01191801	PRKDC|TOP2A	https://citeline.informa.com/?query=#/drugs/details/23029|http://www.selleckchem.com/products/voreloxin-sns-595.html?gclid=CMH35ZvzxcwCFQcfhgodFiIGZg	topoisomerase inhibitor			
menadione	menadione	Kappaxin|Vitamin K 3|kayquinone|menaphthene|menaphthone	CC1=CC(=O)c2ccccc2C1=O	Launched	FDA Orange Book: menadione	PROS1|GGCX|VKORC1|NQO2|NQO1|PKM|AOX1|F10|VKORC1L1|PROC|PROZ|BGLAP|F2|F9|F7	https://www.drugbank.ca/drugs/DB00170|https://www.drugbank.ca/drugs/DB00170|https://www.drugbank.ca/drugs/DB00170|https://www.drugbank.ca/drugs/DB00170|https://www.drugbank.ca/drugs/DB00170|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=218848|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000544|https://www.drugbank.ca/drugs/DB00170|https://www.drugbank.ca/drugs/DB00170|https://www.drugbank.ca/drugs/DB00170|https://www.drugbank.ca/drugs/DB00170|https://www.drugbank.ca/drugs/DB00170|https://www.drugbank.ca/drugs/DB00170|https://www.drugbank.ca/drugs/DB00170|https://www.drugbank.ca/drugs/DB00170	mitochondrial DNA polymerase inhibitor|phosphatase inhibitor	gastroenterology|gastroenterology|neurology/psychiatry|dermatology|rheumatology	ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f159f62-0c66-4292-9255-e6747db6208d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f159f62-0c66-4292-9255-e6747db6208d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f159f62-0c66-4292-9255-e6747db6208d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f159f62-0c66-4292-9255-e6747db6208d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f159f62-0c66-4292-9255-e6747db6208d
cinoctramide	cinoctramide		COc1cc(cc(OC)c1OC)\C=C\C(=O)N1CCCCCCC1	Preclinical							
GR-159897	GR-159897		COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1	Preclinical		TAC1|TACR2	http://www.tocris.com/dispprod.php?ItemId=1488#.Uuf17f30BaE|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2115	tachykinin antagonist			
phenylpiracetam	phenylpiracetam		NC(=O)CN1CC(CC1=O)c1ccccc1	Launched	https://en.wikipedia.org/wiki/Phenylpiracetam			noradrenaline uptake inhibitor	neurology/psychiatry|neurology/psychiatry|neurology/psychiatry	anxiety|fatigue|depression	https://cosmicnootropic.com/products/phenotropil-phenylpiracetam|https://cosmicnootropic.com/products/phenotropil-phenylpiracetam|https://cosmicnootropic.com/products/phenotropil-phenylpiracetam
glutathione-monoisopropyl-ester	glutathione-monoisopropyl-ester		CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O	Phase 2	Integrity			lipid peroxidase inhibitor			
BMS-688521	BMS-688521		CN1C(=O)N(C(=O)[C@]11CN(C[C@H]1c1ccc(cc1)C#N)c1ccc(cn1)C(O)=O)c1cc(Cl)cc(Cl)c1	Preclinical		ICAM1	http://www.asianpharmaonline.org/pdf.php?j=2231-5691&vol=5&issue=1&ab=ab134	leukocyte function-associated antigen receptor antagonist|ICAM1 antagonist			
CGS-9896	CGS-9896		Clc1ccc(cc1)-n1[nH]c2c(cnc3ccccc23)c1=O	Preclinical		GABRG2|GABRB2|GABRA1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011501|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011501|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011501	GABA receptor antagonist			
CP-94253	CP-94253		CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1	Preclinical		HTR1B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3221	serotonin receptor agonist			
pheniramine	pheniramine		CN(C)CCC(c1ccccc1)c1ccccn1	Launched	FDA Orange Book: brompheniramine maleate, chlorpheniramine maleate, chlorpheniramine polistirex, dexbrompheniramine maleate, dexchlorpheniramine maleate, pheniramine maleate	HRH1	https://www.drugbank.ca/drugs/DB01620	histamine receptor antagonist	allergy|allergy	allergic rhinitis|urticaria	https://en.wikipedia.org/wiki/Pheniramine|https://en.wikipedia.org/wiki/Pheniramine
tobramycin	tobramycin	NEBRAMYCIN FACTOR 6|Nebicin|Nebramycin|Obramycin|Tobradex|Tobradex ST|aktob|bethkis|kitabis pak|nebcin|tobi|tobi podhaler|tobramycin sulfate|tobramycin sulfate (pharmacy bulk)|tobrex	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O	Launched	FDA Orange Book: tobramycin, tobramycin sulfate			bacterial 30S ribosomal subunit inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	bacterial septicemia|respiratory tract infections|meningitis|skin infections|urinary tract infections	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49151a62-191a-4ba8-8b8c-bd8535f2fdb3&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49151a62-191a-4ba8-8b8c-bd8535f2fdb3&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49151a62-191a-4ba8-8b8c-bd8535f2fdb3&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49151a62-191a-4ba8-8b8c-bd8535f2fdb3&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49151a62-191a-4ba8-8b8c-bd8535f2fdb3&audience=consumer
halofantrine	halofantrine	halfan	CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F	Launched	FDA Orange Book: halofantrine hydrochloride	CYP3A5|KCNN4|KCNH2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=090740|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000953|https://www.drugbank.ca/drugs/DB01218	antimalarial agent	infectious disease	malaria	https://en.wikipedia.org/wiki/Halofantrine
BE-2254	BE-2254		Oc1ccc(CCNCC2CCc3ccccc3C2=O)cc1	Phase 2	Pharmaprojects	ADRA1A	http://www.tocris.com/dispprod.php?ItemId=1441	adrenergic receptor antagonist			
bruceantin	bruceantin		COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1C(C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/6678872			protein synthesis inhibitor			
PF-4708671	PF-4708671		CCc1cncnc1N1CCN(CC1)Cc1nc2cc(ccc2[nH]1)C(F)(F)F	Preclinical		RPS6KB1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8036	ribosomal protein inhibitor			
alprostadil	alprostadil	PGE1|PROSTAGLANDIN E1|U-10,136|U-10136|caverject|caverject impulse|edex|muse|prostin|prostin vr pediatric	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	Launched	FDA Orange Book: alprostadil	PTGER1|PTGER2|PTGER4|PTGIR|CATSPER4|CATSPER3|CATSPER2|CATSPER1|PTGDR	ChEMBL|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1882|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1882|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1882|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1882|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1882|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1882|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1882	prostanoid receptor agonist	cardiology	congenital heart defects	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb155759-3889-4cb3-9695-42a588f4f689
benztropine-mesylate	benztropine mesylate	benztropine mesylate|cogentin	CN1[C@@H]2CC[C@@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1	Launched	FDA Orange Book: benztropine mesylate	HRH1|CHRM1|SLC6A3	https://www.drugbank.ca/drugs/DB00245|https://www.drugbank.ca/drugs/DB00245|https://www.drugbank.ca/drugs/DB00245	acetylcholine receptor antagonist	neurology/psychiatry|neurology/psychiatry	extrapyramidal symptoms (EPS)|Parkinson's Disease	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95620f40-5ddf-41b8-80a5-f658248f26f0#LINK_f3e3e79b-703a-4933-bc5f-92b50e8fa689|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95620f40-5ddf-41b8-80a5-f658248f26f0#LINK_f3e3e79b-703a-4933-bc5f-92b50e8fa689
salicylamide	salicylamide		NC(=O)c1ccccc1O	Launched	http://www.drugs.com/international/salicylamide.html			analgesic agent	neurology/psychiatry|endocrinology	pain relief|fever	https://en.wikipedia.org/wiki/Salicylamide|https://en.wikipedia.org/wiki/Salicylamide
REV-5901	REV-5901	REV-901	CCCCCC(O)c1cccc(OCc2ccc3ccccc3n2)c1	Phase 2	Pharmaprojects	ALOX5	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC011978	leukotriene receptor antagonist|lipoxygenase inhibitor			
CCG-63802	CCG-63802		Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1	Preclinical		RGS4	https://www.tocris.com/dispprod.php?ItemId=273255#.V-QZ7ZMrLy8	G protein signaling inhibitor			
methylprednisolone	methylprednisolone	depo-medrol|medrol|medrol acetate	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12	Launched	FDA Orange Book: methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate	NR3C1	https://www.drugbank.ca/drugs/DB00959	glucocorticoid receptor agonist	endocrinology|endocrinology|rheumatology|rheumatology|rheumatology|rheumatology|dermatology|infectious disease|allergy|dermatology|hematology|neurology/psychiatry|gastroenterology|gastroenterology	hypercalcemia|thyroiditis|ankylosing spondylitis|bursitis|osteoarthritis|psoriatic arthritis|seborrheic dermatitis|mycosis|allergic rhinitis|psoriasis|anemia|multiple sclerosis|ulcerative colitis|enteritis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf4d3d3-3f8a-4e20-9194-061658efca61
LY364947	LY364947	HTS-466284|LY-364947	c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1	Preclinical		TGFBR1	https://www.drugbank.ca/drugs/DB03921	TGF beta receptor inhibitor|p38 MAPK inhibitor			
refametinib	refametinib		COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01915589	MAP2K1|MAP2K2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7942|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7942	MEK inhibitor			
PD-198306	PD-198306		Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1	Preclinical		MAP2K2|MAP2K1|MAPK1|MAPK3	http://www.tocris.com/dispprod.php?ItemId=5161|http://www.tocris.com/dispprod.php?ItemId=5161|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=311005|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=311005	MAP kinase inhibitor|MEK inhibitor			
CNX-774	CNX-774		CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1	Preclinical		BTK	http://www.biovision.com/btk-inhibitor-cnx-774-8620.html	Bruton's tyrosine kinase (BTK) inhibitor			
cetylpyridinium	cetylpyridinium		CCCCCCCCCCCCCCCC[n+]1ccccc1	Launched	http://www.drugs.com/international/Cetylpyridinium.html				dental|dental	gingivitis|mouth inflammation	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=881d4d08-4b45-486a-93af-18c0e00a5b0e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=881d4d08-4b45-486a-93af-18c0e00a5b0e
nisin	nisin		CCC(C)C(N)C(=O)N\C(=C/C)C(=O)NC1CSCC(NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(NC1=O)C(C)CC)C(=O)NC1C(C)SCC(NC(=O)CNC(=O)C2CCCN2C1=O)C(=O)NC(CCCCN)C(=O)NC1C(C)SCC(NC(=O)CNC(=O)C(CCSC)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC1=O)C(=O)NC(CC(N)=O)C(=O)NC(CCSC)C(=O)NC(CCCCN)C(=O)NC1C(C)SCC2NC(=O)C(NC(=O)C(C)NC1=O)C(C)SCC(NC(=O)C(Cc1c[nH]cn1)NC2=O)C(=O)NC(CO)C(=O)NC(C(C)CC)C(=O)NC(Cc1c[nH]cn1)C(=O)NC(C(C)C)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O	Phase 1	Integrity			bacterial cell wall synthesis inhibitor			
tyrphostin-AG-18	tyrphostin-AG-18	AG-18|TYRPHOSTIN 23	Oc1ccc(C=C(C#N)C#N)cc1O	Preclinical		EGFR	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC008595	EGFR inhibitor|tyrosine kinase inhibitor			
AST-1306	AST-1306	ALL-3|allitinib	Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/24612546	ERBB4|ERBB2|EGFR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=638530|http://www.selleckchem.com/products/ast-1306.html|http://www.selleckchem.com/products/ast-1306.html	EGFR inhibitor			
clomifene	clomifene	RMI 16,312|clomid|isomer a|serophene|transclomiphene|zuclomifene|zuclomiphene	CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1	Launched	http://www.drugs.com/international/Clomifene.html	AR|ESR1	https://citeline.informa.com/?query=#/drugs/details/31778|https://www.drugbank.ca/drugs/DB00882	estrogen receptor antagonist	obstetrics/gynecology	infertility	https://en.wikipedia.org/wiki/Clomifene
levocabastine	levocabastine	R-50547|livostin	C[C@@H]1CN(CC[C@]1(C(O)=O)c1ccccc1)[C@H]1CC[C@](CC1)(C#N)c1ccc(F)cc1	Launched	FDA Orange Book: levocabastine hydrochloride	NTSR2|HRH1	https://www.drugbank.ca/drugs/DB01106|https://www.drugbank.ca/drugs/DB01106	histamine receptor antagonist	ophthalmology	conjunctivitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=420b3f66-87f0-47d8-947c-541e84eb594a
morniflumate	morniflumate	UP 164	FC(F)(F)c1cccc(Nc2ncccc2C(=O)OCCN2CCOCC2)c1	Launched	http://www.drugs.com/international/Morniflumate.html			anti-inflammatory agent	neurology/psychiatry	pain relief	http://www.drugs.com/international/morniflumate.html
doxepin	doxepin	cidoxepin|doxepin hydrochloride|silenor|sinequan|zonalon	CN(C)CC\C=C1\c2ccccc2COc2ccccc12	Launched	FDA Orange Book: doxepin hydrochloride	CYP2C19|ADRA2B|ADRA2C|ADRA2A|ADRA1A|ADRA1B|ADRA1D|KCNH2|HTR1A|HTR2A|HTR2B|HTR2C|HRH1|HRH2|HRH4|HTR6|SLC6A4|SLC6A3|SLC6A2|DRD2|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091437|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142|https://citeline.informa.com/?query=#/drugs/details/31505|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142|https://www.drugbank.ca/drugs/DB01142	histamine receptor antagonist	neurology/psychiatry|neurology/psychiatry	depression|anxiety	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1533343b-f1ed-4c3a-bb36-23a748452b05|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1533343b-f1ed-4c3a-bb36-23a748452b05
ITD-1	ITD-1		CCOC(=O)C1=C(C)NC2=C(C1c1ccc(cc1)-c1ccccc1)C(=O)CC(C)(C)C2	Preclinical		TGFBR2	https://www.tocris.com/products/itd-1_5068	TGF beta receptor inhibitor			
nimesulide	nimesulide	R 805	CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O	Launched	http://www.drugs.com/international/Nimesulide.html	LTF|PTGS1|PTGS2|PLA2G2E	https://www.drugbank.ca/drugs/DB04743|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7401|https://www.drugbank.ca/drugs/DB04743|https://www.drugbank.ca/drugs/DB04743	cyclooxygenase inhibitor	rheumatology|obstetrics/gynecology	osteoarthritis|menstrual pain	https://en.wikipedia.org/wiki/Nimesulide|https://en.wikipedia.org/wiki/Nimesulide
sulfamoxole	sulfamoxole	sulphamoxole	Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C	Launched	http://www.drugs.com/international/Sulfamoxole.html			PABA antagonist	infectious disease	urinary tract infections	http://www.drugs.com/international/sulfamoxole.html
tubastatin-a	Tubastatin A	Tubastatin A	CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO	Preclinical		HDAC6	http://www.selleckchem.com/products/tubastatin-a-hcl.html?gclid=CIjnip6o47oCFQto7AodOhwAXA	HDAC inhibitor			
hyodeoxycholic-acid	hyodeoxycholic acid		C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/6875384			atherosclerosis formation inhibitor			
phenylmercuric-acetate	phenylmercuric acetate		CC(=O)O[Hg]c1ccccc1	Preclinical				other antifungal			
calpeptin	calpeptin		CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O	Preclinical				calpain inhibitor			
cholic-acid	cholic acid	E1000|cholbam|cholic acid	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	Launched	http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm438572.htm	FABP6|ADH1C|GPBAR1|CES1|PLA2G1B|COX4I1|COX7C|COX7B|MT-CO1|MT-CO2|COX8A|MT-CO3|COX5A|COX5B|COX6C|COX6A2|COX6B1|FECH|COX7A1|ESRRG	https://www.drugbank.ca/drugs/DB02659|https://www.drugbank.ca/drugs/DB02659|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=609|https://www.drugbank.ca/drugs/DB02659|https://www.drugbank.ca/drugs/DB02659|https://www.drugbank.ca/drugs/DB02659|https://www.drugbank.ca/drugs/DB02659|https://www.drugbank.ca/drugs/DB02659|https://www.drugbank.ca/drugs/DB02659|https://www.drugbank.ca/drugs/DB02659|https://www.drugbank.ca/drugs/DB02659|https://www.drugbank.ca/drugs/DB02659|https://www.drugbank.ca/drugs/DB02659|https://www.drugbank.ca/drugs/DB02659|https://www.drugbank.ca/drugs/DB02659|https://www.drugbank.ca/drugs/DB02659|https://www.drugbank.ca/drugs/DB02659|https://www.drugbank.ca/drugs/DB02659|https://www.drugbank.ca/drugs/DB02659|https://www.drugbank.ca/drugs/DB02659	bile acid	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5b67402-8550-4604-97a0-c7b149fbf753|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5b67402-8550-4604-97a0-c7b149fbf753|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5b67402-8550-4604-97a0-c7b149fbf753
ethamivan	ethamivan	etamivan|vandid	CCN(CC)C(=O)c1ccc(O)c(OC)c1	Preclinical				respiratory stimulant			
naloxone-benzoylhydrazone	Naloxone Benzoylhydrazone	Naloxone Benzoylhydrazone	Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1	Preclinical		OPRK1|OPRM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1664|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1664	opioid receptor antagonist			
quinolinic-acid	Quinolinic Acid	Pyridine-2,3-Dicarboxylic Acid|Quinolinic Acid	OC(=O)c1cccnc1C(O)=O	Preclinical				glutamate receptor agonist			
topotecan	topotecan	hycamtin|topotecan hydrochloride	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O	Launched	FDA Orange Book: topotecan hydrochloride	TOP1MT|TOP1	https://www.drugbank.ca/drugs/DB01030|https://www.drugbank.ca/drugs/DB01030	topoisomerase inhibitor	oncology|oncology	small cell lung cancer|cervical cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715620fb-614f-40b6-8d3d-8494843d8518&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715620fb-614f-40b6-8d3d-8494843d8518&audience=consumer
doxercalciferol	doxercalciferol	hectorol	CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C	Launched	FDA Orange Book: doxercalciferol	VDR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2790	vitamin D receptor agonist	nephrology|endocrinology	chronic kidney disease (CKD)|hyperparathyroidism	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bb3ce2f-c77a-436f-980f-a02668f99fed|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bb3ce2f-c77a-436f-980f-a02668f99fed
TPPS4	TPPS4		OS(=O)(=O)c1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc([nH]2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc1[nH]2	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/9002262						
ZK-164015	ZK-164015		CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1	Preclinical		ESR2|ESR1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005072|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005072	estrogen receptor antagonist			
1-(2-chloro-5-methylphenoxy)-3-(isopropylamino)-2-propanol	1-(2-chloro-5-methylphenoxy)-3-(isopropylamino)-2-propanol		CC(C)NCC(O)COc1cc(C)ccc1Cl	Preclinical							
flumethasone	flumethasone		C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	Launched	https://www.drugs.com/international/flumetasone.html	PLA2G1B|NR3C1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001184|https://www.drugbank.ca/drugs/DB00223	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses	http://www.drugbank.ca/drugs/DB00663
acrivastine	acrivastine	BW 825C|BW-825C	Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1	Launched	FDA Orange Book: acrivastine	HRH1	ChEMBL	histamine receptor antagonist	allergy	allergic rhinitis	https://en.wikipedia.org/wiki/Acrivastine
CGP-78608	CGP-78608	CGP78608	C[C@@H](NCc1cc(Br)cc2[nH]c(=O)c(=O)[nH]c12)P(O)(O)=O	Preclinical				glutamate receptor antagonist			
nicardipine	nicardipine	cardene|cardene sr|nicardipine hydrochloride	COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1	Launched	FDA Orange Book: nicardipine hydrochloride	CACNB2|CALM1|CACNA1C|CACNA1D|CACNA2D1|PDE1A|PDE1B|ADORA3|CHRM3|CHRM4|CHRM1|CHRM2|CHRM5|ADRA1A|ADRA1B|ADRA1D	https://www.drugbank.ca/drugs/DB00622|https://www.drugbank.ca/drugs/DB00622|https://www.drugbank.ca/drugs/DB00622|https://www.drugbank.ca/drugs/DB00622|https://www.drugbank.ca/drugs/DB00622|https://www.drugbank.ca/drugs/DB00622|https://www.drugbank.ca/drugs/DB00622|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2559|https://www.drugbank.ca/drugs/DB00622|https://www.drugbank.ca/drugs/DB00622|https://www.drugbank.ca/drugs/DB00622|https://www.drugbank.ca/drugs/DB00622|https://www.drugbank.ca/drugs/DB00622|https://www.drugbank.ca/drugs/DB00622|https://www.drugbank.ca/drugs/DB00622|https://www.drugbank.ca/drugs/DB00622	calcium channel blocker	cardiology|cardiology	chronic stable angina|hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8f147b8-955f-4733-9178-2cfa0beb60d6|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8f147b8-955f-4733-9178-2cfa0beb60d6
rosiglitazone	rosiglitazone	Avandamet|Avandaryl|BRL-49653|avandia	CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	CYP2C8|ACSL4|INS|TRPC5|TRPM3|PPARG|FFAR1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=284437|https://www.drugbank.ca/drugs/DB00412|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=284437|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1056|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1056|https://www.drugbank.ca/drugs/DB00412|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1056	insulin sensitizer|PPAR receptor agonist			
testosterone-undecanoate	testosterone undecanoate	ORG 538|andriol|testosterone undecanoate	CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched	https://clinicaltrials.gov/ct2/show/NCT00421460	AR	ChEMBL	androgen receptor agonist	endocrinology	hypogonadism	https://en.wikipedia.org/wiki/Testosterone_undecanoate
Ro-25-6981	Ro-25-6981		C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1	Preclinical		SLC18A2|GRIN2B	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=259847|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001225				
trandolapril	trandolapril	mavik	CCOC(=O)[C@H](CCc1ccccc1)N[C@H](C)C(=O)N1C2CCCCC2C[C@H]1C(O)=O	Launched	FDA Orange Book: trandolapril	ACE	https://www.drugbank.ca/drugs/DB00519	angiotensin converting enzyme inhibitor	cardiology|cardiology	hypertension|myocardial infarction	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10f25119-9970-46fe-bf36-6fec6064895b&audience=consumer|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10f25119-9970-46fe-bf36-6fec6064895b&audience=consumer
CC-223	CC-223		CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT01177397	MTOR	http://www.ncbi.nlm.nih.gov/pubmed/25855786	mTOR inhibitor			
ERK5-IN-1	ERK5-IN-1		COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1	Preclinical		MAPK7|LRRK2	https://www.tocris.com/dispprod.php?ItemId=436602#.V-WJ15MrLy8|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=706805	MAP kinase inhibitor			
zonisamide	zonisamide	AD-810|CI-912|PD-110843|zonegran	NS(=O)(=O)Cc1noc2ccccc12	Launched	FDA Orange Book: zonisamide	CACNA1H|CACNA1G|CACNA1I|CA5B|CA5A|CA10|CA14|CA13|CA12|CA11|SCN7A|SCN5A|SCN4A|SCN4B|SCN9A|SCN8A|SCN3B|SCN3A|SCN2B|SCN2A|SCN1B|SCN1A|SCN11A|SCN10A|MAOA|MAOB|CA9|CA8|CA4|CA7|CA6|CA1|CA3|CA2	https://www.drugbank.ca/drugs/DB00909|https://www.drugbank.ca/drugs/DB00909|https://www.drugbank.ca/drugs/DB00909|https://www.drugbank.ca/drugs/DB00909|https://www.drugbank.ca/drugs/DB00909|https://www.drugbank.ca/drugs/DB00909|https://www.drugbank.ca/drugs/DB00909|https://www.drugbank.ca/drugs/DB00909|https://www.drugbank.ca/drugs/DB00909|https://www.drugbank.ca/drugs/DB00909|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00909|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00909|ChEMBL|https://www.drugbank.ca/drugs/DB00909|ChEMBL|https://www.drugbank.ca/drugs/DB00909|ChEMBL|ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00909|https://www.drugbank.ca/drugs/DB00909|https://www.drugbank.ca/drugs/DB00909|https://www.drugbank.ca/drugs/DB00909|https://www.drugbank.ca/drugs/DB00909|https://www.drugbank.ca/drugs/DB00909|https://www.drugbank.ca/drugs/DB00909|https://www.drugbank.ca/drugs/DB00909|https://www.drugbank.ca/drugs/DB00909|https://www.drugbank.ca/drugs/DB00909	sodium channel blocker|T-type calcium channel blocker	neurology/psychiatry|neurology/psychiatry	seizures|epilepsy	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31bb7426-63ab-4ccb-9b83-eed9fa912992|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31bb7426-63ab-4ccb-9b83-eed9fa912992
tetrahydrozoline	tetrahydrozoline	tetryzoline|tyzine	C1CN=C(N1)C1CCCc2ccccc12	Launched	FDA Orange Book: tetrahydrozoline hydrochloride			adrenergic receptor agonist	ophthalmology	eye irritation	https://en.wikipedia.org/wiki/Tetrahydrozoline
cipemastat	cipemastat	RO 32-3555/000|Ro-32-03555|trocade	CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)NO)C(=O)C1(C)C	Phase 3	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2491719/	ADAM17|MMP1|MMP8|MMP9|MMP2|MMP3|MMP13	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003574|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6466|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003574|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003574|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003574|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003574|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC003574	metalloproteinase inhibitor			
nitarsone	nitarsone		O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O	Veterinary Launched	http://www.drugs.com/international/Nitarsone.html				dermatology	blackhead disease	https://en.wikipedia.org/wiki/Nitarsone
pefloxacin	pefloxacin	1589 RB|EU-5306|Perflacine	CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1	Launched	http://www.drugs.com/international/pefloxacin.html	TOP2A	https://www.drugbank.ca/drugs/DB00487	bacterial DNA gyrase inhibitor	infectious disease|urology|infectious disease|infectious disease	gastrointestinal infections|urethritis|gonorrhea|urinary tract infections	https://en.wikipedia.org/wiki/Pefloxacin|https://en.wikipedia.org/wiki/Pefloxacin|https://en.wikipedia.org/wiki/Pefloxacin|https://en.wikipedia.org/wiki/Pefloxacin
SR-140333	SR-140333		CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1	Phase 2	http://adisinsight.springer.com/drugs/800003930	TACR1	https://www.drugbank.ca/drugs/DB05790	neurokinin receptor antagonist			
tolvaptan	tolvaptan	OPC-41061|samsca	Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc23)c(C)c1	Launched	FDA Orange Book: tolvaptan	AVPR2|AVPR1A	ChEMBL|https://www.drugbank.ca/drugs/DB06212	vasopressin receptor antagonist	endocrinology|cardiology|gastroenterology	hyponatremia|congestive heart failure|hepatic cirrhosis	https://en.wikipedia.org/wiki/Tolvaptan|https://en.wikipedia.org/wiki/Tolvaptan|https://en.wikipedia.org/wiki/Tolvaptan
obeticholic-acid	obeticholic acid	ocaliva	CCC1C(O)C2C3CCC(C(C)CCC(O)=O)C3(C)CCC2C2(C)CCC(O)CC12	Launched	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdfbe0cd-eb15-45a1-ac17-531bcda21aec	NR1H4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3435	FXR agonist	gastroenterology	primary biliary cholangitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdfbe0cd-eb15-45a1-ac17-531bcda21aec
filgotinib	filgotinib	G146034|GLPG-0634|GLPG0634	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01888874	TYK2|JAK2|JAK3|JAK1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7913|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7913|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7913|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7913	JAK inhibitor			
pregnanolone	pregnanolone		CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01336413			GABA receptor positive allosteric modulator			
buclizine	buclizine	bucladin-s	CC(C)(C)c1ccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)cc1	Launched	FDA Orange Book: buclizine hydrochloride	HRH1|CHRM1	https://www.drugbank.ca/drugs/DB00354|https://www.drugbank.ca/drugs/DB00354	histamine receptor antagonist	neurology/psychiatry	migraine headache	https://en.wikipedia.org/wiki/Buclizine
edoxaban	edoxaban	savaysa	CN(C)C(=O)[C@@H]1CC[C@H](NC(=O)C(=O)Nc2ccc(Cl)cn2)[C@H](C1)NC(=O)c1nc2CCN(C)Cc2s1	Launched	FDA Orange Book: edoxaban tosylate	CYP3A5|F10	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=386638|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7575	coagulation factor inhibitor	neurology/psychiatry|hematology|hematology|hematology|cardiology	stroke|pulmonary embolism (PE)|systemic embolism|deep vein thrombosis (DVT)|atrial fibrillation (AF)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e77d3400-56ad-11e3-949a-0800200c9a66|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e77d3400-56ad-11e3-949a-0800200c9a66|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e77d3400-56ad-11e3-949a-0800200c9a66|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e77d3400-56ad-11e3-949a-0800200c9a66|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e77d3400-56ad-11e3-949a-0800200c9a66
TAK-733	TAK-733		Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00948467	MAP2K1	http://www.selleckchem.com/products/tak-733.html?gclid=CIPont_dxcwCFYIfhgodIaYMDQ	MEK inhibitor			
WAY-362450	WAY-362450	FXR-450|XL335|turofexorate isopropyl	CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00509756	NR1H4	http://www.selleckchem.com/products/way-362450.html?gclid=CM_0uOn0xcwCFcdehgod1hcC3w	FXR agonist			
dirithromycin	dirithromycin	dynabac		Launched	FDA Orange Book: dirithromycin			bacterial 50S ribosomal subunit inhibitor	pulmonary	bronchitis	http://www.drugs.com/mtm/dirithromycin.html
luzindole	luzindole		CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12	Preclinical		MTNR1A|MTNR1B	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1363|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1363	melatonin receptor antagonist			
2-hydroxyethyl-salicylate	2-hydroxyethyl salicylate	NSC-72097	OCCOC(=O)c1ccccc1O	Launched	http://www.drugs.com/international/glycol-salicylate.html						
SB-203186	SB-203186		O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12	Preclinical		HTR4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=255	serotonin receptor antagonist			
ioxaglic-acid	ioxaglic acid	P-286|ioxaglic acid	CNC(=O)c1c(I)c(N(C)C(C)=O)c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(O)=O)c(I)c(C(=O)NCCO)c2I)c1I	Launched	http://en.wikipedia.org/wiki/Ioxaglic_acid			radiopaque medium	radiology	contrast agent	https://en.wikipedia.org/wiki/Ioxaglic_acid
piperonyl-butoxide	piperonyl butoxide	piperonyl butoxide	CCCCOCCOCCOCc1cc2OCOc2cc1CCC	Launched	FDA Orange Book: piperonyl butoxide			cytochrome P450 inhibitor	infectious disease	lice	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e19d2378-9800-4375-95e7-28fea074190d
proacipimox	proacipimox		COCc1c[n+]([O-])c(C)cn1	Phase 1	Pharmaprojects			cholesterol inhibitor			
apalutamide	apalutamide	ARN-509	CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F	Launched	FDA Orange Book: apalutamide	AR	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=465113	androgen receptor antagonist	oncology	prostate cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1cda4f7-cb33-46ea-b9ac-431f6452b1a5&audience=consumer
chloramphenicol	chloramphenicol	Amphicol|Chloramex|Chlorbiotic|Chlorofair|Chloroptic s.o.p.|Econochlor|Kernispray|Mychel|Mychel-S|Ophthochlor|Optomycin|Tevcocin|chloromycetin|chloroptic	OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O	Launched	FDA Orange Book: chloramphenicol, chloramphenicol palmitate, chloramphenicol sodium succinate	CD55|CYP2C19	https://www.drugbank.ca/drugs/DB00446|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070258	bacterial 50S ribosomal subunit inhibitor	infectious disease|endocrinology|infectious disease	meningitis|fever|cholera	https://en.wikipedia.org/wiki/Chloramphenicol|https://en.wikipedia.org/wiki/Chloramphenicol|https://en.wikipedia.org/wiki/Chloramphenicol
cevimeline	cevimeline	evoxac	C[C@H]1O[C@]2(CS1)CN1CCC2CC1.C[C@@H]1O[C@@]2(CS1)CN1CCC2CC1	Launched	FDA Orange Book: cevimeline hydrochloride	CHRM3|CHRM1	https://www.drugbank.ca/drugs/DB00185|https://www.drugbank.ca/drugs/DB00185	acetylcholine receptor agonist	rheumatology	sjogren's syndrome	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=773a19e8-4c3e-4414-99a6-aea98c9790ee
mivacurium	mivacurium	mivacron	COc1cc2CC[N+](C)(CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]3(C)CCc4cc(OC)c(OC)cc4[C@H]3Cc3cc(OC)c(OC)c(OC)c3)[C@H](Cc3cc(OC)c(OC)c(OC)c3)c2cc1OC	Launched	FDA Orange Book: mivacurium chloride	BCHE|CHRM3|CHRM2|CHRNA2	https://www.drugbank.ca/drugs/DB01226|https://www.drugbank.ca/drugs/DB01226|https://www.drugbank.ca/drugs/DB01226|https://www.drugbank.ca/drugs/DB01226	acetylcholine receptor antagonist	critical care|neurology/psychiatry	endotracheal intubation|muscle relaxant	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=916b8d1f-3f91-40fb-ab33-13069523c36d|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=916b8d1f-3f91-40fb-ab33-13069523c36d
3PO	3PO		O=C(\C=C\c1cccnc1)c1ccncc1	Preclinical		PFKFB3	https://www.medchemexpress.com/3PO.html	phosphofructokinase inhibitor			
R547	R547	R-547|RG-547	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/17121911	CCND1|CCNE1|CDK7|CDK2|CDK1|CDK4	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=405686|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=405686|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001079|https://www.drugbank.ca/drugs/DB08094|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5707|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5707	CDK inhibitor			
sotrastaurin	sotrastaurin	AEB-071|NVP-AEB071	CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01854606	PRKCQ|PRKCD|PRKCE|PRKCH|PRKCB|PRKCA	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946	PKC inhibitor			
bethanechol	bethanechol	urecholine	CC(C[N+](C)(C)C)OC(N)=O	Launched	FDA Orange Book: bethanechol chloride	CHRM4|CHRM3|CHRM2|CHRM1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=297|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=297|https://www.drugbank.ca/drugs/DB01019|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=297	acetylcholine receptor agonist	urology	urinary retention	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5138965-a698-413c-9981-d25313caa02e
PHA-568487	PHA-568487		O=C(N[C@H]1CN2CCC1CC2)c1ccc2OCCOc2c1	Preclinical		CHRNA7	https://www.tocris.com/products/pha-568487_3134	nicotinic receptor agonist			
lamivudine	lamivudine	GR 109714X|GR-109714X|epivir|epivir-hbv		Launched	FDA Orange Book: lamivudine			nucleoside reverse transcriptase inhibitor	infectious disease|infectious disease|infectious disease	human immunodeficiency virus (HIV-1)|acquired immunodeficiency syndrome (AIDS)|hepatitis B	https://en.wikipedia.org/wiki/Lamivudine|https://en.wikipedia.org/wiki/Lamivudine|https://en.wikipedia.org/wiki/Lamivudine
glucaric-acid	glucaric acid		O[C@@H]([C@H](O)[C@@H](O)C(O)=O)[C@H](O)C(O)=O	Phase 1	Pharmaprojects						
docosanol	docosanol	abreva|behenyl alcohol|lidakol|n-docosanol	CCCCCCCCCCCCCCCCCCCCCCO	Launched	FDA Orange Book: docosanol	TLR7|LPL	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001249|https://citeline.informa.com/?query=#/drugs/details/10488	lipase clearing factor inhibitor	dental	cold sore	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c39b38a7-dcdd-4c32-8f35-b565c4d3cec6
hydroxyzine	hydroxyzine	Orgatrax|atarax|hydroxyzine hydrochloride|vistaril	OCCOCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1	Launched	FDA Orange Book: hydroxyzine hydrochloride, hydroxyzine pamoate	HRH1	https://www.drugbank.ca/drugs/DB00557	antihistamine	neurology/psychiatry|allergy|neurology/psychiatry|dermatology|neurology/psychiatry|allergy|neurology/psychiatry|dermatology	anxiety|urticaria|itching|dermatosis|anxiety|urticaria|itching|dermatosis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7eaf5043-5c73-47af-904b-8e1fae02af2e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7eaf5043-5c73-47af-904b-8e1fae02af2e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7eaf5043-5c73-47af-904b-8e1fae02af2e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7eaf5043-5c73-47af-904b-8e1fae02af2e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7eaf5043-5c73-47af-904b-8e1fae02af2e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7eaf5043-5c73-47af-904b-8e1fae02af2e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7eaf5043-5c73-47af-904b-8e1fae02af2e|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7eaf5043-5c73-47af-904b-8e1fae02af2e
NFKB-activation-inhibitor-II	NFKB-activation-inhibitor-II		Cc1ccc(NCCCc2ccccc2)c(N)c1	Preclinical		RELA	http://www.emdmillipore.com/life-science-research/nf-%CE%BAb-activation-inhibitor-ii-jsh-23/EMD_BIO-481408/p_6Cub.s1LUxkAAAEWxWEfVhTm	NFkB pathway inhibitor			
fexinidazole	fexinidazole		CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1	Phase 2/Phase 3	https://clinicaltrials.gov/ct2/show/NCT01685827						
menadione-bisulfite	menadione-bisulfite	menadione sulfurous acid	CC1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01094444	GGCX|VKORC1L1|VKORC1	https://www.drugbank.ca/drugs/DB00170|https://www.drugbank.ca/drugs/DB00170|https://www.drugbank.ca/drugs/DB00170	vitamin K			
PCA-4248	PCA-4248		COC(=O)C1=C(C)NC(C)=C(C1C)C(=O)OCCSc1ccccc1	Phase 1	Pharmaprojects	PTAFR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6080	platelet activating factor receptor antagonist			
FLI-06	FLI-06		CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1	Preclinical				notch signaling inhibitor			
nintedanib	nintedanib	BIBF 1120|BIBF-1120|ofev	COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1	Launched	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205832s001lbl.pdf	FGFR1|FGFR2|FGFR3|FGFR4|PDGFRA|PDGFRB|FLT1|FLT4|KDR|LYN	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5936|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5936|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5936|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5936|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5936|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5936|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5936|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5936|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5936|https://citeline.informa.com/?query=#/drugs/details/26865	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	pulmonary	idiopathic pulmonary fibrosis (IPF)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da1c9f37-779e-4682-816f-93d0faa4cfc9
temsirolimus	temsirolimus	torisel	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO	Launched	FDA Orange Book: temsirolimus	MTOR|PTEN	https://www.drugbank.ca/drugs/DB06287|https://citeline.informa.com/?query=#/drugs/details/22915	mTOR inhibitor	oncology	renal cell carcinoma (RCC)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95b7dc92-2180-42f1-8699-3c28f609e674&audience=consumer
adenosine-phosphate	adenosine phosphate		Nc1ncnc2n(cnc12)C1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O	Launched	http://www.drugs.com/international/adenosine-phosphate.html	ACSS1|ACSS2|ACSL1|PYGL|TRPM4|PRKAB2|PRKAB1|PRKAA1|PDE4B|PDE4D|FBP1|ADCY1|PIM1|CREB1|ADK|HINT1	https://www.drugbank.ca/drugs/DB00131|https://www.drugbank.ca/drugs/DB00131|https://www.drugbank.ca/drugs/DB00131|https://www.drugbank.ca/drugs/DB00131|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2455|https://www.drugbank.ca/drugs/DB00131|https://www.drugbank.ca/drugs/DB00131|https://www.drugbank.ca/drugs/DB00131|https://www.drugbank.ca/drugs/DB00131|https://www.drugbank.ca/drugs/DB00131|https://www.drugbank.ca/drugs/DB00131|https://www.drugbank.ca/drugs/DB00131|https://www.drugbank.ca/drugs/DB00131|https://www.drugbank.ca/drugs/DB00131|https://www.drugbank.ca/drugs/DB00131|https://www.drugbank.ca/drugs/DB00131	adenosine receptor agonist			
loracarbef	loracarbef	LY-163892|Loracarbef hydrate|lorabid		Launched	FDA Orange Book: loracarbef			bacterial cell wall synthesis inhibitor	infectious disease|otolaryngology|pulmonary|infectious disease|infectious disease|infectious disease	ear infections|laryngitis|bronchitis|pneumonia|urinary tract infections|skin infections	http://www.medicinenet.com/loracarbef/page2.htm|http://www.medicinenet.com/loracarbef/page2.htm|http://www.medicinenet.com/loracarbef/page2.htm|http://www.medicinenet.com/loracarbef/page2.htm|http://www.medicinenet.com/loracarbef/page2.htm|http://www.medicinenet.com/loracarbef/page2.htm
BRD-7389	BRD-7389		O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23	Preclinical		RPS6KA3|RPS6KA2|RPS6KA1	https://www.tocris.com/products/brd-7389_4037|https://www.tocris.com/products/brd-7389_4037|https://www.tocris.com/products/brd-7389_4037	ribosomal protein inhibitor			
LY3009120	LY3009120	LY-3009120	CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C	Phase 1	https://clinicaltrials.gov/ct2/show/NCT02014116	BRAF|RAF1|ARAF	http://www.apexbt.com/ly3009120.html|http://www.apexbt.com/ly3009120.html|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=825749	RAF inhibitor			
diosgenin	diosgenin		C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1	Preclinical				steroid			
AZD5582	AZD5582		CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1	Preclinical		XIAP|BIRC3|BIRC2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7710|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7710|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7710	XIAP inhibitor			
ciclesonide	ciclesonide	RPR251526|alvesco|omnaris|zetonna	CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1	Launched	FDA Orange Book: ciclesonide	SERPINA6|NR3C1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000423|ChEMBL	glucocorticoid receptor agonist	allergy	allergic rhinitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e1c9d9-b8bc-4df9-acbb-d3a9c31a24b0
NVP-TAE226	NVP-TAE226		CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl	Preclinical		IGF1R|PTK2	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=438030|https://www.drugbank.ca/drugs/DB07460	protein tyrosine kinase inhibitor			
dihydrostreptomycin	dihydrostreptomycin		CN[C@H]1C(O)C(O)C(CO)OC1OC1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)OC(C)[C@]1(O)CO	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs			bacterial 30S ribosomal subunit inhibitor			
SC-560	SC-560		COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F	Preclinical		PTGS1	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC005798	cyclooxygenase inhibitor			
magnolol	magnolol		Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O	Preclinical		KCNA2|KCNA5|KCNA3|KCNE4|KCNE3|KCNE2|KCNE1|KCNC3|KCNC2|KCNC1|KCNH1|KCNH2|KCNAB2|KCNQ2|KCNQ1|KCNQ5|KCNQ3|KCNS3|PPARG|GABRA1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=233128|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=233128|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=233128|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=233128|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=233128|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=233128|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=233128|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=233128|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=233128|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=233128|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=233128|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=233128|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=233128|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=233128|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=233128|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=233128|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=233128|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=233128|https://en.wikipedia.org/wiki/Magnolol|https://en.wikipedia.org/wiki/Magnolol	PPAR receptor agonist			
nitisinone	nitisinone	SC-0735|orfadin	[O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F	Launched	FDA Orange Book: nitisinone	HPD	ChEMBL	hydroxyphenylpyruvate dioxygenase inhibitor	metabolism	tyrosinemia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d449b73-d503-4132-b978-d890491975df
GPP-78	GPP-78		O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1	Preclinical		NAMPT	https://www.tocris.com/products/gpp-78-hydrochloride_4835	NAMPT inhibitor			
zolmitriptan	zolmitriptan	311C90|zomig|zomig-zmt	CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12	Launched	FDA Orange Book: zolmitriptan	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F	https://www.drugbank.ca/drugs/DB00315|ChEMBL|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=60|https://www.drugbank.ca/drugs/DB00315	serotonin receptor agonist	neurology/psychiatry	migraine headache	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b4fe798-ccbd-e0cc-d219-5a70d8115f43
SGX523	SGX523	SGX-523	Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/22547164	MET	https://www.drugbank.ca/drugs/DB08584	hepatocyte growth factor receptor inhibitor			
PKI-166	PKI-166	CGP-75166|NVP-PKI166	C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/16203782	EGFR|ERBB2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7642|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=261824	EGFR inhibitor			
vidarabine	vidarabine	ARA-A|Arabinosyladenine|CI 673|CI-673|vira-a	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	Launched	FDA Orange Book: vidarabine	ADCY5|ADA	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=070439|http://www.drugbank.ca/drugs/DB00194	antiviral	infectious disease|infectious disease	virus herpes simplex (HSV)|varicella-zoster virus (VZV)	https://en.wikipedia.org/wiki/Vidarabine|https://en.wikipedia.org/wiki/Vidarabine
tiaprofenic-acid	tiaprofenic acid	RU 15060|tiaprofenic acid	CC(C(O)=O)c1ccc(s1)C(=O)c1ccccc1	Launched	http://en.wikipedia.org/wiki/Tiaprofenic_acid	PTGS1|PTGS2	https://www.drugbank.ca/drugs/DB01600|https://www.drugbank.ca/drugs/DB01600	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis	https://en.wikipedia.org/wiki/Tiaprofenic_acid
linoleic-acid	linoleic acid	OCTADECA-9,12-DIENOIC ACID|linoleate|linoleic acid	CCCCC\C=C/C\C=C/CCCCCCCC(O)=O	Phase 3	https://clinicaltrials.gov/ct2/show/NCT00706745	TRPM8|PPARG|FFAR4|FFAR1|HNF4A|KCNB1|FABP4	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC010899	oxidative stress inducer			
maxacalcitol	maxacalcitol		[2H]C([2H])([2H])C(O)(CCO[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C)C([2H])([2H])[2H]	Launched	http://www.chugai-pharm.co.jp/english/news/detail/20081128000000.html	VDR	http://www.ncbi.nlm.nih.gov/pubmed/26602563	vitamin D receptor agonist	endocrinology	hyperparathyroidism	http://www.drugs.com/international/maxacalcitol.html
teicoplanin	teicoplanin		CCCCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@@H](NC1=O)C(O)=O)c5)cc3Cl	Launched	http://www.drugs.com/international/teicoplanin.html			bacterial cell wall synthesis inhibitor			
betaine	betaine	Betaine, anhydrous|cystadane	C[N+](C)(C)CC(O)=O	Launched	FDA Orange Book: betaine hydrochloride			nitric oxide donor	metabolism	homocystinuria	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05964dae-8b84-467c-af97-c82706a3cad2
SC-12267	SC-12267		COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00820365	DHODH|IL17A|IFNG	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=354705|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL001252|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=354705	dihydroorotate dehydrogenase inhibitor			
CaMKII-IN-1	CaMKII-IN-1		Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12	Preclinical		AKT1|CAMK2A|MYLK|CAMK4	https://www.medchemexpress.com/CaMKII-IN-1.html|https://www.medchemexpress.com/CaMKII-IN-1.html|https://www.medchemexpress.com/CaMKII-IN-1.html|https://www.medchemexpress.com/CaMKII-IN-1.html	calcium/calmodulin dependent protein kinase inhibitor			
vanillylacetone	vanillylacetone	Zingerone	COc1cc(CCC(C)=O)ccc1O	Preclinical							
iocetamic-acid	iocetamic acid	MP-620|cholebrine|iocetamic acid	CC(CN(C(C)=O)c1c(I)cc(I)c(N)c1I)C(O)=O	Launched	FDA Orange Book: iocetamic acid			radiopaque medium	radiology	contrast agent	https://en.wikipedia.org/wiki/Iocetamic_acid
MR-948	MR-948		OCCc1ccc(OCCn2ccnc2)cc1	Phase 1	Pharmaprojects	TBXAS1	https://en.wikipedia.org/wiki/Thromboxane-A_synthase	thromboxane synthase inhibitor			
cotinine	cotinine		CN1[C@@H](CCC1=O)c1cccnc1	Phase 2	http://adisinsight.springer.com/drugs/800012833			nicotine metabolite			
torcitabine	torcitabine	2'-Deoxycytidine|Deoxycytidine	Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00128544	TK2|DCK	https://www.drugbank.ca/drugs/DB02594|https://www.drugbank.ca/drugs/DB02594	DNA polymerase inhibitor			
NNC-711	NNC-711		OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1	Preclinical		SLC6A1|SIGMAR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4669|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DPR000040	GABA uptake inhibitor			
LH846	LH846		Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl	Preclinical		CSNK1D	https://www.tocris.com/dispprod.php?ItemId=377320#.V-rIt5MrLy8	casein kinase inhibitor			
4EGI-1	4EGI-1		OC(=O)C(\Cc1ccccc1[N+]([O-])=O)=N\Nc1nc(cs1)-c1ccc(Cl)c(Cl)c1	Preclinical		EIF4E	https://www.tocris.com/dispprod.php?ItemId=371261#.Vydv32QrImI	protein synthesis inhibitor			
troclosene	troclosene		Cln1c(=O)[nH]c(=O)n(Cl)c1=O	Launched	http://www.drugs.com/international/troclosene.html						
dipyrocetyl	dipyrocetyl	diacetylsalicylic acid	CC(=O)Oc1cccc(C(O)=O)c1OC(C)=O	Launched	http://en.wikipedia.org/wiki/Dipyrocetyl			chelating agent	endocrinology|neurology/psychiatry	fever|pain relief	https://en.wikipedia.org/wiki/Dipyrocetyl|https://en.wikipedia.org/wiki/Dipyrocetyl
AMD11070	AMD11070	AMD070	NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12	Phase 1/Phase 2	https://clinicaltrials.gov/ct2/show/NCT00089466	CXCR4	http://www.ncbi.nlm.nih.gov/pubmed/22146583	CC chemokine receptor antagonist			
plerixafor	plerixafor	AMD3100|mozobil	C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1	Launched	FDA Orange Book: plerixafor	CCR4|CXCR4|ACKR3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=844|ChEMBL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=844	CC chemokine receptor antagonist	hematologic malignancy|hematologic malignancy	non-Hodgkin lymphoma (NHL)|multiple myeloma	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a56b1b78-0ae2-41b4-9c76-98ad9d439199|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a56b1b78-0ae2-41b4-9c76-98ad9d439199
prinaberel	prinaberel	ERB-041|PF-00913086	Oc1cc(C=C)c2oc(nc2c1)-c1ccc(O)c(F)c1	Phase 2	https://business.highbeam.com/436989/article-1G1-146524305/prinaberel-wyeth-phase-change-ii-usa	ESR2|NCOA1	https://www.drugbank.ca/drugs/DB06832|https://www.drugbank.ca/drugs/DB06832	estrogen receptor agonist			
hexoprenaline	hexoprenaline		OC(CNCCCCCCNCC(O)c1ccc(O)c(O)c1)c1ccc(O)c(O)c1	Launched	http://www.drugs.com/international/hexoprenaline.html	ADRB2	https://en.wikipedia.org/wiki/Hexoprenaline	adrenergic receptor agonist	pulmonary	asthma	https://en.wikipedia.org/wiki/Hexoprenaline
pumosetrag	pumosetrag	DDP733	Oc1c(cnc2ccsc12)C(=O)N[C@H]1CN2CCC1CC2	Phase 2	https://clinicaltrials.gov/ct2/show/NCT01161602	HTR3A|HTR4	https://www.ncbi.nlm.nih.gov/pubmed/24001105|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000939	serotonin receptor agonist			
nedaplatin	nedaplatin			Launched	http://www.drugs.com/international/Nedaplatin.html			DNA inhibitor			
perillyl-alcohol	perillyl alcohol		CC(=C)C1CCC(CO)=CC1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00003219	FNTA	http://www.ncbi.nlm.nih.gov/pubmed/9591189	apoptosis stimulant|farnesyltransferase inhibitor			
dimercaptosuccinic-acid	Dimercaptosuccinic Acid	DMSA|Dimercaptosuccinic Acid|chemet|dim-sa|succimer	OC(=O)[C@@H](S)[C@@H](S)C(O)=O	Launched	https://clinicaltrials.gov/ct2/show/NCT00136656	DNMT1	http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0078752#pone-0078752-t001	chelating agent	neurology/psychiatry	metal toxicity	https://en.wikipedia.org/wiki/Dimercaptosuccinic_acid
CGP-52411	CGP-52411	4,5-DIANILINOPHTHALIMIDE|DAPH	O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12	Preclinical		EGFR	http://www.sigmaaldrich.com/catalog/product/sigma/d3943?lang=en&region=US	EGFR inhibitor			
LY2603618	LY2603618	IC-83|LY-2603618|rabusertib	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1	Phase 2	https://clinicaltrials.gov/ct2/show/NCT00988858	CHEK1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7960	CHK inhibitor			
quinine-ethyl-carbonate	quinine ethylcarbonate		CCOC(=O)O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccc(OC)cc12	Launched	http://en.wikipedia.org/wiki/Quinine				infectious disease	malaria	https://en.wikipedia.org/wiki/Quinine
meprylcaine	meprylcaine		CCCNC(C)(C)COC(=O)c1ccccc1	Preclinical				local anesthetic			
milrinone	milrinone	WIN 47,203-2|WIN-47203-2|milrinone lactate|primacor	Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N	Launched	FDA Orange Book: milrinone lactate	PDE5A|PDE2A|PDE3B|PDE3A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5225|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5225|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5225|https://www.drugbank.ca/drugs/DB00235	phosphodiesterase inhibitor	cardiology	congestive heart failure	https://en.wikipedia.org/wiki/Milrinone
octopamine	octopamine	ND 50	NCC(O)c1ccc(O)cc1	Preclinical		TAAR1|F10	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2149|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000184	trace amine associated receptor agonist			
FPL-55712	FPL-55712		CCCc1c(OCC(O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O	Phase 1	Cortellis			leukotriene receptor antagonist			
propylhexedrine	propylhexedrine	dristan inhaler	CNC(C)CC1CCCCC1	Launched	http://www.drugs.com/international/propylhexedrine.html	SLC18A2|TAAR1	https://www.drugbank.ca/drugs/DB06714|https://www.drugbank.ca/drugs/DB06714	adrenergic receptor agonist	otolaryngology|endocrinology|allergy	nasal congestion|fever|allergic rhinitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03a8ef3c-a808-6208-e054-00144ff8d46c|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03a8ef3c-a808-6208-e054-00144ff8d46c|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03a8ef3c-a808-6208-e054-00144ff8d46c
L-Theanine	L-Theanine		CCNC(=O)CCC(N)C(O)=O	Launched	https://clinicaltrials.gov/ct2/show/NCT00981955			glutamate receptor antagonist			
niridazole	niridazole	BA 32644	[O-][N+](=O)c1cnc(s1)N1CCNC1=O	Launched	http://www.drugs.com/international/Niridazole.html			phosphofructokinase inhibitor	infectious disease	schistosomiasis	https://en.wikipedia.org/wiki/Schistosomiasis
aprepitant	aprepitant	emend	C[C@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	Launched	FDA Orange Book: aprepitant, fosaprepitant dimeglumine	CYP2C19|TACR1	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=250157|https://www.drugbank.ca/drugs/DB00673	tachykinin antagonist	gastroenterology|gastroenterology	nausea|vomiting	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=696f9e80-9cae-403b-de9e-078343ce4713|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=696f9e80-9cae-403b-de9e-078343ce4713
moxalactam	moxalactam	Moxam|latamoxef		Launched	FDA Orange Book: moxalactam disodium			bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|infectious disease|infectious disease|infectious disease	skin infections|bone and joint infections|pneumonia|urinary tract infections|meningitis	http://www.drugbank.ca/drugs/DB04570|http://www.drugbank.ca/drugs/DB04570|http://www.drugbank.ca/drugs/DB04570|http://www.drugbank.ca/drugs/DB04570|http://www.drugbank.ca/drugs/DB04570
methyldopate	methyldopate	aldomet|methyldopate hydrochloride	CCOC(=O)[C@@](C)(N)Cc1ccc(O)c(O)c1	Launched	FDA Orange Book: methyldopate hydrochloride				cardiology	hypertension	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5f25053-a9f3-48b9-a412-078f5ee942fd
VU-0240551	VU-0240551		Cc1csc(NC(=O)CSc2ccc(nn2)-c2ccccc2)n1	Preclinical		SLC12A5	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4665	potassium/chloride cotransporter inhibitor			
val	val	D-Valine	CC(C)[C@@H](N)C(O)=O	Phase 2	https://clinicaltrials.gov/show/NCT02145949	PCCB|BCAT1|VARS	https://www.drugbank.ca/drugs/DB00161|https://www.drugbank.ca/drugs/DB00161|https://www.drugbank.ca/drugs/DB00161				
licofelone	licofelone	ML-3000	CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1	Phase 3	http://en.wikipedia.org/wiki/Licofelone	ALOX5|PTGS2|PTGS1|PTGES|PLA2G2E	https://www.drugbank.ca/drugs/DB04725|https://www.drugbank.ca/drugs/DB04725|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=210861|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=210861|https://www.drugbank.ca/drugs/DB04725	cyclooxygenase inhibitor|lipoxygenase inhibitor			
nimorazole	nimorazole	K-1900	[O-][N+](=O)c1cncn1CCN1CCOCC1	Launched	http://www.drugs.com/international/nimorazole.html			bacterial DNA inhibitor	oncology	head and neck squamous cell carcinoma (HNSCC)	https://en.wikipedia.org/wiki/Nimorazole
RS-67506	RS-67506		COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1	Preclinical		HTR4	https://www.tocris.com/dispprod.php?ItemId=2310#.Vyuh-WQrJZI	serotonin receptor partial agonist			
Y-26763	Y-26763		CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	Phase 1	http://www.ncbi.nlm.nih.gov/pubmed/8739023	ABCC9|KCNJ8	https://citeline.informa.com/?query=#/drugs/details/19372|https://www.tocris.com/dispprod.php?ItemId=103301#.VyzPKGQrJZI	potassium channel activator			
flutamide	flutamide	Drogenil|SCH 13521|SCH-13521|eulexin	CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	Launched	FDA Orange Book: flutamide	AHR|AR|CYP2C19	https://www.drugbank.ca/drugs/DB00499|ChEMBL|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091129	androgen receptor antagonist	oncology	prostate cancer	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bae781d4-7101-4008-9af2-6e76b5e1c408
cedrol	cedrol		CC1CCC2C(C)(C)C3CC12CCC3(C)O	Phase 2	http://www.ncbi.nlm.nih.gov/pubmed/22341589						
tetramisole	tetramisole		C1CN2CC(N=C2S1)c1ccccc1	Launched	http://www.drugs.com/international/tetramisole.html			immunostimulant	infectious disease	gastrointestinal parasites	http://www.genera.hr/pro/en/1652/#.Vt2oeowrK-s
remimazolam	remimazolam		COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02290873	GABBR1	https://www.ncbi.nlm.nih.gov/pubmed/21154153	benzodiazepine receptor agonist			
alclometasone-dipropionate	alclometasone dipropionate	aclovate|alclometasone dipropionate	CCC(=O)OCC(=O)C1(OC(=O)CC)[C@H](C)C[C@H]2C3[C@H](Cl)CC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C	Launched	FDA Orange Book: alclometasone dipropionate	NR3C1|CYP3A4|SERPINA6	http://www.drugbank.ca/drugs/DB00240|http://www.drugbank.ca/drugs/DB00240|http://www.drugbank.ca/drugs/DB00240	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e688309-880a-4890-bf00-90afd19084f6
tie2-kinase-inhibitor	tie2-kinase-inhibitor		COc1ccc2cc(ccc2c1)-c1nc([nH]c1-c1ccncc1)-c1ccc(cc1)S(C)=O	Preclinical		TEK|KDR|MAPK14	https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=462876|http://www.scbt.com/datasheet-356156.html|http://www.scbt.com/datasheet-356156.html	TIE tyrosine kinase inhibitor			
fluphenazine	fluphenazine	fluphenazine hydrochloride|permitil|prolixin|prolixin enanthate	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	Launched	FDA Orange Book: fluphenazine decanoate, fluphenazine enanthate, fluphenazine hydrochloride	CALM1|HRH1|HTR7|HTR6|HTR2A|DRD5|DRD1|DRD2|CHRNA7	https://www.drugbank.ca/drugs/DB00623|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=204|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=204|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=204|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=204|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=204|https://www.drugbank.ca/drugs/DB00623|https://www.drugbank.ca/drugs/DB00623|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=091406	dopamine receptor antagonist	neurology/psychiatry	schizophrenia	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8ba014e-aea0-49bc-8345-4e0a384b484e
betamethasone-valerate	betamethasone valerate	beta-val|betaderm|betamethasone valerate|betatrex|dermabet|luxiq|valisone|valnac	CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO	Launched	FDA Orange Book: betamethasone valerate	NR3C1	ChEMBL	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b386ccc-a2d4-4d18-a2d7-e46ff894c674
phenylbutazone	phenylbutazone	Antadol|Butaject|Elmedal|Equiphar|Pro-Bute|azolid|butazolidin|diphenylbutazone	CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	Withdrawn	https://en.wikipedia.org/wiki/List_of_withdrawn_drugs	PTGS1|PTGS2|PTGIS	ChEMBL|ChEMBL|https://www.drugbank.ca/drugs/DB00812	cyclooxygenase inhibitor|prostanoid receptor antagonist			
AMD-3465	AMD-3465		C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1	Preclinical		CXCR4	https://www.tocris.com/products/amd-3465-hexahydrobromide_4179	CC chemokine receptor antagonist			
BW-723C86	BW-723C86		CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12	Preclinical		HTR2B|HTR2C|HTR2A	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=161|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=161|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=161	serotonin receptor agonist			
D-Serine	D-Serine	(d)-serine	N[C@H](CO)C(O)=O	Launched	https://clinicaltrials.gov/ct2/show/NCT01018056	GRIN2A|GRIN2D|GRIN2B|GRIN2C|GLRA1|GRIN1|SERPINB3	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4171|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4171|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4171|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4171|https://www.drugbank.ca/drugs/DB03929|https://www.drugbank.ca/drugs/DB03929|https://www.drugbank.ca/drugs/DB03929	glutamate receptor agonist			
epinastine	epinastine	elestat	NC1=NCC2N1c1ccccc1Cc1ccccc21	Launched	FDA Orange Book: epinastine hydrochloride	HTR2A|HTR7|ADRA1A|ADRA2A|HRH1|HRH2	https://www.drugbank.ca/drugs/DB00751|https://www.drugbank.ca/drugs/DB00751|https://www.drugbank.ca/drugs/DB00751|https://www.drugbank.ca/drugs/DB00751|https://www.drugbank.ca/drugs/DB00751|https://www.drugbank.ca/drugs/DB00751	histamine receptor antagonist	ophthalmology	conjunctivitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df001833-f478-ee51-325a-9e1b56199567
UNC0631	UNC0631		COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C	Preclinical		EHMT2	http://www.selleckchem.com/products/unc0631.html	histone lysine methyltransferase inhibitor			
gamma-aminobutyric-acid	gamma-aminobutyric acid	gamma-aminobutyric acid	NCCCC(O)=O	Preclinical		KCTD8|SLC6A1|GABBR2|GABBR1|KCTD12|KCTD16|GATM|GABRB2|GABRA5|GABRA3|GABRA2|GABRA1|GABRG2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004037|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067|https://www.drugbank.ca/drugs/DB02530|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004037|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004037|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004037|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004037|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004037|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC004037	benzodiazepine receptor agonist			
UNC0638	UNC0638		COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1	Preclinical		EHMT1|EHMT2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7015|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7015	histone lysine methyltransferase inhibitor			
FPL-62064	FPL-62064		COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1	Phase 2	http://adisinsight.springer.com/drugs/800003357			cyclooxygenase inhibitor|lipoxygenase inhibitor			
tozadenant	tozadenant	RO4494351|RO4494351-000|RO4494351-002|SYN115	COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12	Phase 3	https://clinicaltrials.gov/ct2/show/NCT02453386	ADORA2A	http://www.biocentury.com/products/tozadenant	adenosine receptor antagonist			
carboxylosartan	carboxylosartan	Carboxylic Acid Metabolite (E-3174)|carboxylic acid metabolite	CCCCc1nc(Cl)c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1	Phase 1	https://www.ncbi.nlm.nih.gov/pubmed/7702795	AGTR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=586	angiotensin antagonist			
IKK-16	IKK-16		O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1	Preclinical		IKBKB	https://www.tocris.com/dispprod.php?ItemId=160784#.VykEM2QrImI	IKK inhibitor			
BMS-599626	BMS-599626	AC-480	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12	Phase 1	https://clinicaltrials.gov/ct2/show/NCT00207012	ERBB4|ERBB3|ERBB2|EGFR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7647|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=393950|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7647|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7647	EGFR inhibitor|protein tyrosine kinase inhibitor			
4-IBP	4-IBP		Ic1ccc(cc1)C(=O)NC1CCN(Cc2ccccc2)CC1	Preclinical		SIGMAR1	https://www.tocris.com/dispprod.php?ItemId=2021#.VydvaGQrImI	sigma receptor agonist			
1-hexadecanal	1-hexadecanal	Palmitaldehyde	CCCCCCCCCCCCCCCC=O	Preclinical		RHO|DBI	https://www.drugbank.ca/drugs/DB03381|https://www.drugbank.ca/drugs/DB03381	sphingosine 1 phosphate receptor substrate			
naphthoquine-phosphate	naphthoquine phosphate		CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O	Launched	http://www.kpc.com.cn/en/cp/ShowArticle.asp?ArticleID=22			antimalarial agent			
cefadroxil	cefadroxil	duricef	CC1=C(N2[C@H](SC1)[C@H](NC(=O)C(N)c1ccc(O)cc1)C2=O)C(O)=O	Launched	FDA Orange Book: cefadroxil/cefadroxil hemihydrate	SLC22A8|SLC22A6|SLC15A2|SLC15A1	http://www.drugbank.ca/drugs/DB01140|http://www.drugbank.ca/drugs/DB01140|http://www.drugbank.ca/drugs/DB01140|http://www.drugbank.ca/drugs/DB01140	bacterial cell wall synthesis inhibitor	infectious disease|infectious disease|otolaryngology|otolaryngology	urinary tract infections|skin infections|tonsillitis|pharyngitis	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba26618e-4a67-42a3-a194-f4ab6bc04bc7|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba26618e-4a67-42a3-a194-f4ab6bc04bc7|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba26618e-4a67-42a3-a194-f4ab6bc04bc7|https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba26618e-4a67-42a3-a194-f4ab6bc04bc7
3-deazauridine	3-deazauridine		OCC1OC(C(O)C1O)N1C=CC(=O)CC1=O	Preclinical				cytidine deaminase inhibitor			
tribromoethanol	tribromoethanol	avertin	OCC(Br)(Br)Br	Preclinical				analgesic agent			
3-(4-methylbenzylidene)camphor	3-(4-methylbenzylidene)camphor		Cc1ccc(cc1)\C=C1\C2CCC(C)(C1=O)C2(C)C	Launched	http://en.wikipedia.org/wiki/4-Methylbenzylidene_camphor			endocrine disruptor	dermatology	sunscreen lotion	https://en.wikipedia.org/wiki/4-Methylbenzylidene_camphor
seclazone	seclazone	W-2354	Clc1ccc2OC3CCON3C(=O)c2c1	Phase 1	https://books.google.com/books?id=-DZRx_kaaCMC&pg=PA191&lpg=PA191&dq=seclazone+clinical+trial&source=bl&ots=TaRIFVN5uF&sig=Hi5Y0mX8AX62tDTWFox233ckg4o&hl=en&sa=X&ved=0ahUKEwjGwrOqkOjRAhVD22MKHUZECtIQ6AEILjAD#v=onepage&q=seclazone%20clinical%20trial&f=false			anti-inflammatory agent			
enbucrilate	enbucrilate		CCCCOC(=O)C(=C)C#N	Launched	http://www.drugs.com/international/enbucrilate.html				dermatology|dermatology	skin lacerations|tissue adhesive	https://en.wikipedia.org/wiki/Butyl_cyanoacrylate|https://en.wikipedia.org/wiki/Butyl_cyanoacrylate
dibutyl-phthalate	dibutyl phthalate	dibutyl phthalate|dibutylphthalate	CCCCOC(=O)c1ccccc1C(=O)OCCCC	Preclinical		TRPA1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6295				
D-(+)-maltose	D-(+)-maltose		OC[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical							
ZM-226600	ZM-226600		CC(O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c1ccccc1)C(F)(F)F	Preclinical				Kir6 channel (KATP) activator			
tamsulosin	tamsulosin	flomax	CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O	Launched	FDA Orange Book: tamsulosin hydrochloride	ADRA1B|ADRA1A|ADRA1D	https://www.drugbank.ca/drugs/DB00706|https://www.drugbank.ca/drugs/DB00706|https://www.drugbank.ca/drugs/DB00706	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=339c3b57-a339-4578-bfd7-46b25d911ff6&audience=consumer
SB-431542	SB-431542		NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1	Preclinical		ACVR1C|ACVR1B|TGFBR1	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8216|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=315909|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8216	TGF beta receptor inhibitor			
MG-624	MG-624	stilonium	CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1	Preclinical		CHRNA7	http://www.sigmaaldrich.com/catalog/product/sigma/m3184?lang=en&region=US	acetylcholine receptor antagonist			
riboflavin	riboflavin	E101|Riboflavin (Vit B2)|Riboflavine|VITAMIN B2|Vitamin B 2|flavaxin|lactoflavin|photrexa|riboflavin tetrabutyrate|vitamin g		Launched	FDA Orange Book: riboflavin, riboflavin 5'-phosphate sodium	BLVRB|RFK	https://www.drugbank.ca/drugs/DB00140|https://www.drugbank.ca/drugs/DB00140	vitamin B2	gastroenterology	jaundice	https://en.wikipedia.org/wiki/Riboflavin#Medical_uses
sofalcone	sofalcone		CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1	Launched	http://www.drugs.com/international/Sofalcone.html	HPGD|CBR1	https://citeline.informa.com/?query=#/drugs/details/17083|http://www.drugbank.ca/drugs/DB05197	mucus protecting agent	gastroenterology	peptic ulcer disease (PUD)	http://www.drugs.com/international/sofalcone.html
cyromazine	cyromazine	CGA 72662	Nc1nc(N)nc(NC2CC2)n1	Launched	http://www.drugs.com/international/Cyromazine.html						
hexonic-acid	hexonic acid		OCC(O)C(O)C(O)C(O)C(O)=O	Preclinical							
L-655,708	L-655,708		CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21	Preclinical				GABA receptor inverse agonist			
ammonium-glycyrrhizinate	ammonium glycyrrhizinate		C[C@]12CC[C@@](C)(C[C@H]1C1=CC(=O)[C@@H]3[C@]4(C)CC[C@H](O[C@H]5O[C@@H]([C@@H](O)[C@H](O)[C@@H]5O[C@@H]5O[C@@H]([C@@H](O)[C@H](O)[C@H]5O)C(O)=O)C(O)=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2)C(O)=O	Launched	http://en.wikipedia.org/wiki/Glycyrrhizin	SLCO1B1|SLCO1B3|HSD11B2|HSD11B1|F2	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4688|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4688|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009905|http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009905|https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=221049	thrombin inhibitor	dermatology	cosmetic	http://www.ewg.org/skindeep/ingredient/700369/AMMONIUM_GLYCYRRHIZATE/
guaiacol	guaiacol		COc1ccccc1O	Launched	http://www.drugs.com/international/guaiacol.html	CA2	http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC009129	local anesthetic			
Y-11	Y-11		OCC[N+]12CN3CN(CN(C3)C1)C2	Preclinical		PTK2	https://www.tocris.com/products/y-11_4498	focal adhesion kinase inhibitor			
estriol	estriol	estriol acetate benzoate|estriol propionate|estriol succinate|oestriol|theelol		Launched	http://www.drugs.com/international/Estriol.html	ESR2|ESR1	https://www.drugbank.ca/drugs/DB04573|https://www.drugbank.ca/drugs/DB04573	estrogen receptor agonist	endocrinology|obstetrics/gynecology|infectious disease	menopause|vaginal atrophy|urinary tract infections	http://www.virginiahopkinstestkits.com/estriolhormone.html|http://www.virginiahopkinstestkits.com/estriolhormone.html|http://www.virginiahopkinstestkits.com/estriolhormone.html
